PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mega, JL; Close, SL; Wiviott, SD; Shen, L; Walker, JR; Simon, T; Antman, EM; Braunwald, E; Sabatine, MS				Mega, Jessica L.; Close, Sandra L.; Wiviott, Stephen D.; Shen, Lei; Walker, Joseph R.; Simon, Tabassome; Antman, Elliott M.; Braunwald, Eugene; Sabatine, Marc S.			Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis	LANCET			English	Article							PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; DUODENAL ENTEROCYTES; PLATELET INHIBITION; STENT THROMBOSIS; P-GLYCOPROTEIN; MDR1 GENE; EXPRESSION; RESPONSIVENESS; THROMBOLYSIS	Background Clopidogrel and prasugrel are subject to efflux via P-glycoprotein (encoded by ABCB1, also known as MDR1). ABCB1 polymorphisms, particularly 3435C -> T, may affect drug transport and efficacy. We aimed to assess the effect of this polymorphism by itself and alongside variants in CYP2C/9 on cardiovascular outcomes in patients treated with clopidogrel or prasugrel in TRITON-TIMI 38. We also assessed the effect of genotype on the pharmacodynamic and pharmacoldnetic properties of these drugs in healthy individuals. Methods We genotyped ABCB1 in 2932 patients with acute coronary syndromes undergoing percutaneous intervention who were treated with clopidogrel (n=1471) or prasugrel (n=1461) in the TRITON -> TIMI 38 trial. We evaluated the association between ABCB1 3435C -> T and rates of the primary efficacy endpoint (cardiovascular death, myocardial infarction, or stroke) until 15 months. We then assessed the combined effect of ABCB13435C -> T genotype and reduced-function alleles of CYP2C19. 321 healthy individuals were also genotyped, and we tested the association of genetic variants with reduction in maximum platelet aggregation and plasma concentrations of active drug metabolites. Findings In patients treated with clopidogrel, ABCB1 3435C -> T genotype was significantly associated with the risk of cardiovascular death, myocardial infarction, or stroke (p=0.0064). TT homozygotes had a 72% increased risk of the primary endpoint compared with CT/CC individuals (Kaplan-Meier event rates 12.9% [52 of 414] vs 7.8% [80 of 1057 participants]; HR 1.72, 95% CI 1.22-2.44, p=0.002). ABCB1 3435C -> T and CYP2C19 genotypes were significant, independent predictors of the primary endpoint, and 681 (47%) of the 1454 genotyped patients taking clopidogrel who were either CYP2C19 reduced-function allele carriers, ABCB1 3435 TT homozygotes, or both were at increased risk of the primary endpoint (HR 1.97, 95% CI 1.38-2.82, p=0.0002). In healthy participants, 3435 TT homozygotes had an absolute reduction in maximum platelet aggregation with clopidogrel that was 7.3 percentage points less than for CT/CC individuals (p=0.0127). ABCB1 genotypes were not significantly associated with clinical or pharmacological outcomes in patients with an acute coronary syndrome or healthy individuals treated with prasugrel, respectively. Interpretation Individuals with the ABCB1 3435 TT genotype have reduced platelet inhibition and are at increased risk of recurrent ischaemic events during clopidogrel treatment. In patients with acute coronary syndromes who have undergone percutaneous intervention, when both ABCB1 and CYP2C19 are taken into account, nearly half of the population carries a genotype associated with increased risk of major adverse cardiovascular events while on standard doses of clopidogrel.	[Mega, Jessica L.; Wiviott, Stephen D.; Antman, Elliott M.; Braunwald, Eugene] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA; [Mega, Jessica L.; Wiviott, Stephen D.; Antman, Elliott M.; Braunwald, Eugene; Sabatine, Marc S.] Harvard Univ, Sch Med, Boston, MA USA; [Close, Sandra L.] Indiana Univ, Indianapolis, IN 46204 USA; [Close, Sandra L.; Shen, Lei] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Walker, Joseph R.] Daiichi Sankyo Inc, Edison, NJ USA; [Simon, Tabassome] Univ Paris 06, AP HP, F-75252 Paris 05, France	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Daiichi Sankyo Company Limited; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Sorbonne Universite	Mega, JL (corresponding author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave, Boston, MA 02115 USA.	jmega@partners.org; msabatine@partners.org	Sabatine, Marc/AAJ-6751-2020; Wiviott, Stephen/HIK-2534-2022	Sabatine, Marc/0000-0002-0691-3359; SIMON, Tabassome/0000-0002-4550-0450	Daiichi Sankyo; Eli Lilly; Sanofi-Aventis; Bristol-Myers Squibb; AstraZeneca; Schering-Plough/Merck; Johnson Johnson; Bayer Healthcare; National Institutes of Health [K99/R00 HL098461-01]; ARENA; Medco; Portola; Schering-Plough; Servier; Pfizer; Caisse d'Assurance Maladie; Merck; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL098461, K99HL098461] Funding Source: NIH RePORTER	Daiichi Sankyo(Daiichi Sankyo Company Limited); Eli Lilly(Eli Lilly); Sanofi-Aventis(Sanofi-Aventis); Bristol-Myers Squibb(Bristol-Myers Squibb); AstraZeneca(AstraZeneca); Schering-Plough/Merck(Merck & CompanySchering Plough Corporation); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ARENA(Australian Renewable Energy Agency (ARENA)); Medco; Portola; Schering-Plough(Merck & CompanySchering Plough Corporation); Servier(Servier); Pfizer(Pfizer); Caisse d'Assurance Maladie; Merck(Merck & Company); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The TIMI Study Group receives research grant support from Daiichi Sankyo, Eli Lilly, Sanofi-Aventis, Bristol-Myers Squibb, AstraZeneca, Schering-Plough/Merck, Johnson & Johnson, and Bayer Healthcare. Additionally, JLM is supported in part by grant K99/R00 HL098461-01 from the National Institutes of Health and reports consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, and AstraZeneca. SDW reports consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, AstraZeneca, ARENA, Medco, and Portola, and lecture fees for CME from Schering-Plough, Daiichi Sanity, Eli Lilly, Novartis, and AstraZeneca. TS reports research grant support from Servier, Pfizer, Daiichi Sankyo, Eli Lilly, Sanofi-Aventis, AstraZeneca, and Caisse d'Assurance Maladie and consulting fees from Eli Lilly, Daiichi Sankyo, Sanofi-Aventis, Bristol-Myers Squibb, and AstraZeneca. EMA has no additional relationships to disclose. EB reports consulting fees from Daiichi Sankyo and lecture fees from Schering-Plough and Merck. MSS reports consulting fees from AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Daiichi Sanity, and Eli Lilly and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, and Eli Lilly. JRW is an employee of Daiichi Sanity and holds equity ownership or stock options therein. SLC is a former employee of Eli Lilly and holds equity ownership or stock options therein. LS is an employee of Eli Lilly and holds equity ownership or stock options therein.	Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028; Anderson JL, 2009, J AM COLL CARDIOL, V53, pA27; Brandt JT, 2007, J THROMB HAEMOST, V5, P2429, DOI 10.1111/j.1538-7836.2007.02775.x; Collet JP, 2009, LANCET, V373, P309, DOI 10.1016/S0140-6736(08)61845-0; Dumaual C, 2007, PHARMACOGENOMICS, V8, P293, DOI 10.2217/14622416.8.3.293; Farid NA, 2007, RAPID COMMUN MASS SP, V21, P169, DOI 10.1002/rcm.2813; Fontana P, 2007, J THROMB HAEMOST, V5, P2153, DOI 10.1111/j.1538-7836.2007.02722.x; Giusti B, 2009, AM J CARDIOL, V103, P806, DOI 10.1016/j.amjcard.2008.11.048; Gladding P, 2008, JACC-CARDIOVASC INTE, V1, P620, DOI 10.1016/j.jcin.2008.09.008; Gurbel PA, 2003, CIRCULATION, V107, P2908, DOI 10.1161/01.CIR.0000072771.11429.83; Hochholzer W, 2006, J AM COLL CARDIOL, V48, P1742, DOI 10.1016/j.jacc.2006.06.065; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Hulot JS, 2006, BLOOD, V108, P2244, DOI 10.1182/blood-2006-04-013052; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kushner FG, 2009, CIRCULATION, V120, P2271, DOI 10.1161/CIRCULATIONAHA.109.192663; Mega JL, 2009, CIRCULATION, V119, P2553, DOI 10.1161/CIRCULATIONAHA.109.851949; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171; Moriya Y, 2002, BIOL PHARM BULL, V25, P1356, DOI 10.1248/bpb.25.1356; Nakamura T, 2002, CLIN PHARMACOL THER, V71, P297, DOI 10.1067/mcp.2002.122055; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Sibbing D, 2009, EUR HEART J, V30, P916, DOI 10.1093/eurheartj/ehp041; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Taubert D, 2006, CLIN PHARMACOL THER, V80, P486, DOI 10.1016/j.clpt.2006.07.007; Trenk D, 2008, J AM COLL CARDIOL, V51, P1925, DOI 10.1016/j.jacc.2007.12.056; Wiviott SD, 2008, LANCET, V371, P1353, DOI 10.1016/S0140-6736(08)60422-5; Wiviott SD, 2007, CIRCULATION, V116, P2923, DOI 10.1161/CIRCULATIONAHA.107.740324; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Wiviott SD, 2006, AM HEART J, V152, P627, DOI 10.1016/j.ahj.2006.04.012; Zhou SF, 2008, CURR DRUG METAB, V9, P738, DOI 10.2174/138920008786049302	29	468	505	0	40	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1312	1319		10.1016/S0140-6736(10)61273-1	http://dx.doi.org/10.1016/S0140-6736(10)61273-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20801494	Green Accepted			2022-12-28	WOS:000283528600033
J	Sekulic, N; Bassett, EA; Rogers, DJ; Black, BE				Sekulic, Nikolina; Bassett, Emily A.; Rogers, Danielle J.; Black, Ben E.			The structure of (CENP-A-H4)(2) reveals physical features that mark centromeres	NATURE			English	Article							NUCLEOSOME CORE PARTICLE; SMALL-ANGLE SCATTERING; CENP-A NUCLEOSOMES; ANGSTROM RESOLUTION; CHROMATIN; DNA; HISTONES; SYSTEM; DOMAIN; CRYSTALLOGRAPHY	Centromeres are specified epigenetically, and the histone H3 variant CENP-A is assembled into the chromatin of all active centromeres(1). Divergence from H3 raises the possibility that CENP-A generates unique chromatin features to mark physically centromere location. Here we report the crystal structure of a subnucleosomal heterotetramer, human (CENP-A-H4)(2), that reveals three distinguishing properties encoded by the residues that comprise the CENP-A targeting domain (CATD; ref. 2): (1) a CENP-A-CENP-A interface that is substantially rotated relative to the H3-H3 interface; (2) a protruding loop L1 of the opposite charge as that on H3; and (3) strong hydrophobic contacts that rigidify the CENP-A-H4 interface. Residues involved in the CENP-A-CENP-A rotation are required for efficient incorporation into centromeric chromatin, indicating specificity for an unconventional nucleosome shape. DNA topological analysis indicates that CENP-A-containing nucleosomes are octameric with conventional left-handed DNA wrapping, in contrast to other recent proposals(3-6). Our results indicate that CENP-A marks centromere location by restructuring the nucleosome from within its folded histone core.	[Sekulic, Nikolina; Bassett, Emily A.; Rogers, Danielle J.; Black, Ben E.] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Bassett, Emily A.; Black, Ben E.] Univ Penn, Sch Med, Grad Grp Biochem & Mol Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Black, BE (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	blackbe@mail.med.upenn.edu	Sekulic, Nikolina/N-5550-2016; Sekulic, Nikolina/F-8911-2013	Sekulic, Nikolina/0000-0001-7555-3222; 	NIH [GM82989, GM08275]; Burroughs Wellcome Fund; Rita Allen Foundation; American Cancer Society; American Heart Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008275, R01GM082989] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Rita Allen Foundation; American Cancer Society(American Cancer Society); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. Cleveland for plasmids and steadfast encouragement to pursue a physical understanding of the centromere; S. Wood for generating cleaved histone H2A; K. Gupta for help with collecting data and technical suggestions; and K. Ferguson, G. Van Duyne, M. Lemmon, J. Shorter, L. Jansen, D. Foltz, J. Shah, D. Alvarado, K. Moravcevic and T. Panchenko for discussions and comments on the manuscript. This work was supported by the NIH research grant GM82989, a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund, and a Rita Allen Foundation Scholar Award to B.E.B.N.S. is supported by a postdoctoral fellowship from the American Cancer Society and E.A.B. has been supported by the Penn Structural Biology Training Grant (NIH GM08275) and a predoctoral fellowship from the American Heart Association.	Altaf M, 2007, MOL CELL, V28, P1002, DOI 10.1016/j.molcel.2007.12.002; Bassett EA, 2010, J CELL BIOL, V190, P177, DOI 10.1083/jcb.201001035; BINASTEIN M, 1977, CELL, V11, P609, DOI 10.1016/0092-8674(77)90078-2; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; Black BE, 2008, CURR OPIN CELL BIOL, V20, P91, DOI 10.1016/j.ceb.2007.11.007; Black BE, 2007, P NATL ACAD SCI USA, V104, P5008, DOI 10.1073/pnas.0700390104; Black BE, 2007, MOL CELL, V25, P309, DOI 10.1016/j.molcel.2006.12.018; Camahort R, 2009, MOL CELL, V35, P794, DOI 10.1016/j.molcel.2009.07.022; Carroll CW, 2009, NAT CELL BIOL, V11, P896, DOI 10.1038/ncb1899; Carruthers LM, 1999, METHOD ENZYMOL, V304, P19; Dalal Y, 2007, PLOS BIOL, V5, P1798, DOI 10.1371/journal.pbio.0050218; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Englander SW, 2006, J AM SOC MASS SPECTR, V17, P1481, DOI 10.1016/j.jasms.2006.06.006; Erhardt S, 2008, J CELL BIOL, V183, P805, DOI 10.1083/jcb.200806038; ESPOSITO F, 1987, NUCLEIC ACIDS RES, V15, P5105, DOI 10.1093/nar/15.13.5105; Foltz DR, 2009, CELL, V137, P472, DOI 10.1016/j.cell.2009.02.039; Furuyama T, 2009, CELL, V138, P104, DOI 10.1016/j.cell.2009.04.049; Fyodorov DV, 2003, METHOD ENZYMOL, V371, P499; Henikoff S, 2001, SCIENCE, V293, P1098, DOI 10.1126/science.1062939; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91; Lu X, 2008, NAT STRUCT MOL BIOL, V15, P1122, DOI 10.1038/nsmb.1489; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lusser A, 2004, NAT METHODS, V1, P19, DOI 10.1038/nmeth709; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mizuguchi G, 2007, CELL, V129, P1153, DOI 10.1016/j.cell.2007.04.026; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Shuaib M, 2010, P NATL ACAD SCI USA, V107, P1349, DOI 10.1073/pnas.0913709107; Silva NCE, 2007, J MOL BIOL, V370, P555, DOI 10.1016/j.jmb.2007.04.064; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Smith MM, 2002, CURR OPIN CELL BIOL, V14, P279, DOI 10.1016/S0955-0674(02)00331-9; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Vermaak D, 2002, MOL CELL BIOL, V22, P7553, DOI 10.1128/MCB.22.21.7553-7561.2002; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Williams JS, 2009, MOL CELL, V33, P287, DOI 10.1016/j.molcel.2009.01.017; Wriggers Willy, 2010, Biophys Rev, V2, P21, DOI 10.1007/s12551-009-0026-3	41	164	169	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					347	U132		10.1038/nature09323	http://dx.doi.org/10.1038/nature09323			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20739937	Green Accepted			2022-12-28	WOS:000281824900043
J	Higginson, IJ				Higginson, Irene J.			Refractory breathlessness: oxygen or room air?	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; SYMPTOM PREVALENCE; DYSPNEA; MANAGEMENT; CANCER; RELIEF		Kings Coll London, Cicely Saunders Inst, London SE5 9PJ, England	University of London; King's College London	Higginson, IJ (corresponding author), Kings Coll London, Cicely Saunders Inst, London SE5 9PJ, England.	irene.higginson@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				Abernethy AP, 2010, LANCET, V376, P784, DOI 10.1016/S0140-6736(10)61115-4; BAUSEWEIN C, 2008, COCHRANE DB SYST REV, V2, P5623; CRANSTON JM, 2010, COCHRANE DB SYST REV, V3, P4769; Galbraith S, 2010, J PAIN SYMPTOM MANAG, V39, P831, DOI 10.1016/j.jpainsymman.2009.09.024; Gallagher Romayne, 2004, J Pain Palliat Care Pharmacother, V18, P3; Gysels M, 2010, J PAIN SYMPTOM MANAG, V39, P555, DOI 10.1016/j.jpainsymman.2009.08.009; Gysels M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-216; Higginson IJ, 2006, J PALLIATIVE CARE, V22, P158, DOI 10.1177/082585970602200306; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Murtagh FE, 2010, J PAIN SYMPTOM MANAG, V40, P342, DOI 10.1016/j.jpainsymman.2010.01.021; Saleem T, 2007, J PALLIAT CARE, V23, P291, DOI 10.1177/082585970702300408; Simon ST, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007354.pub2; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Uronis HE, 2008, BRIT J CANCER, V98, P294, DOI 10.1038/sj.bjc.6604161; Wilt TJ, 2007, ANN INTERN MED, V147, P639, DOI 10.7326/0003-4819-147-9-200711060-00009	16	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					746	748		10.1016/S0140-6736(10)61346-3	http://dx.doi.org/10.1016/S0140-6736(10)61346-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816528				2022-12-28	WOS:000281831000005
J	Saltiel, AR				Saltiel, Alan R.			Fishing Out a Sensor for Anti-inflammatory Oils	CELL			English	Editorial Material							INDUCED INSULIN-RESISTANCE; INDUCED INFLAMMATION; OBESITY		[Saltiel, Alan R.] Univ Michigan, Dept Internal Med, Inst Life Sci, Sch Med, Ann Arbor, MI 48109 USA; [Saltiel, Alan R.] Univ Michigan, Dept Mol & Integrat Physiol, Inst Life Sci, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Univ Michigan, Dept Internal Med, Inst Life Sci, Sch Med, Ann Arbor, MI 48109 USA.	saltiel@lsi.umich.edu	Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Chiang SH, 2009, CELL, V138, P961, DOI 10.1016/j.cell.2009.06.046; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Rajagopal S, 2010, P NATL ACAD SCI USA, V107, P628, DOI 10.1073/pnas.0912852107; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Shoelson SE, 2009, NAT MED, V15, P373, DOI 10.1038/nm0409-373; Solinas G, 2007, CELL METAB, V6, P386, DOI 10.1016/j.cmet.2007.09.011	10	15	22	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5					672	674		10.1016/j.cell.2010.08.022	http://dx.doi.org/10.1016/j.cell.2010.08.022			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813253	Bronze			2022-12-28	WOS:000281523200008
J	Poulsen, H; Khandelia, H; Morth, JP; Bublitz, M; Mouritsen, OG; Egebjerg, J; Nissen, P				Poulsen, Hanne; Khandelia, Himanshu; Morth, J. Preben; Bublitz, Maike; Mouritsen, Ole G.; Egebjerg, Jan; Nissen, Poul			Neurological disease mutations compromise a C-terminal ion pathway in the Na+/K+-ATPase	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; AMINO-ACID; NA,K-ATPASE; NA+,K+-ATPASE; PUMP; SUBSTITUTIONS; TRANSPORT	The Na+/K+-ATPase pumps three sodium ions out of and two potassium ions into the cell for each ATP molecule that is split, thereby generating the chemical and electrical gradients across the plasma membrane that are essential in, for example, signalling, secondary transport and volume regulation in animal cells. Crystal structures of the potassium-bound form of the pump revealed an intimate docking of the alpha-subunit carboxy terminus at the transmembrane domain(1,2). Here we show that this element is a key regulator of a previously unrecognized ion pathway. Current models of P-type ATPases operate with a single ion conduit through the pump(3-5), but our data suggest an additional pathway in the Na+/K+-ATPase between the ion-binding sites and the cytoplasm. The C-terminal pathway allows a cytoplasmic proton to enter and stabilize site III when empty in the potassium-bound state, and when potassium is released the proton will also return to the cytoplasm, thus allowing an overall asymmetric stoichiometry of the transported ions. The C terminus controls the gate to the pathway. Its structure is crucial for pump function, as demonstrated by at least eight mutations in the region that cause severe neurological diseases(6,7). This novel model for ion transport by the Na+/K+-ATPase is established by electrophysiological studies of C-terminal mutations in familial hemiplegic migraine 2 (FHM2) and is further substantiated by molecular dynamics simulations. A similar ion regulation is likely to apply to the H+/K+-ATPase and the Ca2+-ATPase.	[Poulsen, Hanne; Morth, J. Preben; Bublitz, Maike; Nissen, Poul] Aarhus Univ, Dept Mol Biol, Danish Natl Res Fdn, PUMPKIN Ctr Membrane Pumps Cells & Dis, DK-8000 Aarhus C, Denmark; [Khandelia, Himanshu; Mouritsen, Ole G.] Univ So Denmark, Dept Chem & Phys, Danish Natl Res Fdn, MEMPHYS Ctr Biomembrane Phys, DK-5230 Odense M, Denmark; [Egebjerg, Jan] H Lundbeck & Co AS, DK-2500 Copenhagen, Denmark	Aarhus University; Danmarks Grundforskningsfond; Danmarks Grundforskningsfond; University of Southern Denmark; Lundbeck Corporation	Poulsen, H (corresponding author), Aarhus Univ, Dept Mol Biol, Danish Natl Res Fdn, PUMPKIN Ctr Membrane Pumps Cells & Dis, DK-8000 Aarhus C, Denmark.	hp@mb.au.dk; pn@mb.au.dk	Morth, Jens Preben/G-4450-2013; Morth, Jens Preben/AAP-7834-2021; Nissen, Poul/D-5774-2014	Morth, Jens Preben/0000-0003-4077-0192; Morth, Jens Preben/0000-0003-4077-0192; Nissen, Poul/0000-0003-0948-6628; Bublitz, Maike/0000-0003-3161-418X; Mouritsen, Ole G./0000-0002-4258-8960; Khandelia, Himanshu/0000-0001-9913-6394	European Molecular Biology Organisation; Carlsberg Foundation; Lundbeck Foundation; Danish Ministry of Science and Innovation; Novo Nordisk Foundation; Lundbeck Foundation [R34-2009-3616] Funding Source: researchfish	European Molecular Biology Organisation; Carlsberg Foundation(Carlsberg Foundation); Lundbeck Foundation(Lundbeckfonden); Danish Ministry of Science and Innovation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden)	We acknowledge the Danish Center for Scientific Computing at the University of Southern Denmark, Odense, for computing resources. We thank D. Gadsby, N. Vedovato and A. Gulyas-Kovacs at the Rockefeller University, New York City, for technical advice and discussion, A. Skov Kristensen and M. H. Poulsen (University of Copenhagen) for supplies of oocytes, and M. J. Clausen, G. Hartvigsen and A. M. Nielsen for assistance with experimental procedures. We are grateful to C. Slayman and F. Ashcroft for discussions on electrogenic transport. H. P. was supported by a short-term travel fellowship from the European Molecular Biology Organisation, J. P. M. was supported by grants from the Carlsberg Foundation and the Lundbeck Foundation, and P. N. was supported by an Elite Researcher grant of the Danish Ministry of Science and Innovation and a Hallas-Moller stipend from the Novo Nordisk Foundation.	Anselm IA, 2009, NEUROLOGY, V73, P400, DOI 10.1212/WNL.0b013e3181b04acd; Bas DC, 2008, PROTEINS, V73, P765, DOI 10.1002/prot.22102; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3; Blanco-Arias P, 2009, HUM MOL GENET, V18, P2370, DOI 10.1093/hmg/ddp170; Burnay M, 2003, J BIOL CHEM, V278, P19237, DOI 10.1074/jbc.M300946200; Holmgren M, 2000, NATURE, V403, P898, DOI 10.1038/35002599; Jen JC, 2007, J NEUROL NEUROSUR PS, V78, P523, DOI 10.1136/jnnp.2006.103267; Jespersen T, 2002, BIOTECHNIQUES, V32, P536, DOI 10.2144/02323st05; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Li CM, 2006, J MEMBRANE BIOL, V213, P1, DOI 10.1007/s00232-006-0035-0; Meier S, 2010, J GEN PHYSIOL, V135, P115, DOI 10.1085/jgp.200910301; Morth JP, 2007, NATURE, V450, P1043, DOI 10.1038/nature06419; Morth JP, 2009, PHILOS T R SOC B, V364, P217, DOI 10.1098/rstb.2008.0201; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Olesen C, 2007, NATURE, V450, P1036, DOI 10.1038/nature06418; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Riant F, 2005, HUM MUTAT, V26, DOI 10.1002/humu.9361; Shinoda T, 2009, NATURE, V459, P446, DOI 10.1038/nature07939; SKOU JC, 1980, BIOCHIM BIOPHYS ACTA, V601, P386, DOI 10.1016/0005-2736(80)90543-X; Takeuchi A, 2008, NATURE, V456, P413, DOI 10.1038/nature07350; Toustrup-Jensen MS, 2009, J BIOL CHEM, V284, P18715, DOI 10.1074/jbc.M109.015099; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vasilyev A, 2004, J MEMBRANE BIOL, V198, P65, DOI 10.1007/s00232-004-0660-4; Yamamoto S, 1996, J PHYSIOL-LONDON, V495, P733, DOI 10.1113/jphysiol.1996.sp021629; Yaragatupalli S, 2009, P NATL ACAD SCI USA, V106, P15507, DOI 10.1073/pnas.0903752106; Zanotti-Fregonara P, 2008, J NEUROL SCI, V273, P148, DOI 10.1016/j.jns.2008.06.033	28	97	100	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2010	467	7311					99	102		10.1038/nature09309	http://dx.doi.org/10.1038/nature09309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20720542				2022-12-28	WOS:000281461200043
J	Lasswell, SM; Barfield, WD; Rochat, RW; Blackmon, L				Lasswell, Sarah Marie; Barfield, Wanda Denise; Rochat, Roger William; Blackmon, Lillian			Perinatal Regionalization for Very Low-Birth-Weight and Very Preterm Infants A Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NEONATAL INTENSIVE-CARE; NATIONAL COLLABORATIVE SURVEY; MORTALITY RATES; SOUTH-CAROLINA; UNITED-STATES; LEVEL; SURVIVAL; OUTCOMES; MORBIDITY; TRANSPORT	Context For more than 30 years, guidelines for perinatal regionalization have recommended that very low-birth-weight (VLBW) infants be born at highly specialized hospitals, most commonly designated as level III hospitals. Despite these recommendations, some regions continue to have large percentages of VLBW infants born in lower-level hospitals. Objective To evaluate published data on associations between hospital level at birth and neonatal or predischarge mortality for VLBW and very preterm (VPT) infants. Data Sources Systematic search of published literature (1976-May 2010) in MEDLINE, CINAHL, EMBASE, and PubMed databases and manual searches of reference lists. Study Selection and Data Extraction Forty-one publications met a priori inclusion criteria (randomized controlled trial, cohort, and case-control studies measuring neonatal or predischarge mortality among live-born infants <= 1500 g or <= 32 weeks' gestation delivered at a level III vs lower-level facility). Paired reviewers independently assessed publications for inclusion and extracted data using standardized forms. Discrepancies were decided by a third reviewer. Publications were reviewed for quality by 3 authors based on 2 content areas: adjustment for confounding and description of hospital levels. We calculated weighted, combined odds ratios (ORs) using a random-effects model and comparative unadjusted pooled mortality rates. Data Synthesis We observed increased odds of death for VLBW infants (38% vs 23%; adjusted OR, 1.62; 95% confidence interval [CI], 1.44-1.83) and VPT infants (15% vs 17%; adjusted OR, 1.55; 95% CI, 1.21-1.98) born outside of level III hospitals. Consistent results were obtained when restricted to higher-quality evidence (mortality in VLBW infants, 36% vs 21%; adjusted OR, 1.60; 95% CI, 1.33-1.92 and in VPT infants, 7% vs 12%; adjusted OR, 1.42; 95% CI, 1.06-1.88) and infants weighing less than 1000 g (59% vs 32%; adjusted OR, 1.80; 95% CI, 1.31-2.46). No significant differences were found through subgroup analysis of study characteristics. Meta-regression by year of publication did not reveal a change over time (slope, 0.00; P=.87). Conclusion For VLBW and VPT infants, birth outside of a level III hospital is significantly associated with increased likelihood of neonatal or predischarge death. JAMA. 2010; 304(9): 992-1000 www.jama.com	[Lasswell, Sarah Marie; Barfield, Wanda Denise] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; [Lasswell, Sarah Marie; Rochat, Roger William] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA; [Blackmon, Lillian] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA	Centers for Disease Control & Prevention - USA; Emory University; Rollins School Public Health; University System of Maryland; University of Maryland Baltimore	Barfield, WD (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS K-22, Atlanta, GA 30341 USA.	wbarfield@cdc.gov	Rochat, Roger/J-9802-2012		US Department of Energy; CDC	US Department of Energy(United States Department of Energy (DOE)); CDC(Centre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Ms Lasswell was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy and the CDC.	American Academy of Pediatrics American College of Obstetricians and Gynecologists March of Dimes Birth Defects Foundation, 2007, GUID PER CAR, V6th; Arad I, 1999, EUR J OBSTET GYN R B, V83, P151, DOI 10.1016/S0301-2115(98)00336-4; Arad I, 2008, ISR MED ASSOC J, V10, P457; Arad I, 2006, ISR MED ASSOC J, V8, P477; Attar MA, 2006, J PERINATOL, V26, P210, DOI 10.1038/sj.jp.7211488; Bacak SJ, 2005, AM J OBSTET GYNECOL, V192, P862, DOI 10.1016/j.ajog.2004.07.029; BEVERLEY D, 1986, BRIT MED J, V293, P981, DOI 10.1136/bmj.293.6553.981; Blackmon LR, 2009, J PERINATOL, V29, P788, DOI 10.1038/jp.2009.148; BLAKE AM, 1979, BRIT MED J, V2, P414, DOI 10.1136/bmj.2.6187.414; Bode MM, 2001, AM J OBSTET GYNECOL, V184, P1302, DOI 10.1067/mob.2001.114484; Borenstein M., 2005, COMPREHENSIVE META A; Boulton M. L., 2009, Morbidity and Mortality Weekly Report, V58, P1373; CAMPBELL MK, 1991, CAN MED ASSOC J, V144, P305; Chien LY, 2001, OBSTET GYNECOL, V98, P247, DOI 10.1016/S0029-7844(01)01438-7; Cifuentes J, 2002, PEDIATRICS, V109, P745, DOI 10.1542/peds.109.5.745; COLDITZ GA, 1995, AM J EPIDEMIOL, V142, P371, DOI 10.1093/oxfordjournals.aje.a117644; Committee on Perinatal Health, 1976, IMPR OUTC PREGN REC; Committee on Perinatal Health, 1993, IMPR OUTC PREGN 90S; Cooke S, 1988, RW JOHNSON FDN GRANT; CORDERO L, 1982, AM J OBSTET GYNECOL, V143, P533, DOI 10.1016/0002-9378(82)90543-9; EASA D, 1981, HAWAII MED J, V40, P175; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Empana JP, 2003, ACTA PAEDIATR, V92, P346; Enweronu-Laryea CC, 2008, J PERINATOL, V28, P561, DOI 10.1038/jp.2008.61; Finnstrom O, 1997, ACTA PAEDIATR, V86, P503, DOI 10.1111/j.1651-2227.1997.tb08921.x; Gessner BD, 2001, AM J OBSTET GYNECOL, V185, P623, DOI 10.1067/mob.2001.117663; Goodman DC, 2002, NEW ENGL J MED, V346, P1538, DOI 10.1056/NEJMoa011921; GORTMAKER S, 1985, AM J OBSTET GYNECOL, V152, P517, DOI 10.1016/0002-9378(85)90618-0; Gould Jeffrey B, 2002, J Perinatol, V22, P630, DOI 10.1038/sj.jp.7210824; Hack M, 1996, PEDIATRICS, V98, P931; HEIN HA, 1980, PEDIATRICS, V66, P540; HEIN HA, 1986, EUR J OBSTET GYN R B, V21, P33, DOI 10.1016/0028-2243(86)90043-2; Hernandez J A, 2000, J Perinatol, V20, P21, DOI 10.1038/sj.jp.7200300; HO S, 2006, NEOREVIEWS, V6, pE123; Howell EA, 2008, PEDIATRICS, V121, pE407, DOI 10.1542/peds.2007-0910; Howell EM, 2002, AM J PUBLIC HEALTH, V92, P119, DOI 10.2105/AJPH.92.1.119; Hulsey T C, 1991, J S C Med Assoc, V87, P581; *I MED, 2007, PRET BIRTH CAUS CONS; JOBE AH, 1993, NEW ENGL J MED, V328, P861; Johansson S, 2004, PEDIATRICS, V113, P1230, DOI 10.1542/peds.113.5.1230; Kamath BD, 2008, J PERINATOL, V28, P354, DOI 10.1038/sj.jp.7211918; KILLAM AP, 1981, J TENNESSEE MED ASS, V74, P870; KITCHEN WH, 1983, MED J AUSTRALIA, V2, P314, DOI 10.5694/j.1326-5377.1983.tb122487.x; KOLLEE LAA, 1985, EUR J OBSTET GYN R B, V20, P393, DOI 10.1016/0028-2243(85)90063-2; KOLLEE LAA, 1992, OBSTET GYNECOL, V80, P635; KOLLEE LAA, 1988, OBSTET GYNECOL, V72, P729; Kusuda S, 2006, PEDIATRICS, V118, pE1130, DOI 10.1542/peds.2005-2724; LAMONT RF, 1983, J PERINAT MED, V11, P200, DOI 10.1515/jpme.1983.11.4.200; Lannon C, 2004, PEDIATRICS, V114, P494, DOI 10.1542/peds.114.2.494; Lee SK, 2003, AM J OBSTET GYNECOL, V188, P617, DOI 10.1067/mob.2003.139; LEVY DL, 1981, OBSTET GYNECOL, V57, P500; Little GA, 2009, J PERINATOL, V29, P777, DOI 10.1038/jp.2009.176; LUBCHENCO LO, 1989, AM J OBSTET GYNECOL, V160, P539, DOI 10.1016/S0002-9378(89)80022-5; Lui K, 2006, PEDIATRICS, V118, P2076, DOI 10.1542/peds.2006-1540; LUMLEY J, 1988, MED J AUSTRALIA, V149, P242, DOI 10.5694/j.1326-5377.1988.tb120595.x; Mathews T J, 2008, Natl Vital Stat Rep, V57, P1; MCCORMICK MC, 1995, FUTURE CHILD, V5, P162, DOI 10.2307/1602513; Menard MK, 1998, AM J OBSTET GYNECOL, V179, P374, DOI 10.1016/S0002-9378(98)70367-9; Merlo J, 2005, MED CARE, V43, P1092, DOI 10.1097/01.mlr.0000182484.14608.b9; OBLADEN M, 1994, J PERINAT MED, V22, P53, DOI 10.1515/jpme.1994.22.1.53; Palmer Kristine G, 2005, J Perinatol, V25, P270, DOI 10.1038/sj.jp.7211239; PANETH N, 1982, NEW ENGL J MED, V307, P149, DOI 10.1056/NEJM198207153070303; Phibbs CS, 2007, NEW ENGL J MED, V356, P2165, DOI 10.1056/NEJMsa065029; Philip AGS, 2005, PEDIATR RES, V58, P799, DOI 10.1203/01.PDR.0000151693.46655.66; RICHARDSON DK, 1995, PEDIATRICS, V96, P417; ROSENBLATT RA, 1988, WESTERN J MED, V149, P98; SAIGAL S, 1984, J PEDIATR-US, V105, P969, DOI 10.1016/S0022-3476(84)80093-1; Samuelson JL, 2002, PAEDIATR PERINAT EP, V16, P305, DOI 10.1046/j.1365-3016.2002.00450.x; Sanderson M, 2000, AM J OBSTET GYNECOL, V183, P1504, DOI 10.1067/mob.2000.107357; Schurr P, 2008, NEONATAL NETW, V27, P397, DOI 10.1891/0730-0832.27.6.397; STARK AR, 2005, PEDIATRICS, V115, P1118; *US HLTH RES SERV, 1 US DEP HLTH HUM SE; Van Reempts P, 2007, PEDIATRICS, V120, pe815, DOI 10.1542/peds.2006-3122; VERLOOVEVANHORICK SP, 1988, PEDIATRICS, V81, P404; Vohr BR, 2004, PEDIATRICS, V113, P781, DOI 10.1542/peds.113.4.781; Warner B, 2004, PEDIATRICS, V113, P35, DOI 10.1542/peds.113.1.35; Yeast JD, 1998, AM J OBSTET GYNECOL, V178, P131, DOI 10.1016/S0002-9378(98)70639-8; Yu Victor Y H, 2004, Semin Neonatol, V9, P135	78	232	236	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					992	1000		10.1001/jama.2010.1226	http://dx.doi.org/10.1001/jama.2010.1226			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20810377				2022-12-28	WOS:000281422400025
J	Fudge, N; Redfern, J; Wolfe, C; McKevitt, C				Fudge, Nina; Redfern, Judith; Wolfe, Charles; McKevitt, Christopher			Streamlined research governance: are we there yet?	BRITISH MEDICAL JOURNAL			English	Editorial Material							IN-THE-NHS; MULTICENTER; UK	Despite the promise of a new streamlined process for gaining research ethics and governance approval, Nina Fudge, Judith Redfern, Charles Wolfe, and Christopher McKevitt argue that the process is still dogged by delay and arbitrary decisions	[Fudge, Nina; Redfern, Judith; Wolfe, Charles; McKevitt, Christopher] Kings Coll London, Dept Primary Care & Publ Hlth Sci, London SE1 3QD, England	University of London; King's College London	Fudge, N (corresponding author), Kings Coll London, Dept Primary Care & Publ Hlth Sci, Capital House 7th Floor, 42 Weston St, London SE1 3QD, England.	nina.fudge@kcl.ac.uk	mckevitt, christopher/AAN-7271-2021	MCKEVITT, CHRISTOPHER/0000-0002-5290-4613; Fudge, Nina/0000-0002-7161-4355				*AC MED SCI, 2010, REAP AW VIS UK MED S; *ALL WAL PRIM CAR, 2008, INFORM NEWSL ALL WAL; Asprey D, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1770; Elwyn G, 2005, BRIT MED J, V330, P847, DOI 10.1136/bmj.330.7495.847; Goodacre SW, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c3449; Hackshaw A, 2008, J ROY SOC MED, V101, P299, DOI 10.1258/jrsm.2008.070373; KNOWLES RL, 2009, ARCH DIS CHILDH 0921; Lipsky M., 1980, STREET LEVEL BUREAUC, DOI DOI 10.1007/s13178-012-0092-3; Mallick AA, 2009, J ROY SOC MED, V102, P195, DOI 10.1258/jrsm.2009.080397; *NAT AUD OFF, DEP HLTH PROGR IMPR; *NAT I HLTH RES, 2009, NAT I HLTH RES COORD; *NAT I HLTH RES, NHR COORD SYST GAIN; *NAT PAT SAF AG, 2010, WELC INT RES APPL SY; *RES DEV DIR DH, 2006, BEST RES BEST HLTH N; Shaw S, 2005, J ROY SOC MED, V98, P496, DOI 10.1258/jrsm.98.11.496; Singh S, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c3448; Stewart PM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1732	17	12	12	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 27	2010	341								c4625	10.1136/bmj.c4625	http://dx.doi.org/10.1136/bmj.c4625			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IJ	20802002				2022-12-28	WOS:000281446300017
J	Jones, R				Jones, Rachel			Biomarkers: casting the net wide	NATURE			English	Editorial Material							PARKINSONS-DISEASE; HUMAN PLASMA											Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Booij J, 1997, EUR J NUCL MED, V24, P68, DOI 10.1007/BF01728311; COLLINGWOOD JF, 2008, MOV DIS S1, V23; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; Oakley AE, 2007, NEUROLOGY, V68, P1820, DOI 10.1212/01.wnl.0000262033.01945.9a; POSNEN MM, 2004, ANN NEUROL, V56, P173	7	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					S11	S12		10.1038/466S11a	http://dx.doi.org/10.1038/466S11a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739930				2022-12-28	WOS:000281203600061
J	Safren, SA; Sprich, S; Mimiaga, MJ; Surman, C; Knouse, L; Groves, M; Otto, MW				Safren, Steven A.; Sprich, Susan; Mimiaga, Matthew J.; Surman, Craig; Knouse, Laura; Groves, Meghan; Otto, Michael W.			Cognitive Behavioral Therapy vs Relaxation With Educational Support for Medication-Treated Adults With ADHD and Persistent Symptoms A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; PLACEBO	Context Attention-deficit/hyperactivity disorder (ADHD) in adulthood is a prevalent, distressing, and impairing condition that is not fully treated by pharmacotherapy alone and lacks evidence-based psychosocial treatments. Objective To test cognitive behavioral therapy for ADHD in adults treated with medication but who still have clinically significant symptoms. Design, Setting, and Patients Randomized controlled trial assessing the efficacy of cognitive behavioral therapy for 86 symptomatic adults with ADHD who were already being treated with medication. The study was conducted at a US hospital between November 2004 and June 2008 (follow-up was conducted through July 2009). Of the 86 patients randomized, 79 completed treatment and 70 completed the follow-up assessments. Interventions Patients were randomized to 12 individual sessions of either cognitive behavioral therapy or relaxation with educational support (which is an attention-matched comparison). Main Outcome Measures The primary measures were ADHD symptoms rated by an assessor (ADHD rating scale and Clinical Global Impression scale) at baseline, post-treatment, and at 6- and 12-month follow-up. The assessor was blinded to treatment condition assignment. The secondary outcome measure was self-report of ADHD symptoms. Results Cognitive behavioral therapy achieved lower posttreatment scores on both the Clinical Global Impression scale (magnitude -0.0531; 95% confidence interval [CI], -1.01 to -0.05; P=.03) and the ADHD rating scale (magnitude -4.631; 95% CI, -8.30 to -0.963; P=.02) compared with relaxation with educational support. Throughout treatment, self-reported symptoms were also significantly more improved for cognitive behavioral therapy (beta=-0.41; 95% Cl, -0.64 to -0.17; P<001), and there were more treatment responders in cognitive behavioral therapy for both the Clinical Global Impression scale (53% vs 23%; odds ratio [OR], 3.80; 95% CI, 1.50 to 9.59; P=.01) and the ADHD rating scale (67% vs 33%; OR, 4.29; 95% Cl, 1.74 to 10.58; P=.002). Responders and partial responders in the cognitive behavioral therapy condition maintained their gains over 6 and 12 months. Conclusion Among adults with persistent ADHD symptoms treated with medication, the use of cognitive behavioral therapy compared with relaxation with educational support resulted in improved ADHD symptoms, which were maintained at 12 months.	[Safren, Steven A.; Sprich, Susan; Mimiaga, Matthew J.; Surman, Craig; Knouse, Laura; Groves, Meghan; Otto, Michael W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Safren, Steven A.; Sprich, Susan; Mimiaga, Matthew J.; Surman, Craig; Knouse, Laura] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University	Safren, SA (corresponding author), Massachusetts Gen Hosp Behav Med, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA.	ssafren@partners.org		Otto, Michael/0000-0002-8915-7578	Abbott; Alza; Cephalon; Eli Lilly; ElMinda the Hilda and Preston Davis Foundation; McNeil; Merck; New River; National Institutes of Health; Organon; Pfizer; Shire; Takeda; Jazz Pharmaceuticals; Organon (Schering-Plough); Sanofi-Aventis; National Institutes of Health [5R01MH69812]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069812] Funding Source: NIH RePORTER	Abbott(Abbott Laboratories); Alza; Cephalon; Eli Lilly(Eli Lilly); ElMinda the Hilda and Preston Davis Foundation; McNeil; Merck(Merck & Company); New River; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Organon; Pfizer(Pfizer); Shire; Takeda(Takeda Pharmaceutical Company Ltd); Jazz Pharmaceuticals(Jazz Pharmaceuticals); Organon (Schering-Plough)(Merck & CompanySchering Plough Corporation); Sanofi-Aventis(Sanofi-Aventis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Drs Safren, Sprich, and Otto reported receiving royalty payments from Oxford University Press. Dr Surman reported receiving research support from Abbott, Alza, Cephalon, Eli Lilly, ElMinda the Hilda and Preston Davis Foundation, McNeil, Merck, New River, National Institutes of Health, Organon, Pfizer, Shire, and Takeda; being a speaker for Janssen-Ortho, McNeil, Novartis, Shire, and MGH Academy/Reed Medical Education (which receives funding from multiple pharmaceutical companies); and being a consultant or advisor for McNeil, Shire, and Takeda. Dr Knouse reported receiving consulting income from Eli Lilly. Dr Otto reported receiving consulting income from Jazz Pharmaceuticals, Organon (Schering-Plough), Pfizer, and Sanofi-Aventis; research support from Organon (Schering-Plough); and royalty payments for use of the SIGH-A from Lilly.; This study was funded by National Institutes of Health grant 5R01MH69812.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barkley R.A, 2006, ATTENTION DEFICIT HY, V3rd; Biederman J, 2006, ATTENTION DEFICIT HY, P704; DuPaul G. J., 1998, ADHD RATING SCALE 4; Faries D.E., 2001, J ATTEN DISORD, V5, P107, DOI [DOI 10.1177/108705470100500204, 10.1177/108705470100500204]; First M.B., 2016, STRUCTURED CLIN INTE; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Knouse Laura E, 2008, Expert Rev Neurother, V8, P1537, DOI 10.1586/14737175.8.10.1537; National Institute of Mental Health, 1985, PSYCHOPHARMACOL BULL, V21, P839; ORVASCHEL H, 1985, PSYCHOPHARMACOL BULL, V21, P737; Safren S. A., 2005, MASTERING YOUR ADULT; Safren SA, 2005, BEHAV RES THER, V43, P831, DOI 10.1016/j.brat.2004.07.001; Solanto MV, 2010, AM J PSYCHIAT, V167, P958, DOI 10.1176/appi.ajp.2009.09081123; SPENCER T, 1995, ARCH GEN PSYCHIAT, V52, P434; Steele M, 2006, CLIN THER, V28, P1892, DOI 10.1016/j.clinthera.2006.11.006; Wilens TE, 1996, AM J PSYCHIAT, V153, P1147; Zylowska L, 2008, J ATTEN DISORD, V11, P737, DOI 10.1177/1087054707308502	17	213	219	0	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					875	880		10.1001/jama.2010.1192	http://dx.doi.org/10.1001/jama.2010.1192			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736471	Bronze, Green Accepted			2022-12-28	WOS:000281389900025
J	Yunes, N				Yunes, Nicolas			A Tale of Two Jets	SCIENCE			English	Editorial Material							BLACK-HOLES; SIMULATIONS; MAGNETOSPHERES		[Yunes, Nicolas] Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; [Yunes, Nicolas] MIT, Dept Phys, Cambridge, MA 02139 USA; [Yunes, Nicolas] MIT, Kavli Inst, Cambridge, MA 02139 USA	Princeton University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Yunes, N (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.	nyunes@princeton.edu	Yunes, Nicolas/AAG-3146-2019	Yunes, Nicolas/0000-0001-6147-1736				Baker JG, 2006, PHYS REV D, V73, DOI 10.1103/PhysRevD.73.104002; BLANDFORD RD, 1977, MON NOT R ASTRON SOC, V179, P433, DOI 10.1093/mnras/179.3.433; Campanelli M, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.111101; GOLDREICH P, 1969, ASTROPHYS J, V157, P869, DOI 10.1086/150119; Holz DE, 2005, ASTROPHYS J, V629, P15, DOI 10.1086/431341; Komissarov SS, 2007, MON NOT R ASTRON SOC, V377, pL49, DOI 10.1111/j.1745-3933.2007.00301.x; Komissarov SS, 2004, MON NOT R ASTRON SOC, V350, P1431, DOI 10.1111/j.1365-2966.2004.07738.x; Krolik JH, 2010, LECT NOTES PHYS, V794, P265, DOI 10.1007/978-3-540-76937-8_10; Palenzuela C, 2010, SCIENCE, V329, P927, DOI 10.1126/science.1191766; Pretorius F, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.121101; SCHUTZ BF, 1986, NATURE, V323, P310, DOI 10.1038/323310a0; Semenov V, 2004, SCIENCE, V305, P978, DOI 10.1126/science.1100638; Tchekhovskoy A, 2008, MON NOT R ASTRON SOC, V388, P551, DOI 10.1111/j.1365-2966.2008.13425.x; Yunes N, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.122003	14	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					908	909		10.1126/science.1194182	http://dx.doi.org/10.1126/science.1194182			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724622	Green Submitted			2022-12-28	WOS:000281084800020
J	Simmons, NB; Seymour, KL; Habersetzer, J; Gunnell, GF				Simmons, Nancy B.; Seymour, Kevin L.; Habersetzer, Joerg; Gunnell, Gregg F.			Inferring echolocation in ancient bats	NATURE			English	Letter							HYOID REGION; EVOLUTION; MAMMALS		[Simmons, Nancy B.] Amer Museum Nat Hist, New York, NY 10024 USA; [Seymour, Kevin L.] Royal Ontario Museum, Toronto, ON M5S 2C6, Canada; [Habersetzer, Joerg] Forschungsinst Senckenberg, D-60325 Frankfurt, Germany; [Gunnell, Gregg F.] Univ Michigan, Museum Paleontol, Ann Arbor, MI 48109 USA	American Museum of Natural History (AMNH); Royal Ontario Museum; Senckenberg Gesellschaft fur Naturforschung (SGN); University of Michigan System; University of Michigan	Simmons, NB (corresponding author), Amer Museum Nat Hist, Cent Pk W & 79th St, New York, NY 10024 USA.	simmons@amnh.org		Simmons, Nancy B./0000-0001-8807-7499				[Anonymous], 1987, AM MUS NOVIT; FENTON MB, 1984, Q REV BIOL, V59, P33, DOI 10.1086/413674; Griffiths T.A., 1992, AM MUS NOVIT, V3041, P1; Griffiths Thomas A., 1994, American Museum Novitates, V3090, P1; HABERSETZER J, 1992, NATURWISSENSCHAFTEN, V79, P462, DOI 10.1007/BF01139198; Mason MJ, 2006, J MORPHOL, V267, P678, DOI 10.1002/jmor.10430; Moss CF, 2001, J ACOUST SOC AM, V110, P2207, DOI 10.1121/1.1398051; NOVACEK MJ, 1985, NATURE, V315, P140, DOI 10.1038/315140a0; Simmons NB, 2008, NATURE, V451, P818, DOI 10.1038/nature06549; Simmons NB, 1998, B AM MUS NAT HIST, P1; Sprague JM, 1944, AM J ANAT, V74, P175, DOI 10.1002/aja.1000740203; Sprague JM, 1943, AM J ANAT, V72, P385, DOI 10.1002/aja.1000720304; Veselka N, 2010, NATURE, V463, P939, DOI 10.1038/nature08737	13	27	27	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					E8	E9		10.1038/nature09219	http://dx.doi.org/10.1038/nature09219			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20724993	Bronze			2022-12-28	WOS:000281030300048
J	Bendavid, E; Miller, G				Bendavid, Eran; Miller, Grant			The US Global Health Initiative Informing Policy With Evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Bendavid, Eran; Miller, Grant] Stanford Univ, Div Gen Internal Med, Ctr Hlth Policy, Stanford, CA 94305 USA; [Bendavid, Eran; Miller, Grant] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; [Miller, Grant] Natl Bur Econ Res, Cambridge, MA 02138 USA	Stanford University; Stanford University; National Bureau of Economic Research	Bendavid, E (corresponding author), Stanford Univ, Div Gen Internal Med, Ctr Hlth Policy, 251 Campus Dr X332, Stanford, CA 94305 USA.	ebd@stanford.edu		Miller, Grant/0000-0003-3191-2558	NIAID NIH HHS [K01 AI084582, K01-AI084582] Funding Source: Medline; NIA NIH HHS [P30 AG017253, P30-AG017253] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI084582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG017253] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], JB CLARK MED; Easterly W., 2002, ELUSIVE QUEST GROWTH; Easterly W, 2009, J ECON LIT, V47, P373, DOI 10.1257/jel.47.2.373; Garrett L, 2007, FOREIGN AFF, V86, P14; King G, 2009, LANCET, V373, P1447, DOI 10.1016/S0140-6736(09)60239-7; Miguel E, 2004, ECONOMETRICA, V72, P159, DOI 10.1111/j.1468-0262.2004.00481.x; *PEPFAR, PEPFARS 5 YEAR STRAT; *WHIT HOUS, GLOB HLTH IN WHIT HO; IMPLEMENTATION GLOBA	9	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					791	792		10.1001/jama.2010.1189	http://dx.doi.org/10.1001/jama.2010.1189			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639SB	20716743	Green Accepted			2022-12-28	WOS:000280993700028
J	Reichen, J				Reichen, Juerg			Telaprevir combination therapy induced a sustained virologic response in nonresponsive chronic HCV infection	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Clin Visceral Surg & Med, Bern, Switzerland	University of Bern; University Hospital of Bern	Reichen, J (corresponding author), Univ Clin Visceral Surg & Med, Bern, Switzerland.							Hezode C, 2009, NEW ENGL J MED, V360, P1839, DOI 10.1056/NEJMoa0807650; Kuntzen T, 2008, HEPATOLOGY, V48, P1769, DOI 10.1002/hep.22549	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-7	10.7326/0003-4819-153-4-201008170-02007	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713786				2022-12-28	WOS:000280973000033
J	Whittaker, W; Sutton, M; Maxwell, M; Munoz-Arroyo, R; MacDonald, S; Power, A; Smith, M; Wilson, P; Morrison, J				Whittaker, Will; Sutton, Matt; Maxwell, Margaret; Munoz-Arroyo, Rosalia; MacDonald, Sara; Power, Andrew; Smith, Michael; Wilson, Philip; Morrison, Jill			Predicting which people with psychosocial distress are at risk of becoming dependent on state benefits: analysis of routinely available data	BRITISH MEDICAL JOURNAL			English	Article							SICKNESS CERTIFICATION SYSTEM; GENERAL-PRACTITIONERS; UNITED-KINGDOM; PRIMARY-CARE; INCAPACITY	Objectives To examine whether there was significant variation in levels of claiming incapacity benefit across general practices. To establish whether it is possible to identify people with mental health problems who are more at risk of becoming dependent on state benefits for long term health problems based on their general practice consulting behaviour. Design Interrogation of routinely available data in the Scottish Health Surveys and the British Household Panel Survey. Setting Scotland and the United Kingdom. Participants Respondents to the Scottish Health Surveys in 1995, 1998, and 2003 (7932, 12 939 and 11 472 respondents, respectively). Respondents to the British Household Panel Survey, 1991-2007 (more than 5000 households). Main outcome measures Intracluster correlation coefficient for probability of work incapacity by general practice. Caseness according to the general health questionnaire (GHQ-12) and frequency of consultation with general practitioner in years before and after starting to claim incapacity benefit. Results There was a small and non-significant amount of variation across general practices in Scotland in rate of claims for incapacity benefit after adjustment for other explanatory variables (intracluster correlation coefficient 0.01, P=0.135). There was a significant increase in rates of GHQ-12 caseness from two years before the start of claiming incapacity benefit (odds ratio 1.6, 95% confidence interval 1.3 to 1.9) and an increase in frequent consultation with a general practitioner from three years before the start of claiming incapacity benefit (1.8, 1.3 to 2.4). People with GHQ-12 caseness showed a significant increase in frequent consultations with a general practitioner from two years before the start of claiming incapacity benefit (2.1, 1.4 to 3.2). Conclusions There was no variation in levels of claiming incapacity benefit across general practices in Scotland after adjustment for differences in population characteristics and so initiatives targeted at practices with high levels are unlikely to be effective. People with mental health problems who are likely to have problems remaining in work can be identified up to three years before they transit on to long term benefits related to ill health.	[MacDonald, Sara; Wilson, Philip; Morrison, Jill] Univ Glasgow, Fac Med, Div Community Based Sci, Glasgow G12 9LX, Lanark, Scotland; [Whittaker, Will; Sutton, Matt] Univ Manchester, Sch Community Based Med, Hlth Sci Res Grp, Manchester M13 9PL, Lancs, England; [Maxwell, Margaret] Univ Stirling, Nursing Midwifery & AHP Res Unit, Stirling FK9 4LA, Scotland; [Munoz-Arroyo, Rosalia] NHS Natl Serv Scotland, Informat Serv Div, Area 122A, Edinburgh EH12 9EB, Midlothian, Scotland; [Power, Andrew] Victoria Infirm, Pharm & Prescribing Support Unit, Glasgow G42 9TT, Lanark, Scotland; [Smith, Michael] Gartnavel Royal Hosp, Div Community Based Sci, Dept Psychol Med, Glasgow G12 0XH, Lanark, Scotland	University of Glasgow; University of Manchester; University of Stirling; NHS National Services Scotland; Gartnavel Royal Hospital	Morrison, J (corresponding author), Univ Glasgow, Fac Med, Div Community Based Sci, Glasgow G12 9LX, Lanark, Scotland.	jmm4y@clinmed.gla.ac.uk	Wilson, Philip/V-6519-2019; Whittaker, William/T-9992-2019	Wilson, Philip/0000-0002-4123-8248; Whittaker, William/0000-0003-2530-0360; Sutton, Matt/0000-0002-6635-2127; Maxwell, Margaret/0000-0003-3318-9500	Chief Scientist Office of the Scottish Government [CZH/4/400]; Chief Scientist Office [NMAHP1, CZH/4/400] Funding Source: researchfish	Chief Scientist Office of the Scottish Government; Chief Scientist Office	This study was funded by the Chief Scientist Office of the Scottish Government (No CZH/4/400).	Anyadike-Danes M, 2008, FISC STUD, V29, P415, DOI 10.1111/j.1475-5890.2008.00080.x; Black DC, 2008, WORKING HLTH TOMORRO; Bland JM, 1996, BRIT MED J, V313, P41, DOI 10.1136/bmj.313.7048.41; Carstairs V., 1991, DEPRIVATION HLTH SCO; *DEP SOC DEV, 2009, HEALTHC PROF; *DEP WORK PENS, 2009, EMPL SUPP ALL; *DIR, 2010, STAT FITN WORK FIT N; Freud D., 2007, REDUCING DEPENDENCY; Gill D, 1999, J PSYCHOSOM RES, V47, P115, DOI 10.1016/S0022-3999(98)00118-4; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Hardy JN, 2004, BRIT MED J, V328, P461, DOI 10.1136/bmj.328.7437.461; Heywood PL, 1998, FAM PRACT, V15, P198, DOI 10.1093/fampra/15.3.198; Hussey S, 2004, BRIT MED J, V328, P88, DOI 10.1136/bmj.37949.656389.EE; KARLSSON H, 1995, GEN HOSP PSYCHIAT, V17, P19, DOI 10.1016/0163-8343(94)00059-M; Luciano JV, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X483139; McVicar D., 2008, APPL ECON, V40, P1; Moncrieff J, 2000, J PUBLIC HEALTH MED, V22, P59, DOI 10.1093/pubmed/22.1.59; Roope R, 2009, OCCUP MED-OXFORD, V59, P580, DOI 10.1093/occmed/kqp147; Scottish Government, 2009, SCOTT HLTH SURV; Shiels C, 2004, BRIT J GEN PRACT, V54, P86; Skrondal A., 2004, GEN LATENT VARIABLE; *STAT, 2008, LONG PAN DAT REF MAN; Taylor MF, 2001, BRIT HOUSEHOLD PANEL, VA; Waddell G., 2006, IS WORK GOOD YOUR HL	24	14	14	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 17	2010	341								c3838	10.1136/bmj.c3838	http://dx.doi.org/10.1136/bmj.c3838			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642KQ	20716597	Green Submitted, Green Accepted, hybrid, Green Published			2022-12-28	WOS:000281212500003
J	Coste, B; Mathur, J; Schmidt, M; Earley, TJ; Ranade, S; Petrus, MJ; Dubin, AE; Patapoutian, A				Coste, Bertrand; Mathur, Jayanti; Schmidt, Manuela; Earley, Taryn J.; Ranade, Sanjeev; Petrus, Matt J.; Dubin, Adrienne E.; Patapoutian, Ardem			Piezo1 and Piezo2 Are Essential Components of Distinct Mechanically Activated Cation Channels	SCIENCE			English	Article							CURRENTS; NEURONS; PROTEIN; TRANSDUCTION	Mechanical stimuli drive many physiological processes, including touch and pain sensation, hearing, and blood pressure regulation. Mechanically activated (MA) cation channel activities have been recorded in many cells, but the responsible molecules have not been identified. We characterized a rapidly adapting MA current in a mouse neuroblastoma cell line. Expression profiling and RNA interference knockdown of candidate genes identified Piezo1 (Fam38A) to be required for MA currents in these cells. Piezo1 and related Piezo2 (Fam38B) are vertebrate multipass transmembrane proteins with homologs in invertebrates, plants, and protozoa. Overexpression of mouse Piezo1 or Piezo2 induced two kinetically distinct MA currents. Piezos are expressed in several tissues, and knockdown of Piezo2 in dorsal root ganglia neurons specifically reduced rapidly adapting MA currents. We propose that Piezos are components of MA cation channels.	[Coste, Bertrand; Schmidt, Manuela; Earley, Taryn J.; Ranade, Sanjeev; Dubin, Adrienne E.; Patapoutian, Ardem] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Mathur, Jayanti; Petrus, Matt J.; Patapoutian, Ardem] Novartis Res Fdn GNF, Genom Inst, San Diego, CA 92121 USA	Scripps Research Institute; Novartis	Patapoutian, A (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	ardem@scripps.edu		Coste, Bertrand/0000-0002-0163-2494; Ranade, Sanjeev/0000-0001-8601-3563; Schmidt, Manuela/0000-0003-1972-3519	NIH [DE016927, NS046303]; Novartis Research Foundation; American Heart Association; German Academic Exchange Service (DAAD) [D/07/41089]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046303] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis Research Foundation; American Heart Association(American Heart Association); German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors gratefully acknowledge H. Hu for help in cloning Piezo2, J. Walker for contributing to microarray experiments, S. Batalov for help in bioinformatics analysis, K. Spencer for help with imaging, and N. Hong and U. Muller for comments on the manuscript and helpful discussions. This work was supported by grants from NIH (DE016927 and NS046303) and the Novartis Research Foundation. B. C. is the recipient of an American Heart Association postdoctoral fellowship; M. S. is the recipient of a German Academic Exchange Service (DAAD, D/07/41089) fellowship. A provisional patent has been filed by TSRI and GNF that claims methods of screening for molecules that modulate Piezo-dependent ion channel activities. The Piezo1 and Piezo2 sequences used in the paper have been deposited in GenBank under accession numbers HQ215520 and HQ215521, respectively.	Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Besch SR, 2002, PFLUG ARCH EUR J PHY, V445, P161, DOI 10.1007/s00424-002-0903-0; Burnstock G, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-69; Chalfie M, 2009, NAT REV MOL CELL BIO, V10, P44, DOI 10.1038/nrm2595; Cho H, 2006, EUR J NEUROSCI, V23, P2543, DOI 10.1111/j.1460-9568.2006.04802.x; COREY DP, 1979, BIOPHYS J, V26, P499, DOI 10.1016/S0006-3495(79)85267-4; Coste B, 2007, J GEN PHYSIOL, V129, P57, DOI 10.1085/jgp.200609665; Drew LJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000515; Drew LJ, 2004, J PHYSIOL-LONDON, V556, P691, DOI 10.1113/jphysiol.2003.058693; Drew LJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-12-j0001.2002; Earley S, 2004, CIRC RES, V95, P922, DOI 10.1161/01.RES.0000147311.54833.03; GOLDSTEIN ME, 1991, J NEUROSCI RES, V30, P92, DOI 10.1002/jnr.490300111; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hanlon MR, 2002, BIOCHEMISTRY-US, V41, P2886, DOI 10.1021/bi0119565; Hao Jizhe, 2009, V2, P51, DOI 10.1007/978-1-4020-8716-5_3; Hu J, 2006, J PHYSIOL-LONDON, V577, P815, DOI 10.1113/jphysiol.2006.117648; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; IWATSUKI K, 1995, COMP BIOCHEM PHYS A, V110, P167, DOI 10.1016/0300-9629(94)00125-D; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Lawson SN, 2002, EXP PHYSIOL, V87, P239, DOI 10.1113/eph8702350; LAWSON SN, 1984, J COMP NEUROL, V228, P263, DOI 10.1002/cne.902280211; Lewin GR, 2004, J NEUROBIOL, V61, P30, DOI 10.1002/neu.20078; McCarter GC, 1999, NEUROSCI LETT, V273, P179, DOI 10.1016/S0304-3940(99)00665-5; McHugh BJ, 2010, J CELL SCI, V123, P51, DOI 10.1242/jcs.056424; Monshausen GB, 2009, TRENDS CELL BIOL, V19, P228, DOI 10.1016/j.tcb.2009.02.005; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Rodat-Despoix L, 2009, PFLUG ARCH EUR J PHY, V458, P179, DOI 10.1007/s00424-008-0632-0; SANN H, 1995, CELL TISSUE RES, V282, P155, DOI 10.1007/BF00319142; Satoh K, 2006, BRAIN RES, V1108, P19, DOI 10.1016/j.brainres.2006.06.050; Schmidt M, 2009, NEURON, V64, P498, DOI 10.1016/j.neuron.2009.09.030; Sharif-Naeini R, 2009, CELL, V139, P587, DOI 10.1016/j.cell.2009.08.045; Tucker SJ, 1998, CURR OPIN NEUROBIOL, V8, P316, DOI 10.1016/S0959-4388(98)80055-X; Wetzel C, 2007, NATURE, V445, P206, DOI 10.1038/nature05394	35	1332	1396	75	473	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	2010	330	6000					55	60		10.1126/science.1193270	http://dx.doi.org/10.1126/science.1193270			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656KW	20813920	Green Accepted			2022-12-28	WOS:000282334500031
J	Gibson, PG; McDonald, VM; Marks, GB				Gibson, Peter G.; McDonald, Vanessa M.; Marks, Guy B.			Asthma in older adults	LANCET			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIALS; DRY POWDER INHALERS; QUALITY-OF-CARE; SMOKING-CESSATION; ELDERLY-PATIENTS; GERIATRIC ASSESSMENT; PRACTICE GUIDELINES; EXTERNAL VALIDITY; SELF-MANAGEMENT	Asthma in older people is common and is characterised by underdiagnosis and undertreatment. Ageing is associated with unique issues that modify expression, recognition, and treatment of the disease. In particular, asthma and chronic obstructive pulmonary disease (COPD) both overlap and converge in older people. This concurrence, together with absence of precise diagnostic methods, makes diagnosis complex. A multidimensional assessment that addresses airway problems, comorbidities, risk factors, and management skills will draw attention to key needs for intervention. Increased attention to the complications of asthma and obstructive airway disease in older people is needed, specifically to develop effective systems of care, appropriate clinical practice guidelines, and a research agenda that delivers improved health outcomes.	[Gibson, Peter G.; McDonald, Vanessa M.; Marks, Guy B.] Univ Newcastle, Fac Hlth, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [McDonald, Vanessa M.] Univ Newcastle, Fac Hlth, Sch Nursing & Midwifery, Callaghan, NSW 2308, Australia; [Gibson, Peter G.; McDonald, Vanessa M.] John Hunter Hosp, Hunter Med Res Inst, Dept Resp & Sleep Med, New Lambton, NSW, Australia; [Gibson, Peter G.; Marks, Guy B.] Woolcock Inst Med Res, Sydney, NSW, Australia; [Marks, Guy B.] Liverpool Hosp, Dept Resp Med, Sydney, NSW, Australia; [Marks, Guy B.] Univ New S Wales, S Western Sydney Clin Sch, Sydney, NSW, Australia	University of Newcastle; University of Newcastle; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; University of Sydney; Woolcock Institute of Medical Research; Liverpool Hospital; University of New South Wales Sydney	Gibson, PG (corresponding author), Univ Newcastle, Fac Hlth, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia.	peter.gibson@newcastle.edu.au	Marks, Guy B./F-5058-2013; MCDONALD, VANESSA/AAQ-1845-2020; gibson, peter/G-6194-2014	Marks, Guy B./0000-0002-8976-8053; MCDONALD, VANESSA/0000-0001-9890-3408; gibson, peter/0000-0001-5865-489X	NHMRC; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Pharmaxis; National Health and Medical Research Council (NHMRC) Centre for Respiratory and Sleep Medicine; Australian Department of Health and Ageing through the Australian Institute of Health and Welfare	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Pharmaxis; National Health and Medical Research Council (NHMRC) Centre for Respiratory and Sleep Medicine(National Health and Medical Research Council (NHMRC) of Australia); Australian Department of Health and Ageing through the Australian Institute of Health and Welfare(Australian GovernmentDepartment of Health & Ageing)	PGG holds an NHMRC Practitioner Fellowship. He has participated in educational symposia funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis, and has participated in studies funded by Pharmaxis and GlaxoSmithKline. VMM is supported by the National Health and Medical Research Council (NHMRC) Centre for Respiratory and Sleep Medicine. She has also received honorariums for participation in educational meetings from AstraZeneca and Novartis. G BM is on an advisory board for Novartis and has given lectures at educational seminars sponsored by AstraZeneca and Boehringer Ingelheim. He has undertaken contract research for GlaxoSmithKline. The Australian Centre for Asthma Monitoring, of which he is Director, is funded by the Australian Department of Health and Ageing through the Australian Institute of Health and Welfare. He is the recipient of a Practitioner Fellowship from the Australian National Health and Medical Research Council.	Abdullah Abu Saleh M, 2008, BMC Geriatr, V8, P25, DOI 10.1186/1471-2318-8-25; Allen SC, 2009, INT J CLIN PRACT, V63, P1150, DOI 10.1111/j.1742-1241.2009.02060.x; Allen SC, 2009, AGE AGEING, V38, P548, DOI 10.1093/ageing/afp110; Andrews KL, 2009, HEALTH PROMOT J AUST, V20, P146, DOI 10.1071/HE09146; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; *AUSTR CTR ASTHM M, 2005, HLTH CAR EXP BURD DI; *AUSTR CTR ASTHM M, 2009, BURD DIS DUE ASTHM A; Australian Centre for Asthma Monitoring, 2008, ASTHM AUSTR 2008; Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; Banerji A, 2006, J AM GERIATR SOC, V54, P48, DOI 10.1111/j.1532-5415.2005.00563.x; Barnard Amanda, 2005, Med J Aust, V183, pS41; Barua P, 2005, DRUG AGING, V22, P1029, DOI 10.2165/00002512-200522120-00004; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; Beasley R, 2009, LANCET, V374, P670, DOI 10.1016/S0140-6736(09)61541-5; Bellia V, 2004, AM J RESP CRIT CARE, V170, P100, DOI 10.1164/ajrccm.170.1.962; Bellia V, 2009, EUR RESPIR MONOGR, P56, DOI 10.1183/1025448x.00043005; Bellia V, 2003, EUR RESPIR J, V21, p21S, DOI 10.1183/09031936.03.00402303; Bellia V, 2003, CHEST, V123, P1066, DOI 10.1378/chest.123.4.1066; Bellia V, 2007, CHEST, V132, P1175, DOI 10.1378/chest.06-2824; Berend Norbert, 2005, Med J Aust, V183, pS28; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Board M, 2006, INT J CLIN PRACT, V60, P510, DOI 10.1111/j.1368-5031.2006.00933.x; Borrelli B, 2010, ADDICTION, V105, P1100, DOI 10.1111/j.1360-0443.2010.02900.x; Boulet LP, 2009, EUR RESPIR J, V33, P897, DOI 10.1183/09031936.00121308; Boulet LP, 2003, RESP MED, V97, P739, DOI 10.1053/rmed.2003.1491; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Bozek A, 2010, J ASTHMA, V47, P162, DOI 10.3109/02770900903497204; Brown DW, 2004, AM J PREV MED, V26, P112, DOI 10.1016/j.amepre.2003.10.004; Buist AS, 2006, AM J RESP CRIT CARE, V174, P1075, DOI 10.1164/rccm.200510-1606OC; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Cassino C, 2000, AM J RESP CRIT CARE, V162, P1423, DOI 10.1164/ajrccm.162.4.9912140; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529, DOI 10.1164/ajrccm.155.5.9154853; Chotirmall SH, 2009, J AM GERIATR SOC, V57, P901, DOI 10.1111/j.1532-5415.2009.02216.x; Cosio BG, 2009, EUR RESPIR MONOGR, P205, DOI 10.1183/1025448x.00043014; Cote CG, 2008, EUR RESPIR J, V31, P571, DOI 10.1183/09031936.00104507; Craig BM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-144; De Martinis M, 2005, FEBS LETT, V579, P2035, DOI 10.1016/j.febslet.2005.02.055; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Gadoury MA, 2005, EUR RESPIR J, V26, P853, DOI 10.1183/09031936.05.00093204; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; GIBSON PG, 1995, CHEST, V107, P1003, DOI 10.1378/chest.107.4.1003; Godtfredsen NS, 2008, EUR RESPIR J, V32, P844, DOI 10.1183/09031936.00160007; Goeman DP, 2007, DRUG AGING, V24, P381, DOI 10.2165/00002512-200724050-00003; Goeman Dianne P, 2005, Med J Aust, V183, pS26; Goeman DP, 2009, MED J AUSTRALIA, V191, P113, DOI 10.5694/j.1326-5377.2009.tb02708.x; Harding SM, 2000, AM J RESP CRIT CARE, V162, P34, DOI 10.1164/ajrccm.162.1.9907072; Hargreave FE, 2009, CLIN EXP ALLERGY, V39, P1652, DOI 10.1111/j.1365-2222.2009.03321.x; HARGREAVE FE, 2006, CLIN EXP ALLERGY, V68, P1415; Harrington JJ, 2007, CLIN CHEST MED, V28, P673, DOI 10.1016/j.ccm.2007.07.002; Hewitt J, 2005, THORAX, V60, P331, DOI 10.1136/thx.2004.029579; Horne R, 2006, CHEST, V130, p65S, DOI 10.1378/chest.130.1_suppl.65S; Huang TT, 2009, J ADV NURS, V65, P348, DOI 10.1111/j.1365-2648.2008.04874.x; Incalzi RA, 2009, EUR RESPIR MONOGR, P35; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Jorgensen NR, 2007, RESP MED, V101, P177, DOI 10.1016/j.rmed.2006.03.029; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Kerr S, 2006, HEALTH SOC CARE COMM, V14, P572, DOI 10.1111/j.1365-2524.2006.00659.x; Lavorini F, 2008, RESP MED, V102, P593, DOI 10.1016/j.rmed.2007.11.003; Lehmann S, 2004, RESP MED, V98, P1071, DOI 10.1016/j.rmed.2004.03.019; Luks VP, 2010, EUR RESPIR J, V36, P255, DOI 10.1183/09031936.00165109; Marks GB, 2009, MED J AUSTRALIA, V191, P197, DOI 10.5694/j.1326-5377.2009.tb02751.x; Marsh SE, 2008, THORAX, V63, P761, DOI 10.1136/thx.2007.089193; McDonald VM, 2009, ALLERGY FRONTIERS: DIAGNOSIS AND HEALTH ECONOMICS, VOL 4, P475, DOI 10.1007/978-4-431-98349-1_26; McDonald VM, 2005, MED J AUSTRALIA, V182, P250, DOI 10.5694/j.1326-5377.2005.tb06680.x; MCDONALD VM, AGE AGEING IN PRESS; Meyer KC, 1998, MECH AGEING DEV, V104, P169, DOI 10.1016/S0047-6374(98)00065-7; Molander L, 2001, CLIN PHARMACOL THER, V69, P57, DOI 10.1067/mcp.2001.113181; Morgan R, 1997, BRIT J GEN PRACT, V47, P427; Navaratnam P, 2008, J AM GERIATR SOC, V56, P1312, DOI 10.1111/j.1532-5415.2008.01767.x; Oreopoulos A, 2009, CLIN GERIATR MED, V25, P643, DOI 10.1016/j.cger.2009.07.005; Orimo Hajime, 2006, Nihon Ronen Igakkai Zasshi, V43, P27; Patel R, 2009, J ASTHMA, V46, P30, DOI 10.1080/02770900802460563; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Plaza V, 2000, RESPIRATION, V67, P65, DOI 10.1159/000029465; Quinet P., 2010, Annals of Physical and Rehabilitation Medicine, V53, P69, DOI 10.1016/j.rehab.2009.11.001; Rabell-Santacana V, 2008, ARCH BRONCONEUMOL, V44, P519, DOI 10.1016/S1579-2129(08)60097-X; ROEBUCK J, 1979, J SOC HIST, V12, P416, DOI 10.1353/jsh/12.3.416; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; Savale L, 2009, AM J RESP CRIT CARE, V179, P566, DOI 10.1164/rccm.200809-1398OC; Schneider A, 2006, PATIENT EDUC COUNS, V61, P292, DOI 10.1016/j.pec.2005.04.008; Sharma G, 2006, CLIN INTERV AGING, V1, P253, DOI 10.2147/ciia.2006.1.3.253; Shirtcliffe P, 2012, INTERN MED J, V42, P83, DOI 10.1111/j.1445-5994.2010.02238.x; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Terry DF, 2008, J GERONTOL A-BIOL, V63, P809, DOI 10.1093/gerona/63.8.809; Thomas M, 2001, BRIT MED J, V322, P1098, DOI 10.1136/bmj.322.7294.1098; Thomson NC, 2005, CURR OPIN ALLERGY CL, V5, P57, DOI 10.1097/00130832-200502000-00011; Travers J, 2007, RESP MED, V101, P1313, DOI 10.1016/j.rmed.2006.10.011; UN, 2002, 2 WORLD ASSEMBLY AGE; Vitry AI, 2008, MED J AUSTRALIA, V189, P360, DOI 10.5694/j.1326-5377.2008.tb02079.x; Walters JA, 2008, THORAX, V63, P408, DOI 10.1136/thx.2007.082859; Wang JJ, 2009, OPHTHALMOLOGY, V116, P652, DOI 10.1016/j.ophtha.2008.12.001; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Whitson HE, 2006, J AM GERIATR SOC, V54, P466, DOI 10.1111/j.1532-5415.2005.00641.x; Wieshammer S, 2008, RESPIRATION, V75, P18, DOI 10.1159/000109374; Wilper AP, 2008, ANN INTERN MED, V149, P170, DOI 10.7326/0003-4819-149-3-200808050-00006; Wood LG, 2009, PHARMACOL THERAPEUT, V123, P37, DOI 10.1016/j.pharmthera.2009.03.015; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	105	277	287	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					803	813		10.1016/S0140-6736(10)61087-2	http://dx.doi.org/10.1016/S0140-6736(10)61087-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	650EC	20816547				2022-12-28	WOS:000281831000032
J	Lim, WA; Pawson, T				Lim, Wendell A.; Pawson, Tony			Phosphotyrosine Signaling: Evolving a New Cellular Communication System	CELL			English	Article							PROTEIN-TYROSINE PHOSPHATASES; MONOSIGA-BREVICOLLIS; ANIMAL DEVELOPMENT; EVOLUTION; DICTYOSTELIUM; KINASE; DOMAIN; METAZOAN; GENOME; SH2		[Lim, Wendell A.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA; [Lim, Wendell A.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Pawson, Tony] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Pawson, Tony] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Lim, WA (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA.	lim@cmp.ucsf.edu; pawson@lunenfeld.ca	Pawson, Tony J/E-4578-2013		Howard Hughes Medical Institute; National Institutes of health [GM55040, GM62583, GM081879, EY016546]; Packard Foundation; National Science Foundation Synthetic Biology Engineering Research Center; Canadian Institutes for Health Research [MOP-6849]; Genome Canada; Canadian Cancer Society Research Institute; NATIONAL EYE INSTITUTE [PN2EY016546, PN1EY016546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062583, R01GM055040, P50GM081879] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institutes of health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Packard Foundation(The David & Lucile Packard Foundation); National Science Foundation Synthetic Biology Engineering Research Center; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Genome Canada(Genome Canada); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. Pincus, B. Mayer, P. Beltrao, O. Hoeller, R. Linding, G. Superti-Furga, N.King, N.Helman, L. Holt, A. Horwitz, T. Miller, G. Manning, T. Hunter, D. Morgan, J. Williams, H. Bourne, and I. Ernberg for helpful comments. This work was supported by the Howard Hughes Medical Institute (W.L.), the National Institutes of health (GM55040, GM62583, GM081879, and EY016546-W.L.), the Packard Foundation (W.L.), the National Science Foundation Synthetic Biology Engineering Research Center (W. L.), the Canadian Institutes for Health Research (T.P.-MOP-6849), Genome Canada (T.P.), and the Canadian Cancer Society Research Institute (T.P.).	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Alwayn V., 2004, OPTICAL NETWORK DESI; Bhattacharyya RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI 10.1146/annurev.biochem.75.103004.142710; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; Dengl S, 2009, J MOL BIOL, V389, P211, DOI 10.1016/j.jmb.2009.04.016; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Jin J, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000546; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Kay RR, 1997, CURR BIOL, V7, pR723, DOI 10.1016/S0960-9822(06)00366-6; Kennelly PJ, 2001, CHEM REV, V101, P2291, DOI 10.1021/cr0002543; Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838; King N, 2004, DEV CELL, V7, P313, DOI 10.1016/j.devcel.2004.08.010; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617; Langenick J, 2008, J CELL SCI, V121, P3524, DOI 10.1242/jcs.036798; Lee DC, 2009, TRENDS BIOCHEM SCI, V34, P351, DOI 10.1016/j.tibs.2009.03.003; Li WQ, 2009, BIOCHEMISTRY-US, V48, P5180, DOI 10.1021/bi9000672; Lim WA, 2010, NAT REV MOL CELL BIO, V11, P393, DOI 10.1038/nrm2904; Manning G, 2008, P NATL ACAD SCI USA, V105, P9674, DOI 10.1073/pnas.0801314105; Moniakis J, 2001, GENE DEV, V15, P687, DOI 10.1101/gad.871001; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; Peisajovich SG, 2010, SCIENCE, V328, P368, DOI 10.1126/science.1182376; Pincus D, 2008, P NATL ACAD SCI USA, V105, P9680, DOI 10.1073/pnas.0803161105; Rokas A, 2008, ANNU REV GENET, V42, P235, DOI 10.1146/annurev.genet.42.110807.091513; SCHIEVEN G, 1986, SCIENCE, V231, P390, DOI 10.1126/science.2417318; Srivastava M, 2010, NATURE, V466, P720, DOI 10.1038/nature09201; Sugden C, 2010, J BIOL CHEM, V285, P22925, DOI 10.1074/jbc.M110.139733; Tan CSH, 2009, SCIENCE, V325, P1686, DOI 10.1126/science.1174301; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4	31	244	249	1	34	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5					661	667		10.1016/j.cell.2010.08.023	http://dx.doi.org/10.1016/j.cell.2010.08.023			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813250	Bronze, Green Accepted			2022-12-28	WOS:000281523200005
J	Akech, S; Ledermann, H; Maitland, K				Akech, Samuel; Ledermann, Hannah; Maitland, Kathryn			Choice of fluids for resuscitation in children with severe infection and shock: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CRITICALLY-ILL PATIENTS; HUMAN ALBUMIN; VOLUME EXPANSION; CIRCULATORY SHOCK; HYPOVOLEMIC SHOCK; RANDOMIZED-TRIAL; SEVERE MALARIA; SEVERE SEPSIS; SEPTIC SHOCK; SALINE	Objective To systemically review the evidence from clinical trials comparing the use of crystalloids and colloids for fluid resuscitation in children with severe infection. Data sources Medline (1950-2008), PubMed, the Cochrane Library, Embase (1980-2008), and reference lists. Eligibility criteria Published studies comparing fluid resuscitation with crystalloid or colloidal solutions in severe infectious illness in children aged >1 month to <= 12 years. Controlled trials and randomised controlled trials were separately selected by two unblinded investigators who also independently extracted data. Main outcome measures Efficacy in the treatment of shock, mortality, and reported adverse events. Results Nine trials fulfilled criteria, eight of which compared crystalloids with colloids. All trials were conducted in settings with poor resources and predominantly included patients with malaria or dengue haemorrhagic shock. None of the trials had mortality as a primary outcome. Three out of six studies that reported at least one death showed better survival in children resuscitated with colloids compared with crystalloids (Peto fixed odds ratio ranging from 0.18 (95% confidence interval 0.02 to 1.42) to 0.48 (0.06 to 3.99)). Studies contributing data on mortality had some methodological limitations so caution is recommended when interpreting this finding. Studies were heterogeneous so combined estimates were not calculated. The review was limited by inclusion of only published studies. Conclusions The current evidence on choice of fluids for resuscitation in children with infections is weak. While existing trials have provided important evidence in malaria and dengue, resuscitation in children with paediatric sepsis, for which colloids could theoretically be of benefit, has not been studied. The evidence from existing studies is not robust enough to make any definitive recommendations over the choice of resuscitation fluid and a definitive trial is required to address this.	[Akech, Samuel; Ledermann, Hannah; Maitland, Kathryn] Kenya Med Res Inst Wellcome Trust Programme, Ctr Geog Med Res Coast, Kilifi, Kenya; [Maitland, Kathryn] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Paediat, London W2 1PG, England; [Maitland, Kathryn] Univ London Imperial Coll Sci Technol & Med, Fac Med, Wellcome Trust Ctr Clin Trop Med, London W2 1PG, England	Kenya Medical Research Institute; Imperial College London; Imperial College London; University of London; London School of Hygiene & Tropical Medicine	Maitland, K (corresponding author), Kenya Med Res Inst Wellcome Trust Programme, Ctr Geog Med Res Coast, POB 230, Kilifi, Kenya.	kmaitland@kilifi.kemri-wellcome.org		Maitland, Kathryn/0000-0002-0007-0645	Wellcome Trust [084538]; Medical Research Council; Medical Research Council [G0601027, G0801439] Funding Source: researchfish; MRC [G0601027, G0801439] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded indirectly through programme support by the Wellcome Trust and Medical Research Council. SA is supported by a grant from the Wellcome Trust (No 084538). The Wellcome Trust had no role in the review and in the preparation of this manuscript.	Akech S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010021; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; ALDERSON P, 2000, COCHRANE DB SYST REV, V2; ALDERSON P, 2002, COCHRANE DB SYST REV, V1; Alpar EK, 2004, INJURY, V35, P500, DOI 10.1016/S0020-1383(03)00196-7; [Anonymous], 2008, REV MAN REVMAN COMP; BEARDS SC, 1994, CRIT CARE MED, V22, P600, DOI 10.1097/00003246-199404000-00015; Brierley J, 2008, PEDIATRICS, V122, P752, DOI 10.1542/peds.2007-1979; BUNN F, 2000, COCHRANE DB SYST REV, V2; BUNN F, 2008, COCHRANE DB SYST REV, V1; CARCILLO JA, 1991, JAMA-J AM MED ASSOC, V266, P1242, DOI 10.1001/jama.266.9.1242; Carcillo JA, 2002, CRIT CARE MED, V30, P1365, DOI 10.1097/00003246-200206000-00040; Carcillo JA, 2006, INTENS CARE MED, V32, P958, DOI 10.1007/s00134-006-0189-3; *CFRAD, 2001, UND SYST REV RES EFF; Cifra H, 2003, CRIT CARE SHOCK, V6, P95; Cole RP, 1999, BURNS, V25, P565; de Jonge E, 2001, CRIT CARE MED, V29, P1261, DOI 10.1097/00003246-200106000-00038; Deeks J J, 2003, Health Technol Assess, V7, piii; Dung NM, 1999, CLIN INFECT DIS, V29, P787, DOI 10.1086/520435; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; HAIBACH L, 1976, ANESTH ANALG REANIM, V33, P673; Han YY, 2003, PEDIATRICS, V112, P793, DOI 10.1542/peds.112.4.793; Haynes GR, 2003, EUR J ANAESTH, V20, P771, DOI 10.1097/00003643-200310000-00003; Haynes RB, 2005, BMJ-BRIT MED J, V330, P1179, DOI 10.1136/bmj.38446.498542.8F; Higgins JPT., 2008, COCHRANE HDB SYSTEMA, V1 edn; Hung NT, 2006, AM J TROP MED HYG, V74, P684, DOI 10.4269/ajtmh.2006.74.684; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kunz R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000012.pub2; Liberati A, 2006, INTERN EMERG MED, V1, P243, DOI 10.1007/BF02934748; Maitland K, 2005, CLIN INFECT DIS, V40, P538, DOI 10.1086/427505; Maitland K, 2005, BRIT J HAEMATOL, V128, P393, DOI 10.1111/j.1365-2141.2004.05312.x; Maitland Kathryn, 2003, Pediatr Crit Care Med, V4, P426, DOI 10.1097/01.PCC.0000090293.32810.4E; McKiernan CA, 2005, PEDIATR REV, V26, P451, DOI 10.1542/pir.26-12-451; Mecham Nancy, 2006, J Trauma Nurs, V13, P17; Nhan NT, 2001, CLIN INFECT DIS, V32, P204, DOI 10.1086/318479; Ochocka M, 1984, Pediatr Pol, V59, P873; Perel P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub3; POCKAJ BA, 1994, J IMMUNOTHER, V15, P22, DOI 10.1097/00002371-199401000-00003; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; RAHMAN O, 1988, J PEDIATR-US, V113, P654, DOI 10.1016/S0022-3476(88)80374-3; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; ROBERTS I, 2004, COCHRANE DB SYST REV, V4; Roberts JS, 1998, DRUGS, V55, P621, DOI 10.2165/00003495-199855050-00002; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sparrow A, 2002, EMERG MED J, V19, P114, DOI 10.1136/emj.19.2.114; Tanaka R, 1975, Masui, V24, P873; Upadhyay M, 2005, INDIAN PEDIATR, V42, P223; Veneman TF, 2004, WIEN KLIN WOCHENSCHR, V116, P305, DOI 10.1007/BF03040900; Vincent JL, 2006, BMJ-BRIT MED J, V333, P1029, DOI 10.1136/bmj.39029.490081.80; Vincent JL, 2004, CRIT CARE MED, V32, P2029, DOI 10.1097/01.CCM.0000142574.00425.E9; WEIS KH, 1983, ANAESTHESIST, V32, P488; Wiedermann CJ, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-1; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754; World Health Organization, 2000, MAN CHILD SER INF SE; World Health Organization, 2005, EM TRIAG ASS TREATM; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C	61	56	61	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2010	341								c4416	10.1136/bmj.c4416	http://dx.doi.org/10.1136/bmj.c4416			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647JV	20813823	Green Published, hybrid			2022-12-28	WOS:000281615700001
J	Jacquet, J; Pauly, D; Ainley, D; Holt, S; Dayton, P; Jackson, J				Jacquet, Jennifer; Pauly, Daniel; Ainley, David; Holt, Sidney; Dayton, Paul; Jackson, Jeremy			Seafood stewardship in crisis	NATURE			English	Editorial Material									[Jacquet, Jennifer; Pauly, Daniel] Univ British Columbia, Fisheries Ctr, Sea Around Us Project, Vancouver, BC V6T 1Z4, Canada; [Ainley, David] HT Harvey & Associates, Los Gatos, CA 95032 USA; [Dayton, Paul; Jackson, Jeremy] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92037 USA	University of British Columbia; University of California System; University of California San Diego; Scripps Institution of Oceanography	Jacquet, J (corresponding author), Univ British Columbia, Fisheries Ctr, Sea Around Us Project, Vancouver, BC V6T 1Z4, Canada.	j.jacquet@fisheries.ubc.ca	Pauly, Daniel Marc/AAY-2316-2021	Pauly, Daniel/0000-0003-3756-4793				Atkinson A, 2004, NATURE, V432, P100, DOI 10.1038/nature02996; Chuenpagdee R, 2003, FRONT ECOL ENVIRON, V1, P517; *FISH OC CAN, 2009, CAN ASS PAC HAK US C; lanelli J. N., 2009, ASSESSMENT WALLEYE P; *MAR STEW COUNC, 2010, PRINC CRIT SUST FISH	5	168	169	0	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					28	29		10.1038/467028a	http://dx.doi.org/10.1038/467028a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	645MB	20811437				2022-12-28	WOS:000281461200018
J	Peslier, AH; Woodland, AB; Bell, DR; Lazarov, M				Peslier, Anne H.; Woodland, Alan B.; Bell, David R.; Lazarov, Marina			Olivine water contents in the continental lithosphere and the longevity of cratons	NATURE			English	Article							UPPER-MANTLE BENEATH; THERMAL EVOLUTION; OXYGEN FUGACITY; VISCOSITY; HYDROGEN; GARNET; VATNAJOKULL; CALIBRATION; KIMBERLITE; SOLUBILITY	Cratons, the ancient cores of continents, contain the oldest crust and mantle on the Earth (>2 Gyr old)(1). They extend laterally for hundreds of kilometres, and are underlain to depths of 180-250 km by mantle roots that are chemically and physically distinct from the surrounding mantle(2-4). Forming the thickest lithosphere on our planet, they act as rigid keels isolated from the flowing asthenosphere(5); however, it has remained an open question how these large portions of the mantle can stay isolated for so long from mantle convection. Key physical properties thought to contribute to this longevity include chemical buoyancy due to high degrees of melt-depletion and the stiffness imparted by the low temperatures of a conductive thermal gradient(2,6,7). Geodynamic calculations, however, suggest that these characteristics are not sufficient to prevent the lithospheric mantle from being entrained during mantle convection over billions of years(6,7). Differences in water content are a potential source of additional viscosity contrast between cratonic roots and ambient mantle owing to the well-established hydrolytic weakening effect in olivine(8-10), the most abundant mineral of the upper mantle. However, the water contents of cratonic mantle roots have to date been poorly constrained. Here we show that olivine in peridotite xenoliths from the lithosphere-asthenosphere boundary region of the Kaapvaal craton mantle root are water-poor and provide sufficient viscosity contrast with underlying asthenosphere to satisfy the stability criteria required by geodynamic calculations(9). Our results provide a solution to a puzzling mystery of plate tectonics, namely why the oldest continents, in contrast to short-lived oceanic plates, have resisted recycling into the interior of our tectonically dynamic planet.	[Peslier, Anne H.] ESCG, Houston, TX 77058 USA; [Peslier, Anne H.] NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; [Woodland, Alan B.; Lazarov, Marina] Goethe Univ Frankfurt, Inst Geosci, D-60438 Frankfurt, Germany; [Bell, David R.] Arizona State Univ, Sch Earth & Space Explorat, Tempe, AZ 85287 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Goethe University Frankfurt; Arizona State University; Arizona State University-Tempe	Peslier, AH (corresponding author), ESCG, Mail Code JE23,2224 Bay Area Blvd, Houston, TX 77058 USA.	anne.h.peslier@nasa.gov	Peslier, Anne/F-3956-2010; Lazarov, Marina/A-9592-2010	Peslier, Anne/0000-0002-8152-8709; Lazarov, Marina/0000-0001-7522-1164	NSF [EAR0802652]	NSF(National Science Foundation (NSF))	We thank M. Kurosawa for providing unpublished mineral data so that we could recalculate pressure-temperature conditions for his samples. We also thank C.-T. Lee, Z.-X. A. Li, F. Niu and A. D. Brandon for discussions. Earlier versions of this manuscript were improved by the comments of D. E. James. This work was supported by NSF grant EAR0802652.	BAI Q, 1991, J GEOPHYS RES-SOLID, V96, P2441, DOI 10.1029/90JB01723; BAI Q, 1992, NATURE, V357, P672, DOI 10.1038/357672a0; Bali E, 2008, EARTH PLANET SC LETT, V268, P354, DOI 10.1016/j.epsl.2008.01.035; Bell DR, 2004, J PETROL, V45, P1539, DOI 10.1093/petrology/egh015; Bell DR, 2003, LITHOS, V71, P273, DOI 10.1016/S0024-4937(03)00117-8; BELL DR, 1995, AM MINERAL, V80, P465; Bell DR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000679; BELL DR, 1992, SCIENCE, V255, P1391, DOI 10.1126/science.255.5050.1391; Brey GP, 2008, J PETROL, V49, P3, DOI 10.1093/petrology/egm067; BREY GP, 1990, J PETROL, V31, P1353, DOI 10.1093/petrology/31.6.1353; CRAIG CH, 1986, EARTH PLANET SC LETT, V78, P420, DOI 10.1016/0012-821X(86)90008-7; Dixon JE, 2004, EARTH PLANET SC LETT, V222, P451, DOI 10.1016/j.epsl.2004.03.022; Eaton DW, 2009, LITHOS, V109, P1, DOI 10.1016/j.lithos.2008.05.009; Fleming K, 2007, PURE APPL GEOPHYS, V164, P751, DOI 10.1007/s00024-007-0187-6; Frost DJ, 2008, ANNU REV EARTH PL SC, V36, P389, DOI 10.1146/annurev.earth.36.031207.124322; Grant K, 2007, CONTRIB MINERAL PETR, V154, P15, DOI 10.1007/s00410-006-0177-1; GURNEY JJ, 1980, PHILOS T R SOC A, V297, P273, DOI 10.1098/rsta.1980.0215; Hirth G., 2000, GEOCHEM GEOPHY GEOSY, V1, DOI [10.1029/2000GC000048, DOI 10.1029/2000GC000048]; HIRTH G, 2004, GEOPHYS MONOGR SER, V118, P83; James DE, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000551; James DE, 2001, GEOPHYS RES LETT, V28, P2485, DOI 10.1029/2000GL012578; Ji SC, 2001, TECTONOPHYSICS, V341, P69, DOI 10.1016/S0040-1951(01)00191-3; JORDAN TH, 1978, NATURE, V274, P544, DOI 10.1038/274544a0; KESSON SE, 1989, CHEM GEOL, V78, P97, DOI 10.1016/0009-2541(89)90110-1; Kurosawa M, 1997, PHYS CHEM MINER, V24, P385, DOI 10.1007/s002690050052; KUROSAWA M., 1992, HIGH PRESSURE RES AP, P283; Larsen CF, 2005, EARTH PLANET SC LETT, V237, P548, DOI 10.1016/j.epsl.2005.06.032; Larson AM, 2006, GEOPHYS J INT, V167, P171, DOI 10.1111/j.1365-246X.2006.03005.x; Lazarov M, 2009, LITHOS, V112, P913, DOI 10.1016/j.lithos.2009.03.035; Libowitzky E, 1996, PHYS CHEM MINER, V23, P319, DOI 10.1007/BF00199497; MACKWELL SJ, 1985, J GEOPHYS RES-SOLID, V90, P1319, DOI 10.1029/JB090iB13p11319; Mibe K, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2005JB004125; Michaut C, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004464; Muller MR, 2009, LITHOS, V112, P93, DOI 10.1016/j.lithos.2009.06.023; O'Neill CJ, 2008, LITHOS, V102, P12, DOI 10.1016/j.lithos.2007.04.006; ONEILL HS, 1987, J PETROL, V28, P1169, DOI 10.1093/petrology/28.6.1169; ONEILL HSC, 1979, CONTRIB MINERAL PETR, V70, P59, DOI 10.1007/BF00371872; Peslier AH, 2008, GEOCHIM COSMOCHIM AC, V72, P2711, DOI 10.1016/j.gca.2008.03.019; POLLACK HN, 1986, EARTH PLANET SC LETT, V80, P175, DOI 10.1016/0012-821X(86)90031-2; Pollitz FF, 1998, SCIENCE, V280, P1245, DOI 10.1126/science.280.5367.1245; Rudnick RL, 1998, CHEM GEOL, V145, P395, DOI 10.1016/S0009-2541(97)00151-4; Sjoberg LE, 2000, J GEODYN, V29, P63, DOI 10.1016/S0264-3707(99)00061-7; Sleep NH, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000169; WALKER RJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1583, DOI 10.1016/0016-7037(89)90240-8; WEBB SAC, 1986, CONTRIB MINERAL PETR, V92, P471, DOI 10.1007/BF00374429; Woodland AB, 2003, EARTH PLANET SC LETT, V214, P295, DOI 10.1016/S0012-821X(03)00379-0; Yamamoto J, 2008, PHYS CHEM MINER, V35, P249, DOI 10.1007/s00269-008-0218-6; Yuan TL, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD008632	49	208	228	1	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2010	467	7311					78	U108		10.1038/nature09317	http://dx.doi.org/10.1038/nature09317			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811455				2022-12-28	WOS:000281461200038
J	Makde, RD; England, JR; Yennawar, HP; Tan, S				Makde, Ravindra D.; England, Joseph R.; Yennawar, Hemant P.; Tan, Song			Structure of RCC1 chromatin factor bound to the nucleosome core particle	NATURE			English	Article							CHROMOSOME CONDENSATION RCC1; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; NUCLEAR TRANSPORT; MITOTIC SPINDLE; BETA-GAMMA; RAN; DNA; COMPLEX; BINDING	The small GTPase Ran enzyme regulates critical eukaryotic cellular functions including nuclear transport and mitosis through the creation of a RanGTP gradient around the chromosomes. This concentration gradient is created by the chromatin-bound RCC1 (regulator of chromosome condensation) protein, which recruits Ran to nucleosomes and activates Ran's nucleotide exchange activity. Although RCC1 has been shown to bind directly with the nucleosome, the molecular details of this interaction were not known. Here we determine the crystal structure of a complex of Drosophila RCC1 and the nucleosome core particle at 2.9 angstrom resolution, providing an atomic view of how a chromatin protein interacts with the histone and DNA components of the nucleosome. Our structure also suggests that the Widom 601 DNA positioning sequence present in the nucleosomes forms a 145-base-pair nucleosome core particle, not the expected canonical 147-base-pair particle.	[Makde, Ravindra D.; England, Joseph R.; Yennawar, Hemant P.; Tan, Song] Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Tan, S (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, University Pk, PA 16802 USA.	sxt30@psu.edu		Yennawar, Hemant P./0000-0003-2869-1109; Makde, Ravindra D./0000-0001-7020-0065	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088236] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM088236-02, R01 GM088236, R01 GM088236-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bao YH, 2006, J MOL BIOL, V361, P617, DOI 10.1016/j.jmb.2006.06.051; Barbera AJ, 2006, SCIENCE, V311, P856, DOI 10.1126/science.1120541; Bilbao-Cortes D, 2002, CURR BIOL, V12, P1151, DOI 10.1016/S0960-9822(02)00927-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Chakravarthy S, 2006, J BIOL CHEM, V281, P25522, DOI 10.1074/jbc.M602258200; Chen T, 2007, NAT CELL BIOL, V9, P596, DOI 10.1038/ncb1572; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Clapier CR, 2008, PROTEINS, V71, P1, DOI 10.1002/prot.21720; Clarke PR, 2008, NAT REV MOL CELL BIO, V9, P464, DOI 10.1038/nrm2410; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Davis TL, 2005, BIOCHEMISTRY-US, V44, P10593, DOI 10.1021/bi050655i; DeLano W.L., PYMOL MOL GRAPHICS S; Dorigo B, 2004, SCIENCE, V306, P1571, DOI 10.1126/science.1103124; Edayathumangalam RS, 2005, J MOL BIOL, V345, P103, DOI 10.1016/j.jmb.2004.10.012; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; England JR, 2010, J MOL BIOL, V398, P518, DOI 10.1016/j.jmb.2010.03.037; Gangaraju VK, 2009, MOL CELL, V35, P58, DOI 10.1016/j.molcel.2009.05.013; Hao Y, 2008, J CELL BIOL, V182, P827, DOI 10.1083/jcb.200803110; Kalab P, 2008, J CELL SCI, V121, P1577, DOI 10.1242/jcs.005959; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Koerber RT, 2009, MOL CELL, V35, P889, DOI 10.1016/j.molcel.2009.09.011; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavery R, 2009, NUCLEIC ACIDS RES, V37, P5917, DOI 10.1093/nar/gkp608; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Ong MS, 2007, J MOL BIOL, V368, P1067, DOI 10.1016/j.jmb.2007.02.062; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Partridge JR, 2009, J MOL BIOL, V391, P375, DOI 10.1016/j.jmb.2009.06.011; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Saha A, 2005, NAT STRUCT MOL BIOL, V12, P747, DOI 10.1038/nsmb973; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Suto RK, 2003, J MOL BIOL, V326, P371, DOI 10.1016/S0022-2836(02)01407-9; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Tan S, 2005, PROTEIN EXPRES PURIF, V40, P385, DOI 10.1016/j.pep.2004.12.002; Tsunaka Y, 2005, NUCLEIC ACIDS RES, V33, P3424, DOI 10.1093/nar/gki663; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Zhang CM, 2002, EUR J CELL BIOL, V81, P623, DOI 10.1078/0171-9335-00288	50	271	273	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					562	U81		10.1038/nature09321	http://dx.doi.org/10.1038/nature09321			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20739938	Green Accepted			2022-12-28	WOS:000282273100032
J	Young, BP; Shin, JJH; Orij, R; Chao, JT; Li, SC; Guan, XL; Khong, A; Jan, E; Wenk, MR; Prinz, WA; Smits, GJ; Loewen, CJR				Young, Barry P.; Shin, John J. H.; Orij, Rick; Chao, Jesse T.; Li, Shu Chen; Guan, Xue Li; Khong, Anthony; Jan, Eric; Wenk, Markus R.; Prinz, William A.; Smits, Gertien J.; Loewen, Christopher J. R.			Phosphatidic Acid Is a pH Biosensor That Links Membrane Biogenesis to Metabolism	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; H+-ATPASE; YEAST; PROTEIN; LOCALIZATION; HOMEOSTASIS; VACUOLAR	Recognition of lipids by proteins is important for their targeting and activation in many signaling pathways, but the mechanisms that regulate such interactions are largely unknown. Here, we found that binding of proteins to the ubiquitous signaling lipid phosphatidic acid (PA) depended on intracellular pH and the protonation state of its phosphate headgroup. In yeast, a rapid decrease in intracellular pH in response to glucose starvation regulated binding of PA to a transcription factor, Opi1, that coordinately repressed phospholipid metabolic genes. This enabled coupling of membrane biogenesis to nutrient availability.	[Young, Barry P.; Shin, John J. H.; Chao, Jesse T.; Li, Shu Chen; Loewen, Christopher J. R.] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; [Orij, Rick; Smits, Gertien J.] Univ Amsterdam, Dept Mol Biol & Microbial Food Safety, NL-1018 WV Amsterdam, Netherlands; [Guan, Xue Li] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 119077, Singapore; [Guan, Xue Li; Wenk, Markus R.] Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; [Khong, Anthony; Jan, Eric] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; [Wenk, Markus R.] Natl Univ Singapore, Dept Biol Sci, Singapore 119077, Singapore; [Wenk, Markus R.] Univ Basel, Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Prinz, William A.] NIDDKD, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA; [Loewen, Christopher J. R.] Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of Amsterdam; National University of Singapore; University of Geneva; University of British Columbia; National University of Singapore; University of Basel; Swiss Tropical & Public Health Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of British Columbia	Loewen, CJR (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada.	christopher.loewen@ubc.ca	Wenk, Markus Rene/D-1441-2014; Smits, Gertien J./I-4327-2014; Jan, Eric/O-1923-2019; Khong, Anthony/AHD-6446-2022; Guan, Xue Li/D-2935-2014	Smits, Gertien J./0000-0002-8439-7791; Guan, Xue Li/0000-0002-5189-8178; Chao, Jesse/0000-0002-6995-9581; , John/0000-0002-8905-8350	National Sciences and Engineering Council of Canada (NSERC); Canadian Institute of Health Research (CIHR); Michael Smith Foundation for Health Research (MSFHR); Canada Foundation for Innovation; British Columbia Knowledge Development Fund; National Institute of Diabetes and Digestive and Kidney Diseases; Singapore National Research Foundation [2007-04]; Biomedical Research Council of Singapore [R-183-000-211-305]; National Medical Research Council [R-183-000-224-213]; SystemsX.ch RTD project LipidX; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK060004] Funding Source: NIH RePORTER	National Sciences and Engineering Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); British Columbia Knowledge Development Fund; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Singapore National Research Foundation(National Research Foundation, Singapore); Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); SystemsX.ch RTD project LipidX; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to T. Levine for insight and critical reading of the manuscript; C. Boone for access to SGA technologies; M. Davies and L. Conibear for a preliminary inositol screen; and J. Church for discussions. This research was supported by grants from the National Sciences and Engineering Council of Canada (NSERC), the Canadian Institute of Health Research (CIHR), the Michael Smith Foundation for Health Research (MSFHR), the Canada Foundation for Innovation, and the British Columbia Knowledge Development Fund (C.J.R.L. and E.J.); the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases (W.A.P.); and the Singapore National Research Foundation under CRP Award 2007-04, the Biomedical Research Council of Singapore (R-183-000-211-305), the National Medical Research Council (R-183-000-224-213), and the SystemsX.ch RTD project LipidX (M.R.W.). J.J.H.S. is the recipient of a NSERC Alexander Graham Bell Canada Graduate Scholarship. C.J.R.L. is a CIHR New Investigator, a MSFHR Scholar, and a Tula Foundation Investigator.	BHUSHAN A, 1993, BIOPHYS J, V64, P716, DOI 10.1016/S0006-3495(93)81431-0; Carman GM, 2007, J BIOL CHEM, V282, P37293, DOI 10.1074/jbc.R700038200; Chan G, 2007, J BIOCHEM MOL TOXIC, V21, P252, DOI 10.1002/jbt.20189; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Hancock LC, 2006, GENETICS, V173, P621, DOI 10.1534/genetics.106.057489; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Kooijman EE, 2008, BIOPHYS J, V94, P4320, DOI 10.1529/biophysj.107.121046; Kooijman EE, 2007, J BIOL CHEM, V282, P11356, DOI 10.1074/jbc.M609737200; Kooijman EE, 2009, BIOCHEMISTRY-US, V48, P9360, DOI 10.1021/bi9008616; Kooijman EE, 2005, BIOCHEMISTRY-US, V44, P17007, DOI 10.1021/bi0518794; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Martinez-Munoz GA, 2008, J BIOL CHEM, V283, P20309, DOI 10.1074/jbc.M710470200; Nakanishi H, 2004, MOL BIOL CELL, V15, P1802, DOI 10.1091/mbc.e03-11-0798; Orij R, 2009, MICROBIOL-SGM, V155, P268, DOI 10.1099/mic.0.022038-0; Porat Z, 2005, CELL MOL LIFE SCI, V62, P3106, DOI 10.1007/s00018-005-5341-7; Williams-Hart T, 2002, GENETICS, V160, P1423; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066	20	178	180	2	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1085	1088		10.1126/science.1191026	http://dx.doi.org/10.1126/science.1191026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798321				2022-12-28	WOS:000281253500043
J	Viswanathan, AN				Viswanathan, Akila N.			Childhood cancer survivors: stillbirth and neonatal death	LANCET			English	Editorial Material							FEMALE SURVIVORS; PREGNANCY; FERTILITY; OUTCOMES		Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Viswanathan, AN (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Ctr, Boston, MA 02115 USA.	aviswanathan@lroc.harvard.edu		viswaanathan, akila/0000-0002-1896-2924				Bliss JM, 2007, JNCI-J NATL CANCER I, V99, P516, DOI 10.1093/jnci/djk109; Chemaitilly W, 2006, J CLIN ENDOCR METAB, V91, P1723, DOI 10.1210/jc.2006-0020; Chiarelli AM, 2000, EPIDEMIOLOGY, V11, P161, DOI 10.1097/00001648-200003000-00013; Green DM, 2009, J CLIN ONCOL, V27, P2677, DOI 10.1200/JCO.2008.20.1541; Green DM, 2002, J CLIN ONCOL, V20, P2506, DOI 10.1200/JCO.2002.07.159; Green DN, 2002, AM J OBSTET GYNECOL, V187, P1070, DOI 10.1067/mob.2002.126643; Lobo RA, 2005, NEW ENGL J MED, V353, P64, DOI 10.1056/NEJMra043475; Merchant TE, 2009, CANCER J, V15, P298, DOI 10.1097/PPO.0b013e3181b6d4b7; Signore LB, 2010, LANCET, V376, P624, DOI 10.1016/S0140-6736(10)60752-0; Sklar CA, 2006, J NATL CANCER I, V98, P890, DOI 10.1093/jnci/djj243; WALTERHOUSE D, 2009, ARST0331 STUDY COMMI; Wo JY, 2009, INT J RADIAT ONCOL, V73, P1304, DOI 10.1016/j.ijrobp.2008.12.016	12	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2010	376	9741					570	572		10.1016/S0140-6736(10)61263-9	http://dx.doi.org/10.1016/S0140-6736(10)61263-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	643PB	20728738				2022-12-28	WOS:000281309100006
J	de Jonge, R; van Esse, HP; Kombrink, A; Shinya, T; Desaki, Y; Bours, R; van der Krol, S; Shibuya, N; Joosten, MHAJ; Thomma, BPHJ				de Jonge, Ronnie; van Esse, H. Peter; Kombrink, Anja; Shinya, Tomonori; Desaki, Yoshitake; Bours, Ralph; van der Krol, Sander; Shibuya, Naoto; Joosten, Matthieu H. A. J.; Thomma, Bart P. H. J.			Conserved Fungal LysM Effector Ecp6 Prevents Chitin-Triggered Immunity in Plants	SCIENCE			English	Article							RECEPTOR-LIKE KINASE; CLADOSPORIUM-FULVUM; VIRULENCE FACTOR; BINDING; DEFENSE; TOMATO; CELLS; AVR4; RECOGNITION; ARABIDOPSIS	Multicellular organisms activate immunity upon recognition of pathogen-associated molecular patterns (PAMPs). Chitin is the major component of fungal cell walls, and chitin oligosaccharides act as PAMPs in plant and mammalian cells. Microbial pathogens deliver effector proteins to suppress PAMP-triggered host immunity and to establish infection. Here, we show that the LysM domain-containing effector protein Ecp6 of the fungal plant pathogen Cladosporium fulvum mediates virulence through perturbation of chitin-triggered host immunity. During infection, Ecp6 sequesters chitin oligosaccharides that are released from the cell walls of invading hyphae to prevent elicitation of host immunity. This may represent a common strategy of host immune suppression by fungal pathogens, because LysM effectors are widely conserved in the fungal kingdom.	[de Jonge, Ronnie; van Esse, H. Peter; Kombrink, Anja; Joosten, Matthieu H. A. J.; Thomma, Bart P. H. J.] Wageningen Univ, Phytopathol Lab, NL-6708 PB Wageningen, Netherlands; [Thomma, Bart P. H. J.] Ctr Biosyst Genom, NL-6700 AB Wageningen, Netherlands; [Shinya, Tomonori; Desaki, Yoshitake; Shibuya, Naoto] Meiji Univ, Fac Agr, Dept Life Sci, Kanagawa 2148571, Japan; [Bours, Ralph; van der Krol, Sander] Wageningen Univ, Lab Plant Physiol, NL-6708 PB Wageningen, Netherlands	Wageningen University & Research; Centre for BioSystems Genomics; Meiji University; Wageningen University & Research	Thomma, BPHJ (corresponding author), Wageningen Univ, Phytopathol Lab, Droevendaalsesteeg 1, NL-6708 PB Wageningen, Netherlands.	bart.thomma@wur.nl	Thomma, Bart/E-5959-2011; Joosten, Matthieu/AAB-5131-2022; van Esse, Peter/U-5304-2018; Thomma, Bart/ABH-6344-2020; van der Krol, Alexander/C-5720-2015; Desaki, Yoshitake/M-7264-2015; Joosten, Matthieu/AAB-5150-2022; de Jonge, Ronnie/I-3260-2016	Thomma, Bart/0000-0003-4125-4181; Joosten, Matthieu/0000-0002-6243-4547; van Esse, Peter/0000-0002-3667-060X; Thomma, Bart/0000-0003-4125-4181; van der Krol, Alexander/0000-0001-6585-7572; Desaki, Yoshitake/0000-0002-0916-9051; de Jonge, Ronnie/0000-0001-5065-8538	Research Council for Earth and Life Sciences (ALW) of the Netherlands Organization for Scientific Research (NWO); European Research Area-Network (ERA-NET) Plant Genomics; Centre for BioSystems Genomics (CBSG), Netherlands Genomics Initiative; NWO; Program for Promotion of Basic Research Activities for Innovative Bioscience (PROBRAIN); Ministry of Education, Culture, Sports, Science and Technology, Japan	Research Council for Earth and Life Sciences (ALW) of the Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); European Research Area-Network (ERA-NET) Plant Genomics; Centre for BioSystems Genomics (CBSG), Netherlands Genomics Initiative; NWO(Netherlands Organization for Scientific Research (NWO)); Program for Promotion of Basic Research Activities for Innovative Bioscience (PROBRAIN); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We are indebted to Yaizu Suisankagaku Industrial Co. Ltd. for the supply of chitosan oligosaccharides and to the Consortium for Functional Glycomics (CFG) for performing the glycan array analysis. This research was supported by a Vidi grant of the Research Council for Earth and Life Sciences (ALW) of the Netherlands Organization for Scientific Research (NWO), by the European Research Area-Network (ERA-NET) Plant Genomics and by the Centre for BioSystems Genomics (CBSG), which is part of the Netherlands Genomics Initiative and NWO. Part of this research was supported by the Program for Promotion of Basic Research Activities for Innovative Bioscience (PROBRAIN) and a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The authors thank P. de Wit, F. Govers, T. Bisseling, N. Talbot, and anonymous reviewers for critical evaluation of the manuscript and L. Verhage and L. Kaaij for technical assistance.	Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Bolton MD, 2008, MOL MICROBIOL, V69, P119, DOI 10.1111/j.1365-2958.2008.06270.x; Buist G, 2008, MOL MICROBIOL, V68, P838, DOI 10.1111/j.1365-2958.2008.06211.x; Chisholm ST, 2006, CELL, V124, P803, DOI 10.1016/j.cell.2006.02.008; de Jonge R, 2009, TRENDS MICROBIOL, V17, P151, DOI 10.1016/j.tim.2009.01.002; FELIX G, 1993, PLANT J, V4, P307, DOI 10.1046/j.1365-313X.1993.04020307.x; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Iizasa E, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.027540; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Kaku H, 2006, P NATL ACAD SCI USA, V103, P11086, DOI 10.1073/pnas.0508882103; Lee CG, 2008, CURR OPIN IMMUNOL, V20, P684, DOI 10.1016/j.coi.2008.10.002; Miya A, 2007, P NATL ACAD SCI USA, V104, P19613, DOI 10.1073/pnas.0705147104; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Rooney HCE, 2005, SCIENCE, V308, P1783, DOI 10.1126/science.1111404; SCHLUMBAUM A, 1986, NATURE, V324, P365, DOI 10.1038/324365a0; Shabab M, 2008, PLANT CELL, V20, P1169, DOI 10.1105/tpc.107.056325; Shinya T, 2010, PLANT CELL PHYSIOL, V51, P262, DOI 10.1093/pcp/pcp185; Thomma BPHJ, 2005, MOL PLANT PATHOL, V6, P379, DOI 10.1111/J.1364-3703.2005.00292.X; van den Burg HA, 2004, J BIOL CHEM, V279, P16786, DOI 10.1074/jbc.M312594200; van den Burg HA, 2006, MOL PLANT MICROBE IN, V19, P1420, DOI 10.1094/MPMI-19-1420; van Esse HP, 2008, PLANT CELL, V20, P1948, DOI 10.1105/tpc.108.059394; van Esse HP, 2007, MOL PLANT MICROBE IN, V20, P1092, DOI 10.1094/MPMI-20-9-1092; Wan JR, 2008, PLANT CELL, V20, P471, DOI 10.1105/tpc.107.056754	25	462	468	14	210	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					953	955		10.1126/science.1190859	http://dx.doi.org/10.1126/science.1190859			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724636				2022-12-28	WOS:000281084800037
J	Perry, DC; Bruce, C				Perry, Daniel C.; Bruce, Colin			Evaluating the child who presents with an acute limp	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CAPITAL FEMORAL EPIPHYSIS; CALVE-PERTHES-DISEASE; TRANSIENT SYNOVITIS; SEPTIC ARTHRITIS; HIP PAIN; EPIDEMIOLOGY; MANAGEMENT; OSTEOMYELITIS; ETIOLOGY; DIFFERENTIATION		[Perry, Daniel C.; Bruce, Colin] Univ Liverpool & Alder Hey Hosp, Liverpool L12 2AP, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital	Perry, DC (corresponding author), Univ Liverpool & Alder Hey Hosp, Liverpool L12 2AP, England.	danperry@doctors.org.uk		Perry, Daniel/0000-0001-8420-8252	John Monk hip research fund	John Monk hip research fund	DCP is funded by John Monk hip research fund.	Bhatia NN, 2006, J PEDIATR ORTHOPED, V26, P197, DOI 10.1097/01.bpo.0000218526.36362.3f; Bienvenu-Perrard M, 2007, J RADIOL, V88, P377, DOI 10.1016/S0221-0363(07)89834-9; Blyth MJG, 2001, J BONE JOINT SURG BR, V83B, P99, DOI 10.1302/0301-620X.83B1.10699; BURWELL RG, 1978, J BONE JOINT SURG BR, V60, P461, DOI 10.1302/0301-620X.60B4.711791; Crandall WV, 1999, J PEDIATR GASTR NUTR, V28, P95, DOI 10.1097/00005176-199901000-00021; Delaney RA, 2007, IRISH J MED SCI, V176, P181, DOI 10.1007/s11845-007-0061-7; DUNBAR J S, 1964, J Can Assoc Radiol, V15, P136; Ferguson LP, 2002, BRIT MED J, V324, P1380, DOI 10.1136/bmj.324.7350.1380; Fischer SU, 1999, J BONE JOINT SURG BR, V81B, P1029, DOI 10.1302/0301-620X.81B6.9607; Foster HE, 2006, ARTHRIT RHEUM-ARTHR, V55, P709, DOI 10.1002/art.22230; Goergens ED, 2005, J PAEDIATR CHILD H, V41, P59, DOI 10.1111/j.1440-1754.2005.00538.x; HALL AJ, 1984, AM J EPIDEMIOL, V120, P531, DOI 10.1093/oxfordjournals.aje.a113913; Herring JA, 2004, J BONE JOINT SURG AM, V86A, P2121, DOI 10.2106/00004623-200410000-00002; Jandial S, 2009, J PEDIATR-US, V154, P267, DOI 10.1016/j.jpeds.2008.08.013; Kalliola S, 1999, PEDIATR INFECT DIS J, V18, P806, DOI 10.1097/00006454-199909000-00012; KASTRISSIANAKIS K, 2010, EUR J EMERG MED; Kemp AM, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1518; Kocher MS, 2004, J BONE JOINT SURG AM, V86A, P1629, DOI 10.2106/00004623-200408000-00005; Kocher MS, 1999, J BONE JOINT SURG AM, V81A, P1662, DOI 10.2106/00004623-199912000-00002; Krul M, 2010, FAM PRACT, V27, P166, DOI 10.1093/fampra/cmp092; LANDIN LA, 1987, J BONE JOINT SURG BR, V69, P238, DOI 10.1302/0301-620X.69B2.3818754; Lehmann CL, 2006, J PEDIATR ORTHOPED, V26, P286, DOI 10.1097/01.bpo.0000217718.10728.70; Loder RT, 2007, J PEDIATR ORTHOPED, V27, P421, DOI 10.1097/01.bpb.0000271328.79481.07; Loder RT, 2001, J PEDIATR ORTHOPED, V21, P488, DOI 10.1097/00004694-200107000-00014; LODER RT, 1993, J PEDIATR ORTHOPED, V13, P598; LODER RT, 1995, J PEDIATR ORTHOPED, V15, P349, DOI 10.1097/01241398-199505000-00018; Lowndes S, 2009, BRIT MED BULL, V90, P133, DOI 10.1093/bmb/ldp012; Luhmann SJ, 2004, J BONE JOINT SURG AM, V86A, P956, DOI 10.2106/00004623-200405000-00011; Matava MJ, 1999, J PEDIATR ORTHOPED, V19, P455, DOI 10.1097/00004694-199907000-00007; Mattick A, 1999, J ACCID EMERG MED, V16, P345; MUKAMEL M, 1985, CLIN PEDIATR, V24, P629, DOI 10.1177/000992288502401105; Rahme D, 2006, J PEDIATR ORTHOP B, V15, P93, DOI 10.1097/01.bpb.0000188251.24771.c9; Reed L, 2009, EMERG MED AUSTRALAS, V21, P136, DOI 10.1111/j.1742-6723.2008.01144.x; SCHLONSKY J, 1973, J BONE JOINT SURG AM, VA 55, P1057, DOI 10.2106/00004623-197355050-00015; Sharpe P, 2006, ARCH DIS CHILD-FETAL, V91, pF158, DOI 10.1136/adc.2004.070870; Sheafor DH, 1997, CLIN NUCL MED, V22, P287, DOI 10.1097/00003072-199705000-00001; SUTHERLAND AD, 1980, J BONE JOINT SURG BR, V62, P300, DOI 10.1302/0301-620X.62B3.7410461; SUTHERLAND DH, 1980, J BONE JOINT SURG AM, V62, P336, DOI 10.2106/00004623-198062030-00004; TENENBEIN M, 1990, AM J EMERG MED, V8, P208, DOI 10.1016/0735-6757(90)90324-S; TOLAT V, 1993, J BONE JOINT SURG BR, V75, P973, DOI 10.1302/0301-620X.75B6.7503994; VIJLBRIEF AS, 1992, BRIT J GEN PRACT, V42, P426; WALDENSTROM H, 1923, ACTA CHIR SCAND, V55, P577; Wiig O, 2006, J BONE JOINT SURG BR, V88B, P1217, DOI 10.1302/0301-620X.88B9.17400; WYNNEDAVIES R, 1978, J BONE JOINT SURG BR, V60, P6, DOI 10.1302/0301-620X.60B1.564352	44	8	8	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 20	2010	341								c4250	10.1136/bmj.c4250	http://dx.doi.org/10.1136/bmj.c4250			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KY	20729271				2022-12-28	WOS:000281213600003
J	Yuen, MMA; Tam, TCC; Lau, WWY; Chan, JFW; Chow, WS; Lam, KSL				Yuen, Michele Mae Ann; Tam, Terence Chi Chun; Lau, Winnie Wai Ying; Chan, Jasper Fuk Woo; Chow, Wing Sun; Lam, Karen Siu Ling			Case Report An "unforeseen" complication of urinary tract infection in a patient with diabetes	BRITISH MEDICAL JOURNAL			English	Editorial Material							ENDOGENOUS BACTERIAL ENDOPHTHALMITIS; FUNGAL ENDOPHTHALMITIS; REAPPRAISAL		[Yuen, Michele Mae Ann; Tam, Terence Chi Chun; Chow, Wing Sun; Lam, Karen Siu Ling] Queen Mary Hosp, Hong Kong Spec Administrat Reg, Dept Med, Hong Kong, Peoples R China; [Lau, Winnie Wai Ying] Hong Kong Eye Hosp, Hong Kong Spec Administrat Reg, Hong Kong, Peoples R China; [Chan, Jasper Fuk Woo] Queen Mary Hospital, Dept Microbiol, Hong Kong Spec Administrat Reg, Hong Kong, Peoples R China	University of Hong Kong	Yuen, MMA (corresponding author), Queen Mary Hosp, Hong Kong Spec Administrat Reg, Dept Med, Hong Kong, Peoples R China.	micheleyuen@hotmail.com	Tam, Terence/K-4624-2019; Chan, Jasper F. W./D-8007-2013	Chan, Jasper F. W./0000-0001-6336-6657				Benz MS, 2004, AM J OPHTHALMOL, V137, P38, DOI 10.1016/S0002-9394(03)00896-1; Chee SP, 2001, CURR OPIN OPHTHALMOL, V12, P464, DOI 10.1097/00055735-200112000-00012; DURAND ML, 2010, MANDELL DOUGLAS BENN; GREENWALD MJ, 1986, SURV OPHTHALMOL, V31, P81, DOI 10.1016/0039-6257(86)90076-7; Gupta A, 2000, RETINA-J RET VIT DIS, V20, P262, DOI 10.1097/00006982-200005000-00006; Ho PL, 2010, DIAGN MICR INFEC DIS, V66, P87, DOI 10.1016/j.diagmicrobio.2009.03.027; Jackson TL, 2003, SURV OPHTHALMOL, V48, P403, DOI 10.1016/S0039-6257(03)00054-7; Kernt M, 2010, CLIN OPHTHALMOL, V4, P121; Lemley CA, 2007, RETINA-J RET VIT DIS, V27, P662, DOI 10.1097/IAE.0b013e3180323f96; OKADA AA, 1994, OPHTHALMOLOGY, V101, P832; Okhravi N, 2000, INVEST OPHTH VIS SCI, V41, P3474; Schiedler V, 2004, AM J OPHTHALMOL, V137, P725, DOI 10.1016/j.ajo.2003.11.013; Seale M, 2007, EMERG RADIOL, V13, P209, DOI 10.1007/s10140-006-0550-4; Smith Stephen R., 2007, International Ophthalmology Clinics, V47, P173, DOI 10.1097/IIO.0b013e31803778f7; Sowmya P, 2009, EUR J OPHTHALMOL, V19, P812, DOI 10.1177/112067210901900520; Tang S, 2003, LANCET, V361, P922, DOI 10.1016/S0140-6736(03)12774-2; Wong JS, 2000, OPHTHALMOLOGY, V107, P1483, DOI 10.1016/S0161-6420(00)00216-5; Wong T. Y., 2001, Hong Kong Medical Journal, V7, P303	18	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 18	2010	341								c3073	10.1136/bmj.c3073	http://dx.doi.org/10.1136/bmj.c3073			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KT	20719842				2022-12-28	WOS:000281213100004
J	Tobin, MJ; Laghi, F; Jubran, A				Tobin, Martin J.; Laghi, Franco; Jubran, Amal			Narrative Review: Ventilator-Induced Respiratory Muscle Weakness	ANNALS OF INTERNAL MEDICINE			English	Review							DIAPHRAGMATIC CONTRACTILITY; PRESSURE; DYSFUNCTION; STIMULATION; ATROPHY	Clinicians have long been aware that substantial lung injury results when mechanical ventilation imposes too much stress on the pulmonary parenchyma. Evidence is accruing that substantial injury may also result when the ventilator imposes too little stress on the respiratory muscles. Through adjustment of ventilator settings and administration of pharmacotherapy, the respiratory muscles may be rendered almost (or completely) inactive. Research in animals has shown that diaphragmatic inactivity produces severe injury and atrophy of muscle fibers. Human data have recently revealed that 18 to 69 hours of complete diaphragmatic inactivity associated with mechanical ventilation decreased the cross-sectional areas of diaphragmatic fibers by half or more. The atrophic injury seems to result from increased oxidative stress leading to activation of protein-degradation pathways. Scientific understanding of ventilator-induced respiratory muscle injury has not reached the stage where meaningful controlled trials can be done, and thus, it is not possible to give concrete recommendations for patient management. In the meantime, clinicians are advised to select ventilator settings that avoid both excessive patient effort and excessive respiratory muscle rest. The contour of the airway pressure waveform on a ventilator screen provides the most practical indication of patient effort, and clinicians are advised to pay close attention to the waveform as they titrate ventilator settings. Research on ventilator-induced respiratory muscle injury is in its infancy and portends to be an exciting area to follow.	[Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA; Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	Tobin, MJ (corresponding author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, 111 N 5th Ave & Roosevelt Rd, Hines, IL 60141 USA.	mtobin2@lumc.edu			Veterans Affairs Health Services Research and Development Service; National Institutes of Health [RO1 NR008782]; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR008782] Funding Source: NIH RePORTER	Veterans Affairs Health Services Research and Development Service(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Grant Support: By a Merit Review grant from the Veterans Affairs Health Services Research and Development Service and by a grant from the National Institutes of Health (RO1 NR008782).	ANZUETO A, 1987, American Review of Respiratory Disease, V135, pA201; Ayas NT, 1999, AM J RESP CRIT CARE, V159, P2018, DOI 10.1164/ajrccm.159.6.9806147; Betters JL, 2004, AM J RESP CRIT CARE, V170, P1179, DOI 10.1164/rccm.200407-939OC; Cattapan SE, 2003, THORAX, V58, P58, DOI 10.1136/thorax.58.1.58; Cholette J, 2009, CRIT CARE MED, V37, pA434, DOI 10.1097/CCM.0b013e3181b6e760; DECRAMER M, 1994, AM J RESP CRIT CARE, V150, P11, DOI 10.1164/ajrccm.150.1.8025735; DREYFUSS D, 2006, PRINCIPLES PRACTICE, P903; Gayan-Ramirez G, 2005, CRIT CARE MED, V33, P2804, DOI 10.1097/01.CCM.0000191250.32988.A3; Jubran A, 1997, AM J RESP CRIT CARE, V155, P906, DOI 10.1164/ajrccm.155.3.9117025; KNISELY AS, 1988, J PEDIATR-US, V113, P1074, DOI 10.1016/S0022-3476(88)80585-7; Laghi F, 1998, J APPL PHYSIOL, V85, P1103, DOI 10.1152/jappl.1998.85.3.1103; Laghi F, 2003, AM J RESP CRIT CARE, V168, P10, DOI 10.1164/rccm.2206020; Laghi F, 2006, PRINCIPLES PRACTICE, V2nd, P129; Lee SI, 2008, J ANESTH, V22, P385, DOI 10.1007/s00540-008-0646-y; Leung P, 1997, AM J RESP CRIT CARE, V155, P1940, DOI 10.1164/ajrccm.155.6.9196100; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Maes K, 2007, AM J RESP CRIT CARE, V175, P1134, DOI 10.1164/rccm.200609-1342OC; Mancebo J., 2006, PRINCIPLES PRACTICE, P183; MARINI JJ, 1985, CHEST, V87, P612, DOI 10.1378/chest.87.5.612; McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC; Powers SK, 2002, J APPL PHYSIOL, V92, P1851, DOI 10.1152/japplphysiol.00881.2001; Sassoon CSH, 2002, J APPL PHYSIOL, V92, P2585, DOI 10.1152/japplphysiol.01213.2001; Sassoon CSH, 2004, AM J RESP CRIT CARE, V170, P626, DOI 10.1164/rccm.200401-042OC; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; Shanely RA, 2004, AM J RESP CRIT CARE, V170, P994, DOI 10.1164/rccm.200304-575OC; Smith HK, 2000, CELL TISSUE RES, V302, P235, DOI 10.1007/s004410000280; Tobin MJ, 2001, NEW ENGL J MED, V344, P1986, DOI 10.1056/NEJM200106283442606; Topeli A, 1999, AM J RESP CRIT CARE, V160, P1369, DOI 10.1164/ajrccm.160.4.9806041; VASSILAKOPOULOS T, 2006, PRINCIPLES PRACTICE, P931; WARD ME, 1988, ANESTHESIOLOGY, V69, P29, DOI 10.1097/00000542-198807000-00005; Watson AC, 2001, CRIT CARE MED, V29, P1325, DOI 10.1097/00003246-200107000-00005; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010; Yang LY, 2002, AM J RESP CRIT CARE, V166, P1135, DOI 10.1164/rccm.2202020; Younes M, 1995, THORAX, P2367; Zhang XJ, 2009, BRIT J ANAESTH, V102, P61, DOI 10.1093/bja/aen327	36	50	55	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4					240	245		10.7326/0003-4819-153-4-201008170-00006	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713792	Green Accepted			2022-12-28	WOS:000280973000004
J	Law, KL; Moret-Ferguson, S; Maximenko, NA; Proskurowski, G; Peacock, EE; Hafner, J; Reddy, CM				Law, Kara Lavender; Moret-Ferguson, Skye; Maximenko, Nikolai A.; Proskurowski, Giora; Peacock, Emily E.; Hafner, Jan; Reddy, Christopher M.			Plastic Accumulation in the North Atlantic Subtropical Gyre	SCIENCE			English	Article							MARINE-ENVIRONMENT; PACIFIC-OCEAN; DEBRIS; TRANSPORT; SURFACE; SEA; TAR; INVASIONS; CHEMICALS; WATERS	Plastic marine pollution is a major environmental concern, yet a quantitative description of the scope of this problem in the open ocean is lacking. Here, we present a time series of plastic content at the surface of the western North Atlantic Ocean and Caribbean Sea from 1986 to 2008. More than 60% of 6136 surface plankton net tows collected buoyant plastic pieces, typically millimeters in size. The highest concentration of plastic debris was observed in subtropical latitudes and associated with the observed large-scale convergence in surface currents predicted by Ekman dynamics. Despite a rapid increase in plastic production and disposal during this time period, no trend in plastic concentration was observed in the region of highest accumulation.	[Law, Kara Lavender; Moret-Ferguson, Skye; Proskurowski, Giora] Sea Educ Assoc, Woods Hole, MA 02543 USA; [Moret-Ferguson, Skye; Proskurowski, Giora; Peacock, Emily E.; Reddy, Christopher M.] Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; [Maximenko, Nikolai A.; Hafner, Jan] Univ Hawaii, Sch Ocean & Earth Sci & Technol, Int Pacific Res Ctr, Honolulu, HI 96822 USA	Woods Hole Oceanographic Institution; University of Hawaii System	Law, KL (corresponding author), Sea Educ Assoc, POB 6, Woods Hole, MA 02543 USA.	klavender@sea.edu	Proskurowski, Giora/B-3862-2013	Reddy, Christopher/0000-0002-7814-2071; Law, Kara/0000-0002-5298-6751	National Science Foundation [OCE-0842727]; Hollis and Ermine Lovell Charitable Foundation; National Fish and Wildlife Foundation [2008-0066-006]; NASA [NNX08AR49G, NA17RJ1230]; Japan Agency for Marine-Earth Science and Technology (JAMSTEC), NASA [NNX07AG53G]	National Science Foundation(National Science Foundation (NSF)); Hollis and Ermine Lovell Charitable Foundation; National Fish and Wildlife Foundation; NASA(National Aeronautics & Space Administration (NASA)); Japan Agency for Marine-Earth Science and Technology (JAMSTEC), NASA(National Aeronautics & Space Administration (NASA))	We thank the thousands of students and staff at Sea Education Association who collected plastic samples onboard the research vessel Westward and the sailing school vessel Corwith Cramer. This work was supported by the National Science Foundation (OCE-0842727) and the Hollis and Ermine Lovell Charitable Foundation. N.A.M. and J.H. were supported by the National Fish and Wildlife Foundation (2008-0066-006); the NASA Physical Oceanography Program through membership in its Ocean Surface Topography Science Team (NNX08AR49G); and the Japan Agency for Marine-Earth Science and Technology (JAMSTEC), NASA (NNX07AG53G), and the National Oceanic and Atmospheric Administration (NA17RJ1230), which sponsor research at the International Pacific Research Center.	American Chemistry Council, OP CLEAN SWEEP PELL; ANDRADY AL, 1990, J APPL POLYM SCI, V39, P363, DOI 10.1002/app.1990.070390213; Barnes DKA, 2002, NATURE, V416, P808, DOI 10.1038/416808a; CARPENTER EJ, 1972, SCIENCE, V175, P1240, DOI 10.1126/science.175.4027.1240; COLTON JB, 1974, SCIENCE, V185, P491, DOI 10.1126/science.185.4150.491; Day R. H., 1990, P 2 INT C MAR DEBR 2, P182; DAY RH, 1987, MAR POLLUT BULL, V18, P311, DOI 10.1016/S0025-326X(87)80017-6; EPA (U. S. Environmental Protection Agency), 2009, MUN SOL WAST GEN REC; Feldman D, 2002, J POLYM ENVIRON, V10, P163, DOI 10.1023/A:1021148205366; Graham ER, 2009, J EXP MAR BIOL ECOL, V368, P22, DOI 10.1016/j.jembe.2008.09.007; GREGORY MR, 1983, MAR ENVIRON RES, V10, P73, DOI 10.1016/0141-1136(83)90011-9; Gregory MR, 2009, PHILOS T R SOC B, V364, P2013, DOI 10.1098/rstb.2008.0265; *INT CONV PREV POL, 1988, ANN 5 PREV POLL GARB; International Pacific Research Center, 2008, IPRC CLIMATE, P14; LAIST DW, 1987, MAR POLLUT BULL, V18, P319, DOI 10.1016/S0025-326X(87)80019-X; Mato Y, 2001, ENVIRON SCI TECHNOL, V35, P318, DOI 10.1021/es0010498; Maximenko N, 2009, J ATMOS OCEAN TECH, V26, P1910, DOI 10.1175/2009JTECHO672.1; Moret-Ferguson S, 2010, MAR POLLUT BULL, V60, P1873, DOI 10.1016/j.marpolbul.2010.07.020; *PLASTICSEUROPE MA, 2009, COMP FACTS PLAST 200; Ribic CA, 2010, MAR POLLUT BULL, V60, P1231, DOI 10.1016/j.marpolbul.2010.03.021; SHAW DG, 1994, MAR POLLUT BULL, V28, P39, DOI 10.1016/0025-326X(94)90184-8; SHAW DG, 1979, MAR POLLUT BULL, V10, P160, DOI 10.1016/0025-326X(79)90421-1; Sudhakar M, 2007, POLYM DEGRAD STABIL, V92, P1743, DOI 10.1016/j.polymdegradstab.2007.03.029; Teuten EL, 2007, ENVIRON SCI TECHNOL, V41, P7759, DOI 10.1021/es071737s; Teuten EL, 2009, PHILOS T R SOC B, V364, P2027, DOI 10.1098/rstb.2008.0284; Thompson RC, 2004, SCIENCE, V304, P838, DOI 10.1126/science.1094559; *US EPA, 1993, 842S93001 EPA; Webb HK, 2009, MICROBES ENVIRON, V24, P39, DOI 10.1264/jsme2.ME08538; WILBER RJ, 1987, OCEANUS, V30, P61; WONG CS, 1974, NATURE, V247, P30, DOI 10.1038/247030a0; YE S, 1991, Marine Pollution Bulletin, V22, P608, DOI 10.1016/0025-326X(91)90249-R	31	752	810	19	568	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1185	1188		10.1126/science.1192321	http://dx.doi.org/10.1126/science.1192321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20724586				2022-12-28	WOS:000281485600030
J	Sweeney, LB; Luo, LQ				Sweeney, Lora B.; Luo, Liqun			'Fore Brain: A Hint of the Ancestral Cortex	CELL			English	Editorial Material								By combining gene expression profiling with image registration, Tomer et al. (2010) find that the mushroom body of the segmented worm Platynereis dumerilii shares many features with the mammalian cerebral cortex. The authors propose that the mushroom body and cortex evolved from the same structure in the common ancestor of vertebrates and invertebrates.	[Sweeney, Lora B.; Luo, Liqun] Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; [Sweeney, Lora B.; Luo, Liqun] Stanford Univ, Dept Biol, Stanford, CA 94305 USA; [Sweeney, Lora B.; Luo, Liqun] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Luo, LQ (corresponding author), Stanford Univ, Neurosci Program, Stanford, CA 94305 USA.	lluo@stanford.edu		Sweeney, Lora/0000-0001-9242-5601; Luo, Liqun/0000-0001-5467-9264	NIDCD NIH HHS [R01 DC005982] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005982] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Farris SM, 2008, BRAIN BEHAV EVOLUT, V72, P106, DOI 10.1159/000151471; Hebert JM, 2008, NAT REV NEUROSCI, V9, P678, DOI 10.1038/nrn2463; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Kurylas AE, 2008, CELL TISSUE RES, V333, P125, DOI 10.1007/s00441-008-0620-x; Peterson KJ, 2004, P NATL ACAD SCI USA, V101, P6536, DOI 10.1073/pnas.0401670101; Raible F, 2005, SCIENCE, V310, P1325, DOI 10.1126/science.1119089; Rohlfing T, 2001, IEEE WORKSHOP ON MATHEMATICAL METHODS IN BIOMEDICAL IMAGE ANALYSIS, PROCEEDINGS, P187, DOI 10.1109/MMBIA.2001.991733; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Strausfeld NJ, 1998, LEARN MEMORY, V5, P11; Tomer R, 2010, CELL, V142, P800, DOI 10.1016/j.cell.2010.07.043	10	2	2	1	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5					679	681		10.1016/j.cell.2010.08.024	http://dx.doi.org/10.1016/j.cell.2010.08.024			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813256	Bronze			2022-12-28	WOS:000281523200011
J	Gitlin, LN; Winter, L; Dennis, MP; Hodgson, N; Hauck, WW				Gitlin, Laura N.; Winter, Laraine; Dennis, Marie P.; Hodgson, Nancy; Hauck, Walter W.			A Biobehavioral Home-Based Intervention and the Well-being of Patients With Dementia and Their Caregivers The COPE Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; ALZHEIMERS-DISEASE; OLDER-ADULTS; FUNCTIONAL IMPAIRMENT; COGNITIVE DECLINE; CARE; SCALE; INSTITUTIONALIZATION; METAANALYSIS; INDIVIDUALS	Context Optimal treatment to postpone functional decline in patients with dementia is not established. Objective To test a nonpharmacologic intervention realigning environmental demands with patient capabilities. Design, Setting, and Participants Prospective 2-group randomized trial (Care of Persons with Dementia in their Environments [COPE]) involving patients with dementia and family caregivers (community-living dyads) recruited from March 2006 through June 2008 in Pennsylvania. Interventions Up to 12 home or telephone contacts over 4 months by health professionals who assessed patient capabilities and deficits; obtained blood and urine samples; and trained families in home safety, simplifying tasks, and stress reduction. Control group caregivers received 3 telephone calls and educational materials. Main Outcome Measures Functional dependence, quality of life, frequency of agitated behaviors, and engagement for patients and well-being, confidence using activities, and perceived benefits for caregivers at 4 months. Results Of 284 dyads screened, 270 (95%) were eligible and 237 (88%) randomized. Data were collected from 209 dyads (88%) at 4 months and 173 (73%) at 9 months. At 4 months, compared with controls, COPE patients had less functional dependence (adjusted mean difference, 0.24; 95% CI, 0.03-0.44; P=.02; Cohen d=0.21) and less dependence in instrumental activities of daily living (adjusted mean difference, 0.32; 95% CI, 0.09-0.55; P=.007; Cohen d=0.43), measured by a 15-item scale modeled after the Functional Independence Measure; COPE patients also had improved engagement (adjusted mean difference, 0.12; 95% CI, 0.07-0.22; P=.03; Cohen d=0.26), measured by a 5-item scale. COPE caregivers improved in their wellbeing (adjusted mean difference in Perceived Change Index, 0.22; 95% CI, 0.080.36; P=.002; Cohen d=0.30) and confidence using activities (adjusted mean difference, 0.81; 95% CI, 0.30-1.32; P=.002; Cohen d=0.54), measured by a 5-item scale. By 4 months, 64 COPE dyads (62.7%) vs 48 control group dyads (44.9%) eliminated 1 or more caregiver-identified problems (chi(2)(1)=6.72, P=.01). Conclusion Among community-living dyads, a nonpharmacologic biobehavioral environmental intervention compared with control resulted in better outcomes for COPE dyads at 4 months. Although no group differences were observed at 9 months for patients, COPE caregivers perceived greater benefits. Trial Registration clinicaltrials.gov Identifier: NCT00259454 JAMA. 2010; 304(9): 983-991 www.jama.com	[Gitlin, Laura N.; Winter, Laraine; Dennis, Marie P.; Hodgson, Nancy] Thomas Jefferson Univ, Jefferson Ctr Appl Res Aging & Hlth, Philadelphia, PA 19130 USA; [Hauck, Walter W.] Sycamore Consulting, New Hope, PA USA	Jefferson University	Gitlin, LN (corresponding author), Thomas Jefferson Univ, Jefferson Ctr Appl Res Aging & Hlth, 130 S 9th St,Ste 513, Philadelphia, PA 19130 USA.	laura.gitlin@jefferson.edu			National Institute on Aging and the National Institute on Nursing Research [RO1 AG22254]; Pennsylvania Department of Health, Tobacco Settlement [SAP100027298]; NATIONAL INSTITUTE ON AGING [R01AG022254] Funding Source: NIH RePORTER	National Institute on Aging and the National Institute on Nursing Research; Pennsylvania Department of Health, Tobacco Settlement; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Research reported was supported in part by funds from the National Institute on Aging and the National Institute on Nursing Research (RO1 AG22254) and the Pennsylvania Department of Health, Tobacco Settlement (SAP100027298).	Albert SM, 1996, J AM GERIATR SOC, V44, P1342, DOI 10.1111/j.1532-5415.1996.tb01405.x; Alzheimer's Association, 2010 ALZH DIS FACTS; [Anonymous], 2010, PFIZER MEDIVATION AN; Atchison TB, 2007, ARCH CLIN NEUROPSYCH, V22, P99, DOI 10.1016/j.acn.2006.11.006; Ballard CG, 2009, NAT REV NEUROL, V5, P245, DOI 10.1038/nrneurol.2009.39; BATTLE CC, 1966, AM J PSYCHOTHER, V20, P184, DOI 10.1176/appi.psychotherapy.1966.20.1.184; Belle SH, 2006, ANN INTERN MED, V145, P727, DOI 10.7326/0003-4819-145-10-200611210-00005; BENJAMINI Y, 1995, J R STAT SOC B, V57, P1289; Cotter EM, 2008, J APPL GERONTOL, V27, P215, DOI 10.1177/0733464807310681; Earhart C. A., 2006, ALLEN DIAGNOSTIC MOD; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Gitlin Laura N, 2006, Am J Alzheimers Dis Other Demen, V21, P304, DOI 10.1177/1533317506292283; Gitlin LN, 2008, AM J GERIAT PSYCHIAT, V16, P229, DOI 10.1097/JGP.0b013e318160da72; Gitlin LN, 2010, J AM GERIATR SOC, V58, P1465, DOI 10.1111/j.1532-5415.2010.02971.x; Gitlin LN, 2005, J AGING HEALTH, V17, P148, DOI 10.1177/0898264304274184; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; Green RC, 2009, JAMA-J AM MED ASSOC, V302, P2557, DOI 10.1001/jama.2009.1866; Hill J, 2006, PHARMACOECONOMICS, V24, P265, DOI 10.2165/00019053-200624030-00006; Lingler JH, 2005, J AM GERIATR SOC, V53, P983, DOI 10.1111/j.1532-5415.2005.53313.x; Logsdon RG, 1999, J AM GERIATR SOC, V47, P1354, DOI 10.1111/j.1532-5415.1999.tb07439.x; Logsdon RG, 2002, PSYCHOSOM MED, V64, P510, DOI 10.1097/00006842-200205000-00016; Lopponen MK, 2004, DEMENT GERIATR COGN, V18, P321, DOI 10.1159/000080126; Miller JM, 2006, INT J NEUROSCI, V116, P613, DOI 10.1080/00207450600592164; Nourhashemi F, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2466; Prince MJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000176; Pruchno RA, 2008, GERONTOLOGIST, V48, P820, DOI 10.1093/geront/48.6.820; Rabins PV, 2007, INT PSYCHOGERIATR, V19, P401, DOI 10.1017/S1041610207004863; Roman GC, 2005, DEMENT GERIATR COGN, V20, P338, DOI 10.1159/000088494; Schulz R, 2002, GERONTOLOGIST, V42, P589, DOI 10.1093/geront/42.5.589; Sorensen S, 2006, LANCET NEUROL, V5, P961, DOI 10.1016/S1474-4422(06)70599-3; Soto ME, 2006, AGE AGEING, V35, P308, DOI 10.1093/ageing/afj059; Spillman BC, 2009, INQUIRY-J HEALTH CAR, V46, P140, DOI 10.5034/inquiryjrnl_46.02.140; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; Trinh NH, 2003, JAMA-J AM MED ASSOC, V289, P210, DOI 10.1001/jama.289.2.210; *US DEP LAB, 2008, B US DEP LAB, V2703	37	223	225	2	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					983	991		10.1001/jama.2010.1253	http://dx.doi.org/10.1001/jama.2010.1253			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645AD	20810376	Green Accepted			2022-12-28	WOS:000281422400024
J	Jain, SH; Cassel, CK				Jain, Sachin H.; Cassel, Christine K.			Societal Perceptions of Physicians Knights, Knaves, or Pawns?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Jain, Sachin H.] Off Natl Coordinator Hlth Informat Technol, Washington, DC 20201 USA; [Cassel, Christine K.] Amer Board Internal Med, Philadelphia, PA USA	American Board of Internal Medicine	Jain, SH (corresponding author), Off Natl Coordinator Hlth Informat Technol, 200 Independence Ave SW,Ste 729D, Washington, DC 20201 USA.	sachin.jain@hhs.gov						Choudhry NK, 2005, ANN INTERN MED, V142, P260, DOI 10.7326/0003-4819-142-4-200502150-00008; Committee on Quality of Health Care in America loM, 2001, CROSS QUAL CHASM; ENTHOVEN A, 2004, 21 CENTURY HLTH SYST; Le Grand J., 2003, MOTIVATION AGENCY PU; McClellan M, 2010, HEALTH AFFAIR, V29, P982, DOI 10.1377/hlthaff.2010.0194	5	25	25	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					1009	1010		10.1001/jama.2010.1250	http://dx.doi.org/10.1001/jama.2010.1250			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20810381				2022-12-28	WOS:000281422400030
J	Matsuzaki, Y; Ogawa-Ohnishi, M; Mori, A; Matsubayashi, Y				Matsuzaki, Yo; Ogawa-Ohnishi, Mari; Mori, Ayaka; Matsubayashi, Yoshikatsu			Secreted Peptide Signals Required for Maintenance of Root Stem Cell Niche in Arabidopsis	SCIENCE			English	Article							PHYTOSULFOKINE; PROLIFERATION; PROTEINS; GENES	Stem cells are maintained in the niche by intercellular interactions and signaling networks. In this work, we study extracellular signals required for maintenance of the root stem cell niche in higher plants. We identify a family of functionally redundant homologous peptides that are secreted, tyrosine-sulfated, and expressed mainly in the stem cell area and the innermost layer of central columella cells. We name these peptides root meristem growth factors (RGFs). RGFs are required for maintenance of the root stem cell niche and transit amplifying cell proliferation in Arabidopsis. RGF1 defines expression levels and patterns of the stem cell transcription factor PLETHORA, mainly at the posttranscriptional level. The RGFs function independently of the auxin pathway. These peptide signals play a crucial role in postembryonic root development.	[Matsuzaki, Yo; Ogawa-Ohnishi, Mari; Mori, Ayaka; Matsubayashi, Yoshikatsu] Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Matsubayashi, Y (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	matsu@agr.nagoya-u.ac.jp	MATSUBAYASHI, Yoshikatsu/AAA-9705-2019	Ogawa-Ohnishi, Mari/0000-0002-7581-2607; Matsubayashi, Yoshikatsu/0000-0002-2669-2119	Ministry of Education, Culture, Sports, Science, and Technology [19060010]; Japan Society for the Promotion of Science [19GS0315]	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank P. Doerner for providing the CYCB1; 1: GUS seeds, T. Guilfoyle for the DR5:GUS seeds, and B. Scheres for the plt1-4 plt2-2 seeds. This research was supported by a Grant-in-Aid for Scientific Research for Priority Areas from the Ministry of Education, Culture, Sports, Science, and Technology (no. 19060010) and a Grant-in-Aid for Creative Scientific Research from the Japan Society for the Promotion of Science (no. 19GS0315).	Aida M, 2004, CELL, V119, P109, DOI 10.1016/j.cell.2004.09.018; Amano Y, 2007, P NATL ACAD SCI USA, V104, P18333, DOI 10.1073/pnas.0706403104; Ashe HL, 2006, DEVELOPMENT, V133, P385, DOI 10.1242/dev.02238; Colon-Carmona A, 1999, PLANT J, V20, P503, DOI 10.1046/j.1365-313x.1999.00620.x; Galinha C, 2007, NATURE, V449, P1053, DOI 10.1038/nature06206; Komori R, 2009, P NATL ACAD SCI USA, V106, P15067, DOI 10.1073/pnas.0902801106; Matsubayashi Y, 1996, P NATL ACAD SCI USA, V93, P7623, DOI 10.1073/pnas.93.15.7623; Matsubayashi Y, 2006, PLANT PHYSIOL, V142, P45, DOI 10.1104/pp.106.081109; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; Sarkar AK, 2007, NATURE, V446, P811, DOI 10.1038/nature05703; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963	11	278	313	7	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1065	1067		10.1126/science.1191132	http://dx.doi.org/10.1126/science.1191132			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798316				2022-12-28	WOS:000281253500037
J	Stadler, G; Gurnis, M; Burstedde, C; Wilcox, LC; Alisic, L; Ghattas, O				Stadler, Georg; Gurnis, Michael; Burstedde, Carsten; Wilcox, Lucas C.; Alisic, Laura; Ghattas, Omar			The Dynamics of Plate Tectonics and Mantle Flow: From Local to Global Scales	SCIENCE			English	Article							SUBDUCTION ZONES; MOTION; MODEL; SLABS; LITHOSPHERE; STRENGTH	Plate tectonics is regulated by driving and resisting forces concentrated at plate boundaries, but observationally constrained high-resolution models of global mantle flow remain a computational challenge. We capitalized on advances in adaptive mesh refinement algorithms on parallel computers to simulate global mantle flow by incorporating plate motions, with individual plate margins resolved down to a scale of 1 kilometer. Back-arc extension and slab rollback are emergent consequences of slab descent in the upper mantle. Cold thermal anomalies within the lower mantle couple into oceanic plates through narrow high-viscosity slabs, altering the velocity of oceanic plates. Viscous dissipation within the bending lithosphere at trenches amounts to similar to 5 to 20% of the total dissipation through the entire lithosphere and mantle.	[Gurnis, Michael; Alisic, Laura] CALTECH, Seismol Lab, Pasadena, CA 91125 USA; [Stadler, Georg; Burstedde, Carsten; Wilcox, Lucas C.; Ghattas, Omar] Univ Texas Austin, Inst Computat Engn & Sci, Austin, TX 78712 USA; [Ghattas, Omar] Univ Texas Austin, Jackson Sch Geosci, Austin, TX 78713 USA; [Ghattas, Omar] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA	California Institute of Technology; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Gurnis, M (corresponding author), CALTECH, Seismol Lab, Pasadena, CA 91125 USA.	gurnis@caltech.edu	Stadler, Georg/D-2120-2013		NSF [OCI-0749334, OCI-0748898, CCF-0427985, DMS-072474]; NSF Earth Sciences [EAR-0426271, EAR-0810303]; U.S. Department of Energy Office of Science [DE-FC02-06ER25782, DE-SC0002710]; Gordon and Betty Moore Foundation; Computing resources on Texas Advanced Computing Center through the NSF [TG-MCA04N026]; Office of Polar Programs (OPP) [0941678] Funding Source: National Science Foundation	NSF(National Science Foundation (NSF)); NSF Earth Sciences(National Science Foundation (NSF)); U.S. Department of Energy Office of Science(United States Department of Energy (DOE)); Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); Computing resources on Texas Advanced Computing Center through the NSF; Office of Polar Programs (OPP)(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	We thank W. Leng, T. Becker, and J.-P. Avouac for helpful comments on the manuscript. This work was partially supported by NSF's PetaApps program (OCI-0749334 and OCI-0748898), NSF Earth Sciences (EAR-0426271 and EAR-0810303), U.S. Department of Energy Office of Science's SciDAC program (DE-FC02-06ER25782 and DE-SC0002710), NSF grants CCF-0427985 and DMS-072474, and the Caltech Tectonics Observatory (by the Gordon and Betty Moore Foundation). Computing resources on Texas Advanced Computing Center's Ranger and Spur systems were provided through the NSF TeraGrid under grant TG-MCA04N026.	ABE K, 1979, J GEOPHYS RES, V84, P3589, DOI 10.1029/JB084iB07p03589; ARGUS DF, 1991, GEOPHYS RES LETT, V18, P2039, DOI 10.1029/91GL01532; Becker TW, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2001GC000171; Billen MI, 2008, ANNU REV EARTH PL SC, V36, P325, DOI 10.1146/annurev.earth.36.031207.124129; Billen MI, 2003, GEOPHYS J INT, V153, P359, DOI 10.1046/j.1365-246X.2003.01915.x; Billen MI, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003308; Bird P, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000252; Buffett BA, 2006, EARTH PLANET SC LETT, V245, P359, DOI 10.1016/j.epsl.2006.03.011; Burstedde C., 2008, P 2008 ACM IEEE C SU, P1, DOI DOI 10.1145/1413370.1413434; Burstedde C, 2009, J PHYS CONF SER, V180, DOI 10.1088/1742-6596/180/1/012009; Burstedde C, 2009, COMPUT METHOD APPL M, V198, P1691, DOI 10.1016/j.cma.2008.12.015; Cizkova H, 2002, EARTH PLANET SC LETT, V199, P447, DOI 10.1016/S0012-821X(02)00586-1; Conrad CP, 1999, J GEOPHYS RES-SOL EA, V104, P17551, DOI 10.1029/1999JB900149; Conrad CP, 2002, SCIENCE, V298, P207, DOI 10.1126/science.1074161; Conrad CP, 1999, GEOPHYS RES LETT, V26, P3041, DOI 10.1029/1999GL005397; Davies G.F., 1999, DYNAMIC EARTH PLATES; Davies GF, 2009, EARTH PLANET SC LETT, V287, P513, DOI 10.1016/j.epsl.2009.08.038; Dewey J. F, 1980, CONTINENTAL CRUST IT, P553; Diachin LF, 2006, SOFTW ENVIRON TOOLS, P143, DOI 10.1137/1.9780898718133.ch8; Faccenna C, 2007, EARTH PLANET SC LETT, V257, P29, DOI 10.1016/j.epsl.2007.02.016; Ghosh A, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL040426; GORDON RG, 1992, SCIENCE, V256, P333, DOI 10.1126/science.256.5055.333; Gordon RG, 1998, NATURE, V395, P370, DOI 10.1038/26463; HAGER BH, 1981, J GEOPHYS RES, V86, P4843, DOI 10.1029/JB086iB06p04843; Hebert LB, 2009, EARTH PLANET SC LETT, V278, P243, DOI 10.1016/j.epsl.2008.12.013; Hirth G., 2003, INSIDE SUBDUCTION FA, V138, P83, DOI [10.1029/138GM06, DOI 10.1029/138GM06]; ISACKS B, 1971, REV GEOPHYS SPACE GE, V9, P103, DOI 10.1029/RG009i001p00103; Jadamec MA, 2010, NATURE, V465, P338, DOI 10.1038/nature09053; LENG W, 2010, EARTH PLANET SC LETT, DOI DOI 10.1016/J.ESPL.2010.06.016; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; Muller RD, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2007GC001743; Schellart WP, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB002970; UYEDA S, 1979, J GEOPHYS RES, V84, P1049, DOI 10.1029/JB084iB03p01049; Wu BJ, 2008, EARTH PLANET SC LETT, V272, P412, DOI 10.1016/j.epsl.2008.05.009; Yoshida M, 2009, PHYS EARTH PLANET IN, V172, P278, DOI 10.1016/j.pepi.2008.10.018; Zhong SJ, 1998, J GEOPHYS RES-SOL EA, V103, P15255, DOI 10.1029/98JB00605; ZHONG SJ, 1995, SCIENCE, V267, P838, DOI 10.1126/science.267.5199.838	37	202	214	5	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2010	329	5995					1033	1038		10.1126/science.1191223	http://dx.doi.org/10.1126/science.1191223			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798311				2022-12-28	WOS:000281253500029
J	Foster, KM; Bergin, KB; McKenna, AF; Millard, DL; Perez, LC; Prival, JT; Rainey, DY; Sevian, HM; VanderPutten, EA; Hamos, JE				Foster, K. M.; Bergin, K. B.; McKenna, A. F.; Millard, D. L.; Perez, L. C.; Prival, J. T.; Rainey, D. Y.; Sevian, H. M.; VanderPutten, E. A.; Hamos, J. E.			Partnerships for STEM Education	SCIENCE			English	Editorial Material									[Foster, K. M.; Bergin, K. B.; McKenna, A. F.; Millard, D. L.; Perez, L. C.; Prival, J. T.; Rainey, D. Y.; Sevian, H. M.; VanderPutten, E. A.; Hamos, J. E.] Natl Sci Fdn, Div Undergrad Educ, Arlington, VA 22230 USA; [Foster, K. M.] Univ Texas Austin, Inst Community, Austin, TX 78712 USA; [Foster, K. M.] Univ Texas Austin, Sch Partnerships, Austin, TX 78712 USA	National Science Foundation (NSF); NSF- Directorate for Education & Human Resources (EHR); NSF - Division of Undergraduate Education (DUE); University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Foster, KM (corresponding author), Natl Sci Fdn, Div Undergrad Educ, 4201 Wilson Blvd, Arlington, VA 22230 USA.	kmfoster@mail.utexas.edu						*COMM SCI ENG PUBL, 2007, RIS GATH STORM EN EM; Conant J., 1963, ED AM TEACHERS; Cross R, 2001, ORGAN DYN, V30, P100, DOI 10.1016/S0090-2616(01)00046-8; Editorial, 2010, NATURE, V465, P525; Ellison J., 2008, SCHOLARSHIP PUBLIC K; FRANK J, 2010, MSP LEARN NETW C WAS; Goodlad J. I., 1994, ED RENEWAL BETTER TE; Hamos J., 2009, SCI ED, V18, P14; KARP J, 2008, MSP LEARN NETW C WAS; KETTLEWELL J, 2009, INCREASING COMPETITI; KOZAITIS K, 2008, PRACTIC ANTHR, V30, P14; Kutal C., 2009, INCREASING COMPETITI, P121; *NSF, 2010, 10046 NSF; Pomeroy D., 2010, NAT ASS RES SCI TEAC; Skerrett A, 2010, CULT STUD SCI EDUCAT, V5, P743, DOI 10.1007/s11422-009-9235-0; *U TEX EL PAS, 2010, HDB OP PROC; ZHANG X, 2009, WHO BENEFITS EFFECT	17	17	18	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					906	907		10.1126/science.1191040	http://dx.doi.org/10.1126/science.1191040			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	640WN	20724621				2022-12-28	WOS:000281084800019
J	Kim, HJ; Benner, SA				Kim, Hyo-Joong; Benner, Steven A.			Comment on "The Silicate-Mediated Formose Reaction: Bottom-Up Synthesis of Sugar Silicates"	SCIENCE			English	Editorial Material							MINERALS	Lambert et al. (Reports, 19 February 2010, p. 984) reported that silicate ions catalyze the formation and stabilization of four- and six-carbon sugars from simple sugars, suggesting a possible prebiotic pathway for the synthesis of biologically important sugars. Here, we show that silicate has minimal impact in these respects, especially when compared to borate minerals.	[Kim, Hyo-Joong; Benner, Steven A.] Westheimer Inst Sci & Technol, Fdn Appl Mol Evolut, Gainesville, FL 32601 USA		Benner, SA (corresponding author), Westheimer Inst Sci & Technol, Fdn Appl Mol Evolut, 720 SW 2nd Ave,Suite 201, Gainesville, FL 32601 USA.	sbenner@ffame.org						Hazen RM, 2009, AM MINERAL, V94, P1293, DOI 10.2138/am.2009.3208; KINRADE SD, 2003, J CHEM SOC DA, P3713, DOI DOI 10.1039/B307510A; Lambert JB, 2004, J AM CHEM SOC, V126, P9611, DOI 10.1021/ja031748v; Lambert JB, 2010, SCIENCE, V327, P984, DOI 10.1126/science.1182669; Ricardo A, 2004, SCIENCE, V303, P196, DOI 10.1126/science.1092464	5	27	27	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994								10.1126/science.1188697	http://dx.doi.org/10.1126/science.1188697			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724620				2022-12-28	WOS:000281084800015
J	Seymour, CW; Kahn, JM; Cooke, CR; Watkins, TR; Heckbert, SR; Rea, TD				Seymour, Christopher W.; Kahn, Jeremy M.; Cooke, Colin R.; Watkins, Timothy R.; Heckbert, Susan R.; Rea, Thomas D.			Prediction of Critical Illness During Out-of-Hospital Emergency Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; MYOCARDIAL-INFARCTION; MULTIPLE IMPUTATION; UNITED-STATES; SEVERE SEPSIS; FIELD TRIAGE; PATIENT; MORTALITY; VOLUME; REGIONALIZATION	Context Early identification of nontrauma patients in need of critical care services in the emergency setting may improve triage decisions and facilitate regionalization of critical care. Objectives To determine the out-of-hospital clinical predictors of critical illness and to characterize the performance of a simple score for out-of-hospital prediction of development of critical illness during hospitalization. Design and Setting Population-based cohort study of an emergency medical services (EMS) system in greater King County, Washington (excluding metropolitan Seattle), that transports to 16 receiving facilities. Patients Nontrauma, non cardiac arrest adult patients transported to a hospital by King County EMS from 2002 through 2006. Eligible records with complete data (N=144 913) were linked to hospital discharge data and randomly split into development (n=87 266 [60%]) and validation (n=57 647 [40%]) cohorts. Main Outcome Measure Development of critical illness, defined as severe sepsis, delivery of mechanical ventilation, or death during hospitalization. Results Critical illness occurred during hospitalization in 5% of the development (n=4835) and validation (n=3121) cohorts. Multivariable predictors of critical illness included older age, lower systolic blood pressure, abnormal respiratory rate, lower Glasgow Coma Scale score, lower pulse oximetry, and nursing home residence during out-of-hospital care (P<.01 for all). When applying a summary critical illness prediction score to the validation cohort (range, 0-8), the area under the receiver operating characteristic curve was 0.77 (95% confidence interval [CI], 0.76-0.78), with satisfactory calibration slope (1.0). Using a score threshold of 4 or higher, sensitivity was 0.22 (95% CI, 0.20-0.23), specificity was 0.98 (95% CI, 0.98-0.98), positive likelihood ratio was 9.8 (95% Cl, 8.9-10.6), and negative likelihood ratio was 0.80 (95% Cl, 0.79- 0.82). A threshold of 1 or greater for critical illness improved sensitivity (0.98; 95% CI, 0.97-0.98) but reduced specificity (0.17; 95% CI, 0.17-0.17). Conclusions In a population-based cohort, the score on a prediction rule using out-of-hospital factors was significantly associated with the development of critical illness during hospitalization. This score requires external validation in an independent population. JAMA. 2010;304(7):747-754 www.jama.com	[Seymour, Christopher W.; Watkins, Timothy R.] Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98104 USA; [Watkins, Timothy R.] Univ Washington, Puget Sound Blood Ctr, Div Res, Seattle, WA 98104 USA; [Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA; [Rea, Thomas D.] Univ Washington, Div Gen Internal Med, Seattle, WA 98104 USA; [Kahn, Jeremy M.] Univ Penn, Med Ctr, Leonard Davis Inst Hlth Econ, Div Pulm Allergy & Crit Care,Sch Med, Philadelphia, PA 19104 USA; [Kahn, Jeremy M.] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Sch Med, Philadelphia, PA 19104 USA; [Cooke, Colin R.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Cooke, Colin R.] Univ Michigan, Robert Wood Johnson Clin Scholar Program, Ann Arbor, MI 48109 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Puget Sound Blood Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Michigan System; University of Michigan; Robert Wood Johnson Foundation (RWJF); University of Michigan System; University of Michigan	Seymour, CW (corresponding author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, POB 359762, Seattle, WA 98104 USA.	seymoc@u.washington.edu		Cooke, Colin/0000-0001-9713-5371; Kahn, Jeremy/0000-0001-9688-5576	National Institutes of Health (NIH) [T32 NIH/HL07287, K23 HL082650, K23 GM086729-01, 5UL1RR0205014, R01 HL088576-01A1, R01 HL074098-01A1]; National Center for Research Resources, NIH [KL2 RR025015]; Robert Wood Johnson Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025015, UL1RR025014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074098, K23HL082650, R01HL088576, T32HL007287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM086729] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Dr Seymour is supported in part by extramural training grant T32 NIH/HL07287 from the National Institutes of Health (NIH) and by National Center for Research Resources grant KL2 RR025015 from the NIH. Dr Kahn is supported by a career development award K23 HL082650 from the NIH. Dr Cooke is supported by the Robert Wood Johnson Foundation Clinical Scholars Program. Dr Watkins is supported by career development award K23 GM086729-01 from the NIH. Dr Heckbert is supported by grant 5UL1RR0205014 from the NIH. Dr Rea is supported by grants R01 HL088576-01A1 and R01 HL074098-01A1 from the NIH.	Akaike H., 1971, 2 INT S INF THEOR SE; Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Barnato AE, 2008, AM J RESP CRIT CARE, V177, P279, DOI 10.1164/rccm.200703-480OC; Barnato AE, 2007, CRIT CARE MED, V35, P1003, DOI 10.1097/01.CCM.0000259535.06205.B4; Brier G.W., 1950, MON WEATHER REV, V78, P1, DOI [10.1175/1520-0493(1950)0782.0.CO,2, DOI 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2, 10.1175/1520-0493(1950)0782.0.CO;2]; Brooks SC, 2009, CAN J EMERG MED, V11, P481; Brown JP, 2008, AM J CARDIOL, V101, P158, DOI 10.1016/j.amjcard.2007.07.082; Brown LH, 2009, PREHOSP EMERG CARE, V13, P516, DOI 10.1080/10903120903144809; Carr BG, 2010, ANN EMERG MED, V56, P49, DOI 10.1016/j.annemergmed.2009.12.013; Dawson DE, 2006, PREHOSP EMERG CARE, V10, P314, DOI 10.1080/10903120600724200; Dean JM, 2001, ANN EMERG MED, V37, P616, DOI 10.1067/mem.2001.115214; Durairaj L, 2005, CHEST, V128, P1682, DOI 10.1378/chest.128.3.1682; Ehlenbach WJ, 2010, JAMA-J AM MED ASSOC, V303, P763, DOI 10.1001/jama.2010.167; Feldman MJ, 2006, ACAD EMERG MED, V13, P954, DOI 10.1197/j.aem.2006.04.018; FELLEGI IP, 1969, J AM STAT ASSOC, V64, P1183, DOI 10.2307/2286061; Glance LG, 2006, CRIT CARE MED, V34, P1925, DOI 10.1097/01.CCM.0000226415.93237.84; Grossman DC, 1997, J TRAUMA, V42, P723, DOI 10.1097/00005373-199704000-00024; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Huemer G, 1994, Eur J Emerg Med, V1, P62; Institute of Medicine, 2007, HOSP BAS EM CAR BREA; Kahn JM, 2008, CRIT CARE MED, V36, P3085, DOI 10.1097/CCM.0b013e31818c37b2; Kahn JM, 2008, AM J RESP CRIT CARE, V177, P285, DOI 10.1164/rccm.200708-1214OC; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kahn JM, 2009, CRIT CARE MED, V37, P2149, DOI 10.1097/CCM.0b013e3181a009d0; Kidwell CS, 2000, STROKE, V31, P71, DOI 10.1161/01.STR.31.1.71; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KOTHARI R, 1995, STROKE, V26, P937, DOI 10.1161/01.STR.26.6.937; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Langhelle A, 2003, RESUSCITATION, V56, P247, DOI 10.1016/S0300-9572(02)00409-4; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Levine SD, 2006, J EMERG MED, V31, P1, DOI 10.1016/j.jemermed.2005.08.007; Mackersie RC, 2006, PREHOSP EMERG CARE, V10, P287, DOI 10.1080/10903120600721636; Marshall A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-7; MCKELVEY RD, 1975, J MATH SOCIOL, V4, P103, DOI 10.1080/0022250X.1975.9989847; MILLER ME, 1993, MED DECIS MAKING, V13, P49, DOI 10.1177/0272989X9301300107; Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5; Neely K W, 2000, Prehosp Emerg Care, V4, P238, DOI 10.1080/10903120090941263; Newgard CD, 2006, ACAD EMERG MED, V13, P314, DOI 10.1197/j.aem.2005.09.011; Pearse RM, 2009, CRIT CARE, V13, DOI 10.1186/cc7687; Price Timothy G, 2005, Prehosp Emerg Care, V9, P322, DOI 10.1080/10903120590962012; Quan H, 2004, MED CARE, V42, P801, DOI 10.1097/01.mlr.0000132391.59713.0d; Rehkopf DH, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-383; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Royston P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b604; Sasser Scott M., 2009, Morbidity and Mortality Weekly Report, V58, P1; Sasson C, 2008, JAMA-J AM MED ASSOC, V300, P1432, DOI 10.1001/jama.300.12.1432; Sivagangabalan G, 2009, AM J CARDIOL, V103, P907, DOI 10.1016/j.amjcard.2008.12.007; Sporer KA, 2008, PREHOSP EMERG CARE, V12, P470, DOI 10.1080/10903120802290877; Studnek J, 2009, PREHOSP EMERG CARE, V13, P53, DOI 10.1080/10903120802471964; Wang HE, 2010, RESUSCITATION, V81, P193, DOI 10.1016/j.resuscitation.2009.11.008; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; Yarris LM, 2006, ACAD EMERG MED, V13, P401, DOI 10.1197/j.aem.2005.11.079	53	102	104	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					747	754		10.1001/jama.2010.1140	http://dx.doi.org/10.1001/jama.2010.1140			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20716737	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000280993700021
J	Campion, EW; Scott, L; Bowab, C; Fleming, S; Blizzard, TJ; Lamb, C; Easley, TJ; Drazen, JM				Campion, Edward W.; Scott, Lisa; Bowab, Cynthia; Fleming, Sara; Blizzard, Theodore J.; Lamb, Christine; Easley, Thomas J.; Drazen, Jeffrey M.			The New NEJM.org	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material													Drazen, Jeffrey M/E-5841-2012					Campion EW, 2001, NEW ENGL J MED, V344, P1710, DOI 10.1056/NEJM200105313442209; CAMPION EW, 1996, NEW ENGL J MED, V334, P1129	2	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					677	678		10.1056/NEJMe1007409	http://dx.doi.org/10.1056/NEJMe1007409			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	636TN	20818859				2022-12-28	WOS:000280764600012
J	DELAMOTHE, T				DELAMOTHE, T			AFTER THE SUMMIT	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1988	296	6638					1728	1729		10.1136/bmj.296.6638.1728	http://dx.doi.org/10.1136/bmj.296.6638.1728			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N8893	20743005	Green Published			2022-12-28	WOS:A1988N889300024
J	ALSTEAD, S				ALSTEAD, S			A CAUTIONARY TALE	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1988	296	6635					1515	1516		10.1136/bmj.296.6635.1515	http://dx.doi.org/10.1136/bmj.296.6635.1515			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N6525	20742995	Green Published			2022-12-28	WOS:A1988N652500023
J	WARDEN, J				WARDEN, J			SPRING CLEANING TIME	BRITISH MEDICAL JOURNAL			English	Letter																		1987, BR MED J, V295, P1576; 1987, BR MED J, V294, P716; 1987, BR MED J, V294, P1107	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1988	296	6625					872	872		10.1136/bmj.296.6625.872	http://dx.doi.org/10.1136/bmj.296.6625.872			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M6978	20742973	Green Published			2022-12-28	WOS:A1988M697800055
J	WARDEN, J				WARDEN, J			PRIME MINISTERS MIND NOT CLOSED ON MEDICAL DEFENSE	BRITISH MEDICAL JOURNAL			English	Letter																		1987, BR MED J, V295, P280	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1988	296	6616					221	221		10.1136/bmj.296.6616.221	http://dx.doi.org/10.1136/bmj.296.6616.221			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L7142	20742947	Green Published			2022-12-28	WOS:A1988L714200066
J	Mezic, I; Loire, S; Fonoberov, VA; Hogan, P				Mezic, Igor; Loire, S.; Fonoberov, Vladimir A.; Hogan, P.			A New Mixing Diagnostic and Gulf Oil Spill Movement	SCIENCE			English	Article							LAGRANGIAN COHERENT STRUCTURES; APERIODIC FLOWS; FLUID-FLOWS; 2-DIMENSIONAL TURBULENCE	Chaotic advection has served as the paradigm for mixing in fluid flows with simple time dependence. Its skeletal structure is based on analysis of invariant attracting and repelling manifolds in fluid flows. Here we develop a finite-time theory for two-dimensional incompressible fluid flows with arbitrary time dependence and introduce a new mixing diagnostic based on it. Besides stretching events around attracting and repelling manifolds, this allows us to detect hyperbolic mixing zones. We used the new diagnostic to forecast the spatial location and timing of oil washing ashore in Plaquemines Parish and Grand Isle, Louisiana, and Pensacola, Florida, in May 2010 and the flow of oil toward Panama City Beach, Florida, in June 2010.	[Mezic, Igor; Loire, S.] Univ Calif Santa Barbara, Ctr Control Dynam Syst & Computat, Santa Barbara, CA 93106 USA; [Mezic, Igor; Loire, S.] Univ Calif Santa Barbara, Dept Mech Engn, Santa Barbara, CA 93106 USA; [Fonoberov, Vladimir A.] Aimdyn, Santa Barbara, CA 93101 USA; [Hogan, P.] USN, Res Lab, Stennis Space Ctr, Stennis Space Ctr, MS 39529 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; National Aeronautics & Space Administration (NASA); United States Department of Defense; United States Navy; Naval Research Laboratory	Mezic, I (corresponding author), Univ Calif Santa Barbara, Ctr Control Dynam Syst & Computat, Santa Barbara, CA 93106 USA.	mezic@engineering.ucsb.edu	Mezic, Igor/R-9659-2018	Mezic, Igor/0000-0002-2873-9013	Aimdyn; Naval Research Laboratory in Stennis, MS	Aimdyn; Naval Research Laboratory in Stennis, MS	We thank B. Lipphardt of the University of Delaware, whose initial calculations showed the potential of the concepts described here in the context of the Gulf oil spill; and G. Haller for useful comments. The work of I.M., S.L., and V.A.F. was supported by Aimdyn. I.M. and S.L. were consultants for Aimdyn. P.H.'s work was supported by the Naval Research Laboratory in Stennis, MS. We are thankful to the leadership of the U.S. Coast Guard at the Cocodrie, Louisiana, site for their interest in this work.	Aref H., 1984, J FLUID MECH, V192, P115; BERGER A, 2008, DISCRETE CONT DYN S, V9, P3; Doering CR, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.025301; DRESSELHAUS E, 1992, J FLUID MECH, V236, P415, DOI 10.1017/S0022112092001460; Haller G, 2001, PHYSICA D, V149, P248, DOI 10.1016/S0167-2789(00)00199-8; Haller G, 2002, PHYS FLUIDS, V14, P1851, DOI 10.1063/1.1477449; Haller G, 2001, PHYS FLUIDS, V13, P3365, DOI 10.1063/1.1403336; Haller G, 1998, PHYSICA D, V119, P352, DOI 10.1016/S0167-2789(98)00091-8; Haller G, 2000, PHYSICA D, V147, P352, DOI 10.1016/S0167-2789(00)00142-1; HALLER G, 2000, J NONLINEAR SCI, V10, P99; Lapeyre G, 2001, CHAOS, V11, P427, DOI 10.1063/1.1374241; Lekien F, 2007, J MATH PHYS, V48, DOI 10.1063/1.2740025; Levnajic Z, 2010, CHAOS, V20, DOI 10.1063/1.3458896; Malhotra N, 1998, INT J BIFURCAT CHAOS, V8, P1053, DOI 10.1142/S0218127498000875; Mezic I, 2002, PHYS FLUIDS, V14, P2235, DOI 10.1063/1.1480266; MEZIC I, 1999, J NONLINEAR SCI, V9, P213; OKUBO A, DEEP SEA RES OC ABST, V17, P445; Ottino JM., 1989, KINEMATICS MIXING ST; Plasting SC, 2006, J FLUID MECH, V552, P289, DOI 10.1017/S0022112006008639; Poje AC, 1999, PHYS FLUIDS, V11, P2963, DOI 10.1063/1.870155; Shadden SC, 2005, PHYSICA D, V212, P271, DOI 10.1016/j.physd.2005.10.007; Solomon TH, 2003, NATURE, V425, P376, DOI 10.1038/nature01993; WEISS J, 1991, PHYSICA D, V48, P273, DOI 10.1016/0167-2789(91)90088-Q; WIGGINS S, 1992, CHAOTIC TRANSPORT DY	24	142	146	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2010	330	6003					486	489		10.1126/science.1194607	http://dx.doi.org/10.1126/science.1194607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	669EL	20813922				2022-12-28	WOS:000283329100034
J	Howard, A; Wilson, M				Howard, Andrew; Wilson, Mary			Easily Missed? Septic arthritis in children	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TRANSIENT SYNOVITIS; HIP; DIFFERENTIATION; CHILDHOOD; SEQUELAE		[Howard, Andrew] Hosp Sick Children, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; [Wilson, Mary] Marathon Family Hlth Team, Marathon, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Howard, A (corresponding author), Hosp Sick Children, Div Orthopaed Surg, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	andrew.howard@sickkids.ca		Howard, Andrew/0000-0001-7226-6471				Baskett A, 2009, PEDIATR EMERG CARE, V25, P78, DOI 10.1097/PEC.0b013e318196ea43; Caird MS, 2006, J BONE JOINT SURG AM, V88A, P1251, DOI 10.2106/JBJS.E.00216; Choi IH, 2005, CLIN ORTHOP RELAT R, P102, DOI 10.1097/01.blo.0000162412.93473.68; Forlin E, 2008, J PEDIATR ORTHOPED, V28, P524, DOI 10.1097/BPO.0b013e31817bb079; Givon U, 2004, J PEDIATR ORTHOPED, V24, P266, DOI 10.1097/01241398-200405000-00006; Goergens ED, 2005, J PAEDIATR CHILD H, V41, P59, DOI 10.1111/j.1440-1754.2005.00538.x; Gordon JE, 2002, J PEDIATR ORTHOPED, V22, P312, DOI 10.1097/00004694-200205000-00008; Kocher MS, 2004, J BONE JOINT SURG AM, V86A, P1629, DOI 10.2106/00004623-200408000-00005; Kocher MS, 1999, J BONE JOINT SURG AM, V81A, P1662, DOI 10.2106/00004623-199912000-00002; Luhmann SJ, 2004, J BONE JOINT SURG AM, V86A, P956, DOI 10.2106/00004623-200405000-00011; Nunn TR, 2007, J BONE JOINT SURG BR, V89B, P100, DOI 10.1302/0301-620X.89B1.17940; Peltola H, 2009, CLIN INFECT DIS, V48, P1201, DOI 10.1086/597582; Riise OR, 2008, PEDIATRICS, V121, pE299, DOI 10.1542/peds.2007-0291	13	3	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 7	2010	341								c4407	10.1136/bmj.c4407	http://dx.doi.org/10.1136/bmj.c4407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663JJ	20801999				2022-12-28	WOS:000282880500008
J	Rehani, M; Frush, D				Rehani, Madan; Frush, Donald			Tracking radiation exposure of patients	LANCET			English	Editorial Material							CT		[Rehani, Madan] IAEA, A-1400 Vienna, Austria; [Frush, Donald] Duke Radiol, Durham, NC USA	International Atomic Energy Agency	Rehani, M (corresponding author), IAEA, A-1400 Vienna, Austria.	m.rehani@iaea.org	Rehani, Madan/A-5198-2010	Rehani, Madan/0000-0003-3519-1516				Amis E Stephen Jr, 2007, J Am Coll Radiol, V4, P272, DOI 10.1016/j.jacr.2007.03.002; [Anonymous], ALLIANCE RAD SAFETY; [Anonymous], 2009, 160 NCRP; BERRINGTON DE, 2007, ARCH INTERN MED, V169, P2071; Birnbaum Steven, 2008, J Am Coll Radiol, V5, P714, DOI 10.1016/j.jacr.2008.02.016; FDA, 2010, FDA UNV IN RED UNN R; FDA, 2009, SAF INV CT BRAIN PER; *IAEA, IAEA SMART CARD SMAR; Neumann RD, 2010, J AM COLL RADIOL, V7, P87, DOI 10.1016/j.jacr.2009.07.012; Oikarinen H, 2009, EUR RADIOL, V19, P1161, DOI 10.1007/s00330-008-1256-7; Rehani MM, 2009, IAEA B, V50; Sodickson A, 2009, RADIOLOGY, V251, P175, DOI 10.1148/radiol.2511081296	12	36	36	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	2010	376	9743					754	755		10.1016/S0140-6736(10)60657-5	http://dx.doi.org/10.1016/S0140-6736(10)60657-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816532				2022-12-28	WOS:000281831000010
J	Kobayashi, T; Yamaguchi, T; Hamanaka, S; Kato-Itoh, M; Yamazaki, Y; Ibata, M; Sato, H; Lee, YS; Usui, J; Knisely, AS; Hirabayashi, M; Nakauchi, H				Kobayashi, Toshihiro; Yamaguchi, Tomoyuki; Hamanaka, Sanae; Kato-Itoh, Megumi; Yamazaki, Yuji; Ibata, Makoto; Sato, Hideyuki; Lee, Youn-Su; Usui, Jo-ichi; Knisely, A. S.; Hirabayashi, Masumi; Nakauchi, Hiromitsu			Generation of Rat Pancreas in Mouse by Interspecific Blastocyst Injection of Pluripotent Stem Cells	CELL			English	Article							DIFFERENTIATION; MICE; TRANSPLANTATION; CULTURE; PIGS	The complexity of organogenesis hinders in vitro generation of organs derived from a patient's pluripotent stem cells (PSCs), an ultimate goal of regenerative medicine. Mouse wild-type PSCs injected into Pdx1(-/-) (pancreatogenesis-disabled) mouse blastocysts developmentally compensated vacancy of the pancreatic "developmental niche,'' generating almost entirely PSC-derived pancreas. To examine the potential for xenogenic approaches in blastocyst complementation, we injected mouse or rat PSCs into rat or mouse blastocysts, respectively, generating interspecific chimeras and thus confirming that PSCs can contribute to xenogenic development between mouse and rat. The development of these mouse/rat chimeras was primarily influenced by host blastocyst and/or foster mother, evident by body size and species-specific organogenesis. We further injected rat wild-type PSCs into Pdx1(-/-) mouse blastocysts, generating normally functioning rat pancreas in Pdx1(-/-) mice. These data constitute proof of principle for interspecific blastocyst complementation and for generation in vivo of organs derived from donor PSCs using a xenogenic environment.	[Kobayashi, Toshihiro; Yamaguchi, Tomoyuki; Hamanaka, Sanae; Yamazaki, Yuji; Sato, Hideyuki; Lee, Youn-Su; Usui, Jo-ichi; Nakauchi, Hiromitsu] Univ Tokyo, Inst Med Sci, Ctr Stem Cell Biol & Regenerat Med, Div Stem Cell Therapy,Minato Ku, Tokyo 1088639, Japan; [Kobayashi, Toshihiro; Yamaguchi, Tomoyuki; Hamanaka, Sanae; Kato-Itoh, Megumi; Yamazaki, Yuji; Ibata, Makoto; Sato, Hideyuki; Lee, Youn-Su; Nakauchi, Hiromitsu] Japan Sci & Technol Agcy, ERATO, Nakauchi Stem Cell & Organ Regenerat Project, Minato Ku, Tokyo 1088639, Japan; [Kato-Itoh, Megumi; Hirabayashi, Masumi] Natl Inst Nat Sci, Natl Inst Physiol Sci, Ctr Genet Anal Behav, Okazaki, Aichi 4448585, Japan; [Hirabayashi, Masumi] Grad Univ Adv Studies, Sch Life Sci, Okazaki, Aichi 4448585, Japan; [Knisely, A. S.] Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Nakauchi, H (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Stem Cell Biol & Regenerat Med, Div Stem Cell Therapy,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	nakauchi@ims.u-tokyo.ac.jp	Hirabayashi, Masumi/C-8935-2019	Hirabayashi, Masumi/0000-0002-1059-5883; Kobayashi, Toshihiro/0000-0001-8019-0008	JST, the Ministry of Education, Culture, Sport, Science, and Technology, Japan	JST, the Ministry of Education, Culture, Sport, Science, and Technology, Japan	We thank Ryo Sumazaki for critical advice on this work, Kazuya Ise and Hirofumi Noguchi for technical advice on islet isolation and islet transplantation, and Naoki Iwamori for technical advice on embryo manipulation. This work was supported by grants from JST, the Ministry of Education, Culture, Sport, Science, and Technology, Japan. H.N. is a founder and shareholder of ReproCELL Inc.	Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; DELTOUR L, 1991, DEVELOPMENT, V112, P1115; FEHILLY CB, 1984, NATURE, V307, P634, DOI 10.1038/307634a0; Fraidenraich D, 2004, SCIENCE, V306, P247, DOI 10.1126/science.1102612; Goldstein RS, 2002, DEV DYNAM, V225, P80, DOI 10.1002/dvdy.10108; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Hirabayashi M, 2010, MOL REPROD DEV, V77, P94, DOI 10.1002/mrd.21123; James D, 2006, DEV BIOL, V295, P90, DOI 10.1016/j.ydbio.2006.03.026; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Li P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Miura K, 2009, NAT BIOTECHNOL, V27, P743, DOI 10.1038/nbt.1554; Muller SM, 2005, P NATL ACAD SCI USA, V102, P10587, DOI 10.1073/pnas.0502752102; Nagashima H, 2004, BIOL REPROD, V70, P702, DOI 10.1095/biolreprod.103.022681; Nagy A., 2003, MANIPULATING MOUSE E; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Nichols J, 2009, CELL STEM CELL, V4, P487, DOI 10.1016/j.stem.2009.05.015; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Offield MF, 1996, DEVELOPMENT, V122, P983; OGAWA S, 1971, NATURE, V233, P422, DOI 10.1038/233422a0; Oh SH, 1998, BIOL REPROD, V59, P884, DOI 10.1095/biolreprod59.4.884; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Okabe M, 2009, BLOOD, V114, P1764, DOI 10.1182/blood-2009-02-203695; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; ROSSANT J, 1980, SCIENCE, V208, P419, DOI 10.1126/science.7367871; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V69, P141; Rossant J, 2007, REPROD FERT DEVELOP, V19, P111, DOI 10.1071/RD06125; Satoh M, 2007, TRANSPLANTATION, V83, P1085, DOI 10.1097/01.tp.0000260161.81775.58; Shinohara T, 2006, P NATL ACAD SCI USA, V103, P13624, DOI 10.1073/pnas.0604205103; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Stanger BZ, 2007, NATURE, V445, P886, DOI 10.1038/nature05537; STERN MS, 1973, NATURE, V244, P472; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TARKOWSKI AK, 1962, J EMBRYOL EXP MORPH, V10, P476; Ueno H, 2009, P NATL ACAD SCI USA, V106, P175, DOI 10.1073/pnas.0810325105; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; ZEILMAKER GH, 1973, NATURE, V242, P115, DOI 10.1038/242115a0	43	366	400	3	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					787	799		10.1016/j.cell.2010.07.039	http://dx.doi.org/10.1016/j.cell.2010.07.039			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813264	Bronze			2022-12-28	WOS:000281523200021
J	Verdino, P; Witherden, DA; Havran, WL; Wilson, IA				Verdino, Petra; Witherden, Deborah A.; Havran, Wendy L.; Wilson, Ian A.			The Molecular Interaction of CAR and JAML Recruits the Central Cell Signal Transducer PI3K	SCIENCE			English	Article							JUNCTIONAL ADHESION MOLECULE; GROUP-B COXSACKIEVIRUSES; ADENOVIRUS RECEPTOR; T-CELLS; PROTEIN; BINDING; CD28; ACTIVATION; MIGRATION; 3-KINASE	Coxsackie and adenovirus receptor (CAR) is the primary cellular receptor for group B coxsackieviruses and most adenovirus serotypes and plays a crucial role in adenoviral gene therapy. Recent discovery of the interaction between junctional adhesion molecule-like protein (JAML) and CAR uncovered important functional roles in immunity, inflammation, and tissue homeostasis. Crystal structures of JAML ectodomain (2.2 angstroms) and its complex with CAR (2.8 angstroms) reveal an unusual immunoglobulin-domain assembly for JAML and a charged interface that confers high specificity. Biochemical and mutagenesis studies illustrate how CAR-mediated clustering of JAML recruits phosphoinositide 3-kinase (PI3K) to a JAML intracellular sequence motif as delineated for the ab T cell costimulatory receptor CD28. Thus, CAR and JAML are cell signaling receptors of the immune system with implications for asthma, cancer, and chronic nonhealing wounds.	[Verdino, Petra; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Witherden, Deborah A.; Havran, Wendy L.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu			NIH [AI42266, CA58896, AI52257, AI064811]; Austrian Science Fund; Skaggs Institute.; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042266, R01AI036964, R37AI042266, R01AI052257, R01AI064811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080301] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Austrian Science Fund(Austrian Science Fund (FWF)); Skaggs Institute.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Schiefner for help with the structure solution; S. Ferguson, H. Lindermuth, and J. Vanhasny for technical support; L. Teyton for providing cell lines; J. G. Luz, M. A. Adams-Cioaba, J. Stevens, D. A. Shore, A. L. Corper, R. L. Stanfield, and E. Ollmann Saphire for helpful discussions; and X. Dai and K. Saikatendu for assistance on synchrotron trips. We acknowledge the Advanced Light Source, Stanford Synchrotron Radiation Lightsource, and the Advanced Photon Source for use of their synchrotron facilities. This work was supported by NIH grants AI42266, CA58896 to I. A. W., and AI52257 and AI064811 to W. L. H., an Erwin-Schrodinger Fellowship of the Austrian Science Fund to P. V., and the Skaggs Institute. Atomic coordinates and structure factors for JAML and the CAR-JAML complex have been deposited in the Protein Data Bank with accession numbers 3MJ6 and 3MJ7 respectively. This is manuscript 18641-MB from The Scripps Research Institute.	Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; Carson SD, 2001, REV MED VIROL, V11, P219, DOI 10.1002/rmv.318; Davis SJ, 2003, NAT IMMUNOL, V4, P217, DOI 10.1038/ni0303-217; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Dustin ML, 2001, ANNU REV CELL DEV BI, V17, P133, DOI 10.1146/annurev.cellbio.17.1.133; Freimuth P, 2008, CURR TOP MICROBIOL, V323, P67; Guo YL, 2009, ARTERIOSCL THROM VAS, V29, P75, DOI 10.1161/ATVBAHA.108.177717; He YN, 2001, NAT STRUCT BIOL, V8, P874, DOI 10.1038/nsb1001-874; Howitt J, 2003, CURR TOP MICROBIOL, V272, P331; Jameson J, 2002, SCIENCE, V296, P747, DOI 10.1126/science.1069639; Jiang SK, 2007, PROTEIN SCI, V16, P539, DOI 10.1110/ps.062643507; Kanerva A, 2005, ANN MED, V37, P33, DOI 10.1080/07853890410018934; Luissint AC, 2008, J CELL BIOL, V183, P1159, DOI 10.1083/jcb.200805061; Moog-Lutz C, 2003, BLOOD, V102, P3371, DOI 10.1182/blood-2002-11-3462; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; WITHERDEN DA, 2010, SCIENCE, V329, pR30; Zen K, 2005, MOL BIOL CELL, V16, P2694, DOI 10.1091/mbc.E05-01-0036	25	91	100	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1210	1214		10.1126/science.1187996	http://dx.doi.org/10.1126/science.1187996			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813955	Green Accepted			2022-12-28	WOS:000281485600037
J	Beal, MF				Beal, M. Flint			Parkinson's disease: a model dilemma	NATURE			English	Editorial Material							ALPHA-SYNUCLEIN; TRANSGENIC MICE; MUTATION		[Beal, M. Flint] Weill Med Coll, Dept Neurol & Neurosci, New York, NY USA; [Beal, M. Flint] New York Presbyterian Cornell Campus, Neurol Serv, New York, NY USA	Cornell University	Beal, MF (corresponding author), Weill Med Coll, Dept Neurol & Neurosci, New York, NY USA.							Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Li XT, 2010, J NEUROSCI, V30, P1788, DOI 10.1523/JNEUROSCI.5604-09.2010; Li YP, 2009, NAT NEUROSCI, V12, P826, DOI 10.1038/nn.2349; Lin X, 2009, NEURON, V64, P807, DOI 10.1016/j.neuron.2009.11.006; Lu XH, 2009, J NEUROSCI, V29, P1962, DOI 10.1523/JNEUROSCI.5351-08.2009; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Tong YR, 2009, P NATL ACAD SCI USA, V106, P14622, DOI 10.1073/pnas.0906334106	9	77	80	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					S8	S10		10.1038/466S8a	http://dx.doi.org/10.1038/466S8a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739935	Bronze			2022-12-28	WOS:000281203600060
J	Smith, K				Smith, Kerri			Treatment frontiers	NATURE			English	Editorial Material							GENOME-WIDE ASSOCIATION; PARKINSONS-DISEASE; BRAIN-STIMULATION; RISK-FACTORS; TRANSPLANTATION; NEURONS											BACKLUND EO, 1985, J NEUROSURG, V62, P169, DOI 10.3171/jns.1985.62.2.0169; Edwards TL, 2010, ANN HUM GENET, V74, P97, DOI 10.1111/j.1469-1809.2009.00560.x; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Fregni F, 2005, J NEUROL NEUROSUR PS, V76, P1614, DOI 10.1136/jnnp.2005.069849; Gradinaru V, 2009, SCIENCE, V324, P354, DOI 10.1126/science.1167093; Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747; Kravitz AV, 2010, NATURE, V466, P622, DOI 10.1038/nature09159; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Li YP, 2009, NAT NEUROSCI, V12, P826, DOI 10.1038/nn.2349; Lozano AM, 2008, BIOL PSYCHIAT, V64, P461, DOI 10.1016/j.biopsych.2008.05.034; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Rakovic A, 2010, HUM MOL GENET, V19, P3124, DOI 10.1093/hmg/ddq215; Satake W, 2009, NAT GENET, V41, P1303, DOI 10.1038/ng.485; Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105	17	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					S15	S18		10.1038/466S15a	http://dx.doi.org/10.1038/466S15a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739932	Bronze			2022-12-28	WOS:000281203600063
J	Reid, AWN; Akhtar, J; Shelley, OP				Reid, A. W. N.; Akhtar, J.; Shelley, O. P.			Picture Quiz Management of paediatric burns	BRITISH MEDICAL JOURNAL			English	Editorial Material							TOXIC-SHOCK-SYNDROME; AREA					awnr2@cam.ac.uk		shelley, odhran/0000-0001-7564-4175				Amirsheybani HR, 2001, PLAST RECONSTR SURG, V107, P726, DOI 10.1097/00006534-200103000-00012; Baxter C R, 1974, Clin Plast Surg, V1, P693; Cubison TCS, 2006, BURNS, V32, P992, DOI 10.1016/j.burns.2006.02.007; de Chalain TMB, 1998, J BURN CARE REHABIL, V19, P39, DOI 10.1097/00004630-199801000-00010; Edwards-Jones V, 2000, BURNS, V26, P323, DOI 10.1016/S0305-4179(99)00142-4; Enoch S, 2009, BMJ-BRIT MED J, V338, P937; Grover R, 1996, BURNS, V22, P627, DOI 10.1016/S0305-4179(96)00025-3; *NAT BURN CAR REV, 2001, NAT BURN INJ REF GUI, P68; *NHS, 2010, BURNS SCALDS NHS CLI; Pham TN, 2008, J BURN CARE RES, V29, P257, DOI 10.1097/BCR.0b013e31815f3876; Young AE, 2007, ARCH DIS CHILDHOOD-E, V92, pEP97, DOI 10.1136/adc.2006.101030	11	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 25	2010	341								c4485	10.1136/bmj.c4485	http://dx.doi.org/10.1136/bmj.c4485			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645IH	20739357				2022-12-28	WOS:000281446000010
J	Gill, R				Gill, Ravi			Commentary: practicalities of seeking consent and gaining understanding	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Gill, Ravi] Southampton Univ Hosp NHS Trust, Shackleton Dept Anaesthesia, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust	Gill, R (corresponding author), Southampton Univ Hosp NHS Trust, Shackleton Dept Anaesthesia, Southampton SO16 6YD, Hants, England.	ravi.gill@suht.swest.nhs.uk						FARRELL AM, 2010, BRIT MED J, V310, pC4336; *SER HAZ TRANSF, ANN REP 2008 SUMM	2	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 24	2010	341								c4000	10.1136/bmj.c4000	http://dx.doi.org/10.1136/bmj.c4000			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IG	20736270				2022-12-28	WOS:000281445900004
J	Tunis, SR; Pearson, SD				Tunis, Sean R.; Pearson, Steven D.			US moves to improve health decisions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Tunis, Sean R.] Ctr Med Technol Policy, Baltimore, MD 21210 USA; [Pearson, Steven D.] Massachusetts Gen Hosp, Inst Clin & Econ Rev, Boston, MA USA	Harvard University; Massachusetts General Hospital	Tunis, SR (corresponding author), Ctr Med Technol Policy, Baltimore, MD 21210 USA.	sean.tunis@cmtpnet.org						Committee on Comparative Effectiveness Research Prioritization Institute of Medicine, 2009, IN NAT PRIOR COMP EF; CONWAY PH, 2009, NEW ENGL J MED, V328, P30; Fendrick AM, 2006, AM J MANAG CARE, V12, P18; Garber AM, 2009, NEW ENGL J MED, V360, P1925, DOI 10.1056/NEJMp0901355; Luce BR, 2009, ANN INTERN MED, V151, P206, DOI 10.7326/0003-4819-151-3-200908040-00126; MCCAUGHEY B, 2009, WALL STREET J   0723; *NAT VENT CAP ASS, 2009, NVCA WHIT PAP INN CO; New England Healthcare Institute, 2009, BAL ACT COMP EFF RES; Orszag PR, 2007, HLTH CARE BUDGET ISS; Pearson S, 2009, IMPLEMENTING COMP EF, P55; Rosenthal MB, 2007, JAMA-J AM MED ASSOC, V297, P740, DOI 10.1001/jama.297.7.740; Selker HP, 2009, NEW ENGL J MED, V361, P2595, DOI 10.1056/NEJMp0910747; TUNIS SR, 2010, STAT MED        0616	13	6	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2010	341								c3615	10.1136/bmj.c3615	http://dx.doi.org/10.1136/bmj.c3615			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IF	20732966				2022-12-28	WOS:000281445800001
J	Schmidt, AC				Schmidt, Alexander C.			Response to Dengue Fever -- The Good, the Bad, and the Ugly?.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFECTION; VACCINE		NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schmidt, AC (corresponding author), NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.							Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181; Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0; Pierson TC, 2008, CELL HOST MICROBE, V4, P229, DOI 10.1016/j.chom.2008.08.004; Rodenhuis-Zybert IA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000718; Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690	5	35	38	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					484	487		10.1056/NEJMcibr1005904	http://dx.doi.org/10.1056/NEJMcibr1005904			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818870				2022-12-28	WOS:000280411300016
J	BEECHAM, L				BEECHAM, L			FROM THE CCCMCH - WARM BUT CAUTIOUS WELCOME TO ACHESON REPORT	BRITISH MEDICAL JOURNAL			English	Editorial Material																		1988, CMND289	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1988	296	6619					441	442						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M0221	20742957				2022-12-28	WOS:A1988M022100057
J	CHAPMAN, S				CHAPMAN, S			FIDDLING WHILE TOBACCO BURNS - 6TH WORLD CONFERENCE ON SMOKING AND HEALTH, TOKYO, 9-12 NOVEMBER 1987	BRITISH MEDICAL JOURNAL			English	Editorial Material											CHAPMAN, S (corresponding author), WESTMEAD HOSP,DEPT COMMUNITY MED,WESTMEAD,NSW 2145,AUSTRALIA.							CHAPMAN S, 1986, J HLTH DEV, V1, P222; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; 1984, 1984 WORLD BANK WORL	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1988	296	6614					39	40		10.1136/bmj.296.6614.39	http://dx.doi.org/10.1136/bmj.296.6614.39			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L5704	20742944	Green Published			2022-12-28	WOS:A1988L570400020
J	Lasky, RE; van Drongelen, W				Lasky, Robert E.; van Drongelen, Wim			Is sucrose an effective analgesic for newborn babies?	LANCET			English	Editorial Material							ROSIGLITAZONE STORY; LESSONS		[Lasky, Robert E.] Univ Texas Houston, Med Sch Houston, Ctr Clin Res & Evidence Based Med, Houston, TX 77030 USA; [van Drongelen, Wim] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [van Drongelen, Wim] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA	University of Texas System; University of Texas Health Science Center Houston; University of Chicago; University of Chicago	Lasky, RE (corresponding author), Univ Texas Houston, Med Sch Houston, Ctr Clin Res & Evidence Based Med, Houston, TX 77030 USA.	robert.e.lasky@uth.tmc.edu		van Drongelen, Wim/0000-0001-8950-5424				Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; CHALMERS I, 1985, EARLY HUM DEV, V10, P171, DOI 10.1016/0378-3782(85)90049-0; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Michel CM, 2004, CLIN NEUROPHYSIOL, V115, P2195, DOI 10.1016/j.clinph.2004.06.001; Rosen CJ, 2007, NEW ENGL J MED, V357, P844, DOI 10.1056/NEJMp078167; Rosen CJ, 2010, NEW ENGL J MED, V363, P803, DOI 10.1056/NEJMp1008233; Schulz KF, 2010, BMC MED, V8, DOI [10.1186/1741-7015-8-18, 10.1136/bmj.c332]; Slater R, 2010, LANCET, V376, P1225, DOI 10.1016/S0140-6736(10)61303-7; Slater R, 2010, EUR J PAIN, V14, P321, DOI 10.1016/j.ejpain.2009.05.005	9	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2010	376	9748					1201	1203		10.1016/S0140-6736(10)61358-X	http://dx.doi.org/10.1016/S0140-6736(10)61358-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZT	20817245				2022-12-28	WOS:000283003500007
J	Holmberg, SD				Holmberg, Scott D.			Hepatitis E vaccine: not a moment too soon	LANCET			English	Editorial Material							E VIRUS; LARGE OUTBREAK		Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis TB & STD Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Holmberg, SD (corresponding author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis TB & STD Prevent, Atlanta, GA 30333 USA.	sdh1@cdc.gov						BI SL, 1993, VIRUS RES, V28, P233, DOI 10.1016/0168-1702(93)90024-H; Guthmann JP, 2006, CLIN INFECT DIS, V42, P1685, DOI 10.1086/504321; Kuniholm MH, 2009, J INFECT DIS, V200, P48, DOI 10.1086/599319; NAIK SR, 1992, B WORLD HEALTH ORGAN, V70, P597; Shrestha MP, 2007, NEW ENGL J MED, V356, P895, DOI 10.1056/NEJMoa061847; Teshale EH, 2010, CLIN INFECT DIS, V51, P328, DOI 10.1086/653943; Teshale EH, 2010, CLIN INFECT DIS, V50, P1006, DOI 10.1086/651077; Teshale EH, 2010, EMERG INFECT DIS, V16, P126, DOI 10.3201/eid1601.090764; VISWANATHAN R, 1957, Indian J Med Res, V45, P49; ZHANG H, 1991, GASTROENTEROL JPN, V26, P135; Zhang J, 2009, VACCINE, V27, P1869, DOI 10.1016/j.vaccine.2008.12.061; Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6	12	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					849	851		10.1016/S0140-6736(10)61260-3	http://dx.doi.org/10.1016/S0140-6736(10)61260-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20728933				2022-12-28	WOS:000282069100005
J	Aigouy, B; Farhadifar, R; Staple, DB; Sagner, A; Roper, JC; Julicher, F; Eaton, S				Aigouy, Benoit; Farhadifar, Reza; Staple, Douglas B.; Sagner, Andreas; Roeper, Jens-Christian; Juelicher, Frank; Eaton, Suzanne			Cell Flow Reorients the Axis of Planar Polarity in the Wing Epithelium of Drosophila	CELL			English	Article							TISSUE MORPHOGENESIS; PROLIFERATION CONTROL; CADHERIN SUPERFAMILY; FAT; SHAPE; GENE; MUTATIONS; EXTENSION; MECHANISM; PACKING	Planar cell polarity (PCP) proteins form polarized cortical domains that govern polarity of external structures such as hairs and cilia in both vertebrate and invertebrate epithelia. The mechanisms that globally orient planar polarity are not understood, and are investigated here in the Drosophila wing using a combination of experiment and theory. Planar polarity arises during growth and PCP domains are initially oriented toward the well-characterized organizer regions that control growth and patterning. At pupal stages, the wing hinge contracts, subjecting wing-blade epithelial cells to anisotropic tension in the proximal-distal axis. This results in precise patterns of oriented cell elongation, cell rearrangement and cell division that elongate the blade proximo-distally and realign planar polarity with the proximal-distal axis. Mutation of the atypical Cadherin Dachsous perturbs the global polarity pattern by altering epithelial dynamics. This mechanism utilizes the cellular movements that sculpt tissues to align planar polarity with tissue shape.	[Farhadifar, Reza; Staple, Douglas B.; Juelicher, Frank] Max Planck Inst Phys Komplexer Syst, D-01187 Dresden, Germany; [Aigouy, Benoit; Sagner, Andreas; Roeper, Jens-Christian; Eaton, Suzanne] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Max Planck Society; Max Planck Society	Julicher, F (corresponding author), Max Planck Inst Phys Komplexer Syst, Noethnitzer Str 38, D-01187 Dresden, Germany.	julicher@pks.mpg.de; eaton@mpi-cbg.de	/AAG-7913-2021; Sagner, Andreas/AAF-6235-2020; Eaton, Suzanne/D-7698-2017; Julicher, Frank/B-1828-2009	Sagner, Andreas/0000-0001-5698-8191; Eaton, Suzanne/0000-0002-8319-284X; Julicher, Frank/0000-0003-4731-9185	Max Planck Gesellschaft; Fondation pour la Recherche Medicale; Boehringer Ingelheim Fonds	Max Planck Gesellschaft(Max Planck Society); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Boehringer Ingelheim Fonds(Boehringer Ingelheim)	This work represents a truly collaborative effort. Each author has contributed significantly to the findings and regular group discussions guided the development of the ideas presented here. The manuscript was written jointly by all authors. S.E., A.S., J.R., R.F., and F.J. were supported by the Max Planck Gesellschaft. B.A. was funded by the Fondation pour la Recherche Medicale. D.S. acknowledges the Natural Sciences and Engineering Research Council of Canada and the German Academic Exchange Service. J.R. was supported by a predoctoral fellowship from the Boehringer Ingelheim Fonds. We thank Tony Hyman and Stephan Grill for use of the laser cutting microscope. We are grateful to Stephan Grill, Ewa Paluch, Elisabeth Knust, and Carl-Philipp Heisenberg for critical comments on the manuscript. We thank David Strutt, Seth S.Blair, VDRC and the Bloomington Stock Center for providing fly stocks, Barry Dickson for DNA constructs, Julia Gabel for help with cloning, Sven Ssykor for transgenic injections.	Adler PN, 1998, DEVELOPMENT, V125, P959; Amonlirdviman K, 2005, SCIENCE, V307, P423, DOI 10.1126/science.1105471; Axelrod JD, 2009, SEMIN CELL DEV BIOL, V20, P964, DOI 10.1016/j.semcdb.2009.08.001; Baena-Lopez LA, 2005, CURR BIOL, V15, P1640, DOI 10.1016/j.cub.2005.07.062; Bertet C, 2004, NATURE, V429, P667, DOI 10.1038/nature02590; Blankenship JT, 2006, DEV CELL, V11, P459, DOI 10.1016/j.devcel.2006.09.007; BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5; Burak Y, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000628; Butler LC, 2009, NAT CELL BIOL, V11, P859, DOI 10.1038/ncb1894; Casal J, 2006, DEVELOPMENT, V133, P4561, DOI 10.1242/dev.02641; Chen WS, 2008, CELL, V133, P1093, DOI 10.1016/j.cell.2008.04.048; Cho E, 2004, DEVELOPMENT, V131, P4489, DOI 10.1242/dev.01315; CLARK HF, 1995, GENE DEV, V9, P1530, DOI 10.1101/gad.9.12.1530; Classen AK, 2005, DEV CELL, V9, P805, DOI 10.1016/j.devcel.2005.10.016; Classen Anne-Kathrin, 2008, V420, P265, DOI 10.1007/978-1-59745-583-1_16; Cortes S, 2006, BIOPHYS CHEM, V120, P168, DOI 10.1016/j.bpc.2005.11.002; Daga RR, 2008, J CELL SCI, V121, P1973, DOI 10.1242/jcs.011825; de Gennes P. G., 1993, PHYS LIQUID CRYSTALS; Farhadifar R, 2007, CURR BIOL, V17, P2095, DOI 10.1016/j.cub.2007.11.049; Garoia F, 2005, MECH DEVELOP, V122, P175, DOI 10.1016/j.mod.2004.10.007; Garoia F, 2000, MECH DEVELOP, V94, P95, DOI 10.1016/S0925-4773(00)00306-3; Haase SB, 2007, CURR BIOL, V17, pR249, DOI 10.1016/j.cub.2007.02.003; Ishikawa HO, 2008, SCIENCE, V321, P401, DOI 10.1126/science.1158159; Joanny JF, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/11/422; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; Keller R, 2008, PHYS BIOL, V5, DOI 10.1088/1478-3975/5/1/015007; Lawrence PA, 2007, NAT REV GENET, V8, P555, DOI 10.1038/nrg2125; Le Garrec JF, 2006, DEV DYNAM, V235, P235, DOI 10.1002/dvdy.20617; Lopez-Schier H, 2004, DEV CELL, V7, P401, DOI 10.1016/j.devcel.2004.07.018; Ma D, 2003, NATURE, V421, P543, DOI 10.1038/nature01366; Ma D, 2008, P NATL ACAD SCI USA, V105, P18800, DOI 10.1073/pnas.0808868105; Matakatsu H, 2004, DEVELOPMENT, V131, P3785, DOI 10.1242/dev.01254; Rauzi M, 2008, NAT CELL BIOL, V10, P1401, DOI 10.1038/ncb1798; Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042; Shimada Y, 2006, DEV CELL, V10, P209, DOI 10.1016/j.devcel.2005.11.016; Simons M, 2008, ANNU REV GENET, V42, P517, DOI 10.1146/annurev.genet.42.110807.091432; Strauss B, 2006, DEVELOPMENT, V133, P3883, DOI 10.1242/dev.02578; Strutt H, 2005, BIOESSAYS, V27, P1218, DOI 10.1002/bies.20318; Strutt H, 2002, DEV CELL, V3, P851, DOI 10.1016/S1534-5807(02)00363-5; Strutt H, 2008, CURR BIOL, V18, P1555, DOI 10.1016/j.cub.2008.08.063; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Tree DRP, 2002, SEMIN CELL DEV BIOL, V13, P217, DOI 10.1016/S1084-9521(02)00042-3; Uemura T, 2003, J BIOCHEM, V134, P625, DOI 10.1093/jb/mvg186; VILLANO JL, 1995, DEVELOPMENT, V121, P2767; VINCENT L, 1991, IEEE T PATTERN ANAL, V13, P583, DOI 10.1109/34.87344; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Vladar EK, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002964; Wang JB, 2005, NAT GENET, V37, P980, DOI 10.1038/ng1622; Wu J, 2008, DEV CELL, V15, P462, DOI 10.1016/j.devcel.2008.08.004; Wu J, 2009, TRENDS CELL BIOL, V19, P295, DOI 10.1016/j.tcb.2009.04.003; Zallen JA, 2004, DEV CELL, V6, P343, DOI 10.1016/S1534-5807(04)00060-7; Zallen JA, 2007, CELL, V129, P1051, DOI 10.1016/j.cell.2007.05.050; Zeidler MP, 2000, DEV BIOL, V228, P181, DOI 10.1006/dbio.2000.9940	53	468	471	2	51	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5					773	786		10.1016/j.cell.2010.07.042	http://dx.doi.org/10.1016/j.cell.2010.07.042			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813263	Bronze			2022-12-28	WOS:000281523200020
J	James, WPT; Caterson, ID; Coutinho, W; Finer, N; Van Gaal, LF; Maggioni, AP; Torp-Pedersen, C; Sharma, AM; Shepherd, GM; Rode, RA; Renz, CL				James, W. Philip T.; Caterson, Ian D.; Coutinho, Walmir; Finer, Nick; Van Gaal, Luc F.; Maggioni, Aldo P.; Torp-Pedersen, Christian; Sharma, Arya M.; Shepherd, Gillian M.; Rode, Richard A.; Renz, Cheryl L.		SCOUT Investigators	Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROSPECTIVELY DESIGNED OVERVIEWS; ELEVATED HEART-RATE; BLOOD-PRESSURE; WEIGHT-REDUCTION; MANAGEMENT; MEN; DISEASE; MORTALITY; PATTERNS; EVENTS	BACKGROUND The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.	[James, W. Philip T.] London Sch Hyg & Trop Med, London, England; [Finer, Nick] UCL, Vasc Physiol Unit, London WC1E 6BT, England; [Caterson, Ian D.] Univ Sydney, Inst Obes Nutr & Exercise, Sydney, NSW 2006, Australia; [Coutinho, Walmir] Pontificia Univ Catolica Rio de Janeiro, Rio De Janeiro, Brazil; [Van Gaal, Luc F.] Univ Antwerp Hosp, Antwerp, Belgium; [Maggioni, Aldo P.] Assoc Nazl Medici Cardiol Osped, Res Ctr, Florence, Italy; [Torp-Pedersen, Christian] Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark; [Sharma, Arya M.] Univ Alberta, Royal Alexandra Hosp, Edmonton, AB, Canada; [Shepherd, Gillian M.; Rode, Richard A.; Renz, Cheryl L.] Abbott Labs, Abbott Pk, IL 60064 USA	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of Sydney; Pontificia Universidade Catolica do Rio de Janeiro; University of Antwerp; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); University of Copenhagen; Herlev & Gentofte Hospital; Royal Alexandra Hospital; University of Alberta; Abbott Laboratories	James, WPT (corresponding author), IASO, 28 Portland Pl, London W1B 1LY, England.	jeanhjames@aol.com	DOMINGUEZ, Helena/ABC-1905-2021; MOLINA, HUGO A LAVIADA/F-5201-2018; Salas-Salvado, Jordi/C-7229-2017; Cífková, Renata/O-5731-2017; Colquhoun, David M/F-9078-2013; Torp-Pedersen, Christian/E-5931-2013; Rubio, Miguel Angel/GRJ-0134-2022; Maggioni, Aldo Pietro/AAL-5334-2020; Mijares, Antonio Hernandez/D-3411-2011; Proietto, Joe/B-3780-2012; Ponikowski, Piotr/O-6454-2015; kumar, sudhesh/D-6945-2013; Linhart, Ales/O-2375-2017; Finer, Nicholas/B-9981-2009; Santini, Ferruccio/J-9272-2018; Svacina, Stepan/C-1962-2017; Lopez de la Torre Casares, Martin/C-5239-2017	DOMINGUEZ, Helena/0000-0002-7089-2636; Salas-Salvado, Jordi/0000-0003-2700-7459; Cífková, Renata/0000-0003-2765-3821; Rubio, Miguel Angel/0000-0002-0495-6240; Maggioni, Aldo Pietro/0000-0003-2764-6779; Mijares, Antonio Hernandez/0000-0003-2197-0607; Ponikowski, Piotr/0000-0002-3391-7064; Linhart, Ales/0000-0002-3372-7850; Finer, Nicholas/0000-0003-2468-6804; Santini, Ferruccio/0000-0002-1706-0822; Svacina, Stepan/0000-0002-0894-4116; Ruilope, Luis M/0000-0001-6278-7951; Renz, Cheryl/0000-0002-7051-1653; Narkiewicz, Krzysztof/0000-0001-5949-5018; Kober, Lars/0000-0002-6635-1466; Hancu, Nicolae/0000-0002-4688-5110; Lopez de la Torre Casares, Martin/0000-0002-1736-042X; ESTEVA DE ANTONIO, ISABEL/0000-0001-6144-3057; Garcia Luna, Pedro Pablo/0000-0001-7460-5422; Svendsen, Ole Lander/0000-0003-2846-9532; Caixas, Assumpta/0000-0001-8472-9189	Abbott Laboratories; Pfizer (Australia); Servier Laboratories; Eisai Pharmaceuticals; iNova Pharmaceuticals; Eli Lilly; Sanofi-Aventis; Weight Watchers; Allergan; Ache Laboratorios Farmaceuticos; Roche; Novo Nordisk; Ajinomoto; GlaxoSmithKline; Vivus; Covidien; Neuro-Search	Abbott Laboratories(Abbott Laboratories); Pfizer (Australia)(PfizerPfizer Australia); Servier Laboratories; Eisai Pharmaceuticals(Eisai Co Ltd); iNova Pharmaceuticals; Eli Lilly(Eli Lilly); Sanofi-Aventis(Sanofi-Aventis); Weight Watchers; Allergan(AbbVieAllergan); Ache Laboratorios Farmaceuticos; Roche(Roche Holding); Novo Nordisk(Novo Nordisk); Ajinomoto; GlaxoSmithKline(GlaxoSmithKline); Vivus; Covidien; Neuro-Search	Dr. Caterson reports receiving lecture fees and travel reimbursement from Abbott Laboratories, Pfizer (Australia), Servier Laboratories, Eisai Pharmaceuticals, iNova Pharmaceuticals and Eli Lilly, receiving royalties from Wiley-Blackwell as coeditor of an obesity textbook, and serving on an advisory board for GlaxoSmithKline, and reports that the Boden Institute of Obesity, Nutrition, and Exercise has received grants to conduct clinical trials from Sanofi-Aventis, Pfizer (Australia), Weight Watchers, and Allergan; Dr. Coutinho reports receiving lecture fees from Abbott Laboratories, Ache Laboratorios Farmaceuticos, Roche, and Novo Nordisk, serving on advisory boards for Abbott Laboratories, Ache Laboratorios Farmaceuticos, and Roche, providing expert testimony for Abbott Laboratories, and receiving travel reimbursement from Abbott Laboratories; Dr. Finer reports receiving consulting fees from Ajinomoto, lecture fees from Abbott Laboratories, and travel reimbursement from Abbott Laboratories and Novo Nordisk, serving on advisory boards for Novo Nordisk, Merck, Johnson & Johnson, Sanofi-Aventis, GlaxoSmithKline, and Shionogi, and providing expert testimony for Sanofi-Aventis and reports that Cambridge University received a grant from GlaxoSmithKline; Dr. James reports serving on advisory boards for and receiving travel reimbursement from GlaxoSmithKline; Dr. Renz, Dr. Rode, and Ms. Shepherd report being full-time employees of Abbott Laboratories and having equity interest in the company; Dr. Sharma reports receiving consulting fees from Vivus and Allergan, grants from Abbott Laboratories and Covidien, and fees for developing educational materials for and travel reimbursement from Boehringer Ingelheim, Abbott Laboratories, Novo Nordisk, Allergan, Johnson & Johnson, and Sanofi-Aventis, serving on advisory boards for Abbott Laboratories, Merck, Arena, Novo Nordisk, Sanofi-Aventis, GlaxoSmithKline, Boehringer Ingelheim, and Neuro-Search, and providing expert testimony for GlaxoSmithKline; Dr. Torp-Peder-sen reports receiving consulting fees from Neuro-Search and lecture fees from Abbott Laboratories; and Dr. Van Gaal reports receiving lecture fees from Eli Lilly and Novo Nordisk and travel reimbursement from Abbott Laboratories, AstraZeneca-Bristol-Myers Squibb, Glaxo-SmithKline, Merck, Novo Nordisk and Sanofi-Aventis and serving on advisory boards for Novo Nordisk, GlaxoSmithKline, AstraZeneca-Bristol-Myers Squibb, Eli Lilly, and Merck. No other potential conflict of interest relevant to this article was reported.	Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603; Barr E, 2006, AUSTR DIABETES OBESI; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; Florentin M, 2008, OBES REV, V9, P378, DOI 10.1111/j.1467-789X.2007.00425.x; Fox K, 2008, LANCET, V372, P817, DOI 10.1016/S0140-6736(08)61171-X; Gordon-Larsen P, 2009, AM J CLIN NUTR, V89, P19, DOI 10.3945/ajcn.2008.26147; Gregg EW, 2005, JAMA-J AM MED ASSOC, V294, P182; Halford JCG, 2010, J PSYCHOPHARMACOL, V24, P99, DOI 10.1177/0269881108095195; Heitmann BL, 1999, INT J OBESITY, V23, P1074, DOI 10.1038/sj.ijo.0801035; Heusser K, 2006, CLIN PHARMACOL THER, V79, P500, DOI 10.1016/j.clpt.2006.02.002; *INT ASS STUD OB, INT OB TASKF PREV DA; James WPT, 2005, EUR HEART J SUPPL, V7, pL44, DOI 10.1093/eurheartj/sui086; Johansson K, 2009, OBES REV, V10, P564, DOI 10.1111/j.1467-789X.2009.00581.x; Lawes CMM, 2005, CORONARY HEART DIS E, P152; LEAN MEJ, 1986, LANCET, V1, P723; Lean M, 2006, BRIT MED J, V333, P794, DOI 10.1136/bmj.333.7572.794; Lyznicki JM, 2001, AM FAM PHYSICIAN, V63, P2185; Mallinckrodt CH, 2008, DRUG INF J, V42, P303, DOI 10.1177/009286150804200402; McPherson K, 2007, FORESIGHT TACKLING O; Mindlen F, 1996, CAN J CARDIOL, V12, P127; Ness AR, 2002, J EPIDEMIOL COMMUN H, V56, P218, DOI 10.1136/jech.56.3.218; Palatini P, 2006, J HYPERTENS, V24, P603, DOI 10.1097/01.hjh.0000217838.49842.1e; Palatini P, 2009, PROG CARDIOVASC DIS, V52, P1, DOI 10.1016/j.pcad.2009.06.001; Patel MR, 2006, AM HEART J, V151, P633, DOI 10.1016/j.ahj.2005.03.006; PEDERSEN TR, 1994, LANCET, V344, P1383; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sever PS, 2005, AM J CARDIOL, V96, p39F, DOI 10.1016/j.amjcard.2005.06.025; Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Torp-Pedersen C, 2007, EUR HEART J, V28, P2915, DOI 10.1093/eurheartj/ehm217; TUCK ML, 1981, NEW ENGL J MED, V304, P930, DOI 10.1056/NEJM198104163041602; Turnbull F, 2008, BMJ-BRIT MED J, V336, P1121, DOI 10.1136/bmj.39548.738368.BE; Turnbull F, 2005, ARCH INTERN MED, V165, P1410; Turnbull F, 2008, EUR HEART J, V29, P2669, DOI 10.1093/eurheartj/ehn427; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Wing RR, 2001, ANNU REV NUTR, V21, P323, DOI 10.1146/annurev.nutr.21.1.323	37	591	618	2	75	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					905	917		10.1056/NEJMoa1003114	http://dx.doi.org/10.1056/NEJMoa1003114			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645GW	20818901	Green Published			2022-12-28	WOS:000281441500004
J	Jorgensen, HF; Fisher, AG				Jorgensen, Helle F.; Fisher, Amanda G.			Can controversies be put to REST?	NATURE			English	Letter							EMBRYONIC STEM-CELLS; PLURIPOTENCY		[Jorgensen, Helle F.; Fisher, Amanda G.] Imperial Coll Sch Med, MRC, Ctr Clin Sci, Lymphocyte Dev Grp, London W12 0NN, England; [Jorgensen, Helle F.] Natl Inst Med Res, MRC, Div Syst Biol, London NW7 1AA, England	Imperial College London; MRC National Institute for Medical Research	Jorgensen, HF (corresponding author), Imperial Coll Sch Med, MRC, Ctr Clin Sci, Lymphocyte Dev Grp, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	hjorgen@nimr.mrc.ac.uk; amanda.fisher@csc.mrc.ac.uk		Jorgensen, Helle/0000-0002-7909-2977	Medical Research Council [MC_U120027516] Funding Source: Medline; MRC [MC_U120027516] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Buckley NJ, 2009, NATURE, V457, pE5, DOI 10.1038/nature07784; Jorgensen HF, 2009, NATURE, V457, pE4, DOI 10.1038/nature07783; Jorgensen HF, 2009, DEVELOPMENT, V136, P715, DOI 10.1242/dev.028548; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Singh SK, 2008, NATURE, V453, P223, DOI 10.1038/nature06863; YAMADA Y, 2010, STEM CELLS, V6, P10	7	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					E3	E4		10.1038/nature09305	http://dx.doi.org/10.1038/nature09305			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811409				2022-12-28	WOS:000281461200030
J	Nowak, MA; Tarnita, CE; Wilson, EO				Nowak, Martin A.; Tarnita, Corina E.; Wilson, Edward O.			The evolution of eusociality	NATURE			English	Article							DIVISION-OF-LABOR; GROUP-SELECTION; KIN SELECTION; SOCIAL INTERACTIONS; INCLUSIVE FITNESS; COOPERATION; ALTRUISM; POLYMORPHISM; HYMENOPTERA; MULTILEVEL	Eusociality, in which some individuals reduce their own lifetime reproductive potential to raise the offspring of others, underlies the most advanced forms of social organization and the ecologically dominant role of social insects and humans. For the past four decades kin selection theory, based on the concept of inclusive fitness, has been the major theoretical attempt to explain the evolution of eusociality. Here we show the limitations of this approach. We argue that standard natural selection theory in the context of precise models of population structure represents a simpler and superior approach, allows the evaluation of multiple competing hypotheses, and provides an exact framework for interpreting empirical observations.	[Nowak, Martin A.; Tarnita, Corina E.] Harvard Univ, Dept Math, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA; [Wilson, Edward O.] Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA	Harvard University; Harvard University	Nowak, MA (corresponding author), Harvard Univ, Dept Math, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA.	martin_nowak@harvard.edu	Chapuisat, Michel/T-8686-2017; Nowak, Martin A/A-6977-2008	Chapuisat, Michel/0000-0001-7207-199X; Alizon, Samuel/0000-0002-0779-9543	John Templeton Foundation; NSF/NIH [R01GM078986]; Bill and Melinda Gates Foundation [37874]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078986] Funding Source: NIH RePORTER	John Templeton Foundation; NSF/NIH(National Science Foundation (NSF)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. M. Horton for advice and help in preparing the manuscript. M.A.N. and C.E.T. gratefully acknowledge support from the John Templeton Foundation, the NSF/NIH joint program in mathematical biology (NIH grant R01GM078986), the Bill and Melinda Gates Foundation (Grand Challenges grant 37874), and J. Epstein.	Abouheif E, 2002, SCIENCE, V297, P249, DOI 10.1126/science.1071468; [Anonymous], 1971, INSECT SOC; Antal T, 2009, P NATL ACAD SCI USA, V106, P8597, DOI 10.1073/pnas.0902528106; Bonabeau E, 1996, P ROY SOC B-BIOL SCI, V263, P1565, DOI 10.1098/rspb.1996.0229; Clutton-Brock T, 2009, NATURE, V462, P51, DOI 10.1038/nature08366; Cole BJ, 1999, SCIENCE, V285, P891, DOI 10.1126/science.285.5429.891; Costa J., 2006, OTHER INSECT SOC; Cowan D.P., 1991, P33; Doebeli M, 2006, J EVOLUTION BIOL, V19, P1386, DOI 10.1111/j.1420-9101.2006.01157.x; Duffy J. Emmett, 2007, P387; Fletcher JA, 2004, J THEOR BIOL, V228, P303, DOI 10.1016/j.jtbi.2004.01.004; Fletcher JA, 2006, TRENDS ECOL EVOL, V21, P597, DOI 10.1016/j.tree.2006.08.008; Fletcher JA, 2009, P ROY SOC B-BIOL SCI, V276, P13, DOI 10.1098/rspb.2008.0829; Foster KR, 2005, TRENDS ECOL EVOL, V20, P363, DOI 10.1016/j.tree.2005.05.005; Frank, 1998, FDN SOCIAL EVOLUTION; Gadagkar R, 2001, SOCIAL BIOL ROPALIDI; Grafen A, 2007, J EVOLUTION BIOL, V20, P2278, DOI 10.1111/j.1420-9101.2007.01413.x; Grafen A, 1984, BEHAV ECOLOGY EVOLUT, V2, P62; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Holldobler B., 1990, pi; Hughes WOH, 2004, EVOLUTION, V58, P1251, DOI 10.1111/j.0014-3820.2004.tb01704.x; Hunt JH, 2007, P NATL ACAD SCI USA, V104, P14020, DOI 10.1073/pnas.0705660104; Hunt JH, 2005, SCIENCE, V308, P264, DOI 10.1126/science.1109724; Hunt JH, 2007, EVOLUTION SOCIAL WAS; Jeanson R, 2005, ANIM BEHAV, V70, P1183, DOI 10.1016/j.anbehav.2005.03.004; Johns PM, 2009, P NATL ACAD SCI USA, V106, P17452, DOI 10.1073/pnas.0907961106; Jones JC, 2004, SCIENCE, V305, P402, DOI 10.1126/science.1096340; Khila A, 2010, PHILOS T R SOC B, V365, P617, DOI 10.1098/rstb.2009.0257; Linksvayer TA, 2005, Q REV BIOL, V80, P317, DOI 10.1086/432266; Nowak MA, 2006, SCIENCE, V314, P1560, DOI 10.1126/science.1133755; Ohtsuki H, 2006, P ROY SOC B-BIOL SCI, V273, P2249, DOI 10.1098/rspb.2006.3576; Ohtsuki H, 2006, NATURE, V441, P502, DOI 10.1038/nature04605; Pepper JW, 2002, AM NAT, V160, P205, DOI 10.1086/341018; Queller DC, 1998, BIOSCIENCE, V48, P165, DOI 10.2307/1313262; Rheindt FE, 2005, INSECT SOC, V52, P163, DOI 10.1007/s00040-004-0787-4; ROBINSON GE, 1989, WESTV STUD, P61; Ross KG, 1998, P NATL ACAD SCI USA, V95, P14232, DOI 10.1073/pnas.95.24.14232; Rousset F., 2004, GENETIC STRUCTURE SE; SAKAGAMI S. F., 1960, INSECTES SOCIAUX, V7, P57, DOI 10.1007/BF02225757; Sakagami S. F., 1987, Animal societies: theories and facts., P1; Schwander T, 2005, BEHAV ECOL SOCIOBIOL, V59, P215, DOI 10.1007/s00265-005-0027-6; Swenson W, 2000, P NATL ACAD SCI USA, V97, P9110, DOI 10.1073/pnas.150237597; Tarnita CE, 2009, J THEOR BIOL, V259, P570, DOI 10.1016/j.jtbi.2009.03.035; Tarnita CE, 2009, P NATL ACAD SCI USA, V106, P8601, DOI 10.1073/pnas.0903019106; Thorne BL, 2003, P NATL ACAD SCI USA, V100, P12808, DOI 10.1073/pnas.2133530100; Toth AL, 2007, SCIENCE, V318, P441, DOI 10.1126/science.1146647; Traulsen A, 2006, P NATL ACAD SCI USA, V103, P10952, DOI 10.1073/pnas.0602530103; Traulsen A, 2010, EVOLUTION, V64, P316, DOI 10.1111/j.1558-5646.2009.00899.x; van Veelen M, 2009, J THEOR BIOL, V259, P589, DOI 10.1016/j.jtbi.2009.04.019; Wade MJ, 2010, NATURE, V463, pE8, DOI 10.1038/nature08809; WADE MJ, 1976, P NATL ACAD SCI USA, V73, P4604, DOI 10.1073/pnas.73.12.4604; Wcislo WT, 1997, INSECT SOC, V44, P199, DOI 10.1007/s000400050041; West SA, 2007, CURR BIOL, V17, pR661, DOI 10.1016/j.cub.2007.06.004; West-Eberhard Mary Jane, 2003, pi; Wilson DS, 2008, AM SCI, V96, P380, DOI 10.1511/2008.74.1; Wilson DS, 2007, Q REV BIOL, V82, P327, DOI 10.1086/522809; Wilson E.O., 1975, P1; Wilson EO, 2008, BIOSCIENCE, V58, P17, DOI 10.1641/B580106; Wilson EO, 2005, P NATL ACAD SCI USA, V102, P13367, DOI 10.1073/pnas.0505858102; Wolf JB, 2001, J EVOLUTION BIOL, V14, P347, DOI 10.1046/j.1420-9101.2001.00277.x	61	666	694	7	1043	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2010	466	7310					1057	1062		10.1038/nature09205	http://dx.doi.org/10.1038/nature09205			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740005	Green Accepted			2022-12-28	WOS:000281203600030
J	Soria, C; Estermann, FE; Espantman, KC; O'Shea, CC				Soria, Conrado; Estermann, Fanny E.; Espantman, Kristen C.; O'Shea, Clodagh C.			Heterochromatin silencing of p53 target genes by a small viral protein	NATURE			English	Article							EARLY REGION 4; ADENOVIRUS MUTANT; TUMOR-SUPPRESSOR; CELLS; REPLICATION; METHYLATION; EXPRESSION; E1A; TRANSCRIPTION; ONYX-015	The transcription factor p53 (also known as TP53) guards against tumour and virus replication and is inactivated in almost all cancers. p53-activated transcription of target genes is thought to be synonymous with the stabilization of p53 in response to oncogenes and DNA damage. During adenovirus replication, the degradation of p53 by E1B-55k is considered essential for p53 inactivation, and is the basis for p53-selective viral cancer therapies. Here we reveal a dominant epigenetic mechanism that silences p53-activated transcription, irrespective of p53 phosphorylation and stabilization. We show that another adenoviral protein, E4-ORF3, inactivates p53 independently of E1B-55k by forming a nuclear structure that induces de novo H3K9me3 heterochromatin formation at p53 target promoters, preventing p53-DNA binding. This suppressive nuclear web is highly selective in silencing p53 promoters and operates in the backdrop of global transcriptional changes that drive oncogenic replication. These findings are important for understanding how high levels of wild-type p53 might also be inactivated in cancer as well as the mechanisms that induce aberrant epigenetic silencing of tumour-suppressor loci. Our study changes the longstanding definition of how p53 is inactivated in adenovirus infection and provides key insights that could enable the development of true p53-selective oncolytic viral therapies.	[Soria, Conrado; Estermann, Fanny E.; Espantman, Kristen C.; O'Shea, Clodagh C.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Salk Institute	O'Shea, CC (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	oshea@salk.edu			Alliance of Cancer Gene Therapy; American Cancer Society; Sontag Foundation; Beckman Foundation; National Cancer Institute [R01CA137094]; NATIONAL CANCER INSTITUTE [R01CA137094] Funding Source: NIH RePORTER	Alliance of Cancer Gene Therapy; American Cancer Society(American Cancer Society); Sontag Foundation; Beckman Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank J. Fitzpatrick and the Waitt Advanced Biophotonics Center for assistance with imaging and analysis, J. Karlseder, I. Verma, T. Hunter, R. Shaw and the O'Shea laboratory for critical reading of this manuscript, L. Haro, S. Panda, R. O'Sullivan and A. Rodriguez for advice and protocols, and P. Branton and D. Ornelles for viruses. C.C.O. acknowledges funding from the Alliance of Cancer Gene Therapy, the American Cancer Society, the Sontag Foundation and the Beckman Foundation. This work was supported by R01CA137094 from the National Cancer Institute.	Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Berriz GF, 2003, BIOINFORMATICS, V19, P2502, DOI 10.1093/bioinformatics/btg363; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CUTT JR, 1987, J VIROL, V61, P543, DOI 10.1128/JVI.61.2.543-552.1987; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Downey T, 2006, METHOD ENZYMOL, V411, P256, DOI 10.1016/S0076-6879(06)11013-7; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lane DP, 2005, COLD SH Q B, V70, P489, DOI 10.1101/sqb.2005.70.049; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maehara K, 2005, J CELL BIOL, V168, P553, DOI 10.1083/jcb.200411093; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; McCormick F, 2003, CANCER BIOL THER, V2, pS157; O'Shea CC, 2005, ONCOGENE, V24, P7640, DOI 10.1038/sj.onc.1209047; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Shepard RN, 2003, J VIROL, V77, P8593, DOI 10.1128/JVI.77.15.8593-8595.2003; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang N, 2003, NANO LETT, V3, P475, DOI 10.1021/nl034019m; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yan B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r78; Yondola MA, 2007, J VIROL, V81, P4264, DOI 10.1128/JVI.02629-06	58	105	111	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2010	466	7310					1076	U85		10.1038/nature09307	http://dx.doi.org/10.1038/nature09307			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740008	Green Accepted			2022-12-28	WOS:000281203600033
J	Huang, CS; Sadre-Bazzaz, K; Shen, Y; Deng, BB; Zhou, ZH; Tong, LA				Huang, Christine S.; Sadre-Bazzaz, Kianoush; Shen, Yang; Deng, Binbin; Zhou, Z. Hong; Tong, Liang			Crystal structure of the alpha(6)beta(6) holoenzyme of propionyl-coenzyme A carboxylase	NATURE			English	Article							ACETYL-COA CARBOXYLASE; BIOTIN CARBOXYLASE; CARBOXYLTRANSFERASE DOMAIN; PYRUVATE-CARBOXYLASE; FUNCTIONAL-ANALYSIS; CATALYTIC-ACTIVITY; MCCB MUTATIONS; A CARBOXYLASE; ACIDEMIA; SUBUNIT	Propionyl-coenzyme A carboxylase (PCC), a mitochondrial biotin-dependent enzyme, is essential for the catabolism of the amino acids Thr, Val, Ile and Met, cholesterol and fatty acids with an odd number of carbon atoms. Deficiencies in PCC activity in humans are linked to the disease propionic acidaemia, an autosomal recessive disorder that can be fatal in infants(1-4). The holoenzyme of PCC is an alpha(6)beta(6) dodecamer, with a molecular mass of 750 kDa. The alpha-subunit contains the biotin carboxylase (BC) and biotin carboxyl carrier protein (BCCP) domains, whereas the beta-subunit supplies the carboxyltransferase (CT) activity. Here we report the crystal structure at 3.2-angstrom resolution of a bacterial PCC alpha(6)beta(6) holoenzyme as well as cryo-electron microscopy (cryo-EM) reconstruction at 15-angstrom resolution demonstrating a similar structure for human PCC. The structure defines the overall architecture of PCC and reveals unexpectedly that the alpha-subunits are arranged as monomers in the holoenzyme, decorating a central beta(6) hexamer. A hitherto unrecognized domain in the alpha-subunit, formed by residues between the BC and BCCP domains, is crucial for interactions with the beta-subunit. We have named it the BT domain. The structure reveals for the first time the relative positions of the BC and CT active sites in the holoenzyme. They are separated by approximately 55 angstrom, indicating that the entire BCCP domain must translocate during catalysis. The BCCP domain is located in the active site of the beta-subunit in the current structure, providing insight for its involvement in the CT reaction. The structural information establishes a molecular basis for understanding the large collection of disease-causing mutations in PCC and is relevant for the holoenzymes of other biotin-dependent carboxylases, including 3-methylcrotonyl-CoA carboxylase (MCC)(5-7) and eukaryotic acetyl-CoA carboxylase (ACC)(8,9).	[Huang, Christine S.; Sadre-Bazzaz, Kianoush; Shen, Yang; Tong, Liang] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Deng, Binbin; Zhou, Z. Hong] Univ Texas Houston, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; [Zhou, Z. Hong] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Columbia University; University of Texas System; University of Texas Health Science Center Houston; University of California System; University of California Los Angeles	Tong, LA (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	ltong@columbia.edu	Zhou, Z Hong/HDN-0747-2022	Huang, Christine/0000-0003-4082-3880; Tong, Liang/0000-0002-0563-6468	National Institutes of Health [DK067238, GM071940, AI069015, GM08281]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P30EB009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008281, R01GM071940] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank N. Whalen and H. Robinson for access to the X29A beamline at the National Synchrotron Light Source; J. Schwanof and R. Abramowitz for access to the X4A beamline; M. Sampat for help during the initial stages of the project; and W. W. Cleland for discussions. This research was supported in part by National Institutes of Health grants DK067238 (to L. T.), GM071940 and AI069015 (to Z.H.Z.). C. S. H. was also supported by a National Institutes of Health training program in molecular biophysics (GM08281).	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bilder P, 2006, BIOCHEMISTRY-US, V45, P1712, DOI 10.1021/bi0520479; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chou CY, 2009, J BIOL CHEM, V284, P11690, DOI 10.1074/jbc.M805783200; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Deodato F, 2006, AM J MED GENET C, V142C, P104, DOI 10.1002/ajmg.c.30090; Desviat LR, 2006, J HUM GENET, V51, P992, DOI 10.1007/s10038-006-0068-3; Desviat LR, 2003, MOL GENET METAB, V80, P315, DOI 10.1016/S1096-7192(03)00130-6; Desviat LR, 2004, MOL GENET METAB, V83, P28, DOI 10.1016/j.ymgme.2004.08.001; Diacovich L, 2004, BIOCHEMISTRY-US, V43, P14027, DOI 10.1021/bi049065v; Hall PR, 2003, EMBO J, V22, P2334, DOI 10.1093/emboj/cdg244; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Janiyani K, 2001, J BIOL CHEM, V276, P29864, DOI 10.1074/jbc.M104102200; Jiang H, 2005, J BIOL CHEM, V280, P27719, DOI 10.1074/jbc.M413281200; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lin TW, 2006, P NATL ACAD SCI USA, V103, P3072, DOI 10.1073/pnas.0510580103; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Muro S, 2001, MOL GENET METAB, V74, P476, DOI 10.1006/mgme.2001.3254; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez-Cerda C, 2003, BBA-MOL BASIS DIS, V1638, P43, DOI 10.1016/S0925-4439(03)00039-5; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rodriguez-Pombo P, 2005, BBA-MOL BASIS DIS, V1740, P489, DOI 10.1016/j.bbadis.2004.10.009; Shen Y, 2004, MOL CELL, V16, P881, DOI 10.1016/j.molcel.2004.11.034; Shen Y, 2006, MOL CELL, V22, P807, DOI 10.1016/j.molcel.2006.04.026; Sloane V, 2004, J BIOL CHEM, V279, P15772, DOI 10.1074/jbc.M311982200; St Maurice M, 2007, SCIENCE, V317, P1076, DOI 10.1126/science.1144504; Stadler SC, 2006, HUM MUTAT, V27, P748, DOI 10.1002/humu.20349; Stucki M, 2009, J BIOL CHEM, V284, P28953, DOI 10.1074/jbc.M109.050674; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; Tong L, 2005, CELL MOL LIFE SCI, V62, P1784, DOI 10.1007/s00018-005-5121-4; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; Weatherly SC, 2004, BIOCHEM J, V380, P105, DOI 10.1042/BJ20031960; Wendt KS, 2003, EMBO J, V22, P3493, DOI 10.1093/emboj/cdg358; Xiang S, 2008, NAT STRUCT MOL BIOL, V15, P295, DOI 10.1038/nsmb.1393; Zhang HL, 2003, SCIENCE, V299, P2064, DOI 10.1126/science.1081366	39	64	70	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2010	466	7309					1001	U135		10.1038/nature09302	http://dx.doi.org/10.1038/nature09302			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725044	Green Accepted			2022-12-28	WOS:000281030300040
J	Terkelsen, CJ; Sorensen, JT; Maeng, M; Jensen, LO; Tilsted, HH; Trautner, S; Vach, W; Johnsen, SP; Thuesen, L; Lassen, JF				Terkelsen, Christian Juhl; Sorensen, Jacob Thorsted; Maeng, Michael; Jensen, Lisette Okkels; Tilsted, Hans-Henrik; Trautner, Sven; Vach, Werner; Johnsen, Soren Paaske; Thuesen, Leif; Lassen, Jens Flensted			System Delay and Mortality Among Patients With STEMI Treated With Primary Percutaneous Coronary Intervention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; TO-BALLOON TIME; REPERFUSION THERAPY; PRIMARY ANGIOPLASTY; PRIMARY PCI; ASSOCIATION; SURVIVAL; IMPACT; MATTER; SIZE	Context Timely reperfusion therapy is recommended for patients with ST-segment elevation myocardial infarction (STEMI), and door-to-balloon delay has been proposed as a performance measure in triaging patients for primary percutaneous coronary intervention (PCI). However, focusing on the time from first contact with the health care system to the initiation of reperfusion therapy (system delay) may be more relevant, because it constitutes the total time to reperfusion modifiable by the health care system. No previous studies have focused on the association between system delay and outcome in patients with STEMI treated with primary PCI. Objective To evaluate the associations between system, treatment, patient, and door-to-balloon delays and mortality in patients with STEMI. Design, Setting, and Patients Historical follow-up study based on population-based Danish medical registries of patients with STEMI transported by the emergency medical service and treated with primary PCI from January 1, 2002, to December 31, 2008, at 3 high-volume PCI centers in Western Denmark. Patients (N=6209) underwent primary PCI within 12 hours of symptom onset. The median follow-up time was 3.4 (interquartile range, 1.8-5.2) years. Main Outcome Measures Crude and adjusted hazard ratios of mortality obtained by Cox proportional regression analysis. Results A system delay of 0 through 60 minutes (n=347) corresponded to a long-term mortality rate of 15.4% (n=43); a delay of 61 through 120 minutes (n=2643) to a rate of 23.3% (n=380); a delay of 121 through 180 minutes (n=2092) to a rate of 28.1% (n=378); and a delay of 181 through 360 minutes (n=1127) to a rate of 30.8% (n=275) (P<.001). In multivariable analysis adjusted for other predictors of mortality, system delay was independently associated with mortality (adjusted hazard ratio, 1.10 [95% confidence interval, 1.04-1.16] per 1-hour delay), as was its components, prehospital system delay and door-to-balloon delay. Conclusion System delay was associated with mortality in patients with STEMI treated with primary PCI. JAMA. 2010;304(7):763-771 www.jama.com	[Terkelsen, Christian Juhl; Sorensen, Jacob Thorsted; Maeng, Michael; Thuesen, Leif; Lassen, Jens Flensted] Aarhus Univ Hosp, Dept Cardiol, DK-8200 Aarhus N, Denmark; [Johnsen, Soren Paaske] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8200 Aarhus N, Denmark; [Jensen, Lisette Okkels] Odense Univ Hosp, Dept Cardiol, DK-5000 Odense, Denmark; [Tilsted, Hans-Henrik] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark; [Trautner, Sven] Falck Emergency Med Serv, Copenhagen, Denmark; [Vach, Werner] Univ Med Ctr, Dept Clin Epidemiol, Freiburg, Germany	Aarhus University; Aarhus University; University of Southern Denmark; Odense University Hospital; Aalborg University; Aalborg University Hospital; University of Freiburg	Terkelsen, CJ (corresponding author), Aarhus Univ Hosp, Dept Cardiol, DK-8200 Aarhus N, Denmark.	christian_juhl_terkelsen@hotmail.com	terkelsen, christian/ABD-6294-2021; Vach, Werner/F-2512-2011; Maeng, Michael/AAY-2135-2021; Lassen, Jens Flensted/AAY-2127-2021	Vach, Werner/0000-0003-1865-8399; Maeng, Michael/0000-0002-4310-6433; Lassen, Jens Flensted/0000-0001-7972-9192; terkelsen, christian juhl/0000-0003-0205-9551; Jensen, Lisette Okkels/0000-0002-4838-2429	Helga and Peter Kornings Foundation, Aarhus, Denmark [40-134918]; Central Denmark Region, Aarhus, Denmark [1-45-72-1-08]	Helga and Peter Kornings Foundation, Aarhus, Denmark; Central Denmark Region, Aarhus, Denmark	This study was supported by grants from the Helga and Peter Kornings Foundation, Aarhus, Denmark (J.No. 40-134918) and the Health Research Fund of Central Denmark Region, Aarhus, Denmark (J.No. 1-45-72-1-08).	Allison PD, 2002, MISSING DATA; Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI [10.1016/j.jacc.2008.04.002, 10.1016/j.jacc.2007.10.001]; Aquaro GD, 2007, AM J CARDIOL, V100, P28, DOI 10.1016/j.amjcard.2007.02.050; Arntz HR, 1998, EUR HEART J, V19, P1140; Blohm MB, 1996, HEART, V76, P430, DOI 10.1136/hrt.76.5.430; Boersma E, 2006, EUR HEART J, V27, P779, DOI 10.1093/eurheartj/ehi810; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Bradley EH, 2009, J AM COLL CARDIOL, V54, P2423, DOI 10.1016/j.jacc.2009.11.003; Brodie BR, 1998, J AM COLL CARDIOL, V32, P1312, DOI 10.1016/S0735-1097(98)00395-7; Brodie BR, 2001, AM J CARDIOL, V88, P1085, DOI 10.1016/S0002-9149(01)02039-2; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hedges JR, 2000, ACAD EMERG MED, V7, P862, DOI 10.1111/j.1553-2712.2000.tb02063.x; Le May MR, 2008, NEW ENGL J MED, V358, P231, DOI 10.1056/NEJMoa073102; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LOWEL H, 1991, DEUT MED WOCHENSCHR, V116, P729, DOI 10.1055/s-2008-1063671; McNamara RL, 2006, J AM COLL CARDIOL, V47, P45, DOI 10.1016/j.jacc.2005.04.071; McNamara RL, 2006, J AM COLL CARDIOL, V47, P2180, DOI 10.1016/j.jacc.2005.12.072; Morrison LJ, 2000, JAMA-J AM MED ASSOC, V283, P2686, DOI 10.1001/jama.283.20.2686; Nallamothu BK, 2005, CIRCULATION, V111, P761, DOI 10.1161/01.CIR.0000155258.44268.F8; Nallamothu BK, 2007, NEW ENGL J MED, V357, P1631, DOI 10.1056/NEJMra065985; Pedersen CB, 2006, DAN MED BULL, V53, P441; Rathore SS, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1807; Schemper M, 1997, STAT MED, V16, P73; SCHEMPER M, 1990, STAT MED, V9, P777, DOI 10.1002/sim.4780090707; Sorensen H T, 1997, Int J Risk Saf Med, V10, P1, DOI 10.3233/JRS-1997-10101; Terkelsen CJ, 2009, HEART, V95, P362, DOI 10.1136/hrt.2007.139493; Terkelsen CJ, 2008, J AM COLL CARDIOL, V52, P1211, DOI 10.1016/j.jacc.2008.05.061; Terkelsen CJ, 2009, J ELECTROCARDIOL, V42, P64, DOI 10.1016/j.jelectrocard.2008.08.038; Terkelsen CJ, 2005, EUR HEART J, V26, P770, DOI 10.1093/eurheartj/ehi100; VACH W, 1993, BIOMETRIKA, V80, P353, DOI 10.2307/2337205; Zijistra F, 2002, EUR HEART J, V23, P550, DOI 10.1053/euhj.2001.2901	34	444	464	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					763	771		10.1001/jama.2010.1139	http://dx.doi.org/10.1001/jama.2010.1139			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20716739				2022-12-28	WOS:000280993700023
J	Munro, AJ; Niblock, PG				Munro, Alastair J.; Niblock, Paddy G.			Cancer research in the global village	LANCET			English	Editorial Material							CARCINOMA		[Munro, Alastair J.; Niblock, Paddy G.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Munro, AJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.							Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Grabsch H, 2010, CELL ONCOL, V32, P57, DOI 10.3233/CLO-2009-0497; National Institute for Health and Clinical Excellence CG80, 2009, EARL LOC ADV BREAST; Purdie CA, 2010, HISTOPATHOLOGY, V56, P702, DOI 10.1111/j.1365-2559.2010.03533.x; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Sauter G, 2009, J CLIN ONCOL, V27, P1323, DOI 10.1200/JCO.2007.14.8197; Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723; WHO, WORLD HLTH STAT 2010	10	10	12	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2010	376	9742					659	660		10.1016/S0140-6736(10)61022-7	http://dx.doi.org/10.1016/S0140-6736(10)61022-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	646YW	20728211				2022-12-28	WOS:000281582900004
J	WARDEN, J				WARDEN, J			DOWN TO THE FOUNDATIONS	BRITISH MEDICAL JOURNAL			English	Letter																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1988	296	6636					1612	1612		10.1136/bmj.296.6636.1612	http://dx.doi.org/10.1136/bmj.296.6636.1612			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7292	20742999	Green Published			2022-12-28	WOS:A1988N729200047
J	WARDEN, J				WARDEN, J			RISE OF THE NURSE PRACTITIONER	BRITISH MEDICAL JOURNAL			English	Editorial Material																		PROMOTING BETTER HLT; 1988, BR MED J, V296, P871	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1988	296	6634					1478	1478		10.1136/bmj.296.6634.1478	http://dx.doi.org/10.1136/bmj.296.6634.1478			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N5101	20742994	Green Published			2022-12-28	WOS:A1988N510100053
J	WARDEN, J				WARDEN, J			METAPHYSICS FROM MOORE	BRITISH MEDICAL JOURNAL			English	Editorial Material																		FROGGATT P, SMOKING HLTH	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1988	296	6627					1012	1012		10.1136/bmj.296.6627.1012	http://dx.doi.org/10.1136/bmj.296.6627.1012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	M8425	20742979	Green Published			2022-12-28	WOS:A1988M842500057
J	DUNEA, G				DUNEA, G			STAMPEDE	BRITISH MEDICAL JOURNAL			English	Editorial Material											DUNEA, G (corresponding author), COOK CTY HOSP,CHICAGO,IL 60612, USA.							[Anonymous], 1984, JAMA, V251, P365; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; FIHN SD, 1987, JAMA-J AM MED ASSOC, V258, P2416, DOI 10.1001/jama.258.17.2416; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001	4	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1988	296	6621					561	562		10.1136/bmj.296.6621.561	http://dx.doi.org/10.1136/bmj.296.6621.561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M2314	20742962	Green Published			2022-12-28	WOS:A1988M231400025
J	Cheng, G; Saleh, MN; Marcher, C; Vasey, S; Mayer, B; Aivado, M; Arning, M; Stone, NL; Bussel, JB				Cheng, Gregory; Saleh, Mansoor N.; Marcher, Claus; Vasey, Sandra; Mayer, Bhabita; Aivado, Manuel; Arning, Michael; Stone, Nicole L.; Bussel, James B.			Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study	LANCET			English	Article							FUNCTIONAL ASSESSMENT; PLATELET COUNTS; DOUBLE-BLIND; PURPURA; THERAPY; ROMIPLOSTIM; EFFICACY; FATIGUE; AMG-531; EVENTS	Background Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period. Methods We undertook a phase 3, double-blind, placebo-controlled study in adults with previously treated immune thrombocytopenia of more than 6 months' duration who had baseline platelet counts lower than 30 000 per mu L. Patients were randomly allocated (in a 2:1 ratio) treatment with local standard of care plus 50 mg eltrombopag or matching placebo once daily for 6 months. Randomisation was done centrally with a computer-generated randomisation schedule and was stratified by baseline platelet count (<= 15 000 per mu L), use of treatment for immune thrombocytopenia, and splenectomy status. Patients, investigators, and those assessing data were masked to allocation. Dose modifications were made on the basis of platelet response. Patients were assessed for response to treatment (defined as a platelet count of 50 000-400 000 per mu L) weekly during the first 6 weeks and at least once every 4 weeks thereafter; the primary endpoint was the odds of response to eltrombopag versus placebo. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT00370331. Findings Between Nov 22, 2006, and July 31, 2007, 197 patients were randomly allocated to treatment groups and were included in the intention-to-treat analysis (135 eltrombopag, 62 placebo). 106 (79%) patients in the eltrombopag group responded to treatment at least once during the study, compared with 17 (28%) patients in the placebo group. The odds of responding were greater in patients in the eltrombopag group compared with those in the placebo group throughout the 6-month treatment period (odds ratio 8.2, 99% CI 3.59-18.73; p<0.0001). 37 (59%) patients receiving eltrombopag reduced concomitant treatment versus ten (32%) patients receiving placebo (p=0.016). 24 (18%) patients receiving eltrombopag needed rescue treatment compared with 25(40%) patients receiving placebo (p=0.001). Three (2%) patients receiving eltrombopag had thromboembolic events compared with none in patients on placebo. Nine (7%) eltrombopag-treated patients and two (3%) in the placebo group had mild increases in alanine aminotransferase concentration, and five (4%) eltrombopag-treated patients (vs none allocated to placebo) had increases in total bilirubin. Four (7%) patients taking placebo had serious bleeding events, compared with one (<1%) patient treated with eltrombopag. Interpretation Eltrombopag is effective for management of chronic immune thrombocytopenia, and could be particularly beneficial for patients who have not responded to splenectomy or previous treatment. These benefits should be balanced with the potential risks associated with eltrombopag treatment.	[Cheng, Gregory] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China; [Saleh, Mansoor N.] Georgia Canc Specialists, Atlanta, GA USA; [Marcher, Claus] Odense Univ Hosp, DK-5000 Odense, Denmark; [Vasey, Sandra; Aivado, Manuel; Arning, Michael; Stone, Nicole L.] GlaxoSmithKline, Collegeville, PA USA; [Mayer, Bhabita] GlaxoSmithKline, Stockley Pk, Middx, England; [Bussel, James B.] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA	Chinese University of Hong Kong; University of Southern Denmark; Odense University Hospital; GlaxoSmithKline; GlaxoSmithKline; Cornell University	Cheng, G (corresponding author), Prince Wales Hosp, Dept Med & Therapeut, Ngan Shing St, Shatin, Hong Kong, Peoples R China.	gcheng@cuhk.edu.hk			GlaxoSmithKline; Bristol-Myers Squibb; Amgen; Cangene; Eisai Inc; Genzyme; Immunomedics; Ligand; Sysmex	GlaxoSmithKline(GlaxoSmithKline); Bristol-Myers Squibb(Bristol-Myers Squibb); Amgen(Amgen); Cangene; Eisai Inc(Eisai Co Ltd); Genzyme(Sanofi-AventisGenzyme Corporation); Immunomedics; Ligand; Sysmex	GC reports receiving research support and lecture fees from GlaxoSmithKline. MNS reports receiving lecture fees from Bristol-Myers Squibb and GlaxoSmithKline and consulting fees from GlaxoSmithKline. CM reports participating in an advisory board for GlaxoSmithKline. SV, BM, MAi, MAr, and NLS are full-time employees of GlaxoSmithKline and report having equity ownership in the company. JBB reports receiving research support from Amgen, Cangene, Eisai Inc, Genzyme, GlaxoSmithKline, Immunomedics, Ligand, and Sysmex; having equity ownership in Amgen and GlaxoSmithKline; participating in the speaker's bureau programme for Scienta; and participating in advisory boards for Amgen, Eisai Inc, GlaxoSmithKline, Ligand, and Shionogi.	[Anonymous], 2010, PROMACTA ELTR TABL O; Arnold DM, 2007, SEMIN HEMATOL, V44, pS12, DOI 10.1053/j.seminhematol.2007.11.003; Baranwal A, 2007, SUPPORT CARE CANCER, V15, P761; Boruchov DM, 2007, BLOOD, V110, P3526, DOI 10.1182/blood-2007-01-065763; Bussel JB, 2007, NEW ENGL J MED, V357, P2237, DOI 10.1056/NEJMoa073275; Bussel JB, 2006, NEW ENGL J MED, V355, P1672, DOI 10.1056/NEJMoa054626; Bussel JB, 2009, LANCET, V373, P641, DOI 10.1016/S0140-6736(09)60402-5; Bussel JB, 2009, BLOOD, V113, P2161, DOI 10.1182/blood-2008-04-150078; Bussel JB, 2009, BLOOD, V114; Bussel JB, 2008, BLOOD, V112, P3431; Bussel JB, 2008, BLOOD, V112, P3432; Cella D, 2005, J RHEUMATOL, V32, P811; Cella D, 2006, SUPPORT CARE CANCER, V14, P1220, DOI 10.1007/s00520-006-0102-1; Cines DB, 2005, BLOOD, V106, P2244, DOI 10.1182/blood-2004-12-4598; Cooper N, 2006, BRIT J HAEMATOL, V133, P364, DOI 10.1111/j.1365-2141.2006.06024.x; Fehnel SE, 2004, QUAL LIFE RES, V13, P1321, DOI 10.1023/B:QURE.0000037502.64077.4d; George JN, 2006, J THROMB HAEMOST, V4, P1664, DOI 10.1111/j.1538-7836.2006.02013.x; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; Gernsheimer TB, 2010, J THROMB HAEMOST, V8, P1372, DOI 10.1111/j.1538-7836.2010.03830.x; Grotzinger K, 2009, HAEMATOL-HEMATOL J, V94, P96; Kuter DJ, 2008, LANCET, V371, P395, DOI 10.1016/S0140-6736(08)60203-2; Lai JS, 2003, QUAL LIFE RES, V12, P485, DOI 10.1023/A:1025014509626; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Matzdorff A, 2007, EUR J HAEMATOL, V78, P381, DOI 10.1111/j.1600-0609.2007.00829.x; McHutchison JG, 2007, NEW ENGL J MED, V357, P2227, DOI 10.1056/NEJMoa073255; Newland A, 2006, BRIT J HAEMATOL, V135, P547, DOI 10.1111/j.1365-2141.2006.06339.x; Portielje JEA, 2001, BLOOD, V97, P2549, DOI 10.1182/blood.V97.9.2549; Provan D, 2003, BRIT J HAEMATOL, V120, P574; Psaila B, 2008, BRIT J HAEMATOL, V143, P16, DOI 10.1111/j.1365-2141.2008.07275.x; REINER A, 1995, BLOOD, V85, P351; Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503; Saleh MN, 2009, BLOOD, V114; Sarpatwari A, 2010, HAEMATOL-HEMATOL J, V95, P1167, DOI 10.3324/haematol.2009.018390; Stasi R, 2008, DRUGS, V68, P901, DOI 10.2165/00003495-200868070-00002; Stevens W, 2006, NETH J MED, V64, P356; Ware Jr JE, 2001, SCORE VERSION 2 SF 3; Zelcer S, 2003, J THROMB HAEMOST, V1	37	349	365	1	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2011	377	9763					393	402		10.1016/S0140-6736(10)60959-2	http://dx.doi.org/10.1016/S0140-6736(10)60959-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721ES	20739054				2022-12-28	WOS:000287337000029
J	Lemmers, RJLF; van der Vliet, PJ; Klooster, R; Sacconi, S; Camano, P; Dauwerse, JG; Snider, L; Straasheijm, KR; van Ommen, GJ; Padberg, GW; Miller, DG; Tapscott, SJ; Tawil, R; Frants, RR; van der Maarel, SM				Lemmers, Richard J. L. F.; van der Vliet, Patrick J.; Klooster, Rinse; Sacconi, Sabrina; Camano, Pilar; Dauwerse, Johannes G.; Snider, Lauren; Straasheijm, Kirsten R.; van Ommen, Gert Jan; Padberg, George W.; Miller, Daniel G.; Tapscott, Stephen J.; Tawil, Rabi; Frants, Rune R.; van der Maarel, Silvere M.			A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy	SCIENCE			English	Article							DNA REARRANGEMENTS; FSHD; RNA; 4Q; D4Z4	Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy in adults that is foremost characterized by progressive wasting of muscles in the upper body. FSHD is associated with contraction of D4Z4 macrosatellite repeats on chromosome 4q35, but this contraction is pathogenic only in certain "permissive" chromosomal backgrounds. Here, we show that FSHD patients carry specific single-nucleotide polymorphisms in the chromosomal region distal to the last D4Z4 repeat. This FSHD-predisposing configuration creates a canonical polyadenylation signal for transcripts derived from DUX4, a double homeobox gene of unknown function that straddles the last repeat unit and the adjacent sequence. Transfection studies revealed that DUX4 transcripts are efficiently polyadenylated and are more stable when expressed from permissive chromosomes. These findings suggest that FSHD arises through a toxic gain of function attributable to the stabilized distal DUX4 transcript.	[Lemmers, Richard J. L. F.; van der Vliet, Patrick J.; Klooster, Rinse; Straasheijm, Kirsten R.; van Ommen, Gert Jan; Frants, Rune R.; van der Maarel, Silvere M.] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands; [Sacconi, Sabrina] Univ Nice, Ctr Reference Malad Neuromusculaires, F-06202 Nice, France; [Sacconi, Sabrina] Univ Nice, CNRS, UMR6543, F-06202 Nice, France; [Camano, Pilar] Hosp Donostia, BioDonostia Hlth Res Inst, Dept Neurosci, San Sebastian 20014, Spain; [Camano, Pilar] Inst Salud Carlos III, CIBERNED, Madrid 28029, Spain; [Dauwerse, Johannes G.] Leiden Univ, Med Ctr, Dept Clin Genet, NL-2333 ZA Leiden, Netherlands; [Snider, Lauren; Tapscott, Stephen J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; [Padberg, George W.] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Neurol, NL-6500 HC Nijmegen, Netherlands; [Miller, Daniel G.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Tawil, Rabi] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Instituto de Investigacion Sanitaria Biodonostia; University Hospital Donostia; CIBERNED; Instituto de Salud Carlos III; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Fred Hutchinson Cancer Center; Radboud University Nijmegen; University of Washington; University of Washington Seattle; University of Rochester	van der Maarel, SM (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands.	maarel@lumc.nl	SACCONI, Sabrina/AFT-1096-2022; Padberg, G.W.A.M./H-8079-2014; van der Maarel, Silvere/X-3631-2018; Camaño, Pilar/B-7733-2018	SACCONI, Sabrina/0000-0002-0246-1455; van der Maarel, Silvere/0000-0001-8103-711X; Camaño, Pilar/0000-0002-4116-5579; Miller, Daniel/0000-0002-5700-3048; Tapscott, Stephen/0000-0002-0319-0968	Fields Center for FSHD and Neuromuscular Research; Netherlands Organization for Scientific Research [NWO 917.56.338]; Netherlands Genomics Initiative [NWO 93.51.8001]; National Institutes of Health [P01NS069539]; Muscular Dystrophy Association; Shaw Family Foundation; FSH Society; Dutch FSHD Foundation; Pacific Northwest Friends of FSH Research; Centro Investigacion Biomedica en Red para Enfermedades Neurodegenerativas (CIBERNED); Basque Government [2008111011]; Instituto Carlos III, ILUNDAIN Fundazioa; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS069539] Funding Source: NIH RePORTER	Fields Center for FSHD and Neuromuscular Research; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Genomics Initiative; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); Shaw Family Foundation; FSH Society; Dutch FSHD Foundation; Pacific Northwest Friends of FSH Research; Centro Investigacion Biomedica en Red para Enfermedades Neurodegenerativas (CIBERNED); Basque Government(Basque Government); Instituto Carlos III, ILUNDAIN Fundazioa(Instituto de Salud Carlos III); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank all patients and family members for their participation. This study was supported by the Fields Center for FSHD and Neuromuscular Research, the Netherlands Organization for Scientific Research NWO 917.56.338, a Breakthrough Project Grant by the Netherlands Genomics Initiative NWO 93.51.8001, the National Institutes of Health P01NS069539, the Muscular Dystrophy Association, the Shaw Family Foundation, a Marjorie Bronfman Fellowship grant from the FSH Society, the Dutch FSHD Foundation, the Pacific Northwest Friends of FSH Research, Centro Investigacion Biomedica en Red para Enfermedades Neurodegenerativas (CIBERNED), the Basque Government (Fellowship grant, 2008111011), and Instituto Carlos III, ILUNDAIN Fundazioa.	AHMED F, 2009, SILICO BIOL, V9, P13; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Bosnakovski D, 2008, EMBO J, V27, P2766, DOI 10.1038/emboj.2008.201; de Greef JC, 2009, HUM MUTAT, V30, P1449, DOI 10.1002/humu.21091; de Greef JC, 2008, MUTAT RES-FUND MOL M, V647, P94, DOI 10.1016/j.mrfmmm.2008.07.011; Dixit M, 2007, P NATL ACAD SCI USA, V104, P18157, DOI 10.1073/pnas.0708659104; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; Klooster R, 2009, EUR J HUM GENET, V17, P1615, DOI 10.1038/ejhg.2009.62; Lemmers RJLF, 2007, AM J HUM GENET, V81, P884, DOI 10.1086/521986; Lemmers RJLF, 2010, AM J HUM GENET, V86, P364, DOI 10.1016/j.ajhg.2010.01.035; Lemmers RJLF, 2002, NAT GENET, V32, P235, DOI 10.1038/ng999; Liu HQ, 2005, BIOINFORMATICS, V21, P671, DOI 10.1093/bioinformatics/bth437; Masny PS, 2010, EUR J HUM GENET, V18, P448, DOI 10.1038/ejhg.2009.183; Snider L, 2009, HUM MOL GENET, V18, P2414, DOI 10.1093/hmg/ddp180; Tawil R, 2006, MUSCLE NERVE, V34, P1, DOI 10.1002/mus.20522; Tupler R, 1996, J MED GENET, V33, P366, DOI 10.1136/jmg.33.5.366; van der Maarel SM, 2000, AM J HUM GENET, V66, P26, DOI 10.1086/302730; van Overveld PGM, 2003, NAT GENET, V35, P315, DOI 10.1038/ng1262; VANDEUTEKOM JCT, 1993, HUM MOL GENET, V2, P2037; WIJMENGA C, 1992, NAT GENET, V2, P26, DOI 10.1038/ng0992-26; Zeng WH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000559	22	457	476	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	2010	329	5999					1650	1653		10.1126/science.1189044	http://dx.doi.org/10.1126/science.1189044			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653NK	20724583	Green Accepted, Green Published			2022-12-28	WOS:000282098100043
J	Lane, DA; Lip, GYH				Lane, Deirdre A.; Lip, Gregory Y. H.			Quality of anticoagulation control in atrial fibrillation	LANCET			English	Editorial Material							ORAL ANTICOAGULANT; WARFARIN; THERAPY; STROKE		[Lane, Deirdre A.; Lip, Gregory Y. H.] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Lip, GYH (corresponding author), Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham B18 7QH, W Midlands, England.	g.y.h.lip@bham.ac.uk	Lane, Deirdre/AAX-1866-2020	Lane, Deirdre/0000-0002-5604-9378				Ahrens I, 2010, THROMB HAEMOSTASIS, V104, P49, DOI 10.1160/TH09-05-0327; Beinema M, 2008, THROMB HAEMOSTASIS, V100, P1052, DOI 10.1160/TH08-04-0116; Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Morgan CL, 2009, THROMB RES, V124, P37, DOI 10.1016/j.thromres.2008.09.016; Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134; ROSE AJ, 2009, COMM J QUAL PATIENT, V35, P146; WALLENTIN L, 2010, LANCET, DOI DOI 10.1016/50140-6736(10)63.3.94-4; Wan Y, 2008, CIRC-CARDIOVASC QUAL, V1, P84, DOI 10.1161/CIRCOUTCOMES.108.796185; White HD, 2007, ARCH INTERN MED, V167, P239, DOI 10.1001/archinte.167.3.239	12	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	2010	376	9745					935	937		10.1016/S0140-6736(10)61305-0	http://dx.doi.org/10.1016/S0140-6736(10)61305-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655JZ	20801499				2022-12-28	WOS:000282247600006
J	Horsley, T; Grimshaw, J; Campbell, C				Horsley, T.; Grimshaw, J.; Campbell, C.			Health Systems Perspectives Maintaining the competence of Europe's workforce	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Horsley, T.; Campbell, C.] Royal Coll Phys & Surg Canada, Ctr Learning Practice, Ottawa, ON, Canada; [Grimshaw, J.] Univ Ottawa, Inst Populat Hlth, Ctr Best Practices, Ottawa, ON K1N 6N5, Canada; [Grimshaw, J.] Canadian Cochrane Network & Ctr, Ottawa, ON, Canada; [Campbell, C.] Royal Coll Phys & Surg Canada, Off Profess Affairs, Ottawa, ON, Canada	University of Ottawa	Horsley, T (corresponding author), Royal Coll Phys & Surg Canada, Ctr Learning Practice, Ottawa, ON, Canada.	thorsley@rcpsc.edu	Grimshaw, Jeremy/D-8726-2013; Horsley, Tanya/AAH-8348-2020	Horsley, Tanya/0000-0002-1256-9582; Grimshaw, Jeremy/0000-0001-8015-8243				BANDIERA G, 2010, CANMEDS ASSESSMENT T; *BELG PRES COUNC E, 2010, MIN C INV HLTH PROF; CAMPBELL C, MED TEACH IN PRESS; Cosford PA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c3194; Forsetlund L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003030.pub2; *GEN MED COUNC, 2010, GOOD MED PRACT; HARDING A, 2004, BMJ-BRIT MED J, V29, P328; Harris JM, 2010, J CONTIN EDUC HEALTH, V30, P3, DOI 10.1002/chp.20050; Horsley T, INVESTING EUROPES HL; Kennedy I, 1984, LEARNING BRISTOL REP; Mansouri M, 2007, J CONTIN EDUC HEALTH, V27, P6, DOI 10.1002/chp.88; Marinopoulos SS, 2007, EFFECTIVENESS CONTIN; MERKUR S, 2008, DO LIFELONG LEARNING, P1; Moore DE, 2009, J CONTIN EDUC HEALTH, V29, P1, DOI 10.1002/chp.20001; *SHIPM INQ, 2004, 5 SHIPM INQ; SMITH R, 2010, TELEGRAPH       0618	16	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	2010	341								c4687	10.1136/bmj.c4687	http://dx.doi.org/10.1136/bmj.c4687			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647JZ	20817683				2022-12-28	WOS:000281616100003
J	Olguin, P; Mlodzik, M				Olguin, Patricio; Mlodzik, Marek			A New Spin on Planar Cell Polarity	CELL			English	Editorial Material							DROSOPHILA		[Olguin, Patricio; Mlodzik, Marek] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Mlodzik, M (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA.	marek.mlodzik@mssm.edu	Olguin, Patricio/H-3270-2014	Olguin, Patricio/0000-0002-8847-4969	NIGMS NIH HHS [R01 GM062917-09, R01 GM062917, R01 GM102811, R01 GM062917-10] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062917, R01GM102811] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aigouy B, 2010, CELL, V142, P773, DOI 10.1016/j.cell.2010.07.042; Baena-Lopez LA, 2005, CURR BIOL, V15, P1640, DOI 10.1016/j.cub.2005.07.062; Classen AK, 2005, DEV CELL, V9, P805, DOI 10.1016/j.devcel.2005.10.016; Harumoto T, 2010, DEV CELL, V19, P389, DOI 10.1016/j.devcel.2010.08.004; Lawrence PA, 2007, NAT REV GENET, V8, P555, DOI 10.1038/nrg2125; Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042; Shimada Y, 2006, DEV CELL, V10, P209, DOI 10.1016/j.devcel.2005.11.016; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wu J, 2009, TRENDS CELL BIOL, V19, P295, DOI 10.1016/j.tcb.2009.04.003	10	3	3	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5					674	676		10.1016/j.cell.2010.08.025	http://dx.doi.org/10.1016/j.cell.2010.08.025			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813254	Bronze, Green Accepted			2022-12-28	WOS:000281523200009
J	Gerya, T				Gerya, Taras			Dynamical Instability Produces Transform Faults at Mid-Ocean Ridges	SCIENCE			English	Article							ACCRETION; STRESS; MODEL; CRUST	Transform faults at mid-ocean ridges-one of the most striking, yet enigmatic features of terrestrial plate tectonics-are considered to be the inherited product of preexisting fault structures. Ridge offsets along these faults therefore should remain constant with time. Here, numerical models suggest that transform faults are actively developing and result from dynamical instability of constructive plate boundaries, irrespective of previous structure. Boundary instability from asymmetric plate growth can spontaneously start in alternate directions along successive ridge sections; the resultant curved ridges become transform faults within a few million years. Fracture-related rheological weakening stabilizes ridge-parallel detachment faults. Offsets along the transform faults change continuously with time by asymmetric plate growth and discontinuously by ridge jumps.	Swiss Fed Inst Technol Zurich, Dept Geosci, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Gerya, T (corresponding author), Swiss Fed Inst Technol Zurich, Dept Geosci, Zurich, Switzerland.	taras.gerya@erdw.ethz.ch	Gerya, Taras/V-2330-2019	Gerya, Taras/0000-0002-1062-2722	Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	I thank Y. Podladchikov, J.-P. Burg, B. Kaus, P. Tackley, and three anonymous reviewers for suggestions and discussions. This work was supported by the TopoEurope and 4D-Adamello projects of Swiss National Science Foundation.	Allerton S, 2000, GEOLOGY, V28, P179, DOI 10.1130/0091-7613(2000)28<179:EAMAOO>2.0.CO;2; Behn MD, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015612; Buck WR, 1999, PHILOS T R SOC A, V357, P671, DOI 10.1098/rsta.1999.0348; Buck WR, 2005, NATURE, V434, P719, DOI 10.1038/nature03358; Choi ES, 2008, PHYS EARTH PLANET IN, V171, P374, DOI 10.1016/j.pepi.2008.08.010; Collier JS, 1997, GEOLOGY, V25, P1075, DOI 10.1130/0091-7613(1997)025<1075:EFAAAL>2.3.CO;2; DeMets C, 2010, GEOPHYS J INT, V181, P1, DOI 10.1111/j.1365-246X.2009.04491.x; Dick HJB, 2003, NATURE, V426, P405, DOI 10.1038/nature02128; Escartin J, 2008, NATURE, V455, P790, DOI 10.1038/nature07333; FOX PJ, 1984, TECTONOPHYSICS, V104, P205, DOI 10.1016/0040-1951(84)90124-0; Gregg PM, 2007, NATURE, V448, P183, DOI 10.1038/nature05962; Gudmundsson A, 1995, EARTH PLANET SC LETT, V136, P603, DOI 10.1016/0012-821X(95)00164-8; Hashima A, 2008, GEOPHYS J INT, V175, P992, DOI 10.1111/j.1365-246X.2008.03837.x; Hieronymus CF, 2004, EARTH PLANET SC LETT, V222, P177, DOI 10.1016/j.epsl.2004.02.022; Huismans RS, 2002, GEOLOGY, V30, P211, DOI 10.1130/0091-7613(2002)030<0211:ALETRO>2.0.CO;2; Katz RF, 2005, NEW J PHYS, V7, DOI 10.1088/1367-2630/7/1/037; Kriner KA, 2006, EARTH PLANET SC LETT, V242, P98, DOI 10.1016/j.epsl.2005.05.046; MARKS KM, 1995, MAR GEOPHYS RES, V17, P361, DOI 10.1007/BF01227040; MENARD HW, 1968, NATURE, V219, P463, DOI 10.1038/219463a0; Merkur'ev SA, 2009, GEOTECTONICS+, V43, P194, DOI 10.1134/S0016852109030029; OLDENBUR.DW, 1972, SCIENCE, V178, P301, DOI 10.1126/science.178.4058.301; OLDENBURG DW, 1975, J GEOPHYS RES, V80, P2575, DOI 10.1029/JB080i017p02575; Pockalny RA, 1997, J GEOPHYS RES-SOL EA, V102, P3167, DOI 10.1029/96JB03391; Ragnarsson R, 1996, PHYS REV LETT, V76, P3456, DOI 10.1103/PhysRevLett.76.3456; SANDWELL DT, 1986, J GEOPHYS RES-SOLID, V91, P6405, DOI 10.1029/JB091iB06p06405; Schmalholz SM, 2009, GEOLOGY, V37, P775, DOI 10.1130/G25678A.1; SCHOUTEN H, 1980, GEOLOGY, V8, P175, DOI 10.1130/0091-7613(1980)8<175:ZFZ>2.0.CO;2; Small C, 1998, GEOPH MONOG SERIES, V106, P1; SMITH RB, 1977, GEOL SOC AM BULL, V88, P312, DOI 10.1130/0016-7606(1977)88<312:FOFBAM>2.0.CO;2; STODDARD PR, 1989, MAR GEOPHYS RES, V10, P181, DOI 10.1007/BF00310063; Taylor B, 2009, CR GEOSCI, V341, P428, DOI 10.1016/j.crte.2008.08.010; Tentler T, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2008JB006269; Winterer E, 1976, GEOPHYSICS PACIFIC O, P269	33	76	78	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2010	329	5995					1047	1050		10.1126/science.1191349	http://dx.doi.org/10.1126/science.1191349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798313				2022-12-28	WOS:000281253500032
J	Harrison, SC				Harrison, Stephen C.			Looking Inside Adenovirus	SCIENCE			English	Editorial Material							CRYSTAL-STRUCTURE; PROTEIN; REVEALS		[Harrison, Stephen C.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; [Harrison, Stephen C.] Harvard Univ, Sch Med, Jack & Eileen Connors Lab Struct Biol, Boston, MA 02115 USA; [Harrison, Stephen C.] Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Harrison, SC (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 250 Longwood Ave, Boston, MA 02115 USA.	harrison@crystal.harvard.edu			Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Berk A.J., 2007, FIELDS VIROLOGY, P2356; CRAWTHER RA, 1972, J MOL BIOL, V68, P181; Harrison SC, 2007, FIELDS VIROLOGY, P59; Liu HR, 2010, SCIENCE, V329, P1038, DOI 10.1126/science.1187433; Reddy VS, 2010, SCIENCE, V329, P1071, DOI 10.1126/science.1187292; Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721; Rux JJ, 2003, J VIROL, V77, P9553, DOI 10.1128/JVI.77.17.9553-9566.2003; Saban SD, 2006, J VIROL, V80, P12049, DOI 10.1128/JVI.01652-06; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; Wolf M, 2010, P NATL ACAD SCI USA, V107, P6298, DOI 10.1073/pnas.0914604107; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; Yu XK, 2008, NATURE, V453, P415, DOI 10.1038/nature06893; Zhang X, 2008, P NATL ACAD SCI USA, V105, P1867, DOI 10.1073/pnas.0711623105; Zubieta C, 2005, MOL CELL, V17, P121, DOI 10.1016/j.molcel.2004.11.041	14	26	28	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2010	329	5995					1026	1027		10.1126/science.1194922	http://dx.doi.org/10.1126/science.1194922			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798308				2022-12-28	WOS:000281253500026
J	Green, BM; Finn, KJ; Li, JJ				Green, Brian M.; Finn, Kenneth J.; Li, Joachim J.			Loss of DNA Replication Control Is a Potent Inducer of Gene Amplification	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; MULTIPLE MECHANISMS; TANDEM DUPLICATION; COPY NUMBER; REREPLICATION; RECOMBINATION; CONSEQUENCES; EVOLUTION; CANCER; DAMAGE	Eukaryotic cells use numerous mechanisms to ensure that no segment of their DNA is inappropriately re-replicated, but the importance of this stringent control on genome stability has not been tested. Here we show that re-replication in Saccharomyces cerevisiae can strongly induce the initial step of gene amplification, increasing gene copy number from one to two or more. The resulting amplicons consist of large internal chromosomal segments that are bounded by Ty repetitive elements and are intrachromosomally arrayed at their endogenous locus in direct head-to-tail orientation. These re-replication-induced gene amplifications are mediated by nonallelic homologous recombination between the repetitive elements. We suggest that re-replication may be a contributor to gene copy number changes, which are important in fields such as cancer biology, evolution, and human genetics.	[Li, Joachim J.] UCSF, Dept Microbiol & Immunol, San Francisco, CA 94158 USA; [Green, Brian M.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; [Finn, Kenneth J.] UCSF, Dept Biochem & Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; Johns Hopkins University; University of California System; University of California San Francisco	Li, JJ (corresponding author), UCSF, Dept Microbiol & Immunol, San Francisco, CA 94158 USA.	joachim.li@ucsf.edu			Sandler Program in Basic Sciences; Stewart Trust; UCSF Research Evaluation and Allocation Committee; UCSF Academic Senate; UC Cancer Research Coordinating Committee; NIH [R01 GM59704]; NSF; Department of Defense [W81XWH-04-1-0409]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059704] Funding Source: NIH RePORTER	Sandler Program in Basic Sciences; Stewart Trust; UCSF Research Evaluation and Allocation Committee; UCSF Academic Senate; UC Cancer Research Coordinating Committee; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Department of Defense(United States Department of Defense); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank R. Bainton for the use of his microscope; A. Johnson for the use of his pulsed-field gel electrophoresis system and microscope; and A. Sil, D. Morgan, A. Johnson, D. Toczyski, E. Blackburn, P. O'Farrell, T. Tlsty, J. Haber, S. Elledge, and F. Winston for helpful discussions. This work was supported by grants to J. J. L. from the Sandler Program in Basic Sciences, the Stewart Trust Fund, UCSF Research Evaluation and Allocation Committee, UCSF Academic Senate, UC Cancer Research Coordinating Committee, and NIH (grant R01 GM59704). B.M.G. was supported by an NSF Predoctoral Fellowship and a Department of Defense Breast Cancer Predoctoral Fellowship (W81XWH-04-1-0409). K. J. F. was supported by an NSF Predoctoral Fellowship. Microarray data are deposited with the Gene Expression Omnibus (accession number GSE22018).	Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Archambault V, 2005, MOL CELL BIOL, V25, P6707, DOI 10.1128/MCB.25.15.6707-6721.2005; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Arias EE, 2007, GENE DEV, V21, P497, DOI 10.1101/gad.1508907; Blow JJ, 2008, NAT REV CANCER, V8, P799, DOI 10.1038/nrc2500; DORSEY MJ, 1993, CURR GENET, V23, P392, DOI 10.1007/BF00312624; Gonzalez MA, 2005, NAT REV CANCER, V5, P135, DOI 10.1038/nrc1548; Green BM, 2006, MOL BIOL CELL, V17, P2401, DOI 10.1091/mbc.E05-11-1043; Green BM, 2005, MOL BIOL CELL, V16, P421, DOI 10.1091/mbc.e04-09-0833; Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593; Innan H, 2010, NAT REV GENET, V11, P97, DOI 10.1038/nrg2689; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; Koszul R, 2009, CR BIOL, V332, P254, DOI 10.1016/j.crvi.2008.07.005; Liontos M, 2007, CANCER RES, V67, P10899, DOI 10.1158/0008-5472.CAN-07-2837; Lockwood WW, 2008, ONCOGENE, V27, P4615, DOI 10.1038/onc.2008.98; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; O'Neil J, 2007, J EXP MED, V204, P3059, DOI 10.1084/jem.20071637; Payen C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000175; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; Seo J, 2005, ONCOGENE, V24, P8176, DOI 10.1038/sj.onc.1208881; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217	26	95	95	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					943	946		10.1126/science.1190966	http://dx.doi.org/10.1126/science.1190966			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724634	Green Accepted			2022-12-28	WOS:000281084800034
J	Radoshevich, L; Murrow, L; Chen, N; Fernandez, E; Roy, S; Fung, C; Debnath, J				Radoshevich, Lilliana; Murrow, Lyndsay; Chen, Nan; Fernandez, Estefania; Roy, Srirupa; Fung, Christopher; Debnath, Jayanta			ATG12 Conjugation to ATG3 Regulates Mitochondrial Homeostasis and Cell Death	CELL			English	Article							PROTEIN-ACTIVATING ENZYME; UBIQUITIN-LIKE PROTEINS; CRYSTAL-STRUCTURE; MAMMALIAN HOMOLOG; E2 ENZYME; AUTOPHAGY; LIPIDATION; APOPTOSIS; FISSION; SYSTEM	ATG12, an ubiquitin-like modifier required for macroautophagy, has a single known conjugation target, another autophagy regulator called ATG5. Here, we identify ATG3 as a substrate for ATG12 conjugation. ATG3 is the E2-like enzyme necessary for ATG8/LC3 lipidation during autophagy. ATG12-ATG3 complex formation requires ATG7 as the E1 enzyme and ATG3 autocatalytic activity as the E2, resulting in the covalent linkage of ATG12 onto a single lysine on ATG3. Surprisingly, disrupting ATG12 conjugation to ATG3 does not affect starvation-induced autophagy. Rather, the lack of ATG12-ATG3 complex formation produces an expansion in mitochondrial mass and inhibits cell death mediated by mitochondrial pathways. Overall, these results unveil a role for ATG12-ATG3 in mitochondrial homeostasis and implicate the ATG12 conjugation system in cellular functions distinct from the early steps of autophagosome formation.	[Radoshevich, Lilliana; Murrow, Lyndsay; Chen, Nan; Fernandez, Estefania; Roy, Srirupa; Fung, Christopher; Debnath, Jayanta] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Radoshevich, Lilliana; Murrow, Lyndsay; Chen, Nan; Fernandez, Estefania; Roy, Srirupa; Fung, Christopher; Debnath, Jayanta] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Radoshevich, Lilliana; Murrow, Lyndsay; Debnath, Jayanta] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Debnath, J (corresponding author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.	jayanta.debnath@ucsf.edu	Fung, Christopher/AFM-0101-2022	Fung, Christopher/0000-0003-3585-1385; Radoshevich, Lilliana/0000-0003-0294-9300; Debnath, Jayanta/0000-0002-8745-4069; Murrow, Lyndsay/0000-0002-5935-8977	NIH [RO1CA126792, KO8CA098419]; Culpeper Medical Scholar Award; AACR-Genentech BioOncology Award; HHMI Physician-Scientist Early Career Award; Stewart Family Trust Award; NATIONAL CANCER INSTITUTE [K08CA098419, R01CA126792] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Culpeper Medical Scholar Award; AACR-Genentech BioOncology Award; HHMI Physician-Scientist Early Career Award(Howard Hughes Medical Institute); Stewart Family Trust Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs. Noboru Mizushima, Masaaki Komatsu, and Patrick Dennis for generously providing reagents and Drs. Gerard Evan, Don Ganem, Abul Abbas, and Feroz Papa for critically reading the manuscript. Confocal microscopy was performed in the Biological Imaging Development Center at UCSF. Grant support to J.D. includes the NIH (RO1CA126792, KO8CA098419), a Culpeper Medical Scholar Award (Partnership For Cures), an AACR-Genentech BioOncology Award, a HHMI Physician-Scientist Early Career Award, and a Stewart Family Trust Award. L R. was a Genentech/Sandler Graduate Student Fellow, and E.F. was an HHMI Summer Undergraduate Research Fellow.	Berman SB, 2009, J CELL BIOL, V184, P707, DOI 10.1083/jcb.200809060; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; de Graaf AO, 2004, EXP CELL RES, V299, P533, DOI 10.1016/j.yexcr.2004.06.024; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deng HS, 2008, P NATL ACAD SCI USA, V105, P14503, DOI 10.1073/pnas.0803998105; Dennis PB, 2009, METHOD ENZYMOL, V452, P97, DOI 10.1016/S0076-6879(08)03607-0; Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; GWOZD CS, 1995, BIOCHEMISTRY-US, V34, P6296, DOI 10.1021/bi00019a006; Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200; Hanada T, 2005, AUTOPHAGY, V1, P110, DOI 10.4161/auto.1.2.1858; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lutz AK, 2009, J BIOL CHEM, V284, P22938, DOI 10.1074/jbc.M109.035774; Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Nemoto T, 2003, J BIOL CHEM, V278, P39517, DOI 10.1074/jbc.M300550200; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Rohas LM, 2007, P NATL ACAD SCI USA, V104, P7933, DOI 10.1073/pnas.0702683104; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Suzuki NN, 2005, AUTOPHAGY, V1, P119, DOI 10.4161/auto.1.2.1859; Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, BIOCHEM BIOPH RES CO, V296, P1164, DOI 10.1016/S0006-291X(02)02057-0; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Yamada Y, 2007, J BIOL CHEM, V282, P8036, DOI 10.1074/jbc.M611473200; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697	46	205	219	1	41	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 20	2010	142	4					590	600		10.1016/j.cell.2010.07.018	http://dx.doi.org/10.1016/j.cell.2010.07.018			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723759	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000281115900013
J	Kim, J; Zhang, CZ; Zhang, XH; Springer, TA				Kim, Jongseong; Zhang, Cheng-Zhong; Zhang, Xiaohui; Springer, Timothy A.			A mechanically stabilized receptor-ligand flex-bond important in the vasculature	NATURE			English	Article							VON-WILLEBRAND-FACTOR; IB-IX-V; LEUCINE-RICH REPEATS; FACTOR A1 DOMAIN; PLATELET-ADHESION; SINGLE-MOLECULE; CATCH BONDS; SHEAR; COMPLEX; FORCE	Haemostasis in the arteriolar circulation mediated by von Willebrand factor (VWF) binding to platelets is an example of an adhesive interaction that must withstand strong hydrodynamic forces acting on cells. VWF is a concatenated, multifunctional protein that has binding sites for platelets as well as subendothelial collagen(1,2). Binding of the A1 domain in VWF to the glycoprotein Ib alpha subunit (GPIb alpha) on the surface of platelets mediates crosslinking of platelets to one another and the formation of a platelet plug for arterioles(3,4). The importance of VWF is illustrated by its mutation in von Willebrand disease, a bleeding diathesis(1). Here, we describe a novel mechanochemical specialization of the A1-GPIb alpha bond for force-resistance. We have developed a method that enables, for the first time, repeated measurements of the binding and unbinding of a receptor and ligand in a single molecule (ReaLiSM). We demonstrate two states of the receptor-ligand bond, that is, a flex-bond. One state is seen at low force; a second state begins to engage at 10 pN with a similar to 20-fold longer lifetime and greater force resistance. The lifetimes of the two states, how force exponentiates lifetime, and the kinetics of switching between the two states are all measured. For the first time, single-molecule measurements on this system are in agreement with bulk phase measurements. The results have important implications not only for how platelets bound to VWF are able to resist force to plug arterioles, but also how increased flow activates platelet plug formation.	[Kim, Jongseong; Zhang, Cheng-Zhong; Zhang, Xiaohui; Springer, Timothy A.] Childrens Hosp, Immune Dis Inst, Boston, MA 02115 USA; [Kim, Jongseong; Zhang, Cheng-Zhong; Zhang, Xiaohui; Springer, Timothy A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Springer, TA (corresponding author), Childrens Hosp, Immune Dis Inst, 3 Blackfan Circle, Boston, MA 02115 USA.	springer@idi.harvard.edu	Kim, Jongseong/M-9940-2014; Kim, Jongseong/I-7307-2019; Kim, Jongseong/I-6358-2013	Kim, Jongseong/0000-0001-9595-2765; Kim, Jongseong/0000-0001-9595-2765; Kim, Jongseong/0000-0002-9553-2258; Zhang, Xiaohui (Frank)/0000-0002-8778-595X	NIH [HL-48675]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048675] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by NIH HL-48675 (TAS). The authors are indebted to S. B. Smith and C. Bustamante for help with laser tweezers construction and insightful discussion. We thank B. Coller, O. K. Dudko and C. Lu for reagents and insightful discussions, and J. Dill for software for data analysis.	Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Astrof NS, 2006, BIOCHEMISTRY-US, V45, P15020, DOI 10.1021/bi061566o; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bustamante C, 2000, CURR OPIN STRUC BIOL, V10, P279, DOI 10.1016/S0959-440X(00)00085-3; BUSTAMANTE C, 2004, Patent No. 7133132; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; De Luca M, 2000, BLOOD, V95, P164; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162; Dudko OK, 2008, P NATL ACAD SCI USA, V105, P15755, DOI 10.1073/pnas.0806085105; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Evans E, 1999, BIOPHYS J, V76, P2439, DOI 10.1016/S0006-3495(99)77399-6; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; KIELISZEWSKI M J, 1989, Peptide Research, V2, P246; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; Nesbitt WS, 2009, NAT MED, V15, P665, DOI 10.1038/nm.1955; Phan UT, 2006, NAT IMMUNOL, V7, P883, DOI 10.1038/ni1366; Ruggeri ZM, 2007, CIRC RES, V100, P1673, DOI 10.1161/01.RES.0000267878.97021.ab; Ruggeri ZM, 2006, BLOOD, V108, P1903, DOI 10.1182/blood-2006-04-011551; Sadler JE, 2005, ANNU REV MED, V56, P173, DOI 10.1146/annurev.med.56.082103.104713; Schneider SW, 2007, P NATL ACAD SCI USA, V104, P7899, DOI 10.1073/pnas.0608422104; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; Shen Y, 2006, J BIOL CHEM, V281, P26419, DOI 10.1074/jbc.M604296200; Smith SB, 2003, METHOD ENZYMOL, V361, P134; Springer TA, 2009, P NATL ACAD SCI USA, V106, P91, DOI 10.1073/pnas.0810784105; Thomas W, 2006, BIOPHYS J, V90, P753, DOI 10.1529/biophysj.105.066548; Thomas WE, 2008, ANNU REV BIOPHYS, V37, P399, DOI 10.1146/annurev.biophys.37.032807.125804; Ulrichts H, 2006, J BIOL CHEM, V281, P4699, DOI 10.1074/jbc.M513314200; Yago T, 2008, J CLIN INVEST, V118, P3195, DOI 10.1172/JCI35754; Zhang XH, 2009, SCIENCE, V324, P1330, DOI 10.1126/science.1170905	31	196	203	2	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					992	U123		10.1038/nature09295	http://dx.doi.org/10.1038/nature09295			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725043	Green Accepted			2022-12-28	WOS:000281030300038
J	Tarutani, Y; Shiba, H; Iwano, M; Kakizaki, T; Suzuki, G; Watanabe, M; Isogai, A; Takayama, S				Tarutani, Yoshiaki; Shiba, Hiroshi; Iwano, Megumi; Kakizaki, Tomohiro; Suzuki, Go; Watanabe, Masao; Isogai, Akira; Takayama, Seiji			Trans-acting small RNA determines dominance relationships in Brassica self-incompatibility	NATURE			English	Article							II S-HAPLOTYPES; GENOMIC ORGANIZATION; GENE-EXPRESSION; DNA METHYLATION; POLLEN; LOCUS; CAMPESTRIS; PARAMUTATION; ALLELES; REGION	A diploid organism has two copies of each gene, one inherited from each parent. The expression of two inherited alleles is sometimes biased by the effects known as dominant/recessive relationships, which determine the final phenotype of the organism. To explore the mechanisms underlying these relationships, we have examined the monoallelic expression of S-locus protein 11 genes (SP11), which encode the male determinants of self-incompatibility in Brassica. We previously reported that SP11 expression was monoallelic in some S heterozygotes, and that the promoter regions of recessive SP11 alleles were specifically methylated in the anther tapetum(1-3). Here we show that this methylation is controlled by trans-acting small non-coding RNA(sRNA). We identified inverted genomic sequences that were similar to the recessive SP11 promoters in the flanking regions of dominant SP11 alleles. These sequences were specifically expressed in the anther tapetum and processed into 24-nucleotide sRNA, named SP11 methylation inducer (Smi). Introduction of the Smi genomic region into the recessive S homozygotes triggered the methylation of the promoter of recessive SP11 alleles and repressed their transcription. This is an example showing sRNA encoded in the flanking region of a dominant allele acts in trans to induce transcriptional silencing of the recessive allele. Our finding may provide new insights into the widespread monoallelic gene expression systems.	[Tarutani, Yoshiaki; Shiba, Hiroshi; Iwano, Megumi; Isogai, Akira; Takayama, Seiji] Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300192, Japan; [Kakizaki, Tomohiro] Iwate Univ, Fac Agr, Morioka, Iwate 0208550, Japan; [Suzuki, Go] Osaka Kyoiku Univ, Div Nat Sci, Osaka 5828582, Japan; [Watanabe, Masao] Tohoku Univ, Grad Sch Life Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Nara Institute of Science & Technology; Iwate University; Osaka University of Education; Tohoku University	Takayama, S (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Ikoma 6300192, Japan.	takayama@bs.naist.jp	KAKIZAKI, Tomohiro/E-6304-2011; Watanabe, Masao/N-1465-2019; Isogai, Akira/O-8897-2017; Watanabe, Masao/E-6300-2011	KAKIZAKI, Tomohiro/0000-0002-3636-6616; Watanabe, Masao/0000-0002-9419-5149; Isogai, Akira/0000-0001-8095-0441; Watanabe, Masao/0000-0002-9419-5149	Bio-oriented Technology Research Advancement Institution (BRAIN); Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT)	Bio-oriented Technology Research Advancement Institution (BRAIN); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Q. A. Ngo and P. Kaothien-Nakayama for critical comments and discussion; K. Nakashima for helpful comments; and H. Ichikawa, T. Ohnishi, F. Yamamoto, M. Kawashima and R. Nagai for technical assistance. This work was supported by the Program for Promotion of Basic Research Activities for Innovative Biosciences (to S. T.) from the Bio-oriented Technology Research Advancement Institution (BRAIN), by Grants-in-Aid for Creative Scientific Research (to A. I., M. W. and S. T.) from the Japan Society for the Promotion of Science (JSPS), and by Grants-in-Aid for Scientific Research on Priority Area (to H. S., M. W. and S. T.) and Grants-in-Aid for the Global Center of Excellence Program to NAIST from the Ministry of Education, Culture, Sports, Science and Technology (MEXT).	Alleman M, 2006, NATURE, V442, P295, DOI 10.1038/nature04884; Bao N, 2004, DEV CELL, V7, P653, DOI 10.1016/j.devcel.2004.10.003; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Casselman AL, 2000, PLANT CELL, V12, P23, DOI 10.1105/tpc.12.1.23; Darwin CR, 1876, EFFECTS CROSS SELF F; Erhard KF, 2009, SCIENCE, V323, P1201, DOI 10.1126/science.1164508; Franco-Zorrilla JM, 2007, NAT GENET, V39, P1033, DOI 10.1038/ng2079; Guo M, 2004, PLANT CELL, V16, P1707, DOI 10.1105/tpc.022087; Hale CJ, 2007, PLOS BIOL, V5, P2156, DOI 10.1371/journal.pbio.0050275; Hatakeyama K, 1998, HEREDITY, V80, P241, DOI 10.1046/j.1365-2540.1998.00295.x; Kachroo A, 2001, SCIENCE, V293, P1824, DOI 10.1126/science.1062509; Kakizaki T, 2003, PLANT CELL PHYSIOL, V44, P70, DOI 10.1093/pcp/pcg009; Kakizaki T, 2006, GENES GENET SYST, V81, P63, DOI 10.1266/ggs.81.63; Khraiwesh B, 2010, CELL, V140, P111, DOI 10.1016/j.cell.2009.12.023; Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719; Milani L, 2009, GENOME RES, V19, P1, DOI 10.1101/gr.083931.108; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; Shiba H, 2006, NAT GENET, V38, P297, DOI 10.1038/ng1734; Shiba H, 2000, BIOSCI BIOTECH BIOCH, V64, P1016, DOI 10.1271/bbb.64.1016; Shiba H, 2003, BIOSCI BIOTECH BIOCH, V67, P622, DOI 10.1271/bbb.67.622; Shiba H, 2002, PLANT CELL, V14, P491, DOI 10.1105/tpc.010378; Shiba H, 2001, PLANT PHYSIOL, V125, P2095, DOI 10.1104/pp.125.4.2095; Stam M, 2002, GENE DEV, V16, P1906, DOI 10.1101/gad.1006702; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Suzuki G, 1999, GENETICS, V153, P391; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Takayama S, 2000, P NATL ACAD SCI USA, V97, P1920, DOI 10.1073/pnas.040556397; Takayama S, 2001, NATURE, V413, P534, DOI 10.1038/35097104; Voinnet O, 2009, CELL, V136, P669, DOI 10.1016/j.cell.2009.01.046; Wang JH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001293	31	102	106	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					983	U110		10.1038/nature09308	http://dx.doi.org/10.1038/nature09308			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725042				2022-12-28	WOS:000281030300036
J	Nieuwlaat, R; Connolly, SJ				Nieuwlaat, Robby; Connolly, Stuart J.			Lenient rate control is as effective as strict rate control for preventing cardiovascular events in AF	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ATRIAL-FIBRILLATION; MANAGEMENT		[Nieuwlaat, Robby; Connolly, Stuart J.] Populat Hlth Res Inst, Hamilton, ON, Canada	Population Health Research Institute	Nieuwlaat, R (corresponding author), Populat Hlth Res Inst, Hamilton, ON, Canada.							Fuster V, 2006, J AM COLL CARDIOL, V48, P854, DOI 10.1016/j.jacc.2006.07.009; Nieuwlaat R, 2005, EUR HEART J, V26, P2422, DOI 10.1093/eurheartj/ehi505	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-4	10.7326/0003-4819-153-4-201008170-02004	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713783				2022-12-28	WOS:000280973000030
J	Ng, AK; Abramson, JS; Digumarthy, SR; Reingold, JS; Stone, JR				Ng, Andrea K.; Abramson, Jeremy S.; Digumarthy, Subba R.; Reingold, Jason S.; Stone, James R.			A Woman with a History of Hodgkin's Lymphoma and Sudden Onset of Dyspnea and Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Lymphoma Conference	APR 30, 2010	Massachusetts Gen Hosp, Boston, MA		Massachusetts Gen Hosp		INVOLVED-FIELD RADIOTHERAPY; 2ND MALIGNANT NEOPLASMS; RADIATION-THERAPY; HEART-DISEASE; STAGE-II; ABVD CHEMOTHERAPY; LUNG-CANCER; SURVIVORS; MOPP; MORTALITY		[Ng, Andrea K.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA; [Ng, Andrea K.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Abramson, Jeremy S.] Massachusetts Gen Hosp, Dept Med, Div Med Oncol, Boston, MA 02114 USA; [Reingold, Jason S.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; [Digumarthy, Subba R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Stone, James R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Ng, Andrea K.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA; [Abramson, Jeremy S.; Reingold, Jason S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Digumarthy, Subba R.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA USA; [Stone, James R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ng, AK (corresponding author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.		Abramson, Jeremy/N-5178-2019; Ng, Andrea/AGZ-9678-2022					Aleman BMP, 2007, BLOOD, V109, P1878, DOI 10.1182/blood-2006-07-034405; Aleman BMP, 2003, NEW ENGL J MED, V348, P2396, DOI 10.1056/NEJMoa022628; Aleman BMP, 2003, J CLIN ONCOL, V21, P3431, DOI 10.1200/JCO.2003.07.131; Bradshaw SR, 2009, CARDIOVASC PATHOL, V18, P127, DOI 10.1016/j.carpath.2009.01.001; BROSIUS FC, 1981, AM J MED, V70, P519, DOI 10.1016/0002-9343(81)90574-X; Canellos GP, 2010, J CLIN ONCOL, V28, P1611, DOI 10.1200/JCO.2009.25.3260; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CARLSON RW, 1981, CHEST, V79, P43, DOI 10.1378/chest.79.1.43; Darby SC, 2010, INT J RADIAT ONCOL, V76, P656, DOI 10.1016/j.ijrobp.2009.09.064; Das P, 2006, ANN ONCOL, V17, P785, DOI 10.1093/annonc/mdl023; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; Dominguez AR, 2004, ANN ONCOL, V15, P1798, DOI 10.1093/annonc/mdh465; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Engert A, 2010, NEW ENGL J MED, V363, P640, DOI 10.1056/NEJMoa1000067; FAJARDO LF, 1968, ARCH PATHOL, V86, P512; Furby A, 2010, J NEUROL NEUROSUR PS, V81, P101, DOI 10.1136/jnnp.2008.167577; Heidenreich PA, 2003, J AM COLL CARDIOL, V42, P743, DOI 10.1016/S0735-1097(03)00759-9; Hodgson DC, 2007, J CLIN ONCOL, V25, P1489, DOI 10.1200/JCO.2006.09.0936; Hutchinson RJ, 1998, J CLIN ONCOL, V16, P897, DOI 10.1200/JCO.1998.16.3.897; Jacobs Charlotte DeCroes, 2010, H KAPLAN STORY HODGK; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; National Comprehensive Cancer Network, 2010, CLIN PRACT GUID ONC; Ng AK, 2002, J CLIN ONCOL, V20, P2101, DOI 10.1200/JCO.2002.08.021; Noordijk EM, 2006, J CLIN ONCOL, V24, P3128, DOI 10.1200/JCO.2005.05.2746; O'Brien MM, 2010, J CLIN ONCOL, V28, P1232, DOI 10.1200/JCO.2009.24.8062; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Rosoff PM, 2006, NEW ENGL J MED, V355, P1522, DOI 10.1056/NEJMp068168; Saslow D, 2007, CA-CANCER J CLIN, V57, P185; Saslow D, 2007, CA-CANCER J CLIN, V57, P75, DOI 10.3322/canjclin.57.2.75; Specht L, 1998, J CLIN ONCOL, V16, P830, DOI 10.1200/JCO.1998.16.3.830; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; Travis LB, 2005, JNCI-J NATL CANCER I, V97, P1428, DOI 10.1093/jnci/dji290; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; Veinot JP, 1996, HUM PATHOL, V27, P766, DOI 10.1016/S0046-8177(96)90447-5; Weiner MA, 1997, J CLIN ONCOL, V15, P2769, DOI 10.1200/JCO.1997.15.8.2769; Yeh JM, 2010, ANN INTERN MED, V152, P409, DOI 10.7326/0003-4819-152-7-201004060-00005	37	6	6	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					664	675		10.1056/NEJMcpc1004087	http://dx.doi.org/10.1056/NEJMcpc1004087			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	636TN	20818858				2022-12-28	WOS:000280764600011
J	Sundewall, J; Swanson, RC; Betigeri, A; Sanders, D; Collins, TE; Shakarishvili, G; Brugha, R				Sundewall, Jesper; Swanson, R. Chad; Betigeri, Arvind; Sanders, David; Collins, Tea E.; Shakarishvili, George; Brugha, Ruairi			Health-systems strengthening: current and future activities	LANCET			English	Editorial Material							MILLENNIUM DEVELOPMENT GOALS; ACHIEVE		[Sundewall, Jesper] Div Global Hlth IHCAR, SE-17177 Stockholm, Sweden; [Swanson, R. Chad] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Betigeri, Arvind] Hlth Syst Act Network, New Delhi, India; [Sanders, David] Univ Western Cape, Sch Publ Hlth, Cape Town, Western Cape, South Africa; [Collins, Tea E.] Global Forum Hlth Res, Geneva, Switzerland; [Shakarishvili, George] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland; [Brugha, Ruairi] Royal Coll Surg, Dublin, Ireland; [Brugha, Ruairi] London Sch Hyg & Trop Med, London WC1, England	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of the Western Cape; Royal College of Surgeons - Ireland; University of London; London School of Hygiene & Tropical Medicine	Sundewall, J (corresponding author), Div Global Hlth IHCAR, SE-17177 Stockholm, Sweden.	jesper.sundewall@ki.se	Brugha, Ruairi/C-8420-2012	Brugha, Ruairi/0000-0003-0729-0197; Sundewall, Jesper/0000-0001-5357-5754				Becerra-Posada F, 2004, LANCET, V364, P997, DOI 10.1016/S0140-6736(04)17026-8; DeSavigny D, 2009, SYSTEMS THINKING FOR HEALTH SYSTEMS STRENGTHENING, P1; Fryatt R, 2010, LANCET, V375, P419, DOI 10.1016/S0140-6736(09)61833-X; Samb B, 2009, LANCET, V373, P2137, DOI 10.1016/S0140-6736(09)60919-3; Sanders DM, 2005, BRIT MED J, V331, P755, DOI 10.1136/bmj.331.7519.755; Shakarishvili G., 2010, GLOBAL HLTH GOVERNAN, V3, P1; *STRENGTH HLTH SYS, HLTH SYST STRENGTH C; Swanson RC, 2009, LANCET, V374, P433, DOI 10.1016/S0140-6736(09)61212-5; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; WHO, 2007, EV BUS STRENGTH HLTH; *WORLD BANK, MOV HLTH SYST FUND P; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, TOOLK MON HLTH SYST	13	32	32	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 9	2011	377	9773					1222	1223		10.1016/S0140-6736(10)60679-4	http://dx.doi.org/10.1016/S0140-6736(10)60679-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	751DI	20817246				2022-12-28	WOS:000289597300009
J	Holman, MJ; Fabrycky, DC; Ragozzine, D; Ford, EB; Steffen, JH; Welsh, WF; Lissauer, JJ; Latham, DW; Marcy, GW; Walkowicz, LM; Batalha, NM; Jenkins, JM; Rowe, JF; Cochran, WD; Fressin, F; Torres, G; Buchhave, LA; Sasselov, DD; Borucki, WJ; Koch, DG; Basri, G; Brown, TM; Caldwell, DA; Charbonneau, D; Dunham, EW; Gautier, TN; Geary, JC; Gilliland, RL; Haas, MR; Howell, SB; Ciardi, DR; Endl, M; Fischer, D; Furesz, G; Hartman, JD; Isaacson, H; Johnson, JA; MacQueen, PJ; Moorhead, AV; Morehead, RC; Orosz, JA				Holman, Matthew J.; Fabrycky, Daniel C.; Ragozzine, Darin; Ford, Eric B.; Steffen, Jason H.; Welsh, William F.; Lissauer, Jack J.; Latham, David W.; Marcy, Geoffrey W.; Walkowicz, Lucianne M.; Batalha, Natalie M.; Jenkins, Jon M.; Rowe, Jason F.; Cochran, William D.; Fressin, Francois; Torres, Guillermo; Buchhave, Lars A.; Sasselov, Dimitar D.; Borucki, William J.; Koch, David G.; Basri, Gibor; Brown, Timothy M.; Caldwell, Douglas A.; Charbonneau, David; Dunham, Edward W.; Gautier, Thomas N., III; Geary, John C.; Gilliland, Ronald L.; Haas, Michael R.; Howell, Steve B.; Ciardi, David R.; Endl, Michael; Fischer, Debra; Fueresz, Gabor; Hartman, Joel D.; Isaacson, Howard; Johnson, John A.; MacQueen, Phillip J.; Moorhead, Althea V.; Morehead, Robert C.; Orosz, Jerome A.			Kepler-9: A System of Multiple Planets Transiting a Sun-Like Star, Confirmed by Timing Variations	SCIENCE			English	Article							EXTRA-SOLAR PLANETS; SUPER-EARTHS; SOLID EXOPLANETS; HARPS SEARCH; MASS; RESONANCES; DYNAMICS; MOTION; PERFORMANCE; STABILITY	The Kepler spacecraft is monitoring more than 150,000 stars for evidence of planets transiting those stars. We report the detection of two Saturn-size planets that transit the same Sun-like star, based on 7 months of Kepler observations. Their 19.2- and 38.9-day periods are presently increasing and decreasing at respective average rates of 4 and 39 minutes per orbit; in addition, the transit times of the inner body display an alternating variation of smaller amplitude. These signatures are characteristic of gravitational interaction of two planets near a 2: 1 orbital resonance. Six radial-velocity observations show that these two planets are the most massive objects orbiting close to the star and substantially improve the estimates of their masses. After removing the signal of the two confirmed giant planets, we identified an additional transiting super-Earth-size planet candidate with a period of 1.6 days.	[Holman, Matthew J.; Fabrycky, Daniel C.; Ragozzine, Darin; Latham, David W.; Fressin, Francois; Torres, Guillermo; Buchhave, Lars A.; Sasselov, Dimitar D.; Charbonneau, David; Geary, John C.; Fueresz, Gabor; Hartman, Joel D.] Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; [Ford, Eric B.; Moorhead, Althea V.; Morehead, Robert C.] Univ Florida, Gainesville, FL 32611 USA; [Steffen, Jason H.] Fermilab Ctr Particle Astrophys, Batavia, IL 60510 USA; [Welsh, William F.; Orosz, Jerome A.] San Diego State Univ, San Diego, CA 92182 USA; [Lissauer, Jack J.; Jenkins, Jon M.; Rowe, Jason F.; Borucki, William J.; Koch, David G.; Caldwell, Douglas A.; Haas, Michael R.] NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; [Lissauer, Jack J.] Stanford Univ, Stanford, CA 94305 USA; [Marcy, Geoffrey W.; Walkowicz, Lucianne M.; Basri, Gibor; Isaacson, Howard] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Batalha, Natalie M.] San Jose State Univ, San Jose, CA 95192 USA; [Jenkins, Jon M.; Caldwell, Douglas A.] SETI Inst, Mountain View, CA 94043 USA; [Cochran, William D.; Endl, Michael; MacQueen, Phillip J.] Univ Texas Austin, Austin, TX 78712 USA; [Buchhave, Lars A.] Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; [Ciardi, David R.] CALTECH, NASA, Exoplanet Sci Inst, Pasadena, CA 91125 USA; [Brown, Timothy M.] Global Telescope, Las Cumbres Observ, Goleta, CA 93117 USA; [Dunham, Edward W.] Lowell Observ, Flagstaff, AZ 86001 USA; [Gautier, Thomas N., III] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Gilliland, Ronald L.] Space Telescope Sci Inst, Baltimore, MD 21218 USA; [Howell, Steve B.] Natl Opt Astron Observ, Tucson, AZ 85719 USA; [Fischer, Debra] Yale Univ, New Haven, CT 06510 USA; [Brown, Timothy M.] Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; State University System of Florida; University of Florida; California State University System; San Diego State University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Stanford University; University of California System; University of California Berkeley; California State University System; San Jose State University; University of Texas System; University of Texas Austin; University of Copenhagen; Niels Bohr Institute; California Institute of Technology; National Aeronautics & Space Administration (NASA); California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Space Telescope Science Institute; National Optical Astronomy Observatory; Yale University; University of California System; University of California Santa Barbara	Holman, MJ (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	mholman@cfa.harvard.edu	Buchhave, Lars A./ABF-2000-2020; Ragozzine, Darin/C-4926-2013; Cochran, William D/M-4421-2014; Basri, Gibor B/Y-4048-2018; Steffen, Jason H./A-4320-2013; Fischer, Debra A/C-1639-2014; Caldwell, Douglas A/L-7911-2014; Welsh, William/AAS-3445-2021; Marcy, Geoff/AAC-6050-2019; Ford, Eric B./AAB-5479-2019	Buchhave, Lars A./0000-0003-1605-5666; Cochran, William D/0000-0001-9662-3496; Fischer, Debra A/0000-0003-2221-0861; Caldwell, Douglas A/0000-0003-1963-9616; Ford, Eric B./0000-0001-6545-639X; Rowe, Jason/0000-0002-5904-1865; Fabrycky, Daniel/0000-0003-3750-0183; Ciardi, David/0000-0002-5741-3047; Morehead, Robert/0000-0002-2740-3673; Batalha, Natalie/0000-0002-7030-9519; Steffen, Jason/0000-0003-2202-3847; Hartman, Joel/0000-0001-8732-6166	NASA's Science Mission Directorate; NASA [NCC2-1390]; NSF [0707203]	NASA's Science Mission Directorate; NASA(National Aeronautics & Space Administration (NASA)); NSF(National Science Foundation (NSF))	Funding for this Discovery mission is provided by NASA's Science Mission Directorate. We acknowledge NASA Cooperative Agreement NCC2-1390. D. C. F. acknowledges support from the Michelson Fellowship, supported by NASA and administered by the NASA Exoplanet Science Institute. This material is based on work supported by the NSF under grant no. 0707203. This work is based, in part, on observations obtained at the W. M. Keck Observatory, which is operated by the Univ. of California and the California Institute of Technology. Some of the observations in this paper were obtained at Kitt Peak National Observatory, National Optical Astronomy Observatory, which is operated by the Association of Universities for Research in Astronomy under cooperative agreement with the NSF. J.F.R. is a NASA postdoctoral program fellow. We are grateful to N. Haghighipour for many helpful comments and suggestions.	Adams FC, 2008, ASTROPHYS J, V683, P1117, DOI 10.1086/589986; Agol E, 2005, MON NOT R ASTRON SOC, V359, P567, DOI 10.1111/j.1365-2966.2005.08922.x; Ballard S, 2010, ASTROPHYS J, V716, P1047, DOI 10.1088/0004-637X/716/2/1047; Baraffe I, 2006, ASTRON ASTROPHYS, V450, P1221, DOI 10.1051/0004-6361:20054040; Batalha NM, 2010, ASTROPHYS J LETT, V713, pL103, DOI 10.1088/2041-8205/713/2/L103; BORUCKI WJ, ASTROPHYS J; Caldwell DA, 2010, ASTROPHYS J LETT, V713, pL92, DOI 10.1088/2041-8205/713/2/L92; Correia ACM, 2010, ASTRON ASTROPHYS, V511, DOI 10.1051/0004-6361/200912700; Holman MJ, 2005, SCIENCE, V307, P1288, DOI 10.1126/science.1107822; Jenkins JM, 2010, ASTROPHYS J LETT, V713, pL87, DOI 10.1088/2041-8205/713/2/L87; KISELEVA LG, 1994, MON NOT R ASTRON SOC, V270, P936, DOI 10.1093/mnras/270.4.936; Koch DG, 2010, ASTROPHYS J LETT, V713, pL79, DOI 10.1088/2041-8205/713/2/L79; Lee AT, 2009, ASTROPHYS J, V691, P1684, DOI 10.1088/0004-637X/691/2/1684; Lee MH, 2002, ASTROPHYS J, V567, P596, DOI 10.1086/338504; Lee MH, 2004, ASTROPHYS J, V611, P517, DOI 10.1086/422166; Leger A, 2009, ASTRON ASTROPHYS, V506, P287, DOI 10.1051/0004-6361/200911933; Lissauer JJ, 2001, NATURE, V409, P23, DOI 10.1038/35051182; Marcy GW, 2002, ASTROPHYS J, V581, P1375, DOI 10.1086/344298; Marzari F, 2010, ASTRON ASTROPHYS, V514, DOI 10.1051/0004-6361/201014716; Mayor M, 2004, ASTRON ASTROPHYS, V415, P391, DOI 10.1051/0004-6361:20034250; Meschiari S, 2009, PUBL ASTRON SOC PAC, V121, P1016, DOI 10.1086/605730; Miralda-Escude J, 2002, ASTROPHYS J, V564, P1019, DOI 10.1086/324279; Murray-Clay RA, 2006, ASTROPHYS J, V651, P1194, DOI 10.1086/507514; Pepe F, 2007, ASTRON ASTROPHYS, V462, P769, DOI 10.1051/0004-6361:20066194; RAGOZZINE D, ASTROPHYS J; RIVERA EJ, ASTROPHYS J; Rogers LA, 2010, ASTROPHYS J, V712, P974, DOI 10.1088/0004-637X/712/2/974; Sandor Z, 2006, ASTRON ASTROPHYS, V451, pL31, DOI 10.1051/0004-6361:20065196; Sandor Z, 2007, ASTRON ASTROPHYS, V472, P981, DOI 10.1051/0004-6361:20077345; Seager S, 2007, ASTROPHYS J, V669, P1279, DOI 10.1086/521346; STEFFEN JH, ASTROPHYS J; Terquem C, 2007, ASTROPHYS J, V654, P1110, DOI 10.1086/509497; Tinney CG, 2006, ASTROPHYS J, V647, P594, DOI 10.1086/503706; TORRES G, ASTROPHYS J; Vogt SS, 2005, ASTROPHYS J, V632, P638, DOI 10.1086/432901; VOGT SS, 1994, SPIE, V2198, P362; Winn JN, 2009, IAU SYMP P SERIES, P99, DOI 10.1017/S174392130802629X; Zeng L, 2008, PUBL ASTRON SOC PAC, V120, P983, DOI 10.1086/591807	44	297	298	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	2010	330	6000					51	54		10.1126/science.1195778	http://dx.doi.org/10.1126/science.1195778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656KW	20798283				2022-12-28	WOS:000282334500030
J	Lerman, J				Lerman, Jerrold			Perioperative respiratory complications in children	LANCET			English	Editorial Material							TRACT INFECTION; CARDIAC-ARREST; SLEEP-APNEA; MANAGEMENT; ANESTHESIA; COUGH		Womens & Childrens Hosp, Dept Anesthesia, Buffalo, NY 14222 USA	Women & Children's Hospital of Buffalo	Lerman, J (corresponding author), Womens & Childrens Hosp, Dept Anesthesia, Buffalo, NY 14222 USA.	jerrold.lerman@gmail.com		Lerman, Jerrold/0000-0003-4408-9847				Bhananker SM, 2007, ANESTH ANALG, V105, P344, DOI 10.1213/01.ane.0000268712.00756.dd; Bharti N, 2009, EUR J ANAESTH, V26, P490, DOI 10.1097/EJA.0b013e328323dac0; Brown KA, 2004, ANESTHESIOLOGY, V100, P806, DOI 10.1097/00000542-200404000-00009; de Jongste JC, 2003, THORAX, V58, P998, DOI 10.1136/thorax.58.11.998; Flick RP, 2007, ANESTHESIOLOGY, V106, P226, DOI 10.1097/00000542-200702000-00009; LERMAN J, 2010, MANUAL PEDIAT ANESTH, P171; Mvula M, 2005, J ASTHMA, V42, P9, DOI 10.1081/JAS-200044746; Oberer C, 2005, ANESTHESIOLOGY, V103, P1142, DOI 10.1097/00000542-200512000-00007; Raghavendran S, 2010, ANESTH ANALG, V110, P1093, DOI 10.1213/ANE.0b013e3181cfc435; Shields MD, 2008, THORAX, V63, P1, DOI 10.1136/thx.2007.077370; Tait AR, 2005, ANESTH ANALG, V100, P59, DOI 10.1213/01.ANE.0000139653.53618.91; von Ungern-Sternberg BS, 2010, LANCET, V376, P773, DOI 10.1016/S0140-6736(10)61193-2; von Ungern-Sternberg BS, 2009, PEDIATR ANESTH, V19, P1064, DOI 10.1111/j.1460-9592.2009.03130.x	13	12	15	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					745	746		10.1016/S0140-6736(10)61199-3	http://dx.doi.org/10.1016/S0140-6736(10)61199-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816527				2022-12-28	WOS:000281831000004
J	Rabe, KF; Decramer, M; Siafakas, N				Rabe, Klaus F.; Decramer, Marc; Siafakas, Nikolaos			The Year of the Lung	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE		[Rabe, Klaus F.] Leiden Univ, Med Ctr, Dept Pulmonol, NL-2333 ZA Leiden, Netherlands; [Decramer, Marc] Univ Hosp Gasthuisberg, Dept Pulmonol, Ghent, Belgium; [Siafakas, Nikolaos] Univ Gen Hosp, Dept Pulmonol, Iraklion, Greece	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; KU Leuven; University Hospital Leuven; University Hospital of Heraklion	Rabe, KF (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, NL-2333 ZA Leiden, Netherlands.	k.f.rabe@lumc.nl	Rabe, Klaus F./AAW-6296-2021; Siafakas, Nikolas/AAI-3324-2020	Rabe, Klaus F./0000-0002-7020-1401; 				Beaglehole R, 2003, LANCET, V362, P903, DOI 10.1016/S0140-6736(03)14335-8; *CDCP, 2004, MMWR-MORBID MORTAL W, V58, P29; *GLOB ALL CHRON RE, STOP GLOB EP CHRON D; MacNee W, 2007, EUR RESPIR J, V29, P223, DOI 10.1183/09031936.00159006; *NAT HEART LUNG BL, PARTN GLOB HLTH; Pauwels RA, 2004, LANCET, V364, P613, DOI 10.1016/S0140-6736(04)16855-4; Pawankar R, 2009, ASIAN PAC J ALLERGY, V27, P237; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; World Health Organization, CHRON RESP DIS; World Health Organization, 2007, GLOB SURV PREV CONTR; 2010, YEAR LUNG	11	5	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					753	754		10.1016/S0140-6736(10)61347-5	http://dx.doi.org/10.1016/S0140-6736(10)61347-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	650EC	20816531				2022-12-28	WOS:000281831000009
J	Hardie, DG				Hardie, D. Grahame			Targeting the Core of Transcription	SCIENCE			English	Editorial Material							ACTIVATED PROTEIN-KINASE; SNF1; PHOSPHORYLATION; SUBSTRATE		Univ Dundee, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Hardie, DG (corresponding author), Univ Dundee, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	d.g.hardie@dundee.ac.uk	Hardie, David/Z-1979-2019	Hardie, Grahame/0000-0002-8373-7379				Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Scott JW, 2002, J MOL BIOL, V317, P309, DOI 10.1006/jmbi.2001.5316; Tachibana C, 2007, J BIOL CHEM, V282, P37308, DOI 10.1074/jbc.M707363200; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200	12	7	7	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1158	1159		10.1126/science.1195447	http://dx.doi.org/10.1126/science.1195447			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813944				2022-12-28	WOS:000281485600022
J	Allmann, S; Baldwin, IT				Allmann, Silke; Baldwin, Ian T.			Insects Betray Themselves in Nature to Predators by Rapid Isomerization of Green Leaf Volatiles	SCIENCE			English	Article							OLFACTORY RECEPTOR NEURONS; PLANT VOLATILES; EMISSIONS; MAIZE; PARASITOIDS; ATTRACTION; SUFFICIENT; HERBIVORES; PATHOGENS; ACID	Plants emit green leaf volatiles (GLVs) in response to herbivore damage, thereby attracting predators of the herbivores as part of an indirect defense. The GLV component of this indirect defense was thought to be a general wound signal lacking herbivore-specific information. We found that Manduca sexta-infested Nicotiana attenuata attract the generalist hemipteran predator Geocoris spp. as the result of an herbivore-induced decrease in the (Z)/(E) ratio of released GLVs, and that these changes in the volatile bouquet triple the foraging efficiency of predators in nature. These (E)-isomers are produced from plant-derived (Z)-isomers but are converted by a heat-labile constituent of herbivore oral secretions. Hence, attacking herbivores initiate the release of an indirect defense a full day before the attacked plants manufacture their own defensive compounds.	[Allmann, Silke; Baldwin, Ian T.] Max Planck Inst Chem Ecol, Dept Mol Ecol, DE-07745 Jena, Germany; [Allmann, Silke] Swammerdam Inst Life Sci, Dept Plant Physiol, NL-1098 XH Amsterdam, Netherlands	Max Planck Society; University of Amsterdam	Baldwin, IT (corresponding author), Max Planck Inst Chem Ecol, Dept Mol Ecol, Hans Knoll Str 8, DE-07745 Jena, Germany.	baldwin@ice.mpg.de	Allmann, Silke/Q-6522-2017; Baldwin, Ian T/K-1809-2013	Allmann, Silke/0000-0001-6300-3741; Baldwin, Ian/0000-0001-5371-2974	Max Planck Society	Max Planck Society(Max Planck Society)	Supported by the Max Planck Society. We thank M. Kant, R. Schuurink, E. Gaquerel, G. Bonaventure, and three anonymous reviewers for comments on the manuscript; S. Meldau for providing ir-sipk x ir-wipk seeds; D. Kessler and C. Diezel for help with the field experiments and enzyme assays; M. Kallenbach and A. Weinhold for analytical help; and Brigham Young University for the use of their Lytle Ranch Preserve field station.	Alborn HT, 1997, SCIENCE, V276, P945, DOI 10.1126/science.276.5314.945; Allison JD, 2009, NEW PHYTOL, V184, P768, DOI 10.1111/j.1469-8137.2009.03046.x; Bruce TJA, 2005, TRENDS PLANT SCI, V10, P269, DOI 10.1016/j.tplants.2005.04.003; D'Auria JC, 2007, PLANT J, V49, P194, DOI 10.1111/j.1365-313X.2006.02946.x; De Moraes CM, 2001, NATURE, V410, P577, DOI 10.1038/35069058; De Moraes CM, 1998, NATURE, V393, P570, DOI 10.1038/31219; Dicke M, 2009, PLANT CELL ENVIRON, V32, P654, DOI 10.1111/j.1365-3040.2008.01913.x; Gouinguene SP, 2002, PLANT PHYSIOL, V129, P1296, DOI 10.1104/pp.001941; Halitschke R, 2001, PLANT PHYSIOL, V125, P711, DOI 10.1104/pp.125.2.711; Halitschke R, 2008, ECOL LETT, V11, P24, DOI 10.1111/j.1461-0248.2007.01123.x; Hansson BS, 1999, PHYSIOL ENTOMOL, V24, P121, DOI 10.1046/j.1365-3032.1999.00121.x; Hoballah ME, 2005, J CHEM ECOL, V31, P2003, DOI 10.1007/s10886-005-6074-7; Kant MR, 2004, PLANT PHYSIOL, V135, P483, DOI 10.1104/pp.103.038315; Kessler A, 2001, SCIENCE, V291, P2141, DOI 10.1126/science.291.5511.2141; KLUN JA, 1973, SCIENCE, V181, P661, DOI 10.1126/science.181.4100.661; Mithofer A, 2005, PLANT PHYSIOL, V137, P1160, DOI 10.1104/pp.104.054460; MUELLER MJ, 1994, ANAL BIOCHEM, V218, P425, DOI 10.1006/abio.1994.1202; Noordermeer MA, 1999, FEBS LETT, V443, P201, DOI 10.1016/S0014-5793(98)01706-2; Prost I, 2005, PLANT PHYSIOL, V139, P1902, DOI 10.1104/pp.105.066274; Rostas M, 2006, J CHEM ECOL, V32, P1897, DOI 10.1007/s10886-006-9147-3; Shiojiri K, 2006, P NATL ACAD SCI USA, V103, P16672, DOI 10.1073/pnas.0607780103; Shiojiri K, 2006, J CHEM ECOL, V32, P969, DOI 10.1007/s10886-006-9047-6; Stensmyr MC, 2001, J COMP PHYSIOL A, V187, P509; Takabayashi J, 1996, TRENDS PLANT SCI, V1, P109, DOI 10.1016/S1360-1385(96)90004-7; Takamura H, 1996, BBA-LIPID LIPID MET, V1303, P83, DOI 10.1016/0005-2760(96)00076-8; Turlings TCJ, 1998, PLANTA, V207, P146, DOI 10.1007/s004250050466; von Dahl CC, 2006, PLANT J, V46, P948, DOI 10.1111/j.1365-313X.2006.02760.x; Wu JQ, 2009, PLANT CELL ENVIRON, V32, P1161, DOI 10.1111/j.1365-3040.2009.01943.x	28	171	183	4	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1075	1078		10.1126/science.1191634	http://dx.doi.org/10.1126/science.1191634			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798319				2022-12-28	WOS:000281253500040
J	Gwynne, DT; Judge, KA; Kelly, CD				Gwynne, Darryl T.; Judge, Kevin A.; Kelly, Clint D.			Evidence for male allocation in pipefish?	NATURE			English	Letter									[Gwynne, Darryl T.] Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada; [Judge, Kevin A.] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada; [Kelly, Clint D.] Iowa State Univ, Dept Ecol Evolut & Organismal Biol, Ames, IA 50011 USA	University of Toronto; University Toronto Mississauga; University of Lethbridge; Iowa State University	Gwynne, DT (corresponding author), Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada.	darryl.gwynne@utoronto.ca	Kelly, Clint D./A-2311-2008; Judge, Kevin A/A-5404-2013	Kelly, Clint D./0000-0002-0693-7211; 				BERGLUND A, 1995, BEHAVIOUR, V132, P213, DOI 10.1163/156853995X00702; Berglund A, 2010, NATURE, V464, P364, DOI 10.1038/464364a; Bussiere LF, 2005, BEHAV ECOL, V16, P223, DOI 10.1093/beheco/arh156; FANG J, NATURE, DOI DOI 10.1038/NEWS.2010.127; Jennions Michael D., 2010, P343; Kamler E, 2005, REV FISH BIOL FISHER, V15, P399, DOI 10.1007/s11160-006-0002-y; Paczolt KA, 2010, NATURE, V464, P401, DOI 10.1038/nature08861	7	2	2	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					E11	E11		10.1038/nature09275	http://dx.doi.org/10.1038/nature09275			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739960	Bronze			2022-12-28	WOS:000281203600055
J	Mutter, J				Mutter, John			Disasters widen the rich-poor gap	NATURE			English	Editorial Material									[Mutter, John] Columbia Univ, Dept Earth & Environm Sci, New York, NY 10027 USA; [Mutter, John] Columbia Univ, Dept Int & Publ Affairs, New York, NY 10027 USA	Columbia University; Columbia University	Mutter, J (corresponding author), Columbia Univ, Dept Earth & Environm Sci, New York, NY 10027 USA.	jmutter@ei.columbia.edu						Collier P., 2007, BOTTOM BILLION WHY P; Dacy DC, 1969, EC NATURAL DISASTERS; Elliott JR, 2006, SOC SCI RES, V35, P295, DOI 10.1016/j.ssresearch.2006.02.003; QUIGLEY B, 2008, KATRINA PAIN INDEX M; Skidmore M, 2002, ECON INQ, V40, P664, DOI 10.1093/ei/40.4.664; UNISDR, 2009, RISK POV CHANG CLIM	6	12	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					1042	1042		10.1038/4661042a	http://dx.doi.org/10.1038/4661042a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	642IK	20739992	Bronze			2022-12-28	WOS:000281203600019
J	Williams, R				Williams, Ruth			Slowing the decline	NATURE			English	Editorial Material							EARLY PARKINSON-DISEASE; COENZYME Q(10); DOUBLE-BLIND; CLINICAL-TRIAL; DELAYED-START; RASAGILINE											Beal MF, 1998, BRAIN RES, V783, P109, DOI 10.1016/S0006-8993(97)01192-X; Fahn S, 2006, J NEURAL TRANSM-SUPP, P419; Kieburtz K, 2007, NEUROLOGY, V68, P20; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6; Moon Y, 2005, J NEUROCHEM, V93, P1199, DOI 10.1111/j.1471-4159.2005.03112.x; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Olanow CW, 2009, NEW ENGL J MED, V361, P1268, DOI 10.1056/NEJMoa0809335; Ravina B, 2006, NEUROLOGY, V66, P664; SCHAPIRA A, 2009, PARKINSONISM RELA S2, V15; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561; WARD CD, 1994, J NEUROL NEUROSUR PS, V57, P217, DOI 10.1136/jnnp.57.2.217	13	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					S13	S14		10.1038/466S13a	http://dx.doi.org/10.1038/466S13a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739931	Bronze			2022-12-28	WOS:000281203600062
J	Hulse, RE; Li, QF; Perozo, E				Hulse, Raymond E.; Li, Qufei; Perozo, Eduardo			Up a Hydrophobic Creek with a Short Paddle	CELL			English	Editorial Material							POTASSIUM CHANNEL; VOLTAGE SENSOR; K+ CHANNEL	The mechanism by which voltage-dependent ion channels sense membrane potentials has been the most intensively studied and debated topic in modern ion channel research. In this issue, Xu et al. (2010) provide new insights into the minimal topological and physicochemical features required for voltage sensing.	[Hulse, Raymond E.; Li, Qufei; Perozo, Eduardo] Univ Chicago, Inst Biophys Dynam, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Perozo, E (corresponding author), Univ Chicago, Inst Biophys Dynam, Dept Biochem & Mol Biol, Chicago, IL 60637 USA.	eperozo@uchicago.edu		Hulse, Raymond/0000-0002-0110-3752				Bezanilla F, 2008, NAT REV MOL CELL BIO, V9, P323, DOI 10.1038/nrm2376; Bosmans F, 2008, NATURE, V456, P202, DOI 10.1038/nature07473; Clayton GM, 2008, P NATL ACAD SCI USA, V105, P1511, DOI 10.1073/pnas.0711533105; Gagnon DG, 2009, J GEN PHYSIOL, V133, P467, DOI 10.1085/jgp.200810082; Khalili-Araghi F, 2010, BIOPHYS J, V98, P2189, DOI 10.1016/j.bpj.2010.02.056; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Tombola F, 2005, NEURON, V45, P379, DOI 10.1016/j.neuron.2004.12.047; Xu YP, 2010, CELL, V142, P580, DOI 10.1016/j.cell.2010.07.013; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978	10	1	1	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					515	516		10.1016/j.cell.2010.08.005	http://dx.doi.org/10.1016/j.cell.2010.08.005			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723752	Bronze			2022-12-28	WOS:000281115900005
J	Pryke, SR; Rollins, LA; Griffith, SC				Pryke, Sarah R.; Rollins, Lee A.; Griffith, Simon C.			Females Use Multiple Mating and Genetically Loaded Sperm Competition to Target Compatible Genes	SCIENCE			English	Article							EXTRA-PAIR PATERNITY; SOCIALLY MONOGAMOUS PASSERINES; MATE CHOICE; SELECTION; BIRDS; INFIDELITY; EVOLUTION; INCOMPATIBILITY; FERTILIZATIONS; ALLOCATION	Individuals in socially monogamous species may participate in copulations outside of the pair bond, resulting in extra-pair offspring. Although males benefit from such extra-pair behavior if they produce more offspring, the adaptive function of infidelity to females remains elusive. Here we show that female participation in extra-pair copulations, combined with a genetically loaded process of sperm competition, enables female finches to target genes that are optimally compatible with their own to ensure fertility and optimize offspring viability. Such female behavior, along with the postcopulatory processes demonstrated here, may provide an adaptive function of female infidelity in socially monogamous animals.	[Pryke, Sarah R.; Rollins, Lee A.; Griffith, Simon C.] Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia	Macquarie University	Griffith, SC (corresponding author), Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia.	simon.griffith@mq.edu.au	Griffith, Simon/AAH-3706-2021; Griffith, Simon/A-1996-2010; Pryke, Sarah/G-7484-2011; Rollins, Lee/G-3688-2011	Griffith, Simon/0000-0001-7612-4999; Griffith, Simon/0000-0001-7612-4999; Rollins, Lee/0000-0002-3279-7005	Australian Research Council [DP0770889, DP0881019]; L'Oreal; Save the Gouldian Fund	Australian Research Council(Australian Research Council); L'Oreal(L'Oreal Group); Save the Gouldian Fund	We thank T. Birkhead, R. Brooks, R. Calsbeek, S. Immler, S. Ulfstrand, D. Westneat, and M. Whiting for comments on the manuscript. This work was supported by Discovery Grants DP0770889 (S.R.P.) and DP0881019 (S.C.G.) from the Australian Research Council, a L'Oreal for Women in Science Fellowship (S.R.P.), and the Save the Gouldian Fund. The Animal Care and Ethics Committee of Macquarie University approved this research.	Akcay E, 2007, EVOL ECOL RES, V9, P855; Albrecht T, 2006, AM NAT, V167, P739, DOI 10.1086/502633; Arnqvist G, 2005, AM NAT, V165, pS26, DOI 10.1086/429350; Ball MA, 2003, J THEOR BIOL, V224, P27, DOI 10.1016/S0022-5193(03)00118-8; Birkhead T.R., 1988, Advances in the Study of Behavior, V18, P35; BIRKHEAD TR, 1988, NATURE, V334, P60, DOI 10.1038/334060a0; Cockburn A, 2009, BEHAV ECOL, V20, P501, DOI 10.1093/beheco/arp024; COLEGRAVE N, 1995, P ROY SOC B-BIOL SCI, V259, P223, DOI 10.1098/rspb.1995.0033; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; Griffith SC, 2002, MOL ECOL, V11, P2195, DOI 10.1046/j.1365-294X.2002.01613.x; Griffith SC, 2007, AM NAT, V169, P274, DOI 10.1086/510601; Griffith SC, 2009, J AVIAN BIOL, V40, P97, DOI 10.1111/j.1600-048X.2009.04562.x; Jennions MD, 2000, BIOL REV, V75, P21, DOI 10.1017/S0006323199005423; Merila J, 2001, NATURE, V412, P76, DOI 10.1038/35083580; Merila J, 2003, ANN ZOOL FENN, V40, P269; Olsson M, 1996, NATURE, V383, P585, DOI 10.1038/383585a0; Petrie M, 1998, TRENDS ECOL EVOL, V13, P52, DOI 10.1016/S0169-5347(97)01232-9; Pizzari T, 2003, NATURE, V426, P70, DOI 10.1038/nature02004; Pryke SR, 2007, J EVOLUTION BIOL, V20, P1512, DOI 10.1111/j.1420-9101.2007.01332.x; Pryke SR, 2010, EVOLUTION, V64, P1301, DOI 10.1111/j.1558-5646.2009.00897.x; Pryke SR, 2009, SCIENCE, V323, P1605, DOI 10.1126/science.1168928; Pryke SR, 2009, EVOLUTION, V63, P793, DOI 10.1111/j.1558-5646.2008.00584.x; Pusey A, 1996, TRENDS ECOL EVOL, V11, P201, DOI 10.1016/0169-5347(96)10028-8; Sheldon BC, 1998, P ROY SOC B-BIOL SCI, V265, P1737, DOI 10.1098/rspb.1998.0496; Tregenza T, 2002, NATURE, V415, P71, DOI 10.1038/415071a; Veen T, 2001, NATURE, V411, P45, DOI 10.1038/35075000; Westneat DF, 2003, ANNU REV ECOL EVOL S, V34, P365, DOI 10.1146/annurev.ecolsys.34.011802.132439	27	61	62	0	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2010	329	5994					964	967		10.1126/science.1192407	http://dx.doi.org/10.1126/science.1192407			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724639				2022-12-28	WOS:000281084800040
J	Bonfanti, P; Claudinot, S; Amici, AW; Farley, A; Blackburn, CC; Barrandon, Y				Bonfanti, Paola; Claudinot, Stephanie; Amici, Alessandro W.; Farley, Alison; Blackburn, C. Clare; Barrandon, Yann			Microenvironmental reprogramming of thymic epithelial cells to skin multipotent stem cells	NATURE			English	Article							HAIR-FOLLICLES; PROGENITOR CELLS; CLONAL ANALYSIS; TOLERANCE; IDENTIFICATION; ORGANOGENESIS; REGENERATION; KERATINOCYTE; GENERATION; AIRE	The thymus develops from the third pharyngeal pouch of the anterior gut and provides the necessary environment for thymopoiesis (the process by which thymocytes differentiate into mature T lymphocytes) and the establishment and maintenance of self-tolerance(1-3). It contains thymic epithelial cells (TECs) that form a complex three-dimensional network organized in cortical and medullary compartments, the organization of which is notably different from simple or stratified epithelia(4). TECs have an essential role in the generation of self-tolerant thymocytes through expression of the autoimmune regulator Aire(5,6), but the mechanisms involved in the specification and maintenance of TECs remain unclear(7-9). Despite the different embryological origins of thymus and skin (endodermal and ectodermal, respectively), some cells of the thymic medulla express stratified-epithelium markers(10-12), interpreted as promiscuous gene expression. Here we show that the thymus of the rat contains a population of clonogenic TECs that can be extensively cultured while conserving the capacity to integrate in a thymic epithelial network and to express major histocompatibility complex class II (MHC II) molecules and Aire. These cells can irreversibly adopt the fate of hair follicle multipotent stem cells when exposed to an inductive skin microenvironment; this change in fate is correlated with robust changes in gene expression. Hence, microenvironmental cues are sufficient here to re-direct epithelial cell fate, allowing crossing of primitive germ layer boundaries and an increase in potency(13).	[Bonfanti, Paola; Claudinot, Stephanie; Amici, Alessandro W.; Barrandon, Yann] Ecole Polytech Fed Lausanne, Sch Life Sci, Lab Stem Cell Dynam, CH-1015 Lausanne, Switzerland; [Bonfanti, Paola; Claudinot, Stephanie; Amici, Alessandro W.; Barrandon, Yann] CHU Vaudois, Univ Lausanne Hosp, Dept Expt Surg, CH-1011 Lausanne, Switzerland; [Farley, Alison; Blackburn, C. Clare] Univ Edinburgh, Sch Biol Sci, MRC, Ctr Regenerat Med,Inst Stem Cell Res, Edinburgh EH16 4SB, Midlothian, Scotland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Edinburgh	Barrandon, Y (corresponding author), Ecole Polytech Fed Lausanne, Sch Life Sci, Lab Stem Cell Dynam, CH-1015 Lausanne, Switzerland.	Yann.Barrandon@epfl.ch	Amici, Alessandro W/AGL-7640-2022; Blackburn, Clare/B-2847-2009; Blackburn, Clare/AAM-7954-2020	Blackburn, Clare/0000-0002-6326-640X; Blackburn, Clare/0000-0002-6326-640X; FARLEY, ALISON/0000-0002-9609-8983; Bonfanti, Paola/0000-0001-9655-3766	Swiss National Science Foundation [3100A0-104160]; Juvenile Diabetes Research Foundation; EPFL; CHUV; Leukaemia Research Fund; European Union (EU); Heiwa Nakajima Foundation; Medical Research Council [G0700711B] Funding Source: researchfish	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); EPFL; CHUV; Leukaemia Research Fund; European Union (EU)(CGIAREuropean Commission); Heiwa Nakajima Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to M. Nicolas and A. Smith for discussions and support, M. Okabe for supplying EGFP rats, J. Roberts, M. Garcia and R. Teisanu for help with cell sorting, J. C. Sarria and T. Laroche for confocal imaging, and K. Harsman, O. Hagenbuchle and S. Pradervand from the DAFL for microarray analyses. Y.B was supported in this work by the Swiss National Science Foundation (grant 3100A0-104160), the Juvenile Diabetes Research Foundation, the EPFL and the CHUV. C. B. was supported by a Leukaemia Research Fund grant. The European Union (EU) supported Y.B. and C. B. through the sixth (EuroStemCell) and seventh (EuroSyStem, OptiStem) framework programmes. A. W. A. was supported by a fellowship from the Heiwa Nakajima Foundation.	Abramson J, 2010, CELL, V140, P123, DOI 10.1016/j.cell.2009.12.030; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; Anderson G, 2007, NAT REV IMMUNOL, V7, P954, DOI 10.1038/nri2187; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; Bennett AR, 2002, IMMUNITY, V16, P803, DOI 10.1016/S1074-7613(02)00321-7; Blackburn CC, 2002, TRENDS IMMUNOL, V23, P391, DOI 10.1016/S1471-4906(02)02265-2; Bleul CC, 2006, NATURE, V441, P992, DOI 10.1038/nature04850; Boehm T, 2008, CURR OPIN IMMUNOL, V20, P178, DOI 10.1016/j.coi.2008.03.001; Claudinot S, 2005, P NATL ACAD SCI USA, V102, P14677, DOI 10.1073/pnas.0507250102; Depreter MGL, 2008, P NATL ACAD SCI USA, V105, P961, DOI 10.1073/pnas.0711170105; Gill J, 2002, NAT IMMUNOL, V3, P635, DOI 10.1038/ni812; Hale LP, 2004, J IMMUNOL, V172, P617, DOI 10.4049/jimmunol.172.1.617; Hamazaki Y, 2007, NAT IMMUNOL, V8, P304, DOI 10.1038/ni1438; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Hollander G, 2006, IMMUNOL REV, V209, P28, DOI 10.1111/j.0105-2896.2006.00357.x; Ito T, 2001, J AM SOC NEPHROL, V12, P2625, DOI 10.1681/ASN.V12122625; Kyewski B, 2006, ANNU REV IMMUNOL, V24, P571, DOI 10.1146/annurev.immunol.23.021704.115601; LASTER AJ, 1986, DIFFERENTIATION, V31, P67, DOI 10.1111/j.1432-0436.1986.tb00385.x; Manley NR, 2003, CURR OPIN IMMUNOL, V15, P225, DOI 10.1016/S0952-7915(03)00006-2; Mathis D, 2009, ANNU REV IMMUNOL, V27, P287, DOI 10.1146/annurev.immunol.25.022106.141532; MOSCONA A, 1961, EXP CELL RES, V22, P455, DOI 10.1016/0014-4827(61)90122-7; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Rodewald HR, 2008, ANNU REV IMMUNOL, V26, P355, DOI 10.1146/annurev.immunol.26.021607.090408; Ronfard V, 2000, TRANSPLANTATION, V70, P1588, DOI 10.1097/00007890-200012150-00009; Rossi SW, 2006, NATURE, V441, P988, DOI 10.1038/nature04813; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Sheridan JM, 2009, GENESIS, V47, P346, DOI 10.1002/dvg.20505; Smith A, 2006, NATURE, V441, P1060, DOI 10.1038/nature04954; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; SUN TT, 1984, CELL IMMUNOL, V83, P1, DOI 10.1016/0008-8749(84)90219-3; van Ewijk W, 1999, SEMIN IMMUNOL, V11, P57, DOI 10.1006/smim.1998.0158	33	105	106	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					978	U105		10.1038/nature09269	http://dx.doi.org/10.1038/nature09269			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725041				2022-12-28	WOS:000281030300035
J	Cornwallis, CK; West, SA; Davis, KE; Griffin, AS				Cornwallis, Charlie K.; West, Stuart A.; Davis, Katie E.; Griffin, Ashleigh S.			Promiscuity and the evolutionary transition to complex societies	NATURE			English	Article							KIN SELECTION; BIRDS; PATERNITY; CONSTRAINTS; MONOGAMY; BEHAVIOR; HELPERS; MODELS; SPITE	Theory predicts that the evolution of cooperative behaviour is favoured by low levels of promiscuity leading to high within-group relatedness(1-5). However, in vertebrates, cooperation often occurs between non-relatives and promiscuity rates are among the highest recorded. Here we resolve this apparent inconsistency with a phylogenetic analysis of 267 bird species, demonstrating that cooperative breeding is associated with low promiscuity; that in cooperative species, helping is more common when promiscuity is low; and that intermediate levels of promiscuity favour kin discrimination. Overall, these results suggest that promiscuity is a unifying feature across taxa in explaining transitions to and from cooperative societies.	[Cornwallis, Charlie K.; Griffin, Ashleigh S.] Univ Oxford, Dept Zool, Edward Grey Inst, Oxford OX1 3PS, England; [West, Stuart A.] Univ Oxford, Dept Zool, Oxford OX1 3PS, England; [Davis, Katie E.] Nat Hist Museum, Dept Entomol, London SW7 5BD, England	University of Oxford; University of Oxford; Natural History Museum London	Griffin, AS (corresponding author), Univ Oxford, Dept Zool, Edward Grey Inst, S Parks Rd, Oxford OX1 3PS, England.	ashleigh.griffin@zoo.ox.ac.uk	West, Stuart A/M-3608-2014; Griffin, Ashleigh/C-6244-2014; Cornwallis, Charlie/A-6276-2012	West, Stuart A/0000-0003-2152-3153; Griffin, Ashleigh/0000-0001-7674-9825; 	ERC; Royal Society	ERC(European Research Council (ERC)European Commission); Royal Society(Royal Society of London)	We thank J. Hadfield for statistical advice, K. Boomsma, S. Nakagawa and B. Sheldon for comments and discussion, M. Nelson-Flower and P. Brennan for access to unpublished data, and the ERC and Royal Society for funding. The compilation of our data set was made possible by access to the collections of the Alexander Library.	Arnold KE, 1999, BEHAV ECOL, V10, P465, DOI 10.1093/beheco/10.5.465; Arnold KE, 1998, P ROY SOC B-BIOL SCI, V265, P739, DOI 10.1098/rspb.1998.0355; Bennett P. M., 2002, OX ECOL EV; Boomsma JJ, 2007, CURR BIOL, V17, pR673, DOI 10.1016/j.cub.2007.06.033; Boomsma JJ, 2009, PHILOS T R SOC B, V364, P3191, DOI 10.1098/rstb.2009.0101; Boomsma JJ, 1996, PHILOS T R SOC B, V351, P947, DOI 10.1098/rstb.1996.0087; CHARNOV EL, 1978, J THEOR BIOL, V75, P451, DOI 10.1016/0022-5193(78)90356-9; CHARNOV EL, 1981, ANIM BEHAV, V29, P631, DOI 10.1016/S0003-3472(81)80130-3; Clutton-Brock T, 2002, SCIENCE, V296, P69, DOI 10.1126/science.296.5565.69; Cockburn A, 1998, ANNU REV ECOL SYST, V29, P141, DOI 10.1146/annurev.ecolsys.29.1.141; Cockburn A, 2006, P ROY SOC B-BIOL SCI, V273, P1375, DOI 10.1098/rspb.2005.3458; Cornwallis CK, 2009, J EVOLUTION BIOL, V22, P2445, DOI 10.1111/j.1420-9101.2009.01853.x; DAVIES NB, 1992, DUNNOCK BEHAV SOCIAL, P117; de Magalhaes JP, 2009, J EVOLUTION BIOL, V22, P1770, DOI 10.1111/j.1420-9101.2009.01783.x; Gardner A, 2004, P ROY SOC B-BIOL SCI, V271, P1529, DOI 10.1098/rspb.2004.2756; Geweke J., 1992, BAYESIAN STAT, V4, P169, DOI DOI 10.21034/SR.148; Goloboff P, 2008, CLADISTICS, V24, P91; Griffin AS, 2003, SCIENCE, V302, P634, DOI 10.1126/science.1089402; Griffith SC, 2002, MOL ECOL, V11, P2195, DOI 10.1046/j.1365-294X.2002.01613.x; Hadfield JD, 2010, J EVOLUTION BIOL, V23, P494, DOI 10.1111/j.1420-9101.2009.01915.x; Hadfield JD, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i02; Hamilton W.D., 1972, Annual Rev Ecol Syst, V3, P193, DOI 10.1146/annurev.es.03.110172.001205; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hatchwell BJ, 2009, PHILOS T R SOC B, V364, P3217, DOI 10.1098/rstb.2009.0109; Hatchwell BJ, 2000, ANIM BEHAV, V59, P1079, DOI 10.1006/anbe.2000.1394; HEIDELBERGER P, 1983, OPER RES, V31, P1109, DOI 10.1287/opre.31.6.1109; Hughes WOH, 2008, SCIENCE, V320, P1213, DOI 10.1126/science.1156108; KOMDEUR J, 1992, NATURE, V358, P493, DOI 10.1038/358493a0; KREBS JR, 1993, BEHAV ECOLOGY EVOLUT, P291; MULDER RA, 1994, P ROY SOC B-BIOL SCI, V255, P223, DOI 10.1098/rspb.1994.0032; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Pagel M, 2006, AM NAT, V167, P808, DOI 10.1086/503444; Plummer M., 2006, R NEWS, V6, P7, DOI DOI 10.1159/000323281; Queller DC, 1998, BIOSCIENCE, V48, P165, DOI 10.2307/1313262; Queller DC, 2000, PHILOS T R SOC B, V355, P1647, DOI 10.1098/rstb.2000.0727; Raudenbush S. W., 1994, HDB RES SYNTHESIS, P301, DOI DOI 10.1111/ACPS.12078; SMITH JM, 1995, MAJOR TRANSITIONS EV, P6; Spottiswoode C, 2004, BEHAV ECOL, V15, P41, DOI 10.1093/beheco/arg100; West SA, 2010, SCIENCE, V327, P1341, DOI 10.1126/science.1178332; Wilson E.O., 1975, P1; Zhang BC, 2016, J BASIC MICROB, V56, P670, DOI 10.1002/jobm.201500751	42	244	247	2	347	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 19	2010	466	7309					969	U91		10.1038/nature09335	http://dx.doi.org/10.1038/nature09335			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725039				2022-12-28	WOS:000281030300033
J	Lazarus, SC				Lazarus, Stephen C.			Emergency Treatment of Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE ADULT ASTHMA; CORTICOSTEROID-THERAPY; MAGNESIUM-SULFATE; RACEMIC ALBUTEROL; CONTROLLED TRIAL; SEVERITY SCORE; DOUBLE-BLIND; METHYLPREDNISOLONE; LEVALBUTEROL; MONTELUKAST	A 46-year-old woman who has had two admissions to the intensive care unit (ICU) for asthma during the past year presents with a 4-day history of upper respiratory illness and a 6-hour history of shortness of breath and wheezing. An inhaled corticosteroid has been prescribed, but she takes it only when she has symptoms, which is rarely. She generally uses albuterol twice per day but has increased its use to six to eight times per day for the past 3 days. How should this case be managed in the emergency department?	[Lazarus, Stephen C.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Lazarus, Stephen C.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lazarus, SC (corresponding author), Univ Calif San Francisco, Div Pulm & Crit Care Med, 505 Parnassus Ave, San Francisco, CA 94143 USA.	lazma@ucsf.edu						Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; BOWLER SD, 1992, THORAX, V47, P584, DOI 10.1136/thx.47.8.584; Camargo CA, 2010, J ALLERGY CLIN IMMUN, V125, P374, DOI 10.1016/j.jaci.2009.11.015; Carl JC, 2003, J PEDIATR-US, V143, P731, DOI 10.1067/S0022-3476(03)00493-1; Cates CJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000052.pub2; Chey T, 1999, J CLIN EPIDEMIOL, V52, P1157, DOI 10.1016/S0895-4356(99)00111-0; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DHUPER S, 2008, J EMERG MED     1210; Dockhorn RJ, 2000, THORAX, V55, P260, DOI 10.1136/thorax.55.4.260; EDMONDS ML, 2003, COCHRANE DB SYST REV, V3; EMERMAN CL, 1995, CHEST, V107, P1559, DOI 10.1378/chest.107.6.1559; ENGEL T, 1990, ALLERGY, V45, P224, DOI 10.1111/j.1398-9995.1990.tb00487.x; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; Gelb AF, 2008, PULM PHARMACOL THER, V21, P630, DOI 10.1016/j.pupt.2008.02.005; Gorelick MH, 2004, ACAD EMERG MED, V11, P10, DOI 10.1197/S106-6563(03)00579-7; HARRISON BDW, 1986, LANCET, V1, P181; Jones LA, 2009, EMERG MED J, V26, P783, DOI 10.1136/emj.2008.065938; JONSSON S, 1988, CHEST, V94, P723, DOI 10.1378/chest.94.4.723; Karpel JP, 1997, CHEST, V112, P348, DOI 10.1378/chest.112.2.348; Karras DJ, 2000, ACAD EMERG MED, V7, P327, DOI 10.1111/j.1553-2712.2000.tb02231.x; Kelly AM, 2004, RESP MED, V98, P777, DOI 10.1016/j.rmed.2004.01.008; Krishnan JA, 2009, AM J MED, V122, P977, DOI 10.1016/j.amjmed.2009.02.013; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; MARQUETTE CH, 1995, EUR RESPIR J, V8, P22, DOI 10.1183/09031936.95.08010022; McCarren M, 2000, ACAD EMERG MED, V7, P28, DOI 10.1111/j.1553-2712.2000.tb01887.x; Mohammed S, 2007, EMERG MED J, V24, P823, DOI 10.1136/emj.2007.052050; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; *NIHR HLTH TECHN A, 2010, 3MG TRIAL RAND CONTR; Parameswaran K, 2000, COCHRANE DB SYST REV; Plotnick LH, 2000, COCHRANE DB SYST REV, V4; Qureshi F, 2005, ANN EMERG MED, V46, P29, DOI 10.1016/j.annemergmed.2005.02.001; RATTO D, 1988, JAMA-J AM MED ASSOC, V260, P527, DOI 10.1001/jama.260.4.527; Rodrigo C, 1998, CHEST, V113, P593, DOI 10.1378/chest.113.3.593; Rodrigo CJ, 2000, AM J RESP CRIT CARE, V161, P1862; Rodrigo G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002884.pub2; Rodrigo G, 1999, CHEST, V116, P285, DOI 10.1378/chest.116.2.285; Rodrigo G, 1998, CHEST, V114, P1016, DOI 10.1378/chest.114.4.1016; Rodrigo GJ, 2006, THORAX, V61, P274; Rodrigo GJ, 2002, CHEST, V122, P160, DOI 10.1378/chest.122.1.160; Rowe BH, 1999, JAMA-J AM MED ASSOC, V281, P2119, DOI 10.1001/jama.281.22.2119; Rowe BH, 2004, RESP MED, V98, P275, DOI 10.1016/j.rmed.2003.11.016; Rowe BH, 2003, COCHRANE DB SYST REV, V4; Rowe BH, 2008, CURR OPIN PULM MED, V14, P70, DOI 10.1097/MCP.0b013e3282f19867; Rowe BH, 2009, CHEST, V135, P57, DOI 10.1378/chest.07-3041; Sin DD, 2002, ARCH INTERN MED, V162, P1591, DOI 10.1001/archinte.162.14.1591; Smith SR, 2002, ACAD EMERG MED, V9, P99, DOI 10.1197/aemj.9.2.99; Soroksky A, 2003, CHEST, V123, P1018, DOI 10.1378/chest.123.4.1018; Strauss L, 1997, AM J RESP CRIT CARE, V155, P454, DOI 10.1164/ajrccm.155.2.9032178; Thill Peter J, 2004, Pediatr Crit Care Med, V5, P337, DOI 10.1097/01.PCC.0000128670.36435.83	52	55	58	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					755	764		10.1056/NEJMcp1003469	http://dx.doi.org/10.1056/NEJMcp1003469			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20818877				2022-12-28	WOS:000280996600009
J	Shargorodsky, J; Curhan, SG; Curhan, GC; Eavey, R				Shargorodsky, Josef; Curhan, Sharon G.; Curhan, Gary C.; Eavey, Roland			Change in Prevalence of Hearing Loss in US Adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; NOISE EXPOSURE; UNITED-STATES; CHILDREN 6; PERFORMANCE; IMPAIRMENT; AGE; EPIDEMIOLOGY	Context Hearing loss is common and, in young persons, can compromise social development, communication skills, and educational achievement. Objective To examine the current prevalence of hearing loss in US adolescents and determine whether it has changed over time. Design Cross-sectional analyses of US representative demographic and audiometric data from the 1988 through 1994 and 2005 through 2006 time periods. Setting The Third National Health and Nutrition Examination Survey (NHANES Ill), 1988-1994, and NHANES 2005-2006. Participants NHANES III examined 2928 participants and NHANES 2005-2006 examined 1771 participants, aged 12 to 19 years. Main Outcome Measures We calculated the prevalence of hearing loss in participants aged 12 to 19 years after accounting for the complex survey design. Audiometrically determined hearing loss was categorized as either unilateral or bilateral for low frequency (0.5, 1, and 2 kHz) or high frequency (3, 4, 6, and 8 kHz), and as slight loss (>15 to <25 dB) or mild or greater loss (25 dB) according to hearing sensitivity in the worse ear. The prevalence of hearing loss from NHANES 2005-2006 was compared with the prevalence from NHANES III (1988-1994). We also examined the cross-sectional relations between several potential risk factors and hearing loss. Logistic regression was used to calculate multivariate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Results The prevalence of any hearing loss increased significantly from 14.9% (95% CI, 13.0%-16.9%) in 1988-1994 to 19.5% (95% CI, 15.2%-23.8%) in 2005-2006 (P=.02). In 2005-2006, hearing loss was more commonly unilateral (prevalence, 14.0%; 95% CI, 10.4%-17.6%, vs 11.1%; 95% CI, 9.5%-12.8% in 1988-1994; P=.005) and involved the high frequencies (prevalence, 16.4%; 95% CI, 13.2%-19.7%, vs 12.8%; 95% CI, 11.1%-14.5% in 1988-1994; P=.02). Individuals from families below the federal poverty threshold (prevalence, 23.6%; 95% CI, 18.5%-28.7%) had significantly higher odds of hearing loss (multivariate adjusted OR, 1.60; 95% CI, 1.10-2.32) than those above the threshold (prevalence, 18.4%; 95% CI, 13.6%-23.2%). Conclusion The prevalence of hearing loss among a sample of US adolescents aged 12 to 19 years was greater in 2005-2006 compared with 1988-1994. JAMA. 2010;304(7):772-778 www.jama.com	[Shargorodsky, Josef; Curhan, Sharon G.; Curhan, Gary C.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; [Curhan, Gary C.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; [Shargorodsky, Josef] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; [Eavey, Roland] Vanderbilt Univ, Sch Med, Vanderbilt Bill Wilkerson Ctr Otolaryngol & Commu, Nashville, TN 37212 USA; [Curhan, Gary C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Eye & Ear Infirmary; Vanderbilt University; Harvard University; Harvard T.H. Chan School of Public Health	Shargorodsky, J (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	josef_shargorodsky@meei.harvard.edu			Massachusetts Eye and Ear Infirmary Foundation; Vanderbilt University School of Medicine	Massachusetts Eye and Ear Infirmary Foundation; Vanderbilt University School of Medicine	This work was supported by the Massachusetts Eye and Ear Infirmary Foundation and Vanderbilt University School of Medicine Development Funds.	Agrawal Y, 2008, ARCH INTERN MED, V168, P1522, DOI 10.1001/archinte.168.14.1522; ANDERSON KL, 1992, P ASHA AUD SUP, V21, P38; BAILEY BJ, HEAD NECK SURG OTOLA, P2006; Bainbridge KE, 2008, ANN INTERN MED, V149, P1, DOI 10.7326/0003-4819-149-1-200807010-00231; Bess FH, 1998, EAR HEARING, V19, P339, DOI 10.1097/00003446-199810000-00001; BLAIR JC, 1985, VOLTA REV, V87, P87; Chung JH, 2005, PEDIATRICS, V115, P861, DOI 10.1542/peds.2004-0173; Cone BK, 2010, EAR HEARING, V31, P202, DOI 10.1097/AUD.0b013e3181c62263; Czechowicz JA, 2010, OTOLARYNG HEAD NECK, V142, P272, DOI 10.1016/j.otohns.2009.10.040; Knight KRG, 2005, J CLIN ONCOL, V23, P8588, DOI 10.1200/JCO.2004.00.5355; Mehra S, 2009, OTOLARYNG HEAD NECK, V140, P461, DOI 10.1016/j.otohns.2008.12.022; National Center for Health Statistics, 1988, NAT HLTH NUTR EX SUR; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; Niskar AS, 1998, JAMA-J AM MED ASSOC, V279, P1071, DOI 10.1001/jama.279.14.1071; Niskar AS, 2001, PEDIATRICS, V108, P40, DOI 10.1542/peds.108.1.40; Nondahl DA, 2009, EAR HEARING, V30, P696, DOI 10.1097/AUD.0b013e3181b1d418; Northern JL, 2002, HEARING CHILDREN; PLEIS JR, 2006, VITAL HLTH STAT, V10, P1; Quintanilla-Dieck MD, 2009, J PEDIATR-US, V155, P550, DOI 10.1016/j.jpeds.2009.04.053; Sadhra S, 2002, ANN OCCUP HYG, V46, P455, DOI 10.1093/annhyg/mef051; SCHMIDT JM, 1994, AUDIOLOGY, V33, P185; Smith RJH, 2005, LANCET, V365, P879, DOI 10.1016/S0140-6736(05)71047-3; Stone SI, 2008, AM J PUBLIC HEALTH, V98, P2223, DOI 10.2105/AJPH.2007.110239; Tharpe AM, 1999, PEDIATR CLIN N AM, V46, P65, DOI 10.1016/S0031-3955(05)70081-X; *US BUR CESNS, CURR POP SURV CPS DE; [No title captured]	26	328	339	2	48	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					772	778		10.1001/jama.2010.1124	http://dx.doi.org/10.1001/jama.2010.1124			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20716740				2022-12-28	WOS:000280993700024
J	Hazen, TC; Dubinsky, EA; DeSantis, TZ; Andersen, GL; Piceno, YM; Singh, N; Jansson, JK; Probst, A; Borglin, SE; Fortney, JL; Stringfellow, WT; Bill, M; Conrad, ME; Tom, LM; Chavarria, KL; Alusi, TR; Lamendella, R; Joyner, DC; Spier, C; Baelum, J; Auer, M; Zemla, ML; Chakraborty, R; Sonnenthal, EL; D'haeseleer, P; Holman, HYN; Osman, S; Lu, ZM; Van Nostrand, JD; Deng, Y; Zhou, JZ; Mason, OU				Hazen, Terry C.; Dubinsky, Eric A.; DeSantis, Todd Z.; Andersen, Gary L.; Piceno, Yvette M.; Singh, Navjeet; Jansson, Janet K.; Probst, Alexander; Borglin, Sharon E.; Fortney, Julian L.; Stringfellow, William T.; Bill, Markus; Conrad, Mark E.; Tom, Lauren M.; Chavarria, Krystle L.; Alusi, Thana R.; Lamendella, Regina; Joyner, Dominique C.; Spier, Chelsea; Baelum, Jacob; Auer, Manfred; Zemla, Marcin L.; Chakraborty, Romy; Sonnenthal, Eric L.; D'haeseleer, Patrik; Holman, Hoi-Ying N.; Osman, Shariff; Lu, Zhenmei; Van Nostrand, Joy D.; Deng, Ye; Zhou, Jizhong; Mason, Olivia U.			Deep-Sea Oil Plume Enriches Indigenous Oil-Degrading Bacteria	SCIENCE			English	Article							PETROLEUM-HYDROCARBONS; GEN.-NOV.; CRUDE-OIL; COMMUNITIES; TEMPERATURES; ANTARCTICA; GEOCHIP; SPILL	The biological effects and expected fate of the vast amount of oil in the Gulf of Mexico from the Deepwater Horizon blowout are unknown owing to the depth and magnitude of this event. Here, we report that the dispersed hydrocarbon plume stimulated deep-sea indigenous gamma-Proteobacteria that are closely related to known petroleum degraders. Hydrocarbon-degrading genes coincided with the concentration of various oil contaminants. Changes in hydrocarbon composition with distance from the source and incubation experiments with environmental isolates demonstrated faster-than-expected hydrocarbon biodegradation rates at 5 degrees C. Based on these results, the potential exists for intrinsic bioremediation of the oil plume in the deep-water column without substantial oxygen drawdown.	[Hazen, Terry C.; Dubinsky, Eric A.; DeSantis, Todd Z.; Andersen, Gary L.; Piceno, Yvette M.; Singh, Navjeet; Jansson, Janet K.; Probst, Alexander; Borglin, Sharon E.; Fortney, Julian L.; Stringfellow, William T.; Bill, Markus; Conrad, Mark E.; Tom, Lauren M.; Chavarria, Krystle L.; Alusi, Thana R.; Lamendella, Regina; Joyner, Dominique C.; Baelum, Jacob; Auer, Manfred; Zemla, Marcin L.; Chakraborty, Romy; Sonnenthal, Eric L.; Holman, Hoi-Ying N.; Osman, Shariff; Zhou, Jizhong; Mason, Olivia U.] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; [Stringfellow, William T.; Spier, Chelsea] Univ Pacific, Ecol Engn Res Program, Stockton, CA 95211 USA; [Lu, Zhenmei; Van Nostrand, Joy D.; Deng, Ye; Zhou, Jizhong] Univ Oklahoma, Norman, OK 73072 USA; [D'haeseleer, Patrik] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of the Pacific; University of Oklahoma System; University of Oklahoma - Norman; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Hazen, TC (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, MS 70A-3317,1 Cyclotron Rd, Berkeley, CA 94720 USA.	tchazen@lbl.gov	Jansson, Janet/H-5478-2018; Sonnenthal, Eric LLoyd/A-4336-2009; Dubinsky, Eric A/D-3787-2015; Stringfellow, William T/O-4389-2015; 5.4, ALS Beamline/I-2863-2014; Hazen, Terry C/C-1076-2012; Mason, Olivia/AAP-2627-2021; Lu, Zhenmei/I-3218-2014; 1.4, ALS Beamline/I-1886-2014; Deng, Ye/X-4358-2019; Tom, Lauren/E-9739-2015; 吴, 昊/AAB-1620-2020; Borglin, Sharon E/I-1013-2016; Andersen, Gary/G-2792-2015; Holman, Hoi-Ying/N-8451-2014; Bælum, Jacob/I-2353-2013; Van Nostrand, Joy D/F-1740-2016; Piceno, Yvette/I-6738-2016; Conrad, Mark E/G-2767-2010; Probst, Alexander J/K-2813-2016; Chakraborty, Romy/D-9230-2015; Bill, Markus/D-8478-2013	Jansson, Janet/0000-0002-5487-4315; Sonnenthal, Eric LLoyd/0000-0003-2987-3481; Dubinsky, Eric A/0000-0002-9420-6661; Stringfellow, William T/0000-0003-3189-5604; Hazen, Terry C/0000-0002-2536-9993; Deng, Ye/0000-0002-7584-0632; Andersen, Gary/0000-0002-1618-9827; Holman, Hoi-Ying/0000-0002-7534-2625; Bælum, Jacob/0000-0002-1022-6586; Van Nostrand, Joy D/0000-0001-9548-6450; Piceno, Yvette/0000-0002-7915-4699; Conrad, Mark E/0000-0001-9509-7324; Chakraborty, Romy/0000-0001-9326-554X; Bill, Markus/0000-0001-7002-2174; D'haeseleer, Patrik/0000-0003-0007-8150; Probst, Alexander/0000-0002-9392-6544	University of California at Berkeley, Energy Biosciences Institute under U.S. Department of Energy [DE-AC02-05CH11231]; University of Oklahoma Research Foundation; British Petroleum; Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy	University of California at Berkeley, Energy Biosciences Institute under U.S. Department of Energy; University of Oklahoma Research Foundation; British Petroleum; Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy(United States Department of Energy (DOE))	This work was supported by a subcontract from the University of California at Berkeley, Energy Biosciences Institute, to Lawrence Berkeley National Laboratory under U.S. Department of Energy contract DE-AC02-05CH11231 and by the University of Oklahoma Research Foundation. The Energy Biosciences Institute is funded by British Petroleum. The SR-FTIR work was conducted at the infrared beamline at the Advanced Light Source, which is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy. We thank T. Pollard, K. Keller, M. Carrera, P. Willems, P. Carragher, P. Collinson, S. Lisiecki, P. Vaishampayan, R. Graham, J. Wong, N. Duncan, D. Long, and N. Tam for logistical and technical support. We also thank the captain, crew, and science teams aboard the R/V Ocean Veritas and the R/V Brooks McCall. The National Center for Biotechnology Information accession numbers of the 16S rRNA genes retrieved from clone library analyses are HM587888, HM587889, and HM587890. Sequences for 16S rRNA are also available at greengenes.lbl.gov.	Aries E, 2001, ORG GEOCHEM, V32, P891, DOI 10.1016/S0146-6380(01)00052-3; Atlas R, 2009, MICROB BIOTECHNOL, V2, P213, DOI 10.1111/j.1751-7915.2008.00079.x; Brakstad OG, 2006, BIODEGRADATION, V17, P71, DOI 10.1007/s10532-005-3342-8; Camilli R, 2010, SCIENCE, V330, P201, DOI 10.1126/science.1195223; Gentile G, 2006, ENVIRON MICROBIOL, V8, P2150, DOI 10.1111/j.1462-2920.2006.01097.x; He ZL, 2007, ISME J, V1, P67, DOI 10.1038/ismej.2007.2; He ZL, 2010, ISME J, V4, P1167, DOI 10.1038/ismej.2010.46; Judson RS, 2010, ENVIRON SCI TECHNOL, V44, P5979, DOI 10.1021/es102150z; Kovac N, 2002, MAR CHEM, V78, P205, DOI 10.1016/S0304-4203(02)00033-6; Lasch P., 2015, ENCY ANAL CHEM, P1, DOI DOI 10.1002/9780470027318.A0117.PUB2; Macnaughton SJ, 1999, APPL ENVIRON MICROB, V65, P3566; Pfiffner SM, 2006, GEOMICROBIOL J, V23, P431, DOI 10.1080/01490450600875712; ROBINSON N, 2000, WEARCHECK TECH B; Schlosser A, 2008, INT J SYST EVOL MICR, V58, P2122, DOI 10.1099/ijs.0.65767-0; Socrates G., 1980, INFRARED RAMAN CHARA, V3; Venosa AD, 2007, MAR POLLUT BULL, V54, P545, DOI 10.1016/j.marpolbul.2006.12.013; Yakimov MM, 2007, CURR OPIN BIOTECH, V18, P257, DOI 10.1016/j.copbio.2007.04.006; Yakimov MM, 2004, FEMS MICROBIOL ECOL, V49, P419, DOI 10.1016/j.femsec.2004.04.018; Yakimov MM, 2003, INT J SYST EVOL MICR, V53, P779, DOI 10.1099/ijs.0.02366-0	19	820	860	18	903	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	2010	330	6001					204	208		10.1126/science.1195979	http://dx.doi.org/10.1126/science.1195979			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LP	20736401	Green Submitted			2022-12-28	WOS:000282644600037
J	Ehrenfreund, P; Foing, BH				Ehrenfreund, Pascale; Foing, Bernard H.			Fullerenes and Cosmic Carbon	SCIENCE			English	Editorial Material							INTERSTELLAR-MEDIUM; C-60; BUCKMINSTERFULLERENE; FEATURES		[Ehrenfreund, Pascale] George Washington Univ, Inst Space Policy, Washington, DC 20052 USA; [Foing, Bernard H.] European Space Agcy, Estec, SRE S, NL-2200 AG Noordwijk, Netherlands	George Washington University; European Space Agency	Ehrenfreund, P (corresponding author), George Washington Univ, Inst Space Policy, Washington, DC 20052 USA.	pehren@gwu.edu; bernard.foing@esa.int						Bohme DK, 2009, MASS SPECTROM REV, V28, P672, DOI 10.1002/mas.20227; Cami J, 2010, SCIENCE, V329, P1180, DOI 10.1126/science.1192035; Cataldo F, 2004, ASTROPHYS SPACE SC L, V305, P97; Cataldo F, 2009, MON NOT R ASTRON SOC, V394, P615, DOI 10.1111/j.1365-2966.2008.14369.x; Ehrenfreund P, 2000, ANNU REV ASTRON ASTR, V38, P427, DOI 10.1146/annurev.astro.38.1.427; FOING BH, 1994, NATURE, V369, P296, DOI 10.1038/369296a0; FOING BH, 1997, ASTRON ASTROPHYS, V317, P59; Galazutdinov GA, 2000, MON NOT R ASTRON SOC, V317, P750, DOI 10.1046/j.1365-8711.2000.03566.x; Henning T, 1998, SCIENCE, V282, P2204, DOI 10.1126/science.282.5397.2204; Jager C, 2008, ASTROPHYS J, V689, P249, DOI 10.1086/592729; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0; Kwok S, 2004, NATURE, V430, P985, DOI 10.1038/nature02862; Pendleton YJ, 2002, ASTROPHYS J SUPPL S, V138, P75, DOI 10.1086/322999	14	48	50	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1159	1160		10.1126/science.1194855	http://dx.doi.org/10.1126/science.1194855			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813945				2022-12-28	WOS:000281485600023
J	Oh, DY; Talukdar, S; Bae, EJ; Imamura, T; Morinaga, H; Fan, WQ; Li, PP; Lu, WJ; Watkins, SM; Olefsky, JM				Oh, Da Young; Talukdar, Saswata; Bae, Eun Ju; Imamura, Takeshi; Morinaga, Hidetaka; Fan, WuQiang; Li, Pingping; Lu, Wendell J.; Watkins, Steven M.; Olefsky, Jerrold M.			GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects	CELL			English	Article							FREE FATTY-ACIDS; PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; ADIPOSE-TISSUE; OBESITY; INFLAMMATION; RESISTANCE; ACTIVATION; SECRETION; CELLS	Omega-3 fatty acids (omega-3 FAs), DHA and EPA, exert anti-inflammatory effects, but the mechanisms are poorly understood. Here, we show that the G protein-coupled receptor 120 (GPR120) functions as an omega-3 FA receptor/sensor. Stimulation of GPR120 with omega-3 FAs or a chemical agonist causes broad anti-inflammatory effects in monocytic RAW 264.7 cells and in primary intraperitoneal macrophages. All of these effects are abrogated by GPR120 knock-down. Since chronic macrophage-mediated tissue inflammation is a key mechanism for insulin resistance in obesity, we fed obese WT and GPR120 knockout mice a high-fat diet with or without omega-3 FA supplementation. The omega-3 FA treatment inhibited inflammation and enhanced systemic insulin sensitivity in WT mice, but was without effect in GPR120 knockout mice. In conclusion, GPR120 is a functional omega-3 FA receptor/sensor and mediates potent insulin sensitizing and antidiabetic effects in vivo by repressing macrophage-induced tissue inflammation.	[Oh, Da Young; Talukdar, Saswata; Bae, Eun Ju; Morinaga, Hidetaka; Fan, WuQiang; Li, Pingping; Lu, Wendell J.; Olefsky, Jerrold M.] Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; [Imamura, Takeshi] Shiga Univ Med Sci, Div Pharmacol, Otsu, Shiga 5202192, Japan; [Watkins, Steven M.] Tethys Biosci, W Sacramento, CA 95691 USA	University of California System; University of California San Diego; Shiga University of Medical Science	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Eckhardt, Erik/G-1567-2010; Li, Pingping/F-1109-2019; OH, DA YOUNG/B-2369-2008	Li, Pingping/0000-0003-0679-270X; Talukdar, Saswata/0000-0003-3042-0025	National Institutes of Health [NIDDK DK033651, DK063491, DK 074868]; NICHD/NIH [U54 HD 012303-25]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD012303, P50HD012303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, P30DK063491, R01DK033651, P01DK074868] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Jachelle M. Ofrecio and Sarah Nalbandian for their help with animal maintenance and Elizabeth J. Hansen for editorial assistance. We are grateful to Dr. Robert Lefkowitz (Howard Hughes Medical Institute, Duke University) for the gift of FLAG-tagged serial mutant beta-arrestin2 constructs and to Dr. Maziyar Saberi at NGM Bio Inc. (San Francisco, CA) for GLP-1 measurements. We thank the Flow Cytometry Resource and Neal Sekiya for assistance with FACS analysis at the VA San Diego hospital, the UCSD Histology Core lab for technical help with processing liver specimens, and UCSD Microscope Resource for microscopy analysis. This study was funded in part by the National Institutes of Health grants NIDDK DK033651 (J.M.O.), DK063491 (J.M.O.), DK 074868 (J.M.O.), and the Eunice Kennedy Shriver NICHD/NIH through a cooperative agreement U54 HD 012303-25 as part of the specialized Cooperative Centers Program in Reproduction and Infertility Research.	Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Buettner R, 2006, J MOL ENDOCRINOL, V36, P485, DOI 10.1677/jme.1.01909; Calder PC, 2005, BIOCHEM SOC T, V33, P423, DOI 10.1042/BST0330423; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gonzalez-Periz A, 2009, FASEB J, V23, P1946, DOI 10.1096/fj.08-125674; Gotoh C, 2007, BIOCHEM BIOPH RES CO, V354, P591, DOI 10.1016/j.bbrc.2007.01.028; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jucker BM, 1999, DIABETES, V48, P134, DOI 10.2337/diabetes.48.1.134; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Neschen S, 2007, DIABETES, V56, P1034, DOI 10.2337/db06-1206; Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200; Oh DY, 2005, MOL ENDOCRINOL, V19, P722, DOI 10.1210/me.2004-0220; Polozova A, 2007, J MOL NEUROSCI, V33, P56, DOI 10.1007/s12031-007-0039-y; Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260; Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5; Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059; Solinas G, 2007, CELL METAB, V6, P386, DOI 10.1016/j.cmet.2007.09.011; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tazoe H, 2008, J PHYSIOL PHARMACOL, V59, P251; Ulloa-Aguirre A, 1999, ARCH MED RES, V30, P420, DOI 10.1016/S0188-0128(99)00041-X; Wang JH, 2006, J BIOL CHEM, V281, P34457, DOI 10.1074/jbc.M608019200; Wang YY, 2006, NAT IMMUNOL, V7, P139, DOI 10.1038/ni1294; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	36	1650	1721	16	281	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					687	698		10.1016/j.cell.2010.07.041	http://dx.doi.org/10.1016/j.cell.2010.07.041			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813258	Bronze, Green Accepted			2022-12-28	WOS:000281523200013
J	Doms, RW				Doms, Robert W.			Prime, Boost, and Broaden	SCIENCE			English	Editorial Material							NEUTRALIZATION; HIV-1; ANTIBODIES; REVEAL		Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Doms, RW (corresponding author), Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.	doms@mail.med.upenn.edu						Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Kashyap AK, 2008, P NATL ACAD SCI USA, V105, P5986, DOI 10.1073/pnas.0801367105; Kwong PD, 2009, NAT IMMUNOL, V10, P573, DOI 10.1038/ni.1746; Salzberg S, 2008, NATURE, V454, P160, DOI 10.1038/454160a; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wang TT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000796; Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	9	5	5	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1021	1022		10.1126/science.1195116	http://dx.doi.org/10.1126/science.1195116			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798304				2022-12-28	WOS:000281253500022
J	Liu, HR; Jin, L; Koh, SBS; Atanasov, I; Schein, S; Wu, L; Zhou, ZH				Liu, Hongrong; Jin, Lei; Koh, Sok Boon S.; Atanasov, Ivo; Schein, Stan; Wu, Lily; Zhou, Z. Hong			Atomic Structure of Human Adenovirus by Cryo-EM Reveals Interactions Among Protein Networks	SCIENCE			English	Article							CRYOELECTRON MICROSCOPY STRUCTURE; RESOLUTION; HEXON; VECTORS; TYPE-2; DNA; IX; BACTERIOPHAGE-PRD1; VISUALIZATION; ORGANIZATION	Construction of a complex virus may involve a hierarchy of assembly elements. Here, we report the structure of the whole human adenovirus virion at 3.6 angstroms resolution by cryo-electron microscopy (cryo-EM), revealing in situ atomic models of three minor capsid proteins (IIIa, VIII, and IX), extensions of the (penton base and hexon) major capsid proteins, and interactions within three protein-protein networks. One network is mediated by protein IIIa at the vertices, within group-of-six (GOS) tiles-a penton base and its five surrounding hexons. Another is mediated by ropes (protein IX) that lash hexons together to form group-of-nine (GON) tiles and bind GONs to GONs. The third, mediated by IIIa and VIII, binds each GOS to five surrounding GONs. Optimization of adenovirus for cancer and gene therapy could target these networks.	[Liu, Hongrong; Jin, Lei; Zhou, Z. Hong] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; [Liu, Hongrong; Jin, Lei; Atanasov, Ivo; Schein, Stan; Wu, Lily; Zhou, Z. Hong] Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA 90095 USA; [Liu, Hongrong] Xiangtan Univ, Inst Modern Phys, Xiangtan 411105, Hunan, Peoples R China; [Koh, Sok Boon S.; Wu, Lily] Univ Calif Los Angeles, Sch Med, Inst Mol Med IMED, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Schein, Stan] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Schein, Stan] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Chinese Academy of Sciences; Xiangtan University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Zhou, ZH (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.	Hong.Zhou@ucla.edu	Zhou, Z Hong/HDN-0747-2022; Schein, Stan/G-4942-2018		National Institutes of Health [GM071940, AI069015, CA101904, 1S10RR23057]; National Natural Scientific Foundation of China [10874144]; Congressionally Directed Medical Research Programs [W81XWH-06-1-055]; NATIONAL CANCER INSTITUTE [R01CA101904] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071940] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Congressionally Directed Medical Research Programs(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Berk for advice; W. H. Hui for imaging, C.-O. Yun and O.-J. Kwon for providing the Ad-Delta E1B19/55 virus sample, and X. Zhang and P. Ge for discussion. This project is supported in part by grants from the National Institutes of Health (GM071940 and AI069015 to Z.H.Z.) and (CA101904 to L.W.). We acknowledge use of facilities at the Electron Imaging Center for NanoMachines supported in part by NIH (1S10RR23057). H.L. thanks the National Natural Scientific Foundation of China for support (10874144). S.B.K. was supported by Congressionally Directed Medical Research Programs W81XWH-06-1-055 predoctoral training program. Our structure and atomic model have been deposited in the EM Data Bank and the Protein Data Bank with accession numbers EMD-5172 and 3IYN, respectively.	Abrescia NGA, 2004, NATURE, V432, P68, DOI 10.1038/nature03056; Berk A.J., 2007, FIELDS VIROLOGY, VII, P2356; BOUDIN ML, 1980, VIROLOGY, V101, P144, DOI 10.1016/0042-6822(80)90491-2; BURNETT RM, 1985, J MOL BIOL, V185, P125, DOI 10.1016/0022-2836(85)90187-1; Cockburn JJB, 2004, NATURE, V432, P122, DOI 10.1038/nature03053; COLBY WW, 1981, J VIROL, V39, P977, DOI 10.1128/JVI.39.3.977-980.1981; CROWTHER R A, 1972, Journal of Molecular Biology, V68, P181, DOI 10.1016/0022-2836(72)90273-2; Deng BB, 2007, J VIROL, V81, P3640, DOI 10.1128/JVI.02254-06; EVERITT E, 1975, VIROLOGY, V67, P197, DOI 10.1016/0042-6822(75)90417-1; Everts M, 2004, CURR GENE THER, V4, P337; Fabry CMS, 2009, J VIROL, V83, P1135, DOI 10.1128/JVI.01808-08; Fabry CMS, 2005, EMBO J, V24, P1645, DOI 10.1038/sj.emboj.7600653; Jiang W, 2006, NATURE, V439, P612, DOI 10.1038/nature04487; LAVER WG, 1968, J MOL BIOL, V37, P379, DOI 10.1016/0022-2836(68)90109-5; Lehmberg E, 1999, J CHROMATOGR B, V732, P411, DOI 10.1016/S0378-4347(99)00316-3; Liang YY, 2002, J STRUCT BIOL, V137, P292, DOI 10.1016/S1047-8477(02)00014-X; Marsh MP, 2006, J VIROL, V80, P11881, DOI 10.1128/JVI.01471-06; Matthews DA, 1998, J GEN VIROL, V79, P1671, DOI 10.1099/0022-1317-79-7-1671; McGrath WJ, 2003, BBA-PROTEINS PROTEOM, V1648, P1, DOI 10.1016/S1570-9639(03)00024-4; Ostapchuk P, 2005, J CELL BIOCHEM, V96, P25, DOI 10.1002/jcb.20523; Perez-Berna AJ, 2009, J MOL BIOL, V392, P547, DOI 10.1016/j.jmb.2009.06.057; PRAGE L, 1972, VIROLOGY, V49, P745, DOI 10.1016/0042-6822(72)90531-4; Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721; ROBERTS MM, 1986, SCIENCE, V232, P1148, DOI 10.1126/science.3704642; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; Russell WC, 2009, J GEN VIROL, V90, P1, DOI 10.1099/vir.0.003087-0; Rux JJ, 2003, J VIROL, V77, P9553, DOI 10.1128/JVI.77.17.9553-9566.2003; Saban SD, 2006, J VIROL, V80, P12049, DOI 10.1128/JVI.01652-06; Sargent KL, 2004, GENE THER, V11, P504, DOI 10.1038/sj.gt.3302107; Silvestry M, 2009, J VIROL, V83, P7375, DOI 10.1128/JVI.00331-09; Smith AC, 2009, J VIROL, V83, P2025, DOI 10.1128/JVI.01644-08; SMITH KO, 1965, J BACTERIOL, V90, P254, DOI 10.1128/JB.90.1.254-261.1965; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; Waddington SN, 2008, CELL, V132, P397, DOI 10.1016/j.cell.2008.01.016; Wiethoff CM, 2005, J VIROL, V79, P1992, DOI 10.1128/JVI.79.4.1992-2000.2005; Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]; Zubieta C, 2005, MOL CELL, V17, P121, DOI 10.1016/j.molcel.2004.11.041	40	263	276	3	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1038	1043		10.1126/science.1187433	http://dx.doi.org/10.1126/science.1187433			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798312	Green Accepted			2022-12-28	WOS:000281253500030
J	Pless, ML; Kroshinsky, D; LaRocque, RC; Buchbinder, BR; Duncan, LM				Pless, Misha L.; Kroshinsky, Daniela; LaRocque, Regina C.; Buchbinder, Bradley R.; Duncan, Lyn M.			Case 26-2010: A 54-Year-Old Man with Loss of Vision and a Rash	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPTIC NEUROPATHY; HODGKINS-DISEASE; MANIFESTATION; SECONDARY; PROPTOSIS		[Pless, Misha L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Kroshinsky, Daniela] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; [Buchbinder, Bradley R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Duncan, Lyn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [LaRocque, Regina C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Pless, Misha L.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Kroshinsky, Daniela] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [LaRocque, Regina C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Buchbinder, Bradley R.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Duncan, Lyn M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Pless, ML (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.		Kroshinsky, Daniela/AAM-4608-2020	Kroshinsky, Daniela/0000-0002-4781-9676	Bayer; EMD Serono; Pfizer; Teva Neuroscience	Bayer(Bayer AG); EMD Serono; Pfizer(Pfizer); Teva Neuroscience(Teva Pharmaceutical Industries)	Dr. Pless reports receiving consulting fees from Bayer, EMD Serono, Pfizer, and Teva Neuroscience; gifts from EMD Serono, Pfizer, Teva, Bayer, and Novartis; grants from EMD Serono Clinical Trial; honoraria from EMD Serono, Pfizer, Teva, Bayer, and Novartis; and payment for development of educational presentations from EMD Serono, Bayer, Teva Neuroscience, and Pfizer. No other potential conflict of interest relevant to this article was reported.	Atkins EJ, 2007, SEMIN NEUROL, V27, P211, DOI 10.1055/s-2007-979683; Bhatti M Tariq, 2007, Int Ophthalmol Clin, V47, P37, DOI 10.1097/IIO.0b013e318157202d; Eggenberger E R, 2001, Ophthalmol Clin North Am, V14, P73; Francis PJ, 2003, BRIT J OPHTHALMOL, V87, P512, DOI 10.1136/bjo.87.4.512-a; Gross ND, 1998, OPHTHALMIC PLAST REC, V14, P169, DOI 10.1097/00002341-199805000-00004; Haghighi AB, 2009, EXPERT REV NEUROTHER, V9, P565, DOI [10.1586/ern.09.11, 10.1586/ERN.09.11]; Hayreh SS, 2009, PROG RETIN EYE RES, V28, P34, DOI 10.1016/j.preteyeres.2008.11.002; Ingley AP, 2008, AM J RHINOL, V22, P155, DOI 10.2500/ajr.2008.22.3141; Kesler Anat, 2003, Curr Neurol Neurosci Rep, V3, P410, DOI 10.1007/s11910-003-0024-y; Klapper SR, 1999, OPHTHALMOLOGY, V106, P338, DOI 10.1016/S0161-6420(99)90073-8; Limeau K, 2008, NEUROLOGIST, V14, P341, DOI 10.1097/NRL.0b013e318177394b; Martin-Ezquerra G, 2009, HUM PATHOL, V40, P624, DOI 10.1016/j.humpath.2008.10.017; McFadzean R M, 1998, Curr Opin Ophthalmol, V9, P10; Okcu A, 1997, HAUTARZT, V48, P743, DOI 10.1007/s001050050654; Prokosch V, 2008, RESTOR NEUROL NEUROS, V26, P279; Sahjpaul R, 1996, OPHTHALMIC SURG LAS, V27, P239; SANDERSON PA, 1976, AM J OPHTHALMOL, V81, P146, DOI 10.1016/0002-9394(76)90725-X; SIATKOWSKI RM, 1992, AM J OPHTHALMOL, V114, P625; Smith GT, 2006, POSTGRAD MED J, V82, P36, DOI 10.1136/pgmj.2004.020875; Tornerup NR, 2000, OPHTHALMOLOGY, V107, P397, DOI 10.1016/S0161-6420(99)00053-6; VECCHI V, 1984, TUMORI, V70, P571, DOI 10.1177/030089168407000617; Viallard AM, 1999, DERMATOLOGY, V198, P301, DOI 10.1159/000018136; Whitehouse R, 2006, DANCING TIMES, V96, P8; Workowski K. A., 2006, Morbidity and Mortality Weekly Report, V55, P997; Ziakas PD, 2009, INT J INFECT DIS, V13, P112, DOI 10.1016/j.ijid.2008.01.015; 2006, MMWR MORB MORTAL WKL, V55, P269; 2008, N ENGL J MED, V358, P2619	27	4	4	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					865	874		10.1056/NEJMcpc1000968	http://dx.doi.org/10.1056/NEJMcpc1000968			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642HG	20818848				2022-12-28	WOS:000281196600011
J	Psaty, BM; Siscovick, DS				Psaty, Bruce M.; Siscovick, David S.			Minimizing Bias Due to Confounding by Indication in Comparative Effectiveness Research The Importance of Restriction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; RISK; THERAPIES; BENEFITS		[Psaty, Bruce M.; Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98177 USA; [Psaty, Bruce M.; Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98177 USA; [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98177 USA; [Psaty, Bruce M.; Siscovick, David S.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98121 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, 1730 Minor Ave,Ste 1360, Seattle, WA 98177 USA.	psaty@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078888, R01HL085251, U01HL080295, R01HL087652, R01HL080295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL087652, HL085251, HL078888, HL080295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boger-Megiddo I, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c103; Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Smith NL, 2004, JAMA-J AM MED ASSOC, V292, P1581, DOI 10.1001/jama.292.13.1581; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Vandenbroucke JP, 2008, JAMA-J AM MED ASSOC, V300, P2417, DOI 10.1001/jama.2008.723	10	96	96	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					897	898		10.1001/jama.2010.1205	http://dx.doi.org/10.1001/jama.2010.1205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736474				2022-12-28	WOS:000281389900028
J	Clark, CE; Smith, LFP; Taylor, RS; Campbell, JL				Clark, Christopher E.; Smith, Lindsay F. P.; Taylor, Rod S.; Campbell, John L.			Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; ENHANCED DIABETES CARE; CORONARY-HEART-DISEASE; GENERAL-PRACTICE; CARDIOVASCULAR RISK; SECONDARY PREVENTION; FOLLOW-UP; MANAGEMENT; OUTCOMES; HYPERLIPIDEMIA	Objective To review trials of nurse led interventions for hypertension in primary care to clarify the evidence base, establish whether nurse prescribing is an important intervention, and identify areas requiring further study. Design Systematic review and meta-analysis. Data sources Ovid Medline, Cochrane Central Register of Controlled Trials, British Nursing Index, Cinahl, Embase, Database of Abstracts of Reviews of Effects, and the NHS Economic Evaluation Database. Study selection Randomised controlled trials of nursing interventions for hypertension compared with usual care in adults. Data extraction Systolic and diastolic blood pressure, percentages reaching target blood pressure, and percentages taking antihypertensive drugs. Intervention effects were calculated as relative risks or weighted mean differences, as appropriate, and sensitivity analysis by study quality was undertaken. Data synthesis Compared with usual care, interventions that included a stepped treatment algorithm showed greater reductions in systolic blood pressure (weighted mean difference -8.2 mm Hg, 95% confidence interval -11.5 to -4.9), nurse prescribing showed greater reductions in blood pressure (systolic -8.9 mm Hg, -12.5 to -5.3 and diastolic -4.0 mm Hg, -5.3 to -2.7), telephone monitoring showed higher achievement of blood pressure targets (relative risk 1.24, 95% confidence interval 1.08 to 1.43), and community monitoring showed greater reductions in blood pressure (weighted mean difference, systolic -4.8 mm Hg, 95% confidence interval -7.0 to -2.7 and diastolic -3.5 mm Hg, -4.5 to -2.5). Conclusions Nurse led interventions for hypertension require an algorithm to structure care. Evidence was found of improved outcomes with nurse prescribers from non-UK healthcare settings. Good quality evidence from UK primary health care is insufficient to support widespread employment of nurses in the management of hypertension within such healthcare systems.	[Clark, Christopher E.; Smith, Lindsay F. P.; Taylor, Rod S.; Campbell, John L.] Peninsula Coll Med & Dent, Inst Hlth Services Res, Primary Care Res Grp, Exeter EX1 2LU, England	University of Exeter; University of Plymouth	Clark, CE (corresponding author), Peninsula Coll Med & Dent, Inst Hlth Services Res, Primary Care Res Grp, St Lukes Campus, Exeter EX1 2LU, England.	christopher.clark@pms.ac.uk		Campbell, John/0000-0002-6752-3493	Scientific Foundation Board of the Royal College of General Practitioners; South West GP Trust	Scientific Foundation Board of the Royal College of General Practitioners; South West GP Trust	This research was supported by the Scientific Foundation Board of the Royal College of General Practitioners and by the South West GP Trust.	Adams G, 2004, J CLIN EPIDEMIOL, V57, P785, DOI 10.1016/j.jclinepi.2003.12.013; Artinian NT, 2007, NURS RES, V56, P312, DOI 10.1097/01.NNR.0000289501.45284.6e; Artinian NT, 2001, HEART LUNG, V30, P191, DOI 10.1067/mhl.2001.112684; Bebb C, 2007, BRIT J GEN PRACT, V57, P136; Becker DM, 2005, CIRCULATION, V111, P1298, DOI 10.1161/01.CIR.0000157734.97351.B2; Bellary S, 2008, LANCET, V371, P1769, DOI 10.1016/S0140-6736(08)60764-3; Bengtson Ann, 2003, Clin Nurse Spec, V17, P260, DOI 10.1097/00002800-200309000-00011; Bosworth HB, 2009, AM HEART J, V157, P450, DOI 10.1016/j.ahj.2008.11.003; Campbell NC, 1998, HEART, V80, P447, DOI 10.1136/hrt.80.5.447; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; [Confederation NHS British Medical Association], 2003, NEW GMS CONTR 2003 I; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; Denver EA, 2003, DIABETES CARE, V26, P2256, DOI 10.2337/diacare.26.8.2256; Dierick-van Daele ATM, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X482077; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Fahey T, 2005, COCHRANE DB SYST REV, V1; Garcia-Pena C, 2001, INT J EPIDEMIOL, V30, P1485, DOI 10.1093/ije/30.6.1485; Guerra-Riccio GM, 2004, AM J HYPERTENS, V17, P523, DOI 10.1016/j.amjhyper.2004.02.007; Heneghan C, 2007, BRIT J GEN PRACT, V57, P948, DOI 10.3399/096016407782604965; Hill MN, 2003, AM J HYPERTENS, V16, P906, DOI 10.1016/S0895-7061(03)01034-3; Houston MC, 2009, HDB HYPERTENSION; Inkster M, 2005, BRIT J GEN PRACT, V55, P931; JEWELL D, 1988, PRACTITIONER, V232, P484; Jiang XL, 2007, J CLIN NURS, V16, P1886, DOI 10.1111/j.1365-2702.2007.01838.x; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Kastarinen MJ, 2002, J HYPERTENS, V20, P2505, DOI 10.1097/00004872-200212000-00031; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Kinnersley P, 2000, BRIT MED J, V320, P1043, DOI 10.1136/bmj.320.7241.1043; Ko GTC, 2004, DIABETIC MED, V21, P1274, DOI 10.1111/j.1464-5491.2004.01329.x; Laurant M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001271.pub2; Lee LL, 2007, PREV MED, V44, P160, DOI 10.1016/j.ypmed.2006.09.001; Litaker David, 2003, J Interprof Care, V17, P223, DOI 10.1080/1356182031000122852; LOGAN AG, 1979, LANCET, V2, P1175; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]; McHugh F, 2001, HEART, V86, P317, DOI 10.1136/heart.86.3.317; McLean DL, 2008, ARCH INTERN MED, V168, P2355, DOI 10.1001/archinte.168.21.2355; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; National Centre for Social Research, 2004, HLTH SURV ENGL 2003; National Institute for Health and Clinical Excellence, 2006, HYP MAN HYP AD PRIM; Neal B, BLOOD PRESSURE LOWER; New JP, 2004, DIABETIC MED, V21, P599, DOI 10.1111/j.1464-5491.2004.01213.x; New JP, 2003, DIABETES CARE, V26, P2250, DOI 10.2337/diacare.26.8.2250; NHS Information Centre, 2009, PRACT LEV QOF TABL 2; *NORD COCHR CTR CO, 2008, REV MAN REVMAN COMP; O'Hare JP, 2004, DIABETIC MED, V21, P1357, DOI 10.1111/j.1464-5491.2004.01373.x; Oakeshott P, 2003, FAM PRACT, V20, P469, DOI 10.1093/fampra/cmg424; Page T, 2005, INT J EVID-BASED HEA, V3, P2, DOI 10.1111/j.1479-6988.2005.00019.x; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Rudd P, 2004, AM J HYPERTENS, V17, P921, DOI 10.1016/j.amjhyper.2004.06.006; Schroeder K, 2005, FAM PRACT, V22, P144, DOI 10.1093/fampra/cmh717; Sol BGM, 2005, J VASC NURS, V23, P20, DOI 10.1016/j.jvn.2004.12.003; Taylor CB, 2003, DIABETES CARE, V26, P1058, DOI 10.2337/diacare.26.4.1058; Tobe SW, 2006, CAN MED ASSOC J, V174, P1267, DOI 10.1503/cmaj.050030; Tonstad Serena, 2007, Eur J Cardiovasc Nurs, V6, P160, DOI 10.1016/j.ejcnurse.2006.07.003; WOOLLARD J, 1995, CLIN EXP PHARMACOL P, V22, P466, DOI 10.1111/j.1440-1681.1995.tb02046.x; Woollard J, 2003, J HUM HYPERTENS, V17, P689, DOI 10.1038/sj.jhh.1001593	59	138	143	2	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2010	341								c3995	10.1136/bmj.c3995	http://dx.doi.org/10.1136/bmj.c3995			29	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845KB	20732968	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000296820500001
J	Chen, XJ; Struzhkin, VV; Yu, Y; Goncharov, AF; Lin, CT; Mao, HK; Hemley, RJ				Chen, Xiao-Jia; Struzhkin, Viktor V.; Yu, Yong; Goncharov, Alexander F.; Lin, Cheng-Tian; Mao, Ho-kwang; Hemley, Russell J.			Enhancement of superconductivity by pressure-driven competition in electronic order	NATURE			English	Article							TRANSITION-TEMPERATURE; SINGLE-CRYSTALS; RAMAN-SCATTERING; DEPENDENCE; CUPRATE; COPPER; PLANES; NMR; GPA; TC	Finding ways to achieve higher values of the transition temperature, T-c, in superconductors remains a great challenge. The superconducting phase is often one of several competing types of electronic order, including antiferromagnetism and charge density waves(1-5). An emerging trend documented in heavy-fermion(1) and organic(2) conductors is that the maximum T-c for superconductivity occurs under external conditions that cause the critical temperature for a competing order to go to zero. Recently, such competition has been found in multilayer copper oxide high-temperature superconductors (HTSCs3-5) that possess two crystallographically inequivalent CuO2 planes in the unit cell. However, whether the competing electronic state can be suppressed to enhance T-c in HTSCs remains an open question. Here we show that pressure-driven phase competition leads to an unusual two-step enhancement of T-c in optimally doped trilayer Bi2Sr2Ca2Cu3O10+delta (Bi2223). We find that T-c first increases with pressure and then decreases after passing through a maximum. Unexpectedly, T-c increases again when the pressure is further raised above a critical value of around 24 GPa, surpassing the first maximum. The presence of this critical pressure is a manifestation of the crossover from the competing order to superconductivity in the inner of the three CuO2 planes. We suggest that the increase at higher pressures occurs as a result of competition between pairing and phase ordering in different CuO2 planes.	[Chen, Xiao-Jia; Struzhkin, Viktor V.; Yu, Yong; Goncharov, Alexander F.; Mao, Ho-kwang; Hemley, Russell J.] Carnegie Inst Sci, Geophys Lab, Washington, DC 20015 USA; [Chen, Xiao-Jia] S China Univ Technol, Dept Phys, Guangzhou 510640, Peoples R China; [Lin, Cheng-Tian] Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	Carnegie Institution for Science; South China University of Technology; Max Planck Society	Chen, XJ (corresponding author), Carnegie Inst Sci, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.	xjchen@ciw.edu; hmao@gl.ciw.edu; rhemley@gl.ciw.edu	Goncharov, Alexander F./AAX-9943-2020; Struzhkin, Viktor V/J-9847-2013	Goncharov, Alexander F./0000-0002-6422-8819; Struzhkin, Viktor V/0000-0002-3468-0548	DOE [DE-SC0001057, DE-FG02-02ER45955, DEFC03-03NA00144]; Carnegie Canada; NSFC [10874046]	DOE(United States Department of Energy (DOE)); Carnegie Canada; NSFC(National Natural Science Foundation of China (NSFC))	We thank M. R. Beasley, E. Berg, Y. Chen, C. W. Chu, R. E. Cohen, P. C. Dai, D.-L. Feng, E. Fradkin, T. Geballe, C. D. Gong, C.-Q. Jin, S. Kivelson, H.-Q. Lin, O. Millo, D. Orgad, S. Raghu, J. S. Schilling, Z.-X. Shen, L.-L. Sun, J. Tranquada, W.-F. Tsai, N.-L. Wang, H.-H. Wen, Z.-A. Xu, H. Yao, W.-G. Yin, Z.-X. Zhao and J.-X. Zhu for discussions. This work was supported by the DOE under grant no. DE-SC0001057, grant no. DE-FG02-02ER45955 and grant no. DEFC03-03NA00144, and by Carnegie Canada. X.-J.C. acknowledges financial support from the NSFC under grant no. 10874046.	Berg E, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.094509; BERMAN IV, 1989, PISMA ESKP TEOR FIZ, V49, P668; Chen XJ, 2000, PHYS REV LETT, V85, P2180, DOI 10.1103/PhysRevLett.85.2180; Chen XJ, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.104518; Chen XJ, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.214502; Chen XJ, 1999, PHYS REV B, V59, P4513, DOI 10.1103/PhysRevB.59.4513; Chen XJ, 1996, CHEM PHYS LETT, V258, P1, DOI 10.1016/0009-2614(96)00615-X; Chia EEM, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.147008; Feng DL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.107001; GAO L, 1994, PHYS REV B, V50, P4260, DOI 10.1103/PhysRevB.50.4260; Gregoryanz E, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.064504; Hadjiev VG, 1998, PHYS REV B, V58, P1043, DOI 10.1103/PhysRevB.58.1043; Ideta S, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.227001; Jover DT, 1996, PHYS REV B, V54, P10175, DOI 10.1103/PhysRevB.54.10175; Kivelson SA, 2002, PHYSICA B, V318, P61, DOI 10.1016/S0921-4526(02)00775-5; Kovaleva NN, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.054511; KUBIAK R, 1990, PHYSICA C, V166, P523, DOI 10.1016/0921-4534(90)90054-I; Limonov M, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.054509; Limonov MF, 2000, PHYS REV B, V61, P12412, DOI 10.1103/PhysRevB.61.12412; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; Mori M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.137003; Mukuda H, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.087001; Sadewasser S, 2000, PHYS REV B, V61, P741, DOI 10.1103/PhysRevB.61.741; STATT BW, 1993, PHYS REV B, V48, P3536, DOI 10.1103/PhysRevB.48.3536; TROKINER A, 1991, PHYS REV B, V44, P2426, DOI 10.1103/PhysRevB.44.2426; Uji S, 2001, NATURE, V410, P908, DOI 10.1038/35073531; Yuli O, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.057005; Zhou XJ, 1997, PHYS REV B, V55, P12770, DOI 10.1103/PhysRevB.55.12770	29	78	81	5	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					950	953		10.1038/nature09293	http://dx.doi.org/10.1038/nature09293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725035				2022-12-28	WOS:000281030300029
J	Hunter, DJ				Hunter, David J.			Should the NHS budget be ring fenced? No	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Durham, Durham TS17 6BH, England	Durham University	Hunter, DJ (corresponding author), Univ Durham, Durham TS17 6BH, England.	d.j.hunter@durham.ac.uk						Audit Commission, 2010, HLTH BAL REV PUBL HL; Bernstein H., 2010, ENABLING EFFECTIVE D; Foresight, 2007, TACKL OB FUT CHOIC P; H. M. Treasury & DCLG, 2010, TOT PLAC WHOL AR APP; Lansley A., 2010, COMMUNICATION   0707; Marmot M, 2010, FAIR SOC HLTH LIVES; National Audit Office, 2010, TACKL IN LIF EXP AR; National Institute for Health and Clinical Excellence, 2010, PREV CARD DIS; National Institute for Health and Clinical Excellence, 2010, ALC US DIS PREV HARM; Secretary of State for Health, 2010, EQ EXC LIB NHS; Wanless D., 2004, SECURING GOOD HLTH W	11	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 17	2010	341								c4354	10.1136/bmj.c4354	http://dx.doi.org/10.1136/bmj.c4354			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642KQ	20716599				2022-12-28	WOS:000281212500011
J	Bang, YJ; Van Cutsem, E; Feyereislova, A; Chung, HC; Shen, L; Sawaki, A; Lordick, F; Ohtsu, A; Omuro, Y; Satoh, T; Aprile, G; Kulikov, E; Hill, J; Lehle, M; Ruschoff, J; Kang, YK				Bang, Yung-Jue; Van Cutsem, Eric; Feyereislova, Andrea; Chung, Hyun C.; Shen, Lin; Sawaki, Akira; Lordick, Florian; Ohtsu, Atsushi; Omuro, Yasushi; Satoh, Taroh; Aprile, Giuseppe; Kulikov, Evgeny; Hill, Julie; Lehle, Michaela; Ruschoff, Josef; Kang, Yoon-Koo		ToGA Trial Investigators	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial	LANCET			English	Article							METASTATIC BREAST-CANCER; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; 1ST-LINE THERAPY; SUPPORTIVE CARE; III TRIAL; PLUS; HER2; FLUOROURACIL; PROGNOSIS	Background Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. Methods ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries. Patients with gastric or gastro-oesophageal junction cancer were eligible for inclusion if their tumours showed overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation. Participants were randomly assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in combination with intravenous trastuzumak Allocation was by block randomisation stratified by Eastern Cooperative Oncology Group performance status, chemotherapy regimen, extent of disease, primary cancer site, and measurability of disease, implemented with a central interactive voice recognition system. The primary endpoint was overall survival in all randomised patients who received study medication at least once. This trial is registered with ClinicalTrials.gov, number NCT01041404. Findings 594 patients were randomly assigned to study treatment (trastuzumab plus chemotherapy, n=298; chemotherapy alone, n=296), of whom 584 were included in the primary analysis (n=294; n=290). Median follow-up was 18.6 months (IQR 11-25) in the trastuzumab plus chemotherapy group and 17.1 months (9-25) in the chemotherapy alone group. Median overall survival was 13 8 months (95% Cl 1.2-16) in those assigned to trastuzumab plus chemotherapy compared with 11.1 months (10-13) in those assigned to chemotherapy alone (hazard ratio 0.74; 95% Cl 0.60-0.91; p=0.0046). The most common adverse events in both groups were nausea (trastuzumab plus chemotherapy, 197 [67%] vs chemotherapy alone, 184 [63%]), vomiting (147 [50%] vs 134 [46%]), and neutropenia (157 [53%] vs 165 [57%])} Rates of overall grade 3 or 4 adverse events (201 [68%] vs 198 [68%]) and cardiac adverse events (17 [6%] vs 18 [6%]) did not differ between groups Interpretation Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.	[Bang, Yung-Jue] Seoul Natl Univ, Coll Med, Seoul 110744, South Korea; [Van Cutsem, Eric] Univ Hosp Gasthuisberg, B-3000 Leuven, Belgium; [Feyereislova, Andrea; Lehle, Michaela] F Hoffmann La Roche, Basel, Switzerland; [Chung, Hyun C.] Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Seoul, South Korea; [Shen, Lin] Peking Univ, Beijing Canc Hosp, Beijing 100871, Peoples R China; [Sawaki, Akira] Aichi Canc Ctr, Aichi, Japan; [Lordick, Florian] Natl Centrum Tumorerkrankungen, Heidelberg, Germany; [Ohtsu, Atsushi] East Hosp, Natl Canc Ctr, Kashiwa, Chiba, Japan; [Omuro, Yasushi] Komagome Gen Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan; [Satoh, Taroh] Kinki Univ, Sch Med, Osaka 589, Japan; [Aprile, Giuseppe] Azienda Osped Univ, Udine, Italy; [Kulikov, Evgeny] Reg Clin Oncol Dispensary, Ryazan, Russia; [Hill, Julie] Roche Prod Ltd, Dee Why, NSW, Australia; [Ruschoff, Josef] Targos Mol Pathol, Kassel, Germany; [Kang, Yoon-Koo] Asan Med Ctr, Seoul, South Korea	Seoul National University (SNU); KU Leuven; University Hospital Leuven; Roche Holding; Yonsei University; Yonsei University Health System; Peking University; Aichi Cancer Center; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; National Cancer Center - Japan; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Kindai University (Kinki University); University of Udine; University Hospital of Udine; Roche Holding; Targos Molecular Pathology GmbH	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, 28 Yongon Dong, Seoul 110744, South Korea.		Landaverde, Denis U./V-6273-2017; Satoh, Taroh/AAF-5193-2021; Bang, Yung Jue/J-2759-2012; Satoh, Taroh/AAF-7913-2020; Van+Cutsem, Eric/ABE-1762-2021	Landaverde, Denis U./0000-0002-6522-1061; Satoh, Taroh/0000-0002-4615-2638; Bang, Yung Jue/0000-0001-6000-4597; Chung, Hyun/0000-0002-0920-9471	F Hoffmann-La Roche FL, GA; Chugal-Roche; Chugal Pharmaceutical AF	F Hoffmann-La Roche FL, GA; Chugal-Roche; Chugal Pharmaceutical AF	Y-JB and JR are advisory board members and Y-JB, EVC, FL, and Y-KK are consultants for F Hoffmann-La Roche TS is a consultant for Chugal-Roche, Chugai Pharmaceutical, Merck-Serono. Sanofi-Aventis, Bristol-Myers, Yakult Pharmaceutical, Taiho Pharmaceutical, and Danchi-Sankyo Y-JB, EVC. FL, (Rand Y-KK have received honoraria and Y-JB. EVC, HCC, LS, FL. AO, and GA or their institutions have received grants from F Hoffmann-La Roche FL, GA, and JR have given educational presentations and Y-JB, JR. and Y-KK have received travel or accommodation fees from F Hoffmann-La Roche Travel or accommodation fees have been received by AO from Chugal-Roche, and by TS from Chugal Pharmaceutical AF, JH, and ML are employees of F Hoffmann-La Roche AS, YO, and EK declare that they have no conflicts of interest; This study was sponsored by F Hoffmann-La Roche We thank Jeni Fagan (Health Interactions, UK) who provided editorial support on behalf of F Hoffmann-La Roche	Al-Batran SE, 2008, J CLIN ONCOL, V26, P1435, DOI 10.1200/JCO.2007.13.9378; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Cunningham SC, 2005, J GASTROINTEST SURG, V9, P718, DOI 10.1016/j.gassur.2004.12.002; Dowsett M, 2009, J CLIN ONCOL, V27, P2962, DOI 10.1200/JCO.2008.19.7939; Dybdal N, 2005, BREAST CANCER RES TR, V93, P3, DOI 10.1007/s10549-004-6275-8; Fujimoto-Ouchi K, 2007, CANCER CHEMOTH PHARM, V59, P795, DOI 10.1007/s00280-006-0337-z; Garcia M, 2007, GLOBAL CANC FACTS FI; Glimelius B, 1997, ANN ONCOL, V8, P163, DOI 10.1023/A:1008243606668; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Horner MJ, 2009, SEER CANC STAT REV 1; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kang YK, 2009, ANN ONCOL, V20, P666, DOI 10.1093/annonc/mdn717; Miyahara R, 2007, J GASTROEN HEPATOL, V22, P1435, DOI 10.1111/j.1440-1746.2007.04991.x; Ohtsu A, 2003, J CLIN ONCOL, V21, P54, DOI 10.1200/JCO.2003.04.130; Okines AFC, 2009, ANN ONCOL, V20, P1529, DOI 10.1093/annonc/mdp047; PENAULTHORCA F, 2005, ASCO ANN M ORL FL US; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; PYRHONEN S, 1995, BRIT J CANCER, V71, P587, DOI 10.1038/bjc.1995.114; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064; Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Yamashita K, 2009, HEPATO-GASTROENTEROL, V56, P276; Yoshida M, 2009, J MOL CELL CARDIOL, V47, P698, DOI 10.1016/j.yjmcc.2009.07.024; Zheng HC, 2007, J CLIN PATHOL, V60, P273, DOI 10.1136/jcp.2006.038778	32	782	871	19	299	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2010	376	9742					687	697		10.1016/S0140-6736(10)61121-X	http://dx.doi.org/10.1016/S0140-6736(10)61121-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646YW	20728210				2022-12-28	WOS:000281582900028
J	Kantoff, PW; Higano, CS; Shore, ND; Berger, ER; Small, EJ; Penson, DF; Redfern, CH; Ferrari, AC; Dreicer, R; Sims, RB; Xu, Y; Frohlich, MW; Schellhammer, PF; Ahmed, T; Amin, A; Arseneau, J; Barth, N; Bernstein, G; Bracken, B; Burch, P; Caggiano, V; Chin, J; Chodak, G; Chu, F; Corman, J; Curti, B; Dawson, N; Deeken, JF; Dubernet, T; Fishman, M; Flanigan, R; Gailani, F; Garbo, L; Gardner, T; Gelmann, E; George, D; Godfrey, T; Gomella, L; Guerra, M; Hall, S; Hanson, J; Israeli, R; Jancis, E; Jewett, MAS; Kassabian, V; Katz, J; Klotz, L; Koeneman, K; Koh, H; Kratzke, R; Lance, R; Lech, J; Leichman, L; Lemon, R; Liang, J; Libertino, J; Lilly, M; Malik, I; Martin, SE; McCaffrey, J; McLeod, D; McNeel, D; Miles, B; Murdock, M; Nabhan, C; Nemunaitis, J; Notter, D; Pantuck, A; Perrotte, P; Pessis, D; Petrylak, D; Polikoff, J; Pommerville, P; Ramanathan, S; Rarick, M; Richards, J; Rifkin, R; Rohatgi, N; Rosenbluth, R; Santucci, R; Sayegh, A; Seigne, J; Shapira, I; Shedhadeh, N; Shepherd, D; Sridhar, S; Stephenson, R; Teigland, C; Thaker, N; Vacirca, J; Villa, L; Vogelzang, N; Wertheim, M; Wolff, JH; Wurzel, R; Yang, C; Young, J				Kantoff, Philip W.; Higano, Celestia S.; Shore, Neal D.; Berger, E. Roy; Small, Eric J.; Penson, David F.; Redfern, Charles H.; Ferrari, Anna C.; Dreicer, Robert; Sims, Robert B.; Xu, Yi; Frohlich, Mark W.; Schellhammer, Paul F.; Ahmed, T.; Amin, A.; Arseneau, J.; Barth, N.; Bernstein, G.; Bracken, B.; Burch, P.; Caggiano, V.; Chin, J.; Chodak, G.; Chu, F.; Corman, J.; Curti, B.; Dawson, N.; Deeken, J. F.; Dubernet, T.; Fishman, M.; Flanigan, R.; Gailani, F.; Garbo, L.; Gardner, T.; Gelmann, E.; George, D.; Godfrey, T.; Gomella, L.; Guerra, M.; Hall, S.; Hanson, J.; Israeli, R.; Jancis, E.; Jewett, M. A. S.; Kassabian, V.; Katz, J.; Klotz, L.; Koeneman, K.; Koh, H.; Kratzke, R.; Lance, R.; Lech, J.; Leichman, L.; Lemon, R.; Liang, J.; Libertino, J.; Lilly, M.; Malik, I.; Martin, S. E.; McCaffrey, J.; McLeod, D.; McNeel, D.; Miles, B.; Murdock, M.; Nabhan, C.; Nemunaitis, J.; Notter, D.; Pantuck, A.; Perrotte, P.; Pessis, D.; Petrylak, D.; Polikoff, J.; Pommerville, P.; Ramanathan, S.; Rarick, M.; Richards, J.; Rifkin, R.; Rohatgi, N.; Rosenbluth, R.; Santucci, R.; Sayegh, A.; Seigne, J.; Shapira, I.; Shedhadeh, N.; Shepherd, D.; Sridhar, S.; Stephenson, R.; Teigland, C.; Thaker, N.; Vacirca, J.; Villa, L., Jr.; Vogelzang, N.; Wertheim, M.; Wolff, J. H.; Wurzel, R.; Yang, C.; Young, J.		IMPACT Study Investigators	Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MITOXANTRONE PLUS PREDNISONE; RANDOMIZED CONTROLLED-TRIAL; SURROGATE MARKER; DENDRITIC CELLS; CLINICAL-TRIALS; PHASE-III; SURVIVAL; MEN; DOCETAXEL; LEUKEMIA	Background: Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. Methods: In this double-blind, placebo-controlled, multicenter phase 3 trial, we randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. The primary end point was overall survival, analyzed by means of a stratified Cox regression model adjusted for baseline levels of serum prostate-specific antigen (PSA) and lactate dehydrogenase. Results: In the sipuleucel-T group, there was a relative reduction of 22% in the risk of death as compared with the placebo group (hazard ratio, 0.78; 95% confidence interval [CI], 0.61 to 0.98; P=0.03). This reduction represented a 4.1-month improvement in median survival (25.8 months in the sipuleucel-T group vs. 21.7 months in the placebo group). The 36-month survival probability was 31.7% in the sipuleucel-T group versus 23.0% in the placebo group. The treatment effect was also observed with the use of an unadjusted Cox model and a log-rank test (hazard ratio, 0.77; 95% CI, 0.61 to 0.97; P=0.02) and after adjustment for use of docetaxel after the study therapy (hazard ratio, 0.78; 95% CI, 0.62 to 0.98; P=0.03). The time to objective disease progression was similar in the two study groups. Immune responses to the immunizing antigen were observed in patients who received sipuleucel-T. Adverse events that were more frequently reported in the sipuleucel-T group than in the placebo group included chills, fever, and headache. Conclusions: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer. No effect on the time to disease progression was observed. (Funded by Dendreon; ClinicalTrials.gov number, NCT00065442.) N Engl J Med 2010;363:411-22.	[Kantoff, Philip W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA; [Higano, Celestia S.] Univ Washington, Sch Med, Seattle, WA USA; [Shore, Neal D.] Carolina Urol Res Ctr, Myrtle Beach, SC USA; [Berger, E. Roy] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA; [Small, Eric J.] Univ Calif San Francisco, Urol Oncol Program, San Francisco, CA 94143 USA; [Penson, David F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Redfern, Charles H.] Sharp Healthcare, San Diego, CA USA; [Ferrari, Anna C.] NYU, Ctr Clin Canc, Langone Med Ctr, New York, NY USA; [Dreicer, Robert] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Sims, Robert B.; Xu, Yi; Frohlich, Mark W.] Dendreon Corp, Seattle, WA USA; [Schellhammer, Paul F.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Washington; University of Washington Seattle; Carolina Urologic Research Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California San Francisco; Vanderbilt University; New York University; NYU Langone Medical Center; Cleveland Clinic Foundation; Dendreon; Eastern Virginia Medical School	Kantoff, PW (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 44 Binney St,Dana 1230, Boston, MA 02115 USA.	philip_kantoff@dfci.harvard.edu	Fishman, Mayer/AAG-6640-2021	Kantoff, Philip/0000-0001-7275-0597; McNeel, Douglas/0000-0003-1471-6723; Penson, David/0000-0002-2580-2697	Dendreon	Dendreon	Supported by Dendreon.	ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; Armstrong AJ, 2007, CLIN CANCER RES, V13, P6396, DOI 10.1158/1078-0432.CCR-07-1036; Berry W, 2002, J UROLOGY, V168, P2439, DOI 10.1016/S0022-5347(05)64163-8; Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008; Burch PA, 2000, CLIN CANCER RES, V6, P2175; Carducci MA, 2007, CANCER-AM CANCER SOC, V110, P1959, DOI 10.1002/cncr.22996; CROWTHER JR, 2000, ELISA GUIDEBOOK METH; *DEP HLTH HUM SERV, 2009, GUID IND CLIN UNPUB; Goldman B, 2009, NAT BIOTECHNOL, V27, P129, DOI 10.1038/nbt0209-129; Halabi S, 2003, J CLIN ONCOL, V21, P1232, DOI 10.1200/JCO.2003.06.100; Higano C, 2009, 2009 GEN CANC S ORL; Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429; James ND, 2009, EUR UROL, V55, P1112, DOI 10.1016/j.eururo.2008.11.002; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597; Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506; Kantoff PW, 2002, PROSTATE CANC PRINCI; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lin DY, 1997, STAT MED, V16, P1515, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.3.CO;2-T; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Saad F, 2002, JNCI-J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458; Sheikh NA, 2008, CANCER IMMUNOL IMMUN, V57, P1381, DOI 10.1007/s00262-008-0474-9; Small E, 2009, 2009 GEN CANC S ORL; Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Sternberg CN, 2009, J CLIN ONCOL, V27, P5431, DOI 10.1200/JCO.2008.20.1228; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224	32	3794	3941	8	418	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					411	422		10.1056/NEJMoa1001294	http://dx.doi.org/10.1056/NEJMoa1001294			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818862				2022-12-28	WOS:000280411300005
J	DUNEA, G				DUNEA, G			LETTER FROM CHICAGO - GOOD AND BAD NEWS	BRITISH MEDICAL JOURNAL			English	Editorial Material											DUNEA, G (corresponding author), COOK CTY HOSP,CHICAGO,IL 60612, USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1988	296	6637					1657	1658		10.1136/bmj.296.6637.1657	http://dx.doi.org/10.1136/bmj.296.6637.1657			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N8341	20743001	Green Published			2022-12-28	WOS:A1988N834100028
J	WARDEN, J				WARDEN, J			BEYOND THE TV EYE	BRITISH MEDICAL JOURNAL			English	Editorial Material																		BRITTAN L, NEW DEAL HLTH CARE	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1988	296	6621					582	582		10.1136/bmj.296.6621.582	http://dx.doi.org/10.1136/bmj.296.6621.582			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M2314	20742963	Green Published			2022-12-28	WOS:A1988M231400056
J	Jensen, RB; Carreira, A; Kowalczykowski, SC				Jensen, Ryan B.; Carreira, Aura; Kowalczykowski, Stephen C.			Purified human BRCA2 stimulates RAD51-mediated recombination	NATURE			English	Article							REPLICATION PROTEIN-A; DNA STRAND EXCHANGE; HUMAN RAD51 PROTEIN; SUSCEPTIBILITY GENE BRCA2; HOMOLOGY-DIRECTED REPAIR; RADIATION HYPERSENSITIVITY; NUCLEOPROTEIN FILAMENTS; BINDING SELECTIVITY; COMPLEX-FORMATION; RECA PROTEIN	Mutation of the breast cancer susceptibility gene, BRCA2, leads to breast and ovarian cancers. Mechanistic insight into the functions of human BRCA2 has been limited by the difficulty of isolating this large protein (3,418 amino acids). Here we report the purification of full-length BRCA2 and show that it both binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). BRCA2 acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. BRCA2 does not anneal ssDNA complexed with RPA, implying it does not directly function in repair processes that involve ssDNA annealing. Our findings show that BRCA2 is a key mediator of homologous recombination, and they provide a molecular basis for understanding how this DNA repair process is disrupted by BRCA2 mutations, which lead to chromosomal instability and cancer.	[Jensen, Ryan B.; Carreira, Aura; Kowalczykowski, Stephen C.] Univ Calif Davis, Dept Microbiol, Davis, CA 95616 USA; [Jensen, Ryan B.; Carreira, Aura; Kowalczykowski, Stephen C.] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Dept Microbiol, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu		Carreira, Aura/0000-0001-5489-4343	NIH [NIH GM 62653]; DOD [BC085223]; American Cancer Society [PF-05-225-01-GMC]; Ministerio de Educacion y Ciencia (Spain); American Cancer Society; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062653, R37GM062653] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); American Cancer Society(American Cancer Society); Ministerio de Educacion y Ciencia (Spain)(Spanish Government); American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. Shin for BRCA2 cDNA clones; M. Zdzienicka for VC8 cells; A. Mazin for RAD52; A. Nimonkar for DMC1; W. Heyer and Kowalczykowski laboratory for comments. Supported by grants from NIH (NIH GM 62653) and DOD-Breast Cancer Research Program (BC085223) to S.C.K., American Cancer Society Postdoctoral Fellowship to R.B.J. (PF-05-225-01-GMC), and Postdoctoral Fellowship from Ministerio de Educacion y Ciencia (Spain) to A.C.; R.B.J. acknowledges financial support from C. Hornung, who funded this work through the American Cancer Society and who passed away last year.	Baumann P, 1999, J MOL BIOL, V291, P363, DOI 10.1006/jmbi.1999.2954; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Carreira A, 2009, CELL CYCLE, V8, P3445, DOI 10.4161/cc.8.21.9748; Carreira A, 2009, CELL, V136, P1032, DOI 10.1016/j.cell.2009.02.019; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Esashi F, 2007, NAT STRUCT MOL BIOL, V14, P468, DOI 10.1038/nsmb1245; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Hartley CL, 2008, MOL MICROBIOL, V68, P1237, DOI 10.1111/j.1365-2958.2008.06230.x; Hilario J, 2009, P NATL ACAD SCI USA, V106, P361, DOI 10.1073/pnas.0811965106; Kantake N, 2002, P NATL ACAD SCI USA, V99, P15327, DOI 10.1073/pnas.252633399; LEBOWITZ JH, 1985, THESIS J HOPKINS U; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lio YC, 2003, J BIOL CHEM, V278, P2469, DOI 10.1074/jbc.M211038200; LIU J, NATURE STRU IN PRESS; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mazloum N, 2007, BIOCHEMISTRY-US, V46, P7163, DOI 10.1021/bi700399m; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Mine J, 2007, NUCLEIC ACIDS RES, V35, P7171, DOI 10.1093/nar/gkm752; Mirshad JK, 2003, BIOCHEMISTRY-US, V42, P5945, DOI 10.1021/bi027233i; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Petalcorin MIR, 2006, J MOL BIOL, V361, P231, DOI 10.1016/j.jmb.2006.06.020; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Saeki H, 2006, P NATL ACAD SCI USA, V103, P8768, DOI 10.1073/pnas.0600298103; San Filippo J, 2006, J BIOL CHEM, V281, P11649, DOI 10.1074/jbc.M601249200; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Thorslund T, 2007, EMBO J, V26, P2915, DOI 10.1038/sj.emboj.7601739; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; van der Heijden T, 2007, NUCLEIC ACIDS RES, V35, P5646, DOI 10.1093/nar/gkm629; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wong JMS, 2003, ONCOGENE, V22, P28, DOI 10.1038/sj.onc.1206071; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	53	447	458	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	2010	467	7316					678	U62		10.1038/nature09399	http://dx.doi.org/10.1038/nature09399			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20729832	Green Accepted, Green Submitted			2022-12-28	WOS:000282572500031
J	Choate, KA; Lu, Y; Zhou, J; Choi, M; Elias, PM; Farhi, A; Nelson-Williams, C; Crumrine, D; Williams, ML; Nopper, AJ; Bree, A; Milstone, LM; Lifton, RP				Choate, Keith A.; Lu, Yin; Zhou, Jing; Choi, Murim; Elias, Peter M.; Farhi, Anita; Nelson-Williams, Carol; Crumrine, Debra; Williams, Mary L.; Nopper, Amy J.; Bree, Alanna; Milstone, Leonard M.; Lifton, Richard P.			Mitotic Recombination in Patients with Ichthyosis Causes Reversion of Dominant Mutations in KRT10	SCIENCE			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; REVERTANT MOSAICISM; STEM-CELLS; INTERMEDIATE FILAMENTS; HUMAN EPIDERMIS; KERATIN-10; RNA; RETINOBLASTOMA; ERYTHRODERMA; MECHANISM	Somatic loss of wild-type alleles can produce disease traits such as neoplasia. Conversely, somatic loss of disease-causing mutations can revert phenotypes; however, these events are infrequently observed. Here we show that ichthyosis with confetti, a severe, sporadic skin disease in humans, is associated with thousands of revertant clones of normal skin that arise from loss of heterozygosity on chromosome 17q via mitotic recombination. This allowed us to map and identify disease-causing mutations in the gene encoding keratin 10 (KRT10); all result in frameshifts into the same alternative reading frame, producing an arginine-rich C-terminal peptide that redirects keratin 10 from the cytokeratin filament network to the nucleolus. The high frequency of somatic reversion in ichthyosis with confetti suggests that revertant stem cell clones are under strong positive selection and/or that the rate of mitotic recombination is elevated in individuals with this disorder.	[Choate, Keith A.; Lu, Yin; Choi, Murim; Farhi, Anita; Nelson-Williams, Carol; Lifton, Richard P.] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, New Haven, CT 06510 USA; [Choate, Keith A.; Zhou, Jing; Milstone, Leonard M.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Elias, Peter M.; Crumrine, Debra; Williams, Mary L.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94122 USA; [Nopper, Amy J.] Childrens Mercy Hosp & Clin, Kansas City, MO 64108 USA; [Bree, Alanna] Texas Childrens Hosp, Houston, TX 77030 USA	Howard Hughes Medical Institute; Yale University; Yale University; University of California System; University of California San Francisco; Children's Mercy Hospital; Baylor College of Medicine	Lifton, RP (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, New Haven, CT 06510 USA.	richard.lifton@yale.edu	Choi, Murim/AAP-9120-2021		NIAMS; Foundation for Ichthyosis and Related Skin Types; National Center for Research Resources; Yale Clinical and Translational Science Award; Yale Center for Human Genetics and Genomics; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007016, K08AR056305] Funding Source: NIH RePORTER	NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Foundation for Ichthyosis and Related Skin Types; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Yale Clinical and Translational Science Award; Yale Center for Human Genetics and Genomics; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank the patients studied and their families for their invaluable contributions to this study. We thank L. Boyden and S. Baserga for helpful discussions; N. DeSilva, S. Mane, and the Yale Center for Genome Analysis for assistance in development of critical methodologies; and M. Ceneri for the identification of a previously unreported IWC kindred. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, and the Yale Skin Diseases Research Center provided cell culture support for this work. K. A. C. is supported by a K08 award from NIAMS and a fellowship from the Foundation for Ichthyosis and Related Skin Types. Supported in part by a National Center for Research Resources High-End Instrumentation Grant, the Yale Clinical and Translational Science Award, and the Yale Center for Human Genetics and Genomics. R. P. L. is an investigator of the Howard Hughes Medical Institute.	Almaani N, 2010, J INVEST DERMATOL, V130, P1937, DOI 10.1038/jid.2010.64; BRUSASCO A, 1994, DERMATOLOGY, V188, P40, DOI 10.1159/000247084; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAMENZIND M, 1984, ANN DERMATOL VENER, V111, P675; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Chen JL, 2006, J CELL SCI, V119, P5067, DOI 10.1242/jcs.03298; Darling TN, 1999, J CLIN INVEST, V103, P1371, DOI 10.1172/JCI4338; Davis BR, 2009, IMMUNOL RES, V44, P127, DOI 10.1007/s12026-008-8091-4; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Ghazizadeh S, 2005, J INVEST DERMATOL, V124, P367, DOI 10.1111/j.0022-202X.2004.23599.x; Hirschhorn R, 2003, J MED GENET, V40, P721, DOI 10.1136/jmg.40.10.721; Jensen UB, 1999, DEVELOPMENT, V126, P2409; Jonkman MF, 1997, CELL, V88, P543, DOI 10.1016/S0092-8674(00)81894-2; Kalb R, 2006, GENOME DYN, V1, P218, DOI 10.1159/000092510; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kocer SS, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-359; MARGHESCU S, 1984, HAUTARZT, V35, P522; O'Keefe C, 2010, BLOOD, V115, P2731, DOI 10.1182/blood-2009-10-201848; Ohyama M, 2006, J CLIN INVEST, V116, P249, DOI 10.1172/JCI26043; Pasmooij AMG, 2005, AM J HUM GENET, V77, P727, DOI 10.1086/497344; Pasmooij AMG, 2007, J CLIN INVEST, V117, P1240, DOI 10.1172/JCI30465; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; Schuilenga-Hut PHL, 2002, J INVEST DERMATOL, V118, P626, DOI 10.1046/j.1523-1747.2002.01715.x; Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641; Smith FJD, 2004, J INVEST DERMATOL, V122, P73, DOI 10.1046/j.0022-202X.2003.22129.x; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; Sugaya M, 2008, J PEPT SCI, V14, P924, DOI 10.1002/psc.1027; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	32	126	129	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	2010	330	6000					94	97		10.1126/science.1192280	http://dx.doi.org/10.1126/science.1192280			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656KW	20798280	Green Accepted			2022-12-28	WOS:000282334500043
J	Broberg, CA; Zhang, LL; Gonzalez, H; Laskowski-Arce, MA; Orth, K				Broberg, Christopher A.; Zhang, Lingling; Gonzalez, Herman; Laskowski-Arce, Michelle A.; Orth, Kim			A Vibrio Effector Protein Is an Inositol Phosphatase and Disrupts Host Cell Membrane Integrity	SCIENCE			English	Article							PARAHAEMOLYTICUS; AUTOPHAGY; BINDING; DOMAINS; GENOME	The marine bacterium Vibrio parahaemolyticus causes gastroenteritis in humans and encodes the type III effector protein VPA0450, which contributes to host cell death caused by autophagy, cell rounding, and cell lysis. We found that VPA0450 is an inositol polyphosphate 5-phosphatase that hydrolyzed the D5 phosphate from the plasma membrane phospholipid phosphatidylinositol 4,5-bisphosphate. VPA0450 disrupted cytoskeletal binding sites on the inner surface of membranes of human cells and caused plasma membrane blebbing, which compromised membrane integrity and probably contributed to cell death by facilitating lysis. Thus, bacterial pathogens can disrupt adaptor protein-binding sites required for proper membrane and cytoskeleton dynamics by altering the homeostasis of membrane-bound inositol-signaling molecules.	[Broberg, Christopher A.; Zhang, Lingling; Gonzalez, Herman; Laskowski-Arce, Michelle A.; Orth, Kim] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Orth, K (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.	kim.orth@utsouthwestern.edu	Zhang, Lingling/A-1100-2015; Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620; Broberg, Christopher/0000-0002-9497-5866	NIH [R01-AI056404, R01-AI087808]; Welch Foundation [I-1561]; National Institute of General Medical Sciences [5T32GM008203]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI087808, R01AI056404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank N. Alto, H. Yin, J. Hurley, F. Robinson, J. Albanesi, B. Barylko, K. Luby-Phelps, Chris Smith, T. Iida, T. Honda, L. McCarter, and the Orth lab for insightful discussions, critical reading, and generous supply of reagents. K.O., L.Z., H. G., M. L.-A., and C. A. B. are supported by grants from NIH-Allergy and Infectious Disease (R01-AI056404 and R01-AI087808) and the Welch Foundation (I-1561). C. A. B is supported by National Institute of General Medical Sciences training grant 5T32GM008203 in cellular and molecular biology. K.O. is a Burroughs Wellcome Investigator in Pathogenesis of Infectious Disease and a W. W. Caruth Jr. Biomedical Scholar.	Broberg CA, 2010, CURR OPIN MICROBIOL, V13, P34, DOI 10.1016/j.mib.2009.12.004; Burdette DL, 2008, P NATL ACAD SCI USA, V105, P12497, DOI 10.1073/pnas.0802773105; Burdette DL, 2009, MOL MICROBIOL, V73, P639, DOI 10.1111/j.1365-2958.2009.06798.x; Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453; Cornelis GR, 2006, NAT REV MICROBIOL, V4, P811, DOI 10.1038/nrmicro1526; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Daniels NA, 2000, J INFECT DIS, V181, P1661, DOI 10.1086/315459; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Galan JE, 2009, CELL HOST MICROBE, V5, P571, DOI 10.1016/j.chom.2009.04.008; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Makino K, 2003, LANCET, V361, P743, DOI 10.1016/S0140-6736(03)12659-1; Mallo GV, 2008, J CELL BIOL, V182, P741, DOI 10.1083/jcb.200804131; Ono T, 2006, INFECT IMMUN, V74, P1032, DOI 10.1128/IAI.74.2.1032-1042.2006; Park KS, 2004, INFECT IMMUN, V72, P6659, DOI 10.1128/IAI.72.11.6659-6665.2004; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Reith ME, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-427; Taylor Gregory S, 2004, Methods Mol Biol, V284, P217; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Whisstock JC, 2002, IUBMB LIFE, V53, P15, DOI 10.1080/15216540210814; Yarbrough ML, 2009, SCIENCE, V323, P269, DOI 10.1126/science.1166382	20	78	86	3	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	2010	329	5999					1660	1662		10.1126/science.1192850	http://dx.doi.org/10.1126/science.1192850			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653NK	20724587				2022-12-28	WOS:000282098100046
J	Chen, M; Schliep, M; Willows, RD; Cai, ZL; Neilan, BA; Scheer, H				Chen, Min; Schliep, Martin; Willows, Robert D.; Cai, Zheng-Li; Neilan, Brett A.; Scheer, Hugo			A Red-Shifted Chlorophyll	SCIENCE			English	Article								Chlorophylls are essential for light-harvesting and energy transduction in photosynthesis. Four chemically distinct varieties have been known for the past 60 years. Here we report isolation of a fifth, which we designate chlorophyll f. Its in vitro absorption (706 nanometers) and fluorescence (722 nanometers) maxima are red-shifted compared to all other chlorophylls from oxygenic phototrophs. On the basis of the optical, mass, and nuclear magnetic resonance spectra, we propose that chlorophyll f is [2-formyl]-chlorophyll a (C55H70O6N4Mg). This finding suggests that oxygenic photosynthesis can be extended further into the infrared region and may open associated bioenergy applications.	[Chen, Min; Schliep, Martin; Scheer, Hugo] Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia; [Willows, Robert D.] Macquarie Univ, Dept Chem & Biomol Sci, N Ryde, NSW 2109, Australia; [Cai, Zheng-Li] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; [Neilan, Brett A.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia; [Scheer, Hugo] Univ Munich, Dept Biol 1, D-80638 Munich, Germany	University of Sydney; Macquarie University; University of Sydney; University of New South Wales Sydney; University of Munich	Chen, M (corresponding author), Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia.	min.chen@sydney.edu.au	Neilan, Brett A/I-5767-2012; Willows, Robert/C-1537-2010	Neilan, Brett A/0000-0001-6113-772X; Willows, Robert/0000-0002-0731-2950; Chen, Min/0000-0001-8070-3248	Macquarie University; ARC; National Health and Medical Research Council (NHMRC)	Macquarie University; ARC(Australian Research Council); National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	M.C. and B.A.N. hold Australian Research Council (ARC) fellowships and associated financial support. M.C. thanks K. Donohoe (University of Sydney) for assistance with polymerase chain reactions. M. C. and M. S. thank B. Crossett (University of Sydney) for mass spectral analysis. M.C. and H.S. thank A. Kwan and J. Mackay (University of Sydney) for NMR spectral analysis and A. W. D. Larkum (University of Sydney) for valuable discussions and continued support. R.D.W. acknowledges support from Macquarie University Strategic Infrastructure Scheme and Research and Development Scheme grants and the ARC and National Health and Medical Research Council (NHMRC) fluorescent applications for biotechnology in life sciences network for use of the Leica confocal imaging system. R.D.W. and M.C. thank D. Birch (Macquarie University) for help with the Olympus confocal imaging. Z.-L.C. thanks J. Reimers (University of Sydney) for supercomputer access. The 16S rRNA sequence has been deposited in GenBank under accession number 1370306.	Allen M.B., 1966, CHLOROPHYLLS, P511; Bjorn L, 2009, PHOTOSYNTH RES, V99, P85, DOI 10.1007/s11120-008-9395-x; Falk J. E., 1975, PORPHYRNS MET, P399; Holt A.S., 1966, CHLOROPHYLLS, P111; Kuhl Michael, 2007, V11, P101; Manning WM, 1943, J BIOL CHEM, V151, P1; MEEKS JC, 1974, ALGAL PHYSL BIOCH, V10, P161; Miyashita H, 1996, NATURE, V383, P402, DOI 10.1038/383402a0; Nieuwenburg P, 2003, PHOTOCHEM PHOTOBIOL, V77, P628, DOI 10.1562/0031-8655(2003)077<0628:EOTPPO>2.0.CO;2; Reid RP, 2000, NATURE, V406, P989, DOI 10.1038/35023158; Scheer Hugo, 2006, V25, P1; Strain H.H., 1951, MANUAL PHYCOLOGY, P243; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719	13	333	345	8	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1318	1319		10.1126/science.1191127	http://dx.doi.org/10.1126/science.1191127			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20724585				2022-12-28	WOS:000281657300031
J	Abernethy, AP; McDonald, CF; Frith, PA; Clark, K; Herndon, JE; Marcello, J; Young, IH; Bull, J; Wilcock, A; Booth, S; Wheeler, JL; Tulsky, JA; Crockett, AJ; Currow, DC				Abernethy, Amy P.; McDonald, Christine F.; Frith, Peter A.; Clark, Katherine; Herndon, James E., II; Marcello, Jennifer; Young, Iven H.; Bull, Janet; Wilcock, Andrew; Booth, Sara; Wheeler, Jane L.; Tulsky, James A.; Crockett, Alan J.; Currow, David C.			Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; OBSTRUCTIVE PULMONARY-DISEASE; CANCER-PATIENTS; MANAGEMENT; THERAPY; QUESTIONNAIRE; BENEFIT	Background Palliative oxygen therapy is widely used for treatment of dyspnoea in individuals with life-limiting illness who are ineligible for long-term oxygen therapy. We assessed the effectiveness of oxygen compared with room air delivered by nasal cannula for relief of breathlessness in this population of patients. Methods Adults from outpatient clinics at nine sites in Australia, the USA, and the UK were eligible for enrolment in this double-blind, randomised controlled trial if they had life-limiting illness, refractory dyspnoea, and partial pressure of oxygen in arterial blood (PaO2) more than 7.3 kPa. Participants were randomly assigned in a 1:1 ratio by a central computer-generated system to receive oxygen or room air via a concentrator through a nasal cannula at 2 L per min for 7 days. Participants were instructed to use the concentrator for at least 15 h per day. The randomisation sequence was stratified by baseline PaO2 with balanced blocks of four patients. The primary outcome measure was breathlessness (0-10 numerical rating scale [NRS]), measured twice a day (morning and evening). All randomised patients who completed an assessment were included in the primary analysis for that data point (no data were imputed). This study is registered, numbers NCT00327873 and ISRCTN67448752. Findings 239 participants were randomly assigned to treatment (oxygen, n=120; room air, n=119). 112 (93%) patients assigned to receive oxygen and 99 (83%) assigned to receive room air completed all 7 days of assessments. From baseline to day 6, mean morning breathlessness changed by -0.9 points (95% CI -1.3 to -0.5) in patients assigned to receive oxygen and by -0.7 points (-1.2 to 0.2) in patients assigned to receive room air (p=0.504). Mean evening breathlessness changed by 0.3 points (-0.7 to 0.1) in the oxygen group and by -0.5 (-0.9 to 0.1) in the room air group (p=0.554). The frequency of side-effects did not differ between groups. Extreme drowsiness was reported by 12 (10%) of 116 patients assigned to receive oxygen compared with 14 (13%) of 108 patients assigned to receive room air. Two (2%) patients in the oxygen group reported extreme symptoms of nasal irritation compared with seven (6%) in the room air group. One patient reported an extremely troublesome nose bleed (oxygen group). Interpretation Since oxygen delivered by a nasal cannula provides no additional symptomatic benefit for relief of refractory dyspnoea in patients with fife-limiting illness compared with room air, less burdensome strategies should be considered after brief assessment of the effect of oxygen therapy on the individual patient.	[Abernethy, Amy P.; Wheeler, Jane L.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA; [Herndon, James E., II] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA; [Herndon, James E., II; Marcello, Jennifer] Duke Univ, Med Ctr, Canc Ctr Biostat, Durham, NC 27710 USA; [Tulsky, James A.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA; [Abernethy, Amy P.; Currow, David C.] Flinders Univ S Australia, Div Med, Dept Palliat & Support Serv, Bedford Pk, SA 5042, Australia; [Abernethy, Amy P.; Currow, David C.] Repatriat Gen Hosp, So Adelaide Palliat Serv, Daw Pk, SA, Australia; [Frith, Peter A.] Flinders Univ S Australia, Adelaide, SA 5001, Australia; [Frith, Peter A.] Repatriat Gen Hosp, Adelaide, SA, Australia; [Clark, Katherine] Univ Notre Dame, Cunningham Ctr Palliat Care, Sydney, NSW, Australia; [Young, Iven H.] Univ Sydney, Cent Clin Sch Med, Sydney, NSW 2006, Australia; [Bull, Janet] Four Seasons, Flat Rock, NC USA; [Wilcock, Andrew] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Booth, Sara] Univ Cambridge, Cambridge, England; [Tulsky, James A.] Vet Adm Med Ctr, Ctr Hlth Serv Res, Durham, NC USA; [Crockett, Alan J.] Univ Adelaide, Discipline Gen Practice, Adelaide, SA, Australia	Duke University; Duke University; Duke University; Duke University; Flinders University South Australia; Flinders University South Australia; Flinders University South Australia; University of Notre Dame Australia; University of Sydney; Nottingham University Hospital NHS Trust; University of Cambridge; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Adelaide	Abernethy, AP (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Box 3436, Durham, NC 27710 USA.	amy.abernethy@duke.edu	Crockett, Alan J/F-4553-2013; Crockett, Alan Joseph/K-3859-2019; McDonald, Christine Faye/AAU-9083-2021; Wilcock, Andrew/A-9396-2012	Frith, Peter Anthony/0000-0003-3265-0131; Booth, Sara/0000-0003-2996-4578; Abernethy, Amy/0000-0001-6930-8722; Wilcock, Andrew/0000-0002-3214-1188; Currow, David/0000-0003-1988-1250	AstraZeneca; GlaxoSmithKline; Boehringer Ingelheim; US National Institutes of Health (NIH) [R01 AG026469]; Australian National Health and Medical Research Council [324770, 375127]; Duke Institute for Care at the End of Life; Doris Duke Charitable Foundation; NATIONAL INSTITUTE ON AGING [R01AG026469] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Boehringer Ingelheim(Boehringer Ingelheim); US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Duke Institute for Care at the End of Life; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	CFM has received honoraria for presenting at scientific meetings sponsored by AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim and has served as an advisory board member for these same corporations. JB is on the speaker's bureau for Wyeth Pharmaceuticals, Pfizer, and Meda Pharmaceuticals. All other authors declare that they have no conflicts of interest.; This study was funded through grants from the US National Institutes of Health (NIH; R01 AG026469), Australian National Health and Medical Research Council (324770 and 375127), Duke Institute for Care at the End of Life, and Doris Duke Charitable Foundation. None of the study sponsors had a role in the conduct of this study or its reporting, except through the input of the Data Safety Monitoring Board as mandated by the NIH. We thank the many patients with advanced life-limiting illness who generously participated in this study, and their carers. We also thank Bernadette Kenny and Belinda Fazekas (Southern Adelaide Palliative Services, Adelaide, Australia) for their important contributions in study and data management, and David Woods (Tasmania Statewide Palliative Care Service, Australia) for his assistance with participant recruitment in Tasmania, Australia.	Abernethy AP, 2008, PROG PALLIAT CARE, V16, P15, DOI 10.1179/096992608X291243; Abernethy AP, 2005, PALLIATIVE MED, V19, P168, DOI 10.1177/026921630501900219; Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Bausewein C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005623.pub2; Booth S, 1996, AM J RESP CRIT CARE, V153, P1515, DOI 10.1164/ajrccm.153.5.8630595; Booth S, 2004, RESP MED, V98, P66, DOI 10.1016/j.rmed.2003.08.008; Bruera E, 2003, PALLIATIVE MED, V17, P659, DOI 10.1191/0269216303pm826oa; BURGESS KR, 1988, J APPL PHYSIOL, V64, P371, DOI 10.1152/jappl.1988.64.1.371; Cohen SR, 1997, PALLIATIVE MED, V11, P3; Cranston JM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004769.pub2; Currow DC, 2007, J PAIN SYMPTOM MANAG, V34, P113, DOI 10.1016/j.jpainsymman.2007.03.004; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Fierro-Carrion G, 2004, CHEST, V125, P77, DOI 10.1378/chest.125.1.77; Fisher R.A., 1963, STAT TABLES BIOL AGR, V6th; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALBRAITH S, 2008, DOES HANDHELD FAN IM; Guyatt GH, 2000, CHEST, V118, P1303, DOI 10.1378/chest.118.5.1303; Gysels M, 2008, J PAIN SYMPTOM MANAG, V36, P451, DOI 10.1016/j.jpainsymman.2007.11.008; HEYSEMOORE LH, 1993, DYSPNOEA ADV CANC; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Mercadante S, 2000, J PAIN SYMPTOM MANAG, V20, P104, DOI 10.1016/S0885-3924(00)00160-3; Nonoyama ML, 2007, AM J RESP CRIT CARE, V176, P343, DOI 10.1164/rccm.200702-308OC; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; ODONOHUE WJ, 1995, CHEST, V107, P301, DOI 10.1378/chest.107.2.301; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Robb BW, 2003, J BURN CARE REHABIL, V24, P403, DOI 10.1097/01.BCR.0000096275.27946.68; SCHWARTZSTEIN RM, 1987, AM REV RESPIR DIS, V136, P58, DOI 10.1164/ajrccm/136.1.58; Tanaka K, 2002, J PAIN SYMPTOM MANAG, V23, P484, DOI 10.1016/S0885-3924(02)00394-9; Tierney RM, 1998, PALLIATIVE MED, V12, P333, DOI 10.1191/026921698670933919; Uronis HE, 2008, BRIT J CANCER, V98, P294, DOI 10.1038/sj.bjc.6604161; URONIS HE, 2007, COCHRANE DB SYST REV, V2; Uronis Hope E, 2006, Int J Chron Obstruct Pulmon Dis, V1, P289, DOI 10.2147/copd.2006.1.3.289; Uronis Hope E, 2008, Curr Opin Support Palliat Care, V2, P89, DOI 10.1097/SPC.0b013e3282ff0f5d; Young IH, 1998, MED J AUSTRALIA, V168, P21, DOI 10.5694/j.1326-5377.1998.tb123340.x	38	272	277	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					784	793		10.1016/S0140-6736(10)61115-4	http://dx.doi.org/10.1016/S0140-6736(10)61115-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816546	Green Accepted			2022-12-28	WOS:000281831000029
J	Chao, MP; Alizadeh, AA; Tang, C; Myklebust, JH; Varghese, B; Gill, S; Jan, M; Cha, AC; Chan, CK; Tan, BT; Park, CY; Zhao, FF; Kohrt, HE; Malumbres, R; Briones, J; Gascoyne, RD; Lossos, IS; Levy, R; Weissman, IL; Majeti, R				Chao, Mark P.; Alizadeh, Ash A.; Tang, Chad; Myklebust, June H.; Varghese, Bindu; Gill, Saar; Jan, Max; Cha, Adriel C.; Chan, Charles K.; Tan, Brent T.; Park, Christopher Y.; Zhao, Feifei; Kohrt, Holbrook E.; Malumbres, Raquel; Briones, Javier; Gascoyne, Randy D.; Lossos, Izidore S.; Levy, Ronald; Weissman, Irving L.; Majeti, Ravindra			Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma	CELL			English	Article							B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; DRUG-COMBINATION; CD20 EXPRESSION; CD47; THERAPY; MECHANISMS	Monoclonal antibodies are standard therapeutics for several cancers including the anti-CD20 antibody rituximab for B cell non-Hodgkin lymphoma (NHL). Rituximab and other antibodies are not curative and must be combined with cytotoxic chemotherapy for clinical benefit. Here we report the eradication of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking anti-CD47 antibody. We identified increased expression of CD47 on human NHL cells and determined that higher CD47 expression independently predicted adverse clinical outcomes in multiple NHL subtypes. Blocking anti-CD47 antibodies preferentially enabled phagocytosis of NHL cells and synergized with rituximab. Treatment of human NHL-engrafted mice with anti-CD47 antibody reduced lymphoma burden and improved survival, while combination treatment with rituximab led to elimination of lymphoma and cure. These antibodies synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers.	[Chao, Mark P.; Alizadeh, Ash A.; Tang, Chad; Jan, Max; Cha, Adriel C.; Chan, Charles K.; Park, Christopher Y.; Zhao, Feifei; Weissman, Irving L.; Majeti, Ravindra] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford Canc Ctr, Palo Alto, CA 94304 USA; [Chao, Mark P.; Alizadeh, Ash A.; Tang, Chad; Jan, Max; Cha, Adriel C.; Chan, Charles K.; Park, Christopher Y.; Zhao, Feifei; Weissman, Irving L.; Majeti, Ravindra] Stanford Univ, Ludwig Ctr Stanford, Palo Alto, CA 94304 USA; [Alizadeh, Ash A.; Kohrt, Holbrook E.; Majeti, Ravindra] Stanford Univ, Dept Internal Med, Div Hematol, Palo Alto, CA 94304 USA; [Alizadeh, Ash A.; Myklebust, June H.; Varghese, Bindu; Kohrt, Holbrook E.; Levy, Ronald] Stanford Univ, Div Oncol, Palo Alto, CA 94304 USA; [Tan, Brent T.; Park, Christopher Y.; Weissman, Irving L.] Stanford Univ, Dept Pathol, Palo Alto, CA 94304 USA; [Gill, Saar] Stanford Univ, Div Blood & Bone Marrow Transplantat, Palo Alto, CA 94304 USA; [Malumbres, Raquel; Lossos, Izidore S.] Univ Miami, Miller Sch Med, Div Hematol Oncol, Dept Med, Miami, FL 33136 USA; [Briones, Javier] Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Hematol, E-08193 Barcelona, Spain; [Gascoyne, Randy D.] British Columbia Canc Agcy, Dept Pathol, Vancouver, BC V5Z 1L3, Canada; [Myklebust, June H.] Univ Oslo, Inst Canc Res, Dept Immunol, Oslo Univ Hosp,Ctr Canc Biomed, N-0310 Oslo, Norway	Stanford Cancer Institute; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; University of Miami; Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; British Columbia Cancer Agency; University of Oslo	Chao, MP (corresponding author), Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford Canc Ctr, Palo Alto, CA 94304 USA.	mpchao@stanford.edu	Myklebust, June Helen/ABH-6494-2020; Malumbres, Raquel/N-3745-2014; Alizadeh, Ash A/C-5594-2009	Myklebust, June Helen/0000-0003-0394-9986; Malumbres, Raquel/0000-0003-0767-9442; Alizadeh, Ash A/0000-0002-5153-5625; Majeti, Ravindra/0000-0002-5814-0984; Tan, Brent/0000-0001-7375-6878; Levy, Ronald/0000-0003-2061-0650; Briones Meijide, Javier/0000-0003-2750-3735	HHMI; Stanford Cancer Biology Program; NIH [HL007970, CA122105, P01CA139490]; Fundacion Caja Madrid; AACR; Burroughs Wellcome Fund; Smith Family Fund; NATIONAL CANCER INSTITUTE [R01CA122105, P01CA139490, T32CA009302] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007970, R01HL058770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290, P30AI073961] Funding Source: NIH RePORTER	HHMI(Howard Hughes Medical Institute); Stanford Cancer Biology Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fundacion Caja Madrid; AACR; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Smith Family Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors acknowledge Dr. Christopher Contag for providing luciferase constructs, Dr. Robert Negrin for assistance, Dr. Yaso Natkunam for immunohistochemistry, Libuse Jerabek and Theresa Storm for lab management, and Adriane Mosely for animal husbandry. We also acknowledge the patients and surgeons including Drs. Wapnir, Chang, Cheng, Janisiewicz, Koltai, Liebowitz, and Messner for providing research specimens. M.P.C. is supported by the HHMI and the Stanford Cancer Biology Program, A.A.A. by an NIH T32 Ruth L. Kirschstein National Research Service Award (HL007970), R. Malumbres by a fellowship from Fundacion Caja Madrid, I.S.L. by NIH grant CA122105, and R. Majeti by a grant from the AACR. R. Majeti holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund. I.L.W., M.P.C., A.A.A., and R. Majeti have filed U.S. Patent Application Serial No. 12/321,215 entitled "Methods For Manipulating Phagocytosis Mediated by CD47.'' This research is supported by NIH grant P01CA139490 to I.L.W. and funding from the Smith Family Fund.	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Cheson BD, 2008, NEW ENGL J MED, V359, P613, DOI 10.1056/NEJMra0708875; Chou TC, 2008, LEUKEMIA LYMPHOMA, V49, P2059, DOI 10.1080/10428190802353591; Daniel D, 2007, BLOOD, V110, P4037, DOI 10.1182/blood-2007-02-076075; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Foran JM, 2001, BRIT J HAEMATOL, V114, P881, DOI 10.1046/j.1365-2141.2001.03019.x; Glennie MJ, 2007, MOL IMMUNOL, V44, P3823, DOI 10.1016/j.molimm.2007.06.151; Hiraga J, 2009, BLOOD, V113, P4885, DOI 10.1182/blood-2008-08-175208; Jaiswal S, 2010, TRENDS IMMUNOL, V31, P212, DOI 10.1016/j.it.2010.04.001; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; Kikuchi Y, 2005, LEUKEMIA RES, V29, P445, DOI 10.1016/j.leukres.2004.09.005; Kikuchi Y, 2004, BIOCHEM BIOPH RES CO, V315, P912, DOI 10.1016/j.bbrc.2004.01.128; Kim MJ, 2008, TUMOR BIOL, V29, P28, DOI 10.1159/000132568; Leonard JP, 2007, ANN ONCOL, V18, P1216, DOI 10.1093/annonc/mdm114; Leonard JP, 2008, CANCER-AM CANCER SOC, V113, P2714, DOI 10.1002/cncr.23890; Leonard JP, 2005, J CLIN ONCOL, V23, P5044, DOI 10.1200/JCO.2005.13.821; Maddipatla S, 2007, CLIN CANCER RES, V13, P4556, DOI 10.1158/1078-0432.CCR-07-0680; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; Milush JM, 2009, BLOOD, V114, P4823, DOI 10.1182/blood-2009-04-216374; Nimmerjahn F, 2007, CURR OPIN IMMUNOL, V19, P239, DOI 10.1016/j.coi.2007.01.005; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Tallarida RJ, 2006, J PHARMACOL EXP THER, V319, P1, DOI 10.1124/jpet.106.104117; Taylor RP, 2008, CURR OPIN IMMUNOL, V20, P444, DOI 10.1016/j.coi.2008.05.011; Uno S, 2007, ONCOL REP, V17, P1189	37	713	791	2	105	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5					699	713		10.1016/j.cell.2010.07.044	http://dx.doi.org/10.1016/j.cell.2010.07.044			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813259	Bronze, Green Accepted			2022-12-28	WOS:000281523200014
J	Wells, TNC				Wells, Timothy N. C.			Is the Tide Turning for New Malaria Medicines?	SCIENCE			English	Editorial Material							PLASMODIUM-FALCIPARUM; RESISTANCE; DRUGS		MMV, Geneva, Switzerland		Wells, TNC (corresponding author), MMV, 20 Route Pre Bois,POB 1826, Geneva, Switzerland.	wellst@mmv.org		Wells, Timothy/0000-0001-9796-847X				Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107; Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099; Payne DJ, 2007, NAT REV DRUG DISCOV, V6, P29, DOI 10.1038/nrd2201; Plouffe D, 2008, P NATL ACAD SCI USA, V105, P9059, DOI 10.1073/pnas.0802982105; Rottmann M, 2010, SCIENCE, V329, P1175, DOI 10.1126/science.1193225; Talisuna AO, 2004, CLIN MICROBIOL REV, V17, P235, DOI 10.1128/CMR.17.1.235-254.2004; Wells TNC, 2010, TRENDS PARASITOL, V26, P145, DOI 10.1016/j.pt.2009.12.005; Wells TNC, 2009, NAT REV DRUG DISCOV, V8, P879, DOI 10.1038/nrd2972; White NJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S8	10	33	35	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2010	329	5996					1153	1154		10.1126/science.1194923	http://dx.doi.org/10.1126/science.1194923			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	645SG	20813940				2022-12-28	WOS:000281485600018
J	Reddy, VS; Natchiar, SK; Stewart, PL; Nemerow, GR				Reddy, Vijay S.; Natchiar, S. Kundhavai; Stewart, Phoebe L.; Nemerow, Glen R.			Crystal Structure of Human Adenovirus at 3.5 angstrom Resolution	SCIENCE			English	Article							CRYOELECTRON MICROSCOPY STRUCTURE; PROTEIN; VECTOR; INFECTIVITY; REVEALS; PENTON; TRIALS	Rational development of adenovirus vectors for therapeutic gene transfer is hampered by the lack of accurate structural information. Here, we report the x-ray structure at 3.5 angstrom resolution of the 150-megadalton adenovirus capsid containing nearly 1 million amino acids. We describe interactions between the major capsid protein (hexon) and several accessory molecules that stabilize the capsid. The virus structure also reveals an altered association between the penton base and the trimeric fiber protein, perhaps reflecting an early event in cell entry. The high-resolution structure provides a substantial advance toward understanding the assembly and cell entry mechanisms of a large double-stranded DNA virus and provides new opportunities for improving adenovirus-mediated gene transfer.	[Reddy, Vijay S.; Natchiar, S. Kundhavai; Nemerow, Glen R.] Scripps Res Inst, La Jolla, CA 92037 USA; [Stewart, Phoebe L.] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA	Scripps Research Institute; Vanderbilt University	Reddy, VS (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gnemerow@scripps.edu; reddyv@scripps.edu			National Cancer Institute [Y1-CO-1020]; National Institute of General Medical Science [Y1-GM-1104]; U.S. Department of Energy, Basic Energy Sciences, Office of Science [DE-AC02-06CH11357]; NIH [R01 AI070771, HL054352, EY011431, AI042929]; NATIONAL EYE INSTITUTE [R01EY011431] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070771, R01AI042929, R29AI042929] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U.S. Department of Energy, Basic Energy Sciences, Office of Science(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors express their deep gratitude to J. E. Johnson for advice and guidance during all phases of the structure determination and for reading the manuscript; T.-M. Mullen and L. Gritton for the outstanding technical support for vector production; S. Venkataraman for help with the early crystallization setups of HAdV; I. Mathews of the Stanford Synchrotron Radiation Lightsource for initial help with the data collection; W. Minor and I. Minor for generously providing the larger version of the SCALEPACK program; E. Ollmann-Saphire and J. G. Smith for comments on the manuscript; T. McCarthy for preparation of this paper; and R. Fischetti, N. Sanishvili, and other members at General Medicine and Cancer Institutes Collaborative Access Team (GM/CA CAT) for discussions and technical support. GM/CA CAT has been funded in whole or in part with federal funds from the National Cancer Institute (Y1-CO-1020) and the National Institute of General Medical Science (Y1-GM-1104). The use of the Advance Photon Source was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science (contract no. DE-AC02-06CH11357). The coordinates of Ad35F crystal structure have been deposited in the Protein Data Bank (PDB) with the identification code 1VSZ. This work was supported by NIH grants R01 AI070771 to V. S. R., HL054352 and EY011431 to G.R.N., and AI042929 to P.L.S. This is manuscript no. 20538 from the Scripps Research Institute. G.R.N. holds a patent titled "Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use" (patent no. 7,232,899).	Butt AL, 2006, CORNEA, V25, P199, DOI 10.1097/01.ico.0000170693.13326.fb; Campos SK, 2007, CURR GENE THER, V7, P189, DOI 10.2174/156652307780859062; Edelstein ML, 2004, J GENE MED, V6, P597, DOI 10.1002/jgm.619; Fabry CMS, 2005, EMBO J, V24, P1645, DOI 10.1038/sj.emboj.7600653; Fuschiotti P, 2006, J MOL BIOL, V356, P510, DOI 10.1016/j.jmb.2005.11.048; Gordon YJ, 1996, INVEST OPHTH VIS SCI, V37, P2774; Henry TD, 2007, J AM COLL CARDIOL, V50, P1038, DOI 10.1016/j.jacc.2007.06.010; HILLEMAN MR, 1954, P SOC EXP BIOL MED, V85, P183, DOI 10.3181/00379727-85-20825; Hoffman R, 2006, NETW COMPUT, V17, P18; Lenaerts L, 2008, REV MED VIROL, V18, P357, DOI 10.1002/rmv.589; Metzgar D, 2007, J INFECT DIS, V196, P1465, DOI 10.1086/522970; Reddy VS, 2010, VIROLOGY, V402, P209, DOI 10.1016/j.virol.2010.03.028; Saban SD, 2005, J MOL BIOL, V349, P526, DOI 10.1016/j.jmb.2005.04.034; Saban SD, 2006, J VIROL, V80, P12049, DOI 10.1128/JVI.01652-06; Shayakhmetov DM, 2000, J VIROL, V74, P10274, DOI 10.1128/JVI.74.22.10274-10286.2000; Silvestry M, 2009, J VIROL, V83, P7375, DOI 10.1128/JVI.00331-09; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; von Seggern DJ, 1999, J VIROL, V73, P1601, DOI 10.1128/JVI.73.2.1601-1608.1999; Wiethoff CM, 2005, J VIROL, V79, P1992, DOI 10.1128/JVI.79.4.1992-2000.2005; Zubieta C, 2005, MOL CELL, V17, P121, DOI 10.1016/j.molcel.2004.11.041	22	173	176	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1071	1075		10.1126/science.1187292	http://dx.doi.org/10.1126/science.1187292			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798318	Green Accepted			2022-12-28	WOS:000281253500039
J	Burns, EM; Naseem, H; Bottle, A; Lazzarino, AI; Aylin, P; Darzi, A; Moorthy, K; Faiz, O				Burns, Elaine M.; Naseem, Haris; Bottle, Alex; Lazzarino, Antonio Ivan; Aylin, Paul; Darzi, Ara; Moorthy, Krishna; Faiz, Omar			Introduction of laparoscopic bariatric surgery in England: observational population cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-SERVICE TRUSTS; LONG-TERM MORTALITY; GASTRIC BYPASS; OBESITY SURGERY; PROCEDURE VOLUME; MORBID-OBESITY; OUTCOMES; RISK; MULTICENTER; IMPACT	Objectives To describe national trends in bariatric surgery and examine the factors influencing outcome in bariatric surgery in England. Design Observational population cohort study. Setting Hospital Episode Statistics database. Participants All patients who had primary gastric bypass, gastric banding, or sleeve gastrectomy procedures between April 2000 and March 2008. Main outcome measures 30 day mortality, mortality at one year after surgery, unplanned readmission to hospital within 28 days, and duration of stay in hospital. Results 6953 primary bariatric procedures were carried out during the study period, of which 3649 were gastric band procedures, 3191 were gastric bypass procedures, and 113 were sleeve gastrectomy procedures. A marked increase occurred in the numbers of bariatric procedures done, from 238 in 2000 to 2543 in 2007, with an increase in the percentage of laparoscopic procedures over the study period (28% (66/238) laparoscopic procedures in 2000 compared with 74.5% (1894/2543) in 2007). Overall, 0.3% (19/6953) patients died within 30 days of surgery. The median length of stay in hospital was 3 (interquartile range 2-6) days. An unplanned readmission to hospital within 28 days of surgery occurred in 8% (556/6953) of procedures. No significant increase in mortality or unplanned readmission was seen over the study period, despite the exponential increase in minimal access surgery and consequently bariatric surgery. Conclusions Bariatric surgery has increased exponentially in England. Although postoperative weight loss and reoperation rates were not evaluated in this observational population cohort study, patients selected for gastric banding had lower postoperative mortality and readmission rates and a shorter length of stay than did those selected for gastric bypass.	[Burns, Elaine M.; Naseem, Haris; Darzi, Ara; Moorthy, Krishna; Faiz, Omar] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Surg, London W2 1NY, England; [Bottle, Alex; Lazzarino, Antonio Ivan; Aylin, Paul] Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, Foster Unit, London EC1A 9LA, England	Imperial College London; Imperial College London	Faiz, O (corresponding author), Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Biosurg & Surg Technol, London W2 1NY, England.	omarfaiz@aol.com	Aylin, Paul/A-1073-2014; Lazzarino, Antonio Ivan/F-9011-2010; Burns, Elaine/V-5416-2019	Lazzarino, Antonio Ivan/0000-0001-8045-2346; Moorthy, Krishna/0000-0001-8960-465X; Bottle, Alex/0000-0001-9978-2011; Aylin, Paul/0000-0003-4589-1743	National Institute of Health Research; NIHR Biomedical Research Centre; Dr Foster Intelligence (an independent health service research organisation)	National Institute of Health Research(National Institute for Health Research (NIHR)); NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Dr Foster Intelligence (an independent health service research organisation)	The Dr Foster Unit at Imperial is affiliated with the Centre for Patient Safety and Service Quality at Imperial College Healthcare NHS Trust, which is funded by the National Institute of Health Research. We are grateful for support from the NIHR Biomedical Research Centre funding scheme. The unit is largely funded by a research grant from Dr Foster Intelligence (an independent health service research organisation).	Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603; Aylin P, 2007, EUR J VASC ENDOVASC, V33, P461, DOI 10.1016/j.ejvs.2006.10.033; Aylin P, 2007, BRIT MED J, V335, P839, DOI 10.1136/bmj.39374.474965.BE; Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898; Borowski DW, 2007, BRIT J SURG, V94, P880, DOI 10.1002/bjs.5721; Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724; Buchwald H, 2002, OBES SURG, V12, P705, DOI 10.1381/096089202321019747; Buchwald H, 2009, OBES SURG, V19, P1605, DOI 10.1007/s11695-009-0014-5; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christou NV, 2004, ANN SURG, V240, P416, DOI 10.1097/01.sla.0000137343.63376.19; Colquitt J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003641.pub2; DeMaria EJ, 2007, ANN SURG, V246, P578, DOI 10.1097/SLA.0b013e318157206e; Ells LJ, 2007, OBES SURG, V17, P400, DOI 10.1007/s11695-007-9070-x; Faiz O, 2009, DIS COLON RECTUM, V52, P1695, DOI 10.1007/DCR.0b013e3181b55254; Faiz O, 2010, DIS COLON RECTUM, V53, P393, DOI 10.1007/DCR.0b013e3181cc6fd2; Garb J, 2009, OBES SURG, V19, P1447, DOI 10.1007/s11695-009-9927-2; Gill L, 2003, ENGLISH NATL RECORD; Hamoui N, 2006, OBES SURG, V16, P1445, DOI 10.1381/096089206778870157; Hinojosa MW, 2009, SURG OBES RELAT DIS, V5, P150, DOI 10.1016/j.soard.2008.08.006; Kennedy ED, 2006, DIS COLON RECTUM, V49, P958, DOI 10.1007/s10350-006-0521-6; Kolotkin RL, 2008, SURG OBES RELAT DIS, V4, P651, DOI 10.1016/j.soard.2008.04.012; Lancaster RT, 2008, SURG ENDOSC, V22, P2554, DOI 10.1007/s00464-008-0074-y; le Roux CW, 2007, ANN SURG, V246, P780, DOI 10.1097/SLA.0b013e3180caa3e3; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; *NAT I HLTH CLIN E, 2002, GUID US SURG AID WEI; NGUYEN NT, 2009, ANN SURG; RAND CSW, 1993, INT J OBESITY, V17, P657; Schauer P, 2003, SURG ENDOSC, V17, P212, DOI 10.1007/s00464-002-8857-z; Schirmer B, 2006, SURG ENDOSC, V20, P450, DOI 10.1007/s00464-006-0055-y; Schirmer Bruce, 2007, Bull Am Coll Surg, V92, P21; Schrag D, 2000, JAMA-J AM MED ASSOC, V284, P3028, DOI 10.1001/jama.284.23.3028; Schrag D, 2002, ANN SURG, V236, P583, DOI 10.1097/00000658-200211000-00008; Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254; Spiegelhalter DJ, 2002, BRIT MED J, V324, P261, DOI 10.1136/bmj.324.7332.261	34	61	62	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 26	2010	341								c4296	10.1136/bmj.c4296	http://dx.doi.org/10.1136/bmj.c4296			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645II	20798224	hybrid, Green Accepted			2022-12-28	WOS:000281446100001
J	Kogan, MD; Newacheck, PW; Blumberg, SJ; Ghandour, RM; Singh, GK; Strickland, BB; van Dyck, PC				Kogan, Michael D.; Newacheck, Paul W.; Blumberg, Stephen J.; Ghandour, Reem M.; Singh, Gopal K.; Strickland, Bonnie B.; van Dyck, Peter C.			Underinsurance among Children in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE NEEDS; INSURANCE; ACCESS; IMPACT; GAPS	BACKGROUND Recent interest in policy regarding children's health insurance has focused on expanding coverage. Less attention has been devoted to the question of whether insurance sufficiently meets children's needs. METHODS We estimated underinsurance among U. S. children on the basis of data from the 2007 National Survey of Children's Health (sample size, 91,642 children) regarding parents' or guardians' judgments of whether their children's insurance covered needed services and providers and reasonably covered costs. Data on adequacy were combined with data on continuity of insurance coverage to classify children as never insured during the past year, sometimes insured during the past year, continuously insured but inadequately covered (i.e., underinsured), and continuously insured and adequately covered. We examined the association between this classification and five overall indicators of health care access and quality: delayed or forgone care, difficulty obtaining needed care from a specialist, no preventive care, no developmental screening at a preventive visit, and care not meeting the criteria of a medical home. RESULTS We estimated that in 2007, 11 million children were without health insurance for all or part of the year, and 22.7% of children with continuous insurance coverage - 14.1 million children - were underinsured. Older children, Hispanic children, children in fair or poor health, and children with special health care needs were more likely to be underinsured. As compared with children who were continuously and adequately insured, uninsured and underinsured children were more likely to have problems with health care access and quality. CONCLUSIONS The number of underinsured children exceeded the number of children without insurance for all or part of the year studied. Access to health care and the quality of health care are suboptimal for uninsured and underinsured children. (Funded by the Health Resources and Services Administration.)	[Kogan, Michael D.; Ghandour, Reem M.; Singh, Gopal K.; Strickland, Bonnie B.; van Dyck, Peter C.] US Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, US Dept HHS, Rockville, MD 20857 USA; [Blumberg, Stephen J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; [Newacheck, Paul W.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA; [Newacheck, Paul W.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	United States Health Resources & Service Administration (HRSA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kogan, MD (corresponding author), US Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, US Dept HHS, 5600 Fishers Ln,Rm 18-41, Rockville, MD 20857 USA.	mkogan@hrsa.gov		Blumberg, Stephen/0000-0002-2086-4768	Health Resources and Services Administration	Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA))	Funded by the Health Resources and Services Administration	[Anonymous], 2004, CHARTBOOK MENTAL HLT; Bethell CD, 2002, AMBUL PEDIATR, V2, P38, DOI 10.1367/1539-4409(2002)002<0038:ICWSHC>2.0.CO;2; Blewett LA, 2006, MED CARE RES REV, V63, P663, DOI 10.1177/1077558706293634; BLUMBERG SJ, 2007, VITAL HLTH STAT, V1; Blythe MJ, 2009, PEDIATRICS, V123, P191, DOI 10.1542/peds.2008-3308; Bramlett MD, 2009, MATERN CHILD HLTH J, V13, P151, DOI 10.1007/s10995-008-0339-z; Cassedy A, 2008, AMBUL PEDIATR, V8, P321, DOI 10.1016/j.ambp.2008.04.007; *CENS BUR, 2008, GLOSS CENS 2000 GEOG; Census Bureau, 2009, STAT ABSTR US 2010; Center for Mental Health Services and National Institute of Mental Health, 1999, MENT HLTH REP SURG G; Donelan K, 2000, MedGenMed, V2, pE37; Federico SG, 2007, PEDIATRICS, V120, pe1009, DOI 10.1542/peds.2006-3094; Halterman JS, 2008, AMBUL PEDIATR, V8, P43, DOI 10.1016/j.ambp.2007.10.005; Health Resources and Services Administration Maternal and Child Health Bureau, 2007, NAT SURV CHILDR SPEC; Honberg L, 2005, PEDIATRICS, V115, P1233, DOI 10.1542/peds.2004-1503; Honberg LE, 2009, PEDIATRICS, V124, P1273, DOI 10.1542/peds.2009-0372; Jeffrey AE, 2006, PEDIATRICS, V118, pE1027, DOI 10.1542/peds.2005-2527; Kogan MD, 2005, PEDIATRICS, V116, P1162, DOI 10.1542/peds.2004-2432; KOGAN MD, 1995, JAMA-J AM MED ASSOC, V274, P1429, DOI 10.1001/jama.274.18.1429; Kogan MD, 2010, PEDIATRICS, V125, P673, DOI 10.1542/peds.2009-1055; McPherson M, 1998, PEDIATRICS, V102, P137, DOI 10.1542/peds.102.1.137; Olson LM, 2005, NEW ENGL J MED, V353, P382, DOI 10.1056/NEJMsa043878; Oswald DP, 2007, PEDIATRICS, V119, pE341, DOI 10.1542/peds.2006-2218; Oswald DP, 2005, MATERN CHILD HLTH J, V9, pS67, DOI 10.1007/s10995-005-4749-x; Parish SL, 2006, SOC WORK, V51, P223, DOI 10.1093/sw/51.3.223; Schoen C, 2008, HEALTH AFFAIR, V27, pW298, DOI 10.1377/hlthaff.27.4.w298; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; Sia CJ, 2002, PEDIATRICS, V110, P184; Szilagyi PG, 2009, ACAD PEDIATR, V9, P4, DOI 10.1016/j.acap.2008.12.002; Ward A, 2006, J MED PHILOS, V31, P499, DOI 10.1080/03605310600912691	30	84	84	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					841	851		10.1056/NEJMsa0909994	http://dx.doi.org/10.1056/NEJMsa0909994			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642HG	20818845				2022-12-28	WOS:000281196600007
J	Rao, P; Hayden, MS; Long, MX; Scott, ML; West, AP; Zhang, DK; Oeckinghaus, A; Lynch, C; Hoffmann, A; Baltimore, D; Ghosh, S				Rao, Ping; Hayden, Mathew S.; Long, Meixiao; Scott, Martin L.; West, A. Philip; Zhang, Dekai; Oeckinghaus, Andrea; Lynch, Candace; Hoffmann, Alexander; Baltimore, David; Ghosh, Sankar			I kappa B beta acts to inhibit and activate gene expression during the inflammatory response	NATURE			English	Article							TUMOR NECROSIS FACTOR; C-REL; RHEUMATOID-ARTHRITIS; DEFICIENT MICE; DNA-BINDING; ALPHA; PHOSPHORYLATION; BIOSYNTHESIS; SIMILARITIES; SEQUENCES	The activation of pro-inflammatory gene programs by nuclear factor-kappa B (NF-kappa B) is primarily regulated through cytoplasmic sequestration of NF-kappa B by the inhibitor of kappa B (I kappa B) family of proteins(1). I kappa B beta, a major isoform of I kappa B, can sequester NF-kappa B in the cytoplasm(2), although its biological role remains unclear. Although cells lacking IkBb have been reported(3,4), in vivo studies have been limited and suggested redundancy between I kappa B alpha and I kappa B beta(5). Like I kappa B alpha, I kappa B beta is also inducibly degraded; however, upon stimulation by lipopolysaccharide (LPS), it is degraded slowly and re-synthesized as a hypophosphorylated form that can be detected in the nucleus(6-11). The crystal structure of I kappa B beta bound to p65 suggested this complex might bind DNA(12). In vitro, hypophosphorylated I kappa B beta can bind DNA with p65 and c-Rel, and the DNA-bound NF-kappa B:I kappa B beta complexes are resistant to I kappa B alpha, suggesting hypophosphorylated, nuclear I kappa B beta may prolong the expression of certain genes(9-11). Here we report that in vivo I kappa B beta serves both to inhibit and facilitate the inflammatory response. I kappa B beta degradation releases NF-kappa B dimers which upregulate proinflammatory target genes such as tumour necrosis factor-alpha (TNF-alpha). Surprisingly, absence of I kappa B beta results in a dramatic reduction of TNF-alpha in response to LPS even though activation of NF-kappa B is normal. The inhibition of TNF-alpha messenger RNA (mRNA) expression correlates with the absence of nuclear, hypophosphorylated-I kappa B beta bound to p65:c-Rel heterodimers at a specific kappa B site on the TNF-alpha promoter. Therefore I kappa B beta acts through p65:c-Rel dimers to maintain prolonged expression of TNF-alpha. As a result, I kappa B beta(-/-) mice are resistant to LPS-induced septic shock and collagen-induced arthritis. Blocking I kappa B beta might be a promising new strategy for selectively inhibiting the chronic phase of TNF-alpha production during the inflammatory response.	[Rao, Ping; Hayden, Mathew S.; Long, Meixiao; West, A. Philip; Zhang, Dekai; Oeckinghaus, Andrea; Ghosh, Sankar] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Rao, Ping; Hayden, Mathew S.; Long, Meixiao; West, A. Philip; Zhang, Dekai; Oeckinghaus, Andrea; Ghosh, Sankar] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Hayden, Mathew S.; Long, Meixiao; Oeckinghaus, Andrea; Ghosh, Sankar] Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA; [Scott, Martin L.; Baltimore, David] CALTECH, Dept Biol, Pasadena, CA 91125 USA; [Lynch, Candace; Hoffmann, Alexander] Univ Calif San Diego, Signaling Syst Lab, Dept Chem & Biochem, La Jolla, CA 92093 USA	Yale University; Yale University; Columbia University; California Institute of Technology; University of California System; University of California San Diego	Ghosh, S (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 333 Cedar St, New Haven, CT 06520 USA.	sg2715@columbia.edu	West, A. Phillip/W-8171-2019; Oeckinghaus, Andrea/AAW-9933-2020; West, A. Phillip/A-7867-2009; Hayden, Matthew/C-1263-2008	West, A. Phillip/0000-0003-2884-6895; Hayden, Matthew/0000-0003-1670-6430	National Institutes of Health [R37-AI03343]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083453, R37AI033443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071573] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Lin at the Yale W. M. Keck Biostatistics Resource for analysis of microarray data. S. G. was supported by grants from the National Institutes of Health (R37-AI03343).	BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; ERNST MK, 1995, MOL CELL BIOL, V15, P872; EVANS GF, 1989, CIRC SHOCK, V29, P279; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Goudeau B, 2003, P NATL ACAD SCI USA, V100, P15800, DOI 10.1073/pnas.2535880100; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hertlein E, 2005, MOL CELL BIOL, V25, P4956, DOI 10.1128/MCB.25.12.4956-4968.2005; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kuprash DV, 1999, J IMMUNOL, V162, P4045; Malek S, 2003, J BIOL CHEM, V278, P23094, DOI 10.1074/jbc.M301022200; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Memet S, 1999, J IMMUNOL, V163, P5994; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Weil R, 1997, J BIOL CHEM, V272, P9942	30	140	144	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					1115	U132		10.1038/nature09283	http://dx.doi.org/10.1038/nature09283			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740013	Green Accepted			2022-12-28	WOS:000281203600042
J	Chan, EYY; Griffiths, SM				Chan, Emily Y. Y.; Griffiths, Sian M.			The epidemiology of mine accidents in China	LANCET			English	Editorial Material							OCCUPATIONAL-HEALTH; SAFETY; TRENDS; COAL		[Chan, Emily Y. Y.; Griffiths, Sian M.] Chinese Univ Hong Kong, Fac Med, Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Chan, EYY (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China.	emily.chan@cuhk.edu.hk	Chan, Emily Ying Yang/H-6849-2017	Chan, Emily Ying Yang/0000-0002-8854-5093				BREXTON JJ, 1993, J AM ACAD CHILD ADOL, V32, P438; Elklit A, 1997, ACTA PSYCHIAT SCAND, V96, P1, DOI 10.1111/j.1600-0447.1997.tb05957.x; *EM DAT, 2010, DIS WEEK WEEK 12 APR; Em-DAT,, INT DIS DAT; Hirschberg S, 2003, CHINA ENERGY TECHNOL; Kirchsteiger C, 1999, J LOSS PREVENT PROC, V12, P7, DOI 10.1016/S0950-4230(98)00033-3; Maiti J, 2004, Inj Control Saf Promot, V11, P29, DOI 10.1076/icsp.11.1.29.26305; MOLE DM, 2006, MINING ACCIDENTS DIS, P853; Page K, 2009, J SAFETY RES, V40, P85, DOI 10.1016/j.jsr.2008.12.007; Pringle TE, 2003, INT J OCCUP ENV HEAL, V9, P309, DOI 10.1179/oeh.2003.9.4.309; Sanmiquel L, 2010, J SAFETY RES, V41, P1, DOI 10.1016/j.jsr.2009.09.008; Shen L, 2009, RESOUR POLICY, V34, P150, DOI 10.1016/j.resourpol.2009.01.003; Shi XP, 2009, J SAFETY RES, V40, P207, DOI 10.1016/j.jsr.2009.03.005; Uth HJ, 1999, J LOSS PREVENT PROC, V12, P69, DOI 10.1016/S0950-4230(98)00039-4; Wang S., 2006, J CONT CHINA, V15, P1, DOI [DOI 10.1080/10670560500331658, 10.1080/10670560500331658]; WEEKS JL, 1991, ANNU REV PUBL HEALTH, V12, P195, DOI 10.1146/annurev.pu.12.050191.001211; *WHO, 2003, MENT HLTH EM MENT SO; 2010, XINHUA NEWS     0413	18	8	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2010	376	9741					575	577		10.1016/S0140-6736(10)60660-5	http://dx.doi.org/10.1016/S0140-6736(10)60660-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	643PB	20728741				2022-12-28	WOS:000281309100009
J	Cohen-Bittan, J; Boddaert, J; Guettrot-Imbert, G; Leroux, G; Reiner, P; Psimaras, D; Piette, JC; Amoura, Z; Costedoat-Chalumeau, N				Cohen-Bittan, Judith; Boddaert, Jacques; Guettrot-Imbert, Gaelle; Leroux, Gaelle; Reiner, Peggy; Psimaras, Dimitri; Piette, Jean-Charles; Amoura, Zahir; Costedoat-Chalumeau, Nathalie			Atypical dementia	LANCET			English	Editorial Material							LIMBIC ENCEPHALITIS		[Cohen-Bittan, Judith; Guettrot-Imbert, Gaelle; Leroux, Gaelle; Reiner, Peggy; Piette, Jean-Charles; Amoura, Zahir; Costedoat-Chalumeau, Nathalie] Univ Paris 06, Hop La Pitie Salpetriere, AP HP, Serv Med Interne,Ctr Reference Natl Lupus Syst &, Paris, France; [Cohen-Bittan, Judith; Boddaert, Jacques] Univ Paris 06, Hop La Pitie Salpetriere, AP HP, Serv Geriatrie, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Costedoat-Chalumeau, N (corresponding author), CHU Pitie Salpetriere, Ctr Reference Natl Lupus Syst & Syndrome Antiphos, Serv Med Interne 2, 47-83 Blvd Hop, F-75651 Paris 13, France.	nathalie.costedoat@psl.aphp.fr	AMOURA, Zahir/P-5324-2017; Amoura, Zahir/P-5325-2017	AMOURA, Zahir/0000-0003-0292-9043; , nathalie/0000-0002-1555-9021				Bien CG, 2007, EPILEPSY BEHAV, V10, P529, DOI 10.1016/j.yebeh.2007.03.011; Daffner KR, 2008, NEW ENGL J MED, V359, P2155, DOI 10.1056/NEJMcpc0804643; Graus F, 2008, NEUROLOGY, V70, P500, DOI 10.1212/01.wnl.0000299189.43164.96; SMALL GW, 1982, LANCET, V2, P1443; Tuzun E, 2007, NEUROLOGIST, V13, P261, DOI 10.1097/NRL.0b013e31813e34a5	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2010	376	9741					656	656		10.1016/S0140-6736(10)60877-X	http://dx.doi.org/10.1016/S0140-6736(10)60877-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	643PB	20728757				2022-12-28	WOS:000281309100036
J	Kaochar, S; Paek, AL; Weinert, T				Kaochar, Salma; Paek, Andrew L.; Weinert, Ted			Replication Error Amplified	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; GENE AMPLIFICATION; DNA-REPLICATION; MECHANISMS; CANCER; REREPLICATION; CHROMOSOMES		[Kaochar, Salma; Paek, Andrew L.; Weinert, Ted] Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA	University of Arizona	Kaochar, S (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.	tweinert@email.arizona.edu		Paek, Andrew/0000-0002-2835-8544	NIGMS NIH HHS [T32 GM008659, R01 GM076186] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Blow JJ, 2008, NAT REV CANCER, V8, P799, DOI 10.1038/nrc2500; Debatisse M, 2005, ADV EXP MED BIOL, V570, P343, DOI 10.1007/1-4020-3764-3_12; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Green BM, 2006, MOL BIOL CELL, V17, P2401, DOI 10.1091/mbc.E05-11-1043; Green BM, 2010, SCIENCE, V329, P943, DOI 10.1126/science.1190966; Hook SS, 2007, CURR OPIN CELL BIOL, V19, P663, DOI 10.1016/j.ceb.2007.10.007; Kearsey SE, 2003, MOL CELL, V12, P1067, DOI 10.1016/S1097-2765(03)00441-6; Lockwood WW, 2008, ONCOGENE, V27, P4615, DOI 10.1038/onc.2008.98; McClintock B, 1941, GENETICS, V26, P234; PALMER RE, 1990, GENETICS, V125, P763; Tatsumi Y, 2006, J CELL SCI, V119, P3128, DOI 10.1242/jcs.03031	12	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2010	329	5994					911	913		10.1126/science.1194261	http://dx.doi.org/10.1126/science.1194261			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724625				2022-12-28	WOS:000281084800023
J	Zhao, MS; Running, SW				Zhao, Maosheng; Running, Steven W.			Drought-Induced Reduction in Global Terrestrial Net Primary Production from 2000 Through 2009	SCIENCE			English	Article							FORESTS GREEN-UP; CARBON; ECOSYSTEMS; HEAT; RESPIRATION; VARIABILITY; FEEDBACK; SINKS	Terrestrial net primary production (NPP) quantifies the amount of atmospheric carbon fixed by plants and accumulated as biomass. Previous studies have shown that climate constraints were relaxing with increasing temperature and solar radiation, allowing an upward trend in NPP from 1982 through 1999. The past decade (2000 to 2009) has been the warmest since instrumental measurements began, which could imply continued increases in NPP; however, our estimates suggest a reduction in the global NPP of 0.55 petagrams of carbon. Large-scale droughts have reduced regional NPP, and a drying trend in the Southern Hemisphere has decreased NPP in that area, counteracting the increased NPP over the Northern Hemisphere. A continued decline in NPP would not only weaken the terrestrial carbon sink, but it would also intensify future competition between food demand and proposed biofuel production.	[Zhao, Maosheng; Running, Steven W.] Univ Montana, Numer Terradynam Simulat Grp, Dept Ecosyst & Conservat Sci, Missoula, MT 59812 USA	University of Montana System; University of Montana	Zhao, MS (corresponding author), Univ Montana, Numer Terradynam Simulat Grp, Dept Ecosyst & Conservat Sci, Missoula, MT 59812 USA.	zhao@ntsg.umt.edu	Zhao, Maosheng/G-5706-2010		NASA [NNX08AG87A]	NASA(National Aeronautics & Space Administration (NASA))	We thank the reviewers and L. Jones, C. Cleveland, and Q. Mu for helpful comments. This work would not have been possible without continuous financial support from the NASA Earth Observing System MODIS project (grant NNX08AG87A). Moreover, we gratefully acknowledge all MODIS land product science team members for their efforts in generating high-quality data sets. NCEP_Reanalysis 2 data were provided by the NOAA/OAR/Earth System Research Laboratory Physical Sciences Division, Boulder, Colorado, USA, from their Web site at www.esrl.noaa.gov/psd/.	Allen CD, 2010, FOREST ECOL MANAG, V259, P660, DOI 10.1016/j.foreco.2009.09.001; Angert A, 2005, P NATL ACAD SCI USA, V102, P10823, DOI 10.1073/pnas.0501647102; Baldocchi D, 2008, AUST J BOT, V56, P1, DOI 10.1071/BT07151; Canadell Josep G., 2007, P1; Chen JM, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL025919; Ciais P, 2005, NATURE, V437, P529, DOI 10.1038/nature03972; Cox PM, 2000, NATURE, V408, P184, DOI 10.1038/35041539; Dai A, 2004, J HYDROMETEOROL, V5, P1117, DOI 10.1175/JHM-386.1; Davidson EA, 2006, GLOBAL CHANGE BIOL, V12, P154, DOI 10.1111/j.1365-2486.2005.01065.x; Friedlingstein P, 2006, J CLIMATE, V19, P3337, DOI 10.1175/JCLI3800.1; Fung IY, 2005, P NATL ACAD SCI USA, V102, P11201, DOI 10.1073/pnas.0504949102; Funk C, 2008, P NATL ACAD SCI USA, V105, P11081, DOI 10.1073/pnas.0708196105; Hansen MC, 2008, P NATL ACAD SCI USA, V105, P9439, DOI 10.1073/pnas.0804042105; Huete AR, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025583; Janssens IA, 2010, NAT GEOSCI, V3, P315, DOI [10.1038/NGEO844, 10.1038/ngeo844]; Kanamitsu M, 2002, B AM METEOROL SOC, V83, P1631, DOI [10.1175/BAMS-83-11-1631(2002)083<1631:NAR>2.3.CO;2, 10.1175/Bams-83-11-1631]; KEELING CD, 2001, SIO REFERENCE SERIES, V21; Kurz WA, 2008, NATURE, V452, P987, DOI 10.1038/nature06777; Le Quere C, 2009, NAT GEOSCI, V2, P831, DOI 10.1038/ngeo689; MASARIE KA, 1995, J GEOPHYS RES-ATMOS, V100, P11593, DOI 10.1029/95JD00859; Meehl GA, 2004, SCIENCE, V305, P994, DOI 10.1126/science.1098704; Mildrexler DJ, 2009, REMOTE SENS ENVIRON, V113, P2103, DOI 10.1016/j.rse.2009.05.016; Monteith J L, 1965, Symp Soc Exp Biol, V19, P205; Myneni RB, 2002, REMOTE SENS ENVIRON, V83, P214, DOI 10.1016/S0034-4257(02)00074-3; Nemani RR, 2003, SCIENCE, V300, P1560, DOI 10.1126/science.1082750; Palmer W.C., 1965, METEOROLOGICAL DROUG; Phillips OL, 2009, SCIENCE, V323, P1344, DOI 10.1126/science.1164033; Piao SL, 2008, NATURE, V451, P49, DOI 10.1038/nature06444; Running SW, 2004, BIOSCIENCE, V54, P547, DOI 10.1641/0006-3568(2004)054[0547:ACSMOG]2.0.CO;2; Saleska SR, 2007, SCIENCE, V318, P612, DOI 10.1126/science.1146663; Samanta A, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL042154; Smith P, 2007, AR4 CLIMATE CHANGE 2007: MITIGATION OF CLIMATE CHANGE, P497; van der Werf GR, 2006, ATMOS CHEM PHYS, V6, P3423, DOI 10.5194/acp-6-3423-2006; van der Werf GR, 2008, GLOBAL BIOGEOCHEM CY, V22, DOI 10.1029/2007GB003122; Westerling AL, 2006, SCIENCE, V313, P940, DOI 10.1126/science.1128834; Zhao MS, 2005, REMOTE SENS ENVIRON, V95, P164, DOI 10.1016/j.rse.2004.12.011	36	1721	1872	74	1231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2010	329	5994					940	943		10.1126/science.1192666	http://dx.doi.org/10.1126/science.1192666			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724633				2022-12-28	WOS:000281084800033
J	Nakada, S; Tai, I; Panier, S; Al-Hakim, A; Iemura, S; Juang, YC; O'Donnell, L; Kumakubo, A; Munro, M; Sicheri, F; Gingras, AC; Natsume, T; Suda, T; Durocher, D				Nakada, Shinichiro; Tai, Ikue; Panier, Stephanie; Al-Hakim, Abdallah; Iemura, Shun-ichiro; Juang, Yu-Chi; O'Donnell, Lara; Kumakubo, Ayako; Munro, Meagan; Sicheri, Frank; Gingras, Anne-Claude; Natsume, Tohru; Suda, Toshio; Durocher, Daniel			Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1	NATURE			English	Article							DOUBLE-STRAND BREAKS; STATISTICAL-MODEL; STRUCTURAL BASIS; MAMMALIAN-CELLS; REPAIR PROTEINS; BINDING; COMPLEX; ENZYME; CHAINS; SPECIFICITY	DNA double-strand breaks (DSBs) pose a potent threat to genome integrity. These lesions also contribute to the efficacy of radiotherapy and many cancer chemotherapeutics. DSBs elicit a signalling cascade that modifies the chromatin surrounding the break, first by ATM-dependent phosphorylation and then by RNF8-, RNF168- and BRCA1-dependent regulatory ubiquitination. Here we report that OTUB1, a deubiquitinating enzyme, is an inhibitor of DSB-induced chromatin ubiquitination. Surprisingly, we found that OTUB1 suppresses RNF168-dependent poly-ubiquitination independently of its catalytic activity. OTUB1 does so by binding to and inhibiting UBC13 (also known as UBE2N), the cognate E2 enzyme for RNF168. This unusual mode of regulation is unlikely to be limited to UBC13 because analysis of OTUB1-associated proteins revealed that OTUB1 binds to E2s of the UBE2D and UBE2E subfamilies. Finally, OTUB1 depletion mitigates the DSB repair defect associated with defective ATM signalling, indicating that pharmacological targeting of the OTUB1-UBC13 interaction might enhance the DNA damage response.	[Panier, Stephanie; Al-Hakim, Abdallah; Juang, Yu-Chi; O'Donnell, Lara; Munro, Meagan; Sicheri, Frank; Gingras, Anne-Claude; Durocher, Daniel] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Nakada, Shinichiro; Tai, Ikue] Keio Univ, Sch Med, Ctr Integrated Med Res, Shinjuku Ku, Tokyo 1608582, Japan; [Nakada, Shinichiro; Tai, Ikue; Kumakubo, Ayako; Suda, Toshio] Keio Univ, Sch Med, Dept Cell Differentiat, Sakaguchi Lab Dev Biol,Shinjuku Ku, Tokyo 1608582, Japan; [Panier, Stephanie; Sicheri, Frank; Gingras, Anne-Claude; Durocher, Daniel] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada; [Iemura, Shun-ichiro; Natsume, Tohru] Natl Inst Adv Ind Sci & Technol, Biomed Informat Res Ctr, Biol Syst Control Team, Koto Ku, Tokyo 1350064, Japan	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Keio University; Keio University; University of Toronto; National Institute of Advanced Industrial Science & Technology (AIST)	Durocher, D (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	snakada@z3.keio.jp; durocher@lunenfeld.ca	Sicheri, Frank/F-8856-2013; Gingras, Anne-Claude/E-9982-2010; OsakaU/AAY-3661-2020; Gingras, Anne-Claude/ABA-8341-2020; Suda, Toshio/H-6761-2013; 高, 雨莉/HGU-8187-2022; Natsume, Tohru/M-7627-2018; Panier, Stephanie/GVT-6365-2022; Durocher, Daniel/A-7733-2010	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; Suda, Toshio/0000-0001-7540-1771; Natsume, Tohru/0000-0002-1510-2582; Durocher, Daniel/0000-0003-3863-8635; Nakada, Shinichiro/0000-0001-9297-1565	Ministry of Education, Culture, Sports, Science and Technology (MEXT) Japan; MEXT [21870033]; Takeda Science Foundation; Mitsubishi Pharma Research Foundation; Daiwa Anglo-Japanese Foundation; New Energy and Industrial Technology Development Organization (NEDO); Boehringer Ingelheim Fonds; Canadian Institutes of Health Research [MOP10703115, MOP84314]	Ministry of Education, Culture, Sports, Science and Technology (MEXT) Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Mitsubishi Pharma Research Foundation; Daiwa Anglo-Japanese Foundation(Daiwa Anglo-Japanese Foundation); New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); Boehringer Ingelheim Fonds(Boehringer Ingelheim); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We are grateful to T. Ikura, S. Olivarius, R. Sakasai, A. Shibata, T. Oikawa, J. Unno, Y. Katuski, I. Imoto, S. Koyasu, R. Greenberg and the Core Instrumentation Facility, Keio University School of Medicine for technical support and reagents. We also thank R. Szilard and S. Angers for reading the manuscript. Work in the Nakada group in the Suda laboratory is supported by the Promotion of Environmental Improvement for Independence of Young Researchers, 'Kanrinmaru Project' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) Japan, Grant-in-Aid for Young Scientists (Startup 2009, 21870033) from MEXT, Takeda Science Foundation, Mitsubishi Pharma Research Foundation and the Daiwa Anglo-Japanese Foundation. I. T. is supported by MEXT's Distinctive University Education Support Program 'Good Practice'. Work in the Natsume laboratory is supported by the New Energy and Industrial Technology Development Organization (NEDO). S. P. holds a studentship from the Boehringer Ingelheim Fonds. D. D. is the Thomas Kierans Chair in Mechanisms of Cancer Development and a Canada Research Chair (Tier 2) in Proteomics, Bioinformatics and Functional genomics. Work in the Durocher and Gingras laboratories is supported by grants MOP10703115 (DD) and MOP84314 (ACG) from the Canadian Institutes of Health Research.	Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Beucher A, 2009, EMBO J, V28, P3413, DOI 10.1038/emboj.2009.276; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Eddins MJ, 2006, NAT STRUCT MOL BIOL, V13, P915, DOI 10.1038/nsmb1148; Edelmann MJ, 2009, BIOCHEM J, V418, P379, DOI 10.1042/BJ20081318; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Goudreault M, 2009, MOL CELL PROTEOMICS, V8, P157, DOI 10.1074/mcp.M800266-MCP200; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kim H, 2007, SCIENCE, V316, P1202, DOI 10.1126/science.1139621; Kittler R, 2005, NAT METHODS, V2, P779, DOI 10.1038/nmeth1005-779; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Nicassio F, 2007, CURR BIOL, V17, P1972, DOI 10.1016/j.cub.2007.10.034; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Petroski MD, 2007, J BIOL CHEM, V282, P29936, DOI 10.1074/jbc.M703911200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Quesada V, 2004, BIOCHEM BIOPH RES CO, V314, P54, DOI 10.1016/j.bbrc.2003.12.050; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Shao G, 2009, P NATL ACAD SCI USA, V106, P3166, DOI 10.1073/pnas.0807485106; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stewart GS, 2007, P NATL ACAD SCI USA, V104, P16910, DOI 10.1073/pnas.0708408104; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Tran H, 2008, GENE DEV, V22, P528, DOI 10.1101/gad.463208; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang T, 2009, J MOL BIOL, V386, P1011, DOI 10.1016/j.jmb.2008.12.085; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu JX, 2009, MOL CELL BIOL, V29, P849, DOI 10.1128/MCB.01302-08	38	262	273	4	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2010	466	7309					941	U59		10.1038/nature09297	http://dx.doi.org/10.1038/nature09297			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	640ED	20725033				2022-12-28	WOS:000281030300027
J	Reeves, L				Reeves, Leonard			HbA(1c) levels <= 5.5% ruled out, and levels >= 7.0% ruled in, type 2 diabetes in clinical and community populations	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Reeves, Leonard] Floyd Family Med Residency, Rome, GA USA		Reeves, L (corresponding author), Floyd Family Med Residency, Rome, GA USA.							*AM COLL END, 2010, AACE ACE STAT US A1C; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-11	10.7326/0003-4819-153-4-201008170-02011	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713778				2022-12-28	WOS:000280973000025
J	Berman, BM; Langevin, HH; Witt, CM; Dubner, R				Berman, Brian M.; Langevin, Helene H.; Witt, Claudia M.; Dubner, Ronald			Acupuncture for Chronic Low Back Pain.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE; PSYCHOLOGICAL DISTRESS; PRIMARY-CARE; GRAY-MATTER; TRIAL; BRAIN; INDIVIDUALS; EXPECTANCY; DISABILITY; MANAGEMENT		[Berman, Brian M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21207 USA; [Dubner, Ronald] Univ Maryland, Sch Dent, Baltimore, MD 21207 USA; [Langevin, Helene H.] Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA; [Langevin, Helene H.] Univ Vermont, Coll Med, Program Integrat Hlth, Burlington, VT 05405 USA; [Witt, Claudia M.] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Vermont; University of Vermont; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Berman, BM (corresponding author), Univ Maryland, Sch Med, Ctr Integrat Med, 2200 Kernan Dr, Baltimore, MD 21207 USA.	bberman@compmed.umm.edu	Witt, Claudia M./AAX-2370-2021	Witt, Claudia M./0000-0002-5440-7805				Ammendolia C, 2008, SPINE J, V8, P160, DOI 10.1016/j.spinee.2007.10.014; Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Baliki MN, 2006, J NEUROSCI, V26, P12165, DOI 10.1523/JNEUROSCI.3576-06.2006; Borsook D, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-25; Brinkhaus B, 2006, ARCH INTERN MED, V166, P450; Buckalew N, 2008, PAIN MED, V9, P240, DOI 10.1111/j.1526-4637.2008.00412.x; Carragee Eugene J, 2005, Spine J, V5, P24, DOI 10.1016/j.spinee.2004.05.250; Cheng X., 1987, CHINESE ACUPUNCTURE, P322; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P378; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Chou Roger, 2008, Ann Intern Med, V148, P247; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Chung A, 2003, CAN FAM PHYSICIAN, V49, P985; Dagenais S, 2010, SPINE J, V10, P514, DOI 10.1016/j.spinee.2010.03.032; Demoulin C, 2007, JOINT BONE SPINE, V74, P9, DOI 10.1016/j.jbspin.2006.02.013; Derbyshire, 1999, Curr Rev Pain, V3, P265, DOI 10.1007/s11916-999-0044-7; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Deyo RA, 2006, SPINE, V31, P2724, DOI 10.1097/01.brs.0000244618.06877.cd; Dhond RP, 2007, J ALTERN COMPLEM MED, V13, P603, DOI 10.1089/acm.2007.7040; Dionne CE, 2005, J CLIN EPIDEMIOL, V58, P714, DOI 10.1016/j.jclinepi.2004.12.005; Ee CC, 2008, AM J OBSTET GYNECOL, V198, P254, DOI 10.1016/j.ajog.2007.11.008; Giesecke T, 2004, ARTHRITIS RHEUM-US, V50, P613, DOI 10.1002/art.20063; GOLDMAN N, 2010, NAT NEUROSCI    0530; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; HELMS J, 2007, GETTING KNOW YOU PHY; Hurwitz EL, 2003, J CLIN EPIDEMIOL, V56, P463, DOI 10.1016/S0895-4356(03)00010-6; Jarvik JG, 2005, SPINE, V30, P1541, DOI 10.1097/01.brs.0000167536.60002.87; Jarvik JG, 2002, ANN INTERN MED, V137, P586, DOI 10.7326/0003-4819-137-7-200210010-00010; Jarvik JJ, 2001, SPINE, V26, P1158, DOI 10.1097/00007632-200105150-00014; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; *KAIS FAM FDN HLTH, 2004, EMPL HLTH BEN 2004 A; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kobayashi Yoshitaka, 2009, Spine (Phila Pa 1976), V34, P2431, DOI 10.1097/BRS.0b013e3181b1fb76; Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025; Langevin HM, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-151; Langevin HM, 2002, FASEB J, V16, P872, DOI 10.1096/fj.01-0925fje; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Lewis K, 2010, CLIN J PAIN, V26, P60, DOI 10.1097/AJP.0b013e3181bad71e; Li AH, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-20; Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006; Liu T, 2009, EVID-BASED COMPL ALT, V6, P185, DOI 10.1093/ecam/nen002; Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104; Napadow V, 2007, HUM BRAIN MAPP, V28, P159, DOI 10.1002/hbm.20261; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Pincus Tamar, 2002, Spine (Phila Pa 1976), V27, pE109, DOI 10.1097/00007632-200203010-00017; Pomeranz B, 1996, J Altern Complement Med, V2, P53, DOI 10.1089/acm.1996.2.53; RUBINSTEIN SM, 2010, EUR SPINE J     0314; Sandberg M, 2003, EUR J APPL PHYSIOL, V90, P114, DOI 10.1007/s00421-003-0825-3; Schmidt-Wilcke T, 2006, PAIN, V125, P89, DOI 10.1016/j.pain.2006.05.004; Sherman KJ, 2003, ALTERN THER HEALTH M, V9, P54; Speed C, 2004, BRIT MED J, V328, P1119, DOI 10.1136/bmj.328.7448.1119; Stanton TR, 2008, SPINE, V33, P2923, DOI 10.1097/BRS.0b013e31818a3167; Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C; Tsao H, 2008, BRAIN, V131, P2161, DOI 10.1093/brain/awn154; Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b; White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005; White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485; Witt CM, 2006, AM J EPIDEMIOL, V164, P487, DOI 10.1093/aje/kwj224; Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315; Woby SR, 2004, BEHAV RES THER, V42, P761, DOI 10.1016/S0005-7967(03)00195-5; Yuan J, 2008, SPINE, V33, pE887, DOI 10.1097/BRS.0b013e318186b276; 2009, 88 NAT I HLTH CLIN E	71	145	162	7	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					454	461		10.1056/NEJMct0806114	http://dx.doi.org/10.1056/NEJMct0806114			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818865				2022-12-28	WOS:000280411300009
J	Svensson, L; Bohm, K; Castren, M; Pettersson, H; Engerstrom, L; Herlitz, J; Rosenqvist, M				Svensson, Leif; Bohm, Katarina; Castren, Maaret; Pettersson, Hans; Engerstrom, Lars; Herlitz, Johan; Rosenqvist, Marten			Compression-Only CPR or Standard CPR in Out-of-Hospital Cardiac Arrest.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTINUOUS CHEST COMPRESSIONS; BASIC LIFE-SUPPORT; MOUTH-TO-MOUTH; CARDIOPULMONARY-RESUSCITATION; VENTILATION; SURVIVAL	Background: Emergency medical dispatchers give instructions on how to perform cardiopulmonary resuscitation (CPR) over the telephone to callers requesting help for a patient with suspected cardiac arrest, before the arrival of emergency medical services (EMS) personnel. A previous study indicated that instructions to perform CPR consisting of only chest compression result in a treatment efficacy that is similar or even superior to that associated with instructions given to perform standard CPR, which consists of both compression and ventilation. That study, however, was not powered to assess a possible difference in survival. The aim of this prospective, randomized study was to evaluate the possible superiority of compression-only CPR over standard CPR with respect to survival. Methods: Patients with suspected, witnessed, out-of-hospital cardiac arrest were randomly assigned to undergo either compression-only CPR or standard CPR. The primary end point was 30-day survival. Results: Data for the primary analysis were collected from February 2005 through January 2009 for a total of 1276 patients. Of these, 620 patients had been assigned to receive compression-only CPR and 656 patients had been assigned to receive standard CPR. The rate of 30-day survival was similar in the two groups: 8.7% (54 of 620 patients) in the group receiving compression-only CPR and 7.0% (46 of 656 patients) in the group receiving standard CPR (absolute difference for compression-only vs. standard CPR, 1.7 percentage points; 95% confidence interval, -1.2 to 4.6; P=0.29). Conclusions: This prospective, randomized study showed no significant difference with respect to survival at 30 days between instructions given by an emergency medical dispatcher, before the arrival of EMS personnel, for compression-only CPR and instructions for standard CPR in patients with suspected, witnessed, out-of-hospital cardiac arrest. (Funded by the Swedish Heart-Lung Foundation and others; Karolinska Clinical Trial Registration number, CT20080012.) N Engl J Med 2010;363:434-42.	[Svensson, Leif] Soder Sjukhuset, Stockholm Prehosp Ctr, Karolinska Inst, Dept Clin Sci & Educ, S-11883 Stockholm, Sweden; [Svensson, Leif] Soder Sjukhuset, Karolinska Inst, Sect Prehosp Med, S-11883 Stockholm, Sweden; [Bohm, Katarina; Rosenqvist, Marten] Soder Sjukhuset, Karolinska Inst, Cardiol Sect, S-11883 Stockholm, Sweden; [Castren, Maaret] Soder Sjukhuset, Karolinska Inst, Sect Emergency Med, S-11883 Stockholm, Sweden; [Engerstrom, Lars] Swedish Emergency Med Commun Ctr, SOS Alarm, Stockholm, Sweden; [Herlitz, Johan] Univ Gothenburg, Serv Cardiol, Sahlgrenska Hosp, Gothenburg, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Sahlgrenska University Hospital; University of Gothenburg	Svensson, L (corresponding author), Soder Sjukhuset, Stockholm Prehosp Ctr, Karolinska Inst, Dept Clin Sci & Educ, S-11883 Stockholm, Sweden.	leif.svensson@sodersjukhuset.se			Stockholm County Council, SOS Alarm; Swedish Heart-Lung Foundation	Stockholm County Council, SOS Alarm(Stockholm County Council); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation)	Supported by grants from the Stockholm County Council, SOS Alarm, and the Swedish Heart-Lung Foundation.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Assar D, 2000, RESUSCITATION, V45, P7, DOI 10.1016/S0300-9572(00)00152-0; Berg RA, 1997, CIRCULATION, V96, P4364; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Bohm K, 2009, RESUSCITATION, V80, P1025, DOI 10.1016/j.resuscitation.2009.06.004; Bohm K, 2007, CIRCULATION, V116, P2908, DOI 10.1161/CIRCULATIONAHA.107.710194; Chamberlain D, 2005, RESUSCITATION, V67, P157, DOI 10.1016/j.resuscitation.2005.05.011; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Hollenberg J, 2007, RESUSCITATION, V74, P242, DOI 10.1016/j.resuscitation.2006.12.014; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Jelinek GA, 2001, RESUSCITATION, V51, P239, DOI 10.1016/S0300-9572(01)00411-7; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Kern KB, 1998, RESUSCITATION, V39, P179, DOI 10.1016/S0300-9572(98)00141-5; Nagao K, 2007, LANCET, V369, P920; Odegaard S, 2006, RESUSCITATION, V71, P335, DOI 10.1016/j.resuscitation.2006.05.012; Paal P, 2006, RESUSCITATION, V70, P117, DOI 10.1016/j.resuscitation.2005.03.024; Rea TD, 2001, CIRCULATION, V104, P2513, DOI 10.1161/hc4601.099468; Shibata K, 2000, RESUSCITATION, V44, P187, DOI 10.1016/S0300-9572(00)00143-X; Willerson JT, 2000, CIRCULATION, V102, P1	21	178	197	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					434	442		10.1056/NEJMoa0908991	http://dx.doi.org/10.1056/NEJMoa0908991			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818864	Green Published			2022-12-28	WOS:000280411300007
J	Liao, L; Lin, YC; Bao, MQ; Cheng, R; Bai, JW; Liu, YA; Qu, YQ; Wang, KL; Huang, Y; Duan, XF				Liao, Lei; Lin, Yung-Chen; Bao, Mingqiang; Cheng, Rui; Bai, Jingwei; Liu, Yuan; Qu, Yongquan; Wang, Kang L.; Huang, Yu; Duan, Xiangfeng			High-speed graphene transistors with a self-aligned nanowire gate	NATURE			English	Article							EPITAXIAL GRAPHENE; DIELECTRICS; MOBILITY; PHASE	Graphene has attracted considerable interest as a potential new electronic material(1-11). With its high carrier mobility, graphene is of particular interest for ultrahigh-speed radio-frequency electronics(12-18). However, conventional device fabrication processes cannot readily be applied to produce high-speed graphene transistors because they often introduce significant defects into the monolayer of carbon lattices and severely degrade the device performance(19-21). Here we report an approach to the fabrication of high-speed graphene transistors with a self-aligned nanowire gate to prevent such degradation. A Co(2)Si-Al(2)O(3) core-shell nanowire is used as the gate, with the source and drain electrodes defined through a self-alignment process and the channel length defined by the nanowire diameter. The physical assembly of the nanowire gate preserves the high carrier mobility in graphene, and the self-alignment process ensures that the edges of the source, drain and gate electrodes are automatically and precisely positioned so that no overlapping or significant gaps exist between these electrodes, thus minimizing access resistance. It therefore allows for transistor performance not previously possible. Graphene transistors with a channel length as low as 140 nm have been fabricated with the highest scaled on-current (3.32 mA mu m(-1)) and transconductance (1.27 mS mu m(-1)) reported so far. Significantly, on-chip microwave measurements demonstrate that the self-aligned devices have a high intrinsic cut-off (transit) frequency of f(T) = 100-300 GHz, with the extrinsic f(T) (in the range of a few gigahertz) largely limited by parasitic pad capacitance. The reported intrinsic f(T) of the graphene transistors is comparable to that of the very best high-electron-mobility transistors with similar gate lengths(10).	[Liao, Lei; Qu, Yongquan; Duan, Xiangfeng] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Lin, Yung-Chen; Cheng, Rui; Bai, Jingwei; Liu, Yuan; Huang, Yu] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA; [Bao, Mingqiang; Wang, Kang L.] Univ Calif Los Angeles, Dept Elect Engn, Los Angeles, CA 90095 USA; [Wang, Kang L.; Huang, Yu] Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Duan, XF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	xduan@chem.ucla.edu	Bai, Jingwei/G-4245-2012; Huang, Yu/AAZ-9747-2020; liao, lei/O-4052-2014; Duan, Xiangfeng/AAQ-9674-2020; Liu, Yuan/G-4834-2016; Qu, Yongquan/A-7203-2011; Lin, Yung-Chen/G-7333-2012; Duan, Xiangfeng/E-7522-2011	Huang, Yu/0000-0003-1793-0741; Duan, Xiangfeng/0000-0002-4321-6288; Liu, Yuan/0000-0002-0024-9290; Duan, Xiangfeng/0000-0002-4321-6288; Qu, Yongquan/0000-0002-6202-1929	NSF [0956171]; NIH [1DP2OD004342-01]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD004342] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank A. Jooyaie and S. Martin for discussions. We also acknowledge the Electron Imaging Center for Nanomachines at UCLA for TEM technical support and the Nanoelectronics Research Facility at UCLA for device fabrication technical support. X.D. acknowledges financial support by the NSF CAREER award 0956171 and the NIH Director's New Innovator Award Program, part of the NIH Roadmap for Medical Research, through grant number 1DP2OD004342-01.	[Anonymous], 2007, PHYS SEMICONDUCTOR D; Avouris P, 2007, NAT NANOTECHNOL, V2, P605, DOI 10.1038/nnano.2007.300; Berger C, 2006, SCIENCE, V312, P1191, DOI 10.1126/science.1125925; Bolotin KI, 2008, SOLID STATE COMMUN, V146, P351, DOI 10.1016/j.ssc.2008.02.024; Bunch JS, 2005, NANO LETT, V5, P287, DOI 10.1021/nl048111+; Farmer DB, 2009, NANO LETT, V9, P4474, DOI 10.1021/nl902788u; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Jeon DY, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.091601; Kim DH, 2008, IEEE ELECTR DEVICE L, V29, P830, DOI 10.1109/LED.2008.2000794; Lee BK, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2928228; Lemme MC, 2007, IEEE ELECTR DEVICE L, V28, P282, DOI 10.1109/LED.2007.891668; Liao L, 2010, ADV MATER, V22, P1941, DOI 10.1002/adma.200904415; Liao L, 2010, NANO LETT, V10, P1917, DOI 10.1021/nl100840z; Liao L, 2010, P NATL ACAD SCI USA, V107, P6711, DOI 10.1073/pnas.0914117107; Lin YM, 2010, SCIENCE, V327, P662, DOI 10.1126/science.1184289; Lin YM, 2010, IEEE ELECTR DEVICE L, V31, P68, DOI 10.1109/LED.2009.2034876; Lin YM, 2009, NANO LETT, V9, P422, DOI 10.1021/nl803316h; MERIC I, 2008, P EL DEV M 2008, DOI DOI 10.1109/IEDM.2008.4796738; Meric I, 2008, NAT NANOTECHNOL, V3, P654, DOI 10.1038/nnano.2008.268; Miao F, 2007, SCIENCE, V317, P1530, DOI 10.1126/science.1144359; Moon JS, 2009, IEEE ELECTR DEVICE L, V30, P650, DOI 10.1109/LED.2009.2020699; Murali R, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3147183; Ni ZH, 2008, ACS NANO, V2, P1033, DOI 10.1021/nn800031m; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Schwierz F, 2010, NAT NANOTECHNOL, V5, P487, DOI [10.1038/NNANO.2010.89, 10.1038/nnano.2010.89]; Seo K, 2009, ACS NANO, V3, P1145, DOI 10.1021/nn900191g; Wang XR, 2008, J AM CHEM SOC, V130, P8152, DOI 10.1021/ja8023059; Xuan Y, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2828338; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235	30	1034	1082	20	783	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					305	308		10.1038/nature09405	http://dx.doi.org/10.1038/nature09405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20811365	Green Accepted			2022-12-28	WOS:000281824900034
J	Bush, A; Saglani, S				Bush, Andrew; Saglani, Sejal			Management of severe asthma in children	LANCET			English	Review							EXHALED NITRIC-OXIDE; RECEPTOR-BINDING-AFFINITY; SEVERE CHILDHOOD ASTHMA; AIRWAY WALL THICKNESS; INNER-CITY CHILDREN; SKIN PRICK TESTS; LUNG-FUNCTION; ALLERGEN EXPOSURE; DIFFICULT ASTHMA; CYSTIC-FIBROSIS	Children who are referred to specialist care with asthma that does not respond to treatment (problematic severe asthma) are a heterogeneous group, with substantial morbidity. The evidence base for management is sparse, and is mostly based on data from studies in children with mild and moderate asthma and on extrapolation of data from studies in adults with severe asthma. In many children with severe asthma, the diagnosis is wrong or adherence to treatment is poor. The first step is a detailed diagnostic assessment to exclude an alternative diagnosis ("not asthma at all"), followed by a multidisciplinary approach to exclude comorbidities ("asthma plus") and to assess whether the child has difficult asthma (improves when the basic management needs, such as adherence and inhaler technique, are corrected) or true, therapy-resistant asthma (still symptomatic even when the basic management needs are resolved). In particular, environmental causes of secondary steroid resistance should be identified. An individualised treatment plan should be devised depending on the clinical and pathophysiological characterisation. Licensed therapeutic approaches include high-dose inhaled steroids, the Symbicort maintenance and reliever (SMART) regimen (with budesonide and formoterol fumarate), and anti-IgE therapy. Unlicensed treatments include methotrexate, azathioprine, ciclosporin, and subcutaneous terbutaline infusions. Paediatric data are needed on cytokine-specific monoclonal antibody therapies and bronchial thermoplasty. However, despite the interest in innovative approaches, getting the basics right in children with apparently severe asthma will remain the foundation of management for the foreseeable future.	[Bush, Andrew] Royal Brompton Hosp, Dept Paediat Resp Med, Imperial Sch Med, Natl Heart & Lung Inst, London SW3 6NP, England	Imperial College London; Royal Brompton Hospital	Bush, A (corresponding author), Royal Brompton Hosp, Dept Paediat Resp Med, Imperial Sch Med, Natl Heart & Lung Inst, Sydney St, London SW3 6NP, England.	a.bush@rbh.nthames.nhs.uk	Saglani, Sejal/AAE-5072-2019	Saglani, Sejal/0000-0001-5192-6418	Wellcome Trust [083586] Funding Source: Medline; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Wellcome Trust(Wellcome Trust); National Institute for Health Research(National Institute for Health Research (NIHR))		Abu-Hasan M, 2005, ANN ALLERG ASTHMA IM, V94, P366, DOI 10.1016/S1081-1206(10)60989-1; Adams N. P., 2008, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD3534.PUB3; Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; Amayasu H, 2000, ANN ALLERG ASTHMA IM, V84, P594, DOI 10.1016/S1081-1206(10)62409-X; [Anonymous], 2008, Lancet, V371, P1390, DOI 10.1016/S0140-6736(08)60605-4; Anwar GA, 2008, RESP MED, V102, P1494, DOI 10.1016/j.rmed.2008.06.005; Awadh N, 1998, THORAX, V53, P248, DOI 10.1136/thx.53.4.248; Ayres JG, 1998, THORAX, V53, P315, DOI 10.1136/thx.53.4.315; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bae YJ, 2009, J ASTHMA, V46, P591, DOI 10.1080/02770900902980908; Ballester F, 1999, AM J EPIDEMIOL, V149, P315, DOI 10.1093/oxfordjournals.aje.a009815; Belessis Y, 2004, PEDIATR PULM, V37, P201, DOI 10.1002/ppul.10443; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; Bernstein IL, 1996, J ALLERGY CLIN IMMUN, V98, P317, DOI 10.1016/S0091-6749(96)70156-2; Bijl-Hofland ID, 1999, THORAX, V54, P15, DOI 10.1136/thx.54.1.15; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; BOSSLEY C, 2009, EUR RESP J S53, V34, pS566; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brand PLP, 2010, EUR RESPIR J, V35, P1172, DOI 10.1183/09031936.00198009; Brand PLP, 2003, ARCH DIS CHILD, V88, P1021, DOI 10.1136/adc.88.11.1021; Brouwer AFJ, 2010, ACTA PAEDIATR, V99, P871, DOI 10.1111/j.1651-2227.2010.01715.x; Brouwer AFJ, 2008, PAEDIATR RESPIR REV, V9, P193, DOI 10.1016/j.prrv.2008.03.001; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Cai Y, 1998, EUR RESPIR J, V11, P848, DOI 10.1183/09031936.98.11040848; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; CATES CJ, 2009, COCHRANE DB SYST REV, V2; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chinn S, 2007, AM J RESP CRIT CARE, V176, P20, DOI 10.1164/rccm.200612-1840OC; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Clement A, 2006, THORAX, V61, P895, DOI 10.1136/thx.2005.057950; Cohen J, 2008, EUR RESPIR J, V31, P1213, DOI 10.1183/09031936.00082407; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Coren ME, 1997, ARCH DIS CHILD, V77, P522, DOI 10.1136/adc.77.6.522; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; de Blic J, 2007, J ALLERGY CLIN IMMUN, V119, P808, DOI 10.1016/j.jaci.2006.12.657; De Boeck K, 2009, PEDIATR PULM, V44, P743, DOI 10.1002/ppul.20968; de Jongste JC, 2009, AM J RESP CRIT CARE, V179, P93, DOI 10.1164/rccm.200807-1010OC; De Wachter E, 2003, EUR J PEDIATR, V162, P488, DOI 10.1007/s00431-003-1233-8; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Dougherty RH, 2009, CLIN EXP ALLERGY, V39, P193, DOI 10.1111/j.1365-2222.2008.03157.x; Drazen JM, 2009, NEW ENGL J MED, V360, P1671, DOI 10.1056/NEJMe0902057; Equi A, 2002, LANCET, V360, P978, DOI 10.1016/S0140-6736(02)11081-6; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Farber HJ, 2004, ANN ALLERG ASTHMA IM, V92, P319, DOI 10.1016/S1081-1206(10)61569-4; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fleming L, 2009, AM J RESP CRIT CARE, V179; Fleming L, 2008, THORAX, V63, pA34; FLEMING L, 2007, EUR RESP J S51, V30, pS483; Fujitani Y, 2003, AM J RESP CRIT CARE, V167, P193, DOI 10.1164/rccm.200205-455OC; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Gibson PG, 1999, PEDIATR PULM, V28, P261, DOI 10.1002/(SICI)1099-0496(199910)28:4<261::AID-PPUL5>3.0.CO;2-I; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Gupta S, 2009, CHEST, V136, P1521, DOI 10.1378/chest.09-0174; Gustafsson PM, 2008, THORAX, V63, P129, DOI 10.1136/thx.2007.077784; Gustafsson PM, 2007, PEDIATR PULM, V42, P168, DOI 10.1002/ppul.20554; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P921, DOI 10.1016/j.jaci.2009.09.006; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; Havemann BD, 2007, GUT, V56, P1654, DOI 10.1136/gut.2007.122465; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Jain N, 2005, PEDIATR PULM, V40, P211, DOI 10.1002/ppul.20215; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; Jensen SP, 2002, CLIN RADIOL, V57, P1078, DOI 10.1053/crad.2002.1104; KAM JC, 1993, J IMMUNOL, V151, P3460; Kamps AWA, 2002, ACTA PAEDIATR, V91, P159, DOI 10.1080/080352502317285144; Kamps AWA, 2000, PEDIATR PULM, V29, P39, DOI 10.1002/(SICI)1099-0496(200001)29:1<39::AID-PPUL7>3.0.CO;2-G; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x; Kotses H, 1996, J ASTHMA, V33, P113, DOI 10.3109/02770909609054539; KOTSES H, 1991, J ASTHMA, V28, P287, DOI 10.3109/02770909109073386; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kudoh S, 1998, AM J RESP CRIT CARE, V157, P1829, DOI 10.1164/ajrccm.157.6.9710075; Langley SJ, 2005, THORAX, V60, P17, DOI 10.1136/thx.2004.027839; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lex C, 2005, PEDIATR PULM, V39, P521, DOI 10.1002/ppul.20189; Lex C, 2005, PEDIATR PULM, V39, P318, DOI 10.1002/ppul.20159; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; Livingston E, 2007, EUR RESPIR J, V29, P64, DOI 10.1183/09031936.06.00120505; Male I, 2000, ARCH DIS CHILD, V83, P325, DOI 10.1136/adc.83.4.325; Marchac V, 2002, AM J ROENTGENOL, V179, P1245, DOI 10.2214/ajr.179.5.1791245; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Massanari M, 2009, CLIN PEDIATR, V48, P859, DOI 10.1177/0009922809339054; McKean M, 2000, Cochrane Database Syst Rev, pCD001107, DOI 10.1002/14651858.CD001107; Meagher LC, 1996, J IMMUNOL, V156, P4422; Milanese M, 2001, J APPL PHYSIOL, V91, P1035, DOI 10.1152/jappl.2001.91.3.1035; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87, DOI 10.1164/ajrccm.155.1.9001294; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; O'Driscoll BR, 2009, CLIN EXP ALLERGY, V39, P1677, DOI 10.1111/j.1365-2222.2009.03339.x; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Orrell-Valente JK, 2008, PEDIATRICS, V122, pE1186, DOI 10.1542/peds.2008-0292; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; Panickar JR, 2005, PEDIATR PULM, V39, P421, DOI 10.1002/ppul.20176; Paraskakis E, 2006, AM J RESP CRIT CARE, V174, P260, DOI 10.1164/rccm.200506-962OC; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Payne DNR, 2002, PEDIATR PULM, V33, P356, DOI 10.1002/ppul.10081; Payne DNR, 1998, PEDIATR PULM, V25, P59, DOI 10.1002/(SICI)1099-0496(199801)25:1<59::AID-PPUL7>3.3.CO;2-9; Petsky HL, 2009, COCHRANE DB SYST REV, V4; Pifferi M, 2002, J PEDIATR-US, V141, P104, DOI 10.1067/mpd.2002.125006; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Platts-Mills TAE, 2008, J ALLERGY CLIN IMMUN, V122, P694, DOI 10.1016/j.jaci.2008.07.045; Ranganathan SC, 2001, PEDIATR PULM, V31, P114, DOI 10.1002/1099-0496(200102)31:2<114::AID-PPUL1018>3.0.CO;2-O; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; Rollin M, 2009, RHINOLOGY, V47, P75; Saglani S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-46; Saiman L, 2003, JAMA-J AM MED ASSOC, V290, P1749, DOI 10.1001/jama.290.13.1749; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Sandberg S, 2002, ACTA PAEDIATR, V91, P152, DOI 10.1080/080352502317285135; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Seear M, 2005, ARCH DIS CHILD, V90, P898, DOI 10.1136/adc.2004.063974; Sheikh A, 2007, COCHRANE DB SYST REV, V1; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Simpson AB, 2007, PEDIATR PULM, V42, P489, DOI 10.1002/ppul.20605; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; SMITH JR, 2005, INT SOC TECHNOL ASSE, V19, P172; Sole D, 1996, J INVEST ALLERG CLIN, V6, P126; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; STRACHAN DP, 1995, BRIT MED J, V311, P1053, DOI 10.1136/bmj.311.7012.1053; Strunk RC, 2008, J ALLERGY CLIN IMMUN, V122, P1138, DOI 10.1016/j.jaci.2008.09.028; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; Sundberg R, 2007, J ADOLESCENT HEALTH, V40, P581, DOI 10.1016/j.jadohealth.2007.01.003; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P685, DOI 10.1016/j.jaci.2005.01.031; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Teach SJ, 2006, PEDIATRICS, V117, pS152, DOI 10.1542/peds.2005-2000M; Thakkar K, 2010, PEDIATRICS, V125, pE925, DOI 10.1542/peds.2009-2382; Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Tschopp JM, 1998, ALLERGY, V53, P608, DOI 10.1111/j.1398-9995.1998.tb03937.x; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; Tsoukias NM, 2001, J APPL PHYSIOL, V91, P477, DOI 10.1152/jappl.2001.91.1.477; van Dalen C, 2008, ARCH PEDIAT ADOL MED, V162, P1169, DOI 10.1001/archpedi.162.12.1169; VANDIXHOORN J, 1985, J PSYCHOSOM RES, V29, P199, DOI 10.1016/0022-3999(85)90042-X; Vicencio AG, 2010, PEDIATRICS, V125, pE1255, DOI 10.1542/peds.2009-2443; Walia M, 2006, PEDIATR PULM, V41, P1082, DOI 10.1002/ppul.20498; Wang Fang, 2009, Entomological Research, V39, P89, DOI 10.1111/j.1748-5967.2009.00192.x; Wark PAB, 2002, CLIN EXP ALLERGY, V32, P1750, DOI 10.1046/j.1365-2222.2002.01556.x; Warke TJ, 2002, THORAX, V57, P383, DOI 10.1136/thorax.57.5.383; WARNER JO, 1995, BRIT MED J, V311, P663, DOI 10.1136/bmj.311.7006.663; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608; Wenzel S, 2006, J ALLERGY CLIN IMMUN, V117, P508, DOI 10.1016/j.jaci.2005.12.1316; Wolter J, 2002, THORAX, V57, P212, DOI 10.1136/thorax.57.3.212; Yang SR, 2006, AM J PHYSIOL-LUNG C, V291, pL46, DOI 10.1152/ajplung.00241.2005; Yasui K, 2000, J LEUKOCYTE BIOL, V67, P529, DOI 10.1002/jlb.67.4.529; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC	184	164	174	0	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					814	825		10.1016/S0140-6736(10)61054-9	http://dx.doi.org/10.1016/S0140-6736(10)61054-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816548	Green Accepted			2022-12-28	WOS:000281831000033
J	Liu, HL; Juo, ZS; Shim, AHR; Focia, PJ; Chen, XY; Garcia, KC; He, XL				Liu, Heli; Juo, Z. Sean; Shim, Ann Hye-Ryong; Focia, Pamela J.; Chen, Xiaoyan; Garcia, K. Christopher; He, Xiaolin			Structural Basis of Semaphorin-Plexin Recognition and Viral Mimicry from Sema7A and A39R Complexes with PlexinC1	CELL			English	Article							HIGH-LEVEL EXPRESSION; CRYSTAL-STRUCTURE; MOLECULAR-BIOLOGY; BIVALENT BINDING; KIT RECEPTOR; DIMERIZATION; INTEGRINS; FAMILY; DOMAIN; 7A	Repulsive signaling by Semaphorins and Plexins is crucial for the development and homeostasis of the nervous, immune, and cardiovascular systems. Sema7A acts as both an immune and a neural Semaphorin through PlexinC1, and A39R is a Sema7A mimic secreted by smallpox virus. We report the structures of Sema7A and A39R complexed with the Semaphorin-binding module of PlexinC1. Both structures show two PlexinC1 molecules symmetrically bridged by Semaphorin dimers, in which the Semaphorin and PlexinC1 beta propellers interact in an edge-on, orthogonal orientation. Both binding interfaces are dominated by the insertion of the Semaphorin's 4c-4d loop into a deep groove in blade 3 of the PlexinC1 propeller. A39R appears to achieve Sema7A mimicry by preserving key Plexin-binding determinants seen in the mammalian Sema7A complex that have evolved to achieve higher affinity binding to the host-derived PlexinC1. The complex structures support a conserved Semaphorin-Plexin recognition mode and suggest that Plexins are activated by dimerization.	[Liu, Heli; Shim, Ann Hye-Ryong; Focia, Pamela J.; Chen, Xiaoyan; He, Xiaolin] Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; [Juo, Z. Sean; Garcia, K. Christopher] Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA; [Juo, Z. Sean; Garcia, K. Christopher] Stanford Univ, Dept Mol & Cellular Physiol, Sch Med, Stanford, CA 94305 USA; [Juo, Z. Sean; Garcia, K. Christopher] Stanford Univ, Dept Biol Struct, Sch Med, Stanford, CA 94305 USA	Northwestern University; Feinberg School of Medicine; Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University	He, XL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, Searle 8-417,303 E Chicago Ave, Chicago, IL 60611 USA.	x-he@northwestern.edu			NIH [1R01GM07805, NIH-R01-AI51321]; R.H. Lurie Comprehensive Cancer Center of Northwestern University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098259, R01GM078055] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); R.H. Lurie Comprehensive Cancer Center of Northwestern University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the staff at the LS-CAT beamlines at APS and the staffs of ALS and SSRL for the support in X-ray data collection. We also thank L. Colf, and N. Goriatcheva for help with the expression of A39R. X.H. is supported by the NIH grant 1R01GM07805, and K.C.G. is an Investigator of the Howard Hughes Medical Institute and is supported by NIH-R01-AI51321. The Structural Biology Facility is supported by the R.H. Lurie Comprehensive Cancer Center of Northwestern University.	Antipenko A, 2003, NEURON, V39, P589, DOI 10.1016/S0896-6273(03)00502-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Dukkipati A, 2008, PROTEIN EXPRES PURIF, V62, P160, DOI 10.1016/j.pep.2008.08.004; Gewurz BE, 2001, CURR OPIN IMMUNOL, V13, P442, DOI 10.1016/S0952-7915(00)00239-9; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; He HW, 2009, P NATL ACAD SCI USA, V106, P15610, DOI 10.1073/pnas.0906923106; He XL, 2006, J MOL BIOL, V361, P698, DOI 10.1016/j.jmb.2006.06.060; He Zhigang, 2002, Sci STKE, V2002, pre1, DOI 10.1126/stke.2002.119.re1; Holmes S, 2002, SCAND J IMMUNOL, V56, P270, DOI 10.1046/j.1365-3083.2002.01129.x; Huppa JB, 2010, NATURE, V463, P963, DOI 10.1038/nature08746; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Koppel AM, 1997, NEURON, V19, P531, DOI 10.1016/S0896-6273(00)80369-4; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; LEV S, 1992, J BIOL CHEM, V267, P15970; Love CA, 2003, NAT STRUCT BIOL, V10, P843, DOI 10.1038/nsb977; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Scott GA, 2009, J INVEST DERMATOL, V129, P954, DOI 10.1038/jid.2008.329; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553; Suzuki K, 2007, NATURE, V446, P680, DOI 10.1038/nature05652; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tong Y, 2007, J BIOL CHEM, V282, P37215, DOI 10.1074/jbc.M703800200; Tong YF, 2009, J BIOL CHEM, V284, P35962, DOI 10.1074/jbc.M109.056275; Uniewicz KA, 2008, FRONT BIOSCI-LANDMRK, V13, P4339, DOI 10.2741/3008; Waimey KE, 2006, NEUROSCIENTIST, V12, P398, DOI 10.1177/1073858406292631; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xu XM, 1998, J BIOL CHEM, V273, P22428, DOI 10.1074/jbc.273.35.22428; Yamada A, 1999, J IMMUNOL, V162, P4094	46	100	110	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					749	761		10.1016/j.cell.2010.07.040	http://dx.doi.org/10.1016/j.cell.2010.07.040			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20727575	Bronze, Green Accepted			2022-12-28	WOS:000281523200018
J	Suganuma, T; Mushegian, A; Swanson, SK; Abmayr, SM; Florens, L; Washburn, MP; Workman, JL				Suganuma, Tamaki; Mushegian, Arcady; Swanson, Selene K.; Abmayr, Susan M.; Florens, Laurence; Washburn, Michael P.; Workman, Jerry L.			The ATAC Acetyltransferase Complex Coordinates MAP Kinases to Regulate JNK Target Genes	CELL			English	Article							ACTIVATED PROTEIN-KINASE; C-JUN PROMOTER; MOLYBDOPTERIN SYNTHASE; DNA INTERACTIONS; STRESS; TRANSCRIPTION; OSMOSTRESS; HOG1; EXPRESSION; MISSHAPEN	In response to extracellular cues, signal transduction activates downstream transcription factors like c-Jun to induce expression of target genes. We demonstrate that the ATAC (Ada two A containing) histone acetyltransferase (HAT) complex serves as a transcriptional cofactor for c-Jun at the Jun N-terminal kinase (JNK) target genes Jra and chick-adee. ATAC subunits are required for c-Jun occupancy of these genes and for H4K16 acetylation at the Jra enhancer, promoter, and transcribed sequences. Under conditions of osmotic stress, ATAC colocalizes with c-Jun, recruits the upstream kinases Misshapen, MKK4, and JNK, and suppresses further activation of JNK. Relocalization of these MAPKs and suppression of JNK activation by ATAC are dependent on the CG10238 subunit of ATAC. Thus, ATAC governs the transcriptional response to MAP kinase signaling by serving as both a coactivator of transcription and as a suppressor of upstream signaling.	[Suganuma, Tamaki; Mushegian, Arcady; Swanson, Selene K.; Abmayr, Susan M.; Florens, Laurence; Washburn, Michael P.; Workman, Jerry L.] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Mushegian, Arcady] Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66160 USA; [Swanson, Selene K.; Abmayr, Susan M.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Washburn, Michael P.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Workman, JL (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	jlw@stowers.org	Mushegian, Arcady/ABF-5387-2021	Mushegian, Arcady/0000-0002-6809-9225; Florens, Laurence/0000-0002-9310-6650; Washburn, Michael/0000-0001-7568-2585	Stowers Institute for Medical Research; Workman Lab; Zeitlinger Lab; Conaway Lab; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047867] Funding Source: NIH RePORTER	Stowers Institute for Medical Research; Workman Lab; Zeitlinger Lab; Conaway Lab; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Workman Lab members, Bjoern Gaertner in the Zeitlinger Lab, and Hidehisa Takahashi in the Conaway Lab for advice and support during this project. This research was supported by the Stowers Institute for Medical Research.	Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Alexaki VI, 2008, PIGM CELL MELANOMA R, V21, P429, DOI 10.1111/j.1755-148X.2008.00466.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Ciurciu A, 2006, MOL CELL BIOL, V26, P9413, DOI 10.1128/MCB.01401-06; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; de Nadal E, 2010, EMBO J, V29, P4, DOI 10.1038/emboj.2009.346; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Dioum EM, 2009, CELL, V139, P462, DOI 10.1016/j.cell.2009.10.007; Edmunds JW, 2004, J CELL SCI, V117, P3715, DOI 10.1242/jcs.01346; Fan Y, 2010, CELL DEATH DIFFER, V17, P912, DOI 10.1038/cdd.2009.182; Fukuyama K, 2000, J BIOL CHEM, V275, P21247, DOI 10.1074/jbc.M001488200; Guelman S, 2006, MOL CELL BIOL, V26, P871, DOI 10.1128/MCB.26.3.871-882.2006; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Hu SH, 2009, CELL, V139, P610, DOI 10.1016/j.cell.2009.08.037; Iyer LM, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r60; Jasper H, 2001, DEV CELL, V1, P579, DOI 10.1016/S1534-5807(01)00045-4; Kayali AG, 2000, DIABETES, V49, P1783, DOI 10.2337/diabetes.49.11.1783; Kimura A, 2005, J BIOCHEM, V138, P647, DOI 10.1093/jb/mvi184; Kusch T, 2003, MOL CELL BIOL, V23, P3305, DOI 10.1128/MCB.23.9.3305-3319.2003; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lawrence MC, 2009, P NATL ACAD SCI USA, V106, P22181, DOI 10.1073/pnas.0912596106; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Leimkuhler S, 2003, J BIOL CHEM, V278, P26127, DOI 10.1074/jbc.M303092200; Mas G, 2009, EMBO J, V28, P326, DOI 10.1038/emboj.2008.299; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Proft M, 2006, MOL CELL, V23, P241, DOI 10.1016/j.molcel.2006.05.031; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; ROZEK D, 1995, J CELL BIOCHEM, V57, P479, DOI 10.1002/jcb.240570313; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schwarz G, 2006, ANNU REV PLANT BIOL, V57, P623, DOI 10.1146/annurev.arplant.57.032905.105437; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Suganuma T, 2008, NAT STRUCT MOL BIOL, V15, P364, DOI 10.1038/nsmb.1397; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Wang YL, 2008, J BIOL CHEM, V283, P33808, DOI 10.1074/jbc.M806936200; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Zapater M, 2007, MOL CELL BIOL, V27, P3900, DOI 10.1128/MCB.00089-07; Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031	48	48	49	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					726	736		10.1016/j.cell.2010.07.045	http://dx.doi.org/10.1016/j.cell.2010.07.045			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813260	Bronze			2022-12-28	WOS:000281523200016
J	Lee, HH; Molla, MN; Cantor, CR; Collins, JJ				Lee, Henry H.; Molla, Michael N.; Cantor, Charles R.; Collins, James J.			Bacterial charity work leads to population-wide resistance	NATURE			English	Article							ESCHERICHIA-COLI; ANTIBIOTIC-RESISTANCE; INDUCED MUTAGENESIS; EVOLUTION; INDOLE; DEATH; ADAPTATION; EXPRESSION; MUTATIONS; STRAINS	Bacteria show remarkable adaptability in the face of antibiotic therapeutics. Resistance alleles in drug target-specific sites and general stress responses have been identified in individual end-point isolates(1-7). Less is known, however, about the population dynamics during the development of antibiotic-resistant strains. Here we follow a continuous culture of Escherichia coli facing increasing levels of antibiotic and show that the vast majority of isolates are less resistant than the population as a whole. We find that the few highly resistant mutants improve the survival of the population's less resistant constituents, in part by producing indole, a signalling molecule generated by actively growing, unstressed cells(8). We show, through transcriptional profiling, that indole serves to turn on drug efflux pumps and oxidative-stress protective mechanisms. The indole production comes at a fitness cost to the highly resistant isolates, and whole-genome sequencing reveals that this bacterial altruism is made possible by drug-resistance mutations unrelated to indole production. This work establishes a population-based resistance mechanism constituting a form of kin selection(9) whereby a small number of resistant mutants can, at some cost to themselves, provide protection to other, more vulnerable, cells, enhancing the survival capacity of the overall population in stressful environments.	[Lee, Henry H.; Molla, Michael N.; Collins, James J.] Howard Hughes Med Inst, Ctr BioDynam, Boston, MA 02115 USA; [Lee, Henry H.; Molla, Michael N.; Cantor, Charles R.; Collins, James J.] Boston Univ, Dept Biomed Engn, Ctr Adv Biotechnol, Boston, MA 02215 USA; [Collins, James J.] Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02215 USA	Howard Hughes Medical Institute; Boston University; Harvard University	Collins, JJ (corresponding author), Howard Hughes Med Inst, Ctr BioDynam, Boston, MA 02115 USA.	jcollins@bu.edu	Lee, Henry/GVS-2114-2022	Lee, Henry/0000-0002-0577-2275	National Institutes of Health [DP1OD003644]; National Science Foundation [DMS-0602204]; Howard Hughes Medical Institute; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003644] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank M. Chaparian and Q. Beg for help with bioreactor instrumentation. We also thank A. Herbert and C. Ordija for use of the Covaris sonicator for preparing sequencing libraries. This work was supported by the National Institutes of Health through the NIH Director's Pioneer Award Program, grant number DP1OD003644; the National Science Foundation through RTG grant number DMS-0602204; and the Howard Hughes Medical Institute.	Albert TJ, 2005, NAT METHODS, V2, P951, DOI 10.1038/NMETH805; Altuvia S, 1997, CELL, V90, P43, DOI 10.1016/S0092-8674(00)80312-8; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Bjedov I, 2003, SCIENCE, V300, P1404, DOI 10.1126/science.1082240; Dwyer DJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100135; Friedman L, 2006, ANTIMICROB AGENTS CH, V50, P2137, DOI 10.1128/AAC.00039-06; GOODER H, 1954, BIOCHEM J, V57, P369, DOI 10.1042/bj0570369; Herring CD, 2006, NAT GENET, V38, P1406, DOI 10.1038/ng1906; Hirakawa H, 2005, MOL MICROBIOL, V55, P1113, DOI 10.1111/j.1365-2958.2004.04449.x; Kobayashi A, 2006, J BACTERIOL, V188, P5693, DOI 10.1128/JB.00217-06; Kohanski MA, 2008, CELL, V135, P679, DOI 10.1016/j.cell.2008.09.038; Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049; Kohanski MA, 2010, MOL CELL, V37, P311, DOI 10.1016/j.molcel.2010.01.003; Lee JH, 2010, FEMS MICROBIOL REV, V34, P426, DOI 10.1111/j.1574-6976.2009.00204.x; Lee JT, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-42; Livermore DM, 2003, CLIN INFECT DIS, V36, pS11, DOI 10.1086/344654; Long F, 2008, ANTIMICROB AGENTS CH, V52, P3052, DOI 10.1128/AAC.00475-08; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; MILLER PF, 1994, ANTIMICROB AGENTS CH, V38, P1773, DOI 10.1128/AAC.38.8.1773; Mouneimne H, 1999, ANTIMICROB AGENTS CH, V43, P62, DOI 10.1128/AAC.43.1.62; Smith BT, 1998, GENETICS, V148, P1599; Smith PA, 2007, NAT CHEM BIOL, V3, P549, DOI 10.1038/nchembio.2007.27; Steiling K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005043; Talloen W, 2007, BIOINFORMATICS, V23, P2897, DOI 10.1093/bioinformatics/btm478; Travisano M, 1996, GENETICS, V143, P15; Tucker NP, 2010, TRENDS MICROBIOL, V18, P149, DOI 10.1016/j.tim.2009.12.009; Wang H, 2001, ANTIMICROB AGENTS CH, V45, P1515, DOI 10.1128/AAC.45.5.1515-1521.2001; West SA, 2006, NAT REV MICROBIOL, V4, P597, DOI 10.1038/nrmicro1461; Woodford N, 2007, CLIN MICROBIOL INFEC, V13, P5, DOI 10.1111/j.1469-0691.2006.01492.x	30	401	421	7	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					82	U113		10.1038/nature09354	http://dx.doi.org/10.1038/nature09354			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811456	Green Accepted			2022-12-28	WOS:000281461200039
J	Moster, D; Wilcox, AJ; Vollset, SE; Markestad, T; Lie, RT				Moster, Dag; Wilcox, Allen J.; Vollset, Stein Emil; Markestad, Trond; Lie, Rolv Terje			Cerebral Palsy Among Term and Postterm Births	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GESTATIONAL-AGE; EPIDEMIOLOGIC RESEARCH; PERINATAL FACTORS; PRETERM BIRTH; ANTECEDENTS; OUTCOMES; CHILDREN; COMPLICATIONS; PREVALENCE; INFANTS	Context Although preterm delivery is a well-established risk factor for cerebral palsy (CP), preterm deliveries contribute only a minority of affected infants. There is little information on the relation of CP risk to gestational age in the term range, where most CP occurs. Objective To determine whether timing of birth in the term and postterm period is associated with risk of CP. Design, Setting, and Participants Population-based follow-up study using the Medical Birth Registry of Norway to identify 1 682 441 singleton children born in the years 1967-2001 with a gestational age of 37 through 44 weeks and no congenital anomalies. The cohort was followed up through 2005 by linkage to other national registries. Main Outcome Measures Absolute and relative risk of CP for children surviving to at least 4 years of age. Results Of the cohort of term and postterm children, 1938 were registered with CP in the National Insurance Scheme. Infants born at 40 weeks had the lowest risk of CP, with a prevalence of 0.99/1000 (95% confidence interval [CI], 0.90-1.08). Risk for CP was higher with earlier or later delivery, with a prevalence at 37 weeks of 1.91/1000 (95% CI, 1.58-2.25) and a relative risk (RR) of 1.9 (95% CI, 1.6-2.4), a prevalence at 38 weeks of 1.25/1000 (95% CI, 1.07-1.42) and an RR of 1.3 (95% CI, 1.1-1.6), a prevalence at 42 weeks of 1.36/1000 (95% CI, 1.19-1.53) and an RR of 1.4 (95% CI, 1.2-1.6), and a prevalence after 42 weeks of 1.44 (95% CI, 1.15-1.72) and an RR of 1.4 (95% CI, 1.1-1.8). These associations were even stronger in a subset with gestational age based on ultrasound measurements: at 37 weeks the prevalence was 1.17/1000 (95% CI, 0.30-2.04) and the relative risk was 3.7 (95% CI, 1.5-9.1). At 42 weeks the prevalence was 0.85/1000 (95% CI, 0.33-1.38) and the relative risk was 2.4 (95% CI, 1.1-5.3). Adjustment for infant sex, maternal age, and various socioeconomic measures had little effect. Conclusion Compared with delivery at 40 weeks' gestation, delivery at 37 or 38 weeks or at 42 weeks or later was associated with an increased risk of CP. JAMA. 2010; 304(9): 976-982 www.jama.com	[Moster, Dag; Vollset, Stein Emil; Lie, Rolv Terje] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, N-5020 Bergen, Norway; [Markestad, Trond] Univ Bergen, Dept Clin Med, Sect Pediat, N-5020 Bergen, Norway; [Moster, Dag; Markestad, Trond] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway; [Wilcox, Allen J.] NIEHS, Epidemiol Branch, NIH, Durham, NC USA; [Vollset, Stein Emil; Lie, Rolv Terje] Norwegian Inst Publ Hlth, Med Birth Registry Norway, Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Norwegian Institute of Public Health (NIPH)	Moster, D (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Hlth Care, POB 7804, N-5020 Bergen, Norway.	Dag.Moster@smis.uib.no	Wilcox, Allen J/C-7723-2019	Wilcox, Allen J/0000-0002-3376-1311	National Institutes of Health, National Institute of Environmental Health Sciences; Unger-Vetlesen Charitable Fund; US-Norway Fulbright Foundation; Norwegian Society of Pediatricians; University of Bergen; Research Council of Norway; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES044003] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Unger-Vetlesen Charitable Fund; US-Norway Fulbright Foundation; Norwegian Society of Pediatricians; University of Bergen; Research Council of Norway(Research Council of Norway); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences; the Unger-Vetlesen Charitable Fund; The US-Norway Fulbright Foundation; the Norwegian Society of Pediatricians; the University of Bergen; and the Research Council of Norway.	Allen MC, 2008, CURR OPIN NEUROL, V21, P123, DOI 10.1097/WCO.0b013e3282f88bb4; Backe Bjorn, 1997, Tidsskrift for den Norske Laegeforening, V117, P2314; Blair E, 2009, FETAL NEONATAL NEURO, V4th, P867; Chaudhari BP, 2008, CLIN GENET, V74, P493, DOI 10.1111/j.1399-0004.2008.01124.x; Gulmezoglu AM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004945; Hack M, 2008, CLIN OBSTET GYNECOL, V51, P763, DOI 10.1097/GRF.0b013e3181870922; Himpens E, 2008, DEV MED CHILD NEUROL, V50, P334, DOI 10.1111/j.1469-8749.2008.02047.x; Irgens LM, 2000, ACTA OBSTET GYN SCAN, V79, P435, DOI 10.1034/j.1600-0412.2000.079006435.x; Jones K.L, 2006, SMITHS RECOGNIZABLE, V6th, P13; Kamel RM, 2010, ARCH GYNECOL OBSTET, V281, P975, DOI 10.1007/s00404-010-1365-9; Krageloh-Mann I, 2009, BRAIN DEV-JPN, V31, P537, DOI 10.1016/j.braindev.2009.03.009; Lynch CD, 2007, PAEDIATR PERINAT EP, V21, P86, DOI 10.1111/j.1365-3016.2007.00865.x; MANNINO F, 1988, J REPROD MED, V33, P271; Mesterman R, 2010, J CHILD NEUROL, V25, P36, DOI 10.1177/0883073809336677; Montenegro MA, 2005, J CHILD NEUROL, V20, P675, DOI 10.1177/08830738050200080801; Moster D, 2001, J PEDIATR-US, V138, P798, DOI 10.1067/mpd.2001.114694; Moster D, 2008, NEW ENGL J MED, V359, P262, DOI 10.1056/NEJMoa0706475; Msall ME, 2006, CLIN PERINATOL, V33, P269, DOI 10.1016/j.clp.2006.03.012; Nelson KB, 2008, CLIN OBSTET GYNECOL, V51, P749, DOI 10.1097/GRF.0b013e318187087c; Nelson KB, 2009, DEV MED CHILD NEUROL, V51, P765, DOI 10.1111/j.1469-8749.2009.03489.x; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; *NORW MIN LAB, 2010, SURV NORW SOC INS SC; Pakula AT, 2009, PHYS MED REH CLIN N, V20, P427, DOI 10.1016/j.pmr.2009.06.001; Paneth N, 2008, CLIN OBSTET GYNECOL, V51, P742, DOI 10.1097/GRF.0b013e318187081a; Perlman JM, 2006, CLIN PERINATOL, V33, P335, DOI 10.1016/j.clp.2006.03.004; Rankin J, 2010, DEV MED CHILD NEUROL, V52, P345, DOI 10.1111/j.1469-8749.2009.03415.x; Robertson CMT, 2009, PEDIATR NEUROL, V40, P189, DOI 10.1016/j.pediatrneurol.2008.09.017; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Shea KM, 1998, EPIDEMIOLOGY, V9, P199, DOI 10.1097/00001648-199803000-00017; Skjaerven R, 2000, ACTA OBSTET GYN SCAN, V79, P440, DOI 10.1034/j.1600-0412.2000.079006440.x; *STAT NORW, THIS IS STAT NORW I; The Norwegian Labour and Welfare Administration, MEMB NAT INS SCHEM; Thorngren-Jerneck K, 2006, OBSTET GYNECOL, V108, P1499, DOI 10.1097/01.AOG.0000247174.27979.6b; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; Walstab J, 2002, AUST NZ J OBSTET GYN, V42, P138, DOI 10.1111/j.0004-8666.2002.00138.x; Weijerman ME, 2008, J PEDIATR-US, V152, P15, DOI 10.1016/j.jpeds.2007.09.045; World Health Organization, INT CLASS DIS ICD; Yang S, 2010, AM J EPIDEMIOL, V171, P399, DOI 10.1093/aje/kwp413	39	78	79	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					976	982		10.1001/jama.2010.1271	http://dx.doi.org/10.1001/jama.2010.1271			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20810375	Green Accepted			2022-12-28	WOS:000281422400023
J	Larkin, J; Gore, M				Larkin, James; Gore, Martin			Is advanced renal cell carcinoma becoming a chronic disease?	LANCET			English	Editorial Material							INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; RESISTANCE		[Larkin, James; Gore, Martin] Royal Marsden Hosp, Dept Med, Renal Canc Unit, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Larkin, J (corresponding author), Royal Marsden Hosp, Dept Med, Renal Canc Unit, London SW3 6JJ, England.	james.larkin@rmh.nhs.uk		Larkin, James/0000-0001-5569-9523				Ainsworth NL, 2009, EXPERT REV ANTICANC, V9, P1793, DOI 10.1586/ERA.09.144; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Feldman DR, 2009, J CLIN ONCOL, V27, P1432, DOI 10.1200/JCO.2008.19.0108; Furge KA, 2010, LANCET ONCOL, V11, P571, DOI 10.1016/S1470-2045(09)70380-8; Huang D, 2010, CANCER RES, V70, P1053, DOI 10.1158/0008-5472.CAN-09-3722; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Ravaud A, 2010, ANN ONCOL, V21, DOI 10.1093/annonc/mdp548; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847; Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764	13	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2010	376	9741					574	575		10.1016/S0140-6736(10)60816-1	http://dx.doi.org/10.1016/S0140-6736(10)60816-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	643PB	20728740				2022-12-28	WOS:000281309100008
J	Colgrove, J; Abiola, S; Mello, MM				Colgrove, James; Abiola, Sara; Mello, Michelle M.			HPV Vaccination Mandates - Lawmaking amid Political and Scientific Controversy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC-HEALTH; ADOLESCENTS; COVERAGE		[Abiola, Sara; Mello, Michelle M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Colgrove, James] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Columbia University	Mello, MM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	mmello@hsph.harvard.edu		Mello, Michelle/0000-0003-2877-4270	Robert Wood Johnson Foundation; Greenwall Foundation	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Greenwall Foundation	Supported by the Robert Wood Johnson Foundation and the Greenwall Foundation's Faculty Scholars in Bioethics Program.	*ASS IMM MAN, POS STAT SCH CHILD C; Briss PA, 2000, AM J PREV MED, V18, P97, DOI 10.1016/S0749-3797(99)00118-X; *CDCP, 2007, SCH ENTR IMM ASS REP; Charo RA, 2007, NEW ENGL J MED, V356, P1905, DOI 10.1056/NEJMp078054; Childress JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/j.1748-720X.2002.tb00384.x; COLGROVE J, 2008, PENN CTR GUIDE BIOET, P647; Colgrove James Keith, 2006, STATE IMMUNITY POLIT; Freed GL, 2008, AM J PREV MED, V35, P145, DOI 10.1016/j.amepre.2008.03.033; Gibbs N., 2006, TIME            0621; Giffin R, 2004, HEALTH AFFAIR, V23, P98, DOI 10.1377/hlthaff.23.5.98; Hinman AR, 2000, AM J PREV MED, V18, P92; Lo B, 2006, BMJ-BRIT MED J, V332, P1106, DOI 10.1136/bmj.332.7550.1106; National Conference of State Legislatures, HPV VACC; Olshen E, 2007, J ADOLESCENT HEALTH, V40, P405, DOI 10.1016/j.jadohealth.2006.12.013; OROURKE M, 2007, CANC SLUTS DOES HPV; Salmon DA, 2005, AM J PUBLIC HEALTH, V95, P778, DOI 10.2105/AJPH.2004.046193; Wynia MK, 2007, AM J BIOETHICS, V7, P2, DOI 10.1080/15265160701795809	17	72	72	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					785	791		10.1056/NEJMsr1003547	http://dx.doi.org/10.1056/NEJMsr1003547			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639TE	20818883				2022-12-28	WOS:000280996600016
J	Manuel, DG; Rosella, LC; Stukel, TA				Manuel, Douglas G.; Rosella, Laura C.; Stukel, Therese A.			Importance of accurately identifying disease in studies using electronic health records	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; QUALITY; CARE; MISCLASSIFICATION; VALIDITY; ONTARIO		[Manuel, Douglas G.] Ottawa Hosp Res Inst, Ottawa, ON K1Y 4E9, Canada; [Manuel, Douglas G.] Stats Canada, Ottawa, ON, Canada; [Manuel, Douglas G.] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [Manuel, Douglas G.] Univ Ottawa, Dept Epidemiol, Ottawa, ON, Canada; [Manuel, Douglas G.] Univ Ottawa, Dept Community Med, Ottawa, ON, Canada; [Manuel, Douglas G.; Rosella, Laura C.; Stukel, Therese A.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Manuel, Douglas G.; Rosella, Laura C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Rosella, Laura C.; Stukel, Therese A.] Ontario Agcy Hlth Protect & Promot, Toronto, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; Statistics Canada; University of Ottawa; University of Ottawa; University of Ottawa; University of Toronto; University of Toronto	Manuel, DG (corresponding author), Ottawa Hosp Res Inst, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	dmanuel@ohri.ca		armstrong, benedict/0000-0003-4407-0409; Stukel, Therese/0000-0002-2951-1360				Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Couris CM, 2009, J CLIN EPIDEMIOL, V62, P660, DOI 10.1016/j.jclinepi.2008.07.013; Habbema J.D., 2002, EVIDENCE BASE CLIN D, P117; Health Council of Canada, 2007, WHY HLTH CAR REN MAT; Herrett E, 2010, BRIT J CLIN PHARMACO, V69, P4, DOI 10.1111/j.1365-2125.2009.03537.x; Hurtado M.P., 2001, ENVISIONING NATL HLT; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Joshy G, 2006, DIABETES TECHNOL THE, V8, P587, DOI 10.1089/dia.2006.8.587; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Kelsey JL., 1996, METHODS OBSERVATIONA; Lipscombe LL, 2007, LANCET, V369, P750, DOI 10.1016/S0140-6736(07)60361-4; Lix L, 2006, DEFINING VALIDATING; Lix LM, 2008, J CLIN EPIDEMIOL, V61, P1250, DOI 10.1016/j.jclinepi.2008.02.002; Mower WR, 1999, ANN EMERG MED, V33, P85, DOI 10.1016/S0196-0644(99)70422-1; Mullooly JP, 1996, AM J EPIDEMIOL, V144, P782; Newton J., 2002, DIS REGISTERS ENGLAN; *ONT MIN HLTH LONG, 2008, DIAB STRAT BACKGR; Powell AE, 2003, QUAL SAF HEALTH CARE, V12, P122, DOI 10.1136/qhc.12.2.122; ROGAN WJ, 1978, AM J EPIDEMIOL, V107, P71, DOI 10.1093/oxfordjournals.aje.a112510; Schulz EB, 1998, J AM MED INFORM ASSN, V5, P337, DOI 10.1136/jamia.1998.0050337; Sturmer T, 2002, EPIDEMIOLOGY, V13, P507, DOI 10.1097/01.EDE.0000023361.94572.7C; Tu JV, 2008, CAN MED ASSOC J, V179, P909, DOI 10.1503/cmaj.080749; van Walraven C, 2010, J CLIN EPIDEMIOL, V63, P1000, DOI 10.1016/j.jclinepi.2010.01.023; WHITE E, 1986, AM J EPIDEMIOL, V124, P816, DOI 10.1093/oxfordjournals.aje.a114458; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Woodward G, 2006, CAN MED ASSOC J, V174, P327, DOI 10.1503/cmaj.1031433; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	27	72	72	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2010	341								c4226	10.1136/bmj.c4226	http://dx.doi.org/10.1136/bmj.c4226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KW	20724404				2022-12-28	WOS:000281213400009
J	Bennett-Guerrero, E; Ferguson, TB; Lin, M; Garg, J; Mark, DB; Scavo, VA; Kouchoukos, N; Richardson, JB; Pridgen, RL; Corey, GR				Bennett-Guerrero, Elliott; Ferguson, T. Bruce, Jr.; Lin, Min; Garg, Jyotsna; Mark, Daniel B.; Scavo, Vincent A., Jr.; Kouchoukos, Nicholas; Richardson, John B., Jr.; Pridgen, Rence L.; Corey, G. R.		SWIPE-I Trial Grp	Effect of an Implantable Gentamicin-Collagen Sponge on Sternal Wound Infections Following Cardiac Surgery A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINE SERIES; LOCAL GENTAMICIN; ANTIBIOTIC-PROPHYLAXIS; RISK; SURVEILLANCE; SOCIETY	Context Despite the routine use of prophylactic systemic antibiotics, sternal wound infection still occurs in 5% or more of cardiac surgical patients and is associated with significant excess morbidity, mortality, and cost. The gentamicin-collagen sponge, a surgically implantable topical antibiotic, is currently approved in 54 countries. A large, 2-center, randomized trial in Sweden reported in 2005 that the sponge reduced surgical site infection by 50% in cardiac patients. Objective To test the hypothesis that the sponge prevents infection in cardiac surgical patients at increased risk for sternal wound infection. Design, Setting, and Participants Phase 3 single-blind, prospective randomized controlled trial, 1502 cardiac surgical patients at high risk for sternal wound infection (diabetes, body mass index >30, or both) were enrolled at 48 US sites between December 21, 2007, and March 11, 2009. Intervention Single-blind randomization to insertion of 2 gentamicin-collagen sponges (total gentamicin of 260 mg) between the sternal halves at surgical closure (n=753) vs no intervention (control group: n=749). All patients received standardized care including prophylactic systemic antibiotics and rigid sternal fixation. Main Outcome Measures The primary end point was sternal wound infection occurring through 90 days postoperatively as adjudicated by a clinical events classification committee blinded to study treatment group. The primary study comparison was done in the intent-to-treat population. Secondary outcomes included (1) superficial wound infection (involving subcutaneous tissue but not extending down to sternal fixation wires), (2) deep wound infection (involving the sternal wires, sternal bone, and/or mediastinum), and (3) score for additional treatment, presence of serous discharge, erythema, purulent exudate, separation of the deep tissues, isolation of bacteria, and duration of inpatient stay (ASEPSIS; minimum score of 0 with no theoretical maximum). Results Of 1502 patients, 1006 had diabetes (67%) and 1137 were obese (body mass index >30) (76%). In the primary analysis, there was no significant difference in sternal wound infection in 63 of 753 patients randomized to the gentamicin-collagen sponge group (8.4%) compared with 65 of 749 patients randomized to the control group (8.7%) (P=.83). No significant differences were observed between the gentamicin-collagen sponge group and the control group, respectively, in superficial sternal wound infection (49/753 [6.5%] vs 46/749 [6.1%]; P=.77), deep sternal wound infection (14/753 [1.9%] vs 19/749 [2.5%]; P=.37), ASEPSIS score (mean [SD], 1.9 [6.4] vs 2.0 [7.2]; P=.67), or rehospitalization for sternal wound infection (23/753 [3.1%] vs 24/749 [3.2%]; P=.87). Conclusion Among US patients with diabetes, high body mass index, or both undergoing cardiac surgery, the use of 2 gentamicin-collagen sponges compared with no intervention did not reduce the 90-day sternal wound infection rate. Trial Registration clinicaltrials.gov Identifier: NCT00600483 JAMA. 2010;304(7):755-762 www.jama.com	[Bennett-Guerrero, Elliott] Duke Univ, Med Ctr, Duke Clin Res Inst, Div Perioperat Clin Res, Durham, NC 27710 USA; [Lin, Min; Garg, Jyotsna] Duke Univ, Duke Clin Res Inst, Div Biostat & Bioinformat, Durham, NC 27710 USA; [Mark, Daniel B.] Duke Univ, Duke Clin Res Inst, Div Outcomes Res, Durham, NC 27710 USA; [Pridgen, Rence L.] Duke Univ, Duke Clin Res Inst, Div Project Leadership, Durham, NC 27710 USA; [Corey, G. R.] Duke Univ, Duke Clin Res Inst, Div Infect Dis, Durham, NC 27710 USA; [Ferguson, T. Bruce, Jr.] E Carolina Heart Inst, Dept Cardiovasc Sci, Greenville, NC USA; [Scavo, Vincent A., Jr.] Indiana Ohio Heart, Ft Wayne, IN USA; [Kouchoukos, Nicholas] Missouri Baptist Med Ctr, St Louis, MO USA; [Richardson, John B., Jr.] St Vincents Hosp, Birmingham, AL USA	Duke University; Duke University; Duke University; Duke University; Duke University; University of North Carolina; East Carolina University	Bennett-Guerrero, E (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, Div Perioperat Clin Res, POB 3094, Durham, NC 27710 USA.	Elliott.BennettGuerrero@Duke.edu	Lin, Matthew J/G-8702-2019	Lin, Matthew J/0000-0003-2674-9987; Mark, Daniel/0000-0001-6340-8087	Innocoll Technologies Ltd; Duke Clinical Research Institute, a department of Duke University, Durham, North Carolina	Innocoll Technologies Ltd; Duke Clinical Research Institute, a department of Duke University, Durham, North Carolina	The study was sponsored by Innocoll Technologies Ltd and coordinated by the Duke Clinical Research Institute, a department of Duke University, Durham, North Carolina. Each coauthor received research funding and support from the Innocoll Technologies Ltd. None of the coauthors is or has been employed by Innocoll Technologies Ltd. Role of the Sponsor: The sponsor, Innocoll Technologies Ltd, designed the study and wrote the protocol in conjunction with the Duke Clinical Research Institute and an external member of the steering committee (Dr Ferguson, East Carolina Heart Institute). The sponsor was not involved in collection or management of the data. The sponsor did not conduct any statistical analyses, but did assist in analyzing and interpreting the data. The sponsor did not prepare the manuscript. Drs Bennett-Guerrero and Corey wrote the first draft of the manuscript. The sponsor reviewed the manuscript and provided minor comments. The study agreement provided Duke University freedom to publish the trial results without sponsor approval; therefore, the sponsor did not formally approve the manuscript. The Duke Clinical Research Institute wrote the protocol, gathered the data, maintained and controlled the database, analyzed the data, vouches for the data and analysis, wrote the manuscript, and decided to publish the manuscript.	Bellomo R, 2009, CRIT CARE MED, V37, P3114, DOI 10.1097/CCM.0b013e3181bc7bd5; Bratzler DW, 2004, CLIN INFECT DIS, V38, P1706, DOI 10.1086/421095; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; DEMMY TL, 1990, ANN THORAC SURG, V49, P458, DOI 10.1016/0003-4975(90)90256-6; Edwards FH, 2006, ANN THORAC SURG, V81, P397, DOI 10.1016/j.athoracsur.2005.06.034; Eklund AM, 2005, J HOSP INFECT, V59, P108, DOI 10.1016/j.jhin.2004.10.005; Engelman R, 2007, ANN THORAC SURG, V83, P1569, DOI 10.1016/j.athoracsur.2006.09.046; Fleischmann E, 2005, LANCET, V366, P1101, DOI 10.1016/S0140-6736(05)67422-3; Friberg O, 2007, EUR J CLIN MICROBIOL, V26, P91, DOI 10.1007/s10096-006-0252-6; Friberg O, 2006, THORAC CARDIOV SURG, V54, P468, DOI 10.1055/s-2006-924437; Friberg O, 2006, SCAND CARDIOVASC J, V40, P117, DOI 10.1080/14017430500363024; Friberg O, 2005, ANN THORAC SURG, V79, P153, DOI 10.1016/j.athoracsur.2004.06.043; Friberg O, 2003, SCAND J INFECT DIS, V35, P251, DOI 10.1080/003655400310000184; Fry Donald E, 2002, Surg Infect (Larchmt), V3 Suppl 1, pS37, DOI 10.1089/sur.2002.3.s1-37; Glickman SW, 2009, NEW ENGL J MED, V360, P816, DOI 10.1056/NEJMsb0803929; Gordon D B, 1999, J Palliat Med, V2, P209, DOI 10.1089/jpm.1999.2.209; HALEY RW, 1985, AM J EPIDEMIOL, V121, P206, DOI 10.1093/oxfordjournals.aje.a113991; Moet GJ, 2007, DIAGN MICR INFEC DIS, V57, P7, DOI 10.1016/j.diagmicrobio.2006.05.009; PARSONNET V, 1989, CIRCULATION, V79, P3; Tang Gilbert H L, 2004, Semin Thorac Cardiovasc Surg, V16, P62; Wilson APR, 2004, BRIT MED J, V329, P720, DOI 10.1136/bmj.38232.646227.DE; WILSON APR, 1990, J HOSP INFECT, V16, P297, DOI 10.1016/0195-6701(90)90002-6	22	97	101	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					755	762		10.1001/jama.2010.1152	http://dx.doi.org/10.1001/jama.2010.1152			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20716738				2022-12-28	WOS:000280993700022
J	Kainz, A; Wilflingseder, J; Mitterbauer, C; Haller, M; Burghuber, C; Perco, P; Langer, RM; Heinze, G; Oberbauer, R				Kainz, Alexander; Wilflingseder, Julia; Mitterbauer, Christa; Haller, Maria; Burghuber, Christopher; Perco, Paul; Langer, Robert M.; Heinze, Georg; Oberbauer, Rainer			Steroid Pretreatment of Organ Donors to Prevent Postischemic Renal Allograft Failure A Randomized, Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							GENE-EXPRESSION PATTERNS; KIDNEY-TRANSPLANTATION; GRAFT FUNCTION; MICROARRAY DATA; IN-VITRO; CORTICOSTEROIDS; GLUCOCORTICOIDS; BIOPSIES; SURVIVAL; METHYLPREDNISOLONE	Background: Posttransplantation acute renal failure (ARF) occurs in roughly 25% of recipients of organs from deceased donors. Inflammation in the donor organ is associated with risk for ARF. Objective: To determine whether administering corticosteroids to deceased organ donors reduces the incidence and duration of ARF in organ recipients more than placebo. Design: Parallel, blocked randomized trial, performed between February 2006 and November 2008, with computer-generated randomization and centralized allocation. Investigators were masked to group assignment. (Controlled-trials.com registration number: ISRCTN78828338) Setting: 3 renal transplantation centers in Austria and Hungary. Patients: 306 deceased heart-beating donors and 455 renal transplant recipients. Interventions: Organ donors were administered an intravenous infusion of either 1000 mg of methylprednisolone (136 donors) or placebo (0.9% saline) (133 donors) at least 3 hours before organ harvesting. Measurements: Incidence of ARF, defined as more than 1 dialysis session in the first week after transplantation, was the primary end point. Secondary and other end points included duration of ARF and trajectories of serum creatinine level. The suppression of immune response and inflammation by the intervention was assessed in the donor organ on a genome-wide basis. Results: 52 of 238 recipients (22%) of kidneys from steroid-treated donors and 54 of 217 recipients (25%) of kidneys from placebo-treated donors had ARF (difference, 3 percentage points [95% CI, -11 to 5 percentage points]). One graft was lost on day 1 in each group, and 1 recipient in the placebo group died of cardiac arrest on day 2. The median duration of ARF was 5 days (interquartile range, 2 days) in the steroid group and 4 days (interquartile range, 2 days) in the placebo group (P = 0.31). The groups had similar trajectories of serum creatinine level in the first week (P = 0.72). Genomic analysis showed suppressed inflammation and immune response in kidney biopsies from deceased donors who received corticosteroids. Limitation: Donors and recipients were mainly white, and all were from 3 transplantation centers in central Europe, which may limit generalizability. Conclusion: Systemic suppression of inflammation in deceased donors by corticosteroids did not reduce the incidence or duration of posttransplantation ARF in allograft recipients.	[Oberbauer, Rainer] Med Univ Vienna, Dept Nephrol, A-1090 Vienna, Austria; [Haller, Maria; Perco, Paul] KH Elisabethinen, Nephrol, A-4010 Linz, Austria; [Langer, Robert M.] Semmelweis Univ, H-1085 Budapest, Hungary	Medical University of Vienna; Ordensklinikum Linz Elisabethinen; Semmelweis University	Oberbauer, R (corresponding author), Med Univ Vienna, Dept Nephrol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	alexander.kainz@meduniwien.ac.at; rainer.oberbauer@meduniwien.ac.at	Burghuber, Christopher/AAB-8501-2021; Haller, Maria C./S-8390-2019; Kainz, Alexander/AAM-7296-2021; Perco, Paul/U-2489-2019	Haller, Maria C./0000-0003-4635-6291; Perco, Paul/0000-0003-2087-5691; Wilflingseder, Julia/0000-0002-0230-9349; Heinze, Georg/0000-0003-1147-8491; Burghuber, Christopher/0000-0002-5758-7549	Austrian Science Fund; Austrian Academy of Science	Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Academy of Science	Primary Funding Source: Austrian Science Fund and Austrian Academy of Science.	[Anonymous], 2007, US REN DAT SYST 2007; Ansari AW, 2007, CLIN IMMUNOL, V125, P1, DOI 10.1016/j.clim.2007.07.003; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273; CHATTERJEE SN, 1977, SURG GYNECOL OBSTET, V145, P729; Chen JX, 2006, PROCEEDINGS OF THE 2006 IEEE INTERNATIONAL CONFERENCE ON VEHICULAR ELECTRONICS AND SAFETY, P367; Chen SD, 2008, NEUROSCI LETT, V440, P87, DOI 10.1016/j.neulet.2008.03.092; de Kruif MD, 2008, INTENS CARE MED, V34, P518, DOI 10.1007/s00134-007-0955-x; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Dolce CJ, 2009, SURG ENDOSC, V23, P1564, DOI 10.1007/s00464-009-0340-7; Efron B., 1994, MONOGRAPHS STAT APPL; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; *EUR REN ASS, 2008, ERA EDTA REG 2006 AN; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; GROENEWOUD AF, 1993, TRANSPLANT P, V25, P1582; GUTTMANN RD, 1978, KIDNEY INT, pS99; Hansson AC, 2008, BRAIN RES, V1215, P1, DOI 10.1016/j.brainres.2008.03.080; Hata Y, 2008, BRIT J OPHTHALMOL, V92, P1540, DOI 10.1136/bjo.2008.141002; Hauser P, 2004, LAB INVEST, V84, P353, DOI 10.1038/labinvest.3700037; Heinze G, 2006, J AM SOC NEPHROL, V17, P889, DOI 10.1681/ASN.2005090955; Hoffmann R, 2004, NAT GENET, V36, P664, DOI 10.1038/ng0704-664; Hubler TR, 2004, CELL STRESS CHAPERON, V9, P243, DOI 10.1379/CSC-32R.1; Ishmael FT, 2008, J IMMUNOL, V180, P8342, DOI 10.4049/jimmunol.180.12.8342; Jager KJ, 2007, NEPHROL DIAL TRANSPL, V22, P678, DOI 10.1093/ndt/gfm060; Jassal SV, 2003, J AM SOC NEPHROL, V14, P187, DOI 10.1097/01.ASN.0000042166.70351.57; JEFFERY JR, 1978, TRANSPLANTATION, V25, P287, DOI 10.1097/00007890-197806000-00001; Kainz A, 2004, AM J TRANSPLANT, V4, P1595, DOI 10.1111/j.1600-6143.2004.00554.x; Kainz A, 2007, TRANSPLANTATION, V83, P1048, DOI 10.1097/01.tp.0000259960.56786.ec; Lund T, 2008, TRANSPL INT, V21, P669, DOI 10.1111/j.1432-2277.2008.00664.x; Makrygiannakis D, 2006, ARTHRITIS RHEUM-US, V54, P1463, DOI 10.1002/art.21767; McTiernan CF, 1997, CIRC RES, V81, P493, DOI 10.1161/01.RES.81.4.493; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Moers C, 2009, NEW ENGL J MED, V360, P7, DOI 10.1056/NEJMoa0802289; Ojo AO, 1997, TRANSPLANTATION, V63, P968, DOI 10.1097/00007890-199704150-00011; Ojo AO, 2001, J AM SOC NEPHROL, V12, P589, DOI 10.1681/ASN.V123589; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Perco P, 2009, TRANSPLANTATION, V87, P290, DOI 10.1097/TP.0b013e318191b4c0; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Schabenberger O, 2005, SUGI 30 P; Schnuelle P, 2009, JAMA-J AM MED ASSOC, V302, P1067, DOI 10.1001/jama.2009.1310; Schwarz C, 2003, CURR OPIN UROL, V13, P99, DOI 10.1097/00042307-200303000-00003; SOULILLOU JP, 1979, NEPHRON, V24, P193, DOI 10.1159/000181714; STERIOFF S, 1981, ARCH SURG-CHICAGO, V116, P73; Troppmann C, 2010, TRANSPLANTATION, V89, P858, DOI 10.1097/TP.0b013e3181ca570f; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; ZINCKE H, 1977, SURG GYNECOL OBSTET, V145, P183; ZINCKE H, 1978, TRANSPLANTATION, V26, P207, DOI 10.1097/00007890-197810000-00001	53	52	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4					222	230		10.7326/0003-4819-153-4-201008170-00003	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713790				2022-12-28	WOS:000280973000002
J	Klaus, EM				Klaus, Ernst Markus			Velvet Palms	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Orange Free State, Bloemfontein, South Africa	University of the Free State	Klaus, EM (corresponding author), Univ Orange Free State, Bloemfontein, South Africa.	markusgerdi@yahoo.co.uk							0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					573	573		10.1056/NEJMicm0911773	http://dx.doi.org/10.1056/NEJMicm0911773			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818892				2022-12-28	WOS:000280552700011
J	Bhutto, ZA; Bhutta, SZ				Bhutto, Zulfiqar A.; Bhutta, Shereen Zulfiqar			The unfolding human tragedy in Pakistan: fighting alone	LANCET			English	Editorial Material									[Bhutto, Zulfiqar A.] Aga Khan Univ, Div Women & Child Hlth, Karachi 74800, Pakistan; [Bhutta, Shereen Zulfiqar] Jinnah Postgrad Med Ctr, Dept Obstet & Gynecol, Karachi, Pakistan	Aga Khan University	Bhutto, ZA (corresponding author), Aga Khan Univ, Div Women & Child Hlth, Karachi 74800, Pakistan.							Hussain A, 2003, PAKISTAN NATL HUMAN; *NGO RES CTR, 2000, PHIL PAK REP IN IND; Sullivan KM, 2010, DISASTERS, V34, P176, DOI 10.1111/j.1467-7717.2009.01121.x; *WHO, 2010, FLOOD COMM DIS FACT; 2010, DAILY TIMES     0817; 2010, DAILY TIMES     0815	6	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2010	376	9742					664	665		10.1016/S0140-6736(10)61306-2	http://dx.doi.org/10.1016/S0140-6736(10)61306-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	646YW	20801388				2022-12-28	WOS:000281582900007
J	Sammler, EM; Foley, PL; Lauder, GD; Wilson, SJ; Goudie, AR; O'Riordan, JI				Sammler, Esther M.; Foley, Peter L.; Lauder, Gavin D.; Wilson, Simon J.; Goudie, Andrew R.; O'Riordan, Jonathan I.			A harmless high?	LANCET			English	Editorial Material									[Sammler, Esther M.; Foley, Peter L.; Wilson, Simon J.; O'Riordan, Jonathan I.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Neurol, Dundee DD1 9SY, Scotland; [Lauder, Gavin D.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Biochem Med, Dundee DD1 9SY, Scotland; [Goudie, Andrew R.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Sammler, EM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Neurol, Dundee DD1 9SY, Scotland.			Sammler, Esther/0000-0003-3218-7116; foley, peter/0000-0001-7039-2976; O'Riordan, Jonathan/0000-0001-6774-2488				Henry JA, 1998, LANCET, V351, P1784, DOI 10.1016/S0140-6736(05)78744-4; Rosenson J, 2007, ANN EMERG MED, V49, P164, DOI 10.1016/j.annemergmed.2006.09.018; WINSTOCK AR, BMJ, V340, pC1605; Wood DM, 2010, J MED TOXICOL, V6, P327, DOI 10.1007/s13181-010-0018-5	4	46	48	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2010	376	9742					742	742		10.1016/S0140-6736(10)60891-4	http://dx.doi.org/10.1016/S0140-6736(10)60891-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646YW	20801405				2022-12-28	WOS:000281582900034
J	Nazir, T; Punekar, S				Nazir, Tahir; Punekar, Shuja			Pneumothorax -- An Uncommon Complication of a Common Procedure.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Nazir, Tahir; Punekar, Shuja] Royal Preston Hosp, Preston, Lancs, England	Royal Preston Hospital	Nazir, T (corresponding author), Royal Preston Hosp, Preston, Lancs, England.	drtahirnazir@hotmail.com	Punekar, Shuja/AFO-2604-2022						0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					462	462		10.1056/NEJMicm0912444	http://dx.doi.org/10.1056/NEJMicm0912444			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818866				2022-12-28	WOS:000280411300010
J	BEECHAM, L				BEECHAM, L			NO AGENDA FOR DISMANTLING NHS, FORUM TOLD	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1988	296	6630					1206	1207						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N0662	20742986				2022-12-28	WOS:A1988N066200056
J	Bhatt, DL; Eagle, KA; Ohman, EM; Hirsch, AT; Goto, S; Mahoney, EM; Wilson, PWF; Alberts, MJ; D'Agostino, R; Liau, CS; Mas, JL; Rother, J; Smith, SC; Salette, G; Contant, CF; Massaro, JM; Steg, PG				Bhatt, Deepak L.; Eagle, Kim A.; Ohman, E. Magnus; Hirsch, Alan T.; Goto, Shinya; Mahoney, Elizabeth M.; Wilson, Peter W. F.; Alberts, Mark J.; D'Agostino, Ralph; Liau, Chiau-Suong; Mas, Jean-Louis; Roether, Joachim; Smith, Sidney C., Jr.; Salette, Genevieve; Contant, Charles F.; Massaro, Joseph M.; Steg, Ph. Gabriel		REACH Registry Investigators	Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CORONARY SYNDROME; DISEASE; ROSIGLITAZONE; CLOPIDOGREL; PREVENTION; REDUCTION; CANGRELOR; MORTALITY; OUTCOMES; ASPIRIN	Context Clinicians and trialists have difficulty with identifying which patients are highest risk for cardiovascular events. Prior ischemic events, polyvascular disease, and diabetes mellitus have all been identified as predictors of ischemic events, but their comparative contributions to future risk remain unclear. Objective To categorize the risk of cardiovascular events in stable outpatients with various initial manifestations of atherothrombosis using simple clinical descriptors. Design, Setting, and Patients Outpatients with coronary artery disease, cerebrovascular disease, or peripheral arterial disease or with multiple risk factors for atherothrombosis were enrolled in the global Reduction of Atherothrombosis for Continued Health (REACH) Registry and were followed up for as long as 4 years. Patients from 3647 centers in 29 countries were enrolled between 2003 and 2004 and followed up until 2008. Final database lock was in April 2009. Main Outcome Measures Rates of cardiovascular death, myocardial infarction, and stroke. Results A total of 45 227 patients with baseline data were included in this 4-year analysis. During the follow-up period, a total of 5481 patients experienced at least 1 event, including 2315 with cardiovascular death, 1228 with myocardial infarction, 1898 with stroke, and 40 with both a myocardial infarction and stroke on the same day. Among patients with atherothrombosis, those with a prior history of ischemic events at baseline (n=21 890) had the highest rate of subsequent ischemic events (18.3%; 95% confidence interval [CI], 17.4%-19.1%); patients with stable coronary, cerebrovascular, or peripheral artery disease (n=15 264) had a lower risk (12.2%; 95% CI, 11.4%-12.9%); and patients without established atherothrombosis but with risk factors only (n=8073) had the lowest risk (9.1%; 95% CI, 8.3%-9.9%) (P<.001 for all comparisons). In addition, in multivariable modeling, the presence of diabetes (hazard ratio [HR], 1.44; 95% CI, 1.36-1.53; P<.001), an ischemic event in the previous year (HR, 1.71; 95% CI, 1.57-1.85; P<.001), and polyvascular disease (HR, 1.99; 95% CI, 1.78-2.24; P<.001) each were associated with a significantly higher risk of the primary end point. Conclusion Clinical descriptors can assist clinicians in identifying high-risk patients within the broad range of risk for outpatients with atherothrombosis. JAMA. 2010; 304(12): 1350-1357	[Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA 02132 USA; [Alberts, Mark J.] Northwestern Univ, Sch Med, Chicago, IL USA; [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA; [D'Agostino, Ralph] Boston Univ, Boston, MA 02215 USA; [Eagle, Kim A.] Univ Michigan, Ann Arbor, MI 48109 USA; [Goto, Shinya] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan; [Hirsch, Alan T.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; [Liau, Chiau-Suong] Taiwan Univ Hosp, Taipei, Taiwan; [Liau, Chiau-Suong] Coll Med, Taipei, Taiwan; [Mas, Jean-Louis] Ctr Raymond Garcin, Paris, France; [Ohman, E. Magnus] Duke Univ, Med Ctr, Durham, NC USA; [Roether, Joachim] Asklepios Klin Altona, Dept Neurol, Hamburg, Germany; [Smith, Sidney C., Jr.] Univ N Carolina, Chapel Hill, NC USA; [Steg, Ph. Gabriel] Hop Bichat Claude Bernard, F-75877 Paris 18, France; [Wilson, Peter W. F.] Emory Univ, Sch Med, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Northwestern University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; University of Michigan System; University of Michigan; Tokai University; University of Minnesota System; University of Minnesota Twin Cities; National Taiwan University; Duke University; Asklepios Klinik Altona; University of North Carolina; University of North Carolina Chapel Hill; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Emory University	Bhatt, DL (corresponding author), VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA.	dlbhattmd@post.harvard.edu	Goto, Shinya/AAU-6045-2020; Wilson, Peter W.F./J-2455-2016; STEG, Philippe Gabriel/Z-1567-2019; Statsenko, Mikhail E./N-7573-2015	Goto, Shinya/0000-0002-6821-1504; Statsenko, Mikhail E./0000-0002-3306-0312; STEG, Philippe Gabriel/0000-0001-6896-2941; Massaro, Joseph/0000-0002-2682-4812	AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Heartscape; Sanofi-Aventis; Medicines Company; Blue Cross Blue Shield of Michigan; National Institutes of Health (NIH); Mardigian Foundation; GORE; Hewlett Foundation; CV Therapeutics; Daiichi Sankyo; Datascope; Eli Lilly; Marquet; Schering-Plough; Abbott Vascular; Ono; Otsuka; Sankyo; Daiichi; Takeda; Asteras; Kowa; AGA Medical; Boehringer Ingelheim; EKR; Servier; Waksman Foundation (Tokyo, Japan)	AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Eisai(Eisai Co Ltd); Ethicon; Heartscape; Sanofi-Aventis(Sanofi-Aventis); Medicines Company; Blue Cross Blue Shield of Michigan; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mardigian Foundation; GORE; Hewlett Foundation; CV Therapeutics; Daiichi Sankyo(Daiichi Sankyo Company Limited); Datascope; Eli Lilly(Eli Lilly); Marquet; Schering-Plough(Merck & CompanySchering Plough Corporation); Abbott Vascular(Abbott Laboratories); Ono; Otsuka(Otsuka Pharmaceutical); Sankyo; Daiichi(Daiichi Sankyo Company Limited); Takeda(Takeda Pharmaceutical Company Ltd); Asteras; Kowa; AGA Medical; Boehringer Ingelheim(Boehringer Ingelheim); EKR; Servier(Servier); Waksman Foundation (Tokyo, Japan)	Dr Bhatt reported having received institutional research support from AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi-Aventis, and The Medicines Company. Dr Eagle reported having received grant/research support from Bristol-Myers Squibb, Blue Cross Blue Shield of Michigan, the National Institutes of Health (NIH), Sanofi-Aventis, the Mardigian Foundation Varbedian Fund, GORE, and the Hewlett Foundation and being a consultant for the NIH National Heart, Lung, and Blood Institute, Sanofi-Aventis, and the Robert Wood Johnson Foundation. Dr Ohman reported receiving research grants from Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo, Datascope, Eli Lilly, Marquet, Sanofi-Aventis, Schering-Plough, and The Medicines Company and providing consulting or other services for Abiomed, AstraZeneca, CV Therapeutics, Datascope, Gilead Sciences, Liposcience, Marquet, Northpoint Domain, Pozen, Response Biomedical, Sanofi-Aventis, The Medicines Company, and WebMD (theheart.org). Dr Hirsch reported having received research grants from Bristol-Myers Squibb, Sanofi-Aventis, and Abbott Vascular and served as a consultant to Roche, Cytokinetics, ev3, and Talecris. Dr Goto reported having received research grants from Pfizer, Sanofi-Aventis, Ono, Eisai, Otsuka, Sankyo, Daiichi, Takeda, Asteras, Kowa, and AstraZeneca and honoraria from Sanofi-Aventis, Eisai, Otsuka, Daiichi-Sankyo, and Schering-Plough. Dr Mahoney reported having received grant support from Sanofi-Aventis, Bristol-Myers Squibb, Daiichi-Sankyo, and Eli Lilly and honoraria from Sanofi-Aventis and Bristol-Myers Squibb. Dr Wilson reported having received research grants from Sanofi-Aventis. Dr Alberts reported having received research support from AGA Medical, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, EKR, Sanofi-Aventis, and Schering-Plough; having participated in speakers' bureaus for Bristol-Myers Squibb, Boehringer Ingelheim, DiaDexus, Genentech, MedScape, and Sanofi-Aventis; having received honoraria from Bristol-Myers Squibb, Boehringer Ingelheim, DiaDexus, Genentech, MedScape, and Sanofi-Aventis; and having acted as a consultant or advisory board member for Bristol-Myers Squibb, Boehringer Ingelheim, EKR, Genentech, Merck, Pfizer, and Sanofi-Aventis. Dr D'Agostino reported having received honoraria from Sanofi-Aventis. Dr Liau reported no disclosures. Dr Mas reported having received research grants, honoraria, and consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, and Servier and honoraria and consulting fees from Boehringer Ingelheim. Dr Rother reported having participated in speakers' bureaus for Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, and Lundbeck and having acted as a consultant or advisory board member for Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, and Lundbeck. Dr Smith Jr reported no disclosures. Dr Salette reported being an employee of Sanofi-Aventis. Dr Contant reported no disclosures. Dr Massaro reported having received honoraria from Sanofi-Aventis. Dr Steg reported having received research grants (to his institution) from Servier; participating in consultancy or advisory boards for Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Medtronic, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, and The Medicines Company; and being a stockholder in Aterovax.; The REACH Registry is sponsored by Sanofi-Aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan). The REACH Registry is endorsed by the World Heart Federation.	Alberts MJ, 2009, EUR HEART J, V30, P2318, DOI 10.1093/eurheartj/ehp355; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Bhatt DL, 2010, JAMA-J AM MED ASSOC, V303, P2188, DOI 10.1001/jama.2010.743; Bhatt DL, 2009, NEW ENGL J MED, V361, P2330, DOI 10.1056/NEJMoa0908629; Bhatt DL, 2009, EUR HEART J, V30, P1195, DOI 10.1093/eurheartj/ehp099; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180; Brilakis ES, 2009, CIRCULATION, V120, P560, DOI 10.1161/CIRCULATIONAHA.109.877092; CHANG IM, 1982, J CHRON DIS, V35, P669, DOI 10.1016/0021-9681(82)90019-4; Eagle KA, 2004, JAMA-J AM MED ASSOC, V291, P2727, DOI 10.1001/jama.291.22.2727; Fonarow GC, 2005, JAMA-J AM MED ASSOC, V293, P572, DOI 10.1001/jama.293.5.572; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Harrington RA, 2009, NEW ENGL J MED, V361, P2318, DOI 10.1056/NEJMoa0908628; Home PD, 2007, NEW ENGL J MED, V357, P28, DOI 10.1056/NEJMoa073394; Krempf M, 2010, AM J CARDIOL, V105, P667, DOI 10.1016/j.amjcard.2009.10.048; Mahoney EM, 2008, CIRC-CARDIOVASC QUAL, V1, P38, DOI 10.1161/CIRCOUTCOMES.108.775247; Mehta C, 2009, CIRCULATION, V119, P597, DOI 10.1161/CIRCULATIONAHA.108.809707; Muller-Riemenschneider F, 2010, ARCH INTERN MED, V170, P719, DOI 10.1001/archinternmed.2010.66; Ohman EM, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2005.11.004; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Singh S, 2007, JAMA-J AM MED ASSOC, V298, P1189, DOI 10.1001/jama.298.10.1189; Steg PG, 2007, JAMA-J AM MED ASSOC, V297, P1197, DOI 10.1001/jama.297.11.1197; Topol EJ, 2010, LANCET, V376, P517, DOI 10.1016/S0140-6736(10)60935-X	23	539	591	0	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1350	1357		10.1001/jama.2010.1322	http://dx.doi.org/10.1001/jama.2010.1322			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20805624	Bronze			2022-12-28	WOS:000282007900018
J	Bilguvar, K; Ozturk, AK; Louvi, A; Kwan, KY; Choi, M; Tatli, B; Yalnizoglu, D; Tuysuz, B; Caglayan, AO; Gokben, S; Kaymakcalan, H; Barak, T; Bakircioglu, M; Yasuno, K; Ho, W; Sanders, S; Zhu, Y; Yilmaz, S; Dincer, A; Johnson, MH; Bronen, RA; Kocer, N; Per, H; Mane, S; Pamir, MN; Yalcinkaya, C; Kumandas, S; Topcu, M; Ozmen, M; Sestan, N; Lifton, RP; State, MW; Gunel, M				Bilguvar, Kaya; Ozturk, Ali Kemal; Louvi, Angeliki; Kwan, Kenneth Y.; Choi, Murim; Tatli, Burak; Yalnizoglu, Dilek; Tuysuz, Beyhan; Caglayan, Ahmet Okay; Gokben, Sarenur; Kaymakcalan, Hande; Barak, Tanyeri; Bakircioglu, Mehmet; Yasuno, Katsuhito; Ho, Winson; Sanders, Stephan; Zhu, Ying; Yilmaz, Sanem; Dincer, Alp; Johnson, Michele H.; Bronen, Richard A.; Kocer, Naci; Per, Hueseyin; Mane, Shrikant; Pamir, Mehmet Necmettin; Yalcinkaya, Cengiz; Kumandas, Sefer; Topcu, Meral; Ozmen, Meral; Sestan, Nenad; Lifton, Richard P.; State, Matthew W.; Gunel, Murat			Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations	NATURE			English	Article							HUMAN CEREBRAL-CORTEX; GENETIC MALFORMATIONS; CLASSIFICATION; SLITRK1; CAPTURE	The development of the human cerebral cortex is an orchestrated process involving the generation of neural progenitors in the periventricular germinal zones, cell proliferation characterized by symmetric and asymmetric mitoses, followed by migration of post-mitotic neurons to their final destinations in six highly ordered, functionally specialized layers(1,2). An understanding of the molecular mechanisms guiding these intricate processes is in its infancy, substantially driven by the discovery of rare mutations that cause malformations of cortical development(3-6). Mapping of disease loci in putative Mendelian forms of malformations of cortical development has been hindered by marked locus heterogeneity, small kindred sizes and diagnostic classifications that may not reflect molecular pathogenesis. Here we demonstrate the use of whole-exome sequencing to overcome these obstacles by identifying recessive mutations in WD repeat domain 62 (WDR62) as the cause of a wide spectrum of severe cerebral cortical malformations including microcephaly, pachygyria with cortical thickening as well as hypoplasia of the corpus callosum. Some patients with mutations in WDR62 had evidence of additional abnormalities including lissencephaly, schizencephaly, polymicrogyria and, in one instance, cerebellar hypoplasia, all traits traditionally regarded as distinct entities. In mice and humans, WDR62 transcripts and protein are enriched in neural progenitors within the ventricular and subventricular zones. Expression of WDR62 in the neocortex is transient, spanning the period of embryonic neurogenesis. Unlike other known microcephaly genes, WDR62 does not apparently associate with centrosomes and is predominantly nuclear in localization. These findings unify previously disparate aspects of cerebral cortical development and highlight the use of whole-exome sequencing to identify disease loci in settings in which traditional methods have proved challenging.	[Bilguvar, Kaya; Ozturk, Ali Kemal; Louvi, Angeliki; Choi, Murim; Barak, Tanyeri; Bakircioglu, Mehmet; Yasuno, Katsuhito; Ho, Winson; Sanders, Stephan; Mane, Shrikant; Lifton, Richard P.; State, Matthew W.; Gunel, Murat] Yale Univ, Sch Med, Dept Genet, Ctr Human Genet & Genom, New Haven, CT 06510 USA; [Bilguvar, Kaya; Ozturk, Ali Kemal; Louvi, Angeliki; Choi, Murim; Barak, Tanyeri; Bakircioglu, Mehmet; Yasuno, Katsuhito; Ho, Winson; Sanders, Stephan; Mane, Shrikant; Lifton, Richard P.; State, Matthew W.; Gunel, Murat] Yale Univ, Sch Med, Program Neurogenet, New Haven, CT 06510 USA; [Bilguvar, Kaya; Ozturk, Ali Kemal; Louvi, Angeliki; Barak, Tanyeri; Bakircioglu, Mehmet; Yasuno, Katsuhito; Ho, Winson; Johnson, Michele H.; Bronen, Richard A.; Gunel, Murat] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06510 USA; [Bilguvar, Kaya; Ozturk, Ali Kemal; Louvi, Angeliki; Kwan, Kenneth Y.; Barak, Tanyeri; Bakircioglu, Mehmet; Yasuno, Katsuhito; Ho, Winson; Zhu, Ying; Sestan, Nenad; Gunel, Murat] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA; [Kwan, Kenneth Y.; Zhu, Ying; Sestan, Nenad] Yale Univ, Sch Med, Kavli Inst Neurosci, New Haven, CT 06510 USA; [Tatli, Burak; Ozmen, Meral] Istanbul Univ, Istanbul Fac Med, Dept Pediat, Div Neurol, TR-34093 Istanbul, Turkey; [Yalnizoglu, Dilek; Topcu, Meral] Hacettepe Univ, Sch Med, Dept Pediat, Div Neurol, TR-06100 Ankara, Turkey; [Tuysuz, Beyhan] Istanbul Univ, Cerrahpasa Fac Med, Dept Pediat, Div Genet, TR-34098 Istanbul, Turkey; [Caglayan, Ahmet Okay] Kayseri Educ & Res Hosp, Dept Med Genet, TR-38010 Kayseri, Turkey; [Gokben, Sarenur; Yilmaz, Sanem] Ege Univ, Fac Med, Dept Pediat, Div Neurol, TR-35100 Izmir, Turkey; [Kaymakcalan, Hande] Bahcesehir Univ, Fac Arts & Sci, TR-34353 Istanbul, Turkey; [Sanders, Stephan; State, Matthew W.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA; [Sanders, Stephan; State, Matthew W.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA; [Dincer, Alp] Acibadem Univ, Sch Med, Dept Radiol, TR-34742 Istanbul, Turkey; [Johnson, Michele H.; Bronen, Richard A.] Yale Univ, Sch Med, Dept Radiol, New Haven, CT 06510 USA; [Johnson, Michele H.] Yale Univ, Sch Med, Dept Otolaryngol, New Haven, CT 06510 USA; [Kocer, Naci] Istanbul Univ, Cerrahpasa Fac Med, Dept Radiol, TR-34098 Istanbul, Turkey; [Per, Hueseyin; Kumandas, Sefer] Erciyes Univ, Sch Med, Dept Pediat, Div Neurol, TR-38039 Kayseri, Turkey; [Mane, Shrikant] Yale Univ, Sch Med, Yale Ctr Genome Anal, New Haven, CT 06510 USA; [Pamir, Mehmet Necmettin] Acibadem Univ, Sch Med, Dept Neurosurg, TR-34742 Istanbul, Turkey; [Yalcinkaya, Cengiz] Istanbul Univ, Cerrahpasa Fac Med, Dept Neurol, Div Child Neurol, TR-34098 Istanbul, Turkey; [Lifton, Richard P.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Istanbul University; Hacettepe University; Istanbul University; Istanbul University - Cerrahpasa; Kayseri Training & Research Hospital; Ege University; Bahcesehir University; Yale University; Yale University; Acibadem University; Yale University; Yale University; Istanbul University; Istanbul University - Cerrahpasa; Erciyes University; Yale University; Acibadem University; Istanbul University; Istanbul University - Cerrahpasa; Howard Hughes Medical Institute; Yale University	Lifton, RP (corresponding author), Yale Univ, Sch Med, Dept Genet, Ctr Human Genet & Genom, New Haven, CT 06510 USA.	richard.lifton@yale.edu; matthew.state@yale.edu; murat.gunel@yale.edu	Kwan, Kenneth/AAI-2841-2021; Kwan, Kenneth Y/F-8489-2011; Kaymakcalan, Hande/AAO-4208-2021; Choi, Murim/AAP-9120-2021; Yasuno, Katsuhito/E-1960-2012; Kocer, Naci/AAH-7923-2021; State, Matthew/W-2256-2019; Yalcinkaya, Cengiz/B-6288-2012; Caglayan, Ahmet O/D-1066-2012; Tüysüz, Beyhan/AAN-4858-2020; Sanders, Stephan/S-8645-2019; Kaymakcalan, Hande/AFP-2191-2022; Zhu, Ying/T-2268-2019; Dincer, Alp/D-3658-2015	Kwan, Kenneth/0000-0003-4711-071X; Kwan, Kenneth Y/0000-0003-4711-071X; Kaymakcalan, Hande/0000-0001-7736-7634; Yasuno, Katsuhito/0000-0002-3606-532X; Kocer, Naci/0000-0003-0884-6492; Yalcinkaya, Cengiz/0000-0002-3443-8524; Caglayan, Ahmet O/0000-0002-2332-322X; Dincer, Alp/0000-0001-9158-8353; State, Matthew/0000-0003-1624-8302; Barak, Tanyeri/0000-0002-8522-1552; Tuysuz, Beyhan/0000-0002-9620-5021; Zhu, Ying/0000-0002-6594-3734; Pamir, M Necmettin/0000-0002-5958-8625; Sanders, Stephan/0000-0001-9112-5148	Yale Program on Neurogenetics; Yale Center for Human Genetics and Genomics; National Institutes of Health [RC2 NS070477, UL1 RR024139NIH, UO1MH081896]; National Institutes of Health Neuroscience Microarray Consortium [U24 NS051869-02S1]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH081896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U24NS051869, RC2NS070477] Funding Source: NIH RePORTER	Yale Program on Neurogenetics; Yale Center for Human Genetics and Genomics; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health Neuroscience Microarray Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are indebted to the patients and families who have contributed to this study. We thank J. Noonan for expert advice and C. Camputaro for her help with three-dimensional reconstruction of the magnetic resonance images. This study was supported by the Yale Program on Neurogenetics, the Yale Center for Human Genetics and Genomics, and National Institutes of Health grants RC2 NS070477 (to M.G.), UL1 RR024139NIH (Yale Clinical and Translational Science Award) and UO1MH081896 (to N.S.). SNP genotyping was supported in part by a National Institutes of Health Neuroscience Microarray Consortium award U24 NS051869-02S1 (to S.M.). R.P.L. is an investigator of the Howard Hughes Medical Institute.	Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502; Barkovich AJ, 2005, NEUROLOGY, V65, P1873, DOI 10.1212/01.wnl.0000183747.05269.2d; Barkovich AJ, 2001, NEUROLOGY, V57, P2168, DOI 10.1212/WNL.57.12.2168; Bond J, 2005, NAT GENET, V37, P353, DOI 10.1038/ng1539; Bystron I, 2008, NAT REV NEUROSCI, V9, P110, DOI 10.1038/nrn2252; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Guerrini R, 2005, EPILEPSIA, V46, P32, DOI 10.1111/j.0013-9580.2005.461010.x; Guerrini R, 2001, AM J MED GENET, V106, P160, DOI 10.1002/ajmg.1569; Guerrini R, 2008, TRENDS NEUROSCI, V31, P154, DOI 10.1016/j.tins.2007.12.004; Hartl D, 2008, PROTEOMICS, V8, P1257, DOI 10.1002/pmic.200700724; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kumar A, 2009, AM J HUM GENET, V84, P286, DOI 10.1016/j.ajhg.2009.01.017; Kwan KY, 2008, P NATL ACAD SCI USA, V105, P16021, DOI 10.1073/pnas.0806791105; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Mochida GH, 2001, CURR OPIN NEUROL, V14, P151, DOI 10.1097/00019052-200104000-00003; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rakic P, 2009, NAT REV NEUROSCI, V10, P724, DOI 10.1038/nrn2719; Roberts E, 1999, EUR J HUM GENET, V7, P815, DOI 10.1038/sj.ejhg.5200385; Stillman AA, 2009, J COMP NEUROL, V513, P21, DOI 10.1002/cne.21919; Thornton GK, 2009, TRENDS GENET, V25, P501, DOI 10.1016/j.tig.2009.09.011; Wasserman T, 2010, MOL BIOL CELL, V21, P117, DOI 10.1091/mbc.E09-06-0512	25	355	379	2	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2010	467	7312					207	U93		10.1038/nature09327	http://dx.doi.org/10.1038/nature09327			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20729831	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000281616300034
J	Patten, SM; Sur, E; Sundaram, R; Weinhardt, B				Patten, Simon M.; Sur, Emma; Sundaram, Radha; Weinhardt, Barbara			Dangers in the garden	LANCET			English	Editorial Material							LEGIONNAIRES-DISEASE		[Patten, Simon M.; Sur, Emma; Sundaram, Radha] Royal Alexandra Hosp, Dept Intens Care, Paisley PA2 9PN, Renfrew, Scotland; [Weinhardt, Barbara] Royal Alexandra Hosp, Dept Microbiol, Paisley PA2 9PN, Renfrew, Scotland		Patten, SM (corresponding author), Royal Alexandra Hosp, Dept Intens Care, Corsebar Rd, Paisley PA2 9PN, Renfrew, Scotland.	simonpatten@doctors.net.uk						Amodeo MR, 2010, CLIN MICROBIOL INFEC, V16, P1405, DOI 10.1111/j.1469-0691.2009.03125.x; Muder RR, 2002, CLIN INFECT DIS, V35, P990, DOI 10.1086/342884; Pravinkumar SJ, 2010, EUROSURVEILLANCE, V15, P4; Roig J, 2003, J ANTIMICROB CHEMOTH, V51, P1119, DOI 10.1093/jac/dkg191; *ROYAL HORT SOC, 2010, ADV POTT COMP	5	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	2010	376	9743					844	844		10.1016/S0140-6736(10)60890-2	http://dx.doi.org/10.1016/S0140-6736(10)60890-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	650EC	20816551				2022-12-28	WOS:000281831000036
J	Livingston, EH				Livingston, Edward H.			What to Advise Patients About Hernias	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INGUINAL-HERNIA; REPAIR		Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Livingston, EH (corresponding author), Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, 5323 Harry Hines Blvd,Room E7-126, Dallas, TX 75390 USA.	edward.livingston@utsouthwestern.edu						Birkmeyer JD, 2010, ARCH SURG-CHICAGO, V145, P328, DOI 10.1001/archsurg.2010.19; den Hartog D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006438.pub2; Fitzgibbons RJ, 2006, JAMA-J AM MED ASSOC, V295, P285, DOI 10.1001/jama.295.3.285; Itani KMF, 2010, ARCH SURG-CHICAGO, V145, P322, DOI 10.1001/archsurg.2010.18; Livingston EH, 2010, JAMA-J AM MED ASSOC, V304, P95, DOI 10.1001/jama.2010.905; Neumayer L, 2004, NEW ENGL J MED, V350, P1819, DOI 10.1056/NEJMoa040093; Sorensen LT, 2005, ARCH SURG-CHICAGO, V140, P119, DOI 10.1001/archsurg.140.2.119; *US DEP HHS, HCUP NET STAT HOSP S	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					1001	1002		10.1001/jama.2010.1264	http://dx.doi.org/10.1001/jama.2010.1264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20815104				2022-12-28	WOS:000281422400026
J	Alvarado, D; Klein, DE; Lemmon, MA				Alvarado, Diego; Klein, Daryl E.; Lemmon, Mark A.			Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor	CELL			English	Article							AFFINITY INSULIN-BINDING; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; ALLOSTERIC REGULATION; ACTIVATION; DIMERIZATION; REGION; MODEL; OLIGOMERIZATION	Transmembrane signaling by the epidermal growth factor receptor (EGFR) involves ligand-induced dimerization and allosteric regulation of the intracellular tyrosine kinase domain. Crystallographic studies have shown how ligand binding induces dimerization of the EGFR extracellular region but cannot explain the "high-affinity" and "low-affinity" classes of cell-surface EGF-binding sites inferred from curved Scatchard plots. From a series of crystal structures of the Drosophila EGFR extracellular region, we show here how Scatchard plot curvature arises from negatively cooperative ligand binding. The first ligand-binding event induces formation of an asymmetric dimer with only one bound ligand. The unoccupied site in this dimer is structurally restrained, leading to reduced affinity for binding of the second ligand, and thus negative cooperativity. Our results explain the cell-surface binding characteristics of EGF receptors and suggest how individual EGFR ligands might stabilize distinct dimeric species with different signaling properties.	[Alvarado, Diego; Klein, Daryl E.; Lemmon, Mark A.] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu	Garzon-Alvarado, Diego/AAD-6607-2019	Lemmon, Mark/0000-0002-3379-5319; Klein, Daryl/0000-0002-7188-0450	NCRR [RR-01646]; NCI [Y1-CO-1020]; NIGMS [Y1-GM-1104]; U.S. Department of Energy; NIH [R01-CA125432, R01-CA079992, T32HD007516]; U.S. Army Breast Cancer Research Program; Damon Runyon Cancer Research Foundation [DRG-1884-05]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007516] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA125432, R01CA079992] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER	NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U.S. Department of Energy(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Army Breast Cancer Research Program(United States Department of Defense); Damon Runyon Cancer Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Kate Ferguson, Jim Shorter, Jason Davis, Greg Van Duyne, Ben Black, Steve Stayrook, and members of the Lemmon and Ferguson laboratories for valuable comments. Crystallographic data were collected at Cornell High Energy Synchrotron Source (CHESS) beamline F1, supported by the NSF and NIH/NIGMS under NSF award DMR-0225180, using the Macromolecular Diffraction at CHESS (MacCHESS) facility supported by the NCRR (RR-01646). Additional data were collected at the GM/CA Collaborative Access Team at the Advanced Photon Source (APS), funded by the NCI (Y1-CO-1020), NIGMS (Y1-GM-1104), and the U.S. Department of Energy (contract W-31-109-ENG-38). This work was funded by NIH grants R01-CA125432 and R01-CA079992 (M.A.L.) and predoctoral fellowship W81XWH-04-1-0328 from the U.S. Army Breast Cancer Research Program (D.E.K.). D.A. was supported by NIH postdoctoral training grant T32HD007516 and a postdoctoral fellowship from the Damon Runyon Cancer Research Foundation (DRG-1884-05).	Adams TE, 2009, GROWTH FACTORS, V27, P141, DOI 10.1080/08977190902843565; Alvarado D, 2009, NATURE, V461, P287, DOI 10.1038/nature08297; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; Bouyain S, 2005, P NATL ACAD SCI USA, V102, P15024, DOI 10.1073/pnas.0507591102; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Chung I, 2010, NATURE, V464, P783, DOI 10.1038/nature08827; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Hoyne PA, 2000, FEBS LETT, V479, P15, DOI 10.1016/S0014-5793(00)01872-X; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Klein P, 2004, P NATL ACAD SCI USA, V101, P929, DOI 10.1073/pnas.0307285101; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; LAX I, 1991, J BIOL CHEM, V266, P13828; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Lemmon MA, 2009, EXP CELL RES, V315, P638, DOI 10.1016/j.yexcr.2008.10.024; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Macdonald JL, 2008, P NATL ACAD SCI USA, V105, P112, DOI 10.1073/pnas.0707080105; Macdonald-Obermann JL, 2009, J BIOL CHEM, V284, P13570, DOI 10.1074/jbc.M109.001487; MAGUN BE, 1980, J BIOL CHEM, V255, P6373; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu C, 2008, STRUCTURE, V16, P460, DOI 10.1016/j.str.2007.12.016; Red Brewer M, 2009, MOL CELL, V34, P641, DOI 10.1016/j.molcel.2009.04.034; Saffarian S, 2007, BIOPHYS J, V93, P1021, DOI 10.1529/biophysj.107.105494; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; Schnepp B, 1998, GENE DEV, V12, P908, DOI 10.1101/gad.12.7.908; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shilo BZ, 2005, DEVELOPMENT, V132, P4017, DOI 10.1242/dev.02006; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103; Wilson KJ, 2009, PHARMACOL THERAPEUT, V122, P1, DOI 10.1016/j.pharmthera.2008.11.008; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WOFSY C, 1992, BIOPHYS J, V63, P98, DOI 10.1016/S0006-3495(92)81572-2; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	48	132	134	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					568	579		10.1016/j.cell.2010.07.015	http://dx.doi.org/10.1016/j.cell.2010.07.015			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723758	Green Accepted, Bronze			2022-12-28	WOS:000281115900011
J	Leahy, DJ				Leahy, Daniel J.			The Ins and Outs of EGFR Asymmetry	CELL			English	Editorial Material							GROWTH-FACTOR RECEPTOR; ERBB RECEPTORS; KINASE DOMAIN; ACTIVATION; BINDING	The epidermal growth factor receptor (EGFR) regulates cell proliferation in many tissues. A new structure of the Drosophila EGFR presented by Alvarado et al. (2010) reveals an asymmetric dimer with the ligand bound to only one subunit. The structure provides a rationale for the receptor's negative cooperativity and necessitates a reconsideration of models for activation of human EGFR.	[Leahy, Daniel J.] Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Leahy, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.	dleahy@jhmi.edu			NIGMS NIH HHS [R01 GM099321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM099321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarado D, 2010, CELL, V142, P568, DOI 10.1016/j.cell.2010.07.015; Alvarado D, 2009, NATURE, V461, P287, DOI 10.1038/nature08297; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lemmon MA, 2009, EXP CELL RES, V315, P638, DOI 10.1016/j.yexcr.2008.10.024; Macdonald JL, 2008, P NATL ACAD SCI USA, V105, P112, DOI 10.1073/pnas.0707080105; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang XW, 2007, NATURE, V450, P741, DOI 10.1038/nature05998	10	8	8	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 20	2010	142	4					513	515		10.1016/j.cell.2010.08.003	http://dx.doi.org/10.1016/j.cell.2010.08.003			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723751	Bronze			2022-12-28	WOS:000281115900004
J	Mastrandrea, MD				Mastrandrea, Michael D.			Stephen Henry Schneider (1945-2010) OBITUARY	NATURE			English	Biographical-Item									[Mastrandrea, Michael D.] Stanford Univ, Intergovt Panel Climate Change Working Grp 2, Stanford, CA 94305 USA; [Mastrandrea, Michael D.] Stanford Univ, Woods Inst Environm, Stanford, CA 94305 USA	Stanford University; Stanford University	Mastrandrea, MD (corresponding author), Stanford Univ, Intergovt Panel Climate Change Working Grp 2, Stanford, CA 94305 USA.	mikemas@stanford.edu							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					933	933		10.1038/466933a	http://dx.doi.org/10.1038/466933a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725032				2022-12-28	WOS:000281030300025
J	Cruz-Flores, S				Cruz-Flores, Salvador			Review: Clinical pathways reduce in-hospital complications but not in-hospital mortality or readmissions	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									St Louis Univ, St Louis, MO 63103 USA	Saint Louis University	Cruz-Flores, S (corresponding author), St Louis Univ, St Louis, MO 63103 USA.		Cruz-Flores, Salvador/AAR-1233-2020	Cruz-Flores, Salvador/0000-0003-4998-1471					0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-12	10.7326/0003-4819-153-4-201008170-02012	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713779				2022-12-28	WOS:000280973000026
J	Stanbrook, MB				Stanbrook, Matthew B.			Low-dose computed tomography was associated with higher risk for false-positive lung cancer screening than chest radiography	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Toronto, Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Health Network Toronto	Stanbrook, MB (corresponding author), Univ Toronto, Univ Hlth Network, Toronto, ON, Canada.							Henschke CI, 2006, NEW ENGL J MED, V355, P1763, DOI 10.1056/NEJMoa060476; Manser RL, 2004, COCHRANE DB SYST REV, P1, DOI [10.1002/14651858.CD001991.pub2, DOI 10.1002/14651858.CD001991.PUB2]	2	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-5	10.7326/0003-4819-153-4-201008170-02005	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713784				2022-12-28	WOS:000280973000031
J	de Ziegler, D; Borghese, B; Chapron, C				de Ziegler, Dominique; Borghese, Bruno; Chapron, Charles			Endometriosis and infertility: pathophysiology and management	LANCET			English	Review							IN-VITRO FERTILIZATION; STEROIDOGENIC-FACTOR-I; CONTROLLED OVARIAN HYPERSTIMULATION; MIGRATION INHIBITORY FACTOR; TUMOR-NECROSIS-FACTOR; PERITONEAL-FLUID; EUTOPIC ENDOMETRIUM; UNEXPLAINED INFERTILITY; UTERINE CONTRACTILITY; PROSTAGLANDIN E-2	Endometriosis and infertility are associated clinically. Medical and surgical treatments for endometriosis have different effects on a woman's chances of conception, either spontaneously or via assisted reproductive technologies (ART). Medical treatments for endometriosis are contraceptive. Data, mostly uncontrolled, indicate that surgery at any stage of endometriosis enhances the chances of natural conception. Criteria for non-removal of endometriomas are: bilateral cysts, history of past surgery, and altered ovarian reserve. Fears that surgery can alter ovarian function that is already compromised sparked a rule of no surgery before ART. Exceptions to this guidance are pain, hydrosalpinges, and very large endometriomas. Medical treatment eg, 3-6 months of gonadotropin-releasing hormone analogues improves the outcome of ART. When age, ovarian reserve, and male and tubal status permit, surgery should be considered immediately so that time is dedicated to attempts to conceive naturally. In other cases, the preference is for administration of gonadotropin-releasing hormone analogues before ART, and no surgery beforehand. The strategy of early surgery, however, seems counterintuitive because of beliefs that milder non-surgical options should be offered first and surgery last (only if initial treatment attempts fail). Weighing up the relative advantages of surgery, medical treatment and ART are the foundations for a global approach to infertility associated with endometriosis	[de Ziegler, Dominique; Borghese, Bruno; Chapron, Charles] Univ Paris 05, Paris, France; [de Ziegler, Dominique; Borghese, Bruno; Chapron, Charles] CHU Cochin, Serv Gynecol Obstet & Med Reprod 2, Paris, France; [Borghese, Bruno; Chapron, Charles] INSERM, U1016, Paris, France; [Borghese, Bruno; Chapron, Charles] CNRS, UMR 8104, Inst Cochin, Paris, France	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	de Ziegler, D (corresponding author), Hop Cochin St Vincent de Paul, Dept Obstet & Gynaecol 2, F-75014 Paris, France.		Chapron, Charles/O-8567-2017					Aboulghar MA, 2003, AM J OBSTET GYNECOL, V188, P371, DOI 10.1067/mob.2003.13; Aeby TC, 1996, AM J OBSTET GYNECOL, V174, P1779, DOI 10.1016/S0002-9378(96)70210-7; Akoum A, 2008, FERTIL STERIL, V89, P1618, DOI 10.1016/j.fertnstert.2007.06.019; Al-Azemi M, 2000, HUM REPROD, V15, P72, DOI 10.1093/humrep/15.1.72; Allen C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004753.pub3; [Anonymous], 2008, FERTIL STERIL, V90, pS260, DOI 10.1016/j.fertnstert.2008.08.057; Attar E, 2009, J CLIN ENDOCR METAB, V94, P623, DOI 10.1210/jc.2008-1180; Baker MA, 2004, MOL CELL ENDOCRINOL, V216, P47, DOI 10.1016/j.mce.2003.10.068; Barbonetti A, 2008, MOL HUM REPROD, V14, P387, DOI 10.1093/molehr/gan031; Barcelos ID, 2009, FERTIL STERIL, V92, P1749, DOI 10.1016/j.fertnstert.2009.05.006; Berbic M, 2009, HUM REPROD, V24, P325, DOI 10.1093/humrep/den393; Bianchi PHM, 2009, J MINIM INVAS GYN, V16, P174, DOI 10.1016/j.jmig.2008.12.009; Borghese B, 2008, MOL ENDOCRINOL, V22, P2557, DOI 10.1210/me.2008-0322; Broekmans FJ, 2009, ENDOCR REV, V30, P465, DOI 10.1210/er.2009-0006; BUCH JP, 1994, FERTIL STERIL, V62, P186; Bulletti C, 2004, ANN NY ACAD SCI, V1034, P64, DOI 10.1196/annals.1335.007; Bulletti C, 2002, FERTIL STERIL, V77, P1156, DOI 10.1016/S0015-0282(02)03087-X; Bulun SE, 2009, MOL CELL ENDOCRINOL, V300, P104, DOI 10.1016/j.mce.2008.12.012; Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690; Burney RO, 2007, ENDOCRINOLOGY, V148, P3814, DOI 10.1210/en.2006-1692; Busacca M, 2009, J MINIM INVAS GYN, V16, P142, DOI 10.1016/j.jmig.2008.12.013; Carli C, 2007, FERTIL STERIL, V88, P1240, DOI 10.1016/j.fertnstert.2007.04.002; Carli C, 2009, ENDOCRINOLOGY, V150, P3128, DOI 10.1210/en.2008-1088; Chapron C, 2006, HUM REPROD, V21, P1839, DOI 10.1093/humrep/del079; Chapron C, 2010, HUM REPROD, V25, P884, DOI 10.1093/humrep/deq017; Cicinelli E, 2009, FERTIL STERIL, V92, P306, DOI 10.1016/j.fertnstert.2008.05.044; D'Hooghe TM, 2003, SEMIN REPROD MED, V21, P243; Daftary GS, 2007, FERTIL STERIL, V87, P367, DOI 10.1016/j.fertnstert.2006.06.041; Dassen H, 2007, HUM REPROD, V22, P3148, DOI 10.1093/humrep/dem310; de Ziegler D, 2006, CLIN OBSTET GYNECOL, V49, P93, DOI 10.1097/01.grf.0000197521.61306.51; Demirol A, 2006, REPROD BIOMED ONLINE, V12, P639, DOI 10.1016/S1472-6483(10)61192-3; DEZIEGLER D, 2009, YEN JAFFES REPROD EN, P825; Dmowski WP, 1998, HUM REPROD UPDATE, V4, P696, DOI 10.1093/humupd/4.5.696; Dousset B, 2010, ANN SURG, V251, P887, DOI 10.1097/SLA.0b013e3181d9722d; Faber BM, 2001, OBSTET GYNECOL, V98, P668, DOI 10.1016/S0029-7844(01)01510-1; Falconer H, 2009, REPROD BIOMED ONLINE, V18, P582, DOI 10.1016/S1472-6483(10)60138-1; Fauconnier A, 2005, HUM REPROD UPDATE, V11, P595, DOI 10.1093/humupd/dmi029; Garcia-Velasco JA, 2004, FERTIL STERIL, V81, P1194, DOI 10.1016/j.fertnstert.2003.04.006; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Gupta S, 2008, FERTIL STERIL, V90, P247, DOI 10.1016/j.fertnstert.2008.02.093; HALME J, 1983, AM J OBSTET GYNECOL, V145, P333, DOI 10.1016/0002-9378(83)90720-2; Hammadieh N, 2008, HUM REPROD, V23, P1113, DOI 10.1093/humrep/den071; Hart RJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004992.pub3; Hughes E, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000155.pub2; Hunter RHF, 2007, ACTA OBSTET GYN SCAN, V86, P260, DOI 10.1080/00016340601155098; Iborra A, 2005, CHEM IMMUNOL ALLERGY, V88, P150, DOI 10.1159/000087832; Jacobson TZ, 2010, COCHRANE DB SYST REV, V1; Jha P, 1996, AM J REPROD IMMUNOL, V36, P235; Kahyaoglu S, 2008, J OBSTET GYNAECOL RE, V34, P1010, DOI 10.1111/j.1447-0756.2008.00825.x; Kats R, 2002, FERTIL STERIL, V78, P69, DOI 10.1016/S0015-0282(02)03189-8; Kelada E, 2007, J ASSIST REPROD GEN, V24, P143, DOI 10.1007/s10815-006-9090-9; Kennedy S, 2005, HUM REPROD, V20, P2698, DOI 10.1093/humrep/dei135; Kim YA, 2009, GYNECOL OBSTET INVES, V68, P73, DOI 10.1159/000214844; Kyama CM, 2008, FERTIL STERIL, V89, P301, DOI 10.1016/j.fertnstert.2007.02.057; Lebovic DI, 2001, FERTIL STERIL, V75, P1, DOI 10.1016/S0015-0282(00)01630-7; Leyendecker G, 2009, ARCH GYNECOL OBSTET, V280, P529, DOI 10.1007/s00404-009-1191-0; Littman E, 2005, FERTIL STERIL, V84, P1574, DOI 10.1016/j.fertnstert.2005.02.059; Mansour G, 2009, FERTIL STERIL, V92, P61, DOI 10.1016/j.fertnstert.2008.05.048; Marcoux S, 1997, NEW ENGL J MED, V337, P217, DOI 10.1056/NEJM199707243370401; Matalliotakis IM, 2007, FERTIL STERIL, V88, P1568, DOI 10.1016/j.fertnstert.2007.01.037; Matos L, 2009, MOL HUM REPROD, V15, P411, DOI 10.1093/molehr/gap034; Matsunaga Y, 2003, AM J PERINAT, V20, P277; Matsuura K, 1999, GYNECOL OBSTET INVES, V47, P18, DOI 10.1159/000052855; Matzuk MM, 2005, NAT MED, V11, P24, DOI 10.1038/nm0105-24; Mendelson CR, 2009, MOL ENDOCRINOL, V23, P947, DOI 10.1210/me.2009-0016; Minici F, 2008, HUM REPROD, V23, P530, DOI 10.1093/humrep/dem399; Ngo C, 2009, AM J PATHOL, V175, P225, DOI 10.2353/ajpath.2009.080804; Noel JC, 2010, APPL IMMUNOHISTO M M, V18, P258, DOI 10.1097/PAI.0b013e3181c06948; Omland AK, 1998, HUM REPROD, V13, P2602, DOI 10.1093/humrep/13.9.2602; OOSTERLYNCK DJ, 1992, FERTIL STERIL, V58, P290; Perdichizzi A, 2007, J CLIN IMMUNOL, V27, P152, DOI 10.1007/s10875-007-9071-5; Pillai S, 1998, AM J REPROD IMMUNOL, V39, P235; Practice Committee of the American Society for Reproductive Medicine Endometriosis and infertility, 2006, FERTIL STERIL, V86, pS156; Rana N, 1996, FERTIL STERIL, V65, P925, DOI 10.1016/S0015-0282(16)58262-4; REINDOLLAR RH, FERTIL STERIL, DOI DOI 10.1016/J.FERTOSTERT.2009.04.022; Said TM, 2005, FERTIL STERIL, V83, P1665, DOI 10.1016/j.fertnstert.2004.11.068; Sales KJ, 2003, REPRODUCTION, V126, P559, DOI 10.1530/rep.0.1260559; Sallam HN, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004635.pub2; Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X; Schulke L, 2009, HUM REPROD, V24, P1695, DOI 10.1093/humrep/dep071; Sharma RK, 1999, INT J FERTIL WOMEN M, V44, P31; Sharpe-Timms KL, 2002, FERTIL STERIL, V78, P810, DOI 10.1016/S0015-0282(02)03317-4; Shebl O, 2009, GYNECOL ENDOCRINOL, V25, P713, DOI 10.3109/09513590903159615; Somigliana E, 2008, HUM REPROD, V23, P1526, DOI 10.1093/humrep/den133; Somigliana E, 2006, FERTIL STERIL, V86, P192, DOI 10.1016/j.fertnstert.2005.12.034; Steures P, 2006, LANCET, V368, P216, DOI 10.1016/S0140-6736(06)69042-9; Streuli I, 2008, FERTIL STERIL, V90, P395, DOI 10.1016/j.fertnstert.2007.06.023; Streuli I, 2009, FERTIL STERIL, V91, P226, DOI 10.1016/j.fertnstert.2007.10.067; SUELDO CE, 1990, J REPROD MED, V35, P868; Sukhikh GT, 2004, B EXP BIOL MED+, V137, P568, DOI 10.1023/B:BEBM.0000042714.32571.6b; Surrey ES, 2001, FERTIL STERIL, V75, P612, DOI 10.1016/S0015-0282(00)01742-8; Surrey ES, 2002, FERTIL STERIL, V78, P699, DOI 10.1016/S0015-0282(02)03373-3; TAKETANI Y, 1992, AM J OBSTET GYNECOL, V167, P265, DOI 10.1016/S0002-9378(11)91672-X; TAYLOR RN, 2009, HUM REPROD, V24, P496; Tokushige N, 2007, FERTIL STERIL, V88, P795, DOI 10.1016/j.fertnstert.2006.12.078; Tokushige N, 2006, HUM REPROD, V21, P3001, DOI 10.1093/humrep/del260; Tokushige N, 2009, FERTIL STERIL, V92, P1234, DOI 10.1016/j.fertnstert.2008.07.1774; Velarde MC, 2009, ENDOCRINOLOGY, V150, P4701, DOI 10.1210/en.2009-0389; Vercellini P, 2006, HUM REPROD, V21, P2679, DOI 10.1093/humrep/del230; Vercellini P, 2009, DRUGS, V69, P649, DOI 10.2165/00003495-200969060-00002; Vercellini P, 2009, HUM REPROD, V24, P254, DOI 10.1093/humrep/den379; Wang GY, 2009, HUM REPROD, V24, P827, DOI 10.1093/humrep/den464; Werbrouck E, 2006, FERTIL STERIL, V86, P566, DOI 10.1016/j.fertnstert.2006.01.044; Xue Q, 2007, J CLIN ENDOCR METAB, V92, P3261, DOI 10.1210/jc.2007-0494; YAP C, 2004, COCHRANE DB SYST REV, V3; Yoshida S, 2004, HUM REPROD, V19, P1821, DOI 10.1093/humrep/deh324; Zeitoun K, 1999, MOL ENDOCRINOL, V13, P239, DOI 10.1210/me.13.2.239	107	486	507	3	113	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2010	376	9742					730	738		10.1016/S0140-6736(10)60490-4	http://dx.doi.org/10.1016/S0140-6736(10)60490-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646YW	20801404				2022-12-28	WOS:000281582900032
J	WARDEN, J				WARDEN, J			CREDENTIALS FOR SUCCESS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1988	296	6637					1681	1681		10.1136/bmj.296.6637.1681	http://dx.doi.org/10.1136/bmj.296.6637.1681			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N8341	20743002	Green Published			2022-12-28	WOS:A1988N834100070
J	Burns, CM; Wortmann, RL				Burns, Christopher M.; Wortmann, Robert L.			Gout therapeutics: new drugs for an old disease	LANCET			English	Article							PURINE SELECTIVE INHIBITOR; EVIDENCE BASED RECOMMENDATIONS; PEGLOTICASE PGL THERAPY; TREATMENT-FAILURE GOUT; URATE OXIDASE; DOUBLE-BLIND; SERUM URATE; XANTHINE-OXIDASE; ASPERGILLUS-FLAVUS; FEBUXOSTAT TMX-67	The approval of febuxostat, a non-purine-analogue inhibitor of xanthine oxidase, by the European Medicines Agency and the US Food and Drug Administration heralds a new era in the treatment of gout. The use of modified uricases to rapidly reduce serum urate concentrations in patients with otherwise untreatable gout is progressing. Additionally, advances in our understanding of the transport of uric acid in the renal proximal tubule and the inflammatory response to monosodium urate crystals are translating into potential new treatments. In this Review, we focus on the clinical trials of febuxostat. We also review results from studies of pegloticase, a pegylated uricase in development, and we summarise data for several other pipeline drugs for gout, such as the selective uricosuric drug RDEA594 and various interleukin-1 inhibitors. Finally, we issue a word of caution about the proper use of the new drugs and the already available drugs for gout. At a time of important advances, we need to recommit ourselves to a rational approach to the treatment of gout.	[Burns, Christopher M.; Wortmann, Robert L.] Dartmouth Med Sch, Lebanon, NH 03756 USA	Dartmouth College	Burns, CM (corresponding author), Dartmouth Med Sch, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	chris.burns@hitchcock.org						ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Annemans L, 2008, ANN RHEUM DIS, V67, P960, DOI 10.1136/ard.2007.076232; Anzai N, 2008, J BIOL CHEM, V283, P26834, DOI 10.1074/jbc.C800156200; Augustin R, 2004, J BIOL CHEM, V279, P16229, DOI 10.1074/jbc.M312226200; Baraf HS, 2008, ARTHRITIS RHEUM, V58, pS176; Baraf HSB, 2008, ARTHRITIS RHEUM-US, V58, P3632, DOI 10.1002/art.23993; Becker GM, 2008, ARTHRITIS RHEUM, V58, P4029; Becker MA, 2008, ARTHRITIS RHEUM, V58, pS880; Becker MA, 2004, NUCLEOS NUCLEOT NUCL, V23, P1111, DOI 10.1081/NCN-200027372; Becker MA, 2005, NEW ENGL J MED, V353, P2450, DOI 10.1056/NEJMoa050373; Becker MA, 2008, CURR OPIN RHEUMATOL, V20, P167, DOI 10.1097/BOR.0b013e3282f54d03; Becker MA, 2006, ARTHRITIS RHEUM, V54, pS646; Becker MA, 2005, ARTHRITIS RHEUM, V52, P916, DOI 10.1002/art.20935; Becker MA, 2009, J RHEUMATOL, V36, P1273, DOI 10.3899/jrheum.080814; Caulfield MJ, 2008, PLOS MED, V5, P1509, DOI 10.1371/journal.pmed.0050197; Chen CJ, 2006, J CLIN INVEST, V116, P2262, DOI 10.1172/JCI28075; Cronstein BN, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1908; Dalbeth N, 2009, RHEUMATOLOGY, V48, P222, DOI 10.1093/rheumatology/ken460; Dalbeth N, 2007, SEMIN DIALYSIS, V20, P391, DOI 10.1111/j.1525-139X.2007.00270.x; Dalbeth N, 2006, J RHEUMATOL, V33, P1646; Davidson MB, 2004, AM J MED, V116, P546, DOI 10.1016/j.amjmed.2003.09.045; de Bont JM, 2004, NUCLEOS NUCLEOT NUCL, V23, P1431, DOI 10.1081/NCN-200027656; DIGIOVINE FS, 1987, J IMMUNOL, V138, P3213; Edwards NL, 2008, ARTHRITIS RHEUM, V58, pS178; Endou H, 2008, NUCLEOS NUCLEOT NUCL, V27, P578, DOI 10.1080/15257770802136024; Enomoto A, 2002, NATURE, V417, P447, DOI 10.1038/nature742; European Medicines Agency, 2008, CHMP ASS REP AD; Ganson NJ, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1861; GOLDFARB E, 1966, ARTHRITIS RHEUM, V9, P414, DOI 10.1002/art.1780090306; Grabowski BA, 2005, ARTHRITIS RHEUM-US, V52, pS103; Hagos Y, 2007, J AM SOC NEPHROL, V18, P430, DOI 10.1681/ASN.2006040415; HANDE KR, 1984, AM J MED, V76, P47, DOI 10.1016/0002-9343(84)90743-5; Harrold LR, 2007, ARTHRIT RHEUM-ARTHR, V57, P103, DOI 10.1002/art.22474; Keenan RT, 2009, ARTHRITIS RHEUM, V60, pS415; Khosravan R, 2006, J CLIN PHARMACOL, V46, P88, DOI 10.1177/0091270005282634; Khosravan R, 2005, CLIN PHARMACOL THER, V77, pP43, DOI 10.1016/j.clpt.2004.12.059; Khosravan R, 2005, ARTHRITIS RHEUM-US, V52, pS102; Khosravan R, 2006, CLIN PHARMACOKINET, V45, P821, DOI 10.2165/00003088-200645080-00005; Khosravan R, 2006, J CLIN PHARMACOL, V46, P855, DOI 10.1177/0091270006289848; Komoriya K, 2004, NUCLEOS NUCLEOT NUCL, V23, P1119, DOI 10.1081/NCN-200027381; Krishnan E, 2008, J RHEUMATOL, V35, P498; LABOUREUR P, 1968, B SOC CHIM BIOL, V50, P811; Lasko B, 2009, ARTHRITIS RHEUM, V60, pS413; LEPLATOIS P, 1992, GENE, V122, P139, DOI 10.1016/0378-1119(92)90041-M; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mayer CT, 2009, ARTHRITIS RHEUM, V60, pS729; Mayer Michael D, 2005, Am J Ther, V12, P22, DOI 10.1097/00045391-200501000-00005; MCCARTY DJ, 1961, ANN INTERN MED, V54, P452, DOI 10.7326/0003-4819-54-3-452; Mukoyoshi M, 2008, XENOBIOTICA, V38, P496, DOI 10.1080/00498250801956350 ; Navolanic PM, 2003, LEUKEMIA, V17, P499, DOI 10.1038/sj.leu.2402847; Okamoto K, 2003, J BIOL CHEM, V278, P1848, DOI 10.1074/jbc.M208307200; Perez-Ruiz F, 2000, NEPHRON, V86, P287, DOI 10.1159/000045783; Perez-Ruiz F, 2002, ARTHRIT RHEUM-ARTHR, V47, P356, DOI 10.1002/art.10511; Perez-Ruiz F, 1998, ANN RHEUM DIS, V57, P545, DOI 10.1136/ard.57.9.545; Perez-Ruiz F, 2007, ARTHRIT RHEUM-ARTHR, V57, P1324, DOI 10.1002/art.23007; Pui CH, 1997, LEUKEMIA, V11, P1813, DOI 10.1038/sj.leu.2400850; Richette P, 2007, J RHEUMATOL, V34, P2093; Richette P, 2006, NAT CLIN PRACT RHEUM, V2, P338, DOI 10.1038/ncprheum0214; Richette P, 2010, LANCET, V375, P318, DOI 10.1016/S0140-6736(09)60883-7; Roddy E, 2007, NAT CLIN PRACT RHEUM, V3, P443, DOI 10.1038/ncprheum0556; Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238; Saag KG, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1907; Sarawate CA, 2006, MAYO CLIN PROC, V81, P925, DOI 10.4065/81.7.925; Sarawate CA, 2006, JCR-J CLIN RHEUMATOL, V12, P61, DOI 10.1097/01.rhu.0000209882.50228.9f; Schlesinger N, 2001, CURR OPIN RHEUMATOL, V13, P240, DOI 10.1097/00002281-200105000-00016; Schumacher HR, 2009, RHEUMATOLOGY, V48, P188, DOI 10.1093/rheumatology/ken457; Schumacher HR, 2008, ARTHRIT RHEUM-ARTHR, V59, P1540, DOI 10.1002/art.24209; Schumacher HRJr, 2009, ARTHRITIS RHEUM, V60, pS410; Sherman MR, 2008, ADV DRUG DELIVER REV, V60, P59, DOI 10.1016/j.addr.2007.06.011; Silverberg MS, 2009, ARTHRITIS RHEUM, V60, pS414; Simkin PA, 2003, ARTHRIT RHEUM-ARTHR, V49, P735, DOI 10.1002/art.11376; Siu YP, 2006, AM J KIDNEY DIS, V47, P51, DOI 10.1053/j.ajkd.2005.10.006; So A, 2009, ARTHRITIS RHEUM, V60, pL84; So A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2143; Stamp L, 2000, AUST NZ J MED, V30, P567, DOI 10.1111/j.1445-5994.2000.tb00857.x; Stamp L, 2009, ARTHRITIS RHEUM, V60, pS729; Sundy JS, 2008, ARTHRIT RHEUM-ARTHR, V59, P1535, DOI 10.1002/art.24201; Sundy JS, 2008, ARTHRITIS RHEUM, V58, P2882, DOI 10.1002/art.23810; Sundy JS, 2007, ARTHRITIS RHEUM-US, V56, P1021, DOI 10.1002/art.22403; Sundy JS, 2009, ANN RHEUM DIS, V68, P318; Sundy JS, 2009, ARTHRITIS RHEUM S10, V60, pS417; Takano Y, 2005, LIFE SCI, V76, P1835, DOI 10.1016/j.lfs.2004.10.031; Terkeltaub R, 2009, ANN RHEUM DIS, V68, P1613, DOI 10.1136/ard.2009.108936; Terkeltaub R, 2007, J RHEUMATOL, V34, P1955; Terkeltaub R, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2738; US Food and Drug Administration, BRIEF DOC ARTH ADV C; Vitart V, 2008, NAT GENET, V40, P437, DOI 10.1038/ng.106; Wallace KL, 2004, J RHEUMATOL, V31, P1582; Wortmann R, 2006, CRYSTAL INDUCED ARTH; Wright D, 2009, ARTHRITIS RHEUM S10, V60, pS413; WU XW, 1989, P NATL ACAD SCI USA, V86, P9412, DOI 10.1073/pnas.86.23.9412; Wyngaarden JB, 1976, GOUT HYPERURICEMIA, P149; Yang X, 2009, ARTHRITIS RHEUM, V60, pS412; Yeh L, 2009, ANN RHEUM DIS, V68, P320; Yeh L, 2008, ANN RHEUM DIS, V67, P249; Yeh L, 2008, ANN RHEUM DIS, V67, P248; Zhang W, 2006, ANN RHEUM DIS, V65, P1312, DOI 10.1136/ard.2006.055269; Zhang W, 2006, ANN RHEUM DIS, V65, P1301, DOI 10.1136/ard.2006.055251	98	146	161	4	78	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2011	377	9760					165	177		10.1016/S0140-6736(10)60665-4	http://dx.doi.org/10.1016/S0140-6736(10)60665-4			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	707NH	20719377				2022-12-28	WOS:000286292800029
J	Chapman, S				Chapman, Simon			Health and philanthropy-the tobacco connection	LANCET			English	Editorial Material									Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney	Chapman, S (corresponding author), Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.	simon.chapman@sydney.edu.au	Chapman, Simon/D-4114-2009					[Anonymous], 2010, REUTERS         0614; *BILL M GAT FDN, 2010, STAT REG IDRC TOB CO; BLOOMBERG GH, 2008, GATES SET 500 MILLIO; Chapman S, 2008, TOB CONTROL, V17, P1, DOI 10.1136/tc.2007.024562; DIAS FC, 2010, P MORRIS INITIATES A; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; OSCHNER A, 1971, CHEST, V59, P358; *P MORR INT, 2007, P MORR INT ANN AGR P; *P MORR INT, FIN COMM CHART; *P MORR INT, PROD INN REG AFF COM; *REP I, GLOB REP PULSETM REP; TODKILL A, 2010, OPEN MED, V4; Webb WH, 1984, STATUS MARLBORO DEV; CS HELU BIOGRAPHY; CS HELU BUSINESS ACT; 2010, GATES FDN PULLS FUND	16	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 1	2011	377	9759					11	13		10.1016/S0140-6736(10)61036-7	http://dx.doi.org/10.1016/S0140-6736(10)61036-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	709MQ	20797780				2022-12-28	WOS:000286445200009
J	Camilli, R; Reddy, CM; Yoerger, DR; Van Mooy, BAS; Jakuba, MV; Kinsey, JC; McIntyre, CP; Sylva, SP; Maloney, JV				Camilli, Richard; Reddy, Christopher M.; Yoerger, Dana R.; Van Mooy, Benjamin A. S.; Jakuba, Michael V.; Kinsey, James C.; McIntyre, Cameron P.; Sylva, Sean P.; Maloney, James V.			Tracking Hydrocarbon Plume Transport and Biodegradation at Deepwater Horizon	SCIENCE			English	Article							OIL	The Deepwater Horizon blowout is the largest offshore oil spill in history. We present results from a subsurface hydrocarbon survey using an autonomous underwater vehicle and a ship-cabled sampler. Our findings indicate the presence of a continuous plume of oil, more than 35 kilometers in length, at approximately 1100 meters depth that persisted for months without substantial biodegradation. Samples collected from within the plume reveal monoaromatic petroleum hydrocarbon concentrations in excess of 50 micrograms per liter. These data indicate that monoaromatic input to this plume was at least 5500 kilograms per day, which is more than double the total source rate of all natural seeps of the monoaromatic petroleum hydrocarbons in the northern Gulf of Mexico. Dissolved oxygen concentrations suggest that microbial respiration rates within the plume were not appreciably more than 1 micromolar oxygen per day.	[Camilli, Richard; Yoerger, Dana R.; Kinsey, James C.] Woods Hole Oceanog Inst, Dept Appl Ocean Phys & Engn, Woods Hole, MA 02543 USA; [Reddy, Christopher M.; Van Mooy, Benjamin A. S.; McIntyre, Cameron P.; Sylva, Sean P.] Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; [Jakuba, Michael V.] Univ Sydney, Australian Ctr Field Robot, Sydney, NSW 2006, Australia; [Maloney, James V.] Monitor Instruments Co, Cheswick, PA 15024 USA	Woods Hole Oceanographic Institution; Woods Hole Oceanographic Institution; University of Sydney	Camilli, R (corresponding author), Woods Hole Oceanog Inst, Dept Appl Ocean Phys & Engn, Woods Hole, MA 02543 USA.	rcamilli@whoi.edu	Sylva, Sean/D-4400-2014; McIntyre, Cameron P/D-1222-2016	Sylva, Sean/0000-0002-4727-440X; McIntyre, Cameron P/0000-0001-8517-9836; Reddy, Christopher/0000-0002-7814-2071	NSF [OCE-1045025, OCE-0537173, OCE-1043976, OCE-1045670, OCE-0644290]; U.S. Coast Guard [HSCG3210CR0020]; NASA [NNX09AB76G]	NSF(National Science Foundation (NSF)); U.S. Coast Guard; NASA(National Aeronautics & Space Administration (NASA))	This research was supported by NSF grants OCE-1045025 (RAPID Response Research) and OCE-0537173 (National Oceanographic Partnership Program for TETHYS development) to R. C., OCE-1043976 (RAPID) to C. M. R., OCE-1045670 (RAPID) to B. A. S. V. M., and OCE-0644290 [NSF Ocean Sciences (OCE)-Submersible] for Sentry development and integration to D.R.Y.; by U.S. Coast Guard HSCG3210CR0020 to R. C.; and by NASA Astrobiology Science and Technology for Exploring Planets (ASTEP) NNX09AB76G for integrating technology with Sentry to D.R.Y. We thank the officers and crew of the R/V Endeavor and J. Parker and J. Kusek of the U. S. Coast Guard for assistance during marine operations at the Deepwater Horizon well site. We thank K. Keteles (U. S. Environmental Protection Agency); D. Hollander and E. Goddard (Univ. of South Florida); and A. Billings, A. Duester, S. McCue, D. Torres, M. Swartz, C. Murphy, R. Catanach, and J. Fenwick (Woods Hole Oceanographic Institution) for logistics, operations, experimental, and administrative support. We acknowledge J. Ledwell, C. German, R. Munier, and especially J. Farrington for valuable discussions and guidance.	Camilli R., 2007, Oceans 2007, P1; Camilli R, 2009, MAR POLLUT BULL, V58, P1505, DOI 10.1016/j.marpolbul.2009.05.016; Camilli R, 2009, ENVIRON SCI TECHNOL, V43, P5014, DOI 10.1021/es803717d; Chen FH, 2004, J MARINE SYST, V45, P189, DOI 10.1016/j.jmarsys.2003.11.005; Dasanayaka LK, 2009, J HYDRO-ENVIRON RES, V2, P243, DOI 10.1016/j.jher.2009.01.004; GARCIA HE, 2006, WORLD OCEAN ATLAS 20, V3, P342; German CR, 2008, DEEP-SEA RES PT I, V55, P203, DOI 10.1016/j.dsr.2007.11.004; German CR, 1998, EARTH PLANET SC LETT, V156, P267, DOI 10.1016/S0012-821X(98)00020-X; Gillis J., 2010, NY TIMES, pA1; GOLDENBERG S, 2010, GUARDIAN        0701, P26; *INT JOINT AN GROU, REV PREL DAT EX SUBS; Johansen O, 2003, MAR POLLUT BULL, V47, P360, DOI 10.1016/S0025-326X(03)00202-9; Johansen O, 2000, SPILL SCI TECHNOL B, V6, P103, DOI 10.1016/S1353-2561(00)00042-6; Kvenvolden KA, 2003, GEO-MAR LETT, V23, P140, DOI 10.1007/s00367-003-0135-0; Mau S, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031344; *MONT BAY AQ RES I, DAT REP NOAA SHIP GO; OUDOT C, 1988, LIMNOL OCEANOGR, V33, P146, DOI 10.4319/lo.1988.33.1.0146; Rabalais NN, 2010, BIOGEOSCIENCES, V7, P585, DOI 10.5194/bg-7-585-2010; *SEA BIRD EL, 2010, 64 SEA BIRD EL; Simecek-Beatty D, 2007, OIL SPILL ENVIRONMENTAL FORENSICS: FINGERPRINTING AND SOURCE IDENTIFICATION, P405, DOI 10.1016/B978-012369523-9.50017-3; STEVENSON LH, 1991, DICT ENV SCI, P294; *UN COMM DEEPW HOR, 2010, US SCI TEAMS REF EST; Valentine DL, 2010, NAT GEOSCI, V3, P345, DOI 10.1038/NGEO848; WANG ZD, 1995, ANAL CHEM, V67, P3491, DOI 10.1021/ac00115a018; Winkler, 1888, BER DTSCH CHEM GES, V21, P2843, DOI [10.1002/cber.188802102122, DOI 10.1002/CBER.188802102122]	25	576	598	10	411	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	2010	330	6001					201	204		10.1126/science.1195223	http://dx.doi.org/10.1126/science.1195223			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LP	20724584				2022-12-28	WOS:000282644600036
J	FitzGerald, JM; Quon, BS				FitzGerald, J. Mark; Quon, Bradley S.			The impact of asthma guidelines	LANCET			English	Editorial Material							MAINTENANCE TREATMENT; MANAGEMENT		[FitzGerald, J. Mark; Quon, Bradley S.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Ctr Lung Res, Vancouver, BC V7V 2J3, Canada	University of British Columbia; Vancouver Coastal Health Research Institute	FitzGerald, JM (corresponding author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, Ctr Lung Res, Vancouver, BC V7V 2J3, Canada.	markf@interchange.ubc.ca						Bahadori K, 2010, J ASTHMA ALLERGY, V3, P33; Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Ernst P, 2006, ANN INTERN MED, V145, P692, DOI 10.7326/0003-4819-145-9-200611070-00012; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; *INT UN TUB LUNG D, 2010, ASTHM DRUG FAC; Lemiere C, 2002, CAN MED ASSOC J, V167, P1008; Lougheed MD, 2010, CAN RESPIR J, V17, P15, DOI 10.1155/2010/827281; *LUNG ASS ONT, 2009, ASTHM CME ONL EV BAS; Poureslami Iraj M, 2007, MedGenMed, V9, P40; Public Health Agency of Canada, 2007, LIF BREATH RESP DIS; QUON B, 2009, COCHRANE DB SYST REV, V1; Thier Sara L, 2008, Manag Care, V17, P48	14	10	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					751	753		10.1016/S0140-6736(10)61159-2	http://dx.doi.org/10.1016/S0140-6736(10)61159-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	650EC	20816530				2022-12-28	WOS:000281831000008
J	Solter, D				Solter, Davor			Viable Rat-Mouse Chimeras: Where Do We Go from Here?	CELL			English	Editorial Material							EMBRYONIC STEM-CELLS; BLASTOCYSTS		ASTAR, Inst Med Biol, Singapore 138648, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Solter, D (corresponding author), ASTAR, Inst Med Biol, Singapore 138648, Singapore.	davor.solter@imb.a-star.edu.sg	Solter, Davor/Q-5476-2019	Solter, Davor/0000-0002-8438-347X				Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007; FEHILLY CB, 1984, NATURE, V307, P634, DOI 10.1038/307634a0; GARDNER RL, 1973, NATURE-NEW BIOL, V246, P86, DOI 10.1038/newbio246086a0; James D, 2006, DEV BIOL, V295, P90, DOI 10.1016/j.ydbio.2006.03.026; Kobayashi T, 2010, CELL, V142, P787, DOI 10.1016/j.cell.2010.07.039; Li P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006; MYSTKOWSKA ET, 1975, J EMBRYOL EXP MORPH, V33, P731; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V69, P141; TARKOWSKI AK, 1961, NATURE, V190, P857, DOI 10.1038/190857a0	10	5	9	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5					676	678		10.1016/j.cell.2010.08.021	http://dx.doi.org/10.1016/j.cell.2010.08.021			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813255	Bronze			2022-12-28	WOS:000281523200010
J	Westby, M; Bullock, I; Cooper, PN; Davis, S				Westby, Maggie; Bullock, Ian; Cooper, Paul N.; Davis, Sarah		Guideline Dev Grp	Guidelines Transient loss of consciousness-initial assessment, diagnosis, and specialist referral: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Cooper, Paul N.] Hope Hosp, Salford Royal Fdn Trust, Greater Manchester Neurosci Ctr, Salford M6 8HD, Lancs, England; [Westby, Maggie; Bullock, Ian] Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England; [Davis, Sarah] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England	Salford Royal NHS Foundation Trust; Royal College of Physicians; University of Sheffield	Cooper, PN (corresponding author), Hope Hosp, Salford Royal Fdn Trust, Greater Manchester Neurosci Ctr, Salford M6 8HD, Lancs, England.	paul.cooper@manchester.ac.uk	Westby, Maggie/O-8794-2014; Cooper, Paul N/L-9819-2013; Westby, Maggie/GWZ-2119-2022	Westby, Maggie/0000-0003-4273-3942; Cooper, Paul N/0000-0002-7232-3365; Davis, Sarah/0000-0002-6609-4287				*ALL PART PARL GRO, 2008, HUM EC COST EP ENGL; COLMAN N, 2009, CLIN AUTONOM RES S1, V14, P9; *DRIV VEH LIC AG, 2010, GLANC CURR MED STAND; Fitzpatrick AP, 2006, HEART, V92, P559, DOI 10.1136/hrt.2005.068650; Ganzeboom KS, 2006, J CARDIOVASC ELECTR, V17, P1172, DOI 10.1111/j.1540-8167.2006.00595.x; National Institute for Health and Clinical Excellence, 2004, EP DIAGN MAN EP AD C; National Institute for Health and Clinical Excellence, 2010, TRANS LOSS CONS BLAC	7	4	4	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2010	341								c4457	10.1136/bmj.c4457	http://dx.doi.org/10.1136/bmj.c4457			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647JV	20813824				2022-12-28	WOS:000281615700004
J	Domchek, SM; Friebel, TM; Singer, CF; Evans, DG; Lynch, HT; Isaacs, C; Garber, JE; Neuhausen, SL; Matloff, E; Eeles, R; Pichert, G; Van T'veer, L; Tung, N; Weitzel, JN; Couch, FJ; Rubinstein, WS; Ganz, PA; Daly, MB; Olopade, OI; Tomlinson, G; Schildkraut, J; Blum, JL; Rebbeck, TR				Domchek, Susan M.; Friebel, Tara M.; Singer, Christian F.; Evans, D. Gareth; Lynch, Henry T.; Isaacs, Claudine; Garber, Judy E.; Neuhausen, Susan L.; Matloff, Ellen; Eeles, Rosalind; Pichert, Gabriella; Van T'veer, Laura; Tung, Nadine; Weitzel, Jeffrey N.; Couch, Fergus J.; Rubinstein, Wendy S.; Ganz, Patricia A.; Daly, Mary B.; Olopade, Olufunmilayo I.; Tomlinson, Gail; Schildkraut, Joellen; Blum, Joanne L.; Rebbeck, Timothy R.			Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BILATERAL PROPHYLACTIC OOPHORECTOMY; PROSE-STUDY-GROUP; BREAST-CANCER; SALPINGO-OOPHORECTOMY; OVARIAN-CANCER; UNDERWENT OOPHORECTOMY; PREMENOPAUSAL WOMEN; PENETRANCE; MENOPAUSE; THERAPY	Context Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer. Objective To estimate risk and mortality reduction stratified by mutation and prior cancer status. Design, Setting, and Participants Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations ascertained between 1974 and 2008. The study was conducted at 22 clinical and research genetics centers in Europe and North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes. The women were followed up until the end of 2009. Main Outcomes Measures Breast and ovarian cancer risk, cancer-specific mortality, and overall mortality. Results No breast cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372 diagnosed with breast cancer who did not have risk-reducing mastectomy. Compared with women who did not undergo risk-reducing salpingo-oophorectomy, womenwho underwent salpingo-oophorectomy had a lower risk of ovarian cancer, including those with prior breast cancer (6% vs 1%, respectively; hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.04-0.59) and those without prior breast cancer (6% vs 2%; HR, 0.28 [95% CI, 0.12-0.69]), and a lower risk of first diagnosis of breast cancer in BRCA1 mutation carriers (20% vs 14%; HR, 0.63 [95% CI, 0.41-0.96]) and BRCA2 mutation carriers (23% vs 7%; HR, 0.36 [95% CI, 0.16-0.82]). Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortality (10% vs 3%; HR, 0.40 [95% CI, 0.26-0.61]), breast cancerspecific mortality (6% vs 2%; HR, 0.44 [95% CI, 0.26-0.76]), and ovarian cancerspecific mortality (3% vs 0.4%; HR, 0.21 [95% CI, 0.06-0.80]). Conclusions Among a cohort of women with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian cancer, first diagnosis of breast cancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality. JAMA. 2010; 304(9): 967-975 www.jama.com	[Friebel, Tara M.; Rebbeck, Timothy R.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Domchek, Susan M.; Rebbeck, Timothy R.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Domchek, Susan M.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Singer, Christian F.] Med Univ Vienna, Div Special Gynecol, Vienna, Austria; [Evans, D. Gareth] St Marys Hosp, Dept Clin Genet, Manchester M13 0JH, Lancs, England; [Lynch, Henry T.] Creighton Univ, Dept Prevent Med, Omaha, NE 68178 USA; [Isaacs, Claudine] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA; [Garber, Judy E.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Neuhausen, Susan L.] Univ Calif Irvine, Sch Med, Div Epidemiol, Irvine, CA 92717 USA; [Matloff, Ellen] Yale Univ, Canc Genet Counseling Program, New Haven, CT USA; [Eeles, Rosalind] Royal Marsden NHS Fdn Trust, Inst Canc Res, London, England; [Pichert, Gabriella] Guys & St Thomas Fdn Trust, London, England; [Van T'veer, Laura] Netherlands Canc Inst, Amsterdam, Netherlands; [Tung, Nadine] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Weitzel, Jeffrey N.] City Hope Natl Med Ctr, Duarte, CA 91010 USA; [Couch, Fergus J.] Mayo Clin, Coll Med, Rochester, MN USA; [Rubinstein, Wendy S.] NorthShore Univ HealthSyst, Evanston, IL USA; [Rubinstein, Wendy S.; Olopade, Olufunmilayo I.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA; [Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Daly, Mary B.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Tomlinson, Gail] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Oncol, San Antonio, TX 78229 USA; [Schildkraut, Joellen] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA; [Blum, Joanne L.] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Medical University of Vienna; University of Manchester; Creighton University; Georgetown University; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California Irvine; Yale University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Netherlands Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; City of Hope; Mayo Clinic; NorthShore University Health System; University of Chicago; University of Chicago Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Fox Chase Cancer Center; University of Texas System; University of Texas Health San Antonio; Duke University; Baylor University Medical Center; Texas Oncology-Baylor Charles A Sammons Cancer Center	Rebbeck, TR (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 217 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	reb-beck@mail.med.upenn.edu	Evans, D Gareth/AAB-4308-2022; Friebel-Klingner, Tara/ABF-4212-2021; Tomlinson, Gail/AAR-9776-2020; Rebbeck, Timothy/GLU-8348-2022	Evans, D Gareth/0000-0002-8482-5784; Rebbeck, Timothy/0000-0002-4799-1900; Eeles, Rosalind/0000-0002-3698-6241; Friebel, Tara/0000-0002-3726-9527	Public Health Service [R01-CA83855, R01-CA102776, NO1-CN-6700]; University of Pennsylvania Cancer Center; Cancer Genetics Network [HHSN21620074400C]; Marjorie Cohen Research Fund; Dana-Farber/Harvard Cancer Center [BC P50 CA-089393]; US Department of Defense [DAMD-17-96-I-6088, DAMD-17-94-J-4340, DAMD-17-97-I-7112, DAMD-17-03-I-0619]; Utah State Department of Health; Nebraska State Cancer and Smoking-Related Diseases Research [LB595, P30-CA-16042]; Cancer Research UK [C5047/A7357]; National Cancer Institute [P30 CA51008-12]; Doris Duke Distinguished Clinical Scientist; National Institute for Health Research;  [P30-CA51008-15]; NATIONAL CANCER INSTITUTE [P30CA016042, P30CA051008, R01CA102776, RC4CA153828, R01CA083855, P50CA089393] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); University of Pennsylvania Cancer Center; Cancer Genetics Network; Marjorie Cohen Research Fund; Dana-Farber/Harvard Cancer Center; US Department of Defense(United States Department of Defense); Utah State Department of Health; Nebraska State Cancer and Smoking-Related Diseases Research; Cancer Research UK(Cancer Research UK); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Doris Duke Distinguished Clinical Scientist(Doris Duke Charitable Foundation (DDCF)); National Institute for Health Research(National Institute for Health Research (NIHR)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants R01-CA83855 and R01-CA102776 from the Public Health Service (awarded to Dr Rebbeck); funding from the University of Pennsylvania Cancer Center (awarded to Dr Rebbeck); grant HHSN21620074400C from the Cancer Genetics Network (awarded to Drs Domchek and Isaacs); funding from the Marjorie Cohen Research Fund (awarded to Dr Domchek); SPORE grant BC P50 CA-089393 from the Dana-Farber/Harvard Cancer Center (awarded to Dr Garber); grants DAMD-17-96-I-6088 (awarded to Andrew K. Godwin), DAMD-17-94-J-4340 and DAMD-17-97-I-7112 (awarded to Dr Lynch), and DAMD-17-03-I-0619 (awarded to Dr Domchek) from the US Department of Defense; grant P30-CA51008-15 (awarded to Georgetown University); funding from the Utah Cancer registry (which was funded by Public Health Service grant NO1-CN-6700) and the Utah State Department of Health; Nebraska State Cancer and Smoking-Related Diseases Research Program grants LB595 (awarded to Dr Lynch) and P30-CA-16042 (awarded to Dr Ganz); Cancer Research UK grant C5047/A7357 (awarded to Dr Eeles); and National Cancer Institute grant P30 CA51008-12 (awarded to Dr Isaacs). Dr Olopade receives funding as the Doris Duke Distinguished Clinical Scientist. Dr Eeles received funding from the National Institute for Health Research (awarded to the Biomedical Research Centre at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust).	Chang-Claude J, 2007, CANCER EPIDEM BIOMAR, V16, P740, DOI 10.1158/1055-9965.EPI-06-0829; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Davidson NE, 2005, J CLIN ONCOL, V23, P5973, DOI 10.1200/JCO.2005.05.551; Domchek SM, 2006, LANCET ONCOL, V7, P223, DOI 10.1016/S1470-2045(06)70585-X; Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; Evans DGR, 2009, J MED GENET, V46, P254, DOI 10.1136/jmg.2008.062232; Finch A, 2006, JAMA-J AM MED ASSOC, V296, P185, DOI 10.1001/jama.296.2.185; Fisher B, 2004, LANCET, V364, P858, DOI 10.1016/S0140-6736(04)16981-X; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Hartmann LC, 2004, J CLIN ONCOL, V22, P981, DOI 10.1200/JCO.2004.01.925; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Kauff ND, 2008, J CLIN ONCOL, V26, P1331, DOI 10.1200/JCO.2007.13.9626; Kauff ND, 2007, J CLIN ONCOL, V25, P2921, DOI 10.1200/JCO.2007.11.3449; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Klaren HM, 2003, J NATL CANCER I, V95, P941, DOI 10.1093/jnci/95.13.941; Kramer JL, 2005, J CLIN ONCOL, V23, P8629, DOI 10.1200/JCO.2005.02.9199; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Metcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033; Parker WH, 2009, WOMENS HEALTH, V5, P565, DOI 10.2217/WHE.09.42; Parker WH, 2009, MENOPAUSE, V16, P1, DOI 10.1097/gme.0b013e31818d64d6; Parker WH, 2009, OBSTET GYNECOL, V113, P1027, DOI 10.1097/AOG.0b013e3181a11c64; Pierce LJ, 2006, J CLIN ONCOL, V24, P2437, DOI 10.1200/JCO.2005.02.7888; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Rebbeck TR, 2005, J CLIN ONCOL, V23, P7804, DOI 10.1200/JCO.2004.00.8151; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; Rocca WA, 2008, NEUROLOGY, V70, P200, DOI 10.1212/01.wnl.0000280573.30975.6a; Rocca WA, 2007, NEUROLOGY, V69, P1074, DOI 10.1212/01.wnl.0000276984.19542.e6; Rocca WA, 2006, LANCET ONCOL, V7, P821, DOI 10.1016/S1470-2045(06)70869-5; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rutter JL, 2003, JNCI-J NATL CANCER I, V95, P1072, DOI 10.1093/jnci/95.14.1072; Satagopan JM, 2002, CLIN CANCER RES, V8, P3776; Shah P, 2009, BREAST CANCER RES TR, V118, P539, DOI 10.1007/s10549-009-0475-1; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001	38	941	970	0	70	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					967	975		10.1001/jama.2010.1237	http://dx.doi.org/10.1001/jama.2010.1237			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20810374	Green Accepted, Bronze			2022-12-28	WOS:000281422400022
J	Federoff, HJ; Rubin, ER				Federoff, Howard J.; Rubin, Elaine R.			A New Research and Development Policy Framework for the Biomedical Research Enterprise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Federoff, Howard J.] Georgetown Univ, Med Ctr, Sch Med, Off Execut Vice President, Washington, DC 20057 USA; [Rubin, Elaine R.] Assoc Acad Hlth Ctr, Washington, DC USA	Georgetown University	Federoff, HJ (corresponding author), Georgetown Univ, Med Ctr, Sch Med, Off Execut Vice President, 120 Bldg D,4000 Reservoir Rd NW, Washington, DC 20057 USA.	hjf8@georgetown.edu						*BAT TECHN PARTN P, 2010, GON TOM CALL PROM ME; Boat TF, 2010, JAMA-J AM MED ASSOC, V303, P170, DOI 10.1001/jama.2009.1992; DUGA J, 2008, R D MAGAZINE     DEC, P19; Garrison HH, 2005, FASEB J, V19, P1938, DOI 10.1096/fj.05-1203ufm; Olefsky JM, 2007, J CLIN INVEST, V117, P270, DOI 10.1172/JCI31318; Palazzo R, 2008, SCIENTIST, V22, P25	6	5	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					1003	1004		10.1001/jama.2010.1270	http://dx.doi.org/10.1001/jama.2010.1270			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20810378				2022-12-28	WOS:000281422400027
J	Herne, MC; Nair, JP; Salisbury, SW				Herne, Matthew C.; Nair, Jay P.; Salisbury, Steven W.			Comment on "A Southern Tyrant Reptile"	SCIENCE			English	Editorial Material							DINOSAURIA; OSTEOLOGY; AUSTRALIA	Benson et al. (Brevia, 26 March 2010, p. 1613) reported on an Australian tyrannosauroid, represented by a pubis from the late Early Cretaceous of Victoria. However, our examination of this specimen reveals that the critical character used for this referral is not present. We contend that the bone likely belongs to a currently recognized group of Australian theropod or another group not currently known.	[Herne, Matthew C.; Nair, Jay P.; Salisbury, Steven W.] Univ Queensland, Sch Biol Sci, Brisbane, Qld 4072, Australia; [Salisbury, Steven W.] Carnegie Museum Nat Hist, Vertebrate Paleontol Sect, Pittsburgh, PA 15213 USA	University of Queensland	Herne, MC (corresponding author), Univ Queensland, Sch Biol Sci, Brisbane, Qld 4072, Australia.	m.herne@uq.edu.au	Salisbury, Steven W./A-7518-2011; Herne, Matthew C/C-5388-2017	Salisbury, Steven W./0000-0003-4097-8567; Herne, Matthew C/0000-0001-6355-0331; Nair, Jay/0000-0001-9218-8124				Agnolin FL, 2010, J SYST PALAEONTOL, V8, P257, DOI 10.1080/14772011003594870; Benson RBJ, 2010, SCIENCE, V327, P1613, DOI 10.1126/science.1187456; Benson RBJ, 2010, NATURWISSENSCHAFTEN, V97, P71, DOI 10.1007/s00114-009-0614-x; Brochu CA, 2003, J VERTEBR PALEONTOL, V22, P1, DOI [10.1080/02724634.2003.10010947, DOI 10.1080/02724634.2003.10010947, 10.2307/3889334, DOI 10.2307/3889334]; CURRIE PJ, 1993, CAN J EARTH SCI, V30, P2037, DOI 10.1139/e93-179; DONG ZM, 1985, VERTEBRAT PALASIATIC, V23, P77; Hutchinson JR, 2001, ZOOL J LINN SOC-LOND, V131, P123, DOI 10.1006/zjls.2000.0254; Norell Mark A., 1997, American Museum Novitates, V3215, P1; Rauhut OWM, 2010, ZOOL J LINN SOC-LOND, V158, P155, DOI 10.1111/j.1096-3642.2009.00591.x; Rauhut OWM, 2003, SPEC PAP PALAEONTOL, P1; Smith ND, 2008, P ROY SOC B-BIOL SCI, V275, P2085, DOI 10.1098/rspb.2008.0504	11	20	20	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2010	329	5995								10.1126/science.1190100	http://dx.doi.org/10.1126/science.1190100			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798297				2022-12-28	WOS:000281253500016
J	Flaherty, KT; Puzanov, I; Kim, KB; Ribas, A; McArthur, GA; Sosman, JA; O'Dwyer, PJ; Lee, RJ; Grippo, JF; Nolop, K; Chapman, PB				Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'Dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.			Inhibition of Mutated, Activated BRAF in Metastatic Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MISMATCH REPAIR DEFICIENCY; PAPILLARY CARCINOMAS; MALIGNANT-MELANOMA; TUMOR PROGRESSION; KRAS MUTATIONS; PHASE-III; CANCER; RAF; DACARBAZINE; SORAFENIB	BACKGROUND The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease. METHODS We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the maximum dose that could be administered without adverse effects (the recommended phase 2 dose). Patients received PLX4032 twice daily until they had disease progression. Pharmacokinetic analysis and tumor-response assessments were conducted in all patients. In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition. RESULTS A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 additional patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase. The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia. In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response. Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response. The estimated median progression-free survival among all patients was more than 7 months. CONCLUSIONS Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)	[Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Flaherty, Keith T.; O'Dwyer, Peter J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Puzanov, Igor; Sosman, Jeffrey A.] Vanderbilt Univ, Nashville, TN USA; [Kim, Kevin B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA USA; [McArthur, Grant A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Lee, Richard J.; Grippo, Joseph F.] Roche Pharmaceut, Nutley, NJ USA; [Nolop, Keith] Plexxikon, Berkeley, CA USA; [Chapman, Paul B.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; University of Pennsylvania; Pennsylvania Medicine; Vanderbilt University; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; Peter Maccallum Cancer Center; Roche Holding; Plexxikon; Memorial Sloan Kettering Cancer Center	Flaherty, KT (corresponding author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.	kflaherty@partners.org	PUZANOV, IGOR/AAP-2966-2020	PUZANOV, IGOR/0000-0002-9803-3497; McArthur, Grant/0000-0001-8908-6071	Plexxikon; Roche Pharmaceuticals; NATIONAL CANCER INSTITUTE [K24CA097588] Funding Source: NIH RePORTER	Plexxikon; Roche Pharmaceuticals(Roche Holding); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Plexxikon and Roche Pharmaceuticals.	Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Bedikian AY, 2006, J CLIN ONCOL, V24, P4738, DOI 10.1200/JCO.2006.06.0483; Carvajal RD, 2009, J CLIN ONCOL S, V27, p15S; Cho NY, 2006, INT J CANCER, V119, P1858, DOI 10.1002/ijc.22071; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; COMIS RL, 1976, CANCER TREAT REP, V60, P165; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Honecker F, 2009, J CLIN ONCOL, V27, P2129, DOI 10.1200/JCO.2008.18.8623; Kimura ET, 2003, CANCER RES, V63, P1454; Koch WH, 2004, NAT REV DRUG DISCOV, V3, P749, DOI 10.1038/nrd1496; McDermott DF, 2008, J CLIN ONCOL, V26, P2178, DOI 10.1200/JCO.2007.14.8288; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Wang L, 2003, CANCER RES, V63, P5209; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yuen ST, 2002, CANCER RES, V62, P6451	29	2717	2822	3	256	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					809	819		10.1056/NEJMoa1002011	http://dx.doi.org/10.1056/NEJMoa1002011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642HG	20818844	Bronze, Green Accepted			2022-12-28	WOS:000281196600004
J	Brook, RH				Brook, Robert H.			Physician Compensation, Cost, and Quality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PERFORMANCE; CARE; PAY		RAND Corp, Santa Monica, CA 90401 USA	RAND Corporation	Brook, RH (corresponding author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.	robert_brook@rand.org						*AM MED ASS, 2007, CURR PROC TERM; Campbell SM, 2009, NEW ENGL J MED, V361, P368, DOI 10.1056/NEJMsa0807651; Hibbard JH, 2005, HEALTH AFFAIR, V24, P1150, DOI 10.1377/hlthaff.24.4.1150; Meyer H, 2010, HEALTH AFFAIR, V29, P844, DOI 10.1377/hlthaff.2010.0345; Newhouse J.P., 2002, PRICING PRICELESS HL; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Tu JV, 2009, JAMA-J AM MED ASSOC, V302, P2330, DOI 10.1001/jama.2009.1731	7	9	9	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					795	796		10.1001/jama.2010.1174	http://dx.doi.org/10.1001/jama.2010.1174			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20716745				2022-12-28	WOS:000280993700030
J	Cordoba, G; Schwartz, L; Woloshin, S; Bae, H; Gotzsche, PC				Cordoba, Gloria; Schwartz, Lisa; Woloshin, Steven; Bae, Harold; Gotzsche, Peter C.			Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							END-POINTS; RANDOMIZED-TRIALS	Objective To study how composite outcomes, which have combined several components into a single measure, are defined, reported, and interpreted. Design Systematic review of parallel group randomised clinical trials published in 2008 reporting a binary composite outcome. Two independent observers extracted the data using a standardised data sheet, and two other observers, blinded to the results, selected the most important component. Results Of 40 included trials, 29 (73%) were about cardiovascular topics and 24 (60%) were entirely or partly industry funded. Composite outcomes had a median of three components (range 2-9). Death or cardiovascular death was the most important component in 33 trials (83%). Only one trial provided a good rationale for the choice of components. We judged that the components were not of similar importance in 28 trials (70%); in 20 of these, death was combined with hospital admission. Other major problems were change in the definition of the composite outcome between the abstract, methods, and results sections (13 trials); missing, ambiguous, or uninterpretable data (9 trials); and post hoc construction of composite outcomes (4 trials). Only 24 trials (60%) provided reliable estimates for both the composite and its components, and only six trials (15%) had components of similar, or possibly similar, clinical importance and provided reliable estimates. In 11 of 16 trials with a statistically significant composite, the abstract conclusion falsely implied that the effect applied also to the most important component. Conclusions The use of composite outcomes in trials is problematic. Components are often unreasonably combined, inconsistently defined, and inadequately reported. These problems will leave many readers confused, often with an exaggerated perception of how well interventions work.	[Cordoba, Gloria; Gotzsche, Peter C.] Rigshosp, Nord Cochrane Ctr, DK-2100 Copenhagen, Denmark; [Cordoba, Gloria; Gotzsche, Peter C.] Univ Copenhagen, DK-2100 Copenhagen, Denmark; [Schwartz, Lisa; Woloshin, Steven; Bae, Harold] Dartmouth Med Sch, Dartmouth Inst Hlth Policy, Hanover, NH USA	Rigshospitalet; University of Copenhagen; University of Copenhagen; Dartmouth College	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	pcg@cochrane.dk		Cordoba, Gloria/0000-0002-2609-0468				Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79; Ferreira-Gonzalez I, 2007, BRIT MED J, V334, P786, DOI 10.1136/bmj.39136.682083.AE; Ferreira-Gonzalez I, 2007, J CLIN EPIDEMIOL, V60, P651, DOI 10.1016/j.jclinepi.2006.10.020; Freemantle N, 2003, JAMA-J AM MED ASSOC, V289, P2554, DOI 10.1001/jama.289.19.2554; Gotzsche PC, 2006, BMJ-BRIT MED J, V333, P231, DOI 10.1136/bmj.38895.410451.79; Krogsboll LT, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-1; Lim E, 2008, ANN INTERN MED, V149, P612, DOI 10.7326/0003-4819-149-9-200811040-00004; Lubsen J, 2002, STAT MED, V21, P2959, DOI 10.1002/sim.1300; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; ROSS S, 2007, AM J OBSTET GYNECOL, V196; SHERRY S, 1980, NEW ENGL J MED, V302, P250; TEMPLE R, 1980, NEW ENGL J MED, V303, P1488, DOI 10.1056/NEJM198012183032534; Tomlinson G, 2010, JAMA-J AM MED ASSOC, V303, P267, DOI 10.1001/jama.2009.2017	15	203	204	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2010	341								c3920	10.1136/bmj.c3920	http://dx.doi.org/10.1136/bmj.c3920			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KT	20719825	hybrid, Green Published			2022-12-28	WOS:000281213100006
J	Arana, A; Wentworth, CE; Ayuso-Mateos, JL; Arellano, FM				Arana, Alejandro; Wentworth, Charles E.; Ayuso-Mateos, Jose L.; Arellano, Felix M.			Suicide-Related Events in Patients Treated with Antiepileptic Drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMORBIDITY SURVEY REPLICATION; RISK-FACTORS; BIPOLAR DISORDER; EPILEPSY; ANTIDEPRESSANTS; UK; PREVENTION; VALIDATION; ALGORITHM; DEATH	BACKGROUND A previous meta-analysis of data from clinical trials showed an association between antiepileptic drugs and suicidality (suicidal ideation, behavior, or both). We used observational data to examine the association between the use or nonuse of antiepileptic drugs and suicide-related events (attempted suicides and completed suicides) in patients with epilepsy, depression, or bipolar disorder. METHODS We used data collected as part of the clinical care of patients who were representative of the general population in the United Kingdom to identify patients with epilepsy, depression, or bipolar disorder and to determine whether they received antiepileptic drugs. We estimated the incidence rate of suicide-related events and used logistic regression to compute odds ratios, controlling for confounding factors. RESULTS In a cohort of 5,130,795 patients, the incidence of suicide-related events per 100,000 person-years was 15.0 (95% confidence interval [CI], 14.6 to 15.5) among patients without epilepsy, depression, bipolar disorder, or antiepileptic-drug treatment, 38.2 (95% CI, 26.3 to 53.7) among patients with epilepsy who did not receive antiepileptic drugs, and 48.2 (95% CI, 39.4 to 58.5) among patients with epilepsy who received antiepileptic drugs. In adjusted analyses, the use of antiepileptic drugs was not associated with an increased risk of suicide-related events among patients with epilepsy (odds ratio, 0.59; 95% CI, 0.35 to 0.98) or bipolar disorder (1.13; 95% CI, 0.35 to 3.61) but was significantly associated with an increased risk among patients with depression (1.65; 95% CI, 1.24 to 2.19) and those who did not have epilepsy, depression, or bipolar disorder (2.57; 95% CI, 1.78 to 3.71). CONCLUSIONS The current use of antiepileptic drugs was not associated with an increased risk of suicide-related events among patients with epilepsy, but it was associated with an increased risk of such events among patients with depression and among those who did not have epilepsy, depression, or bipolar disorder.	[Arana, Alejandro; Arellano, Felix M.] Risk MR Pharmacovigilance Serv, Zaragoza 50001, Spain; [Ayuso-Mateos, Jose L.] Univ Autonoma Madrid, Hosp Univ Princesa, Dept Psychiat, Madrid, Spain; [Ayuso-Mateos, Jose L.] Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Madrid, Spain; [Wentworth, Charles E.; Arellano, Felix M.] RiskMR, Bridgewater, NJ USA	Autonomous University of Madrid; Hospital de La Princesa; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Instituto de Salud Carlos III	Arana, A (corresponding author), Risk MR Pharmacovigilance Serv, Jeronimo Zurita 14,1-D, Zaragoza 50001, Spain.	arana.riskmr@gmail.com		ARANA, Alejandro/0000-0002-1593-3124; Ayuso-Mateos, Jose Luis/0000-0002-7544-826X				American Foundation for Suicide Prevention, RISK FACT SUIC; ARCLLANO FM, 2009, J ALLERGY CLIN IMMUN, V123, P1111; Arellano FM, 2006, PHARMACOEPIDEM DR S, V15, P861, DOI 10.1002/pds.1343; Bell GS, 2009, CNS DRUGS, V23, P281, DOI 10.2165/00023210-200923040-00002; Blumer D, 2002, EPILEPSY BEHAV, V3, P232, DOI 10.1016/S1525-5050(02)00006-9; Braden JB, 2008, J PAIN, V9, P1106, DOI 10.1016/j.jpain.2008.06.004; Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8; DeLeo D., 2002, WORLD REPORT VIOLENC, P183; Gibbons RD, 2007, AM J PSYCHIAT, V164, P1044, DOI 10.1176/appi.ajp.164.7.1044; Gibbons RD, 2009, ARCH GEN PSYCHIAT, V66, P1354, DOI 10.1001/archgenpsychiatry.2009.159; Goodwin FK, 2003, JAMA-J AM MED ASSOC, V290, P1467, DOI 10.1001/jama.290.11.1467; Hall GC, 2009, PHARMACOEPIDEM DR S, V18, P120, DOI 10.1002/pds.1686; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Hippisley-Cox J, 2008, HEART, V94, P34, DOI 10.1136/hrt.2007.134890; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Mortensen PB, 2000, LANCET, V355, P9, DOI 10.1016/S0140-6736(99)06376-X; Moscicki EK, 2001, CLIN NEUROSCI RES, V1, P310, DOI 10.1016/S1566-2772(01)00032-9; MOSCICKI EK, 1985, SUICIDE PREVENTION Y, P22; NHS Centre for Coding and Classification, 1996, READ COD VERS 3; Nilsson L, 2002, EPILEPSIA, V43, P644, DOI 10.1046/j.1528-1157.2002.40001.x; *OFF NAT STAT, 2009, SUIC UK SUIC RAT CON; Patorno E, 2010, JAMA-J AM MED ASSOC, V303, P1401, DOI 10.1001/jama.2010.410; Posner K, 2007, AM J PSYCHIAT, V164, P1035, DOI 10.1176/appi.ajp.164.7.1035; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Vigo DV, 2009, HARVARD REV PSYCHIAT, V17, P231, DOI 10.1080/10673220903129814; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G	28	120	127	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					542	551		10.1056/NEJMoa0909801	http://dx.doi.org/10.1056/NEJMoa0909801			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818889	Bronze			2022-12-28	WOS:000280552700008
J	PANDYA, SK				PANDYA, SK			YEARNING FOR BABY BOYS	BRITISH MEDICAL JOURNAL			English	Article									KEM HOSP,BOMBAY,INDIA		PANDYA, SK (corresponding author), SETH GS MED COLL,DEPT NEUROSURG,BOMBAY 400012,INDIA.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 7	1988	296	6632					1312	1312		10.1136/bmj.296.6632.1312	http://dx.doi.org/10.1136/bmj.296.6632.1312			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N3627	20742991	Green Published			2022-12-28	WOS:A1988N362700017
J	Stone, GW				Stone, Gregg W.			Acute coronary syndromes: finding meaning in OASIS 7	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PRIMARY ANGIOPLASTY; RANDOMIZED-TRIALS; CLOPIDOGREL; METAANALYSIS; CARE		Columbia Univ, Med Ctr, New York Presbyterian Hosp, Cardiovasc Res Fdn, New York, NY 10022 USA	Cardiovascular Research Foundation (CRF); Columbia University; NewYork-Presbyterian Hospital	Stone, GW (corresponding author), Columbia Univ, Med Ctr, New York Presbyterian Hosp, Cardiovasc Res Fdn, New York, NY 10022 USA.	gs2184@columbia.edu						Cuisset T, 2009, EUROINTERVENTION, V5, P325, DOI 10.4244/51; Dangas G, 2009, J AM COLL CARDIOL, V54, P1438, DOI 10.1016/j.jacc.2009.06.021; Fiorentino R. P., 2010, NDA 22 433 BRIL TIC; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Lotrionte M, 2007, AM J CARDIOL, V100, P1199, DOI 10.1016/j.amjcard.2007.05.048; Mehta SR, 2010, LANCET, V376, P1233, DOI 10.1016/S0140-6736(10)61088-4; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P2908, DOI 10.1001/jama.293.23.2908; ORIORDAN M, 2009, CURRENT OASIS 7 BENE; Pocock SJ, 2010, CIRCULATION, V121, P43, DOI 10.1161/CIRCULATIONAHA.109.878017; Roden DM, 2010, CIRCULATION, V122, P445, DOI 10.1161/CIRCULATIONAHA.110.973362; Serebruany VL, 2005, J AM COLL CARDIOL, V45, P246, DOI 10.1016/j.jacc.2004.09.067; Sibbing D, 2009, J AM COLL CARDIOL, V53, P849, DOI 10.1016/j.jacc.2008.11.030; Stone GW, 2010, LANCET, V375, P263, DOI 10.1016/S0140-6736(10)60070-0	13	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 9	2010	376	9748					1203	1205		10.1016/S0140-6736(10)61262-7	http://dx.doi.org/10.1016/S0140-6736(10)61262-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZT	20817280				2022-12-28	WOS:000283003500008
J	Bohm, M; Swedberg, K; Komajda, M; Borer, JS; Ford, I; Dubost-Brama, A; Lerebours, G; Tavazzi, L				Boehm, Michael; Swedberg, Karl; Komajda, Michel; Borer, Jeffrey S.; Ford, Ian; Dubost-Brama, Ariane; Lerebours, Guy; Tavazzi, Luigi		SHIFT Investigators	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial	LANCET			English	Article							CORONARY-ARTERY-DISEASE; SYSTOLIC DYSFUNCTION BEAUTIFUL; LEFT-VENTRICULAR FUNCTION; RATE REDUCTION; BETA-BLOCKER; CARDIOVASCULAR-DISEASE; HUMAN MYOCARDIUM; DOUBLE-BLIND; IVABRADINE; ATHEROSCLEROSIS	Background Raised resting heart rate is a marker of cardiovascular risk. We postulated that heart rate is also a risk factor for cardiovascular events in heart failure. In the SHIFT trial, patients with chronic heart failure were treated with the selective heart-rate-lowering agent ivabradine. We aimed to test our hypothesis by investigating the association between heart rate and events in this patient population. Methods We analysed cardiovascular outcomes in the placebo (n=3264) and ivabradine groups (n=3241) of this randomised trial, divided by quintiles of baseline heart rate in the placebo group. The primary composite endpoint was cardiovascular death or hospital admission for worsening heart failure. In the ivabradine group, heart rate achieved at 28 days was also analysed in relation to subsequent outcomes. Analysis adjusted to change in heart rate was used to study heart-rate reduction as mechanism for risk reduction by ivabradine directly. Findings In the placebo group, patients with the highest heart rates (87 beats per min [bpm], n=682, 286 events) were at more than two-fold higher risk for the primary composite endpoint than were patients with the lowest heart rates (70 to <72 bpm, n=461, 92 events; hazard ratio [HR] 2.34, 95% CI 1.84-2.98, p<0.0001). Risk of primary composite endpoint events increased by 3% with every beat increase from baseline heart rate and 16% for every 5-bpm increase. In the ivabradine group, there was a direct association between heart rate achieved at 28 days and subsequent cardiac outcomes. Patients with heart rates lower than 60 bpm at 28 days on treatment had fewer primary composite endpoint events during the study (n=1192; event rate 17.4%, 95% CI 15.3-19.6) than did patients with higher heart rates. The effect of ivabradine is accounted for by heart-rate reduction, as shown by the neutralisation of the treatment effect after adjustment for change of heart rate at 28 days (HR 0.95, 0.85-1.06, p=0-352). Interpretation Our analysis confirms that high heart rate is a risk factor in heart failure. Selective lowering of heart rates with ivabradine improves cardiovascular outcomes. Heart rate is an important target for treatment of heart failure.	[Boehm, Michael] Univ Klinikum Saarlandes, Innere Med Klin 3, D-66424 Homburg, Germany; [Swedberg, Karl] Univ Gothenburg, Sahlgrenska Acad, Dept Emergency & Cardiovasc Med, Gothenburg, Sweden; [Komajda, Michel] Univ Paris 06, Dept Cardiol, La Pitie Salpetriere Hosp, Paris, France; [Borer, Jeffrey S.] Suny Downstate Med Ctr, Div Cardiovasc Med, Brooklyn, NY 11203 USA; [Borer, Jeffrey S.] Suny Downstate Med Ctr, Howard Gilman Inst Heart Valve Dis, Brooklyn, NY 11203 USA; [Borer, Jeffrey S.] Suny Downstate Med Ctr, Div Cardiovasc Med, New York, NY USA; [Borer, Jeffrey S.] Suny Downstate Med Ctr, Howard Gilman Inst Heart Valve Dis, New York, NY USA; [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Dubost-Brama, Ariane; Lerebours, Guy] Inst Rech Int Servier, F-92415 Courbevoie, France; [Tavazzi, Luigi] Maria Cecilia Hosp, GVM Care & Res, Ettore Sansavini Hlth Sci Fdn, Cotignola, Italy	Universitatsklinikum des Saarlandes; University of Gothenburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Glasgow; Servier; Institut de Recherches Internationales Servier; Maria Cecilia Hospital	Bohm, M (corresponding author), Univ Klinikum Saarlandes, Innere Med Klin 3, Kirrberger Str 1, D-66424 Homburg, Germany.	boehm@uks.eu	Böhm, Michael/C-3638-2011; Ford, Ian/ABE-6145-2020; Tavazzi, Luigi/ABD-5119-2020; Swedberg, Karl/B-2475-2008	Tavazzi, Luigi/0000-0003-0336-8356; 	Servier; Amgen; AstraZeneca; Nile Therapeutics; Bristol-Myers Squibb; Sanofi-Aventis; Menarini; Merck; Medtronic; BioTronik; Solvay; Vifor Pharma; IKKT; GlaxoSmithKline	Servier(Servier); Amgen(Amgen); AstraZeneca(AstraZeneca); Nile Therapeutics; Bristol-Myers Squibb(Bristol-Myers Squibb); Sanofi-Aventis(Sanofi-Aventis); Menarini(Menarini Group); Merck(Merck & Company); Medtronic(Medtronic); BioTronik; Solvay(Solvay SA); Vifor Pharma; IKKT; GlaxoSmithKline(GlaxoSmithKline)	MB, KS, MK, JSB, IF, and LT have received fees, research grants, or both from Servier. ADB and GL are employees of Servier. MB has received research grants and speakers' honoraria from AstraZeneca, Boehringer Ingelheim, Sanofi-Aventis, and Pfizer. KS has also received research grants from Amgen and AstraZeneca, and speakers honoraria from Amgen, Novartis, and AstraZeneca. MK has received consultancy fees from Nile Therapeutics and Bristol-Myers Squibb, and payment for service on speakers' bureau from Sanofi-Aventis, Menarini, Bristol-Myers Squibb, Merck, and AstraZeneca. JB has received consulting honoraria from Celladon, Gilead, Sanofi-Aventis, ARMGO, Novartis, Novocardia (Merck), Biomarin, Roche, Pfizer, Rigel, BioTronik, Salix, XOMA, Lux, Cardiopep, Bristol-Myers Squibb, and Cardioxyl. IF has received research grants or honoraria from Medtronic, BioTronik, Solvay, Vifor Pharma, IKKT, and GlaxoSmithKline. LT has received consulting honoraria from Medtronic and Menarini and speakers' honoraria from Abbot, AstraZeneca, and Pfizer.	BEERE PA, 1984, SCIENCE, V226, P180, DOI 10.1126/science.6484569; Bucchi A, 2002, J GEN PHYSIOL, V120, P1, DOI 10.1085/jgp.20028593; Colin P, 2004, J PHARMACOL EXP THER, V308, P236, DOI 10.1124/jpet.103.059717; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; CONWAY MA, 1991, LANCET, V338, P973, DOI 10.1016/0140-6736(91)91838-L; Custodis F, 2008, CIRCULATION, V117, P2377, DOI 10.1161/CIRCULATIONAHA.107.746537; DiFrancesco D, 2004, DRUGS, V64, P1757, DOI 10.2165/00003495-200464160-00003; Flannery G, 2008, AM J CARDIOL, V101, P865, DOI 10.1016/j.amjcard.2007.11.023; Fox K, 2008, LANCET, V372, P807, DOI 10.1016/S0140-6736(08)61170-8; Fox K, 2008, LANCET, V372, P817, DOI 10.1016/S0140-6736(08)61171-X; Fox K, 2007, J AM COLL CARDIOL, V50, P823, DOI 10.1016/j.jacc.2007.04.079; Gheorghiade M, 2003, CIRCULATION, V107, P1570, DOI 10.1161/01.CIR.0000065187.80707.18; Gullestad L, 2005, J AM COLL CARDIOL, V45, P252, DOI 10.1016/j.jacc.2004.10.032; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; HASENFUSS G, 1994, EUR HEART J, V15, P164, DOI 10.1093/oxfordjournals.eurheartj.a060471; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; KELLY RP, 1992, CIRCULATION, V86, P513, DOI 10.1161/01.CIR.86.2.513; Kindermann M, 2002, EUR HEART J, V23, P1301, DOI 10.1053/euhj.2001.3078; Kolloch R, 2008, EUR HEART J, V29, P1327, DOI 10.1093/eurheartj/ehn123; Kurita T, 2007, EUR J HEART FAIL, V9, P637, DOI 10.1016/j.ejheart.2007.03.002; Lechat P, 2001, CIRCULATION, V103, P1428, DOI 10.1161/01.CIR.103.10.1428; Logeart D, 2009, EUR J HEART FAIL, V11, P53, DOI 10.1093/eurjhf/hfn016; Lohse MJ, 1996, BASIC RES CARDIOL, V91, P29, DOI 10.1007/BF00795359; McAlister FA, 2009, ANN INTERN MED, V150, P784, DOI 10.7326/0003-4819-150-11-200906020-00006; Metra M, 2005, EUR HEART J, V26, P2259, DOI 10.1093/eurheartj/ehi386; Mulder P, 2004, CIRCULATION, V109, P1674, DOI 10.1161/01.CIR.0000118464.48959.1C; MULIERI LA, 1992, CIRCULATION, V85, P1743, DOI 10.1161/01.CIR.85.5.1743; PERSKI A, 1988, AM HEART J, V116, P1369, DOI 10.1016/0002-8703(88)90469-3; Pocock SJ, 2006, EUR HEART J, V27, P65, DOI 10.1093/eurheartj/ehi555; Reil JC, 2008, LANCET, V372, P779, DOI 10.1016/S0140-6736(08)61172-1; Reil JC, 2009, TRENDS CARDIOVAS MED, V19, P152, DOI 10.1016/j.tcm.2009.09.002; Swedberg K, 2010, LANCET, V376, P875, DOI 10.1016/S0140-6736(10)61198-1; Swedberg K, 2010, EUR J HEART FAIL, V12, P75, DOI 10.1093/eurjhf/hfp154	33	658	687	2	39	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					886	894		10.1016/S0140-6736(10)61259-7	http://dx.doi.org/10.1016/S0140-6736(10)61259-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653DW	20801495				2022-12-28	WOS:000282069100029
J	Kirby, T				Kirby, Tony			Heather Zar-improving lung health for children in Africa	LANCET			English	Editorial Material												tony.kirby@lancet.com							0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	2010	376	9743					763	763		10.1016/S0140-6736(10)61366-9	http://dx.doi.org/10.1016/S0140-6736(10)61366-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	650EC	20816534				2022-12-28	WOS:000281831000014
J	Alroy, J				Alroy, J.			The Shifting Balance of Diversity Among Major Marine Animal Groups	SCIENCE			English	Article							PHANEROZOIC TAXONOMIC DIVERSITY; FOSSIL RECORD; MASS EXTINCTIONS; KINETIC-MODEL; DIVERSIFICATION; PATTERNS; FAMILIES; HISTORY; TRENDS	The fossil record demonstrates that each major taxonomic group has a consistent net rate of diversification and a limit to its species richness. It has been thought that long-term changes in the dominance of major taxonomic groups can be predicted from these characteristics. However, new analyses show that diversity limits may rise or fall in response to adaptive radiations or extinctions. These changes are idiosyncratic and occur at different times in each taxa. For example, the end-Permian mass extinction permanently reduced the diversity of important, previously dominant groups such as brachiopods and crinoids. The current global crisis may therefore permanently alter the biosphere's taxonomic composition by changing the rules of evolution.	[Alroy, J.] Univ Calif Santa Barbara, Santa Barbara, CA 93101 USA	University of California System; University of California Santa Barbara	Alroy, J (corresponding author), Macquarie Univ, Fac Sci, Dept Biol Sci, Sydney, NSW 2109, Australia.		Alroy, John/B-4585-2009	Alroy, John/0000-0002-9882-2111				Alroy J, 2004, EVOL ECOL RES, V6, P1; Alroy J, 2008, P NATL ACAD SCI USA, V105, P11536, DOI 10.1073/pnas.0802597105; Alroy J, 2008, SCIENCE, V321, P97, DOI 10.1126/science.1156963; Bambach RK, 1999, GEOBIOS-LYON, V32, P131, DOI 10.1016/S0016-6995(99)80025-4; Bambach RK, 2002, P NATL ACAD SCI USA, V99, P6854, DOI 10.1073/pnas.092150999; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; GILINSKY NL, 1994, PALEOBIOLOGY, V20, P445, DOI 10.1017/S0094837300012926; HOFFMAN A, 1986, PALAEONTOLOGY, V29, P655; Kiessling W, 2008, NAT GEOSCI, V1, P527, DOI 10.1038/ngeo251; McKinney FK, 1998, SCIENCE, V281, P807, DOI 10.1126/science.281.5378.807; MILLER AI, 1988, PALEOBIOLOGY, V14, P364, DOI 10.1017/S0094837300012100; NEWELL NORMAN D., 1952, JOUR PALEONTOL, V26, P371; Peters SE, 2008, NATURE, V454, P626, DOI 10.1038/nature07032; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; SEPKOSKI JJ, 1978, PALEOBIOLOGY, V4, P223, DOI 10.1017/S0094837300005972; Sepkoski JJ, 1997, J PALEONTOL, V71, P533, DOI 10.1017/S0022336000040026; Sepkoski JJ, 2000, PALEOBIOLOGY, V26, P7, DOI 10.1666/0094-8373(2000)026<0007:CDAPPC>2.0.CO;2; SEPKOSKI JJ, 1984, PALEOBIOLOGY, V10, P246, DOI 10.1017/S0094837300008186; SEPKOSKI JJ, 1979, PALEOBIOLOGY, V5, P222, DOI 10.1017/S0094837300006539; SEPKOSKI JJ, 1981, PALEOBIOLOGY, V7, P36, DOI 10.1017/S0094837300003778; Stanley SM, 2007, PALEOBIOLOGY, V33, P1, DOI 10.1666/06020.1; VERMEIJ G J, 1977, Paleobiology, V3, P245; Wagner PJ, 2006, SCIENCE, V314, P1289, DOI 10.1126/science.1133795; Wagner PJ, 1995, PALEOBIOLOGY, V21, P410, DOI 10.1017/S0094837300013464	24	305	313	4	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1191	1194		10.1126/science.1189910	http://dx.doi.org/10.1126/science.1189910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813951				2022-12-28	WOS:000281485600032
J	Shaw, AS; Huang, YN				Shaw, Andrey S.; Huang, Yina			CAR'ing for the Skin	SCIENCE			English	Editorial Material							JUNCTIONAL ADHESION MOLECULE; RECEPTOR; MIGRATION; COXSACKIE; PROTEIN; CD28		[Shaw, Andrey S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Shaw, AS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	shaw@pathology.wustl.edu		Huang, Yina/0000-0002-0125-9351	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Boomer JS, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002436; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Dodson LF, 2009, MOL CELL BIOL, V29, P3710, DOI 10.1128/MCB.01869-08; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Holdorf AD, 2002, NAT IMMUNOL, V3, P259, DOI 10.1038/ni761; Moog-Lutz C, 2003, BLOOD, V102, P3371, DOI 10.1182/blood-2002-11-3462; Sharp LL, 2005, CRIT REV IMMUNOL, V25, P1, DOI 10.1615/CritRevImmunol.v25.i1.10; Strid J, 2009, SEMIN IMMUNOL, V21, P110, DOI 10.1016/j.smim.2009.03.002; Verdino P, 2010, SCIENCE, V329, P1210, DOI 10.1126/science.1187996; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; Wang CQF, 2007, J CELL BIOL, V178, P549, DOI 10.1083/jcb.200704061; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Witherden DA, 2010, SCIENCE, V329, P1205, DOI 10.1126/science.1192698; Zen K, 2005, MOL BIOL CELL, V16, P2694, DOI 10.1091/mbc.E05-01-0036	16	1	1	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1154	1155		10.1126/science.1195337	http://dx.doi.org/10.1126/science.1195337			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813941				2022-12-28	WOS:000281485600019
J	He, G; Luo, WJ; Li, P; Remmers, C; Netzer, WJ; Hendrick, J; Bettayeb, K; Flajolet, M; Gorelick, F; Wennogle, LP; Greengard, P				He, Gen; Luo, Wenjie; Li, Peng; Remmers, Christine; Netzer, William J.; Hendrick, Joseph; Bettayeb, Karima; Flajolet, Marc; Gorelick, Fred; Wennogle, Lawrence P.; Greengard, Paul			Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; TERMINAL FRAGMENT; EPSILON; NOTCH; DIFFERENTIATION; PROTEOLYSIS; GENERATION; MUTATIONS; CLEAVAGE; GENES	Accumulation of neurotoxic amyloid-beta is a major hallmark of Alzheimer's disease(1). Formation of amyloid-beta is catalysed by gamma-secretase, a protease with numerous substrates(2,3). Little is known about the molecular mechanisms that confer substrate specificity on this potentially promiscuous enzyme. Knowledge of the mechanisms underlying its selectivity is critical for the development of clinically effective gamma-secretase inhibitors that can reduce amyloid-beta formation without impairing cleavage of other gamma-secretase substrates, especially Notch, which is essential for normal biological functions(3,4). Here we report the discovery of a novel gamma-secretase activating protein (GSAP) that drastically and selectively increases amyloid-beta production through a mechanism involving its interactions with both gamma-secretase and its substrate, the amyloid precursor protein carboxy-terminal fragment (APP-CTF). GSAP does not interact with Notch, nor does it affect its cleavage. Recombinant GSAP stimulates amyloid-beta production in vitro. Reducing GSAP concentrations in cell lines decreases amyloid-beta concentrations. Knockdown of GSAP in a mouse model of Alzheimer's disease reduces levels of amyloid-beta and plaque development. GSAP represents a type of gamma-secretase regulator that directs enzyme specificity by interacting with a specific substrate. We demonstrate that imatinib, an anticancer drug previously found to inhibit amyloid-beta formation without affecting Notch cleavage 5, achieves its amyloid-beta-lowering effect by preventing GSAP interaction with the gamma-secretase substrate, APP-CTF. Thus, GSAP can serve as an amyloid-beta-lowering therapeutic target without affecting other key functions of gamma-secretase.	[He, Gen; Luo, Wenjie; Remmers, Christine; Netzer, William J.; Bettayeb, Karima; Flajolet, Marc; Greengard, Paul] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10065 USA; [Li, Peng; Hendrick, Joseph; Wennogle, Lawrence P.] Intra Cellular Therapies Inc, New York, NY 10032 USA; [Gorelick, Fred] Yale Univ, Sch Med, Dept Internal Med & Cell Biol, New Haven, CT 06520 USA; [Gorelick, Fred] VA Connecticut Healthcare, New Haven, CT 06520 USA	Rockefeller University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Greengard, P (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10065 USA.	greengard@rockefeller.edu	Luo, Wenjie/ABF-8451-2020	Wennogle, Lawrence/0000-0002-3795-409X; Gorelick, Fred/0000-0001-8293-6803	NIH [AG09464]; DOD [W81XWH-09-1-0402]; Fisher Center for Alzheimer's Research Foundation; F. M. Kirby Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Fisher Center for Alzheimer's Research Foundation; F. M. Kirby Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank E. Woo and B. Chait for their help with protein identification. We thank Y. M. Li for providing us with the biotinylated transition-state analogue. We thank B. Turner and S. Ku for their technical support. This work was supported by NIH grant AG09464 to P. G., DOD grant W81XWH-09-1-0402 to P. G., the Fisher Center for Alzheimer's Research Foundation and the F. M. Kirby Foundation.	Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Bentahir M, 2006, J NEUROCHEM, V96, P732, DOI 10.1111/j.1471-4159.2005.03578.x; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Dai HQ, 2003, J PHARMACOL EXP THER, V304, P1085, DOI 10.1124/jpet.102.045260; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Green RC, 2009, JAMA-J AM MED ASSOC, V302, P2557, DOI 10.1001/jama.2009.1866; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Kume H, 2006, BIOCHEM BIOPH RES CO, V349, P1356, DOI 10.1016/j.bbrc.2006.08.181; Lathia JD, 2008, J NEUROCHEM, V107, P1471, DOI 10.1111/j.1471-4159.2008.05715.x; Lefranc-Jullien S, 2006, J NEUROCHEM, V97, P807, DOI 10.1111/j.1471-4159.2006.03748.x; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Netzer WJ, 2003, P NATL ACAD SCI USA, V100, P12444, DOI 10.1073/pnas.1534745100; Placanica L, 2009, J BIOL CHEM, V284, P2967, DOI 10.1074/jbc.M807269200; Seibler J, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm122; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Serneels L, 2009, SCIENCE, V324, P639, DOI 10.1126/science.1171176; Steiner H, 2008, J BIOL CHEM, V283, P29627, DOI 10.1074/jbc.R800010200; Takami M, 2009, J NEUROSCI, V29, P13042, DOI 10.1523/JNEUROSCI.2362-09.2009; Thathiah A, 2009, SCIENCE, V323, P946, DOI 10.1126/science.1160649; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Wiley JC, 2005, J NEUROCHEM, V94, P1189, DOI 10.1111/j.1471-4159.2005.03266.x; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447	26	249	281	4	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					95	U129		10.1038/nature09325	http://dx.doi.org/10.1038/nature09325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811458	Green Accepted			2022-12-28	WOS:000281461200042
J	Perera, D; Stables, R; Thomas, M; Booth, J; Pitt, M; Blackman, D; de Belder, A; Redwood, S				Perera, Divaka; Stables, Rodney; Thomas, Martyn; Booth, Jean; Pitt, Michael; Blackman, Daniel; de Belder, Adam; Redwood, Simon		BCIS-1 Investigators	Elective Intra-aortic Balloon Counterpulsation During High-Risk Percutaneous Coronary Intervention A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-FLOW; OUTCOMES; BYPASS; FRACTIONS; SURVIVAL; REGISTRY; IMPACT; STENT; PUMP	Context Observational studies have previously reported that elective intra-aortic balloon pump (IABP) insertion may improve outcomes following high-risk percutaneous coronary intervention (PCI). To date, this assertion has not been tested in a randomized trial. Objective To determine whether routine intra-aortic balloon counterpulsation before PCI reduces major adverse cardiac and cardiovascular events (MACCE) in patients with severe left ventricular dysfunction and extensive coronary disease. Design, Setting, and Patients The Balloon Pump Assisted Coronary Intervention Study, a prospective, open, multicenter, randomized controlled trial conducted in 17 tertiary referral cardiac centers in the United Kingdom between December 2005 and January 2009. Patients (n=301) had severe left ventricular dysfunction (ejection fraction <= 30%) and extensive coronary disease (Jeopardy Score >= 8/12); those with contraindications to or class I indications for IABP therapy were excluded. Intervention Elective insertion of IABP before PCI. Main Outcome Measures Primary end point was MACCE, defined as death, acute myocardial infarction, cerebrovascular event, or further revascularization at hospital discharge (capped at 28 days). Secondary end points included all-cause mortality at 6 months, major procedural complications, bleeding, and access-site complications. Results MACCE at hospital discharge occurred in 15.2% (23/151) of the elective IABP and 16.0% (24/150) of the no planned IABP groups (P=.85; odds ratio [OR], 0.94 [95% confidence interval (Cl), 0.51-1.76]). All-cause mortality at 6 months was 4.6% and 7.4% in the respective groups (P=.32; OR, 0.61 [95% CI, 0.24-1.62]). Fewer major procedural complications occurred with elective IABP insertion compared with no planned IABP use (1.3% vs 10.7%, P<.001; OR, 0.11 [95% Cl, 0.01-0.49]). Major or minor bleeding occurred in 19.2% and 11.3% (P=.06; OR, 1.86 [95% CI, 0.93-3.79]) and access-site complications in 3.3% and 0% (P=.06) of the elective and no planned IABP groups, respectively. Conclusions Elective IABP insertion did not reduce the incidence of MACCE following PCI. These results do not support a strategy of routine IABP placement before PCI in all patients with severe left ventricular dysfunction and extensive coronary disease.	[Redwood, Simon] Kings Coll London, BHF Ctr Excellence, Div Cardiovasc, London SE1 7EH, England; [Stables, Rodney] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England; [Booth, Jean] Royal Brompton Hosp, Clin Trials & Evaluat Unit, London SW3 6LY, England; [Pitt, Michael] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; [Blackman, Daniel] Leeds Teaching Hosp, Leeds, W Yorkshire, England; [de Belder, Adam] Brighton & Sussex Univ Hosp, Brighton, E Sussex, England	University of London; King's College London; Liverpool Heart & Chest Hospital; Royal Brompton Hospital; Heart of England NHS Foundation Trust; University of Birmingham; University of Leeds; Brighton and Sussex University Hospitals NHS Trust	Redwood, S (corresponding author), Kings Coll London, BHF Ctr Excellence, Div Cardiovasc, St Thomas Hosp Campus, London SE1 7EH, England.	simon.redwood@gstt.nhs.uk	Blackman, Dan/AAW-9540-2021	Perera, Divaka/0000-0001-6362-1291; Stables, Rodney Hilton/0000-0002-9244-7015	UK Department of Health via the National Institute for Health Research Comprehensive Biomedical Research Centre; King's College London; British Cardiovascular Intervention Society; Maquet Cardiovascular (Mawah, New Jersey); Cordis; Johnson & Johnson (Wokingham, United Kingdom)	UK Department of Health via the National Institute for Health Research Comprehensive Biomedical Research Centre; King's College London(General Electric); British Cardiovascular Intervention Society; Maquet Cardiovascular (Mawah, New Jersey); Cordis; Johnson & Johnson (Wokingham, United Kingdom)(Johnson & JohnsonJohnson & Johnson USA)	Dr Perera and Dr Redwood reported receiving financial support from the UK Department of Health via the National Institute for Health Research Comprehensive Biomedical Research Centre Award to Guy's & St Thomas' National Health Service Foundation Trust in partnership with King's College London. No other authors reported disclosures.; This trial was sponsored by the British Cardiovascular Intervention Society, which in turn received funding from Maquet Cardiovascular (previously Datascope) (Mawah, New Jersey), Cordis, and Johnson & Johnson (Wokingham, United Kingdom) by way of unrestricted educational grants, and by Lilly (Hampshire, United Kingdom), which provided abciximab for use in the trial.	Allman KC, 2002, J AM COLL CARDIOL, V39, P1151, DOI 10.1016/S0735-1097(02)01726-6; American College of Cardiology, 2006, J Am Coll Cardiol, V48, pe1, DOI 10.1016/j.jacc.2006.05.021; Briguori C, 2003, AM HEART J, V145, P700, DOI 10.1067/mhj.2003.14; Brodie BR, 1999, AM J CARDIOL, V84, P18, DOI 10.1016/S0002-9149(99)00185-X; CALIFF RM, 1985, J AM COLL CARDIOL, V5, P1055, DOI 10.1016/S0735-1097(85)80005-X; Chowdhary S, 2009, AM HEART J, V157, P156, DOI 10.1016/j.ahj.2008.08.026; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Cohen M, 2003, EUR HEART J, V24, P1763, DOI 10.1016/j.ehj.2003.07.002; Gioia G, 2006, CATHETER CARDIO INTE, V68, P392, DOI 10.1002/ccd.20833; Hannan EL, 2005, CIRCULATION, V112, P1171, DOI 10.1161/CIRCULATIONAHA.104.528455; Holper EM, 2006, AM HEART J, V151, P69, DOI 10.1016/j.ahj.2005.03.053; Jones RH, 2009, NEW ENGL J MED, V360, P1705, DOI 10.1056/NEJMoa0900559; Keelan PC, 2003, AM J CARDIOL, V91, P1168, DOI 10.1016/S0002-9149(03)00261-3; KERN MJ, 1993, CIRCULATION, V87, P500, DOI 10.1161/01.CIR.87.2.500; Ludman Peter F, BRIT CARDIOVASCULAR; Mishra S, 2006, AM J CARDIOL, V98, P608, DOI 10.1016/j.amjcard.2006.03.036; Perera D, 2009, AM HEART J, V158, P910, DOI 10.1016/j.ahj.2009.09.015; Sedlis SP, 2004, AM J CARDIOL, V94, P118, DOI 10.1016/j.amjcard.2004.03.041; Sianos Georgios, 2005, EuroIntervention, V1, P219; Singh M, 2007, MAYO CLIN PROC, V82, P701; Sjauw KD, 2009, EUR HEART J, V30, P459, DOI 10.1093/eurheartj/ehn602; Stahle E, 1997, ANN THORAC SURG, V64, P437; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; Wallace TW, 2009, AM J CARDIOL, V103, P355, DOI 10.1016/j.amjcard.2008.09.088; WILLIAMS DO, 1982, CIRCULATION, V66, P593, DOI 10.1161/01.CIR.66.3.593; Zahn R, 2008, HEART, V94, P329, DOI 10.1136/hrt.2007.118737	26	237	264	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					867	874		10.1001/jama.2010.1190	http://dx.doi.org/10.1001/jama.2010.1190			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736470	Bronze			2022-12-28	WOS:000281389900024
J	Mazon, G; Mimitou, EP; Symington, LS				Mazon, Gerard; Mimitou, Eleni P.; Symington, Lorraine S.			SnapShot: Homologous Recombination in DNA Double-Strand Break Repair	CELL			English	Editorial Material							MAINTAINS GENOMIC STABILITY		[Mazon, Gerard; Mimitou, Eleni P.; Symington, Lorraine S.] Columbia Univ, Med Ctr, Dept Microbiol & Immunol, New York, NY 10032 USA	Columbia University	Mazon, G (corresponding author), Columbia Univ, Med Ctr, Dept Microbiol & Immunol, New York, NY 10032 USA.			Mazon Busquets, Gerard/0000-0002-9791-5666	NIH [GM041784]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041784] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank W.K. Holloman and H.L. Klein for helpful comments. We are supported by NIH grant GM041784.	Barber LJ, 2008, CELL, V135, P261, DOI 10.1016/j.cell.2008.08.016; Chen ZC, 2008, NATURE, V453, P489, DOI 10.1038/nature06971; Dupaigne P, 2008, MOL CELL, V29, P243, DOI 10.1016/j.molcel.2007.11.033; Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255; Li X, 2009, MOL CELL, V36, P704, DOI 10.1016/j.molcel.2009.09.036; Mimitou EP, 2009, DNA REPAIR, V8, P983, DOI 10.1016/j.dnarep.2009.04.017; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Prakash R, 2009, GENE DEV, V23, P67, DOI 10.1101/gad.1737809; Svendsen JM, 2010, GENE DEV, V24, P521, DOI 10.1101/gad.1903510; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253	10	39	40	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4							648.e2	10.1016/j.cell.2010.08.006	http://dx.doi.org/10.1016/j.cell.2010.08.006			1	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723763	Bronze			2022-12-28	WOS:000281115900018
J	Carey, T				Carey, Tim			Review: Some instruments predict development of persistent, disabling low back pain	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	Carey, T (corresponding author), Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27515 USA.							Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Lamb SE, 2010, LANCET, V375, P916, DOI 10.1016/S0140-6736(09)62164-4; Pengel LHM, 2003, BMJ-BRIT MED J, V327, P323, DOI 10.1136/bmj.327.7410.323	3	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-13	10.7326/0003-4819-153-4-201008170-02013	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713780				2022-12-28	WOS:000280973000027
J	WARDEN, J				WARDEN, J			CHANGING THE SCRIPT	BRITISH MEDICAL JOURNAL			English	Editorial Material																		WHITNEY R, NATIONAL HLTH CRISIS	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1988	296	6623					726	726		10.1136/bmj.296.6623.726	http://dx.doi.org/10.1136/bmj.296.6623.726			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M4461	20742967	Green Published			2022-12-28	WOS:A1988M446100059
J	Yang, JY; Reth, M				Yang, Jianying; Reth, Michael			Oligomeric organization of the B-cell antigen receptor on resting cells	NATURE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; IG-ALPHA/IG-BETA; LIVING CELLS; PROTEIN INTERACTIONS; ACTIVATION; VISUALIZATION; INITIATION; ITAM; BCR	B lymphocytes are activated by many different antigens to produce specific antibodies protecting higher organisms from infection. To detect its cognate antigen, each B cell contains up to 120,000 B-cell antigen receptor (BCR) complexes on its cell surface. How these abundant receptors stay silent on resting B cells and how they can be activated by a molecularly diverse set of ligands is poorly understood(1). Here we show, with the use of a quantitative bifluorescence complementation assay (BiFC)(2,3), that the BCR has an intrinsic ability to form oligomers on the surface of living cells. A BCR mutant that fails to form oligomers is more active and cannot be expressed stably on the B-cell surface, whereas BiFC-stabilized BCR oligomers are less active and more strongly expressed on the surface. We propose that oligomers are the autoinhibited form of the BCR and that it is the shift from closed BCR oligomers to clustered monomers that drives B-cell activation in a way that is independent of the structural input from the antigen.	[Yang, Jianying; Reth, Michael] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Dept Mol Immunol, Fac Biol, D-79108 Freiburg, Germany; [Yang, Jianying; Reth, Michael] Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Freiburg; Max Planck Society	Reth, M (corresponding author), Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Dept Mol Immunol, Fac Biol, Stubeweg 51, D-79108 Freiburg, Germany.	michael.reth@bioss.uni-freiburg.de		YANG, JIANYING/0000-0001-8197-5413	Excellence Initiative of the German Federal and State Governments [EXC 294]; Deutsche Forschungsgemeinschaft [SFB746]; FRISYS	Excellence Initiative of the German Federal and State Governments; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); FRISYS	We thank L. Leclercq, P. Nielsen, H. Jumaa and W. Schamel for critical reading of this manuscript. This study was supported by the Excellence Initiative of the German Federal and State Governments (EXC 294), by the Deutsche Forschungsgemeinschaft through SFB746 and by the FRISYS programme.	Chiorazzi N, 2003, ANNU REV IMMUNOL, V21, P841, DOI 10.1146/annurev.immunol.21.120601.141018; Engels N, 2008, ADV IMMUNOL, V97, P251, DOI 10.1016/S0065-2776(08)00005-9; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Harwood NE, 2008, IMMUNITY, V28, P609, DOI 10.1016/j.immuni.2008.04.007; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Kawauchi K, 2002, INT J HEMATOL, V75, P508, DOI 10.1007/BF02982115; Kerppola TK, 2008, ANNU REV BIOPHYS, V37, P465, DOI 10.1146/annurev.biophys.37.032807.125842; Kim JH, 2005, J IMMUNOL, V175, P147, DOI 10.4049/jimmunol.175.1.147; Kim YM, 2006, P NATL ACAD SCI USA, V103, P3327, DOI 10.1073/pnas.0511315103; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; Lankester AC, 1996, LEUKEMIA LYMPHOMA, V24, P27, DOI 10.3109/10428199609045711; Lillemeier BF, 2010, NAT IMMUNOL, V11, P90, DOI 10.1038/ni.1832; Meixlsperger S, 2007, IMMUNITY, V26, P323, DOI 10.1016/j.immuni.2007.01.012; Minguet S, 2007, IMMUNITY, V26, P43, DOI 10.1016/j.immuni.2006.10.019; Monroe JG, 2006, NAT REV IMMUNOL, V6, P283, DOI 10.1038/nri1808; Payelle-Brogard B, 2002, BRIT J HAEMATOL, V118, P976, DOI 10.1046/j.1365-2141.2002.03759.x; Peng SL, 2009, AUTOIMMUN REV, V8, P179, DOI 10.1016/j.autrev.2008.07.040; Pugh-Bernard AE, 2006, CURR OPIN RHEUMATOL, V18, P451, DOI 10.1097/01.bor.0000240353.99808.5f; Reth M, 2001, TRENDS IMMUNOL, V22, P356, DOI 10.1016/S1471-4906(01)01964-0; Rolli V, 2002, MOL CELL, V10, P1057, DOI 10.1016/S1097-2765(02)00739-6; Schamel WWA, 2000, IMMUNITY, V13, P5, DOI 10.1016/S1074-7613(00)00003-0; Schamel WWA, 2005, J EXP MED, V202, P493, DOI 10.1084/jem.20042155; Schrum Adam G, 2007, Sci STKE, V2007, ppl2, DOI 10.1126/stke.3892007pl2; Semichon M, 1997, LEUKEMIA, V11, P1921, DOI 10.1038/sj.leu.2400832; Siegers GM, 2006, INT IMMUNOL, V18, P1385, DOI 10.1093/intimm/dxl072; Storch B, 2007, EUR J IMMUNOL, V37, P252, DOI 10.1002/eji.200636667; Tolar P, 2005, NAT IMMUNOL, V6, P1168, DOI 10.1038/ni1262; Tolar P, 2008, IMMUNOL REV, V221, P64, DOI 10.1111/j.1600-065X.2008.00583.x; Treanor B, 2010, IMMUNITY, V32, P187, DOI 10.1016/j.immuni.2009.12.005; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0	31	126	128	0	29	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					465	U117		10.1038/nature09357	http://dx.doi.org/10.1038/nature09357			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20818374				2022-12-28	WOS:000282090200044
J	Centola, D				Centola, Damon			The Spread of Behavior in an Online Social Network Experiment	SCIENCE			English	Article							DIFFUSION; DYNAMICS	How do social networks affect the spread of behavior? A popular hypothesis states that networks with many clustered ties and a high degree of separation will be less effective for behavioral diffusion than networks in which locally redundant ties are rewired to provide shortcuts across the social space. A competing hypothesis argues that when behaviors require social reinforcement, a network with more clustering may be more advantageous, even if the network as a whole has a larger diameter. I investigated the effects of network structure on diffusion by studying the spread of health behavior through artificially structured online communities. Individual adoption was much more likely when participants received social reinforcement from multiple neighbors in the social network. The behavior spread farther and faster across clustered-lattice networks than across corresponding random networks.	MIT, Alfred P Sloan Sch Management, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT)	Centola, D (corresponding author), MIT, Alfred P Sloan Sch Management, Cambridge, MA 02142 USA.	dcentola@mit.edu			James S. McDonnell Foundation; Robert Wood Johnson Foundation	James S. McDonnell Foundation; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	I thank A. van de Rijt and V. Eguiluz for helpful comments, N. Christakis for useful discussion and guidance, G. Pickard for programming assistance, A. Wagner for developing the Healthy Lifestyle Network Web site, T. Groves for all of the design work, and J. Kreckler and K. Campbell at www.prevention.com and G. Colditz of www.yourdiseaserisk.com for their assistance recruiting participants. This work was supported in part by the James S. McDonnell Foundation and the Robert Wood Johnson Foundation.	Berkman L. F., 2000, SOCIAL EPIDEMIOLOGY, V1, P137, DOI DOI 10.4135/9781412952576.N192]; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; Centola D, 2007, AM J SOCIOL, V113, P702, DOI 10.1086/521848; Centola D, 2007, J CONFLICT RESOLUT, V51, P905, DOI 10.1177/0022002707307632; Centola D, 2007, PHYSICA A, V374, P449, DOI 10.1016/j.physa.2006.06.018; Christakis NA, 2008, NEW ENGL J MED, V358, P2249, DOI 10.1056/NEJMsa0706154; Christakis NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMsa066082; GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469; HEDSTROM P, 1994, AM J SOCIOL, V99, P1157, DOI 10.1086/230408; Kearns M, 2006, SCIENCE, V313, P824, DOI 10.1126/science.1127207; Kossinets G, 2006, SCIENCE, V311, P88, DOI 10.1126/science.1116869; Kossinets G, 2009, AM J SOCIOL, V115, P405, DOI 10.1086/599247; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Maslov S., 2003, HDB GRAPHS NETWORKS; McPherson M, 2001, ANNU REV SOCIOL, V27, P415, DOI 10.1146/annurev.soc.27.1.415; Newman MEJ, 2000, J STAT PHYS, V101, P819, DOI 10.1023/A:1026485807148; Newman MEJ, 1999, PHYS REV E, V60, P7332, DOI 10.1103/PhysRevE.60.7332; Rogers E.M., 1995, DIFFUSION INNOVATION, V4th; Salganik MJ, 2006, SCIENCE, V311, P854, DOI 10.1126/science.1121066; Smith KP, 2008, ANNU REV SOCIOL, V34, P405, DOI 10.1146/annurev.soc.34.040507.134601; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Watts D. J, 1999, SMALL WORLDS DYNAMIC; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	23	1433	1502	30	614	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2010	329	5996					1194	1197		10.1126/science.1185231	http://dx.doi.org/10.1126/science.1185231			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	645SG	20813952	Green Submitted			2022-12-28	WOS:000281485600033
J	Freilich, DV; Bianchi, DM; Kaufman, AM; Langin, TK; Hall, DS				Freilich, D. V.; Bianchi, D. M.; Kaufman, A. M.; Langin, T. K.; Hall, D. S.			Real-Time Dynamics of Single Vortex Lines and Vortex Dipoles in a Bose-Einstein Condensate	SCIENCE			English	Article							SUPERFLUID-HELIUM; VORTICES; GASES; ATOMS; HE-3	Understanding the behavior of quantized vortices is essential to gaining insight into diverse superfluid phenomena, from critical-current densities in superconductors to quantum turbulence in superfluids. We observe the real-time dynamics of quantized vortices in trapped dilute-gas Bose-Einstein condensates by repeatedly imaging the vortex cores. The precession frequency of a single vortex is measured by explicitly observing its time dependence and is found to be in good agreement with theory. We further characterize the dynamics of vortex dipoles in two distinct configurations: (i) an asymmetric configuration, in which the vortex trajectories are dynamic and nontrivial, and (ii) a stable, symmetric configuration, in which the dipole is stationary.	[Freilich, D. V.; Bianchi, D. M.; Kaufman, A. M.; Langin, T. K.; Hall, D. S.] Amherst Coll, Dept Phys, Amherst, MA 01002 USA	Amherst College	Hall, DS (corresponding author), Amherst Coll, Dept Phys, Amherst, MA 01002 USA.	dshall@amherst.edu		Hall, David/0000-0002-2839-7623	NSF [PHY-0855475]	NSF(National Science Foundation (NSF))	We thank J. R. Friedman, R. P. Anderson, and P. G. Kevrekidis for interesting conversations and A. Dewan, E. Altuntas, and A. W. Eddins for experimental assistance. This work was supported by the NSF through grant PHY-0855475.	Anderson BP, 2000, PHYS REV LETT, V85, P2857, DOI 10.1103/PhysRevLett.85.2857; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; [Anonymous], 1991, QUANTIZED VORTICES H; [Anonymous], 1990, SUPERFLUIDITY SUPERC; Bewley GP, 2006, NATURE, V441, P588, DOI 10.1038/441588a; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; Burt EA, 1997, PHYS REV LETT, V79, P337, DOI 10.1103/PhysRevLett.79.337; Crasovan LC, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.063609; Dalfovo F, 1999, REV MOD PHYS, V71, P463, DOI 10.1103/RevModPhys.71.463; Dalfovo F, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.023605; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Eltsov VB, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.265301; Eltsov VB, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.215302; Eltsov VB, 2000, PHYS REV LETT, V85, P4739, DOI 10.1103/PhysRevLett.85.4739; Eltsov VB, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.065301; Engels P, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.100403; Fetter AL, 2001, J PHYS-CONDENS MAT, V13, pR135, DOI 10.1088/0953-8984/13/12/201; Fetter AL, 2009, REV MOD PHYS, V81, P647, DOI 10.1103/RevModPhys.81.647; Haljan PC, 2001, PHYS REV LETT, V86, P2922, DOI 10.1103/PhysRevLett.86.2922; KIBBLE TWB, 1976, J PHYS A-MATH GEN, V9, P1387, DOI 10.1088/0305-4470/9/8/029; Li WB, 2008, PHYS REV A, V77, DOI 10.1103/PhysRevA.77.053610; Madison KW, 2000, PHYS REV LETT, V84, P806, DOI 10.1103/PhysRevLett.84.806; Mertes KM, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.190402; Mottonen M, 2005, PHYS REV A, V71, DOI 10.1103/PhysRevA.71.033626; Neely TW, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.160401; Packard RE, 1998, REV MOD PHYS, V70, P641, DOI 10.1103/RevModPhys.70.641; PETRICH W, 1995, PHYS REV LETT, V74, P3352, DOI 10.1103/PhysRevLett.74.3352; Rokhsar DS, 1997, PHYS REV LETT, V79, P2164, DOI 10.1103/PhysRevLett.79.2164; Ruutu VMH, 1996, NATURE, V382, P334, DOI 10.1038/382334a0; Weiler CN, 2008, NATURE, V455, P948, DOI 10.1038/nature07334; ZUREK WH, 1985, NATURE, V317, P505, DOI 10.1038/317505a0	31	196	197	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1182	1185		10.1126/science.1191224	http://dx.doi.org/10.1126/science.1191224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813949				2022-12-28	WOS:000281485600029
J	Malzahn, E; Ciprianidis, S; Kaldi, K; Schafmeier, T; Brunner, M				Malzahn, Erik; Ciprianidis, Stilianos; Kaldi, Krisztina; Schafmeier, Tobias; Brunner, Michael			Photoadaptation in Neurospora by Competitive Interaction of Activating and Inhibitory LOV Domains	CELL			English	Article							BLUE-LIGHT PHOTORECEPTOR; CIRCADIAN GENE-EXPRESSION; CLOCK GENE; TRANSCRIPTION FACTOR; BINDING DOMAINS; WHITE COLLAR-1; PROTEIN; TRANSFORMATION; ORGANIZATION; ARABIDOPSIS	Light responses and photoadaptation of Neurospora depend on the photosensory light-oxygen-voltage (LOV) domains of the circadian transcription factor White Collar Complex (WCC) and its negative regulator VIVID (VVD). We found that light triggers LOV-mediated dimerization of the WCC. The activated WCC induces expression of VVD, which then disrupts and inactivates the WCC homodimers by the competitive formation of WCC-VVD heterodimers, leading to photoadaptation. During the day, expression levels of VVD correlate with light intensity, allowing photoadaptation over several orders of magnitude. At night, previously synthesized VVD serves as a molecular memory of the brightness of the preceding day and suppresses responses to light cues of lower intensity. We show that VVD is essential to discriminate between day and night, even in naturally ambiguous photoperiods with moonlight.	[Malzahn, Erik; Ciprianidis, Stilianos; Schafmeier, Tobias; Brunner, Michael] Heidelberg Univ, Biochem Ctr, D-69120 Heidelberg, Germany; [Kaldi, Krisztina] Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary	Ruprecht Karls University Heidelberg; Semmelweis University	Brunner, M (corresponding author), Heidelberg Univ, Biochem Ctr, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	michael.brunner@bzh.uni-heidelberg.de	Káldi, Krisztina/X-4080-2019	Brunner, Michael/0000-0001-9798-3047; Kaldi, Krisztina/0000-0002-5724-0182	DFG [BR 1375-3-1, SFB 638]; FCI [GP1188]; Hungarian OTKA [K 68960]; ETT [477-05]	DFG(German Research Foundation (DFG)); FCI(Fonds der Chemischen Industrie); Hungarian OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); ETT	We thank Johanna Scholz and Krisztina Makara for excellent technical assistance. We are grateful to Cornelia Ulbrich for her experienced help with setting up the yeast two-hybrid system. This work was supported by the DFG grant BR 1375-3-1 to M.B. and T.S., SFB 638 and the FCI to M.B., GP1188 to E.M. and by an EMBO-HHMI startup grant by the Hungarian OTKA (K 68960) and ETT (477-05) to K.K., M.B. is a member of CellNetworks and S.C. is a member of HBIGS.	Bachleitner W, 2007, P NATL ACAD SCI USA, V104, P3538, DOI 10.1073/pnas.0606870104; Belden WJ, 2007, GENE DEV, V21, P1494, DOI 10.1101/gad.1551707; Brunner M, 2006, GENE DEV, V20, P1061, DOI 10.1101/gad.1410406; Cho HY, 2007, PLANT PHYSIOL, V143, P517, DOI 10.1104/pp.106.089839; Christie JM, 2002, PLANT J, V32, P205, DOI 10.1046/j.1365-313X.2002.01415.x; Christie JM, 2007, ANNU REV PLANT BIOL, V58, P21, DOI 10.1146/annurev.arplant.58.032806.103951; Corchnoy SB, 2003, J BIOL CHEM, V278, P724, DOI 10.1074/jbc.M209119200; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; Doyle S, 2007, COLD SPRING HARB SYM, V72, P499, DOI 10.1101/sqb.2007.72.003; Elvin M, 2005, GENE DEV, V19, P2593, DOI 10.1101/gad.349305; Foster Russell G, 2007, Methods Mol Biol, V362, P3; Froehlich AC, 2002, SCIENCE, V297, P815, DOI 10.1126/science.1073681; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Harper SM, 2003, SCIENCE, V301, P1541, DOI 10.1126/science.1086810; He QY, 2005, GENE DEV, V19, P2888, DOI 10.1101/gad.1369605; He QY, 2002, SCIENCE, V297, P840, DOI 10.1126/science.1072795; Heintzen C, 2001, CELL, V104, P453, DOI 10.1016/S0092-8674(01)00232-X; Helfrich-Forster C, 2002, ZOOLOGY, V105, P297, DOI 10.1078/0944-2006-00074; Herzberg C, 2007, PROTEOMICS, V7, P4032, DOI 10.1002/pmic.200700491; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Kaiserli E, 2009, PLANT CELL, V21, P3226, DOI 10.1105/tpc.109.067876; Kaldi K, 2006, EMBO REP, V7, P199, DOI 10.1038/sj.embor.7400595; Kasahara M, 2002, PLANT PHYSIOL, V129, P762, DOI 10.1104/pp.002410; Krauss U, 2009, J BACTERIOL, V191, P7234, DOI 10.1128/JB.00923-09; Liu Y, 2003, J BIOL RHYTHM, V18, P195, DOI 10.1177/0748730403018003002; Loros JJ, 2007, COLD SPRING HARB SYM, V72, P201, DOI 10.1101/sqb.2007.72.067; McClung CR, 2008, CURR OPIN PLANT BIOL, V11, P514, DOI 10.1016/j.pbi.2008.06.010; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; Merrow M, 2007, COLD SPRING HARB SYM, V72, P279, DOI 10.1101/sqb.2007.72.032; Merrow M, 1999, NATURE, V399, P584, DOI 10.1038/21190; Nayak SK, 2007, CELL MOL LIFE SCI, V64, P144, DOI 10.1007/s00018-006-5581-1; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; Schafmeier T, 2006, GENE DEV, V20, P297, DOI 10.1101/gad.360906; Schafmeier T, 2005, CELL, V122, P235, DOI 10.1016/j.cell.2005.05.032; Schafmeier T, 2008, GENE DEV, V22, P3397, DOI 10.1101/gad.507408; Schwerdtfeger C, 2003, EMBO J, V22, P4846, DOI 10.1093/emboj/cdg451; Schwerdtfeger C, 2001, MOL MICROBIOL, V39, P1080, DOI 10.1046/j.1365-2958.2001.02306.x; Siepka SM, 2007, COLD SPRING HARB SYM, V72, P251, DOI 10.1101/sqb.2007.72.052; SMITH KM, 2010, CELL IN PRESS, DOI DOI 10.1128/EC.00154-10; Swartz TE, 2001, J BIOL CHEM, V276, P36493, DOI 10.1074/jbc.M103114200; Tan Y, 2004, J BIOL RHYTHM, V19, P135, DOI 10.1177/0748730404263015; Vitalini MW, 2006, J BIOL RHYTHM, V21, P432, DOI 10.1177/0748730406294396; Woelfle MA, 2006, J BIOL RHYTHM, V21, P419, DOI 10.1177/0748730406294418; Zoltowski BD, 2008, BIOCHEMISTRY-US, V47, P7012, DOI 10.1021/bi8007017; Zoltowski BD, 2007, SCIENCE, V316, P1054, DOI 10.1126/science.1137128; Zoltowski BD, 2009, NAT CHEM BIOL, V5, P827, DOI 10.1038/nchembio.210	47	115	120	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					762	772		10.1016/j.cell.2010.08.010	http://dx.doi.org/10.1016/j.cell.2010.08.010			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813262	Bronze			2022-12-28	WOS:000281523200019
J	McKenna, NJ; O'Malley, BW				McKenna, Neil J.; O'Malley, Bert W.			SnapShot: Nuclear Receptors I	CELL			English	Editorial Material							UNION-OF-PHARMACOLOGY; SUPERFAMILY		[McKenna, Neil J.; O'Malley, Bert W.] Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	McKenna, NJ (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.			McKenna, Neil/0000-0001-6689-0104	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19-DK62434] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auwerx J, 1999, CELL, V97, P161; Flamant F, 2006, PHARMACOL REV, V58, P705, DOI 10.1124/pr.58.4.3; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Mark Manuel, 2009, Nucl Recept Signal, V7, pe002, DOI 10.1621/nrs.07002; Moore DD, 2006, PHARMACOL REV, V58, P742, DOI 10.1124/pr.58.4.6; Pyper Sean R, 2010, Nucl Recept Signal, V8, pe002, DOI 10.1621/nrs.08002; Scarpin Katherine M, 2009, Nucl Recept Signal, V7, pe009, DOI 10.1621/nrs.07009; Sonoda J, 2008, FEBS LETT, V582, P2, DOI 10.1016/j.febslet.2007.11.016; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Zhou Changcheng, 2009, Nucl Recept Signal, V7, pe001, DOI 10.1621/nrs.07001	10	12	12	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5							882.e1	10.1016/j.cell.2010.08.026	http://dx.doi.org/10.1016/j.cell.2010.08.026			1	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813267	Bronze			2022-12-28	WOS:000281523200024
J	Xu, K; Cao, PG; Heath, JR				Xu, Ke; Cao, Peigen; Heath, James R.			Graphene Visualizes the First Water Adlayers on Mica at Ambient Conditions	SCIENCE			English	Article							THIN-FILM WATER; SPECTROSCOPY; MICROSCOPY; ADSORPTION; LAYER	The dynamic nature of the first water adlayers on solid surfaces at room temperature has made the direct detection of their microscopic structure challenging. We used graphene as an atomically flat coating for atomic force microscopy to determine the structure of the water adlayers on mica at room temperature as a function of relative humidity. Water adlayers grew epitaxially on the mica substrate in a layer-by-layer fashion. Submonolayers form atomically flat, faceted islands of height 0.37 +/- 0.02 nanometers, in agreement with the height of a monolayer of ice. The second adlayers, observed at higher relative humidity, also appear icelike, and thicker layers appear liquidlike. Our results also indicate nanometer-scale surface defects serve as nucleation centers for the formation of both the first and the second adlayers.	[Heath, James R.] CALTECH, Kavli Nanosci Inst, MC 127-72, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Heath, JR (corresponding author), CALTECH, Kavli Nanosci Inst, MC 127-72, Pasadena, CA 91125 USA.	heath@caltech.edu	Cao, Peigen/F-5958-2012; Xu, Ke/A-9476-2011	Xu, Ke/0000-0002-2788-194X	U.S. Department of Energy, Basic Energy Sciences [DE-FG02-04ER46175]	U.S. Department of Energy, Basic Energy Sciences(United States Department of Energy (DOE))	We thank G. Rossman for generous assistance in using the micro-Raman spectrometer and L. Qin and W. Li for helpful discussions. This work was supported by the U.S. Department of Energy, Basic Energy Sciences (grant no. DE-FG02-04ER46175).	BEAGLEHOLE D, 1991, PHYS REV LETT, V66, P2084, DOI 10.1103/PhysRevLett.66.2084; Bluhm H, 1999, J CHEM PHYS, V111, P6947, DOI 10.1063/1.479987; Bolina AS, 2005, J PHYS CHEM B, V109, P16836, DOI 10.1021/jp0528111; Bunch JS, 2008, NANO LETT, V8, P2458, DOI 10.1021/nl801457b; Cantrell W, 2001, J PHYS CHEM B, V105, P5434, DOI 10.1021/jp004305b; DOERING DL, 1982, SURF SCI, V123, P305, DOI 10.1016/0039-6028(82)90331-4; Ewing GE, 2006, CHEM REV, V106, P1511, DOI 10.1021/cr040369x; Feibelman PJ, 2010, PHYS TODAY, V63, P34, DOI 10.1063/1.3326987; Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401; Fletcher NH, 1970, CHEM PHYS ICE, P49; Graf D, 2007, NANO LETT, V7, P238, DOI 10.1021/nl061702a; Herman M.A., 2004, EPITAXY PHYS PRINCIP; HU J, 1995, SCIENCE, V268, P267, DOI 10.1126/science.268.5208.267; Ishigami M, 2007, NANO LETT, V7, P1643, DOI 10.1021/nl070613a; Lee C, 2010, SCIENCE, V328, P76, DOI 10.1126/science.1184167; Leenaerts O, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.235440; Lui CH, 2009, NATURE, V462, P339, DOI 10.1038/nature08569; Miranda PB, 1998, PHYS REV LETT, V81, P5876, DOI 10.1103/PhysRevLett.81.5876; Nair RR, 2008, SCIENCE, V320, P1308, DOI 10.1126/science.1156965; Novoselov KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/pnas.0502848102; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Ogawa K, 1999, MICROSCALE THERM ENG, V3, P101; Piner RD, 1997, LANGMUIR, V13, P6864, DOI 10.1021/la970921w; Shin YJ, 2010, LANGMUIR, V26, P3798, DOI 10.1021/la100231u; Stolyarova E, 2009, NANO LETT, V9, P332, DOI 10.1021/nl803087x; Stolyarova E, 2007, P NATL ACAD SCI USA, V104, P9209, DOI 10.1073/pnas.0703337104; THIEL PA, 1987, SURF SCI REP, V7, P211, DOI 10.1016/0167-5729(87)90001-X; Verdaguer A, 2006, CHEM REV, V106, P1478, DOI 10.1021/cr040376l; Xu K, 2009, NANO LETT, V9, P4446, DOI 10.1021/nl902729p; Xu L, 2002, NANO-SURFACE CHEMISTRY, P243	30	385	394	6	387	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2010	329	5996					1188	1191		10.1126/science.1192907	http://dx.doi.org/10.1126/science.1192907			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813950				2022-12-28	WOS:000281485600031
J	Decin, L; Agundez, M; Barlow, MJ; Daniel, F; Cernicharo, J; Lombaert, R; De Beck, E; Royer, P; Vandenbussche, B; Wesson, R; Polehampton, ET; Blommaert, JADL; De Meester, W; Exter, K; Feuchtgruber, H; Gear, WK; Gomez, HL; Groenewegen, MAT; Guelin, M; Hargrave, PC; Huygen, R; Imhof, P; Ivison, RJ; Jean, C; Kahane, C; Kerschbaum, F; Leeks, SJ; Lim, T; Matsuura, M; Olofsson, G; Posch, T; Regibo, S; Savini, G; Sibthorpe, B; Swinyard, BM; Yates, JA; Waelkens, C				Decin, L.; Agundez, M.; Barlow, M. J.; Daniel, F.; Cernicharo, J.; Lombaert, R.; De Beck, E.; Royer, P.; Vandenbussche, B.; Wesson, R.; Polehampton, E. T.; Blommaert, J. A. D. L.; De Meester, W.; Exter, K.; Feuchtgruber, H.; Gear, W. K.; Gomez, H. L.; Groenewegen, M. A. T.; Guelin, M.; Hargrave, P. C.; Huygen, R.; Imhof, P.; Ivison, R. J.; Jean, C.; Kahane, C.; Kerschbaum, F.; Leeks, S. J.; Lim, T.; Matsuura, M.; Olofsson, G.; Posch, T.; Regibo, S.; Savini, G.; Sibthorpe, B.; Swinyard, B. M.; Yates, J. A.; Waelkens, C.			Warm water vapour in the sooty outflow from a luminous carbon star	NATURE			English	Article							CIRCUMSTELLAR ENVELOPE; MODEL ATMOSPHERES; INNER WIND; RICH; IRC+10216; CHEMISTRY; EMISSION; AMMONIA; SILICON	The detection(1) of circumstellar water vapour around the ageing carbon star IRC + 10216 challenged the current understanding of chemistry in old stars, because water was predicted(2) to be almost absent in carbon-rich stars. Several explanations for the water were postulated, including the vaporization of icy bodies (comets or dwarf planets) in orbit around the star(1), grain surface reactions(3), and photochemistry in the outer circumstellar envelope(4). With a single water line detected so far from this one carbon-rich evolved star, it is difficult to discriminate between the different mechanisms proposed. Here we report the detection of dozens of water vapour lines in the far-infrared and sub-millimetre spectrum of IRC + 10216 using the Herschel satellite(5). This includes some high-excitation lines with energies corresponding to similar to 1,000 K, which can be explained only if water is present in the warm inner sooty region of the envelope. A plausible explanation for the warm water appears to be the penetration of ultraviolet photons deep into a clumpy circumstellar envelope. This mechanism also triggers the formation of other molecules, such as ammonia, whose observed abundances(6) are much higher than hitherto predicted(7).	[Decin, L.; Lombaert, R.; De Beck, E.; Royer, P.; Vandenbussche, B.; Blommaert, J. A. D. L.; De Meester, W.; Exter, K.; Huygen, R.; Jean, C.; Regibo, S.; Waelkens, C.] Katholieke Univ Leuven, Inst Sterrenkunde, B-3001 Louvain, Belgium; [Decin, L.] Univ Amsterdam, Sterrenkundig Inst Anton Pannekoek, NL-1098 Amsterdam, Netherlands; [Agundez, M.; Daniel, F.; Cernicharo, J.] INTA CSIC, CAB, Dept Astrophys, Lab Mol Astrophys, Madrid 28850, Spain; [Barlow, M. J.; Wesson, R.; Matsuura, M.; Savini, G.; Yates, J. A.] UCL, Dept Phys & Astron, London WC1E 6BT, England; [Polehampton, E. T.; Leeks, S. J.; Lim, T.; Swinyard, B. M.] Rutherford Appleton Lab, Space Sci & Technol Dept, Didcot OX11 0QX, Oxon, England; [Polehampton, E. T.] Univ Lethbridge, Inst Space Imaging Sci, Lethbridge, AB T1J 1B1, Canada; [Agundez, M.] Observ Paris, LUTH, F-92190 Meudon, France; [Feuchtgruber, H.] Max Planck Inst Extraterr Phys, D-85748 Garching, Germany; [Gear, W. K.; Gomez, H. L.; Hargrave, P. C.] Cardiff Univ, Sch Phys & Astron, Cardiff CF24 3AA, S Glam, Wales; [Groenewegen, M. A. T.] Royal Observ Belgium, B-1180 Brussels, Belgium; [Imhof, P.] Blue Sky Spect, Lethbridge, AB T1J 0N9, Canada; [Ivison, R. J.; Sibthorpe, B.] Royal Observ, UK Astron Technol Ctr, Edinburgh EH9 3HJ, Midlothian, Scotland; [Olofsson, G.] Stockholm Univ, AlbaNova Univ Ctr, Dept Astron, S-10691 Stockholm, Sweden; [Kerschbaum, F.; Posch, T.] Univ Vienna, Dept Astron, A-1180 Vienna, Austria; [Matsuura, M.] Univ Coll London, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; [Guelin, M.] Inst Radioastron Millimetr, F-38406 St Martin Dheres, France; [Kahane, C.] Observ Grenoble, Astrophys Lab, F-38041 Grenoble 9, France	KU Leuven; University of Amsterdam; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); University of London; University College London; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; University of Lethbridge; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Universite Paris Cite; Max Planck Society; Cardiff University; University of Edinburgh; Stockholm University; University of Vienna; University of London; University College London; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Decin, L (corresponding author), Katholieke Univ Leuven, Inst Sterrenkunde, Celestijnenlaan 200D, B-3001 Louvain, Belgium.	Leen.Decin@ster.kuleuven.be	Barlow, Michael J/A-5638-2009; De Beck, Elvire/U-1372-2018; Kerschbaum, Franz/AAB-1523-2019; Ivison, R. J./G-4450-2011; hargrave, peter/L-7900-2017; Agundez, Marcelino/I-5369-2012; Cernicharo, Jose/G-3059-2015; Savini, Giorgio/F-5753-2019	Barlow, Michael J/0000-0002-3875-1171; De Beck, Elvire/0000-0002-7441-7189; Kerschbaum, Franz/0000-0001-6320-0980; Ivison, R. J./0000-0001-5118-1313; hargrave, peter/0000-0002-3109-6629; Agundez, Marcelino/0000-0003-3248-3564; Cernicharo, Jose/0000-0002-3518-2524; Wesson, Roger/0000-0002-4000-4394; Matsuura, Mikako/0000-0002-5529-5593; Exter, Katrina/0000-0002-5911-1536; Polehampton, Edward/0000-0003-3153-813X; Gear, Walter/0000-0001-6789-6196; Savini, Giorgio/0000-0003-4449-9416; Vandenbussche, Bart/0000-0002-1368-3109; Gomez, Haley/0000-0003-3398-0052; Decin, Leen/0000-0002-5342-8612; Groenewegen, Martin/0000-0003-2723-6075	BMVIT (Austria); ESA-PRODEX (Belgium); CEA/CNES (France); DLR (Germany); ASI (Italy); CICT/MCT (Spain); CSA (Canada); NAOC (China); CEA, CNES, CNRS (France); MCINN (Spain); SNSB (Sweden); STFC (UK); NASA (USA); INSU/CNRS (France); MPG (Germany); IGN (Spain); STFC [ST/G002827/1, ST/H008543/1] Funding Source: UKRI; Science and Technology Facilities Council [PP/E001181/1, ST/G002827/1, ST/H008543/1] Funding Source: researchfish	BMVIT (Austria); ESA-PRODEX (Belgium); CEA/CNES (France)(French Atomic Energy CommissionCentre National D'etudes Spatiales); DLR (Germany)(Helmholtz AssociationGerman Aerospace Centre (DLR)); ASI (Italy)(Agenzia Spaziale Italiana (ASI)); CICT/MCT (Spain); CSA (Canada); NAOC (China); CEA, CNES, CNRS (France)(French Atomic Energy CommissionCentre National de la Recherche Scientifique (CNRS)Centre National D'etudes Spatiales); MCINN (Spain)(Spanish Government); SNSB (Sweden); STFC (UK)(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); NASA (USA)(National Aeronautics & Space Administration (NASA)); INSU/CNRS (France)(Centre National de la Recherche Scientifique (CNRS)); MPG (Germany)(Max Planck Society); IGN (Spain); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	Herschel is an ESA space observatory with science instruments provided by European-led Principal Investigator (PI) consortia and with important participation from NASA. PACS has been developed by a consortium of institutes led by MPE (Germany) and including UVIE (Austria); KUL, CSL, IMEC (Belgium); CEA, OAMP (France); MPIA (Germany); IFSI, OAP/AOT, OAA/CAISMI, LENS, SISSA (Italy); and IAC (Spain). This development has been supported by the funding agencies BMVIT (Austria), ESA-PRODEX (Belgium), CEA/CNES (France), DLR (Germany), ASI (Italy) and CICT/MCT (Spain). SPIRE has been developed by a consortium of institutes led by Cardiff University (UK) and including the University of Lethbridge (Canada); NAOC (China); CEA, LAM (France); IFSI, the University of Padua (Italy); IAC (Spain); Stockholm Observatory (Sweden); Imperial College London, RAL, UCL-MSSL, UKATC, University of Sussex (UK); and Caltech, JPL, NHSC, the University of Colorado (USA). This development has been supported by national funding agencies: CSA (Canada); NAOC (China); CEA, CNES, CNRS (France); ASI (Italy); MCINN (Spain); SNSB (Sweden); STFC (UK); and NASA (USA). IRAM is supported by INSU/CNRS (France), MPG (Germany) and IGN (Spain).	AGUNDEZ M, ASTROPHYS J UNPUB; Agundez M, 2006, ASTROPHYS J, V650, P374, DOI 10.1086/506313; BUJARRABAL V, 1994, ASTRON ASTROPHYS, V285, P247; Cherchneff I, 2006, ASTRON ASTROPHYS, V456, P1001, DOI 10.1051/0004-6361:20064827; CHERCHNEFF I, 1992, ASTROPHYS J, V394, P703, DOI 10.1086/171624; Decin L, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014562; Decin L, 2010, ASTRON ASTROPHYS, V516, DOI 10.1051/0004-6361/201014136; Dinh-V-Trung, 2008, APJ, V678, P303; Duari D, 1999, ASTRON ASTROPHYS, V341, pL47; FONG D, 2003, APJ, V582, P39; Glassgold AE, 1996, ANNU REV ASTRON ASTR, V34, P241, DOI 10.1146/annurev.astro.34.1.241; Gonzalez-Alfonso E, 2007, ASTROPHYS J, V669, P412, DOI 10.1086/521426; Griffin MJ, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014519; GUELIN M, 1993, ASTRON ASTROPHYS, V280, pL19; Gustafsson B, 2008, ASTRON ASTROPHYS, V486, P951, DOI 10.1051/0004-6361:200809724; Hasegawa TI, 2006, ASTROPHYS J, V637, P791, DOI 10.1086/498561; IBEN I, 1983, ANNU REV ASTRON ASTR, V21, P271, DOI 10.1146/annurev.aa.21.090183.001415; Leao IC, 2006, ASTRON ASTROPHYS, V455, P187, DOI 10.1051/0004-6361:20054577; MCCABE EM, 1979, NATURE, V281, P263, DOI 10.1038/281263a0; Melnick GJ, 2001, NATURE, V412, P160, DOI 10.1038/35084024; MENTEN KM, 1995, ASTROPHYS J, V448, P416, DOI 10.1086/175971; Pilbratt GL, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014759; Poglitsch A, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014535; QUERCI F, 1974, ASTRON ASTROPHYS, V31, P265; Talbi D, 2010, CHEM PHYS LETT, V485, P56, DOI 10.1016/j.cplett.2009.12.045; Tsuji T., 1964, ANN TOKYO ASTRON OBS, V9, P1; Weigelt G, 1998, ASTRON ASTROPHYS, V333, pL51; Willacy K, 1998, ASTRON ASTROPHYS, V330, P676; WILLACY K, 2004, APJ, V600, P87; WINTERS JM, 1994, ASTRON ASTROPHYS, V288, P255	30	81	81	2	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 2	2010	467	7311					64	67		10.1038/nature09344	http://dx.doi.org/10.1038/nature09344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811453	Green Submitted			2022-12-28	WOS:000281461200035
J	Fisher, DE; James, WD				Fisher, David E.; James, William D.			Indoor Tanning - Science, Behavior, and Policy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MELANOMA		[Fisher, David E.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; [Fisher, David E.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Fisher, David E.] Harvard Univ, Sch Med, Boston, MA USA; [James, William D.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Pennsylvania	Fisher, DE (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.		Fisher, David/AAH-2878-2019		NIAMS NIH HHS [R01 AR043369] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Lazovich D, 2010, CANCER EPIDEM BIOMAR, V19, P1557, DOI 10.1158/1055-9965.EPI-09-1249; Mosher CE, 2010, ARCH DERMATOL, V146, P412, DOI 10.1001/archdermatol.2009.385; Purdue MP, 2008, J INVEST DERMATOL, V128, P2905, DOI 10.1038/jid.2008.159	5	72	73	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					901	903		10.1056/NEJMp1005999	http://dx.doi.org/10.1056/NEJMp1005999			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645GW	20818900	Green Accepted			2022-12-28	WOS:000281441500003
J	Gutovich, JM				Gutovich, Jordan M.			Holding the Hand	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												jmg349@drexel.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					941	942		10.1001/jama.2010.1251	http://dx.doi.org/10.1001/jama.2010.1251			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20810363				2022-12-28	WOS:000281422400001
J	Bahrami, B; Olsen, K; Latham, PE; Roepstorff, A; Rees, G; Frith, CD				Bahrami, Bahador; Olsen, Karsten; Latham, Peter E.; Roepstorff, Andreas; Rees, Geraint; Frith, Chris D.			Optimally Interacting Minds	SCIENCE			English	Article							POPULATION CODES; DECISION-MAKING; INTEGRATION; PERFORMANCE	In everyday life, many people believe that two heads are better than one. Our ability to solve problems together appears to be fundamental to the current dominance and future survival of the human species. But are two heads really better than one? We addressed this question in the context of a collective low-level perceptual decision-making task. For two observers of nearly equal visual sensitivity, two heads were definitely better than one, provided they were given the opportunity to communicate freely, even in the absence of any feedback about decision outcomes. But for observers with very different visual sensitivities, two heads were actually worse than the better one. These seemingly discrepant patterns of group behavior can be explained by a model in which two heads are Bayes optimal under the assumption that individuals accurately communicate their level of confidence on every trial.	[Bahrami, Bahador; Rees, Geraint] UCL, Inst Cognit Neurosci, London WC1N 3AR, England; [Bahrami, Bahador; Rees, Geraint; Frith, Chris D.] UCL, Inst Neurol, Wellcome Trust Ctr Neuroimaging, London WC1N 3BG, England; [Bahrami, Bahador; Olsen, Karsten; Roepstorff, Andreas; Frith, Chris D.] Aarhus Univ, Interacting Minds Project, Inst Anthropol, DK-8000 Aarhus C, Denmark; [Bahrami, Bahador; Olsen, Karsten; Roepstorff, Andreas; Frith, Chris D.] Aarhus Univ Hosp, Ctr Functionally Integrat Neurosci, DK-8000 Aarhus C, Denmark; [Latham, Peter E.] Gatsby Computat Neurosci Unit, London WC1N 3AR, England	University of London; University College London; University of London; University College London; Aarhus University; Aarhus University; University of London; University College London	Bahrami, B (corresponding author), UCL, Inst Cognit Neurosci, Alexandra House,17 Queen Sq, London WC1N 3AR, England.	bbahrami@gmail.com	Frith, Chris D/A-2171-2009; Olsen, Karsten/D-1678-2010; Rees, Geraint/C-1493-2008	Frith, Chris D/0000-0002-8665-0690; Olsen, Karsten/0000-0002-1513-4736; Rees, Geraint/0000-0002-9623-7007	European Union; Danish National Research Foundation; Danish Research Council for Culture and Communication; Gatsby Charitable Foundation; Wellcome Trust; Danish Ministry of Science, Technology and Innovation	European Union(European Commission); Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Research Council for Culture and Communication; Gatsby Charitable Foundation; Wellcome Trust(Wellcome TrustEuropean Commission); Danish Ministry of Science, Technology and Innovation	We thank D. Bang for generous help with data collection in experiments 2 and 4 and F. Scharnowski for his insightful comments in the early stages of the project. This work was supported by the European Union MindBridge project (B.B.), the Danish National Research Foundation and the Danish Research Council for Culture and Communication (A.R. and C.D.F.), the Gatsby Charitable Foundation (P.E.L.), and the Wellcome Trust (G.R.). Support from the MIND Lab UNIK initiative at Aarhus University was funded by the Danish Ministry of Science, Technology and Innovation.	Alais D, 2004, CURR BIOL, V14, P257, DOI 10.1016/j.cub.2004.01.029; Bovens L, 2003, BAYESIAN EPISTEMOLOG; Deneve S, 2001, NAT NEUROSCI, V4, P826, DOI 10.1038/90541; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Green DM, 1966, SIGNAL DETECTION THE; Hastie R, 2005, PSYCHOL REV, V112, P494, DOI 10.1037/0033-295X.112.2.494; HILL GW, 1982, PSYCHOL BULL, V91, P517, DOI 10.1037/0033-2909.91.3.517; Kerr NL, 2004, ANNU REV PSYCHOL, V55, P623, DOI 10.1146/annurev.psych.55.090902.142009; Kording KP, 2004, NATURE, V427, P244, DOI 10.1038/nature02169; LATANE B, 1979, J PERS SOC PSYCHOL, V37, P822, DOI 10.1037//0022-3514.37.6.822; LAUGHLIN PR, 1986, J EXP SOC PSYCHOL, V22, P177, DOI 10.1016/0022-1031(86)90022-3; Ma WJ, 2006, NAT NEUROSCI, V9, P1432, DOI 10.1038/nn1790; Nitzan S., 1985, COLLECTIVE DECISION; Sorkin RD, 2001, PSYCHOL REV, V108, P183, DOI 10.1037//0033-295X.108.1.183; Turner ME, 1998, ORGAN BEHAV HUM DEC, V73, P105, DOI 10.1006/obhd.1998.2756	15	345	347	4	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1081	1085		10.1126/science.1185718	http://dx.doi.org/10.1126/science.1185718			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	642WZ	20798320	Green Accepted, Green Published			2022-12-28	WOS:000281253500042
J	Pravec, P; Vokrouhlicky, D; Polishook, D; Scheeres, DJ; Harris, AW; Galad, A; Vaduvescu, O; Pozo, F; Barr, A; Longa, P; Vachier, F; Colas, F; Pray, DP; Pollock, J; Reichart, D; Ivarsen, K; Haislip, J; LaCluyze, A; Kusnirak, P; Henych, T; Marchis, F; Macomber, B; Jacobson, SA; Krugly, YN; Sergeev, AV; Leroy, A				Pravec, P.; Vokrouhlicky, D.; Polishook, D.; Scheeres, D. J.; Harris, A. W.; Galad, A.; Vaduvescu, O.; Pozo, F.; Barr, A.; Longa, P.; Vachier, F.; Colas, F.; Pray, D. P.; Pollock, J.; Reichart, D.; Ivarsen, K.; Haislip, J.; LaCluyze, A.; Kusnirak, P.; Henych, T.; Marchis, F.; Macomber, B.; Jacobson, S. A.; Krugly, Yu. N.; Sergeev, A. V.; Leroy, A.			Formation of asteroid pairs by rotational fission	NATURE			English	Article							FULL 2-BODY PROBLEM; BINARY ASTEROIDS; STABILITY; ORIGIN	Pairs of asteroids sharing similar heliocentric orbits, but not bound together, were found recently(1-3). Backward integrations of their orbits indicated that they separated gently with low relative velocities, but did not provide additional insight into their formation mechanism. A previously hypothesized rotational fission process 4 may explain their formation-critical predictions are that the mass ratios are less than about 0.2 and, as the mass ratio approaches this upper limit, the spin period of the larger body becomes long. Here we report photometric observations of a sample of asteroid pairs, revealing that the primaries of pairs with mass ratios much less than 0.2 rotate rapidly, near their critical fission frequency. As the mass ratio approaches 0.2, the primary period grows long. This occurs as the total energy of the system approaches zero, requiring the asteroid pair to extract an increasing fraction of energy from the primary's spin in order to escape. We do not find asteroid pairs with mass ratios larger than 0.2. Rotationally fissioned systems beyond this limit have insufficient energy to disrupt. We conclude that asteroid pairs are formed by the rotational fission of a parent asteroid into a proto-binary system, which subsequently disrupts under its own internal system dynamics soon after formation.	[Pravec, P.; Galad, A.; Kusnirak, P.; Henych, T.] Astron Inst AS CR, CZ-25165 Ondrejov, Czech Republic; [Vokrouhlicky, D.] Charles Univ Prague, Inst Astron, CZ-18000 Prague, Czech Republic; [Polishook, D.] Tel Aviv Univ, Wise Observ, IL-69978 Tel Aviv, Israel; [Polishook, D.] Tel Aviv Univ, Dept Geophys & Planetary Phys, IL-69978 Tel Aviv, Israel; [Scheeres, D. J.] Univ Colorado, Dept Aerosp Engn Sci, Boulder, CO 80309 USA; [Harris, A. W.] Space Sci Inst, La Canada Flintridge, CA 91011 USA; [Galad, A.] Comenius Univ, Modra Observ, SK-84248 Bratislava, Slovakia; [Vaduvescu, O.; Pozo, F.; Barr, A.; Longa, P.] Univ Catolica Norte, Inst Astron, Antofagasta, Chile; [Vaduvescu, O.] Isaac Newton Grp Telescopes, E-38700 Santa Cruz De La Palma, Canary Isl, Spain; [Vachier, F.; Colas, F.] IMCCE CNRS Observ Paris, F-75014 Paris, France; [Pray, D. P.] Carbuncle Hill Observ, W Brookfield, MA 01585 USA; [Pollock, J.] Appalachian State Univ, Dept Phys & Astron, Boone, NC 28608 USA; [Reichart, D.; Ivarsen, K.; Haislip, J.; LaCluyze, A.] Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27514 USA; [Marchis, F.; Macomber, B.] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Marchis, F.; Macomber, B.] SETI Inst, Mountain View, CA 94043 USA; [Jacobson, S. A.] Univ Colorado, Dept Astrophys & Planetary Sci, Boulder, CO 80309 USA; [Krugly, Yu. N.; Sergeev, A. V.] Kharkov Natl Univ, Inst Astron, UA-61022 Kharkov, Ukraine; [Leroy, A.] Observ Midi Pyrenees & Assoc, Pic Du Midi, France	Czech Academy of Sciences; Astronomical Institute of the Czech Academy of Sciences; Charles University Prague; Tel Aviv University; Tel Aviv University; University of Colorado System; University of Colorado Boulder; Comenius University Bratislava; Universidad Catolica del Norte; Isaac Newton Group of Telescopes; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of North Carolina; Appalachian State University; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Berkeley; University of Colorado System; University of Colorado Boulder; Ministry of Education & Science of Ukraine; VN Karazin Kharkiv National University	Pravec, P (corresponding author), Astron Inst AS CR, Fricova 1, CZ-25165 Ondrejov, Czech Republic.	ppravec@asu.cas.cz	Sergeyev, Alexey V/F-3340-2019; Marchis, Franck/H-3971-2012; Galad, Adrian/G-9011-2014; Pozo Nunez, Francisco/AAA-2812-2022; Krugly, Yurij/O-7164-2018; Vaduvescu, Ovidiu/GYJ-3429-2022; Pravec, Petr/AAE-2695-2019; Jacobson, Seth/I-7029-2015; Pravec, Petr/G-9037-2014; Henych, Tomas/AAG-2900-2019; Henych, Tomas/H-7157-2014; Vokrouhlický, David/Q-4359-2017	Galad, Adrian/0000-0002-5971-1136; Pozo Nunez, Francisco/0000-0002-6716-4179; Krugly, Yurij/0000-0002-3171-9873; Pravec, Petr/0000-0001-8434-9776; Jacobson, Seth/0000-0002-4952-9007; Henych, Tomas/0000-0003-2630-2077; Henych, Tomas/0000-0003-2630-2077; Vokrouhlický, David/0000-0002-6034-5452; SCHEERES, DANIEL/0000-0003-0558-3842; Sergeyev, Alexey/0000-0003-3425-5178; Vachier, Frederic/0000-0002-4289-4466; Polishook, David/0000-0002-6977-3146	Grant Agency of the Czech Republic; Czech Ministry of Education; Israeli Ministry of Science; NASA; NSF; Slovak Grant Agency for Science; CNRS; Planetary Society; Division Of Astronomical Sciences [0807468] Funding Source: National Science Foundation	Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Czech Ministry of Education(Ministry of Education, Youth & Sports - Czech Republic); Israeli Ministry of Science(Ministry of Science, Technology and Space (MOST), Israel); NASA(National Aeronautics & Space Administration (NASA)); NSF(National Science Foundation (NSF)); Slovak Grant Agency for Science(Vedecka grantova agentura MSVVaS SR a SAV (VEGA)); CNRS(Centre National de la Recherche Scientifique (CNRS)); Planetary Society; Division Of Astronomical Sciences(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	Research at Ondrejov was supported by the Grant Agency of the Czech Republic. D.V. was supported by the Czech Ministry of Education. D.P. was supported by an Ilan Ramon grant from the Israeli Ministry of Science, and is grateful for the guidance of N. Brosch and D. Prialnik. D.J.S. and S.A.J. acknowledge support by NASA's PG&G and OPR research programs. A.W.H. was supported by NASA and NSF. Work at Modra Observatory was supported by the Slovak Grant Agency for Science. The observations at Cerro Tololo were performed with the support of CTIO and J. Vasquez, using telescopes operated by the SMARTS Consortium. Work at Pic du Midi Observatory was supported by CNRS, Programme de Planetologie. Operations at Carbuncle Hill Observatory were supported by the Planetary Society's Gene Shoemaker NEO Grant. Support for PROMPT has been provided by the NSF. F.M. and B.M. were supported by the NSF. We thank O. Bautista, T. Moulinier and P. Eclancher for assistance with observations with the T60 on Pic du Midi.	Bottke WF, 2006, ANNU REV EARTH PL SC, V34, P157, DOI 10.1146/annurev.earth.34.031405.125154; GALAD A, 2009, MINOR PLANET B, V37, P9; Milani A, 2010, ICARUS, V207, P769, DOI 10.1016/j.icarus.2009.12.022; Pravec P, 2007, ICARUS, V190, P250, DOI 10.1016/j.icarus.2007.02.023; Pravec P, 2009, ICARUS, V204, P580, DOI 10.1016/j.icarus.2009.07.004; Scheeres DJ, 2007, ICARUS, V189, P370, DOI 10.1016/j.icarus.2007.02.015; Scheeres DJ, 2009, CELEST MECH DYN ASTR, V104, P103, DOI 10.1007/s10569-009-9184-7; Scheeres DJ, 2009, PLANET SPACE SCI, V57, P154, DOI 10.1016/j.pss.2008.03.009; Scheeres DJ, 2002, CELEST MECH DYN ASTR, V83, P155, DOI 10.1023/A:1020143116091; Vokrouhlicky D, 2008, ASTRON J, V136, P280, DOI 10.1088/0004-6256/136/1/280; Vokrouhlicky D, 2009, ASTRON J, V137, P111, DOI 10.1088/0004-6256/137/1/111; Walsh KJ, 2008, NATURE, V454, P188, DOI 10.1038/nature07078; Warner B.-D., 2009, MINOR PLANET B, V36, P7; Warner BD, 2009, ICARUS, V202, P134, DOI 10.1016/j.icarus.2009.02.003	14	131	132	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					1085	1088		10.1038/nature09315	http://dx.doi.org/10.1038/nature09315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740010	Green Submitted			2022-12-28	WOS:000281203600035
J	Turner, DB; Nelson, KA				Turner, Daniel B.; Nelson, Keith A.			Coherent measurements of high-order electronic correlations in quantum wells	NATURE			English	Article							COULOMB CORRELATIONS; OPTICAL-RESPONSE; SPECTROSCOPY; SEMICONDUCTORS; GAAS; BIEXCITONS; SIGNATURES	Strong, long-range Coulomb interactions can lead to correlated motions of multiple charged particles, which can induce important many-body effects in semiconductors. The exciton states formed from correlated electron-hole pairs have been studied extensively(1,2), but basic properties of multiple-exciton correlations-such as coherence times, population lifetimes, binding energies and the number of particles that can be correlated-are largely unknown because they are not spectroscopically accessible from the ground state. Here we present direct observations of high-order coherences in gallium arsenide quantum wells, achieved using two-dimensional multiple-quantum spectroscopy methods in which up to seven successive light fields were used. The measurements were made possible by the combination of a reconfigurable spatial beam-shaper that formed multiple beams in specified geometries and a spatiotemporal pulse-shaper that controlled the relative optical phases and temporal delays among pulses in all the beams. The results reveal triexciton coherences (correlations of three excitons or six particles), whose existence was not obvious because the third exciton spin is unpaired, and the values of their coherence times and binding energies. Rephasing of biexcitons, triexcitons and unbound two-exciton coherences was demonstrated. We also determined that there are no significant unbound correlations of three excitons and no bound or unbound four-exciton (eight-particle) correlations. Thus, the limits, as well as the properties, of many-body correlations in this system were revealed. The measurement methods open a new window into high-order many-body interactions in materials and molecules(3), and the present results should guide ongoing work on first-principles calculations of electronic interactions in semiconductor nanostructures(4).	[Turner, Daniel B.; Nelson, Keith A.] MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Nelson, KA (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	kanelson@mit.edu		Turner, Daniel/0000-0002-3148-5317	National Defense Science and Engineering; National Science Foundation [CHE-0616939]	National Defense Science and Engineering; National Science Foundation(National Science Foundation (NSF))	D.B.T. was supported by the National Defense Science and Engineering Graduate Fellowship programme and the National Science Foundation Graduate Fellowship programme and wishes to thank M. Zanni for an inspirational conversation. This work was supported in part by National Science Foundation grant CHE-0616939.	Abramavicius D, 2008, P NATL ACAD SCI USA, V105, P8525, DOI 10.1073/pnas.0802926105; Bolton SR, 2000, PHYS REV LETT, V85, P2002, DOI 10.1103/PhysRevLett.85.2002; Breunig HG, 2003, J OPT SOC AM B, V20, P1769, DOI 10.1364/JOSAB.20.001769; Chemla DS, 2001, NATURE, V411, P549, DOI 10.1038/35079000; Cundiff ST, 2008, OPT EXPRESS, V16, P4639, DOI 10.1364/OE.16.004639; Ernst R, 1988, PRINCIPLES NUCL MAGN; Fulmer EC, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.067402; Kim J, 2009, ACCOUNTS CHEM RES, V42, P1375, DOI 10.1021/ar9000795; Kirm M, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.233103; Klimov VI, 2000, SCIENCE, V287, P1011, DOI 10.1126/science.287.5455.1011; KLIMOV VI, 2000, SCIENCE, V314, P290; Langbein W, 2001, J OPT SOC AM B, V18, P1318, DOI 10.1364/JOSAB.18.001318; Li XQ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.057406; Li XQ, 2003, SCIENCE, V301, P809, DOI 10.1126/science.1083800; Meier T, 2000, PHYS REV B, V62, P4218, DOI 10.1103/PhysRevB.62.4218; MEIERS T, 2007, COHERENT SEMICONDUCT; MILLER RC, 1982, PHYS REV B, V25, P6545, DOI 10.1103/PhysRevB.25.6545; Nair G, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.081304; Ostreich T, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.245203; Shacklette JM, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.045309; Shah J., 1999, ULTRAFAST SPECTROSCO; Stevenson RM, 2006, NATURE, V439, P179, DOI 10.1038/nature04446; Stone KW, 2009, SCIENCE, V324, P1169, DOI 10.1126/science.1170274; Sukiasyan S, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.223002; Turner DB, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3245964; Utsunomiya S, 2008, NAT PHYS, V4, P700, DOI 10.1038/nphys1034; Vaughan JC, 2007, J PHYS CHEM A, V111, P4873, DOI 10.1021/jp0662911; WANG HL, 1993, PHYS REV LETT, V71, P1261, DOI 10.1103/PhysRevLett.71.1261; WEGENER M, 1990, PHYS REV A, V42, P5675, DOI 10.1103/PhysRevA.42.5675; Zhang TH, 2007, P NATL ACAD SCI USA, V104, P14227, DOI 10.1073/pnas.0701273104	30	137	137	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					1089	1092		10.1038/nature09286	http://dx.doi.org/10.1038/nature09286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740011				2022-12-28	WOS:000281203600036
J	van Deventer, S; Neefjes, J				van Deventer, Sjoerd; Neefjes, Jacques			The Immunoproteasome Cleans up after Inflammation	CELL			English	Editorial Material							UBIQUITIN-PROTEASOME SYSTEM; ANTIGEN PRESENTATION; DEGRADATION	Immune cells and cells activated by the inflammatory cytokine interferon express variant proteasomes called immunoproteasomes that are characterized by unique catalytic subunits. Seifert et al. (2010) now show in mouse models of inflammatory disease that immunoproteasomes help prevent the accumulation of harmful protein aggregates.	[van Deventer, Sjoerd; Neefjes, Jacques] Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Neefjes, J (corresponding author), Netherlands Canc Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.neefjes@nki.nl	van Deventer, Sjoerd/F-3225-2016; Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Seifert U, 2010, CELL, V142, P613, DOI 10.1016/j.cell.2010.07.036; Strehl B, 2005, IMMUNOL REV, V207, P19, DOI 10.1111/j.0105-2896.2005.00308.x; Van den Eynde BJ, 2001, CURR OPIN IMMUNOL, V13, P147, DOI 10.1016/S0952-7915(00)00197-7; Yewdell JW, 2001, TRENDS CELL BIOL, V11, P294, DOI 10.1016/S0962-8924(01)02030-X; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250	10	33	33	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					517	518		10.1016/j.cell.2010.08.002	http://dx.doi.org/10.1016/j.cell.2010.08.002			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723753	Bronze			2022-12-28	WOS:000281115900006
J	Wang, CC; Schmid, CH; Rones, R; Kalish, R; Yinh, J; Goldenberg, DL; Lee, Y; McAlindon, T				Wang, Chenchen; Schmid, Christopher H.; Rones, Ramel; Kalish, Robert; Yinh, Janeth; Goldenberg, Don L.; Lee, Yoojin; McAlindon, Timothy			A Randomized Trial of Tai Chi for Fibromyalgia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TREATING KNEE OSTEOARTHRITIS; MINDFULNESS MEDITATION; IMPACT QUESTIONNAIRE; HEALTH OUTCOMES; EXERCISE; MANAGEMENT; PAIN; INTERVENTION; EDUCATION; EFFICACY	BACKGROUND Previous research has suggested that tai chi offers a therapeutic benefit in patients with fibromyalgia. METHODS We conducted a single-blind, randomized trial of classic Yang-style tai chi as compared with a control intervention consisting of wellness education and stretching for the treatment of fibromyalgia (defined by American College of Rheumatology 1990 criteria). Sessions lasted 60 minutes each and took place twice a week for 12 weeks for each of the study groups. The primary end point was a change in the Fibromyalgia Impact Questionnaire (FIQ) score (ranging from 0 to 100, with higher scores indicating more severe symptoms) at the end of 12 weeks. Secondary end points included summary scores on the physical and mental components of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). All assessments were repeated at 24 weeks to test the durability of the response. RESULTS Of the 66 randomly assigned patients, the 33 in the tai chi group had clinically important improvements in the FIQ total score and quality of life. Mean (+/- SD) baseline and 12-week FIQ scores for the tai chi group were 62.9 +/- 15.5 and 35.1 +/- 18.8, respectively, versus 68.0 +/- 11 and 58.6 +/- 17.6, respectively, for the control group (change from baseline in the tai chi group vs. change from baseline in the control group, -18.4 points; P<0.001). The corresponding SF-36 physical-component scores were 28.5 +/- 8.4 and 37.0 +/- 10.5 for the tai chi group versus 28.0 +/- 7.8 and 29.4 +/- 7.4 for the control group (between-group difference, 7.1 points; P = 0.001), and the mental-component scores were 42.6 +/- 12.2 and 50.3 +/- 10.2 for the tai chi group versus 37.8 +/- 10.5 and 39.4 +/- 11.9 for the control group (between-group difference, 6.1 points; P = 0.03). Improvements were maintained at 24 weeks (between-group difference in the FIQ score, -18.3 points; P<0.001). No adverse events were observed. CONCLUSIONS Tai chi may be a useful treatment for fibromyalgia and merits long-term study in larger study populations.	[Wang, Chenchen; Kalish, Robert; Yinh, Janeth; McAlindon, Timothy] Tufts Univ, Sch Med, Div Rheumatol, Tufts Med Ctr, Boston, MA 02111 USA; [Schmid, Christopher H.; Lee, Yoojin] Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Tufts Med Ctr, Boston, MA 02111 USA; [Rones, Ramel] Mind Body Therapies, Boston, MA USA; [Goldenberg, Don L.] Newton Wellesley Hosp, Newton, MA USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Newton Wellesley Hospital	Wang, CC (corresponding author), Tufts Univ, Sch Med, Div Rheumatol, Tufts Med Ctr, 800 Washington St,Box 406, Boston, MA 02111 USA.	cwang2@tuftsmedicalcenter.org	Schmid, Christopher H./J-2398-2014	Schmid, Christopher H./0000-0002-0855-5313	National Center for Complementary and Alternative Medicine of the National Institutes of Health [R21AT003621]; American College of Rheumatology Research and Education Foundation; Boston Claude D. Pepper Older Americans Independence Center; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT003621] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); American College of Rheumatology Research and Education Foundation; Boston Claude D. Pepper Older Americans Independence Center; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by a grant (R21AT003621) from the National Center for Complementary and Alternative Medicine of the National Institutes of Health, the American College of Rheumatology Research and Education Foundation Health Professional Investigator Award, and the Boston Claude D. Pepper Older Americans Independence Center Research Career Development Award.	Astin JA, 2003, J RHEUMATOL, V30, P2257; Barnes P. M., 2007, COMPLEMENTARY ALTERN; Bennett RM, 2009, J RHEUMATOL, V36, P1304, DOI 10.3899/jrheum.081090; Birdee GS, 2009, J ALTERN COMPLEM MED, V15, P969, DOI 10.1089/acm.2009.0174; Burckhardt C., 2005, APS CLIN PRACTICE GU; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; Burckhardt CS, 2006, CURR PHARM DESIGN, V12, P59, DOI 10.2174/138161206775193217; Busch AJ, 2008, J RHEUMATOL, V35, P1130; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carville SF, 2008, ANN RHEUM DIS, V67, P536, DOI 10.1136/ard.2007.071522; CHINA SPORTS, 1983, SIMPL TAIJ, P1; Creamer P, 2000, ARTHRIT CARE RES, V13, P198, DOI 10.1002/1529-0131(200008)13:4<198::AID-ANR4>3.0.CO;2-P; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goldenberg DL, 2004, JAMA-J AM MED ASSOC, V292, P2388, DOI 10.1001/jama.292.19.2388; Hauser W, 2009, ARTHRIT RHEUM-ARTHR, V61, P216, DOI 10.1002/art.24276; Irwin MR, 2007, J AM GERIATR SOC, V55, P511, DOI 10.1111/j.1532-5415.2007.01109.x; Jones KD, 2009, RHEUM DIS CLIN N AM, V35, P373, DOI 10.1016/j.rdc.2009.05.004; KAPLAN KH, 1993, GEN HOSP PSYCHIAT, V15, P284, DOI 10.1016/0163-8343(93)90020-O; King S, 1999, J RHEUMATOL, V26, P2233; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; Lush E, 2009, J CLIN PSYCHOL MED S, V16, P200, DOI 10.1007/s10880-009-9153-z; Mannerkorpi K, 2000, J RHEUMATOL, V27, P2473; National Food and Agriculture Organization. Ministry of Agriculture and Cooperatives, 2004, QUEST ANSW FIBR, P1; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ramel J, 2009, CURR RHEUMATOL REV, V5, P188, DOI 10.2174/157339709790192459; Rooks DS, 2007, ARCH INTERN MED, V167, P2192, DOI 10.1001/archinte.167.20.2192; Schulz R, 2002, GERONTOLOGIST, V42, P589, DOI 10.1093/geront/42.5.589; Sephton SE, 2007, ARTHRIT RHEUM-ARTHR, V57, P77, DOI 10.1002/art.22478; Shapiro SL, 2006, J CLIN PSYCHOL, V62, P373, DOI 10.1002/jclp.20237; Sinclair D, 2005, MANUAL TENDER POINT; STEINHARDT MA, 1989, J OCCUP ENVIRON MED, V31, P536, DOI 10.1097/00043764-198906000-00011; Taggart Helen M, 2003, Orthop Nurs, V22, P353, DOI 10.1097/00006416-200309000-00013; Valkeinen H, 2006, ARTHRITIS RHEUM, V54, P1334, DOI 10.1002/art.21751; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; Wang CC, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-23; Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832; Wang CC, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-108; Wang Chenchen, 2008, V52, P218, DOI 10.1159/000134302; Ware J., 2001, SF 36 PHYS MENTAL HL, P1994; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P95, DOI 10.1089/acm.2007.7170A; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1560, DOI 10.1002/art.1780400904; Yocum DE, 2000, RHEUM DIS CLIN N AM, V26, P145, DOI 10.1016/S0889-857X(05)70128-9	47	257	275	3	128	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					743	754		10.1056/NEJMoa0912611	http://dx.doi.org/10.1056/NEJMoa0912611			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639TE	20818876	Green Accepted, Bronze			2022-12-28	WOS:000280996600008
J	Sudore, RL; Fried, TR				Sudore, Rebecca L.; Fried, Terri R.			Redefining the "Planning" in Advance Care Planning: Preparing for End-of-Life Decision Making	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNICATION-SKILLS; SUSTAINING TREATMENT; PATIENT PREFERENCES; FAMILY-MEMBERS; TRANSTHEORETICAL MODEL; POSTTRAUMATIC STRESS; PALLIATIVE CARE; DIRECTIVES; PHYSICIANS; DEATH	The traditional objective of advance care planning has been to have patients make treatment decisions in advance so that clinicians can attempt to provide care consistent with their goals. The authors contend that the objective for advance care planning ought to be the preparation of patients and surrogates to participate with clinicians in making the best possible in-the-moment medical decisions. They provide practical steps for clinicians to help patients and surrogate decision makers achieve this objective in the outpatient setting. Preparation for in-the-moment decision making shifts the focus from having patients make premature decisions based on incomplete information to preparing them and their surrogates for the types of decisions and conflicts they may encounter when they do have to make in-the-moment decisions. Advance directives, although important, are just one piece of information to be used at the time of decision making.	[Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, Vet Affairs Med Ctr, San Francisco, CA 94121 USA; San Francisco VA Med Ctr, San Francisco, CA 94121 USA; Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA; Yale Univ, Sch Med, New Haven, CT USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Sudore, RL (corresponding author), Univ Calif San Francisco, Div Geriatr, Vet Affairs Med Ctr, 4150 Clement St,Box 151R, San Francisco, CA 94121 USA.	Rebecca.Sudore@ucsf.edu	Sudore, Rebecca/AAF-1635-2021		Veterans Affairs Career Development Award; Pfizer Fellowship in Clear Health Communication; National Institutes of Health [K24 AG028443]; NATIONAL INSTITUTE ON AGING [K24AG028443] Funding Source: NIH RePORTER	Veterans Affairs Career Development Award; Pfizer Fellowship in Clear Health Communication; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Grant Support: Dr. Sudore is supported by a Veterans Affairs Career Development Award and a Pfizer Fellowship in Clear Health Communication. Dr. Fried is supported by the National Institutes of Health (grant K24 AG028443).	Anderson WG, 2008, J GEN INTERN MED, V23, P1871, DOI 10.1007/s11606-008-0770-2; [Anonymous], 1991, JAMA, V265, P1868; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Back AL, 2007, ARCH INTERN MED, V167, P453, DOI 10.1001/archinte.167.5.453; Berger JT, 2008, ANN INTERN MED, V149, P48, DOI 10.7326/0003-4819-149-1-200807010-00010; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; Briggs Linda, 2004, J Palliat Med, V7, P341, DOI 10.1089/109662104773709503; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; Coppola KM, 2001, ARCH INTERN MED, V161, P431, DOI 10.1001/archinte.161.3.431; Coppola KM, 1999, DEATH STUD, V23, P617, DOI 10.1080/074811899200803; Danis M, 1996, CRIT CARE MED, V24, P1811, DOI 10.1097/00003246-199611000-00009; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Ditto PH, 2006, MED DECIS MAKING, V26, P313, DOI 10.1177/0272989X06290494; Ditto PH, 2005, HEALTH PSYCHOL, V24, pS63, DOI 10.1037/0278-6133.24.4.S63; Ditto PH, 1996, HEALTH PSYCHOL, V15, P332, DOI 10.1037/0278-6133.15.5.332; Ditto PH, 2001, ARCH INTERN MED, V161, P421, DOI 10.1001/archinte.161.3.421; DOUKAS DJ, 1991, J FAM PRACTICE, V32, P145; Drazen JM, 2009, NEW ENGL J MED, V360, P444, DOI 10.1056/NEJMp0809496; Emanuel LL, 2000, ARCH FAM MED, V9, P1181, DOI 10.1001/archfami.9.10.1181; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Fagerlin A, 2004, HASTINGS CENT REP, V34, P30, DOI 10.2307/3527683; Fagerlin A, 2001, HEALTH PSYCHOL, V20, P166, DOI 10.1037/0278-6133.20.3.166; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; FORROW L, 1994, HASTINGS CENT REP, V24, pS29, DOI 10.2307/3563481; Fried TR, 2008, J GEN INTERN MED, V23, P1602, DOI 10.1007/s11606-008-0748-0; Fried TR, 2007, J AM GERIATR SOC, V55, P1007, DOI 10.1111/j.1532-5415.2007.01232.x; Fried Terri R, 2003, J Palliat Med, V6, P237, DOI 10.1089/109662103764978489; Fried TR, 2009, J AM GERIATR SOC, V57, P1547, DOI 10.1111/j.1532-5415.2009.02396.x; Fried TR, 2006, ARCH INTERN MED, V166, P890, DOI 10.1001/archinte.166.8.890; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gillick M R, 2001, J Am Med Dir Assoc, V2, P305, DOI 10.1016/S1525-8610(04)70227-3; Gillick MR, 2004, NEW ENGL J MED, V350, P7, DOI 10.1056/NEJMp038202; GILLICK MR, 1995, ANN INTERN MED, V123, P621, DOI 10.7326/0003-4819-123-8-199510150-00009; Goldstein NE, 2008, ARCH INTERN MED, V168, P1733, DOI 10.1001/archinte.168.16.1733; Halpern J, 2008, J GEN INTERN MED, V23, P1708, DOI 10.1007/s11606-008-0719-5; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hauser Joshua M, 2006, Am J Hosp Palliat Care, V23, P105, DOI 10.1177/104990910602300207; Hawkins NA, 2005, GERONTOLOGIST, V45, P107, DOI 10.1093/geront/45.1.107; HIGH DM, 1994, HASTINGS CENT REP, V24, pS16, DOI 10.2307/3563476; Jezewski MA, 2009, RES NURS HEALTH, V32, P606, DOI 10.1002/nur.20352; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; Kim SYH, 2002, AM J GERIAT PSYCHIAT, V10, P151, DOI 10.1176/appi.ajgp.10.2.151; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Knight SJ, 2007, J PALLIAT MED, V10, P1190, DOI 10.1089/jpm.2006.0068; Koch T, 2001, SOC SCI MED, V52, P453, DOI 10.1016/S0277-9536(00)00154-4; Lo B, 2004, ARCH INTERN MED, V164, P1501, DOI 10.1001/archinte.164.14.1501; Lockhart LK, 2001, DEATH STUD, V25, P299, DOI 10.1080/07481180126279; Loewenstein G, 2005, MED DECIS MAKING, V25, P96, DOI 10.1177/0272989X04273799; LYNN J, 2001, J AM MED DIR ASSOC, V2, P305; Medvene LJ, 2007, J APPL SOC PSYCHOL, V37, P2298, DOI 10.1111/j.1559-1816.2007.00259.x; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Meier DE, 2009, J PALLIAT MED, V12, P291, DOI 10.1089/jpm.2009.9648; Meier DE, 2009, J PALLIAT MED, V12, P593, DOI 10.1089/jpm.2009.9596; Pantilat SZ, 2004, JAMA-J AM MED ASSOC, V291, P2476, DOI 10.1001/jama.291.20.2476; Patrick DL, 1997, ANN INTERN MED, V127, P509, DOI 10.7326/0003-4819-127-7-199710010-00002; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; Pearlman RA, 2005, ARCH INTERN MED, V165, P667, DOI 10.1001/archinte.165.6.667; Perkins HS, 2007, ANN INTERN MED, V147, P51, DOI 10.7326/0003-4819-147-1-200707030-00008; Prendergast TJ, 2001, CRIT CARE MED, V29, pN34, DOI 10.1097/00003246-200102001-00007; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rosenfeld KE, 2000, J GEN INTERN MED, V15, P620, DOI 10.1046/j.1525-1497.2000.06289.x; Rosenfeld KE, 1996, ARCH INTERN MED, V156, P1558, DOI 10.1001/archinte.156.14.1558; Schickedanz AD, 2009, J AM GERIATR SOC, V57, P31, DOI 10.1111/j.1532-5415.2008.02093.x; Schonwetter RS, 1996, J AM GERIATR SOC, V44, P954, DOI 10.1111/j.1532-5415.1996.tb01867.x; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; Silveira MJ, 2010, NEW ENGL J MED, V362, P1211, DOI 10.1056/NEJMsa0907901; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Skinner CS, 2009, PATIENT EDUC COUNS, V77, P90, DOI 10.1016/j.pec.2009.02.010; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Straton JB, 2004, J AM GERIATR SOC, V52, P577, DOI 10.1111/j.1532-5415.2004.52165.x; Sudore RL, 2009, JAMA-J AM MED ASSOC, V302, P1629, DOI 10.1001/jama.2009.1422; Sudore RL, 2008, J GEN INTERN MED, V23, P1854, DOI 10.1007/s11606-008-0733-7; Teno JM, 1998, J GEN INTERN MED, V13, P439, DOI 10.1046/j.1525-1497.1998.00132.x; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; Teno JM, 2007, J AM GERIATR SOC, V55, P189, DOI 10.1111/j.1532-5415.2007.01045.x; Tilden VP, 2001, NURS RES, V50, P105, DOI 10.1097/00006199-200103000-00006; Torke AM, 2007, ARCH INTERN MED, V167, P1117, DOI 10.1001/archinte.167.11.1117; Torke AM, 2010, J AM GERIATR SOC, V58, P533, DOI 10.1111/j.1532-5415.2010.02720.x; Torke AM, 2009, J GEN INTERN MED, V24, P1023, DOI 10.1007/s11606-009-1065-y; Tulsky JA, 2005, JAMA-J AM MED ASSOC, V294, P359, DOI 10.1001/jama.294.3.359; Tulsky James A, 2005, J Palliat Med, V8 Suppl 1, pS95; Ubel PA, 2005, HEALTH PSYCHOL, V24, pS57, DOI 10.1037/0278-6133.24.4.S57; Ubel PA, 2005, J EXP PSYCHOL-APPL, V11, P111, DOI 10.1037/1076-898X.11.2.111; Ubel PA, 2005, MED DECIS MAKING, V25, P95, DOI 10.1177/0272989X04273143; Vig EK, 2007, J GEN INTERN MED, V22, P1274, DOI 10.1007/s11606-007-0252-y; Vig EK, 2006, J AM GERIATR SOC, V54, P1688, DOI 10.1111/j.1532-5415.2006.00911.x; Winter L, 2003, INT J AGING HUM DEV, V56, P155, DOI 10.2190/4G9A-UT53-ENVK-CC3N; Winzelberg GS, 2005, J AM GERIATR SOC, V53, P1046, DOI 10.1111/j.1532-5415.2005.53317.x	92	551	556	0	86	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4					256	261		10.7326/0003-4819-153-4-201008170-00008	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639KF	20713793	Green Accepted			2022-12-28	WOS:000280973000006
J	Zar, FA				Zar, Fred A.			Dexamethasone did not reduce mortality or neurologic sequelae in bacterial meningitis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Zar, Fred A.] Univ Illinois, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Zar, FA (corresponding author), Univ Illinois, Chicago, IL USA.							LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; van de Beek D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub2	3	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-10	10.7326/0003-4819-153-4-201008170-02010	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713777				2022-12-28	WOS:000280973000024
J	Burre, J; Sharma, M; Tsetsenis, T; Buchman, V; Etherton, MR; Sudhof, TC				Burre, Jacqueline; Sharma, Manu; Tsetsenis, Theodoros; Buchman, Vladimir; Etherton, Mark R.; Suedhof, Thomas C.			alpha-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro	SCIENCE			English	Article							MEMBRANE-FUSION; GAMMA-SYNUCLEIN; CSP-ALPHA; NEURODEGENERATION; DEGENERATION; MICE	Presynaptic nerve terminals release neurotransmitters repeatedly, often at high frequency, and in relative isolation from neuronal cell bodies. Repeated release requires cycles of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-complex assembly and disassembly, with continuous generation of reactive SNARE-protein intermediates. Although many forms of neurodegeneration initiate presynaptically, only few pathogenic mechanisms are known, and the functions of presynaptic proteins linked to neurodegeneration, such as a-synuclein, remain unclear. Here, we show that maintenance of continuous presynaptic SNARE-complex assembly required a nonclassical chaperone activity mediated by synucleins. Specifically, a-synuclein directly bound to the SNARE-protein synaptobrevin-2/vesicle-associated membrane protein 2 (VAMP2) and promoted SNARE-complex assembly. Moreover, triple-knockout mice lacking synucleins developed age-dependent neurological impairments, exhibited decreased SNARE-complex assembly, and died prematurely. Thus, synucleins may function to sustain normal SNARE-complex assembly in a presynaptic terminal during aging.	[Burre, Jacqueline; Sharma, Manu; Tsetsenis, Theodoros; Etherton, Mark R.; Suedhof, Thomas C.] Stanford Univ, Dept Mol & Cellular Physiol, Palo Alto, CA 94304 USA; [Burre, Jacqueline; Sharma, Manu; Tsetsenis, Theodoros; Etherton, Mark R.; Suedhof, Thomas C.] Stanford Univ, Howard Hughes Med Inst, Palo Alto, CA 94304 USA; [Buchman, Vladimir] Cardiff Univ, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales	Stanford University; Howard Hughes Medical Institute; Stanford University; Cardiff University	Sudhof, TC (corresponding author), Stanford Univ, Dept Mol & Cellular Physiol, 1050 Arastradero Rd, Palo Alto, CA 94304 USA.	tcs1@stanford.edu	Buchman, Vladimir L/A-4814-2010	Buchman, Vladimir L/0000-0002-7631-8352; Tsetsenis, Theodoros/0000-0002-4642-6539	Human Frontiers Program [LT00527/2006-L, LT000135/2009-L]; Deutsche Akademie der Naturforscher Leopoldina [BMBF-LPD 9901/8-161]	Human Frontiers Program; Deutsche Akademie der Naturforscher Leopoldina	We thank S. Chandra for advice. This work was supported by postdoctoral fellowships from the Human Frontiers Program (LT00527/2006-L to M. S. and LT000135/2009-L to T. T.) and the Deutsche Akademie der Naturforscher Leopoldina (BMBF-LPD 9901/8-161 to J.B.).	Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ahmad M, 2007, FASEB J, V21, P3419, DOI 10.1096/fj.07-8379rev; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4; Garcia-Junco-Clemente P, 2010, J NEUROSCI, V30, P7377, DOI 10.1523/JNEUROSCI.0924-10.2010; Gray BC, 2009, NEUROBIOL DIS, V35, P63, DOI 10.1016/j.nbd.2009.04.001; Gupta A, 2008, ANN NEUROL, V64, pS3, DOI 10.1002/ana.21573; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kramer ML, 2007, J NEUROSCI, V27, P1405, DOI 10.1523/JNEUROSCI.4564-06.2007; Liu CW, 2005, J BIOL CHEM, V280, P22670, DOI 10.1074/jbc.M501508200; Liu SM, 2004, EMBO J, V23, P4506, DOI 10.1038/sj.emboj.7600451; Martens S, 2008, NAT REV MOL CELL BIO, V9, P543, DOI 10.1038/nrm2417; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Ninkina N, 2003, MOL CELL BIOL, V23, P8233, DOI 10.1128/MCB.23.22.8233-8245.2003; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Scheff SW, 2007, NEUROLOGY, V68, P1501, DOI 10.1212/01.wnl.0000260698.46517.8f; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sudhof TC, 2009, SCIENCE, V323, P474, DOI 10.1126/science.1161748; Takeda A, 1998, AM J PATHOL, V152, P367; Wickner W, 2008, NAT STRUCT MOL BIOL, V15, P658, DOI 10.1038/nsmb.1451	25	1115	1137	3	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	2010	329	5999					1663	1667		10.1126/science.1195227	http://dx.doi.org/10.1126/science.1195227			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653NK	20798282	Green Accepted			2022-12-28	WOS:000282098100047
J	Ji, H; Ehrlich, LIR; Seita, J; Murakami, P; Doi, A; Lindau, P; Lee, H; Aryee, MJ; Irizarry, RA; Kim, K; Rossi, DJ; Inlay, MA; Serwold, T; Karsunky, H; Ho, LN; Daley, GQ; Weissman, IL; Feinberg, AP				Ji, Hong; Ehrlich, Lauren I. R.; Seita, Jun; Murakami, Peter; Doi, Akiko; Lindau, Paul; Lee, Hwajin; Aryee, Martin J.; Irizarry, Rafael A.; Kim, Kitai; Rossi, Derrick J.; Inlay, Matthew A.; Serwold, Thomas; Karsunky, Holger; Ho, Lena; Daley, George Q.; Weissman, Irving L.; Feinberg, Andrew P.			Comprehensive methylome map of lineage commitment from haematopoietic progenitors	NATURE			English	Article							DNA METHYLTRANSFERASE; TRANSCRIPTION FACTOR; STEM; METHYLATION; CELLS; MICE; MEIS1	Epigenetic modifications must underlie lineage-specific differentiation as terminally differentiated cells express tissue-specific genes, but their DNA sequence is unchanged. Haematopoiesis provides a well-defined model to study epigenetic modifications during cell-fate decisions, as multipotent progenitors (MPPs) differentiate into progressively restricted myeloid or lymphoid progenitors. Although DNA methylation is critical for myeloid versus lymphoid differentiation, as demonstrated by the myeloerythroid bias in Dnmt1 hypomorphs(1), a comprehensive DNA methylation map of haematopoietic progenitors, or of any multipotent/oligopotent lineage, does not exist. Here we examined 4.6 million CpG sites throughout the genome for MPPs, common lymphoid progenitors (CLPs), common myeloid progenitors (CMPs), granulocyte/macrophage progenitors (GMPs), and thymocyte progenitors (DN1, DN2, DN3). Marked epigenetic plasticity accompanied both lymphoid and myeloid restriction. Myeloid commitment involved less global DNA methylation than lymphoid commitment, supported functionally by myeloid skewing of progenitors following treatment with a DNA methyltransferase inhibitor. Differential DNA methylation correlated with gene expression more strongly at CpG island shores than CpG islands. Many examples of genes and pathways not previously known to be involved in choice between lymphoid/myeloid differentiation have been identified, such as Arl4c and Jdp2. Several transcription factors, including Meis1, were methylated and silenced during differentiation, indicating a role in maintaining an undifferentiated state. Additionally, epigenetic modification of modifiers of the epigenome seems to be important in haematopoietic differentiation. Our results directly demonstrate that modulation of DNA methylation occurs during lineage-specific differentiation and defines a comprehensive map of the methylation and transcriptional changes that accompany myeloid versus lymphoid fate decisions.	[Ji, Hong; Murakami, Peter; Doi, Akiko; Lee, Hwajin; Irizarry, Rafael A.; Feinberg, Andrew P.] Johns Hopkins Univ, Sch Med, Ctr Epigenet, Baltimore, MD 21205 USA; [Ji, Hong; Murakami, Peter; Doi, Akiko; Lee, Hwajin; Irizarry, Rafael A.; Feinberg, Andrew P.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Ehrlich, Lauren I. R.; Seita, Jun; Lindau, Paul; Rossi, Derrick J.; Inlay, Matthew A.; Serwold, Thomas; Karsunky, Holger; Ho, Lena; Weissman, Irving L.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Aryee, Martin J.; Irizarry, Rafael A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA; [Aryee, Martin J.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; [Kim, Kitai; Daley, George Q.] Childrens Hosp, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Div Pediat Hematol Oncol,Stem Cell Transplantat P, Boston, MA 02115 USA; [Kim, Kitai; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Kim, Kitai; Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; [Kim, Kitai; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Kim, Kitai; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins University; Stanford University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University	Feinberg, AP (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Epigenet, 570 Rangos,725 N Wolfe St, Baltimore, MD 21205 USA.	afeinberg@jhu.edu	Feinberg, Andrew/AAY-7666-2020; Seita, Jun/AAM-1478-2020; Aryee, Martin/AAC-8113-2020; Grieshaber-Bouyer, Ricardo/R-7512-2016	Seita, Jun/0000-0002-3008-3615; Grieshaber-Bouyer, Ricardo/0000-0002-2873-5135; Ho, Lena/0000-0002-9358-621X; Ehrlich, Lauren/0000-0002-1697-1755; Ji, Hong/0000-0002-9558-0620; Feinberg, Andrew/0000-0002-8364-1991	National Institutes of Health [R37CA053458, P50HG003233, R01AI047457, R01AI047458, R00AGO29760, CA09151, F32AI058521]; Thomas and Stacey Siebel Foundation; Leukemia and Lymphoma Society; California Institute for Regenerative Medicine [T1-00001]; NATIONAL CANCER INSTITUTE [T32CA009151, R37CA054358, R01CA086065] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG003233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047458, F32AI058521, R01AI047457, T32AI007290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R00AG029760] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Thomas and Stacey Siebel Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank L. Jerabek for laboratory management, C. Richter and N. Teja for antibody production, A. Mosley, J. Dollaga and D. Escoto for animal care, E. Zuo and the Stanford PAN facility for microarray processing, and E. Briem and A. N. Allen for CHARM array processing. This investigation was supported by National Institutes of Health grants R37CA053458 and P50HG003233 (to A. P. F), R01AI047457 and R01AI047458 (to I.L.W.), and a grant from the Thomas and Stacey Siebel Foundation (to I.L.W). L.I.R.E. was supported by Special Fellow Career Development award from the Leukemia and Lymphoma Society; J. S. was supported by a fellowship from the California Institute for Regenerative Medicine (T1-00001); D.J.R. was supported by National Institutes of Health grant R00AGO29760; M.A.I. was supported by National Institutes of Health grant CA09151 and a fellowship from the California Institute for Regenerative Medicine (T1-00001); T.S. was supported by a fellowship from the National Institutes of Health (F32AI058521).	Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515; Bell JJ, 2008, NATURE, V452, P764, DOI 10.1038/nature06840; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Chadwick K, 2005, BLOOD, V105, P1905, DOI 10.1182/blood-2004-03-0881; Chao MP, 2008, COLD SH Q B, V73, P439, DOI 10.1101/sqb.2008.73.031; Claus R, 2005, SEMIN ONCOL, V32, P511, DOI 10.1053/j.seminoncol.2005.07.024; Crable SC, 2003, BLOOD, V101, P4757, DOI 10.1182/blood-2002-09-2702; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Du Y, 2005, BLOOD, V106, P3932, DOI 10.1182/blood-2005-03-1113; Engel N, 2009, EPIGENETICS-US, V4, P98, DOI 10.4161/epi.4.2.7858; Feinberg AP, 2010, P NATL ACAD SCI USA, V107, P1757, DOI 10.1073/pnas.0906183107; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gupta SK, 2006, ONCOGENE, V25, P5537, DOI 10.1038/sj.onc.1209555; Hu YL, 2009, MOL CELL BIOL, V29, P5181, DOI 10.1128/MCB.00545-09; Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jin CY, 2006, NAT STRUCT MOL BIOL, V13, P331, DOI 10.1038/nsmb1063; Kim K., 2010, NATURE, V467, P285, DOI [10.1038/nature09342, DOI 10.1038/NATURE09342]; King AG, 2002, P NATL ACAD SCI USA, V99, P4508, DOI 10.1073/pnas.072087899; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Pillay LM, 2010, DEV BIOL, V340, P306, DOI 10.1016/j.ydbio.2010.01.033; Popov VM, 2010, TRENDS ENDOCRIN MET, V21, P41, DOI 10.1016/j.tem.2009.08.002; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; Tadokoro Y, 2007, J EXP MED, V204, P715, DOI 10.1084/jem.20060750; Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016; Wada H, 2008, NATURE, V452, P768, DOI 10.1038/nature06839; Wei SM, 2009, BIOCHEM BIOPH RES CO, V384, P352, DOI 10.1016/j.bbrc.2009.04.125	30	466	475	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	2010	467	7313					338	U120		10.1038/nature09367	http://dx.doi.org/10.1038/nature09367			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20720541	Green Accepted, Green Submitted			2022-12-28	WOS:000281824900041
J	Lambrecht, BN; Hammad, H				Lambrecht, Bart N.; Hammad, Hamida			The role of dendritic and epithelial cells as master regulators of allergic airway inflammation	LANCET			English	Review							HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; RESPIRATORY SYNCYTIAL VIRUS; CD4(+) T-CELLS; IMMUNE-RESPONSES; INHALED ANTIGEN; CIGARETTE-SMOKE; LYMPH-NODES; IN-VIVO; EXPERIMENTAL ASTHMA	Lung dendritic cells bridge innate and adaptive immunity, integrating a variety of stimuli from allergens, microbial colonisation, environmental pollution, and innate immune cells into a signal for T lymphocytes of the adaptive immune system. Dendritic cells have a pivotal role in the activation of T helper (Th) 2 cells and allergic inflammation. Lung dendritic cells can also prevent harmful immune responses to innocuous inhaled antigens via induction of regulatory T cells or Th1 cells. In our Review, we discuss how understanding the biology of dendritic cells is crucial for understanding the interaction between allergens, the environment, and genetics, and focus on how dendritic cells conspire with airway epithelial cells and innate pro-Th2 cells to cause allergic sensitisation and asthma.	[Lambrecht, Bart N.; Hammad, Hamida] Ghent Univ Hosp, Dept Pulm Med, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Lambrecht, BN (corresponding author), Ghent Univ Hosp, Dept Pulm Med, Lab Immunoregulat & Mucosal Immunol, De Pintelaan 185, B-9000 Ghent, Belgium.	bart.lambrecht@ugent.be	Lambrecht, Bart N/K-2484-2014; Hammad, Hamida/J-9391-2015	Lambrecht, Bart N/0000-0003-4376-6834; Hammad, Hamida/0000-0003-3762-8603				Adam E, 2010, EUR J IMMUNOL, V40, P1995, DOI 10.1002/eji.200939913; Bachem A, 2010, J EXP MED, V207, P1273, DOI 10.1084/jem.20100348; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Beaty SR, 2007, J IMMUNOL, V178, P1882, DOI 10.4049/jimmunol.178.3.1882; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; de Haar C, 2008, J ALLERGY CLIN IMMUN, V121, P1246, DOI 10.1016/j.jaci.2008.01.010; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Didierlaurent A, 2008, J EXP MED, V205, P323, DOI 10.1084/jem.20070891; Dodge IL, 2003, J IMMUNOL, V170, P4457, DOI 10.4049/jimmunol.170.9.4457; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gangl K, 2009, ALLERGY, V64, P398, DOI 10.1111/j.1398-9995.2008.01861.x; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; GeurtsvanKessel CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007187; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jakubzick C, 2006, J IMMUNOL, V176, P3578, DOI 10.4049/jimmunol.176.6.3578; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Keber MM, 2005, J ENDOTOXIN RES, V11, P186, DOI 10.1179/096805105X35206; Kessel CHG, 2008, MUCOSAL IMMUNOL, V1, P442, DOI 10.1038/mi.2008.39; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Lagranderie M, 2010, J IMMUNOL, V184, P1062, DOI 10.4049/jimmunol.0901822; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; MacLean JA, 1996, AM J PATHOL, V148, P657; MacRedmond RE, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-84; Medoff BD, 2009, J IMMUNOL, V182, P623, DOI 10.4049/jimmunol.182.1.623; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; Monick MM, 2003, J BIOL CHEM, V278, P53035, DOI 10.1074/jbc.M308093200; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Pace E, 2008, IMMUNOLOGY, V124, P401, DOI 10.1111/j.1365-2567.2007.02788.x; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Provoost S, 2010, J IMMUNOL, V184, P426, DOI 10.4049/jimmunol.0902564; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Rangasamy T, 2010, AM J RESP CELL MOL, V43, P276, DOI 10.1165/rcmb.2008-0438OC; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Ritz SA, 2002, TRENDS IMMUNOL, V23, P396, DOI 10.1016/S1471-4906(02)02278-0; Robays LJ, 2009, MUCOSAL IMMUNOL, V2, P206, DOI 10.1038/mi.2009.7; Robays LJ, 2009, J IMMUNOL, V183, P2758, DOI 10.4049/jimmunol.0802204; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schneider E, 2009, J IMMUNOL, V183, P3591, DOI 10.4049/jimmunol.0900328; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Sung SSJ, 2006, J IMMUNOL, V176, P2161, DOI 10.4049/jimmunol.176.4.2161; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; TAZI A, 1993, J CLIN INVEST, V91, P566, DOI 10.1172/JCI116236; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Yamamoto N, 2000, EUR J IMMUNOL, V30, P316, DOI 10.1002/1521-4141(200001)30:1<316::AID-IMMU316>3.0.CO;2-0; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	95	173	182	2	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					835	843		10.1016/S0140-6736(10)61226-3	http://dx.doi.org/10.1016/S0140-6736(10)61226-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816550				2022-12-28	WOS:000281831000035
J	Cheng, G; Cox, J; Wang, PH; Krishnan, MN; Dai, JF; Qian, F; Anderson, JF; Fikrig, E				Cheng, Gong; Cox, Jonathan; Wang, Penghua; Krishnan, Manoj N.; Dai, Jianfeng; Qian, Feng; Anderson, John F.; Fikrig, Erol			A C-Type Lectin Collaborates with a CD45 Phosphatase Homolog to Facilitate West Nile Virus Infection of Mosquitoes	CELL			English	Article							MANNOSE-BINDING LECTIN; PROTEIN-TYROSINE PHOSPHATASES; DENGUE-VIRUS; DC-SIGN; DENDRITIC CELL; COMPLEMENT; RECEPTOR; IDENTIFICATION; EPIDEMIOLOGY; ACTIVATION	West Nile virus (WNV) is the most common arthropod-borne flavivirus in the United States; however, the vector ligand(s) that participate in infection are not known. We now show that an Aedes aegypti C-type lectin, mosGCTL-1, is induced by WNV, interacts with WNV in a calcium-dependent manner, and facilitates infection in vivo and in vitro. A mosquito homolog of human CD45 in A. aegypti, designated mosPTP-1, recruits mosGCTL-1 to enable viral attachment to cells and to enhance viral entry. In vivo experiments show that mosGCTL-1 and mosPTP-1 function as part of the same pathway and are critical for WNV infection of mosquitoes. A similar phenomenon was also observed in Culex quinquefasciatus, a natural vector of WNV, further demonstrating that these genes participate in WNV infection. During the mosquito blood-feeding process, WNV infection was blocked in vivo with mosGCTL-1 antibodies. A molecular understanding of flaviviral-arthropod interactions may lead to strategies to control viral dissemination in nature.	[Cheng, Gong; Cox, Jonathan; Wang, Penghua; Krishnan, Manoj N.; Dai, Jianfeng; Fikrig, Erol] Yale Univ, Sch Med, Infect Dis Sect, Dept Internal Med, New Haven, CT 06520 USA; [Qian, Feng] Yale Univ, Sch Med, Rheumatol Sect, Dept Internal Med, New Haven, CT 06520 USA; [Anderson, John F.] Connecticut Agr Expt Stn, Dept Entomol, New Haven, CT 06504 USA; [Fikrig, Erol] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Yale University; Yale University; Connecticut Agricultural Experiment Station; Howard Hughes Medical Institute	Fikrig, E (corresponding author), Yale Univ, Sch Med, Infect Dis Sect, Dept Internal Med, 333 Cedar St, New Haven, CT 06520 USA.	erol.fikrig@yale.edu	Dai, Jianfeng/ACP-1114-2022; wang, Penghua/AAL-4011-2020; Qian, Feng/F-8186-2010		National Institutes of Health [AI 50031, AI 070343]; Northeast Biodefense Center [U54-AI057158-Lipkin]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI050031, R01AI032947, U54AI057158, U01AI070343, R01AI041440] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Northeast Biodefense Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health grants AI 50031 and AI 070343. We thank Yue Zhang, Lei Liu, Lili Zhang, and Sukanya Narasimhan for help with the biochemical studies, Debbie Beck for technical assistance, and Michel Ledizet for providing the purified WNV E protein and the flaviviral E protein antibodies. G.C. is a James Hudson Brown-Alexander Brown Coxe Postdoctoral Fellow at the Yale School of Medicine. P.W. is supported by a Career Development Award from Northeast Biodefense Center (U54-AI057158-Lipkin). E.F. is an investigator with the Howard Hughes Medical Institute. G.C. and E.F. designed the experiments and wrote the manuscript; G.C. performed the majority of the experiments and analyzed data; J.C. assisted the mosquito techniques; J.F.A. provided the A. aegypti and C. quinque-fasciatus mosquitoes and helped with the mosquito feeding; J.D. and F.Q. assisted in FACS and confocal microscopy; and P.W., M.N.K. and J.D. provided suggestions for the project. All authors reviewed, critiqued, and provided comments on the text.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; [Anonymous], FLAVIVIRUSES; Arnold JN, 2006, IMMUNOL LETT, V106, P103, DOI 10.1016/j.imlet.2006.05.007; Bai FW, 2007, J VIROL, V81, P2047, DOI 10.1128/JVI.01840-06; Baldwin TA, 2001, J IMMUNOL, V167, P3829, DOI 10.4049/jimmunol.167.7.3829; Blandin S, 2004, CELL, V116, P661, DOI 10.1016/S0092-8674(04)00173-4; Brackney DE, 2008, AM J TROP MED HYG, V79, P267, DOI 10.4269/ajtmh.2008.79.267; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013; Cheng G, 2009, J INTERF CYTOK RES, V29, P461, DOI 10.1089/jir.2008.0078; Chong WP, 2005, HEPATOLOGY, V42, P1037, DOI 10.1002/hep.20891; Coleman Judy, 2007, J Vis Exp, P228, DOI 10.3791/228; Dauphin G, 2007, VACCINE, V25, P5563, DOI 10.1016/j.vaccine.2006.12.005; Davis CW, 2006, J VIROL, V80, P1290, DOI 10.1128/JVI.80.3.1290-1301.2006; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Halstead SB, 2008, ANNU REV ENTOMOL, V53, P273, DOI 10.1146/annurev.ento.53.103106.093326; Han YS, 1999, DEV COMP IMMUNOL, V23, P553, DOI 10.1016/S0145-305X(99)00047-6; Hanna SL, 2005, J VIROL, V79, P13262, DOI 10.1128/JVI.79.21.13262-13274.2005; Hayes EB, 2005, EMERG INFECT DIS, V11, P1167, DOI 10.3201/eid1108.050289a; Hubalek Z, 1999, EMERG INFECT DIS, V5, P643, DOI 10.3201/eid0505.990505; Keene KM, 2004, P NATL ACAD SCI USA, V101, P17240, DOI 10.1073/pnas.0406983101; Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003; Krishnan MN, 2008, NATURE, V455, P242, DOI 10.1038/nature07207; Krishnan MN, 2007, J VIROL, V81, P4881, DOI 10.1128/JVI.02210-06; Leis AA, 2002, NEW ENGL J MED, V347, P1279, DOI 10.1056/NEJM2002c021587; Lin CC, 2007, VIRUS RES, V124, P176, DOI 10.1016/j.virusres.2006.11.002; Lindsey NP, 2009, PEDIATRICS, V123, pE1084, DOI 10.1542/peds.2008-3278; Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017; Mustelin T, 2005, NAT REV IMMUNOL, V5, P43, DOI 10.1038/nri1530; Nene V, 2007, SCIENCE, V316, P1718, DOI 10.1126/science.1138878; Neth O, 2002, J IMMUNOL, V169, P4430, DOI 10.4049/jimmunol.169.8.4430; NIR Y, 1968, AM J EPIDEMIOL, V87, P496, DOI 10.1093/oxfordjournals.aje.a120839; Pal U, 2004, CELL, V119, P457, DOI 10.1016/j.cell.2004.10.027; PIZZI M, 1950, Hum Biol, V22, P151; Povelones M, 2009, SCIENCE, V324, P258, DOI 10.1126/science.1171400; Reisen W, 2007, PEST MANAG SCI, V63, P641, DOI 10.1002/ps.1325; Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417; Saifuddin M, 2000, J GEN VIROL, V81, P949, DOI 10.1099/0022-1317-81-4-949; Sessions OM, 2009, NATURE, V458, P1047, DOI 10.1038/nature07967; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Tanji T, 2006, BIOCHEM J, V396, P127, DOI 10.1042/BJ20051921; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Turell MJ, 2000, AM J TROP MED HYG, V62, P413, DOI 10.4269/ajtmh.2000.62.413; van der Meulen KM, 2005, ARCH VIROL, V150, P637, DOI 10.1007/s00705-004-0463-z; Vanlandingham DL, 2007, AM J TROP MED HYG, V77, P925, DOI 10.4269/ajtmh.2007.77.925; Wilson R, 1999, J IMMUNOL, V162, P1590; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	53	125	128	1	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					714	725		10.1016/j.cell.2010.07.038	http://dx.doi.org/10.1016/j.cell.2010.07.038			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20797779	Green Accepted, Bronze			2022-12-28	WOS:000281523200015
J	Tuli, K				Tuli, Karunesh			Personal View The Commonwealth games and "Delhi belly": what India can learn from LA	BRITISH MEDICAL JOURNAL			English	Editorial Material												karuneshtuli@hotmail.com							0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 1	2010	341								c4507	10.1136/bmj.c4507	http://dx.doi.org/10.1136/bmj.c4507			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647JT	20810484				2022-12-28	WOS:000281615500001
J	Mayer, L; Kazantzidis, S; Escala, A; Callegari, S				Mayer, L.; Kazantzidis, S.; Escala, A.; Callegari, S.			Direct formation of supermassive black holes via multi-scale gas inflows in galaxy mergers	NATURE			English	Article							ACCRETION; EVOLUTION; GROWTH; COLLAPSE; QUASARS; SPIN	Observations of distant quasars indicate that supermassive black holes of billions of solar masses already existed less than a billion years after the Big Bang(1). Models in which the 'seeds' of such black holes form by the collapse of primordial metal-free stars(2,3) cannot explain the rapid appearance of these supermassive black holes because gas accretion is not sufficiently efficient(4-6). Alternatively, these black holes may form by direct collapse of gas within isolated protogalaxies(7,8), but current models require idealized conditions, such as metal-free gas, to prevent cooling and star formation from consuming the gas reservoir(9-11). Here we report simulations showing that mergers between massive protogalaxies naturally produce the conditions for direct collapse into a supermassive black hole with no need to suppress cooling and star formation. Merger-driven gas inflows give rise to an unstable, massive nuclear gas disk of a few billion solar masses, which funnels more than 10(8) solar masses of gas to a sub-parsec-scale gas cloud in only 100,000 years. The cloud undergoes gravitational collapse, which eventually leads to the formation of a massive black hole. The black hole can subsequently grow to a billion solar masses on timescales of about 10(8) years by accreting gas from the surrounding disk.	[Mayer, L.; Callegari, S.] Univ Zurich, Inst Theoret Phys, CH-8057 Zurich, Switzerland; [Kazantzidis, S.] Ohio State Univ, Ctr Cosmol & Astroparticle Phys, Columbus, OH 43210 USA; [Kazantzidis, S.] Ohio State Univ, Dept Phys, Columbus, OH 43210 USA; [Kazantzidis, S.] Ohio State Univ, Dept Astron, Columbus, OH 43210 USA; [Escala, A.] Univ Chile, Dept Astron, Santiago 7550000, Chile; [Escala, A.] Stanford Univ, KIPAC, Menlo Pk, CA 94025 USA	University of Zurich; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Universidad de Chile; Stanford University	Mayer, L (corresponding author), Univ Zurich, Inst Theoret Phys, 190 Winterthurestr, CH-8057 Zurich, Switzerland.	lmayer@physik.unizh.ch	Bullock, James/K-1928-2015; Escala, Andrés/J-6618-2016	Bullock, James/0000-0003-4298-5082; Callegari, Simone/0000-0001-7598-1809	Swiss National Science Foundation (SNF); Center for Cosmology and Astro Particle Physics (CCAPP) at Ohio State University; Kavli Institute for Particle Astrophysics (KIPAC) at Stanford University	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Center for Cosmology and Astro Particle Physics (CCAPP) at Ohio State University; Kavli Institute for Particle Astrophysics (KIPAC) at Stanford University	We thank M. Colpi, R. Durisen, F. Governato, P. Madau, T. Quinn, M. Volonteri, D. Weinberg, R. Teyssier and S. White for discussions. This research has been supported by the Swiss National Science Foundation (SNF), by the Center for Cosmology and Astro Particle Physics (CCAPP) at Ohio State University, and by the Kavli Institute for Particle Astrophysics (KIPAC) at Stanford University. L.M., S.K. and S.C. acknowledge the Kavli Institute for Theoretical Physics at the University of California in Santa Barbara (KITP) for hospitality during the initial stages of this work on the "Building the Milky Way'' programme. L.M. also thanks the KITP for hospitality during the final completion of the article while on the "Exoplanets Rising'' programme. All computations were performed on the Zbox3 supercomputer at the University of Zurich and on the Brutus cluster at ETH Zurich.	Alvarez MA, 2009, ASTROPHYS J LETT, V701, pL133, DOI 10.1088/0004-637X/701/2/L133; Begelman MC, 2006, MON NOT R ASTRON SOC, V370, P289, DOI 10.1111/j.1365-2966.2006.10467.x; Bromm V, 2003, ASTROPHYS J, V596, P34, DOI 10.1086/377529; DJORGOVSKI SG, P 11 M GROS IN PRESS; EISENSTEIN DJ, 1995, ASTROPHYS J, V443, P11, DOI 10.1086/175498; Escala A, 2007, ASTROPHYS J, V671, P1264, DOI 10.1086/523092; Fan XH, 2006, NEW ASTRON REV, V50, P665, DOI 10.1016/j.newar.2006.06.077; Governato F, 2010, NATURE, V463, P203, DOI 10.1038/nature08640; Haehnelt MG, 1998, MON NOT R ASTRON SOC, V300, P817, DOI 10.1046/j.1365-8711.1998.01951.x; Haiman Z, 2004, ASTROPHYS J, V613, P36, DOI 10.1086/422910; Johnson JL, 2007, MON NOT R ASTRON SOC, V374, P1557, DOI 10.1111/j.1365-2966.2006.11275.x; Kazantzidis S, 2005, ASTROPHYS J, V623, pL67, DOI 10.1086/430139; Klessen RS, 2007, MON NOT R ASTRON SOC, V374, pL29, DOI 10.1111/j.1745-3933.2006.00258.x; Levine R, 2008, ASTROPHYS J, V678, P154, DOI 10.1086/529064; Li YL, 2007, ASTROPHYS J, V665, P187, DOI 10.1086/519297; Lodato G, 2006, MON NOT R ASTRON SOC, V371, P1813, DOI 10.1111/j.1365-2966.2006.10801.x; Madau P, 2001, ASTROPHYS J, V551, pL27, DOI 10.1086/319848; Mayer L, 2007, SCIENCE, V316, P1874, DOI 10.1126/science.1141858; Milosavljevic M, 2009, ASTROPHYS J LETT, V696, pL146, DOI 10.1088/0004-637X/696/2/L146; Mo HJ, 1998, MON NOT R ASTRON SOC, V295, P319, DOI 10.1046/j.1365-8711.1998.01227.x; Omukai K, 2008, ASTROPHYS J, V686, P801, DOI 10.1086/591636; Pelupessy FI, 2007, ASTROPHYS J, V665, P107, DOI 10.1086/519235; Shapiro SL, 2005, ASTROPHYS J, V620, P59, DOI 10.1086/427065; SHLOSMAN I, 1989, NATURE, V338, P45, DOI 10.1038/338045a0; Spaans M, 2000, ASTROPHYS J, V538, P115, DOI 10.1086/309118; Volonteri M, 2008, MON NOT R ASTRON SOC, V383, P1079, DOI 10.1111/j.1365-2966.2007.12589.x; Volonteri M, 2006, ASTROPHYS J, V650, P669, DOI 10.1086/507444; Walter F, 2004, ASTROPHYS J, V615, pL17, DOI 10.1086/426017; Wise JH, 2008, ASTROPHYS J, V682, P745, DOI 10.1086/588209	30	150	150	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2010	466	7310					1082	1084		10.1038/nature09294	http://dx.doi.org/10.1038/nature09294			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740009	Green Submitted, Green Accepted			2022-12-28	WOS:000281203600034
J	Wani, L				Wani, Lubna			Hope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												lubna-wani@ouhsc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					835	835		10.1001/jama.2010.1204	http://dx.doi.org/10.1001/jama.2010.1204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736458				2022-12-28	WOS:000281389900001
J	Olivier, N; Luengo-Oroz, MA; Duloquin, L; Faure, E; Savy, T; Veilleux, I; Solinas, X; Debarre, D; Bourgine, P; Santos, A; Peyrieras, N; Beaurepaire, E				Olivier, Nicolas; Luengo-Oroz, Miguel A.; Duloquin, Louise; Faure, Emmanuel; Savy, Thierry; Veilleux, Israel; Solinas, Xavier; Debarre, Delphine; Bourgine, Paul; Santos, Andres; Peyrieras, Nadine; Beaurepaire, Emmanuel			Cell Lineage Reconstruction of Early Zebrafish Embryos Using Label-Free Nonlinear Microscopy	SCIENCE			English	Article							3RD-HARMONIC GENERATION MICROSCOPY; 2ND-HARMONIC GENERATION; DEVELOPMENTAL BIOLOGY; HARMONIC-GENERATION; ZYGOTIC TRANSITION; ORIGIN; EMBRYOGENESIS; FLUORESCENCE	Quantifying cell behaviors in animal early embryogenesis remains a challenging issue requiring in toto imaging and automated image analysis. We designed a framework for imaging and reconstructing unstained whole zebrafish embryos for their first 10 cell division cycles and report measurements along the cell lineage with micrometer spatial resolution and minute temporal accuracy. Point-scanning multiphoton excitation optimized to preferentially probe the innermost regions of the embryo provided intrinsic signals highlighting all mitotic spindles and cell boundaries. Automated image analysis revealed the phenomenology of cell proliferation. Blastomeres continuously drift out of synchrony. After the 32-cell stage, the cell cycle lengthens according to cell radial position, leading to apparent division waves. Progressive amplification of this process is the rule, contrasting with classical descriptions of abrupt changes in the system dynamics.	[Duloquin, Louise; Peyrieras, Nadine] CNRS, Inst Neurobiol Alfred Fessard, Gif Sur Yvette, France; [Olivier, Nicolas; Veilleux, Israel; Solinas, Xavier; Debarre, Delphine; Beaurepaire, Emmanuel] Ecole Polytech, CNRS, INSERM, Lab Opt & Biosci, F-91128 Palaiseau, France; [Luengo-Oroz, Miguel A.; Santos, Andres] Univ Politecn Madrid, Madrid, Spain; [Luengo-Oroz, Miguel A.; Santos, Andres] CIBER, Biomed Res Ctr, BBN, Madrid, Spain; [Faure, Emmanuel; Savy, Thierry; Bourgine, Paul] Ecole Polytech, CNRS, Ctr Rech Epistemol Appl, F-75230 Paris, France; [Bourgine, Paul] Reseau Natl Syst Complexes, Paris, France; [Peyrieras, Nadine] Inst Syst Complexes Paris Ile de France, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Universidad Politecnica de Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Centre National de la Recherche Scientifique (CNRS)	Peyrieras, N (corresponding author), CNRS, Inst Neurobiol Alfred Fessard, Gif Sur Yvette, France.	nadine.peyrieras@inaf.cnrs-gif.fr; emmanuel.beaurepaire@polytechnique.edu	Olivier, Nicolas/AAM-4414-2021; Beaurepaire, Emmanuel/C-6343-2014; Luengo-Oroz, Miguel A/C-2245-2011; Santos, Andres/C-4012-2009	Beaurepaire, Emmanuel/0000-0002-2082-8214; Luengo-Oroz, Miguel A/0000-0002-8694-2001; Santos, Andres/0000-0001-7423-9135; savy, thierry/0000-0001-5970-3817; Olivier, Nicolas/0000-0001-9042-5456; Faure, Emmanuel/0000-0003-2787-0885; Debarre, Delphine/0000-0002-0513-6172; Peyrieras, Nadine/0000-0002-4905-6414	Direction Generale de l'Armament; Agence Nationale de la Recherche,; FP6 New Emerging Science and Technology program; Association pour le Recherche Contre le Cancer; Egide Picasso France-Spain; Fondation Louis D.; Institut de France	Direction Generale de l'Armament; Agence Nationale de la Recherche,(French National Research Agency (ANR)); FP6 New Emerging Science and Technology program; Association pour le Recherche Contre le Cancer; Egide Picasso France-Spain; Fondation Louis D.; Institut de France	We thank G. Lutfalla for pAct26H2B/mcherry, pAct26mcherry-F DNA constructs, and transgenic fish lines. We thank P. Herbomel, C. Little, J.-L. Martin, H. Myllykallio, and J.-L. Rubio for critical reading of the manuscript. This work was supported by Direction Generale de l'Armament, Agence Nationale de la Recherche, FP6 New Emerging Science and Technology program, Association pour le Recherche Contre le Cancer, Egide Picasso France-Spain, and Fondation Louis D., Institut de France. Patent application PCT/FR2010/050173 describes the combination of conformal acquisition and beam conditioning in scanning microscopy of 3D objects.	Abrams EW, 2009, CURR OPIN GENET DEV, V19, P396, DOI 10.1016/j.gde.2009.06.002; Barad Y, 1997, APPL PHYS LETT, V70, P922, DOI 10.1063/1.118442; Campagnola PJ, 2002, BIOPHYS J, V82, P493, DOI 10.1016/S0006-3495(02)75414-3; Debarre D, 2005, OPT LETT, V30, P2134, DOI 10.1364/OL.30.002134; Debarre D, 2004, OPT LETT, V29, P2881, DOI 10.1364/OL.29.002881; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; KANE DA, 1992, NATURE, V360, P735, DOI 10.1038/360735a0; KANE DA, 1993, DEVELOPMENT, V119, P447; Keller PJ, 2008, SCIENCE, V322, P1065, DOI 10.1126/science.1162493; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kwan AC, 2008, P NATL ACAD SCI USA, V105, P11370, DOI 10.1073/pnas.0805199105; Levraud JP, 2007, J IMMUNOL, V178, P4385, DOI 10.4049/jimmunol.178.7.4385; Lu XM, 2009, DEVELOPMENT, V136, P2101, DOI 10.1242/dev.034421; Mathavan S, 2005, PLOS GENET, V1, P260, DOI 10.1371/journal.pgen.0010029; McMahon A, 2008, SCIENCE, V322, P1546, DOI 10.1126/science.1167094; Muzzey D, 2009, ANNU REV CELL DEV BI, V25, P301, DOI 10.1146/annurev.cellbio.042308.113408; Oates AC, 2009, NAT REV GENET, V10, P517, DOI 10.1038/nrg2548; Oron D, 2004, J STRUCT BIOL, V147, P3, DOI 10.1016/S1047-8477(03)00125-4; Schier AF, 2007, SCIENCE, V316, P406, DOI 10.1126/science.1140693; Sun CK, 2004, J STRUCT BIOL, V147, P19, DOI 10.1016/j.jsb.2003.10.017; Tadros W, 2009, DEVELOPMENT, V136, P3033, DOI 10.1242/dev.033183; TRINKAUS JP, 1993, J EXP ZOOL, V265, P258, DOI 10.1002/jez.1402650308; Vachier C, 2005, J MATH IMAGING VIS, V22, P251, DOI 10.1007/s10851-005-4893-3; Yabe T, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000518; Zimmer C, 2006, IEEE SIGNAL PROC MAG, V23, P54, DOI 10.1109/MSP.2006.1628878; Zipfel WR, 2003, P NATL ACAD SCI USA, V100, P7075, DOI 10.1073/pnas.0832308100	27	258	264	4	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					967	971		10.1126/science.1189428	http://dx.doi.org/10.1126/science.1189428			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724640	Green Submitted			2022-12-28	WOS:000281084800041
J	van Ham, TJ; Holmberg, MA; van der Goot, AT; Teuling, E; Garcia-Arencibia, M; Kim, HE; Du, D; Thijssen, KL; Wiersma, M; Burggraaff, R; van Bergeijk, P; van Rheenen, J; van Veluw, GJ; Hofstra, RMW; Rubinsztein, DC; Nollen, EAA				van Ham, Tjakko J.; Holmberg, Mats A.; van der Goot, Annemieke T.; Teuling, Eva; Garcia-Arencibia, Moises; Kim, Hyun-eui; Du, Deguo; Thijssen, Karen L.; Wiersma, Marit; Burggraaff, Rogier; van Bergeijk, Petra; van Rheenen, Jeroen; van Veluw, G. Jerre; Hofstra, Robert M. W.; Rubinsztein, David C.; Nollen, Ellen A. A.			Identification of MOAG-4/SERF as a Regulator of Age-Related Proteotoxicity	CELL			English	Article							INCLUSION-BODY FORMATION; POLYGLUTAMINE EXPANSIONS; CAENORHABDITIS-ELEGANS; PROTEIN-DEGRADATION; CELLULAR TOXICITY; MUTANT HUNTINGTIN; AGGREGATION; NEURODEGENERATION; TRANSCRIPTION; LONGEVITY	Fibrillar protein aggregates are the major pathological hallmark of several incurable, age-related, neurodegenerative disorders. These aggregates typically contain aggregation-prone pathogenic proteins, such as amyloid-beta in Alzheimer's disease and alpha-synuclein in Parkinson's disease. It is, however, poorly understood how these aggregates are formed during cellular aging. Here we identify an evolutionarily highly conserved modifier of aggregation, MOAG-4, as a positive regulator of aggregate formation in C. elegans models for polyglutamine diseases. Inactivation of MOAG-4 suppresses the formation of compact polyglutamine aggregation intermediates that are required for aggregate formation. The role of MOAG-4 in driving aggregation extends to amyloid-beta and alpha-synuclein and is evolutionarily conserved in its human orthologs SERF1A and SERF2. MOAG-4/SERF appears to act independently from HSF-1-induced molecular chaperones, proteasomal degradation, and autophagy. Our results suggest that MOAG-4/SERF regulates age-related proteotoxicity through a previously unexplored pathway, which will open up new avenues for research on age-related, neurodegenerative diseases.	[van Ham, Tjakko J.; Holmberg, Mats A.; van der Goot, Annemieke T.; Teuling, Eva; Thijssen, Karen L.; Wiersma, Marit; Burggraaff, Rogier; van Bergeijk, Petra; van Rheenen, Jeroen; van Veluw, G. Jerre; Hofstra, Robert M. W.; Nollen, Ellen A. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands; [Garcia-Arencibia, Moises; Rubinsztein, David C.] Univ Cambridge, Dept Med Genet, Cambridge Inst Med Res, Addenbrookes Hosp, Cambridge CB2 0XY, England; [Kim, Hyun-eui] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; [Du, Deguo] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Du, Deguo] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Du, Deguo] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Groningen; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Salk Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Nollen, EAA (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	e.a.a.nollen@medgen.umcg.nl	Garcia-Arencibia, Moises/B-5538-2012; van Ham, Tjakko/W-8614-2019; Kim, Hyun-Eui/GOV-5988-2022; Garcia-Arencibia, Moises/K-9920-2013; van Ham, Tjakko/A-1989-2015; Rubinsztein, David C/C-3472-2011; van Ham, Tjakko/I-2382-2013	van Ham, Tjakko/0000-0002-2175-8713; Kim, Hyun-Eui/0000-0003-1495-1993; Garcia-Arencibia, Moises/0000-0002-1618-4487; van Ham, Tjakko/0000-0002-2175-8713; Hofstra, Robert/0000-0001-7498-3829	GUIDE; Wellcome Trust; MRC Program; NIA [P01 AG031097]; ZonMw Research Institute of the Elderly; Prinses Beatrix Fonds; de Vereniging van Huntington; Nederlandse Hersenstichting; UMCG Rosalind Franklin Fellowship; Medical Research Council [G0600194] Funding Source: researchfish; NATIONAL INSTITUTE ON AGING [P01AG031097] Funding Source: NIH RePORTER; MRC [G0600194] Funding Source: UKRI	GUIDE; Wellcome Trust(Wellcome TrustEuropean Commission); MRC Program(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); ZonMw Research Institute of the Elderly; Prinses Beatrix Fonds; de Vereniging van Huntington; Nederlandse Hersenstichting; UMCG Rosalind Franklin Fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the Caenorhabditis Genetics Center, funded by the NIH National Center for Research Resources, Rick Morimoto, Tali Gidalevitz, Chris Link, and the Mitani lab for C. elegans strains, Ronald Plasterk for advice, Lieke Geerts for assistance, Andy Dillin and Jeff Kelly for reagents and support, and Jackie Senior for editing the manuscript. We thank Klaas Sjollema from the UMCG Microscopy and Imaging Center (UMIC) and Anke Terwisscha van Scheltinga for advice, Ritsert Jansen and Cisca Wijmenga for reading the manuscript, and the anonymous reviewers for suggestions. This project was funded by a GUIDE Top Master's fellowship (to A.T.v.d.G.), a Wellcome Trust Senior Fellowship (to D.C.R.), an MRC Program Grant (to D.C.R.), NIA P01 AG031097 (A.D. and J.W.K.), the ZonMw Research Institute of the Elderly, the Prinses Beatrix Fonds, de Vereniging van Huntington, the Nederlandse Hersenstichting, and a UMCG Rosalind Franklin Fellowship (to E.A.A.N.).	Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Behrends C, 2006, MOL CELL, V23, P887, DOI 10.1016/j.molcel.2006.08.017; BRENNER S, 1974, GENETICS, V77, P71; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Cohen E, 2008, NAT REV NEUROSCI, V9, P759, DOI 10.1038/nrn2474; Cohen E, 2009, CELL, V139, P1157, DOI 10.1016/j.cell.2009.11.014; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; Garcia SM, 2007, GENE DEV, V21, P3006, DOI 10.1101/gad.1575307; Gidalevitz T, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000399; Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814; Goehler H, 2004, MOL CELL, V15, P853, DOI 10.1016/j.molcel.2004.09.016; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Jorgensen EM, 2002, NAT REV GENET, V3, P356, DOI 10.1038/nrg794; Kaganovich D, 2008, NATURE, V454, P1088, DOI 10.1038/nature07195; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kitamura A, 2006, NAT CELL BIOL, V8, P1163, DOI 10.1038/ncb1478; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Maji SK, 2009, SCIENCE, V325, P328, DOI 10.1126/science.1173155; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Nagai Y, 2007, NAT STRUCT MOL BIOL, V14, P332, DOI 10.1038/nsmb1215; Narain Y, 1999, J MED GENET, V36, P739, DOI 10.1136/jmg.36.10.739; Nollen EAA, 2001, P NATL ACAD SCI USA, V98, P12038, DOI 10.1073/pnas.201112398; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ofran Y, 2003, FEBS LETT, V544, P236, DOI 10.1016/S0014-5793(03)00456-3; Ofran Y, 2007, BIOINFORMATICS, V23, pI347, DOI 10.1093/bioinformatics/btm174; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scharf JM, 1998, NAT GENET, V20, P83, DOI 10.1038/1753; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Tam S, 2006, NAT CELL BIOL, V8, P1155, DOI 10.1038/ncb1477; Tissenbaum HA, 1998, GENETICS, V148, P703; van Ham TJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000027; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wicks SR, 2001, NAT GENET, V28, P160, DOI 10.1038/88878; Williams AJ, 2008, TRENDS NEUROSCI, V31, P521, DOI 10.1016/j.tins.2008.07.004; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zhai RG, 2008, NATURE, V452, P887, DOI 10.1038/nature06721	55	77	82	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					601	612		10.1016/j.cell.2010.07.020	http://dx.doi.org/10.1016/j.cell.2010.07.020			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723760	Bronze			2022-12-28	WOS:000281115900014
J	Lentine, KL; Schnitzler, MA; Xiao, HL; Saab, G; Salvalaggio, PR; Axelrod, D; Davis, CL; Abbott, KC; Brennan, DC				Lentine, Krista L.; Schnitzler, Mark A.; Xiao, Huiling; Saab, Georges; Salvalaggio, Paolo R.; Axelrod, David; Davis, Connie L.; Abbott, Kevin C.; Brennan, Daniel C.			Racial Variation in Medical Outcomes among Living Kidney Donors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE RENAL-DISEASE; HYPERTENSION PREVALENCE; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; TRANSPLANTATION; RATES; AWARENESS; RISK; DISPARITIES; INSURANCE	BACKGROUND Data regarding health outcomes among living kidney donors are lacking, especially among nonwhite persons. METHODS We linked identifiers from the Organ Procurement and Transplantation Network (OPTN) with administrative data of a private U. S. health insurer and performed a retrospective study of 4650 persons who had been living kidney donors from October 1987 through July 2007 and who had post-donation nephrectomy benefits with this insurer at some point from 2000 through 2007. We ascertained post-nephrectomy medical diagnoses and conditions requiring medical treatment from billing claims. Cox regression analyses with left and right censoring to account for observed periods of insurance benefits were used to estimate absolute prevalence and prevalence ratios for diagnoses after nephrectomy. We then compared prevalence patterns with those in the 2005-2006 National Health and Nutrition Examination Survey (NHANES) for the general population. RESULTS Among the donors, 76.3% were white, 13.1% black, 8.2% Hispanic, and 2.4% another race or ethnic group. The median time from donation to the end of insurance benefits was 7.7 years. After kidney donation, black donors, as compared with white donors, had an increased risk of hypertension (adjusted hazard ratio, 1.52; 95% confidence interval [CI], 1.23 to 1.88), diabetes mellitus requiring drug therapy (adjusted hazard ratio, 2.31; 95% CI, 1.33 to 3.98), and chronic kidney disease (adjusted hazard ratio, 2.32; 95% CI, 1.48 to 3.62); findings were similar for Hispanic donors. The absolute prevalence of diabetes among all donors did not exceed that in the general population, but the prevalence of hypertension exceeded NHANES estimates in some subgroups. End-stage renal disease was identified in less than 1% of donors but was more common among black donors than among white donors. CONCLUSIONS As in the general U. S. population, racial disparities in medical conditions occur among living kidney donors. Increased attention to health outcomes among demographically diverse kidney donors is needed.	[Lentine, Krista L.] St Louis Univ, Ctr Outcomes Res, Salus Ctr, Sch Med, St Louis, MO 63104 USA; [Lentine, Krista L.] St Louis Univ, Sch Med, Div Nephrol, St Louis, MO 63104 USA; [Saab, Georges; Brennan, Daniel C.] Washington Univ, Div Nephrol, Sch Med, St Louis, MO 63130 USA; [Salvalaggio, Paolo R.; Davis, Connie L.] Univ Washington, Kidney & Pancreas Transplant Program, Seattle, WA 98195 USA; [Axelrod, David] Dartmouth Hitchcock Med Ctr, Dept Surg, Hanover, NH USA; [Abbott, Kevin C.] Walter Reed Army Med Ctr, Serv Nephrol, Washington, DC 20307 USA	Saint Louis University; Saint Louis University; Washington University (WUSTL); University of Washington; University of Washington Seattle; Dartmouth College; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Lentine, KL (corresponding author), St Louis Univ, Ctr Outcomes Res, Salus Ctr, Sch Med, 4th Fl,3545 Lafayette Ave, St Louis, MO 63104 USA.	lentinek@slu.edu	Lentine, Krista/AAQ-6549-2020	Lentine, Krista/0000-0002-9423-4849; Abbott, Kevin/0000-0003-2111-7112; Axelrod, David/0000-0001-5684-0613	National Institute of Diabetes and Digestive and Kidney Diseases [K08DK073036, P30DK079333]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002886, P30DK079333, K08DK073036] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by grants (K08DK073036 and P30DK079333) from the National Institute of Diabetes and Digestive and Kidney Diseases.	Agency for Healthcare Research and Quality, CREAT VAL IND SOC ST; Boudville N, 2006, ANN INTERN MED, V145, P185, DOI 10.7326/0003-4819-145-3-200608010-00006; BRANCATI FL, 1992, JAMA-J AM MED ASSOC, V268, P3079, DOI 10.1001/jama.268.21.3079; Brown RS, 2009, AM J TRANSPLANT, V9, P31, DOI 10.1111/j.1600-6143.2008.02433.x; Carter JS, 1996, ANN INTERN MED, V125, P221, DOI 10.7326/0003-4819-125-3-199608010-00011; Centers for Disease Control and Prevention, NAT HLTH NUTR EX SUR; Cherikh WS, 2008, AM J TRANSPLANT, V8, P335; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; Cutler JA, 2008, HYPERTENSION, V52, P818, DOI 10.1161/HYPERTENSIONAHA.108.113357; Delmonico FL, 2005, TRANSPLANTATION, V79, pS53; Garg AX, 2008, TRANSPLANTATION, V86, P399, DOI 10.1097/TP.0b013e31817ba9e3; Gibney EM, 2007, TRANSPLANTATION, V84, P647, DOI 10.1097/01.tp.0000277288.78771.c2; Gore JL, 2009, AM J TRANSPLANT, V9, P1124, DOI 10.1111/j.1600-6143.2009.02620.x; Graham W, 2008, LIVING DONOR FOLLOW; HAFFNER SM, 1990, HYPERTENSION, V16, P225, DOI 10.1161/01.HYP.16.3.225; Hebert P L, 1999, Am J Med Qual, V14, P270, DOI 10.1177/106286069901400607; Herring AA, 2008, INT J HEALTH SERV, V38, P641, DOI 10.2190/HS.38.4.d; Horvat LD, 2009, KIDNEY INT, V75, P1088, DOI 10.1038/ki.2009.20; Ibrahim HN, 2009, NEW ENGL J MED, V360, P459, DOI 10.1056/NEJMoa0804883; Kasiske BL, 2003, AM J TRANSPLANT, V3, P178, DOI 10.1034/j.1600-6143.2003.00010.x; Lentine KL, 2009, CLIN J AM SOC NEPHRO, V4, P1213, DOI 10.2215/CJN.00670109; Mandelbrot DA, 2009, TRANSPLANTATION, V88, P855, DOI 10.1097/TP.0b013e3181b6dfb9; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; National Institute of Diabetes and Digestive and Kidney Diseases, 2008, US REN DAT SYST USRD; Nogueira JM, 2009, TRANSPLANTATION, V88, P1371, DOI 10.1097/TP.0b013e3181c1e156; Ommen ES, 2010, AM J TRANSPLANT, V10, P747, DOI 10.1111/j.1600-6143.2009.02994.x; Ommen ES, 2006, CLIN J AM SOC NEPHRO, V1, P885, DOI 10.2215/CJN.00840306; *ORG PROC TRANSPL, AB OPTN DAT; Organ Procurement and Transplantation Network, ORG PROC TRANSPL NET; PAPPAS G, 1990, AM J PUBLIC HEALTH, V80, P1431, DOI 10.2105/AJPH.80.12.1431; RAMIREZ E A, 1991, Ethnicity and Disease, V1, P188; Reeves-Daniel A, 2009, CLIN TRANSPLANT, V23, P39, DOI 10.1111/j.1399-0012.2008.00898.x; Segev DL, 2010, JAMA-J AM MED ASSOC, V303, P959, DOI 10.1001/jama.2010.237; Stevens LA, 2005, J AM SOC NEPHROL, V16, P2439, DOI 10.1681/ASN.2005020192; STORSLEY LJ, 2010, TRANSPLANTATION 0618; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; Textor SC, 2004, TRANSPLANTATION, V78, P276, DOI 10.1097/01.TP.0000128168.97735.B3; Wainright JL, 2009, AM J TRANSPLANT, V9, P310; Young CJ, 2000, NEW ENGL J MED, V343, P1545, DOI 10.1056/NEJM200011233432107	39	203	204	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					724	732		10.1056/NEJMoa1000950	http://dx.doi.org/10.1056/NEJMoa1000950			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20818874	Green Accepted, Green Published			2022-12-28	WOS:000280996600006
J	Arie, S				Arie, Sophie			Male circumcision Circumcision: Divided we fall	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HIV PREVENTION; UNITED-STATES; MEN; INFECTION; HEALTH					ariesophie@yahoo.co.uk						*AUSTR ASS PAED SU, 1996, GUID CIRC; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Binagwaho A, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000211; BMA, 2006, LAW ETH MAL CIRC GUI, DOI 10.1136/jme.2004.008540; Changedia SM, 2002, 14 INT AIDS C BARC S; Connolly CA, 2004, 15 INT AIDS C BANGK; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Smith DK, 2010, PUBLIC HEALTH REP, V125, P72, DOI 10.1177/00333549101250S110; Thomas AG, 2004, 15 INT AIDS C BANGK; Tobian AAR, 2010, ARCH PEDIAT ADOL MED, V164, P78, DOI 10.1001/archpediatrics.2009.232; Weiss HA, 2010, BMC UROL, V10, DOI 10.1186/1471-2490-10-2; WHO UNAIDS, 2015, MAL CIRC GLOB TRENDS; Xu F, 2007, SEX TRANSM DIS, V34, P479, DOI 10.1097/01.olq.0000253335.41841.04	14	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	2010	341								c4266	10.1136/bmj.c4266	http://dx.doi.org/10.1136/bmj.c4266			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KQ	20716601				2022-12-28	WOS:000281212500004
J	DYER, C				DYER, C			LITIGATION FOR MEDICAL ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1988	296	6628					1058	1059		10.1136/bmj.296.6628.1058	http://dx.doi.org/10.1136/bmj.296.6628.1058			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M9668	20742981	Green Published			2022-12-28	WOS:A1988M966800021
J	Alsheikh-Ali, AA; Kitsios, GD; Balk, EM; Lau, J; Ip, S				Alsheikh-Ali, Alawi A.; Kitsios, Georgios D.; Balk, Ethan M.; Lau, Joseph; Ip, Stanley			The Vulnerable Atherosclerotic Plaque: Scope of the Literature	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE CORONARY SYNDROME; OPTICAL COHERENCE TOMOGRAPHY; C-REACTIVE PROTEIN; HISTOLOGY-INTRAVASCULAR ULTRASOUND; ACUTE MYOCARDIAL-INFARCTION; MULTISLICE COMPUTED-TOMOGRAPHY; NEAR-INFRARED SPECTROSCOPY; CAROTID-ARTERY-DISEASE; FIBROUS-CAP THICKNESS; MULTIDETECTOR-ROW CT	The scope of recent literature on the concept of "vulnerable plaque" was reviewed by examining 463 abstracts of primary and review articles identified through MEDLINE (2003 to April 2010). Proposed definition criteria of vulnerable plaque included active inflammation, a thin cap with a large lipid core, endothelial denudation, fissured cap, severe stenosis, or combinations of these findings. In 242 primary studies, histopathology, biomarkers, and imaging of carotid and coronary artery plaques were evaluated for features suggestive of vulnerability. Notably, 89% of these studies were cross-sectional in design and were exclusively conducted in patients with known cardiovascular disease. None of the imaging studies documented whether the identified lesions were responsible for cardiovascular events. Cross-sectional design precludes evaluation of the predictive utility of biomarkers. Because vulnerable plaque is not an established medical diagnosis, no studies have been done that explicitly evaluate the treatment of vulnerable plaques. Few studies examined potential systemic treatments (for example, statins) to modify vulnerability features. Large prospective studies in patients with and without previous cardiovascular events during long follow-up are required to validate this concept.	[Ip, Stanley] Tufts Univ, Sch Med, Tufts Med Ctr, Boston, MA 02111 USA; [Alsheikh-Ali, Alawi A.; Ip, Stanley] Sheikh Khalifa Med City, Inst Cardiac Sci, Abu Dhabi, U Arab Emirates	Tufts Medical Center; Tufts University	Ip, S (corresponding author), Tufts Univ, Sch Med, Tufts Med Ctr, Box 63,800 Washington St, Boston, MA 02111 USA.	SIp@tuftsmedicalcenter.org	Balk, Ethan/AAJ-2547-2020	Kitsios, Georgios/0000-0002-1018-948X	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [290-02-0022]	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	By the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (contract 290-02-0022).	AIDINIAN G, 2006, VASCULAR SURG, V18, P63; Aikawa M, 2004, CARDIOVASC PATHOL, V13, P125, DOI 10.1016/S1054-8807(04)00004-3; Akabame S, 2008, CIRC J, V72, P618; Akdim F, 2007, CURR PHARM DESIGN, V13, P1003, DOI 10.2174/138161207780487548; ALSHEIKHALI AA, VULNER ABLE ATHEROSC; Altaf N, 2008, RADIOLOGY, V248, P202, DOI 10.1148/radiol.2481070300; Altaf N, 2007, J VASC SURG, V46, P31, DOI 10.1016/j.jvs.2007.02.072; Altaf N, 2007, STROKE, V38, P1633, DOI 10.1161/STROKEAHA.106.473066; Alvarez B, 2004, J VASC SURG, V40, P469, DOI 10.1016/j.jvs.2004.06.023; *AM HEART ASS, 2009, HEART DIS STROK STAT; Amano T, 2007, J AM COLL CARDIOL, V49, P1149, DOI 10.1016/j.jacc.2006.12.028; Amano T, 2008, JACC-CARDIOVASC IMAG, V1, P39, DOI 10.1016/j.jcmg.2007.09.003; Ambrose JA, 2005, AM J CARDIOL, V95, P379, DOI 10.1016/j.amjcard.2004.09.037; AMBROSE JA, 1986, J AM COLL CARDIOL, V7, P472, DOI 10.1016/S0735-1097(86)80455-7; Ambrose JA, 2008, J AM COLL CARDIOL, V51, P1539, DOI 10.1016/j.jacc.2007.12.041; Ambrose JA, 2010, AM J MED, V123, P10, DOI 10.1016/j.amjmed.2009.07.019; Angheloiu GO, 2006, ARTERIOSCL THROM VAS, V26, P1594, DOI 10.1161/01.ATV.0000225699.36212.23; Annovazzi A, 2006, EUR J NUCL MED MOL I, V33, P117, DOI 10.1007/s00259-005-1899-4; Anselmi M, 2006, ATHEROSCLEROSIS, V185, P114, DOI 10.1016/j.atherosclerosis.2005.05.020; Anzidei M, 2009, RADIOLOGY, V251, P457, DOI 10.1148/radiol.2512081197; Avanzas P, 2004, HEART, V90, P847, DOI 10.1136/hrt.2003.015826; BALDEWSING RA, 2009, J HYPERTENS, V27, P219; Barlis P, 2008, AM J CARDIOL, V102, P391, DOI 10.1016/j.amjcard.2008.03.071; Bayturan O, 2009, JACC-CARDIOVASC INTE, V2, P672, DOI 10.1016/j.jcin.2009.05.007; Beaudeux JL, 2003, ARTERIOSCL THROM VAS, V23, pE7, DOI 10.1161/01.ATV.0000047448.76485.B8; Ben-Haim S, 2006, Q J NUCL MED MOL IM, V50, P53; Bernard S, 2009, ATHEROSCLEROSIS, V203, P429, DOI 10.1016/j.atherosclerosis.2008.07.039; Bhatia V, 2003, SOUTH MED J, V96, P1142, DOI 10.1097/01.SMJ.0000089063.76530.04; Bhatnagar SK, 2003, J TROP PEDIATRICS, V49, P361, DOI 10.1093/tropej/49.6.361; Biasucci LM, 2008, ANGIOLOGY, V59, p73S, DOI 10.1177/0003319708319747; Blum A, 2008, ISR MED ASSOC J, V10, P909; Bobryshev YV, 2008, J CELL MOL MED, V12, P2073, DOI 10.1111/j.1582-4934.2008.00230.x; Bochaton-Piallat ML, 2006, CIRC RES, V98, P448, DOI 10.1161/01.RES.0000214330.15785.46; Bot PTG, 2009, STROKE, V40, P439, DOI 10.1161/STROKEAHA.108.522284; Brajovic MD, 2009, THESCIENTIFICWORLDJO, V9, P509, DOI 10.1100/tsw.2009.74; Braunwald E, 2009, J AM COLL CARDIOL, V54, P58, DOI 10.1016/j.jacc.2009.03.040; Brevetti G, 2009, VASC MED, V14, P13, DOI 10.1177/1358863X08097066; Brezinski ME, 2006, INT J CARDIOL, V107, P154, DOI 10.1016/j.ijcard.2005.07.066; Briley-Saebo KC, 2007, J MAGN RESON IMAGING, V26, P460, DOI 10.1002/jmri.20989; Brodoefel H, 2009, BRIT J RADIOL, V82, P805, DOI 10.1259/bjr/35768497; Broedl UC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004733; Broz P, 2007, TRENDS CARDIOVAS MED, V17, P190, DOI 10.1016/j.tcm.2007.05.002; Bruggink JLM, 2010, INT J CARDIOVAS IMAG, V26, P111, DOI 10.1007/s10554-009-9500-z; Burgstahler C, 2007, SEMIN THROMB HEMOST, V33, P165, DOI 10.1055/s-2007-969030; Burke AP, 2001, CIRCULATION, V103, P934; Cademartiri F, 2007, RADIOL MED, V112, P637, DOI 10.1007/s11547-007-0170-4; Cai JM, 2005, CIRCULATION, V112, P3437, DOI 10.1161/CIRCULATIONAHA.104.528174; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Caplan JD, 2006, J AM COLL CARDIOL, V47, pC92, DOI 10.1016/j.jacc.2005.12.045; Cappendijk VC, 2005, RADIOLOGY, V234, P487, DOI 10.1148/radiol.2342032101; Cappendijk VC, 2008, J MAGN RESON IMAGING, V27, P1356, DOI 10.1002/jmri.21359; Carlier Stephane, 2005, Curr Atheroscler Rep, V7, P164, DOI 10.1007/s11883-005-0040-2; Casscells W, 2003, CIRCULATION, V107, P2072, DOI 10.1161/01.CIR.0000069329.70061.68; Castillo M, 2006, ACAD RADIOL, V13, P1177, DOI 10.1016/j.acra.2006.08.002; Caussin C, 2004, AM J CARDIOL, V94, P99, DOI 10.1016/j.amjcard.2004.03.036; Cevik C, 2008, J CARDIOVASC MED, V9, P1274, DOI 10.2459/JCM.0b013e328316912f; Chalela JA, 2009, CEREBROVASC DIS, V27, P19, DOI 10.1159/000200438; Chen F, 2005, CORONARY ARTERY DIS, V16, P191, DOI 10.1097/00019501-200505000-00009; Chen JW, 2005, NEUROIMAG CLIN N AM, V15, P609, DOI 10.1016/j.nic.2005.08.005; Chen LC, 2005, ALLELOPATHY J, V15, P57; Chen WG, 2009, EUR J NUCL MED MOL I, V36, P144, DOI 10.1007/s00259-008-0947-2; Cheng C, 2009, CIRCULATION, V119, P3017, DOI 10.1161/CIRCULATIONAHA.108.808618; Choi BJ, 2008, AM J CARDIOL, V102, P988, DOI 10.1016/j.amjcard.2008.05.060; Choi SH, 2007, CURR OPIN BIOTECH, V18, P73, DOI 10.1016/j.copbio.2007.01.001; Chu BC, 2004, STROKE, V35, P1079, DOI 10.1161/01.STR.0000125856.25309.86; Cilingiroglu Mehmet, 2006, Curr Atheroscler Rep, V8, P140, DOI 10.1007/s11883-006-0051-7; Cilingiroglu M, 2009, CURR ATHEROSCLER REP, V11, P146, DOI 10.1007/s11883-009-0023-9; Cipollone F, 2004, STROKE, V35, P2253, DOI 10.1161/01.STR.0000140739.45472.9c; Cipollone F, 2005, J THROMB HAEMOST, V3, P1962, DOI 10.1111/j.1538-7836.2005.01355.x; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1665, DOI 10.1161/01.ATV.0000172632.96987.2d; Cola C, 2007, ACTA CHIR BELG, V107, P129, DOI 10.1080/00015458.2007.11680029; Coli S, 2008, J AM COLL CARDIOL, V52, P223, DOI 10.1016/j.jacc.2008.02.082; Corsten MF, 2007, CURR OPIN BIOTECH, V18, P83, DOI 10.1016/j.copbio.2007.01.008; Corti R, 2004, J THROMB THROMBOLYS, V17, P35, DOI 10.1023/B:THRO.0000036027.39353.70; Corti R, 2003, J AM COLL CARDIOL, V41, p7S, DOI 10.1016/S0735-1097(02)02833-4; Corti R, 2009, EUR HEART J, V30, P2295, DOI 10.1093/eurheartj/ehp354; Crea F, 2009, EUR HEART J, V30, P1821, DOI 10.1093/eurheartj/ehp266; Cui S, 2008, CHINESE MED J-PEKING, V121, P128, DOI 10.1097/00029330-200801020-00007; Cyrus T, 2007, J CARDIOVASC MAGN R, V9, P827, DOI 10.1080/10976640701693766; Cyrus T, 2009, J NUCL CARDIOL, V16, P466, DOI 10.1007/s12350-009-9084-y; Dandona Sonny, 2009, Curr Cardiol Rep, V11, P282; Daskalopoulou SS, 2007, CURR MED RES OPIN, V23, P659, DOI 10.1185/030079907X178829; Davies JR, 2005, J NUCL CARDIOL, V12, P234, DOI 10.1016/j.nuclcard.2005.01.008; Davies JR, 2006, J AM COLL CARDIOL, V47, pC57, DOI 10.1016/j.jacc.2005.11.049; DAVIES MJ, 1994, BRIT MED BULL, V50, P789, DOI 10.1093/oxfordjournals.bmb.a072926; De Palma R, 2006, CIRCULATION, V113, P640, DOI 10.1161/CIRCULATIONAHA.105.537712; de Weer TT, 2009, STROKE, V40, P1334, DOI 10.1161/STROKEAHA.108.538439; Di Stefano R, 2009, CURR PHARM DESIGN, V15, P1095, DOI 10.2174/138161209787846892; Diamantopoulos Leonidas, 2003, J Interv Cardiol, V16, P261, DOI 10.1034/j.1600-0854.2003.8041.x; Dickson BC, 2003, CARDIOVASC PATHOL, V12, P237, DOI 10.1016/S1054-8807(03)00072-3; Didangelos A, 2009, CURR ATHEROSCLER REP, V11, P188, DOI 10.1007/s11883-009-0030-x; Diethrich EB, 2007, J ENDOVASC THER, V14, P676, DOI 10.1583/1545-1550(2007)14[676:VHIUAO]2.0.CO;2; Ding SF, 2008, AM J MED SCI, V336, P27, DOI 10.1097/MAJ.0b013e31815b60a1; Dunmore BJ, 2007, J VASC SURG, V45, P155, DOI 10.1016/j.jvs.2006.08.072; DUNPHY MP, 2008, MOLECULAR IMAGING, V10, P121; Ehara S, 2004, CIRCULATION, V110, P3424, DOI 10.1161/01.CIR.0000148131.41425.E9; Eijgelaar WJ, 2009, THROMB HAEMOSTASIS, V102, P231, DOI 10.1160/TH09-01-0030; Elkhawad M, 2009, CARDIOL CLIN, V27, P345, DOI 10.1016/j.ccl.2008.12.006; Erbel C, 2007, BASIC RES CARDIOL, V102, P123, DOI 10.1007/s00395-006-0636-x; ESTARDA JLN, 2006, AM HEART J, V151, P1093; Estrada JLN, 2004, CORONARY ARTERY DIS, V15, P477, DOI 10.1097/00019501-200412000-00004; Fabiano S, 2008, EUR RADIOL, V18, P2912, DOI 10.1007/s00330-008-1091-x; Farooq MU, 2009, VASC MED, V14, P63, DOI 10.1177/1358863X08095153; Finet G, 2007, ARCH MAL COEUR VAISS, V100, P547; Fiotti N, 2008, INT J CARDIOL, V127, P350, DOI 10.1016/j.ijcard.2007.05.011; Fishbein MC, 2010, CARDIOVASC PATHOL, V19, P6, DOI 10.1016/j.carpath.2008.08.004; Fisher M, 2005, STROKE, V36, P253, DOI 10.1161/01.STR.0000152336.71224.21; Foin N, 2008, CURR OPIN LIPIDOL, V19, P98, DOI 10.1097/MOL.0b013e3282f41b60; Formato M, 2004, ARTERIOSCL THROM VAS, V24, P129, DOI 10.1161/01.ATV.0000104013.71118.53; Fox JJ, 2009, J NUCL MED, V50, P497, DOI 10.2967/jnumed.108.056325; Friedewald VE, 2008, AM J CARDIOL, V102, P1644, DOI 10.1016/j.amjcard.2008.09.001; Frutkin AD, 2007, EUR HEART J, V28, P1783, DOI 10.1093/eurheartj/ehm145; Fujii K, 2003, CIRCULATION, V108, P2473, DOI 10.1161/01.CIR.0000097121.95451.39; Furukado S, 2009, CEREBROVASC DIS, V27, P91, DOI 10.1159/000175767; Fuster V, 2005, J AM COLL CARDIOL, V46, P937, DOI 10.1016/j.jacc.2005.03.074; Galis ZS, 2004, CIRCULATION, V110, P244, DOI 10.1161/01.CIR.0000135195.60131.59; Gao TL, 2009, CEREBROVASC DIS, V27, P345, DOI 10.1159/000202011; Garcia BA, 2003, J VASC SURG, V38, P1018, DOI 10.1016/S0741-5214(03)00709-2; Garcia-Garcia Hector M, 2008, Expert Rev Cardiovasc Ther, V6, P209, DOI 10.1586/14779072.6.2.209; Giacconi R, 2005, MECH AGEING DEV, V126, P866, DOI 10.1016/j.mad.2005.03.007; Giannoni MF, 2009, EUR J VASC ENDOVASC, V37, P722, DOI 10.1016/j.ejvs.2008.12.028; Giannoni MF, 2009, CURR VASC PHARMACOL, V7, P180, DOI 10.2174/157016109787455626; Giattina SD, 2006, INT J CARDIOL, V107, P400, DOI 10.1016/J.IJCARD.2005.11.036; GIBSON M, 1992, AM J CARDIOL, V69, P1286, DOI 10.1016/0002-9149(92)91222-P; GILLARD JH, 2007, CEREBROVASC DIS SUPP, V24, P1; GIROUD D, 1992, AM J CARDIOL, V69, P729, DOI 10.1016/0002-9149(92)90495-K; Gossl M, 2007, MED CLIN N AM, V91, P573, DOI 10.1016/j.mcna.2007.03.004; Goldberg SL, 2008, J INVASIVE CARDIOL, V20, P640; Graebe M, 2009, EUR J VASC ENDOVASC, V37, P714, DOI 10.1016/j.ejvs.2008.11.018; Granada JF, 2004, CATHETER CARDIO INTE, V62, P364, DOI 10.1002/ccd.20059; Grogan JK, 2005, J VASC SURG, V42, P435, DOI 10.1016/j.jvs.2005.05.033; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; Halvorsen B, 2008, PROG CARDIOVASC DIS, V51, P183, DOI 10.1016/j.pcad.2008.09.001; HAMDAN A, 2007, EUR J NUCL MED MOL I, V34, pS1; Hamdan A, 2007, CATHETER CARDIO INTE, V70, P65, DOI 10.1002/ccd.21117; Haraguchi K, 2008, MINIM INVAS NEUROSUR, V51, P91, DOI 10.1055/s-2007-1022550; HARTUNG D, 2009, VEGF ANN MED, V41, P257; Hashimoto H, 2009, CEREBROVASC DIS, V28, P357, DOI 10.1159/000229554; Hatakeyama K, 2005, AM J CARDIOL, V95, P632, DOI 10.1016/j.amjcard.2004.11.012; Hazen SL, 2004, ARTERIOSCL THROM VAS, V24, P1143, DOI 10.1161/01.ATV.0000135267.82813.52; Heistad DD, 2003, NEW ENGL J MED, V349, P2285, DOI 10.1056/NEJMp038161; Heliopoulos J, 2008, ATHEROSCLEROSIS, V198, P129, DOI 10.1016/j.atherosclerosis.2007.11.036; Hellings WE, 2008, STROKE, V39, P1029, DOI 10.1161/STROKEAHA.107.496703; Hellings WE, 2007, TRENDS CARDIOVAS MED, V17, P162, DOI 10.1016/j.tcm.2007.03.006; Hennerici MG, 2004, CEREBROVASC DIS, V17, P17, DOI 10.1159/000075300; Hermus L, 2010, EUR J VASC ENDOVASC, V39, P125, DOI 10.1016/j.ejvs.2009.11.020; Higashida T, 2008, J NEUROSURG, V109, P83, DOI 10.3171/JNS/2008/109/7/0083; Hirano M, 2009, ATHEROSCLEROSIS, V203, P483, DOI 10.1016/j.atherosclerosis.2008.07.023; Hirayama A, 2009, CIRC J, V73, P718, DOI 10.1253/circj.CJ-08-0755; Honda M, 2006, NEUROSURGERY, V58, P338, DOI 10.1227/01.NEU.0000195097.31033.66; Honda O, 2004, J AM COLL CARDIOL, V43, P1177, DOI 10.1016/j.jacc.2003.09.063; Hong MK, 2007, AM J CARDIOL, V100, P953, DOI 10.1016/j.amjcard.2007.04.034; Hong YJ, 2009, CORONARY ARTERY DIS, V20, P518, DOI 10.1097/MCA.0b013e32832a196e; Hong YJ, 2009, JACC-CARDIOVASC IMAG, V2, P339, DOI 10.1016/j.jcmg.2008.10.017; Howarth SPS, 2009, EUR J RADIOL, V70, P555, DOI 10.1016/j.ejrad.2008.01.047; Hur J, 2009, J COMPUT ASSIST TOMO, V33, P186, DOI 10.1097/RCT.0b013e31817c420f; Hurks R, 2009, THROMB HAEMOSTASIS, V101, P48, DOI 10.1160/TH08-07-0488; IDENTIFYING THE, 2003, J INVASIVE CARDIOL, V15, P280; Ikuta T, 2005, INT J MOL MED, V15, P573; Inoue F, 2004, CIRC J, V68, P840, DOI 10.1253/circj.68.840; Inoue T, 2005, J AM COLL CARDIOL, V46, P239, DOI 10.1016/j.jacc.2005.04.029; Ishibashi Fumiyuki, 2006, J Interv Cardiol, V19, P17, DOI 10.1111/j.1540-8183.2006.00099.x; Ishikawa T, 2004, HEART, V90, P1206, DOI 10.1136/hrt.2003.017921; Ishikawa Y, 2008, CLIN SCI, V115, P133, DOI 10.1042/CS20070379; Isoviita PM, 2010, STROKE, V41, P389, DOI 10.1161/STROKEAHA.109.567636; Jain RK, 2007, NAT CLIN PRACT CARD, V4, P491, DOI 10.1038/ncpcardio0979; JIALAL I, 2005, J INTERV CARDIOL, V18, P375; Jiang X, 2004, CHINESE MED J-PEKING, V117, P1825; JO JA, 2006, P IEEE, V1, P2663; Kadoglou NPE, 2008, EUR J VASC ENDOVASC, V35, P661, DOI 10.1016/j.ejvs.2007.12.011; Kadoglou NPE, 2008, J VASC SURG, V47, P55, DOI 10.1016/j.jvs.2007.09.058; Kahn Jason, 2006, J Interv Cardiol, V19, P27, DOI 10.1111/j.1540-8183.2006.00100.x; Kajiwara K, 2004, CIRC J, V68, P198, DOI 10.1253/circj.68.198; Kampschulte A, 2004, CIRCULATION, V110, P3239, DOI 10.1161/01.CIR.0000147287.23741.9A; Kanai H, 2003, CIRCULATION, V107, P3018, DOI 10.1161/01.CIR.0000078633.31922.8A; Kashiwagi M, 2009, CIRC J, V73, P1291, DOI 10.1253/circj.CJ-08-0968; Katritsis DG, 2007, CORONARY ARTERY DIS, V18, P229, DOI 10.1097/MCA.0b013e328012a93d; Katritsis DG, 2009, CORONARY ARTERY DIS, V20, P199, DOI 10.1097/MCA.0b013e32832397fe; Katsargyris A, 2010, EXPERT OPIN THER TAR, V14, P1, DOI 10.1517/14728220903401294; KAVURMA MM, 2007, J INVASIVE CARDIOL, V19, P55; Kawahara I, 2007, HUM PATHOL, V38, P1378, DOI 10.1016/j.humpath.2007.02.004; Kawahara I, 2007, SURG NEUROL, V68, P60, DOI 10.1016/j.surneu.2006.09.037; Kawano T, 2008, INT J CARDIOL, V125, P74, DOI 10.1016/j.ijcard.2007.02.044; Kereiakes DJ, 2003, CIRCULATION, V107, P2076, DOI 10.1161/01.CIR.0000069942.72072.2E; Kerwin W, 2003, CIRCULATION, V107, P851, DOI 10.1161/01.CIR.0000048145.52309.31; Khan T, 2005, CARDIOLOGY, V103, P10, DOI 10.1159/000081846; Kietselaer BLJH, 2004, NEW ENGL J MED, V350, P1472, DOI 10.1056/NEJM200404013501425; Kim SH, 2009, AM J CARDIOL, V103, P1221, DOI 10.1016/j.amjcard.2009.01.015; KINGIM JM, 2005, HEART, V3, P249; Kitagawa T, 2009, JACC-CARDIOVASC IMAG, V2, P153, DOI 10.1016/j.jcmg.2008.09.015; Knollmann F, 2008, INT J CARDIOVAS IMAG, V24, P301, DOI 10.1007/s10554-007-9262-4; Knollmann FD, 2009, ACAD RADIOL, V16, P1251, DOI 10.1016/j.acra.2009.05.015; Kobayashi S, 2003, ARTERIOSCL THROM VAS, V23, P1398, DOI 10.1161/01.ATV.0000081637.36475.BC; Kock SA, 2008, J BIOMECH, V41, P1651, DOI 10.1016/j.jbiomech.2008.03.019; Konig A, 2008, NAT CLIN PRACT CARD, V5, P219, DOI 10.1038/ncpcardio1123; Koenig W, 2007, ARTERIOSCL THROM VAS, V27, P15, DOI 10.1161/01.ATV.0000251503.35795.4f; Kolodgie FD, 2004, HEART, V90, P1385, DOI 10.1136/hrt.2004.041798; Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655; Kolodgie FD, 2006, ARTERIOSCL THROM VAS, V26, P2523, DOI 10.1161/01.ATV.0000244681.72738.bc; KOPP AF, 1932, EUR J RADIOL, V1, pS32; Kotani J, 2003, CIRCULATION, V107, P2889, DOI 10.1161/01.CIR.0000072768.80031.74; Koutouzis M, 2007, ATHEROSCLEROSIS, V192, P457, DOI 10.1016/j.atherosclerosis.2007.01.035; Kovanen PT, 2005, HANDB EXP PHARM, V170, P745; Krams Rob, 2003, J Interv Cardiol, V16, P107, DOI 10.1046/j.1540-8183.2003.08021.x; Krupinski J, 2006, STROKE, V37, P1200, DOI 10.1161/01.STR.0000217386.37107.be; Krupinski J, 2007, INT J CARDIOL, V116, P174, DOI 10.1016/j.ijcard.2006.02.014; Kubo T, 2007, J AM COLL CARDIOL, V50, P933, DOI 10.1016/j.jacc.2007.04.082; Kubo T, 2010, AM J CARDIOL, V105, P318, DOI 10.1016/j.amjcard.2009.09.032; Kubo T, 2008, JACC-CARDIOVASC INTE, V1, P74, DOI 10.1016/j.jcin.2007.11.001; Kuchulakanti Pramod, 2003, Cardiovasc Radiat Med, V4, P225; KUKREJA N, 2008, NEUROLOGY, V70, P2401; Kume T, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.06.030; Kunimasa T, 2005, CIRC J, V69, P1346, DOI 10.1253/circj.69.1346; Kunte H, 2008, J VASC SURG, V47, P513, DOI 10.1016/j.jvs.2007.11.045; LABELLE EF, 2003, HEART, V89, P1262; LAKORPELA M, 2006, ANN MED, V38, P322; Lal BK, 2006, ANN VASC SURG, V20, P167, DOI 10.1007/s10016-006-9000-8; Langer H, 2007, SEMIN THROMB HEMOST, V33, P151, DOI 10.1055/s-2007-969028; Langer HF, 2008, J AM COLL CARDIOL, V52, P1, DOI 10.1016/j.jacc.2008.03.036; Lastas A, 2004, MED SCI MONITOR, V10, pCR606; LAU J, 2010, VULNERABLE PLAQUES A; Laufer EM, 2009, Q J NUCL MED MOL IM, V53, P26; Laufer EM, 2009, ARTERIOSCL THROM VAS, V29, P1031, DOI 10.1161/ATVBAHA.108.165522; Lavezzi AM, 2003, INT J CARDIOL, V92, P59, DOI 10.1016/S0167-5273(03)00055-X; Lavi S, 2009, HEART, V95, P1525, DOI 10.1136/hrt.2009.166017; Lee SG, 2004, AM HEART J, V147, P281, DOI 10.1016/j.ahj.2003.09.012; Lee WS, 2009, J KOREAN MED SCI, V24, P596, DOI 10.3346/jkms.2009.24.4.596; Lepedda AJ, 2009, ATHEROSCLEROSIS, V203, P112, DOI 10.1016/j.atherosclerosis.2008.07.001; Lerakis S, 2008, AM J MED SCI, V336, P342, DOI 10.1097/MAJ.0b013e31816c7bdf; Lerman Amir, 2005, J Invasive Cardiol, V17, P239; Levin RI, 2010, J AM COLL CARDIOL, V55, P133, DOI 10.1016/j.jacc.2009.10.010; Li W, 2009, ATHEROSCLEROSIS, V202, P92, DOI 10.1016/j.atherosclerosis.2008.03.027; Li XM, 2008, CHINESE MED J-PEKING, V121, P534, DOI 10.1097/00029330-200803020-00013; Li ZY, 2008, CIRC J, V72, P1092, DOI 10.1253/circj.72.1092; Libby P, 2005, J AM COLL CARDIOL, V45, P1600, DOI 10.1016/j.jacc.2005.02.058; Libby P, 2003, CLIN CARDIOL, V26, pI11; Lilledahl MB, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772652; Lin K, 2006, ACAD RADIOL, V13, P1180, DOI 10.1016/j.acra.2006.07.004; Lindstedt KA, 2004, CURR OPIN LIPIDOL, V15, P567, DOI 10.1097/00041433-200410000-00011; Lindstedt KA, 2007, J CELL MOL MED, V11, P739, DOI 10.1111/j.1582-4934.2007.00052.x; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; Liu F, 2006, MAGN RESON MED, V55, P659, DOI 10.1002/mrm.20814; Lombardo A, 2004, CIRCULATION, V109, P3158, DOI 10.1161/01.CIR.0000130786.28008.56; Lovett JK, 2004, CIRCULATION, V110, P2190, DOI 10.1161/01.CIR.0000144307.82502.32; Low AF, 2006, NAT CLIN PRACT CARD, V3, P154, DOI 10.1038/ncpcardio0482; LOW AF, 2009, IN VIVO, V4, P626; Lutgens E, 2003, ARTERIOSCL THROM VAS, V23, P2123, DOI 10.1161/01.ATV.0000097783.01596.E2; MacNeill BD, 2005, J NUCL CARDIOL, V12, P460, DOI 10.1016/j.nuclcard.2005.05.013; MacNeill BD, 2003, ARTERIOSCL THROM VAS, V23, P1333, DOI 10.1161/01.ATV.0000080948.08888.BF; Madjd M, 2006, J AM COLL CARDIOL, V47, pC80, DOI 10.1016/j.jacc.2005.11.050; Madjid M, 2004, ARTERIOSCL THROM VAS, V24, P1775, DOI 10.1161/01.ATV.0000142373.72662.20; MADJID M, 2004, APOPTOSIS, V66, P61; Madjid M, 2007, J NUCL CARDIOL, V14, P244, DOI 10.1016/j.nuclcard.2007.01.036; Marcu L, 2009, ATHEROSCLEROSIS, V204, P156, DOI 10.1016/j.atherosclerosis.2008.08.035; Marfella R, 2006, J AM COLL CARDIOL, V47, P2444, DOI 10.1016/j.jacc.2006.01.073; Martin RM, 2008, J CLIN ENDOCR METAB, V93, P1331, DOI 10.1210/jc.2007-2295; Maseri A, 2003, CIRCULATION, V107, P2068, DOI 10.1161/01.CIR.0000070585.48035.D1; Mattock KL, 2010, ATHEROSCLEROSIS, V208, P83, DOI 10.1016/j.atherosclerosis.2009.07.022; Mauriello A, 2005, J AM COLL CARDIOL, V45, P1585, DOI 10.1016/j.jacc.2005.01.054; Mehta SK, 2007, EUR HEART J, V28, P1283, DOI 10.1093/eurheartj/ehm112; Meijs MFL, 2009, AM J CARDIOL, V104, P305, DOI 10.1016/j.amjcard.2009.03.049; Meuwissen M, 2003, AM J MED, V114, P521, DOI 10.1016/S0002-9343(03)00078-0; Meuwissen M, 2006, J CLIN PATHOL, V59, P196, DOI 10.1136/jcp.2005.027235; Mezzetti A, 2005, LUPUS, V14, P769, DOI 10.1191/0961203305lu2218oa; Mitra AK, 2004, CAN J PHYSIOL PHARM, V82, P860, DOI 10.1139/Y04-095; Mitsumori LM, 2003, J MAGN RESON IMAGING, V17, P410, DOI 10.1002/jmri.10264; Miyagi M, 2010, NEPHROL DIAL TRANSPL, V25, P175, DOI 10.1093/ndt/gfp423; Miyamoto S, 2008, HEART, V94, P1002, DOI 10.1136/hrt.2007.121640; Miyata K, 2008, BIOCHEM BIOPH RES CO, V365, P207, DOI 10.1016/j.bbrc.2007.10.127; MOLINARI F, 2007, P IEEE ENG MED BIOL, V2007, P335; Molloy KJ, 2004, CIRCULATION, V110, P337, DOI 10.1161/01.CIR.0000135588.65188.14; Monroe VS, 2003, J AM COLL CARDIOL, V41, p23S, DOI 10.1016/S0735-1097(02)02774-2; MONTECUCCO F, 2008, INSULIN RESISTANCE, V2008; Montecucco F, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/75805; Montero I, 2006, J AM COLL CARDIOL, V47, P1369, DOI 10.1016/j.jacc.2005.10.070; Moreno Pedro R, 2003, J Interv Cardiol, V16, P243, DOI 10.1034/j.1600-0854.2003.8040.x; Moreno Pedro R, 2010, Cardiol Clin, V28, P1, DOI 10.1016/j.ccl.2009.09.008; Morioka M, 2004, SURG NEUROL, V62, P292, DOI 10.1016/j.surneu.2004.02.027; Motoyama S, 2007, J AM COLL CARDIOL, V50, P319, DOI 10.1016/j.jacc.2007.03.044; Motoyama S, 2009, J AM COLL CARDIOL, V54, P49, DOI 10.1016/j.jacc.2009.02.068; Motz JT, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2190967; Muller JE, 2006, J AM COLL CARDIOL, V47, pC2, DOI 10.1016/j.jacc.2005.12.044; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; Murashige A, 2005, J AM COLL CARDIOL, V45, P1954, DOI 10.1016/j.jacc.2004.10.080; Muscari A, 2003, EUR J VASC ENDOVASC, V26, P81, DOI 10.1053/ejvs.2002.1879; Myoishi M, 2007, CIRCULATION, V116, P1226, DOI 10.1161/CIRCULATIONAHA.106.682054; Nadkarni SK, 2009, LASER MED SCI, V24, P439, DOI 10.1007/s10103-007-0535-x; Naghavi M, 2003, CIRCULATION, V108, P1772, DOI 10.1161/01.CIR.0000087481.55887.C9; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; NAGHAVI M, 2006, AM J CARDIOL, V98, P2, DOI DOI 10.1016/J.AMJCARD.2006.03.002; NAGHAVI M, 2000, ARTERIOSCLER THROMB, V20, P1262; Nakamura Mamoo, 2004, Rev Cardiovasc Med, V5 Suppl 2, pS22; Nakamura T, 2008, J CARDIOVASC PHARM, V51, P365, DOI 10.1097/FJC.0b013e318165dcad; Nakamura Tomohiro, 2009, Clin Cardiol, V32, pE9, DOI 10.1002/clc.20471; NAQVI TZ, 2004, HEART PMID, V90, P1385; Narula J, 2008, NAT CLIN PRACT CARD, V5, pS2, DOI 10.1038/ncpcardio1247; Narula J, 2009, J NUCL CARDIOL, V16, P860, DOI 10.1007/s12350-009-9141-6; Nasu K, 2006, J AM COLL CARDIOL, V47, P2405, DOI 10.1016/j.jacc.2006.02.044; Nemirovsky D, 2003, CARDIOLOGY, V100, P160, DOI 10.1159/000074810; Newby AC, 2008, ARTERIOSCL THROM VAS, V28, P2108, DOI 10.1161/ATVBAHA.108.173898; Newby AC, 2007, TRENDS CARDIOVAS MED, V17, P253, DOI 10.1016/j.tcm.2007.09.001; Newby AC, 2006, CURR OPIN LIPIDOL, V17, P556, DOI 10.1097/01.mol.0000245262.48258.b4; Nighoghossian N, 2005, STROKE, V36, P2764, DOI 10.1161/01.STR.0000190895.51934.43; Nijmeijer R, 2008, EUR J CLIN INVEST, V38, P205, DOI 10.1111/j.1365-2362.2008.01933.x; Nilsson J, 2006, CURR OPIN INVEST DR, V7, P815; Nishibe A, 2008, PROSTAG LEUKOTR ESS, V78, P257, DOI 10.1016/j.plefa.2008.03.001; Nishihira K, 2006, EUR HEART J, V27, P1685, DOI 10.1093/eurheartj/ehl058; Nishihira K, 2008, ATHEROSCLEROSIS, V201, P360, DOI 10.1016/j.atherosclerosis.2008.03.005; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Nissen SE, 2009, JACC-CARDIOVASC IMAG, V2, P483, DOI 10.1016/j.jcmg.2008.12.015; Norja S, 2007, J CLIN PATHOL, V60, P545, DOI 10.1136/jcp.2006.038729; Ohtani T, 2005, AM HEART J, V150, P227, DOI 10.1016/j.ahj.2004.09.051; OHTANI T, 2004, AM HEART J, V147, P281; Ohtani T, 2006, J AM COLL CARDIOL, V47, P2194, DOI 10.1016/j.jacc.2006.01.064; Oikawa M, 2009, CIRC J, V73, P1765, DOI 10.1253/circj.CJ-09-0617; Okada Katsuki, 2007, J Interv Cardiol, V20, P324, DOI 10.1111/j.1540-8183.2007.00276.x; OMALLEY SM, 2005, INT C MED IM COMP CO, V8, P343; Otsuka F, 2006, J AM COLL CARDIOL, V48, P1155, DOI 10.1016/j.jacc.2006.05.054; Ozer Kerem, 2005, Curr Atheroscler Rep, V7, P121, DOI 10.1007/s11883-005-0034-0; Panayiotou A, 2008, INT ANGIOL, V27, P74; PANAYIOTOU A, 2004, CEREBROVASC DIS, V18, P160; Paoletti Rodolfo, 2003, Curr Atheroscler Rep, V5, P423, DOI 10.1007/s11883-003-0030-1; Papas TT, 2008, VASC ENDOVASC SURG, V42, P249, DOI 10.1177/1538574408314437; Papaspyridonos M, 2008, ARTERIOSCL THROM VAS, V28, P433, DOI 10.1161/ATVBAHA.107.159160; Papaspyridonos M, 2006, ARTERIOSCL THROM VAS, V26, P1837, DOI 10.1161/01.ATV.0000229695.68416.76; Parahuleva MS, 2008, ATHEROSCLEROSIS, V196, P164, DOI 10.1016/j.atherosclerosis.2007.03.042; Paramo J. A., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P195, DOI 10.2174/187153007781662558; Parthasarathy S, 2008, BBA-MOL CELL BIOL L, V1781, P221, DOI 10.1016/j.bbalip.2008.03.002; Pasterkamp G, 2007, CURR PHARM DESIGN, V13, P979, DOI 10.2174/138161207780487539; Peeters W, 2009, ARTERIOSCL THROM VAS, V29, P128, DOI 10.1161/ATVBAHA.108.173658; Pelisek J, 2009, CEREBROVASC DIS, V28, P601, DOI 10.1159/000247605; Pilarczyk K, 2008, ATHEROSCLEROSIS, V196, P333, DOI 10.1016/j.atherosclerosis.2006.10.038; Prabhudesai V, 2006, CARDIOVASC INTER RAD, V29, P1039, DOI 10.1007/s00270-005-0176-z; PRIMARY S, 2003, MED SCI, V32, P381; Pucci A, 2008, EUR J CLIN INVEST, V38, P281, DOI 10.1111/j.1365-2362.2008.01944.x; Pucci A, 2007, ATHEROSCLEROSIS, V194, P189, DOI 10.1016/j.atherosclerosis.2006.07.026; Puppini G, 2006, RADIOL MED, V111, P921, DOI 10.1007/s11547-006-0091-7; Qian JY, 2009, CHINESE MED J-PEKING, V122, P610, DOI 10.3760/cma.j.issn.0366-6999.2009.06.003; RAMAN SV, 2008, IN VIVO, V1, P49; RAMMOS G, 2007, J CARDIOL, V28, P165; Randi AM, 2003, J THROMB HAEMOST, V1, P829, DOI 10.1046/j.1538-7836.2003.00113.x; Ravnskov U, 2009, ANN CLIN LAB SCI, V39, P3; Redgrave JNE, 2006, CIRCULATION, V113, P2320, DOI 10.1161/CIRCULATIONAHA.105.589044; Reiter M, 2008, RADIOLOGY, V248, P1050, DOI 10.1148/radiol.2483071817; Ren MY, 2008, ACTA CARDIOL, V63, P615, DOI 10.2143/AC.63.5.2033230; Ribichini F, 2006, J AM COLL CARDIOL, V47, P1143, DOI 10.1016/j.jacc.2005.12.022; Riou LM, 2009, CURR MED CHEM, V16, P1499, DOI 10.2174/092986709787909596; Rivera JJ, 2009, ATHEROSCLEROSIS, V206, P451, DOI 10.1016/j.atherosclerosis.2009.05.027; Rohde Luis E P, 2003, Semin Vasc Med, V3, P347; Rudd JHF, 2005, TRENDS CARDIOVAS MED, V15, P17, DOI 10.1016/j.tcm.2004.12.001; Russell DA, 2008, BRIT J SURG, V95, P576, DOI 10.1002/bjs.6100; Russell DA, 2010, EUR J VASC ENDOVASC, V39, P134, DOI 10.1016/j.ejvs.2009.11.003; Saam T, 2007, RADIOLOGY, V244, P64, DOI 10.1148/radiol.2441051769; Saba L, 2007, AM J NEURORADIOL, V28, P1061, DOI 10.3174/ajnr.A0486; Saba L, 2007, AM J NEURORADIOL, V28, P716; Saba L, 2009, CLIN RADIOL, V64, P767, DOI 10.1016/j.crad.2009.03.009; Saba L, 2009, CEREBROVASC DIS, V27, P322, DOI 10.1159/000202008; Sadat U, 2010, J NEUROL NEUROSUR PS, V81, P286, DOI 10.1136/jnnp.2009.190363; Sadat U, 2009, NAT CLIN PRACT CARD, V6, P200, DOI 10.1038/ncpcardio1455; Saia F, 2006, J CARDIOVASC MED, V7, P21, DOI 10.2459/01.JCM.0000199783.56642.39; Saloner D, 2007, STROKE, V38, P637, DOI 10.1161/01.STR.0000254127.52214.2b; Sangiorgi G, 2006, J AM COLL CARDIOL, V47, P2201, DOI 10.1016/j.jacc.2005.11.086; Sangiorgi GM, 2007, CATHETER CARDIO INTE, V70, P203, DOI 10.1002/ccd.21134; Sano K, 2006, J AM COLL CARDIOL, V47, P734, DOI 10.1016/j.jacc.2005.09.061; Sapienza P, 2005, SURGERY, V137, P355, DOI 10.1016/j.surg.2004.10.011; Sapienza P, 2004, EUR J VASC ENDOVASC, V28, P89, DOI 10.1016/j.ejvs.2004.02.022; Sarno Giovanna, 2008, EuroIntervention, V4, P318, DOI 10.4244/EIJV4I3A58; Sarzynska-Dlugosz I, 2008, NEUROL NEUROCHIR POL, V42, P91; Sayed S, 2009, EUR J VASC ENDOVASC, V38, P20, DOI 10.1016/j.ejvs.2009.02.020; Schaar JA, 2006, J AM COLL CARDIOL, V47, pC86, DOI 10.1016/j.jacc.2006.01.035; Schaar JA, 2003, CIRCULATION, V108, P2636, DOI 10.1161/01.CIR.0000097067.96619.1F; Schaar JA, 2004, EUR HEART J, V25, P1077, DOI 10.1016/j.ehj.2004.01.002; Schaar JA, 2007, CURR PHARM DESIGN, V13, P995, DOI 10.2174/138161207780487511; Schiro BJ, 2008, J CARDIOVASC SURG, V49, P729; Schmidt C, 2003, J INTERN MED, V253, P430, DOI 10.1046/j.1365-2796.2003.01129.x; Schoenhagen Paul, 2003, Am Heart Hosp J, V1, P164; Schwartz Robert S, 2003, J Interv Cardiol, V16, P231, DOI 10.1034/j.1600-0854.2003.8025.x; Serruys PW, 2008, CIRCULATION, V118, P1172, DOI 10.1161/CIRCULATIONAHA.108.771899; Shaalan WE, 2004, J VASC SURG, V40, P262, DOI 10.1016/j.jvs.2004.04.025; Shah PK, 2003, J AM COLL CARDIOL, V41, p15S, DOI 10.1016/S0735-1097(02)02834-6; Shah PK, 2007, CURR OPIN LIPIDOL, V18, P492, DOI 10.1097/MOL.0b013e3282efa326; Shah PK, 2009, CARDIOVASC DRUG THER, V23, P31, DOI 10.1007/s10557-008-6147-2; Sharif F, 2010, CATHETER CARDIO INTE, V75, P135, DOI 10.1002/ccd.22164; Shi HR, 2008, PHYS MED BIOL, V53, P6377, DOI 10.1088/0031-9155/53/22/008; Shin Jinho, 2003, Current Vascular Pharmacology, V1, P183, DOI 10.2174/1570161033476727; Sibinga NES, 2009, J MOL CELL CARDIOL, V46, P289, DOI 10.1016/j.yjmcc.2008.11.013; Sigala F, 2003, EUR J VASC ENDOVASC, V26, P523, DOI 10.1016/S1078-5884(03)00342-3; Sipahi I, 2006, J NUCL CARDIOL, V13, P91, DOI 10.1016/j.nuclcard.2005.11.001; Slager CJ, 2005, NAT CLIN PRACT CARD, V2, P401, DOI 10.1038/ncpcardio0274; Slager CJ, 2005, NAT CLIN PRACT CARD, V2, P456, DOI 10.1038/ncpcardio0298; Smeglin Anthony, 2004, Cardiol Rev, V12, P141, DOI 10.1097/01.crd.0000105000.46909.81; SoRelle R, 2003, CIRCULATION, V108, pE9036, DOI 10.1161/01.CIR.0000098900.38396.AF; Sosnovik DE, 2009, RADIOLOGY, V251, P309, DOI 10.1148/radiol.2512090268; Stamper D, 2006, J AM COLL CARDIOL, V47, pC69, DOI 10.1016/j.jacc.2005.10.067; Staniloae Cezar S, 2003, Expert Rev Cardiovasc Ther, V1, P353, DOI 10.1586/14779072.1.3.353; Staub D, 2010, STROKE, V41, P41, DOI 10.1161/STROKEAHA.109.560342; Stefanadis Christodoulos, 2003, J Interv Cardiol, V16, P273, DOI 10.1034/j.1600-0854.2003.8043.x; Sztajzel R, 2005, SWISS MED WKLY, V135, P635; Tabas I, 2009, ANTIOXID REDOX SIGN, V11, P2333, DOI [10.1089/ars.2009.2469, 10.1089/ARS.2009.2469]; Tabas I, 2009, ANN NY ACAD SCI, V1173, pE40, DOI 10.1111/j.1749-6632.2009.04957.x; Tahara N, 2009, J NUCL MED, V50, P331, DOI 10.2967/jnumed.108.060376; Takano M, 2008, AM J CARDIOL, V101, P471, DOI 10.1016/j.amjcard.2007.09.106; Takarada S, 2009, ATHEROSCLEROSIS, V202, P491, DOI 10.1016/j.atherosclerosis.2008.05.014; Takaya N, 2006, STROKE, V37, P818, DOI 10.1161/01.STR.0000204638.91099.91; Takaya N, 2005, CIRCULATION, V111, P2768, DOI 10.1161/CIRCULATIONAHA.104.504167; Takeuchi H, 2009, ATHEROSCLEROSIS, V202, P476, DOI 10.1016/j.atherosclerosis.2008.05.052; Tan KT, 2008, INT J CARDIOL, V127, P157, DOI 10.1016/j.ijcard.2007.11.054; Tang D, 2005, ANN BIOMED ENG, V33, P1789, DOI 10.1007/s10439-005-8267-1; Tang DL, 2009, STROKE, V40, P3258, DOI 10.1161/STROKEAHA.109.558676; Tang DL, 2009, BIOMED ENG ONLINE, V8, DOI 10.1186/1475-925X-8-15; Tang TY, 2009, J AM COLL CARDIOL, V53, P2039, DOI 10.1016/j.jacc.2009.03.018; Tavora FR, 2009, BMC CARDIOVASC DISOR, V9, DOI 10.1186/1471-2261-9-27; Tearney GJ, 2003, CIRCULATION, V107, P113, DOI 10.1161/01.CIR.0000044384.41037.43; Tearney GJ, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192697; Thies F, 2003, LANCET, V361, P477, DOI 10.1016/S0140-6736(03)12468-3; Thim T, 2008, J INTERN MED, V263, P506, DOI 10.1111/j.1365-2796.2008.01947.x; Thorn EM, 2007, INT J CARDIOL, V117, P370, DOI 10.1016/j.ijcard.2006.11.001; TOUTOUZAS K, 2006, J CARDIOL, V47, P129; Toutouzas Konstantinos, 2005, J Interv Cardiol, V18, P485, DOI 10.1111/j.1540-8183.2005.00090.x; Trivedi RA, 2008, BRIT J NEUROSURG, V22, P350, DOI 10.1080/02688690802007891; Trivedi RA, 2004, NEURORADIOLOGY, V46, P738, DOI 10.1007/s00234-004-1247-6; Trivedi RA, 2004, STROKE, V35, P1631, DOI 10.1161/01.STR.0000131268.50418.b7; Trivedi RA, 2007, J NEUROSURG, V107, P536, DOI 10.3171/JNS-07/09/0536; Trivedi RA, 2006, ARTERIOSCL THROM VAS, V26, P1601, DOI 10.1161/01.ATV.0000222920.59760.df; Trostdorf F, 2005, EUR J VASC ENDOVASC, V29, P528, DOI 10.1016/j.ejvs.2004.11.012; Tuzcu EM, 2003, J AM COLL CARDIOL, V42, P1033, DOI 10.1016/S0735-1097(03)00904-5; Ueda Y, 2004, AM HEART J, V148, P333, DOI 10.1016/j.ahj.2004.03.047; Ueda Y, 2003, HERZ, V28, P501, DOI 10.1007/s00059-003-2486-8; Underhill HR, 2010, AM J NEURORADIOL, V31, P487, DOI 10.3174/ajnr.A1842; Vaina Sophia, 2005, Int J Cardiovasc Intervent, V7, P75; Valgimigli M, 2006, EUR HEART J, V27, P655, DOI 10.1093/eurheartj/ehi716; Valgimigli M, 2007, J CARDIOVASC MED, V8, P221, DOI 10.2459/01.JCM.0000263487.36993.37; van der Hoeven BL, 2006, AM J CARDIOL, V98, P309, DOI 10.1016/j.amjcard.2006.02.035; van der Wal AC, 2006, SEMIN THROMB HEMOST, V32, P40, DOI 10.1055/s-2006-933339; van Velzen JE, 2009, HEART, V95, P1990, DOI 10.1136/hrt.2009.176933; Verhoeven B, 2005, J VASC SURG, V42, P1075, DOI 10.1016/j.jvs.2005.08.009; Vicenzini Edoardo, 2009, Cerebrovasc Dis, V27 Suppl 2, P48, DOI 10.1159/000203126; Vink Aryan, 2003, J Interv Cardiol, V16, P115, DOI 10.1046/j.1540-8183.2003.08022.x; Virani SS, 2008, DIABETES OBES METAB, V10, P824, DOI 10.1111/j.1463-1326.2007.00812.x; Virmani R, 2006, J AM COLL CARDIOL, V47, pC13, DOI 10.1016/j.jacc.2005.10.065; Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18; Virmani Renu, 2003, J Interv Cardiol, V16, P267, DOI 10.1034/j.1600-0854.2003.8042.x; Waddington EI, 2003, ATHEROSCLEROSIS, V167, P111, DOI 10.1016/S0021-9150(02)00391-X; Wahlgren CM, 2009, CEREBROVASC DIS, V27, P193, DOI 10.1159/000189204; Wainstein Marco, 2007, J Invasive Cardiol, V19, P49; Waki H, 2003, CIRC J, V67, P1013, DOI 10.1253/circj.67.1013; WALLIS DE, 2008, J VASC SURG, V48, P1620; Wang HB, 2008, CHINESE MED J-PEKING, V121, P540, DOI 10.1097/00029330-200803020-00015; Wasserman EJ, 2006, MT SINAI J MED, V73, P431; Watanabe K, 2005, J AM COLL CARDIOL, V46, P2022, DOI 10.1016/j.jacc.2005.04.070; Waxman S, 2003, AM J CARDIOL, V92, P16, DOI 10.1016/S0002-9149(03)00457-0; Waxman S, 2007, J NUCL CARDIOL, V14, P719, DOI 10.1016/j.nuclcard.2007.08.001; Waxman S, 2006, CIRCULATION, V114, P2390, DOI 10.1161/CIRCULATIONAHA.105.540013; WEINTRAUB HS, 2008, AM J CARDIOL S, V101, P3; White AJ, 2009, ATHEROSCLEROSIS, V206, P179, DOI 10.1016/j.atherosclerosis.2009.02.025; Wilensky RL, 2006, J AM COLL CARDIOL, V47, pC48, DOI 10.1016/j.jacc.2005.11.048; Wilensky RL, 2008, J INTERV CARDIOL, V21, P443, DOI 10.1111/j.1540-8183.2008.00401.x; Wilensky RL, 2007, CURR OPIN CARDIOL, V22, P545, DOI 10.1097/HCO.0b013e3282f028fe; Wintermark M, 2008, AM J NEURORADIOL, V29, P875, DOI 10.3174/ajnr.A0950; World Health Organization (WHO), 2009, CARD DIS; Yamada K, 2009, CEREBROVASC DIS, V28, P417, DOI 10.1159/000235746; Yamamoto M, 2009, CIRC J, V73, P497, DOI 10.1253/circj.CJ-08-0762; Yoshida K, 2008, AM J NEURORADIOL, V29, P868, DOI 10.3174/ajnr.A1015; Young JJ, 2008, CATHETER CARDIO INTE, V71, P367, DOI 10.1002/ccd.21354; Young JJ, 2008, JACC-CARDIOVASC IMAG, V1, P649, DOI 10.1016/j.jcmg.2008.07.003; Yunoki K, 2009, EUR HEART J, V30, P1844, DOI 10.1093/eurheartj/ehp257; Zaninotto M, 2007, CLIN CHIM ACTA, V381, P14, DOI 10.1016/j.cca.2007.02.028; Zhang XW, 2006, CHINESE MED J-PEKING, V119, P1689, DOI 10.1097/00029330-200610020-00004; Zheng J, 2005, MAGNET RESON MED, V54, P1360, DOI 10.1002/mrm.20724; Zurornskis T, 2008, EUR J VASC ENDOVASC, V35, P534, DOI 10.1016/j.ejvs.2008.01.001; 2006, J AM COLL CARDIOL, V47, pC1; 2003, HARV HLTH LETT, V28, P6	472	88	95	0	31	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					387	395		10.7326/0003-4819-153-6-201009210-00272	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00272			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20713770				2022-12-28	WOS:000282043100005
J	Liu, H; Takeda, S; Kumar, R; Westergard, TD; Brown, EJ; Pandita, TK; Cheng, EHY; Hsieh, JJD				Liu, Han; Takeda, Shugaku; Kumar, Rakesh; Westergard, Todd D.; Brown, Eric J.; Pandita, Tej K.; Cheng, Emily H. -Y.; Hsieh, James J. -D.			Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint	NATURE			English	Article							CELL-CYCLE; DNA-DAMAGE; FUSION GENE; MAINTENANCE; PROTEINS; COMPLEX; ASSOCIATION; ACTIVATION; EXPRESSION; STABILITY	Cell cycle checkpoints are implemented to safeguard the genome, avoiding the accumulation of genetic errors(1,2). Checkpoint loss results in genomic instability and contributes to the evolution of cancer. Among G1-, S-, G2- and M-phase checkpoints, genetic studies indicate the role of an intact S-phase checkpoint in maintaining genome integrity(3,4). Although the basic framework of the S-phase checkpoint in multicellular organisms has been outlined, the mechanistic details remain to be elucidated. Human chromosome-11 band-q23 translocations disrupting the MLL gene lead to poor prognostic leukaemias(5-9). Here we assign MLL as a novel effector in the mammalian S-phase checkpoint network and identify checkpoint dysfunction as an underlying mechanism of MLL leukaemias. MLL is phosphorylated at serine 516 by ATR in response to genotoxic stress in the S phase, which disrupts its interaction with, and hence its degradation by, the SCFSkp2 E3 ligase, leading to its accumulation. Stabilized MLL protein accumulates on chromatin, methylates histone H3 lysine 4 at late replication origins and inhibits the loading of CDC45 to delay DNA replication. Cells deficient in MLL showed radioresistant DNA synthesis and chromatid-type genomic abnormalities, indicative of S-phase checkpoint dysfunction. Reconstitution of Mll(-/-) (Mll also known as Mll1) mouse embryonic fibroblasts with wild-type but not S516A or Delta SET mutant MLL rescues the S-phase checkpoint defects. Moreover, murine myeloid progenitor cells carrying an Mll-CBP knock-in allele that mimics human t(11;16) leukaemia show a severe radioresistant DNA synthesis phenotype. MLL fusions function as dominant negative mutants that abrogate the ATR-mediated phosphorylation/stabilization of wild-type MLL on damage to DNA, and thus compromise the S-phase checkpoint. Together, our results identify MLL as a key constituent of the mammalian DNA damage response pathway and show that deregulation of the S-phase checkpoint incurred by MLL translocations probably contributes to the pathogenesis of human MLL leukaemias.	[Liu, Han; Takeda, Shugaku; Westergard, Todd D.; Cheng, Emily H. -Y.; Hsieh, James J. -D.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Kumar, Rakesh; Pandita, Tej K.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA; [Brown, Eric J.] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	Washington University (WUSTL); University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania	Hsieh, JJD (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	jhsieh@dom.wustl.edu	Pandita, Tej K/AAM-9188-2020	Liu, Han/0000-0002-0022-1861; kumar, rakesh/0000-0002-0741-3663	American Society of Hematology [CA119008, CA129537/CA123232]; NATIONAL CANCER INSTITUTE [R01CA123232, R01CA129537, R01CA119008] Funding Source: NIH RePORTER	American Society of Hematology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank J. Y. Wang and Z. You for discussions during the inception and the completion of this study, respectively. H.L. is supported by the Scholar award of the American Society of Hematology. The Mll<SUP>+1/ex7(stop)CBP</SUP> mice were provided by S. Armstrong and the late S. Korsmeyer. This study is supported by CA119008, the Scholar award of the American Society of Hematology, the Scholar award of the American Cancer Society, to J.J.-D.H., and CA129537/CA123232, to T.K.P.	Arias EE, 2007, GENE DEV, V21, P497, DOI 10.1101/gad.1508907; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Eguchi M, 2006, GENE CHROMOSOME CANC, V45, P754, DOI 10.1002/gcc.20338; Goren A, 2008, GENE DEV, V22, P1319, DOI 10.1101/gad.468308; Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Jude CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kumar AR, 2004, BLOOD, V103, P1823, DOI 10.1182/blood-2003-07-2582; Liedtke M, 2009, BLOOD, V113, P6061, DOI 10.1182/blood-2008-12-197061; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Liu K, 2006, EMBO J, V25, P4795, DOI 10.1038/sj.emboj.7601355; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Meyer C, 2009, LEUKEMIA, V23, P1490, DOI 10.1038/leu.2009.33; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Rodriguez-Perales S, 2008, INT J HEMATOL, V87, P3, DOI 10.1007/s12185-007-0001-3; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sheu YJ, 2006, MOL CELL, V24, P101, DOI 10.1016/j.molcel.2006.07.033; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406; Theunissen JWF, 2006, METHOD ENZYMOL, V409, P251, DOI 10.1016/S0076-6879(05)09015-4; Tu HC, 2009, P NATL ACAD SCI USA, V106, P1093, DOI 10.1073/pnas.0808173106; Tyagi S, 2007, MOL CELL, V27, P107, DOI 10.1016/j.molcel.2007.05.030; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Xia ZB, 2005, P NATL ACAD SCI USA, V102, P14028, DOI 10.1073/pnas.0506464102; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	38	101	105	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	2010	467	7313					343	U126		10.1038/nature09350	http://dx.doi.org/10.1038/nature09350			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20818375	Green Accepted			2022-12-28	WOS:000281824900042
J	Busse, WW; Lemanske, RF; Gern, JE				Busse, William W.; Lemanske, Robert F., Jr.; Gern, James E.			Role of viral respiratory infections in asthma and asthma exacerbations	LANCET			English	Review							IDENTIFIED HUMAN RHINOVIRUS; SYNCYTIAL VIRUS-INFECTION; 1ST 6 YEARS; EARLY-LIFE; EPITHELIAL-CELLS; TRACT INFECTIONS; RISK; CHILDREN; ILLNESSES; RESPONSES	Viral respiratory tract infections are common and usually selflimited illnesses. For patients at risk of asthma, or with existing asthma, viral respiratory tract infections can have a profound effect on the expression of disease or loss of control. New evidence has shown that wheezing episodes early in life due to human rhinoviruses are a major risk factor for the later diagnosis of asthma at age 6 years. For those with existing asthma, exacerbations are a major cause of morbidity, can need acute care, and can, albeit rarely, result in death. Viral respiratory tract infections, predominantly those caused by human rhinoviruses, are associated with asthma exacerbations. There is also evidence that deficiencies in antiviral activity and the integrity of the airway epithelial barrier could make individuals with asthma more likely to have severe viral respiratory infections of the lower airway, and thus increase the risk of exacerbation. In view of the effect of respiratory viruses on many aspects of asthma, efforts to understand the mechanisms and risk factors by which these airway infections cause changes in airway pathophysiology are a first step towards improved treatment.	[Busse, William W.; Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA; [Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin Hosp, K4-910 CSC,MC 9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu			Novartis; AstraZeneca; GlaxoSmithKline; MedImmune; Ception; MAP; Gray Consulting; Smith Research; Quintiles; Scienomics; Genentech; Pharmaxis; Merck Inc; NIAID/NIH [HHSN272200900052C, R01 HL097134]; NIH [R01 HL097134, P01 HL070831, U10 HL064305, U10 HL074212, U10 HL098090, U19 AI070503]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097134, U10HL098090, P01HL070831, U10HL074212, U10HL064305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503] Funding Source: NIH RePORTER	Novartis(Novartis); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Ception; MAP; Gray Consulting; Smith Research; Quintiles; Scienomics; Genentech(Roche HoldingGenentech); Pharmaxis; Merck Inc(Merck & Company); NIAID/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	WWB has provided consultant and advisory board services to Altair, Amgen, Centocor, GlaxoSmithKline, Merck, Pfizer, Wyeth, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim, Novartis, and TEVA; honoraria from Merck; and grant support from Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, and Ception. RFL has received consulting fees from MAP, Gray Consulting, Smith Research, Quintiles, Scienomics, R C Horowitz, Merck, AstraZeneca, Novartis; honoraria from Medicus Group, Merck, AstraZeneca; and grant support from Genentech and Pharmaxis. JEG has provided consultant and advisory board services to GlaxoSmithKline, Centocor, 3V Biosciences, Biota Inc, Synairgen, and Boehringer Ingelheim; has stock options for 3V BioSciences and EraGen Biosciences; and received grant support from Merck Inc and AstraZeneca.; WWB received funding from NIAID/NIH grant HHSN272200900052C. RFL received grant support from NIH grants P01 HL070831, U10 H L064305, U10 H L074212, U10 HL098090, and R01 HL097134. JEG received research support from NIH grants U19 AI070503, P01 HL070831, NIAID/NIH HHSN272200900052C, and R01 HL097134,	Benoit LA, 2010, ANN NY ACAD SCI, V1183, P195, DOI 10.1111/j.1749-6632.2009.05136.x; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Brooks GD, 2003, AM J RESP CRIT CARE, V168, P1091, DOI 10.1164/rccm.200306-737OC; Calvo C, 2007, PEDIATR INFECT DIS J, V26, P904, DOI 10.1097/INF.0b013e31812e52e6; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Cheuk DKL, 2007, PEDIATR INFECT DIS J, V26, P995, DOI 10.1097/INF.0b013e3181586b63; COME JM, 2002, LANCET, V359, P831; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; DeMore JP, 2009, J ALLERGY CLIN IMMUN, V124, P245, DOI 10.1016/j.jaci.2009.05.030; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; GAMA RE, 1989, J MED VIROL, V28, P73, DOI 10.1002/jmv.1890280204; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Hansbro NG, 2008, PHARMACOL THERAPEUT, V117, P313, DOI 10.1016/j.pharmthera.2007.11.002; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; HORN MEC, 1973, CHEST              S, V63, P44; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; Jin Y, 2009, J CLIN MICROBIOL, V47, P2895, DOI 10.1128/JCM.00745-09; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816; Kistler AL, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-40; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lachowicz-Scroggins ME, 2010, AM J RESP CELL MOL, V43, P652, DOI 10.1165/rcmb.2009-0244OC; Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012; McErlean P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001847; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Papadopoulos NG, 2002, CLIN EXP ALLERGY, V32, P537, DOI 10.1046/j.0954-7894.2002.01313.x; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; Renwick N, 2007, J INFECT DIS, V196, P1754, DOI 10.1086/524312; SAKAMOTO M, 1984, J IMMUNOL, V132, P2614; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; Tapparel C, 2009, J CLIN VIROL, V45, P157, DOI 10.1016/j.jcv.2009.03.014; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Thompson EE, 2007, J ALLERGY CLIN IMMUN, V119, P1423, DOI 10.1016/j.jaci.2007.03.029; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; Venarske DL, 2006, J INFECT DIS, V193, P1536, DOI 10.1086/503809; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	74	497	514	0	64	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					826	834		10.1016/S0140-6736(10)61380-3	http://dx.doi.org/10.1016/S0140-6736(10)61380-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816549	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000281831000034
J	Lenhardt, JM; Ong, MT; Choe, R; Evenhuis, CR; Martinez, TJ; Craig, SL				Lenhardt, Jeremy M.; Ong, Mitchell T.; Choe, Robert; Evenhuis, Christian R.; Martinez, Todd J.; Craig, Stephen L.			Trapping a Diradical Transition State by Mechanochemical Polymer Extension	SCIENCE			English	Article							MOLECULE FORCE SPECTROSCOPY; MECHANICAL ACTIVATION; BROWNIAN RATCHETS; COVALENT BONDS; STEREOMUTATION; STABILIZATION; PREFERENCE; PATHWAYS; SCISSION	Transition state structures are central to the rates and outcomes of chemical reactions, but their fleeting existence often leaves their properties to be inferred rather than observed. By treating polybutadiene with a difluorocarbene source, we embedded gem-difluorocyclopropanes (gDFCs) along the polymer backbone. We report that mechanochemical activation of the polymer under tension opens the gDFCs and traps a 1,3-diradical that is formally a transition state in their stress-free electrocyclic isomerization. The trapped diradical lives long enough that we can observe its noncanonical participation in bimolecular addition reactions. Furthermore, the application of a transient tensile force induces a net isomerization of the trans-gDFC into its less-stable cis isomer, leading to the counterintuitive result that the gDFC contracts in response to a transient force of extension.	[Ong, Mitchell T.; Evenhuis, Christian R.; Martinez, Todd J.] Stanford Univ, Dept Chem, Stanford, CA 94305 USA; [Lenhardt, Jeremy M.; Choe, Robert; Craig, Stephen L.] Duke Univ, Dept Chem, Durham, NC 27708 USA	Stanford University; Duke University	Martinez, TJ (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	todd.martinez@stanford.edu; stephen.craig@duke.edu	Martinez, Todd/HDN-6985-2022; Craig, Stephen/AAP-6717-2020; Martinez, Todd J/F-4306-2010; Craig, Stephen L/D-3484-2011	Craig, Stephen/0000-0002-8810-0369; Martinez, Todd J/0000-0002-4798-8947; Craig, Stephen L/0000-0002-8810-0369; Lenhardt, Jeremy/0000-0003-0643-9543; Evenhuis, Christian/0000-0001-9903-7716	U.S. Army Research Laboratory; Army Research Office [W911NF-07-1-0409]; American Chemical Society Division of Organic Chemistry Schering-Plough	U.S. Army Research Laboratory(United States Department of DefenseUS Army Research Laboratory (ARL)); Army Research Office; American Chemical Society Division of Organic Chemistry Schering-Plough	This material is based on work supported by the U.S. Army Research Laboratory and the Army Research Office under grant number W911NF-07-1-0409. J.M.L. is supported by the American Chemical Society Division of Organic Chemistry Schering-Plough Fellowship.	Adam W, 1998, J AM CHEM SOC, V120, P593, DOI 10.1021/ja972977i; Ainavarapu SRK, 2008, J AM CHEM SOC, V130, P6479, DOI 10.1021/ja800180u; Beyer MK, 2005, CHEM REV, V105, P2921, DOI 10.1021/cr030697h; Beyer MK, 2000, J CHEM PHYS, V112, P7307, DOI 10.1063/1.481330; Davis DA, 2009, NATURE, V459, P68, DOI 10.1038/nature07970; Dolbier WR, 2003, CHEM REV, V103, P1071, DOI 10.1021/cr010023b; Dong VM, 2006, J AM CHEM SOC, V128, P14464, DOI 10.1021/ja0657915; GETTY SJ, 1994, J AM CHEM SOC, V116, P1521, DOI 10.1021/ja00083a041; Henkelman G, 2000, J CHEM PHYS, V113, P9901, DOI 10.1063/1.1329672; Hickenboth CR, 2007, NATURE, V446, P423, DOI 10.1038/nature05681; Iwasawa T, 2007, SCIENCE, V317, P493, DOI 10.1126/science.1143272; Kersey FR, 2006, J AM CHEM SOC, V128, P3886, DOI 10.1021/ja058516b; Kucharski TJ, 2009, ANGEW CHEM INT EDIT, V48, P7040, DOI 10.1002/anie.200901511; Kuijpers MWA, 2004, POLYMER, V45, P6461, DOI 10.1016/j.polymer.2004.06.051; Lenhardt JM, 2009, J AM CHEM SOC, V131, P10818, DOI 10.1021/ja9036548; Mal P, 2009, SCIENCE, V324, P1697, DOI 10.1126/science.1175313; Matthias S, 2003, NATURE, V424, P53, DOI 10.1038/nature01736; Neumark DM, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2216709; Ong MT, 2009, J AM CHEM SOC, V131, P6377, DOI 10.1021/ja8095834; Paik DH, 2004, ANGEW CHEM INT EDIT, V43, P2830, DOI 10.1002/anie.200453962; Piermattei A, 2009, NAT CHEM, V1, P133, DOI [10.1038/NCHEM.167, 10.1038/nchem.167]; Ribas-Arino J, 2009, ANGEW CHEM INT EDIT, V48, P4190, DOI 10.1002/anie.200900673; Roberts ST, 2009, P NATL ACAD SCI USA, V106, P15154, DOI 10.1073/pnas.0901571106; Roos B.O., 1987, ADV CHEM PHYS, V69, P399, DOI DOI 10.1002/9780470142943.CH7; Roos BO, 1999, ACCOUNTS CHEM RES, V32, P137, DOI 10.1021/ar960091y; Sheiko SS, 2006, NATURE, V440, P191, DOI 10.1038/nature04576; Sobek J, 2001, J AM CHEM SOC, V123, P2849, DOI 10.1021/ja0036460; Tian F, 1998, J AM CHEM SOC, V120, P6187, DOI 10.1021/ja980969b; van Oudenaarden A, 1999, SCIENCE, V285, P1046, DOI 10.1126/science.285.5430.1046; Wiggins KM, 2010, J AM CHEM SOC, V132, P3256, DOI 10.1021/ja910716s; Yang QZ, 2009, NAT NANOTECHNOL, V4, P302, DOI [10.1038/NNANO.2009.55, 10.1038/nnano.2009.55]	31	217	217	3	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1057	1060		10.1126/science.1193412	http://dx.doi.org/10.1126/science.1193412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798315				2022-12-28	WOS:000281253500035
J	Grayson, M				Grayson, Michelle			PARKINSON'S DISEASE	NATURE			English	Editorial Material																			0	7	8	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					S1	S1		10.1038/466S2a	http://dx.doi.org/10.1038/466S2a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739929	Bronze			2022-12-28	WOS:000281203600057
J	Laiteerapong, N; Huang, ES				Laiteerapong, Neda; Huang, Elbert S.			Health Care Reform and Chronic Diseases Anticipating the Health Consequences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							10-YEAR FOLLOW-UP; MEDICARE BENEFICIARIES; ACCESS; ADULTS		[Laiteerapong, Neda; Huang, Elbert S.] Univ Chicago, Gen Internal Med Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	Laiteerapong, N (corresponding author), Univ Chicago, Gen Internal Med Sect, Dept Med, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.	nlaiteer@medicine.bsd.uchicago.edu	Laiteerapong, Neda/ABC-5566-2021; Laiteerapong, Neda/AAO-2596-2020	Laiteerapong, Neda/0000-0003-0124-4325; 	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK089973, P60DK020595] Funding Source: NIH RePORTER; AHRQ HHS [T32HS000084] Funding Source: Medline; NIDDK NIH HHS [F32DK089973, F32 DK089973, P60 DK20595] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; HOFFMAN C, 2009, PUBLICATION HJ KAIS; Hoffman C, 2008, HEALTH AFFAIR, V27, pW340, DOI 10.1377/hlthaff.27.5.w340; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Paez KA, 2009, HEALTH AFFAIR, V28, P15, DOI 10.1377/hlthaff.28.1.15; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Thorpe KE, 2006, HEALTH AFFAIR, V25, pW378, DOI 10.1377/hlthaff.25.w378; Weissman JS, 2008, J HEALTH CARE POOR U, V19, P307, DOI 10.1353/hpu.2008.0021	9	9	9	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					899	900		10.1001/jama.2010.1209	http://dx.doi.org/10.1001/jama.2010.1209			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	644OY	20736475				2022-12-28	WOS:000281389900029
J	Davies, P				Davies, Peter			Health White Paper New kids on the block	BRITISH MEDICAL JOURNAL			English	Editorial Material												petergdavies@ntlworld.com						Department of Health, 2002, GROW CAP NEW ROL EXT; *GEN HEALTHC GROUP, 2010, UK HEALTHC DOES IT N; Manning K, 2010, LIBERATING NHS NEXT	3	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 24	2010	341								c4421	10.1136/bmj.c4421	http://dx.doi.org/10.1136/bmj.c4421			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IG	20736273				2022-12-28	WOS:000281445900017
J	Larson, HJ; Brocard, P; Garnett, G				Larson, Heidi J.; Brocard, Pauline; Garnett, Geoffrey			The India HPV-vaccine suspension	LANCET			English	Editorial Material									[Larson, Heidi J.; Brocard, Pauline; Garnett, Geoffrey] Univ London Imperial Coll Sci Technol & Med, Inst Global Hlth, London SW7 1NA, England	Imperial College London	Larson, HJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Global Hlth, London SW7 1NA, England.	h.larson@imperial.ac.uk	Garnett, Geoffrey P/A-9312-2008; Larson, Heidi J./N-1018-2017	Larson, Heidi J./0000-0002-8477-7583				Agosti JM, 2007, NEW ENGL J MED, V356, P1908, DOI 10.1056/NEJMp078053; Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987; Ramanathan Mala, 2010, Indian J Med Ethics, V7, P43; *SAH WOM RES CTR S, 2009, WOM ORG OPP HPV VACC; *SAM RES GROUP WOM, 2009, CONC HPV VACC MEM HL; *SAM RES GROUP WOM, 2010, MEM HLTH MIN WORLD H; SINHA K, 2010, TIMES INDIA     0409; THACKER T, 2010, MINISTRY ADMITS LAPS; 2010, UPDATE PATHS HPV VAC; 2010, TIMES INDIA     0422; 2010, GLAXOSMITHKLINE RESP	11	60	61	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 21	2010	376	9741					572	573		10.1016/S0140-6736(10)60881-1	http://dx.doi.org/10.1016/S0140-6736(10)60881-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	643PB	20728739				2022-12-28	WOS:000281309100007
J	Curto, AG; Volpe, G; Taminiau, TH; Kreuzer, MP; Quidant, R; van Hulst, NF				Curto, Alberto G.; Volpe, Giorgio; Taminiau, Tim H.; Kreuzer, Mark P.; Quidant, Romain; van Hulst, Niek F.			Unidirectional Emission of a Quantum Dot Coupled to a Nanoantenna	SCIENCE			English	Article							SINGLE-MOLECULE FLUORESCENCE; YAGI-UDA ANTENNA; LIGHT; EMITTERS; PATTERN	Nanoscale quantum emitters are key elements in quantum optics and sensing. However, efficient optical excitation and detection of such emitters involves large solid angles because their interaction with freely propagating light is omnidirectional. Here, we present unidirectional emission of a single emitter by coupling to a nanofabricated Yagi-Uda antenna. A quantum dot is placed in the near field of the antenna so that it drives the resonant feed element of the antenna. The resulting quantum-dot luminescence is strongly polarized and highly directed into a narrow forward angular cone. The directionality of the quantum dot can be controlled by tuning the antenna dimensions. Our results show the potential of optical antennas to communicate energy to, from, and between nano-emitters.	[Curto, Alberto G.; Volpe, Giorgio; Taminiau, Tim H.; Kreuzer, Mark P.; Quidant, Romain; van Hulst, Niek F.] ICFO, Castelldefels 08860, Barcelona, Spain; [Quidant, Romain; van Hulst, Niek F.] ICREA, Barcelona 08015, Spain	Barcelona Institute of Science & Technology; Universitat Politecnica de Catalunya; Institut de Ciencies Fotoniques (ICFO); ICREA	van Hulst, NF (corresponding author), ICFO, Mediterranean Technol Pk, Castelldefels 08860, Barcelona, Spain.	niek.vanhulst@icfo.es	Taminiau, Tim Hugo H/A-8094-2008; van Hulst, Niek/J-2121-2012; Volpe, Giorgio/E-9162-2010; Curto, Alberto G./D-1076-2009; Quidant, Romain/A-4954-2017	Taminiau, Tim Hugo H/0000-0002-2355-727X; van Hulst, Niek/0000-0003-4630-1776; Volpe, Giorgio/0000-0001-9993-5348; Curto, Alberto G./0000-0003-3628-5311; Quidant, Romain/0000-0001-8995-8976	Spanish Ministry of Science and Innovation (MICINN); Ministry of Education [FIS2009-08203, CSD2007-046]; European Research Council; ICREA Funding Source: Custom	Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Ministry of Education; European Research Council(European Research Council (ERC)European Commission); ICREA(ICREA)	We thank M. Castro-Lopez for help in developing the fabrication method and M. U. Gonzalez, F. Kulzer, F. D. Stefani, D. Brinks, and R. Hildner for helpful discussions. This research was funded by the Spanish Ministry of Science and Innovation (MICINN) and the Ministry of Education through programs FIS2009-08203, CONSOLIDER CSD2007-046, FPU (A.G.C. and G.V.), FPI (T.H.T.) and Ramon y Cajal (M.P.K.), Fundacio CELLEX Barcelona (G.V., M.P.K., R.Q., and N.F.v.H.), and the European Research Council Advanced Grant (N.F.v.H.).	Badolato A, 2005, SCIENCE, V308, P1158, DOI 10.1126/science.1109815; Balanis C. A., 2005, ANTENNA THEORY ANAL; Bharadwaj P, 2009, ADV OPT PHOTONICS, V1, P438, DOI 10.1364/AOP.1.000438; Brokmann X, 2005, CHEM PHYS, V318, P91, DOI 10.1016/j.chemphys.2005.06.032; Farahani JN, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.017402; Gersen H, 2000, PHYS REV LETT, V85, P5312, DOI 10.1103/PhysRevLett.85.5312; Hofmann HF, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/7/217; Kinkhabwala A, 2009, NAT PHOTONICS, V3, P654, DOI 10.1038/NPHOTON.2009.187; Koberling F, 2003, J PHYS CHEM B, V107, P7463, DOI 10.1021/jp027800b; Koenderink AF, 2009, NANO LETT, V9, P4228, DOI 10.1021/nl902439n; Kosako T, 2010, NAT PHOTONICS, V4, P312, DOI 10.1038/NPHOTON.2010.34; Kramper P, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.113903; Kuhn S, 2008, MOL PHYS, V106, P893, DOI 10.1080/00268970802002510; Kuhn S, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.017402; Lezec HJ, 2002, SCIENCE, V297, P820, DOI 10.1126/science.1071895; Li JJ, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.245403; Lieb MA, 2004, J OPT SOC AM B, V21, P1210, DOI 10.1364/JOSAB.21.001210; Muskens OL, 2007, NANO LETT, V7, P2871, DOI 10.1021/nI0715847; Pelton M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.233602; Ringler M, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.203002; Shegai T, 2008, P NATL ACAD SCI USA, V105, P16448, DOI 10.1073/pnas.0808365105; TAKLA NK, 1977, IEEE T ANTENN PROPAG, V25, P913, DOI 10.1109/TAP.1977.1141713; Taminiau TH, 2008, NAT PHOTONICS, V2, P234, DOI 10.1038/nphoton.2008.32; Taminiau TH, 2008, OPT EXPRESS, V16, P10858, DOI 10.1364/OE.16.010858; Taminiau TH, 2007, NANO LETT, V7, P28, DOI 10.1021/nl061726h; Yagi H, 1928, P IRE, V16, P715, DOI 10.1109/JRPROC.1928.221464; Yu NF, 2008, NAT PHOTONICS, V2, P564, DOI 10.1038/nphoton.2008.152	27	1136	1154	11	600	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					930	933		10.1126/science.1191922	http://dx.doi.org/10.1126/science.1191922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724630				2022-12-28	WOS:000281084800030
J	Yoshida, Y; Kuroiwa, H; Misumi, O; Yoshida, M; Ohnuma, M; Fujiwara, T; Yagisawa, F; Hirooka, S; Imoto, Y; Matsushita, K; Kawano, S; Kuroiwa, T				Yoshida, Yamato; Kuroiwa, Haruko; Misumi, Osami; Yoshida, Masaki; Ohnuma, Mio; Fujiwara, Takayuki; Yagisawa, Fumi; Hirooka, Shunsuke; Imoto, Yuuta; Matsushita, Kazunobu; Kawano, Shigeyuki; Kuroiwa, Tsuneyoshi			Chloroplasts Divide by Contraction of a Bundle of Nanofilaments Consisting of Polyglucan	SCIENCE			English	Article							ALGA CYANIDIOSCHYZON-MEROLAE; PLASTID DIVISION; DYNAMIN; MACHINERY; MITOCHONDRIA; GLYCOGENIN; ORGANELLES; APPARATUS; MECHANISM; SEQUENCE	In chloroplast division, the plastid-dividing (PD) ring is a main structure of the PD machinery and is a universal structure in the plant kingdom. However, the components and formation of the PD ring have been enigmatic. By proteomic analysis of PD machineries isolated from Cyanidioschyzon merolae, we identified the glycosyltransferase protein plastid-dividing ring 1 (PDR1), which constructs the PD ring and is widely conserved from red alga to land plants. Electron microscopy showed that the PDR1 protein forms a ring with carbohydrates at the chloroplast-division site. Fluorometric saccharide ingredient analysis of purified PD ring filaments showed that only glucose was included, and down-regulation of PDR1 impaired chloroplast division. Thus, the chloroplasts are divided by the PD ring, which is a bundle of PDR1-mediated polyglucan filaments.	[Yoshida, Yamato; Kuroiwa, Haruko; Misumi, Osami; Yoshida, Masaki; Ohnuma, Mio; Fujiwara, Takayuki; Yagisawa, Fumi; Imoto, Yuuta; Kuroiwa, Tsuneyoshi] Rikkyo Univ, Cell Biol Lab, Dept Life Sci, Coll Sci,Res Informat Ctr Extremophile, Tokyo 1718501, Japan; [Hirooka, Shunsuke] Chiba Univ, Dept Nanobiol, Grad Sch Adv Integrat Sci, Chiba 2718510, Japan; [Matsushita, Kazunobu] Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan; [Kawano, Shigeyuki] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan	Rikkyo University; Chiba University; Yamaguchi University; University of Tokyo	Kuroiwa, T (corresponding author), Rikkyo Univ, Cell Biol Lab, Dept Life Sci, Coll Sci,Res Informat Ctr Extremophile, Tokyo 1718501, Japan.	tsune@rikkyo.ne.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan;  [22247007];  [22657061]; Grants-in-Aid for Scientific Research [22370024] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); ; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank S. Y. Miyagishima and K. Nishida for thoughtful advice on the research. This work was supported by grants from the Scientific Research (22247007 and 22657061 to T. K.) and by the Frontier Project "Adaptation and Evolution of Extremophiles" from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Gao HB, 2003, P NATL ACAD SCI USA, V100, P4328, DOI 10.1073/pnas.0530206100; GILLHAM NW, 1994, ANNU REV GENET, V28, P71, DOI 10.1146/annurev.ge.28.120194.000443; Glynn JM, 2007, TRAFFIC, V8, P451, DOI 10.1111/j.1600-0854.2007.00545.x; Hirabaru C, 2010, PLANT CELL PHYSIOL, V51, P682, DOI 10.1093/pcp/pcq046; Kuroiwa H, 2002, PLANTA, V215, P185, DOI 10.1007/s00425-002-0734-4; Kuroiwa T, 2008, INT REV CEL MOL BIO, V271, P97, DOI 10.1016/S1937-6448(08)01203-3; Kuroiwa T, 1998, INT REV CYTOL, V181, P1, DOI 10.1016/S0074-7696(08)60415-5; Lomako J, 2004, BBA-GEN SUBJECTS, V1673, P45, DOI 10.1016/j.bbagen.2004.03.017; Margolin W, 2005, NAT REV MOL CELL BIO, V6, P862, DOI 10.1038/nrm1745; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; Miyagishima S, 2003, PLANT CELL, V15, P655, DOI 10.1105/tpc.009373; Miyagishima SY, 2001, PLANT CELL, V13, P2257, DOI 10.1105/tpc.010185; Miyagishima SY, 2001, PLANT CELL, V13, P707; Nozaki H, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-28; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; OSTERYOUNG KW, 1995, NATURE, V376, P473, DOI 10.1038/376473b0; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Pyke KA, 1999, PLANT CELL, V11, P549, DOI 10.1105/tpc.11.4.549; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; Yoo SH, 2002, CARBOHYD RES, V337, P2195, DOI 10.1016/S0008-6215(02)00228-8; Yoshida Y, 2006, SCIENCE, V313, P1435, DOI 10.1126/science.1129689; Yoshida Y, 2009, CURR BIOL, V19, P1491, DOI 10.1016/j.cub.2009.07.035	22	63	66	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					949	953		10.1126/science.1190791	http://dx.doi.org/10.1126/science.1190791			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724635				2022-12-28	WOS:000281084800036
J	Berne, O; Marcelino, N; Cernicharo, J				Berne, Olivier; Marcelino, Nuria; Cernicharo, Jose			Waves on the surface of the Orion molecular cloud	NATURE			English	Article							H-2 EMISSION; GAS; PHOTOEVAPORATION; REGION; STARS	Massive stars influence their parental molecular cloud, and it has long been suspected that the development of hydrodynamical instabilities can compress or fragment the cloud(1,2). Identifying such instabilities has proved difficult. It has been suggested that elongated structures (such as the 'pillars of creation'(3)) and other shapes arise because of instabilities(4,5), but alternative explanations are available(6,7). One key signature of an instability is a wave-like structure in the gas, which has hitherto not been seen. Here we report the presence of 'waves' at the surface of the Orion molecular cloud near where massive stars are forming. The waves seem to be a Kelvin-Helmholtz instability that arises during the expansion of the nebula as gas heated and ionized by massive stars is blown over pre-existing molecular gas.	[Berne, Olivier; Marcelino, Nuria; Cernicharo, Jose] CSIC INTA, Ctr Astrobiol, Torrejon De Ardoz 28850, Spain; [Berne, Olivier] Leiden Univ, Leiden Observ, NL-2300 RA Leiden, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); Leiden University; Leiden University - Excl LUMC	Berne, O (corresponding author), CSIC INTA, Ctr Astrobiol, Carretera Torrejon Ajalvir,Km 4, Torrejon De Ardoz 28850, Spain.	berne@strw.leidenuniv.nl	Marcelino, Nuria/H-4400-2017; Cernicharo, Jose/G-3059-2015	Marcelino, Nuria/0000-0001-7236-4047; Cernicharo, Jose/0000-0002-3518-2524	NASA	NASA(National Aeronautics & Space Administration (NASA))	We thank J. Bally and M. Pound for their comments, which contributed to the improvement of the manuscript. We also acknowledge B. Lefloc'h, J. Goicoechea and J. Martin-Pintado for discussions. D. Hochberg is acknowledged for his reading of the manuscript. O.B. acknowledges C. Joblin for support. This work is based in part on observations made with the Spitzer Space Telescope, which is operated by the Jet Propulsion Laboratory, California Institute of Technology under a contract with NASA.	Bachiller R, 1996, ANNU REV ASTRON ASTR, V34, P111, DOI 10.1146/annurev.astro.34.1.111; Bally J, 2006, ASTRON J, V131, P473, DOI 10.1086/498265; Bally J, 2008, MONOGR ASTRON SOC PA, V4, P459; Berne O, 2009, ASTROPHYS J LETT, V706, pL160, DOI 10.1088/0004-637X/706/1/L160; CHANDRASEKHAR S, 1961, HYDRODYNAMIC HYDROMA, pCH11; GENZEL R, 1989, ANNU REV ASTRON ASTR, V27, P41, DOI 10.1146/annurev.aa.27.090189.000353; Gudel M, 2008, SCIENCE, V319, P309, DOI 10.1126/science.1149926; Hester JJ, 1996, ASTRON J, V111, P2349, DOI 10.1086/117968; Johnstone D, 1998, ASTROPHYS J, V499, P758, DOI 10.1086/305658; Kaufman MJ, 2006, ASTROPHYS J, V644, P283, DOI 10.1086/503596; Lefloch B, 2003, ASTROPHYS J, V590, pL41, DOI 10.1086/376673; Menten KM, 2007, ASTRON ASTROPHYS, V474, P515, DOI 10.1051/0004-6361:20078247; Neufeld DA, 2009, ASTROPHYS J, V706, P170, DOI 10.1088/0004-637X/706/1/170; Pound MW, 1998, ASTROPHYS J, V493, pL113, DOI 10.1086/311131; Pound MW, 2003, ASTRON J, V125, P2108, DOI 10.1086/368138; RODRIGUEZFRANCO A, 1992, ASTRON ASTROPHYS, V264, P592; Ryutov DD, 2007, ASTROPHYS SPACE SCI, V307, P173, DOI 10.1007/s10509-006-9233-6; Ryutov DD, 2003, PLASMA PHYS CONTR F, V45, P769, DOI 10.1088/0741-3335/45/5/319; Schuster KF, 2004, ASTRON ASTROPHYS, V423, P1171, DOI 10.1051/0004-6361:20034179; SPITZER L, 1978, PHYSICAL PROCESSES I, P223; Tappe A, 2008, ASTROPHYS J LETT, V680, pL117, DOI 10.1086/589998; TENORIOTAGLE G, 1988, ANNU REV ASTRON ASTR, V26, P145; TIELENS AGGM, 1993, SCIENCE, V262, P86, DOI 10.1126/science.262.5130.86; Weingartner JC, 2001, ASTROPHYS J, V548, P296, DOI 10.1086/318651; Wilms J, 2000, ASTROPHYS J, V542, P914, DOI 10.1086/317016; WOODWARD PR, 1976, ASTROPHYS J, V207, P484, DOI 10.1086/154516	26	32	32	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2010	466	7309					947	949		10.1038/nature09289	http://dx.doi.org/10.1038/nature09289			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725034	Green Submitted			2022-12-28	WOS:000281030300028
J	Hunt, C; McNamee, D				Hunt, Chloe; McNamee, David			The potato: fertile ground for more funding	LANCET			English	Editorial Material									[Hunt, Chloe] Queen Mary Univ London, Sch English & Drama, London E1 4NS, England; [McNamee, David] The Lancet, London, England	University of London; Queen Mary University London	Hunt, C (corresponding author), Queen Mary Univ London, Sch English & Drama, London E1 4NS, England.								0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2010	376	9742					669	669		10.1016/S0140-6736(10)61318-9	http://dx.doi.org/10.1016/S0140-6736(10)61318-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	646YW	20801390				2022-12-28	WOS:000281582900010
J	Gale, DP; de Jorge, EG; Cook, HT; Martinez-Barricarte, R; Hadjisavvas, A; McLean, AG; Pusey, CD; Pierides, A; Kyriacou, K; Athanasiou, Y; Voskarides, K; Deltas, C; Palmer, A; Fremeaux-Bacchi, V; de Cordoba, SR; Maxwell, PH; Pickering, MC				Gale, Daniel P.; de Jorge, Elena Goicoechea; Cook, H. Terence; Martinez-Barricarte, Ruben; Hadjisavvas, Andreas; McLean, Adam G.; Pusey, Charles D.; Pierides, Alkis; Kyriacou, Kyriacos; Athanasiou, Yiannis; Voskarides, Konstantinos; Deltas, Constantinos; Palmer, Andrew; Fremeaux-Bacchi, Veronique; Rodriguez de Cordoba, Santiago; Maxwell, Patrick H.; Pickering, Matthew C.			Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis	LANCET			English	Article							HEMOLYTIC-UREMIC SYNDROME; TRANSLATIONAL MINIREVIEW SERIES; MACULAR DEGENERATION; LINKAGE ANALYSIS; DISEASE; AGE; DEPOSITS; RISK	Background Complement is a key component of the innate immune system, and variation in genes that regulate its activation is associated with renal and other disease. We aimed to establish the genetic basis for a familial disorder of complement regulation associated with persistent microscopic haematuria, recurrent macroscopic haematuria, glomerulonephritis, and progressive renal failure. Methods We sought patients from the West London Renal and Transplant Centre (London, UK) with unusual renal disease and affected family members as a method of identification of new genetic causes of kidney disease. Two families of Cypriot origin were identified in which renal disease was consistent with autosomal dominant transmission and renal biopsy of at least one individual showed C3 glomerulonephritis. A mutation was identified via a genomewide linkage study and candidate gene analysis. A PCR-based diagnostic test was then developed and used to screen for the mutation in population-based samples and in individuals and families with renal disease. Findings Occurrence of familial renal disease cosegregated with the same mutation in the complement factor H-related protein 5 gene (CFHR5). In a cohort of 84 Cypriots with unexplained renal disease, four had mutation in CFHR5. Overall, we identified 26 individuals with the mutation and evidence of renal disease from 11 ostensibly unrelated kindreds, including the original two families. A mutant CFHR5 protein present in patient serum had reduced affinity for surface-bound complement. We term this renal disease CFHR5 nephropathy. Interpretation CFHR5 nephropathy accounts for a substantial burden of renal disease in patients of Cypriot origin and can be diagnosed with a specific molecular test. The high risk of progressive renal disease in carriers of the CFHR5 mutation implies that isolated microscopic haematuria or recurrent macroscopic haematuria should not be regarded as a benign finding in individuals of Cypriot descent.	[Maxwell, Patrick H.] UCL, Rayne Inst, Div Med, London WC1E 6JF, England; [de Jorge, Elena Goicoechea; Cook, H. Terence; Pickering, Matthew C.] Univ London Imperial Coll Sci Technol & Med, Ctr Complement & Inflammat Res, London, England; [Gale, Daniel P.; McLean, Adam G.; Pusey, Charles D.; Palmer, Andrew] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Kidney & Transplant Inst, London, England; [Martinez-Barricarte, Ruben; Rodriguez de Cordoba, Santiago] CSIC, Ctr Invest Biol, Ctr Invest Biomed Enfermedades Raras, Madrid, Spain; [Martinez-Barricarte, Ruben; Rodriguez de Cordoba, Santiago] Inst Reina Sofia Invest Nefrol, Madrid, Spain; [Hadjisavvas, Andreas; Kyriacou, Kyriacos] Cyprus Inst Neurol & Genet, Dept Electron Microscopy & Pathol, Nicosia, Cyprus; [Pierides, Alkis] Hippocrateon Hosp, Dept Nephrol, Nicosia, Cyprus; [Athanasiou, Yiannis] Nicosia Gen Hosp, Dept Nephrol, Nicosia, Cyprus; [Voskarides, Konstantinos; Deltas, Constantinos] Univ Cyprus, Dept Biol Sci, Nicosia, Cyprus; [Fremeaux-Bacchi, Veronique] Hop Europeen Georges Pompidou, AP HP, Serv Immunol Biol, Paris, France; [Fremeaux-Bacchi, Veronique] Cordeliers Res Ctr, INSERM, UMRS 872, Paris, France	University of London; King's College London; University College London; Imperial College London; Imperial College London; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Hippocrateon Private Hospital; University of Cyprus; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Maxwell, PH (corresponding author), UCL, Rayne Inst, Div Med, 5 Univ St, London WC1E 6JF, England.	p.maxwell@ucl.ac.uk	Deltas, Constantinos/J-9345-2013; de Cordoba, Santiago Rodriguez/K-6727-2014; Voskarides, Konstantinos/A-4669-2013; Maxwell, Patrick H/C-5557-2008; Barricarte, Ruben Martinez/W-8695-2019; Gale, Daniel/D-5594-2013; Deltas, Constantinos/A-4936-2013; de Jorge, Elena Goicoechea/L-4580-2016	Deltas, Constantinos/0000-0001-5549-9169; de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; Voskarides, Konstantinos/0000-0002-3705-3451; Maxwell, Patrick H/0000-0002-0338-2679; Barricarte, Ruben Martinez/0000-0001-7925-449X; Gale, Daniel/0000-0002-9170-1579; Deltas, Constantinos/0000-0001-5549-9169; de Jorge, Elena Goicoechea/0000-0002-4978-2483; Pickering, Matthew/0000-0002-1153-0192	UK Medical Research Council; Wellcome Trust [WT082291MA]; UK National Institute for Health Research Biomedical Research Centre; Cyprus Research Promotion Foundation; Cyprus Research Promotion Foundation [ENISigmaX/0505/02, ENISigmaX/0308/08]; EU; St Peter's Trust; UK National Institute for Health Research; Medical Research Council [G0600420] Funding Source: researchfish; National Institute for Health Research [NF-SI-0507-10315] Funding Source: researchfish; MRC [G0600420] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); UK National Institute for Health Research Biomedical Research Centre(National Institute for Health Research (NIHR)); Cyprus Research Promotion Foundation; Cyprus Research Promotion Foundation; EU(European Commission); St Peter's Trust; UK National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	DPG is supported by the UK Medical Research Council and EGdJ and MCP are supported by the Wellcome Trust. Additional support was provided by the UK National Institute for Health Research Biomedical Research Centre Funding Scheme and the Cyprus Research Promotion Foundation. No payment was received for the writing of this article. We thank the patients and their families. DPG is supported by a UK Medical Research Council Clinical Research Training Fellowship. MCP is a Wellcome Trust Senior Fellow in Clinical Science (WT082291MA) and EGdJ is funded by this fellowship. CD is supported by the Cyprus Research Promotion Foundation through grants ENI Sigma X/0505/02 and ENI Sigma X/0308/08. Additional support was obtained from the UK National Institute for Health Research Biomedical Research Centre Funding Scheme. PHM is supported by the EU large scale collaborative project Metoxia, the St Peter's Trust, and a Senior Investigator Award from the UK National Institute for Health Research.	BERGER J, 1968, J UROL NEPHROL, V74, P694; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cohen RA, 2003, NEW ENGL J MED, V348, P2330, DOI 10.1056/NEJMcp012694; de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x; de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103; Dragon-Durey MA, 2009, J MED GENET, V46, P447, DOI 10.1136/jmg.2008.064766; Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702; Genin E, 2004, J MED GENET, V41, P445, DOI 10.1136/jmg.2003.017962; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648; Hoffmann K, 2005, BIOINFORMATICS, V21, P3565, DOI 10.1093/bioinformatics/bti571; Loizidou MA, 2008, BREAST CANCER RES TR, V112, P575, DOI 10.1007/s10549-007-9881-4; Markianos K, 2001, AM J HUM GENET, V68, P963, DOI 10.1086/319507; McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250; McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200; Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873; Narendra U, 2009, MOL VIS, V15, P731; *NAT COLL CTR CHRO, 2008, CHRON KIDN DIS NAT C, P147; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x; Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301; Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328; Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356; Thiele H, 2005, BIOINFORMATICS, V21, P1730, DOI 10.1093/bioinformatics/bth488; Voskarides K, 2007, J AM SOC NEPHROL, V18, P3004, DOI 10.1681/ASN.2007040444; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147	26	228	244	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					794	801		10.1016/S0140-6736(10)60670-8	http://dx.doi.org/10.1016/S0140-6736(10)60670-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20800271	Green Published, Green Submitted			2022-12-28	WOS:000281831000030
J	Walsh, TS; Wyncoll, DLA; Stanworth, SJ				Walsh, Timothy S.; Wyncoll, Duncan L. A.; Stanworth, Simon J.			Managing anaemia in critically ill adults	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BLOOD-CELL TRANSFUSION; CLINICAL-PRACTICE; CRITICAL ILLNESS; CRITICAL-CARE; REQUIREMENTS; EFFICACY; DISEASE; SEPSIS		[Walsh, Timothy S.] Royal Infirm Edinburgh NHS Trust, Edinburgh EH16 2SA, Midlothian, Scotland; [Wyncoll, Duncan L. A.] Guys & St Thomas NHS Fdn Trust, London SE1 7EH, England; [Stanworth, Simon J.] Oxford Radcliffe Hosp Trust, NHS Blood & Transplant, Oxford OX3 9BQ, England	Royal Infirmary of Edinburgh; University of Edinburgh; Guy's & St Thomas' NHS Foundation Trust	Walsh, TS (corresponding author), Royal Infirm Edinburgh NHS Trust, Edinburgh EH16 2SA, Midlothian, Scotland.	twalsh@staffmail.ed.ac.uk			Chief Scientist Office [CZB/4/698] Funding Source: Medline	Chief Scientist Office		Ba VN, 2003, CRIT CARE MED, V31, P406, DOI 10.1097/01.CCM.0000048623.00778.3F; Bassand JP, 2008, HEART, V94, P661, DOI 10.1136/hrt.2007.125047; CARDIGAN R, 2009, PRACTICAL TRANSFUSIO, P209; Carson JL, 2008, CRIT CARE MED, V36, P2707, DOI 10.1097/CCM.0b013e3181843ee7; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Gerber DR, 2008, CRIT CARE MED, V36, P1068, DOI 10.1097/CCM.0b013e318169251f; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HILL SR, 2002, COCHRANE DB SYST REV, V2; Klein HG, 2007, LANCET, V370, P415, DOI 10.1016/S0140-6736(07)61197-0; Leal-Noval SR, 2008, CURR OPIN CRIT CARE, V14, P156, DOI 10.1097/MCC.0b013e3282f57577; Madjdpour C, 2005, BRIT J ANAESTH, V95, P33, DOI 10.1093/bja/aeh290; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Mukhopadhyay A, 2010, CRIT CARE, V14, DOI 10.1186/cc8859; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Piagnerelli M, 2003, INTENS CARE MED, V29, P1052, DOI 10.1007/s00134-003-1783-2; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Scharte M, 2003, CRIT CARE MED, V31, pS651, DOI 10.1097/01.CCM.0000098036.90796.ED; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; von Ahsen N, 1999, CRIT CARE MED, V27, P2630, DOI 10.1097/00003246-199912000-00005; Walsh TS, 2006, BRIT J ANAESTH, V97, P278, DOI 10.1093/bja/ael189; Walsh TS, 2004, TRANSFUSION, V44, P1405, DOI 10.1111/j.1537-2995.2004.04085.x; Weiskopf RB, 1998, JAMA-J AM MED ASSOC, V279, P217, DOI 10.1001/jama.279.3.217; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809; Wells AW, 2002, BRIT MED J, V325, P803, DOI 10.1136/bmj.325.7368.803; Zimrin AB, 2009, VOX SANG, V96, P93, DOI 10.1111/j.1423-0410.2008.01117.x	27	12	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	2010	341								c4408	10.1136/bmj.c4408	http://dx.doi.org/10.1136/bmj.c4408			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647JZ	20817679				2022-12-28	WOS:000281616100001
J	Nikoletopoulou, V; Lickert, H; Frade, JM; Rencurel, C; Giallonardo, P; Zhang, LX; Bibel, M; Barde, YA				Nikoletopoulou, Vassiliki; Lickert, Heiko; Frade, Jose Maria; Rencurel, Chantal; Giallonardo, Patrizia; Zhang, Lixin; Bibel, Miriam; Barde, Yves-Alain			Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not	NATURE			English	Article							NERVE GROWTH-FACTOR; EMBRYONIC STEM-CELLS; SYMPATHETIC NEURONS; GENETIC-EVIDENCE; MESSENGER-RNA; P75; EXPRESSION; DEPENDENCE; GANGLIA; MICE	Neurons of the peripheral nervous system have long been known to require survival factors to prevent their death during development. But why they selectively become dependent on secretory molecules has remained a mystery, as is the observation that in the central nervous system, most neurons do not show this dependency. Using engineered embryonic stem cells, we show here that the neurotrophin receptors TrkA and TrkC (tropomyosin receptor kinase A and C, also known as Ntrk1 and Ntrk3, respectively) instruct developing neurons to die, both in vitro and in vivo. By contrast, TrkB (also known as Ntrk2), a closely related receptor primarily expressed in the central nervous system, does not. These results indicate that TrkA and TrkC behave as dependence receptors, explaining why developing sympathetic and sensory neurons become trophic-factor-dependent for survival. We suggest that the expansion of the Trk gene family that accompanied the segregation of the peripheral from the central nervous system generated a novel mechanism of cell number control.	[Nikoletopoulou, Vassiliki; Rencurel, Chantal; Zhang, Lixin; Barde, Yves-Alain] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; [Lickert, Heiko; Giallonardo, Patrizia] Helmholtz Zentrum Munchen, Inst Stem Cell Res, D-85764 Neuherberg, Germany; [Frade, Jose Maria] CSIC, Inst Cajal, E-28002 Madrid, Spain; [Bibel, Miriam] Novartis Inst BioMed Res, Neurodegenerat Dept, CH-4002 Basel, Switzerland	University of Basel; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Novartis	Nikoletopoulou, V (corresponding author), Univ Basel, Biozentrum, CH-4056 Basel, Switzerland.	n.vassiliki@unibas.ch; yves.barde@unibas.ch	Zhang, Li/GWM-7501-2022; Lickert, Heiko/K-9045-2013; Frade, Jose M/E-7913-2013; Barde, Yves/F-6019-2011	Frade, Jose M/0000-0001-7067-2505; Nikoletopoulou, Vassiliki/0000-0003-3646-992X; Barde, Yves/0000-0002-7627-461X	DFG; consortium EuTRACC; Swiss National Foundation	DFG(German Research Foundation (DFG)); consortium EuTRACC; Swiss National Foundation(Swiss National Science Foundation (SNSF))	H.L. is supported by an Emmy-Nother fellowship of the DFG. V.N. and Y.-A.B. thank S. Arber, G. Dechant as well as members of our laboratory for discussions and suggestions.; Tetraploid embryos were generated by P. G. and H. L.; J.M.F. initiated the comparison of the Ngf and TrkA mutant embryos; C. R performed the cloning of the HA-tagged Trk cDNAs; ES lines expressing non-tagged Trk cDNAs from the Mapt locus were generated by M. B.; L.Z. made the first observations with the neuronal differentiation of Trk-expressing ES cells. V.N. and Y.-A.B designed and carried out all other experiments. This work was supported by the consortium EuTRACC and the Swiss National Foundation.	Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; Benito-Gutierrez E, 2005, DEVELOPMENT, V132, P2191, DOI 10.1242/dev.01803; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bibel M, 2007, NAT PROTOC, V2, P1034, DOI 10.1038/nprot.2007.147; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; Brennan C, 1999, NAT NEUROSCI, V2, P699, DOI 10.1038/11158; Chao MV, 2010, DEV NEUROBIOL, V70, P269, DOI 10.1002/dneu.20779; COUGHLIN MD, 1981, DEV BIOL, V82, P56, DOI 10.1016/0012-1606(81)90428-0; Davies AM, 2003, EMBO J, V22, P2537, DOI 10.1093/emboj/cdg254; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1989, NEURON, V2, P1605, DOI 10.1016/0896-6273(89)90049-4; ESCANDON E, 1994, J NEUROSCI, V14, P2054; Frade JM, 1999, DEVELOPMENT, V126, P683; GAESE F, 1994, DEVELOPMENT, V120, P1613; Gschwendtner A, 2003, MOL CELL NEUROSCI, V24, P307, DOI 10.1016/S1044-7431(03)00167-2; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; Holland LZ, 2009, NAT REV NEUROSCI, V10, P736, DOI 10.1038/nrn2703; KAHANE N, 1994, J NEUROBIOL, V25, P571, DOI 10.1002/neu.480250509; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kenchappa RS, 2006, NEURON, V50, P219, DOI 10.1016/j.neuron.2006.03.011; Kolbeck R, 1999, J NEUROCHEM, V72, P1930, DOI 10.1046/j.1471-4159.1999.0721930.x; LEE KF, 1994, SCIENCE, V263, P1447, DOI 10.1126/science.8128229; LIU X, 1995, NATURE, V375, P238, DOI 10.1038/375238a0; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Molliver DC, 1997, NEURON, V19, P849, DOI 10.1016/S0896-6273(00)80966-6; Moqrich A, 2004, NAT NEUROSCI, V7, P812, DOI 10.1038/nn1283; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Nikoletopoulou V, 2007, CELL STEM CELL, V1, P529, DOI 10.1016/j.stem.2007.08.011; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Plachta N, 2007, NAT NEUROSCI, V10, P712, DOI 10.1038/nn1897; Rauskolb S, 2010, J NEUROSCI, V30, P1739, DOI 10.1523/JNEUROSCI.5100-09.2010; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Schecterson LC, 2010, DEV NEUROBIOL, V70, P332, DOI 10.1002/dneu.20767; Sendtner M, 1996, NEUROCHEM RES, V21, P831, DOI 10.1007/BF02532307; Singh KK, 2008, NAT NEUROSCI, V11, P649, DOI 10.1038/nn.2114; Stenqvist A, 2005, EMBO REP, V6, P973, DOI 10.1038/sj.embor.7400512; Tauszig-Delamasure S, 2007, P NATL ACAD SCI USA, V104, P13361, DOI 10.1073/pnas.0701243104; Tucker KL, 2001, NAT NEUROSCI, V4, P29, DOI 10.1038/82868; von Bartheld CS, 1998, HISTOL HISTOPATHOL, V13, P437, DOI 10.14670/HH-13.437; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wernig M, 2002, J NEUROSCI RES, V69, P918, DOI 10.1002/jnr.10395; White FA, 1996, J NEUROSCI, V16, P4662; WYATT S, 1993, DEVELOPMENT, V119, P635; WYATT S, 1995, J CELL BIOL, V130, P1435, DOI 10.1083/jcb.130.6.1435; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001	48	153	158	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2010	467	7311					59	U87		10.1038/nature09336	http://dx.doi.org/10.1038/nature09336			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811452	Green Submitted			2022-12-28	WOS:000281461200034
J	Bonasio, R; Zhang, GJ; Ye, CY; Mutti, NS; Fang, XD; Qin, N; Donahue, G; Yang, PC; Li, QY; Li, C; Zhang, P; Huang, ZY; Berger, SL; Reinberg, D; Wang, J; Liebig, J				Bonasio, Roberto; Zhang, Guojie; Ye, Chaoyang; Mutti, Navdeep S.; Fang, Xiaodong; Qin, Nan; Donahue, Greg; Yang, Pengcheng; Li, Qiye; Li, Cai; Zhang, Pei; Huang, Zhiyong; Berger, Shelley L.; Reinberg, Danny; Wang, Jun; Liebig, Juergen			Genomic Comparison of the Ants Camponotus floridanus and Harpegnathos saltator	SCIENCE			English	Article							HYMENOPTERA; WORKERS; QUEENS; SMYD4; LIVE	The organized societies of ants include short-lived worker castes displaying specialized behavior and morphology and long-lived queens dedicated to reproduction. We sequenced and compared the genomes of two socially divergent ant species: Camponotus floridanus and Harpegnathos saltator. Both genomes contained high amounts of CpG, despite the presence of DNA methylation, which in non-Hymenoptera correlates with CpG depletion. Comparison of gene expression in different castes identified up-regulation of telomerase and sirtuin deacetylases in longer-lived H. saltator reproductives, caste-specific expression of microRNAs and SMYD histone methyltransferases, and differential regulation of genes implicated in neuronal function and chemical communication. Our findings provide clues on the molecular differences between castes in these two ants and establish a new experimental model to study epigenetics in aging and behavior.	[Ye, Chaoyang; Donahue, Greg; Berger, Shelley L.] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Bonasio, Roberto; Reinberg, Danny] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; [Zhang, Guojie] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Chinese Acad Sci,Max Planck Jr Res Grp, Kunming 650223, Yunnan, Peoples R China; [Zhang, Guojie; Fang, Xiaodong; Qin, Nan; Yang, Pengcheng; Li, Qiye; Li, Cai; Zhang, Pei; Huang, Zhiyong; Wang, Jun] Beijing Genom Inst Shenzhen, Shenzhen 518083, Peoples R China; [Mutti, Navdeep S.; Liebig, Juergen] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; [Reinberg, Danny] NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; [Wang, Jun] Univ Copenhagen, Dept Biol, DK-2200 Copenhagen, Denmark	University of Pennsylvania; New York University; Chinese Academy of Sciences; Kunming Institute of Zoology; Beijing Genomics Institute (BGI); Arizona State University; Arizona State University-Tempe; Howard Hughes Medical Institute; New York University; University of Copenhagen	Berger, SL (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.	bergers@mail.med.upenn.edu; danny.reinberg@nyumc.org; wangj@genomics.cn; juergen.liebig@asu.edu	Li, Qiye/C-1348-2015; Fang, Xiaodong/K-6743-2018; Yang, Pengcheng/N-1037-2014; Zhang, Guojie/J-7273-2019; Bonasio, Roberto/P-1356-2014; Wang, Jun/C-8434-2016; Wang, Jun/B-9503-2016	Li, Qiye/0000-0002-5993-0312; Fang, Xiaodong/0000-0001-7061-3337; Yang, Pengcheng/0000-0001-5496-8357; Zhang, Guojie/0000-0001-6860-1521; Bonasio, Roberto/0000-0002-0767-0889; Wang, Jun/0000-0002-8540-8931; Berger, Shelley/0000-0001-5398-4400; Li, Cai/0000-0001-7843-2151; Reinberg, Danny/0000-0003-4288-2016; Wang, Jun/0000-0002-2113-5874	Howard Hughes Medical Institute [2009005]	Howard Hughes Medical Institute(Howard Hughes Medical Institute)	We thank T. Bloss for ant colony maintenance, B. Kopenhaver for technical help, A. Alekseyenko and J. Wang for bioinformatic support, W. Wang for advice on evolutionary analysis, and P. Voigt and D. Simola for careful reading of the manuscript. R.B. is a fellow of the Helen Hay Whitney Foundation. This work was funded by Howard Hughes Medical Institute Collaborative Innovation Award #2009005 to S.L.B., D.R., and J.L. Raw sequencing data have been deposited in the National Center for Biotechnology Information as SRA020747 (C. floridanus genome), SRA020748 (H. saltator genome), and GSE22680 (RNA-seq). Assemblies and annotations have been deposited at DNA Data Bank of Japan-European Molecular Biology Laboratory-GenBank under the accession AEAB00000000 and AEAC00000000. The versions described in this paper are the first deposited versions: AEAB01000000 and AEAC01000000.	Allis CD, 2007, EPIGENETICS; Blomquist GJ, 2010, INSECT HYDROCARBONS: BIOLOGY, BIOCHEMISTRY, AND CHEMICAL ECOLOGY, P1, DOI 10.1017/CBO9780511711909; Dulac C, 2010, NATURE, V465, P728, DOI 10.1038/nature09231; Fishilevich E, 2005, CURR BIOL, V15, P1548, DOI 10.1016/j.cub.2005.07.066; Hartmann A, 2003, EVOLUTION, V57, P2424, DOI 10.1111/j.0014-3820.2003.tb00254.x; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Holldobler B., 1990, pi; Hoyer SC, 2005, ARTHROPOD STRUCT DEV, V34, P429, DOI 10.1016/j.asd.2005.03.003; Hu LP, 2009, CANCER RES, V69, P4067, DOI 10.1158/0008-5472.CAN-08-4097; Jemielity S, 2005, AGE, V27, P241, DOI 10.1007/s11357-005-2916-z; Kronforst MR, 2008, CURR BIOL, V18, pR287, DOI 10.1016/j.cub.2008.02.015; Liebig J, 2000, P NATL ACAD SCI USA, V97, P4124, DOI 10.1073/pnas.97.8.4124; Lorenzen MD, 2007, INSECT MOL BIOL, V16, P265, DOI 10.1111/j.1365-2583.2007.00727.x; Peeters C, 2000, INSECT SOC, V47, P325, DOI 10.1007/PL00001724; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Sumitani M, 2003, INSECT BIOCHEM MOLEC, V33, P449, DOI 10.1016/S0965-1748(03)00009-2; Thompson EC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003008; Vaquero A, 2009, GENE DEV, V23, P1849, DOI 10.1101/gad.1807009; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260; Werren JH, 2010, SCIENCE, V327, P343, DOI 10.1126/science.1178028; WHEELER DE, 1986, AM NAT, V128, P13, DOI 10.1086/284536; Zube C, 2008, J COMP NEUROL, V506, P425, DOI 10.1002/cne.21548	23	345	390	3	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2010	329	5995					1068	1071		10.1126/science.1192428	http://dx.doi.org/10.1126/science.1192428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798317	Green Accepted			2022-12-28	WOS:000281253500038
J	Fienberg, SE; Prewitt, K				Fienberg, Stephen E.; Prewitt, Kenneth			Save your census	NATURE			English	Editorial Material									[Fienberg, Stephen E.] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA; [Fienberg, Stephen E.] Carnegie Mellon Univ, Dept Machine Learning, Pittsburgh, PA 15213 USA; [Prewitt, Kenneth] Columbia Univ, Sch Int & Publ Affairs, New York, NY 10027 USA	Carnegie Mellon University; Carnegie Mellon University; Columbia University	Fienberg, SE (corresponding author), Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.	fienberg@stat.cmu.edu							0	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					1043	1043		10.1038/4661043a	http://dx.doi.org/10.1038/4661043a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739993	Bronze			2022-12-28	WOS:000281203600020
J	Giessen, H; Lippitz, M				Giessen, Harald; Lippitz, Markus			Directing Light Emission from Quantum Dots	SCIENCE			English	Editorial Material									[Giessen, Harald] Univ Stuttgart, Inst Phys 4, D-70569 Stuttgart, Germany; [Giessen, Harald] Univ Stuttgart, Res Ctr SCoPE, D-70569 Stuttgart, Germany; [Lippitz, Markus] Max Planck Inst Solid State Phys, D-70569 Stuttgart, Germany	University of Stuttgart; University of Stuttgart; Max Planck Society	Giessen, H (corresponding author), Univ Stuttgart, Inst Phys 4, D-70569 Stuttgart, Germany.	giessen@physik.uni-stuttgart.de	Giessen, Harald/AAG-7586-2019	Giessen, Harald/0000-0002-4270-3850; Lippitz, Markus/0000-0003-1218-6511				Akimov AV, 2007, NATURE, V450, P402, DOI 10.1038/nature06230; Alu A, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.213902; Curto AG, 2010, SCIENCE, V329, P930, DOI 10.1126/science.1191922; Farahani JN, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.017402; Hanke T, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.257404; Kinkhabwala A, 2009, NAT PHOTONICS, V3, P654, DOI 10.1038/NPHOTON.2009.187; Kolesov R, 2009, NAT PHYS, V5, P470, DOI 10.1038/NPHYS1278; Kosako T, 2010, NAT PHOTONICS, V4, P312, DOI 10.1038/NPHOTON.2010.34; Kuhn S, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.017402; Wrachtrup J, 2010, P NATL ACAD SCI USA, V107, P9479, DOI 10.1073/pnas.1004033107	10	25	25	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					910	911		10.1126/science.1194352	http://dx.doi.org/10.1126/science.1194352			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724624				2022-12-28	WOS:000281084800022
J	Berry, MPR; Graham, CM; McNab, FW; Xu, ZH; Bloch, SAA; Oni, T; Wilkinson, KA; Banchereau, R; Skinner, J; Wilkinson, RJ; Quinn, C; Blankenship, D; Dhawan, R; Cush, JJ; Mejias, A; Ramilo, O; Kon, OM; Pascual, V; Banchereau, J; Chaussabel, D; O'Garra, A				Berry, Matthew P. R.; Graham, Christine M.; McNab, Finlay W.; Xu, Zhaohui; Bloch, Susannah A. A.; Oni, Tolu; Wilkinson, Katalin A.; Banchereau, Romain; Skinner, Jason; Wilkinson, Robert J.; Quinn, Charles; Blankenship, Derek; Dhawan, Ranju; Cush, John J.; Mejias, Asuncion; Ramilo, Octavio; Kon, Onn M.; Pascual, Virginia; Banchereau, Jacques; Chaussabel, Damien; O'Garra, Anne			An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis	NATURE			English	Article							GENE-EXPRESSION PATTERNS; MYCOBACTERIUM-TUBERCULOSIS; INFECTION; RESPONSES; IMMUNITY; CELLS	Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis, is a major cause of morbidity and mortality worldwide. Efforts to control it are hampered by difficulties with diagnosis, prevention and treatment(1,2). Most people infected with M. tuberculosis remain asymptomatic, termed latent TB, with a 10% lifetime risk of developing active TB disease. Current tests, however, cannot identify which individuals will develop disease(3). The immune response to M. tuberculosis is complex and incompletely characterized, hindering development of new diagnostics, therapies and vaccines(4,5). Here we identify a whole-blood 393 transcript signature for active TB in intermediate and high-burden settings, correlating with radiological extent of disease and reverting to that of healthy controls after treatment. A subset of patients with latent TB had signatures similar to those in patients with active TB. We also identify a specific 86-transcript signature that discriminates active TB from other inflammatory and infectious diseases. Modular and pathway analysis revealed that the TB signature was dominated by a neutrophil-driven interferon (IFN)-inducible gene profile, consisting of both IFN-gamma and type I IFN-alpha beta signalling. Comparison with transcriptional signatures in purified cells and flow cytometric analysis suggest that this TB signature reflects changes in cellular composition and altered gene expression. Although an IFN-inducible signature was also observed in whole blood of patients with systemic lupus erythematosus (SLE), their complete modular signature differed from TB, with increased abundance of plasma cell transcripts. Our studies demonstrate a hitherto underappreciated role of type I IFN-alpha beta signalling in the pathogenesis of TB, which has implications for vaccine and therapeutic development. Our study also provides a broad range of transcriptional biomarkers with potential as diagnostic and prognostic tools to combat the TB epidemic.	[Berry, Matthew P. R.; Graham, Christine M.; McNab, Finlay W.; O'Garra, Anne] Natl Inst Med Res, MRC, Div Immunoregulat, London NW7 1AA, England; [Wilkinson, Katalin A.; Wilkinson, Robert J.] Natl Inst Med Res, MRC, Div Mycobacterial Res, London NW7 1AA, England; [Bloch, Susannah A. A.; Kon, Onn M.] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Dept Resp Med, London W2 1NY, England; [Oni, Tolu; Wilkinson, Katalin A.; Wilkinson, Robert J.] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Observatory, South Africa; [Oni, Tolu] Univ London Imperial Coll Sci Technol & Med, Wright Fleming Inst, Div Med, London W2 1PG, England; [Xu, Zhaohui; Skinner, Jason; Quinn, Charles; Cush, John J.; Pascual, Virginia; Banchereau, Jacques; Chaussabel, Damien] ANRS Ctr Human Vaccines, INSERM, U899, Baylor Inst Immunol Res, Dallas, TX 75204 USA; [Blankenship, Derek] Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, Dallas, TX 75206 USA; [Dhawan, Ranju] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Dept Radiol, London W2 1NY, England; [Banchereau, Romain] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Mejias, Asuncion; Ramilo, Octavio] Nationwide Childrens Hosp, Ctr Vaccines & Immun, Res Inst, Columbus, OH 43205 USA	MRC National Institute for Medical Research; MRC National Institute for Medical Research; Imperial College London; University of Cape Town; Imperial College London; Baylor Scott & White Health; Institut National de la Sante et de la Recherche Medicale (Inserm); Baylor Health Care System; Imperial College London; University of Texas System; University of Texas Southwestern Medical Center Dallas; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital	O'Garra, A (corresponding author), Natl Inst Med Res, MRC, Div Immunoregulat, Mill Hill, London NW7 1AA, England.	aogarra@nimr.mrc.ac.uk	Pascual, Virginia/ABD-3099-2020; Wilkinson, Katalin/AAQ-7713-2021; Mejias, Maria Asuncion/E-3659-2011; Chaussabel, Damien/AAX-1909-2020; Wilkinson, Katalin/AAF-6805-2020; Mejias, Asuncion/AAC-5998-2019	Wilkinson, Katalin/0000-0002-9796-2040; Mejias, Asuncion/0000-0002-5983-8006; Oni, Tolu/0000-0003-4499-1910; Xu, Zhaohui/0000-0003-0645-1737; Graham, Christine/0000-0001-9329-6231; Chaussabel, Damien/0000-0002-6131-7242; Wilkinson, Robert/0000-0002-2753-1800; Skinner, Jason/0000-0002-2408-7695; O'Garra, Anne/0000-0001-9845-6134; Kon, Onn Min/0000-0003-2647-4688	MRC; Dana Foundation; Medical Research Council, UK [U117565642]; National Institutes of Health (NIH) [R01 AR050770-01, P50 ARO54083, 1 U19 AI082715-01, U19 AIO57234-02, U01 AI082110, P01 CA084512]; Baylor Health Care System Foundation; Medical Research Council [MC_U117588499, MC_U117565642] Funding Source: researchfish; MRC [MC_U117588499, MC_U117565642] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [P01CA084512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI057234, U19AI082715, U01AI082110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050770, P50AR054083] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Dana Foundation; Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baylor Health Care System Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank the patients and volunteer participants. We thank D. Kioussis (MRC National Institute for Medical Research (NIMR)) and D. Young (NIMR) for discussion and input. We thank N. Baldwin (Baylor Institute for Immunology Research (BIIR)) for advice and support on bioinformatics analysis, Q.-A. Nguyen (BIIR) and colleagues for providing technical assistance with microarray processing, and S. Caidan (NIMR), J. Wills (NIMR) and S. Phillips (BIIR) for help and advice with sample storage and transport. We thank the TB service at Imperial College Healthcare NHS Trust, B. M. Haselden and the TB service at Hillingdon Hospital, Uxbridge, UK. We also thank H. Giedon and R. Seldon for help in laboratory analyses, and Y. Hlombe for recruitment of patients and follow-up in South Africa. A. Rae (NIMR), T. Dipucchio (BIIR) and K. Palucka (BIIR) provided advice on flow cytometry. We thank G. Hayward for help depositing the microarray data. We thank J. Brock (NIMR) for help with graphics. M. P. R. B. was supported by an MRC career development fellowship and a grant from the Dana Foundation Program in Human Immunology. The research was funded by the Medical Research Council, UK, MRC Grant U117565642 and The Dana Foundation Program in Human Immunology. A.O'G., C. M. G. and F.W.McN. are funded by the Medical Research Council, UK. V. P. is supported by National Institutes of Health (NIH) R01 AR050770-01, NIH P50 ARO54083 and NIH 1 U19 AI082715-01. The work of J. B., D. C. and V. P. is supported by the Baylor Health Care System Foundation and the NIH (U19 AIO57234-02, U01 AI082110, P01 CA084512).	Allantaz F, 2007, J EXP MED, V204, P2131, DOI 10.1084/jem.20070070; Ardura MI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005446; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236; BECK JS, 1985, CLIN EXP IMMUNOL, V60, P49; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012; Cooper AM, 2000, INFECT IMMUN, V68, P6879, DOI 10.1128/IAI.68.12.6879-6882.2000; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Decker T, 2005, NAT REV IMMUNOL, V5, P675, DOI 10.1038/nri1684; DYE C, 2008, GLOBAL TUBERCULOSIS, P17; Eruslanov EB, 2005, INFECT IMMUN, V73, P1744, DOI 10.1128/IAI.73.3.1744-1753.2005; EURN SY, 2010, CHEST, V137, P122; Falk A, 1969, DIAGNOSTIC STANDARDS, P68; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Jacobsen M, 2007, J MOL MED, V85, P613, DOI 10.1007/s00109-007-0157-6; Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221; Manca C, 2005, J INTERF CYTOK RES, V25, P694, DOI 10.1089/jir.2005.25.694; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Mistry R, 2007, J INFECT DIS, V195, P357, DOI 10.1086/510397; Ordway D, 2007, J IMMUNOL, V179, P522, DOI 10.4049/jimmunol.179.1.522; Pankla R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r127; Pascual V, 2010, ANNU REV IMMUNOL, V28, P535, DOI 10.1146/annurev-immunol-030409-101221; Ramilo O, 2007, BLOOD, V109, P2066, DOI 10.1182/blood-2006-02-002477; SALISBURY DM, 2006, IMMUNIZATION INFECTI, P391; Telesca Claudia, 2007, J Infect, V54, pe223, DOI 10.1016/j.jinf.2006.12.009; Young DB, 2008, J CLIN INVEST, V118, P1255, DOI 10.1172/JCI34614; [No title captured]	30	1267	1320	5	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2010	466	7309					973	U98		10.1038/nature09247	http://dx.doi.org/10.1038/nature09247			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725040	Green Accepted			2022-12-28	WOS:000281030300034
J	Wittrock, U				Wittrock, Ulrich			Laryngeally echolocating bats	NATURE			English	Letter									Munster Univ Appl Sci, D-48565 Steinfurt, Germany	University of Munster	Wittrock, U (corresponding author), Munster Univ Appl Sci, Stegerwaldstr 39, D-48565 Steinfurt, Germany.	wittrock@fh-muenster.de						Veselka N, 2010, NATURE, V463, P939, DOI 10.1038/nature08737	1	3	3	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					E6	E6		10.1038/nature09156	http://dx.doi.org/10.1038/nature09156			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20724991				2022-12-28	WOS:000281030300046
J	Thomson, S; Foubister, T; Mossialos, E				Thomson, Sarah; Foubister, Thomas; Mossialos, Elias			Health Systems Perspectives Can user charges make health care more efficient?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SERVICES	Sarah Thomson, Thomas Foubister, and Elias Mossialos explain why charging patients for health services we want them to use makes little economic sense The United Kingdom's new government has promised not to cut public spending on health. It has also said that the NHS in England will have to make more than 20bn pound ((sic)24bn; $30bn) in efficiency savings over the next few years if it is to meet patient demand. This may lead to calls for an expanded role for user charges-both to bring more money into the health system and to make health care more efficient. Most healthcare systems require patients to pay something at the point of use (table.). Some countries apply user charges to all health services; others, like England, use them more sparingly (box 1). In this article we explain why user charges may undermine efficiency, and show how a few countries are developing a more sophisticated approach to user charges to ensure this does not happen. We also ask whether the English NHS should follow their example.	[Thomson, Sarah; Foubister, Thomas; Mossialos, Elias] LSE Hlth, London WC2A 2AE, England; [Thomson, Sarah; Mossialos, Elias] European Observ Hlth Syst & Policies, London, England	University of London; London School Economics & Political Science; European Observatory on Health Systems & Policies	Thomson, S (corresponding author), LSE Hlth, London WC2A 2AE, England.	s.thomson@lse.ac.uk	Mossialos, Elias/ABE-1301-2021					[Anonymous], PRESCR DISP COMM STA; BLUM K, 2007, HLTH POLICY MONI JUL; BLUMEL M, 2009, HLTH POLICY MONI APR; Braithwaite RS, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000234; Chernew M, 2010, J GEN INTERN MED, V25, P243, DOI 10.1007/s11606-009-1219-y; Chernew ME, 2008, AM J MANAG CARE, V14, P412; Chernew ME, 2007, HEALTH AFFAIR, V26, pW195, DOI 10.1377/hlthaff.26.2.w195; *CIT ADV BUR, 2001, UNH CHARG; DOURGNON P, 2007, HLTH EC LETT, V124, P1; DURANDZALESKI I, 2008, MANAGING CHRONIC CON; Furness D., 2009, FEAST FAMINE REFORMI; Gemmill MC, 2008, INT J EQUITY HEALTH, V7, DOI 10.1186/1475-9276-7-12; *HC COMM PUBL ACC, 2008, SESS 2007 08; *HC HLTH COMM, 2006, NHS CHARG, V1; HESSE S, 2004, HLTH POLICY MONI DEC; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; *KAIS FAM FDN, 2008, PRESCR DRUG TRENDS; Kmietowicz Z, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2600; Liebman J, 2008, 14330 NBER; LOHR KN, 1986, MED CARE, V24, pUS1; Newhouse JP, 1993, FREE ALL LESSONS RAN; PAULY MV, 1968, AM ECON REV, V58, P531; POLTON D, 2004, HLTH POLICY MONI OCT; Roland M, 2004, NEW ENGL J MED, V351, P1448, DOI 10.1056/NEJMhpr041294; Ruckert IM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-232; SANDIER S, 2004, FRANCE HLTH CARE SYS; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006	28	22	23	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2010	341								c3759	10.1136/bmj.c3759	http://dx.doi.org/10.1136/bmj.c3759			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642KT	20719824				2022-12-28	WOS:000281213100008
J	Ofri, D				Ofri, Danielle			Quality Measures and the Individual Physician	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OF-CARE; PERFORMANCE; GUIDELINES		[Ofri, Danielle] NYU, Sch Med, New York, NY 10003 USA; [Ofri, Danielle] Bellevue Hosp, New York, NY USA	New York University; Bellevue Hospital Center	Ofri, D (corresponding author), NYU, Sch Med, New York, NY 10003 USA.			Ofri, Danielle/0000-0001-9865-7104				Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Persell SD, 2010, ANN INTERN MED, V152, P225, DOI 10.7326/0003-4819-152-4-201002160-00007; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Werner RM, 2005, JAMA-J AM MED ASSOC, V293, P1239, DOI 10.1001/jama.293.10.1239	5	11	12	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					606	607		10.1056/NEJMp1006298	http://dx.doi.org/10.1056/NEJMp1006298			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	636TN	20818853				2022-12-28	WOS:000280764600003
J	Koenigs, M; Young, L; Adolphs, R; Tranel, D; Cushman, F; Hauser, M; Damasio, A				Koenigs, M.; Young, L.; Adolphs, R.; Tranel, D.; Cushman, F.; Hauser, M.; Damasio, A.			Do abnormal responses show utilitarian bias? Reply	NATURE			English	Letter							MORAL JUDGMENT		[Koenigs, M.; Adolphs, R.; Tranel, D.; Damasio, A.] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA; [Young, L.; Cushman, F.; Hauser, M.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; [Adolphs, R.] CALTECH, Div Humanities & Social Sci, Pasadena, CA 91125 USA; [Adolphs, R.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Damasio, A.] Univ So Calif, Brain & Creativ Inst, Los Angeles, CA 90089 USA; [Damasio, A.] Univ So Calif, Dornsife Ctr Cognit Neuroimaging, Los Angeles, CA 90089 USA	University of Iowa; Harvard University; California Institute of Technology; California Institute of Technology; University of Southern California; University of Southern California	Koenigs, M (corresponding author), Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA.	radolphs@hss.caltech.edu	Damasio, Antonio/AAD-1342-2019	Koenigs, Michael/0000-0002-5799-4881; Cushman, Fiery/0000-0002-6929-9982; Tranel, Daniel/0000-0002-1338-1389				Ciaramelli E, 2007, SOC COGN AFFECT NEUR, V2, P84, DOI 10.1093/scan/nsm001; Cushman F, 2006, PSYCHOL SCI, V17, P1082, DOI 10.1111/j.1467-9280.2006.01834.x; Hauser M.D., 2006, MORAL MINDS; KAHANE G, 2008, NATURE, V452; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Valdesolo P, 2006, PSYCHOL SCI, V17, P476, DOI 10.1111/j.1467-9280.2006.01731.x; Wheatley T, 2005, PSYCHOL SCI, V16, P780, DOI 10.1111/j.1467-9280.2005.01614.x; Young L, 2007, P NATL ACAD SCI USA, V104, P8235, DOI 10.1073/pnas.0701408104	8	6	6	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2008	452	7185					E5	E6		10.1038/nature06804	http://dx.doi.org/10.1038/nature06804			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276BX	20721302				2022-12-28	WOS:000254117400036
J	WARDEN, J				WARDEN, J			PARLIAMENTS 2 WAY PULL ON THE NHS	BRITISH MEDICAL JOURNAL			English	Letter																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1988	296	6638					1749	1749		10.1136/bmj.296.6638.1749	http://dx.doi.org/10.1136/bmj.296.6638.1749			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	N8893	20743006	Green Published			2022-12-28	WOS:A1988N889300060
J	Tsukahara, T; Tanno, Y; Watanabe, Y				Tsukahara, Tatsuya; Tanno, Yuji; Watanabe, Yoshinori			Phosphorylation of the CPC by Cdk1 promotes chromosome bi-orientation	NATURE			English	Article							SISTER-CHROMATID COHESION; FISSION YEAST; CELL-DIVISION; SCHIZOSACCHAROMYCES-POMBE; AURORA-B; MICROTUBULE ATTACHMENT; PASSENGER COMPLEX; INNER CENTROMERE; MITOTIC SPINDLE; MEIOSIS-I	Successful partition of replicated genomes at cell division requires chromosome attachment to opposite poles of mitotic spindle (bi-orientation). Any defects in this regulation bring about chromosomal instability, which may accelerate tumour progression in humans. To achieve chromosome bi-orientation at prometaphase, the chromosomal passenger complex (CPC), composed of catalytic kinase Aurora B and regulatory components (INCENP, Survivin and Borealin), must be localized to centromeres to phosphorylate kinetochore substrates(1-7). Although the CPC dynamically changes the subcellular localization, the regulation of centromere targeting is largely unknown(1). Here we isolated a fission yeast cyclin B mutant defective specifically in chromosome bi-orientation. Accordingly, we identified Cdk1 (also known as Cdc2)-cyclin-B-dependent phosphorylation of Survivin. Preventing Survivin phosphorylation impairs centromere CPC targeting as well as chromosome bi-orientation, whereas phosphomimetic Survivin suppresses the bi-orientation defect in the cyclin B mutant. Survivin phosphorylation promotes direct binding with shugoshin(8,9), which we now define as a conserved centromeric adaptor of the CPC. In human cells, the phosphorylation of Borealin has a comparable role. Thus, our study resolves the conserved mechanisms of CPC targeting to centromeres, highlighting a key role of Cdk1-cyclin B in chromosome bi-orientation.	[Tsukahara, Tatsuya; Watanabe, Yoshinori] Univ Tokyo, Grad Sch Sci, Grad Program Biophys & Biochem, Tokyo 1130032, Japan; [Tsukahara, Tatsuya; Tanno, Yuji; Watanabe, Yoshinori] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Chromosome Dynam, Tokyo 1130032, Japan	University of Tokyo; University of Tokyo	Watanabe, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Grad Program Biophys & Biochem, Tokyo 1130032, Japan.	ywatanab@iam.u-tokyo.ac.jp	Tsukahara, Tatsuya/AAO-1707-2021	Tsukahara, Tatsuya/0000-0002-6928-8562; Watanabe, Yoshinori/0000-0002-5488-4812	Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms); JSPS; MEXT, Japan; Grants-in-Aid for Scientific Research [21000010] Funding Source: KAKEN	Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank S. Hauf for critically reading the manuscript and the Yeast Genetic Resource Center (YGRC) for yeast strains, and all the members of our laboratory, particularly S. A. Kawashima, for their valuable support and discussion. This work was supported in part by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), JSPS Research Fellowship (to T.T. and Y.T.) and a Grant-in-Aid for Specially Promoted Research, MEXT, Japan (to Y.W.).	Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bohnert KA, 2009, MOL BIOL CELL, V20, P3646, DOI 10.1091/mbc.E09-04-0289; Boyarchuk Y, 2007, J CELL BIOL, V176, P919, DOI 10.1083/jcb.200609044; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Chen Q, 2008, CELL RES, V18, P268, DOI 10.1038/cr.2008.11; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; Holt LJ, 2009, SCIENCE, V325, P1682, DOI 10.1126/science.1172867; Huang HM, 2007, J CELL BIOL, V177, P413, DOI 10.1083/jcb.200701122; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Kawashima SA, 2007, GENE DEV, V21, P420, DOI 10.1101/gad.1497307; Kawashima SA, 2010, SCIENCE, V327, P172, DOI 10.1126/science.1180189; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Kitajima TS, 2005, CURR BIOL, V15, P353, DOI 10.1016/j.cub.2004.12.044; Klein UR, 2006, MOL BIOL CELL, V17, P2547, DOI 10.1091/mbc.E05-12-1133; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Liu D, 2009, SCIENCE, V323, P1350, DOI 10.1126/science.1167000; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Rajagopalan S, 2002, GENETICS, V160, P445; Resnick TD, 2006, DEV CELL, V11, P57, DOI 10.1016/j.devcel.2006.04.021; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Tanaka TU, 2008, CHROMOSOMA, V117, P521, DOI 10.1007/s00412-008-0173-5; Tang ZY, 2004, P NATL ACAD SCI USA, V101, P18012, DOI 10.1073/pnas.0408600102; Vanoosthuyse V, 2007, MOL BIOL CELL, V18, P1657, DOI 10.1091/mbc.E06-10-0890; Watanabe Y, 2005, CURR OPIN CELL BIOL, V17, P590, DOI 10.1016/j.ceb.2005.10.003; Xu Z, 2009, MOL CELL, V35, P426, DOI 10.1016/j.molcel.2009.06.031; Yamagishi Y, 2008, NATURE, V455, P251, DOI 10.1038/nature07217; Yokobayashi S, 2003, MOL CELL BIOL, V23, P3965, DOI 10.1128/MCB.23.11.3965-3973.2003; Yokobayashi S, 2005, CELL, V123, P803, DOI 10.1016/j.cell.2005.09.013	35	179	183	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	2010	467	7316					719	U111		10.1038/nature09390	http://dx.doi.org/10.1038/nature09390			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20739936				2022-12-28	WOS:000282572500041
J	Balskus, EP; Walsh, CT				Balskus, Emily P.; Walsh, Christopher T.			The Genetic and Molecular Basis for Sunscreen Biosynthesis in Cyanobacteria	SCIENCE			English	Article							AMINO-ACIDS; MYCOSPORINES; SUPERFAMILY; ORGANISMS; PATHWAY; ENZYMES; GENOME	Ultraviolet UV-A and UV-B radiation is harmful to living systems, causing damage to biological macromolecules. An important strategy for dealing with UV exposure is the biosynthesis of small-molecule sunscreens. Among such metabolites, the mycosporine and mycosporine-like amino acids (MAAs) are remarkable for their wide phylogenetic distribution and their unique chemical structures. Here, we report the identification of a MAA biosynthetic gene cluster in a cyanobacterium and the discovery of analogous pathways in other sequenced organisms. We have expressed the cluster in a heterologous bacterial host and characterized all four biosynthetic enzymes in vitro. In addition to clarifying the origin of the MAAs, these efforts have revealed two unprecedented enzymatic strategies for imine formation.	[Balskus, Emily P.; Walsh, Christopher T.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walsh, CT (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	christopher_walsh@hms.harvard.edu			NIH [GM-20011]; NIH NRSA [GM-084625]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, F32GM084625, R37GM020011] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a grant from the NIH (GM-20011). E. P. B. is the recipient of an NIH NRSA postdoctoral fellowship (GM-084625). We acknowledge Tri-K Industries (Northvale, NJ) for providing a sample of Helioguard 365 containing authentic standards of shinorine and porphyra-334.	Adams NL, 2001, MAR BIOL, V138, P267, DOI 10.1007/s002270000463; Bandaranayake WM, 1998, NAT PROD REP, V15, P159; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7555, DOI 10.1021/bi00445a009; Cockell CS, 1999, BIOL REV, V74, P311, DOI 10.1017/S0006323199005356; de la Coba F, 2009, J DERMATOL SCI, V55, P161, DOI 10.1016/j.jdermsci.2009.06.004; DEHORTER B, 1980, PHYTOCHEMISTRY, V19, P2311, DOI 10.1016/S0031-9422(00)91017-3; Dunlap WC, 1998, J PHYCOL, V34, P418, DOI 10.1046/j.1529-8817.1998.340418.x; FAVREBONVIN J, 1987, PHYTOCHEMISTRY, V26, P2509, DOI 10.1016/S0031-9422(00)83866-2; FAVREBONVIN J, 1976, CAN J CHEM, V54, P1105, DOI 10.1139/v76-158; Fischbach MA, 2006, CHEM REV, V106, P3468, DOI 10.1021/cr0503097; Galperin MY, 1997, PROTEIN SCI, V6, P2639; LEMOYNE F, 1985, Zeitschrift fuer Naturforschung Section C Journal of Biosciences, V40, P612; Mahmud T, 2007, J NAT PROD, V70, P1384, DOI 10.1021/np070210q; Neale PJ, 1998, J PHYCOL, V34, P928, DOI 10.1046/j.1529-8817.1998.340928.x; Oren A, 1997, GEOMICROBIOL J, V14, P231, DOI 10.1080/01490459709378046; Oren A, 2007, FEMS MICROBIOL LETT, V269, P1, DOI 10.1111/j.1574-6968.2007.00650.x; Portwich A, 2003, PHYCOLOGIA, V42, P384, DOI 10.2216/i0031-8884-42-4-384.1; Shick JM, 2002, ANNU REV PHYSIOL, V64, P223, DOI 10.1146/annurev.physiol.64.081501.155802; Singh SP, 2010, GENOMICS, V95, P120, DOI 10.1016/j.ygeno.2009.10.002; Singh SP, 2008, PHOTOCHEM PHOTOBIOL, V84, P1500, DOI 10.1111/j.1751-1097.2008.00376.x; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; Starcevic A, 2008, P NATL ACAD SCI USA, V105, P2533, DOI 10.1073/pnas.0707388105; TRIONE EJ, 1966, NATURE, V212, P163, DOI 10.1038/212163a0; WHITE JD, 1989, J AM CHEM SOC, V111, P8970, DOI 10.1021/ja00206a059; Wu X, 2007, CHEMBIOCHEM, V8, P239, DOI 10.1002/cbic.200600446; Yakovleva I, 2004, COMP BIOCHEM PHYS B, V139, P721, DOI 10.1016/j.cbpc.2004.08.016	26	224	236	1	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	2010	329	5999					1653	1656		10.1126/science.1193637	http://dx.doi.org/10.1126/science.1193637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653NK	20813918	Green Accepted, Green Submitted			2022-12-28	WOS:000282098100044
J	Muenzner, P; Bachmann, V; Zimmermann, W; Hentschel, J; Hauck, CR				Muenzner, Petra; Bachmann, Verena; Zimmermann, Wolfgang; Hentschel, Jochen; Hauck, Christof R.			Human-Restricted Bacterial Pathogens Block Shedding of Epithelial Cells by Stimulating Integrin Activation	SCIENCE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; NEISSERIA-GONORRHOEAE; HOST DEFENSES; CARCINOEMBRYONIC ANTIGENS; FOCAL ADHESIONS; ORGAN-CULTURE; OPA PROTEINS; EXPRESSION; INFECTION; RECEPTORS	Colonization of mucosal surfaces is the key initial step in most bacterial infections. One mechanism protecting the mucosa is the rapid shedding of epithelial cells, also termed exfoliation, but it is unclear how pathogens counteract this process. We found that carcinoembryonic antigen (CEA)-binding bacteria colonized the urogenital tract of CEA transgenic mice, but not of wild-type mice, by suppressing exfoliation of mucosal cells. CEA binding triggered de novo expression of the transforming growth factor receptor CD105, changing focal adhesion composition and activating beta(1) integrins. This manipulation of integrin inside-out signaling promotes efficient mucosal colonization and represents a potential target to prevent or cure bacterial infections.	[Muenzner, Petra; Bachmann, Verena; Hentschel, Jochen; Hauck, Christof R.] Univ Konstanz, Fachbereich Biol, Lehrstuhl Zellbiol, D-78457 Constance, Germany; [Zimmermann, Wolfgang] Univ Munich, LIFE Ctr, Tumor Immunol Lab, D-81377 Munich, Germany; [Hentschel, Jochen] Univ Konstanz, Fachbereich Biol, EM Serv, D-78457 Constance, Germany; [Hauck, Christof R.] Univ Konstanz, Konstanz Res Sch Chem Biol, D-78457 Constance, Germany	University of Konstanz; University of Munich; University of Konstanz; University of Konstanz	Hauck, CR (corresponding author), Univ Konstanz, Fachbereich Biol, Lehrstuhl Zellbiol, D-78457 Constance, Germany.	christof.hauck@uni-konstanz.de	Zimmermann, Wolfgang/L-9277-2013		Deutsche Forschungsgemeinschaft [Ha2856/6-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank M. C. Beckerle for zyxin-deficient fibroblasts and antibodies; M. Chudakov for the mKate cDNA; J. W. Greiner for sending the CEAtg mice; T. F. Meyer for bacterial strains; D. W. Piston for cDNA of mCerulean; A. J. Schaeffer for hVEC cells; D. Vestweber for providing antibody; C. Hentschel, J. Scharrer, and R. Mak'anyengo for assistance with SEM; and B. Planitz for expert animal care. Supported by Deutsche Forschungsgemeinschaft grant Ha2856/6-1 (C.R.H.).	Berger CN, 2004, MOL MICROBIOL, V52, P963, DOI 10.1111/j.1365-2958.2004.04033.x; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; EADESPERNER AM, 1994, CANCER RES, V54, P4169; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Hauck CR, 2003, CURR OPIN MICROBIOL, V6, P43, DOI 10.1016/S1369-5274(03)00004-3; Hill DJ, 2003, MOL MICROBIOL, V48, P117, DOI 10.1046/j.1365-2958.2003.03433.x; Hoffman LM, 2006, J CELL BIOL, V172, P771, DOI 10.1083/jcb.200512115; JERSE AE, 1994, J EXP MED, V179, P911, DOI 10.1084/jem.179.3.911; Kim M, 2009, NATURE, V459, P578, DOI 10.1038/nature07952; MCGEE ZA, 1981, J INFECT DIS, V143, P413, DOI 10.1093/infdis/143.3.413; MELLY MA, 1981, J INFECT DIS, V143, P423, DOI 10.1093/infdis/143.3.423; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; Mosleh IM, 1997, INFECT IMMUN, V65, P3391, DOI 10.1128/IAI.65.8.3391-3398.1997; Muenzner P, 2005, J CELL BIOL, V170, P825, DOI 10.1083/jcb.200412151; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Mysorekar IU, 2002, J BIOL CHEM, V277, P7412, DOI 10.1074/jbc.M110560200; Pearson JP, 2005, COLONIZATION OF MUCOSAL SURFACES, P3; SWANSON J, 1988, J EXP MED, V168, P2121, DOI 10.1084/jem.168.6.2121; TJIA KF, 1988, GRAEF ARCH CLIN EXP, V226, P341, DOI 10.1007/BF02172964; Toleman M, 2001, CELL MICROBIOL, V3, P33, DOI 10.1046/j.1462-5822.2001.00089.x; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; Virji M, 2000, MOL MICROBIOL, V36, P784, DOI 10.1046/j.1365-2958.2000.01885.x; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; Virji M, 2009, NAT REV MICROBIOL, V7, P274, DOI 10.1038/nrmicro2097; Voges M, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-117; WHO World Health Organisation STD Statistics, 2001, GLOB PREV INC SEL CU; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	30	69	71	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1197	1201		10.1126/science.1190892	http://dx.doi.org/10.1126/science.1190892			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813953	Green Submitted			2022-12-28	WOS:000281485600034
J	Si, QM; Steglich, F				Si, Qimiao; Steglich, Frank			Heavy Fermions and Quantum Phase Transitions	SCIENCE			English	Review							LIQUID BEHAVIOR; KONDO-LATTICE; HIDDEN ORDER; SUPERCONDUCTIVITY; CRITICALITY; SURFACE; MAGNETISM; PRESSURE; ELECTRON	Quantum phase transitions arise in many-body systems because of competing interactions that promote rivaling ground states. Recent years have seen the identification of continuous quantum phase transitions, or quantum critical points, in a host of antiferromagnetic heavy-fermion compounds. Studies of the interplay between the various effects have revealed new classes of quantum critical points and are uncovering a plethora of new quantum phases. At the same time, quantum criticality has provided fresh insights into the electronic, magnetic, and superconducting properties of the heavy-fermion metals. We review these developments, discuss the open issues, and outline some directions for future research.	[Si, Qimiao] Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA; [Steglich, Frank] Max Planck Inst Chem Phys Solids, D-01187 Dresden, Germany	Rice University; Max Planck Society	Si, QM (corresponding author), Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA.	qmsi@rice.edu; steglich@cpfs.mpg.de			NSF; Robert A. Welch Foundation [C-1411]; DFG Research Unit 960	NSF(National Science Foundation (NSF)); Robert A. Welch Foundation(The Welch Foundation); DFG Research Unit 960(German Research Foundation (DFG))	We thank E. Abrahams, M. Brando, P. Coleman, S. Friedemann, P. Gegenwart, C. Geibel, F. M. Grosche, S. Kirchner, C. Krellner, M. Nicklas, T. Park, J. Pixley, O. Stockert, J. D. Thompson, S. Wirth, and S. Yamamoto for useful discussions. This work has been supported by NSF and the Robert A. Welch Foundation grant C-1411 (Q. S.) and by the DFG Research Unit 960 "Quantum Phase Transitions" (F.S.).	ARONSON MC, 1995, PHYS REV LETT, V75, P725, DOI 10.1103/PhysRevLett.75.725; Aynajian P, 2010, P NATL ACAD SCI USA, V107, P10383, DOI 10.1073/pnas.1005892107; Balents L, 2010, NATURE, V464, P199, DOI 10.1038/nature08917; BREDL CD, 1978, Z PHYS B CON MAT, V29, P327, DOI 10.1007/BF01324030; Coleman P, 2001, J PHYS-CONDENS MAT, V13, pR723, DOI 10.1088/0953-8984/13/35/202; CONTINENTINO MA, 1993, PHYS REV B, V47, P11587, DOI 10.1103/PhysRevB.47.11587; Cooper RA, 2009, SCIENCE, V323, P603, DOI 10.1126/science.1165015; Custers J, 2003, NATURE, V424, P524, DOI 10.1038/nature01774; Doiron-Leyraud N, 2007, NATURE, V447, P565, DOI 10.1038/nature05872; DONIACH S, 1977, PHYSICA B & C, V91, P231, DOI 10.1016/0378-4363(77)90190-5; Friedemann S, 2009, NAT PHYS, V5, P465, DOI 10.1038/NPHYS1299; FRIEDEMANN S, 2010, P NATL ACAD SCI US; Gegenwart P, 2007, SCIENCE, V315, P969, DOI 10.1126/science.1136020; Gegenwart P, 2008, NAT PHYS, V4, P186, DOI 10.1038/nphys892; Grigera SA, 2001, SCIENCE, V294, P329, DOI 10.1126/science.1063539; Grosche FM, 2001, J PHYS-CONDENS MAT, V13, P2845, DOI 10.1088/0953-8984/13/12/309; Hegger H, 2000, PHYS REV LETT, V84, P4986, DOI 10.1103/PhysRevLett.84.4986; HERTZ JA, 1976, PHYS REV B, V14, P1165, DOI 10.1103/PhysRevB.14.1165; Hewson A C, 1993, KONDO PROBLEM HEAVY; Klebanov IR, 2009, PHYS TODAY, V62, P28, DOI 10.1063/1.3074260; Klein M, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.266404; Knafo W, 2009, NAT PHYS, V5, P753, DOI 10.1038/NPHYS1374; Krellner C, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.196402; Ma S. K., 2000, MODERN THEORY CRITIC; MAPLE MB, 1994, J LOW TEMP PHYS, V95, P225, DOI 10.1007/BF00754938; MILLIS AJ, 1993, PHYS REV B, V48, P7183, DOI 10.1103/PhysRevB.48.7183; Moriya T., 1985, SPIN FLUCTUATIONS IT; Nakatsuji S, 2008, NAT PHYS, V4, P603, DOI 10.1038/nphys1002; Osborne I, 2008, SCIENCE, V319, P1201, DOI 10.1126/science.319.5867.1201; Paschen S, 2004, NATURE, V432, P881, DOI 10.1038/nature03129; Paul I, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.026402; Rost AW, 2009, SCIENCE, V325, P1360, DOI 10.1126/science.1176627; Schmidt AR, 2010, NATURE, V465, P570, DOI 10.1038/nature09073; Schroder A, 2000, NATURE, V407, P351, DOI 10.1038/35030039; Sebastian SE, 2009, P NATL ACAD SCI USA, V106, P7741, DOI 10.1073/pnas.0811859106; Senthil T, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.035111; Shishido H, 2005, J PHYS SOC JPN, V74, P1103, DOI 10.1143/JPSJ.74.1103; Shishido H, 2010, SCIENCE, V327, P980, DOI 10.1126/science.1183376; Si QM, 2006, PHYSICA B, V378-80, P23, DOI 10.1016/j.physb.2006.01.156; Si QM, 2001, NATURE, V413, P804, DOI 10.1038/35101507; STEGLICH F, 1979, PHYS REV LETT, V43, P1892, DOI 10.1103/PhysRevLett.43.1892; Stockert O, 2008, PHYSICA B, V403, P973, DOI 10.1016/j.physb.2007.10.110; Stockert O, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.237203; Stockert O, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.136401; Tokiwa Y, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.066401; Tokiwa Y, 2009, J PHYS SOC JPN, V78, DOI 10.1143/JPSJ.78.123708; VARMA CM, 1976, REV MOD PHYS, V48, P219, DOI 10.1103/RevModPhys.48.219; von Lohneysen H, 2007, REV MOD PHYS, V79, P1015, DOI 10.1103/RevModPhys.79.1015; Watanabe S, 2009, J PHYS SOC JPN, V78, DOI 10.1143/JPSJ.78.104706; 2010, PHYS STATUS SOLIDI B, V247, P457	51	386	389	8	204	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2010	329	5996					1161	1166		10.1126/science.1191195	http://dx.doi.org/10.1126/science.1191195			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813946	Green Submitted			2022-12-28	WOS:000281485600024
J	Cabernard, C; Prehoda, KE; Doe, CQ				Cabernard, Clemens; Prehoda, Kenneth E.; Doe, Chris Q.			A spindle-independent cleavage furrow positioning pathway	NATURE			English	Article							NONMUSCLE MYOSIN-II; DROSOPHILA NEUROBLASTS; ASYMMETRIC DIVISIONS; CELL-DIVISION; CORTICAL POLARITY; CONTRACTILE RING; PROTEIN COMPLEX; ALPHA-I; CYTOKINESIS; ORIENTATION	The mitotic spindle determines the cleavage furrow site during metazoan cell division(1,2), but whether other mechanisms exist remains unknown. Here we identify a spindle-independent mechanism for cleavage furrow positioning in Drosophila neuroblasts. We show that early and late furrow proteins (Pavarotti, Anillin, and Myosin) are localized to the neuroblast basal cortex at anaphase onset by a Pins cortical polarity pathway, and can induce a basally displaced furrow even in the complete absence of a mitotic spindle. Rotation or displacement of the spindle results in two furrows: an early polarity-induced basal furrow and a later spindle-induced furrow. This spindle-independent cleavage furrow mechanism may be relevant to other highly polarized mitotic cells, such as mammalian neural progenitors.	[Cabernard, Clemens; Doe, Chris Q.] Univ Oregon, Howard Hughes Med Inst, Eugene, OR 97403 USA; [Cabernard, Clemens; Prehoda, Kenneth E.; Doe, Chris Q.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; [Cabernard, Clemens; Doe, Chris Q.] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon; University of Oregon; University of Oregon	Doe, CQ (corresponding author), Univ Oregon, Howard Hughes Med Inst, Eugene, OR 97403 USA.	cdoe@uoregon.edu	Cabernard, Clemens/A-9033-2010	Cabernard, Clemens/0000-0003-3706-6401; Prehoda, Ken/0000-0003-4214-6158	National Institutes of Health [GM068032]; American Heart Association; Swiss National Science Foundation; HHMI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068032] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); HHMI(Howard Hughes Medical Institute); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Brand, D. Glover, C.-Y. Lee, M. Peifer, J. Raff, E. Wieschaus, A. Wilde, and the Bloomington and Vienna Drosophila RNAi Center stock centres for fly stocks and/or antibody reagents; R. Andersen, B. Bowerman, M. Goulding and B. Nolan for comments on the manuscript; and T. Gillies and K. Hirono for technical support. This work was supported by the National Institutes of Health (GM068032; to K. P.), the American Heart Association (to C. C. and K. P.), the Swiss National Science Foundation (to C. C.) and HHMI (to C.Q.D.).	Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Barros CS, 2003, DEV CELL, V5, P829, DOI 10.1016/S1534-5807(03)00359-9; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Bonaccorsi S, 2000, NAT CELL BIOL, V2, P54, DOI 10.1038/71378; Bonaccorsi S, 1998, J CELL BIOL, V142, P751, DOI 10.1083/jcb.142.3.751; Bowman SK, 2006, DEV CELL, V10, P731, DOI 10.1016/j.devcel.2006.05.005; Buszczak M, 2007, GENETICS, V175, P1505, DOI 10.1534/genetics.106.065961; Cabernard C, 2009, DEV CELL, V17, P134, DOI 10.1016/j.devcel.2009.06.009; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; CONRAD GW, 1974, DEV BIOL, V36, P363, DOI 10.1016/0012-1606(74)90058-X; Deng MQ, 2007, DEV CELL, V12, P301, DOI 10.1016/j.devcel.2006.11.008; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; Foe VE, 2008, J CELL BIOL, V183, P457, DOI 10.1083/jcb.200807128; Fuse N, 2003, CURR BIOL, V13, P947, DOI 10.1016/S0960-9822(03)00334-8; Giansanti MG, 2008, CURR BIOL, V18, P303, DOI 10.1016/j.cub.2008.01.058; Giansanti MG, 2001, DEVELOPMENT, V128, P1137; Guan ZH, 2000, P NATL ACAD SCI USA, V97, P8122, DOI 10.1073/pnas.97.14.8122; Hickson GRX, 2006, CURR BIOL, V16, P359, DOI 10.1016/j.cub.2005.12.043; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Izumi Y, 2006, NAT CELL BIOL, V8, P586, DOI 10.1038/ncb1409; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; Kosodo Y, 2008, EMBO J, V27, P3151, DOI 10.1038/emboj.2008.227; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Martin AC, 2009, NATURE, V457, P495, DOI 10.1038/nature07522; Megraw TL, 2001, CURR BIOL, V11, P116, DOI 10.1016/S0960-9822(01)00017-3; Minestrini G, 2003, MOL BIOL CELL, V14, P4028, DOI 10.1091/mbc.E03-04-0214; Oliferenko S, 2009, GENE DEV, V23, P660, DOI 10.1101/gad.1772009; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Royou A, 2002, J CELL BIOL, V158, P127, DOI 10.1083/jcb.200203148; Siegrist SE, 2005, CELL, V123, P1323, DOI 10.1016/j.cell.2005.09.043; Siegrist SE, 2006, DEVELOPMENT, V133, P529, DOI 10.1242/dev.02211; Siller KH, 2006, NAT CELL BIOL, V8, P594, DOI 10.1038/ncb1412; Silverman-Gavrila RV, 2008, MOL BIOL CELL, V19, P3735, DOI 10.1091/mbc.E08-01-0049; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; von Dassow G, 2009, TRENDS CELL BIOL, V19, P165, DOI 10.1016/j.tcb.2009.01.008; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174	41	123	123	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					91	U124		10.1038/nature09334	http://dx.doi.org/10.1038/nature09334			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811457	Green Accepted			2022-12-28	WOS:000281461200041
J	Pasternak, B; Hviid, A				Pasternak, Bjorn; Hviid, Anders			Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HERPES-SIMPLEX-VIRUS; GENITAL HERPES; REGISTRATION; INFECTION; ZOSTER; OUTCOMES; SAFETY; TYPE-1; RATES	Context Herpes simplex and herpes zoster infections are common and often treated with antiviral drugs including acyclovir, valacyclovir, and famciclovir. Safety of these antivirals when used in the first trimester of pregnancy is insufficiently documented. Objective To investigate associations between exposure to acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and risk of major birth defects. Design, Setting, and Participants Population-based historical cohort study of 837 795 live-born infants in Denmark from January 1, 1996, to September 30, 2008. Participants had no diagnoses of chromosomal aberrations, genetic syndromes, birth defect syndromes with known causes, or congenital viral infections. Nationwide registries were used to ascertain individual-level information on dispensed antiviral drugs, birth defect diagnoses (categorized according to a standardized classification scheme), and potential confounders. Main Outcome Measure Prevalence odds ratios (PORs) of any major birth defect diagnosed within the first year of life by exposure to antiviral drugs. Results Among 1804 pregnancies exposed to acyclovir, valacyclovir, or famciclovir in the first trimester, 40 infants (2.2%) were diagnosed with a major birth defect compared with 19 920 (2.4%) among the unexposed (adjusted POR, 0.89; 95% confidence interval [CI], 0.65-1.22). For individual antivirals, a major birth defect was diagnosed in 32 of 1561 infants (2.0%) with first-trimester exposure to acyclovir (adjusted POR, 0.82; 95% Cl, 0.57-1.17) and in 7 of 229 infants (3.1%) with first-trimester exposure to valacyclovir (adjusted POR, 1.21; 95% CI, 0.56-2.62). Famciclovir exposure was uncommon (n=26), with 1 infant (3.8%) diagnosed with a birth defect. Exploratory analyses revealed no associations between antiviral drug exposure and 13 different subgroups of birth defects, but the number of exposed cases in each subgroup was small. Conclusion In this large nationwide cohort, exposure to acyclovir or valacyclovir in the first trimester of pregnancy was not associated with an increased risk of major birth defects. JAMA. 2010;304(8):859-866	[Pasternak, Bjorn; Hviid, Anders] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark	Statens Serum Institut	Pasternak, B (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	bjp@ssi.dk	Hviid, Anders/AAH-4319-2020; Pasternak, Bjorn/H-5739-2012	Hviid, Anders/0000-0002-7509-9127; Pasternak, Bjorn/0000-0002-2097-8466	Danish Medical Research Council; Lundbeck Foundation	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden)	This work was supported by grants from the Danish Medical Research Council and the Lundbeck Foundation.	Andersen TF, 1999, DAN MED BULL, V46, P263; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; Buhimschi CS, 2009, OBSTET GYNECOL, V113, P166, DOI 10.1097/AOG.0b013e31818d6788; Cernik C, 2008, ARCH INTERN MED, V168, P1137, DOI 10.1001/archinte.168.11.1137; CHAHOUD I, 1988, ARCH TOXICOL, V62, P8, DOI 10.1007/BF00316250; *DANM STAT, RES DAT DAT SOURC AV; *EUR NETW, COD EUR SUBGR CONG A; *EUR NETW, MIN AN EXCL; Jepsen P, 2006, INT J RISK SAF MED, V18, P77; Jorgensen Finn Stener, 2003, Ugeskr Laeger, V165, P4409; Knudsen LB, 1998, DAN MED BULL, V45, P320; Kristensen J, 1996, J CLIN EPIDEMIOL, V49, P893, DOI 10.1016/0895-4356(96)00018-2; Larsen H, 2003, SCAND J PUBLIC HEALT, V31, P12, DOI 10.1080/14034940210134194; MOORE HL, 1983, FUND APPL TOXICOL, V3, P560, DOI 10.1016/S0272-0590(83)80105-5; Pedersen CB, 2006, DAN MED BULL, V53, P441; Ratanajamit C, 2003, SCAND J INFECT DIS, V35, P255, DOI 10.1080/00365540310000229; SALTZMAN R, 1994, ANTIMICROB AGENTS CH, V38, P2454, DOI 10.1128/AAC.38.10.2454; Sen P, 2007, BMJ-BRIT MED J, V334, P1048, DOI 10.1136/bmj.39189.504306.55; Smith JS, 2002, J INFECT DIS, V186, pS3, DOI 10.1086/343739; Stone KM, 2004, BIRTH DEFECTS RES A, V70, P201, DOI 10.1002/bdra.20013; Tyring SK, 2002, J INFECT DIS, V186, pS40, DOI 10.1086/342966; *US FDA, 2005, ZOV AC PROD INF; *US FDA, 2008, VALTR VAL PROD INF; *US FDA, 2009, FAMV FAMC PROD INF; Wareham DW, 2007, BMJ-BRIT MED J, V334, P1211, DOI 10.1136/bmj.39206.571042.AE; Wilton LV, 1998, BRIT J OBSTET GYNAEC, V105, P882, DOI 10.1111/j.1471-0528.1998.tb10234.x; Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964; Yawn BP, 2007, MAYO CLIN PROC, V82, P1341, DOI 10.4065/82.11.1341	29	114	118	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					859	866		10.1001/jama.2010.1206	http://dx.doi.org/10.1001/jama.2010.1206			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736469	Bronze			2022-12-28	WOS:000281389900023
J	Corbett, KD; Yip, CK; Ee, LS; Walz, T; Amon, A; Harrison, SC				Corbett, Kevin D.; Yip, Calvin K.; Ee, Ly-Sha; Walz, Thomas; Amon, Angelika; Harrison, Stephen C.			The Monopolin Complex Crosslinks Kinetochore Components to Regulate Chromosome-Microtubule Attachments	CELL			English	Article							PROTEIN-INTERACTION MAP; MEIOSIS-I; SACCHAROMYCES-CEREVISIAE; MOLECULAR ARCHITECTURE; DNA-REPLICATION; SISTER KINETOCHORES; YEAST KINETOCHORE; NDC80 COMPLEX; RIBOSOMAL DNA; CELL-CYCLE	The monopolin complex regulates different types of kinetochore-microtubule attachments in fungi, ensuring sister chromatid co-orientation in Saccharomyces cerevisiae meiosis I and inhibiting merotelic attachment in Schizosaccharomyces pombe mitosis. In addition, the monopolin complex maintains the integrity and silencing of ribosomal DNA ( rDNA) repeats in the nucleolus. We show here that the S. cerevisiae Csm1/Lrs4 monopolin subcomplex has a distinctive V-shaped structure, with two pairs of protein-protein interaction domains positioned similar to 10 nm apart. Csm1 presents a conserved hydrophobic surface patch that binds two kinetochore proteins: Dsn1, a subunit of the outer-kinetochore MIND/Mis12 complex, and Mif2/CENP-C. Csm1 point-mutations that disrupt kinetochore-subunit binding also disrupt sister chromatid co-orientation in S. cerevisiae meiosis I. We further show that the same Csm1 point-mutations affect rDNA silencing, probably by disrupting binding to the rDNA-associated protein Tof2. We propose that Csm1/Lrs4 functions as a molecular clamp, crosslinking kinetochore components to enforce sister chromatid co-orientation in S. cerevisiae meiosis I and to suppress merotelic attachment in S. pombe mitosis, and crosslinking rDNA repeats to aid rDNA silencing.	[Corbett, Kevin D.; Harrison, Stephen C.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Yip, Calvin K.; Walz, Thomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Ee, Ly-Sha; Amon, Angelika] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Walz, Thomas; Amon, Angelika; Harrison, Stephen C.] Howard Hughes Med Inst, Chevy Chase, MD USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute	Harrison, SC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	harrison@crystal.harvard.edu		Amon, Angelika/0000-0001-9837-0314; Walz, Thomas/0000-0003-2606-2835; Corbett, Kevin/0000-0001-5854-2388; Yip, Calvin/0000-0003-1779-9501	Helen Hay Whitney Foundation; Jane Coffin Childs Memorial Fund for Medical Research; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062207] Funding Source: NIH RePORTER	Helen Hay Whitney Foundation; Jane Coffin Childs Memorial Fund for Medical Research; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the staff at the Advanced Photon Source NE-CAT beamlines for advice and assistance with data collection and interpretation; D. Moazed for the gift of S. cerevisiae strains and valuable advice; M. Sawaya for providing advice and script files for anisotropic scaling; J. Al-Bassam for assistance with electron microscopy; members of the Amon laboratory, especially I. Brito and E. Unal, for advice, assistance with yeast strain construction, and light microscopy; and members of the Harrison laboratory and I. Cheeseman for helpful discussions. K.D.C. acknowledges a postdoctoral fellowship from the Helen Hay Whitney Foundation; C.K.Y. acknowledges a postdoctoral fellowship from the Jane Coffin Childs Memorial Fund for Medical Research; T.W., A.A, and S.C.H. are Investigators in the Howard Hughes Medical Institute.	Brito IL, 2010, GENETICS, V185, P55, DOI 10.1534/genetics.110.115139; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Choi SH, 2009, CURR BIOL, V19, P985, DOI 10.1016/j.cub.2009.05.042; Ciferri C, 2008, CELL, V133, P427, DOI 10.1016/j.cell.2008.03.020; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DING R, 1993, J CELL BIOL, V120, P141, DOI 10.1083/jcb.120.1.141; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gregan J, 2007, CURR BIOL, V17, P1190, DOI 10.1016/j.cub.2007.06.044; Huang J, 2003, GENE DEV, V17, P2162, DOI 10.1101/gad.1108403; Huang J, 2006, GENE DEV, V20, P2887, DOI 10.1101/gad.1472706; Joglekar AP, 2008, J CELL BIOL, V181, P587, DOI 10.1083/jcb.200803027; Joglekar AP, 2006, NAT CELL BIOL, V8, P581, DOI 10.1038/ncb1414; Johzuka K, 2009, MOL CELL, V34, P26, DOI 10.1016/j.molcel.2009.02.021; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Katis VL, 2004, CURR BIOL, V14, P2183, DOI 10.1016/j.cub.2004.12.020; Lee B, 2001, CURR OPIN CELL BIOL, V13, P770, DOI 10.1016/S0955-0674(00)00282-9; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Li XX, 2009, NAT CELL BIOL, V11, P1103, DOI 10.1038/ncb1923; LO HC, 1980, MOL BIOL CELL, V19, P4956; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Marston AL, 2004, NAT REV MOL CELL BIO, V5, P983, DOI 10.1038/nrm1526; Matos J, 2008, CELL, V135, P662, DOI 10.1016/j.cell.2008.10.026; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; Mekhail K, 2008, NATURE, V456, P667, DOI 10.1038/nature07460; Monje-Casas F, 2007, CELL, V128, P477, DOI 10.1016/j.cell.2006.12.040; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70; Petronczki M, 2006, CELL, V126, P1049, DOI 10.1016/j.cell.2006.07.029; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Tanaka K, 2009, DEV CELL, V17, P334, DOI 10.1016/j.devcel.2009.08.004; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Wei RR, 2007, NAT STRUCT MOL BIOL, V14, P54, DOI 10.1038/nsmb1186; Wei RR, 2006, STRUCTURE, V14, P1003, DOI 10.1016/j.str.2006.04.007; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Winey M, 2005, MOL BIOL CELL, V16, P1178, DOI 10.1091/mbc.E04-09-0765; Wong J, 2007, MOL BIOL CELL, V18, P3800, DOI 10.1091/mbc.E07-06-0536; Wysocka M, 2004, EXP CELL RES, V294, P592, DOI 10.1016/j.yexcr.2003.12.008; Yokobayashi S, 2005, CELL, V123, P803, DOI 10.1016/j.cell.2005.09.013; Yu HY, 2008, SCIENCE, V322, P104, DOI 10.1126/science.1158684	44	90	91	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					556	567		10.1016/j.cell.2010.07.017	http://dx.doi.org/10.1016/j.cell.2010.07.017			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723757	Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000281115900010
J	Zhou, XL; Wang, JL; Lu, J; Song, YP; Kwak, KS; Jiao, QS; Rosenfeld, R; Chen, Q; Boone, T; Simonet, WS; Lacey, DL; Goldberg, AL; Han, HQ				Zhou, Xiaolan; Wang, Jin Lin; Lu, John; Song, Yanping; Kwak, Keith S.; Jiao, Qingsheng; Rosenfeld, Robert; Chen, Qing; Boone, Thomas; Simonet, W. Scott; Lacey, David L.; Goldberg, Alfred L.; Han, H. Q.			Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival	CELL			English	Article							ACTIVIN-A; SATELLITE CELL; TUMOR PROGRESSION; HEART-FAILURE; MYOSTATIN; ATROPHY; INHIBIN; ACTIVATION; MECHANISMS; EXPRESSION	Muscle wasting and cachexia have long been postulated to be key determinants of cancer-related death, but there has been no direct experimental evidence to substantiate this hypothesis. Here, we show that in several cancer cachexia models, pharmacological blockade of ActRIIB pathway not only prevents further muscle wasting but also completely reverses prior loss of skeletal muscle and cancer-induced cardiac atrophy. This treatment dramatically prolongs survival, even of animals in which tumor growth is not inhibited and fat loss and production of proinflammatory cytokines are not reduced. ActRIIB pathway blockade abolished the activation of the ubiquitin-proteasome system and the induction of atrophy-specific ubiquitin ligases in muscles and also markedly stimulated muscle stem cell growth. These findings establish a crucial link between activation of the ActRIIB pathway and the development of cancer cachexia. Thus ActRIIB antagonism is a promising new approach for treating cancer cachexia, whose inhibition per se prolongs survival.	[Zhou, Xiaolan; Wang, Jin Lin; Lu, John; Song, Yanping; Kwak, Keith S.; Jiao, Qingsheng; Rosenfeld, Robert; Chen, Qing; Boone, Thomas; Simonet, W. Scott; Lacey, David L.; Han, H. Q.] Amgen Res, Dept Metab Disorders, Thousand Oaks, CA 91360 USA; [Zhou, Xiaolan; Wang, Jin Lin; Lu, John; Song, Yanping; Kwak, Keith S.; Jiao, Qingsheng; Rosenfeld, Robert; Chen, Qing; Boone, Thomas; Simonet, W. Scott; Lacey, David L.; Han, H. Q.] Amgen Res, Dept Prot Sci, Thousand Oaks, CA 91360 USA; [Goldberg, Alfred L.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Han, HQ (corresponding author), Amgen Res, Dept Metab Disorders, Thousand Oaks, CA 91360 USA.	hqhan@amgen.com			National Institutes of Health (NIA); Muscular Dystrophy Association	National Institutes of Health (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Muscular Dystrophy Association(Muscular Dystrophy Association)	We thank Dr. Martin Matzuk for breeding pairs of inhibin-alpha KO mice. We also thank Amgen Protein Science for reagent support, George Doellgast for PK assay, Keith Kelley for confocal microscopy and Keith Langley for helpful comment.; X.Z., J.L.W., J.L., Y.S., K.S.K., R.R., Q.J., Q.C., T.B., W.S.S., D.L.L. and H.Q.H. are all current or former employees of Amgen Inc. A.L.G. is professor of Harvard Medical School and has a consulting agreement with Amgen. His research is supported by grants from the National Institutes of Health (NIA) and the Muscular Dystrophy Association.	Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004; Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Cipriano SC, 2000, ENDOCRINOLOGY, V141, P2319, DOI 10.1210/en.141.7.2319; Coerver KA, 1996, MOL ENDOCRINOL, V10, P534, DOI 10.1210/me.10.5.534; Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052; Costelli P, 2008, EUR J CLIN INVEST, V38, P531, DOI 10.1111/j.1365-2362.2008.01970.x; Dhawan J, 2005, TRENDS CELL BIOL, V15, P666, DOI 10.1016/j.tcb.2005.10.007; Fearon KCH, 2008, EUR J CANCER, V44, P1124, DOI 10.1016/j.ejca.2008.02.033; Glass DJ, 2005, INT J BIOCHEM CELL B, V37, P1974, DOI 10.1016/j.biocel.2005.04.018; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Harada K, 1996, J CLIN ENDOCR METAB, V81, P2125, DOI 10.1210/jc.81.6.2125; Heineke J, 2010, CIRCULATION, V121, P419, DOI 10.1161/CIRCULATIONAHA.109.882068; HELLERSTEIN HK, 1950, CIRCULATION, V1, P93, DOI 10.1161/01.CIR.1.1.93; Kuang S, 2008, TRENDS MOL MED, V14, P82, DOI 10.1016/j.molmed.2007.12.004; Kwak KS, 2004, CANCER RES, V64, P8193, DOI 10.1158/0008-5472.CAN-04-2102; Lee SJ, 2005, P NATL ACAD SCI USA, V102, P18117, DOI 10.1073/pnas.0505996102; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Li QL, 2007, MOL HUM REPROD, V13, P675, DOI 10.1093/molehr/gam055; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; MOORE R, 1993, DEVELOPMENT, V117, P1409; MORI M, 1991, CANCER RES, V51, P6656; Otani T, 2001, GYNECOL ONCOL, V83, P31, DOI 10.1006/gyno.2001.6350; Petraglia F, 1998, J CLIN ENDOCR METAB, V83, P1194, DOI 10.1210/jc.83.4.1194; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; RODGERS BD, 2009, J PHYSL, V15, P4873; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sartori R, 2009, AM J PHYSIOL-CELL PH, V296, pC1248, DOI 10.1152/ajpcell.00104.2009; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Seder CW, 2009, NEOPLASIA, V11, P388, DOI 10.1593/neo.81582; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Souza TA, 2008, MOL ENDOCRINOL, V22, P2689, DOI 10.1210/me.2008-0290; Springer J, 2010, CIRCULATION, V121, P354, DOI 10.1161/CIR.0b013e3181d0ba8b; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; TANAKA M, 1993, CANCER LETT, V72, P65, DOI 10.1016/0304-3835(93)90012-X; Thomas TZ, 1997, J CLIN ENDOCR METAB, V82, P3851, DOI 10.1210/jc.82.11.3851; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; Trendelenburg AU, 2009, AM J PHYSIOL-CELL PH, V296, pC1258, DOI 10.1152/ajpcell.00105.2009; Wildi S, 2001, GUT, V49, P409, DOI 10.1136/gut.49.3.409; Yndestad A, 2004, CIRCULATION, V109, P1379, DOI 10.1161/01.CIR.0000120704.97934.41; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	48	639	685	4	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					531	543		10.1016/j.cell.2010.07.011	http://dx.doi.org/10.1016/j.cell.2010.07.011			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723755	Bronze			2022-12-28	WOS:000281115900008
J	Gladman, DD; Callen, JP				Gladman, Dafna D.; Callen, Jeffrey P.			Early-Onset Obesity and Risk for Psoriatic Arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								Objective: To study whether obesity increases the risk of psoriatic arthritis (PsA), given that obesity is a risk factor for psoriasis and is associated with more severe disease. Design: Case series. We used Cox regression analysis to study the relationship between obesity and PsA while controlling for age at psoriasis onset, current body mass index (BMI), sex, family history of psoriasis, worst-ever body surface area (BSA) involvement, Koebner phenomenon, and nail involvement. Setting: Dermatology clinics at the University of Utah School of Medicine. Patients: Volunteer sample of patients with dermatologist-diagnosed psoriasis enrolled in the Utah Psoriasis Initiative from November 2002 to October 2008 (943 subjects; 50.2% women, 49.8% men). Main Outcome Measures: Physician diagnosis of PsA from self-report questionnaire. Results: In our subjects, we found that BMI at age 18 years was predictive of PsA (odds ratio [OR], 1.06) (P<.01) over and above control variables. Other variables that were predictors of PsA included younger age at psoriasis onset (odds ratio [OR], 0.98) (P<.01), female sex (OR, 1.45) (P=.01), higher worst-ever BSA involvement with psoriasis (OR, 1.01) (P=.04), Koebner phenomenon (OR, 1.59) (P<.01), and nail involvement (OR, 1.76) (P<.01). Current BMI and family history of psoriasis were not significant predictors of PsA. Conclusions: This study suggests that obesity at age 18 years increases the risk of developing PsA. Adiposity is associated with higher levels of inflammatory cytokines known to be associated with psoriasis. This inflammatory milieu could increase the risk of PsA in predisposed subjects. Prevention and early treatment of obesity may decrease the risk of PsA. Arch Dermatol. 2010;146(7):721-726	[Callen, Jeffrey P.] Univ Louisville, Sch Med, Div Dermatol, Louisville, KY 40202 USA; [Gladman, Dafna D.] Univ Toronto, Toronto Western Hosp, Toronto Western Res Inst,Univ Hlth Network, Ctr Prognosis Studies Rheumat Dis, Toronto, ON M5T 2S8, Canada	University of Louisville; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Callen, JP (corresponding author), Univ Louisville, Sch Med, Div Dermatol, 310 E Broadway, Louisville, KY 40202 USA.	jefca@aol.com						Gladman DD, 2008, CLIN EXP RHEUMATOL, V26, pS62; Gladman DD, 2009, ANN RHEUM DIS, V68, P1131, DOI 10.1136/ard.2008.094839; Gladman DD, 2009, DERMATOL THER, V22, P40, DOI 10.1111/j.1529-8019.2008.01215.x; Kurd SK, 2009, J AM ACAD DERMATOL, V60, P218, DOI 10.1016/j.jaad.2008.09.022; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Pattison E, 2008, ANN RHEUM DIS, V67, P672, DOI 10.1136/ard.2007.073932; Rahman P, 1999, ARTHRITIS RHEUM, V42, P822; Soltani-Arabshahi R, 2010, ARCH DERMATOL, V146, P721, DOI 10.1001/archdermatol.2010.141; Taylor W, 2006, ARTHRITIS RHEUM, V54, P2665, DOI 10.1002/art.21972; Wilson FC, 2009, ARTHRIT RHEUM-ARTHR, V61, P233, DOI 10.1002/art.24172	10	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					787	788		10.1001/jama.2010.1162	http://dx.doi.org/10.1001/jama.2010.1162			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20726050				2022-12-28	WOS:000280993700026
J	Kanwal, F; Schnitzler, MS; Bacon, BR; Hoang, TY; Buchanan, PM; Asch, SM				Kanwal, Fasiha; Schnitzler, Mark S.; Bacon, Bruce R.; Hoang, Tuyen; Buchanan, Paula M.; Asch, Steven M.			Quality of Care in Patients With Chronic Hepatitis C Virus Infection A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; B VACCINATION; MISSED OPPORTUNITIES; ANTIVIRAL THERAPY; LIVER-DISEASE; VETERANS; PREDICTORS; RIBAVIRIN; IMPACT; MANAGEMENT	Background: Medicare has proposed quality-of-care indicators for chronic hepatitis C virus (HCV) infection. The extent to which these standards are met in practice is largely unknown. Objective: To evaluate the quality of health care that patients with HCV receive and the factors associated with receipt of quality care. Design: Retrospective cohort study. Setting: Nationwide U. S. health insurance company research database. Participants: 10 385 patients with HCV enrolled in the database between 2003 and 2006. Patients were included if they were eligible for at least 1 quality indicator. Measurements: Quality of HCV care received by patients, as measured by 7 explicit quality indicators included in Medicare's 2009 Physician Quality Reporting Initiative. Results: Proportions of patients meeting quality indicators varied, ranging from 21.5% for vaccination to 79% for the HCV genotype testing indicator. Overall, 18.5% of patients (95% CI, 18% to 19%) received all recommended care. Older age and presence of comorbid conditions were associated with lower quality, whereas elevated liver enzyme levels, cirrhosis, and HIV infection were associated with higher quality. Patients who saw both generalists and specialists received the best care (odds ratio of receiving care for which a patient is eligible: specialists alone, 0.79 [CI, 0.66 to 0.95]; primary care physician alone, 0.44 [CI, 0.40 to 0.48]). Limitations: The study had an observational retrospective design, used a convenience sample, and had no information on patient ethnicity. It may be that the indicators or the reporting of the indicators of HCV care-and not the care itself-is suboptimum. Conclusion: Health care quality, based on Medicare criteria, is suboptimum for HCV. Care that included both specialists and generalists is associated with the best quality. Our results support the development of specialist and primary care collaboration to improve the quality of HCV care.	[Kanwal, Fasiha] John Cochran Vet Affairs Med Ctr, St Louis, MO 63106 USA; St Louis Univ, Sch Med, St Louis, MO 63110 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; RAND Corp, Santa Monica, CA USA	Saint Louis University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; RAND Corporation	Kanwal, F (corresponding author), John Cochran Vet Affairs Med Ctr, 915 N Grand Blvd,111 JC GI, St Louis, MO 63106 USA.	fasiha.kanwal@va.gov; schnitm@slu.edu; pbuchan1@slu.edu			Saint Louis University Liver Center; Veterans Affairs Health Services Research and Development Service [IIR-07-111]	Saint Louis University Liver Center; Veterans Affairs Health Services Research and Development Service(US Department of Veterans Affairs)	Primary Funding Source: Saint Louis University Liver Center.; Grant Support: Dr. Kanwal is supported by Veterans Affairs Health Services Research and Development Service Investigator Initiated Research Award IIR-07-111. This study was supported by an intramural grant from the Saint Louis University Liver Center.	*AM HEART ASS, 2007, HEART DIS STROK STAT; ARMSTRONG GL, 2006, ANN INTERN MED, V705, P1999; Ayanian JZ, 2002, NEW ENGL J MED, V347, P1678, DOI 10.1056/NEJMsa020080; Backus LI, 2007, HEPATOLOGY, V46, P37, DOI 10.1002/hep.21662; Butt AA, 2007, GUT, V56, P385, DOI 10.1136/gut.2006.099150; Centers for Disease Control and Prevention, 1980, NUMB MILL CIV NON PE; Centers for Medicare and Medicaid Services, OV PHYS QUAL REP IN; *COPD INT, COPD STAT; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dominitz JA, 2005, HEPATOLOGY, V41, P88, DOI 10.1002/hep.20502; El-Serag HB, 2002, GASTROENTEROLOGY, V123, P476, DOI 10.1053/gast.2002.34750; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759; Hachem CY, 2008, ALIMENT PHARM THER, V28, P1078, DOI 10.1111/j.1365-2036.2008.03827.x; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Hernandez B, 2009, AM J GASTROENTEROL, V104, P1961, DOI 10.1038/ajg.2009.252; Kanwal F, 2007, HEPATOLOGY, V46, P1741, DOI 10.1002/hep.21927; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Kim WR, 2002, HEPATOLOGY, V36, P227, DOI 10.1053/jhep.2002.34734; LANZA LL, 1995, ARCH INTERN MED, V155, P1371, DOI 10.1001/archinte.155.13.1371; Ong JP, 2005, J CLIN GASTROENTEROL, V39, P826, DOI 10.1097/01.mcg.0000177258.95562.43; Poynard T, 2002, GASTROENTEROLOGY, V122, P1303, DOI 10.1053/gast.2002.33023; Puoti C, 1997, HEPATOLOGY, V26, P1393; Puoti C, 1997, ITAL J GASTROENTEROL, V29, P383; RAFIQ N, 2009, 44 ANN M EUR ASS STU; Rongey CA, 2009, AM J PREV MED, V36, P235, DOI 10.1016/j.amepre.2008.10.013; Rousseau CM, 2008, AM J PUBLIC HEALTH, V98, P846, DOI 10.2105/AJPH.2007.113225; Shim M, 2005, HEPATOLOGY, V42, P688, DOI 10.1002/hep.20830; Shiratori Y, 2005, ANN INTERN MED, V142, P105, DOI 10.7326/0003-4819-142-2-200501180-00009; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; Volk ML, 2009, HEPATOLOGY, V50, P1750, DOI 10.1002/hep.23220; Weinbaum C., 2006, Morbidity and Mortality Weekly Report, V55, P509; Wong VS, 1996, BRIT MED J, V312, P1336, DOI 10.1136/bmj.312.7042.1336; Yoshida H, 2002, GASTROENTEROLOGY, V123, P483, DOI 10.1053/gast.2002.34785	34	53	53	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4					231	239		10.7326/0003-4819-153-4-201008170-00005	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713791				2022-12-28	WOS:000280973000003
J	Zuraw, BL; Busse, PJ; White, M; Jacobs, J; Lumry, W; Baker, J; Craig, T; Grant, JA; Hurewitz, D; Bielory, L; Cartwright, WE; Koleilat, M; Ryan, W; Schaefer, O; Manning, M; Patel, P; Bernstein, JA; Friedman, RA; Wilkinson, R; Tanner, D; Kohler, G; Gunther, G; Levy, R; McClellan, J; Redhead, J; Guss, D; Heyman, E; Blumenstein, BA; Kalfus, I; Frank, MM				Zuraw, Bruce L.; Busse, Paula J.; White, Martha; Jacobs, Joshua; Lumry, William; Baker, James; Craig, Timothy; Grant, J. Andrew; Hurewitz, David; Bielory, Leonard; Cartwright, William. E.; Koleilat, Majed; Ryan, Walter; Schaefer, Oren; Manning, Michael; Patel, Pragnesh; Bernstein, Jonathan A.; Friedman, Roger A.; Wilkinson, Robert; Tanner, David; Kohler, Gary; Gunther, Glenne; Levy, Robyn; McClellan, James; Redhead, Joseph; Guss, David; Heyman, Eugene; Blumenstein, Brent A.; Kalfus, Ira; Frank, Michael M.			Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM PROPHYLAXIS; ANGIONEUROTIC-EDEMA; C1-INHIBITOR CONCENTRATE; THERAPY; DEFICIENCY; MANAGEMENT; EFFICACY; EPISODES; DANAZOL; PLASMA	BACKGROUND Hereditary angioedema due to C1 inhibitor deficiency is characterized by recurrent acute attacks of swelling that can be painful and sometimes life-threatening. METHODS We conducted two randomized trials to evaluate nanofiltered C1 inhibitor concentrate in the management of hereditary angioedema. The first study compared nanofiltered C1 inhibitor concentrate with placebo for treatment of an acute attack of angioedema. A total of 68 subjects (35 in the C1 inhibitor group and 33 in the placebo group) were given one or two intravenous injections of the study drug (1000 units each). The primary end point was the time to the onset of unequivocal relief. The second study was a crossover trial involving 22 subjects with hereditary angio-edema that compared prophylactic twice-weekly injections of nanofiltered C1 inhibitor concentrate (1000 units) with placebo during two 12-week periods. The primary end point was the number of attacks of angioedema per period, with each subject acting as his or her own control. RESULTS In the first study, the median time to the onset of unequivocal relief from an attack was 2 hours in the subjects treated with C1 inhibitor concentrate but longer than 4 hours in those given placebo (P=0.02). In the second study, the number of attacks per 12-week period was 6.26 with C1 inhibitor concentrate given as prophylaxis, as compared with 12.73 with placebo (P<0.001); the subjects who received the C1 inhibitor concentrate also had significant reductions in both the severity and the duration of attacks, in the need for open-label rescue therapy, and in the total number of days with swelling. CONCLUSIONS In subjects with hereditary angioedema, nanofiltered C1 inhibitor concentrate shortened the duration of acute attacks. When used for prophylaxis, nanofiltered C1 inhibitor concentrate reduced the frequency of acute attacks. (Funded by Lev Pharmaceuticals; ClinicalTrials.govnumbers, NCT00289211, NCT01005888, NCT00438815, and NCT00462709.)	[Zuraw, Bruce L.; Guss, David] Univ Calif San Diego, San Diego, CA 92103 USA; [Zuraw, Bruce L.] San Diego Vet Affairs Healthcare Syst, La Jolla, CA USA; [Jacobs, Joshua] Allergy & Asthma Clin Res, Walnut Creek, CA USA; [Busse, Paula J.] Mt Sinai Sch Med, New York, NY USA; [Kalfus, Ira] M2G Consulting & Lev Pharmaceut, New York, NY USA; [White, Martha] Inst Asthma & Allergy, Wheaton, IL USA; [Lumry, William] Asthma & Allergy Res Associates, Dallas, TX USA; [Grant, J. Andrew] Univ Texas Med Branch, Galveston, TX USA; [Baker, James] Allergy Asthma & Dermatol Res Ctr, Lake Oswego, OR USA; [Craig, Timothy] Penn State Univ, Hershey, PA USA; [Hurewitz, David] Allergy Clin Tulsa, Tulsa, OK USA; [Bielory, Leonard] Univ Med & Dent New Jersey, Newark, NJ 07103 USA; [Cartwright, William. E.] Cornerstone Healthcare St Josephs Healthcare Syst, Parkersburg, WV USA; [Koleilat, Majed] Welborn Clin, Evansville, IN USA; [Ryan, Walter] Ctr Asthma & Allergy, Falmouth, MA USA; [Schaefer, Oren] Univ Massachusetts, Worcester, MA 01605 USA; [Manning, Michael] Allergy & Immunol Associates, Scottsdale, AZ USA; [Patel, Pragnesh] Allergy Asthma Specialists, Altamonte Springs, FL USA; [Bernstein, Jonathan A.] Univ Cincinnati, Cincinnati, OH USA; [Friedman, Roger A.] Buckeye Allergy & Asthma, Columbus, OH USA; [Wilkinson, Robert] Hawaii Pacific Hlth Res Inst, Honolulu, HI USA; [Tanner, David] Atlanta Allergy & Asthma Clin, Suwanee, GA USA; [Levy, Robyn] Family Allergy & Asthma Ctr, Atlanta, GA USA; [Kohler, Gary] Lake Charles Mem Hosp, Lake Charles, LA USA; [Redhead, Joseph] Baton Rouge Clin, Baton Rouge, LA USA; [Gunther, Glenne] Libby Clin, Libby, MT USA; [McClellan, James] Grand Traverse Allergy, Traverse City, MI USA; [Blumenstein, Brent A.] Trial Architecture Consulting, Washington, DC USA; [Frank, Michael M.] Duke Univ, Durham, NC USA	University of California System; University of California San Diego; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Medical Branch Galveston; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Massachusetts System; University of Massachusetts Worcester; University System of Ohio; University of Cincinnati; Pacific Health Research & Education Institute; Duke University	Zuraw, BL (corresponding author), 9500 Gilman Dr,Mailcode 0732, La Jolla, CA 92093 USA.	bzuraw@ucsd.edu		Zuraw, Bruce/0000-0003-0640-6768; Bernstein, Jonathan/0000-0002-3476-1196	ViroPharma Biologics; CSL Behring; Shire; Dyax; Pharming; Shire Pharmaceuticals; ViroPharma	ViroPharma Biologics; CSL Behring; Shire; Dyax; Pharming; Shire Pharmaceuticals; ViroPharma	Supported by grants from Lev Pharmaceuticals (now owned by ViroPharma Biologics).; Dr. Zuraw reports receiving consulting fees from Lev Pharmaceuticals, CSL Behring, Jerini (now Shire), and Dyax; reimbursements for travel or accommodation expenses from Lev Pharmaceuticals, Shire, and Dyax; fees for serving on the speakers bureau of the Robert Michael Educational Institute; grant support from Lev Pharmaceuticals, Pharming, and Shire; and fees for providing expert testimony for Lev Pharmaceuticals; Dr. Busse, receiving consulting fees and reimbursements for travel or accommodation expenses from Lev Pharmaceuticals; grant support from Lev Pharmaceuticals and Shire Pharmaceuticals; fees for reviewing a patient file from Eichorn and Eichorn; -payment for manuscript preparation from Innovative Strategic Communications; and fees for serving on the speakers bureaus of ViroPharma and the Robert Michael Educational Institute; Dr. White, receiving consulting fees from Lev Pharmaceuticals and Dyax; reimbursements for travel or accommodation expenses from Dyax; honoraria from Dyax; grant support from Lev Pharmaceuticals, Dyax, Shire, ViroPharma, and Pharming; and fees for serving on the speakers bureau of ViroPharma; Dr. Jacobs, receiving consulting fees from ViroPharma; reimbursements for travel or accommodation expenses from Lev Pharmaceuticals and ViroPharma; honoraria from ViroPharma; grant support from Lev Pharmaceuticals; and fees for serving on the speakers bureaus of ViroPharma and Lev Pharmaceuticals; Dr. Lumry, receiving consulting fees and honoraria from ViroPharma; consulting fees from Dyax and Shire; reimbursements for travel or accommodation expenses from ViroPharma, Dyax, and Shire; grant support from Lev Pharmaceuticals, Dyax, and Shire; and payment for development of educational presentations from Dyax; Dr. Baker, receiving grant support from Lev Pharmaceuticals, Shire, Dyax, and Pharming; Dr. Craig, receiving consulting fees from ViroPharma, Dyax, and CSL Behring; fees for participation in review activities and reimbursements for travel or accommodation expenses from ViroPharma; honoraria from ViroPharma, Dyax, and CSL Behring; grant support from Lev Pharmaceuticals, ViroPharma, Dyax, CSL Behring, Pharming, and Shire; and payment for development of educational presentations from Dyax, CSL Behring, and ViroPharma; Dr. Grant, receiving reimbursements for travel or accommodation expenses from Lev Pharmaceuticals and Dyax and grant support from Lev Pharmaceuticals, Dyax, and Shire; Dr. Hurewitz, receiving consulting fees from Shire; reimbursements for travel or accommodation expenses from ViroPharma, Shire, Dyax, and CSL Behring; honoraria from Shire; and grant support from Lev Pharmaceuticals, ViroPharma, Shire, Dyax, and CSL Behring; Dr. Bielory, receiving reimbursements for travel or accommodation expenses from Lev Pharmaceuticals and grant support from Lev Pharmaceuticals and STARx Clinical Research Center; Dr. Cartwright, receiving grant support and consulting fees or honoraria from Lev Pharmaceuticals and ViroPharma; Dr. Koleilat, receiving grant support from Lev Pharmaceuticals; Dr. Ryan, receiving grant support from Lev Pharmaceuticals; Dr. Schaefer, receiving grant support from Lev Pharmaceuticals and reimbursements for travel or accommodation expenses from ViroPharma; Dr. Manning, receiving reimbursements for travel or accommodation expenses and grant support from Lev Pharmaceuticals and ViroPharma; honoraria from ViroPharma; and payment for development of educational presentations from ViroPharma; Dr. Patel, receiving grant support from Lev Pharmaceuticals; Dr.; Bernstein, receiving consulting fees from Dnova, Lantheus, and Flint Hills Resources; honoraria from AstraZeneca, Alcon Labs, Dyax, ViroPharma, and CSL Behring; fees for providing expert testimony on environmental and drug reaction cases; and grant support from Lev Pharmaceuticals, Dyax, ViroPharma, CSL Behring, Shire, Pharming, Dynova, and Flint Hills Resources; and being listed as a patent holder on a patent held by the University of Cincinnati for a biosensor to detect airborne chemicals from Biosensors; Dr. Friedman, receiving reimbursements for travel or accommodation expenses from ViroPharma and grant support from Lev Pharmaceuticals; Dr. Wilkinson, receiving fees for study visits from Lev Pharmaceuticals and grant support from Dyax; Dr. Tanner, receiving grant support from Lev Pharmaceuticals; Dr. Gunther, receiving grant support from Lev Pharmaceuticals; Dr. Levy, receiving grant support from Lev Pharmaceuticals and ViroPharma; consulting fees from CSL Behring, Alcon Labs, Dyax, Jerini, and Sepracor; reimbursements for travel or accommodation expenses from CSL Behring and Dyax; and payment for manuscript preparation from Cadent Communications; Dr. McClellan, receiving a grant from Lev Pharmaceuticals; Dr. Redhead, receiving a grant from Lev Pharmaceuticals; Dr. Guss, receiving grant support from Lev Pharmaceuticals; Dr. Heyman, receiving consulting fees from Lev Pharmaceuticals; Dr. Blumenstein, receiving consulting fees and reimbursements for travel or accommodation expenses from Lev Pharmaceuticals and ViroPharma; Dr. Kalfus, receiving consulting fees and reimbursements for travel or accommodation expenses from Lev Pharmaceuticals and ViroPharma; payment for development of educational presentations from ViroPharma; and stocks and stock options from Lev Pharmaceuticals; and being previously employed as vice president of medical affairs at Lev Pharmaceuticals; and Dr. Frank, receiving consulting fees from ViroPharma, CSL Behring, Shire, Dyax, and Pharming; fees for providing expert testimony for Lev Pharmaceuticals, Jerini, and CSL Behring; reimbursements for travel or accommodation expenses from ViroPharma; and grant support from Lev Pharmaceuticals and CSL Behring. No other potential conflict of interest relevant to this article was reported.	Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; BORK K, 1989, J ALLERGY CLIN IMMUN, V83, P677, DOI 10.1016/0091-6749(89)90082-1; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bowen T, 2008, ANN ALLERG ASTHMA IM, V100, pS30, DOI 10.1016/S1081-1206(10)60584-4; Burnouf T, 2003, HAEMOPHILIA, V9, P24, DOI 10.1046/j.1365-2516.2003.00701.x; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; Cicardi M, 2003, TRANSFUS APHER SCI, V29, P221, DOI 10.1016/S1473-0502(03)00164-2; Craig TJ, 2009, J ALLERGY CLIN IMMUN, V124, P801, DOI 10.1016/j.jaci.2009.07.017; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; De Serres J, 2003, TRANSFUS APHER SCI, V29, P247, DOI 10.1016/j.transci.2003.08.006; Farkas H, 2007, J ALLERGY CLIN IMMUN, V120, P941, DOI 10.1016/j.jaci.2007.06.026; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; Levi M, 2006, J ALLERGY CLIN IMMUN, V117, P904, DOI 10.1016/j.jaci.2006.01.002; Prematta M, 2007, ANN ALLERG ASTHMA IM, V98, P383, DOI 10.1016/S1081-1206(10)60886-1; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; Szeplaki G, 2005, J ALLERGY CLIN IMMUN, V115, P864, DOI 10.1016/j.jaci.2004.12.1130; Verpy E, 1996, AM J HUM GENET, V59, P308; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; ZEGER SL, 1989, BIOMETRICS, V45, P347; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; Zuraw BL, 2000, J ALLERGY CLIN IMMUN, V105, P541, DOI 10.1067/mai.2000.104780; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977	30	327	332	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					513	522		10.1056/NEJMoa0805538	http://dx.doi.org/10.1056/NEJMoa0805538			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818886				2022-12-28	WOS:000280552700005
J	Rea, TD; Fahrenbruch, C; Culley, L; Donohoe, RT; Hambly, C; Innes, J; Bloomingdale, M; Subido, C; Romines, S; Eisenberg, MS				Rea, Thomas D.; Fahrenbruch, Carol; Culley, Linda; Donohoe, Rachael T.; Hambly, Cindy; Innes, Jennifer; Bloomingdale, Megan; Subido, Cleo; Romines, Steven; Eisenberg, Mickey S.			CPR with Chest Compression Alone or with Rescue Breathing.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; BYSTANDER CARDIOPULMONARY-RESUSCITATION; AMERICAN-HEART-ASSOCIATION; CLINICAL-TRIALS; SURVIVAL; MODEL; CARE; VENTILATION; COMMITTEE	Background: The role of rescue breathing in cardiopulmonary resuscitation (CPR) performed by a layperson is uncertain. We hypothesized that the dispatcher instructions to bystanders to provide chest compression alone would result in improved survival as compared with instructions to provide chest compression plus rescue breathing. Methods: We conducted a multicenter, randomized trial of dispatcher instructions to bystanders for performing CPR. The patients were persons 18 years of age or older with out-of-hospital cardiac arrest for whom dispatchers initiated CPR instruction to bystanders. Patients were randomly assigned to receive chest compression alone or chest compression plus rescue breathing. The primary outcome was survival to hospital discharge. Secondary outcomes included a favorable neurologic outcome at discharge. Results: Of the 1941 patients who met the inclusion criteria, 981 were randomly assigned to receive chest compression alone and 960 to receive chest compression plus rescue breathing. We observed no significant difference between the two groups in the proportion of patients who survived to hospital discharge (12.5% with chest compression alone and 11.0% with chest compression plus rescue breathing, P=0.31) or in the proportion who survived with a favorable neurologic outcome in the two sites that assessed this secondary outcome (14.4% and 11.5%, respectively; P=0.13). Prespecified subgroup analyses showed a trend toward a higher proportion of patients surviving to hospital discharge with chest compression alone as compared with chest compression plus rescue breathing for patients with a cardiac cause of arrest (15.5% vs. 12.3%, P=0.09) and for those with shockable rhythms (31.9% vs. 25.7%, P=0.09). Conclusions: Dispatcher instruction consisting of chest compression alone did not increase the survival rate overall, although there was a trend toward better outcomes in key clinical subgroups. The results support a strategy for CPR performed by laypersons that emphasizes chest compression and minimizes the role of rescue breathing. (Funded in part by the Laerdal Foundation for Acute Medicine and the Medic One Foundation; ClinicalTrials.gov number, NCT00219687.) N Engl J Med 2010;363:423-33.	[Rea, Thomas D.; Fahrenbruch, Carol; Culley, Linda; Bloomingdale, Megan; Subido, Cleo; Eisenberg, Mickey S.] Emergency Med Serv, Div Publ Hlth Seattle & King Cty, Seattle, WA USA; [Rea, Thomas D.; Eisenberg, Mickey S.] Univ Washington, Seattle, WA 98195 USA; [Donohoe, Rachael T.; Innes, Jennifer] London Ambulance Serv, London, England; [Hambly, Cindy; Romines, Steven] Thurston Cty Med One, Olympia, WA USA	University of Washington; University of Washington Seattle	Rea, TD (corresponding author), 401 5th Ave,Suite 1200, Seattle, WA 98104 USA.	rea123@u.washington.edu		Fothergill, Rachael/0000-0003-1341-6200	Laerdal Foundation for Acute Medicine; Medic One Foundation; Philips Medical Systems and Physio-Control; Medtronic Foundation	Laerdal Foundation for Acute Medicine; Medic One Foundation; Philips Medical Systems and Physio-Control; Medtronic Foundation	Supported in part by grants from the Laerdal Foundation for Acute Medicine and the Medic One Foundation.; Drs. Rea and Eisenberg report receiving defibrillators and funding from Philips Medical Systems and Physio-Control to evaluate research questions related to automated external defibrillator training and use, and report that their institutions, the University of Washington and Public Health for Seattle and King County, have received funding from the Medtronic Foundation involving community-based translation of resuscitation science. Dr. Rea reports being a member of the American Heart Association Basic Life Support Committee. No other potential conflict of interest relevant to this article was reported.	Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Berg RA, 2000, CRIT CARE MED, V28, pN193, DOI 10.1097/00003246-200011001-00005; Bohm K, 2007, CIRCULATION, V116, P2908, DOI 10.1161/CIRCULATIONAHA.107.710194; Ewy GA, 2007, CIRCULATION, V116, P2525, DOI 10.1161/CIRCULATIONAHA.107.711820; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Hauff SR, 2003, ANN EMERG MED, V42, P731, DOI 10.1016/S0196-0644(03)00423-2; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Kouwenhoven WB, 1960, JAMA-J AM MED ASSOC, V173, P94; LOCKE CJ, 1995, ARCH INTERN MED, V155, P938, DOI 10.1001/archinte.155.9.938; Mercer SL, 2007, AM J PREV MED, V33, P139, DOI 10.1016/j.amepre.2007.04.005; Nagao K, 2007, LANCET, V369, P920; NICHOL G, 2008, JAMA-J AM MED ASSOC, V300, P1763; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Paredes VL, 2004, ACAD EMERG MED, V11, P71, DOI 10.1197/S1069-6563(03)00587-6; Ramaraj R, 2009, HEART, V95, P1978, DOI 10.1136/hrt.2009.174268; Rea TD, 2001, CIRCULATION, V104, P2513, DOI 10.1161/hc4601.099468; Rea TD, 2008, RESUSCITATION, V77, P6, DOI 10.1016/j.resuscitation.2007.10.010; Rea TD, 2010, RESUSCITATION, V81, P293, DOI 10.1016/j.resuscitation.2009.12.002; Rea TD, 2010, CIRCULATION, V121, P1134, DOI 10.1161/CIRCULATIONAHA.109.899799; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; STEEN PA, 2008, CIRCULATION, V117, pE20; Steen PA, 2007, CIRCULATION, V116, P2514, DOI 10.1161/CIRCULATIONAHA.107.739086; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; White L, 2010, CIRCULATION, V121, P91, DOI 10.1161/CIRCULATIONAHA.109.872366; Williams JG, 2006, PREHOSP EMERG CARE, V10, P247, DOI 10.1080/10903120500541027; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466	31	188	199	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					423	433		10.1056/NEJMoa0908993	http://dx.doi.org/10.1056/NEJMoa0908993			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818863				2022-12-28	WOS:000280411300006
J	WARDEN, J				WARDEN, J			PERFORMANCE INDICATORS - FLAVOR OF THE MONTH	BRITISH MEDICAL JOURNAL			English	Editorial Material																		LOWRY S, 1988, BRIT MED J, V296, P992, DOI 10.1136/bmj.296.6627.992	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1988	296	6629					1139	1139		10.1136/bmj.296.6629.1139	http://dx.doi.org/10.1136/bmj.296.6629.1139			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N0661	20742984	Green Published			2022-12-28	WOS:A1988N066100049
J	Moellering, ER; Muthan, B; Benning, C				Moellering, Eric R.; Muthan, Bagyalakshmi; Benning, Christoph			Freezing Tolerance in Plants Requires Lipid Remodeling at the Outer Chloroplast Membrane	SCIENCE			English	Article							COLD RESPONSE PATHWAY; ARABIDOPSIS-THALIANA; GALACTOLIPID GALACTOSYLTRANSFERASE; BETA-GLUCOSIDASE; PLASMA-MEMBRANE; ACCLIMATION; MECHANISMS; BIOSYNTHESIS; ENVELOPES; SYSTEMS	Plants show complex adaptations to freezing that prevent cell damage caused by cellular dehydration. Lipid remodeling of cell membranes during dehydration is one critical mechanism countering loss of membrane integrity and cell death. SENSITIVE TO FREEZING 2 (SFR2), a gene essential for freezing tolerance in Arabidopsis, encodes a galactolipid remodeling enzyme of the outer chloroplast envelope membrane. SFR2 processively transfers galactosyl residues from the abundant monogalactolipid to different galactolipid acceptors, forming oligogalactolipids and diacylglycerol, which is further converted to triacylglycerol. The combined activity of SFR2 and triacylglycerol-biosynthetic enzymes leads to the removal of monogalactolipids from the envelope membrane, changing the ratio of bilayer-to non-bilayer-forming membrane lipids. This SFR2-based mechanism compensates for changes in organelle volume and stabilizes membranes during freezing.	[Moellering, Eric R.; Muthan, Bagyalakshmi; Benning, Christoph] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; [Moellering, Eric R.] Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Benning, C (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	benning@msu.edu	Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667	U.S. Department of Energy [DE-FG02-98ER20305]; Michigan Agricultural Experiment Station	U.S. Department of Energy(United States Department of Energy (DOE)); Michigan Agricultural Experiment Station	We thank S. Marshall and T. Durret for help with proton-NMR and mass spectrometry analyses, respectively, and the laboratory of M. Thomashow for use of equipment and advice on the plant freezing experiments conducted in this work. This work was supported in parts by a grant from the U.S. Department of Energy (DE-FG02-98ER20305) and Michigan Agricultural Experiment Station.	Benning C, 2005, J BIOL CHEM, V280, P2397, DOI 10.1074/jbc.R400032200; BROWSE J, 1989, PLANT PHYSIOL, V90, P522, DOI 10.1104/pp.90.2.522; Cook D, 2004, P NATL ACAD SCI USA, V101, P15243, DOI 10.1073/pnas.0406069101; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Du ZY, 2010, PLANT PHYSIOL, V152, P1585, DOI 10.1104/pp.109.147066; Fourrier N, 2008, PLANT J, V55, P734, DOI 10.1111/j.1365-313X.2008.03549.x; Fowler S, 2002, PLANT CELL, V14, P1675, DOI 10.1105/tpc.003483; HEEMSKERK JW, 1983, BIOCHIM BIOPHYS ACTA, V754, P181, DOI 10.1016/0005-2760(83)90160-1; HEINZ E, 1996, ADV LIPID METHODOLOG, P211; Hill AD, 2008, BIOPOLYMERS, V89, P1021, DOI 10.1002/bip.21052; Hirayama T, 2010, PLANT J, V61, P1041, DOI 10.1111/j.1365-313X.2010.04124.x; Kelly AA, 2003, PLANT CELL, V15, P2694, DOI 10.1105/tpc.016675; Li W, 2008, J BIOL CHEM, V283, P461, DOI 10.1074/jbc.M706692200; Marques AR, 2003, BIOCHEM J, V370, P793, DOI 10.1042/BJ20021249; McKown R, 1996, J EXP BOT, V47, P1919, DOI 10.1093/jxb/47.12.1919; Perugino G, 2004, TRENDS BIOTECHNOL, V22, P31, DOI 10.1016/j.tibtech.2003.10.008; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STEPONKUS PL, 1984, ANNU REV PLANT PHYS, V35, P543, DOI 10.1146/annurev.pp.35.060184.002551; Steponkus PL, 1998, P NATL ACAD SCI USA, V95, P14570, DOI 10.1073/pnas.95.24.14570; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; Thorlby G, 2004, PLANT CELL, V16, P2192, DOI 10.1105/tpc.104.024018; Uemura M, 2003, PLANT PHYSIOL, V131, P1800, DOI 10.1104/pp.102.013227; UEMURA M, 1995, PLANT PHYSIOL, V109, P15, DOI 10.1104/pp.109.1.15; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; WIESLANDER A, 1986, BIOCHEMISTRY-US, V25, P7511, DOI 10.1021/bi00371a038; Wolfe J, 1999, CRYOBIOLOGY, V39, P103, DOI 10.1006/cryo.1999.2195	28	322	335	10	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	2010	330	6001					226	228		10.1126/science.1191803	http://dx.doi.org/10.1126/science.1191803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LP	20798281				2022-12-28	WOS:000282644600043
J	Beasley, R; Perrin, K; Weatherall, M; Wijesinghe, M				Beasley, Richard; Perrin, Kyle; Weatherall, Mark; Wijesinghe, Meme			Call for withdrawal of LABA single-therapy inhaler in asthma	LANCET			English	Editorial Material							ACTING BETA-AGONISTS; CORTICOSTEROIDS; SALMETEROL; MORTALITY; RISK; METAANALYSIS; FORMOTEROL		[Beasley, Richard; Perrin, Kyle; Wijesinghe, Meme] Med Res Inst New Zealand, Wellington 6242, New Zealand; [Beasley, Richard; Perrin, Kyle; Weatherall, Mark] Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Weatherall, Mark] Univ Otago Wellington, Wellington, New Zealand	Medical Research Institute Of New Zealand; University of Otago	Beasley, R (corresponding author), Med Res Inst New Zealand, Wellington 6242, New Zealand.	richard.beasley@mrinz.ac.nz	Weatherall, Mark/Y-6824-2019; Beasley, Richard/AAH-3908-2019	Weatherall, Mark/0000-0002-0051-9107; Beasley, Richard/0000-0003-0337-406X				Bateman E, 2008, ANN INTERN MED, V149, P33, DOI 10.7326/0003-4819-149-1-200807010-00229; Chowdhury BA, 2010, NEW ENGL J MED, V362, P1169, DOI 10.1056/NEJMp1002074; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; Nelson H, 2010, J ALLERGY CLIN IMMUN, V125, P390, DOI 10.1016/j.jaci.2009.11.036; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; Stempel DA, 2005, RESP MED, V99, P1263, DOI 10.1016/j.rmed.2005.03.002; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Taylor DR, 2008, NEW ZEAL MED J, V121, P106; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608; Wijesinghe M, 2008, POSTGRAD MED J, V84, P467, DOI 10.1136/pgmj.2007.067165; Wijesinghe M, 2009, EUR RESPIR J, V34, P803, DOI 10.1183/09031936.00159708	12	34	34	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					750	751		10.1016/S0140-6736(10)61158-0	http://dx.doi.org/10.1016/S0140-6736(10)61158-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816529				2022-12-28	WOS:000281831000007
J	Tomer, R; Denes, AS; Tessmar-Raible, K; Arendt, D				Tomer, Raju; Denes, Alexandru S.; Tessmar-Raible, Kristin; Arendt, Detlev			Profiling by Image Registration Reveals Common Origin of Annelid Mushroom Bodies and Vertebrate Pallium	CELL			English	Article							IN-SITU HYBRIDIZATION; PLATYNEREIS-DUMERILII; CELL-TYPES; EVOLUTION; BRAIN; TELENCEPHALON; EXPRESSION; FATE; WNT; FOREBRAIN	The evolution of the highest-order human brain center, the "pallium'' or "cortex,'' remains enigmatic. To elucidate its origins, we set out to identify related brain parts in phylogenetically distant animals, to then unravel common aspects in cellular composition and molecular architecture. Here, we compare vertebrate pallium development to that of the mushroom bodies, sensory-associative brain centers, in an annelid. Using a newly developed protocol for cellular profiling by image registration (PrImR), we obtain a high-resolution gene expression map for the developing annelid brain. Comparison to the vertebrate pallium reveals that the annelid mushroom bodies develop from similar molecular coordinates within a conserved overall molecular brain topology and that their development involves conserved patterning mechanisms and produces conserved neuron types that existed already in the protostome- deuterostome ancestors. These data indicate deep homology of pallium and mushroom bodies and date back the origin of higher brain centers to prebilaterian times.	[Tomer, Raju; Denes, Alexandru S.; Tessmar-Raible, Kristin; Arendt, Detlev] European Mol Biol Lab, Dev Biol Unit, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Tomer, R (corresponding author), European Mol Biol Lab, Dev Biol Unit, D-69117 Heidelberg, Germany.	tomer@embl.de; arendt@embl.de	Tessmar-Raible, Kristin/F-9642-2011; Tomer, Raju/F-2335-2010	Tessmar-Raible, Kristin/0000-0002-8038-1741; 	Marie Curie RTN ZOONET [MRTN-CT-2004-005624]; DFG Collaborative Research Network [SFB-488]; Louis Jeantet Foundation	Marie Curie RTN ZOONET(European Commission); DFG Collaborative Research Network(German Research Foundation (DFG)); Louis Jeantet Foundation	We thank F. Christodoulou for providing larvae stained with mir-9, 9*, H. Snyman for expert technical assistance, and the Arendt lab for support. The electron micrograph in Figure 5 was taken with C. Nielsen during a practical course. R.T. and K.T.-R. were supported by fellowships of the Marie Curie RTN ZOONET (MRTN-CT-2004-005624), R.T. by DFG Collaborative Research Network SFB-488, and A.D. by a Louis Jeantet Foundation fellowship. R.T. conceived and developed PrImR, designed and performed the experiments, analyzed and interpreted the data, and wrote the paper. A.S.D. contributed clones of vglut and gad. K.T.-R. contributed clones of brn124 and emx. D.A. proposed to study annelid mushroom bodies, provided ideas, interpreted the data, and wrote the paper.	Arendt D, 2005, THEOR BIOSCI, V124, P185, DOI 10.1016/j.thbio.2005.08.002; Arendt D, 2002, DEVELOPMENT, V129, P1143; Arendt D, 2008, NAT REV GENET, V9, P868, DOI 10.1038/nrg2416; Backman M, 2005, DEV BIOL, V279, P155, DOI 10.1016/j.ydbio.2004.12.010; Bani-Yaghoub M, 2006, DEV BIOL, V295, P52, DOI 10.1016/j.ydbio.2006.03.007; Caubit X, 1999, DEV DYNAM, V214, P66, DOI 10.1002/(SICI)1097-0177(199901)214:1<66::AID-DVDY7>3.0.CO;2-7; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; Danesin C, 2009, DEV CELL, V16, P576, DOI 10.1016/j.devcel.2009.03.007; Denes AS, 2007, CELL, V129, P277, DOI 10.1016/j.cell.2007.02.040; Deo M, 2006, DEV DYNAM, V235, P2538, DOI 10.1002/dvdy.20847; Ekonomou A, 2005, PLOS BIOL, V3, P1111, DOI 10.1371/journal.pbio.0030186; EVANS SM, 1966, NATURE, V211, P945, DOI 10.1038/211945a0; Farris SA, 2005, ARTHROPOD STRUCT DEV, V34, P211, DOI 10.1016/j.asd.2005.01.008; Farris SM, 2008, BRAIN BEHAV EVOLUT, V72, P106, DOI 10.1159/000151471; Fischer A, 2004, BIOESSAYS, V26, P314, DOI 10.1002/bies.10409; Forster E, 2006, NAT REV NEUROSCI, V7, P259, DOI 10.1038/nrn1882; Garel S, 1999, DEVELOPMENT, V126, P5285; Hebert JM, 2008, NAT REV NEUROSCI, V9, P678, DOI 10.1038/nrn2463; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Houart C, 2002, NEURON, V35, P255, DOI 10.1016/S0896-6273(02)00751-1; Inoue T, 2000, DEV BIOL, V219, P373, DOI 10.1006/dbio.2000.9616; Jekely G, 2007, BIOTECHNIQUES, V42, P751, DOI 10.2144/000112462; Kandel E., 2000, PRINCIPLES NEURAL SC; Keeble TR, 2006, J NEUROSCI, V26, P5840, DOI 10.1523/JNEUROSCI.1175-06.2006; Kimura J, 2005, J NEUROSCI, V25, P5097, DOI 10.1523/JNEUROSCI.0239-05.2005; Liu X, 2009, CELL, V139, P623, DOI 10.1016/j.cell.2009.08.044; Marin O, 2001, NAT REV NEUROSCI, V2, P780, DOI 10.1038/35097509; McEvilly RJ, 2002, SCIENCE, V295, P1528, DOI 10.1126/science.1067132; Miura H, 1997, MECH DEVELOP, V65, P99, DOI 10.1016/S0925-4773(97)00062-2; MULLER WA, 1973, Z ZELLFORSCH MIK ANA, V139, P487, DOI 10.1007/BF02028390; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Nieuwenhuys R, 2002, BRAIN RES BULL, V57, P257, DOI 10.1016/S0361-9230(01)00668-2; Noveen A, 2000, DEVELOPMENT, V127, P3475; Raible F, 2005, SCIENCE, V310, P1325, DOI 10.1126/science.1119089; Schneider SQ, 2007, DEV CELL, V13, P73, DOI 10.1016/j.devcel.2007.05.002; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Stigloher C, 2006, DEVELOPMENT, V133, P2925, DOI 10.1242/dev.02450; Strausfeld NJ, 2006, P ROY SOC B-BIOL SCI, V273, P1857, DOI 10.1098/rspb.2006.3536; Strausfeld NJ, 2009, J COMP NEUROL, V513, P265, DOI 10.1002/cne.21948; STRAUSFELD NJ, 1993, J COMP NEUROL, V328, P43, DOI 10.1002/cne.903280104; Strausfeld NJ, 1998, LEARN MEMORY, V5, P11; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; Swanson LW, 2000, BRAIN RES, V886, P113, DOI 10.1016/S0006-8993(00)02905-X; Taglialatela P, 2004, DEVELOPMENT, V131, P4239, DOI 10.1242/dev.01299; Tessmar-Raible K, 2005, BIOTECHNIQUES, V39, P460, DOI 10.2144/000112023; Tessmar-Raible K, 2007, CELL, V129, P1389, DOI 10.1016/j.cell.2007.04.041; Tole S, 2000, DEV BIOL, V217, P254, DOI 10.1006/dbio.1999.9509; Tuoc TC, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-23; Urbach R, 2003, DEVELOPMENT, V130, P3621, DOI 10.1242/dev.00533; Viola P, 1997, INT J COMPUT VISION, V24, P137, DOI 10.1023/A:1007958904918; Wang B, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-5; Woodger J. H., 1945, ESSAYS GROWTH FORM P, P95; Yun K, 2001, DEVELOPMENT, V128, P193	53	204	205	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					800	809		10.1016/j.cell.2010.07.043	http://dx.doi.org/10.1016/j.cell.2010.07.043			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813265	Bronze			2022-12-28	WOS:000281523200022
J	Lister, S				Lister, Sam			Health White Paper NHS franchise for sale	BRITISH MEDICAL JOURNAL			English	Editorial Material									Times, London, England		Lister, S (corresponding author), Times, London, England.	Sam.Lister@thetimes.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 31	2010	341								c4584	10.1136/bmj.c4584	http://dx.doi.org/10.1136/bmj.c4584			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647JS	20807732				2022-12-28	WOS:000281615400002
J	Ernst, MO				Ernst, Marc O.			Decisions Made Better	SCIENCE			English	Editorial Material									Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany	Max Planck Society	Ernst, MO (corresponding author), Max Planck Inst Biol Cybernet, Spemannstr 41, D-72076 Tubingen, Germany.	marc.ernst@tuebingen.mpg.de		Ernst, Marc/0000-0003-4197-8569				Alais D, 2004, CURR BIOL, V14, P257, DOI 10.1016/j.cub.2004.01.029; Bahrami B, 2010, SCIENCE, V329, P1081, DOI 10.1126/science.1185718; COCHRAN W. G., 1937, J. Roy. Statist. Soc. 1937., (Suppl.), V4, P102; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Faisal AA, 2008, NAT REV NEUROSCI, V9, P292, DOI 10.1038/nrn2258; Jordan M. I, 1997, SELF ORG COMPUTATION, P117, DOI DOI 10.1016/S0166-4115(97)80006-4; LANDY MS, 1995, VISION RES, V35, P389, DOI 10.1016/0042-6989(94)00176-M	7	19	19	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1022	1023		10.1126/science.1194920	http://dx.doi.org/10.1126/science.1194920			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798305				2022-12-28	WOS:000281253500023
J	Lilford, RJ; Chilton, PJ; Hemming, K; Girling, AJ; Taylor, CA; Barach, P				Lilford, Richard J.; Chilton, Peter J.; Hemming, Karla; Girling, Alan J.; Taylor, Celia A.; Barach, Paul			Evaluating policy and service interventions: framework to guide selection and interpretation of study end points	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENT SAFETY RESEARCH; MEDICAL ERRORS; ADVERSE EVENTS; DESIGN; EPISTEMOLOGY; EXPERIENCE; MANAGEMENT; TRIALS		[Lilford, Richard J.; Chilton, Peter J.; Hemming, Karla; Girling, Alan J.] Univ Birmingham, Publ Hlth Epidemiol Biostat, Edgbaston B15 2TT, W Midlands, England; [Taylor, Celia A.] Univ Birmingham, Dept Clin Expt Med, Edgbaston B15 2TT, W Midlands, England; [Barach, Paul] Univ Med Ctr Utrecht, Patient Safety Ctr, NL-3058 GA Utrecht, Netherlands	University of Birmingham; University of Birmingham; Utrecht University; Utrecht University Medical Center	Lilford, RJ (corresponding author), Univ Birmingham, Publ Hlth Epidemiol Biostat, Edgbaston B15 2TT, W Midlands, England.	r.j.lilford@bham.ac.uk	Barach, paul/B-9915-2016; Girling, Alan J/A-7843-2012; Hemming, karla/AAB-3391-2021; Barach, Paul/AAX-5315-2020	Barach, paul/0000-0002-7906-698X; Hemming, karla/0000-0002-2226-6550; Barach, Paul/0000-0002-7906-698X; Girling, Alan/0000-0003-2022-045X; Chilton, Peter/0000-0001-8809-9735; Brown, Celia/0000-0002-7526-0793	National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country; European Union; EPSRC [GR/S29874/01]; EPSRC [EP/F063822/1] Funding Source: UKRI; MRC [G0800808] Funding Source: UKRI; Engineering and Physical Sciences Research Council [GR/S29874/01, EP/F063822/1] Funding Source: researchfish; Medical Research Council [G0800808] Funding Source: researchfish	National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country; European Union(European Commission); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country; European Union FP7 handover project: improving the continuity of patient care through identification and implementation of novel patient handoff processes in Europe; and the MATCH programme (EPSRC Grant GR/S29874/01). The views expressed in this work do not necessarily reflect those of the funders.	[Anonymous], 1980, EXPLORATIONS QUALITY; Barach P, 2008, J THORAC CARDIOV SUR, V136, P1422, DOI 10.1016/j.jtcvs.2008.03.071; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brown C, 2008, QUAL SAF HEALTH CARE, V17, P158, DOI 10.1136/qshc.2007.023630; Brown C, 2008, QUAL SAF HEALTH CARE, V17, P170, DOI 10.1136/qshc.2007.023655; Brown C, 2008, QUAL SAF HEALTH CARE, V17, P163, DOI 10.1136/qshc.2007.023648; Brown C. A., 2009, Journal of Infection Prevention, V10, P143, DOI 10.1177/1757177409106227; Brown C, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2764; Campbell MK, 2005, CLIN TRIALS, V2, P99, DOI 10.1191/1740774505cn071oa; CHARLETON W, 1657, 2 DIALOGUES; Conti S, 2009, MED DECIS MAKING, V29, P643, DOI 10.1177/0272989X09336142; CORNFORD T, 1994, OMEGA-INT J MANAGE S, V22, P491, DOI 10.1016/0305-0483(94)90030-2; Cosh E, 2007, J COMMER BIOTECHNOL, V13, P263, DOI DOI 10.1057/PALGRAVE.JCB.3050062; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; DEMEULEMEESTER JL, 2009, ECONOMIST-LONDON, V392, P15; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; Edwards SJL, 1999, BMJ-BRIT MED J, V318, P1407, DOI 10.1136/bmj.318.7195.1407; Francis J, 2006, J CONTIN EDUC HEALTH, V26, P63, DOI 10.1002/chp.52; Girling AJ, 2007, INT J TECHNOL ASSESS, V23, P269, DOI 10.1017/S0266462307070365; Girling AJ, 2007, CLIN TRIALS, V4, P15, DOI 10.1177/1740774506075872; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Lilford Richard, 2007, J Health Serv Res Policy, V12, P173, DOI 10.1258/135581907781543012; Lilford RJ, 2003, PUBLIC MONEY MANAGE, V23, P203, DOI 10.1111/1467-9302.00369; Lilford RJ, 2003, QUAL SAF HLTH CAR S2, V12, P118, DOI DOI 10.1136/QHC.12.SUPPL_2.II8; Murray DM, 2003, EVALUATION REV, V27, P79, DOI 10.1177/0193841X02239019; *NAT I HLTH CLIN E, 2008, N0515 NAT I HLTH CLI; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; RUNCIMAN WB, 1993, ANAESTH INTENS CARE, V21, P502, DOI 10.1177/0310057X9302100504; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; Shirley PJ, 2008, MED J AUSTRALIA, V189, P414, DOI 10.5694/j.1326-5377.2008.tb02101.x; THORNTON JG, 1995, BRIT MED J, V310, P791, DOI 10.1136/bmj.310.6982.791; Vohra PD, 2007, JT COMM J QUAL PATIE, V33, P493, DOI 10.1016/S1553-7250(07)33053-5	34	52	57	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 27	2010	341								c4413	10.1136/bmj.c4413	http://dx.doi.org/10.1136/bmj.c4413			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IJ	20802000				2022-12-28	WOS:000281446300004
J	Dietz, HC				Dietz, Harry C.			New Therapeutic Approaches to Mendelian Disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GILFORD-PROGERIA-SYNDROME; ADENOSINE-DEAMINASE DEFICIENCY; DUCHENNE MUSCULAR-DYSTROPHY; LYSOSOMAL STORAGE DISEASES; TYPE-1 GAUCHER-DISEASE; MARFAN-SYNDROME; STOP MUTATIONS; MOUSE MODEL; NONSENSE MUTATIONS; CYSTIC-FIBROSIS		Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University	Dietz, HC (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, 733 N Broadway St, Baltimore, MD 21205 USA.	hdietz@jhmi.edu						Aartsma-Rus A, 2004, AM J HUM GENET, V74, P83, DOI 10.1086/381039; Aartsma-Rus A, 2009, HUM MUTAT, V30, P293, DOI 10.1002/humu.20918; Aiuti A, 2009, IMMUNOL RES, V44, P150, DOI 10.1007/s12026-009-8107-8; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Auld DS, 2009, P NATL ACAD SCI USA, V106, P3585, DOI 10.1073/pnas.0813345106; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; Bedwell DM, 1997, NAT MED, V3, P1280, DOI 10.1038/nm1197-1280; Begley DJ, 2008, CURR PHARM DESIGN, V14, P1566, DOI 10.2174/138161208784705504; Booth C, 2007, CLIN IMMUNOL, V123, P139, DOI 10.1016/j.clim.2006.12.009; Brooke BS, 2008, NEW ENGL J MED, V358, P2787, DOI 10.1056/NEJMoa0706585; BURKE JF, 1985, NUCLEIC ACIDS RES, V13, P6265, DOI 10.1093/nar/13.17.6265; Capell BC, 2008, P NATL ACAD SCI USA, V105, P15902, DOI 10.1073/pnas.0807840105; Chung AWY, 2008, CIRC RES, V102, pE73, DOI 10.1161/CIRCRESAHA.108.174367; Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086; Clancy JP, 2007, AM J RESP CELL MOL, V37, P57, DOI 10.1165/rcmb.2006-0173OC; Conn PM, 2009, TRENDS PHARMACOL SCI, V30, P228, DOI 10.1016/j.tips.2009.02.002; Coucke PJ, 2006, NAT GENET, V38, P452, DOI 10.1038/ng1764; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Du M, 2008, P NATL ACAD SCI USA, V105, P2064, DOI 10.1073/pnas.0711795105; Dunant P, 2003, MUSCLE NERVE, V27, P624, DOI 10.1002/mus.10341; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fan JQ, 2008, BIOL CHEM, V389, P1, DOI 10.1515/BC.2008.009; Ficicioglu Can, 2008, Ther Clin Risk Manag, V4, P425; FRATANTONI JC, 1968, SCIENCE, V162, P570, DOI 10.1126/science.162.3853.570; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Giraldo P, 2009, HAEMATOL-HEMATOL J, V94, P1771, DOI 10.3324/haematol.2009.008078; Gomez D, 2009, J PATHOL, V218, P131, DOI 10.1002/path.2516; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Hanada K, 2007, CIRC RES, V100, P738, DOI 10.1161/01.RES.0000260181.19449.95; HICKMAN S, 1972, BIOCHEM BIOPH RES CO, V49, P992, DOI 10.1016/0006-291X(72)90310-5; Hirawat S, 2007, J CLIN PHARMACOL, V47, P430, DOI 10.1177/0091270006297140; Hollak CEM, 2009, PHARMACOEPIDEM DR S, V18, P770, DOI 10.1002/pds.1779; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; Judge DP, 2008, ANNU REV MED, V59, P43, DOI 10.1146/annurev.med.59.103106.103801; Kakkis E, 2004, P NATL ACAD SCI USA, V101, P829, DOI 10.1073/pnas.0305480101; Keeling KM, 2001, HUM MOL GENET, V10, P291, DOI 10.1093/hmg/10.3.291; Kerem E, 2008, LANCET, V372, P719, DOI 10.1016/S0140-6736(08)61168-X; Klionsky DJ, 2009, NEW ENGL J MED, V360, P1785, DOI 10.1056/NEJMcibr0810347; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; Lacro RV, 2007, AM HEART J, V154, P624, DOI 10.1016/j.ahj.2007.06.024; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; Loeys BL, 2006, NEW ENGL J MED, V355, P788, DOI 10.1056/NEJMoa055695; Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511; Lu QL, 2003, NAT MED, V9, P1009, DOI 10.1038/nm897; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Matt P, 2009, CIRCULATION, V120, P526, DOI 10.1161/CIRCULATIONAHA.108.841981; Merideth MA, 2008, NEW ENGL J MED, V358, P592, DOI 10.1056/NEJMoa0706898; Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106; Mu TW, 2008, CELL, V134, P769, DOI 10.1016/j.cell.2008.06.037; Mu TW, 2008, PLOS BIOL, V6, P253, DOI 10.1371/journal.pbio.0060026; Muhlrad D, 1999, MOL BIOL CELL, V10, P3971, DOI 10.1091/mbc.10.11.3971; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Pastores GM, 2009, CURR MED RES OPIN, V25, P23, DOI 10.1185/03007990802576518 ; Politano L, 2003, Acta Myol, V22, P15; Ponder KP, 2008, J CLIN INVEST, V118, P2686, DOI 10.1172/JCI36521; Radin NS, 1996, GLYCOCONJUGATE J, V13, P153, DOI 10.1007/BF00731489; Rapoport M, 2009, EXPERT OPIN DRUG DEL, V6, P453, DOI [10.1517/17425240902887029, 10.1517/17425240902887029 ]; Rigat B, 2009, MOL GENET METAB, V96, P225, DOI 10.1016/j.ymgme.2008.12.008; Schiffmann R, 2008, ANN NEUROL, V64, P514, DOI 10.1002/ana.21491; Sleat D E, 2001, Eur J Paediatr Neurol, V5 Suppl A, P57, DOI 10.1053/ejpn.2000.0436; Toth JI, 2005, P NATL ACAD SCI USA, V102, P12873, DOI 10.1073/pnas.0505767102; van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108; Vitiello L, 2008, NEUROMUSCULAR DISORD, V18, P597, DOI 10.1016/j.nmd.2008.05.011; Wagner KR, 2001, ANN NEUROL, V49, P706, DOI 10.1002/ana.1023.abs; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Wilschanski M, 2003, NEW ENGL J MED, V349, P1433, DOI 10.1056/NEJMoa022170; Wu B, 2009, MOL THER, V17, P864, DOI 10.1038/mt.2009.38; Xiong W, 2008, J VASC SURG, V47, P166, DOI 10.1016/j.jvs.2007.09.016; Yang SH, 2008, BBA-MOL CELL BIOL L, V1781, P36, DOI 10.1016/j.bbalip.2007.11.003; Yano T, 2009, NAT IMMUNOL, V10, P134, DOI 10.1038/ni0209-134	72	64	66	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					852	863		10.1056/NEJMra0907180	http://dx.doi.org/10.1056/NEJMra0907180			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642HG	20818846				2022-12-28	WOS:000281196600008
J	Kon, AA				Kon, Alexander A.			The Shared Decision-Making Continuum	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Kon, Alexander A.] Univ Calif Davis, Dept Pediat, Div Pediat Crit Care Med, Program Bioeth, Sacramento, CA 95817 USA; [Kon, Alexander A.] Univ Calif Davis, Clin & Translat Sci Ctr, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kon, AA (corresponding author), Univ Calif Davis, Dept Pediat, Div Pediat Crit Care Med, Program Bioeth, 2516 Stockton Blvd, Sacramento, CA 95817 USA.	aakon@ucdavis.edu			NCRR NIH HHS [UL1 RR024146-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024146] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		American Medical Association, D373999 AM MED ASS; Carlet J, 2004, INTENS CARE MED, V30, P770, DOI 10.1007/s00134-004-2241-5; Davidson JE, 2007, CRIT CARE MED, V35, P605, DOI 10.1097/01.CCM.0000254067.14607.EB; Johnson MF, 2000, J GEN INTERN MED, V15, P248, DOI 10.1046/j.1525-1497.2000.015004248.x; Kon AA, 2006, PEDIATRICS, V118, P393, DOI 10.1542/peds.2005-2655; Kon AA, 2009, AM J BIOETHICS, V9, P55, DOI 10.1080/15265160802716811; Mazur DJ, 2005, HEALTH EXPECT, V8, P97, DOI 10.1111/j.1369-7625.2005.00315.x; Mercurio MR, 2008, PEDIATR REV, V29, pE15, DOI 10.1542/pir.29-3-e15; Murray E, 2007, PATIENT EDUC COUNS, V65, P189, DOI 10.1016/j.pec.2006.07.007; Shields Cleveland G, 2004, Support Cancer Ther, V1, P119, DOI 10.3816/SCT.2004.n.005	10	263	273	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					903	904		10.1001/jama.2010.1208	http://dx.doi.org/10.1001/jama.2010.1208			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	644OY	20736477				2022-12-28	WOS:000281389900031
J	Baum, M				Baum, Michael			Homoeopathy waives the rules	LANCET			English	Editorial Material									Royal Free & Univ Coll Med Sch, Ctr Clin Sci & Technol, Clin Trials Grp, London N19 5LW, England	University of London; University College London	Baum, M (corresponding author), Royal Free & Univ Coll Med Sch, Ctr Clin Sci & Technol, Clin Trials Grp, London N19 5LW, England.	michael@mbaum.freeserve.co.uk						Department of Health, 2010, GOV RESP SCI TECHN C; Kmietowicz Z, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1091; Vaidya JS, 2010, LANCET, V376, P91, DOI 10.1016/S0140-6736(10)60837-9; DISCUSSIONS DEP HLTH	4	2	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 21	2010	376	9741					577	577		10.1016/S0140-6736(10)61227-5	http://dx.doi.org/10.1016/S0140-6736(10)61227-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	643PB	20728742				2022-12-28	WOS:000281309100010
J	Cryan, JF; O'Leary, OF				Cryan, John F.; O'Leary, Olivia F.			A Glutamate Pathway to Faster-Acting Antidepressants?	SCIENCE			English	Editorial Material							D-ASPARTATE ANTAGONIST; DEPRESSION; RECEPTORS; RAPAMYCIN; KETAMINE; TRIAL		[Cryan, John F.; O'Leary, Olivia F.] Natl Univ Ireland Univ Coll Cork, Sch Pharm, Dept Pharmacol & Therapeut, Alimentary Pharmabiot Ctr, Cork, Ireland	University College Cork	Cryan, JF (corresponding author), Natl Univ Ireland Univ Coll Cork, Sch Pharm, Dept Pharmacol & Therapeut, Alimentary Pharmabiot Ctr, Coll Rd, Cork, Ireland.	j.cryan@ucc.ie	O'Leary, Olivia/E-7964-2013; Cryan, John F./A-6950-2013	Cryan, John F./0000-0001-5887-2723; O'Leary, Olivia/0000-0002-9171-2032				Adell A, 2005, DRUG DISCOV TODAY, V10, P578, DOI 10.1016/S1359-6446(05)03398-2; Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9; Castren E, 2005, NAT REV NEUROSCI, V6, P241, DOI 10.1038/nrn1629; Cleary C, 2008, BRAIN RES BULL, V76, P469, DOI 10.1016/j.brainresbull.2008.03.005; Cryan JF, 2000, HUM PSYCHOPHARM CLIN, V15, P113, DOI 10.1002/(SICI)1099-1077(200003)15:2<113::AID-HUP150>3.0.CO;2-W; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; Diazgranados N, 2010, ARCH GEN PSYCHIAT, V67, P793, DOI 10.1001/archgenpsychiatry.2010.90; Fava M, 2003, BIOL PSYCHIAT, V53, P649, DOI 10.1016/S0006-3223(03)00231-2; Hajszan T, 2009, BIOL PSYCHIAT, V65, P392, DOI 10.1016/j.biopsych.2008.09.031; Hoeffer CA, 2010, TRENDS NEUROSCI, V33, P67, DOI 10.1016/j.tins.2009.11.003; Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287; Maeng S, 2008, BIOL PSYCHIAT, V63, P349, DOI 10.1016/j.biopsych.2007.05.028; Mazella J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000355; O'Leary OF, 2009, PSYCHONEUROENDOCRINO, V34, P367, DOI 10.1016/j.psyneuen.2008.09.015; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Shor B, 2009, CELL CYCLE, V8, P3831, DOI 10.4161/cc.8.23.10070; Skolnick P, 2009, TRENDS PHARMACOL SCI, V30, P563, DOI 10.1016/j.tips.2009.09.002; Slattery DA, J PSYCHOPHARMACOL; Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856	19	31	33	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					913	914		10.1126/science.1194313	http://dx.doi.org/10.1126/science.1194313			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724626				2022-12-28	WOS:000281084800024
J	Gray, DC; Mahrus, S; Wells, JA				Gray, Daniel C.; Mahrus, Sami; Wells, James A.			Activation of Specific Apoptotic Caspases with an Engineered Small-Molecule-Activated Protease	CELL			English	Article							CELL-DEATH; KEY MEDIATORS; GRANZYME-B; CLEAVAGE; INHIBITION; DROSOPHILA; PATHWAYS; PROTEINS; NEURONS; MYELOMA	Apoptosis is a conserved cellular pathway that results in the activation of cysteine-aspartyl proteases, or caspases. To dissect the nonredundant roles of the executioner caspase-3, -6, and -7 in orchestrating apoptosis, we have developed an orthogonal protease to selectively activate each isoform in human cells. Our approach uses a split-tobacco etch virus (TEV) protease under small-molecule control, which we call the SNIPer, with caspase alleles containing genetically encoded TEV cleavage sites. These studies reveal that all three caspases are transiently activated but only activation of caspase-3 or -7 is sufficient to induce apoptosis. Proteomic analysis shown here and from others reveals that 20 of the 33 subunits of the 26S proteasome can be cut by caspases, and we demonstrate synergy between proteasome inhibition and dose-dependent caspase activation. We propose a model of proteolytic reciprocal negative regulation with mechanistic implications for the combined clinical use of proteasome inhibitors and proapoptotic drugs.	[Gray, Daniel C.; Mahrus, Sami; Wells, James A.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Wells, James A.] Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94158 USA; [Gray, Daniel C.] Univ Calif San Francisco, Grad Grp Chem & Chem Biol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wells, JA (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA.	jim.wells@ucsf.edu	Wells, Jim A/O-9854-2016		NIH [R01 GM081051, CA136779]; Hartwell Foundation; University of California [2008-23]; NATIONAL CANCER INSTITUTE [R01CA136779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081051] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hartwell Foundation; University of California(University of California System); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to members of the Wells lab for useful discussions and to Emily Crawford for curation of the laboratory caspase substrate database. We also thank the UCSF NIKON Imaging Center and Dr. Kurt Thorn for assistance with live-cell imaging. We also thank Drs. Al Burlingame, David Maltby, and Jon Trinidad for use of the Mass Spectrometry Facility at the Mission Bay Campus of UCSF. This work was supported by NIH R01 GM081051 and CA136779 (J.A.W.), The Hartwell Foundation (J.A.W.), and the University of California Systemwide Biotechnology Research & Education Program GREAT Training Grant 2008-23 (D.C.G.).	Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; Albeck JG, 2008, MOL CELL, V30, P11, DOI 10.1016/j.molcel.2008.02.012; Albeck JG, 2008, PLOS BIOL, V6, P2831, DOI 10.1371/journal.pbio.0060299; Bedford L, 2008, J NEUROSCI, V28, P8189, DOI 10.1523/JNEUROSCI.2218-08.2008; Casciola-Rosen L, 2007, J BIOL CHEM, V282, P4545, DOI 10.1074/jbc.M606564200; Choi YE, 2009, J BIOL CHEM, V284, P12772, DOI 10.1074/jbc.M807550200; Dix MM, 2008, CELL, V134, P679, DOI 10.1016/j.cell.2008.06.038; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ernst JD, 1998, ANAL BIOCHEM, V260, P18, DOI 10.1006/abio.1998.2677; Feeney B, 2006, BIOCHEMISTRY-US, V45, P13249, DOI 10.1021/bi0611964; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Hell K, 2003, CELL DEATH DIFFER, V10, P1234, DOI 10.1038/sj.cdd.4401298; Jang M, 2007, BIOCHEM BIOPH RES CO, V363, P388, DOI 10.1016/j.bbrc.2007.08.183; Klaiman G, 2009, BBA-MOL CELL RES, V1793, P592, DOI 10.1016/j.bbamcr.2008.12.004; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Mahrus S, 2008, CELL, V134, P866, DOI 10.1016/j.cell.2008.08.012; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Pauli A, 2008, DEV CELL, V14, P239, DOI 10.1016/j.devcel.2007.12.009; Pop C, 2009, J BIOL CHEM, V284, P21777, DOI 10.1074/jbc.R800084200; Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140-6736(09)60221-X; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Shi YG, 2004, PROTEIN SCI, V13, P1979, DOI 10.1110/ps.04789804; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thiede B, 2005, PROTEOMICS, V5, P2123, DOI 10.1002/pmic.200401110; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Van Damme P, 2005, NAT METHODS, V2, P771, DOI 10.1038/NMETH792; Wang JJ, 2008, J CELL BIOL, V180, P1177, DOI 10.1083/jcb.200709080; Wehr MC, 2006, NAT METHODS, V3, P985, DOI 10.1038/nmeth967; Williams DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007474; Wolan DW, 2009, SCIENCE, V326, P853, DOI 10.1126/science.1177585; Yi CH, 2009, DEV CELL, V16, P21, DOI 10.1016/j.devcel.2008.12.012	38	147	160	3	57	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					637	646		10.1016/j.cell.2010.07.014	http://dx.doi.org/10.1016/j.cell.2010.07.014			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723762	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000281115900017
J	Soth, MD				Soth, Mark D.			Early tracheotomy did not reduce ventilator-associated pneumonia in adults ventilated for acute respiratory failure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									McMaster Univ, Hamilton, ON, Canada	McMaster University	Soth, MD (corresponding author), McMaster Univ, Hamilton, ON, Canada.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-9	10.7326/0003-4819-153-4-201008170-02009	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713788				2022-12-28	WOS:000280973000035
J	Armitage, JO				Armitage, James O.			CURRENT CONCEPTS Early-Stage Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INVOLVED-FIELD RADIOTHERAPY; COMBINED-MODALITY THERAPY; RADIATION-THERAPY; COMBINATION CHEMOTHERAPY; ABVD CHEMOTHERAPY; LUNG-CANCER; FOLLOW-UP; DISEASE; RISK; TRIAL		Univ Nebraska, Med Ctr, Div Hematol Oncol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Armitage, JO (corresponding author), Univ Nebraska, Med Ctr, Div Hematol Oncol, 8722 LTC,42nd & Emile, Omaha, NE 68198 USA.	joarmita@unmc.edu			Allos Therapeutics; Ziopharm Oncology; Biogen IDEC; Eisai Pharmaceuticals; Amgen; L'Oreal; Groupe d'Etude des Lymphomes de l'Adulte (French lymphoma cooperative group)	Allos Therapeutics; Ziopharm Oncology; Biogen IDEC(Biogen); Eisai Pharmaceuticals(Eisai Co Ltd); Amgen(Amgen); L'Oreal(L'Oreal Group); Groupe d'Etude des Lymphomes de l'Adulte (French lymphoma cooperative group)	Dr. Armitage reports serving on the boards of MGI Pharma and the Roche Foundation for Anemia Research; receiving consulting fees from Allos Therapeutics, Ziopharm Oncology, Biogen IDEC, Eisai Pharmaceuticals, Amgen, L'Oreal, and Groupe d'Etude des Lymphomes de l'Adulte (French lymphoma cooperative group); and receiving speaking fees from and participating in educational activities for Imedex, Clinical Care Options, PRIME Oncology, and the Institute for Medical Education and Research. No other potential conflict of interest relevant to this article was reported.	Adams MJ, 2004, J CLIN ONCOL, V22, P3139, DOI 10.1200/JCO.2004.09.109; Al-Mansour M, 2010, J CLIN ONCOL, V28, P793, DOI 10.1200/JCO.2009.24.9516; Aleman BMP, 2007, BLOOD, V109, P1878, DOI 10.1182/blood-2006-07-034405; Barnes JA, 2008, BLOOD, V112, P518; BARTLETT NL, 1995, J CLIN ONCOL, V13, P1080, DOI 10.1200/JCO.1995.13.5.1080; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; Bonadonna G, 2004, J CLIN ONCOL, V22, P2835, DOI 10.1200/JCO.2004.12.170; Borchmann P, 2009, BLOOD, V114, P299; Canellos GP, 2010, J CLIN ONCOL, V28, P1611, DOI 10.1200/JCO.2009.25.3260; CARBONE PP, 1971, CANCER RES, V31, P1860; Chen RC, 2010, J CLIN ONCOL, V28, P136, DOI 10.1200/JCO.2009.24.0945; De Bruin ML, 2009, JNCI-J NATL CANCER I, V101, P928, DOI 10.1093/jnci/djp147; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; Dominguez AR, 2004, ANN ONCOL, V15, P1798, DOI 10.1093/annonc/mdh465; EASSON EC, 1963, BRIT MED J, P1704, DOI 10.1136/bmj.1.5347.1704; Engert A, 2003, J CLIN ONCOL, V21, P3601, DOI 10.1200/JCO.2003.03.023; ENGERT A, 2010, NEW ENGL J MED, V363, P32; Evens AM, 2008, ONCOLOGY-NY, V22, P1369; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Franklin J, 2006, ANN ONCOL, V17, P1749, DOI 10.1093/annonc/mdl302; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Heidenreich PA, 2005, AM HEART J, V150, P977, DOI 10.1016/j.ahj.2004.12.026; Hentrich M, 2006, ANN ONCOL, V17, P914, DOI 10.1093/annonc/mdl063; Heutte N, 2009, LANCET ONCOL, V10, P1160, DOI 10.1016/S1470-2045(09)70258-X; KAPLAN HS, 1962, RADIOLOGY, V78, P553, DOI 10.1148/78.4.553; Klimm B, 2007, ANN ONCOL, V18, P357, DOI 10.1093/annonc/mdl379; Longo DL, 2006, BLOOD, V108, p33A; MACMAHON B, 1971, CANCER RES, V31, P1854; MACMAHON B, 1966, CANCER RES, V26, P1189; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; National Comprehensive Cancer Network Inc, NCCN GUID CLIN RES; Ng AK, 2004, ANN ONCOL, V15, P261, DOI 10.1093/annonc/mdh044; Noordijk EM, 2006, J CLIN ONCOL, V24, P3128, DOI 10.1200/JCO.2005.05.2746; OLWENY CLM, 1978, CANCER-AM CANCER SOC, V42, P787, DOI 10.1002/1097-0142(197808)42:2<787::AID-CNCR2820420251>3.0.CO;2-4; Pavone V, 2008, ANN ONCOL, V19, P763, DOI 10.1093/annonc/mdm575; PETERS MV, 1958, AMER J ROENTGENOL RA, V79, P114; Rizack T, 2009, AM J HEMATOL, V84, P830, DOI 10.1002/ajh.21547; Rosenberg SA, 1999, HODGKIN'S DISEASE, P47; Sher DJ, 2009, ANN ONCOL, V20, P1848, DOI 10.1093/annonc/mdp071; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; Swerdlow AJ, 2001, J CLIN ONCOL, V19, P1610, DOI 10.1200/JCO.2001.19.6.1610; Swerdlow AJ, 2007, J NATL CANCER I, V99, P206, DOI 10.1093/jnci/djk029; Swerdlow SH, 2008, WHO CLASSIFICATION T; Travis LB, 2005, JNCI-J NATL CANCER I, V97, P1428, DOI 10.1093/jnci/dji290; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; van Leeuwen FE, 2003, JNCI-J NATL CANCER I, V95, P971, DOI 10.1093/jnci/95.13.971; Weekes CD, 2002, J CLIN ONCOL, V20, P1087, DOI 10.1200/JCO.20.4.1087; ZIEGLER JL, 1972, LANCET, V2, P679	48	104	115	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					653	662		10.1056/NEJMra1003733	http://dx.doi.org/10.1056/NEJMra1003733			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20818856				2022-12-28	WOS:000280764600008
J	Frohman, EM; Wingerchuk, DM				Frohman, Elliot M.; Wingerchuk, Dean M.			Transverse Myelitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIPLE-SCLEROSIS; NEUROMYELITIS-OPTICA; PLASMA-EXCHANGE; DOUBLE-BLIND; NEUROPATHIC PAIN; EFFICACY; FATIGUE; CORTICOSTEROIDS; MODAFINIL; DIAGNOSIS	An otherwise healthy 28-year-old woman presents to the emergency department with progressive weakness that began 3 days earlier. She reports difficulty walking, numbness in the body below her breasts, and urinary urgency, and she notes that neck flexion triggers an electrical sensation that radiates to the coccyx. Physical examination reveals moderate paraparesis with hyperreflexia, a left extensor plantar response, impairment of vibratory and proprioceptive sensation, and a sensory level at T6. Magnetic resonance imaging (MRI) reveals a lower cervical cord lesion that enhances after gadolinium administration, a finding that is consistent with transverse myelitis. How should she be further evaluated and treated?	[Frohman, Elliot M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75235 USA; [Frohman, Elliot M.] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75235 USA; [Wingerchuk, Dean M.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Mayo Clinic; Mayo Clinic Phoenix	Frohman, EM (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	elliot.frohman@utsouthwestern.edu			Biogen Idec; Teva Neuroscience; Bayer; Novartis; Abbott; Genzyme; Alexion; Genentech; Organon (now part of Merck); National Multiple Sclerosis Society; VLST; Guthy-Jackson Charitable Foundation	Biogen Idec(Biogen); Teva Neuroscience(Teva Pharmaceutical Industries); Bayer(Bayer AG); Novartis(Novartis); Abbott(Abbott Laboratories); Genzyme(Sanofi-AventisGenzyme Corporation); Alexion; Genentech(Roche HoldingGenentech); Organon (now part of Merck); National Multiple Sclerosis Society(National Multiple Sclerosis Society); VLST; Guthy-Jackson Charitable Foundation	Dr. Frohman reports receiving speaking fees from Biogen Idec, Teva Neuroscience, Bayer, and Novartis and consulting fees from Biogen Idec, Teva Neuroscience, Abbott, and Genzyme; and Dr. Wingerchuk, receiving research support from Alexion, Genzyme, Genentech, Organon (now part of Merck), and the National Multiple Sclerosis Society and consulting fees from Novartis, Teva Neuroscience, VLST, and the Guthy-Jackson Charitable Foundation. No other potential conflict of interest relevant to this article was reported.	Abrams P, 1998, BRIT J UROL, V81, P801; [Anonymous], 2007, COCHRANE DATABASE SY, DOI 10.1002/14651858.CD005454.pub2; Barnes G, 2002, NEUROLOGY, V59, P499, DOI 10.1212/wnl.59.4.499; Bennett JK, 2000, MOL UROL, V4, P415; BERMAN M, 1981, NEUROLOGY, V31, P969; Bhat A, 2010, AUTOIMMUN REV, V9, pA395, DOI 10.1016/j.autrev.2009.12.007; Bonnan M, 2009, MULT SCLER J, V15, P487, DOI 10.1177/1352458508100837; Branas P., 2000, HLTH TECHNOL ASSESS, V4, P1, DOI [DOI 10.3310/HTA4270, 10.3310/hta4270]; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Courtney AM, 2009, MED CLIN N AM, V93, P451, DOI 10.1016/j.mcna.2008.09.014; de Seze J, 2005, NEUROLOGY, V65, P1950, DOI 10.1212/01.wnl.0000188896.48308.26; de Seze J, 2001, BRAIN, V124, P1509, DOI 10.1093/brain/124.8.1509; Debette S, 2009, J NEUROL, V256, P980, DOI 10.1007/s00415-009-5058-x; Fletcher SG, 2009, NAT CLIN PRACT UROL, V6, P96, DOI 10.1038/ncpuro1298; Frohman EM, 2007, NEUROTHERAPEUTICS, V4, P618, DOI 10.1016/j.nurt.2007.07.008; Goodman AD, 2009, LANCET, V373, P732, DOI 10.1016/S0140-6736(09)60442-6; Greenberg BM, 2007, NEUROLOGY, V68, P1614, DOI 10.1212/01.wnl.0000260970.63493.c8; Groves L, 1998, ADV THER, V15, P241; Hummers LK, 2004, NEUROLOGY, V62, P147, DOI 10.1212/01.WNL.0000101715.32569.1A; Jacob A, 2008, SEMIN NEUROL, V28, P105, DOI 10.1055/s-2007-1019132; Kaplin AI, 2005, NEUROLOGIST, V11, P2, DOI 10.1097/01.nrl.0000149975.39201.0b; Kesselring J, 2005, LANCET NEUROL, V4, P643, DOI 10.1016/S1474-4422(05)70193-9; Kumar N, 2004, ARCH NEUROL-CHICAGO, V61, P586, DOI 10.1001/archneur.61.4.586; Lemack GE, 2006, UROLOGY, V67, P960, DOI 10.1016/j.urology.2005.11.061; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Martinelli V, 2009, NEUROLOGY, V73, P1842, DOI 10.1212/WNL.0b013e3181c3fd5b; Misu T, 2005, NEUROLOGY, V65, P1479, DOI 10.1212/01.wnl.0000183151.19351.82; Namaka Michael, 2009, Consult Pharm, V24, P885, DOI 10.4140/TCP.n.2009.885; Pidcock FS, 2007, NEUROLOGY, V68, P1474, DOI 10.1212/01.wnl.0000260609.11357.6f; Pittock SJ, 2008, ARCH NEUROL-CHICAGO, V65, P78, DOI 10.1001/archneurol.2007.17; Pittock SJ, 2006, CURR OPIN NEUROL, V19, P362, DOI 10.1097/01.wco.0000236615.59215.d3; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; SAARTO T, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD005454; Scott TF, 2007, ACTA NEUROL SCAND, V115, P371, DOI 10.1111/j.1600-0404.2007.00835.x; Spivack S B, 1997, J Spinal Cord Med, V20, P402; Stankoff B, 2005, NEUROLOGY, V64, P1139, DOI 10.1212/01.WNL.0000158272.27070.6A; Tomassini V, 2004, J NEUROL SCI, V218, P103, DOI 10.1016/j.jns.2003.11.005; Tzellos TG, 2008, EUR J CLIN PHARMACOL, V64, P851, DOI 10.1007/s00228-008-0523-5; Watanabe S, 2007, MULT SCLER J, V13, P128, DOI 10.1177/1352458506071174; Weinshenker BG, 2006, ANN NEUROL, V59, P566, DOI 10.1002/ana.20770; Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q; Wiffen PJ, 2005, COCHRANE DB SYST REV, V3; Wingerchuk DM, 2006, NEUROLOGY, V66, P1485, DOI 10.1212/01.wnl.0000216139.44259.74; Wingerchuk DM, 2008, CURR TREAT OPTION NE, V10, P55, DOI 10.1007/s11940-008-0007-z; Wingerchuk DM, 2007, LANCET NEUROL, V6, P805, DOI 10.1016/S1474-4422(07)70216-8; Wingerchuk Dean M, 2003, Curr Neurol Neurosci Rep, V3, P256, DOI 10.1007/s11910-003-0086-x; Wingerchuk DM, 1999, NEUROLOGY, V53, P1107, DOI 10.1212/WNL.53.5.1107	47	104	110	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					564	572		10.1056/NEJMcp1001112	http://dx.doi.org/10.1056/NEJMcp1001112			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818891				2022-12-28	WOS:000280552700010
J	[Anonymous]				[Anonymous]			HEALTH MANAGERS SUPPORT TAXATION BASED SERVICE	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1988	296	6637					1682	1682						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	N8341	20743003				2022-12-28	WOS:A1988N834100072
J	DUNEA, G				DUNEA, G			DISTRUST	BRITISH MEDICAL JOURNAL			English	Editorial Material											DUNEA, G (corresponding author), COOK CTY HOSP,CHICAGO,IL 60612, USA.							CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; MELLRATH S, 1987, AM MED NEWS     1225, P1; Pear Robert, 1987, NY TIMES A      0911, P1; RUNDLE RL, 1987, WALL STREET J   0728, P31; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1988	296	6631					1251	1252		10.1136/bmj.296.6631.1251	http://dx.doi.org/10.1136/bmj.296.6631.1251			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N1960	20742988	Green Published			2022-12-28	WOS:A1988N196000020
J	Morris, PJ				Morris, Peter J.			Kidneys donated after cardiac death are acceptable	LANCET			English	Editorial Material							TRANSPLANTATION		[Morris, Peter J.] Royal Coll Surgeons England, Ctr Evidence Transplantat, London WC21 3PE, England; [Morris, Peter J.] London Sch Hyg & Trop Med, London WC21 3PE, England	Royal College of Surgeons of England; University of London; London School of Hygiene & Tropical Medicine	Morris, PJ (corresponding author), Royal Coll Surgeons England, Ctr Evidence Transplantat, London WC21 3PE, England.	pmorris@rcseng.ac.uk						Barlow AD, 2009, BRIT J SURG, V96, P685, DOI 10.1002/bjs.6607; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893; MARSHALL V, 1968, LANCET, V291, P927; Moers C, 2009, NEW ENGL J MED, V360, P7, DOI 10.1056/NEJMoa0802289; MORRIS PJ, 1978, LANCET, V312, P1353; *NHS BLOOD TRANSPL, 2009, TRANSPL ACT UK 2008; Pratschke J, 1999, TRANSPLANTATION, V67, P343, DOI 10.1097/00007890-199902150-00001; SUMMERS DM, 2010, LANCET, DOI DOI 10.1016/S0140-6736(10)60827-8; Watson C, 2008, TRANSPLANTATION S, V86, P81	9	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 16	2010	376	9749					1276	1278		10.1016/S0140-6736(10)61078-1	http://dx.doi.org/10.1016/S0140-6736(10)61078-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20727577				2022-12-28	WOS:000283528600005
J	France, K; McCray, R; Heng, K; Kirshner, RP; Challis, P; Bouchet, P; Crotts, A; Dwek, E; Fransson, C; Garnavich, PM; Larsson, J; Lawrence, SS; Lundqvist, P; Panagia, N; Pun, CSJ; Smith, N; Sollerman, J; Sonneborn, G; Stocke, JT; Wang, LF; Wheeler, JC				France, Kevin; McCray, Richard; Heng, Kevin; Kirshner, Robert P.; Challis, Peter; Bouchet, Patrice; Crotts, Arlin; Dwek, Eli; Fransson, Claes; Garnavich, Peter M.; Larsson, Josefin; Lawrence, Stephen S.; Lundqvist, Peter; Panagia, Nino; Pun, Chun S. J.; Smith, Nathan; Sollerman, Jesper; Sonneborn, George; Stocke, John T.; Wang, Lifan; Wheeler, J. Craig			Observing Supernova 1987A with the Refurbished Hubble Space Telescope	SCIENCE			English	Article							BALMER-DOMINATED SHOCKS; SNR 1987A; REVERSE SHOCK; CIRCUMSTELLAR RING; OPTICAL-EMISSION; LINE EMISSION; SN-1987A; ULTRAVIOLET; REMNANTS; NEBULA	Observations with the Hubble Space Telescope (HST), conducted since 1990, now offer an unprecedented glimpse into fast astrophysical shocks in the young remnant of supernova 1987A. Comparing observations taken in 2010 with the use of the refurbished instruments on HST with data taken in 2004, just before the Space Telescope Imaging Spectrograph failed, we find that the Ly alpha and H alpha lines from shock emission continue to brighten, whereas their maximum velocities continue to decrease. We observe broad, blueshifted Ly alpha, which we attribute to resonant scattering of photons emitted from hot spots on the equatorial ring. We also detect N v lambda lambda 1239, 1243 angstrom line emission, but only to the red of Ly alpha. The profiles of the N v lines differ markedly from that of H alpha, suggesting that the N(4+) ions are scattered and accelerated by turbulent electromagnetic fields that isotropize the ions in the collisionless shock.	[Heng, Kevin] ETH, Inst Astron, CH-8093 Zurich, Switzerland; [France, Kevin; Stocke, John T.] Univ Colorado, Ctr Astrophys & Space Astron, Boulder, CO 80309 USA; [McCray, Richard] Univ Colorado, JILA, Boulder, CO 80309 USA; [Heng, Kevin] Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; [Kirshner, Robert P.; Challis, Peter] Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; [Bouchet, Patrice] Commissariat Energie Atom & Energies Alternat, Serv Astrophys, FR-91191 Gif Sur Yvette, France; [Crotts, Arlin] Columbia Univ, Dept Astron, New York, NY 10027 USA; [Dwek, Eli; Sonneborn, George] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Fransson, Claes; Larsson, Josefin; Sollerman, Jesper] Stockholm Univ, Oskar Klein Ctr, Dept Astron, S-10691 Stockholm, Sweden; [Garnavich, Peter M.] Univ Notre Dame, Notre Dame, IN 46556 USA; [Lawrence, Stephen S.] Hofstra Univ, Dept Phys & Astron, Hempstead, NY 11549 USA; [Panagia, Nino] Space Telescope Sci Inst, Baltimore, MD 21218 USA; [Panagia, Nino] Osserv Astrofis Catania, Inst Nazl Astrofis, I-95123 Catania, Italy; [Pun, Chun S. J.] Univ Hong Kong, Dept Phys, Hong Kong, Hong Kong, Peoples R China; [Smith, Nathan] Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; [Wang, Lifan] Texas A&M Univ, Dept Phys & Astron, College Stn, TX USA; [Wheeler, J. Craig] Univ Texas Austin, Dept Astron, Austin, TX 78712 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Institute for Advanced Study - USA; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; CEA; UDICE-French Research Universities; Universite Paris Saclay; Columbia University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Oskar Klein Centre; Stockholm University; University of Notre Dame; Hofstra University; Space Telescope Science Institute; Istituto Nazionale Astrofisica (INAF); University of Hong Kong; University of California System; University of California Berkeley; Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Austin	Heng, K (corresponding author), ETH, Inst Astron, Wolfgang Pauli Str 27, CH-8093 Zurich, Switzerland.	kheng@phys.ethz.ch	Dwek, Eli/C-3995-2012; Pun, Chun Shing Jason/AAO-9345-2020; Sonneborn, George/D-5255-2012; Lawrence, Stephen/R-6057-2019	Lawrence, Stephen/0000-0002-7491-7052; FRANCE, KEVIN/0000-0002-1002-3674; Dwek, Eli/0000-0001-8033-1181; Sollerman, Jesper/0000-0003-1546-6615; /0000-0003-0065-2933	Space Telescope Science Institute [GO-11181]; NASA [NAS5-26555]	Space Telescope Science Institute(Space Telescope Science Institute); NASA(National Aeronautics & Space Administration (NASA))	K.F. thanks M. Beasley for enjoyable discussions. Support for this research was provided by NASA through grant GO-11181 from the Space Telescope Science Institute, which is operated by the Association of Universities for Research in Astronomy, under NASA contract NAS5-26555.	ARNETT WD, 1989, ANNU REV ASTRON ASTR, V27, P629, DOI 10.1146/annurev.aa.27.090189.003213; Borkowski KJ, 1997, ASTROPHYS J, V476, pL31, DOI 10.1086/310487; CHEVALIER RA, 1978, ASTROPHYS J, V225, pL27, DOI 10.1086/182785; CHEVALIER RA, 1980, ASTROPHYS J, V235, P186, DOI 10.1086/157623; CHEVALIER RA, 1982, ASTROPHYS J, V258, P790, DOI 10.1086/160126; CROTTS APS, 1991, NATURE, V350, P683, DOI 10.1038/350683a0; GARNAVICH P, 1997, 6710 IAU; Groningsson P, 2008, ASTRON ASTROPHYS, V479, P761, DOI 10.1051/0004-6361:20077604; Heng K, 2007, ASTROPHYS J, V654, P923, DOI 10.1086/509601; Heng K, 2006, ASTROPHYS J, V644, P959, DOI 10.1086/503896; Heng K, 2010, PUBL ASTRON SOC AUST, V27, P23, DOI 10.1071/AS09057; Laming JM, 1996, ASTROPHYS J, V472, P267, DOI 10.1086/178061; Lawrence SS, 2000, ASTROPHYS J, V537, pL123, DOI 10.1086/312771; Lundqvist P, 1996, ASTROPHYS J, V464, P924, DOI 10.1086/177380; MCCRAY R, 1993, ANNU REV ASTRON ASTR, V31, P175, DOI 10.1146/annurev.aa.31.090193.001135; McCray R, 2007, AIP CONF PROC, V937, P3, DOI 10.1063/1.2803599; Michael E, 2003, ASTROPHYS J, V593, P809, DOI 10.1086/376725; Morris T, 2007, SCIENCE, V315, P1103, DOI 10.1126/science.1136351; Osterbrock D. E., 2006, ASTROPHYSICS GASEOUS; PANAGIA N, 1991, ASTROPHYS J, V380, pL23, DOI 10.1086/186164; Pun CSJ, 2002, ASTROPHYS J, V572, P906, DOI 10.1086/340453; Scuderi S, 1996, ASTROPHYS J, V465, P956, DOI 10.1086/177480; Smith N, 2005, ASTROPHYS J, V635, pL41, DOI 10.1086/499101; SUNTZEFF NB, 1990, ASTRON J, V99, P650, DOI 10.1086/115358	25	23	24	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	2010	329	5999					1624	1627		10.1126/science.1192134	http://dx.doi.org/10.1126/science.1192134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653NK	20813921	Green Submitted			2022-12-28	WOS:000282098100034
J	Kagey, MH; Newman, JJ; Bilodeau, S; Zhan, Y; Orlando, DA; van Berkum, NL; Ebmeier, CC; Goossens, J; Rahl, PB; Levine, SS; Taatjes, DJ; Dekker, J; Young, RA				Kagey, Michael H.; Newman, Jamie J.; Bilodeau, Steve; Zhan, Ye; Orlando, David A.; van Berkum, Nynke L.; Ebmeier, Christopher C.; Goossens, Jesse; Rahl, Peter B.; Levine, Stuart S.; Taatjes, Dylan J.; Dekker, Job; Young, Richard A.			Mediator and cohesin connect gene expression and chromatin architecture	NATURE			English	Article							EMBRYONIC STEM-CELLS; DE-LANGE-SYNDROME; TRANSCRIPTIONAL REGULATORY CIRCUITRY; INTEGRATION HOST FACTOR; NIPPED-B; COACTIVATOR; ACTIVATION; PROTEINS; COMPLEX; MED12	Transcription factors control cell-specific gene expression programs through interactions with diverse coactivators and the transcription apparatus. Gene activation may involve DNA loop formation between enhancer-bound transcription factors and the transcription apparatus at the core promoter, but this process is not well understood. Here we report that mediator and cohesin physically and functionally connect the enhancers and core promoters of active genes in murine embryonic stem cells. Mediator, a transcriptional coactivator, forms a complex with cohesin, which can form rings that connect two DNA segments. The cohesin-loading factor Nipbl is associated with mediator-cohesin complexes, providing a means to load cohesin at promoters. DNA looping is observed between the enhancers and promoters occupied by mediator and cohesin. Mediator and cohesin co-occupy different promoters in different cells, thus generating cell-type-specific DNA loops linked to the gene expression program of each cell.	[Kagey, Michael H.; Newman, Jamie J.; Bilodeau, Steve; Orlando, David A.; Rahl, Peter B.; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Newman, Jamie J.; Levine, Stuart S.; Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Zhan, Ye; van Berkum, Nynke L.; Dekker, Job] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; [Zhan, Ye; van Berkum, Nynke L.; Dekker, Job] Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA; [Ebmeier, Christopher C.; Goossens, Jesse; Taatjes, Dylan J.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Colorado System; University of Colorado Boulder	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	Dylan.Taatjes@Colorado.EDU; young@wi.mit.edu	Young, Richard A/F-6495-2012; Taatjes, Dylan J/G-2027-2011	Young, Richard A/0000-0001-8855-8647; Levine, Stuart/0000-0001-7363-562X; Bilodeau, Steve/0000-0002-9799-3832; Goossens, Jesse/0000-0002-9078-8182	NIH [HG003143, HG002668]; Canadian Institutes of Health Research; American Cancer Society; Keck Distinguished young scholar award; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003143, R01HG002668] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); American Cancer Society(American Cancer Society); Keck Distinguished young scholar award; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank T. Lee for discussions; D. Root, S. Silver, T. Neiland and H. Le at the RNAi Screening Platform at the Broad Institute for screening advice and technical support; and J.-A. Kwon, J. Love, S. Gupta and T. Volkert for assistance with ChIP-Seq. Immunofluorescence images were collected using the W. M. Keck Foundation Biological Imagining Facility at the Whitehead Institute and Whitehead-MIT Bioimaging Center. This work was supported by Susan Whitehead and Landon and Lavinia Clay, an NIH Fellowship (M. H. K.), a Canadian Institutes of Health Research Fellowship (S. B.), the American Cancer Society (D. J. T.), a Keck Distinguished young scholar award (J. D.) and by NIH grants HG003143 (J. D.) and HG002668 (R.A.Y.).	ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; Bose T, 2010, J CELL BIOL, V189, P201, DOI 10.1083/jcb.200912129; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bulger M, 2010, DEV BIOL, V339, P250, DOI 10.1016/j.ydbio.2009.11.035; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; Conaway RC, 2005, TRENDS BIOCHEM SCI, V30, P250, DOI 10.1016/j.tibs.2005.03.002; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Ding N, 2008, MOL CELL, V31, P347, DOI 10.1016/j.molcel.2008.05.023; Dorsett D, 2007, CHROMOSOMA, V116, P1, DOI 10.1007/s00412-006-0072-6; Ebmeier CC, 2010, P NATL ACAD SCI USA, V107, P11283, DOI 10.1073/pnas.0914215107; Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533; Hadjur S, 2009, NATURE, V460, P410, DOI 10.1038/nature08079; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Jiang HM, 2008, MOL CELL BIOL, V28, P907, DOI 10.1128/MCB.00909-07; Knuesel MT, 2009, GENE DEV, V23, P439, DOI 10.1101/gad.1767009; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Krantz ID, 2004, NAT GENET, V36, P631, DOI 10.1038/ng1364; Liu JL, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000119; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Luijsterburg MS, 2008, CRIT REV BIOCHEM MOL, V43, P393, DOI [10.1080/10409230802528488, 10.1080/10409230802528488 ]; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; Miele A, 2008, MOL BIOSYST, V4, P1046, DOI 10.1039/b803580f; Nasmyth K, 2009, ANNU REV GENET, V43, P525, DOI 10.1146/annurev-genet-102108-134233; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okumura-Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200; Panne D, 2008, CURR OPIN STRUC BIOL, V18, P236, DOI 10.1016/j.sbi.2007.12.002; Philiber RA, 2007, PHARMACOGENOMICS, V8, P909, DOI 10.2217/14622416.8.8.909; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; PTASHNE M, 2002, GENES SIGNALS; Risheg H, 2007, NAT GENET, V39, P451, DOI 10.1038/ng1992; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Saiz L, 2006, CURR OPIN STRUC BIOL, V16, P344, DOI 10.1016/j.sbi.2006.05.008; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109; Schwartz CE, 2007, J MED GENET, V44, P472, DOI 10.1136/jmg.2006.048637; Strachan T, 2005, CURR OPIN GENET DEV, V15, P258, DOI 10.1016/j.gde.2005.04.005; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Taatjes DJ, 2010, TRENDS BIOCHEM SCI, V35, P315, DOI 10.1016/j.tibs.2010.02.004; Tonkin ET, 2004, NAT GENET, V36, P636, DOI 10.1038/ng1363; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; Wood AJ, 2010, NAT REV GENET, V11, P391, DOI 10.1038/nrg2794; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; Yeom YI, 1996, DEVELOPMENT, V122, P881	50	1317	1349	1	181	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					430	435		10.1038/nature09380	http://dx.doi.org/10.1038/nature09380			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20720539	Green Submitted, Green Accepted			2022-12-28	WOS:000282090200036
J	Zhu, FC; Zhang, J; Zhang, XF; Zhou, C; Wang, ZZ; Huang, SJ; Wang, H; Yang, CL; Jiang, HM; Cai, JP; Wang, YJ; Ai, X; Hu, YM; Tang, QA; Yao, X; Yan, QA; Xian, YL; Wu, T; Li, YM; Miao, J; Ng, MH; Shih, JWK; Xia, NS				Zhu, Feng-Cai; Zhang, Jun; Zhang, Xue-Feng; Zhou, Cheng; Wang, Zhong-Ze; Huang, Shou-Jie; Wang, Hua; Yang, Chang-Lin; Jiang, Han-Min; Cai, Jia-Ping; Wang, Yi-Jun; Ai, Xing; Hu, Yue-Mei; Tang, Quan; Yao, Xin; Yan, Qiang; Xian, Yang-Ling; Wu, Ting; Li, Yi-Min; Miao, Ji; Ng, Mun-Hon; Shih, James Wai-Kuo; Xia, Ning-Shao			Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial	LANCET			English	Article							CHRONIC LIVER-DISEASE; E VIRUS-INFECTION; VIRAL-HEPATITIS; PREGNANCY; ZOONOSIS; IGG	Background Seroprevalence data suggest that a third of the world's population has been infected with the hepatitis E virus. Our aim was to assess efficacy and safety of a recombinant hepatitis E vaccine, HEV 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China) in a randomised, double-blind, placebo-controlled, phase 3 trial. Methods Healthy adults aged 16-65 years in, Jiangsu Province, China were randomly assigned in a 1:1 ratio to receive three doses of HEV 239 (30 jig of purified recombinant hepatitis E antigen adsorbed to 0.8 mg aluminium hydroxide suspended in 0.5 mL buffered saline) or placebo (hepatitis B vaccine) given intramuscularly at 0, 1, and 6 months. Randomisation was done by computer-generated permuted blocks and stratified by age and sex. Participants were followed up for 19 months. The primary endpoint was prevention of hepatitis E during 12 months from the 31st day after the third dose. Analysis was based on participants who received all three doses per protocol. Study participants, care givers, and investigators were all masked to group and vaccine assignments. This trial is registered with ClinicalTrials.gov, number NCT01014845. Findings 11165 of the trial participants were tested for hepatitis E virus IgG, of which 5285 (47%) were seropositive for hepatitis E virus. Participants were randomly assigned to vaccine (n=56302) or placebo (n=56302). 48 693 (86%) participants in the vaccine group and 48 663 participants (86%) in the placebo group received three vaccine doses and were included in the primary efficacy analysis. During the 12 months after 30 days from receipt of the third dose 15 per-protocol participants in the placebo group developed hepatitis E compared with none in the vaccine group. Vaccine efficacy after three doses was 100.0% (95% CI 72.1-100.0). Adverse effects attributable to the vaccine were few and mild. No vaccination-related serious adverse event was noted. Interpretation HEV 239 is well tolerated and effective in the prevention of hepatitis E in the general population in China, including both men and women age 16-65 years.	[Zhang, Jun; Huang, Shou-Jie; Yan, Qiang; Wu, Ting; Miao, Ji; Ng, Mun-Hon; Shih, James Wai-Kuo; Xia, Ning-Shao] Xiamen Univ, Minist Educ Cell Biol & Tumour Cell Engn, Key Lab, Natl Inst Diagnost & Vaccine Dev Infect Dis, Xiamen 361005, Peoples R China; [Zhu, Feng-Cai; Zhang, Xue-Feng; Wang, Hua; Ai, Xing; Hu, Yue-Mei; Tang, Quan] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu Prov, Peoples R China; [Zhou, Cheng; Yao, Xin] Natl Inst Control Pharmaceut & Biol Prod, Beijing, Peoples R China; [Wang, Zhong-Ze; Yang, Chang-Lin; Jiang, Han-Min; Cai, Jia-Ping; Wang, Yi-Jun] Dongtai Ctr Dis Control & Prevent, Dongtai, Jiangsu Prov, Peoples R China; [Xian, Yang-Ling; Li, Yi-Min] Xiamen Innovax Biotech, Xiamen, Peoples R China	Xiamen University; Jiangsu Provincial Center for Disease Control & Prevention; National Institute of Food & Drug Control - China	Xia, NS (corresponding author), Xiamen Univ, Minist Educ Cell Biol & Tumour Cell Engn, Key Lab, Natl Inst Diagnost & Vaccine Dev Infect Dis, 422nd Siming S Rd, Xiamen 361005, Peoples R China.	nsxia@xmu.edu.cn	Wang, Yijun/GXW-1763-2022; Zhang, Jun/G-4598-2010; Hu, Yue/HGE-1673-2022; Xia, NS/G-4647-2010	Zhang, Jun/0000-0002-6601-9180; Xia, Ningshao/0000-0003-0179-5266; Wu, Ting/0000-0002-1806-3056	Chinese Government [2006AA02A209, 2005DFA30820]; Chinese National Key Technologies RD Programme [2009ZX10004-704]; Chinese National Science Fund for Distinguished Young Scholars [30925030]; Fujian Provincial Department of Sciences and Technology [2004YZ01]; Xiamen Science and Technology Bureau [3502Z20041008]; Fujian Provincial Science Fund for Distinguished Young Scholars [2009J06020]	Chinese Government; Chinese National Key Technologies RD Programme(National Key Technology R&D Program); Chinese National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Fujian Provincial Department of Sciences and Technology; Xiamen Science and Technology Bureau; Fujian Provincial Science Fund for Distinguished Young Scholars	We thank the volunteers for their participation in this clinical study and Robert H Purcell of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (Bethesda, MD, USA) for his valuable suggestions and input. This trial was funded by multiple grants from the Chinese Government: Chinese National High-tech R&D Programme (863 programme; 2006AA02A209 and 2005DFA30820); Chinese National Key Technologies R&D Programme (2009ZX10004-704); Chinese National Science Fund for Distinguished Young Scholars (30925030); Fujian Provincial Department of Sciences and Technology (2004YZ01); Xiamen Science and Technology Bureau (3502Z20041008); and Fujian Provincial Science Fund for Distinguished Young Scholars (2009J06020).	Acharya SK, 2007, J HEPATOL, V46, P387, DOI 10.1016/j.jhep.2006.09.016; Bendall R, 2008, J MED VIROL, V80, P95, DOI 10.1002/jmv.21033; Chan ISF, 1998, COMMUN STAT-THEOR M, V27, P1305, DOI 10.1080/03610929808832160; Chen HY, 2005, CLIN DIAGN LAB IMMUN, V12, P593, DOI 10.1128/CDLI.12.5.593-598.2005; Dalton HR, 2007, LANCET, V369, P1260, DOI 10.1016/S0140-6736(07)60595-9; Dalton HR, 2008, LANCET INFECT DIS, V8, P698, DOI 10.1016/S1473-3099(08)70255-X; Dalton HR, 2009, NEW ENGL J MED, V361, P1025, DOI 10.1056/NEJMc0903778; Emerson SU, 2003, REV MED VIROL, V13, P145, DOI 10.1002/rmv.384; EMERSON SU, 2004, VIRUS TAXONOMY, P853; FitzSimons David, 2010, Vaccine, V28, P583, DOI 10.1016/j.vaccine.2009.10.136; Hamid SS, 2002, HEPATOLOGY, V36, P474, DOI 10.1053/jhep.2002.34856; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; Khuroo MS, 2003, J VIRAL HEPATITIS, V10, P61, DOI 10.1046/j.1365-2893.2003.00398.x; Krawczynski K, 2005, VIRAL HEPATITIS, 3RD EDITION, P624, DOI 10.1002/9780470987131.ch41; Labrique AB, 1999, EPIDEMIOL REV, V21, P162, DOI 10.1093/oxfordjournals.epirev.a017994; Li RC, 2006, EMERG INFECT DIS, V12, P1682, DOI 10.3201/eid1211.060332; Li SW, 2005, VACCINE, V23, P2893, DOI 10.1016/j.vaccine.2004.11.064; Lu L, 2006, REV MED VIROL, V16, P5, DOI 10.1002/rmv.482; Pavio N, 2008, FRONT BIOSCI-LANDMRK, V13, P7172, DOI 10.2741/3219; Purcell RH, 2008, J HEPATOL, V48, P494, DOI 10.1016/j.jhep.2007.12.008; Purcell RH, 2005, VIRAL HEPATITIS, 3RD EDITION, P635, DOI 10.1002/9780470987131.ch42; Said B, 2009, EMERG INFECT DIS, V15, P1738, DOI 10.3201/eid1511.091094; Shrestha MP, 2007, NEW ENGL J MED, V356, P895, DOI 10.1056/NEJMoa061847; Teshale EH, 2010, EMERG INFECT DIS, V16, P126, DOI 10.3201/eid1601.090764; Worm HC, 2004, DRUGS, V64, P1517, DOI 10.2165/00003495-200464140-00002; Zhang J, 2003, J MED VIROL, V71, P518, DOI 10.1002/jmv.10523; Zhang J, 2009, VACCINE, V27, P1869, DOI 10.1016/j.vaccine.2008.12.061; Zhou Cheng, 2009, Zhonghua Weishengwuxue He Mianyixue Zazhi, V29, P854, DOI 10.3760/cma.j.issn.0254-5101.2009.09.021	28	475	546	1	101	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					895	902		10.1016/S0140-6736(10)61030-6	http://dx.doi.org/10.1016/S0140-6736(10)61030-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653DW	20728932				2022-12-28	WOS:000282069100030
J	Kertesz, M; Wan, Y; Mazor, E; Rinn, JL; Nutter, RC; Chang, HY; Segal, E				Kertesz, Michael; Wan, Yue; Mazor, Elad; Rinn, John L.; Nutter, Robert C.; Chang, Howard Y.; Segal, Eran			Genome-wide measurement of RNA secondary structure in yeast	NATURE			English	Article							MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; TRANSLATION; SITE; PREDICTION; TRANSPORT; ELEMENTS	The structures of RNA molecules are often important for their function and regulation(1-6), yet there are no experimental techniques for genome-scale measurement of RNA structure. Here we describe a novel strategy termed parallel analysis of RNA structure (PARS), which is based on deep sequencing fragments of RNAs that were treated with structure-specific enzymes, thus providing simultaneous in vitro profiling of the secondary structure of thousands of RNA species at single nucleotide resolution. We apply PARS to profile the secondary structure of the messenger RNAs (mRNAs) of the budding yeast Saccharomyces cerevisiae and obtain structural profiles for over 3,000 distinct transcripts. Analysis of these profiles reveals several RNA structural properties of yeast transcripts, including the existence of more secondary structure over coding regions compared with untranslated regions, a three-nucleotide periodicity of secondary structure across coding regions and an anti-correlation between the efficiency with which an mRNA is translated and the structure over its translation start site. PARS is readily applicable to other organisms and to profiling RNA structure in diverse conditions, thus enabling studies of the dynamics of secondary structure at a genomic scale.	[Wan, Yue; Chang, Howard Y.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Program Epithelial Biol, Stanford, CA 94305 USA; [Kertesz, Michael; Mazor, Elad; Segal, Eran] Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel; [Rinn, John L.] Harvard Univ, Broad Inst, Cambridge, MA 02142 USA; [Rinn, John L.] MIT, Cambridge, MA 02142 USA; [Nutter, Robert C.] Life Technol, Foster City, CA 94404 USA; [Segal, Eran] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Howard Hughes Medical Institute; Stanford University; Weizmann Institute of Science; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Thermo Fisher Scientific; Weizmann Institute of Science	Chang, HY (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Program Epithelial Biol, Stanford, CA 94305 USA.	howchang@stanford.edu; eran@weizmann.ac.il	Segal, Eran/AAF-4855-2019	Rinn, John/0000-0002-7231-7539; Segal, Eran/0000-0002-6859-1164	National Institutes of Health [RO1HG004361]; Agency of Science, Technology and Research of Singapore; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004361] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Agency of Science, Technology and Research of Singapore(Agency for Science Technology & Research (A*STAR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank D. Herschlag's group, A. Adler, A. Fire, M. Kay, the Life Technologies SOLiD team, M. Rabani, G. Sherlock and A. Weinberger for assistance and critiques. This work was supported by a National Institutes of Health grant (RO1HG004361). Y.W. is funded by the Agency of Science, Technology and Research of Singapore. H.Y.C. is an Early Career Scientist of the Howard Hughes Medical Institute. E. S. is the incumbent of the Soretta and Henry Shapiro career development chair.	Arava Y, 2003, P NATL ACAD SCI USA, V100, P3889, DOI 10.1073/pnas.0635171100; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Chartrand P, 2002, MOL CELL, V10, P1319, DOI 10.1016/S1097-2765(02)00694-9; Guo F, 2004, MOL CELL, V16, P351, DOI 10.1016/S1097-2765(04)00592-1; Hofacker IL, 2002, J MOL BIOL, V319, P1059, DOI 10.1016/S0022-2836(02)00308-X; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Kudla G, 2009, SCIENCE, V324, P255, DOI 10.1126/science.1170160; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; Palazzo AF, 2007, PLOS BIOL, V5, P2862, DOI 10.1371/journal.pbio.0050322; Reineke LC, 2008, J BIOL CHEM, V283, P19011, DOI 10.1074/jbc.M803109200; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Shabalina SA, 2006, NUCLEIC ACIDS RES, V34, P2428, DOI 10.1093/nar/gkl287; Shepard KA, 2003, P NATL ACAD SCI USA, V100, P11429, DOI 10.1073/pnas.2033246100; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; Tucker BJ, 2005, CURR OPIN STRUC BIOL, V15, P342, DOI 10.1016/j.sbi.2005.05.003; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237; Ziehler W A, 2001, Curr Protoc Nucleic Acid Chem, VChapter 6, DOI 10.1002/0471142700.nc0601s00	20	538	564	5	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					103	107		10.1038/nature09322	http://dx.doi.org/10.1038/nature09322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811459	Green Accepted			2022-12-28	WOS:000281461200044
J	Piao, SL; Ciais, P; Huang, Y; Shen, ZH; Peng, SS; Li, JS; Zhou, LP; Liu, HY; Ma, YC; Ding, YH; Friedlingstein, P; Liu, CZ; Tan, K; Yu, YQ; Zhang, TY; Fang, JY				Piao, Shilong; Ciais, Philippe; Huang, Yao; Shen, Zehao; Peng, Shushi; Li, Junsheng; Zhou, Liping; Liu, Hongyan; Ma, Yuecun; Ding, Yihui; Friedlingstein, Pierre; Liu, Chunzhen; Tan, Kun; Yu, Yongqiang; Zhang, Tianyi; Fang, Jingyun			The impacts of climate change on water resources and agriculture in China	NATURE			English	Review							YANGTZE-RIVER BASIN; YELLOW-RIVER; FUTURE CLIMATE; WINTER-WHEAT; ELEVATED CO2; CARBON-DIOXIDE; SPRING WHEAT; CROP YIELD; TRENDS; PRECIPITATION	China is the world's most populous country and a major emitter of greenhouse gases. Consequently, much research has focused on China's influence on climate change but somewhat less has been written about the impact of climate change on China. China experienced explosive economic growth in recent decades, but with only 7% of the world's arable land available to feed 22% of the world's population, China's economy may be vulnerable to climate change itself. We find, however, that notwithstanding the clear warming that has occurred in China in recent decades, current understanding does not allow a clear assessment of the impact of anthropogenic climate change on China's water resources and agriculture and therefore China's ability to feed its people. To reach a more definitive conclusion, future work must improve regional climate simulations-especially of precipitation-and develop a better understanding of the managed and unmanaged responses of crops to changes in climate, diseases, pests and atmospheric constituents.	[Piao, Shilong; Shen, Zehao; Peng, Shushi; Zhou, Liping; Liu, Hongyan; Ma, Yuecun; Tan, Kun; Fang, Jingyun] Peking Univ, Minist Educ, Key Lab Earth Surface Proc, Coll Urban & Environm Sci,Dept Geog,Dept Ecol, Beijing 100871, Peoples R China; [Piao, Shilong; Shen, Zehao; Peng, Shushi; Zhou, Liping; Liu, Hongyan; Ma, Yuecun; Tan, Kun; Fang, Jingyun] Peking Univ, Ctr Climate Res, Beijing 100871, Peoples R China; [Ciais, Philippe; Friedlingstein, Pierre] UMR CEA CNRS UVSQ, Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France; [Huang, Yao; Yu, Yongqiang; Zhang, Tianyi] Chinese Acad Sci, Inst Atmospher Phys, State Key Lab Atmospher Boundary Layer Phys & Atm, Beijing 100029, Peoples R China; [Li, Junsheng] Chinese Res Inst Environm Sci, Beijing 100012, Peoples R China; [Ding, Yihui] China Meteorol Adm, Natl Climate Ctr, Lab Climate Studies, Beijing 100081, Peoples R China; [Friedlingstein, Pierre] Univ Bristol, Dept Earth Sci, QUEST, Bristol BS8 1RJ, Avon, England; [Liu, Chunzhen] China Water Informat Ctr, Hydrol Bur, Beijing 100053, Peoples R China	Peking University; Peking University; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Chinese Academy of Sciences; Institute of Atmospheric Physics, CAS; Chinese Research Academy of Environmental Sciences; China Meteorological Administration; University of Bristol	Piao, SL (corresponding author), Peking Univ, Minist Educ, Key Lab Earth Surface Proc, Coll Urban & Environm Sci,Dept Geog,Dept Ecol, Beijing 100871, Peoples R China.	slpiao@pku.edu.cn	Friedlingstein, Pierre/H-2700-2014; Shen, Zehao/GQI-1121-2022; Huang, Yao/O-6832-2014; Peng, Shushi/J-4779-2014; PENG, Shushi/AAS-2603-2020; LAPC, IAP/AAI-6991-2020; huang, yao/GWR-5388-2022; Huang, Yao/GQH-3308-2022; Zhang, Tianyi/AAJ-6909-2020; Yu, Yongqiang/C-9661-2011; Ciais, Philippe/A-6840-2011	Friedlingstein, Pierre/0000-0003-3309-4739; Peng, Shushi/0000-0001-5098-726X; PENG, Shushi/0000-0001-5098-726X; LAPC, IAP/0000-0002-0025-3484; Huang, Yao/0000-0002-0192-1421; Zhang, Tianyi/0000-0002-9266-6082; Yu, Yongqiang/0000-0002-9345-2211; Ciais, Philippe/0000-0001-8560-4943	National Natural Science Foundation of China [30970511, 90711002, 30721140306, 40638039]; Chinese Academy of Sciences [KZCX2-YW-305]; National Basic Research Program of China [2004CB720207]; Foundation for the Author of National Excellent Doctoral Dissertation of PR China [FANEDD-200737]; NERC [quest010001] Funding Source: UKRI; Natural Environment Research Council [quest010001] Funding Source: researchfish	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); National Basic Research Program of China(National Basic Research Program of China); Foundation for the Author of National Excellent Doctoral Dissertation of PR China(Foundation for the Author of National Excellent Doctoral Dissertation of China); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank X. L. Yang and G. N. Liu for detailed and constructive comments. We thank J. H. Gash, M. Minnock and C. Koven for English language editing. We also thank Y. Li and Y. Kuang for providing photos of glacier retreat between 1985 and 2005 at Mt Anyemaqen, Qinghai. This study was supported by the National Natural Science Foundation of China (30970511, 90711002, 30721140306 and 40638039), the Knowledge Innovation Program of the Chinese Academy of Sciences (KZCX2-YW-305), the National Basic Research Program of China (2004CB720207) and the Foundation for the Author of National Excellent Doctoral Dissertation of PR China (FANEDD-200737).	Arnell NW, 2004, GLOBAL ENVIRON CHANG, V14, P31, DOI 10.1016/j.gloenvcha.2003.10.006; Baker JT, 2004, AGR FOREST METEOROL, V122, P129, DOI 10.1016/j.agrformet.2003.09.012; Bannayan M, 2005, FIELD CROP RES, V93, P237, DOI 10.1016/j.fcr.2004.10.003; Barnett TP, 2005, NATURE, V438, P303, DOI 10.1038/nature04141; Becker S, 2008, INT J CLIMATOL, V28, P579, DOI 10.1002/joc.1572; Chavas DR, 2009, AGR FOREST METEOROL, V149, P1118, DOI 10.1016/j.agrformet.2009.02.001; CHEN SD, 2003, 50 YEARS PLANT PROTE; CHEN YY, 2005, CLIMATE ENV CHANGES; [初子莹 CHU ZiYing], 2005, [气候与环境研究, Climatic and environmental research], V10, P826; Ci L.-J., 1997, J DESERT RES, V17, P107; Dai A, 2004, J HYDROMETEOROL, V5, P1117, DOI 10.1175/JHM-386.1; Ding Y., 2005, CHANGES CLIMATE ENV, V1, P398; Ding YH, 2008, INT J CLIMATOL, V28, P1139, DOI 10.1002/joc.1615; Ding YH, 2007, ADV ATMOS SCI, V24, P954, DOI 10.1007/s00376-007-0954-4; Ding YJ, 2006, ANN GLACIOL-SER, V43, P97, DOI 10.3189/172756406781812005; [段建平 DUAN Jianping], 2009, [地理科学进展, Progress in Geography], V28, P231; *ED BOARD, 2007, CHIN NAT ASS REP CLI; Fu GB, 2004, CLIMATIC CHANGE, V65, P149, DOI 10.1023/B:CLIM.0000037491.95395.bb; Fuhrer J, 2003, AGR ECOSYST ENVIRON, V97, P1, DOI 10.1016/S0167-8809(03)00125-7; Gao X, 2008, METEOROL ATMOS PHYS, V100, P73, DOI 10.1007/s00703-008-0296-5; Ge QS, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL041281; Gemmer M, 2008, QUATERN INT, V186, P12, DOI 10.1016/j.quaint.2007.10.001; Gong DY, 2004, THEOR APPL CLIMATOL, V77, P25, DOI 10.1007/s00704-003-0019-2; Hao XM, 2008, WATER RESOUR MANAG, V22, P1159, DOI 10.1007/s11269-007-9218-4; Hu ZZ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003651; Huang JK, 2002, SCIENCE, V295, P674, DOI 10.1126/science.1067226; Huang Y, 2007, ECOL APPL, V17, P692, DOI 10.1890/05-1792; Jiang T, 2007, GEOMORPHOLOGY, V85, P143, DOI 10.1016/j.geomorph.2006.03.015; Zhang JL, 2007, PROCEEDINGS OF THE FIRST INTERNATIONAL SYMPOSIUM ON DATA, PRIVACY, AND E-COMMERCE, P138, DOI 10.1109/ISDPE.2007.53; Kang E.S., 2000, GLACIERS THEIR ENV S, P190; Li WL, 2007, AGR WATER MANAGE, V87, P106, DOI 10.1016/j.agwat.2006.06.027; Li X, 2008, GLOBAL PLANET CHANGE, V62, P210, DOI 10.1016/j.gloplacha.2008.02.001; [李忠勤 LI Zhongqin], 2007, [冰川冻土, Journal of Glaciology and Geocryology], V29, P333; LI ZX, 2009, QUATERN INT, DOI DOI 10.1016/J.QUAINT.2009.05.010; LI ZX, 2007, HYDROL EARTH SYST SC, V4, P3395; LIN E, 2007, ADV CLIM CHANG RES, V3, P6; Lin ED, 2005, PHILOS T R SOC B, V360, P2149, DOI 10.1098/rstb.2005.1743; [刘时银 Liu Shiyin], 2006, [第四纪研究, Quaternary Sciences], V26, P762; Liu SY, 2009, J GLACIOL, V55, P353, DOI 10.3189/002214309788608778; Liu YA, 2010, GLOBAL CHANGE BIOL, V16, P2287, DOI 10.1111/j.1365-2486.2009.02077.x; Long SP, 2005, PHILOS T R SOC B, V360, P2011, DOI 10.1098/rstb.2005.1749; Longo F, 2006, ANN ONCOL, V17, P74; LU AG, 2005, CHINA J MOUNT SCI, V2, P313; Ma HL, 2007, PLANT SOIL, V294, P137, DOI 10.1007/s11104-007-9241-5; Ma ZG, 2005, CHINESE J GEOPHYS-CH, V48, P1270; Meehl GA, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P747; *MIN WAT RES PEOPL, 2007, B WAT RES CHIN; Nakicenovic N., 2000, SPECIAL REPORT EMISS; *NAT BUR STAT CHIN, 2009, CHIN STAT YB 2009, P38; National Development and Reform Commission P. R. China, 2007, CHIN NAT CLIM CHANG; Piao SL, 2006, GLOBAL CHANGE BIOL, V12, P672, DOI 10.1111/j.1365-2486.2006.01123.x; Qian WH, 2004, CLIM RES, V27, P119, DOI 10.3354/cr027119; [秦年秀 Qin Nianxiu], 2005, [长江流域资源与环境, Resources and Environment in the Yangtze Basin], V14, P589; REN G, 2004, CLIMATE CHANGE YANGT; REN GY, 2007, CLIMATE CHANGE CHINA; *RUR SOC SURV ORG, 2009, NAT BUR STAT CHIN AG; Sakai H, 2006, NEW PHYTOL, V170, P321, DOI 10.1111/j.1469-8137.2006.01688.x; Seneviratne SI, 2006, NATURE, V443, P205, DOI 10.1038/nature05095; [沈永平 Shen Yongping], 2003, [冰川冻土, Journal of Glaciology and Geocryology], V25, P124; Shen YP, 2006, ADV CLIM CHANG RES, V2, P32; Shi Y., 2001, J GLACIOL GEOCRYOL, V23, P333, DOI DOI 10.3969/J.ISSN.1000-0240.2001.04.001; Shi YF, 2007, CLIMATIC CHANGE, V80, P379, DOI 10.1007/s10584-006-9121-7; Shi YF, 2000, CHINESE SCI BULL, V45, P668, DOI 10.1007/BF02886048; Solomon S, 2009, P NATL ACAD SCI USA, V106, P1704, DOI 10.1073/pnas.0812721106; State Council Information Office, 2008, CHIN POL ACT CLIM CH; Tao F, 2008, AGR FOREST METEOROL, V148, P94, DOI 10.1016/j.agrformet.2007.09.012; Tao FL, 2008, CLIM RES, V38, P83, DOI 10.3354/cr00771; Tao H, 2008, WATER RESOUR RES, V44, DOI 10.1029/2007WR006186; Thomas A, 2000, AGR FOREST METEOROL, V102, P71, DOI 10.1016/S0168-1923(00)00126-X; Thomas A, 2008, GLOBAL PLANET CHANGE, V60, P306, DOI 10.1016/j.gloplacha.2007.03.009; Wang FH, 2009, FIELD CROP RES, V111, P181, DOI 10.1016/j.fcr.2008.12.004; Wang GL, 2005, CLIM DYNAM, V25, P739, DOI 10.1007/s00382-005-0057-9; Wang HL, 2008, AGR FOREST METEOROL, V148, P1242, DOI 10.1016/j.agrformet.2008.03.003; Wang JX, 2009, AGR ECON-BLACKWELL, V40, P323, DOI 10.1111/j.1574-0862.2009.00379.x; Wang XP, 2004, ATMOS ENVIRON, V38, P4383, DOI 10.1016/j.atmosenv.2004.03.067; [王瑗 WANG Yuan], 2008, [水资源与水工程学报, Journal of Water Resources and Water Engineering], V19, P10; Wei K, 2009, ATMOS OCEAN SCI LETT, V2, P153, DOI 10.1080/16742834.2009.11446795; Wentz FJ, 2007, SCIENCE, V317, P233, DOI 10.1126/science.1140746; Xiao JF, 2009, EARTH INTERACT, V13, DOI 10.1175/2009EI275.1; [谢自楚 XIE Zichu], 2006, [冰川冻土, Journal of Glaciology and Geocryology], V28, P457; Xiong W, 2008, IMPACTS CLIMATE CHAN; Xiong W, 2010, AGR ECOSYST ENVIRON, V135, P58, DOI 10.1016/j.agee.2009.08.015; Xu JJ, 2008, QUATERN INT, V186, P32, DOI 10.1016/j.quaint.2007.10.014; Yang W, 2008, CHINESE SCI BULL, V53, P2547, DOI 10.1007/s11434-008-0288-3; Yang XL, 2006, FRONT ECOL ENVIRON, V4, P362, DOI 10.1890/1540-9295(2006)004[0362:ICWA]2.0.CO;2; Yao T, 2007, ARCT ANTARCT ALP RES, V39, P642, DOI 10.1657/1523-0430(07-510)[YAO]2.0.CO;2; You LZ, 2009, AGR FOREST METEOROL, V149, P1009, DOI 10.1016/j.agrformet.2008.12.004; [翟建青 Zhai Jianqing], 2009, [气候变化研究进展, Advances in Climate Change Research], V5, P220; Zhai JQ, 2010, J CLIMATE, V23, P649, DOI 10.1175/2009JCLI2968.1; Zhai P -M, 2005, ADV CLIM CHANG RES, V1, P16, DOI [10.3969/j.issn.1673-1719.2005.01.004, DOI 10.3969/J.ISSN.1673-1719.2005.01.004]; Zhai PM, 2005, J CLIMATE, V18, P1096, DOI 10.1175/JCLI-3318.1; Zhai PM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018004; Zhang GH, 2007, T ASABE, V50, P911, DOI 10.13031/2013.23155; Zhang Q, 2009, WATER RESOUR MANAG, V23, P1157, DOI 10.1007/s11269-008-9320-2; Zhang Y, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027229; Zhou Y, 2007, CROP SCI, V47, P245, DOI 10.2135/cropsci2006.03.0175; Ziska LH, 2008, FIELD CROP RES, V108, P54, DOI 10.1016/j.fcr.2008.03.006; Zong YQ, 2000, NAT HAZARDS, V22, P165, DOI 10.1023/A:1008119805106	98	2115	2397	246	3157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2010	467	7311					43	51		10.1038/nature09364	http://dx.doi.org/10.1038/nature09364			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811450	Green Submitted			2022-12-28	WOS:000281461200032
J	Sarewitz, D				Sarewitz, Daniel			Politicize me	NATURE			English	Editorial Material									Arizona State Univ, Consortium Sci Policy & Outcomes, Washington, DC USA	Arizona State University	Sarewitz, D (corresponding author), Arizona State Univ, Consortium Sci Policy & Outcomes, Washington, DC USA.	dsarewitz@gmail.com							0	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					26	26		10.1038/467026a	http://dx.doi.org/10.1038/467026a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	645MB	20811432	Bronze			2022-12-28	WOS:000281461200013
J	Schaller, V; Weber, C; Semmrich, C; Frey, E; Bausch, AR				Schaller, Volker; Weber, Christoph; Semmrich, Christine; Frey, Erwin; Bausch, Andreas R.			Polar patterns of driven filaments	NATURE			English	Article							SELF-ORGANIZATION; ACTIVE GELS; MOTORS; HYDRODYNAMICS; MICROTUBULES; VORTICES; DYNAMICS	The emergence of collective motion exhibited by systems ranging from flocks of animals to self-propelled microorganisms to the cytoskeleton is a ubiquitous and fascinating self-organization phenomenon(1-12). Similarities between these systems, such as the inherent polarity of the constituents, a density-dependent transition to ordered phases or the existence of very large density fluctuations(13-16), suggest universal principles underlying pattern formation. This idea is followed by theoretical models at all levels of description: micro-or mesoscopic models directly map local forces and interactions using only a few, preferably simple, interaction rules(12,17-21), and more macroscopic approaches in the hydrodynamic limit rely on the systems' generic symmetries(8,22,23). All these models characteristically have a broad parameter space with a manifold of possible patterns, most of which have not yet been experimentally verified. The complexity of interactions and the limited parameter control of existing experimental systems are major obstacles to our understanding of the underlying ordering principles(13). Here we demonstrate the emergence of collective motion in a high-density motility assay that consists of highly concentrated actin filaments propelled by immobilized molecular motors in a planar geometry. Above a critical density, the filaments self-organize to form coherently moving structures with persistent density modulations, such as clusters, swirls and interconnected bands. These polar nematic structures are long lived and can span length scales orders of magnitudes larger than their constituents. Our experimental approach, which offers control of all relevant system parameters, complemented by agent-based simulations, allows backtracking of the assembly and disassembly pathways to the underlying local interactions. We identify weak and local alignment interactions to be essential for the observed formation of patterns and their dynamics. The presented minimal polar-pattern-forming system may thus provide new insight into emerging order in the broad class of active fluids(8,23,24) and self-propelled particles(17,25)	[Schaller, Volker; Semmrich, Christine; Bausch, Andreas R.] Tech Univ Munich, Lehrstuhl Biophy E27, D-85748 Garching, Germany; [Weber, Christoph; Frey, Erwin] Univ Munich, Dept Phys, Arnold Sommerfeld Ctr Theoret Phys, D-80333 Munich, Germany; [Weber, Christoph; Frey, Erwin] Univ Munich, Dept Phys, CENS, D-80333 Munich, Germany	Technical University of Munich; University of Munich; University of Munich	Bausch, AR (corresponding author), Tech Univ Munich, Lehrstuhl Biophy E27, D-85748 Garching, Germany.	abausch@ph.tum.de	Frey, Erwin/M-2613-2017	Frey, Erwin/0000-0001-8792-3358	DFG [SFB 863]; German Excellence Initiatives via the 'Nano-Initiative Munich (NIM)'; Technische Universitat Munchen - Institute for Advanced Study; Elite Network of Bavaria	DFG(German Research Foundation (DFG)); German Excellence Initiatives via the 'Nano-Initiative Munich (NIM)'; Technische Universitat Munchen - Institute for Advanced Study; Elite Network of Bavaria	We thank A. Baskaran and C. Marchetti for discussions. Financial support from the DFG in the framework of the SFB 863 and the German Excellence Initiatives via the 'Nano-Initiative Munich (NIM)' and the Technische Universitat Munchen - Institute for Advanced Study is gratefully acknowledged. V. S. and C. W. acknowledge support from the Elite Network of Bavaria by the graduate programmes CompInt and NanoBioTechnology.	Aranson IS, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.050901; Backouche F, 2006, PHYS BIOL, V3, P264, DOI 10.1088/1478-3975/3/4/004; Baskaran A, 2009, P NATL ACAD SCI USA, V106, P15567, DOI 10.1073/pnas.0906586106; Baskaran A, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.011920; Baskaran A, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.268101; Chate H, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.046113; Couzin ID, 2005, NATURE, V433, P513, DOI 10.1038/nature03236; Czirok A, 1996, PHYS REV E, V54, P1791, DOI 10.1103/PhysRevE.54.1791; Dombrowski C, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.098103; Fulga F, 2009, INTEGR BIOL-UK, V1, P150, DOI 10.1039/b814985b; Ginelli F, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.184502; Grossman D, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/2/023036; Joanny JF, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/11/422; Julicher F, 2007, PHYS REP, V449, P3, DOI 10.1016/j.physrep.2007.02.018; Karsenti E, 2008, NAT REV MOL CELL BIO, V9, P255, DOI 10.1038/nrm2357; Kraikivski P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.258103; Kruse K, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.078101; Loose M, 2008, SCIENCE, V320, P789, DOI 10.1126/science.1154413; Mishra S, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.061916; Narayan V, 2007, SCIENCE, V317, P105, DOI 10.1126/science.1140414; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; Riedel IH, 2005, SCIENCE, V309, P300, DOI 10.1126/science.1110329; SHEETZ MP, 1984, J CELL BIOL, V99, P1867, DOI 10.1083/jcb.99.5.1867; Simha RA, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.058101; Surrey T, 2001, SCIENCE, V292, P1167, DOI 10.1126/science.1059758; Toner J, 2005, ANN PHYS-NEW YORK, V318, P170, DOI 10.1016/j.aop.2005.04.011; van den Heuvel MGL, 2007, SCIENCE, V317, P333, DOI 10.1126/science.1139570; VICSEK T, 1995, PHYS REV LETT, V75, P1226, DOI 10.1103/PhysRevLett.75.1226	28	551	553	6	193	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					73	77		10.1038/nature09312	http://dx.doi.org/10.1038/nature09312			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811454				2022-12-28	WOS:000281461200037
J	Wolf, P; Blanchet, L; Borde, CJ; Reynaud, S; Salomon, C; Cohen-Tannoudji, C				Wolf, Peter; Blanchet, Luc; Borde, Christian J.; Reynaud, Serge; Salomon, Christophe; Cohen-Tannoudji, Claude			Atom gravimeters and gravitational redshift	NATURE			English	Letter									[Wolf, Peter; Borde, Christian J.] Univ Paris 06, Observ Paris, Lab Natl Metrol & Essais, CNRS,UMR 8630, F-75014 Paris, France; [Blanchet, Luc] UPMC, CNRS, UMR 7095, Inst Astrophys Paris,GRECO, F-75014 Paris, France; [Reynaud, Serge] UPMC, Ecole Normale Super, CNRS, Lab Kastler Brossel,UMR 8552, F-75252 Paris, France; [Salomon, Christophe; Cohen-Tannoudji, Claude] UPMC, ENS, CNRS, Lab Kastler Brossel,UMR 8552, F-75231 Paris, France; [Salomon, Christophe; Cohen-Tannoudji, Claude] UPMC, ENS, CNRS, Coll France,UMR 8552, F-75231 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Laboratoire National de Metrologie et d'Essais (LNE); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; College de France; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; College de France; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; College de France; Ecole Normale Superieure (ENS)	Wolf, P (corresponding author), Univ Paris 06, Observ Paris, Lab Natl Metrol & Essais, CNRS,UMR 8630, 61 Ave Observ, F-75014 Paris, France.	peter.wolf@obspm.fr	Reynaud, Serge/J-8061-2014	Reynaud, Serge/0000-0002-1494-696X				Amsler C, 2008, PHYS LETT B, V667, P1, DOI 10.1016/j.physletb.2008.07.018; Borde CJ, 2008, EUR PHYS J-SPEC TOP, V163, P315, DOI 10.1140/epjst/e2008-00827-3; Cacciapuoti L, 2009, EUR PHYS J-SPEC TOP, V172, P57, DOI 10.1140/epjst/e2009-01041-7; Muller H, 2010, NATURE, V463, P926, DOI 10.1038/nature08776; Peters A, 1999, NATURE, V400, P849, DOI 10.1038/23655; Schlamminger S, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.041101; STOREY P, 1994, J PHYS II, V4, P1999, DOI 10.1051/jp2:1994103; VESSOT RFC, 1980, PHYS REV LETT, V45, P2081, DOI 10.1103/PhysRevLett.45.2081; WILL CM, 2000, THEORY EXPT GRAVITAT, pCH2; Williams JG, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.261101	10	44	44	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2010	467	7311					E1	E1		10.1038/nature09340	http://dx.doi.org/10.1038/nature09340			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811407	Green Submitted, Bronze			2022-12-28	WOS:000281461200028
J	Moynihan, R				Moynihan, Ray			Prediseases Who benefits from treating prehypertension?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Moynihan, Ray] Univ Newcastle, Newcastle, NSW 2300, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Newcastle, NSW 2300, Australia.	ray.moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					*AM SOC HYP, 1986, 2010 ANN SCI M EXP 2; ARMSTRONG D, 1995, SOCIOL HEALTH ILL, V17, P393, DOI 10.1111/1467-9566.ep10933329; BARKIS G, J CLIN HYPE IN PRESS; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Julius S, 2006, NEW ENGL J MED, V354, P1685, DOI 10.1056/NEJMoa060838; Meltzer JI, 2006, AM J HYPERTENS, V19, P1098, DOI 10.1016/j.amjhyper.2006.09.014; *NAT HEART LUNG BL, 7 JOINT NAT COMM PRE; *PREH CARD SYNDR I, 2010, SPONS EXH PROSP	8	12	12	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	2010	341								c4442	10.1136/bmj.c4442	http://dx.doi.org/10.1136/bmj.c4442			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IG	20736255				2022-12-28	WOS:000281445900025
J	Johannes, L; Mayor, S				Johannes, Ludger; Mayor, Satyajit			Induced Domain Formation in Endocytic Invagination, Lipid Sorting, and Scission	CELL			English	Article							CLATHRIN-INDEPENDENT ENDOCYTOSIS; GPI-ANCHORED PROTEINS; PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; CURVATURE; ACTIN; VESICLES; DRIVEN; REORGANIZATION; CELL	Lipid segregation occurs in biological membranes, but how this plays into cellular processes like endocytosis has been unclear. Here, we discuss how the active or passive induction of lipid-protein domain formation in membranes can alter membrane mechanics and thus affect processes such as the generation of curvature, the scission of buds and tubules, and lipid sorting.	[Johannes, Ludger] Inst Curie, Ctr Rech, Traff Signaling & Delivery Lab, F-75248 Paris 05, France; [Johannes, Ludger] CNRS, UMR144, F-75700 Paris, France; [Mayor, Satyajit] Natl Ctr Biol Sci, Cellular Org & Signaling Grp, Bangalore 560065, Karnataka, India	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Johannes, L (corresponding author), Inst Curie, Ctr Rech, Traff Signaling & Delivery Lab, F-75248 Paris 05, France.	johannes@curie.fr; mayor@ncbs.res.in	Johannes, Ludger/M-9778-2017; Johannes, Ludger/W-8593-2019	Johannes, Ludger/0000-0002-2168-0004; Johannes, Ludger/0000-0002-2168-0004	Human Frontier Science Program; Indo-French Centre for the Promotion of Advanced Research (CEFIPRA) [3803]	Human Frontier Science Program(Human Frontier Science Program); Indo-French Centre for the Promotion of Advanced Research (CEFIPRA)(French National Research Agency (ANR))	We thank Patricia Bassereau, Madan Rao, Robert Parton, Pierre Sens, Winfried Romer, and Christophe Lamaze for stimulating discussions. The authors are supported by the Human Frontier Science Program and a grant from the Indo-French Centre for the Promotion of Advanced Research (CEFIPRA Project No. 3803).	Allain JM, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.158104; Antonny B, 2006, CURR OPIN CELL BIOL, V18, P386, DOI 10.1016/j.ceb.2006.06.003; Bashkirov PV, 2008, CELL, V135, P1276, DOI 10.1016/j.cell.2008.11.028; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; Baumgart T, 2007, P NATL ACAD SCI USA, V104, P3165, DOI 10.1073/pnas.0611357104; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Chiantia S, 2007, LANGMUIR, V23, P7659, DOI 10.1021/la7010919; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Ewers H, 2010, NAT CELL BIOL, V12, P11, DOI 10.1038/ncb1999; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Fujita A, 2007, MOL BIOL CELL, V18, P2112, DOI 10.1091/mbc.E07-01-0071; Goswami D, 2008, CELL, V135, P1085, DOI 10.1016/j.cell.2008.11.032; Heimburg T, 2005, P NATL ACAD SCI USA, V102, P9790, DOI 10.1073/pnas.0503823102; Henne WM, 2010, SCIENCE, V328, P1281, DOI 10.1126/science.1188462; Howes MT, 2010, CURR OPIN CELL BIOL, V22, P519, DOI 10.1016/j.ceb.2010.04.001; Idrissi FZ, 2008, J CELL BIOL, V180, P1219, DOI 10.1083/jcb.200708060; Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600-0854.2002.30701.x; JULICHER F, 1993, PHYS REV LETT, V70, P2964, DOI 10.1103/PhysRevLett.70.2964; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Lingwood D, 2008, P NATL ACAD SCI USA, V105, P10005, DOI 10.1073/pnas.0804374105; Liu AP, 2006, BIOPHYS J, V91, P4064, DOI 10.1529/biophysj.106.090852; Liu J, 2006, P NATL ACAD SCI USA, V103, P10277, DOI 10.1073/pnas.0601045103; Liu J, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000204; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Plowman SJ, 2005, P NATL ACAD SCI USA, V102, P15500, DOI 10.1073/pnas.0504114102; Polozov IV, 2008, NAT CHEM BIOL, V4, P248, DOI 10.1038/nchembio.77; Pucadyil TJ, 2008, CELL, V135, P1263, DOI 10.1016/j.cell.2008.11.020; Reynwar BJ, 2007, NATURE, V447, P461, DOI 10.1038/nature05840; Romer W, 2007, NATURE, V450, P670, DOI 10.1038/nature05996; Romer W, 2010, CELL, V140, P540, DOI 10.1016/j.cell.2010.01.010; Roux A, 2005, EMBO J, V24, P1537, DOI 10.1038/sj.emboj.7600631; Roux A, 2008, CELL, V135, P1163, DOI 10.1016/j.cell.2008.12.003; Sarasij RC, 2007, BIOPHYS J, V92, P3140, DOI 10.1529/biophysj.106.085662; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Sorre B, 2009, P NATL ACAD SCI USA, V106, P5622, DOI 10.1073/pnas.0811243106; Souza CM, 2007, BBA-MOL CELL BIOL L, V1771, P442, DOI 10.1016/j.bbalip.2006.08.006; Tian A, 2009, BIOPHYS J, V96, P2676, DOI 10.1016/j.bpj.2008.11.067; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Windschiegl B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006238	42	57	57	0	27	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 20	2010	142	4					507	510		10.1016/j.cell.2010.08.007	http://dx.doi.org/10.1016/j.cell.2010.08.007			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723749	Bronze			2022-12-28	WOS:000281115900002
J	Park, J; Myong, S; Niedziela-Majka, A; Lee, KS; Yu, J; Lohman, TM; Ha, T				Park, Jeehae; Myong, Sua; Niedziela-Majka, Anita; Lee, Kyung Suk; Yu, Jin; Lohman, Timothy M.; Ha, Taekjip			PcrA Helicase Dismantles RecA Filaments by Reeling in DNA in Uniform Steps	CELL			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI RECBCD; VIRUS NS3 HELICASE; UVRD HELICASE; REP HELICASE; NUCLEOPROTEIN FILAMENTS; UNWINDING MECHANISM; CRYSTAL-STRUCTURES; TRANSLOCATION; RNA	Translocation of helicase-like proteins on nucleic acids underlies key cellular functions. However, it is still unclear how translocation can drive removal of DNA-bound proteins, and basic properties like the elementary step size remain controversial. Using single-molecule fluorescence analysis on a prototypical superfamily 1 helicase, Bacillus stearothermophilus PcrA, we discovered that PcrA preferentially translocates on the DNA lagging strand instead of unwinding the template duplex. PcrA anchors itself to the template duplex using the 2B subdomain and reels in the lagging strand, extruding a single-stranded loop. Static disorder limited previous ensemble studies of a PcrA stepping mechanism. Here, highly repetitive looping revealed that PcrA translocates in uniform steps of 1 nt. This reeling-in activity requires the open conformation of PcrA and can rapidly dismantle a preformed RecA filament even at low PcrA concentrations, suggesting a mode of action for eliminating potentially deleterious recombination intermediates.	[Park, Jeehae; Ha, Taekjip] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; [Myong, Sua; Ha, Taekjip] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA; [Lee, Kyung Suk; Ha, Taekjip] Univ Illinois, Dept Phys, Urbana, IL 61801 USA; [Lee, Kyung Suk; Ha, Taekjip] Univ Illinois, Ctr Phys Living Cells, Urbana, IL 61801 USA; [Niedziela-Majka, Anita; Lohman, Timothy M.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; [Ha, Taekjip] Howard Hughes Med Inst, Urbana, IL 61801 USA; [Yu, Jin] Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Washington University (WUSTL); Howard Hughes Medical Institute; University of California System; University of California Berkeley	Ha, T (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.	tjha@illinois.edu	Ha, Taekjip/B-9506-2009; Yu, Jin/X-6895-2019	Ha, Taekjip/0000-0003-2195-6258; Yu, Jin/0000-0001-8224-1374	National Institutes of Health [GM-065367, GM-045948]; National Science Foundation [0822613, 0646550]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948, R01GM065367] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank C. Joo, R. Roy, M. Schlierf, S. Syed, M.C. McKinney, M.K. Nahas, B. Okumus, S.A. McKinney, E. Bozek, and J.D. Smith for experimental help; S. Arslan, J. Yodh, H. Balci, I. Cisse, B.C. Stevens, G. Lee, M. Brenner, E. Tomko, C. Fischer, and M. Spies for helpful discussion; I. Cann and his lab for providing Staphylococcus aureus PcrA for the initial studies; R. Pugh for help on ExoIII footprint assay; M. Schlierf, J. Yodh, H. Balci, and E. Tomko for careful reading of the manuscript. Funds were provided by the National Institutes of Health (GM-065367 to T.H. and GM-045948 to T.M.L.) and by the National Science Foundation (0822613 and 0646550 to T.H.). T.H. is an investigator with the Howard Hughes Medical Institute.	Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Anand SP, 2004, NUCLEIC ACIDS RES, V32, P3190, DOI 10.1093/nar/gkh641; Antony E, 2009, MOL CELL, V35, P105, DOI 10.1016/j.molcel.2009.05.026; ARAMENDIA PF, 1994, J PHYS CHEM-US, V98, P3165, DOI 10.1021/j100063a020; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Bidnenko V, 2006, MOL MICROBIOL, V62, P382, DOI 10.1111/j.1365-2958.2006.05382.x; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; Dumont S, 2006, NATURE, V439, P105, DOI 10.1038/nature04331; Eoff RL, 2006, NAT STRUCT MOL BIOL, V13, P242, DOI 10.1038/nsmb1055; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; Flores MJ, 2005, MOL MICROBIOL, V57, P1664, DOI 10.1111/j.1365-2958.2005.04753.x; Galletto R, 2004, J MOL BIOL, V343, P83, DOI 10.1016/j.jmb.2004.07.055; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Joo C, 2006, CELL, V126, P515, DOI 10.1016/j.cell.2006.06.042; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Lee JY, 2006, CELL, V127, P1349, DOI 10.1016/j.cell.2006.10.049; Lestini R, 2007, EMBO J, V26, P3804, DOI 10.1038/sj.emboj.7601804; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Lohman TM, 2008, NAT REV MOL CELL BIO, V9, P391, DOI 10.1038/nrm2394; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lucius AL, 2002, J MOL BIOL, V324, P409, DOI 10.1016/S0022-2836(02)01067-7; Luo G, 2007, P NATL ACAD SCI USA, V104, P12610, DOI 10.1073/pnas.0700920104; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; Murphy MC, 2004, BIOPHYS J, V86, P2530, DOI 10.1016/S0006-3495(04)74308-8; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Myong S, 2007, SCIENCE, V317, P513, DOI 10.1126/science.1144130; Myong S, 2009, SCIENCE, V323, P1070, DOI 10.1126/science.1168352; Neuman KC, 2003, CELL, V115, P437, DOI 10.1016/S0092-8674(03)00845-6; Niedziela-Majka A, 2007, J BIOL CHEM, V282, P27076, DOI 10.1074/jbc.M704399200; Perkins TT, 2004, BIOPHYS J, V86, P1640, DOI 10.1016/S0006-3495(04)74232-0; Pyle AM, 2008, ANNU REV BIOPHYS, V37, P317, DOI 10.1146/annurev.biophys.37.032807.125908; RANEY KD, 1995, J BIOL CHEM, V270, P22236, DOI 10.1074/jbc.270.38.22236; Sanborn ME, 2007, J PHYS CHEM B, V111, P11064, DOI 10.1021/jp072912u; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300; Slatter AF, 2009, BIOCHEMISTRY-US, V48, P6326, DOI 10.1021/bi900101h; Spies M, 2003, CELL, V114, P647, DOI 10.1016/S0092-8674(03)00681-0; Tan E, 2003, P NATL ACAD SCI USA, V100, P9308, DOI 10.1073/pnas.1233536100; Tomko EJ, 2007, MOL CELL, V26, P335, DOI 10.1016/j.molcel.2007.03.024; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Wu CG, 2008, J MOL BIOL, V382, P312, DOI 10.1016/j.jmb.2008.07.012; Yang Y, 2008, NUCLEIC ACIDS RES, V36, P1976, DOI 10.1093/nar/gkm1174; Zhuang XW, 2002, SCIENCE, V296, P1473, DOI 10.1126/science.1069013; ZIEG J, 1978, J BACTERIOL, V134, P958, DOI 10.1128/JB.134.3.958-966.1978	56	136	136	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					544	555		10.1016/j.cell.2010.07.016	http://dx.doi.org/10.1016/j.cell.2010.07.016			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723756	Bronze, Green Accepted			2022-12-28	WOS:000281115900009
J	Beavan, J; Wang, X; Holden, C; Wilson, K; Power, W; Prasetya, G; Bevis, M; Kautoke, R				Beavan, J.; Wang, X.; Holden, C.; Wilson, K.; Power, W.; Prasetya, G.; Bevis, M.; Kautoke, R.			Near-simultaneous great earthquakes at Tongan megathrust and outer rise in September 2009	NATURE			English	Article							STRESS TRANSFER; TSUNAMI	The Earth's largest earthquakes and tsunamis are usually caused by thrust-faulting earthquakes on the shallow part of the subduction interface between two tectonic plates, where stored elastic energy due to convergence between the plates is rapidly released(1,2). The tsunami that devastated the Samoan and northern Tongan islands on 29 September 2009 was preceded by a globally recorded magnitude-8 normal-faulting earthquake in the outer-rise region, where the Pacific plate bends before entering the subduction zone. Preliminary interpretation suggested that this earthquake was the source of the tsunami(3). Here we show that the outer-rise earthquake was accompanied by a nearly simultaneous rupture of the shallow subduction interface, equivalent to a magnitude-8 earthquake, that also contributed significantly to the tsunami. The subduction interface event was probably a slow earthquake with a rise time of several minutes that triggered the outer-rise event several minutes later. However, we cannot rule out the possibility that the normal fault ruptured first and dynamically triggered the subduction interface event. Our evidence comes from displacements of Global Positioning System stations and modelling of tsunami waves recorded by ocean-bottom pressure sensors, with support from seismic data and tsunami field observations. Evidence of the subduction earthquake in global seismic data is largely hidden because of the earthquake's slow rise time or because its ground motion is disguised by that of the normal-faulting event. Earthquake doublets where subduction interface events trigger large outer-rise earthquakes have been recorded previously(4), but this is the first well-documented example where the two events occur so closely in time and the triggering event might be a slow earthquake. As well as providing information on strain release mechanisms at subduction zones, earthquakes such as this provide a possible mechanism for the occasional large tsunamis generated at the Tonga subduction zone(5), where slip between the plates is predominantly aseismic(6).	[Beavan, J.; Wang, X.; Holden, C.; Wilson, K.; Power, W.; Prasetya, G.] GNS Sci, Lower Hutt 5040, New Zealand; [Bevis, M.] Ohio State Univ, Sch Earth Sci, Columbus, OH 43210 USA; [Kautoke, R.] Minist Lands Survey Nat Resources & Environm, Nukualofa, Tonga	GNS Science - New Zealand; University System of Ohio; Ohio State University	Beavan, J (corresponding author), GNS Sci, POB 30368, Lower Hutt 5040, New Zealand.	j.beavan@gns.cri.nz; x.wang@gns.cri.nz		Wang, Xiaoming/0000-0002-0977-7145				AKI K, 1980, QUANTITATIVE SEISMOL, V2, P799; Ammon CJ, 2008, NATURE, V451, P561, DOI 10.1038/nature06521; BEVIS M, 1995, NATURE, V374, P249, DOI 10.1038/374249a0; Blewitt G, 2009, J GEODESY, V83, P335, DOI 10.1007/s00190-008-0262-5; Bonnardot MA, 2007, TECTONICS, V26, DOI 10.1029/2006TC002044; CIFUENTES IL, 1989, J GEOPHYS RES-SOLID, V94, P643, DOI 10.1029/JB094iB01p00643; COUTANT O, 1994, EXPRESSION GREENS FU; Dach R., 2007, GPS SOFTWARE VERSION; DOMINEY-HOWES D., 2009, 2 U NEW S WAL AUST T, P26; Freed AM, 2005, ANNU REV EARTH PL SC, V33, P335, DOI 10.1146/annurev.earth.33.092203.122505; Frohlich C, 2009, GEOLOGY, V37, P131, DOI 10.1130/G25277A.1; KANAMORI H, 1986, ANNU REV EARTH PL SC, V14, P293, DOI 10.1146/annurev.ea.14.050186.001453; Kanamori H., 1972, Physics of the Earth and Planetary Interiors, V6, P346, DOI 10.1016/0031-9201(72)90058-1; Linde AT, 2002, EARTH PLANET SC LETT, V203, P265, DOI 10.1016/S0012-821X(02)00849-X; *NAT OC ATM ADM, 2010, DART BUOY COMP MOD R; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; Okal EA, 2004, GEOPHYS J INT, V157, P164, DOI 10.1111/j.1365-246X.2004.02177.x; PACHECO JF, 1992, B SEISMOL SOC AM, V82, P1306; Satake K, 1999, PURE APPL GEOPHYS, V154, P467, DOI 10.1007/s000240050240; Sobolev SV, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004640; Song YT, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031681; THATCHER W, 1990, J GEOPHYS RES-SOLID, V95, P2609, DOI 10.1029/JB095iB03p02609; *US GEOL SURV, 2009, USGS CENTR MOM TENS; *US GEOL SURV, 2009, GLOB CMT PROJ MOM TE; *US GEOL SURV, 2009, FIN FAULT MOD; *US GEOL SURV, 2010, LARG EARTHQ WORLD 19; *US GEOL SURV, 2009, POST SAM ISL REG EAR; Wang XM, 2006, J HYDRAUL RES, V44, P147, DOI 10.1080/00221686.2006.9521671; WILSON KJ, 2009, 200971 GNS I GEOL NU	29	85	85	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					959	U78		10.1038/nature09292	http://dx.doi.org/10.1038/nature09292			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725037				2022-12-28	WOS:000281030300031
J	Fuchs, VR				Fuchs, Victor R.			New Priorities for Future Biomedical Innovations	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Stanford, CA 94305 USA	Stanford University	Fuchs, VR (corresponding author), Stanford Univ, Stanford, CA 94305 USA.							*CDCP, 2007, US LIF TABL; Emanuel EJ, 2008, JAMA-J AM MED ASSOC, V299, P1057, DOI 10.1001/jama.299.9.1057; Pauly MV, 2005, HEALTH AFFAIR, V24, P1523, DOI 10.1377/hlthaff.24.6.1523; Schoenborn CA., 2009, NATL HLTH STAT REPOR, V16, P1, DOI DOI 10.1037/E623972009-001; U. S. Bureau of theCensus, 2009, STAT ABSTR US	5	17	17	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					704	706		10.1056/NEJMp0906597	http://dx.doi.org/10.1056/NEJMp0906597			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639TE	20818873				2022-12-28	WOS:000280996600002
J	la Cour, JL; Brok, J; Gotzsche, PC				la Cour, Jeppe Lerche; Brok, Jesper; Gotzsche, Peter C.			Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONSORT STATEMENT	Objective To assess if authors of randomised clinical trials convey the fact that they have used surrogate outcomes and discussed their validity. Design Cohort study. Setting Six major general medical journals. Participants Randomised clinical trials published in 2005 and 2006 that used a surrogate as a primary outcome. Results Of 626 published randomised clinical trials, 109 (17%) used a surrogate as a primary outcome. Of these trials, 62 (57%, 95% confidence interval 47% to 67%) clearly reported that the primary outcome was a surrogate. Only 38 (35%, 26% to 45%) also discussed the validity of the surrogate. Conclusion Only about one third of authors of randomised clinical trials that used a surrogate as a primary outcome reported adequately on the surrogate. Better reporting is needed.	[la Cour, Jeppe Lerche; Brok, Jesper] Copenhagen Univ Hosp, Rigshosp, Copenhagen Trial Unit, DK-2100 Copenhagen, Denmark; [Brok, Jesper] Hvidovre Univ Hosp, Dept Pediat, Copenhagen, Denmark; [la Cour, Jeppe Lerche; Gotzsche, Peter C.] Rigshosp, Nord Cochrane Ctr, Copenhagen, Denmark; [la Cour, Jeppe Lerche; Gotzsche, Peter C.] Univ Copenhagen, DK-1168 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen	la Cour, JL (corresponding author), Copenhagen Univ Hosp, Rigshosp, Copenhagen Trial Unit, DK-2100 Copenhagen, Denmark.	Jeppelerche@hotmail.com		la Cour, Jeppe Lerche/0000-0001-6351-9430	Copenhagen Trial Unit, Centre for Clinical Intervention Research; Nordic Cochrane Centre, Denmark	Copenhagen Trial Unit, Centre for Clinical Intervention Research; Nordic Cochrane Centre, Denmark	This study was supported by the Copenhagen Trial Unit, Centre for Clinical Intervention Research, and the Nordic Cochrane Centre, Denmark. All authors worked independently of any funders. Competing interest: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any company for the submitted work; no financial relationships with any companies that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.	Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455; Baker Stuart G, 2003, BMC Med Res Methodol, V3, P16, DOI 10.1186/1471-2288-3-16; Bucher HC, 1999, JAMA-J AM MED ASSOC, V282, P771, DOI 10.1001/jama.282.8.771; Burns KEA, 2005, JAMA-J AM MED ASSOC, V294, P342, DOI 10.1001/jama.294.3.342; Crotty M, 2005, BMJ-BRIT MED J, V331, P1110, DOI 10.1136/bmj.38638.441933.63; Cuzick J, 2007, J MED SCREEN, V14, P178, DOI 10.1258/096914107782912059; *FOOD DRUG ADM, 2008, DRUG APPR DAT; Gluud C, 1997, LANCET, V349, P665, DOI 10.1016/S0140-6736(05)60131-6; Gluud C, 2007, J HEPATOL, V46, P734, DOI 10.1016/j.jhep.2007.01.003; Gotzsche PC, 1996, INT J TECHNOL ASSESS, V12, P238, DOI 10.1017/S0266462300009594; Hoj L, 2005, BMJ-BRIT MED J, V331, P723, DOI 10.1136/bmj.331.7519.723; MAZZONE T, 2006, JAMA-J AM MED ASSOC, V295, P2262; Mazzone T, 2006, JAMA-J AM MED ASSOC, V296, P2572, DOI 10.1001/jama.296.21.joc60158; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Moll E, 2006, BRIT MED J, V332, P1485, DOI 10.1136/bmj.38867.631551.55; Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699; Rosen CJ, 2007, NEW ENGL J MED, V357, P844, DOI 10.1056/NEJMp078167; Weir CJ, 2006, STAT MED, V25, P183, DOI 10.1002/sim.2319	20	37	37	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2010	341								c3653	10.1136/bmj.c3653	http://dx.doi.org/10.1136/bmj.c3653			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KT	20719823	Green Published, hybrid			2022-12-28	WOS:000281213100005
J	Lafita, FR; Castella, JM				Ramirez Lafita, Francisco; Castella, Joan M.			Review: Joint lavage does not reduce pain or improve function in knee osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CORTICOSTEROIDS		[Ramirez Lafita, Francisco; Castella, Joan M.] Hosp Tortosa Verge Cinta, Tortosa, Spain		Lafita, FR (corresponding author), Hosp Tortosa Verge Cinta, Tortosa, Spain.							Al-Omran AS, 2009, SAUDI MED J, V30, P809; Bannuru RR, 2009, ARTHRIT RHEUM-ARTHR, V61, P1704, DOI 10.1002/art.24925; Reichenbach S, 2010, COCHRANE DB SYST REV, V5; van Oosterhout M, 2008, Ned Tijdschr Geneeskd, V152, P1973	4	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-2	10.7326/0003-4819-153-4-201008170-02002	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713781				2022-12-28	WOS:000280973000028
J	Petit-Zeman, S; Firkins, L; Scadding, JW				Petit-Zeman, Sophie; Firkins, Lester; Scadding, John W.			The James Lind Alliance: tackling research mismatches	LANCET			English	Editorial Material									[Petit-Zeman, Sophie] Assoc Med Res Charities, London WC1X 8TL, England; [Firkins, Lester] James Lind Initiat, James Lind Alliance Secretariat, Oxford, England; [Scadding, John W.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Petit-Zeman, S (corresponding author), Assoc Med Res Charities, London WC1X 8TL, England.							*ASS MED RES CHANT, 2009, AMRC JLA NAT VOIC IN; *ASS MED RES CHART, PAT PUBL INV NAT GRO; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; FENTON M, 2006, DEV DATABASE UNCERTA; *J LIND ALL, UR INC WORK PARTN; *J LIND ALL, ASTHM WORK PARTN; *NIHR HLTH TECHN A, ANN REP 2008; Oliver S, 2006, BIBLIO RES REPORTS P; Partridge N, 2004, LANCET, V364, P1923, DOI 10.1016/S0140-6736(04)17494-1; STALEY K, 2008, J LIND ALLIANCE SCOP; Stewart R, 2008, SYSTEMATIC MAP STUDI; UK DUETS RESOURCE MA	12	57	57	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2010	376	9742					667	669		10.1016/S0140-6736(10)60712-X	http://dx.doi.org/10.1016/S0140-6736(10)60712-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	646YW	20801389				2022-12-28	WOS:000281582900009
J	Duce, JA; Tsatsanis, A; Cater, MA; James, SA; Robb, E; Wikhe, K; Leong, SL; Perez, K; Johanssen, T; Greenough, MA; Cho, HH; Galatis, D; Moir, RD; Masters, CL; McLean, C; Tanzi, RE; Cappai, R; Barnham, KJ; Ciccotosto, GD; Rogers, JT; Bush, AI				Duce, James A.; Tsatsanis, Andrew; Cater, Michael A.; James, Simon A.; Robb, Elysia; Wikhe, Krutika; Leong, Su Ling; Perez, Keyla; Johanssen, Timothy; Greenough, Mark A.; Cho, Hyun-Hee; Galatis, Denise; Moir, Robert D.; Masters, Colin L.; McLean, Catriona; Tanzi, Rudolph E.; Cappai, Roberto; Barnham, Kevin J.; Ciccotosto, Giuseppe D.; Rogers, Jack T.; Bush, Ashley I.			Iron-Export Ferroxidase Activity of beta-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease	CELL			English	Article							ISOFORM MESSENGER-RNAS; TARGETING A-BETA; SENILE PLAQUE; METAL-BINDING; BRAIN; CERULOPLASMIN; EXPRESSION; ACCUMULATION; AGE; OXIDATION	Alzheimer's Disease (AD) is complicated by pro-oxidant intraneuronal Fe2+ elevation as well as extracellular Zn2+ accumulation within amyloid plaque. We found that the AD beta-amyloid protein precursor (APP) possesses ferroxidase activity mediated by a conserved H-ferritin-like active site, which is inhibited specifically by Zn2+. Like ceruloplasmin, APP catalytically oxidizes Fe2+, loads Fe3+ into transferrin, and has a major interaction with ferroportin in HEK293T cells (that lack ceruloplasmin) and in human cortical tissue. Ablation of APP in HEK293T cells and primary neurons induces marked iron retention, whereas increasing APP695 promotes iron export. Unlike normal mice, APP(-/-) mice are vulnerable to dietary iron exposure, which causes Fe2+ accumulation and oxidative stress in cortical neurons. Paralleling iron accumulation, APP ferroxidase activity in AD postmortem neocortex is inhibited by endogenous Zn2+, which we demonstrate can originate from Zn2+-laden amyloid aggregates and correlates with A beta burden. Abnormal exchange of cortical zinc may link amyloid pathology with neuronal iron accumulation in AD.	[Leong, Su Ling; Perez, Keyla; Johanssen, Timothy; Cappai, Roberto; Barnham, Kevin J.; Ciccotosto, Giuseppe D.; Rogers, Jack T.] Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic 3010, Australia; [Greenough, Mark A.] Univ Melbourne, Dept Genet, Melbourne, Vic 3010, Australia; [Leong, Su Ling; Perez, Keyla; Galatis, Denise; Cappai, Roberto; Barnham, Kevin J.; Ciccotosto, Giuseppe D.; Bush, Ashley I.] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; [Duce, James A.; Tsatsanis, Andrew; Cater, Michael A.; James, Simon A.; Robb, Elysia; Wikhe, Krutika; Perez, Keyla; Greenough, Mark A.; Masters, Colin L.; Barnham, Kevin J.; Ciccotosto, Giuseppe D.; Bush, Ashley I.] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3052, Australia; [Cho, Hyun-Hee; Rogers, Jack T.] Harvard Univ, Sch Med, Dept Psychiat, Neurochem Lab, Boston, MA 02129 USA; [Moir, Robert D.; Tanzi, Rudolph E.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Boston, MA 02129 USA; [McLean, Catriona] Alfred Hosp, Dept Anat Pathol, Melbourne, Vic 3004, Australia	University of Melbourne; University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Florey Institute of Neuroscience & Mental Health	Rogers, JT (corresponding author), Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic 3010, Australia.	jrogers@partners.org; abush@mhri.edu.au	Moir, Robert D./M-7612-2017; Johanssen, Tim/G-6106-2014; Bush, Ashley I/A-1186-2007; James, Simon/ABA-8646-2020; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley/Y-2457-2019; Greenough, Mark/AAK-1615-2021; James, Simon/J-5320-2012; Cappai, Roberto/B-3347-2010	Moir, Robert D./0000-0001-5431-3553; Johanssen, Tim/0000-0001-6757-586X; Bush, Ashley I/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley/0000-0001-8259-9069; James, Simon/0000-0001-9369-3288; McLean, Catriona/0000-0002-0302-5727; Duce, James/0000-0002-8762-2245; Greenough, Mark/0000-0001-6767-0584; Rogers, Jack/0000-0003-1262-8578; Cappai, Roberto/0000-0002-9505-8496	National Institute on Aging [1RO1AG12686]; Australian Research Council; Australian National Health & Medical Research Council (NHMRC); NATIONAL INSTITUTE ON AGING [R01AG012686] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Australian Research Council(Australian Research Council); Australian National Health & Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by funds from the National Institute on Aging (1RO1AG12686), the Australian Research Council, the Australian National Health & Medical Research Council (NHMRC), Operational Infrastructure Support Victorian State Government, and the Alzheimer's Association. The Victorian Brain Bank Network is supported by The University of Melbourne, The Mental Health Research Institute, The Alfred Hospital, and the Victorian Forensic Institute of Medicine and funded by Neurosciences Australia and the NHMRC. We thank Gerd Multhaup for helpful comments and for providing APP reagents for pilot studies, Paul Adlard for human tissue samples, and Wilma Wasco for the APLP2 construct. C. L. M., R. E. T., K.J.B., and A. I. B. are shareholders, paid consultants, and advisory board members of Prana Biotechnology Ltd. A.I.B. is a shareholder of Cogstate Ltd and Eucalyptus Biosciences Pty Ltd. M. A. C. is a shareholder in Prana Biotechnology Ltd.	Adlard PA, 2008, NEURON, V59, P43, DOI 10.1016/j.neuron.2008.06.018; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; Bartzokis G, 2000, CELL MOL BIOL, V46, P821; BARTZOKIS G, 1994, AM J NEURORADIOL, V15, P1129; BARTZOKIS G, 1994, BIOL PSYCHIAT, V35, P480, DOI 10.1016/0006-3223(94)90047-7; BODOVITZ S, 1995, J NEUROCHEM, V64, P307; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Chinnery PF, 2007, BRAIN, V130, P110, DOI 10.1093/brain/awl319; CRAS P, 1991, P NATL ACAD SCI USA, V88, P7552, DOI 10.1073/pnas.88.17.7552; DE DOMENICO I, 2008, CELL METAB, V8, P146; DE DOMENICO I, 2007, EMBO J, V26, P2823; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; Ding B, 2009, J MAGN RESON IMAGING, V29, P793, DOI 10.1002/jmri.21730; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; EL TAYARA NE, 2006, NEUROBIOL DIS, V22, P199; Falangola MF, 2005, NEUROCHEM RES, V30, P201, DOI 10.1007/s11064-004-2442-x; Faux NG, 2010, J ALZHEIMERS DIS, V20, P509, DOI 10.3233/JAD-2010-1390; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Gonzalez-Cuyar LF, 2008, NEUROPATHOLOGY, V28, P466, DOI 10.1111/j.1440-1789.2008.00901.x; GRAY CW, 1993, NEUROREPORT, V4, P811, DOI 10.1097/00001756-199306000-00054; GRUNDKEIQBAL I, 1990, ACTA NEUROPATHOL, V81, P105, DOI 10.1007/BF00334497; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; HALLGREN B, 1958, J NEUROCHEM, V3, P41, DOI 10.1111/j.1471-4159.1958.tb12607.x; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Honda K, 2005, J BIOL CHEM, V280, P20978, DOI 10.1074/jbc.M500526200; Jack CR, 2005, J NEUROSCI, V25, P10041, DOI 10.1523/JNEUROSCI.2588-05.2005; Jeong SY, 2006, J NEUROSCI, V26, P9810, DOI 10.1523/JNEUROSCI.2922-06.2006; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; Lannfelt L, 2008, LANCET NEUROL, V7, P779, DOI 10.1016/S1474-4422(08)70167-4; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Mantovan MC, 2006, EUR J NEUROL, V13, P827, DOI 10.1111/j.1468-1331.2006.01363.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Meloni G, 2008, NAT CHEM BIOL, V4, P366, DOI 10.1038/nchembio.89; Miller LM, 2006, J STRUCT BIOL, V155, P30, DOI 10.1016/j.jsb.2005.09.004; MITA S, 1989, AM J PATHOL, V134, P1253; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; OSAKI S, 1966, J BIOL CHEM, V241, P5053; Patel BN, 2002, J NEUROSCI, V22, P6578; Qian ZM, 2007, BBA-MOL BASIS DIS, V1772, P527, DOI 10.1016/j.bbadis.2007.02.006; Religa D, 2006, NEUROLOGY, V67, P69, DOI 10.1212/01.wnl.0000223644.08653.b5; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; ROBINSON SR, 1995, ALZ RES, V1, P191; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X; Takahashi M, 2000, NEURON, V28, P461, DOI 10.1016/S0896-6273(00)00125-2; Toussaint L, 2007, J MOL BIOL, V365, P440, DOI 10.1016/j.jmb.2006.10.010; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Visser CC, 2004, PHARM RES-DORDR, V21, P761, DOI 10.1023/B:PHAM.0000026425.69874.8e; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; Yamamoto A, 2002, J NEUROCHEM, V82, P1137; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537	64	477	495	2	84	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	2010	142	6					857	867		10.1016/j.cell.2010.08.014	http://dx.doi.org/10.1016/j.cell.2010.08.014			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20817278	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000281855000009
J	Laube, JC; Kaiser, J; Sturges, WT; Bonisch, H; Engel, A				Laube, J. C.; Kaiser, J.; Sturges, W. T.; Boenisch, H.; Engel, A.			Chlorine Isotope Fractionation in the Stratosphere	SCIENCE			English	Article							IUPAC TECHNICAL REPORT; NITROUS-OXIDE; CHEMISTRY; ELEMENTS; N2O		[Laube, J. C.; Kaiser, J.; Sturges, W. T.] Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England; [Boenisch, H.; Engel, A.] Goethe Univ Frankfurt, Inst Atmosphere & Environm, D-60438 Frankfurt, Germany	University of East Anglia; Goethe University Frankfurt	Laube, JC (corresponding author), Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England.	j.laube@uea.ac.uk	Engel, Andreas/E-3100-2014; Sturges, William/B-8248-2012; Laube, Johannes C/P-6772-2017; Kaiser, Jan/D-3327-2009	Engel, Andreas/0000-0003-0557-3935; Laube, Johannes C/0000-0001-9683-5931; Kaiser, Jan/0000-0002-1553-4043; Bonisch, Harald/0000-0002-1004-0861	Natural Environment Research Council [NE/F015585/1]; Royal Society [WM052632]; European Space Agency, European Union [GOCE-CT-2003-505390]; Deutsches Zentrum fur Luft- und Raumfahrt [50EE0016]; Deutsche Forschungsgemeinschaft [EN 367/4]; NERC [NE/F015585/1] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Royal Society(Royal Society of London); European Space Agency, European Union(European Space Agency); Deutsches Zentrum fur Luft- und Raumfahrt(Helmholtz AssociationGerman Aerospace Centre (DLR)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank the Centre National d'Etudes Spatiales (CNES) balloon team and the anonymous reviewers and acknowledge funding from Natural Environment Research Council (fellowship NE/F015585/1), Royal Society (WM052632), European Space Agency, European Union (project GOCE-CT-2003-505390), Deutsches Zentrum fur Luft- und Raumfahrt (project 50EE0016), and Deutsche Forschungsgemeinschaft (project EN 367/4).	Brenninkmeijer CAM, 2003, CHEM REV, V103, P5125, DOI 10.1021/cr020644k; Brenninkmeijer CAM, 1996, GEOPHYS RES LETT, V23, P2125, DOI 10.1029/96GL01471; CLERBAUX C, 2007, SCI ASSESSMENT OZONE, pCH3; Cliff SS, 1999, J GEOPHYS RES-ATMOS, V104, P16171, DOI 10.1029/1999JD900152; Coplen TB, 2002, PURE APPL CHEM, V74, P1987, DOI 10.1351/pac200274101987; De Laeter JR, 2003, PURE APPL CHEM, V75, P683, DOI 10.1351/pac200375060683; FORSTER VRP, 2007, CLIMATE CHANGE 2007, pCH2; Gaudette H., 1990, GEOL SOC AM ABSTR, V22, pA173; Johnson MS, 2002, CHEM SOC REV, V31, P313, DOI 10.1039/b108011n; Kaiser J, 2006, ATMOS CHEM PHYS, V6, P3535, DOI 10.5194/acp-6-3535-2006; Krankowsky D, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007855; Laube JC, 2010, ATMOS CHEM PHYS, V10, P1093, DOI 10.5194/acp-10-1093-2010; Laube JC, 2008, ATMOS CHEM PHYS, V8, P7325, DOI 10.5194/acp-8-7325-2008; LEV SM, 1999, 9 ANN GOLDSCHM C LUN, P169; Liang MC, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004539; Nanbu S, 2004, J PHYS CHEM A, V108, P8905, DOI 10.1021/jp048853r; Patra PK, 1997, J ATMOS SOL-TERR PHY, V59, P1149, DOI 10.1016/S1364-6826(96)00109-5; Prakash MK, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2102908; SHIELDS WR, 1962, J AM CHEM SOC, V84, P1519, DOI 10.1021/ja00868a001; Smith JA, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024078; STEWART MA, 2004, GEOCHEMISTRY NONTRAD, pCH7	21	16	18	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1167	1167		10.1126/science.1191809	http://dx.doi.org/10.1126/science.1191809			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813947				2022-12-28	WOS:000281485600025
J	Robertson, A; Cresswell, K; Takian, A; Petrakaki, D; Crowe, S; Cornford, T; Barber, N; Avery, A; Fernando, B; Jacklin, A; Prescott, R; Klecun, E; Paton, J; Lichtner, V; Quinn, C; Ali, M; Morrison, Z; Jani, Y; Waring, J; Marsden, K; Sheikh, A				Robertson, Ann; Cresswell, Kathrin; Takian, Amirhossein; Petrakaki, Dimitra; Crowe, Sarah; Cornford, Tony; Barber, Nicholas; Avery, Anthony; Fernando, Bernard; Jacklin, Ann; Prescott, Robin; Klecun, Ela; Paton, James; Lichtner, Valentina; Quinn, Casey; Ali, Maryam; Morrison, Zoe; Jani, Yogini; Waring, Justin; Marsden, Kate; Sheikh, Aziz			Implementation and adoption of nationwide electronic health records in secondary care in England: qualitative analysis of interim results from a prospective national evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION-TECHNOLOGY	Objectives To describe and evaluate the implementation and adoption of detailed electronic health records in secondary care in England and thereby provide early feedback for the ongoing local and national rollout of the NHS Care Records Service. Design A mixed methods, longitudinal, multisite, socio-technical case study. Setting Five NHS acute hospital and mental health trusts that have been the focus of early implementation efforts and at which interim data collection and analysis are complete. Data sources and analysis Dataset for the evaluation consists of semi-structured interviews, documents and field notes, observations, and quantitative data. Qualitative data were analysed thematically with a socio-technical coding matrix, combined with additional themes that emerged from the data. Main results Hospital electronic health record applications are being developed and implemented far more slowly than was originally envisioned; the top-down, standardised approach has needed to evolve to admit more variation and greater local choice, which hospital trusts want in order to support local activity. Despite considerable delays and frustrations, support for electronic health records remains strong, including from NHS clinicians. Political and financial factors are now perceived to threaten nationwide implementation of electronic health records. Interviewees identified a range of consequences of long term, centrally negotiated contracts to deliver the NHS Care Records Service in secondary care, particularly as NHS trusts themselves are not party to these contracts. These include convoluted communication channels between different stakeholders, unrealistic deployment timelines, delays, and applications that could not quickly respond to changing national and local NHS priorities. Our data suggest support for a "middle-out" approach to implementing hospital electronic health records, combining government direction with increased local autonomy, and for restricting detailed electronic health record sharing to local health communities. Conclusions Experiences from the early implementation sites, which have received considerable attention, financial investment and support, indicate that delivering improved healthcare through nationwide electronic health records will be a long, complex, and iterative process requiring flexibility and local adaptability both with respect to the systems and the implementation strategy. The more tailored, responsive approach that is emerging is becoming better aligned with NHS organisations' perceived needs and is, if pursued, likely to deliver clinically useful electronic health record systems.	[Robertson, Ann; Cresswell, Kathrin; Fernando, Bernard; Prescott, Robin; Morrison, Zoe; Sheikh, Aziz] Univ Edinburgh, Ctr Populat Hlth Sci, Ehlth Res Grp, Edinburgh EH8 9AG, Midlothian, Scotland; [Takian, Amirhossein; Barber, Nicholas; Jani, Yogini] Univ London, Sch Pharm, Dept Practice & Policy, London WC1E 7HU, England; [Petrakaki, Dimitra; Cornford, Tony; Klecun, Ela; Lichtner, Valentina; Ali, Maryam] Univ London London Sch Econ & Polit Sci, Dept Management, London WC2A 2AE, England; [Crowe, Sarah; Avery, Anthony; Quinn, Casey; Waring, Justin; Marsden, Kate] Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England; [Jacklin, Ann] Imperial Coll Healthcare NHS Trust, London, England; [Paton, James] Burton Hosp NHS Fdn Trust, Burton Upon Trent, England	University of Edinburgh; University of London; University College London; University of London School of Pharmacy; University of London; London School Economics & Political Science; University of Nottingham; Imperial College London	Sheikh, A (corresponding author), Univ Edinburgh, Ctr Populat Hlth Sci, Ehlth Res Grp, Edinburgh EH8 9AG, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Jani, Yogini/AAM-4436-2020; Sheikh, Aziz/D-2818-2009; Jani, Yogini/GRF-6258-2022; Waring, Justin/C-5436-2015	Jani, Yogini/0000-0001-5927-5429; Sheikh, Aziz/0000-0001-7022-3056; Petrakaki, Dimitra/0000-0003-2136-3858; Klecun, Ela/0000-0002-0329-1566; Avery, Anthony/0000-0001-7591-4438; Waring, Justin/0000-0003-1459-5896	National Institute for Health Research; NHS	National Institute for Health Research(National Institute for Health Research (NIHR)); NHS	This report is independent research commissioned by the National Institute for Health Research. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.; All authors have completed the Unified Competing Interest form at www.icmje.orge/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) all authors have support in the form of a grant from the NHS CFHEP for the submitted work; (2) no author has a relationship with any company that might have an interest in the submitted work in the previous three years; (3) no author's spouse, partner, or children have financial relationships that may be relevant to the submitted work; and (4) no author has non-financial interests that may be relevant to the submitted work.	Blumenthal D, 2009, NEW ENGL J MED, V360, P1477, DOI 10.1056/NEJMp0901592; British Computer Society, 2006, WAY FORW NHS HLTH IN; CAR J, 2008, IMPACT EHEALTH QUALI; Catwell Lorraine, 2009, Inform Prim Care, V17, P1; Catwell L, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000126; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Coiera E, 2004, BRIT MED J, V328, P1197, DOI 10.1136/bmj.328.7449.1197; Coiera E, 2009, J AM MED INFORM ASSN, V16, P271, DOI 10.1197/jamia.M3183; Corbin J.M., 2008, BASICS QUALITATIVE R; CORNFORD T, 1994, OMEGA-INT J MANAGE S, V22, P491, DOI 10.1016/0305-0483(94)90030-2; Cresswell Kathrin, 2009, Inform Prim Care, V17, P153; CRUICKSHANK J, 2010, FIXINGNHS IT PLAN AC; *DEP HLTH, 2008, HIGH QUAL CAR ALL NH; *DEP HLTH, 2008, HLTH INF REV REP; Department of Health, 2002, DEL 21 CENT IT SUPP; Department of Health, 2010, EQ EXC LIB NHS; Greenhalgh T, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c3111; Greenhalgh T, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1786; Harrison MI., 2004, IMPLEMENTING CHANGE; Hendy J, 2007, BRIT MED J, V334, P1360, DOI 10.1136/bmj.39195.598461.551; *HOUS COMM COMM PU, 2007, 20 REP SESS 2006 07; *HOUS COMM LIB, 2002, NHS FUND REF WANL RE; *HOUS COMM PUBL AC, 2009, NAT PROGR IT NHS PRO; *J ROWNTR REF TRUS, 2009, DAT STAT; Jha AK, 2009, NEW ENGL J MED, V360, P1628, DOI 10.1056/NEJMsa0900592; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Mays N., 1999, QUALITATIVE RES HLTH; Murray SA, 2006, LANCET, V368, P901, DOI 10.1016/S0140-6736(06)69350-1; *NAT AUD OFF, 2006, DEP HLTH NAT PROGR I; *NAT AUD OFF, 2008, NAT PROGR IT NHS PRO; NHS Executive, 1998, INF HLTH INF STRAT M; Patton M., 2015, QUALITATIVE RES EVAL, V4th; PEITU M, 2008, SOCIOTECHNICAL APPRO; Protti D., 2007, HEALTHC Q, V10, P107; *ROYAL AC ENG, 2004, CHALL COMPL IT PROJ; Royal College of General Practitioners, 2009, INF SHAR CLIN CAR FI; Schiff GD, 2010, NEW ENGL J MED, V362, P1066, DOI 10.1056/NEJMp0911734; Silverman D., 2017, DOING QUALITATIVE RE, V5th	38	120	122	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2010	341								c4564	10.1136/bmj.c4564	http://dx.doi.org/10.1136/bmj.c4564			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647JV	20813822	Green Accepted, hybrid, Green Submitted, Green Published			2022-12-28	WOS:000281615700003
J	Swartzendruber, A; Zenilman, JM				Swartzendruber, Andrea; Zenilman, Jonathan M.			A National Strategy to Improve Sexual Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Zenilman, Jonathan M.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA; [Swartzendruber, Andrea] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Zenilman, JM (corresponding author), Johns Hopkins Univ, Sch Med, 4940 Eastern Ave, Baltimore, MD 21224 USA.	jzenilma@jhmi.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD042854] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERENSON A, 2005, NY TIMES        1204; Buller JL, 2007, MIL MED, V172, P511, DOI 10.7205/MILMED.172.5.511; Centers for Disease Control and Prevention, FREQ ASK QUEST HPV V; Centers for Disease Control and Prevention, HIV INC; DOUGLAS J, 2009, CHALL OPP STD PREV U; Lottes IL, 2002, J SEX RES, V39, P79, DOI 10.1080/00224490209552125; Medical Foundation for AIDS and Sexual Health, 2008, PROGR PRIOR WORK TOG; Satcher D., 2001, SURG GEN CALL ACTION; *WHIT HOUS, 2009, JOINT SESS C FEBR 24; WHO, GEND HUM RIGHTS	10	43	43	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					1005	1006		10.1001/jama.2010.1252	http://dx.doi.org/10.1001/jama.2010.1252			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20810379				2022-12-28	WOS:000281422400028
J	Lin, YY; Su, WF				Lin, Yuan-Yung; Su, Wan-Fu			Liposarcoma of the Anterior Mediastinum and Neck	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lin, Yuan-Yung; Su, Wan-Fu] Tri Serve Gen Hosp, Taipei, Taiwan	Tri-Service General Hospital	Lin, YY (corresponding author), Tri Serve Gen Hosp, Taipei, Taiwan.	wfs19582001@yahoo.com.tw							0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					864	864		10.1056/NEJMicm0912793	http://dx.doi.org/10.1056/NEJMicm0912793			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642HG	20818847				2022-12-28	WOS:000281196600009
J	Palenzuela, C; Lehner, L; Liebling, SL				Palenzuela, Carlos; Lehner, Luis; Liebling, Steven L.			Dual Jets from Binary Black Holes	SCIENCE			English	Article							MASS-LOSS; MERGERS; ELECTRODYNAMICS; MAGNETOSPHERES; SIMULATIONS; DISK	The coalescence of supermassive black holes-a natural outcome when galaxies merge-should produce gravitational waves and would likely be associated with energetic electromagnetic events. We have studied the coalescence of such binary black holes within an external magnetic field produced by the expected circumbinary disk surrounding them. Solving the Einstein equations to describe black holes interacting with surrounding plasma, we present numerical evidence for possible jets driven by these systems. Extending the process described by Blandford and Znajek for a single, spinning black hole, the picture that emerges suggests that the electromagnetic field extracts energy from the orbiting black holes, which ultimately merge and settle into the standard Blandford-Znajek scenario. Emissions along these jets could potentially be observable at large distances.	[Lehner, Luis] Perimeter Inst Theoret Phys, Waterloo, ON N2L 2Y5, Canada; [Palenzuela, Carlos] Canadian Inst Theoret Astrophys, Toronto, ON M5S 3H8, Canada; [Palenzuela, Carlos] Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA; [Lehner, Luis] Univ Guelph, Dept Phys, Guelph, ON N1G 2W1, Canada; [Liebling, Steven L.] Long Isl Univ, Dept Phys, Brookville, NY 11548 USA	Perimeter Institute for Theoretical Physics; Louisiana State University System; Louisiana State University; University of Guelph	Lehner, L (corresponding author), Perimeter Inst Theoret Phys, Waterloo, ON N2L 2Y5, Canada.	llehner@perimeterinstitute.ca	liebling, steven/AAF-1068-2019; Palenzuela, Carlos/I-7791-2017	liebling, steven/0000-0002-5008-6119; Palenzuela, Carlos/0000-0003-0634-531X	NSF [PHY-0803629, PHY-0803624]; Natural Sciences and Engineering Research Council of Canada; Industry Canada; Ministry of Research and Innovation	NSF(National Science Foundation (NSF)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Industry Canada; Ministry of Research and Innovation(Ministry of Research and Innovation, Ontario)	We thank A. Broderick, N. Afshordi, T. Garrett, R. MacNamara, E. Poisson, A. Spitkovsky, and C. Thompson, as well as our longtime collaborators D. Neilsen, E. Hirschmann, P. Motl, and M. Anderson, for useful discussions and comments. Supported by NSF grants PHY-0803629 (to Louisiana State University) and PHY-0803624 (to Long Island University) and by a Natural Sciences and Engineering Research Council of Canada Discovery Grant. Research at Perimeter Institute is supported through Industry Canada and by the Province of Ontario through the Ministry of Research and Innovation. The computations were performed in Teragrid and Scinet. C.P. and L.L. thank the Princeton Center for Theoretical Physics, where parts of this work were completed, for its hospitality.	Armitage PJ, 2005, ASTROPHYS J, V634, P921, DOI 10.1086/497108; Aylott B, 2009, CLASSICAL QUANT GRAV, V26, DOI 10.1088/0264-9381/26/16/165008; BLANDFORD RD, 1977, MON NOT R ASTRON SOC, V179, P433, DOI 10.1093/mnras/179.3.433; Blandford RD, 2002, ESO ASTROPHY SYMP, P381, DOI 10.1007/10856495_59; Bode T, 2010, ASTROPHYS J, V715, P1117, DOI 10.1088/0004-637X/715/2/1117; Corrales LR, 2010, MON NOT R ASTRON SOC, V404, P947, DOI 10.1111/j.1365-2966.2010.16324.x; GOLDREICH P, 1969, ASTROPHYS J, V157, P869, DOI 10.1086/150119; Komissarov SS, 2007, MON NOT R ASTRON SOC, V377, pL49, DOI 10.1111/j.1745-3933.2007.00301.x; Komissarov SS, 2004, MON NOT R ASTRON SOC, V350, P427, DOI 10.1111/j.1365-2966.2004.07598.x; Krolik JH, 2010, LECT NOTES PHYS, V794, P265, DOI 10.1007/978-3-540-76937-8_10; Krolik JH, 2010, ASTROPHYS J, V709, P774, DOI 10.1088/0004-637X/709/2/774; Lippai Z, 2008, ASTROPHYS J LETT, V676, pL5, DOI 10.1086/587034; MacFadyen AI, 2008, ASTROPHYS J, V672, P83, DOI 10.1086/523869; MATZNER RA, 1995, SCIENCE, V270, P941, DOI 10.1126/science.270.5238.941; Megevand M, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.024012; Milosavljevic M, 2005, ASTROPHYS J, V622, pL93, DOI 10.1086/429618; Mosta P, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.064017; O'Neill SM, 2009, ASTROPHYS J, V700, P859, DOI 10.1088/0004-637X/700/1/859; Palenzuela C, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.084007; Palenzuela C, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.081101; Rafikov RR, 2005, ASTROPHYS J, V631, P488, DOI 10.1086/432248; Rossi EM, 2010, MON NOT R ASTRON SOC, V401, P2021, DOI 10.1111/j.1365-2966.2009.15802.x; Semenov V, 2004, SCIENCE, V305, P978, DOI 10.1126/science.1100638; Shields GA, 2008, ASTROPHYS J, V682, P758, DOI 10.1086/589427; Tchekhovskoy A, 2008, MON NOT R ASTRON SOC, V388, P551, DOI 10.1111/j.1365-2966.2008.13425.x; Vecchio A, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.042001; Vietri M, 1996, ASTROPHYS J, V471, pL95, DOI 10.1086/310340	27	131	132	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					927	930		10.1126/science.1191766	http://dx.doi.org/10.1126/science.1191766			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724629	Green Submitted			2022-12-28	WOS:000281084800029
J	Macilwain, C				Macilwain, Colin			Leaders wanted	NATURE			English	Editorial Material												cfmworldview@gmail.com							0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					919	919		10.1038/466919a	http://dx.doi.org/10.1038/466919a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	640ED	20725016	Bronze			2022-12-28	WOS:000281030300011
J	Roccaforte, R				Roccaforte, Rosa			Review: Therapy guided by B-type natriuretic peptide levels reduces mortality in chronic heart failure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Ctr Diagnost Italiano, Milan, Italy		Roccaforte, R (corresponding author), Ctr Diagnost Italiano, Milan, Italy.							Harrison A, 2002, ANN EMERG MED, V39, P131, DOI 10.1067/mem.2002.121483; ROCCAFORTE R, EUR J HEART FAIL	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-3	10.7326/0003-4819-153-4-201008170-02003	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713782				2022-12-28	WOS:000280973000029
J	WARDEN, J				WARDEN, J			THE THINK TANKS ROLL	BRITISH MEDICAL JOURNAL			English	Editorial Material																		WARDEN J, 1988, BRIT MED J, V296, P440, DOI 10.1136/bmj.296.6619.440	1	0	0	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1988	296	6620					510	510		10.1136/bmj.296.6620.510	http://dx.doi.org/10.1136/bmj.296.6620.510			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M1529	20742959	Green Published			2022-12-28	WOS:A1988M152900052
J	Taylor, MJ; Hoerauf, A; Bockarie, M				Taylor, Mark J.; Hoerauf, Achim; Bockarie, Moses			Lymphatic filariasis and onchocerciasis	LANCET			English	Article							ENDOSYMBIOTIC WOLBACHIA-BACTERIA; GROWTH FACTOR-A; BANCROFTIAN FILARIASIS; MACROFILARICIDAL ACTIVITY; DOXYCYCLINE TREATMENT; WUCHERERIA-BANCROFTI; GLOBAL PROGRAM; CLINICAL-TRIAL; BRUGIA-MALAYI; ENDEMIC FOCI	Lymphatic filariasis and onchocerciasis are parasitic helminth diseases that constitute a serious public health issue in tropical regions. The filarial nematodes that cause these diseases are transmitted by blood-feeding insects and produce chronic and long-term infection through suppression of host immunity. Disease pathogenesis is linked to host inflammation invoked by the death of the parasite, causing hydrocoele, lymphoedema, and elephantiasis in lymphatic filariasis, and skin disease and blindness in onchocerciasis. Most filarial species that infect people co-exist in mutualistic symbiosis with Wolbachia bacteria, which are essential for growth, development, and survival of their nematode hosts. These endosymbionts contribute to inflammatory disease pathogenesis and are a target for doxycycline therapy, which delivers macrofilaricidal activity, improves pathological outcomes, and is effective as monotherapy. Drugs to treat filariasis include diethylcarbamazine, ivermectin, and albendazole, which are used mostly in combination to reduce microfilariae in blood (lymphatic filariasis) and skin (onchocerciasis). Global programmes for control and elimination have been developed to provide sustained delivery of drugs to affected communities to interrupt transmission of disease and ultimately eliminate this burden on public health.	[Taylor, Mark J.; Bockarie, Moses] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Hoerauf, Achim] Univ Bonn, Inst Med Microbiol Immunol & Parasitol, D-5300 Bonn, Germany	Liverpool School of Tropical Medicine; University of Liverpool; University of Bonn	Taylor, MJ (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	mark.taylor@liv.ac.uk	Bockarie, Moses/AAW-3130-2021; Franzeck, Fabian C/B-5055-2011; Bockarie, Moses/AAV-4578-2020; /A-1783-2011	/0000-0003-2422-1847; Taylor, Mark/0000-0003-3396-9275	Bill & Melinda Gates Foundation; Liverpool School of Tropical Medicine; EU; Volkswagen Foundation; DFG (German Research Foundation); UK Department for International Development	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Liverpool School of Tropical Medicine; EU(European Commission); Volkswagen Foundation(Volkswagen); DFG (German Research Foundation)(German Research Foundation (DFG)); UK Department for International Development	MJT is supported by the AWOL consortium at the Liverpool School of Tropical Medicine, which is funded by the Bill & Melinda Gates Foundation. AN is funded by A-WOL through a grant from the Liverpool School of Tropical Medicine, EU FP6 and FP7 Programmes, Volkswagen Foundation and DFG (German Research Foundation). MB is funded by the UK Department for International Development.	Ali MMM, 2007, AM J TROP MED HYG, V77, P1074, DOI 10.4269/ajtmh.2007.77.1074; Ali MMM, 2002, ACTA TROP, V84, P49, DOI 10.1016/S0001-706X(02)00117-1; [Anonymous], 2009, Wkly Epidemiol Rec, V84, P437; Awadzi K, 2004, ANN TROP MED PARASIT, V98, P231, DOI 10.1179/000349804225003253; Awadzi K, 2004, ANN TROP MED PARASIT, V98, P359, DOI 10.1179/000349804225003442; Awadzi K, 2003, ANN TROP MED PARASIT, V97, P165, DOI 10.1179/000349803235001697; Babu S, 2006, J IMMUNOL, V176, P3248, DOI 10.4049/jimmunol.176.5.3248; Babu S, 2006, J IMMUNOL, V176, P3885, DOI 10.4049/jimmunol.176.7.3885; Babu S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000489; Babu S, 2009, J INFECT DIS, V200, P288, DOI 10.1086/599797; Babu S, 2009, J INFECT DIS, V199, P1827, DOI 10.1086/599090; Babu S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000420; Basanez MG, 2008, LANCET INFECT DIS, V8, P310, DOI 10.1016/S1473-3099(08)70099-9; Basanez MG, 2006, PLOS MED, V3, P1454, DOI 10.1371/journal.pmed.0030371; Boatin BA, 2006, ADV PARASIT, V61, P349, DOI 10.1016/S0065-308X(05)61009-3; Bockarie MJ, 2002, NEW ENGL J MED, V347, P1841, DOI 10.1056/NEJMoa021309; Bockarie MJ, 2009, EXPERT REV ANTI-INFE, V7, P595, DOI [10.1586/eri.09.36, 10.1586/ERI.09.36]; Bockarie MJ, 2009, ANNU REV ENTOMOL, V54, P469, DOI 10.1146/annurev.ento.54.110807.090626; Bourguinat C, 2006, PARASITOLOGY, V132, P255, DOI 10.1017/S0031182005008899; Bourguinat C, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000072; Boussinesq M, 2006, TRENDS PARASITOL, V22, P244, DOI 10.1016/j.pt.2006.04.006; Brattig NW, 2004, MICROBES INFECT, V6, P113, DOI 10.1016/j.micinf.2003.11.003; Burbelo PD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000438; Buttner Dietrich W, 2003, Filaria J, V2, P10, DOI 10.1186/1475-2883-2-10; Churcher TS, 2009, P NATL ACAD SCI USA, V106, P16716, DOI 10.1073/pnas.0906176106; Coulibaly YI, 2009, NEW ENGL J MED, V361, P1448, DOI 10.1056/NEJMoa0900863; Critchley J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003753.pub3; Critchley J, 2005, TROP MED INT HEALTH, V10, P818, DOI 10.1111/j.1365-3156.2005.01458.x; Cross HF, 2001, LANCET, V358, P1873, DOI 10.1016/S0140-6736(01)06899-4; Cuenco KT, 2009, J INFECT DIS, V200, P1271, DOI 10.1086/605844; Cuenco KT, 2004, AM J TROP MED HYG, V70, P180, DOI 10.4269/ajtmh.2004.70.180; Cuenco KT, 2004, AM J TROP MED HYG, V70, P185, DOI 10.4269/ajtmh.2004.70.185; Curtis CF, 2002, ANN TROP MED PARASIT, V96, pS97, DOI 10.1179/000349802125002446; Dadzie Yankum, 2003, Filaria J, V2, P2, DOI 10.1186/1475-2883-2-2; Debrah AY, 2009, AM J TROP MED HYG, V80, P956, DOI 10.4269/ajtmh.2009.80.956; Debrah AY, 2007, TROP MED INT HEALTH, V12, P1433, DOI 10.1111/j.1365-3156.2007.01949.x; Debrah AY, 2007, AM J TROP MED HYG, V77, P601, DOI 10.4269/ajtmh.2007.77.601; Debrah AY, 2006, PLOS PATHOG, V2, P829, DOI 10.1371/journal.ppat.0020092; Diawara L, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000497; Donfack J, 1999, B SOC PATHOL EXOT, V92, P85; Dreyer G, 1999, T ROY SOC TROP MED H, V93, P413, DOI 10.1016/S0035-9203(99)90140-2; Dreyer G, 2000, PARASITOL TODAY, V16, P544, DOI 10.1016/S0169-4758(00)01778-6; Dreyer G, 2006, TROP MED INT HEALTH, V11, P1475, DOI 10.1111/j.1365-3156.2006.01687.x; Duerr HP, 2005, TRENDS PARASITOL, V21, P88, DOI 10.1016/j.pt.2004.11.011; Duke BOL, 2005, PARASITOLOGY, V130, P447, DOI 10.1017/S0031182004006766; El Setouhy M, 2004, AM J TROP MED HYG, V70, P191, DOI 10.4269/ajtmh.2004.70.191; El-Setouhy M, 2007, AM J TROP MED HYG, V77, P1069, DOI 10.4269/ajtmh.2007.77.1069; Eng JKL, 2006, MOL BIOCHEM PARASIT, V150, P229, DOI 10.1016/j.molbiopara.2006.08.007; Farid HA, 2005, AM J TROP MED HYG, V73, P108, DOI 10.4269/ajtmh.2005.73.108; Farid HA, 2007, AM J TROP MED HYG, V77, P593, DOI 10.4269/ajtmh.2007.77.593; Figueredo-Silva J, 2002, ANN TROP MED PARASIT, V96, P531, DOI 10.1179/000349802125001348; Filipe JAN, 2005, P NATL ACAD SCI USA, V102, P15265, DOI 10.1073/pnas.0502659102; Fox LM, 2006, CURR OPIN INFECT DIS, V19, P588, DOI 10.1097/QCO.0b013e328010774c; Gardon J, 1997, LANCET, V350, P18, DOI 10.1016/S0140-6736(96)11094-1; Gentil K, 2009, INFECT IMMUN, V77, P1606, DOI 10.1128/IAI.00671-08; Gillette-Ferguson I, 2004, INFECT IMMUN, V72, P5687, DOI 10.1128/IAI.72.10.5687-5692.2004; Gillette-Ferguson I, 2007, INFECT IMMUN, V75, P5908, DOI 10.1128/IAI.00991-07; Gyapong JO, 2005, EXPERT OPIN PHARMACO, V6, P179, DOI 10.1517/14656566.6.2.179; Gyapong JO, 2002, ANN TROP MED PARASIT, V96, P695, DOI 10.1179/000349802125001735; Helmy H, 2006, T ROY SOC TROP MED H, V100, P656, DOI 10.1016/j.trstmh.2005.08.015; Higazi TB, 2005, MOL BIOCHEM PARASIT, V141, P109, DOI 10.1016/j.molbiopara.2005.02.006; Hise AG, 2007, J IMMUNOL, V178, P1068, DOI 10.4049/jimmunol.178.2.1068; Hodgkin C, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000074; Hoerauf A, 2000, LANCET, V355, P1242, DOI 10.1016/S0140-6736(00)02095-X; Hoerauf A, 2005, PARASITE IMMUNOL, V27, P417, DOI 10.1111/j.1365-3024.2005.00792.x; Hoerauf A, 2003, MICROBES INFECT, V5, P261, DOI 10.1016/S1286-4579(03)00026-1; Hoerauf A, 2002, MICROBES INFECT, V4, P37, DOI 10.1016/S1286-4579(01)01507-6; Hoerauf A, 2001, LANCET, V357, P1415, DOI 10.1016/S0140-6736(00)04581-5; Hoerauf A, 2009, PARASITOL RES, V104, P437, DOI 10.1007/s00436-008-1217-8; Hoerauf A, 2008, CURR OPIN INFECT DIS, V21, P673, DOI 10.1097/QCO.0b013e328315cde7; Hoerauf A, 2008, MED MICROBIOL IMMUN, V197, P295, DOI 10.1007/s00430-007-0062-1; Horton J, 2002, CURR OPIN INFECT DIS, V15, P599, DOI 10.1097/00001432-200212000-00008; Keiser PB, 2002, J INFECT DIS, V185, P805, DOI 10.1086/339344; Kyelem D, 2008, AM J TROP MED HYG, V79, P480; Mand S, 2009, AM J TROP MED HYG, V81, P702, DOI 10.4269/ajtmh.2009.09-0155; McGarry Helen F, 2005, Filaria J, V4, P4, DOI 10.1186/1475-2883-4-4; McGarry Helen F., 2003, Filaria Journal, V2, pUnpaginated, DOI 10.1186/1475-2883-2-9; McPherson T, 2006, BRIT J DERMATOL, V154, P933, DOI 10.1111/j.1365-2133.2005.07081.x; Metenou S, 2009, J IMMUNOL, V183, P916, DOI 10.4049/jimmunol.0900257; MEYER CG, 1994, P NATL ACAD SCI USA, V91, P7515, DOI 10.1073/pnas.91.16.7515; Michael E, 2007, ADV PARASIT, V65, P191, DOI 10.1016/S0065-308X(07)65003-9; Mladonicky JM, 2009, AM J TROP MED HYG, V80, P769, DOI 10.4269/ajtmh.2009.80.769; Molyneux DH, 2009, T ROY SOC TROP MED H, V103, P338, DOI 10.1016/j.trstmh.2008.12.016; Murdoch ME, 2002, ANN TROP MED PARASIT, V96, P283, DOI 10.1179/000349802125000826; Murdoch ME, 1997, HUM IMMUNOL, V55, P46, DOI 10.1016/S0198-8859(97)00089-X; Noroes J, 2003, T ROY SOC TROP MED H, V97, P561, DOI 10.1016/S0035-9203(03)80029-9; Osei-Atweneboano MY, 2007, LANCET, V369, P2021, DOI 10.1016/S0140-6736(07)60942-8; Ottesen EA, 2006, ADV PARASIT, V61, P395, DOI 10.1016/S0065-308X(05)61010-X; Ottesen EA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000317; Ozoh G, 2007, TROP MED INT HEALTH, V12, P123, DOI 10.1111/j.1365-3156.2006.01750.x; Pfarr KM, 2009, PARASITE IMMUNOL, V31, P664, DOI 10.1111/j.1365-3024.2009.01133.x; Ramaiah KD, 2009, TRENDS PARASITOL, V25, P7, DOI 10.1016/j.pt.2008.10.001; Ramaiah KD, 2001, TROP MED INT HEALTH, V6, P1062, DOI 10.1046/j.1365-3156.2001.00813.x; Ramzy RMR, 2006, LANCET, V367, P992, DOI 10.1016/S0140-6736(06)68426-2; Ramzy RMR, 2002, AM J TROP MED HYG, V67, P196, DOI 10.4269/ajtmh.2002.67.196; Ravindran B, 2003, TRENDS PARASITOL, V19, P105, DOI 10.1016/S1471-4922(03)00004-7; Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732; Satapathy AK, 2006, MICROBES INFECT, V8, P2414, DOI 10.1016/j.micinf.2006.05.003; Shenoy RK, 2008, KOREAN J PARASITOL, V46, P119, DOI 10.3347/kjp.2008.46.3.119; Specht S, 2009, PARASITOL RES, V106, P23, DOI 10.1007/s00436-009-1624-5; Stolk WA, 2004, PARASITOLOGY, V129, P605, DOI 10.1017/S0031182004005980; Stolk Wilma A, 2006, Filaria J, V5, P5, DOI 10.1186/1475-2883-5-5; Supali T, 2008, CLIN INFECT DIS, V46, P1385, DOI 10.1086/586753; Taylor MJ, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-7; Taylor MJ, 2005, ADV PARASIT, V60, P245, DOI 10.1016/S0065-308X(05)60004-8; Taylor MJ, 2005, LANCET, V365, P2116, DOI 10.1016/S0140-6736(05)66591-9; Thylefors B, 2008, ANN TROP MED PARASIT, V102, P39, DOI 10.1179/136485908X337481; Timmann C, 2008, J INFECT DIS, V198, P427, DOI 10.1086/589720; Tisch DJ, 2005, LANCET INFECT DIS, V5, P514, DOI 10.1016/S1473-3099(05)70192-4; Townson S, 2007, EXPERT OPIN DRUG DIS, V2, pS63, DOI 10.1517/17460441.2.S1.S63; Turner JD, 2006, CLIN INFECT DIS, V42, P1081, DOI 10.1086/501351; Turner JD, 2006, J IMMUNOL, V177, P1240, DOI 10.4049/jimmunol.177.2.1240; Turner JD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000660; Turner JD, 2009, J BIOL CHEM, V284, P22364, DOI 10.1074/jbc.M901528200; Wanji S, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-39; Weil GJ, 2007, TRENDS PARASITOL, V23, P78, DOI 10.1016/j.pt.2006.12.001; Weil GJ, 2000, J INFECT DIS, V182, P1796, DOI 10.1086/317629; Witt C, 2001, TROP MED INT HEALTH, V6, P582, DOI 10.1046/j.1365-3156.2001.00765.x; Wolstenholme AJ, 2005, PARASITOLOGY, V131, pS85, DOI 10.1017/S0031182005008218; 2009, WKLY EPIDEMIOL REC, V84, P385; STUDY COMP MOXIDECTI; STUDY EVALUATING ORA	123	416	421	0	165	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	2010	376	9747					1175	1185		10.1016/S0140-6736(10)60586-7	http://dx.doi.org/10.1016/S0140-6736(10)60586-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20739055				2022-12-28	WOS:000282915700034
J	Ohta, S; Bukowski-Wills, JC; Sanchez-Pulido, L; Alves, FD; Wood, L; Chen, ZA; Platani, M; Fischer, L; Hudson, DF; Ponting, CP; Fukagawa, T; Earnshaw, WC; Rappsilber, J				Ohta, Shinya; Bukowski-Wills, Jimi-Carlo; Sanchez-Pulido, Luis; Alves, Flavia de Lima; Wood, Laura; Chen, Zhuo A.; Platani, Melpi; Fischer, Lutz; Hudson, Damien F.; Ponting, Chris P.; Fukagawa, Tatsuo; Earnshaw, William C.; Rappsilber, Juri			The Protein Composition of Mitotic Chromosomes Determined Using Multiclassifier Combinatorial Proteomics	CELL			English	Article							QUANTITATIVE PROTEOMICS; CENP-A; REVEALS; COMPLEX; IDENTIFICATION	Despite many decades of study, mitotic chromosome structure and composition remain poorly characterized. Here, we have integrated quantitative proteomics with bioinformatic analysis to generate a series of independent classifiers that describe the similar to 4,000 proteins identified in isolated mitotic chromosomes. Integrating these classifiers by machine learning uncovers functional relationships between protein complexes in the context of intact chromosomes and reveals which of the similar to 560 uncharacterized proteins identified here merits further study. Indeed, of 34 GFP-tagged predicted chromosomal proteins, 30 were chromosomal, including 13 with centromere-association. Of 16 GFP-tagged predicted nonchromosomal proteins, 14 were confirmed to be nonchromosomal. An unbiased analysis of the whole chromosome proteome from genetic knockouts of kinetochore protein Ska3/Rama1 revealed that the APC/C and RanBP2/RanGAP1 complexes depend on the Ska complex for stable association with chromosomes. Our integrated analysis predicts that up to 97 new centromere-associated proteins remain to be discovered in our data set.	[Ohta, Shinya; Bukowski-Wills, Jimi-Carlo; Alves, Flavia de Lima; Wood, Laura; Chen, Zhuo A.; Platani, Melpi; Fischer, Lutz; Hudson, Damien F.; Earnshaw, William C.; Rappsilber, Juri] Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Sch Biol Sci, Edinburgh EH9 3JR, Midlothian, Scotland; [Bukowski-Wills, Jimi-Carlo] Univ Edinburgh, Ctr Syst Biol Edinburgh, Sch Biol Sci, Edinburgh EH9 3JR, Midlothian, Scotland; [Fukagawa, Tatsuo] Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan; [Fukagawa, Tatsuo] Grad Univ Adv Studies, Mishima, Shizuoka 4118540, Japan; [Sanchez-Pulido, Luis; Ponting, Chris P.] Univ Oxford, Dept Physiol Anat & Genet, MRC Funct Genom Unit, Oxford OX1 3QX, England	University of Edinburgh; University of Edinburgh; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; University of Oxford	Earnshaw, WC (corresponding author), Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Sch Biol Sci, Edinburgh EH9 3JR, Midlothian, Scotland.	bill.earnshaw@ed.ac.uk; juri.rappsilber@ed.ac.uk	Rappsilber, Juri/B-7265-2015; Rappsilber, Juri/ABF-3328-2020; Earnshaw, William/AAY-7438-2020; Fukagawa, Tatsuo/AAK-3922-2021; Ponting, Chris/AAV-2621-2021	Rappsilber, Juri/0000-0001-5999-1310; Ponting, Chris/0000-0003-0202-7816; Earnshaw, William/0000-0002-7191-0621; Fischer, Lutz/0000-0003-4978-0864; Ohta, Shinya/0000-0003-2424-1741; Sanchez Pulido, Luis/0000-0002-2300-8502; Wills, Jimi/0000-0003-1669-007X; CHEN, ZHUO/0000-0003-0811-8348; Platani, Melpomeni/0000-0001-6408-4774	European Community; MRC; EMBO; Wellcome Trust; Biotechnology and Biological Sciences Research Council [BB/D019621/1] Funding Source: researchfish; Medical Research Council [MC_U137761446] Funding Source: researchfish; BBSRC [BB/D019621/1] Funding Source: UKRI; MRC [MC_U137761446] Funding Source: UKRI	European Community(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EMBO(European Molecular Biology Organization (EMBO)); Wellcome Trust(Wellcome TrustEuropean Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We dedicate this paper to Uli Laemmli on the occasion of his 70th birthday. We thank Mayumi Takahashi for assistance with preparation of the Ska3/Rama1 knockout, Frauke Melchior for anti-RanBP2 and David Tollervey, Margarete Heck, Robin Allshire, Iain Cheeseman, Kumiko Samejima, Susana Ribeiro and Jan Bergmann for critical reading of the manuscript. This work was supported by a European Community Marie Curie Excellence Grant (JR), the MRC (CPP), EMBO (LSP) and the Wellcome Trust (WCE, JR). WCE and JR are Principal and Senior Research Fellows of The Wellcome Trust, respectively.	ALTAF M, 2010, J BIOL CHEM IN PRESS; Amano M, 2009, J CELL BIOL, V186, P173, DOI 10.1083/jcb.200903100; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Andrade MA, 2000, J MOL BIOL, V298, P521, DOI 10.1006/jmbi.2000.3684; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Daum JR, 2009, CURR BIOL, V19, P1467, DOI 10.1016/j.cub.2009.07.017; de Godoy LMF, 2008, NATURE, V455, P1251, DOI 10.1038/nature07341; Dejardin J, 2009, CELL, V136, P175, DOI 10.1016/j.cell.2008.11.045; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Finn RD, 2010, NUCLEIC ACIDS RES, V38, pD211, DOI 10.1093/nar/gkp985; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gaitanos TN, 2009, EMBO J, V28, P1442, DOI 10.1038/emboj.2009.96; Gassmann R, 2005, CHROMOSOMA, V113, P385, DOI 10.1007/s00412-004-0326-0; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hori T, 2008, CELL, V135, P1039, DOI 10.1016/j.cell.2008.10.019; Hubner NC, 2010, J CELL BIOL, V189, P739, DOI 10.1083/jcb.200911091; Hudson DF, 2003, DEV CELL, V5, P323, DOI 10.1016/S1534-5807(03)00199-0; Hutchins JRA, 2010, SCIENCE, V328, P593, DOI 10.1126/science.1181348; Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200; Ishihama Y, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-102; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kops GJPL, 2010, J CELL SCI, V123, P1623, DOI 10.1242/jcs.061549; Kulukian A, 2009, DEV CELL, V16, P105, DOI 10.1016/j.devcel.2008.11.005; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; Li XZ, 2009, MOL CELL, V36, P290, DOI 10.1016/j.molcel.2009.07.031; Maiato H, 2002, J CELL BIOL, V157, P749, DOI 10.1083/jcb.200201101; Marin I, 2003, J MOL EVOL, V56, P527, DOI 10.1007/s00239-002-2422-1; Morrison C, 2002, NUCLEIC ACIDS RES, V30, P5318, DOI 10.1093/nar/gkf665; Neumann B, 2010, NATURE, V464, P721, DOI 10.1038/nature08869; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Okada M, 2006, NAT CELL BIOL, V8, P446, DOI 10.1038/ncb1396; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Porter IM, 2007, J CELL BIOL, V179, P187, DOI 10.1083/jcb.200704098; Raaijmakers JA, 2009, J CELL SCI, V122, P2436, DOI 10.1242/jcs.051912; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Takata H, 2007, GENES CELLS, V12, P269, DOI 10.1111/j.1365-2443.2007.01051.x; Theis M, 2009, EMBO J, V28, P1453, DOI 10.1038/emboj.2009.114; Tkaczuk KL, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-73; Uchiyama S, 2005, J BIOL CHEM, V280, P16994, DOI 10.1074/jbc.M412774200; Van Hooser AA, 2005, CHROMOSOMA, V114, P377, DOI 10.1007/s00412-005-0021-9; Welburn JPI, 2009, DEV CELL, V16, P374, DOI 10.1016/j.devcel.2009.01.011; Wen H, 2010, J BIOL CHEM, V285, P9322, DOI 10.1074/jbc.C109.097667; Wu WH, 2005, NAT STRUCT MOL BIOL, V12, P1064, DOI 10.1038/nsmb1023	50	213	234	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					810	821		10.1016/j.cell.2010.07.047	http://dx.doi.org/10.1016/j.cell.2010.07.047			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813266	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000281523200023
J	Altshuler, DM; Gibbs, RA; Peltonen, L; Dermitzakis, E; Schaffner, SF; Yu, FL; Bonnen, PE; de Bakker, PIW; Deloukas, P; Gabriel, SB; Gwilliam, R; Hunt, S; Inouye, M; Jia, XM; Palotie, A; Parkin, M; Whittaker, P; Chang, K; Hawes, A; Lewis, LR; Ren, YR; Wheeler, D; Muzny, DM; Barnes, C; Darvishi, K; Hurles, M; Korn, JM; Kristiansson, K; Lee, C; McCarroll, SA; Nemesh, J; Keinan, A; Montgomery, SB; Pollack, S; Price, AL; Soranzo, N; Gonzaga-Jauregui, C; Anttila, V; Brodeur, W; Daly, MJ; Leslie, S; McVean, G; Moutsianas, L; Nguyen, H; Zhang, QR; Ghori, MJR; McGinnis, R; McLaren, W; Takeuchi, F; Grossman, SR; Shlyakhter, I; Hostetter, EB; Sabeti, PC; Adebamowo, CA; Foster, MW; Gordon, DR; Licinio, J; Manca, MC; Marshall, PA; Matsuda, I; Ngare, D; Wang, VO; Reddy, D; Rotimi, CN; Royal, CD; Sharp, RR; Zeng, CQ; Brooks, LD; McEwen, JE				Altshuler, David M.; Gibbs, Richard A.; Peltonen, Leena; Dermitzakis, Emmanouil; Schaffner, Stephen F.; Yu, Fuli; Bonnen, Penelope E.; de Bakker, Paul I. W.; Deloukas, Panos; Gabriel, Stacey B.; Gwilliam, Rhian; Hunt, Sarah; Inouye, Michael; Jia, Xiaoming; Palotie, Aarno; Parkin, Melissa; Whittaker, Pamela; Chang, Kyle; Hawes, Alicia; Lewis, Lora R.; Ren, Yanru; Wheeler, David; Muzny, Donna Marie; Barnes, Chris; Darvishi, Katayoon; Hurles, Matthew; Korn, Joshua M.; Kristiansson, Kati; Lee, Charles; McCarroll, Steven A.; Nemesh, James; Keinan, Alon; Montgomery, Stephen B.; Pollack, Samuela; Price, Alkes L.; Soranzo, Nicole; Gonzaga-Jauregui, Claudia; Anttila, Verneri; Brodeur, Wendy; Daly, Mark J.; Leslie, Stephen; McVean, Gil; Moutsianas, Loukas; Nguyen, Huy; Zhang, Qingrun; Ghori, Mohammed J. R.; McGinnis, Ralph; McLaren, William; Takeuchi, Fumihiko; Grossman, Sharon R.; Shlyakhter, Ilya; Hostetter, Elizabeth B.; Sabeti, Pardis C.; Adebamowo, Clement A.; Foster, Morris W.; Gordon, Deborah R.; Licinio, Julio; Manca, Maria Cristina; Marshall, Patricia A.; Matsuda, Ichiro; Ngare, Duncan; Wang, Vivian Ota; Reddy, Deepa; Rotimi, Charles N.; Royal, Charmaine D.; Sharp, Richard R.; Zeng, Changqing; Brooks, Lisa D.; McEwen, Jean E.		Int HapMap 3 Consortium	Integrating common and rare genetic variation in diverse human populations	NATURE			English	Article							GENOME-WIDE ASSOCIATION; COPY NUMBER VARIATION; POSITIVE SELECTION; HAPLOTYPE MAP; VARIANTS; DISEASES; SIGNALS; REGIONS; SNPS	Despite great progress in identifying genetic variants that influence human disease, most inherited risk remains unexplained. A more complete understanding requires genome-wide studies that fully examine less common alleles in populations with a wide range of ancestry. To inform the design and interpretation of such studies, we genotyped 1.6 million common single nucleotide polymorphisms (SNPs) in 1,184 reference individuals from 11 global populations, and sequenced ten 100-kilobase regions in 692 of these individuals. This integrated data set of common and rare alleles, called 'HapMap 3', includes both SNPs and copy number polymorphisms (CNPs). We characterized population-specific differences among low-frequency variants, measured the improvement in imputation accuracy afforded by the larger reference panel, especially in imputing SNPs with a minor allele frequency of <= 5%, and demonstrated the feasibility of imputing newly discovered CNPs and SNPs. This expanded public resource of genome variants in global populations supports deeper interrogation of genomic variation and its role in human disease, and serves as a step towards a high-resolution map of the landscape of human genetic variation.	[Altshuler, David M.; Schaffner, Stephen F.; de Bakker, Paul I. W.; Gabriel, Stacey B.; Jia, Xiaoming; Parkin, Melissa; Korn, Joshua M.; McCarroll, Steven A.; Pollack, Samuela; Brodeur, Wendy; Nguyen, Huy; Shlyakhter, Ilya] Broad Inst, Cambridge, MA 02138 USA; [Gibbs, Richard A.; Yu, Fuli; Bonnen, Penelope E.; Chang, Kyle; Hawes, Alicia; Lewis, Lora R.; Ren, Yanru; Wheeler, David; Muzny, Donna Marie; Gonzaga-Jauregui, Claudia] Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA; [Dermitzakis, Emmanouil; Montgomery, Stephen B.] Univ Geneva, Sch Med, Dept Genet Med & Dev, Fac Med, CH-1211 Geneva, Switzerland; [de Bakker, Paul I. W.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Genet, Boston, MA 02115 USA; [Deloukas, Panos; Gwilliam, Rhian; Hunt, Sarah; Inouye, Michael; Palotie, Aarno; Whittaker, Pamela; Barnes, Chris; Hurles, Matthew; Kristiansson, Kati; Soranzo, Nicole; Anttila, Verneri; Zhang, Qingrun; Ghori, Mohammed J. R.; McGinnis, Ralph; McLaren, William; Takeuchi, Fumihiko] Wellcome Trust Sanger Inst, Dept Human Genet, Cambridge CB10 1HH, England; [Palotie, Aarno; Anttila, Verneri] Univ Helsinki, Inst Mol Med Finland, FIN-00290 Helsinki, Finland; [Palotie, Aarno; Anttila, Verneri] Univ Helsinki, Dept Med Genet, FIN-00290 Helsinki, Finland; [Palotie, Aarno; Anttila, Verneri] Univ Cent Hosp, Helsinki 00290, Finland; [Darvishi, Katayoon; Lee, Charles] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Keinan, Alon] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA; [Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Simches Res Ctr, Boston, MA 02114 USA; [Leslie, Stephen; McVean, Gil; Moutsianas, Loukas] Univ Oxford, Dept Stat, Oxford OX1 3TG, England; [Grossman, Sharon R.; Hostetter, Elizabeth B.; Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Ctr Syst Biol, Cambridge, MA 02215 USA; [Adebamowo, Clement A.] Univ Maryland, Sch Med, Dept Epidemiol & Preventat Med, Inst Human Virol N406, Baltimore, MD 21201 USA; [Foster, Morris W.] Univ Oklahoma, Dept Anthropol, Norman, OK 73019 USA; [Gordon, Deborah R.] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA; [Licinio, Julio] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2603, Australia; [Manca, Maria Cristina] Inst Oncol Study & Prevent, I-50139 Florence, Italy; [Marshall, Patricia A.] Case Western Reserve Univ, Dept Bioeth, Sch Med TA200, Cleveland, OH 44106 USA; [Matsuda, Ichiro] Hlth Sci Univ Hokkaido, Tobetsu, Hokkaido 0610293, Japan; [Ngare, Duncan] Moi Univ, Dept Populat & Family Hlth, Eldoret 30100, Kenya; [Wang, Vivian Ota; Brooks, Lisa D.; McEwen, Jean E.] NHGRI, NIH, Bethesda, MD 20892 USA; [Reddy, Deepa] Univ Houston Clear Lake City, Dept Anthropol, Houston, TX 77058 USA; [Rotimi, Charles N.] NHGRI, Ctr Res Genom & Global Hlth, Bethesda, MD 20892 USA; [Royal, Charmaine D.] Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA; [Sharp, Richard R.] Cleveland Clin, Dept Bioeth, Cleveland, OH 44124 USA; [Zeng, Changqing] Chinese Acad Sci, Beijing Inst Genom, Beijing 101300, Peoples R China	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Baylor College of Medicine; University of Geneva; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Wellcome Trust Sanger Institute; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; University of Oxford; Harvard University; University System of Maryland; University of Maryland Baltimore; University of Oklahoma System; University of Oklahoma - Norman; University of California System; University of California San Francisco; Australian National University; John Curtin School of Medical Research; Case Western Reserve University; Health Sciences University of Hokkaido; Moi University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Houston System; University of Houston; University of Houston Clear Lake; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Duke University; Cleveland Clinic Foundation; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS	Altshuler, DM (corresponding author), Broad Inst, 7 Cambridge Ctr, Cambridge, MA 02138 USA.	altshuler@molbio.mgh.harvard.edu; agibbs@bcm.edu	Dermitzakis, Emmanouil/B-7687-2013; Wheeler, David A/M-9740-2018; Altshuler, David M/A-4476-2009; Deloukas, Panos/B-2922-2013; Nguyen, Huy/GWQ-6433-2022; de Bakker, Paul IW/B-8730-2009; Schaffner, Stephen F/D-1189-2011; Licinio, Julio/L-4244-2013; Sabeti, Pardis/GQH-8610-2022; Daly, Mark J/B-2453-2017; Adebamowo, Clement/C-8778-2011; Nguyen, Huy/AAF-9560-2019; Gonzaga-Jauregui, Claudia/H-4752-2019	Wheeler, David A/0000-0002-9056-6299; Altshuler, David M/0000-0002-7250-4107; Deloukas, Panos/0000-0001-9251-070X; de Bakker, Paul IW/0000-0001-7735-7858; Licinio, Julio/0000-0001-6905-5884; Daly, Mark J/0000-0002-0949-8752; Adebamowo, Clement/0000-0002-6571-2880; Nguyen, Huy/0000-0002-5896-9661; Gonzaga-Jauregui, Claudia/0000-0002-4667-3679; Chang, Kyle/0000-0001-5295-9676; Schaffner, Stephen/0000-0001-6699-3568; Inouye, Michael/0000-0001-9413-6520; McLaren, William/0000-0001-6218-1116; Barnes, Chris/0000-0002-9459-1395; Montgomery, Stephen/0000-0002-5200-3903; Hunt, Sarah/0000-0002-8350-1235; Anttila, Verneri/0000-0002-0073-4675; Palotie, Aarno/0000-0002-2527-5874; McGinnis, Ralph/0000-0003-4540-9857; Jia, Xiaoming/0000-0002-5104-5431; Kristiansson, Kati/0000-0003-4688-107X; Keinan, Alon/0000-0002-9760-1122; Soranzo, Nicole/0000-0003-1095-3852	USA National Institutes of Health; National Human Genome Research Institute; National Institute on Deafness and Other Communication Disorders; Wellcome Trust [068545/Z/02, 076113]; Louis-Jeantet Foundation; NCCR 'Frontiers in Genetics' (Swiss National Science Foundation); UK Medical Research Council [G0000934]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER; Medical Research Council [G0000934] Funding Source: researchfish; MRC [G0000934] Funding Source: UKRI	USA National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institute on Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Wellcome Trust(Wellcome TrustEuropean Commission); Louis-Jeantet Foundation; NCCR 'Frontiers in Genetics' (Swiss National Science Foundation)(Swiss National Science Foundation (SNSF)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We dedicate this work to Leena Peltonen for her vital leadership role in this study, and in memory of a valued friend and colleague. We thank E. Boerwinkle and R. Durbin for critical reading of the manuscript. We thank the USA National Institutes of Health, the National Human Genome Research Institute, the National Institute on Deafness and Other Communication Disorders and the Wellcome Trust for supporting the majority of this work. Funding was also provided by the Louis-Jeantet Foundation and the NCCR 'Frontiers in Genetics' (Swiss National Science Foundation). We thank the people from the following communities who were generous in donating their blood samples to be studied in this project: the Yoruba in Ibadan, Nigeria; the Maasai in Kinyawa, Kenya; the Luhya in Webuye, Kenya; the Han Chinese in Beijing, China; the Japanese in Tokyo, Japan; the Chinese in metropolitan Denver, Colorado; the Gujarati Indians in Houston, Texas; the Toscani in Italia; the community of African ancestry in the southwestern USA; and the community of Mexican ancestry in Los Angeles, California. We also thank the people in the Utah Centre d'Etude du Polymorphisme Humain community who allowed the samples they donated earlier to be used for the project. The authors acknowledge use of DNA from the 1958 British birth cohort collection, funded by the UK Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. The Illumina 550K genotype data for the 1958 British birth cohort samples were made available by the Sanger Institute. For the 1958 British birth cohort Affymetrix 500K genotype data, we thank the Wellcome Trust Case Control Consortium (http://www.wtccc.org.uk), which was funded by Wellcome Trust award 076113.	Akey JM, 2009, GENOME RES, V19, P711, DOI 10.1101/gr.086652.108; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Barnes C, 2008, NAT GENET, V40, P1245, DOI 10.1038/ng.206; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Campbell MC, 2008, ANNU REV GENOM HUM G, V9, P403, DOI 10.1146/annurev.genom.9.081307.164258; Carlson CS, 2005, GENOME RES, V15, P1553, DOI 10.1101/gr.4326505; Colella S, 2007, NUCLEIC ACIDS RES, V35, P2013, DOI 10.1093/nar/gkm076; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; Donnelly P, 2008, NATURE, V456, P728, DOI 10.1038/nature07631; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Grossman SR, 2010, SCIENCE, V327, P883, DOI 10.1126/science.1183863; Gu JJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005767; Keinan A, 2007, NAT GENET, V39, P1251, DOI 10.1038/ng2116; Korn JM, 2008, NAT GENET, V40, P1253, DOI 10.1038/ng.237; Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li Y, 2006, AM J HUM GENET S, VS79, P2290; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238; Pe'er I, 2006, AM J HUM GENET, V78, P588, DOI 10.1086/502803; Pickrell JK, 2009, GENOME RES, V19, P826, DOI 10.1101/gr.087577.108; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Teo YY, 2007, BIOINFORMATICS, V23, P2741, DOI 10.1093/bioinformatics/btm443; van Heel DA, 2007, NAT GENET, V39, P827, DOI 10.1038/ng2058; Zhang JH, 2005, PLOS COMPUT BIOL, V1, P395, DOI 10.1371/journal.pcbi.0010053	27	1883	1912	3	189	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					52	58		10.1038/nature09298	http://dx.doi.org/10.1038/nature09298			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811451	Green Accepted			2022-12-28	WOS:000281461200033
J	Raddick, MJ; Szalay, AS				Raddick, M. Jordan; Szalay, Alexander S.			The Universe Online	SCIENCE			English	Editorial Material							DIGITAL-SKY-SURVEY; GALAXY ZOO		[Raddick, M. Jordan; Szalay, Alexander S.] Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University	Raddick, MJ (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA.	raddick@jhu.edu						American Association for the Advancement of Science, 1993, BENCHM SCI LIT PROJ; Bamford SP, 2009, MON NOT R ASTRON SOC, V393, P1324, DOI 10.1111/j.1365-2966.2008.14252.x; Belokurov V, 2006, ASTROPHYS J, V642, pL137, DOI 10.1086/504797; Bransford JD., 2000, PEOPLE LEARN; Cardamone C, 2009, MON NOT R ASTRON SOC, V399, P1191, DOI 10.1111/j.1365-2966.2009.15383.x; Gray J, 2005, SIGMOD RECORD, V34, P34, DOI 10.1145/1107499.1107503; Ivezic Z, 2001, ASTRON J, V122, P2749, DOI 10.1086/323452; LEMONICK M, 2009, DISCOVER; Lintott CJ, 2008, MON NOT R ASTRON SOC, V389, P1179, DOI 10.1111/j.1365-2966.2008.13689.x; Lintott CJ, 2009, MON NOT R ASTRON SOC, V399, P129, DOI 10.1111/j.1365-2966.2009.15299.x; Michaels S., 2008, READY SET SCI PUTTIN; Nieto-Santisteban MA, 2004, ASTR SOC P, V314, P666; Slosar A, 2009, MON NOT R ASTRON SOC, V392, P1225, DOI 10.1111/j.1365-2966.2008.14127.x; Sparks R, 2004, ASTR SOC P, V319, P394; York DG, 2000, ASTRON J, V120, P1579, DOI 10.1086/301513	16	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1028	1029		10.1126/science.1186936	http://dx.doi.org/10.1126/science.1186936			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798309				2022-12-28	WOS:000281253500027
J	Kerr, DJ; Midgley, R				Kerr, David J.; Midgley, Rachel			Can We Treat Cancer for a Dollar a Day? Guidelines for Low-Income Countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kerr, David J.] Sidra Med & Res Ctr, Doha, Qatar; [Midgley, Rachel] Univ Oxford, Dept Clin Pharmacol, Oxford, England	Sidra Medical & Research Center; University of Oxford	Kerr, DJ (corresponding author), Sidra Med & Res Ctr, Doha, Qatar.			Kerr, Rachel/0000-0002-7240-3269				CanTreat Int, 2010, ANN ONCOL, V21, P680, DOI 10.1093/annonc/mdq055; Groot MT, 2006, BREAST J, V12, pS81, DOI 10.1111/j.1075-122X.2006.00206.x; Kerr F, 2006, ANN ONCOL, V17, P1730, DOI 10.1093/annonc/mdl442; Lingwood RJ, 2008, NAT REV CANCER, V8, P398, DOI 10.1038/nrc2372; Tan-Torres ET, 2003, MAKING CHOICES HLTH	5	43	44	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					801	803		10.1056/NEJMp1002812	http://dx.doi.org/10.1056/NEJMp1002812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642HG	20818843				2022-12-28	WOS:000281196600001
J	Kindig, D; Mullahy, J				Kindig, David; Mullahy, John			Comparative Effectiveness-of What? Evaluating Strategies to Improve Population Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kindig, David; Mullahy, John] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53726 USA; [Mullahy, John] Natl Bur Econ Res, Cambridge, MA 02138 USA	University of Wisconsin System; University of Wisconsin Madison; National Bureau of Economic Research	Kindig, D (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, 610 Walnut Room,760 WARF, Madison, WI 53726 USA.	dakindig@wisc.edu						CONWAY PH, 2009, COMP EFFECTIVENESS R; Federal Coordinating Council for Comparative Effectiveness Research, COMP EFF RES FUND; Fuchs V., 1974, WHO SHALL LIVE; KEHRER BH, 1979, J HUM RESOUR, V14, P434, DOI 10.2307/145316; Mullahy J, 2010, PREV CHRONIC DIS, V7; STODDART G, 1995, 46 CAN I ADV RES; Stringhini S, 2010, JAMA-J AM MED ASSOC, V303, P1159, DOI 10.1001/jama.2010.297; Vlopp KG, 2009, NEW ENGL J MED, V361, P331, DOI 10.1056/NEJMp0903496	8	17	17	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					901	902		10.1001/jama.2010.1215	http://dx.doi.org/10.1001/jama.2010.1215			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736476				2022-12-28	WOS:000281389900030
J	Li, NX; Lee, B; Liu, RJ; Banasr, M; Dwyer, JM; Iwata, M; Li, XY; Aghajanian, G; Duman, RS				Li, Nanxin; Lee, Boyoung; Liu, Rong-Jian; Banasr, Mounira; Dwyer, Jason M.; Iwata, Masaaki; Li, Xiao-Yuan; Aghajanian, George; Duman, Ronald S.			mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists	SCIENCE			English	Article							MAJOR DEPRESSIVE DISORDER; D-ASPARTATE ANTAGONIST; KETAMINE; DISEASE	The rapid antidepressant response after ketamine administration in treatment-resistant depressed patients suggests a possible new approach for treating mood disorders compared to the weeks or months required for standard medications. However, the mechanisms underlying this action of ketamine [a glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonist] have not been identified. We observed that ketamine rapidly activated the mammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the prefrontal cortex of rats. Moreover, blockade of mTOR signaling completely blocked ketamine induction of synaptogenesis and behavioral responses in models of depression. Our results demonstrate that these effects of ketamine are opposite to the synaptic deficits that result from exposure to stress and could contribute to the fast antidepressant actions of ketamine.	[Duman, Ronald S.] Yale Univ, Sch Med, Dept Psychiat, Lab Mol Psychiat,Ctr Genes & Behav, New Haven, CT 06508 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06508 USA	Yale University; Yale University	Duman, RS (corresponding author), Yale Univ, Sch Med, Dept Psychiat, Lab Mol Psychiat,Ctr Genes & Behav, 34 Pk St, New Haven, CT 06508 USA.	ronald.duman@yale.edu	Lee, Boyoung/AAV-8719-2021; Iwata, Masaaki/AAP-3732-2020; Li, Nanxin/D-9755-2011	Lee, Boyoung/0000-0001-9445-510X; Iwata, Masaaki/0000-0002-6143-0181; 	U.S. Public Health Service [MH45481, 2P01 MH25642]; Connecticut Mental Health Center; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH045481, P01MH025642, R37MH045481, R01MH045481] Funding Source: NIH RePORTER	U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Connecticut Mental Health Center; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work is supported by U.S. Public Health Service grants MH45481 and 2P01 MH25642 and by the Connecticut Mental Health Center.	Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9; Drevets WC, 1998, ANNU REV MED, V49, P341, DOI 10.1146/annurev.med.49.1.341; Farber NB, 1998, PROG BRAIN RES, V116, P421, DOI 10.1016/S0079-6123(08)60453-7; Hoeffer CA, 2010, TRENDS NEUROSCI, V33, P67, DOI 10.1016/j.tins.2009.11.003; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Krystal JH, 2007, SWISS MED WKLY, V137, P215; Lambe EK, 2007, NEUROSCIENCE, V145, P900, DOI 10.1016/j.neuroscience.2006.12.048; Liu RJ, 2008, P NATL ACAD SCI USA, V105, P359, DOI 10.1073/pnas.0706679105; Maeng S, 2008, BIOL PSYCHIAT, V63, P349, DOI 10.1016/j.biopsych.2007.05.028; Preskorn SH, 2008, J CLIN PSYCHOPHARM, V28, P631, DOI 10.1097/JCP.0b013e31818a6cea; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Yoshihara Y, 2009, CURR OPIN NEUROBIOL, V19, P146, DOI 10.1016/j.conb.2009.05.013; Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856	14	1877	1972	12	380	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					959	964		10.1126/science.1190287	http://dx.doi.org/10.1126/science.1190287			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724638	Green Accepted			2022-12-28	WOS:000281084800039
J	Wang, K; Harnden, A; Thomson, A				Wang, Kay; Harnden, Anthony; Thomson, Anne			Easily Missed? Foreign body inhalation in children	BRITISH MEDICAL JOURNAL			English	Editorial Material							CHEST RADIOGRAPHY; BODIES; ASPIRATION; DIAGNOSIS; BRONCHOSCOPY		[Thomson, Anne] John Radcliffe Hosp, Oxford OX3 9DU, England; [Wang, Kay; Harnden, Anthony] Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford; University of Oxford	Thomson, A (corresponding author), John Radcliffe Hosp, Oxford OX3 9DU, England.	anne.thomson@orh.nhs.uk			Department of Health [DRF-2009-02-145] Funding Source: Medline; National Institute for Health Research [DRF-2009-02-145] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		ABDULMAJID O, 1976, THORAX, V31, P635, DOI 10.1136/thx.31.6.635; Chiu CY, 2005, PEDIATR EMERG CARE, V21, P161; Cohen S, 2009, J PEDIATR-US, V155, P276, DOI 10.1016/j.jpeds.2009.02.040; DAVIES H, 1990, ARCH DIS CHILD, V65, P619, DOI 10.1136/adc.65.6.619; ESCLAMADO RM, 1987, AM J DIS CHILD, V141, P259, DOI 10.1001/archpedi.1987.04460030037019; *HOSP EP STAT, 2008, EXT CAUS; Karakoc F, 2007, INT J PEDIATR OTORHI, V71, P241, DOI 10.1016/j.ijporl.2006.10.006; Kiyan G, 2009, INT J PEDIATR OTORHI, V73, P963, DOI 10.1016/j.ijporl.2009.03.021; MANTOR PC, 1989, AM J SURG, V158, P622, DOI 10.1016/0002-9610(89)90208-0; Righini CA, 2007, INT J PEDIATR OTORHI, V71, P1383, DOI 10.1016/j.ijporl.2007.05.012; Saki N, 2009, INT J MED SCI, V6, P322, DOI 10.7150/ijms.6.322; Sersar SI, 2006, OTOLARYNG HEAD NECK, V134, P92, DOI 10.1016/j.otohns.2005.08.019; SVEDSTROM E, 1989, PEDIATR RADIOL, V19, P520, DOI 10.1007/BF02389562; Tan HKK, 2000, INT J PEDIATR OTORHI, V56, P91, DOI 10.1016/S0165-5876(00)00391-8	14	9	9	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 18	2010	341								c3924	10.1136/bmj.c3924	http://dx.doi.org/10.1136/bmj.c3924			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KT	20719826	Green Submitted			2022-12-28	WOS:000281213100013
J	Kachalia, A; Kaufman, SR; Boothman, R; Anderson, S; Welch, K; Saint, S; Rogers, MAM				Kachalia, Allen; Kaufman, Samuel R.; Boothman, Richard; Anderson, Susan; Welch, Kathleen; Saint, Sanjay; Rogers, Mary A. M.			Liability Claims and Costs Before and After Implementation of a Medical Error Disclosure Program	ANNALS OF INTERNAL MEDICINE			English	Article							PLAN MEMBERS VIEWS; PHYSICIANS ATTITUDES; RISK-MANAGEMENT; PATIENT SAFETY; SYSTEMS	Background: Since 2001, the University of Michigan Health System (UMHS) has fully disclosed and offered compensation to patients for medical errors. Objective: To compare liability claims and costs before and after implementation of the UMHS disclosure-with-offer program. Design: Retrospective before-after analysis from 1995 to 2007. Setting: Public academic medical center and health system. Patients: Inpatients and outpatients involved in claims made to UMHS. Measurements: Number of new claims for compensation, number of claims compensated, time to claim resolution, and claims-related costs. Results: After full implementation of a disclosure-with-offer program, the average monthly rate of new claims decreased from 7.03 to 4.52 per 100 000 patient encounters (rate ratio [RR], 0.64 [95% CI, 0.44 to 0.95]). The average monthly rate of lawsuits decreased from 2.13 to 0.75 per 100 000 patient encounters RR, 0.35 [CI, 0.22 to 0.58]). Median time from claim reporting to resolution decreased from 1.36 to 0.95 years. Average monthly cost rates decreased for total liability (RR, 0.41 [CI, 0.26 to 0.66]), patient compensation (RR, 0.41 [CI, 0.26 to 0.67]), and non-compensation-related legal costs (RR, 0.39 [CI, 0.22 to 0.67]). Limitations: The study design cannot establish causality. Malpractice claims generally declined in Michigan during the latter part of the study period. The findings might not apply to other health systems, given that UMHS has a closed staff model covered by a captive insurance company and often assumes legal responsibility. Conclusion: The UMHS implemented a program of full disclosure of medical errors with offers of compensation without increasing its total claims and liability costs.	[Kachalia, Allen] Brigham & Womens Hosp, Boston, MA 02115 USA; [Kaufman, Samuel R.] Blue Cross Blue Shield Michigan Cardiovasc Consor, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48105 USA; [Anderson, Susan] Univ Michigan Hlth Syst, Risk Management Dept, Ann Arbor, MI 48109 USA; [Welch, Kathleen] Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA; [Saint, Sanjay] Univ Michigan, Ann Arbor Vet Affairs Med Ctr, Div Gen Med, Dept Internal Med, Ann Arbor, MI 48109 USA	Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Kachalia, A (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	akachalia@partners.org	Saint, Sanjay/AAF-5126-2019	Rogers, Mary/0000-0001-5519-3223	Blue Cross Blue Shield of Michigan Foundation [1217.II]; Health Services Research & Development Service of the Department of Veterans Affairs; National Institutes of Health [R21-DK078717, R01-NR010700]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK078717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010700] Funding Source: NIH RePORTER	Blue Cross Blue Shield of Michigan Foundation; Health Services Research & Development Service of the Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Primary Funding Source: Blue Cross Blue Shield of Michigan Foundation.; Grant Support: By Blue Cross Blue Shield of Michigan Foundation (1217.II). In addition, Dr. Saint was supported by an Advanced Career Development Award from the Health Services Research & Development Service of the Department of Veterans Affairs during a portion of the time this study was conducted. Dr. Saint is currently supported by awards R21-DK078717 and R01-NR010700 from the National Institutes of Health.	Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; Boothman Richard C, 2009, J Health Life Sci Law, V2, P125; Butcher Lola, 2006, Physician Exec, V32, P20; Clinton HR, 2006, NEW ENGL J MED, V354, P2205, DOI 10.1056/NEJMp068100; Gallagher TH, 2003, JAMA-J AM MED ASSOC, V289, P1001, DOI 10.1001/jama.289.8.1001; Gallagher TH, 2007, NEW ENGL J MED, V356, P2713, DOI 10.1056/NEJMra070568; Gallagher TH, 2006, ARCH INTERN MED, V166, P1605, DOI 10.1001/archinte.166.15.1605; *JOINT COMM ACCR H, 2008, HOSP ACCR STAND; Kachalia Allen, 2003, Jt Comm J Qual Saf, V29, P503; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Lamb RM, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.2.73; Leape LL, 2002, NEW ENGL J MED, V347, P1633, DOI 10.1056/NEJMNEJMhpr011493; Levinson W, 2007, CAN MED ASSOC J, V177, P265, DOI 10.1503/cmaj.061413; Loren DJ, 2008, ARCH PEDIAT ADOL MED, V162, P922, DOI 10.1001/archpedi.162.10.922; Mazor KM, 2005, AM J MANAG CARE, V11, P49; Mazor KM, 2004, ANN INTERN MED, V140, P409, DOI 10.7326/0003-4819-140-6-200403160-00006; Mello MM, 2006, MILBANK Q, V84, P459, DOI 10.1111/j.1468-0009.2006.00455.x; National Quality Forum, 2009, SAF PRACT BETT HEALT; *OFF FIN INS REG, 2009, EV MICH MED PROF LIA; Peto RR, 2009, JT COMM J QUAL PATIE, V35, P487, DOI 10.1016/S1553-7250(09)35067-9; *PHYS INS ASS AM, 2009, CLAIMS TREND AN COMP; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; Studdert DM, 2007, HEALTH AFFAIR, V26, P215, DOI 10.1377/hlthaff.26.1.215; Studdert DM, 2006, NEW ENGL J MED, V354, P2024, DOI 10.1056/NEJMsa054479; Studdert DM, 2004, NEW ENGL J MED, V350, P283, DOI 10.1056/NEJMhpr035470; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7; Weissman JS, 2005, JAMA-J AM MED ASSOC, V293, P1359, DOI 10.1001/jama.293.11.1359; Witman AB, 1996, ARCH INTERN MED, V156, P2565, DOI 10.1001/archinte.156.22.2565; Wojcieszak D, 2006, JT COMM J QUAL PATIE, V32, P344, DOI 10.1016/S1553-7250(06)32044-2; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; Xu X, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.08.043	32	229	230	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4					213	221		10.7326/0003-4819-153-4-201008170-00002	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639KF	20713789				2022-12-28	WOS:000280973000001
J	Lee, WL; Slutsky, AS				Lee, Warren L.; Slutsky, Arthur S.			Sepsis and Endothelial Permeability	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lee, Warren L.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; Univ Toronto, Div Respirol, Toronto, ON, Canada; Univ Toronto, Div Crit Care Med, Toronto, ON, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto	Lee, WL (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, 30 Bond St, Toronto, ON M5B 1W8, Canada.		Slutsky, Arthur/M-3325-2019	Lee, Warren/0000-0002-1788-6587				Groger M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005391; London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Russell JA, 2006, NEW ENGL J MED, V355, P2267; Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393	5	336	367	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					689	691		10.1056/NEJMcibr1007320	http://dx.doi.org/10.1056/NEJMcibr1007320			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	636TN	20818861				2022-12-28	WOS:000280764600016
J	Wagner, JE; Ishida-Yamamoto, A; McGrath, JA; Hordinsky, M; Keene, DR; Riddle, MJ; Osborn, MJ; Lund, T; Dolan, M; Blazar, BR; Tolar, J				Wagner, John E.; Ishida-Yamamoto, Akemi; McGrath, John A.; Hordinsky, Maria; Keene, Douglas R.; Riddle, Megan J.; Osborn, Mark J.; Lund, Troy; Dolan, Michelle; Blazar, Bruce R.; Tolar, Jakub			Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DERMAL-EPIDERMAL JUNCTION; VII COLLAGEN; GENE-THERAPY; MUTATION ANALYSIS; SKIN TISSUE; INJECTION; FIBROBLASTS; PHENOTYPE; CORRECTS; DISEASE	BACKGROUND Recessive dystrophic epidermolysis bullosa is an incurable, often fatal mucocutaneous blistering disease caused by mutations in COL7A1, the gene encoding type VII collagen (C7). On the basis of preclinical data showing biochemical correction and prolonged survival in col7(-/-) mice, we hypothesized that allogeneic marrow contains stem cells capable of ameliorating the manifestations of recessive dystrophic epidermolysis bullosa in humans. METHODS Between October 2007 and August 2009, we treated seven children who had recessive dystrophic epidermolysis bullosa with immunomyeloablative chemotherapy and allogeneic stem-cell transplantation. We assessed C7 expression by means of immunofluorescence staining and used transmission electron microscopy to visualize anchoring fibrils. We measured chimerism by means of competitive polymerase-chain-reaction assay, and documented blister formation and wound healing with the use of digital photography. RESULTS One patient died of cardiomyopathy before transplantation. Of the remaining six patients, one had severe regimen-related cutaneous toxicity, with all having improved wound healing and a reduction in blister formation between 30 and 130 days after transplantation. We observed increased C7 deposition at the dermal-epidermal junction in five of the six recipients, albeit without normalization of anchoring fibrils. Five recipients were alive 130 to 799 days after transplantation; one died at 183 days as a consequence of graft rejection and infection. The six recipients had substantial proportions of donor cells in the skin, and none had detectable anti-C7 antibodies. CONCLUSIONS Increased C7 deposition and a sustained presence of donor cells were found in the skin of children with recessive dystrophic epidermolysis bullosa after allogeneic bone marrow transplantation. Further studies are needed to assess the long-term risks and benefits of such therapy in patients with this disorder. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT00478244.)	[Wagner, John E.] Univ Minnesota, Dept Pediat, Blood & Marrow Transplant Program, Div Pediat Hematol Oncol & Blood & Marrow Transpl, Minneapolis, MN 55455 USA; [Wagner, John E.; Blazar, Bruce R.; Tolar, Jakub] Univ Minnesota, Ctr Translat Med, Minneapolis, MN 55455 USA; [Hordinsky, Maria] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA; [Dolan, Michelle] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Ishida-Yamamoto, Akemi] Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 078, Japan; [McGrath, John A.] Kings Coll London, St Johns Inst Dermatol, London WC2R 2LS, England; [Keene, Douglas R.] Shriners Hosp Children, Microimaging Ctr, Portland, OR 97201 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Asahikawa Medical College; University of London; King's College London	Wagner, JE (corresponding author), Univ Minnesota, Dept Pediat, Blood & Marrow Transplant Program, Div Pediat Hematol Oncol & Blood & Marrow Transpl, Mayo Mail Code 366,420 Delaware St SE, Minneapolis, MN 55455 USA.	wagne002@umn.edu	McGrath, John/N-3529-2019; osborn, mark/ABD-4727-2020; McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964; Tolar, Jakub/0000-0002-0957-4380	National Institutes of Health [5R01-HL049997]; Ministry of Health, Labor, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan; University of Minnesota Academic Health Center; Epidermolysis Bullosa (Liao Family) Research Fund; Sarah Rose Mooreland EB Fund; Children's Cancer Research Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033625] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); University of Minnesota Academic Health Center; Epidermolysis Bullosa (Liao Family) Research Fund; Sarah Rose Mooreland EB Fund; Children's Cancer Research Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by grants from the National Institutes of Health (5R01-HL049997, to Dr. Blazar), from the Ministry of Health, Labor, and Welfare of Japan and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to Dr. Ishida-Yamamoto), and from the University of Minnesota Academic Health Center, the Epidermolysis Bullosa (Liao Family) Research Fund, the Sarah Rose Mooreland EB Fund, and the Children's Cancer Research Fund.	Abercrombie Elizabeth M, 2008, Br J Nurs, V17, ppassim; ABERCROMBIE EM, 2008, BR J NURS, V17, pS10; ABERCROMBIE EM, 2008, BR J NURS, V17, pS8; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; Brunstein CG, 2007, BLOOD, V110, P3064, DOI 10.1182/blood-2007-04-067215; Chen M, 2002, NAT GENET, V32, P670, DOI 10.1038/ng1041; Chen M, 1997, J INVEST DERMATOL, V108, P68, DOI 10.1111/1523-1747.ep12285634; Dang NN, 2008, EXP DERMATOL, V17, P553, DOI 10.1111/j.1600-0625.2008.00723.x; De Luca M, 2009, BRIT J DERMATOL, V161, P19, DOI 10.1111/j.1365-2133.2009.09243.x; Ferrari S, 2006, EXPERT OPIN BIOL TH, V6, P367, DOI 10.1517/14712598.6.4.367; Ferrari S, 2005, CLIN DERMATOL, V23, P430, DOI 10.1016/j.clindermatol.2004.07.017; Fine JD, 2009, LIFE EPIDERMOLYSIS B, P197; Fine JD, 2008, J AM ACAD DERMATOL, V58, P931, DOI 10.1016/j.jaad.2008.02.004; Fine JD, 2009, J AM ACAD DERMATOL, V60, P203, DOI 10.1016/j.jaad.2008.09.035; Fivenson DP, 2003, J AM ACAD DERMATOL, V48, P886, DOI 10.1067/mjd.2003.502; Fritsch A, 2008, J CLIN INVEST, V118, P1669, DOI 10.1172/JCI34292; Gache Y, 2004, HUM GENE THER, V15, P921, DOI 10.1089/hum.2004.15.921; Heinonen S, 1999, J CELL SCI, V112, P3641; Ly L, 2008, J Wound Care, V17, P484; LY L, 2008, J WOUND CARE, V482, P484; Ly L., 2008, J WOUND CARE, V17, P488; Mecklenbeck S, 2002, HUM GENE THER, V13, P1655, DOI 10.1089/10430340260201743; Mellerio JE, 2007, INT J DERMATOL, V46, P795, DOI 10.1111/j.1365-4632.2007.03316.x; Ortiz-Urda S, 2003, J CLIN INVEST, V111, P251, DOI 10.1172/JCI200317193; Ortiz-Urda S, 2003, NAT MED, V9, P237, DOI 10.1038/nm0203-237; PILLAY E, 2008, BR J NURS, V17, P413; Pillay Elizabeth, 2008, Br J Nurs, V17, P292; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; Remington J, 2009, MOL THER, V17, P26, DOI 10.1038/mt.2008.234; Shimizu H, 1996, J INVEST DERMATOL, V106, P119, DOI 10.1111/1523-1747.ep12329600; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P374, DOI 10.1111/1523-1747.ep12265460; TIDMAN MJ, 1984, J INVEST DERMATOL, V83, P448, DOI 10.1111/1523-1747.ep12273562; Tolar J, 2009, BLOOD, V113, P1167, DOI 10.1182/blood-2008-06-161299; Wessagowit V, 2005, J INVEST DERMATOL, V124, P863, DOI 10.1111/j.0022-202X.2005.23650.x; Wong T, 2008, J INVEST DERMATOL, V128, P2179, DOI 10.1038/jid.2008.78; Woodley DT, 2008, J BIOL CHEM, V283, P17838, DOI 10.1074/jbc.M709452200; Woodley DT, 2007, MOL THER, V15, P628, DOI 10.1038/sj.mt.6300041; Woodley DT, 2004, MOL THER, V10, P318, DOI 10.1016/j.ymthe.2004.05.016; Woodley DT, 2004, NAT MED, V10, P693, DOI 10.1038/nm1063; Woodley DT, 2003, J INVEST DERMATOL, V121, P1021, DOI 10.1046/j.1523-1747.2003.12571.x	40	234	249	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					629	639		10.1056/NEJMoa0910501	http://dx.doi.org/10.1056/NEJMoa0910501			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20818854	Green Accepted, Bronze			2022-12-28	WOS:000280764600006
J	Ho, CY; Lopez, B; Coelho-Filho, OR; Lakdawala, NK; Cirino, AL; Jarolim, P; Kwong, R; Gonzalez, A; Colan, SD; Seidman, JG; Diez, J; Seidman, CE				Ho, Carolyn Y.; Lopez, Begona; Coelho-Filho, Otavio R.; Lakdawala, Neal K.; Cirino, Allison L.; Jarolim, Petr; Kwong, Raymond; Gonzalez, Arantxa; Colan, Steven D.; Seidman, J. G.; Diez, Javier; Seidman, Christine E.			Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC MAGNETIC-RESONANCE; EXTRACELLULAR-MATRIX TURNOVER; LEFT-VENTRICULAR FUNCTION; HEART-FAILURE; DILATED CARDIOMYOPATHY; DELAYED ENHANCEMENT; BIOCHEMICAL MARKERS; GENE-MUTATIONS; SERUM; ECHOCARDIOGRAPHY	BACKGROUND Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy and a proposed substrate for arrhythmias and heart failure. In animal models, profibrotic genetic pathways are activated early, before hypertrophic remodeling. Data showing early profibrotic responses to sarcomere-gene mutations in patients with hypertrophic cardiomyopathy are lacking. METHODS We used echocardiography, cardiac magnetic resonance imaging (MRI), and serum biomarkers of collagen metabolism, hemodynamic stress, and myocardial injury to evaluate subjects with hypertrophic cardiomyopathy and a confirmed genotype. RESULTS The study involved 38 subjects with pathogenic sarcomere mutations and overt hypertrophic cardiomyopathy, 39 subjects with mutations but no left ventricular hypertrophy, and 30 controls who did not have mutations. Levels of serum C-terminal propeptide of type I procollagen (PICP) were significantly higher in mutation carriers without left ventricular hypertrophy and in subjects with overt hypertrophic cardiomyopathy than in controls (31% and 69% higher, respectively; P<0.001). The ratio of PICP to C-terminal telopeptide of type I collagen was increased only in subjects with overt hypertrophic cardiomyopathy, suggesting that collagen synthesis exceeds degradation. Cardiac MRI studies showed late gadolinium enhancement, indicating myocardial fibrosis, in 71% of subjects with overt hypertrophic cardiomyopathy but in none of the mutation carriers without left ventricular hypertrophy. CONCLUSIONS Elevated levels of serum PICP indicated increased myocardial collagen synthesis in sarcomere-mutation carriers without overt disease. This profibrotic state preceded the development of left ventricular hypertrophy or fibrosis visible on MRI. (Funded by the National Institutes of Health and others.)	[Ho, Carolyn Y.; Coelho-Filho, Otavio R.; Lakdawala, Neal K.; Cirino, Allison L.; Kwong, Raymond; Seidman, J. G.; Seidman, Christine E.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; [Jarolim, Petr] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Colan, Steven D.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; [Seidman, J. G.; Seidman, Christine E.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Lopez, Begona; Gonzalez, Arantxa; Diez, Javier] Univ Navarra, Div Cardiovasc Sci, Ctr Appl Med Res, E-31080 Pamplona, Spain; [Lopez, Begona; Gonzalez, Arantxa; Diez, Javier] Univ Navarra, Univ Clin, E-31080 Pamplona, Spain; [Seidman, Christine E.] Howard Hughes Med Inst, Chevy Chase, MD USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Navarra; University of Navarra; Howard Hughes Medical Institute	Ho, CY (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	cho@partners.org	Coelho-Filho, Otavio/G-9250-2012; Díez, Javier/D-7014-2017; Coelho-Filho, Otavio/AAV-9557-2021; Colan, Steven/ABB-4580-2020; Kwong, Raymond Y/R-1925-2016; González, Arantxa/D-6860-2017	Coelho-Filho, Otavio/0000-0003-4428-5186; Díez, Javier/0000-0002-3414-6919; Coelho-Filho, Otavio/0000-0003-4428-5186; Kwong, Raymond Y/0000-0001-8212-0759; González, Arantxa/0000-0001-5986-6528; Lopez Salazar, Begona/0000-0001-8508-698X; Ho, Carolyn/0000-0002-7334-7924	National Institutes of Health; Arthur L. Lenahan Sr. Family Foundation; GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease; Howard Hughes Medical Institute; Foundation for Applied Medical Research; Institute of Health Carlos III, Ministry of Science and Innovation; European Union InGenious HyperCare; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P20HL101408, R01HL084553, K23HL078901] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arthur L. Lenahan Sr. Family Foundation; GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease(GlaxoSmithKline); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Foundation for Applied Medical Research; Institute of Health Carlos III, Ministry of Science and Innovation(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government); European Union InGenious HyperCare(European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Institutes of Health (to Drs. Ho, J.G. Seidman, and C.E. Seidman), the Arthur L. Lenahan Sr. Family Foundation (to Dr. Ho), the GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease (to Dr. Ho), the Howard Hughes Medical Institute (to Dr. C. E. Seidman), and the Foundation for Applied Medical Research and Union Temporal de Empresas project Centro de Investigacion Medica Aplicada, the Red Tematica de Investigacion Cooperativa en Enfermedades Cardiovasculares from the Institute of Health Carlos III, Ministry of Science and Innovation, and the European Union InGenious HyperCare (all to Drs. Lopez, Gonzalez, and Diez).	Adabag AS, 2008, J AM COLL CARDIOL, V51, P1369, DOI 10.1016/j.jacc.2007.11.071; Basso C, 2000, HUM PATHOL, V31, P988, DOI 10.1053/hupa.2000.16659; Camici PG, 2007, NEW ENGL J MED, V356, P830, DOI 10.1056/NEJMra061889; Choudhury L, 2002, J AM COLL CARDIOL, V40, P2156, DOI 10.1016/S0735-1097(02)02602-5; Crilley JG, 2003, J AM COLL CARDIOL, V41, P1776, DOI 10.1016/S0735-1097(02)03009-7; Debold EP, 2007, AM J PHYSIOL-HEART C, V293, pH284, DOI 10.1152/ajpheart.00128.2007; Fassbach M, 2005, Z KARDIOL, V94, P328, DOI 10.1007/s00392-005-0214-5; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Germans T, 2006, J AM COLL CARDIOL, V48, P2518, DOI 10.1016/j.jacc.2006.08.036; Gonzalez A, 2009, CARDIOVASC RES, V81, P509, DOI 10.1093/cvr/cvn235; Grothues F, 2002, AM J CARDIOL, V90, P29, DOI 10.1016/S0002-9149(02)02381-0; Ho CY, 2009, CIRC-CARDIOVASC GENE, V2, P314, DOI 10.1161/CIRCGENETICS.109.862128; Ho CY, 2002, CIRCULATION, V105, P2992, DOI 10.1161/01.CIR.0000019070.70491.6D; Kim JB, 2007, SCIENCE, V316, P1481, DOI 10.1126/science.1137325; Kim RJ, 1999, CIRCULATION, V100, P1992, DOI 10.1161/01.CIR.100.19.1992; KLAPPACHER G, 1995, AM J CARDIOL, V75, P913, DOI 10.1016/S0002-9149(99)80686-9; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Lombardi R, 2003, CIRCULATION, V108, P1455, DOI 10.1161/01.CIR.0000090687.97972.10; Lombardi R, 2009, CIRCULATION, V119, P1398, DOI 10.1161/CIRCULATIONAHA.108.790501; Lopez B, 2010, CIRCULATION, V121, P1645, DOI 10.1161/CIRCULATIONAHA.109.912774; Marino P, 2002, J AM SOC ECHOCARDIOG, V15, P935, DOI 10.1067/mje.2002.121196; Maron BJ, 2004, J AM COLL CARDIOL, V44, P2125, DOI 10.1016/j.jacc.2004.08.052; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; Maron MS, 2008, CIRC-HEART FAIL, V1, P184, DOI 10.1161/CIRCHEARTFAILURE.108.768119; McKenna WJ, 1997, HEART, V77, P130, DOI 10.1136/hrt.77.2.130; Moon JC, 2005, HEART, V91, P1036, DOI 10.1136/hrt.2004.041384; Moon JCC, 2003, J AM COLL CARDIOL, V41, P1561, DOI 10.1016/S0735-1097(03)00189-X; Nagueh SF, 2004, CIRCULATION, V110, P155, DOI 10.1161/01.CIR.0000135591.37759.AF; Nagueh SF, 2001, CIRCULATION, V104, P128, DOI 10.1161/01.CIR.104.2.128; Niimura H, 2002, CIRCULATION, V105, P446, DOI 10.1161/hc0402.102990; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; Noji Y, 2004, CIRC J, V68, P355, DOI 10.1253/circj.68.355; Ommen SR, 2000, CIRCULATION, V102, P1788; Poulsen SH, 2001, CARDIOLOGY, V96, P45, DOI 10.1159/000047385; Querejeta R, 2004, CIRCULATION, V110, P1263, DOI 10.1161/01.CIR.0000140973.60992.9A; Ricciardi MJ, 2001, CIRCULATION, V103, P2780, DOI 10.1161/hc2301.092121; Richard P, 2006, J AM COLL CARDIOL, V48, pA79, DOI 10.1016/j.jacc.2006.09.014; Roldan V, 2008, AM HEART J, V156, P85, DOI 10.1016/j.ahj.2008.01.035; Rudolph A, 2009, J AM COLL CARDIOL, V53, P284, DOI 10.1016/j.jacc.2008.08.064; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Shirani J, 2000, J AM COLL CARDIOL, V35, P36, DOI 10.1016/S0735-1097(99)00492-1; Sluysmans T, 2005, J APPL PHYSIOL, V99, P445, DOI 10.1152/japplphysiol.01144.2004; Strauss DG, 2008, CIRC-ARRHYTHMIA ELEC, V1, P327, DOI 10.1161/CIRCEP.108.798660; Tardiff JC, 2005, HEART FAIL REV, V10, P237, DOI 10.1007/s10741-005-5253-5; TRIVEDI P, 1991, PEDIATR RES, V30, P276, DOI 10.1203/00006450-199109000-00016; Varnava AM, 2000, HEART, V84, P476, DOI 10.1136/heart.84.5.476; Varnava AM, 2001, AM J CARDIOL, V88, P275, DOI 10.1016/S0002-9149(01)01640-X; Wu E, 2001, LANCET, V357, P21, DOI 10.1016/S0140-6736(00)03567-4; Zannad F, 2000, CIRCULATION, V102, P2700, DOI 10.1161/01.CIR.102.22.2700	49	442	465	2	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					552	563		10.1056/NEJMoa1002659	http://dx.doi.org/10.1056/NEJMoa1002659			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818890	Green Accepted, Green Published			2022-12-28	WOS:000280552700009
J	Lee, JS; Smith, E; Shilatifard, A				Lee, Jung-Shin; Smith, Edwin; Shilatifard, Ali			The Language of Histone Crosstalk	CELL			English	Review							H3 PHOSPHORYLATION; METHYLATION; TRANSCRIPTION; COMPLEX; BINDING; ACETYLATION; DISTINCT; PROTEIN; FINGER; MODULE		[Lee, Jung-Shin; Smith, Edwin; Shilatifard, Ali] Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Shilatifard, A (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	ash@stowers.org			NIH [R01CA89455, R01GM069905, R01CA150265]; NATIONAL CANCER INSTITUTE [R01CA089455, R01CA150265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069905] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. E. Park for the critical reading of the manuscript. We also thank L. Shilatifard for editorial assistance. Studies in the Shilatifard laboratory are supported in part by grants from the NIH: R01CA89455, R01GM069905, and R01CA150265.	Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kirmizis A, 2007, NATURE, V449, P928, DOI 10.1038/nature06160; Li XZ, 2009, MOL CELL, V36, P290, DOI 10.1016/j.molcel.2009.07.031; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06; Mateescu B, 2008, EMBO REP, V9, P267, DOI 10.1038/embor.2008.1; Nakanishi S, 2008, NAT STRUCT MOL BIOL, V15, P881, DOI 10.1038/nsmb.1454; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Suganuma T, 2008, NAT STRUCT MOL BIOL, V15, P364, DOI 10.1038/nsmb.1397; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Wang YM, 2001, CELL, V105, P433, DOI 10.1016/S0092-8674(01)00325-7; Wang YL, 2008, J BIOL CHEM, V283, P33808, DOI 10.1074/jbc.M806936200; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031	20	379	383	0	74	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 3	2010	142	5					682	685		10.1016/j.cell.2010.08.011	http://dx.doi.org/10.1016/j.cell.2010.08.011			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813257	Bronze, Green Accepted			2022-12-28	WOS:000281523200012
J	Green, J; Czanner, G; Reeves, G; Watson, J; Wise, L; Beral, V				Green, Jane; Czanner, Gabriela; Reeves, Gillian; Watson, Joanna; Wise, Lesley; Beral, Valerie			Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW BONE-DENSITY; PREVENT FRACTURES; BREAST-CANCER; OSTEOPOROSIS; WOMEN; MANAGEMENT; DIAGNOSIS; VALIDITY; MEN	Objective To examine the hypothesis that risk of oesophageal, but not of gastric or colorectal, cancer is increased in users of oral bisphosphonates. Design Nested case-control analysis within a primary care cohort of about 6 million people in the UK, with prospectively recorded information on prescribing of bisphosphonates. Setting UK General Practice Research Database cohort. Participants Men and women aged 40 years or over-2954 with oesophageal cancer, 2018 with gastric cancer, and 10 641 with colorectal cancer, diagnosed in 19952005; five controls per case matched for age, sex, general practice, and observation time. Main outcome measures Relative risks for incident invasive cancers of the oesophagus, stomach, and colorectum, adjusted for smoking, alcohol, and body mass index. Results The incidence of oesophageal cancer was increased in people with one or more previous prescriptions for oral bisphosphonates compared with those with no such prescriptions (relative risk 1.30, 95% confidence interval 1.02 to 1.66; P=0.02). Risk of oesophageal cancer was significantly higher for 10 or more prescriptions (1.93, 1.37 to 2.70) than for one to nine prescriptions (0.93, 0.66 to 1.31) (P for heterogeneity=0.002), and for use for over 3 years (on average, about 5 years: relative risk v no prescription, 2.24, 1.47 to 3.43). Risk of oesophageal cancer did not differ significantly by bisphosphonate type, and risk in those with 10 or more bisphosphonate prescriptions did not vary by age, sex, smoking, alcohol intake, or body mass index; by diagnosis of osteoporosis, fracture, or upper gastrointestinal disease; or by prescription of acid suppressants, non-steroidal anti-inflammatory drugs, or corticosteroids. Cancers of the stomach and colorectum were not associated with prescription of bisphosphonate: relative risks for one or more versus no prescriptions were 0.87 (0.64 to 1.19) and 0.87 (0.77 to 1.00). The specificity of the association for oesophageal cancer argues against methodological problems in the selection of cases and controls or in the analysis. Conclusions The risk of oesophageal cancer increased with 10 or more prescriptions for oral bisphosphonates and with prescriptions over about a five year period. In Europe and North America, the incidence of oesophageal cancer at age 60-79 is typically 1 per 1000 population over five years, and this is estimated to increase to about 2 per 1000 with five years' use of oral bisphosphonates.	[Green, Jane; Czanner, Gabriela; Reeves, Gillian; Watson, Joanna; Beral, Valerie] Univ Oxford, Canc Epidemiol Unit, Oxford OX3 7LF, England; [Wise, Lesley] Med & Healthcare Prod Regulatory Agcy, Pharmacoepidemiol Res Unit, London SW8 5NQ, England	University of Oxford; The Medicines & Healthcare Products Regulatory Agency	Green, J (corresponding author), Univ Oxford, Canc Epidemiol Unit, Oxford OX3 7LF, England.	jane.green@ceu.ox.ac.uk	Czanner, Gabriela/ABC-7569-2021	Czanner, Gabriela/0000-0002-1157-2093; Watson, Joanna/0000-0002-2532-2423	Medical Research Council; Cancer Research UK	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK)	The General Practice Research Database dataset for this study was obtained under the collaborative research licence funded by the Medical Research Council, and the study was approved by the Independent Scientific Advisory Committee of the General Practice Research Database (protocol number 06_090). Cancer Research UK provided further funding for the study. The funders had no role in study design, in the analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.	Abrahamsen B, 2009, NEW ENGL J MED, V360, P1789, DOI 10.1056/NEJMc096026; Allen NE, 2009, JNCI-J NATL CANCER I, V101, P296, DOI 10.1093/jnci/djn514; [Anonymous], 2021, CANC INCIDENCE 5 CON; Cardwell CR, 2010, JAMA-J AM MED ASSOC, V304, P657, DOI 10.1001/jama.2010.1098; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; Compston J, 2009, MATURITAS, V62, P105, DOI 10.1016/j.maturitas.2008.11.022; Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198-006-0322-8; Ebeling PR, 2008, NEW ENGL J MED, V358, P1474, DOI 10.1056/NEJMcp0707217; *GRPD, 2010, DAT; Hamilton SR, 2000, WHO CLASSIFICATION T; Herrett E, 2010, BRIT J CLIN PHARMACO, V69, P4, DOI 10.1111/j.1365-2125.2009.03537.x; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; Jorgensen EB, 2008, KAIS, V2021, P1, DOI [DOI 10.1002/14651858.CD001155.PUB2, 10.1002/mp.15257]; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; MacLean C, 2008, ANN INTERN MED, V148, P197, DOI 10.7326/0003-4819-148-3-200802050-00198; *NAT I HLTH CLIN E, 2010, TECHN APPR GUID 160; Newcomb PA, 2010, BRIT J CANCER, V102, P799, DOI 10.1038/sj.bjc.6605555; NGUYEN DM, 2010, DIG DIS SCI; Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003-4819-149-6-200809160-00007; Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE; Solomon DH, 2009, NEW ENGL J MED, V360, P1789; Solomon DH, 2009, CURR OPIN RHEUMATOL, V21, P363, DOI 10.1097/BOR.0b013e32832ca433; Vestergaard P, 2010, CALCIFIED TISSUE INT, V86, P110, DOI 10.1007/s00223-009-9323-x; Watson J, 2007, EUR J CLIN PHARMACOL, V63, P843, DOI 10.1007/s00228-007-0320-6; Wysowski DK, 2009, NEW ENGL J MED, V360, P89, DOI 10.1056/NEJMc0808738	25	156	156	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2010	341								c4444	10.1136/bmj.c4444	http://dx.doi.org/10.1136/bmj.c4444			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647JV	20813820	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000281615700002
J	Sherson, JF; Weitenberg, C; Endres, M; Cheneau, M; Bloch, I; Kuhr, S				Sherson, Jacob F.; Weitenberg, Christof; Endres, Manuel; Cheneau, Marc; Bloch, Immanuel; Kuhr, Stefan			Single-atom-resolved fluorescence imaging of an atomic Mott insulator	NATURE			English	Article							TONKS-GIRARDEAU GAS; 3D OPTICAL LATTICE; QUANTUM GAS; TRANSITION	The reliable detection of single quantum particles has revolutionized the field of quantum optics and quantum information processing. For several years, researchers have aspired to extend such detection possibilities to larger-scale, strongly correlated quantum systems(1,2) in order to record in situ images of a quantum fluid in which each underlying quantum particle is detected. Here we report fluorescence imaging of strongly interacting bosonic Mott insulators in an optical lattice with single-atom and single-site resolution. From our images, we fully reconstruct the atom distribution on the lattice and identify individual excitations with high fidelity. A comparison of the radial density and variance distributions with theory provides a precise in situ temperature and entropy measurement from single images. We observe Mott-insulating plateaus with near-zero entropy and clearly resolve the high-entropy rings separating them, even though their width is of the order of just a single lattice site. Furthermore, we show how a Mott insulator melts with increasing temperature, owing to a proliferation of local defects. The ability to resolve individual lattice sites directly opens up new avenues for the manipulation, analysis and applications of strongly interacting quantum gases on a lattice. For example, one could introduce local perturbations or access regions of high entropy, a crucial requirement for the implementation of novel cooling schemes(3).	[Sherson, Jacob F.; Weitenberg, Christof; Endres, Manuel; Cheneau, Marc; Bloch, Immanuel; Kuhr, Stefan] Max Planck Inst Quantum Opt, D-85748 Garching, Germany; [Bloch, Immanuel] Univ Munich, D-80799 Munich, Germany	Max Planck Society; University of Munich	Kuhr, S (corresponding author), Max Planck Inst Quantum Opt, Hans Kopfermann Str 1, D-85748 Garching, Germany.	stefan.kuhr@mpq.mpg.de	Bloch, Immanuel/G-3174-2010; Bloch, Immanuel/N-9169-2019; Kuhr, Stefan/F-7296-2011; Cheneau, Marc/O-9312-2014; Kuhr, Stefan/ABC-8654-2020	Bloch, Immanuel/0000-0002-0679-4759; Kuhr, Stefan/0000-0001-8386-5357; Cheneau, Marc/0000-0001-7261-566X; Kuhr, Stefan/0000-0001-8386-5357	MPG; DFG; Stiftung Rheinland-Pfalz fur Innovation; Carl-Zeiss Stiftung; EU	MPG(Max Planck Society); DFG(German Research Foundation (DFG)); Stiftung Rheinland-Pfalz fur Innovation; Carl-Zeiss Stiftung; EU(European Commission)	We thank R. Glockner and R. Labouvie for assistance during the set-up of the experiment and S. Trotzky for discussions. We acknowledge funding by the MPG, the DFG, the Stiftung Rheinland-Pfalz fur Innovation, the Carl-Zeiss Stiftung, the EU (NAMEQUAM, AQUTE and Marie Curie fellowships to J.F.S. and M.C.).	Bakr WS, 2010, SCIENCE, V329, P547, DOI 10.1126/science.1192368; Bakr WS, 2009, NATURE, V462, P74, DOI 10.1038/nature08482; Bernier JS, 2009, PHYS REV A, V79, DOI 10.1103/PhysRevA.79.061601; Bloch I, 2008, REV MOD PHYS, V80, P885, DOI 10.1103/RevModPhys.80.885; Campbell GK, 2006, SCIENCE, V313, P649, DOI 10.1126/science.1130365; Capogrosso-Sansone B, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.053622; DePue MT, 1999, PHYS REV LETT, V82, P2262, DOI 10.1103/PhysRevLett.82.2262; FISHER MPA, 1989, PHYS REV B, V40, P546, DOI 10.1063/1.38820; Folling S, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.060403; Gemelke N, 2009, NATURE, V460, P995, DOI 10.1038/nature08244; Gerbier F, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.090401; Gerbier F, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.120405; Gericke T, 2008, NAT PHYS, V4, P949, DOI 10.1038/nphys1102; GREINER M, 2002, NATURE, V39, P415; Ho TL, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.120404; Hung CL, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.160403; Hung CL, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.011604; Jaksch D, 2005, ANN PHYS-NEW YORK, V315, P52, DOI 10.1016/j.aop.2004.09.010; Jordens R, 2008, NATURE, V455, P204, DOI 10.1038/nature07244; Karski M, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.053001; Kinoshita T, 2004, SCIENCE, V305, P1125, DOI 10.1126/science.1100700; KRAUTH W, 1991, EUROPHYS LETT, V14, P627, DOI 10.1209/0295-5075/14/7/003; Nelson KD, 2007, NAT PHYS, V3, P556, DOI 10.1038/nphys645; Paredes B, 2004, NATURE, V429, P277, DOI 10.1038/nature02530; Rigol M, 2009, PHYS REV A, V79, DOI 10.1103/PhysRevA.79.053605; Schneider U, 2008, SCIENCE, V322, P1520, DOI 10.1126/science.1165449; Spielman IB, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.080404; Zhang CW, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.042316	30	958	961	7	166	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					68	U97		10.1038/nature09378	http://dx.doi.org/10.1038/nature09378			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20720540	Green Submitted, Green Accepted			2022-12-28	WOS:000281461200036
J	Howard, A; Wilson, M				Howard, Andrew; Wilson, Mary			Easily Missed? Septic arthritis in children	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TRANSIENT SYNOVITIS; HIP; DIFFERENTIATION; CHILDHOOD		[Howard, Andrew] Hosp Sick Children, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; [Wilson, Mary] Marathon Family Hlth Team, Marathon, ON P0T 2E0, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Howard, A (corresponding author), Hosp Sick Children, Div Orthopaed Surg, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	andrew.howard@sickkids.ca		Howard, Andrew/0000-0001-7226-6471				Baskett A, 2009, PEDIATR EMERG CARE, V25, P78, DOI 10.1097/PEC.0b013e318196ea43; Caird MS, 2006, J BONE JOINT SURG AM, V88A, P1251, DOI 10.2106/JBJS.E.00216; Choi IH, 2005, CLIN ORTHOP RELAT R, P102, DOI 10.1097/01.blo.0000162412.93473.68; Forlin E, 2008, J PEDIATR ORTHOPED, V28, P524, DOI 10.1097/BPO.0b013e31817bb079; Givon U, 2004, J PEDIATR ORTHOPED, V24, P266, DOI 10.1097/01241398-200405000-00006; Goergens ED, 2005, J PAEDIATR CHILD H, V41, P59, DOI 10.1111/j.1440-1754.2005.00538.x; Gordon JE, 2002, J PEDIATR ORTHOPED, V22, P312, DOI 10.1097/00004694-200205000-00008; Kocher MS, 2004, J BONE JOINT SURG AM, V86A, P1629, DOI 10.2106/00004623-200408000-00005; Kocher MS, 1999, J BONE JOINT SURG AM, V81A, P1662, DOI 10.2106/00004623-199912000-00002; Luhmann SJ, 2004, J BONE JOINT SURG AM, V86A, P956, DOI 10.2106/00004623-200405000-00011; Nunn TR, 2007, J BONE JOINT SURG BR, V89B, P100, DOI 10.1302/0301-620X.89B1.17940; Peltola H, 2009, CLIN INFECT DIS, V48, P1201, DOI 10.1086/597582; Riise OR, 2008, PEDIATRICS, V121, pE299, DOI 10.1542/peds.2007-0291	13	3	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 27	2010	341								c4407	10.1136/bmj.c4407Easily	http://dx.doi.org/10.1136/bmj.c4407Easily			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645IJ	20801999				2022-12-28	WOS:000281446300016
J	[Anonymous]				[Anonymous]			A SOFTWARE SPOT	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					1139	1139		10.1038/4661139a	http://dx.doi.org/10.1038/4661139a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740020	Bronze			2022-12-28	WOS:000281203600052
J	Kurth, T; Kase, CS; Schurks, M; Tzourio, C; Buring, JE				Kurth, Tobias; Kase, Carlos S.; Schuerks, Markus; Tzourio, Christophe; Buring, Julie E.			Migraine and risk of haemorrhagic stroke in women: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ISCHEMIC-STROKE; LOGISTIC-REGRESSION; PRIMARY PREVENTION; PROPENSITY SCORE; HEADACHE; MODELS; CLASSIFICATION; POLYMORPHISM; ASSOCIATION	Objectives To examine the association between migraine and migraine aura status with risk of haemorrhagic stroke. Design Prospective cohort study. Setting Women's Health Study, United States. Participants 27 860 women aged >= 45 who were free from stroke or other major disease at baseline and had provided information on self reported migraine, aura status, and lipid values. Main outcome measures Time to first haemorrhagic stroke and subtypes of haemorrhagic stroke. Results At baseline, 5130 (18%) women reported any history of migraine; of the 3612 with active migraine (migraine in the previous year), 1435 (40%) described having aura. During a mean of 13.6 years of follow-up, 85 haemorrhagic strokes were confirmed after review of medical records. Compared with women without a history of migraine, there was no increased risk of haemorrhagic stroke in those who reported any history of migraine (adjusted hazard ratio 0.98, 95% confidence interval 0.56 to 1.71, P = 0.93). In contrast, risk was increased in women with active migraine with aura (2.25, 1.11 to 4.54, P = 0.024). The age adjusted increased risk was stronger for intracerebral haemorrhage (2.78, 1.09 to 7.07, P = 0.032) and for fatal events (3.56, 1.23 to 10.31, P = 0.02). Four additional haemorrhagic stroke events were attributable to migraine with aura per 10 000 women per year. Women who reported active migraine without aura had no increased risk for haemorrhagic stroke. Conclusion Migraine with aura might, in addition to ischaemic events, also be a risk factor for haemorrhagic stroke. The relatively low number of events and attributable risk should caution against definitive conclusions and call for further confirmation of these observations.	[Kurth, Tobias] Hop La Pitie Salpetriere, INSERM, Neuroepidemiol U708, F-75651 Paris 13, France; [Kurth, Tobias; Schuerks, Markus; Buring, Julie E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA; [Kurth, Tobias; Tzourio, Christophe] Univ Paris 06, F-75005 Paris, France; [Kurth, Tobias; Buring, Julie E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Kase, Carlos S.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Buring, Julie E.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Harvard University; Brigham & Women's Hospital; Harvard Medical School; UDICE-French Research Universities; Sorbonne Universite; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Harvard University; Harvard Medical School	Kurth, T (corresponding author), Hop La Pitie Salpetriere, INSERM, Neuroepidemiol U708, 47 Blvd Hop, F-75651 Paris 13, France.	tkurth@rics.bwh.harvard.edu	Kurth, Tobias/A-9243-2012; Tzourio, christophe/B-4015-2009; Tzourio, christophe/L-6344-2019	Kurth, Tobias/0000-0001-7169-2620; Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; Kase, Carlos/0000-0002-3047-5010	National Heart, Lung, and Blood Institute [HL-043851, HL-080467]; National Cancer Institute [CA-47988]; Donald W Reynolds Foundation; Leducq Foundation; Doris Duke Charitable Foundation; French National Research Agency; National Institutes of Health; Merck; Migraine Research Foundation; Dow Corning Corporation; Bayer Heath Care; Natural Source Vitamin E Association; NATIONAL CANCER INSTITUTE [R01CA047988] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080467, R01HL043851] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Donald W Reynolds Foundation; Leducq Foundation(Leducq Foundation); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); French National Research Agency(French National Research Agency (ANR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Merck(Merck & Company); Migraine Research Foundation; Dow Corning Corporation; Bayer Heath Care; Natural Source Vitamin E Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Women's Health Study is supported by grants from the National Heart, Lung, and Blood Institute (HL-043851 and HL-080467), and the National Cancer Institute (CA-47988). The research for this work was supported by grants from the Donald W Reynolds Foundation, the Leducq Foundation, and the Doris Duke Charitable Foundation. The sponsors of the study played no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: TK has received investigator initiated research funding from the French National Research Agency, the National Institutes of Health, Merck, and the Migraine Research Foundation. He is a consultant to i3 Drug Safety and World Health Information Science Consultants, LLC (www.whiscon.com), and has received honorariums from Genzyme, Merck, and Pfizer for educational lectures. CK has received honorariums as a consultant for Sanofi-Aventis. MS has received investigator initiated research funds from the Migraine Research Foundation and honorariums from LEK. CT has received investigator initiated research funding from the French National Research Agency and received fees from Sanofi-Synthelabo for participating in a data safety monitoring board and from Merck Sharp & Dohme and the Servier company for participating in scientific committees. JEB has received investigator initiated research funding and support from the National Institutes of Health and Dow Corning Corporation and research support for pills and/or packaging from Bayer Heath Care and the Natural Source Vitamin E Association.	[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; Atiya M, 2003, STROKE, V34, P565, DOI 10.1161/01.STR.0000054159.21017.7C; Bigal ME, 2010, NEUROLOGY, V74, P628, DOI 10.1212/WNL.0b013e3181d0cc8b; Bigal ME, 2006, NEUROLOGY, V66, P545, DOI 10.1212/01.wnl.0000197218.05284.82; Bousser MG, 2005, LANCET NEUROL, V4, P533, DOI 10.1016/S1474-4422(05)70164-2; Bushnell CD, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b664; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cook NR, 2002, HEADACHE, V42, P715, DOI 10.1046/j.1526-4610.2002.02173.x; DANDREA G, 1995, CEPHALALGIA, V15, P265, DOI 10.1046/j.1468-2982.1995.1504265.x; Etminan M, 2005, BMJ-BRIT MED J, V330, P63, DOI 10.1136/bmj.38302.504063.8F; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; Hering-Hanit R, 2001, CEPHALALGIA, V21, P137, DOI 10.1046/j.1468-2982.2001.00181.x; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Kurth T, 2005, NEUROLOGY, V64, P1020, DOI 10.1212/01.WNL.0000154528.21485.3A; Kurth T, 2005, CIRCULATION, V111, P1992, DOI 10.1161/01.CIR.0000161822.83163.B6; Kurth T, 2003, STROKE, V34, P2792, DOI 10.1161/01.STR.0000100165.36466.95; Kurth T, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a636; Kurth T, 2006, ARCH INTERN MED, V166, P1403, DOI 10.1001/archinte.166.13.1403; Kurth T, 2006, JAMA-J AM MED ASSOC, V296, P283, DOI 10.1001/jama.296.3.283; Launer LJ, 1999, NEUROLOGY, V53, P537, DOI 10.1212/WNL.53.3.537; Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56; Lee ST, 2008, NEUROLOGY, V70, P1510, DOI 10.1212/01.wnl.0000294329.93565.94; Lipton R.B., 2005, HEADACHE, V4, P3, DOI [DOI 10.1111/J.1526-4610.2005.4501001.X, 10.1111/j.1526-4610.2005.4501001.x]; Lipton RB, 2005, AM J MED, V118, p3S, DOI 10.1016/j.amjmed.2005.01.014; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; MacClellan LR, 2007, STROKE, V38, P2438, DOI 10.1161/STROKEAHA.107.488395; MONTEIRO JMP, 1993, HEADACHE, V33, P563, DOI 10.1111/j.1526-4610.1993.hed3310563.x; Napoli R, 2009, NEUROLOGY, V72, P2111, DOI 10.1212/WNL.0b013e3181aa53ce; Olesen J, 2004, J NEUROL NEUROSUR PS, V75, P808, DOI 10.1136/jnnp.2003.031286; Rexrode KM, 2000, J WOMEN HEALTH GEN-B, V9, P19, DOI 10.1089/152460900318911; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sato T, 2003, EPIDEMIOLOGY, V14, P680, DOI 10.1097/01.EDE.0000081989.82616.7d; Scher AI, 2005, NEUROLOGY, V64, P614, DOI 10.1212/01.WNL.0000151857.43225.49; Scher AI, 2009, JAMA-J AM MED ASSOC, V301, P2563, DOI 10.1001/jama.2009.932; Schurks M, 2009, CEPHALALGIA, V29, P1086, DOI 10.1111/j.1468-2982.2008.01835.x; Schurks M, 2009, NEUROLOGY, V72, P650, DOI 10.1212/01.wnl.0000342517.97178.f6; Schurks M, 2008, NEUROLOGY, V71, P505, DOI 10.1212/01.wnl.0000316198.34558.e5; Schurks Markus, 2009, BMJ, V339, pb3914, DOI 10.1136/bmj.b3914; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Stang PE, 2005, NEUROLOGY, V64, P1573, DOI 10.1212/01.WNL.0000158326.31368.04; Tietjen GE, 2007, THROMB RES, V119, P217, DOI 10.1016/j.thromres.2005.12.020; Tikka-Kleemola P, 2009, CEPHALALGIA, V29, P1224, DOI 10.1111/j.1468-2982.2009.01855.x; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; Tzourio C, 2001, NEUROLOGY, V56, P1273, DOI 10.1212/WNL.56.10.1273; Vanmolkot FH, 2007, NEUROLOGY, V68, P1563, DOI 10.1212/01.wnl.0000260964.28393.ed	51	70	73	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	2010	341								c3659	10.1136/bmj.c3659	http://dx.doi.org/10.1136/bmj.c3659			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645IG	20736268	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000281445900002
J	Singh, H; Demarco, IA				Singh, Harinder; Demarco, Ignacio A.			Double TIP-ping	SCIENCE			English	Editorial Material							CLASS SWITCH RECOMBINATION; HYPERMUTATION; AID		[Singh, Harinder; Demarco, Ignacio A.] Genentech Inc, Dept Discovery Immunol, San Francisco, CA 94080 USA; [Singh, Harinder] Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Roche Holding; Genentech; University of Chicago	Singh, H (corresponding author), Genentech Inc, Dept Discovery Immunol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.	singh.harinder@gene.com						Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Daniel JA, 2010, SCIENCE, V329, P917, DOI 10.1126/science.1187942; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Jankovic M, 2007, NAT IMMUNOL, V8, P801, DOI 10.1038/ni1498; Longerich S, 2006, CURR OPIN IMMUNOL, V18, P164, DOI 10.1016/j.coi.2006.01.008; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Patel SR, 2007, DEV CELL, V13, P580, DOI 10.1016/j.devcel.2007.09.004; Ramachandran S, 2010, P NATL ACAD SCI USA, V107, P809, DOI 10.1073/pnas.0913790107; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Wu JX, 2009, J BIOL CHEM, V284, P18078, DOI 10.1074/jbc.M109.002527	10	0	0	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					914	915		10.1126/science.1194316	http://dx.doi.org/10.1126/science.1194316			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724627				2022-12-28	WOS:000281084800025
J	Temel, JS; Greer, JA; Muzikansky, A; Gallagher, ER; Admane, S; Jackson, VA; Dahlin, CM; Blinderman, CD; Jacobsen, J; Pirl, WF; Billings, JA; Lynch, TJ				Temel, Jennifer S.; Greer, Joseph A.; Muzikansky, Alona; Gallagher, Emily R.; Admane, Sonal; Jackson, Vicki A.; Dahlin, Constance M.; Blinderman, Craig D.; Jacobsen, Juliet; Pirl, William F.; Billings, J. Andrew; Lynch, Thomas J.			Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; ELDERLY-PATIENTS; SUPPORTIVE CARE; THERAPY-LUNG; DEPRESSION; SURVIVAL; CISPLATIN; TRIAL; INTERVENTION	BACKGROUND Patients with metastatic non-small-cell lung cancer have a substantial symptom burden and may receive aggressive care at the end of life. We examined the effect of introducing palliative care early after diagnosis on patient-reported outcomes and end-of-life care among ambulatory patients with newly diagnosed disease. METHODS We randomly assigned patients with newly diagnosed metastatic non-small-cell lung cancer to receive either early palliative care integrated with standard oncologic care or standard oncologic care alone. Quality of life and mood were assessed at baseline and at 12 weeks with the use of the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale and the Hospital Anxiety and Depression Scale, respectively. The primary outcome was the change in the quality of life at 12 weeks. Data on end-of-life care were collected from electronic medical records. RESULTS Of the 151 patients who underwent randomization, 27 died by 12 weeks and 107 (86% of the remaining patients) completed assessments. Patients assigned to early palliative care had a better quality of life than did patients assigned to standard care (mean score on the FACT-L scale [in which scores range from 0 to 136, with higher scores indicating better quality of life], 98.0 vs. 91.5; P = 0.03). In addition, fewer patients in the palliative care group than in the standard care group had depressive symptoms (16% vs. 38%, P = 0.01). Despite the fact that fewer patients in the early palliative care group than in the standard care group received aggressive end-of-life care (33% vs. 54%, P = 0.05), median survival was longer among patients receiving early palliative care (11.6 months vs. 8.9 months, P = 0.02). CONCLUSIONS Among patients with metastatic non-small-cell lung cancer, early palliative care led to significant improvements in both quality of life and mood. As compared with patients receiving standard care, patients receiving early palliative care had less aggressive care at the end of life but longer survival. (Funded by an American Society of Clinical Oncology Career Development Award and philanthropic gifts; ClinicalTrials.gov number, NCT01038271.)	[Temel, Jennifer S.; Greer, Joseph A.; Muzikansky, Alona; Gallagher, Emily R.; Jackson, Vicki A.; Dahlin, Constance M.; Jacobsen, Juliet; Pirl, William F.; Billings, J. Andrew] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Admane, Sonal] SUNY Buffalo, Buffalo, NY 14260 USA; [Blinderman, Craig D.] Columbia Univ, Med Ctr, Dept Anesthesiol, New York, NY USA; [Lynch, Thomas J.] Yale Univ, New Haven, CT USA	Harvard University; Massachusetts General Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Columbia University; Yale University	Temel, JS (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA.	jtemel@partners.org	Admane, Sonal/K-7486-2019	admane, sonal/0000-0002-1616-5462; Pirl, William/0000-0001-5226-9886	American Society of Clinical Oncology; Joanne Hill Monahan Cancer Fund and Golf Fights Cancer; Roche; Boehringer Ingelheim; Merck; AstraZeneca; Bristol-Myers Squibb; Sanofi-Aventis	American Society of Clinical Oncology; Joanne Hill Monahan Cancer Fund and Golf Fights Cancer; Roche(Roche Holding); Boehringer Ingelheim(Boehringer Ingelheim); Merck(Merck & Company); AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Sanofi-Aventis(Sanofi-Aventis)	Supported by an American Society of Clinical Oncology Career Development Award and philanthropic gifts from the Joanne Hill Monahan Cancer Fund and Golf Fights Cancer.; Dr. Temel reports receiving payment for developing continuing medical education (CME) programs from InforMEDical; and Dr. Lynch, serving on the board of Infinity Pharmaceuticals, receiving consulting fees from Roche, Boehringer Ingelheim, Merck, AstraZeneca, Bristol-Myers Squibb, and Sanofi-Aventis, royalties from Partners HealthCare, and payment for developing CME programs from InforMEDical. No other potential conflict of interest relevant to this article was reported.	ALBERTI W, 1995, BRIT MED J, V311, P899; *AM SOC CLIN ONC Q, 2009, ASCO QOPI SUMM MEAS; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623; Brown J, 2005, J CLIN ONCOL, V23, P7417, DOI 10.1200/JCO.2005.09.158; Cella D, 2004, SEMIN ONCOL, V31, P11, DOI 10.1053/j.seminoncol.2004.04.008; Cella D, 2002, J CLIN EPIDEMIOL, V55, P285, DOI 10.1016/S0895-4356(01)00477-2; CELLA DF, 1995, LUNG CANCER-J IASLC, V12, P199, DOI 10.1016/0169-5002(95)00450-F; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Emanuel EJ, 2002, ARCH INTERN MED, V162, P1722, DOI 10.1001/archinte.162.15.1722; Ferris FD, 2009, J CLIN ONCOL, V27, P3052, DOI 10.1200/JCO.2008.20.1558; Follwell M, 2009, J CLIN ONCOL, V27, P206, DOI 10.1200/JCO.2008.17.7568; HOPWOOD P, 1995, BRIT J CANCER, V71, P633, DOI 10.1038/bjc.1995.124; Hopwood P, 2000, J CLIN ONCOL, V18, P893, DOI 10.1200/JCO.2000.18.4.893; JACKSON VA, 2009, J CLIN ONCOL S, V27, P20635; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Langer CJ, 2002, JNCI-J NATL CANCER I, V94, P173; Levy MH, 2009, J NATL COMPR CANC NE, V7, P436, DOI 10.6004/jnccn.2009.0031; Lutz S, 2001, J Palliat Med, V4, P157, DOI 10.1089/109662101750290191; Maione P, 2005, J CLIN ONCOL, V23, P6865, DOI 10.1200/JCO.2005.02.527; Mongan JJ, 2008, NEW ENGL J MED, V358, P1509, DOI 10.1056/NEJMsb0707912; Morita T, 2005, J CLIN ONCOL, V23, P2637, DOI 10.1200/JCO.2005.12.107; Movsas B, 2009, J CLIN ONCOL, V27, P5816, DOI 10.1200/JCO.2009.23.7420; National Consensus Project, 2009, CLIN PRACT GUID QUAL; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pirl WF, 2008, PSYCHOSOMATICS, V49, P218, DOI 10.1176/appi.psy.49.3.218; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Rummans TA, 2006, J CLIN ONCOL, V24, P635, DOI 10.1200/JCO.2006.06.209; Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122; Spiro SG, 2004, THORAX, V59, P828, DOI 10.1136/thx.2003.020164; Tang ST, 2009, J CLIN ONCOL, V27, P4613, DOI 10.1200/JCO.2008.20.5096; Temel JS, 2007, J CLIN ONCOL, V25, P2377, DOI 10.1200/JCO.2006.09.2627; Temel JS, 2010, J GEN INTERN MED, V25, P150, DOI 10.1007/s11606-009-1161-z; Walling A, 2008, J CLIN ONCOL, V26, P3896, DOI 10.1200/JCO.2007.15.9509; Weinstein MC, 2010, NEW ENGL J MED, V362, P460, DOI 10.1056/NEJMsb0911104; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zimmermann C, 2008, JAMA-J AM MED ASSOC, V299, P1698, DOI 10.1001/jama.299.14.1698	39	4493	4549	12	456	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					733	742		10.1056/NEJMoa1000678	http://dx.doi.org/10.1056/NEJMoa1000678			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20818875				2022-12-28	WOS:000280996600007
J	Appleby, J				Appleby, John			Should NHS funding be ring fenced? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London W1G 0AN, England		Appleby, J (corresponding author), Kings Fund, London W1G 0AN, England.	j.appleby@kingsfund.org.uk						Appleby J, 2009, COLD WILL IT BE PROS; Appleby J, 2010, IMPROVING NHS PRODUC; Appleby J., 2009, BRIT SOCIAL ATTITUDE, P25; Chote R., 2010, POST BUDGET PRESENTA; *HM TREAS, BUDG 2010; *IPS MOR, POL PUBL SERV SOC CO	6	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 17	2010	341								c4350	10.1136/bmj.c4350	http://dx.doi.org/10.1136/bmj.c4350			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642KQ	20716598				2022-12-28	WOS:000281212500010
J	Bastos-Carvalho, A; Damato, B				Bastos-Carvalho, Ana; Damato, Bertil			Retinal Hemangioblastoma in von Hippel-Lindau Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bastos-Carvalho, Ana] Hosp Santa Maria, Lisbon, Portugal; [Damato, Bertil] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England	Universidade de Lisboa; Hospital Santa Maria; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Bastos-Carvalho, A (corresponding author), Hosp Santa Maria, Lisbon, Portugal.		Damato, Bertil/AGR-6072-2022						0	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					663	663		10.1056/NEJMicm0912768	http://dx.doi.org/10.1056/NEJMicm0912768			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	636TN	20818857				2022-12-28	WOS:000280764600009
J	Bazari, H; Attar, EC; Dahl, DM; Uppot, RN; Colvin, RB				Bazari, Hasan; Attar, Eyal C.; Dahl, Douglas M.; Uppot, Raul N.; Colvin, Robert B.			Case 23-2010: A 49-Year-Old Man with Erythrocytosis, Perinephric Fluid Collections, and Renal Failure.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEPHROTIC SYNDROME; LYMPHANGIECTASIA; LYMPHANGIOMATOSIS; SECONDARY; CYSTS; CT; INSUFFICIENCY; POLYCYTHEMIA; DIAGNOSIS; DISEASE		[Bazari, Hasan] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Attar, Eyal C.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA; [Dahl, Douglas M.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA; [Uppot, Raul N.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Colvin, Robert B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Bazari, Hasan; Attar, Eyal C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Dahl, Douglas M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Uppot, Raul N.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Colvin, Robert B.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Bazari, H (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.		Uppot, Raul/AAF-1859-2019					Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Ashraf K, 2007, Br J Radiol, V80, pe117, DOI 10.1259/bjr/16931054; Bisceglia M, 2006, ADV ANAT PATHOL, V13, P26, DOI 10.1097/01.pap.0000201831.77472.d3; BURTON IE, 1994, POSTGRAD MED J, V70, P515, DOI 10.1136/pgmj.70.825.515; Cadnapaphornchai MA, 2000, PEDIATR NEPHROL, V15, P129, DOI 10.1007/s004670000413; CAGLIOTI A, 1993, BRIT MED J, V306, P430, DOI 10.1136/bmj.306.6875.430; Colucci S, 2006, J BONE MINER RES, V21, P207, DOI 10.1359/JBMR.051019; Colvin RB, 2004, J AM SOC NEPHROL, V15, P827, DOI 10.1097/01.ASN.0000117895.24143.87; Eisner BH, 2009, KIDNEY INT, V76, P126, DOI 10.1038/ki.2009.64; Fakhuri T, 2004, ANN INTERN MED, V140, P492, DOI 10.7326/0003-4819-140-6-200403160-00032; Gandhi GY, 2007, MAYO CLIN PROC, V82, P836, DOI 10.4065/82.7.836; GREER JP, 2004, WINTROBES CLIN HEMAT; HENTHORNE JOHN C., 1938, AMER JOUR CLIN PATH, V8, P28; Ishikawa Y, 2006, HISTOPATHOLOGY, V49, P265, DOI 10.1111/j.1365-2559.2006.02478.x; Kerjaschki D, 2004, J AM SOC NEPHROL, V15, P603, DOI 10.1097/01.ASN.0000113316.52371.2E; Krishnan SGS, 2007, AM J MED SCI, V333, P313, DOI 10.1097/MAJ.0b013e318053ce83; Langer RM, 2002, TRANSPLANTATION, V74, P804, DOI 10.1097/00007890-200209270-00012; Lee H, 2008, AM J DERMATOPATH, V30, P539, DOI 10.1097/DAD.0b013e318182c800; LEVINE E, 1992, RADIOLOGY, V182, P582, DOI 10.1148/radiology.182.2.1580908; Llorente JG, 2002, ABDOM IMAGING, V27, P637, DOI 10.1007/s00261-001-0147-z; Mani N B S, 2003, Australas Radiol, V47, P184, DOI 10.1046/j.0004-8461.2003.01149.x; MATTOO TK, 1990, PEDIATR NEPHROL, V4, P228, DOI 10.1007/BF00857660; Meltzer E, 2008, AM J MED SCI, V336, P445, DOI 10.1097/MAJ.0b013e3181623391; MEREDITH WT, 1988, AM J ROENTGENOL, V151, P965, DOI 10.2214/ajr.151.5.965; Minor TX, 2004, AM J ROENTGENOL, V183, P1393, DOI 10.2214/ajr.183.5.1831393; MURRAY KK, 1991, RADIOLOGY, V180, P455, DOI 10.1148/radiology.180.2.2068311; RIVALTA F, 1889, ARCH SCI MED, V13, P73; Sanders P W, 1993, Curr Opin Nephrol Hypertens, V2, P246, DOI 10.1097/00041552-199303000-00011; Sarikaya B, 2006, ABDOM IMAGING, V31, P732, DOI 10.1007/s00261-005-8014-y; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Shaheen M, 2003, LANCET, V362, P806, DOI 10.1016/S0140-6736(03)14291-2; SOLLINGER HW, 1983, TRANSPLANT P, V15, P2157; Swerdlow SH, 2008, WHO CLASSIFICATION T; Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955; Ueda S, 2007, CLIN NEPHROL, V68, P416; Upreti L, 2008, CLIN RADIOL, V63, P1057, DOI 10.1016/j.crad.2007.12.013; Wadhwa P, 2007, INT UROL NEPHROL, V39, P365, DOI 10.1007/s11255-006-9002-z; YOUNATHAN CM, 1992, UROL RADIOL, V14, P161, DOI 10.1007/BF02926920; Zapzalka DM, 2002, J UROLOGY, V168, P220, DOI 10.1016/S0022-5347(05)64895-1	39	22	23	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					463	475		10.1056/NEJMcpc1004086	http://dx.doi.org/10.1056/NEJMcpc1004086			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818867				2022-12-28	WOS:000280411300012
J	Kocher, R; Emanuel, EJ; DeParle, NAM				Kocher, Robert; Emanuel, Ezekiel J.; DeParle, Nancy-Ann M.			The Affordable Care Act and the Future of Clinical Medicine: The Opportunities and Challenges	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH; REFORM	The Affordable Care Act is a once-in-a-generation change to the U.S. health system. It guarantees access to health care for all Americans, creates new incentives to change clinical practice to foster better coordination and quality, gives physicians more information to make them better clinicians and patients more information to make them more value-conscious consumers, and changes the payment system to reward value. The Act and the health information technology provisions in the American Recovery and Reinvestment Act remove many barriers to delivering high-quality care, such as unnecessary administrative complexity, inaccessible clinical data, and insufficient access to primary care and allied health providers. We hope that physicians will embrace the opportunities created by the Affordable Care Act that will enable them to provide better care for their patients and lead the U.S. health system in a more positive direction. To fully realize the benefits of the Affordable Care Act for their practices and their patients, physicians will design their offices for seamless care, employing new practice models and using technology to integrate patient information with professional society guidelines to keep patients with chronic conditions healthy and out of the hospital. Under the Affordable Care Act, physicians who effectively collaborate with other providers to improve patient outcomes, the value of medical services, and patient experiences will thrive and be the leaders of the health care system.	[Emanuel, Ezekiel J.] Off Management & Budget, Natl Econ Council, Washington, DC 20502 USA; Off Hlth Reform, Washington, DC USA		Emanuel, EJ (corresponding author), Off Management & Budget, Natl Econ Council, White House,1600 Penn Ave, Washington, DC 20502 USA.							[Anonymous], 2010, COMMUNICATION   0320; Cutler DM, 2010, NEW ENGL J MED, V362, P1553, DOI 10.1056/NEJMp1002305; de Brantes F, 2009, NEW ENGL J MED, V361, P1033, DOI 10.1056/NEJMp0906121; Doherty RB, 2010, ANN INTERN MED, V152, P679, DOI 10.7326/0003-4819-153-1-201007060-00235; Goodson JD, 2010, ANN INTERN MED, V152, P742, DOI 10.7326/0003-4819-152-11-201006010-00249; *KAIS COMM MED UN, 2006, UN PRIM; National center for chronic disease prevention and health promotion, 2009, CHRON DIS POW PREV C; Solanki G, 1999, AM J PREV MED, V17, P127, DOI 10.1016/S0749-3797(99)00057-4; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; U.S. Department of Health and Human Services Agency for Healthcare Research and Quality, 2010, AHRQ PUBL	10	157	159	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2010	153	8					536	539		10.7326/0003-4819-153-8-201010190-00274	http://dx.doi.org/10.7326/0003-4819-153-8-201010190-00274			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665SA	20733178				2022-12-28	WOS:000283054600007
J	Rottmann, M; McNamara, C; Yeung, BKS; Lee, MCS; Zou, B; Russell, B; Seitz, P; Plouffe, DM; Dharia, NV; Tan, J; Cohen, SB; Spencer, KR; Gonzalez-Paez, GE; Lakshminarayana, SB; Goh, A; Suwanarusk, R; Jegla, T; Schmitt, EK; Beck, HP; Brun, R; Nosten, F; Renia, L; Dartois, V; Keller, TH; Fidock, DA; Winzeler, EA; Diagana, TT				Rottmann, Matthias; McNamara, Case; Yeung, Bryan K. S.; Lee, Marcus C. S.; Zou, Bin; Russell, Bruce; Seitz, Patrick; Plouffe, David M.; Dharia, Neekesh V.; Tan, Jocelyn; Cohen, Steven B.; Spencer, Kathryn R.; Gonzalez-Paez, Gonzalo E.; Lakshminarayana, Suresh B.; Goh, Anne; Suwanarusk, Rossarin; Jegla, Timothy; Schmitt, Esther K.; Beck, Hans-Peter; Brun, Reto; Nosten, Francois; Renia, Laurent; Dartois, Veronique; Keller, Thomas H.; Fidock, David A.; Winzeler, Elizabeth A.; Diagana, Thierry T.			Spiroindolones, a Potent Compound Class for the Treatment of Malaria	SCIENCE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; CALCIUM-PUMP; DRUG-RESISTANCE; SARCOPLASMIC-RETICULUM; ARTEMISININ; VIVAX; IDENTIFICATION; ANTIMALARIALS; ERADICATION; CHLOROQUINE	Recent reports of increased tolerance to artemisinin derivatives-the most recently adopted class of antimalarials-have prompted a need for new treatments. The spirotetrahydro-beta-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clinical isolates at low nanomolar concentration. Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4). The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.	[McNamara, Case; Plouffe, David M.; Cohen, Steven B.; Winzeler, Elizabeth A.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; [Rottmann, Matthias; Seitz, Patrick; Beck, Hans-Peter; Brun, Reto] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland; [Rottmann, Matthias; Seitz, Patrick; Beck, Hans-Peter; Brun, Reto] Univ Basel, CH-4003 Basel, Switzerland; [Yeung, Bryan K. S.; Zou, Bin; Tan, Jocelyn; Lakshminarayana, Suresh B.; Goh, Anne; Dartois, Veronique; Keller, Thomas H.; Diagana, Thierry T.] Novartis Inst Trop Dis, Singapore 138670, Singapore; [Lee, Marcus C. S.; Fidock, David A.] Columbia Univ, Med Ctr, Dept Microbiol & Immunol, New York, NY 10032 USA; [Russell, Bruce; Suwanarusk, Rossarin; Renia, Laurent] ASTAR, Singapore Immunol Network, Lab Malaria Immunobiol, Biopolis 138648, Singapore; [Russell, Bruce] Natl Univ Singapore, Dept Microbiol, Singapore 117597, Singapore; [Dharia, Neekesh V.; Spencer, Kathryn R.; Gonzalez-Paez, Gonzalo E.; Winzeler, Elizabeth A.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Jegla, Timothy] Penn State Univ, Dept Biol, University Pk, PA 16802 USA; [Jegla, Timothy] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA; [Schmitt, Esther K.] Novartis Pharma AG, Nat Prod Unit, CH-4002 Basel, Switzerland; [Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot 63110, Tak, Thailand; [Nosten, Francois] Mahidol Univ, Fac Trop Med, Bangkok, Thailand; [Nosten, Francois] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 7LJ, England; [Fidock, David A.] Columbia Univ, Med Ctr, Dept Med, Div Infect Dis, New York, NY 10032 USA	Novartis; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Novartis; Columbia University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); National University of Singapore; Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Novartis; Mahidol University; Mahidol University; University of Oxford; Columbia University	Winzeler, EA (corresponding author), Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.	winzeler@scripps.edu; thierry.diagana@novartis.com	Suwanarusk, Rossarin/E-2115-2013; Dharia, Neekesh/AAC-1245-2020; Russell, Bruce/A-9240-2011; Winzeler, Elizabeth/AAP-6752-2020; Renia, Laurent/E-2117-2011; Nosten, Francois/AAC-5509-2019	Suwanarusk, Rossarin/0000-0002-7310-245X; Dharia, Neekesh/0000-0001-5048-067X; Russell, Bruce/0000-0003-2333-4348; Winzeler, Elizabeth/0000-0002-4049-2113; Renia, Laurent/0000-0003-0349-1557; Nosten, Francois/0000-0002-7951-0745; Beck, Hans-Peter/0000-0001-8326-4834; Keller, Thomas/0000-0002-7553-6235; Yeung, Bryan KS/0000-0002-8866-1764; Fidock, David/0000-0001-6753-8938; Jegla, Timothy/0000-0001-8616-2390; Lee, Marcus/0000-0002-4973-0915; Gonzalez-Paez, Gonzalo/0000-0003-4708-5753; Rottmann, Matthias/0000-0002-2207-7899	Fidock laboratory, Medicines for Malaria Venture [MMV08/0015]; Wellcome Trust of Great Britain, Oxford Tropical Medicine Research Programme of Wellcome Trust-Mahidol University; Singapore Immunology Network, A*STAR; Wellcome Trust [WT078285]; Genomics Institute of the Novartis Research Foundation; Swiss Tropical Institute; W. M. Keck Foundation; NIH [R01AI059472]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059472] Funding Source: NIH RePORTER	Fidock laboratory, Medicines for Malaria Venture; Wellcome Trust of Great Britain, Oxford Tropical Medicine Research Programme of Wellcome Trust-Mahidol University(Wellcome Trust); Singapore Immunology Network, A*STAR(Agency for Science Technology & Research (A*STAR)); Wellcome Trust(Wellcome Trust); Genomics Institute of the Novartis Research Foundation; Swiss Tropical Institute; W. M. Keck Foundation(W.M. Keck Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank A. Matter, M. Tanner, and P. Herrling for their foresight and support in establishing a malaria drug discovery program in the context of a public-private partnership. We thank T. A. Smith (SwissTPH) for the statistical analysis of the stage and rate of action studies. We thank S. Rao (Novartis Institute for Tropical Diseases) and M. Traebert (Novartis-preclinical safety), respectively, for the cytotoxicity and hERG inhibition data. We also thank M. Weaver (Novartis-preclinical safety) for the interpretation of the preclinical toxicology data. The team acknowledges P. Schultz, who had the vision to see the potential of the drug resistance experiments in the exploratory phase. In addition, we are grateful to T. Eastman for providing guidance to establish the in vitro drug-selection protocol and for providing the cloned Dd2 parasites. Finally, the scientific expertise provided by S. E. R. Bopp and S. K. Sharma and their helpful discussions throughout this project are greatly appreciated. Funding for the PfATP4 transfectants was provided to the Fidock laboratory in part by the Medicines for Malaria Venture (MMV08/0015; PI D. Fidock). The Shoklo Malaria Research Unit is sponsored by the Wellcome Trust of Great Britain, as part of the Oxford Tropical Medicine Research Programme of Wellcome Trust-Mahidol University. Laurent Renia's laboratory is supported by a core grant from the Singapore Immunology Network, A*STAR. This work was supported by a grant from the Medicines for Malaria Venture and a translational research grant (WT078285) from the Wellcome Trust to the Novartis Institute for Tropical Diseases, the Genomics Institute of the Novartis Research Foundation and the Swiss Tropical Institute, and by grants to E. A. W. from the W. M. Keck Foundation and the NIH (R01AI059472). NITD609 is described in the Novartis patent application WO2009/132921. All requests for spiroindolones or related compounds are subject to a Material Transfer Agreement. T. H. K. and E. A. W. own shares in Novartis (Switzerland).	AMES BN, 1973, P NATL ACAD SCI USA, V70, P782, DOI 10.1073/pnas.70.3.782; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Dharia NV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-r21; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Dyer M, 1996, MOL BIOCHEM PARASIT, V78, P1, DOI 10.1016/S0166-6851(96)02593-5; Eastman RT, 2009, NAT REV MICROBIOL, V7, P864, DOI 10.1038/nrmicro2239; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Greenwood BM, 2008, J CLIN INVEST, V118, P1266, DOI 10.1172/JCI33996; Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099; Guthmann JP, 2008, TROP MED INT HEALTH, V13, P91, DOI 10.1111/j.1365-3156.2007.01978.x; Hayton K, 2008, CURR GENET, V54, P223, DOI 10.1007/s00294-008-0214-x; Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931; Jensen AML, 2006, EMBO J, V25, P2305, DOI 10.1038/sj.emboj.7601135; Krishna S, 2001, J BIOL CHEM, V276, P10782, DOI 10.1074/jbc.M010554200; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Lee MCS, 2008, MOL MICROBIOL, V68, P1535, DOI 10.1111/j.1365-2958.2008.06250.x; Moncoq K, 2007, J BIOL CHEM, V282, P9748, DOI 10.1074/jbc.M611653200; Nkrumah LJ, 2006, NAT METHODS, V3, P615, DOI 10.1038/NMETH904; Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011; Nzila A, 2010, J ANTIMICROB CHEMOTH, V65, P390, DOI 10.1093/jac/dkp449; Olliaro P, 2009, CLIN PHARMACOL THER, V85, P584, DOI 10.1038/clpt.2009.51; Plouffe D, 2008, P NATL ACAD SCI USA, V105, P9059, DOI 10.1073/pnas.0802982105; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; Russell BM, 2003, ANTIMICROB AGENTS CH, V47, P170, DOI 10.1128/AAC.47.1.170-173.2003; Sharrock WW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-94; Takahashi M, 2007, P NATL ACAD SCI USA, V104, P5800, DOI 10.1073/pnas.0700979104; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Traebert Martin, 2005, Expert Opin Drug Saf, V4, P421, DOI 10.1517/14740338.4.3.421; TROTTEIN F, 1995, GENE, V158, P133, DOI 10.1016/0378-1119(95)00158-3; Vennerstrom JL, 2004, NATURE, V430, P900, DOI 10.1038/nature02779; Volkman SK, 2007, NAT GENET, V39, P113, DOI 10.1038/ng1930; Wells TNC, 2009, NAT REV DRUG DISCOV, V8, P879, DOI 10.1038/nrd2972; White NJ, 2008, SCIENCE, V320, P330, DOI 10.1126/science.1155165; White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; *WHO, WORLD MAL REP 2009; Winzeler EA, 2008, NATURE, V455, P751, DOI 10.1038/nature07361; Yatime L, 2009, BBA-BIOENERGETICS, V1787, P207, DOI 10.1016/j.bbabio.2008.12.019	41	892	898	5	434	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2010	329	5996					1175	1180		10.1126/science.1193225	http://dx.doi.org/10.1126/science.1193225			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813948	Green Accepted			2022-12-28	WOS:000281485600027
J	Bhatia, M				Bhatia, Mickie			Microenvironment Mimicry	SCIENCE			English	Editorial Material							STEM-CELL NICHE; SELF-RENEWAL		McMaster Univ, Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada	McMaster University	Bhatia, M (corresponding author), McMaster Univ, Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada.	mbhatia@mcmaster.ca						Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035; Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758; Hess D, 2003, NAT BIOTECHNOL, V21, P763, DOI 10.1038/nbt841; Johnston LA, 2009, SCIENCE, V324, P1679, DOI 10.1126/science.1163862; Kuang S, 2008, CELL STEM CELL, V2, P22, DOI 10.1016/j.stem.2007.12.012; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Schroeder T, 2010, CELL STEM CELL, V6, P203, DOI 10.1016/j.stem.2010.02.006; Stewart MH, 2008, J MOL MED, V86, P875, DOI 10.1007/s00109-008-0356-9	12	14	14	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1024	1025		10.1126/science.1194919	http://dx.doi.org/10.1126/science.1194919			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798306				2022-12-28	WOS:000281253500024
J	Wright, PA				Wright, Paul A.			Opening the Door to Peptide-Based Porous Solids	SCIENCE			English	Editorial Material							MECHANOSENSITIVE CHANNEL; ADSORPTION; FRAMEWORKS; GASES		Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland	University of St Andrews	Wright, PA (corresponding author), Univ St Andrews, Sch Chem, Purdie Bldg,North Haugh, St Andrews KY16 9ST, Fife, Scotland.	paw2@st-andrews.ac.uk						Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Cabrita LD, 2010, CURR OPIN STRUC BIOL, V20, P33, DOI 10.1016/j.sbi.2010.01.005; Ferey G, 2005, ACCOUNTS CHEM RES, V38, P217, DOI 10.1021/ar040163i; Ferey G, 2009, CHEM SOC REV, V38, P1380, DOI 10.1039/b804302g; Kitagawa S, 2004, ANGEW CHEM INT EDIT, V43, P2334, DOI 10.1002/anie.200300610; Kitaura R, 2003, ANGEW CHEM INT EDIT, V42, P428, DOI 10.1002/anie.200390130; Llewellyn PL, 2006, ANGEW CHEM INT EDIT, V45, P7751, DOI 10.1002/anie.200602278; Millange F, 2008, ANGEW CHEM INT EDIT, V47, P4100, DOI 10.1002/anie.200705607; Miller SR, 2008, J AM CHEM SOC, V130, P15967, DOI 10.1021/ja804936z; Rabone J, 2010, SCIENCE, V329, P1053, DOI 10.1126/science.1190672; Vaidhyanathan R, 2006, ANGEW CHEM INT EDIT, V45, P6495, DOI 10.1002/anie.200602242; Wang WJ, 2008, SCIENCE, V321, P1179, DOI 10.1126/science.1159262; Yaghi OM, 2003, NATURE, V423, P705, DOI 10.1038/nature01650	13	11	11	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1025	1026		10.1126/science.1195176	http://dx.doi.org/10.1126/science.1195176			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798307				2022-12-28	WOS:000281253500025
J	Schnabel, J				Schnabel, Jim			Secrets of the shaking palsy	NATURE			English	Editorial Material							NEURONAL CELL-DEATH; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; LEWY BODIES; TRANSMISSION; PROPAGATION; PATHOLOGY; BRAIN											Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Cookson MR, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-9; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Sulzer D, 2010, MOVEMENT DISORD, V25, pS27, DOI 10.1002/mds.22639; Taylor TN, 2009, J NEUROSCI, V29, P8103, DOI 10.1523/JNEUROSCI.1495-09.2009	14	12	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					S2	S5		10.1038/466S2b	http://dx.doi.org/10.1038/466S2b			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739933				2022-12-28	WOS:000281203600058
J	[Anonymous]				[Anonymous]			CELLULAR IMAGING A LONG-TERM LIVE-CELL COMMITMENT	NATURE			English	Editorial Material																			0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					1138	1138		10.1038/4661138a	http://dx.doi.org/10.1038/4661138a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740019	Bronze			2022-12-28	WOS:000281203600051
J	Al-Mohammad, A; Mant, J; Laramee, P; Swain, S				Al-Mohammad, Abdallah; Mant, Jonathan; Laramee, Philippe; Swain, Sharon		Chronic Heart Failure Guideline De	Guidelines Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Al-Mohammad, Abdallah] Sheffield Teaching Hosp NHS Fdn Trust, S Yorkshire Cardiothorac Ctr, Sheffield S5 7AU, S Yorkshire, England; [Mant, Jonathan] Univ Cambridge, Gen Practice & Primary Care Res Unit, Cambridge CB2 0SR, England; [Laramee, Philippe; Swain, Sharon] Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England	University of Sheffield; University of Cambridge; Royal College of Physicians	Al-Mohammad, A (corresponding author), Sheffield Teaching Hosp NHS Fdn Trust, S Yorkshire Cardiothorac Ctr, Sheffield S5 7AU, S Yorkshire, England.	a.al.mohammad.87@googlemail.com	Al-Mohammad, Abdallah/I-5663-2019; Dawda, Paresh/I-6947-2015	Al-Mohammad, Abdallah/0000-0001-6517-8692; Dawda, Paresh/0000-0003-2727-8320; Foley, Paul/0000-0002-4856-832X; Mant, Jonathan/0000-0002-9531-0268				Cowie MR, 1999, EUR HEART J, V20, P421, DOI 10.1053/euhj.1998.1280; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Mehta PA, 2009, HEART, V95, P1851, DOI 10.1136/hrt.2008.156034; *NAT I CLIN EXC, 2003, CHRON HEART FAIL MAN; *NAT I HLTH CLIN E, 2007, HEART FAIL CARD RES; National Institute for Health and Clinical Excellence, 2006, ARRH IMPL CARD DEF I; National Institute Health and Clinical Excellence, 2010, CHRON HEART FAIL MAN; Owan TE, 2006, NEW ENGL J MED, V355, P251, DOI 10.1056/NEJMoa052256; Petersen S, 2002, CORONARY HEART DIS S	9	30	30	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 25	2010	341								c4130	10.1136/bmj.c4130	http://dx.doi.org/10.1136/bmj.c4130			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IH	20739363				2022-12-28	WOS:000281446000003
J	Psaty, BM; Prentice, RL				Psaty, Bruce M.; Prentice, Ross L.			Minimizing Bias in Randomized Trials The Importance of Blinding	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARDIOVASCULAR MORBIDITY; MYOCARDIAL-INFARCTION; ROSIGLITAZONE; HYPERTENSION; MORTALITY; RISK		[Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA; [Psaty, Bruce M.] Grp Hlth, Ctr Hlth Studies, Seattle, WA USA; [Prentice, Ross L.] Fred Hutchinson Canc Res Ctr, Ctr Hlth Studies, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Psaty, BM (corresponding author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Ste 1360, Seattle, WA 98101 USA.	psaty@u.washington.edu			NCI NIH HHS [CA53996] Funding Source: Medline; NHLBI NIH HHS [HL085251, HL087652, HL078888, HL080295] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA053996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL080295, R01HL087652, R01HL080295, R01HL078888, R01HL085251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bero L, 2007, PLOS MED, V4, P1001, DOI 10.1371/journal.pmed.0040184; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Psaty BM, 2007, NEW ENGL J MED, V357, P67, DOI 10.1056/NEJMe078116; Psaty BM, 2009, JAMA-J AM MED ASSOC, V302, P1698, DOI 10.1001/jama.2009.1497	8	70	70	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					793	794		10.1001/jama.2010.1161	http://dx.doi.org/10.1001/jama.2010.1161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20716744				2022-12-28	WOS:000280993700029
J	Middleton, LJ; Champaneria, R; Daniels, JP; Bhattacharya, S; Cooper, KG; Hilken, NH; O'Donovan, P; Gannon, M; Gray, R; Khan, KS				Middleton, L. J.; Champaneria, R.; Daniels, J. P.; Bhattacharya, S.; Cooper, K. G.; Hilken, N. H.; O'Donovan, P.; Gannon, M.; Gray, R.; Khan, K. S.		Int Heavy Menstrual Bleeding	Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THERMAL BALLOON ABLATION; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; 5-YEAR FOLLOW-UP; TRANSCERVICAL RESECTION; HYSTEROSCOPIC ENDOMETRIAL; ROLLERBALL ABLATION; ABDOMINAL HYSTERECTOMY; EPISODE STATISTICS; COST-EFFECTIVENESS	Objective To evaluate the relative effectiveness of hysterectomy, endometrial destruction (both "first generation" hysteroscopic and "second generation" non-hysteroscopic techniques), and the levonorgestrel releasing intrauterine system (Mirena) in the treatment of heavy menstrual bleeding. Design Meta-analysis of data from individual patients, with direct and indirect comparisons made on the primary outcome measure of patients' dissatisfaction. Data sources Data were sought from the 30 randomised controlled trials identified after a comprehensive search of the Cochrane Library, Medline, Embase, and CINAHL databases, reference lists, and contact with experts. Raw data were available from 2814 women randomised into 17 trials (seven trials including 1359 women for first v second generation endometrial destruction; six trials including 1042 women for hysterectomy v first generation endometrial destruction; one trial including 236 women for hysterectomy v Mirena; three trials including 177 women for second generation endometrial destruction v Mirena). Eligibility criteria for selecting studies Randomised controlled trials comparing hysterectomy, first and second generation endometrial destruction, and Mirena for women with heavy menstrual bleeding unresponsive to other medical treatment. Results At around 12 months, more women were dissatisfied with outcome with first generation hysteroscopic techniques than with hysterectomy (13% v 5%; odds ratio 2.46, 95% confidence interval 1.54 to 3.9, P<0.001), but hospital stay (weighted mean difference 3.0 days, 2.9 to 3.1 days, P<0.001) and time to resumption of normal activities (5.2 days, 4.7 to 5.7 days, P<0.001) were longer for hysterectomy. Unsatisfactory outcomes were comparable with first and second generation techniques (odds ratio 1.2, 0.9 to 1.6, P=0.2), although second generation techniques were quicker (weighted mean difference 14.5 minutes, 13.7 to 15.3 minutes, P<0.001) and women recovered sooner (0.48 days, 0.20 to 0.75 days, P<0.001), with fewer procedural complications. Indirect comparison suggested more unsatisfactory outcomes with second generation techniques than with hysterectomy (11% v 5%; odds ratio 2.3, 1.3 to 4.2, P=0.006). Similar estimates were seen when Mirena was indirectly compared with hysterectomy (17% v 5%; odds ratio 2.2, 0.9 to 5.3, P=0.07), although this comparison lacked power because of the limited amount of data available for analysis. Conclusions More women are dissatisfied after endometrial destruction than after hysterectomy. Dissatisfaction rates are low after all treatments, and hysterectomy is associated with increased length of stay in hospital and a longer recovery period. Definitive evidence on effectiveness of Mirena compared with more invasive procedures is lacking.	[Middleton, L. J.; Champaneria, R.; Daniels, J. P.; Hilken, N. H.; Gray, R.] Univ Birmingham, Birmingham Clin Trials Unit, Birmingham B15 2TT, W Midlands, England; [Bhattacharya, S.] Univ Aberdeen, Sch Med & Dent, Aberdeen Matern Hosp, Sect Appl Clin Sci,Div Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland; [Cooper, K. G.] Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB25 2ZN, Scotland; [O'Donovan, P.] Bradford Teaching Hosp NHS Fdn Trust, Bradford Royal Infirm, Bradford BD6 6RJ, W Yorkshire, England; [O'Donovan, P.] Univ Bradford, Bradford BD7 1DP, W Yorkshire, England; [Gannon, M.] Midland Reg Hosp, Dept Obstet & Gynaecol, Mullingar, Westmeath, Ireland; [Khan, K. S.] Univ Birmingham, Acad Dept Obstet & Gynaecol, Birmingham Womens Hosp, Div Reprod & Child Hlth, Birmingham B15 2TG, W Midlands, England	University of Birmingham; University of Aberdeen; University of Aberdeen; Bradford Royal Infirmary; University of Bradford; Birmingham Women's Hospital; University of Birmingham	Middleton, LJ (corresponding author), Univ Birmingham, Birmingham Clin Trials Unit, Birmingham B15 2TT, W Midlands, England.	l.j.middleton@bham.ac.uk	Khan, Khalid S/AAT-8824-2020; Tam, Hung/AAE-3628-2020	Khan, Khalid S/0000-0001-5084-7312; Tam, Hung/0000-0003-1189-740X; cooper, kevin/0000-0003-1486-0071; Gray, Richard/0000-0003-4440-574X; Bhattacharya, Siladitya/0000-0002-4588-356X; Middleton, Lee/0000-0003-4621-1922	National Institute for Health Research [05/45/02]; Medical Research Council [MC_U137686861] Funding Source: researchfish; MRC [MC_U137686861] Funding Source: UKRI	National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This review was funded by the Health Technology Assessment Programme of the National Institute for Health Research (05/45/02).	Abbott J, 2003, FERTIL STERIL, V80, P203, DOI 10.1016/S0015-0282(03)00549-1; Abbott JA, 2002, HUM REPROD UPDATE, V8, P68, DOI 10.1093/humupd/8.1.68; Barrington JW, 2003, EUR J OBSTET GYN R B, V108, P72, DOI 10.1016/S0301-2115(02)00408-6; Bhattacharya S, 1997, BRIT J OBSTET GYNAEC, V104, P601, DOI 10.1111/j.1471-0528.1997.tb11540.x; Bongers MY, 2004, BJOG-INT J OBSTET GY, V111, P1095, DOI 10.1111/j.1471-0528.2004.00253.x; Brown PM, 2006, BJOG-INT J OBSTET GY, V113, P797, DOI 10.1111/j.1471-0528.2006.00944.x; Brun JL, 2006, J MINIM INVAS GYN, V13, P424, DOI 10.1016/j.jmig.2006.05.006; Busfield RA, 2006, BJOG-INT J OBSTET GY, V113, P257, DOI 10.1111/j.1471-0528.2006.00863.x; Chapple A, 1999, J ADV NURS, V29, P1500, DOI 10.1046/j.1365-2648.1999.01038.x; Clark TJ, 2002, EUR J OBSTET GYN R B, V104, P96, DOI 10.1016/S0301-2115(02)00076-3; Cooper J, 2002, J AM ASSOC GYN LAP, V9, P418, DOI 10.1016/S1074-3804(05)60513-0; Cooper JM, 2004, J AM ASSOC GYN LAP, V11, P394, DOI 10.1016/S1074-3804(05)60057-6; Cooper KG, 2005, BJOG-INT J OBSTET GY, V112, P470, DOI 10.1111/j.1471-0528.2004.00511.x; Cooper KG, 1999, LANCET, V354, P1859, DOI 10.1016/S0140-6736(99)04101-X; Cooper KG, 2001, BRIT J OBSTET GYNAEC, V108, P1222, DOI 10.1016/S0306-5456(01)00275-3; Corson SL, 2001, J AM ASSOC GYN LAP, V8, P359, DOI 10.1016/S1074-3804(05)60331-3; Corson SL, 2000, J AM ASSOC GYN LAP, V7, P489, DOI 10.1016/S1074-3804(05)60361-1; Crosignani PG, 1997, OBSTET GYNECOL, V90, P257, DOI 10.1016/S0029-7844(97)00226-3; Crosignani PG, 1997, AM J OBSTET GYNECOL, V177, P95, DOI 10.1016/S0002-9378(97)70445-9; Dickersin K, 2007, OBSTET GYNECOL, V110, P1279, DOI 10.1097/01.AOG.0000292083.97478.38; Duleba AJ, 2003, J AM ASSOC GYN LAP, V10, P17, DOI 10.1016/S1074-3804(05)60229-0; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATM EARL BREAST C; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GANNON MJ, 1991, BRIT MED J, V303, P1362, DOI 10.1136/bmj.303.6814.1362; Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1; Hasselblad V, 1998, MED DECIS MAKING, V18, P37, DOI 10.1177/0272989X9801800110; Hawe J, 2003, BJOG-INT J OBSTET GY, V110, P350, DOI 10.1016/S1470-0328(03)02924-0; Higgins J.P., 2011, COCHRANE HDB SYSTEMA, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HIGHAM JM, 1990, BRIT J OBSTET GYNAEC, V97, P734, DOI 10.1111/j.1471-0528.1990.tb16249.x; Hurskainen R, 2004, JAMA-J AM MED ASSOC, V291, P1456, DOI 10.1001/jama.291.12.1456; Hurskainen R, 2001, LANCET, V357, P273, DOI 10.1016/S0140-6736(00)03615-1; Kittelsen N, 1998, GYNAECOL ENDOSC, V7, P61, DOI 10.1046/j.1365-2508.1998.00165.x; Lethaby A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001501.pub2; Lethaby A, 2003, BMJ-BRIT MED J, V327, P1243, DOI 10.1136/bmj.327.7426.1243; Lethaby A, 1999, COCHRANE DB SYST REV, V2; Lethaby AE, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002126.pub2; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Loffer FD, 2002, J AM ASSOC GYN LAP, V9, P429, DOI 10.1016/S1074-3804(05)60514-2; Loffer FD, 2001, J AM ASSOC GYN LAP, V8, P48, DOI 10.1016/S1074-3804(05)60548-8; Malak KA, 2006, GYNECOL SURG, V3, P275, DOI 10.1007/s10397-006-0234-9; Maresh MJA, 2002, BJOG-INT J OBSTET GY, V109, P302, DOI 10.1111/j.1471-0528.2002.01282.x; Marjoribanks J, 2006, COCHRANE DB SYST REV, V2; Meyer WR, 1998, OBSTET GYNECOL, V92, P98, DOI 10.1016/S0029-7844(98)00141-0; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; National Collaborating Centre for Women's and Children's Health, 2007, HEAV MENSTR BLEED; OConnor H, 1997, LANCET, V349, P897, DOI 10.1016/S0140-6736(96)07285-6; Overton C, 1997, BRIT J OBSTET GYNAEC, V104, P1351, DOI 10.1111/j.1471-0528.1997.tb11003.x; Pellicano M, 2002, AM J OBSTET GYNECOL, V187, P545, DOI 10.1067/mob.2002.124958; Perino A, 2004, FERTIL STERIL, V82, P731, DOI 10.1016/j.fertnstert.2004.01.045; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979; Prentice A, 1999, BEST PRACT RES CL OB, V13, P181, DOI 10.1053/beog.1999.0016; Reid PC, 2005, BRIT MED J, V330, P938, DOI 10.1136/bmj.38376.505382.AE; Reid PC, 2007, EUR J OBSTET GYN R B, V135, P191, DOI 10.1016/j.ejogrb.2006.08.008; Riley RD, 2008, STAT MED, V27, P1870, DOI 10.1002/sim.3165; Romer T, 1998, Zentralbl Gynakol, V120, P511; Sambrook AM, 2009, BJOG-INT J OBSTET GY, V116, P1038, DOI 10.1111/j.1471-0528.2009.02181.x; Sambrook AM, 2009, BJOG-INT J OBSTET GY, V116, P1033, DOI 10.1111/j.1471-0528.2009.02201.x; Shapley M, 2004, BRIT J GEN PRACT, V54, P359; Shaw RW, 2007, AUST NZ J OBSTET GYN, V47, P335, DOI 10.1111/j.1479-828X.2007.00747.x; Soysal ME, 2001, GYNECOL OBSTET INVES, V51, P128, DOI 10.1159/000052908; Soysal Mehmet, 2002, Zentralbl Gynakol, V124, P213, DOI 10.1055/s-2002-32434; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Stewart LA, 2002, EVAL HEALTH PROF, V25, P76, DOI 10.1177/0163278702025001006; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Tam WH, 2006, GYNECOL OBSTET INVES, V62, P84, DOI 10.1159/000092660; Van Zon-Rabelink IAA, 2004, EUR J OBSTET GYN R B, V114, P97, DOI 10.1016/j.ejogrb.2003.10.010; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whitehead A., 2002, METAANALYSIS CONTROL; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zupi E, 2003, AM J OBSTET GYNECOL, V188, P7, DOI 10.1067/mob.2003.60	74	74	74	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 16	2010	341								c3929	10.1136/bmj.c3929	http://dx.doi.org/10.1136/bmj.c3929			30	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845KA	20713583	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000296820400001
J	WARDEN, J				WARDEN, J			PATIENT POWER ON THE MARCH	BRITISH MEDICAL JOURNAL			English	Editorial Material																		1988, REV RESTRICTIVE TRAD; 1988, BR MED J, V296, P1391	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1988	296	6635					1547	1547		10.1136/bmj.296.6635.1547	http://dx.doi.org/10.1136/bmj.296.6635.1547			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N6525	20742996	Green Published			2022-12-28	WOS:A1988N652500064
J	WARDEN, J				WARDEN, J			CONSENSUS OUT OF CRISIS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1988	296	6628					1078	1078		10.1136/bmj.296.6628.1078	http://dx.doi.org/10.1136/bmj.296.6628.1078			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M9668	20742982	Green Published			2022-12-28	WOS:A1988M966800053
J	WARDEN, J				WARDEN, J			PENDULUM POLITICS OF ABORTION	BRITISH MEDICAL JOURNAL			English	Letter																		ALTON D, 1988, BR MED J, V296, P446	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1988	296	6622					653	653		10.1136/bmj.296.6622.653	http://dx.doi.org/10.1136/bmj.296.6622.653			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	M3498	20742965	Green Published			2022-12-28	WOS:A1988M349800052
J	Rodriguez-Trigo, G; Zock, JP; Pozo-Rodriguez, F; Gomez, FP; Monyarch, G; Bouso, L; Coll, MD; Verea, H; Anto, JM; Fuster, C; Barbera, JA				Rodriguez-Trigo, Gema; Zock, Jan-Paul; Pozo-Rodriguez, Francisco; Gomez, Federico P.; Monyarch, Gemma; Bouso, Laura; Dolors Coll, M.; Verea, Hector; Anto, Josep M.; Fuster, Carme; Albert Barbera, Joan		SEPAR Soc Espanola Neumologia Ciru	Health Changes in Fishermen 2 Years After Clean-up of the Prestige Oil Spill	ANNALS OF INTERNAL MEDICINE			English	Article							EXHALED BREATH CONDENSATE; CHROMOSOMAL-ABERRATIONS; OXIDATIVE STRESS; TANKER BRAER; INCREASED 8-ISOPROSTANE; ASTHMATIC-CHILDREN; REFERENCE VALUES; CANCER-RISK; EXPOSURE; BIOMARKERS	Background: In 2002, the oil tanker Prestige spilled more than 67 000 tons of bunker oil, heavily contaminating the coast of northwestern Spain. Objective: To assess respiratory effects and chromosomal damage in clean-up workers of the oil spill 2 years after the exposure. Design: Cross-sectional study. Setting: Fishermen cooperatives in coastal villages. Participants: Local fishermen who were highly exposed (n = 501) or not exposed (n = 177) to oil 2 years after the spill. Measurements: Respiratory symptoms; forced spirometry; methacholine challenge; markers of oxidative stress (8-isoprostane), airway inflammation (interleukins, tumor necrosis factor-alpha, and interferon-gamma), and growth factor activity in exhaled breath condensate; and chromosomal lesions and structural alterations in circulating lymphocytes. Results: Compared with nonexposed participants, persons exposed to oil were at increased risk for lower respiratory tract symptoms (risk difference, 8.0 [95% CI, 1.1 to 14.8]). Lung function did not significantly differ between the groups. Among nonsmoking participants, exposed individuals had higher exhaled 8-isoprostane levels than nonexposed individuals (geometric mean ratio, 2.5 [CI, 1.7 to 3.7]), and exposed individuals with lower respiratory tract symptoms had higher 8-isoprostane levels than those of exposed individuals without symptoms. Exposed nonsmoking participants also had higher levels of exhaled vascular endothelial growth factor (risk difference, 44.8 [CI, 27.9 to 61.6]) and basic fibroblast growth factor (risk difference, 16.0 [CI, 3.5 to 28.6]). A higher proportion of exposed participants had structural chromosomal alterations (risk difference, 27.4 [CI, 10.0 to 44.8]), predominantly unbalanced alterations. The risk for elevated levels of exhaled 8-isoprostane, vascular endothelial growth factor, and basic fibroblast growth factor and structural chromosomal alterations seemed to increase with intensity of exposure to clean-up work. Limitations: The clinical significance of exhaled biomarkers and chromosomal findings are uncertain. The association between oil exposure and the observed changes may not be causal. The findings may not apply to spills involving other types of oil or to different populations of oil spill workers. Conclusion: Participation in clean-up of a major oil spill was associated with persistent respiratory symptoms, elevated markers of airway injury in breath condensate, and chromosomal damage.	Complexo Hosp Univ A Coruna, La Coruna, Spain; Hosp Clin San Carlos, Madrid, Spain; Univ Hosp 12 Octubre, Madrid, Spain; Autonomous Univ Barcelona, Ctr Res Environm Epidemiol CREAL, Hosp Clin Inst Invest Biomed August Pi & Sunyer I, IMIM Hosp Mar,CIBERESP,Municipal Inst Med Res, Barcelona, Spain; Pompeu Fabra Univ, Barcelona, Spain; Ctr Invest Biomed Red Enfermedades Resp CIBERES, Bunyola, Mallorca, Spain	Complejo Hospitalario Universitario A Coruna; Universidade da Coruna; Hospital Clinico San Carlos; Hospital Universitario 12 de Octubre; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Barbera, JA (corresponding author), Hosp Clin Barcelona, Serv Pneumol, Villarroel 170, E-08036 Barcelona, Spain.	jbarbera@clinic.ub.es	Zock, Jan-Paul/P-5034-2018; Burgos, Felip/J-3055-2014; Burgos, Felip/E-5734-2015; Anto, J M/H-2676-2014	Zock, Jan-Paul/0000-0002-2941-6259; Burgos, Felip/0000-0002-4938-4581; Burgos, Felip/0000-0002-4938-4581; Anto, J M/0000-0002-4736-8529; Barbera, Joan Albert/0000-0003-1469-4990; Serrano-Mollar, Anna/0000-0002-4990-8162	Complexo Hospitalario Universitario A Coruna; Instituto de Salud Carlos III/European Regional Development Fund [PI03/1685, PI05/0548, BAE 06/90018, 01-3058]; SEPAR; Centro de Investigacion en Red de Enfermedades Respiratorias	Complexo Hospitalario Universitario A Coruna; Instituto de Salud Carlos III/European Regional Development Fund(Instituto de Salud Carlos IIIEuropean Commission); SEPAR; Centro de Investigacion en Red de Enfermedades Respiratorias	The authors thank the participating fishermen, the staff of their cooperatives, and the efforts made by A. Devesa; the SEPAR-Prestige data collection team (Y. Torralba, A. Souto, M. Rodriguez-Valcarcel, and L. Vazquez-Rey) for their outstanding work; the staff of Complexo Hospitalario Universitario A Coruna (S. Lamela, E. Rodriguez, M. Garea, and M. Saleta) for their support; D. Macfarlane for assistance with data management and reviewing the manuscript; A. Espinosa for her contribution to the statistical analyses; A. Serrano-Mollar and G. Gay for analysis of EBC; A. Lopez-Rodriguez and C. Rodriguez-Escudero, formerly of Servizo Galego de Saude, for their valuable collaboration; and J.L. Alvarez-Sala and J. Ancochea, past presidents of SEPAR, for their initiative and continuous support.; By Instituto de Salud Carlos III/European Regional Development Fund (grants PI03/1685 and PI05/0548), SEPAR, and Centro de Investigacion en Red de Enfermedades Respiratorias. The Instituto de Salud Carlos III/European Regional Development Fund also provided grants to Dr. Rodriguez-Trigo (grant BAE 06/90018) and Dr. Zock (grant Miguel Servet 01-3058).	*AG TOX SUBST DIS, 1995, TOX PROF FUEL OILS A; [Anonymous], 2009, OIL TANK SPILL STAT; Antczak Adam, 2002, Int J Occup Med Environ Health, V15, P317; Au WW, 2007, INT J HYG ENVIR HEAL, V210, P239, DOI 10.1016/j.ijheh.2006.11.001; Barreto M, 2009, CHEST, V135, P66, DOI 10.1378/chest.08-0722; Beinert T, 1999, Eur J Med Res, V4, P328; Biernacki WA, 2003, THORAX, V58, P294, DOI 10.1136/thorax.58.4.294; Bonassi S, 2008, CARCINOGENESIS, V29, P1178, DOI 10.1093/carcin/bgn075; CAMPBELL D, 1993, BRIT MED J, V307, P1251, DOI 10.1136/bmj.307.6914.1251; CAMPBELL D, 1994, BRIT MED J, V309, P773, DOI 10.1136/bmj.309.6957.773; Celik M, 2007, MUTAT RES-GEN TOX EN, V627, P158, DOI 10.1016/j.mrgentox.2006.11.003; Cole J, 1997, ENVIRON MOL MUTAGEN, V30, P97; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Forni A, 1996, ENVIRON HEALTH PERSP, V104, P1309, DOI 10.2307/3433181; Frohling S, 2008, NEW ENGL J MED, V359, P722, DOI 10.1056/NEJMra0803109; Hagmar L, 2004, CANCER RES, V64, P2258, DOI 10.1158/0008-5472.CAN-03-3360; Holeckova B, 2004, ANN AGR ENV MED, V11, P175; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Idali F, 2006, EUR RESPIR J, V27, P451, DOI 10.1183/09031936.06.00067105; *INT AG RES CANC, 1998, IARC MON OV EV CA S7, V1; Jang An-Soo, 2007, Korean Journal of Internal Medicine, V22, P8; Koutsokera A, 2008, CURR MED CHEM, V15, P620; Laffon B, 2006, FOOD CHEM TOXICOL, V44, P1714, DOI 10.1016/j.fct.2006.05.010; Leung TF, 2005, INT ARCH ALLERGY IMM, V137, P66, DOI 10.1159/000085106; LGSM Shaffer, 2009, ISCN 2009 INT SYSTEM, DOI DOI 10.1007/S00439-009-0726-6; LITTLEFIELD LG, 1986, MUTAT RES, V170, P145, DOI 10.1016/0165-1218(86)90028-5; Lyons RA, 1999, J EPIDEMIOL COMMUN H, V53, P306, DOI 10.1136/jech.53.5.306; McHale Cliona M, 2008, J Natl Cancer Inst Monogr, P74, DOI 10.1093/jncimonographs/lgn010; Meo SA, 2008, MAR POLLUT BULL, V56, P88, DOI 10.1016/j.marpolbul.2007.09.039; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Norppa H, 2006, MUTAT RES-FUND MOL M, V600, P37, DOI 10.1016/j.mrfmmm.2006.05.030; Norppa H, 2004, TOXICOL LETT, V149, P309, DOI 10.1016/j.toxlet.2003.12.042; Pelclova D, 2008, IND HEALTH, V46, P484, DOI 10.2486/indhealth.46.484; Perez-Cadahia B, 2008, MUTAT RES-GEN TOX EN, V653, P117, DOI 10.1016/j.mrgentox.2008.04.002; Perez-Cadahia B, 2007, ENVIRON INT, V33, P176, DOI 10.1016/j.envint.2006.09.006; Podechard N, 2008, TOXICOL LETT, V177, P130, DOI 10.1016/j.toxlet.2008.01.006; ROCA J, 1986, B EUR PHYSIOPATH RES, V22, P217; Rodriguez-Trigo G, 2007, ARCH BRONCONEUMOL, V43, P628; Roma-Torres J, 2006, MUTAT RES-GEN TOX EN, V604, P19, DOI 10.1016/j.mrgentox.2005.12.005; Rossner P, 2005, ENVIRON HEALTH PERSP, V113, P517, DOI 10.1289/ehp.6925; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; Tompa A, 2005, INT J HYG ENVIR HEAL, V208, P509, DOI 10.1016/j.ijheh.2005.01.029; Zhang LP, 2002, CRIT REV TOXICOL, V32, P1, DOI 10.1080/20024091064165; Zock JP, 2007, AM J RESP CRIT CARE, V176, P610, DOI 10.1164/rccm.200701-016OC	45	54	55	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2010	153	8					489	498		10.7326/0003-4819-153-8-201010190-00279	http://dx.doi.org/10.7326/0003-4819-153-8-201010190-00279			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665SA	20733177				2022-12-28	WOS:000283054600001
J	Steg, PG; Jolly, SS; Mehta, SR; Afzal, R; Xavier, D; Rupprecht, HJ; Lopez-Sendon, JL; Budaj, A; Diaz, R; Avezum, A; Widimsky, P; Rao, SV; Chrolavicius, S; Joyner, C; Pogue, J; Yusuf, S				Steg, Philippe Gabriel; Jolly, Sanjit S.; Mehta, Shamir R.; Afzal, Rizwan; Xavier, Denis; Rupprecht, Hans-Jurgen; Lopez-Sendon, Jose L.; Budaj, Andrzej; Diaz, Rafael; Avezum, Alvaro; Widimsky, Petr; Rao, Sunil V.; Chrolavicius, Susan; Joyner, Campbell; Pogue, Janice; Yusuf, Salim		FUTURA OASIS-8 Trial Grp	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux The FUTURA/OASIS-8 Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED CLOTTING TIME; EUROPEAN-SOCIETY; TASK-FORCE; ANTICOAGULATION; ENOXAPARIN; OUTCOMES; IMPACT	Context The optimal unfractionated heparin regimen for percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndromes treated with fondaparinux is uncertain. Objective To compare the safety of 2 unfractionated heparin regimens during PCI in high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Design, Setting, and Participants Double-blind randomized parallel-group trial in 179 hospitals in 18 countries involving 2026 patients undergoing PCI within 72 hours, nested within a cohort of 3235 high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux enrolled from February 2009 to March 2010. Interventions Patients received intravenously either low-dose unfractionated heparin, 50 U/kg, regardless of use of glycoprotein IIb/IIIa (GpIIb-IIIa) inhibitors or standard-dose unfractionated heparin, 85 U/kg (60 U/kg with GpIIb-IIIa inhibitors), adjusted by blinded activated clotting time (ACT). Main Outcome Measures Composite of major bleeding, minor bleeding, or major vascular access-site complications up to 48 hours after PCI. Key secondary outcomes include composite of major bleeding at 48 hours with death, myocardial infarction, or target vessel revascularization within day 30. Results The primary outcome occurred in 4.7% of those in the low-dose group vs 5.8% in the standard-dose group (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.54-1.19; P=.27). The rates of major bleeding were not different but the rates of minor bleeding were lower with 0.7% in the low-dose group vs 1.7% in the standard-dose group (OR, 0.40; 95% CI, 0.16-0.97; P=.04). For the key secondary outcome, the rates for low-dose group were 5.8% vs 3.9% in the standard-dose group (OR, 1.51; 95% CI, 1.00-2.28; P=.05) and for death, myocardial infarction, or target vessel revascularization it was 4.5% for the low-dose group vs 2.9% for the standard-dose group (OR, 1.58; 95% CI, 0.98-2.53; P=.06). Catheter thrombus rates were very low (0.5% in the low-dose group and 0.1% in the standard-dose group, P=.15). Conclusion Low-dose compared with standard-dose unfractionated heparin did not reduce major peri-PCI bleeding and vascular access-site complications.	[Steg, Philippe Gabriel] INSERM, U Rech Clin Atherothrombose 698, Paris, France; [Steg, Philippe Gabriel] Univ Paris 07, Paris, France; [Steg, Philippe Gabriel] Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France; [Jolly, Sanjit S.; Mehta, Shamir R.; Afzal, Rizwan; Chrolavicius, Susan; Pogue, Janice; Yusuf, Salim] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Jolly, Sanjit S.; Mehta, Shamir R.; Afzal, Rizwan; Chrolavicius, Susan; Pogue, Janice; Yusuf, Salim] McMaster Univ, Hamilton, ON, Canada; [Xavier, Denis] St Johns Med Coll, Bangalore, Karnataka, India; [Rupprecht, Hans-Jurgen] Klinikum Russelsheim, Med Klin, Russelsheim, Germany; [Lopez-Sendon, Jose L.] Hosp Univ La Paz, Dept Cardiol, Madrid, Spain; [Budaj, Andrzej] Grochowski Hosp, Dept Cardiol, Warsaw, Poland; [Diaz, Rafael] Inst Cardiovasc Rosario, Rosario, Santa Fe, Argentina; [Avezum, Alvaro] Pazzanese Inst Cardiol, Sao Paulo, Brazil; [Widimsky, Petr] Charles Univ Prague, Med Sch 3, Univ Hosp Vinohrady, Cardioctr, Prague, Czech Republic; [Rao, Sunil V.] Duke Univ, Med Ctr, Durham, NC USA; [Joyner, Campbell] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; McMaster University; Population Health Research Institute; McMaster University; St. John's National Academy of Health Sciences; St. John's Medical College; Hospital Universitario La Paz; Centre of Postgraduate Medical Education - Poland; Instituto Dante Pazzanese de Cardiologia; Charles University Prague; University Hospital Vinohrady; Duke University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Jolly, SS (corresponding author), Hamilton Gen Hosp, 237 Barton St E,Room C3 118,CVSRI Bldg, Hamilton, ON L8L 2X2, Canada.	jollyss@mcmaster.ca	Boldueva, Svetlana/AAH-3862-2019; Widimsky, Petr/P-8088-2016; STEG, Philippe Gabriel/Z-1567-2019; Vasilieva, Elena/B-2137-2016; Avezum, Alvaro AA/K-6137-2016; Jolly, Sanjit/O-2534-2015; Avezum, Alvaro/AAP-7687-2020; Turazza, Fabio/AAB-8736-2020; FERNANDEZ-VAZQUEZ, FELIPE FFV/R-8969-2018; Kokorin, Valentin Alexandrovich/ABG-9667-2021; Stefanadis, Christodoulos/ABH-2232-2020; Pershukov, Igor/D-2135-2016	Boldueva, Svetlana/0000-0002-1898-084X; Widimsky, Petr/0000-0001-5686-7752; Vasilieva, Elena/0000-0003-4111-0874; Avezum, Alvaro AA/0000-0002-3073-6890; Turazza, Fabio/0000-0002-2348-5309; FERNANDEZ-VAZQUEZ, FELIPE FFV/0000-0001-7187-1290; Kokorin, Valentin Alexandrovich/0000-0001-8614-6542; Stefanadis, Christodoulos/0000-0001-5974-6454; Wlodarczak, Adrian/0000-0003-3104-7728; ELBAZ, Meyer/0000-0002-3520-7883; TEIGER, emmanuel/0000-0001-7515-4344; Pershukov, Igor/0000-0002-5356-1886; STEG, Philippe Gabriel/0000-0001-6896-2941; Yusuf, Salim/0000-0003-4776-5601; Moreno, Raul/0000-0001-7179-1426; Baumbach, Andreas/0000-0001-7707-2254	Servier; GlaxoSmithKline; Sanofi-aventis; Medtronic; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers-Squibb; Cadila; Pfizer; UnitedHealth Group; Daiichi-Sankyo-Lilly; Menarini; Merck-Sharpe-Dohme; Portola Pharmaceuticals; Cordis Corporation	Servier(Servier); GlaxoSmithKline(GlaxoSmithKline); Sanofi-aventis(Sanofi-Aventis); Medtronic(Medtronic); AstraZeneca(AstraZeneca); Boehringer-Ingelheim(Boehringer Ingelheim); Bristol-Myers-Squibb(Bristol-Myers Squibb); Cadila; Pfizer(Pfizer); UnitedHealth Group; Daiichi-Sankyo-Lilly(Daiichi Sankyo Company LimitedEli Lilly); Menarini(Menarini Group); Merck-Sharpe-Dohme(Merck & Company); Portola Pharmaceuticals; Cordis Corporation	Dr Steg reports receiving research grants from Servier; speaking or consulting for Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Menarini, Medtronic, Merck-Sharpe-Dohme, Otsuka, Pierre Fabre, sanofi-aventis, Servier, and the Medicines Company; and being a stockholder in Aterovax. Dr Jolly reports receiving honoraria or research grants from GlaxoSmithKline, sanofi-aventis, and Medtronic. Dr Mehta reports receiving research grants and serving as a consultant or receiving speaking honoraria from AstraZeneca, Astellas, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, and sanofi-aventis. Dr Xavier reports receiving research funding from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Cadila, Pfizer, sanofi-aventis, and UnitedHealth Group. Dr Rupprecht reports receiving honoraria from lectures and advisory board meetings for sanofi-aventis, Bristol-Myers-Squibb, GlaxoSmithKline, and Lilly. Dr Lopez-Sendon reports receiving research grants, speaking or consulting for AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Menarini, Merck-Sharpe-Dohme, sanofi-aventis, and Servier. Dr Budaj reports receiving research grants from sanofi-aventis, Boehringer-Ingelheim, AstraZeneca, GlaxoSmithKline, Bristol-Myers-Squibb; consulting fees from sanofi-aventis, Eli Lilly, and AstraZeneca, Novartis, and lecture fees from sanofi-aventis, Boehringer-Ingelheim, AstraZeneca, and GlaxoSmithKline. Dr Avezum reports receiving honoraria from GlaxoSmithKline for speaking. Dr Rao reports receiving research funding from Portola Pharmaceuticals and Cordis Corporation, servings a consultant to the Medicines Company, sanofi-aventis, Bristol-Myers-Squibb, AstraZeneca, and Terumo Corp. Dr Joyner reports receiving institutional research grants from Bristol-Myers-Squibb and sanofi-aventis. Dr Yusuf reports receiving research grants and honoraria for lectures, reimbursement of travel expenses, and occasional consulting fees from GlaxoSmithKline, sanofi-aventis, AstraZeneca, Bristol-Myers-Squibb, Boehringer-Ingelheim, Novartis, Merck. The remaining authors have reported no disclosures.	Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Bertrand OF, 2009, AM J CARDIOL, V104, P1235, DOI 10.1016/j.amjcard.2009.06.036; Boccara A, 1997, EUR HEART J, V18, P631; Brener SJ, 2004, CIRCULATION, V110, P994, DOI 10.1161/01.CIR.0000139868.53594.24; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Lincoff AM, 1997, AM J CARDIOL, V79, P286, DOI 10.1016/S0002-9149(96)00749-7; Mehran R, 2009, LANCET, V374, P1149, DOI 10.1016/S0140-6736(09)61484-7; Mehta SR, 2008, CIRCULATION, V118, P2038, DOI 10.1161/CIRCULATIONAHA.108.789479; Mehta SR, 2007, J AM COLL CARDIOL, V50, P1742, DOI 10.1016/j.jacc.2007.07.042; Montalescot G, 2008, INT J CARDIOL, V129, P379, DOI 10.1016/j.ijcard.2007.07.127; Montalescot G, 2008, EUR HEART J, V29, P462, DOI 10.1093/eurheartj/ehn008; Silber S, 2005, EUR HEART J, V26, P804, DOI 10.1093/eurheartj/ehi138; Smith SC, 2006, CIRCULATION, V113, pE166, DOI 10.1161/CIRCULATIONAHA.106.173220; Stabile E, 2008, J AM COLL CARDIOL, V52, P2008, DOI 10.1016/j.jacc.2008.07.026; Tolleson TR, 2003, J AM COLL CARDIOL, V41, P386, DOI 10.1016/S0735-1097(02)02767-5; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Vainer J, 1996, AM J CARDIOL, V78, P964, DOI 10.1016/S0002-9149(96)00480-8; Yusuf S, 2006, JAMA-J AM MED ASSOC, V295, P1519; Yusuf S, 2006, NEW ENGL J MED, V354, P1464	20	103	114	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1339	1349		10.1001/jama.2010.1320	http://dx.doi.org/10.1001/jama.2010.1320			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20805623	Bronze			2022-12-28	WOS:000282007900017
J	Wallentin, L; Yusuf, S; Ezekowitz, MD; Alings, M; Flather, M; Franzosi, MG; Pais, P; Dans, A; Eikelboom, J; Oldgren, J; Pogue, J; Reilly, PA; Yang, S; Connolly, SJ				Wallentin, Lars; Yusuf, Salim; Ezekowitz, Michael D.; Alings, Marco; Flather, Marcus; Franzosi, Maria Grazia; Pais, Prem; Dans, Antonio; Eikelboom, John; Oldgren, Jonas; Pogue, Janice; Reilly, Paul A.; Yang, Sean; Connolly, Stuart J.		RE-LY Investigators	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial	LANCET			English	Article							ORAL ANTICOAGULANT-THERAPY; INTENSITY; OUTCOMES; FREQUENCY	Background Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of 2.0-3.0. In the Randomised Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, dabigatran versus warfarin reduced both stroke and haemorrhage. We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population. Methods In the RE-LY trial, 18 113 patients at 951 sites were randomly assigned to 110 mg or 150 mg dabigatran twice daily versus warfarin dose adjusted to INR 2.0-3.0. Median follow-up was 2.0 years. For 18 024 patients at 906 sites, the cTTR was estimated by averaging TTR for individual warfarin-treated patients calculated by the Rosendaal method. We compared the outcomes of RE-LY across the three treatment groups within four groups defined by the quartiles of RE-LY is registered with ClinicalTrials.gov, number NCT00262600. Findings The quartiles of cTTR for patients in the warfarin group were: less than 57.1%, 57.1-65.5%, 65.5-72.6%, and greater than 72.6%. There were no significant interactions between cTTR and prevention of stroke and systemic embolism with either 110 mg dabigatran (interaction p=0.89) or 150 mg dabigatran (interaction p=0.20) versus warfarin. Neither were any significant interactions recorded with cTTR with regards to intracranial bleeding with 110 mg dabigatran (interaction p=0.71) or 150 mg dabigatran (interaction p=0.89) versus warfarin. There was a significant interaction between cTTR and major bleeding when comparing 150 mg dabigatran with warfarin (interaction p=0.03), with less bleeding events at lower cTTR but similar events at higher cTTR, whereas rates of major bleeding were lower with 110 mg dabigatran than with warfarin irrespective of cTTR. There were significant interactions between cTTR and effects of both 110 mg and 150 mg dabigatran versus warfarin on the composite of all cardiovascular events (interaction p=0.036 and p=0.0006, respectively) and total mortality (interaction p=0.066 and p=0.052, respectively) with reduced event rates at low cITR, and similar rates at high cTTR. Interpretation The benefits of 150 mg dabigatran at reducing stroke, 110 mg dabigatran at reducing bleeding, and both doses at reducing intracranial bleeding versus warfarin were consistent irrespective of centres' quality of INR control. For all vascular events, non-haemorrhagic events, and mortality, advantages of dabigatran were greater at sites with poor INR control than at those with good INR control. Overall, these results show that local standards of care affect the benefits of use of new treatment alternatives.	[Wallentin, Lars; Oldgren, Jonas] Uppsala Univ, Uppsala Clin Res Ctr, SE-75185 Uppsala, Sweden; [Yusuf, Salim; Eikelboom, John; Pogue, Janice; Yang, Sean] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Yusuf, Salim; Eikelboom, John; Pogue, Janice; Yang, Sean] McMaster Univ, Hamilton, ON, Canada; [Ezekowitz, Michael D.] Lankenau Inst Med Res, Wynnewood, PA USA; [Ezekowitz, Michael D.] Ctr Heart, Wynnewood, PA USA; [Alings, Marco] Working Grp Cardiovasc Res, Utrecht, Netherlands; [Flather, Marcus] Royal Brompton Hosp, Clin Trials & Evaluat Unit, London SW3 6LY, England; [Franzosi, Maria Grazia] Ist Mario Negri, Dept Cardiovasc Res, Milan, Italy; [Pais, Prem] St Johns Med Coll & Res Inst, Bangalore, Karnataka, India; [Dans, Antonio] Univ Philippines, Coll Med, Manila, Philippines; [Reilly, Paul A.] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA	Uppsala University; McMaster University; Population Health Research Institute; McMaster University; Lankenau Medical Center; Lankenau Institute for Medical Research; Royal Brompton Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; St. John's National Academy of Health Sciences; St. John's Medical College; University of the Philippines System; University of the Philippines Manila; Boehringer Ingelheim	Wallentin, L (corresponding author), Uppsala Univ, Uppsala Clin Res Ctr, SE-75185 Uppsala, Sweden.	lars.wallentin@ucr.uu.se	Eikelboom, John/AAG-6117-2019; Ezekowitz, Michael/AAJ-2543-2021	Eikelboom, John/0000-0003-4126-1285; Yusuf, Salim/0000-0003-4776-5601	Boehringer Ingelheim; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Schering-Plough; Athera Biotechnologies; Eli Lilly; Regado Biotechnologies; Sanofi-Aventis; ARYx Therapeutics; Daiichi Sankyo; Portola Pharmaceuticals; Pfizer; Medtronic; MSD; SPA; Sigma Tau; Novartis; Takeda	Boehringer Ingelheim(Boehringer Ingelheim); AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); GlaxoSmithKline(GlaxoSmithKline); Schering-Plough(Merck & CompanySchering Plough Corporation); Athera Biotechnologies; Eli Lilly(Eli Lilly); Regado Biotechnologies; Sanofi-Aventis(Sanofi-Aventis); ARYx Therapeutics; Daiichi Sankyo(Daiichi Sankyo Company Limited); Portola Pharmaceuticals; Pfizer(Pfizer); Medtronic(Medtronic); MSD; SPA; Sigma Tau; Novartis(Novartis); Takeda(Takeda Pharmaceutical Company Ltd)	LW has received consulting and lecture fees, honoraria, and research grants from Boehringer Ingelheim; research grants from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Schering-Plough; honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Schering-Plough; consultant fees from Athera Biotechnologies, AstraZeneca, Eli Lilly, GlaxoSmithKline, and Regado Biotechnologies; and lecture fees from AstraZeneca and Eli Lilly. SYu has received consulting fees, honoraria, and travel and grant support from Boehringer Ingelheim; and consulting fees from AstraZeneca, Bristol-Myers Squibb, and Sanofi-Aventis. MDE has received consulting fees and grant support from Boehringer Ingelheim, ARYx Therapeutics, Daiichi Sankyo, and Portola Pharmaceuticals; and consulting fees from Sanofi-Aventis, Pfizer, Bristol-Meyers Squibb, AstraZeneca, and Medtronic. MA has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, MSD, and Sanofi-Aventis; lecture fees from Boehringer Ingelheim; and a non-personal research grant from Boston Scientific. MF has received research grant and travel support from Boehringer Ingelheim. MGF has received travel support from AstraZeneca, Boehringer Ingelheim, Pfizer, Sanofi-Aventis, SPA, and Sigma Tau; lecture fees from AstraZeneca and Boehringer Ingelheim; and non-personal research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Sanofi-Aventis, Pfizer, SPA, Sigma Tau, and Takeda. PP has received consulting fees and travel support from Boehringer Ingelheim. AD has received consulting fees, honoraria, and travel support from Boehringer Ingelheim. JE has been an advisory board member for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, and Sanofi-Aventis; has received consulting fees, honoraria, and travel and grant support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, and Sanofi-Aventis; and has received honoraria from Corgenix Medical Corporation, Daiichi-Sankyo Eisai Pharmaceuticals, Eli Lilly, and McNeil. JO has been an advisory board member and has received lecture fees and travel and grant support from Boehringer Ingelheim; and has received lecture fees from AstraZeneca. PAR is an employee of Boehringer Ingelheim. SJC has received consulting fees and grant and travel support from Boehringer Ingelheim. No other potential conflict of interest relevant to this article was reported.	AGUILAR MI, 2005, COCHRANE DB SYST REV, V3; Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Ezekowitz MD, 2009, AM HEART J, V157, P805, DOI 10.1016/j.ahj.2009.02.005; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Indredavik B, 2005, J INTERN MED, V258, P133, DOI 10.1111/j.1365-2796.2005.01512.x; Jones M, 2005, HEART, V91, P472, DOI 10.1136/hrt.2004.042465; McBride D, 2007, J THROMB THROMBOLYS, V24, P65, DOI 10.1007/s11239-006-0002-8; Morgan CL, 2009, THROMB RES, V124, P37, DOI 10.1016/j.thromres.2008.09.016; Oake N, 2008, CAN MED ASSOC J, V179, P235, DOI 10.1503/cmaj.080171; Oake N, 2007, CAN MED ASSOC J, V176, P1589, DOI 10.1503/cmaj.061523; Pengo V, 2006, J THROMB THROMBOLYS, V21, P73, DOI 10.1007/s11239-006-5580-y; Reynolds MW, 2004, CHEST, V126, P1938, DOI 10.1378/chest.126.6.1938; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; van Walraven C, 2006, CHEST, V129, P1155, DOI 10.1378/chest.129.5.1155; White HD, 2007, ARCH INTERN MED, V167, P239, DOI 10.1001/archinte.167.3.239	19	776	802	1	102	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	2010	376	9745					975	983		10.1016/S0140-6736(10)61194-4	http://dx.doi.org/10.1016/S0140-6736(10)61194-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655JZ	20801496				2022-12-28	WOS:000282247600029
J	Boggs, GR				Boggs, George R.			Growing Roles for Science Education in Community Colleges	SCIENCE			English	Editorial Material									Amer Assoc Community Coll, Washington, DC 20036 USA		Boggs, GR (corresponding author), Amer Assoc Community Coll, Washington, DC 20036 USA.	gboggs@aacc.nche.edu						*AAAC, VOL FRAM ACC; *AACC, 2010, NAT ORG SIGN STUD CO; AACC, 2010, 2010 FACT SHEET; *ATE CTR, 2008, ATE CTR IMP 2008 201; BERKNER L, 2002, DESCRIPTIVE SUMMARY, P81; BIDEN J, 2009, UNESCO WORLD C HIGH; Bowen WG., 2009, CROSSING FINISH LINE; BRESSOUD BM, PROBLEM PERSISTENCE; Doyle W.R., 2006, CHANGE MAGAZINE HIGH, V38, P56, DOI [https://doi.org/10.3200/CHNG.38.3.56-58, DOI 10.3200/CHNG.38.3.56-58]; JASCHIK S, 2010, INSIDE HIGHER E 0601; *LUM FDN ED, 2010, GOAL 2025; National Science Board, 2008, SCI ENG IND 2008; OBAMA BH, 2009, REMARKS PRESIDENT AM; Shkodriani G, 2004, SEAMLESS PIPELINE 2; Strohl, 2010, HELP WANTED PROJECTI; TSAPOGAS J, 2004, ROLE COMMUNITY COLL; VANNOY M, 2009, DIGITAL LEARNING JUN, P42	17	9	9	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2010	329	5996					1151	1152		10.1126/science.1194214	http://dx.doi.org/10.1126/science.1194214			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	645SG	20813939				2022-12-28	WOS:000281485600017
J	Witherden, DA; Verdino, P; Rieder, SE; Garijo, O; Mills, RE; Teyton, L; Fischer, WH; Wilson, IA; Havran, WL				Witherden, Deborah A.; Verdino, Petra; Rieder, Stephanie E.; Garijo, Olivia; Mills, Robyn E.; Teyton, Luc; Fischer, Wolfgang H.; Wilson, Ian A.; Havran, Wendy L.			The Junctional Adhesion Molecule JAML Is a Costimulatory Receptor for Epithelial gamma delta T Cell Activation	SCIENCE			English	Article							ADENOVIRUS RECEPTOR; SKIN; CAR; COXSACKIE; RECOGNITION; HOMEOSTASIS; PROTEIN	gamma delta T cells present in epithelial tissues provide a crucial first line of defense against environmental insults, including infection, trauma, and malignancy, yet the molecular events surrounding their activation remain poorly defined. Here we identify an epithelial gamma delta T cell-specific costimulatory molecule, junctional adhesion molecule-like protein (JAML). Binding of JAML to its ligand Coxsackie and adenovirus receptor (CAR) provides costimulation leading to cellular proliferation and cytokine and growth factor production. Inhibition of JAML costimulation leads to diminished gamma delta T cell activation and delayed wound closure akin to that seen in the absence of gamma delta T cells. Our results identify JAML as a crucial component of epithelial gamma delta T cell biology and have broader implications for CAR and JAML in tissue homeostasis and repair.	[Witherden, Deborah A.; Rieder, Stephanie E.; Garijo, Olivia; Mills, Robyn E.; Teyton, Luc; Havran, Wendy L.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Verdino, Petra; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Fischer, Wolfgang H.] Salk Inst Biol Studies, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Salk Institute	Havran, WL (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.	havran@scripps.edu			NIH [AI52257, AI064811, AI42266, CA58896, NS057096]; Austrian Science Fund; Leukemia and Lymphoma Society; Vincent J. Coates Foundation; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052257, R01AI064811, R01AI042266, R37AI042266, R01AI036964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS057096] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Austrian Science Fund(Austrian Science Fund (FWF)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Vincent J. Coates Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank M. Park and W. Low for MS analysis; G. Nemerow for Fiber 5 and Fiber 11 reagents; J. Kaye for the DPK cell line; and M. Haynes, M. Svoboda, J. Barcas, K. Sendaydiego, D. Yeh, and B. Atteberry for technical assistance. J. Lewis provided advice on culture of short-term DETC lines. M. Kronenberg, R. Boismenu, J. Jameson, K. Mowen, T. Meehan, and K. Komori provided advice and critical reading of the manuscript. This work was supported by NIH grants to W. L. H. (AI52257, AI064811) and I. A. W. (AI42266, CA58896), as well as an Erwin-Schroedinger Fellowship of the Austrian Science Fund (P. V.) and the Leukemia and Lymphoma Society (S. E. R.). MS instrumentation was acquired with an NSF shared equipment grant. The MS Laboratory at the Salk Institute is supported by the Vincent J. Coates Foundation and NIH Blueprint NS057096. This is manuscript number 17711-IMM from The Scripps Research Institute.	Bazzoni G, 2003, CURR OPIN CELL BIOL, V15, P525, DOI 10.1016/S0955-0674(03)00104-2; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Coyne CB, 2005, ADV DRUG DELIVER REV, V57, P869, DOI 10.1016/j.addr.2005.01.007; Croft M, 1997, CRIT REV IMMUNOL, V17, P89, DOI 10.1615/CritRevImmunol.v17.i1.40; Davis MM, 2003, ANNU REV BIOCHEM, V72, P717, DOI 10.1146/annurev.biochem.72.121801.161625; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Frauwirth KA, 2002, J CLIN INVEST, V109, P295, DOI 10.1172/JCI200214941; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Havran WL, 2010, J IMMUNOL, V184, P5423, DOI 10.4049/jimmunol.0902733; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; Howitt J, 2003, CURR TOP MICROBIOL, V272, P331; Jameson J, 2002, SCIENCE, V296, P747, DOI 10.1126/science.1069639; Jameson J, 2007, IMMUNOL REV, V215, P114, DOI 10.1111/j.1600-065X.2006.00483.x; Kirby I, 2001, J VIROL, V75, P7210, DOI 10.1128/JVI.75.15.7210-7214.2001; Luissint AC, 2008, J CELL BIOL, V183, P1159, DOI 10.1083/jcb.200805061; Moog-Lutz C, 2003, BLOOD, V102, P3371, DOI 10.1182/blood-2002-11-3462; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Sharp LL, 2005, NAT IMMUNOL, V6, P73, DOI 10.1038/ni1152; Strid J, 2009, SEMIN IMMUNOL, V21, P110, DOI 10.1016/j.smim.2009.03.002; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Verdino P, 2010, SCIENCE, V329, P1210, DOI 10.1126/science.1187996; Whang MI, 2009, J IMMUNOL, V182, P4557, DOI 10.4049/jimmunol.0802439; Zen K, 2005, MOL BIOL CELL, V16, P2694, DOI 10.1091/mbc.E05-01-0036	25	149	161	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1205	1210		10.1126/science.1192698	http://dx.doi.org/10.1126/science.1192698			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813954	Green Accepted			2022-12-28	WOS:000281485600036
J	Becker, T				Becker, Thorsten			Fine-Scale Modeling of Global Plate Tectonics	SCIENCE			English	Editorial Material							DRIVING FORCES; LITHOSPHERE; STRENGTH; EARTH		Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA	University of Southern California	Becker, T (corresponding author), Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA.	thorstinski@gmail.com	Becker, Thorsten W/ABF-7643-2021	Becker, Thorsten W/0000-0002-5656-4564				Becker TW, 2006, GEOPHYS J INT, V167, P943, DOI 10.1111/j.1365-246X.2006.03172.x; Bercovici D., 2000, GEOPHYS MONOGR SER, V121, P5; Capitanio FA, 2009, GEOCHEM GEOPHY GEOSY, V10, DOI 10.1029/2008GC002348; Conrad CP, 2002, SCIENCE, V298, P207, DOI 10.1126/science.1074161; Conrad CP, 1999, GEOPHYS RES LETT, V26, P3041, DOI 10.1029/1999GL005397; Di Giuseppe E, 2009, LITHOSPHERE-US, V1, P121, DOI 10.1130/L26.1; FORSYTH D, 1975, GEOPHYS J ROY ASTR S, V43, P163, DOI 10.1111/j.1365-246X.1975.tb00631.x; Stadler G, 2010, SCIENCE, V329, P1033, DOI 10.1126/science.1191223; Tackley P.J., 2000, GEOPHYS MONOGR SER, V121, P47; van Hunen J, 2008, LITHOS, V103, P217, DOI 10.1016/j.lithos.2007.09.016	10	0	0	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1020	1021		10.1126/science.1194858	http://dx.doi.org/10.1126/science.1194858			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798303				2022-12-28	WOS:000281253500021
J	Ma, RCW; Tam, CHT; Wang, Y; Luk, AO; Hu, C; Yang, XL; Lam, V; Chan, AWH; Ho, JSK; Chow, CC; Tong, PCY; Jia, WP; Ng, MCY; So, WY; Chan, JCN				Ma, Ronald C. W.; Tam, Claudia H. T.; Wang, Ying; Luk, Andrea O.; Hu, Cheng; Yang, Xilin; Lam, Vincent; Chan, Alfred W. H.; Ho, Janice S. K.; Chow, Chun-Chung; Tong, Peter C. Y.; Jia, Weiping; Ng, Maggie C. Y.; So, Wing-Yee; Chan, Juliana C. N.			Genetic Variants of the Protein Kinase C-beta 1 Gene and Development of End-Stage Renal Disease in Patients With Type 2 Diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							KONG CHINESE PATIENTS; GROWTH-FACTOR-BETA; C-BETA; OXIDATIVE STRESS; KIDNEY-DISEASE; RISK SCORE; NEPHROPATHY; EXPRESSION; LOCI; ASSOCIATION	Context Protein kinase C-beta (PKC-beta) is a cell-signaling intermediate implicated in development of diabetic complications. Objective To examine the risk association of PKC-beta 1 gene (PRKCB1) polymorphisms and end-stage renal disease (ESRD) in an 8-year prospective cohort of Chinese patients with type 2 diabetes. Design, Setting, and Participants We genotyped 18 common tag single-nucleotide polymorphisms (SNPs) that span the PRKCB1 gene (r(2)=0.80) in 1172 Chinese patients (recruited 1995-1998) without renal disease at baseline. A validation cohort included an additional 1049 patients with early-onset diabetes who were free of renal disease at baseline and were recruited after 1998. Main Outcome Measures Associations of PRKCB1 polymorphisms under additive, dominant, and recessive genetic models with new onset of ESRD (defined as estimated glomerular filtration rate <15 mL/min/1.73 m(2) or dialysis or renal-related death) were assessed by Cox proportional hazard regression, adjusted for all conventional risk factors including use of medications. Results After a mean (SD) of 7.9 (1.9) years, 90 patients (7.7%) progressed to ESRD. Four common SNPs were associated with ESRD (P<.05). The closely linked T allele at rs3760106 and G allele rs2575390 (r(2)=0.98) showed the strongest association with ESRD (hazard ratio [HR], 2.25; 95% confidence interval [Cl], 1.31-3.87; P=.003, and HR, 2.26; 95% Cl, 1.31-3.88; P=.003, respectively). Four common variants predicted ESRD in separate models. The HR for ESRD increased with increasing number of risk alleles (P<.001) in the joint effect analysis. The adjusted risk for ESRD was 6.04 (95% Cl, 2.00-18.31) for patients with 4 risk alleles compared with patients with 0 or 1 risk allele. Incidence was 4.4 per 1000 person-years (95% Cl, 0.5-8.2) among individuals with 0 or 1 risk allele compared with 20.0 per 1000 person-years (95% Cl, 8.8-31.1) in those carrying 4 risk alleles (6.9% of the cohort). These results were validated in a separate prospective cohort of young-onset diabetic patients. Of 1049 patients in the validation cohort, 151 (14.3%) developed chronic kidney disease (CKD) during follow-up, and there were significant associations between both the T allele of rs3760106 and the G allele of rs2575390 and development of CKD (HR, 1.68; 95% Cl, 1.10-2.57; P=.02, and HR, 1.62; 95% Cl, 1.07-2.47; P=.02, respectively). Conclusion Genetic variants in the PRKCB1 gene were independently associated with development of ESRD in Chinese patients with type 2 diabetes. JAMA. 2010;304(8):881-889	[Ma, Ronald C. W.; Tam, Claudia H. T.; Wang, Ying; Luk, Andrea O.; Yang, Xilin; Lam, Vincent; Chan, Alfred W. H.; Ho, Janice S. K.; Chow, Chun-Chung; Tong, Peter C. Y.; Ng, Maggie C. Y.; So, Wing-Yee; Chan, Juliana C. N.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Ma, Ronald C. W.; Chan, Juliana C. N.] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong Inst Diabet & Obes, Shatin, Hong Kong, Peoples R China; [Chan, Juliana C. N.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Hu, Cheng; Jia, Weiping] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6,Shanghai Diabet Inst, Shanghai Key Lab Diabet Mellitus, Dept Endocrinol & Metab,Shanghai Clin Ctr Diabet, Shanghai 200030, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Shanghai Jiao Tong University	Ma, RCW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	rcwma@cuhk.edu.hk	Luk, Andrea/B-5766-2016; Jia, Weiping/B-7483-2012; Chan, Juliana/B-7918-2016; Ma, Ronald/C-2788-2009; Hu, Cheng/C-3346-2008; Chan, Anthony/N-6719-2016	Chan, Juliana/0000-0003-1325-1194; Ma, Ronald/0000-0002-1227-803X; Hu, Cheng/0000-0003-4314-2386; Chan, Anthony/0000-0002-1771-163X	AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi-Sankyo; GlaxoSmithKline; Lilly; Merck Serono; Merck Sharp Dohme; Novo Nordisk; Pfizer; Roche; Sanofi-Aventis; Chinese University of Hong Kong; Hong Kong Government Research Grant Committee; Innovation and Technology Fund [ITS/088/08]; Department of Medicine and Therapeutics, Chinese University of Hong Kong	AstraZeneca(AstraZeneca); Bayer(Bayer AG); Bristol-Myers Squibb(Bristol-Myers Squibb); Daiichi-Sankyo(Daiichi Sankyo Company Limited); GlaxoSmithKline(GlaxoSmithKline); Lilly(Eli Lilly); Merck Serono(Merck & Company); Merck Sharp Dohme(Merck & Company); Novo Nordisk(Novo Nordisk); Pfizer(Pfizer); Roche(Roche Holding); Sanofi-Aventis(Sanofi-Aventis); Chinese University of Hong Kong(Chinese University of Hong Kong); Hong Kong Government Research Grant Committee; Innovation and Technology Fund; Department of Medicine and Therapeutics, Chinese University of Hong Kong(Chinese University of Hong Kong)	Dr Ma reported receiving speakers' honoraria from Sanofi-Aventis and serving as a member of an advisory board for Pfizer, the proceeds of which go to the Chinese University of Hong Kong to support ongoing research. Dr J. Chan reported receiving research funding or speakers' honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck Serono, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Roche, and Sanofi-Aventis; serving as a member of advisory boards, and/or speaker forums, and/or steering committees of international projects sponsored by AstraZeneca, Bayer, Lilly, and Merck Sharp & Dohme; with her group and on behalf of the Chinese University of Hong Kong, holding patents to use genetic markers to predict risk of diabetes and diabetic kidney disease in Chinese populations; and in a technology transfer project, establishing a university-affiliated diabetes center (Qualigenics) to deliver a multidisciplinary chronic care program in the community (all related revenues and proceeds go to the Chinese University of Hong Kong to support ongoing research and development in diabetes). None of the coauthors reported currently holding or having filed patents relating to the information contained in the article, namely, the use of the genetic variants of the protein kinase C-beta 1 gene (rs3760106, rs7404928, and rs4787733) for the prediction of diabetic kidney disease. The authors reported that they will not be pursuing any patent application relating to this information, in China or in the United States, until this information has appeared in JAMA.; The study was supported by the Hong Kong Foundation for Research and Development in Diabetes established under the auspices of the Chinese University of Hong Kong, the Hong Kong Government Research Grant Committee, the Innovation and Technology Fund (ITS/088/08), and the Research Fund of the Department of Medicine and Therapeutics, Chinese University of Hong Kong.	Araki SI, 2006, DIABETES CARE, V29, P864, DOI 10.2337/diacare.29.04.06.dc05-1723; Araki SI, 2003, J AM SOC NEPHROL, V14, P2015, DOI 10.1097/01.ASN.0000077347.27669.5C; Asaba K, 2005, KIDNEY INT, V67, P1890, DOI 10.1111/j.1523-1755.2005.00287.x; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Chambers JC, 2010, NAT GENET, V42, P149, DOI 10.1038/ng.516; Chan JC, 2009, DIABETES CARE, V32, P977, DOI 10.2337/dc08-1908; Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726; Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520; Etoh T, 2003, DIABETOLOGIA, V46, P1428, DOI 10.1007/s00125-003-1205-6; Ferretti V, 2007, NUCLEIC ACIDS RES, V35, pD122, DOI 10.1093/nar/gkl879; Fioretto P, 2008, DIABETOLOGIA, V51, P1347, DOI 10.1007/s00125-008-1051-7; Fioretto P, 1996, DIABETOLOGIA, V39, P1569, DOI 10.1007/s001250050616; Forbes JM, 2008, DIABETES, V57, P1446, DOI 10.2337/db08-0057; Freedman BI, 2007, CLIN J AM SOC NEPHRO, V2, P1306, DOI 10.2215/CJN.02560607; Gao L, 2009, CARDIOVASC RES, V82, P9, DOI 10.1093/cvr/cvp031; Gilbert RE, 2007, DIABETES CARE, V30, P995, DOI 10.2337/dc06-2079; Gorin Y, 2005, J BIOL CHEM, V280, P39616, DOI 10.1074/jbc.M502412200; HE Z, 2004, DIABETES CARDIOVASCU, P37; Hu C, 2010, DIABETOLOGIA, V53, P290, DOI 10.1007/s00125-009-1594-2; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Karter AJ, 2002, JAMA-J AM MED ASSOC, V287, P2519, DOI 10.1001/jama.287.19.2519; Kelly DJ, 2009, NEPHROL DIAL TRANSPL, V24, P1782, DOI 10.1093/ndt/gfn729; Kottgen A, 2010, NAT GENET, V42, P376, DOI 10.1038/ng.568; Kottgen A, 2009, NAT GENET, V41, P712, DOI 10.1038/ng.377; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Kramer HJ, 2003, JAMA-J AM MED ASSOC, V289, P3273, DOI 10.1001/jama.289.24.3273; Langham RG, 2008, DIABETOLOGIA, V51, P668, DOI 10.1007/s00125-008-0927-x; Luk AOY, 2008, DIABETES CARE, V31, P2357, DOI 10.2337/dc08-0971; MA RC, 2004, KIDNEY HYPERTENSION; Ma YC, 2006, J AM SOC NEPHROL, V17, P2937, DOI 10.1681/ASN.2006040368; MACLSAAC RJ, 2004, DIABETES CARE, V27, P195; Morrish NJ, 2001, DIABETOLOGIA, V44, pS14, DOI 10.1007/PL00002934; Ng MCY, 2008, DIABETES, V57, P2226, DOI 10.2337/db07-1583; Noh H, 2007, KIDNEY INT, V72, pS49, DOI 10.1038/sj.ki.5002386; Ohshiro Y, 2006, DIABETES, V55, P3112, DOI 10.2337/db06-0895; Parving HH, 2008, J AM SOC NEPHROL, V19, P771, DOI 10.1681/ASN.2007050582; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ramachandran A, 2010, LANCET, V375, P408, DOI 10.1016/S0140-6736(09)60937-5; Ritz E, 1999, AM J KIDNEY DIS, V34, P795, DOI 10.1016/S0272-6386(99)70035-1; Robertson G, 2006, NUCLEIC ACIDS RES, V34, pD68, DOI 10.1093/nar/gkj075; Rothman KJ, 2005, AM J PUBLIC HEALTH, V95, pS144, DOI 10.2105/AJPH.2004.059204; Sabo PJ, 2004, P NATL ACAD SCI USA, V101, P16837, DOI 10.1073/pnas.0407387101; Sarafidis PA, 2006, AM J NEPHROL, V26, P232, DOI 10.1159/000093632; Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Soldatos G, 2008, DIABETES RES CLIN PR, V82, pS75, DOI 10.1016/j.diabres.2008.09.042; Song XY, 2009, DIABETOLOGIA, V52, P1543, DOI 10.1007/s00125-009-1400-1; Toyoda M, 2004, KIDNEY INT, V66, P1107, DOI 10.1111/j.1523-1755.2004.00798.x; Tuttle KR, 2008, DIABETES RES CLIN PR, V82, pS70, DOI 10.1016/j.diabres.2008.09.041; Tuttle KR, 2005, DIABETES CARE, V28, P2686, DOI 10.2337/diacare.28.11.2686; TUTTLE KR, 2007, J AM SOC NEPHROL, V18, pA48; Wu AYT, 2005, DIABETOLOGIA, V48, P17, DOI 10.1007/s00125-004-1599-9; Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292; Yang XL, 2007, DIABETOLOGIA, V50, P1348, DOI 10.1007/s00125-007-0639-7; Yang XL, 2006, DIABETOLOGIA, V49, P2299, DOI 10.1007/s00125-006-0376-3; Yang XL, 2008, ARCH INTERN MED, V168, P451, DOI 10.1001/archinte.168.5.451; Yang X, 2007, DIABETES CARE, V30, P65, DOI 10.2337/dc06-1273; Yoon KH, 2006, LANCET, V368, P1681, DOI 10.1016/S0140-6736(06)69703-1	60	49	58	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					881	889		10.1001/jama.2010.1191	http://dx.doi.org/10.1001/jama.2010.1191			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736472	Bronze			2022-12-28	WOS:000281389900026
J	Visintin, C; Mugglestone, MA; Almerie, MQ; Nherera, LM; James, D; Walkinshaw, S				Visintin, Cristina; Mugglestone, Moira A.; Almerie, Muhammad Q.; Nherera, Leo M.; James, David; Walkinshaw, Stephen		Guideline Dev Grp	Guidelines Management of hypertensive disorders during pregnancy: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Visintin, Cristina; Mugglestone, Moira A.; Nherera, Leo M.; James, David] Natl Collaborating Ctr Womens & Childrens Hlth, London W1T 2QA, England; [Almerie, Muhammad Q.] Diana Princess Wales Hosp, N Yorkshire & E Coast Fdn Sch, Grimsby DN33 2BA, Lincs, England; [Walkinshaw, Stephen] Liverpool Womens Hosp, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Mugglestone, MA (corresponding author), Natl Collaborating Ctr Womens & Childrens Hlth, London W1T 2QA, England.	mmugglestone@ncc-wch.org.uk	Nherera, Leo/L-1978-2019; Nherera, Leo/P-1567-2018	Nherera, Leo/0000-0003-1758-9504; Nherera, Leo/0000-0003-1758-9504				[Anonymous], 2008, ANT CAR ROUT CAR HLT; Lyons G, 2008, INT J OBSTET ANESTH, V17, P103, DOI 10.1016/j.ijoa.2008.01.006; National Institute for Health and Clinical Excellence, 2007, INTR CAR MAN DEL CAR; National Institute for Health and Clinical Excellence, 2006, POSTN CAR ROUT POSTN; National Institute for Health and Clinical Excellence, 2006, HYP MAN HYP AD PRIM; National Institute for Health and Clinical Excellence: Guidance, 2010, HYP PREGN MAN HYP DI; Royal College of Obstetricians and Gynaecologists, 2006, MAN SEV PREECL ECL; Waterstone M, 2001, BMJ-BRIT MED J, V322, P1089, DOI 10.1136/bmj.322.7294.1089	8	119	133	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 25	2010	341								c2207	10.1136/bmj.c2207	http://dx.doi.org/10.1136/bmj.c2207			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IH	20739360				2022-12-28	WOS:000281446000009
J	Wong, CL; Holroyd-Ledue, J; Simel, DL; Straus, SE				Wong, Camilla L.; Holroyd-Ledue, Jayna; Simel, David L.; Straus, Sharon E.			Does This Patient Have Delirium? Value of Bedside Instruments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFUSION ASSESSMENT METHOD; HOSPITALIZED OLDER PATIENTS; FEMORAL-NECK FRACTURE; RATING-SCALE; ELDERLY-PATIENTS; CLINICAL UTILITY; DETECTING DELIRIUM; GERIATRIC-PATIENTS; SEARCH STRATEGIES; CHINESE VERSION	Context Delirium occurs in many hospitalized older patients and has serious consequences including increased risk for death and admission to long-term care. Despite its importance, health care clinicians often fail to recognize delirium. Simple bedside instruments may lead to improved identification. Objective To systematically review the evidence on the accuracy of bedside instruments in diagnosing the presence of delirium in adults. Data Sources Search of MEDLINE (from 1950 to May 2010), EMBASE (from 1980 to May 2010), and references of retrieved articles to identify studies of delirium among inpatients. Study Selection Prospective studies of diagnostic accuracy that compared at least 1 delirium bedside instrument to the Diagnostic and Statistical Manual of Mental Disorders based diagnosis made by a geriatrician, psychiatrist, or neurologist. Data Synthesis There were 6570 unique citations identified with 25 prospectively conducted studies (N=3027 patients) meeting inclusion criteria and describing use of 11 instruments. Positive results that suggested delirium with likelihood ratios (LRs) greater than 5.0 were present for the Global Attentiveness Rating (GAR), Memorial Delirium Assessment Scale (MDAS), Confusion Assessment Method (CAM), Delirium Rating Scale Revised-98 (DRS-R-98), Clinical Assessment of Confusion (CAC), and Delirium Observation Screening Scale (DOSS). Normal results that decreased the likelihood of delirium with LRs less than 0.2 were calculated for the GAR, MDAS, CAM, DRS-R-98, Delirium Rating Scale (DRS), DOSS, Nursing Delirium Screening Scale (Nu-DESC), and Mini-Mental State Examination (MMSE). The Digit Span test and Vigilance "A" test in isolation have limited utility in diagnosing delirium. Considering the instrument's ease of use, test performance, and clinical importance of the heterogeneity in the confidence intervals (CIs) of the LRs, the CAM has the best available supportive data as a bedside delirium instrument (summary-positive LR, 9.6; 95% CI, 5.8-16.0; summary-negative LR, 0.16; 95% CI, 0.09-0.29). Of all scales, the MMSE (score <24) was the least useful for identifying a patient with delirium (LR, 1.6; 95% CI, 1.2-2.0). Conclusion The choice of instrument may be dictated by the amount of time available and the discipline of the examiner; however, the best evidence supports use of the CAM, which takes 5 minutes to administer. JAMA. 2010;304(7):779-786 www.jama.com	[Wong, Camilla L.; Straus, Sharon E.] Univ Toronto, St Michaels Hosp, Div Geriatr, Toronto, ON M5B 1W8, Canada; [Wong, Camilla L.; Straus, Sharon E.] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Holroyd-Ledue, Jayna] Univ Calgary, Div Gen Internal Med, Calgary, AB, Canada; [Holroyd-Ledue, Jayna] Univ Calgary, Div Geriatr, Calgary, AB, Canada; [Simel, David L.] Durham VA Med Ctr, Durham, NC USA; [Simel, David L.] Duke Univ, Durham, NC USA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Calgary; University of Calgary; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University	Wong, CL (corresponding author), 30 Bond St, Toronto, ON M5B 1W8, Canada.	camilla.wong@utoronto.ca	Wong, Camilla/J-6419-2019	Wong, Camilla/0000-0002-4430-2321	Tier 2 Canada Research Chair; Alberta Heritage Foundation for Medical Research; Health Scholar Award	Tier 2 Canada Research Chair(Canada Research Chairs); Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric); Health Scholar Award	Dr Straus was supported by a Tier 2 Canada Research Chair and a Health Scholar Award from the Alberta Heritage Foundation for Medical Research.; Supporters for the Tier 2 Canada Research Chair and the Health Scholar Award, and the Alberta Heritage Foundation had no role in the design and conduct of the study, the collection, management, analysis, or for the interpretation of the data; or for the preparation, review, or approval of the manuscript.	American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andrew MK, 2009, AGE AGEING, V38, P241, DOI 10.1093/ageing/afn298; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; CAMERON DJ, 1987, J AM GERIATR SOC, V35, P1007, DOI 10.1111/j.1532-5415.1987.tb04004.x; de Negreiros DP, 2008, INT J GERIATR PSYCH, V23, P472, DOI 10.1002/gps.1906; de Rooij SE, 2006, INT J GERIATR PSYCH, V21, P876, DOI 10.1002/gps.1577; Dosa D, 2007, J AM GERIATR SOC, V55, P1099, DOI 10.1111/j.1532-5415.2007.01239.x; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; FARRELL KR, 1995, ARCH INTERN MED, V155, P2459, DOI 10.1001/archinte.155.22.2459; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; Gaudreau JD, 2005, J PAIN SYMPTOM MANAG, V29, P368, DOI 10.1016/j.jpainsymman.2004.07.009; Gonzalez M, 2004, PSYCHOSOMATICS, V45, P426, DOI 10.1176/appi.psy.45.5.426; Grassi L, 2001, J PAIN SYMPTOM MANAG, V21, P59, DOI 10.1016/S0885-3924(00)00241-4; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P760, DOI 10.1111/j.1532-5415.1991.tb02697.x; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Haynes RB, 2004, BMJ-BRIT MED J, V328, P1040, DOI 10.1136/bmj.38068.557998.EE; Hestermann U, 2009, PSYCHOPATHOLOGY, V42, P270, DOI 10.1159/000224151; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Huang MC, 2009, COMPR PSYCHIAT, V50, P81, DOI 10.1016/j.comppsych.2008.05.011; Inouye SK, 1999, AM J MED, V106, P565, DOI 10.1016/S0002-9343(99)00070-4; Inouye SK, 2001, ARCH INTERN MED, V161, P2467, DOI 10.1001/archinte.161.20.2467; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; Kazmierski J, 2008, PSYCHOSOMATICS, V49, P73, DOI 10.1176/appi.psy.49.1.73; Laurila JV, 2002, INT J GERIATR PSYCH, V17, P1112, DOI 10.1002/gps.753; Laurila JV, 2004, INT J GERIATR PSYCH, V19, P271, DOI 10.1002/gps.1079; Leung JLM, 2008, GEN HOSP PSYCHIAT, V30, P171, DOI 10.1016/j.genhosppsych.2007.12.007; LEWIS LM, 1995, AM J EMERG MED, V13, P142, DOI 10.1016/0735-6757(95)90080-2; LIPTZIN B, 1992, BRIT J PSYCHIAT, V161, P843, DOI 10.1192/bjp.161.6.843; Lundstrom M, 2007, AGING CLIN EXP RES, V19, P178; Marchandin H, 2001, PATHOL BIOL, V49, P522, DOI 10.1016/S0369-8114(01)00212-7; Matsuoka Y, 2001, GEN HOSP PSYCHIAT, V23, P36, DOI 10.1016/S0163-8343(00)00121-3; McCusker J, 2002, ARCH INTERN MED, V162, P457, DOI 10.1001/archinte.162.4.457; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; OKeeffe ST, 1997, J AM GERIATR SOC, V45, P470, DOI 10.1111/j.1532-5415.1997.tb05173.x; POMPEI P, 1995, ARCH INTERN MED, V155, P301, DOI 10.1001/archinte.155.3.301; Rockwood K, 1996, J AM GERIATR SOC, V44, P839, DOI 10.1111/j.1532-5415.1996.tb03745.x; Rolfson D B, 1999, Int Psychogeriatr, V11, P431, DOI 10.1017/S1041610299006043; ROSEN J, 1994, J NEUROPSYCH CLIN N, V6, P30; Ryan K, 2009, PALLIATIVE MED, V23, P40, DOI 10.1177/0269216308099210; Schuurmans Marieke J, 2003, Res Theory Nurs Pract, V17, P207, DOI 10.1891/088971803780956272; Schuurmans Marieke J, 2003, Res Theory Nurs Pract, V17, P31, DOI 10.1891/088971803780956425; Schuurmans MJ, 2002, J AM GERIATR SOC, V50, pS3; Simel DL, 2009, J CLIN EPIDEMIOL, V62, P1292, DOI 10.1016/j.jclinepi.2009.02.007; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Simel DL, 2008, RATIONAL CLIN EXAMIN, P9; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; Van Gemert LA, 2007, BMC NURS, V6, DOI 10.1186/1472-6955-6-3; Vermeersch P E, 1990, Appl Nurs Res, V3, P128, DOI 10.1016/S0897-1897(05)80132-6; Vidan M, 2005, J AM GERIATR SOC, V53, P1476, DOI 10.1111/j.1532-5415.2005.53466.x; Wei LA, 2008, J AM GERIATR SOC, V56, P823, DOI 10.1111/j.1532-5415.2008.01674.x; Wilczynski NL, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-7; Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31; Zou Y, 1998, Int Psychogeriatr, V10, P303, DOI 10.1017/S1041610298005390	60	255	266	0	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					779	786		10.1001/jama.2010.1182	http://dx.doi.org/10.1001/jama.2010.1182			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639SB	20716741				2022-12-28	WOS:000280993700025
J	Story, BT; Kowdley, KV				Story, Brian T.; Kowdley, Kris V.			Rifaximin maintained remission from hepatic encephalopathy longer than placebo in patients with cirrhosis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Story, Brian T.; Kowdley, Kris V.] Virginia Mason Med Ctr, Seattle, WA 98101 USA	Virginia Mason Medical Center	Story, BT (corresponding author), Virginia Mason Med Ctr, Seattle, WA 98101 USA.		Kowdley, Kris/AAF-5202-2019					Bajaj JS, 2010, ALIMENT PHARM THER, V31, P537, DOI 10.1111/j.1365-2036.2009.04211.x; Sharma BC, 2009, GASTROENTEROLOGY, V137, P885, DOI 10.1053/j.gastro.2009.05.056	2	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-8	10.7326/0003-4819-153-4-201008170-02008	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713787				2022-12-28	WOS:000280973000034
J	Cicardi, M; Levy, RJ; McNeil, DL; Li, HH; Sheffer, AL; Campion, M; Horn, PT; Pullman, WE				Cicardi, Marco; Levy, Robyn J.; McNeil, Donald L.; Li, H. Henry; Sheffer, Albert L.; Campion, Marilyn; Horn, Patrick T.; Pullman, William E.			Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KALLIKREIN INHIBITOR; PLASMA KALLIKREIN; HIGH-AFFINITY; C1 INHIBITOR; DEFICIENCY; KININ; EDEMA	BACKGROUND Hereditary angioedema is a rare genetic disorder characterized by acute, intermittent, and potentially life-threatening attacks of edema of the skin and mucosa. We evaluated ecallantide, a newly developed recombinant plasma kallikrein inhibitor, for the treatment of acute attacks of angioedema. METHODS In this double-blind, placebo-controlled trial, patients with hereditary angioedema presenting with an acute attack were randomly assigned, in a 1: 1 ratio, to receive subcutaneous ecallantide, at a dose of 30 mg, or placebo. Two measures of patient-reported outcomes were used to assess the response: treatment outcome scores, which range from +100 (designated in the protocol as significant improvement in symptoms) to -100 (significant worsening of symptoms), and the change from baseline in the mean symptom complex severity score, which range from +2 (representing a change from mild symptoms at baseline to severe symptoms after) to -3 (representing a change from severe symptoms at baseline to no symptoms after). The primary end point was the treatment outcome score 4 hours after study-drug administration. Secondary end points included the change from baseline in the mean symptom complex severity score at 4 hours and the time to significant improvement. RESULTS A total of 71 of the 72 patients completed the trial. The median treatment outcome score at 4 hours was 50.0 in the ecallantide group and 0.0 in the placebo group (interquartile range [IQR], 0.0 to 100.0 in both groups; P=0.004). The median change in the mean symptom complex severity score at 4 hours was -1.00 (IQR, -1.50 to 0.00) with ecallantide, versus -0.50 (IQR, -1.00 to 0.00) with placebo (P=0.01). The estimated time to significant improvement was 165 minutes with ecallantide versus more than 240 minutes with placebo (P=0.14). There were no deaths, treatment-related serious adverse events, or withdrawals owing to adverse events. CONCLUSIONS Four hours after administration of ecallantide or placebo for acute attacks of angioedema in patients with hereditary angioedema, patient-reported treatment outcome scores and mean symptom complex severity scores were significantly better with ecallantide than with placebo. (Funded by Dyax; ClinicalTrials.gov number, NCT00262080.)	[Cicardi, Marco] Univ Milan, Dept Internal Med, Osped Luigi Sacco, I-20157 Milan, Italy; [Levy, Robyn J.] Family Allergy & Asthma Ctr, Atlanta, GA USA; [McNeil, Donald L.] Optimed Res, Columbus, OH USA; [Li, H. Henry] Inst Asthma & Allergy, Wheaton, MD USA; [Sheffer, Albert L.] Harvard Univ, Sch Med, Boston, MA USA; [Sheffer, Albert L.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Horn, Patrick T.; Pullman, William E.] Dyax, Cambridge, MA USA	University of Milan; Luigi Sacco Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Cicardi, M (corresponding author), Univ Milan, Dept Internal Med, Osped Luigi Sacco, Via Giovanni Battista Grassi 74, I-20157 Milan, Italy.	marco.cicardi@unimi.it	cicardi, marco/K-9219-2016	cicardi, marco/0000-0003-1251-225X	Dyax	Dyax	Supported by Dyax.	AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Bork K, 2003, ARCH INTERN MED, V163, P1229, DOI 10.1001/archinte.163.10.1229; Bygum A, 2009, BRIT J DERMATOL, V161, P1153, DOI 10.1111/j.1365-2133.2009.09366.x; Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510; Davis AE, 2008, ANN ALLERG ASTHMA IM, V100, pS7, DOI 10.1016/S1081-1206(10)60580-7; Epstein TG, 2008, DRUGS, V68, P2561, DOI 10.2165/0003495-200868180-00003; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; GIGLI I, 1970, J IMMUNOL, V104, P574; Gompels MM, 2005, CLIN EXP IMMUNOL, V141, P189, DOI 10.1111/j.1365-2249.2005.02781.x; Lehmann A, 2008, EXPERT OPIN BIOL TH, V8, P1187, DOI [10.1517/14712598.8.8.1187, 10.1517/14712598.8.8.1187 ]; Levy JH, 2006, EXPERT OPIN INV DRUG, V15, P1077, DOI 10.1517/13543784.15.9.1077; Ley AC, 1996, MOL DIVERS, V2, P119, DOI 10.1007/BF01718709; Markland W, 1996, BIOCHEMISTRY-US, V35, P8058, DOI 10.1021/bi952629y; Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498, DOI 10.1016/S1081-1206(10)61121-0; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; SCHREIBER AD, 1973, J CLIN INVEST, V52, P1402, DOI 10.1172/JCI107313; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; Sloane DE, 2007, J ALLERGY CLIN IMMUN, V120, P654, DOI 10.1016/j.jaci.2007.06.037; Thompson CA, 2010, AM J HEALTH-SYST PH, V67, P93, DOI 10.2146/news100005; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358, DOI 10.1016/S0171-2985(98)80040-5; TOSI M, 1999, IMMUNOBIOLOGY, V200, P166; Traynor K, 2010, AM J HEALTH-SYST PH, V67, P254, DOI 10.2146/news100013; Vernon MK, 2009, QUAL LIFE RES, V18, P929, DOI 10.1007/s11136-009-9509-8	23	239	241	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					523	531		10.1056/NEJMoa0905079	http://dx.doi.org/10.1056/NEJMoa0905079			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818887				2022-12-28	WOS:000280552700006
J	Teerlink, JR				Teerlink, John R.			Ivabradine in heart failure-no paradigm SHIFT ... yet	LANCET			English	Editorial Material							CARDIAC-INSUFFICIENCY BISOPROLOL; PLACEBO-CONTROLLED TRIAL; RATE REDUCTION; RANDOMIZED-TRIAL; I-F; CARVEDILOL; DISEASE; DYSFUNCTION; METOPROLOL; CIBIS		[Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Teerlink, JR (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.	john.teerlink@ucsf.edu	Teerlink, John R/D-2986-2012					BOHM M, 2010, LANCET, DOI DOI 10.1016/50140-6736(10)61259-7; BROWN H, 1979, J EXP BIOL, V81, P175; Cerbai E, 2001, J MOL CELL CARDIOL, V33, P441, DOI 10.1006/jmcc.2000.1316; Custodis F, 2008, CIRCULATION, V117, P2377, DOI 10.1161/CIRCULATIONAHA.107.746537; DiFrancesco D, 2010, CIRC RES, V106, P434, DOI 10.1161/CIRCRESAHA.109.208041; Drouin A, 2008, BRIT J PHARMACOL, V154, P749, DOI 10.1038/bjp.2008.116; Fox K, 2008, LANCET, V372, P807, DOI 10.1016/S0140-6736(08)61170-8; Heusch G, 2008, EUR HEART J, V29, P2265, DOI 10.1093/eurheartj/ehn337; Hjalmarson A, 1999, LANCET, V353, P2001; Lechat P, 1999, LANCET, V353, P9; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; MacMahon S, 1997, LANCET, V349, P375; Michels G, 2008, CARDIOVASC RES, V78, P466, DOI 10.1093/cvr/cvn032; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Palatini P, 2009, PROG CARDIOVASC DIS, V52, P46, DOI 10.1016/j.pcad.2009.05.005; Poole-Wilson PA, 2003, LANCET, V362, P7, DOI 10.1016/S0140-6736(03)13800-7; SWEDBERG K, 2010, LANCET, DOI DOI 10.1016/501406736(10)61198-1; Swedberg K, 2009, HEART, V95, P1464, DOI 10.1136/hrt.2008.154542	19	38	41	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					847	849		10.1016/S0140-6736(10)61314-1	http://dx.doi.org/10.1016/S0140-6736(10)61314-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653DW	20801501				2022-12-28	WOS:000282069100004
J	Park, SY; Cromie, MJ; Lee, EJ; Groisman, EA				Park, Sun-Yang; Cromie, Michael J.; Lee, Eun-Jin; Groisman, Eduardo A.			A Bacterial mRNA Leader that Employs Different Mechanisms to Sense Disparate Intracellular Signals	CELL			English	Article							ESCHERICHIA-COLI K-12; SALMONELLA-ENTERICA; GENE-EXPRESSION; TRANSCRIPTION ATTENUATION; OSMOTIC-STRESS; MG2+; RIBOSWITCH; TRANSPORT; VIRULENCE; MGTA	Bacterial mRNAs often contain leader sequences that respond to specific metabolites or ions by altering expression of the associated downstream protein-coding sequences. Here we report that the leader RNA of the Mg2+ transporter gene mgtA of Salmonella enterica, which was previously known to function as a Mg2+-sensing riboswitch, harbors an 18 codon proline-rich open reading frame-termed mgtL-that permits intracellular proline to regulate mgtA expression. Interfering with mgtL translation by genetic, pharmacological, or environmental means was observed to increase the mRNA levels from the mgtA coding region. Substitution of the mgtL proline codons by other codons abolished the response to proline and to hyperosmotic stress but not to Mg2+. Our findings show that mRNA leader sequences can consist of complex regulatory elements that utilize different mechanisms to sense separate signals and mediate an appropriate cellular response.	[Cromie, Michael J.; Lee, Eun-Jin; Groisman, Eduardo A.] Washington Univ, Howard Hughes Med Inst, Sch Med, St Louis, MO 63110 USA; [Park, Sun-Yang; Cromie, Michael J.; Lee, Eun-Jin; Groisman, Eduardo A.] Washington Univ, Dept Mol Microbiol, Sch Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Groisman, EA (corresponding author), Yale Univ, Sch Med, Sect Microbial Pathogenesis, Howard Hughes Med Inst,Boyer Ctr Mol Med, 295 Congress Ave, New Haven, CT 06536 USA.	eduardo.groisman@yale.edu			NIH [AI49561]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049561] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Laszlo Csonka, Kerry Hollands, Robert Landick, and Charles Yanofsky for comments on the manuscript; Henry Huang for the plasmid harboring supF; and John Roth for strains. This work was supported, in part, by grant AI49561 from the NIH to E.A.G., who is an Investigator of the Howard Hughes Medical Institute.	Bader MW, 2005, CELL, V122, P461, DOI 10.1016/j.cell.2005.05.030; Barchiesi J, 2008, J BACTERIOL, V190, P4951, DOI 10.1128/JB.00195-08; BlancPotard AB, 1997, EMBO J, V16, P5376, DOI 10.1093/emboj/16.17.5376; Brennan RG, 2007, CURR OPIN MICROBIOL, V10, P125, DOI 10.1016/j.mib.2007.03.015; CAYLEY S, 1992, J BACTERIOL, V174, P1586, DOI 10.1128/jb.174.5.1586-1595.1992; CHEN JW, 1991, J BACTERIOL, V173, P2328, DOI 10.1128/JB.173.7.2328-2340.1991; Choi E, 2009, J BACTERIOL, V191, P7174, DOI 10.1128/JB.00958-09; Cromie MJ, 2010, J BACTERIOL, V192, P604, DOI 10.1128/JB.01239-09; Cromie MJ, 2006, CELL, V125, P71, DOI 10.1016/j.cell.2006.01.043; Csonka L.N., 2007, ECOSALESCHERICHIA CO; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Eguchi Y, 2004, J BACTERIOL, V186, P3006, DOI 10.1128/JB.186.10.3006-3014.2004; Froschauer EM, 2004, FEMS MICROBIOL LETT, V237, P49, DOI 10.1016/j.femsle.2004.06.013; Grundy FJ, 2006, CRIT REV BIOCHEM MOL, V41, P329, DOI 10.1080/10409230600914294; Hammarlof DL, 2008, MOL MICROBIOL, V70, P1194, DOI 10.1111/j.1365-2958.2008.06472.x; Henkin TM, 2008, GENE DEV, V22, P3383, DOI 10.1101/gad.1747308; Henkin TM, 2002, BIOESSAYS, V24, P700, DOI 10.1002/bies.10125; LANDICK R, 1996, ESCHERICHIA COLI SAL; LANDICK R, 1987, ESCHERICHIA COLI SAL; Laursen BS, 2005, MICROBIOL MOL BIOL R, V69, P101, DOI 10.1128/MMBR.69.1.101-123.2005; Lejona S, 2003, J BACTERIOL, V185, P6287, DOI 10.1128/JB.185.21.6287-6294.2003; Loh E, 2009, CELL, V139, P770, DOI 10.1016/j.cell.2009.08.046; MAGUIRE ME, 1992, J BIOENERG BIOMEMBR, V24, P319; Maguire ME, 2006, FRONT BIOSCI-LANDMRK, V11, P3149, DOI 10.2741/2039; Merino E, 2005, TRENDS GENET, V21, P260, DOI 10.1016/j.tig.2005.03.002; O'Connor K, 2009, P NATL ACAD SCI USA, V106, P17522, DOI 10.1073/pnas.0906160106; Perez-Arellano I, 2005, FEBS LETT, V579, P6903, DOI 10.1016/j.febslet.2005.11.037; Prost LR, 2007, MOL CELL, V26, P165, DOI 10.1016/j.molcel.2007.03.008; Schiller D, 2000, J BACTERIOL, V182, P6247, DOI 10.1128/JB.182.21.6247-6249.2000; Shin D, 2006, SCIENCE, V314, P1607, DOI 10.1126/science.1134930; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Spinelli SV, 2008, FEMS MICROBIOL LETT, V280, P226, DOI 10.1111/j.1574-6968.2008.01065.x; Sudarsan N, 2006, SCIENCE, V314, P300, DOI 10.1126/science.1130716; Turnbough CL, 2008, MICROBIOL MOL BIOL R, V72, P266, DOI 10.1128/MMBR.00001-08; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Winkler WC, 2005, ANNU REV MICROBIOL, V59, P487, DOI 10.1146/annurev.micro.59.030804.121336; Wortham BW, 2007, ADV EXP MED BIOL, V603, P106; YANOFSKY C, 1994, J BACTERIOL, V176, P6245, DOI 10.1128/jb.176.20.6245-6254.1994	40	66	68	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2010	142	5					737	748		10.1016/j.cell.2010.07.046	http://dx.doi.org/10.1016/j.cell.2010.07.046			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	646FL	20813261	Green Accepted, Bronze			2022-12-28	WOS:000281523200017
J	Baker, M				Baker, Monya			CELLULAR IMAGING Taking a long, hard look	NATURE			English	Editorial Material																		Carlton PM, 2010, P NATL ACAD SCI USA, V107, P16016, DOI 10.1073/pnas.1004037107; Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580; Cohen AR, 2010, NAT METHODS, V7, P213, DOI [10.1038/NMETH.1424, 10.1038/nmeth.1424]; Huth J, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-24; Qian XM, 1998, DEVELOPMENT, V125, P3143; Rieger MA, 2009, SCIENCE, V325, P217, DOI 10.1126/science.1171461	6	34	35	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2010	466	7310					1137	1142		10.1038/4661137a	http://dx.doi.org/10.1038/4661137a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740018	Bronze			2022-12-28	WOS:000281203600050
J	Elden, AC; Kim, HJ; Hart, MP; Chen-Plotkin, AS; Johnson, BS; Fang, XD; Armakola, M; Geser, F; Greene, R; Lu, MM; Padmanabhan, A; Clay-Falcone, D; McCluskey, L; Elman, L; Juhr, D; Gruber, PJ; Rub, U; Auburger, G; Trojanowski, JQ; Lee, VMY; Van Deerlin, VM; Bonini, NM; Gitler, AD				Elden, Andrew C.; Kim, Hyung-Jun; Hart, Michael P.; Chen-Plotkin, Alice S.; Johnson, Brian S.; Fang, Xiaodong; Armakola, Maria; Geser, Felix; Greene, Robert; Lu, Min Min; Padmanabhan, Arun; Clay-Falcone, Dana; McCluskey, Leo; Elman, Lauren; Juhr, Denise; Gruber, Peter J.; Rueb, Udo; Auburger, Georg; Trojanowski, John Q.; Lee, Virginia M. -Y.; Van Deerlin, Vivianna M.; Bonini, Nancy M.; Gitler, Aaron D.			Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS	NATURE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; SPINOCEREBELLAR ATAXIA; ALPHA-SYNUCLEIN; SACCHAROMYCES-CEREVISIAE; TRINUCLEOTIDE REPEAT; STRESS GRANULES; P-BODIES; TDP-43; TOXICITY; AGGREGATION	The causes of amyotrophic lateral sclerosis (ALS), a devastating human neurodegenerative disease, are poorly understood, although the protein TDP-43 has been suggested to have a critical role in disease pathogenesis. Here we show that ataxin 2 (ATXN2), a polyglutamine (polyQ) protein mutated in spinocerebellar ataxia type 2, is a potent modifier of TDP-43 toxicity in animal and cellular models. ATXN2 and TDP-43 associate in a complex that depends on RNA. In spinal cord neurons of ALS patients, ATXN2 is abnormally localized; likewise, TDP-43 shows mislocalization in spinocerebellar ataxia type 2. To assess the involvement of ATXN2 in ALS, we analysed the length of the polyQ repeat in the ATXN2 gene in 915 ALS patients. We found that intermediate-length polyQ expansions (27-33 glutamines) in ATXN2 were significantly associated with ALS. These data establish ATXN2 as a relatively common ALS susceptibility gene. Furthermore, these findings indicate that the TDP-43-ATXN2 interaction may be a promising target for therapeutic intervention in ALS and other TDP-43 proteinopathies.	[Elden, Andrew C.; Hart, Michael P.; Johnson, Brian S.; Fang, Xiaodong; Armakola, Maria; Lu, Min Min; Padmanabhan, Arun; Gitler, Aaron D.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Kim, Hyung-Jun; Bonini, Nancy M.] Univ Penn, Howard Hughes Med Inst, Dept Biol, Philadelphia, PA 19104 USA; [Chen-Plotkin, Alice S.; Geser, Felix; Greene, Robert; Clay-Falcone, Dana; Trojanowski, John Q.; Lee, Virginia M. -Y.; Van Deerlin, Vivianna M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Chen-Plotkin, Alice S.; Geser, Felix; Greene, Robert; Clay-Falcone, Dana; Trojanowski, John Q.; Lee, Virginia M. -Y.; Van Deerlin, Vivianna M.] Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; [Chen-Plotkin, Alice S.; McCluskey, Leo; Elman, Lauren] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Juhr, Denise; Gruber, Peter J.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Rueb, Udo] Goethe Univ Frankfurt, Inst Clin Neuroanat, D-60590 Frankfurt, Germany; [Auburger, Georg] Goethe Univ Frankfurt, Dept Neurol, D-60528 Frankfurt, Germany	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Goethe University Frankfurt; Goethe University Frankfurt	Gitler, AD (corresponding author), Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.	nbonini@sas.upenn.edu; gitler@mail.med.upenn.edu	Sander-Effron, Samuel/AAX-2231-2020; Resource Center, NINDS Human Genetics/AGF-2474-2022	Hart, Michael/0000-0001-8865-3062; Johnson, Brian/0000-0003-3711-5920; Gitler, Aaron/0000-0001-8603-1526	University of Pennsylvania Institute on Aging; NIH [1DP2OD004417-01, 1R01NS065317-01, P01 AG-09215, AG-10124, AG-17586, K08 AG-033101-01]; Pew Charitable Trusts; Burroughs Wellcome Fund; Howard Hughes Medical Institute; Deutsche Heredo-Ataxie Gesellschaft (DHAG); Autosomal Dominant Cerebellar Ataxia (ADCA) Vereniging Nederland; Spinocerebellar Ataxias (EuroSCA); Deutsche Forschungsgemeinschaft (DFG) [AU96/11-1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS065317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG033101, P01AG017586, P30AG010124, P01AG009215] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD004417] Funding Source: NIH RePORTER	University of Pennsylvania Institute on Aging; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pew Charitable Trusts; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Deutsche Heredo-Ataxie Gesellschaft (DHAG); Autosomal Dominant Cerebellar Ataxia (ADCA) Vereniging Nederland; Spinocerebellar Ataxias (EuroSCA); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by a Pilot grant from the University of Pennsylvania Institute on Aging (A.D.G.), an NIH Director's New Innovator Award 1DP2OD004417-01 (A.D.G.), 1R01NS065317-01 (A.D.G.), P01 AG-09215 (N.M.B.), AG-10124 (J.Q.T., V.M.V.D.) and AG-17586, (V.M.-Y.L., V.M.V.D.). A.D.G. is a Pew Scholar in the Biomedical Sciences, supported by The Pew Charitable Trusts. A.S.C.-P. is supported by a Burroughs Wellcome Fund Career Award and NIH K08 AG-033101-01. N.M.B. is an Investigator of the Howard Hughes Medical Institute. U.R. has support from the Deutsche Heredo-Ataxie Gesellschaft (DHAG) and Autosomal Dominant Cerebellar Ataxia (ADCA) Vereniging Nederland, G.A. from the European Integrated Project on Spinocerebellar Ataxias (EuroSCA) and the Deutsche Forschungsgemeinschaft (DFG) (AU96/11-1). We acknowledge W. den Dunnen and E. Brunt for autopsy tissue and M. Babl for technical assistance. We thank J. Epstein, J. Shorter, A. Cashmore and members of the Gitler laboratory for comments on the manuscript and discussions. We are grateful for the dedication of the patients and their families and for their invaluable contributions to this research.	Al-Ramahi I, 2007, PLOS GENET, V3, P2551, DOI 10.1371/journal.pgen.0030234; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Buchan JR, 2008, J CELL BIOL, V183, P441, DOI 10.1083/jcb.200807043; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Colombrita C, 2009, J NEUROCHEM, V111, P1051, DOI 10.1111/j.1471-4159.2009.06383.x; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Freibaum BD, 2010, J PROTEOME RES, V9, P1104, DOI 10.1021/pr901076y; Gitler AD, 2009, NAT GENET, V41, P308, DOI 10.1038/ng.300; Huynh DP, 2003, HUM MOL GENET, V12, P1485, DOI 10.1093/hmg/ddg175; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Infante J, 2004, MOVEMENT DISORD, V19, P848, DOI 10.1002/mds.20090; Jackson M, 2002, EXPERT OPIN INV DRUG, V11, P1343, DOI 10.1517/13543784.11.10.1343; Johnson BS, 2008, P NATL ACAD SCI USA, V105, P6439, DOI 10.1073/pnas.0802082105; Johnson BS, 2009, J BIOL CHEM, V284, P20329, DOI 10.1074/jbc.M109.010264; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Lagier-Tourenne C, 2009, CELL, V136, P1001, DOI 10.1016/j.cell.2009.03.006; Lessing D, 2008, PLOS BIOL, V6, P266, DOI 10.1371/journal.pbio.0060029; Li LB, 2008, NATURE, V453, P1107, DOI 10.1038/nature06909; Lorenzetti D, 1997, NEUROLOGY, V49, P1009, DOI 10.1212/WNL.49.4.1009; Mangus DA, 1998, MOL CELL BIOL, V18, P7383, DOI 10.1128/MCB.18.12.7383; Nanetti L, 2009, J NEUROL, V256, P1926, DOI 10.1007/s00415-009-5237-9; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nonhoff U, 2007, MOL BIOL CELL, V18, P1385, DOI 10.1091/mbc.E06-12-1120; Orr HT, 2007, ANNU REV NEUROSCI, V30, P575, DOI 10.1146/annurev.neuro.29.051605.113042; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Pesiridis GS, 2009, HUM MOL GENET, V18, pR156, DOI 10.1093/hmg/ddp303; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Winton MJ, 2008, J BIOL CHEM, V283, P13302, DOI 10.1074/jbc.M800342200	33	834	856	3	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2010	466	7310					1069	U77		10.1038/nature09320	http://dx.doi.org/10.1038/nature09320			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740007	Green Accepted			2022-12-28	WOS:000281203600032
J	Shackleton, M				Shackleton, Mark			Moving Targets That Drive Cancer Progression	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CELLS		[Shackleton, Mark] Peter MacCallum Canc Ctr, Melanoma Res Lab, Melbourne, Australia; [Shackleton, Mark] Peter MacCallum Canc Ctr, Dept Hematol & Med Oncol, Melbourne, Australia; [Shackleton, Mark] Univ Melbourne, Dept Pathol, Fac Med Dent & Hlth Sci, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Shackleton, M (corresponding author), Peter MacCallum Canc Ctr, Melanoma Res Lab, Melbourne, Australia.							Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027	5	13	13	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					885	886		10.1056/NEJMcibr1006328	http://dx.doi.org/10.1056/NEJMcibr1006328			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642HG	20818851				2022-12-28	WOS:000281196600015
J	Koster, DA; Crut, A; Shuman, S; Bjornsti, MA; Dekker, NH				Koster, Daniel A.; Crut, Aurelien; Shuman, Stewart; Bjornsti, Mary-Ann; Dekker, Nynke H.			Cellular Strategies for Regulating DNA Supercoiling: A Single-Molecule Perspective	CELL			English	Review							HUMAN TOPOISOMERASE-I; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TORQUE MEASUREMENTS; TRANSITION-STATE; RNA-POLYMERASE; MECHANISM; TRANSCRIPTION; PROTEIN; RELAXATION	Entangling and twisting of cellular DNA (i.e., supercoiling) are problems inherent to the helical structure of double-stranded DNA. Supercoiling affects transcription, DNA replication, and chromosomal segregation. Consequently the cell must fine-tune supercoiling to optimize these key processes. Here, we summarize how supercoiling is generated and review experimental and theoretical insights into supercoil relaxation. We distinguish between the passive dissipation of supercoils by diffusion and the active removal of supercoils by topoisomerase enzymes. We also review single-molecule studies that elucidate the timescales and mechanisms of supercoil removal.	[Dekker, Nynke H.] Delft Univ Technol, Fac Appl Phys, Kavli Inst Nanosci, NL-2628 CJ Delft, Netherlands; [Koster, Daniel A.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Bjornsti, Mary-Ann] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; [Shuman, Stewart] Sloan Kettering Inst, Program Mol Biol, New York, NY 10065 USA; [Crut, Aurelien] Univ Lyon 1, LASIM, CNRS, F-69622 Villeurbanne, France	Delft University of Technology; Weizmann Institute of Science; University of Alabama System; University of Alabama Birmingham; Memorial Sloan Kettering Cancer Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dekker, NH (corresponding author), Delft Univ Technol, Fac Appl Phys, Kavli Inst Nanosci, Lorentzweg 1, NL-2628 CJ Delft, Netherlands.	n.h.dekker@tudelft.nl		Dekker, Nynke/0000-0003-4029-0973	TU Delft; Dutch Foundation for Research on Matter (FOM); European Science Foundation; NIH [CA058755, CA111542, GM46330]; NATIONAL CANCER INSTITUTE [R01CA058755, R01CA111542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER	TU Delft; Dutch Foundation for Research on Matter (FOM)(FOM (The Netherlands)); European Science Foundation(European Science Foundation (ESF)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Vincent Croquette and Elise Praly for providing us with an unpublished trace of TopII, Elisa Bot and Komaraiah Palle for contributions to earlier work, and Jan Lipfert, Keir Neuman, and John Marko for useful discussions. N.H.D. acknowledges financial support from TU Delft, the Dutch Foundation for Research on Matter (FOM), and the European Science Foundation. M.-A. B. acknowledges support from NIH (CA058755 and CA111542). S.S. is supported by NIH grant GM46330.	Abbondanzieri EA, 2005, NATURE, V438, P460, DOI 10.1038/nature04268; Bishop AI, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.033802; Bohbot-Raviv Y, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.098101; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Bryant Z, 2003, NATURE, V424, P338, DOI 10.1038/nature01810; Capitanio M, 2004, OPT LETT, V29, P2231, DOI 10.1364/OL.29.002231; Carey JF, 2003, P NATL ACAD SCI USA, V100, P5640, DOI 10.1073/pnas.1031537100; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2005, ANNU REV BIOPH BIOM, V34, P201, DOI 10.1146/annurev.biophys.34.040204.144433; Coelho Neto J, 2005, PHYSICA A, V345, P173, DOI 10.1016/j.physa.2004.07.029; Corbett KD, 2005, J MOL BIOL, V351, P545, DOI 10.1016/j.jmb.2005.06.029; Corbett KD, 2007, NAT STRUCT MOL BIOL, V14, P611, DOI 10.1038/nsmb1264; Crisona NJ, 2000, GENE DEV, V14, P2881, DOI 10.1101/gad.838900; Crut A, 2007, P NATL ACAD SCI USA, V104, P11957, DOI 10.1073/pnas.0700333104; Davies DR, 2006, J MOL BIOL, V357, P1202, DOI 10.1016/j.jmb.2006.01.022; Dekker NH, 2003, J MOL BIOL, V329, P271, DOI 10.1016/S0022-2836(03)00320-6; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; DROGE P, 1991, NUCLEIC ACIDS RES, V19, P2941, DOI 10.1093/nar/19.11.2941; Drolet M, 2006, MOL MICROBIOL, V59, P723, DOI 10.1111/j.1365-2958.2005.05006.x; Feingold M, 2001, PHYSICA E, V9, P616, DOI 10.1016/S1386-9477(00)00270-8; FISHER LM, 1984, NATURE, V307, P686, DOI 10.1038/307686a0; FRANKKAMENETSKI.MD, 1990, DNA TOPOLOGY ITS BIO, P185; Gadelle D, 2003, BIOESSAYS, V25, P232, DOI 10.1002/bies.10245; GARTENBERG MR, 1993, P NATL ACAD SCI USA, V90, P10514, DOI 10.1073/pnas.90.22.10514; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Gore J, 2006, NATURE, V439, P100, DOI 10.1038/nature04319; Goshen E, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.061920; Graille M, 2008, STRUCTURE, V16, P360, DOI 10.1016/j.str.2007.12.020; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; Koster DA, 2007, NATURE, V448, P213, DOI 10.1038/nature05938; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Leng FF, 2002, P NATL ACAD SCI USA, V99, P9139, DOI 10.1073/pnas.142002099; LEVINTHAL C, 1956, P NATL ACAD SCI USA, V42, P436, DOI 10.1073/pnas.42.7.436; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Neuman KC, 2009, P NATL ACAD SCI USA, V106, P6986, DOI 10.1073/pnas.0900574106; Neuman KC, 2004, REV SCI INSTRUM, V75, P2787, DOI 10.1063/1.1785844; Oroszi L, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.058301; Pan CQ, 1996, J MOL BIOL, V264, P675, DOI 10.1006/jmbi.1996.0669; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; Perry K, 2010, STRUCTURE, V18, P127, DOI 10.1016/j.str.2009.10.020; Peter BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r87; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Revyakin A, 2004, P NATL ACAD SCI USA, V101, P4776, DOI 10.1073/pnas.0307241101; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Romano G, 2003, OPT COMMUN, V215, P323, DOI 10.1016/S0030-4018(02)02247-2; Sacconi L, 2001, OPT LETT, V26, P1359, DOI 10.1364/OL.26.001359; Saleh OA, 2005, NAT STRUCT MOL BIOL, V12, P436, DOI 10.1038/nsmb926; Schoeffler AJ, 2008, Q REV BIOPHYS, V41, P41, DOI 10.1017/S003358350800468X; Seidel R, 2004, NAT STRUCT MOL BIOL, V11, P838, DOI 10.1038/nsmb816; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Shusterman R, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.098102; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; Stone MD, 2003, P NATL ACAD SCI USA, V100, P8654, DOI 10.1073/pnas.1133178100; Strick TR, 2000, NATURE, V404, P901, DOI 10.1038/35009144; Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835; Stupina VA, 2004, P NATL ACAD SCI USA, V101, P8608, DOI 10.1073/pnas.0402849101; Swinger KK, 2003, EMBO J, V22, P3749, DOI 10.1093/emboj/cdg351; Taneja B, 2007, P NATL ACAD SCI USA, V104, P14670, DOI 10.1073/pnas.0701989104; Thomen P, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.248102; Tian LG, 2005, STRUCTURE, V13, P513, DOI 10.1016/j.str.2005.02.001; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Travers A, 2005, NAT REV MICROBIOL, V3, P157, DOI 10.1038/nrmicro1088; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; Xie XS, 2008, ANNU REV BIOPHYS, V37, P417, DOI 10.1146/annurev.biophys.37.092607.174640; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	82	106	107	2	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					519	530		10.1016/j.cell.2010.08.001	http://dx.doi.org/10.1016/j.cell.2010.08.001			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723754	Green Accepted, Bronze			2022-12-28	WOS:000281115900007
J	Watters, TR; Robinson, MS; Beyer, RA; Banks, ME; Bell, JF; Pritchard, ME; Hiesinger, H; van der Bogert, CH; Thomas, PC; Turtle, EP; Williams, NR				Watters, Thomas R.; Robinson, Mark S.; Beyer, Ross A.; Banks, Maria E.; Bell, James F., III; Pritchard, Matthew E.; Hiesinger, Harald; van der Bogert, Carolyn H.; Thomas, Peter C.; Turtle, Elizabeth P.; Williams, Nathan R.			Evidence of Recent Thrust Faulting on the Moon Revealed by the Lunar Reconnaissance Orbiter Camera	SCIENCE			English	Article							THERMAL HISTORY; TECTONICS; MERCURY; ORIGIN	Lunar Reconnaissance Orbiter Camera images reveal previously undetected lobate thrust-fault scarps and associated meter-scale secondary tectonic landforms that include narrow extensional troughs or graben, splay faults, and multiple low-relief terraces. Lobate scarps are among the youngest landforms on the Moon, based on their generally crisp appearance, lack of superposed large-diameter impact craters, and the existence of crosscut small-diameter impact craters. Identification of previously known scarps was limited to high-resolution Apollo Panoramic Camera images confined to the equatorial zone. Fourteen lobate scarps were identified, seven of which are at latitudes greater than +/- 60 degrees, indicating that the thrust faults are globally distributed. This detection, coupled with the very young apparent age of the faults, suggests global late-stage contraction of the Moon.	[Watters, Thomas R.; Banks, Maria E.] Smithsonian Inst, Ctr Earth & Planetary Studies, Washington, DC 20560 USA; [Robinson, Mark S.] Arizona State Univ, Sch Earth & Space Explorat, Scottsdale, AZ 85251 USA; [Beyer, Ross A.] SETI Inst, Carl Sagan Ctr, Mountain View, CA 94043 USA; [Beyer, Ross A.] NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; [Bell, James F., III] Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; [Pritchard, Matthew E.; Williams, Nathan R.] Cornell Univ, Dept Earth & Atmospher Sci, Ithaca, NY 14853 USA; [Hiesinger, Harald; van der Bogert, Carolyn H.] Univ Munster, Inst Planetol, D-48149 Munster, Germany; [Hiesinger, Harald] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Thomas, Peter C.] Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA; [Turtle, Elizabeth P.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA	Smithsonian Institution; Arizona State University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Cornell University; Cornell University; University of Munster; Brown University; Cornell University; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Watters, TR (corresponding author), Smithsonian Inst, Ctr Earth & Planetary Studies, Washington, DC 20560 USA.	watterst@si.edu	Pritchard, Matthew/L-5892-2015; Robinson, Mark/ABI-6841-2020; Turtle, Elizabeth/K-8673-2012	Pritchard, Matthew/0000-0003-3616-3373; Turtle, Elizabeth/0000-0003-1423-5751; Williams, Nathan/0000-0003-0602-484X; van der Bogert, Carolyn/0000-0003-2882-7037; Beyer, Ross/0000-0003-4503-3335	NASA [NNX08AM73G, NNG07EK00C]; Deutsches Zentrum fur Luft- und Raumfahrt [50 OW 0901]	NASA(National Aeronautics & Space Administration (NASA)); Deutsches Zentrum fur Luft- und Raumfahrt(Helmholtz AssociationGerman Aerospace Centre (DLR))	We thank the three anonymous reviewers for helpful comments that improved the manuscript. We gratefully acknowledge the Lunar Orbiter Laser Altimeter team for the lunar topographic model and the LRO and LROC engineers and technical support personnel. This work was supported by the LRO Project, NASA grants NNX08AM73G and NNG07EK00C, and through Deutsches Zentrum fur Luft- und Raumfahrt grant 50 OW 0901.	Binder A. B., 1986, ORIGIN MOON, P425; BINDER AB, 1985, ICARUS, V63, P421, DOI 10.1016/0019-1035(85)90055-7; BINDER AB, 1977, MOON PLANETS, V17, P29, DOI 10.1007/BF00566851; BINDER AB, 1982, EARTH MOON PLANETS, V26, P117; Collins G. C., 2010, PLANETARY TECTONICS, P264, DOI [10.1017/CBO9780511691645.008, DOI 10.1017/CBO9780511691645.008]; COOPER MR, 1974, REV GEOPHYS, V12, P291, DOI 10.1029/RG012i003p00291; Freed AM, 2001, J GEOPHYS RES-PLANET, V106, P20603, DOI 10.1029/2000JE001347; HOWARD KA, 1973, NASA SP330 SPEC PUBL, P31; Lucchitta B.K., 1976, GEOCHIM COSMOSHIM S, V3, P2761; MACDONALD GJF, 1960, PLANET SPACE SCI, V2, P249, DOI 10.1016/0032-0633(60)90023-4; MASURSKY H, 1978, NASA SPEC PUBL, P255; MATTINGLY TK, 1972, NASA SPEC PUBL, P28; MELOSH HJ, 1980, ICARUS, V43, P334, DOI 10.1016/0019-1035(80)90178-5; PLESCIA JB, 1986, GEOL SOC AM BULL, V97, P1289, DOI 10.1130/0016-7606(1986)97<1289:OOPWRB>2.0.CO;2; Pritchard M.E., 2000, ORIGIN EARTH MOON, P179, DOI [10.2307/j.ctv1v7zdrp.16, DOI 10.2307/J.CTV1V7ZDRP.16]; SCHMITT HH, 1973, NASA SPEC PUBL, P5; Schultz P.H, 1976, MOON MORPHOLOGY INTE; SCOTT DH, 1973, NASA SPEC PUBL, P31; Shearer CK, 2006, REV MINERAL GEOCHEM, V60, P365, DOI 10.2138/rmg.2006.60.4; Solomon S.C., 1986, ORIGIN MOON, P311; Solomon S. C., 1976, P LUNAR PLANET SCI C, V3, P3229; SOLOMON SC, 1979, J GEOPHYS RES, V84, P1667, DOI 10.1029/JB084iB04p01667; Solomon SC, 2008, SCIENCE, V321, P59, DOI 10.1126/science.1159706; Stoffler D, 2001, SPACE SCI REV, V96, P9, DOI 10.1023/A:1011937020193; STROM RG, 1975, J GEOPHYS RES, V80, P2478, DOI 10.1029/JB080i017p02478; TRASK NJ, 1971, US GEOL SURV PROF D, V750, pD138; Turcotte D. L., 2002, GEODYNAMICS APPL CON, VSecond; Watters T.R., 2010, PLANETARY TECTONICS, P15; Watters T. R., 2010, PLANETARY TECTONICS, P121; Watters TR, 2009, EARTH PLANET SC LETT, V285, P283, DOI 10.1016/j.epsl.2009.01.025; Watters TR, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001934; WATTERS TR, 1988, J GEOPHYS RES-SOLID, V93, P10236, DOI 10.1029/JB093iB09p10236; Weber RC, 2009, J GEOPHYS RES-PLANET, V114, DOI 10.1029/2008JE003286; Wilhelms D.E., 1987, US GEOLOGICAL SURVEY, DOI [10.3133/pp1348, DOI 10.3133/PP1348]	34	79	86	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					936	940		10.1126/science.1189590	http://dx.doi.org/10.1126/science.1189590			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724632				2022-12-28	WOS:000281084800032
J	Lay, T; Ammon, CJ; Kanamori, H; Rivera, L; Koper, KD; Hutko, AR				Lay, Thorne; Ammon, Charles J.; Kanamori, Hiroo; Rivera, Luis; Koper, Keith D.; Hutko, Alexander R.			The 2009 Samoa-Tonga great earthquake triggered doublet	NATURE			English	Article							COUPLED SUBDUCTION ZONES; STRESS TRANSFER; SEISMICITY; INVERSION; CYCLE; TIMES	Great earthquakes (having seismic magnitudes of at least 8) usually involve abrupt sliding of rock masses at a boundary between tectonic plates. Such interplate ruptures produce dynamic and static stress changes that can activate nearby intraplate aftershocks, as is commonly observed in the trench-slope region seaward of a great subduction zone thrust event(1-4). The earthquake sequence addressed here involves a rare instance in which a great trench-slope intraplate earthquake triggered extensive interplate faulting, reversing the typical pattern and broadly expanding the seismic and tsunami hazard. On 29 September 2009, within two minutes of the initiation of a normal faulting event with moment magnitude 8.1 in the outer trench-slope at the northern end of the Tonga subduction zone, two major interplate underthrusting subevents (both with moment magnitude 7.8), with total moment equal to a second great earthquake of moment magnitude 8.0, ruptured the nearby subduction zone megathrust. The collective faulting produced tsunami waves with localized regions of about 12 metres run-up that claimed 192 lives in Samoa, American Samoa and Tonga. Overlap of the seismic signals obscured the fact that distinct faults separated by more than 50km had ruptured with different geometries, with the triggered thrust faulting only being revealed by detailed seismic wave analyses. Extensive interplate and intraplate aftershock activity was activated over a large region of the northern Tonga subduction zone.	[Lay, Thorne] Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA; [Ammon, Charles J.] Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; [Kanamori, Hiroo] CALTECH, Seismol Lab, Pasadena, CA 91125 USA; [Rivera, Luis] Univ Strasbourg, CNRS, UMR7516, Inst Phys Globe Strasbourg, Strasbourg, France; [Koper, Keith D.] St Louis Univ, Dept Earth & Atmospher Sci, St Louis, MO 63108 USA; [Hutko, Alexander R.] US Geol Survey, NEIC, Denver, CO 80225 USA	University of California System; University of California Santa Cruz; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; California Institute of Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Saint Louis University; United States Department of the Interior; United States Geological Survey	Lay, T (corresponding author), Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA.	tlay@ucsc.edu	Lay, Thorne/ABE-6272-2021		NSF [EAR0635570]; USGS [05HQGR0174]	NSF(National Science Foundation (NSF)); USGS(United States Geological Survey)	This work made use of GMT and SAC software and Federation of Digital Seismic Networks (FDSN) seismic data. The Incorporated Research Institutions for Seismology (IRIS) Data Management System (DMS) and the F-Net and Hi-Net data centres were used to access the data. C. Ji kindly shared details of his model. Z. Duputel wrote the W-Phase software version used in this study. We thank H. Savage and E. Brodsky for discussions of frictional conditional stability. This work was supported by NSF grant EAR0635570 and USGS Award Number 05HQGR0174.	Ammon CJ, 2008, NATURE, V451, P561, DOI 10.1038/nature06521; Boschi L, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000059; CHRISTENSEN DH, 1988, J GEOPHYS RES-SOLID, V93, P13421, DOI 10.1029/JB093iB11p13421; DMOWSKA R, 1988, J GEOPHYS RES-SOLID, V93, P7869, DOI 10.1029/JB093iB07p07869; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; *EARTHQ HAZ PROGR, 2009, MAGN 8 1 SAM ISL REG; EKSTROM G, 2009, GLOBAL CENTROID MOME; Faccenda M, 2009, NAT GEOSCI, V2, P790, DOI 10.1038/NGEO656; Fujii Y., 2009, SAMOA ISLANDS TSUNAM; Gutenberg B., 1954, SEISMICITY EARTH ASS; HARTZELL SH, 1983, B SEISMOL SOC AM, V73, P1153; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; IIDA K, 1967, HIG6710261 U HAW HAW; Ishii M, 2005, NATURE, V435, P933, DOI 10.1038/nature03675; JAFFE B, 2009, SURPRISES DEADLY SEP; Kanamori H., 1971, PHYS EARTH PLANET IN, V4, P289, DOI [DOI 10.1016/0031-9201(71)90013-6, 10.1016/0031-9201(71)90013-6]; Kanamori H, 2008, GEOPHYS J INT, V175, P222, DOI 10.1111/j.1365-246X.2008.03887.x; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; KIKUCHI M, 1991, B SEISMOL SOC AM, V81, P2335; LAY T, 1989, PHYS EARTH PLANET IN, V54, P258, DOI 10.1016/0031-9201(89)90247-1; Lay T, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB006280; LI X, 2009, EOS; LYNNES CS, 1988, J GEOPHYS RES-SOLID, V93, P13407, DOI 10.1029/JB093iB11p13407; *NOAA CTR TSUN RES, 2009, TSUN EV SEPT 29; OKAL E, 2009, EOS S, V90; Ranero CR, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2005GC000997; Scholz CH, 1998, NATURE, V391, P37, DOI 10.1038/34097; Taylor MAJ, 1996, J GEOPHYS RES-SOL EA, V101, P8363, DOI 10.1029/95JB03561; TONINI R, 2009, EOS S, V90; UMINO N, 2007, ANN MEET SEISMOL SOC; VANDECAR JC, 1990, B SEISMOL SOC AM, V80, P150; Velasco AA, 2008, NAT GEOSCI, V1, P375, DOI 10.1038/ngeo204; Xu Y, 2009, GEOCHEM GEOPHY GEOSY, V10, DOI 10.1029/2008GC002335	33	142	142	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2010	466	7309					964	U85		10.1038/nature09214	http://dx.doi.org/10.1038/nature09214			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725038				2022-12-28	WOS:000281030300032
J	Tompkins, J				Tompkins, Joshua			Journalist Feels Palpitations, Enrolls in Medical School	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												joshua.tompkins@usc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					723	724		10.1001/jama.2010.1119	http://dx.doi.org/10.1001/jama.2010.1119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20716729				2022-12-28	WOS:000280993700001
J	[Anonymous]				[Anonymous]			EARLY AND PARTIAL RETIREMENT FOR CONSULTANTS	BRITISH MEDICAL JOURNAL			English	Editorial Material																		1987, HOSPITAL MED STAFFIN; 1987, DHSS HC8738 DEP HLTH	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1988	296	6617					305	305						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L8774	20742951				2022-12-28	WOS:A1988L877400054
J	Giusti, B; Abbate, R				Giusti, Betti; Abbate, Rosanna			Response to antiplatelet treatment: from genes to outcome	LANCET			English	Editorial Material							P-GLYCOPROTEIN EXPRESSION; OF-FUNCTION POLYMORPHISM; CLOPIDOGREL; RISK; PRASUGREL; ALLELE		[Giusti, Betti; Abbate, Rosanna] Univ Florence, Dept Med & Surg Crit Care, Careggi Hosp, Atherothrombot Dis Ctr, I-50134 Florence, Italy	University of Florence; Azienda Ospedaliero Universitaria Careggi	Giusti, B (corresponding author), Univ Florence, Dept Med & Surg Crit Care, Careggi Hosp, Atherothrombot Dis Ctr, I-50134 Florence, Italy.	betti.giusti@unifi.it	Giusti, Betti/K-6978-2016	Giusti, Betti/0000-0002-8708-9444				Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Giusti B, 2007, PHARMACOGENET GENOM, V17, P1057, DOI 10.1097/FPC.0b013e3282f1b2be; Giusti B, 2010, EXPERT OPIN DRUG MET, V6, P393, DOI 10.1517/17425251003598878; Gurbel PA, 2008, CURR OPIN INVEST DR, V9, P324; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Hulot JS, 2010, J AM COLL CARDIOL, V56, P134, DOI 10.1016/j.jacc.2009.12.071; Kushner FG, 2009, CIRCULATION, V120, P2271, DOI 10.1161/CIRCULATIONAHA.109.192663; Mega JL, 2010, LANCET, V376, P1312, DOI 10.1016/S0140-6736(10)61273-1; Mehta SR, 2008, AM HEART J, V156, P1080, DOI 10.1016/j.ahj.2008.07.026; Owen A, 2005, BRIT J CLIN PHARMACO, V59, P365, DOI 10.1111/j.1365-2125.2005.02229.x; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Sofi F, 2011, PHARMACOGENOMICS J, V11, P199, DOI 10.1038/tpj.2010.21; Sofi F, 2010, THROMB HAEMOSTASIS, V103, P841, DOI 10.1160/TH09-06-0418; Taubert D, 2006, CLIN PHARMACOL THER, V80, P486, DOI 10.1016/j.clpt.2006.07.007; US FDA, 2009, PLAV CLOP BIS 75 MG; Wallentin L, 2010, LANCET, V376, P1320, DOI 10.1016/S0140-6736(10)61274-3; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482	19	17	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1278	1281		10.1016/S0140-6736(10)61313-X	http://dx.doi.org/10.1016/S0140-6736(10)61313-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20801497	Green Submitted			2022-12-28	WOS:000283528600006
J	Wallentin, L; James, S; Storey, RF; Armstrong, M; Barratt, BJ; Horrow, J; Husted, S; Katus, H; Steg, PG; Shah, SH; Becker, RC				Wallentin, Lars; James, Stefan; Storey, Robert F.; Armstrong, Martin; Barratt, Bryan J.; Horrow, Jay; Husted, Steen; Katus, Hugo; Steg, P. Gabriel; Shah, Svati H.; Becker, Richard C.		PLATO Investigators	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial	LANCET			English	Article							OF-FUNCTION POLYMORPHISM; P-GLYCOPROTEIN EXPRESSION; TREATED PATIENTS; PLATELET-AGGREGATION; STENT THROMBOSIS; PRASUGREL; ALLELE; PHARMACOGENETICS; INHIBITION; ANTAGONIST	Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death, myocardial infarction, and stroke, but increased events of major bleeding related to non-coronary artery bypass graft (CABG). CYP2C19 and ABCB1 genotypes are known to influence the effects of clopidogrel. In this substudy, we investigated the effects of these genotypes on outcomes between and within treatment groups. Methods DNA samples obtained from patients in the PLATO trial were genotyped for CYP2C19 loss-of-function alleles (*2, *3, *4, *5, *6, *7, and *8), the CYP2C19 gain-of-function allele *17, and the ABCB1 single nucleotide polymorphism 3435C -> T. For the CYP2C19 genotype, patients were stratified by the presence or absence of any loss-of-function allele, and for the ABCB1 genotype, patients were stratified by predicted gene expression (high, intermediate, or low). The primary efficacy endpoint was the composite of cardiovascular death, myocardial infarction, or stroke after up to 12 months' treatment with ticagrelor or clopidogrel. Findings 10 285 patients provided samples for genetic analysis. The primary outcome occurred less often with ticagrelor versus clopidogrel, irrespective of CYP2C19 genotype: 8.6% versus 11.2% (hazard ratio 0.77, 95% CI 0.60-0.99, p=0.0380) in patients with any loss-of-function allele; and 8.8% versus 10.0% (0.86, 0.74-1.01, p=0.0608) in those without any loss-of-function allele (interaction p=0.46). For the ABCB1 genotype, event rates for the primary outcome were also consistently lower in the ticagrelor than in the clopidogrel group for all genotype groups (interaction p=0.39; 8.8% vs 11.9%; 0.71, 0.55-0.92 for the high-expression genotype). In the clopidogrel group, the event rate at 30 days was higher in patients with than in those without any loss-of-function CYP2C19 alleles (5.7% vs 3.8%, p=0.028), leading to earlier separation of event rates between treatment groups in patients with loss-of-function alleles. Patients on clopidogrel who had any gain-of-function CYP2C19 allele had a higher frequency of major bleeding (11.9%) than did those without any gain-of-function or loss-of-function alleles (9.5%; p=0.022), but interaction between treatment and genotype groups was not significant for any type of major bleeding. Interpretation Ticagrelor is a more efficacious treatment for acute coronary syndromes than is dopidogrel, irrespective of CYP2C19 and ABCB1 polymorphisms. Use of ticagrelor instead of clopidogrel eliminates the need for presently recommended genetic testing before dual antiplatelet treatment.	[Wallentin, Lars; James, Stefan] Uppsala Univ, Uppsala Clin Res Ctr, SE-75185 Uppsala, Sweden; [Storey, Robert F.] Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England; [Armstrong, Martin; Barratt, Bryan J.; Horrow, Jay] AstraZeneca Res & Dev, Alderley Pk, England; [Armstrong, Martin; Barratt, Bryan J.; Horrow, Jay] AstraZeneca Res & Dev, Wilmington, DE USA; [Husted, Steen] Arhus Univ Hosp, Dept Cardiol, Aarhus, Denmark; [Katus, Hugo] Univ Klinikum Heidelberg, Med Klin, Heidelberg, Germany; [Steg, P. Gabriel] INSERM, U698, Paris, France; [Steg, P. Gabriel] Univ Paris 07, Paris, France; [Steg, P. Gabriel] Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France; [Shah, Svati H.; Becker, Richard C.] Duke Clin Res Inst, Durham, NC USA	Uppsala University; University of Sheffield; AstraZeneca; AstraZeneca; Aarhus University; Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Duke University	Wallentin, L (corresponding author), Uppsala Univ, Uppsala Clin Res Ctr, SE-75185 Uppsala, Sweden.	lars.wallentin@ucr.uu.se	STEG, Philippe Gabriel/Z-1567-2019; James, Stefan K/J-4554-2014; Storey, Robert/AAA-6853-2019	STEG, Philippe Gabriel/0000-0001-6896-2941; Storey, Robert/0000-0002-6677-6229; Barratt, Bryan/0000-0002-5598-2422	AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Schering-Plough; Regado Biotechnologies; Athera Biotechnologies; Eli Lilly; Eli Lilly/Daiichi Sankyo alliance; Teva; Novartis; Sanofi-Aventis/Bristol-Myers Squibb; Medicines Company; Bayer; Leo Pharmaceuticals; Servier; Johnson and Johnson; Regado Biosciences; Portola Pharmaceuticals	AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Bristol-Myers Squibb(Bristol-Myers Squibb); GlaxoSmithKline(GlaxoSmithKline); Schering-Plough(Merck & CompanySchering Plough Corporation); Regado Biotechnologies; Athera Biotechnologies; Eli Lilly(Eli Lilly); Eli Lilly/Daiichi Sankyo alliance(Eli Lilly); Teva(Teva Pharmaceutical Industries); Novartis(Novartis); Sanofi-Aventis/Bristol-Myers Squibb(Sanofi-AventisBristol-Myers Squibb); Medicines Company; Bayer(Bayer AG); Leo Pharmaceuticals(LEO Pharma); Servier(Servier); Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Regado Biosciences; Portola Pharmaceuticals	LW has received research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, and Schering-Plough; honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Schering-Plough, and Eli Lilly; consultancy fees from Regado Biotechnologies, Athera Biotechnologies, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, and Eli Lilly; and lecture fees from AstraZeneca, Boehringer Ingelheim, and Eli Lilly. Si has received research grants from AstraZeneca and Eli Lilly; advisory board member fees, travel support, and lecture fees from AstraZeneca; and honoraria from AstraZeneca, Bristol-Myers Squibb, Merck, Sanofi-Aventis, and Eli-Lilly. RFS has received research grants from AstraZeneca, Dynabyte, Eli Lilly/Daiichi Sankyo alliance, and Schering-Plough; advisory board fees from Eli Lilly/Daiichi Sankyo alliance and Schering-Plough; honoraria from AstraZeneca, Eli Lilly/Daiichi Sankyo alliance, Novartis, Medscape, GlaxoSmithKline, and Schering-Plough; consultancy fees from AstraZeneca, Eli Lilly/Daiichi Sankyo alliance, Schering-Plough, Teva, Novartis, GlaxoSmithKline, Sanofi-Aventis/Bristol-Myers Squibb, and the Medicines Company; travel support from AstraZeneca, Eli Lilly/Daiichi Sankyo alliance, and Schering-Plough. MA, BJB, and JH are employees of AstraZeneca and have equity ownership in AstraZeneca. SH has received advisory board membership fees from AstraZeneca, Bristol-Myers Squibb, Pfizer, Sanofi-Aventis, and Bayer; research grants from AstraZeneca, Bristol-Myers Squibb, Pfizer, Sanofi-Aventis, Bayer, and Boehringer Ingelheim; honoraria from AstraZeneca, Bristol-Myers Squibb, Bayer, Sanofi-Aventis, and Pfizer; lecture fees from AstraZeneca; travel support from AstraZeneca, Boehringer Ingelheim, Pfizer, and Eli Lilly; and consultancy fees from AstraZeneca and Leo Pharmaceuticals. HK has received honoraria from Eli-Lilly, GlaxoSmithKline, Roche, and Bayer; and holds a patent jointly with Roche and receives royalties for this patent. PGS has received research grants from Servier; has received fees for consultancy or participation in advisory board meetings from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo/Eli Lilly alliance, GlaxoSmithKline, Medtronic, Merck, Otsuka Pharmaceutical, Roche, Sanofi-Aventis, Servier, and the Medicines Company; has received payment for development of educational presentations from Boehringer Ingelheim, AstraZeneca, and Merck; and has equity ownership in Aterovax. SHS has no conflicts of interest. RCB has received research grants from AstraZeneca, Bristol-Myers Squibb/Sanofi-Aventis, Johnson and Johnson, Regado Biosciences, Schering-Plough, and the Medicines Company; consultancy fees from Portola Pharmaceuticals, Regado Biosciences, and the Medicines Company; travel or accommodation expenses from AstraZeneca, Regado Biosciences, and Merck; and honoraria from AstraZeneca and Daiichi Sankyo/Eli Lilly alliance.	Ameyaw MM, 2001, PHARMACOGENETICS, V11, P217, DOI 10.1097/00008571-200104000-00005; Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Collet JP, 2009, LANCET, V373, P309, DOI 10.1016/S0140-6736(08)61845-0; Giusti B, 2009, AM J CARDIOL, V103, P806, DOI 10.1016/j.amjcard.2008.11.048; Gurbel PA, 2009, CIRCULATION, V120, P2577, DOI 10.1161/CIRCULATIONAHA.109.912550; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Hulot JS, 2006, BLOOD, V108, P2244, DOI 10.1182/blood-2006-04-013052; Hulot JS, 2010, J AM COLL CARDIOL, V56, P134, DOI 10.1016/j.jacc.2009.12.071; Husted S, 2006, EUR HEART J, V27, P1038, DOI 10.1093/eurheartj/ehi754; James S, 2009, AM HEART J, V157, P599, DOI 10.1016/j.ahj.2009.01.003; Kushner FG, 2009, CIRCULATION, V120, P2271, DOI 10.1161/CIRCULATIONAHA.109.192663; Marin F, 2009, J AM COLL CARDIOL, V54, P1041, DOI 10.1016/j.jacc.2009.04.084; Mega JL, 2009, CIRCULATION, V119, P2553, DOI 10.1161/CIRCULATIONAHA.109.851949; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171; Owen A, 2005, BRIT J CLIN PHARMACO, V59, P365, DOI 10.1111/j.1365-2125.2005.02229.x; Ragia G, 2009, PHARMACOGENOMICS, V10, P43, DOI 10.2217/14622416.10.1.43; Savi P, 2000, THROMB HAEMOSTASIS, V84, P891, DOI 10.1055/s-0037-1614133; Savi P, 2005, SEMIN THROMB HEMOST, V31, P174, DOI 10.1055/s-2005-869523; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Sibbing D, 2010, CIRCULATION, V121, P512, DOI 10.1161/CIRCULATIONAHA.109.885194; Sibbing D, 2009, EUR HEART J, V30, P916, DOI 10.1093/eurheartj/ehp041; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Sofi F, 2011, PHARMACOGENOMICS J, V11, P199, DOI 10.1038/tpj.2010.21; Storey RF, 2009, PLATELETS, V20, P341, DOI 10.1080/09537100903075324; Taubert D, 2006, CLIN PHARMACOL THER, V80, P486, DOI 10.1016/j.clpt.2006.07.007; Trenk D, 2008, J AM COLL CARDIOL, V51, P1925, DOI 10.1016/j.jacc.2007.12.056; Van de Werf F, 2008, EUR HEART J, V29, P2909, DOI 10.1093/eurheartj/ehn416; Varenhorst C, 2009, EUR HEART J, V30, P1744, DOI 10.1093/eurheartj/ehp157; Varenhorst C, 2009, AM HEART J, V157, DOI 10.1016/j.ahj.2008.11.021; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815	33	598	658	1	65	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1320	1328		10.1016/S0140-6736(10)61274-3	http://dx.doi.org/10.1016/S0140-6736(10)61274-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20801498				2022-12-28	WOS:000283528600034
J	Garaj, S; Hubbard, W; Reina, A; Kong, J; Branton, D; Golovchenko, JA				Garaj, S.; Hubbard, W.; Reina, A.; Kong, J.; Branton, D.; Golovchenko, J. A.			Graphene as a subnanometre trans-electrode membrane	NATURE			English	Article							CARBON NANOTUBES; LARGE-AREA; DNA; NANOPORES; MOLECULES; WATER	Isolated, atomically thin conducting membranes of graphite, called graphene, have recently been the subject of intense research with the hope that practical applications in fields ranging from electronics to energy science will emerge(1). The atomic thinness, stability and electrical sensitivity of graphene motivated us to investigate the potential use of graphene membranes and graphene nanopores to characterize single molecules of DNA in ionic solution. Here we show that when immersed in an ionic solution, a layer of graphene becomes a new electrochemical structure that we call a transelectrode. The trans-electrode's unique properties are the consequence of the atomic-scale proximity of its two opposing liquid-solid interfaces together with graphene's well known inplane conductivity. We show that several trans-electrode properties are revealed by ionic conductance measurements on a graphene membrane that separates two aqueous ionic solutions. Although our membranes are only one to two atomic layers(2,3) thick, we find they are remarkable ionic insulators with a very small stable conductance that depends on the ion species in solution. Electrical measurements on graphene membranes in which a single nanopore has been drilled show that the membrane's effective insulating thickness is less than one nanometre. This small effective thickness makes graphene an ideal substrate for very high resolution, high throughput nanopore-based single-molecule detectors. The sensitivity of graphene's in-plane electronic conductivity to its immediate surface environment and trans-membrane solution potentials will offer new insights into atomic surface processes and sensor development opportunities.	[Garaj, S.; Golovchenko, J. A.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; [Hubbard, W.; Golovchenko, J. A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Reina, A.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Kong, J.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Branton, D.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University	Golovchenko, JA (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	sgaraj@fas.harvard.edu; golovchenko@physics.harvard.edu	Garaj, Slaven/AAA-9824-2020; Garaj, Slaven/B-9782-2013	Garaj, Slaven/0000-0001-5529-4040; Hubbard, William/0000-0002-2924-0820	National Human Genome Research Institute, National Institutes of Health [R01 HG003703]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003703] Funding Source: NIH RePORTER	National Human Genome Research Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was funded by a grant (number R01 HG003703) to J.A.G. and D.B. from the National Human Genome Research Institute, National Institutes of Health.	Alexiadis A, 2008, CHEM REV, V108, P5014, DOI 10.1021/cr078140f; Bard A.J., 2001, ELECTROCHEMICAL METH, P534; Branton D, 2008, NAT BIOTECHNOL, V26, P1146, DOI 10.1038/nbt.1495; Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401; Geim AK, 2009, SCIENCE, V324, P1530, DOI 10.1126/science.1158877; HALL JE, 1975, J GEN PHYSIOL, V66, P531, DOI 10.1085/jgp.66.4.531; Hille B., 2001, ION CHANNELS EXCITAB; Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298; Hoogerheide DP, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.256804; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; Li JL, 2003, NAT MATER, V2, P611, DOI 10.1038/nmat965; Liu HT, 2010, SCIENCE, V327, P64, DOI 10.1126/science.1181799; MERCHANT CA, 2010, NANO LETT, DOI DOI 10.1021/NL101046T; Reina A, 2009, NANO RES, V2, P509, DOI 10.1007/s12274-009-9059-y; Reina A, 2009, NANO LETT, V9, P30, DOI 10.1021/nl801827v; Schneider GF, 2010, NANO LETT, V10, P3163, DOI [10.1021/nl102069z, 10.1021/nl101046t]; Sint K, 2008, J AM CHEM SOC, V130, P16448, DOI 10.1021/ja804409f; Storm AJ, 2003, NAT MATER, V2, P537, DOI 10.1038/nmat941; Werder T, 2003, J PHYS CHEM B, V107, P1345, DOI 10.1021/jp0268112; Zwolak M, 2008, REV MOD PHYS, V80, P141, DOI 10.1103/RevModPhys.80.141; Zwolak M, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.128102	21	1088	1184	26	1053	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2010	467	7312					190	U73		10.1038/nature09379	http://dx.doi.org/10.1038/nature09379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20720538	Green Accepted, Green Submitted			2022-12-28	WOS:000281616300030
J	Marshall, CR				Marshall, Charles R.			Marine Biodiversity Dynamics over Deep Time	SCIENCE			English	Editorial Material							SAMPLING-STANDARDIZATION; DIVERSITY; DIVERSIFICATION; HISTORY		Univ Calif Berkeley, Dept Integrat Biol, Univ Calif Museum Paleontol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Marshall, CR (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Univ Calif Museum Paleontol, Berkeley, CA 94720 USA.	crmarshall@berkeley.edu						Alroy J, 2010, SCIENCE, V329, P1191, DOI 10.1126/science.1189910; Alroy J, 2001, P NATL ACAD SCI USA, V98, P6261, DOI 10.1073/pnas.111144698; Alroy J, 2008, SCIENCE, V321, P97, DOI 10.1126/science.1156963; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; Bush AM, 2004, J GEOL, V112, P625, DOI 10.1086/424576; Bush AM, 2004, PALEOBIOLOGY, V30, P666, DOI 10.1666/0094-8373(2004)030<0666:RBFDCT>2.0.CO;2; Erwin DH, 2009, CURR BIOL, V19, pR575, DOI 10.1016/j.cub.2009.05.047; Jackson JBC, 2001, SCIENCE, V293, P2401, DOI 10.1126/science.1063789; Krug AZ, 2009, ASTROBIOLOGY, V9, P113, DOI 10.1089/ast.2008.0253; Phillips J, 1860, LIFE EARTH ITS ORIGI; Rabosky DL, 2009, NATURE, V457, P183, DOI 10.1038/nature07435; Sepkoski JJ, 1997, J PALEONTOL, V71, P533, DOI 10.1017/S0022336000040026; Stanley SM, 2007, PALEOBIOLOGY, V33, P1, DOI 10.1666/06020.1	13	7	8	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1156	1157		10.1126/science.1194924	http://dx.doi.org/10.1126/science.1194924			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813942				2022-12-28	WOS:000281485600020
J	Jiao, XF; Xiang, S; Oh, C; Martin, CE; Tong, LA; Kiledjian, M				Jiao, Xinfu; Xiang, Song; Oh, ChanSeok; Martin, Charles E.; Tong, Liang; Kiledjian, Megerditch			Identification of a quality-control mechanism for mRNA 5 '-end capping	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; DECAPPING ENZYME; CAP METHYLTRANSFERASE; POLYMERASE-II; YEAST-CELLS; PROTEIN; COMPLEX; DEADENYLATION; TRANSLATION; EXPRESSION	The 7-methylguanosine cap structure at the 5' end of eukaryotic messenger RNAs is a critical determinant of their stability and translational efficiency(1-3). It is generally believed that 5'-end capping is a constitutive process that occurs during mRNA maturation and lacks the need for a quality-control mechanism to ensure its fidelity. We recently reported that the yeast Rai1 protein has pyrophosphohydrolase activity towards mRNAs lacking a 5'-end cap(4). Here we show that, in vitro as well as in yeast cells, Rai1 possesses a novel decapping endonuclease activity that can also remove the entire cap structure dinucleotide from an mRNA. This activity is targeted preferentially towards mRNAs with unmethylated caps in contrast to the canonical decapping enzyme, Dcp2, which targets mRNAs with a methylated cap. Capped but unmethylated mRNAs generated in yeast cells with a defect in the methyltransferase gene are more stable in a rai1-gene-disrupted background. Moreover, rai1 Delta yeast cells with wild-type capping enzymes show significant accumulation of mRNAs with 5'-end capping defects under nutritional stress conditions of glucose starvation or amino acid starvation. These findings provide evidence that 5'-end capping is not a constitutive process that necessarily always proceeds to completion and demonstrates that Rai1 has an essential role in clearing mRNAs with aberrant 5'-end caps. We propose that Rai1 is involved in an as yet uncharacterized quality control process that ensures mRNA 5'-end integrity by an aberrant-cap-mediated mRNA decay mechanism.	[Jiao, Xinfu; Oh, ChanSeok; Martin, Charles E.; Kiledjian, Megerditch] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; [Xiang, Song; Tong, Liang] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Rutgers State University New Brunswick; Columbia University	Kiledjian, M (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA.	kiledjian@biology.rutgers.edu	Xiang, Song/AAF-6422-2019	Xiang, Song/0000-0001-9314-4684; Tong, Liang/0000-0002-0563-6468	National Institutes of Health (NIH) [GM077175, GM67005]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077175, R01GM090059, R01GM067005] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank B. Schwer for the abd1-5 yeast strain and A. Shatkin for discussions. This research was supported by grants from the National Institutes of Health (NIH) to L.T. (GM077175) and M.K. (GM67005).	Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Fischer PM, 2009, CELL CYCLE, V8, P2535, DOI 10.4161/cc.8.16.9301; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Goodfellow IG, 2008, INT J BIOCHEM CELL B, V40, P2675, DOI 10.1016/j.biocel.2007.10.023; He F, 2001, MOL CELL BIOL, V21, P1515, DOI 10.1128/MCB.21.5.1515-1530.2001; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Hilgers V, 2006, RNA, V12, P1835, DOI 10.1261/rna.241006; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Jiao XF, 2009, J NEUROSCI, V29, P12419, DOI 10.1523/JNEUROSCI.5954-08.2009; Jimeno-Gonzalez S, 2010, MOL CELL, V37, P580, DOI 10.1016/j.molcel.2010.01.019; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Li Y, 2010, WIRES RNA, V1, P253, DOI 10.1002/wrna.15; Liu HD, 2005, MOL CELL BIOL, V25, P9764, DOI 10.1128/MCB.25.22.9764-9772.2005; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Mannan MAU, 2009, ANAL BIOCHEM, V389, P77, DOI 10.1016/j.ab.2009.03.014; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Otsuka Y, 2009, MOL CELL BIOL, V29, P2155, DOI 10.1128/MCB.01325-08; Piccirillo C, 2003, RNA, V9, P1138, DOI 10.1261/rna.5690503; Schwer B, 2000, GENETICS, V155, P1561; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Wen YX, 2000, GENE DEV, V14, P2944, DOI 10.1101/gad.848200; Xiang S, 2009, NATURE, V458, P784, DOI 10.1038/nature07731; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Zhang S, 1999, METHODS, V17, P46, DOI 10.1006/meth.1998.0706	35	119	120	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					608	U137		10.1038/nature09338	http://dx.doi.org/10.1038/nature09338			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20802481	Green Accepted			2022-12-28	WOS:000282273100043
J	Lowe, AR; Siegel, JJ; Kalab, P; Siu, M; Weis, K; Liphardt, JT				Lowe, Alan R.; Siegel, Jake J.; Kalab, Petr; Siu, Merek; Weis, Karsten; Liphardt, Jan T.			Selectivity mechanism of the nuclear pore complex characterized by single cargo tracking	NATURE			English	Article							PHENYLALANINE-GLYCINE NUCLEOPORINS; PROTEIN IMPORT; TRANSLOCATION; TRANSPORT; MOLECULE; DIFFUSION; HYDROGEL; BETA	The nuclear pore complex (NPC) mediates all exchange between the cytoplasm and the nucleus. Small molecules can passively diffuse through the NPC, whereas larger cargos require transport receptors to translocate(1). How the NPC facilitates the translocation of transport receptor/cargo complexes remains unclear. To investigate this process, we tracked single protein-functionalized quantum dot cargos as they moved through human NPCs. Here we show that import proceeds by successive substeps comprising cargo capture, filtering and translocation, and release into the nucleus. Most quantum dots are rejected at one of these steps and return to the cytoplasm, including very large cargos that abort at a size-selective barrier. Cargo movement in the central channel is subdiffusive and cargos that can bind more transport receptors diffuse more freely. Without Ran GTPase, a critical regulator of transport directionality(1), cargos still explore the entire NPC, but have a markedly reduced probability of exit into the nucleus, suggesting that NPC entry and exit steps are not equivalent and that the pore is functionally asymmetric to importing cargos. The overall selectivity of the NPC seems to arise from the cumulative action of multiple reversible substeps and a final irreversible exit step.	[Lowe, Alan R.; Siegel, Jake J.; Weis, Karsten; Liphardt, Jan T.] Univ Calif Berkeley, QB3, Berkeley, CA 94720 USA; [Lowe, Alan R.; Liphardt, Jan T.] Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; [Lowe, Alan R.; Liphardt, Jan T.] Univ Calif Berkeley, Bay Area Phys Sci Oncol Ctr, Berkeley, CA 94720 USA; [Siegel, Jake J.; Siu, Merek; Liphardt, Jan T.] Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA; [Kalab, Petr; Weis, Karsten] Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; [Lowe, Alan R.; Liphardt, Jan T.] Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Weis, K (corresponding author), Univ Calif Berkeley, QB3, Berkeley, CA 94720 USA.	kweis@berkeley.edu	Weis, Karsten/F-5719-2011; Liphardt, Jan/A-5906-2012; Kalab, Petr/B-2478-2009	Weis, Karsten/0000-0001-7224-925X; Liphardt, Jan/0000-0003-2835-5025; Lowe, Alan/0000-0002-0558-3597	NIH [GM058065, GM77856]; NCI [U54CA143836]; NATIONAL CANCER INSTITUTE [ZIABC011084, U54CA143836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084716, R01GM058065, R01GM077856] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank H. Agarwal for help with initial experiments; H. Aaron, A. Fischer and B. Cohen for use of facilities and discussions; the Bustamante, Chu and Krantz laboratories for use of equipment; and C. Bustamante, M. Welch and D. Grunwald for discussions and comments on the manuscript. This work was partially funded by the NIH (GM058065 to K.W. and GM77856 to J.T.L.) and the NCI (U54CA143836 to J.T.L.).	ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Arhel N, 2006, NAT METHODS, V3, P817, DOI 10.1038/nmeth928; Beck M, 2007, NATURE, V449, P611, DOI 10.1038/nature06170; Bickel T, 2002, BIOPHYS J, V83, P3079, DOI 10.1016/S0006-3495(02)75312-5; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Dange T, 2008, J CELL BIOL, V183, P77, DOI 10.1083/jcb.200806173; Frey S, 2007, CELL, V130, P512, DOI 10.1016/j.cell.2007.06.024; Frey S, 2006, SCIENCE, V314, P815, DOI 10.1126/science.1132516; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Huber J, 2002, J CELL BIOL, V156, P467, DOI 10.1083/jcb.200108114; Kubitscheck U, 2005, J CELL BIOL, V168, P233, DOI 10.1083/jcb.200411005; Lacoste TD, 2000, P NATL ACAD SCI USA, V97, P9461, DOI 10.1073/pnas.170286097; Lim RYH, 2007, J STRUCT BIOL, V159, P277, DOI 10.1016/j.jsb.2007.01.018; Lim RYH, 2007, SCIENCE, V318, P640, DOI 10.1126/science.1145980; Lim RYH, 2006, P NATL ACAD SCI USA, V103, P9512, DOI 10.1073/pnas.0603521103; Mitrousis G, 2008, J BIOL CHEM, V283, P7877, DOI 10.1074/jbc.M709093200; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01-06-0308; Patel SS, 2007, CELL, V129, P83, DOI 10.1016/j.cell.2007.01.044; Peters R, 2005, TRAFFIC, V6, P421, DOI 10.1111/j.1600-0854.2005.00287.x; Peters R, 2009, BIOESSAYS, V31, P466, DOI 10.1002/bies.200800159; Pyhtila B, 2003, J BIOL CHEM, V278, P42699, DOI 10.1074/jbc.M307135200; Rabe B, 2003, P NATL ACAD SCI USA, V100, P9849, DOI 10.1073/pnas.1730940100; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2003, TRENDS CELL BIOL, V13, P622, DOI 10.1016/j.tcb.2003.10.007; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Weis K, 2007, CELL, V130, P405, DOI 10.1016/j.cell.2007.07.029; Yang WD, 2004, P NATL ACAD SCI USA, V101, P12887, DOI 10.1073/pnas.0403675101	28	123	125	0	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					600	U126		10.1038/nature09285	http://dx.doi.org/10.1038/nature09285			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20811366	Green Accepted			2022-12-28	WOS:000282273100041
J	Rabone, J; Yue, YF; Chong, SY; Stylianou, KC; Bacsa, J; Bradshaw, D; Darling, GR; Berry, NG; Khimyak, YZ; Ganin, AY; Wiper, P; Claridge, JB; Rosseinsky, MJ				Rabone, J.; Yue, Y. -F.; Chong, S. Y.; Stylianou, K. C.; Bacsa, J.; Bradshaw, D.; Darling, G. R.; Berry, N. G.; Khimyak, Y. Z.; Ganin, A. Y.; Wiper, P.; Claridge, J. B.; Rosseinsky, M. J.			An Adaptable Peptide-Based Porous Material	SCIENCE			English	Article							METAL-ORGANIC FRAMEWORKS; ADSORPTION; COMPLEXES	Porous materials find widespread application in storage, separation, and catalytic technologies. We report a crystalline porous solid with adaptable porosity, in which a simple dipeptide linker is arranged in a regular array by coordination to metal centers. Experiments reinforced by molecular dynamics simulations showed that low-energy torsions and displacements of the peptides enabled the available pore volume to evolve smoothly from zero as the guest loading increased. The observed cooperative feedback in sorption isotherms resembled the response of proteins undergoing conformational selection, suggesting an energy landscape similar to that required for protein folding. The flexible peptide linker was shown to play the pivotal role in changing the pore conformation.	[Rabone, J.; Yue, Y. -F.; Chong, S. Y.; Stylianou, K. C.; Bacsa, J.; Bradshaw, D.; Darling, G. R.; Berry, N. G.; Khimyak, Y. Z.; Ganin, A. Y.; Wiper, P.; Claridge, J. B.; Rosseinsky, M. J.] Univ Liverpool, Dept Chem, Liverpool L69 7ZD, Merseyside, England	University of Liverpool	Rosseinsky, MJ (corresponding author), Univ Liverpool, Dept Chem, Liverpool L69 7ZD, Merseyside, England.	m.j.rosseinsky@liverpool.ac.uk	BACSA, JOHN/L-8501-2016; Berry, Neil G/B-7960-2009; Yue, Yanfeng/F-9332-2011; Claridge, John B/I-7395-2012; Chong, Samantha Y/B-4031-2009; Khimyak, Yaroslav/A-4624-2012; Stylianou, Kyriakos/G-7117-2012; Bradshaw, Darren/D-6174-2013	Berry, Neil G/0000-0003-1928-0738; Claridge, John B/0000-0003-4849-6714; Chong, Samantha Y/0000-0002-3095-875X; Khimyak, Yaroslav/0000-0003-0424-4128; Stylianou, Kyriakos/0000-0003-1670-0020; Ganin, Alexey/0000-0002-3754-5819; Darling, George/0000-0001-9329-9993; Wiper, Paul/0000-0003-1350-2299	UK Engineering and Physical Sciences Research Council [EP/F027443]; EPSRC [EP/F027443/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/F027443/1] Funding Source: researchfish	UK Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We thank the UK Engineering and Physical Sciences Research Council for funding under grant EP/F027443.	ALLISON SA, 1969, J CHEM SOC A, P1717, DOI 10.1039/j19690001717; Anedda R, 2008, CHEM MATER, V20, P2908, DOI 10.1021/cm8001805; Asakura T, 2005, PROTEIN SCI, V14, P2654, DOI 10.1110/ps.051525505; Atwood JL, 2002, SCIENCE, V296, P2367, DOI 10.1126/science.1072252; Bell JA, 1999, PROTEIN SCI, V8, P2033, DOI 10.1110/ps.8.10.2033; Boehr DD, 2009, NAT CHEM BIOL, V5, P789, DOI 10.1038/nchembio.232; Choi HJ, 2008, J AM CHEM SOC, V130, P7848, DOI 10.1021/ja8024092; Comotti A, 2009, CHEM COMMUN, P284, DOI 10.1039/b820200a; DAVIS ME, 1991, IND ENG CHEM RES, V30, P1675, DOI 10.1021/ie00056a001; Dubbeldam D, 2007, MOL SIMULAT, V33, P305, DOI 10.1080/08927020601156418; Duren T, 2009, CHEM SOC REV, V38, P1237, DOI 10.1039/b803498m; Gorbitz CH, 2008, J PEPT SCI, V14, P210, DOI 10.1002/psc.985; Gorbitz CH, 2007, CHEM-EUR J, V13, P1022, DOI 10.1002/chem.200601427; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; Horike S, 2009, NAT CHEM, V1, P695, DOI [10.1038/NCHEM.444, 10.1038/nchem.444]; Kitaura R, 2003, ANGEW CHEM INT EDIT, V42, P428, DOI 10.1002/anie.200390130; Lee HY, 2008, CRYST GROWTH DES, V8, P296, DOI 10.1021/cg700724h; Mantion A, 2008, J AM CHEM SOC, V130, P2517, DOI 10.1021/ja0762588; MIZUKAMI H, 1977, P SOC EXP BIOL MED, V154, P304, DOI 10.3181/00379727-154-39659; Ohgo K, 2006, BIOMACROMOLECULES, V7, P1210, DOI 10.1021/bm0600522; Okay O, 2000, PROG POLYM SCI, V25, P711, DOI 10.1016/S0079-6700(00)00015-0; OLSON DH, 1981, J PHYS CHEM-US, V85, P2238, DOI 10.1021/j150615a020; Peterca M, 2006, J AM CHEM SOC, V128, P6713, DOI 10.1021/ja0611902; Salles F, 2008, ANGEW CHEM INT EDIT, V47, P8487, DOI 10.1002/anie.200803067; Serre C, 2007, SCIENCE, V315, P1828, DOI 10.1126/science.1137975; Sing K. S. W., 1995, POROSITY CARBONS, P49; SMART OS, 1993, BIOPHYS J, V65, P2455, DOI 10.1016/S0006-3495(93)81293-1; Soldatov DV, 2006, J CHEM CRYSTALLOGR, V36, P747, DOI 10.1007/s10870-006-9133-1; Soldatov DV, 2004, ANGEW CHEM INT EDIT, V43, P6308, DOI 10.1002/anie.200460952; Takayama T, 1996, B CHEM SOC JPN, V69, P1579, DOI 10.1246/bcsj.69.1579; Tiliakos M, 2005, INORG CHEM COMMUN, V8, P1085, DOI 10.1016/j.inoche.2005.09.008; Tranchemontagne DJ, 2009, CHEM SOC REV, V38, P1257, DOI 10.1039/b817735j; Ueda E, 2004, B CHEM SOC JPN, V77, P981, DOI 10.1246/bcsj.77.981; Winston EB, 2008, PHYS CHEM CHEM PHYS, V10, P5188, DOI 10.1039/b808104b	34	287	293	18	392	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2010	329	5995					1053	1057		10.1126/science.1190672	http://dx.doi.org/10.1126/science.1190672			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798314				2022-12-28	WOS:000281253500034
J	Cornia, PB; Hersh, AL; Lipsky, BA; Newman, TB; Gonzales, R				Cornia, Paul B.; Hersh, Adam L.; Lipsky, Benjamin A.; Newman, Thomas B.; Gonzales, Ralph			Does This Coughing Adolescent or Adult Patient Have Pertussis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; EOSINOPHILIC BRONCHITIS; ADVISORY-COMMITTEE; PREVENTING TETANUS; PERSISTENT COUGH; EPIDEMIOLOGY; RECOMMENDATIONS; DIAGNOSIS; CLARITHROMYCIN; ERYTHROMYCIN	Context Pertussis is often overlooked as a cause of chronic cough, especially in adolescents and adults. Several symptoms are classically thought to be suggestive of pertussis, but the diagnostic value of each of them is uncertain. Objective To systematically review the evidence regarding the diagnostic value of 3 classically described symptoms of pertussis: paroxysmal cough, posttussive emesis, and inspiratory whoop. Data Sources, Study Selection, and Data Extraction We searched MEDLINE (January 1966 April 2010), EMBASE (January 1969 to April 2010), and the bibliographies of pertinent articles to identify relevant English-language studies. Articles were selected that included children older than 5 years, adolescents, or adults and confirmed the diagnosis of pertussis among patients with cough illness (of any duration) with an a priori defined accepted reference standard. Two authors independently extracted data from articles that met selection criteria and resolved any discrepancies by consensus. Data Synthesis Five prospective studies met inclusion criteria; 3 were used in the analysis. Presence of posttussive emesis (summary likelihood ratio [LR], 1.8; 95% confidence interval [Cl], 1.4-2.2) or inspiratory whoop (summary LR, 1.9; 95% Cl, 1.4-2.6) increases the likelihood of pertussis. Absence of paroxysmal cough (summary LR, 0.52; 95% Cl, 0.27-1.0) or posttussive emesis (summary LR, 0.58; 95% Cl, 0.44-0.77) reduced the likelihood. Absence of inspiratory whoop was less useful (summary LR, 0.78; 95% Cl, 0.66-0.93). No studies evaluated combinations of findings. Conclusions In a nonoutbreak setting, data to determine the diagnostic usefulness of symptoms classically associated with pertussis are limited and of relatively weak quality. The presence or absence of posttussive emesis or inspiratory whoop modestly change the likelihood of pertussis; therefore, clinicians must use their overall clinical impression to decide about additional testing or empirical treatment. JAMA. 2010;304(8):890-896	[Gonzales, Ralph] Univ Calif San Francisco, Dept Med, Div Clin Epidemiol, San Francisco, CA 94118 USA; [Gonzales, Ralph] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94118 USA; [Hersh, Adam L.; Newman, Thomas B.] Univ Calif San Francisco, Div Gen Pediat, San Francisco, CA 94118 USA; [Hersh, Adam L.] Univ Calif San Francisco, Div Pediat Infect Dis, San Francisco, CA 94118 USA; [Cornia, Paul B.; Lipsky, Benjamin A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Cornia, Paul B.; Lipsky, Benjamin A.] Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Gonzales, R (corresponding author), Univ Calif San Francisco, Dept Med, Div Clin Epidemiol, 3333 Calif St,Box 1211,Ste 430, San Francisco, CA 94118 USA.	ralphg@medicine.ucsf.edu	Lipsky, Benjamin A/B-4645-2013	Lipsky, Benjamin A./0000-0001-9886-5114; Cornia, Paul/0000-0002-4949-9637				Aoyama T, 1996, J PEDIATR-US, V129, P761, DOI 10.1016/S0022-3476(96)70163-4; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; Broder Karen R., 2006, Morbidity and Mortality Weekly Report, V55, P1; *CDCP, PERT BORD PERT WHOOP; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P73; *CDCP, 2005, MMWR-MORBID MORTAL W, V54, P1283; Centers for Disease Control and Prevention, 2000, GUID CONTR PERT OUTB; Cherry James D, 2005, Pediatr Infect Dis J, V24, pS25, DOI 10.1097/01.inf.0000160926.89577.3b; Cornia PB, 2007, NEW ENGL J MED, V357, P1432, DOI 10.1056/NEJMcps062357; Darling N., 2008, Morbidity and Mortality Weekly Report, V57, P961; Dworkin MS, 2005, ANN INTERN MED, V142, P832, DOI 10.7326/0003-4819-142-10-200505170-00008; Edwards KM, 2005, PEDIATR INFECT DIS J, V24, pS104, DOI 10.1097/01.inf.0000166154.47013.47; Fine PEM, 1997, BIOLOGICALS, V25, P195, DOI 10.1006/biol.1997.0083; GIBSON PG, 1989, LANCET, V1, P1346; Gonzales R, 2001, ANN INTERN MED, V134, P521, DOI 10.7326/0003-4819-134-6-200103200-00021; Guris D, 1999, CLIN INFECT DIS, V28, P1230, DOI 10.1086/514776; Harnden A, 2006, BRIT MED J, V333, P174, DOI 10.1136/bmj.38870.655405.AE; Hewlett EL, 2005, NEW ENGL J MED, V352, P1215, DOI 10.1056/NEJMcp041025; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Irwin RS, 2000, NEW ENGL J MED, V343, P1715, DOI 10.1056/NEJM200012073432308; Irwin RS, 2006, CHEST, V129, p25S, DOI 10.1378/chest.129.1_suppl.25S; Irwin RS, 2006, CHEST, V129, p54S, DOI 10.1378/chest.129.1_suppl.54S; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; Kirkland K. B., 2007, Morbidity and Mortality Weekly Report, V56, P837; Kretsinger Katrina, 2006, Morbidity and Mortality Weekly Report, V55, P1; Kwon NH, 2006, CHEST, V129, P1142, DOI 10.1378/chest.129.5.1142; LAMBERT HJ, 1965, PUBLIC HEALTH REP, V80, P365, DOI 10.2307/4592424; Langley JM, 2004, PEDIATRICS, V114, pE96, DOI 10.1542/peds.114.1.e96; Lebel MH, 2001, PEDIATR INFECT DIS J, V20, P1149, DOI 10.1097/00006454-200112000-00011; Lievano FA, 2002, J CLIN MICROBIOL, V40, P2801, DOI 10.1128/JCM.40.8.2801-2805.2002; Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005; McNabb Scott J. N., 2006, Morbidity and Mortality Weekly Report, V55, P1; Muller FMC, 1997, J CLIN MICROBIOL, V35, P2435; Newman TB, 2009, EVIDENCE-BASED DIAGNOSIS, P94, DOI 10.1017/CBO9780511759512.006; Park WB, 2005, EUR J CLIN MICROBIOL, V24, P156, DOI 10.1007/s10096-005-1277-y; Pichichero ME, 2003, PEDIATR INFECT DIS J, V22, P847, DOI 10.1097/01.inf.0000083884.75901.1e; Pratter MR, 2006, CHEST, V129, p59S, DOI 10.1378/chest.129.1_suppl.59S; Pratter MR, 2006, CHEST, V129, p222S, DOI 10.1378/chest.129.1_suppl.222S; Simel DL, 2009, J CLIN EPIDEMIOL, V62, P1292, DOI 10.1016/j.jclinepi.2009.02.007; Simel DL, 2008, RATIONAL CLIN EXAMIN, P9; Strebel P, 2001, J INFECT DIS, V183, P1353, DOI 10.1086/319853; Tanaka M, 2003, JAMA-J AM MED ASSOC, V290, P2968, DOI 10.1001/jama.290.22.2968; Taylor Zachary, 2005, Morbidity and Mortality Weekly Report, V54, P1; Vitek CR, 2003, PEDIATR INFECT DIS J, V22, P628, DOI 10.1097/00006454-200307000-00012; von Konig CHW, 2002, LANCET INFECT DIS, V2, P744, DOI 10.1016/S1473-3099(02)00452-8; Wirsing von Konig Carl-Heinz, 2005, Pediatr Infect Dis J, V24, pS87, DOI 10.1097/01.inf.0000160920.75623.a3; YOUNG S A, 1987, Clinical Microbiology Newsletter, V9, P176, DOI 10.1016/0196-4399(87)90061-4	47	72	79	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					890	896		10.1001/jama.2010.1181	http://dx.doi.org/10.1001/jama.2010.1181			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736473				2022-12-28	WOS:000281389900027
J	Hamilton, W; Watson, J; Round, A				Hamilton, William; Watson, Jessica; Round, Alison			Rational Testing Investigating fatigue in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GENERAL-PRACTICE; FAMILY-PHYSICIANS; COMMON SYMPTOMS; CONSULTATION; PREVALENCE; TIREDNESS; DIAGNOSES; PROGNOSIS; PATIENT		[Hamilton, William] Mt Pleasant Hlth Ctr, Exeter EX4 7BW, Devon, England; [Hamilton, William] Peninsula Coll Med & Dent, Exeter EX2 4SG, Devon, England; [Watson, Jessica] Univ Bristol, Dept Community Based Med, Acad Unit Primary Hlth Care, Bristol BS8 2AA, Avon, England; [Round, Alison] Castle Pl Practice, Tiverton, ON EX16 6NP, Canada	University of Exeter; University of Plymouth; University of Bristol	Hamilton, W (corresponding author), Mt Pleasant Hlth Ctr, Exeter EX4 7BW, Devon, England.	w.t.hamilton@btopenworld.com	Hamilton, Willie/G-8612-2014	Watson, Jessica/0000-0002-8177-6438; Hamilton, William/0000-0003-1611-1373	National Institute for Health Research [ACF-2008-25-003] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; Coeliac Disease, 2009, COEL DIS REC ASS COE; Cullen W, 2002, IRISH J MED SCI, V171, P10, DOI 10.1007/BF03168931; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; Gallagher AM, 2004, J ROY SOC MED, V97, P571, DOI 10.1258/jrsm.97.12.571; Gialamas Angela, 2003, Aust Fam Physician, V32, P663; Godwin M, 1999, CAN FAM PHYSICIAN, V45, P373; Hamilton WT, 2005, FAM PRACT, V22, P383, DOI 10.1093/fampra/cmi021; Harrison M, 2008, AUST FAM PHYSICIAN, V37, P908; Hin H, 1999, BMJ-BRIT MED J, V318, P164, DOI 10.1136/bmj.318.7177.164; Kenter EGH, 2003, FAM PRACT, V20, P434, DOI 10.1093/fampra/cmg418; Koch H, 2009, BRIT J GEN PRACT, V59, P243, DOI 10.3399/bjgp09X420310; Kroenke K, 1998, FAM PRACT, V15, P398, DOI 10.1093/fampra/15.5.398; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Melbye H, 2004, BRIT J GEN PRACT, V54, P653; *NAT I HLTH CLIN E, 2007, CHRON FAT SYNDR MY E; *NHS CLIN KNOWL SU, TIR FAT AD MAN; Okkes IM, 2002, J FAM PRACTICE, V51, P31; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; RIDSDALE L, 1994, BRIT J GEN PRACT, V44, P413; Stolper E, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-17; Summerton N, 2003, BRIT J GEN PRACT, V53, P50; Verdon F, 2003, BRIT MED J, V326, P1124, DOI 10.1136/bmj.326.7399.1124; WESSELY S, 1995, LANCET, V345, P1333, DOI 10.1016/S0140-6736(95)92537-6; White PD, 1998, BRIT J PSYCHIAT, V173, P475, DOI 10.1192/bjp.173.6.475	25	15	15	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	2010	341								c4259	10.1136/bmj.c4259	http://dx.doi.org/10.1136/bmj.c4259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IG	20736254				2022-12-28	WOS:000281445900012
J	Starr, DA				Starr, Daniel A.			Nuclei Get TAN Lines	SCIENCE			English	Editorial Material							ACTIN CYTOSKELETON; MIGRATION; ENVELOPE		Univ Calif Davis, Dept Mol & Cellular Biol, Coll Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Starr, DA (corresponding author), Univ Calif Davis, Dept Mol & Cellular Biol, Coll Biol Sci, Davis, CA 95616 USA.	dastarr@ucdavis.edu		Starr, Daniel/0000-0001-7339-6606	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073874] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Crisp M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/jcb.200509124; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Haque F, 2010, J BIOL CHEM, V285, P3487, DOI 10.1074/jbc.M109.071910; Koszul R, 2008, CELL, V133, P1188, DOI 10.1016/j.cell.2008.04.050; Luxton GWG, 2010, SCIENCE, V329, P956, DOI 10.1126/science.1189072; Malone CJ, 1999, DEVELOPMENT, V126, P3171; Starr DA, 2003, J CELL SCI, V116, P211, DOI 10.1242/jcs.00248; Starr DA, 2002, SCIENCE, V298, P406, DOI 10.1126/science.1075119; Starr DA, 2010, ANN REV CELL DEV BIO; Zhang XC, 2009, NEURON, V64, P173, DOI 10.1016/j.neuron.2009.08.018; Zhen YY, 2002, J CELL SCI, V115, P3207	11	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					909	910		10.1126/science.1194562	http://dx.doi.org/10.1126/science.1194562			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724623				2022-12-28	WOS:000281084800021
J	Ko, SB; Lee, K				Ko, Sang-Bae; Lee, Kiwon			Acute Optic-Nerve Infarction in Carotid Dissection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ko, Sang-Bae; Lee, Kiwon] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Ko, SB (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	kl2356@columbia.edu		Whang, Kum/0000-0002-3701-847X; Ko, Sang-Bae/0000-0002-9429-9597					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					765	765		10.1056/NEJMicm0909070	http://dx.doi.org/10.1056/NEJMicm0909070			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639TE	20818878				2022-12-28	WOS:000280996600010
J	Engert, A; Plutschow, A; Eich, HT; Lohri, A; Dorken, B; Borchmann, P; Berger, B; Greil, R; Willborn, KC; Wilhelm, M; Debus, J; Eble, MJ; Sokler, M; Ho, A; Rank, A; Ganser, A; Trumper, L; Bokemeyer, C; Kirchner, H; Schubert, J; Kral, Z; Fuchs, M; Muller-Hermelink, HK; Muller, RP; Diehl, V				Engert, Andreas; Pluetschow, Annette; Eich, Hans Theodor; Lohri, Andreas; Doerken, Bernd; Borchmann, Peter; Berger, Bernhard; Greil, Richard; Willborn, Kay C.; Wilhelm, Martin; Debus, Juergen; Eble, Michael J.; Soekler, Martin; Ho, Antony; Rank, Andreas; Ganser, Arnold; Truemper, Lorenz; Bokemeyer, Carsten; Kirchner, Hartmut; Schubert, Joerg; Kral, Zdenek; Fuchs, Michael; Mueller-Hermelink, Hans-Konrad; Mueller, Rolf-Peter; Diehl, Volker			Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; INVOLVED-FIELD RADIOTHERAPY; COMBINED-MODALITY THERAPY; RADIATION-THERAPY; PROGNOSTIC SCORE; 2ND MALIGNANCY; CLINICAL-TRIAL; 2 CYCLES; CHEMOTHERAPY; DISEASE	BACKGROUND Whether it is possible to reduce the intensity of treatment in early (stage I or II) Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a multicenter, randomized trial comparing four treatment groups consisting of a combination chemotherapy regimen of two different intensities followed by involved-field radiation therapy at two different dose levels. METHODS We randomly assigned 1370 patients with newly diagnosed early-stage Hodgkin's lymphoma with a favorable prognosis to one of four treatment groups: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of radiation therapy (group 1), four cycles of ABVD followed by 20 Gy of radiation therapy (group 2), two cycles of ABVD followed by 30 Gy of radiation therapy (group 3), or two cycles of ABVD followed by 20 Gy of radiation therapy (group 4). The primary end point was freedom from treatment failure; secondary end points included efficacy and toxicity of treatment. RESULTS The two chemotherapy regimens did not differ significantly with respect to freedom from treatment failure (P = 0.39) or overall survival (P = 0.61). At 5 years, the rates of freedom from treatment failure were 93.0% (95% confidence interval [CI], 90.5 to 94.8) with the four-cycle ABVD regimen and 91.1% (95% CI, 88.3 to 93.2) with the two-cycle regimen. When the effects of 20-Gy and 30-Gy doses of radiation therapy were compared, there were also no significant differences in freedom from treatment failure (P = 1.00) or overall survival (P = 0.61). Adverse events and acute toxic effects of treatment were most common in the patients who received four cycles of ABVD and 30 Gy of radiation therapy (group 1). CONCLUSIONS In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of involved-field radiation therapy. Long-term effects of these treatments have not yet been fully assessed. (Funded by the Deutsche Krebshilfe and the Swiss Federal Government; ClinicalTrials.gov number, NCT00265018.)	[Engert, Andreas; Pluetschow, Annette; Borchmann, Peter; Fuchs, Michael; Diehl, Volker] Univ Cologne, Dept Internal Med, German Hodgkin Study Grp, Cologne, Germany; [Eich, Hans Theodor; Mueller, Rolf-Peter] Univ Cologne, Dept Radiat Oncol, Cologne, Germany; [Doerken, Bernd] Charite, Dept Hematol & Oncol, D-13353 Berlin, Germany; [Berger, Bernhard] Univ Tubingen, Dept Radiat Oncol, Tubingen, Germany; [Soekler, Martin] Univ Tubingen, Dept Internal Med 2, Tubingen, Germany; [Willborn, Kay C.] Pius Hosp Oldenburg, Klin Strahlentherapie & Internist Onkol, Oldenburg, Germany; [Wilhelm, Martin] Schwerpunkt Hamatol Onkol, Med Klin 5, Klinikum Nurnberg Nord, Nurnberg, Germany; [Debus, Juergen] Heidelberg Univ, Dept Radiat Oncol, Heidelberg, Germany; [Ho, Antony] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; [Eble, Michael J.] Rhein Westfal TH Aachen, Dept Radiotherapy, Aachen, Germany; [Rank, Andreas] Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany; [Ganser, Arnold] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, D-3000 Hannover, Germany; [Truemper, Lorenz] Univ Gottingen, Dept Hematol & Oncol, Gottingen, Germany; [Bokemeyer, Carsten] Univ Med Ctr Hamburg, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany; [Kirchner, Hartmut] Siloah Clin, Dept Hematol Oncol, Hannover, Germany; [Schubert, Joerg] Evangel Krankenhaus Hamm, Med Klin, Abt Hamatoonkol, Hamm, Germany; [Mueller-Hermelink, Hans-Konrad] Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany; [Lohri, Andreas] Swiss Grp Clin Canc Res, Bern, Switzerland; [Greil, Richard] Salzburg Univ, Dept Med 3, A-5020 Salzburg, Austria; [Kral, Zdenek] Univ Hosp, Dept Internal Med Hematooncol, Brno, Czech Republic; [Kral, Zdenek] Masaryk Univ, Fac Med, Brno, Czech Republic	University of Cologne; University of Cologne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Pius-Hospital Oldenburg; Klinikum Nurnberg Nord; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; RWTH Aachen University; University of Munich; Hannover Medical School; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; Swiss Group for Clinical Cancer Research (SAKK); Salzburg University; University Hospital Brno; Masaryk University Brno	Engert, A (corresponding author), Kerpenerstr 62, D-50937 Cologne, Germany.	a.engert@uni-koeln.de	Wilhelm, Martin/J-3964-2014; Greil, Richard F/C-7673-2017	Greil, Richard F/0000-0002-4462-3694	Deutsche Krebshilfe; Swiss Federal Government	Deutsche Krebshilfe(Deutsche Krebshilfe); Swiss Federal Government	Supported by grants from the Deutsche Krebshilfe and the Swiss Federal Government.	Aviles A, 1998, CLIN LAB HAEMATOL, V20, P95, DOI 10.1046/j.1365-2257.1998.00096.x; BLOOMFIELD CD, 1982, CANCER TREAT REP, V66, P835; BOIVIN JF, 1995, JNCI-J NATL CANCER I, V87, P732, DOI 10.1093/jnci/87.10.732; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; Canellos GP, 2005, J CLIN ONCOL, V23, P4574, DOI 10.1200/JCO.2005.01.911; CARDE P, 1988, J CLIN ONCOL, V6, P239, DOI 10.1200/JCO.1988.6.2.239; Connors JM, 2005, J CLIN ONCOL, V23, P6400, DOI 10.1200/JCO.2005.05.016; Eghbali H, 2005, BLOOD, V106, p240A; Engert A, 2003, J CLIN ONCOL, V21, P3601, DOI 10.1200/JCO.2003.03.023; Engert A, 2007, J CLIN ONCOL, V25, P3495, DOI 10.1200/JCO.2006.07.0482; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Franklin J, 2006, ANN ONCOL, V17, P1749, DOI 10.1093/annonc/mdl302; Gallamini A, 2007, J CLIN ONCOL, V25, P3746, DOI 10.1200/JCO.2007.11.6525; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Hutchings M, 2006, BLOOD, V107, P52, DOI 10.1182/blood-2005-06-2252; Kobe C, 2008, BLOOD, V112, P3989, DOI 10.1182/blood-2008-06-155820; Mauch P, 1999, HODGKINS DIS; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; National Comprehensive Cancer Network, 2008, NCCN CLIN PRACT GUID; Ng AK, 2002, J CLIN ONCOL, V20, P2101, DOI 10.1200/JCO.2002.08.021; Noordijk EM, 2006, J CLIN ONCOL, V24, P3128, DOI 10.1200/JCO.2005.05.2746; PAVLOVSKY S, 1988, JNCI-J NATL CANCER I, V80, P1466, DOI 10.1093/jnci/80.18.1466; Spaepen K, 2001, BRIT J HAEMATOL, V115, P272, DOI 10.1046/j.1365-2141.2001.03169.x; Specht L, 1998, J CLIN ONCOL, V16, P830, DOI 10.1200/JCO.1998.16.3.830; Specht L, 2003, BLOOD, V102, p637A; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; van Leeuwen FE, 2000, J CLIN ONCOL, V18, P487, DOI 10.1200/JCO.2000.18.3.487; Yahalom J, 2006, J CLIN ONCOL, V24, P544, DOI 10.1200/JCO.2005.04.4396; Zinzani PL, 2006, ANN ONCOL, V17, P1296, DOI 10.1093/annonc/mdl122	30	606	624	2	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					640	652		10.1056/NEJMoa1000067	http://dx.doi.org/10.1056/NEJMoa1000067			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20818855	Green Accepted, Bronze			2022-12-28	WOS:000280764600007
J	Conway, PH; VanLare, JM				Conway, Patrick H.; VanLare, Jordan M.			Improving Access to Health Care Data The Open Government Strategy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Conway, Patrick H.] Cincinnati Childrens Hosp, Med Ctr, Anderson Ctr Hlth Syst Excellence, Div Gen Pediat, Cincinnati, OH USA; [Conway, Patrick H.] Cincinnati Childrens Hosp, Med Ctr, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH USA; [Conway, Patrick H.; VanLare, Jordan M.] Dept Hlth & Human Serv, Washington, DC USA; [VanLare, Jordan M.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Columbia University	Conway, PH (corresponding author), 3333 Burnet Ave,MLC 2011, Cincinnati, OH 45229 USA.	patrick.conway@cchmc.org						[Anonymous], OFFICE NATL COORDINA; Conway PH, 2009, NEW ENGL J MED, V361, P328, DOI 10.1056/NEJMp0905631; *CTR MED MED SERV, 2010, ARRA SOL TECHN IMPL; HOBAN N, 2010, MULTIPAYOR CLAIMS DA; ORZAG P, OPEN GOVT DIRECTIVE; U.S. Department of Health and Human Services, 2010, HHS OP GOV PLAN; *US GEN SERV ADM, 2010, CONTR RES DAT ASS CT	7	13	13	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2010	304	9					1007	1008		10.1001/jama.2010.1249	http://dx.doi.org/10.1001/jama.2010.1249			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645AD	20810380				2022-12-28	WOS:000281422400029
J	Jullo, E; Natarajan, P; Kneib, JP; D'Aloisio, A; Limousin, M; Richard, J; Schimd, C				Jullo, Eric; Natarajan, Priyamvada; Kneib, Jean-Paul; D'Aloisio, Anson; Limousin, Marceau; Richard, Johan; Schimd, Carlo			Cosmological Constraints from Strong Gravitational Lensing in Clusters of Galaxies	SCIENCE			English	Article							HUBBLE-SPACE-TELESCOPE; DARK ENERGY; MATTER; PARAMETERS; MASS	Current efforts in observational cosmology are focused on characterizing the mass-energy content of the universe. We present results from a geometric test based on strong lensing in galaxy clusters. Based on Hubble Space Telescope images and extensive ground-based spectroscopic follow-up of the massive galaxy cluster Abell 1689, we used a parametric model to simultaneously constrain the cluster mass distribution and dark energy equation of state. Combining our cosmological constraints with those from x-ray clusters and the Wilkinson Microwave Anisotropy Probe 5-year data gives Omega(m) = 0.25 +/- 0.05 and W-x = -0.97 +/- 0.07, which are consistent with results from other methods. Inclusion of our method with all other available techniques brings down the current 2 sigma contours on the dark energy equation-of-state parameter W-x by similar to 30%.	[Natarajan, Priyamvada] Yale Univ, Dept Astron, New Haven, CT 06511 USA; [Jullo, Eric] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Jullo, Eric; Kneib, Jean-Paul; Limousin, Marceau; Schimd, Carlo] Univ Aix Marseille 1, CNRS, Lab Astrophys Marseille, F-13388 Marseille 13, France; [Natarajan, Priyamvada; D'Aloisio, Anson] Yale Univ, Dept Phys, New Haven, CT 06504 USA; [Limousin, Marceau] Univ Copenhagen, Niels Bohr Inst, Dark Cosmol Ctr, DK-2100 Copenhagen, Denmark; [Richard, Johan] Univ Durham, Dept Phys, Inst Computat Cosmol, Durham DH1 3LE, England	Yale University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Yale University; University of Copenhagen; Niels Bohr Institute; Durham University	Natarajan, P (corresponding author), Yale Univ, Dept Astron, POB 208101, New Haven, CT 06511 USA.	priyamvada.natarajan@yale.edu	Kneib, Jean-Paul/A-7919-2015; JULLO, Eric/N-8351-2015; Natarajan, Priyamvada/AAG-2086-2021	Kneib, Jean-Paul/0000-0002-4616-4989; JULLO, Eric/0000-0002-9253-053X; Richard, Johan/0000-0001-5492-1049; Schimd, Carlo/0000-0002-0003-1873	NASA; Radcliffe Fellowship; Guggenheim Fellowship; CNRS	NASA(National Aeronautics & Space Administration (NASA)); Radcliffe Fellowship; Guggenheim Fellowship; CNRS(Centre National de la Recherche Scientifique (CNRS))	E.J. and J.-P.K. acknowledge fruitful discussions with D. Coe, L. Koopmans, L. Moustakas, and M. Auger. The authors are thankful for computational resources from Institut du Developpement et des Ressources en Informatique Scientifique acknowledges a NASA postdoctoral fellowship, and P.N. acknowledges a Radcliffe Fellowship and a Guggenheim Fellowship. J.-P.K., M.L., and C.S. acknowledge support from CNRS, and M.L. thanks Centre National d'Etudes Spatiales and Ville de Marseille. The authors thank A. Vikhlinin for providing data on cosmological constraints from x-ray clusters to combine with our strong lensing results.	Allen SW, 2004, MON NOT R ASTRON SOC, V353, P457, DOI 10.1111/j.1365-2966.2004.08080.x; Astier P, 2006, ASTRON ASTROPHYS, V447, P31, DOI 10.1051/0004-6361:20054185; Bacon DJ, 2000, MON NOT R ASTRON SOC, V318, P625, DOI 10.1046/j.1365-8711.2000.03851.x; Broadhurst T, 2005, ASTROPHYS J, V621, P53, DOI 10.1086/426494; Cooray AR, 1999, ASTROPHYS J, V511, P562, DOI 10.1086/306713; Czoske O., 2004, IAU C, P183; Ebeling H, 1996, MON NOT R ASTRON SOC, V281, P799, DOI 10.1093/mnras/281.3.799; Efstathiou G, 2002, MON NOT R ASTRON SOC, V330, pL29, DOI 10.1046/j.1365-8711.2002.05215.x; Gilmore J, 2009, MON NOT R ASTRON SOC, V396, P354, DOI 10.1111/j.1365-2966.2009.14612.x; Golse G, 2002, ASTRON ASTROPHYS, V387, P788, DOI 10.1051/0004-6361:20020448; HINSHAW G, 2008, ARXIV E PRINTS; Jullo E, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/12/447; KAISER N, 2000, ARXIV E PRINTS; Kessler R, 2009, ASTROPHYS J SUPPL S, V185, P32, DOI 10.1088/0067-0049/185/1/32; Kneib JP, 1996, ASTROPHYS J, V471, P643, DOI 10.1086/177995; Komatsu E, 2009, ASTROPHYS J SUPPL S, V180, P330, DOI 10.1088/0067-0049/180/2/330; Link R, 1998, ASTROPHYS J, V502, P63, DOI 10.1086/305892; Natarajan P, 1998, ASTROPHYS J, V499, P600, DOI 10.1086/305660; Natarajan P, 1997, MON NOT R ASTRON SOC, V287, P833, DOI 10.1093/mnras/287.4.833; Natarajan P, 2007, MON NOT R ASTRON SOC, V376, P180, DOI [10.1111/j.1365-2966.2007.11399.x, 10.1111/j.1365-2966.2006.11199.x]; Natarajan P, 2009, ASTROPHYS J, V693, P970, DOI 10.1088/0004-637X/693/1/970; PACZYNSKI B, 1981, ASTROPHYS J, V248, pL101, DOI 10.1086/183634; PERLMUTTER S, 1998, NATURE, V51, P391; Riess AG, 2004, ASTROPHYS J, V607, P665, DOI 10.1086/383612; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Seljak U, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.103515; Semboloni E, 2006, ASTRON ASTROPHYS, V452, P51, DOI 10.1051/0004-6361:20054479; Sereno M, 2002, ASTRON ASTROPHYS, V393, P757, DOI 10.1051/0004-6361:20021048; Smith GP, 2005, MON NOT R ASTRON SOC, V359, P417, DOI 10.1111/j.1365-2966.2005.08911.x; Soucail G, 2004, ASTRON ASTROPHYS, V417, pL33, DOI 10.1051/0004-6361:20040077; Spergel DN, 2007, ASTROPHYS J SUPPL S, V170, P377, DOI 10.1086/513700; Springel V, 2006, NATURE, V440, P1137, DOI 10.1038/nature04805; SUYU SH, 2009, ARXIV E PRINTS; Tonry JL, 2003, ASTROPHYS J, V594, P1, DOI 10.1086/376865; Van Waerbeke L, 2000, ASTRON ASTROPHYS, V358, P30; Vikhlinin A, 2009, ASTROPHYS J, V692, P1060, DOI 10.1088/0004-637X/692/2/1060; Wittman DM, 2000, NATURE, V405, P143, DOI 10.1038/35012001; Wood-Vasey WM, 2007, ASTROPHYS J, V666, P694, DOI 10.1086/518642	40	111	112	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2010	329	5994					924	927		10.1126/science.1185759	http://dx.doi.org/10.1126/science.1185759			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724628	Green Submitted			2022-12-28	WOS:000281084800028
J	Luxton, GWG; Gomes, ER; Folker, ES; Vintinner, E; Gundersen, GG				Luxton, G. W. Gant; Gomes, Edgar R.; Folker, Eric S.; Vintinner, Erin; Gundersen, Gregg G.			Linear Arrays of Nuclear Envelope Proteins Harness Retrograde Actin Flow for Nuclear Movement	SCIENCE			English	Article							MICROFILAMENT BUNDLES BENEATH; NEURONAL MIGRATION; MYOSIN-II; F-ACTIN; CENTROSOME; GROWTH; DYNEIN; ROLES; NEUROGENESIS; FIBROBLASTS	Nuclei move to specific locations to polarize migrating and differentiating cells. Many nuclear movements are microtubule-dependent. However, nuclear movement to reorient the centrosome in migrating fibroblasts occurs through an unknown actin-dependent mechanism. We found that linear arrays of outer (nesprin2G) and inner (SUN2) nuclear membrane proteins assembled on and moved with retrogradely moving dorsal actin cables during nuclear movement in polarizing fibroblasts. Inhibition of nesprin2G, SUN2, or actin prevented nuclear movement and centrosome reorientation. The coupling of actin cables to the nuclear membrane for nuclear movement via specific membrane proteins indicates that, like plasma membrane integrins, nuclear membrane proteins assemble into actin-dependent arrays for force transduction.	[Luxton, G. W. Gant; Gomes, Edgar R.; Folker, Eric S.; Vintinner, Erin; Gundersen, Gregg G.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Gomes, Edgar R.] Univ Paris 06, INSERM, UMR S 787, F-75634 Paris, France; [Gomes, Edgar R.] Grp Hosp Pitie Salpetriere, Inst Myol, F-75013 Paris, France	Columbia University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Gundersen, GG (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.	ggg1@columbia.edu	Luxton, GW Gant/A-7212-2017; Gomes, Edgar/ABH-7441-2020; Gomes, Edgar r/D-9000-2015	Gomes, Edgar/0000-0002-6941-4872; Gomes, Edgar r/0000-0002-6941-4872; Folker, Eric/0000-0003-1619-7330; Luxton, GW Gant/0000-0002-6180-8906	Dystonia Medical Research Foundation; American Heart Association; Muscular Dystrophy Association; Association pour la Recherche sur le Cancer; Ligue Nacionale contre le Cancer; NIH [GM06929, NS059352]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM099481, R01GM062939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS059352, R01NS059352] Funding Source: NIH RePORTER	Dystonia Medical Research Foundation; American Heart Association(American Heart Association); Muscular Dystrophy Association(Muscular Dystrophy Association); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nacionale contre le Cancer; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank W. Dauer, H. Herrmann, E. Marcantonio, G. Morris, S. Shackleton, R. Wedlich-Soldner, and H. Worman for providing reagents; members of the Dauer, Hirano, and Worman labs for helpful discussions; and Y. Zhao for analysis. This work was supported by a Dystonia Medical Research Foundation Fellowship (G.W.G.L.), an American Heart Association fellowship (E.S.F.), a Muscular Dystrophy Association grant (E.R.G.), an Association pour la Recherche sur le Cancer grant (E.R.G.), a Ligue Nacionale contre le Cancer grant (E.R.G.), a Dystonia Medical Research Foundation grant (G.G.G.), and NIH (GM06929 and NS059352) grants (G.G.G.).	Crisp M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/jcb.200509124; Del Bene F, 2008, CELL, V134, P1055, DOI 10.1016/j.cell.2008.07.017; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Goulding MB, 2007, J CELL BIOL, V178, P1177, DOI 10.1083/jcb.200703159; HEATH JP, 1981, CELL BIOL INT REP, V5, P975, DOI 10.1016/0309-1651(81)90214-9; HEATH JP, 1983, J CELL SCI, V60, P331; Ketelaar T, 2002, PLANT CELL, V14, P2941, DOI 10.1105/tpc.005892; King MC, 2008, CELL, V134, P427, DOI 10.1016/j.cell.2008.06.022; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; Lei K, 2009, P NATL ACAD SCI USA, V106, P10207, DOI 10.1073/pnas.0812037106; Luke Y, 2008, J CELL SCI, V121, P1887, DOI 10.1242/jcs.019075; Naumanen P, 2008, J MICROSC-OXFORD, V231, P446, DOI 10.1111/j.1365-2818.2008.02057.x; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Ramos-Garcia SL, 2009, EUKARYOT CELL, V8, P1880, DOI 10.1128/EC.00062-09; Reinsch S, 1998, J CELL SCI, V111, P2283; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Schmoranzer J, 2009, CURR BIOL, V19, P1065, DOI 10.1016/j.cub.2009.05.065; Solecki DJ, 2009, NEURON, V63, P63, DOI 10.1016/j.neuron.2009.05.028; Starr DA, 2002, SCIENCE, V298, P406, DOI 10.1126/science.1075119; Starr DA, 2009, J CELL SCI, V122, P577, DOI 10.1242/jcs.037622; Tsai JW, 2007, NAT NEUROSCI, V10, P970, DOI 10.1038/nn1934; Wilhelmsen K, 2006, J CELL SCI, V119, P5021, DOI 10.1242/jcs.03295; Zhang XC, 2007, DEVELOPMENT, V134, P901, DOI 10.1242/dev.02783; Zhang XC, 2009, NEURON, V64, P173, DOI 10.1016/j.neuron.2009.08.018	26	326	333	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					956	959		10.1126/science.1189072	http://dx.doi.org/10.1126/science.1189072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724637	Green Accepted			2022-12-28	WOS:000281084800038
J	Seifert, U; Bialy, LP; Ebstein, F; Bech-Otschir, D; Voigt, A; Schroter, F; Prozorovski, T; Lange, N; Steffen, J; Rieger, M; Kuckelkorn, U; Aktas, O; Kloetzel, PM; Kruger, E				Seifert, Ulrike; Bialy, Lukasz P.; Ebstein, Frederic; Bech-Otschir, Dawadschargal; Voigt, Antje; Schroeter, Friederike; Prozorovski, Timour; Lange, Nicole; Steffen, Janos; Rieger, Melanie; Kuckelkorn, Ulrike; Aktas, Orhan; Kloetzel, Peter-M.; Krueger, Elke			Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress	CELL			English	Article							NEWLY SYNTHESIZED PROTEINS; CD8(+) T-CELLS; PROTEASOME SYSTEM; GAMMA-INTERFERON; HEAT-SHOCK; INDUCTION; DEGRADATION; UBIQUITIN; IMMUNITY; PATHWAY	Interferon (IFN)-induced immunoproteasomes (i-proteasomes) have been associated with improved processing of major histocompatibility complex (MHC) class I antigens. Here, we show that i-proteasomes function to protect cell viability under conditions of IFN-induced oxidative stress. IFNs trigger the production of reactive oxygen species, which induce protein oxidation and the formation of nascent, oxidant-damaged proteins. We find that the ubiquitylation machinery is concomitantly upregulated in response to IFNs, functioning to target defective ribosomal products (DRiPs) for degradation by i-proteasomes. i-proteasome-deficiency in cells and in murine inflammation models results in the formation of aggresome-like induced structures and increased sensitivity to apoptosis. Efficient clearance of these aggregates by the enhanced proteolytic activity of the i-proteasome is important for the preservation of cell viability upon IFN-induced oxidative stress. Our findings suggest that rather than having a specific role in the production of class I antigens, i-proteasomes increase the peptide supply for antigen presentation as part of a more general role in the maintenance of protein homeostasis.	[Seifert, Ulrike; Bialy, Lukasz P.; Ebstein, Frederic; Bech-Otschir, Dawadschargal; Schroeter, Friederike; Lange, Nicole; Steffen, Janos; Rieger, Melanie; Kuckelkorn, Ulrike; Kloetzel, Peter-M.; Krueger, Elke] Charite, Inst Biochem CC2, D-13347 Berlin, Germany; [Voigt, Antje] Charite, Med Klin Kardiol & Angiol CC13, D-10117 Berlin, Germany; [Prozorovski, Timour; Aktas, Orhan] Univ Dusseldorf, Fac Med, Dept Neurol, D-40225 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Kloetzel, PM (corresponding author), Charite, Inst Biochem CC2, Oudenarder Str 16, D-13347 Berlin, Germany.	p-m.kloetzel@charite.de; elke.krueger@charite.de	Voigt, Antje/E-4332-2013; Biały, Lukasz/AAW-8500-2021; Beling, Antje/AAW-5380-2020; Aktas, Orhan/B-7623-2009; Bialy, Lukasz P./I-1785-2019; Krueger, Elke/B-1462-2012; Steffen, Janos/AAI-7646-2020	Aktas, Orhan/0000-0002-2020-9210; Bialy, Lukasz P./0000-0001-6931-6431; Krueger, Elke/0000-0002-2551-242X; Beling, Antje/0000-0002-1826-5248; Kuckelkorn, Ulrike/0000-0002-3085-9161	Deutsche Forschungsgemeinschaft [SFB421, SFB740, Transregio 19, Transregio 43, KR1915/4-1, SPP 1365]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	D. Ludwig and E. Burger are acknowledged for their excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (SFB421, SFB740, Transregio 19, Transregio 43, KR1915/4-1, SPP 1365).	AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; Bech-Otschir D, 2009, NAT STRUCT MOL BIOL, V16, P219, DOI 10.1038/nsmb.1547; Bose S, 2001, BIOCHEM J, V353, P291, DOI 10.1042/0264-6021:3530291; Callahan MK, 2006, J IMMUNOL, V177, P8393, DOI 10.4049/jimmunol.177.12.8393; Chen WS, 2001, J EXP MED, V193, P1319, DOI 10.1084/jem.193.11.1319; Chou B, 2008, MICROBES INFECT, V10, P241, DOI 10.1016/j.micinf.2007.11.010; Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; Deol P, 2007, J IMMUNOL, V178, P7557, DOI 10.4049/jimmunol.178.12.7557; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Ebstein F, 2009, INT J BIOCHEM CELL B, V41, P1205, DOI 10.1016/j.biocel.2008.10.023; Ehrnhoefer DE, 2008, NAT STRUCT MOL BIOL, V15, P558, DOI 10.1038/nsmb.1437; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; Heink S, 2005, P NATL ACAD SCI USA, V102, P9241, DOI 10.1073/pnas.0501711102; Ishii K, 2006, MICROBES INFECT, V8, P1045, DOI 10.1016/j.micinf.2005.10.023; Kaur S, 2008, P NATL ACAD SCI USA, V105, P4808, DOI 10.1073/pnas.0710907105; Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kotamraju S, 2006, FREE RADICAL BIO MED, V40, P1034, DOI 10.1016/j.freeradbiomed.2005.10.052; Kruger E, 2004, REV PHYSIOL BIOCH P, V148, P81, DOI 10.1007/s10254-003-0010-4; Lelouard H, 2004, J CELL BIOL, V164, P667, DOI 10.1083/jcb.200312073; Lelouard H, 2007, J CELL BIOL, V179, P1427, DOI 10.1083/jcb.200707166; Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731; Medicherla B, 2008, J CELL BIOL, V182, P663, DOI 10.1083/jcb.200803022; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Nussbaum AK, 2005, J IMMUNOL, V175, P1153, DOI 10.4049/jimmunol.175.2.1153; Pearl-Yafe M, 2003, BIOCHEM PHARMACOL, V65, P833, DOI 10.1016/S0006-2952(02)01620-9; Puttaparthi K, 2005, EXP NEUROL, V196, P441, DOI 10.1016/j.expneurol.2005.08.027; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; SASAKI M, 2008, FREE RADICAL RES, V4, P1; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Sijts AJAM, 2000, J EXP MED, V191, P503, DOI 10.1084/jem.191.3.503; Strehl B, 2008, J BIOL CHEM, V283, P17891, DOI 10.1074/jbc.M710042200; Strehl B, 2006, J IMMUNOL, V177, P6238, DOI 10.4049/jimmunol.177.9.6238; Szeto J, 2006, AUTOPHAGY, V2, P189, DOI 10.4161/auto.2731; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Toes REM, 2001, J EXP MED, V194, P1, DOI 10.1084/jem.194.1.1; Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925; VAN KL, 1994, IMMUNITY, V1, P533; Voigt A, 2010, AMINO ACIDS, V39, P243, DOI 10.1007/s00726-009-0434-5; Watanabe Y, 2003, J CELL BIOCHEM, V89, P244, DOI 10.1002/jcb.10501; Yewdell JW, 2006, TRENDS IMMUNOL, V27, P368, DOI 10.1016/j.it.2006.06.008; Yewdell JW, 2005, IMMUNOL REV, V207, P8; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102	49	394	402	1	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					613	624		10.1016/j.cell.2010.07.036	http://dx.doi.org/10.1016/j.cell.2010.07.036			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723761	Bronze			2022-12-28	WOS:000281115900015
J	Klempner, MS; Talbot, EA; Lee, SI; Zaki, S; Ferraro, MJ				Klempner, Mark S.; Talbot, Elizabeth A.; Lee, Susanna I.; Zaki, Sherif; Ferraro, Mary Jane			A Woman with Abdominal Pain and Shock Intestinal anthrax	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY RESPONSE SYNDROME; DANGER; SEPSIS; DAMPS		[Klempner, Mark S.] Boston Univ, Med Ctr, Natl Emerging Infect Dis Labs, Sch Med, Boston, MA 02118 USA; [Klempner, Mark S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Lee, Susanna I.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Ferraro, Mary Jane] Massachusetts Gen Hosp, Clin Microbiol Lab, Dept Pathol, Boston, MA 02114 USA; [Lee, Susanna I.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Ferraro, Mary Jane] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Talbot, Elizabeth A.] Dartmouth Hitchcock Med Ctr, Dept Infect Dis & Int Hlth, Lebanon, NH 03766 USA; [Talbot, Elizabeth A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; [Zaki, Sherif] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA	Boston University; Boston University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Dartmouth College; Dartmouth College; Centers for Disease Control & Prevention - USA	Klempner, MS (corresponding author), Boston Univ, Med Ctr, Natl Emerging Infect Dis Labs, Sch Med, Boston, MA 02118 USA.			Lee, Susanna I/0000-0003-2195-2943				Adib-Conquy M, 2007, FEBS LETT, V581, P3723, DOI 10.1016/j.febslet.2007.03.074; Beatty ME, 2003, ARCH INTERN MED, V163, P2527, DOI 10.1001/archinte.163.20.2527; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; BLACK RE, 1978, NEW ENGL J MED, V298, P76, DOI 10.1056/NEJM197801122980204; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Lucey BC, 2005, RADIOGRAPHICS, V25, P351, DOI 10.1148/rg.252045108; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Riley A., 2007, REPORT MANAGEMENT AN; Sharma MP, 2004, INDIAN J MED RES, V120, P305; Triantafilou M, 2007, CELL MICROBIOL, V9, P2880, DOI 10.1111/j.1462-5822.2007.01003.x; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; 2008, MMWR MORB MORTAL WKL, V57, P628; 2006, MMWR MORB MORTAL WKL, V55, P280	14	23	24	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					766	777		10.1056/NEJMcpc1003887	http://dx.doi.org/10.1056/NEJMcpc1003887			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20818879				2022-12-28	WOS:000280996600012
J	Wassersug, RJ; Lieberman, T				Wassersug, Richard J.; Lieberman, Tucker			Personal View Contemporary castration: why the modern day eunuch remains invisible	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ANDROGEN-DEPRIVATION THERAPY; CHARACTERIZING MEN		[Wassersug, Richard J.] Dalhousie Univ, Halifax, NS, Canada	Dalhousie University	Wassersug, RJ (corresponding author), La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic, Australia.	Richard.Wassersug@dal.ca						Alibhai SMH, 2010, CRIT REV ONCOL HEMAT, V73, P167, DOI 10.1016/j.critrevonc.2009.03.005; Cherner MM, 2009, PSYCHO-ONCOLOGY, V18, P237, DOI 10.1002/pon.1401; Cushman M. A., 2010, INT J MENS HLTH, V9, P3, DOI [10.3149/jmh.0901.3, DOI 10.3149/JMH.0901.3]; DiBlasio CJ, 2008, BJU INT, V102, P39, DOI 10.1111/j.1464-410X.2008.07505.x; Engstrom CA, 2008, AM J MENS HEALTH, V2, P122, DOI 10.1177/1557988306298802; Higano C, 2006, HEMATOL ONCOL CLIN N, V20, P909, DOI 10.1016/j.hoc.2006.03.013; Jim HSL, 2010, SUPPORT CARE CANCER, V18, P21, DOI 10.1007/s00520-009-0625-3; Johnson TW, 2007, J SEX MED, V4, P930, DOI 10.1111/j.1743-6109.2007.00521.x; Mohile SG, 2010, J GERIATR ONCOL, V1, P13, DOI [10.1016/j.jgo.2010.03.001, 10.1016/j.critrevonc.2010.06.009]; Murthy V, 2007, BJU INT, V99, P1380, DOI 10.1111/j.1464-410X.2007.06843.x; Navon L, 2004, SOC SCI MED, V58, P2337, DOI 10.1016/j.socscimed.2003.08.029; Nelson CJ, 2008, CANCER, V113, P1097, DOI 10.1002/cncr.23658; Roberts LF, 2008, J SEX MED, V5, P1669, DOI 10.1111/j.1743-6109.2007.00636.x; Smith Matthew R, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P247, DOI 10.1097/MED.0b013e32814db88c; Smith MR, 2004, UROLOGY, V63, P742, DOI 10.1016/j.urology.2003.10.063; Wassersug R, 2010, ANTHROPOL TODAY, V26, P1, DOI 10.1111/j.1467-8322.2010.00707.x; Wassersug RJ, 2007, PERSPECT BIOL MED, V50, P544, DOI 10.1353/pbm.2007.0058; Wassersug RJ, 2009, J RELIG HEALTH, V48, P381, DOI 10.1007/s10943-008-9231-9	18	7	7	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2010	341								c4509	10.1136/bmj.c4509	http://dx.doi.org/10.1136/bmj.c4509			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642KT	20719851				2022-12-28	WOS:000281213100009
J	WARDEN, J				WARDEN, J			FROM BUDGETS TO BABIES	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1988	296	6626					943	943		10.1136/bmj.296.6626.943	http://dx.doi.org/10.1136/bmj.296.6626.943			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	M7851	20742975	Green Published			2022-12-28	WOS:A1988M785100066
J	Summers, DM; Johnson, RJ; Allen, J; Fuggle, SV; Collett, D; Watson, CJ; Bradley, JA				Summers, Dominic M.; Johnson, Rachel J.; Allen, Joanne; Fuggle, Susan V.; Collett, David; Watson, Christopher J.; Bradley, J. Andrew			Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study	LANCET			English	Article							DELAYED GRAFT FUNCTION; BEATING DONOR KIDNEYS; RENAL-TRANSPLANTATION; UNITED-KINGDOM; BRAIN-DEATH; HEART; REJECTION; SURVIVAL; ALLOCATION; EXPERIENCE	Background A third of all kidneys from deceased donors in the UK are donated after cardiac death, but concerns have been raised about the long-term outcome of such transplants. We aimed to establish these outcomes for kidneys donated after controlled cardiac death versus brain death, and to identify the factors that affect graft survival and function. Methods We used data from the UK transplant registry to select a cohort of deceased kidney donors and the corresponding transplant recipients (aged years) for transplantations done between Jan 1, 2000, and Dec 31, 2007. Kaplan-Meier estimates were used to assess graft survival, and multivariate analyses were used to identify factors associated with graft survival and with long-term renal function, which was measured from estimated glomerular filtration rate (eGFR). Findings 9134 kidney transplants were done in 23 centres; 8289 kidneys were donated after brain death and 845 after controlled cardiac death. First-time recipients of kidneys from cardiac-death donors (n=739) or brain-death donors (n=6759) showed no difference in graft survival up to 5 years (hazard ratio 1.01, 95% CI 0.83 to 1.19, p=0.97), or in eGFR at 1-5 years after transplantation (at 12 months -0.36 mL/min per 1.73 m(2), 95% CI -2.00 to 1.27, p=0.66). For recipients of kidneys from cardiac-death donors, increasing age of donor and recipient, repeat transplantation, and cold ischaemic time of more than 12 h were associated with worse graft survival; grafts from cardiac-death donors that were poorly matched for HLA had an association with inferior outcome that was not significant, and delayed graft function and warm ischaemic time had no effect on outcome. Interpretation Kidneys from controlled cardiac-death donors provide good graft survival and function up to 5 years in first-time recipients, and are equivalent to kidneys from brain-death donors. Allocation policy for kidneys from cardiac-death donors should reduce cold ischaemic time, avoid large age mismatches between donors and recipients, and restrict use of kidneys poorly matched for HLA in young recipients.	[Summers, Dominic M.; Watson, Christopher J.; Bradley, J. Andrew] Univ Cambridge, Sch Clin Med, Dept Surg, Cambridge, England; [Summers, Dominic M.; Watson, Christopher J.; Bradley, J. Andrew] Biomed Res Ctr, Cambridge Natl Inst Hlth Res, Cambridge, England; [Summers, Dominic M.; Johnson, Rachel J.; Allen, Joanne; Fuggle, Susan V.; Collett, David] Natl Hlth Serv Blood & Transplant, Bristol, Avon, England; [Fuggle, Susan V.] Univ Oxford, Nuffield Dept Surg, Oxford, England	University of Cambridge; University of Cambridge; NHS Blood & Transplant (NHSBT); University of Oxford	Bradley, JA (corresponding author), Addenbrookes Hosp, Univ Dept Surg, Box 202, Cambridge CB2 0QQ, England.	jab52@cam.ac.uk	Summers, D. M./H-8678-2019	Summers, D. M./0000-0003-3360-0726; Collett, David/0000-0003-4861-7627; Johnson, Rachel/0000-0001-9199-3455	Astellas; Novartis; Roche; Wyeth; Organ Recovery Systems; NHS Blood and Transplant; Cambridge NIHR Biomedical Research Centre	Astellas(Astellas Pharmaceuticals); Novartis(Novartis); Roche(Roche Holding); Wyeth(Wyeth); Organ Recovery Systems; NHS Blood and Transplant; Cambridge NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	JAB is a trustee of Roche Organ Transplant Foundation; his department has received grants from pharmaceutical companies which market immunosuppressive therapy, notably Astellas, Novartis, Roche, and Wyeth, and from machine preservation manufacturers Organ Recovery Systems; and he has received travel and accommodation costs from Astellas to attend a training course. CJW has received research grants and honoraria for travel, accommodation, and registration to transplant conferences from Astellas, Novartis, Roche, and Wyeth; and research grants from Organ Recovery Systems. All other authors declare that they have no conflicts of interest.; This study was supported by NHS Blood and Transplant, and Cambridge NIHR Biomedical Research Centre. DMS was supported by a grant from NHS Blood and Transplant.	Barlow AD, 2009, BRIT J SURG, V96, P685, DOI 10.1002/bjs.6607; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; *BRIT TRANSPL SOC, 2004, GUID REL SOL ORG TRA; Brook NR, 2003, AM J TRANSPLANT, V3, P614, DOI 10.1034/j.1600-6143.2003.00113.x; Cecka J Michael, 2008, Clin Transpl, P1; Chapman J, 2006, TRANSPL INT, V19, P715, DOI 10.1111/j.1432-2277.2006.00337.x; Cooper JT, 2004, AM J TRANSPLANT, V4, P1490, DOI 10.1111/j.1600-6143.2004.00531.x; De Fijter JW, 2001, J AM SOC NEPHROL, V12, P1538, DOI 10.1681/ASN.V1271538; Devey LR, 2007, TRANSPLANTATION, V84, P70, DOI 10.1097/01.tp.0000268072.04260.69; Doshi MD, 2007, AM J TRANSPLANT, V7, P122, DOI 10.1111/j.1600-6143.2006.01587.x; Johnson Rachel, 2008, Clin Transpl, P75; Johnson RJ, 2010, TRANSPLANTATION, V89, P387, DOI 10.1097/TP.0b013e3181c9029d; Johnson RJ, 2010, TRANSPLANTATION, V89, P379, DOI 10.1097/TP.0b013e3181c90287; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kokkinos C, 2007, TRANSPLANTATION, V83, P1193, DOI 10.1097/01.tp.0000261710.53848.51; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893; Lachmann N, 2009, TRANSPLANTATION, V87, P1505, DOI 10.1097/TP.0b013e3181a44206; LEVEY AS, 2000, J AM SOC NEPHROL, V11, P828; Locke JE, 2007, AM J TRANSPLANT, V7, P1797, DOI 10.1111/j.1600-6143.2007.01852.x; Moreso F, 1999, NEPHROL DIAL TRANSPL, V14, P930, DOI 10.1093/ndt/14.4.930; Morris PJ, 1999, LANCET, V354, P1147, DOI 10.1016/S0140-6736(99)01104-6; *NAT HLTH SERV BLO, TRANSPL ACT UK 2008; Novitzky D, 1997, TRANSPLANT P, V29, P3770, DOI 10.1016/S0041-1345(97)01149-4; OPELZ G, 1992, TRANSPLANT INT, V5, pS601; Pessione F, 2003, TRANSPLANTATION, V75, P361, DOI 10.1097/01.TP.0000044171.97375.61; Pratschke J, 1999, TRANSPLANTATION, V67, P343, DOI 10.1097/00007890-199902150-00001; Pratschke J, 2000, ANN SURG, V232, P263, DOI 10.1097/00000658-200008000-00017; Rao PS, 2009, TRANSPLANTATION, V88, P231, DOI 10.1097/TP.0b013e3181ac620b; Rudich SM, 2002, TRANSPLANTATION, V74, P1715, DOI 10.1097/01.TP.0000039165.58547.87; Shoskes DA, 1998, TRANSPLANTATION, V66, P1697, DOI 10.1097/00007890-199812270-00022; Taylor CJ, 2010, TRANSPLANTATION, V89, P185, DOI 10.1097/TP.0b013e3181c926f2; Wells AC, 2009, BRIT J SURG, V96, P299, DOI 10.1002/bjs.6485; Wolfe RA, 2009, AM J TRANSPLANT, V9, P869, DOI 10.1111/j.1600-6143.2009.02564.x	33	236	245	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1303	1311		10.1016/S0140-6736(10)60827-6	http://dx.doi.org/10.1016/S0140-6736(10)60827-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20727576				2022-12-28	WOS:000283528600032
J	Mehta, SR; Tanguay, JF; Eikelboom, JW; Jolly, SS; Joyner, CD; Granger, CB; Faxon, DP; Rupprecht, HJ; Budaj, A; Avezum, A; Widimsky, P; Steg, PG; Bassand, JP; Montalescot, G; Macaya, C; Di Pasquale, G; Niemela, K; Ajani, AE; White, HD; Chrolavicius, S; Gao, P; Fox, KAA; Yusuf, S				Mehta, Shamir R.; Tanguay, Jean-Francois; Eikelboom, John W.; Jolly, Sanjit S.; Joyner, Campbell D.; Granger, Christopher B.; Faxon, David P.; Rupprecht, Hans-Jurgen; Budaj, Andrzej; Avezum, Alvaro; Widimsky, Petr; Steg, Philippe Gabriel; Bassand, Jean-Pierre; Montalescot, Gilles; Macaya, Carlos; Di Pasquale, Giuseppe; Niemela, Kari; Ajani, Andrew E.; White, Harvey D.; Chrolavicius, Susan; Gao, Peggy; Fox, Keith A. A.; Yusuf, Salim		CURRENT-OASIS 7 Trial Investigator	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial	LANCET			English	Article							THROMBOTIC STENT OCCLUSION; MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; EUROPEAN-SOCIETY; ISCHEMIC EVENTS; DOUBLE-BLIND; TASK-FORCE; ST; METAANALYSIS; PRETREATMENT	Background Clopidogrel and aspirin are the most commonly used antiplatelet therapies for percutaneous coronary intervention (PCI). We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI. Methods The CURRENT-OASIS 7 trial was undertaken in 597 centres in 39 countries. 25 086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin. Randomisation was done with a 24 h computerised central automated voice response system. The clopidogrel dose comparison was double-blind and the aspirin dose comparison was open label with blinded assessment of outcomes. This prespecified analysis is of the 17 263 individuals who underwent PCI. The primary outcome was cardiovascular death, myocardial infarction, or stroke at 30 days. Analyses were by intention to treat, adjusted for propensity to undergo PCI. This trial is registered with ClinicalTrials.gov, number NCT00335452. Findings 8560 patients were assigned to double-dose and 8703 to standard-dose clopidogrel (8558 and 8702 completed 30-day follow-up, respectively), and 8624 to high-dose and 8639 to low-dose aspirin (8622 and 8638 completed 30-day follow-up, respectively). Compared with the standard dose, double-dose clopidogrel reduced the rate of the primary outcome (330 events [3.9%] vs 392 events [4.5%]; adjusted hazard ratio 0.86, 95% Cl 0.74-0.99, p=0.039) and definite stent thrombosis (58 [0.7%] vs 111 [1.3%]; 0.54 [0.39-0.74], p=0.0001). High-dose and low-dose aspirin did not differ for the primary outcome (356 [4.1%] vs 366 [4.2%]; 0.98, 0.84-1.13, p=0.76). Major bleeding was more common with double-dose than with standard-dose clopidogrel (139 [1.6%] vs 99 [1.1%]; 1.41, 1.09-1.83, p=0.009) and did not differ between high-dose and low-dose aspirin (128 [1.5%] vs 110 [1.3%]; 1-18, 0.92-1.53, p=0.20). Interpretation In patients undergoing PCI for acute coronary syndromes, a 7-day double-dose clopidogrel regimen was associated with a reduction in cardiovascular events and stent thrombosis compared with the standard dose. Efficacy and safety did not differ between high-dose and low-dose aspirin. A double-dose clopidogrel regimen can be considered for all patients with acute coronary syndromes treated with an early invasive strategy and intended early PCI.	[Mehta, Shamir R.; Eikelboom, John W.; Jolly, Sanjit S.; Chrolavicius, Susan; Gao, Peggy; Yusuf, Salim] McMaster Univ, Hamilton, ON, Canada; [Mehta, Shamir R.; Eikelboom, John W.; Jolly, Sanjit S.; Chrolavicius, Susan; Gao, Peggy; Yusuf, Salim] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Tanguay, Jean-Francois] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; [Tanguay, Jean-Francois] Univ Montreal, Montreal, PQ, Canada; [Joyner, Campbell D.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Granger, Christopher B.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Faxon, David P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Rupprecht, Hans-Jurgen] Med Clin 2, Russelsheim, Germany; [Budaj, Andrzej] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland; [Avezum, Alvaro] Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil; [Widimsky, Petr] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Steg, Philippe Gabriel] Univ Paris 07, INSERM, U698, Paris, France; [Steg, Philippe Gabriel] AP HP, Paris, France; [Bassand, Jean-Pierre] Univ Hosp Jean Minjoz, Besancon, France; [Montalescot, Gilles] Univ Paris 06, Pitie Salpetriere Hosp, INSERM, Inst Cardiol,CMR937, Paris, France; [Macaya, Carlos] Univ Hosp Clin San Carlos, Madrid, Spain; [Di Pasquale, Giuseppe] Maggiore Hosp, Bologna, Italy; [Ajani, Andrew E.] Univ Melbourne, Royal Melbourne Hosp, Melbourne, Vic 3050, Australia; [White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand; [Widimsky, Petr] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Widimsky, Petr] Tampere Univ Hosp, Ctr Heart, Tampere, Finland; [Fox, Keith A. A.] Univ Edinburgh, Royal Infirm, Edinburgh EH3 9YW, Midlothian, Scotland	McMaster University; McMaster University; Population Health Research Institute; Universite de Montreal; Universite de Montreal; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Duke University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Centre of Postgraduate Medical Education - Poland; Instituto Dante Pazzanese de Cardiologia; University Hospital Vinohrady; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite de Franche-Comte; CHU Besancon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Hospital Clinico San Carlos; AUSL di Bologna; Royal Melbourne Hospital; University of Melbourne; Auckland City Hospital; University Hospital Vinohrady; Tampere University; Tampere University Hospital; Royal Infirmary of Edinburgh; University of Edinburgh	Mehta, SR (corresponding author), Hamilton Gen Hosp, Vasc & Stroke Inst, Room 3-119,237 Barton St E, Hamilton, ON L8L 2X2, Canada.	smehta@mcmaster.ca	Granger, Christopher B/D-3458-2014; Widimsky, Petr/P-8088-2016; Avezum, Alvaro AA/K-6137-2016; Avezum, Alvaro/AAP-7687-2020; Eikelboom, John/AAG-6117-2019; Fox, keith A A/I-3742-2013; Jolly, Sanjit/O-2534-2015; Benedek, Theodora/F-6353-2016; Benedek, Imre/E-7052-2017; STEG, Philippe Gabriel/Z-1567-2019	Granger, Christopher B/0000-0002-0045-3291; Widimsky, Petr/0000-0001-5686-7752; Avezum, Alvaro AA/0000-0002-3073-6890; Eikelboom, John/0000-0003-4126-1285; Benedek, Theodora/0000-0001-8326-1537; Benedek, Imre/0000-0003-0051-4047; Budaj, Andrzej/0000-0002-6395-2098; Naslund, Ulf/0000-0003-4100-8298; Fox, Keith/0000-0002-0140-2752; Yusuf, Salim/0000-0003-4776-5601; Lanas, Fernando/0000-0003-3595-9759; STEG, Philippe Gabriel/0000-0001-6896-2941	Sanofi-Aventis; Bristol-Myers Squibb; AstraZeneca; Astellas; Eli Lilly; GlaxoSmithKline; Pfizer; Abbott Vascular; Accumetrics; Boehringer Ingelheim; Medtronic; Medicines Company; Hoffmann LaRoche; Novartis; Merck; Duke University; Boston Scientific; Johnson and Johnson; Servier; Bayer; Daiichi-Sankyo-Lilly; Otsuka; Roche; Schering-Plough; Cordis; Federation Francaise de Cardiologie; Fondation de France; Guerbet Medical; INSERM; ITC Edison; Metronic; SFC; Stago; Eisai; Menarini; Portola; Merck Sharpe Dohme; Daiichi-Sankyo Pharma; National Institutes of Health	Sanofi-Aventis(Sanofi-Aventis); Bristol-Myers Squibb(Bristol-Myers Squibb); AstraZeneca(AstraZeneca); Astellas(Astellas Pharmaceuticals); Eli Lilly(Eli Lilly); GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Abbott Vascular(Abbott Laboratories); Accumetrics; Boehringer Ingelheim(Boehringer Ingelheim); Medtronic(Medtronic); Medicines Company; Hoffmann LaRoche(Hoffmann-La Roche); Novartis(Novartis); Merck(Merck & Company); Duke University; Boston Scientific(Boston Scientific); Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Servier(Servier); Bayer(Bayer AG); Daiichi-Sankyo-Lilly(Daiichi Sankyo Company LimitedEli Lilly); Otsuka(Otsuka Pharmaceutical); Roche(Roche Holding); Schering-Plough(Merck & CompanySchering Plough Corporation); Cordis; Federation Francaise de Cardiologie; Fondation de France(Fondation de France); Guerbet Medical; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ITC Edison; Metronic; SFC; Stago; Eisai(Eisai Co Ltd); Menarini(Menarini Group); Portola; Merck Sharpe Dohme(Merck & Company); Daiichi-Sankyo Pharma(Daiichi Sankyo Company Limited); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	SRM reports receiving institutional research grants from Sanofi-Aventis and Bristol-Myers Squibb; and consulting fees or honoraria from AstraZeneca, Astellas, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and Sanofi-Aventis. J-FT reports receiving institutional research grants from Abbott Vascular, Accumetrics, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Sanofi-Aventis; consulting fees or honoraria from Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Sanofi-Aventis; and payment for development of educational presentations from Abbott Vascular, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Sanofi-Aventis. SSJ reports receiving institutional research grants from Sanofi-Aventis and Bristol-Myers Squibb; and consulting fees or honoraria, and payment for development of educational presentations, from Sanofi-Aventis. (WE reports receiving institutional research grants from Bristol-Myers Squibb and Sanofi-Aventis; consulting fees or honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, and Sanofi-Aventis; and is a member of the advisory board for Bristol-Myers Squibb and Sanofi-Aventis. CDJ reports receiving institutional research grants from Bristol-Myers Squibb and Sanofi-Aventis. CBG reports receiving institutional research grants from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Medtronic, Sanofi-Aventis, Astellas, and The Medicines Company; consulting fees or honoraria from Sanofi-Aventis, Boehringer Ingelheim, Bristol-Myers Squibb, The Medicines Company, Hoffmann LaRoche, GlaxoSmithKline, Novartis, and Merck; and an institutional grant from Duke University. DPF reports receiving consulting fees or honoraria from Boston Scientific and Johnson and Johnson; and holds stock options for REVA Medical. H-JR reports receiving research grants from Sanofi-Aventis and Bristol-Myers Squibb; and consulting fees or honoraria from Sanofi-Aventis and Bristol-Myers Squibb. AB reports receiving institutional research grants from Sanofi-Aventis, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Bristol-Myers Squibb; consulting fees or honoraria from Sanofi-Aventis, Eli Lilly, AstraZeneca, and Novarits; and payments for development of educational presentations and travel from Sanofi-Aventis, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. PGS reports receiving institutional research grants Servier, consulting fees or honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Merck, Otsuka, Roche, Sanofi-Aventis, Servier, and The Medicines Company; and stock options in Aterovax. J-PB reports receiving consulting fees and honoraria from Sanofi-Aventis, Lilly, GlaxoSmithKline, Servier, AstraZeneca, and Schering-Plough. GM reports receiving institutional research grants from Abbott Vascular, Bristol-Myers Squibb, Boston Scientific, Cordis, Eli Lilly, Federation Francaise de Cardiologie, Fondation de France, Guerbet Medical, INSERM, ITC Edison, Metronic, Pfizer, Sanofi-Aventis, SFC, and Stago; and consulting fees or honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Eisai, Eli Lilly, Menarini, Novartis, Pfizer, Portola, Sanofi-Aventis, Schering Plough, and The Medicines Company. GDP reports receiving consulting fees or honoraria from Boehringer Ingelheim.; HDW reports receiving institutional research grants from Sanofi-Aventis, Eli Lilly, The Medicines Company, Pfzer, Roche, Johnson and Johnson, Schering-Plough, Merck Sharpe & Dohme, AstraZeneca, Daiichi-Sankyo Pharma, Bristol-Myers Squibb, and National Institutes of Health; and consultant fees or honoraria from Regado Biosciences. KAAF reports receiving institutional research grants from Sanofi-Aventis and consultancy fees or honoraria from Sanofi-Aventis and Bristol-Myers Squibb. SY reports receiving institutional research grants from Sanofi-Aventis and Bristol-Myers Squibb; and consulting fees or honoraria from Sanofi-Aventis, Bristol-Myers Squibb, Novartis, AstraZeneca, Boehringer Ingelheim, and Novartis. AA, CM, KN, AEA, SC, PW, and PG declare that they have no conflicts of interest.	Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028; Angiolillo DJ, 2004, EUR HEART J, V25, P1903, DOI 10.1016/j.ehj.2004.07.036; Angiolillo DJ, 2007, CIRCULATION, V115, P708, DOI 10.1161/CIRCULATIONAHA.106.667741; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Bavry AA, 2006, J AM COLL CARDIOL, V48, P1319, DOI 10.1016/j.jacc.2006.06.050; Cannon CP, 2010, LANCET, V375, P283, DOI 10.1016/S0140-6736(09)62191-7; Chen ZM, 2005, LANCET, V366, P1607, DOI 10.1016/s0140-6736(05)67660-x; Cuisset T, 2006, J AM COLL CARDIOL, V48, P1339, DOI 10.1016/j.jacc.2006.06.049; *CURRENT OASIS 7, N ENGL J ME IN PRESS; Cutlip DE, 2001, CIRCULATION, V103, P1967; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; FOX KA, 2006, BMJ-BRIT MED J, V333, P1091, DOI DOI 10.1136/BMJ.38985.646481.55; Harrington RA, 2008, CHEST, V133, p670S, DOI 10.1378/chest.08-0691; Hochholzer W, 2005, CIRCULATION, V111, P2560, DOI 10.1161/01.CIR.0000160869.75810.98; Jolly SS, 2009, EUR HEART J, V30, P900, DOI 10.1093/eurheartj/ehn417; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; King Spencer B 3rd, 2008, J Am Coll Cardiol, V51, P172, DOI 10.1016/j.jacc.2007.10.002; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Lotrionte M, 2007, AM J CARDIOL, V100, P1199, DOI 10.1016/j.amjcard.2007.05.048; Mehta SR, 2009, NEW ENGL J MED, V360, P2165, DOI 10.1056/NEJMoa0807986; Mehta SR, 2008, AM HEART J, V156, P1080, DOI 10.1016/j.ahj.2008.07.026; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P2908, DOI 10.1001/jama.293.23.2908; Montalescot G, 2006, J AM COLL CARDIOL, V48, P931, DOI 10.1016/j.jacc.2006.04.090; Muller I, 2001, HEART, V85, P92, DOI 10.1136/heart.85.1.92; Ong ATL, 2005, J AM COLL CARDIOL, V45, P947, DOI 10.1016/j.jacc.2004.09.079; Patti G, 2005, CIRCULATION, V111, P2099, DOI 10.1161/01.CIR.0000161383.06692.D4; Peters RJG, 2003, CIRCULATION, V108, P1682, DOI 10.1161/01.CIR.0000091201.39590.CB; Regar E, 2004, AM J CARDIOL, V93, P1271, DOI 10.1016/j.amjcard.2004.02.013; Reynolds Matthew R, 2002, J Invasive Cardiol, V14, P364; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Sabatine MS, 2005, JAMA-J AM MED ASSOC, V294, P1224, DOI 10.1001/jama.294.10.1224; Silber S, 2005, EUR HEART J, V26, P804, DOI 10.1093/eurheartj/ehi138; Topol EJ, 2003, CIRCULATION, V108, P399, DOI 10.1161/01.CIR.0000084501.48570.F6; von Beckerath N, 2005, CIRCULATION, V112, P2946, DOI 10.1161/CIRCULATIONAHA.105.559088; Von Beckerath N, 2007, EUR HEART J, V28, P1814, DOI 10.1093/eurheartj/ehl489; Wiviott SD, 2008, LANCET, V371, P1353, DOI 10.1016/S0140-6736(08)60422-5; Yusuf S, 2001, NEW ENGL J MED, V345, P494	39	609	675	0	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2010	376	9748					1233	1243		10.1016/S0140-6736(10)61088-4	http://dx.doi.org/10.1016/S0140-6736(10)61088-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZT	20817281				2022-12-28	WOS:000283003500033
J	Katsnelson, MI				Katsnelson, Mikhail I.			Just Add Water	SCIENCE			English	Editorial Material							GRAPHENE; MEMBRANES		Radboud Univ Nijmegen, Inst Mol & Mat, NL-6525 AJ Nijmegen, Netherlands	Radboud University Nijmegen	Katsnelson, MI (corresponding author), Radboud Univ Nijmegen, Inst Mol & Mat, NL-6525 AJ Nijmegen, Netherlands.	m.katsnelson@science.ru.nl	Katsnelson, Mikhail I./D-4359-2012					Booth TJ, 2008, NANO LETT, V8, P2442, DOI 10.1021/nl801412y; Bunch JS, 2008, NANO LETT, V8, P2458, DOI 10.1021/nl801457b; Feibelman PJ, 2010, PHYS TODAY, V63, P34, DOI 10.1063/1.3326987; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Geim AK, 2009, SCIENCE, V324, P1530, DOI 10.1126/science.1158877; Katsnelson MI, 2007, MATER TODAY, V10, P20, DOI 10.1016/S1369-7021(06)71788-6; Sabio J, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.195409; THIEL PA, 1987, SURF SCI REP, V7, P211, DOI 10.1016/0167-5729(87)90001-X; Verdaguer A, 2006, CHEM REV, V106, P1478, DOI 10.1021/cr040376l; Wehling TO, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3033202; Xu K, 2010, SCIENCE, V329, P1188, DOI 10.1126/science.1192907	11	7	7	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2010	329	5996					1157	1158		10.1126/science.1195392	http://dx.doi.org/10.1126/science.1195392			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645SG	20813943				2022-12-28	WOS:000281485600021
J	Cejka, P; Cannavo, E; Polaczek, P; Masuda-Sasa, T; Pokharel, S; Campbell, JL; Kowalczykowski, SC				Cejka, Petr; Cannavo, Elda; Polaczek, Piotr; Masuda-Sasa, Taro; Pokharel, Subhash; Campbell, Judith L.; Kowalczykowski, Stephen C.			DNA end resection by Dna2-Sgs1-RPA and its stimulation by Top3-Rmi1 and Mre11-Rad50-Xrs2	NATURE			English	Article							REPLICATION-PROTEIN-A; DOUBLE-STRAND BREAKS; RECOMBINATIONAL REPAIR; MRE11 NUCLEASE; RECQ HELICASE; RECBCD ENZYME; BLM HELICASE; IN-VIVO; SGS1; YEAST	The repair of DNA double-strand breaks (DSBs) by homologous recombination requires processing of broken ends. For repair to start, the DSB must first be resected to generate a 3'-single-stranded DNA (ssDNA) overhang, which becomes a substrate for the DNA strand exchange protein, Rad51 (ref. 1). Genetic studies have implicated a multitude of proteins in the process, including helicases, nucleases and topoisomerases(2-4). Here we biochemically reconstitute elements of the resection process and reveal that it requires the nuclease Dna2, the RecQ-family helicase Sgs1 and the ssDNA-binding protein replication protein-A (RPA). We establish that Dna2, Sgs1 and RPA constitute a minimal protein complex capable of DNA resection in vitro. Sgs1 helicase unwinds the DNA to produce an intermediate that is digested by Dna2, and RPA stimulates DNA unwinding by Sgs1 in a species-specific manner. Interestingly, RPA is also required both to direct Dna2 nucleolytic activity to the 5'-terminated strand of the DNA break and to inhibit 39 to 59 degradation by Dna2, actions that generate and protect the 3'-ssDNA overhang, respectively. In addition to this core machinery, we establish that both the topoisomerase 3 (Top3) and Rmi1 complex and the Mre11-Rad50-Xrs2 complex (MRX) have important roles as stimulatory components. Stimulation of end resection by the Top3-Rmi1 heterodimer and the MRX proteins is by complex formation with Sgs1 (refs 5, 6), which unexpectedly stimulates DNA unwinding. We suggest that Top3-Rmi1 and MRX are important for recruitment of the Sgs1-Dna2 complex to DSBs. Our experiments provide a mechanistic framework for understanding the initial steps of recombinational DNA repair in eukaryotes.	[Cejka, Petr; Cannavo, Elda; Kowalczykowski, Stephen C.] Univ Calif Davis, Dept Microbiol, Davis, CA 95616 USA; [Cejka, Petr; Cannavo, Elda; Kowalczykowski, Stephen C.] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; [Polaczek, Piotr; Masuda-Sasa, Taro; Pokharel, Subhash; Campbell, Judith L.] CALTECH, Div Biol, Pasadena, CA 91125 USA	University of California System; University of California Davis; University of California System; University of California Davis; California Institute of Technology	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Dept Microbiol, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu	Cejka, Petr/B-4829-2009	Cejka, Petr/0000-0002-9087-032X	Swiss National Science Foundation; National Institutes of Health [GM-78666, GM-41347, GM-62653]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347, R37GM062653, R01GM078666, R01GM062653] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J.-B. Boule, A. Nicolas, X. Veaute, B. Rad, J. L. Plank and P. Sung for purified proteins and DNA substrates, L. Symington for discussions, and W. D. Heyer and the members of the Kowalczykowski and Campbell laboratories for their comments on the manuscript. We are particularly grateful to P. Sung and colleagues for communicating their results to us before their publication. This work was supported by a Swiss National Science Foundation Fellowship (to P. C.), and National Institutes of Health grants GM-78666 (to J. L. C.), GM-41347 (to S. C. K.) and GM-62653 (to S.C.K.).	ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Bae KH, 2003, NUCLEIC ACIDS RES, V31, P3006, DOI 10.1093/nar/gkg422; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Budd ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004267; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; CEJKA P, NAT STRUCT IN PRESS; Cejka Petr, 2010, J Biol Chem, V285, P8290, DOI 10.1074/jbc.M109.083196; Chang M, 2005, EMBO J, V24, P2024, DOI 10.1038/sj.emboj.7600684; Chiolo I, 2005, MOL CELL BIOL, V25, P5738, DOI 10.1128/MCB.25.13.5738-5751.2005; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Dillingham MS, 2008, MICROBIOL MOL BIOL R, V72, P642, DOI 10.1128/MMBR.00020-08; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Handa N, 2009, GENE DEV, V23, P1234, DOI 10.1101/gad.1780709; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Hartsuiker E, 2009, MOL CELL, V33, P117, DOI 10.1016/j.molcel.2008.11.021; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; LEBOWITZ JH, 1985, THESIS J HOPKINS U; Li X, 2009, MOL CELL, V36, P704, DOI 10.1016/j.molcel.2009.09.036; Llorente B, 2004, MOL CELL BIOL, V24, P9682, DOI 10.1128/MCB.24.21.9682-9694.2004; Masuda-Sasa T, 2008, J BIOL CHEM, V283, P24359, DOI 10.1074/jbc.M802244200; Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312; Mullen JR, 2005, MOL CELL BIOL, V25, P4476, DOI 10.1128/MCB.25.11.4476-4487.2005; Neale MJ, 2005, NATURE, V436, P1053, DOI 10.1038/nature03872; Nimonkar AV, 2008, P NATL ACAD SCI USA, V105, P16906, DOI 10.1073/pnas.0809380105; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037; Zierhut C, 2008, EMBO J, V27, P1875, DOI 10.1038/emboj.2008.111	35	333	341	3	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					112	U149		10.1038/nature09355	http://dx.doi.org/10.1038/nature09355			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811461	Green Submitted, Green Accepted			2022-12-28	WOS:000281461200046
J	Niu, HY; Chung, WH; Zhu, Z; Kwon, Y; Zhao, WX; Chi, P; Prakash, R; Seong, CH; Liu, DQ; Lu, L; Ira, G; Sung, P				Niu, Hengyao; Chung, Woo-Hyun; Zhu, Zhu; Kwon, Youngho; Zhao, Weixing; Chi, Peter; Prakash, Rohit; Seong, Changhyun; Liu, Dongqing; Lu, Lucy; Ira, Grzegorz; Sung, Patrick			Mechanism of the ATP-dependent DNA end-resection machinery from Saccharomyces cerevisiae	NATURE			English	Article							REPLICATION-PROTEIN-A; HOMOLOGOUS RECOMBINATION; BREAK REPAIR; IN-VITRO; YEAST; HELICASE; MRE11; SGS1; RECOGNITION; MAINTENANCE	If not properly processed and repaired, DNA double-strand breaks (DSBs) can give rise to deleterious chromosome rearrangements, which could ultimately lead to the tumour phenotype(1,2). DSB ends are resected in a 5' to 3' fashion in cells, to yield single-stranded DNA (ssDNA) for the recruitment of factors critical for DNA damage checkpoint activation and repair by homologous recombination 2. The resection process involves redundant pathways consisting of nucleases, DNA helicases and associated proteins(3). Being guided by recent genetic studies(4-6), we have reconstituted the first eukaryotic ATP-dependent DNA end-resection machinery comprising the Saccharomyces cerevisiae Mre11-Rad50-Xrs2 (MRX) complex, the Sgs1-Top3-Rmi1 complex, Dna2 protein and the heterotrimeric ssDNA-binding protein RPA. Here we show that DNA strand separation during end resection is mediated by the Sgs1 helicase function, in a manner that is enhanced by Top3-Rmi1 and MRX. In congruence with genetic observations(6), although the Dna2 nuclease activity is critical for resection, the Mre11 nuclease activity is dispensable. By examining the top3 Y356F allele and its encoded protein, we provide evidence that the topoisomerase activity of Top3, although critical for the suppression of crossover recombination(2,7), is not needed for resection either in cells or in the reconstituted system. Our results also unveil a multifaceted role of RPA, in the sequestration of ssDNA generated by DNA unwinding, enhancement of 5' strand incision, and protection of the 3' strand. Our reconstituted system should serve as a useful model for delineating the mechanistic intricacy of the DNA break resection process in eukaryotes.	[Chung, Woo-Hyun; Zhu, Zhu; Ira, Grzegorz] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Niu, Hengyao; Kwon, Youngho; Zhao, Weixing; Chi, Peter; Prakash, Rohit; Seong, Changhyun; Liu, Dongqing; Lu, Lucy; Sung, Patrick] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Baylor College of Medicine; Yale University	Ira, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	gira@bcm.edu; patrick.sung@yale.edu	Niu, Hengyao/AAE-9269-2020; zhao, weixing/H-3154-2013; Niu, Hengyao/J-4593-2013; Niu, Hengyao/B-5026-2014; Chi, Peter/AAI-1580-2019; Classen, Scott/AAY-8176-2020; Huang, Wenchi/F-3981-2010	Chi, Peter/0000-0001-9229-8729; Huang, Wenchi/0000-0001-5556-1460; zhao, weixing/0000-0001-5746-3696	US National Institutes of Health; Susan G. Komen for the Cure Foundation; NATIONAL CANCER INSTITUTE [R01CA146940, P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015252, R01ES007061, R01ES015632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814, R01GM080600] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Campbell, S. Brill and L. Symington for providing materials, X. Xue for the double Holliday junction substrate and S. Kowalczykowski for communicating results. This work was supported by grants from the US National Institutes of Health and by a postdoctoral fellowship from the Susan G. Komen for the Cure Foundation.	Bae KH, 2003, NUCLEIC ACIDS RES, V31, P3006, DOI 10.1093/nar/gkg422; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bressan DA, 1998, GENETICS, V150, P591; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Chen CF, 2007, J BIOL CHEM, V282, P28971, DOI 10.1074/jbc.M705427200; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Chiolo I, 2005, MOL CELL BIOL, V25, P5738, DOI 10.1128/MCB.25.13.5738-5751.2005; Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Masuda-Sasa T, 2008, J BIOL CHEM, V283, P24359, DOI 10.1074/jbc.M802244200; Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312; Mimitou EP, 2009, TRENDS BIOCHEM SCI, V34, P264, DOI 10.1016/j.tibs.2009.01.010; Moreau S, 1999, MOL CELL BIOL, V19, P556; Niu HY, 2009, GENE DEV, V23, P1481, DOI 10.1101/gad.1824209; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Trujillo KM, 2003, J BIOL CHEM, V278, P48957, DOI 10.1074/jbc.M309877200; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	29	279	282	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2010	467	7311					108	U143		10.1038/nature09318	http://dx.doi.org/10.1038/nature09318			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	645MB	20811460	Green Accepted			2022-12-28	WOS:000281461200045
J	Machlis, GE; McNutt, MK				Machlis, Gary E.; McNutt, Marcia K.			Scenario-Building for the Deepwater Horizon Oil Spill	SCIENCE			English	Editorial Material							CONSERVATION		[Machlis, Gary E.] US Dept Interior, Strateg Sci Working Grp, Washington, DC 20024 USA; [Machlis, Gary E.] Natl Pk Serv, Washington, DC 20024 USA; [McNutt, Marcia K.] US Geol Survey, Washington, DC 20024 USA	United States Department of the Interior; United States Department of the Interior; United States Department of the Interior; United States Geological Survey	Machlis, GE (corresponding author), US Dept Interior, Strateg Sci Working Grp, Washington, DC 20024 USA.	gary_machlis@nps.gov		McNutt, Marcia/0000-0003-0117-7716; Machlis, Gary/0000-0002-8915-5695				Burley D, 2007, ORGAN ENVIRON, V20, P347, DOI 10.1177/1086026607305739; Castillo S. A., 1996, J COAST CONSERV, V2, P13, DOI DOI 10.1007/BF02743033; Chermack T.J., 2001, FUTURES RES Q, V17, P7, DOI DOI 10.1016/j.futures.2005.12.010; Colten C.E., 2008, COMMUNITY RESILIENCE; *DEP INT, 2010, STRAT SCI WORK GROUP; Felder D. L., 2009, GULF MEXICO ORIGIN W, V1, P1; Holling C.S., 1973, Annual Rev Ecol Syst, V4, P1, DOI 10.1146/annurev.es.04.110173.000245; Kates RW, 2006, P NATL ACAD SCI USA, V103, P14653, DOI 10.1073/pnas.0605726103; Kates RW., 1977, RECONSTRUCTION FOLLO, P261; KHAN H, 1965, THINKING UNTHINKABLE; Machlis GE, 1997, SOC NATUR RESOUR, V10, P347, DOI 10.1080/08941929709381034; MAGUIRE JJ, 2005, FISHERIES TOPICS ECO; Peterson GD, 2003, CONSERV BIOL, V17, P358, DOI 10.1046/j.1523-1739.2003.01491.x; Rabalais NN, 2001, J ENVIRON QUAL, V30, P320, DOI 10.2134/jeq2001.302320x; Robison BH, 2009, CONSERV BIOL, V23, P847, DOI 10.1111/j.1523-1739.2009.01219.x; Sheppard ES., 2004, SCALE GEOGRAPHIC INQ, DOI [10.1002/9780470999141, DOI 10.1002/9780470999141]; Tibbetts J, 2004, ENVIRON HEALTH PERSP, V112, pA282, DOI 10.1289/ehp.112-a282; *US DOI, DEEPW HOR RESP; Wang D, 2005, SCIENCE, V308, P1036, DOI 10.1126/science.1108791; [No title captured], DOI DOI 10.1093/LPR/2.1.25	20	32	32	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2010	329	5995					1018	1019		10.1126/science.1195382	http://dx.doi.org/10.1126/science.1195382			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798302				2022-12-28	WOS:000281253500020
J	Yuan, HY; Romanowicz, B				Yuan, Huaiyu; Romanowicz, Barbara			Lithospheric layering in the North American craton	NATURE			English	Article							AZIMUTHAL ANISOTROPY; SEISMIC ANISOTROPY; UPPER-MANTLE; PETROLOGICAL CONSTRAINTS; CONTINENTAL TECTOSPHERE; ASTHENOSPHERE BOUNDARY; SHEAR VELOCITY; UNITED-STATES; GLOBAL VIEW; WAVE	How cratons-extremely stable continental areas of the Earth's crust-formed and remained largely unchanged for more than 2,500 million years is much debated. Recent studies of seismic-wave receiver function data have detected a structural boundary under continental cratons at depths too shallow to be consistent with the lithosphere-asthenosphere boundary, as inferred from seismic tomography and other geophysical studies. Here we show that changes in the direction of azimuthal anisotropy with depth reveal the presence of two distinct lithospheric layers throughout the stable part of the North American continent. The top layer is thick (similar to 150 km) under the Archaean core and tapers out on the surrounding Palaeozoic borders. Its thickness variations follow those of a highly depleted layer inferred from thermo-barometric analysis of xenoliths. The lithosphere-asthenosphere boundary is relatively flat (ranging from 180 to 240 km in depth), in agreement with the presence of a thermal conductive root that subsequently formed around the depleted chemical layer. Our findings tie together seismological, geochemical and geodynamical studies of the cratonic lithosphere in North America. They also suggest that the horizon detected in receiver function studies probably corresponds to the sharp mid-lithospheric boundary rather than to the more gradual lithosphere-asthenosphere boundary.	[Yuan, Huaiyu; Romanowicz, Barbara] Berkeley Seismol Lab, Berkeley, CA 94720 USA		Romanowicz, B (corresponding author), Berkeley Seismol Lab, 209 McCone Hall, Berkeley, CA 94720 USA.	barbara.romanowicz@gmail.com	Yuan, Huaiyu/E-4231-2010; Romanowicz, barbara A/H-6726-2017	Romanowicz, barbara A/0000-0002-6208-6044; Yuan, Huaiyu/0000-0003-3512-7856	National Science Foundation	National Science Foundation(National Science Foundation (NSF))	We thank the IRIS Data Management Center, the Geological Survey of Canada and the Northern California Earthquake Data Center for providing the waveform data used in this study. Discussion with K. Fischer helped improve the manuscript. We thank K. Liu, R. Allen, M. Fouch, A. Frederiksen and A. Courtier for providing their SKS compilations, and W. Griffin and S. O'Reilly for their North American olivine composition measurements. This study was supported by a grant from the National Science Foundation/EarthScope programme. This is the Berkeley Seismological Laboratory contribution number 10-08.	Abt DL, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006710; Arndt NT, 2009, LITHOS, V109, P61, DOI 10.1016/j.lithos.2008.10.019; BABUSKA V, 1991, SEISMIC ANISOTROPY E, pCH5; Bostock MG, 1998, J GEOPHYS RES-SOL EA, V103, P21183, DOI 10.1029/98JB01069; Canil D, 2008, GSA TODAY, V18, P4, DOI DOI 10.1130/GSAT01806A.1; Carlson RW, 2005, REV GEOPHYS, V43, DOI 10.1029/2004RG000156; Cooper CM, 2004, EARTH PLANET SC LETT, V222, P807, DOI 10.1016/j.epsl.2004.04.008; CULOTTA RC, 1990, GEOLOGY, V18, P646, DOI 10.1130/0091-7613(1990)018<0646:ATOTSC>2.3.CO;2; Darbyshire FA, 2009, GEOPHYS J INT, V176, P215, DOI 10.1111/j.1365-246X.2008.03982.x; Deschamps F, 2008, EARTH PLANET SC LETT, V274, P489, DOI 10.1016/j.epsl.2008.07.058; Griffin WL, 2004, LITHOS, V77, P873, DOI 10.1016/j.lithos.2004.03.034; Griffin WL, 2003, PRECAMBRIAN RES, V127, P19, DOI 10.1016/S0301-9268(03)00180-3; Gripp AE, 2002, GEOPHYS J INT, V150, P321, DOI 10.1046/j.1365-246X.2002.01627.x; Gung YC, 2003, NATURE, V422, P707, DOI 10.1038/nature01559; Haggerty SE, 1999, SCIENCE, V285, P851, DOI 10.1126/science.285.5429.851; HOFFMAN PF, 1988, ANNU REV EARTH PL SC, V16, P543, DOI 10.1146/annurev.ea.16.050188.002551; Jones AG, 2003, LITHOS, V71, P505, DOI 10.1016/j.lithos.2003.08.001; JORDAN TH, 1978, NATURE, V274, P544, DOI 10.1038/274544a0; King SD, 2005, EARTH PLANET SC LETT, V234, P1, DOI 10.1016/j.epsl.2005.03.007; Lee CTA, 2006, GEOPHYS MONOGR SER, V164, P89, DOI 10.1029/164GM08; Lekic V, 2010, GEOPHYS J INT, V182, P265, DOI 10.1111/j.1365-246X.2010.04602.x; LEKIC V, 2009, THESIS U CALIFORNIA; Lenardic A, 2000, GEOPHYS RES LETT, V27, P1235, DOI 10.1029/1999GL008410; Levin V, 1999, J GEOPHYS RES-SOL EA, V104, P17975, DOI 10.1029/1999JB900168; Li AB, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002259; Li AB, 1998, NATURE, V395, P160, DOI 10.1038/25972; LI XD, 1995, GEOPHYS J INT, V121, P695, DOI 10.1111/j.1365-246X.1995.tb06432.x; Long MD, 2008, SCIENCE, V319, P315, DOI 10.1126/science.1150809; Mareschal JC, 2004, EARTH PLANET SC LETT, V223, P65, DOI 10.1016/j.epsl.2004.04.002; Marone F, 2007, GEOPHYS J INT, V171, P206, DOI 10.1111/j.1365-246X.2007.03465.x; Marone F, 2007, NATURE, V447, P198, DOI 10.1038/nature05742; Megnin C, 2000, GEOPHYS J INT, V143, P709, DOI 10.1046/j.1365-246X.2000.00298.x; Mierdel K, 2007, SCIENCE, V315, P364, DOI 10.1126/science.1135422; MONTAGNER JP, 1986, J GEOPHYS RES-SOLID, V91, P511, DOI 10.1029/JB091iB01p00511; MONTAGNER JP, 1989, PHYS EARTH PLANET IN, V54, P82, DOI 10.1016/0031-9201(89)90189-1; MONTAGNER JP, 1988, GEOPHYS J INT, V94, P295, DOI 10.1111/j.1365-246X.1988.tb05903.x; Montagner JP, 2000, J GEOPHYS RES-SOL EA, V105, P19015, DOI 10.1029/2000JB900015; Panning M, 2006, GEOPHYS J INT, V167, P361, DOI 10.1111/j.1365-246X.2006.03100.x; Percival J. A., 2006, CAN J EARTH SCI, V43, DOI [10. 1139/E1106-1062, DOI 10.1139/E1106-1062]; Plomerova J., 2010, LITHOS IN PRESS, DOI [10. 1016/j. lithos. 2010. 1001. 1008, DOI 10.1016/J.LITHOS.2010.1001.1008]; Romanowicz B, 2009, SCIENCE, V324, P474, DOI 10.1126/science.1172879; Rychert CA, 2005, NATURE, V436, P542, DOI 10.1038/nature03904; Rychert CA, 2009, SCIENCE, V324, P495, DOI 10.1126/science.1169754; Shapiro SS, 1999, LITHOS, V48, P135, DOI 10.1016/S0024-4937(99)00027-4; SILVER PG, 1991, J GEOPHYS RES-SOL EA, V96, P16429, DOI 10.1029/91JB00899; Sleep NH, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000169; Sleep NH, 2009, GEOCHEM GEOPHY GEOSY, V10, DOI 10.1029/2009GC002702; Snyder DB, 2002, TECTONOPHYSICS, V355, P7, DOI 10.1016/S0040-1951(02)00131-2; St-Onge MR, 2007, J PETROL, V48, P271, DOI 10.1093/petrology/egl060; TARANTOLA A, 1982, REV GEOPHYS, V20, P219, DOI 10.1029/RG020i002p00219; Thybo H, 1997, SCIENCE, V275, P1626, DOI 10.1126/science.275.5306.1626; van der Velden AJ, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003333; VINNIK LP, 1992, GEOPHYS J INT, V111, P433, DOI 10.1111/j.1365-246X.1992.tb02102.x; Whitmeyer SJ, 2007, GEOSPHERE, V3, P220, DOI 10.1130/GES00055.1; YUAN H, EARTH PLANET S UNPUB; YUAN H, GEOPHYS J INT UNPUB; Yuan HY, 2005, GEOPHYS MONOGR SER, V154, P329, DOI 10.1029/154GM25; Yuan XH, 2006, GEOPHYS J INT, V165, P555, DOI 10.1111/j.1365-246X.2006.02885.x	58	374	382	3	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					1063	U68		10.1038/nature09332	http://dx.doi.org/10.1038/nature09332			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740006				2022-12-28	WOS:000281203600031
J	Farmer, JA; Campbell, CT				Farmer, Jason A.; Campbell, Charles T.			Ceria Maintains Smaller Metal Catalyst Particles by Strong Metal-Support Bonding	SCIENCE			English	Article							WATER-GAS-SHIFT; METHANE OXIDATION; GOLD; PLATINUM; MODEL; MGO; CO; NANOPARTICLES; ADSORPTION; MICROSCOPY	The energies of silver (Ag) atoms in Ag nanoparticles supported on different cerium and magnesium oxide surfaces, determined from previous calorimetric measurements of metal adsorption energies, were analyzed with respect to particle size. Their stability was found to increase with particle size below 5000 atoms per particle. Silver nanoparticles of any given size below 1000 atoms had much higher stability (30 to 70 kilojoules per mole of silver atoms) on reduced CeO(2)(111) than on MgO(100). This effect is the result of the very large adhesion energy (similar to 2.3 joules per square meter) of Ag nanoparticles to reduced CeO(2)(111), which we found to be a result of strong bonding to both defects and CeO(2)(111) terraces, apparently localized by lattice strain. These results explain the unusual sinter resistance of late transition metal catalysts when supported on ceria.	[Farmer, Jason A.; Campbell, Charles T.] Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Campbell, CT (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	campbell@chem.washington.edu			U.S. Department of Energy, Office of Basic Energy Sciences, Chemical Sciences Division [DE-FG02-96ER14630]; Center for Nanotechnology, University of Washington [DGE-0504573]	U.S. Department of Energy, Office of Basic Energy Sciences, Chemical Sciences Division(United States Department of Energy (DOE)); Center for Nanotechnology, University of Washington(University of Washington)	Supported by the U.S. Department of Energy, Office of Basic Energy Sciences, Chemical Sciences Division, grant DE-FG02-96ER14630, and by, NSF Integrative Graduate Education and Research Traineeship DGE-0504573 from the Center for Nanotechnology, University of Washington (J.A.F.).	Bozo C, 2001, J CATAL, V203, P393, DOI 10.1006/jcat.2001.3320; Bunluesin T, 1998, APPL CATAL B-ENVIRON, V15, P107, DOI 10.1016/S0926-3373(97)00040-4; Campbell CT, 2002, SCIENCE, V298, P811, DOI 10.1126/science.1075094; COULTER K, 1994, J PHYS CHEM-US, V98, P1245, DOI 10.1021/j100055a033; Deluga GA, 2004, SCIENCE, V303, P993, DOI 10.1126/science.1093045; Farmer JA, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.035418; Farmer JA, 2010, J PHYS CHEM C, V114, P17166, DOI 10.1021/jp104593y; Farmer JA, 2009, J AM CHEM SOC, V131, P3098, DOI 10.1021/ja808986b; Farrauto R, 2003, ANNU REV MATER RES, V33, P1, DOI 10.1146/annurev.matsci.33.022802.091348; Freund HJ, 2007, SURF SCI, V601, P1438, DOI 10.1016/j.susc.2007.01.025; Fu Q, 2001, CATAL LETT, V77, P87, DOI 10.1023/A:1012666128812; Giordano L, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.115403; GOODMAN DW, 1995, CHEM REV, V95, P523, DOI 10.1021/cr00035a004; Haruta M, 2002, CATTECH, V6, P102, DOI 10.1023/A:1020181423055; Haruta M, 1997, CATAL TODAY, V36, P153, DOI 10.1016/S0920-5861(96)00208-8; Hilaire S, 2001, APPL CATAL A-GEN, V215, P271, DOI 10.1016/S0926-860X(01)00535-X; KALAKKAD D, 1992, APPL CATAL B-ENVIRON, V1, P191, DOI 10.1016/0926-3373(92)80023-S; Kundakovic L, 1998, J CATAL, V179, P203, DOI 10.1006/jcat.1998.2213; Larsen JH, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.195410; Liu XS, 2002, APPL CATAL A-GEN, V226, P293, DOI 10.1016/S0926-860X(01)00915-2; Lu JL, 2006, SURF SCI, V600, P5004, DOI 10.1016/j.susc.2006.08.023; OH SH, 1991, J CATAL, V132, P287, DOI 10.1016/0021-9517(91)90149-X; Parker SC, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.035430; Ricci D, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.036106; Rodriguez JA, 2007, TOP CATAL, V44, P73, DOI 10.1007/s11244-007-0280-1; ROMEO M, 1993, SURF INTERFACE ANAL, V20, P508, DOI 10.1002/sia.740200604; Sanchez A, 1999, J PHYS CHEM A, V103, P9573, DOI 10.1021/jp9935992; SCHWARTZ JM, 1992, J CATAL, V138, P283, DOI 10.1016/0021-9517(92)90023-B; Sepulveda-Escribano A, 1998, J CATAL, V178, P649, DOI 10.1006/jcat.1998.2199; Starr DE, 2001, J CHEM PHYS, V114, P3752, DOI 10.1063/1.1337097; Tibiletti D, 2004, CHEM COMMUN, P1636, DOI 10.1039/b403438d; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Valden M, 1998, CATAL LETT, V56, P7, DOI 10.1023/A:1019028205985; VENABLES JA, 1994, SURF SCI, V299, P798, DOI 10.1016/0039-6028(94)90698-X; Vijay A, 2003, J CHEM PHYS, V118, P6536, DOI 10.1063/1.1557919; Wahlstrom E, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.026101; Wang JH, 2006, SOLID STATE IONICS, V177, P939, DOI 10.1016/j.ssi.2006.02.029; Yan Z, 2005, J AM CHEM SOC, V127, P1604, DOI 10.1021/ja043652m; Yoon B, 2005, SCIENCE, V307, P403, DOI 10.1126/science.1104168	39	649	660	24	807	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2010	329	5994					933	936		10.1126/science.1191778	http://dx.doi.org/10.1126/science.1191778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640WN	20724631				2022-12-28	WOS:000281084800031
J	Tisdale, MJ				Tisdale, Michael J.			Reversing Cachexia	CELL			English	Editorial Material							CANCER CACHEXIA; SKELETAL-MUSCLE	Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.	Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England	Aston University	Tisdale, MJ (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	m.j.tisdale@aston.ac.uk						Bonetto A, 2009, CURR CANCER DRUG TAR, V9, P608, DOI 10.2174/156800909789057015; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Gilson H, 2007, ENDOCRINOLOGY, V148, P452, DOI 10.1210/en.2006-0539; Klimek MEB, 2010, BIOCHEM BIOPH RES CO, V391, P1548, DOI 10.1016/j.bbrc.2009.12.123; Lagirand-Cantaloube J, 2008, EMBO J, V27, P1266, DOI 10.1038/emboj.2008.52; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011	9	38	40	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2010	142	4					511	512		10.1016/j.cell.2010.08.004	http://dx.doi.org/10.1016/j.cell.2010.08.004			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	641HR	20723750	Bronze			2022-12-28	WOS:000281115900003
J	Barbash, GI; Glied, SA				Barbash, Gabriel I.; Glied, Sherry A.			New Technology and Health Care Costs - The Case of Robot-Assisted Surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Barbash, Gabriel I.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Barbash, Gabriel I.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Glied, Sherry A.] Columbia Univ, Mailman Sch Publ Hlth, Dept Hlth Policy & Management, New York, NY USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Columbia University	Barbash, GI (corresponding author), Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.							ALTEKRUSE SF, 1975, SEER CANC STAT REV; Healthcare Cost and Utilization Project, 2020, NAT NAT INP SAMPL NI; Hu JC, 2009, JAMA-J AM MED ASSOC, V302, P1557, DOI 10.1001/jama.2009.1451; NGUYEN PL, 2002, ASCO GEN CANC S 2010; Wilt TJ, 2008, ANN INTERN MED, V148, P435, DOI 10.7326/0003-4819-148-6-200803180-00209	5	623	633	8	83	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					701	704		10.1056/NEJMp1006602	http://dx.doi.org/10.1056/NEJMp1006602			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639TE	20818872				2022-12-28	WOS:000280996600001
J	Lee, JH; Fang, L; Vlahos, E; Ke, XL; Jung, YW; Kourkoutis, LF; Kim, JW; Ryan, PJ; Heeg, T; Roeckerath, M; Goian, V; Bernhagen, M; Uecker, R; Hammel, PC; Rabe, KM; Kamba, S; Schubert, J; Freeland, JW; Muller, DA; Fennie, CJ; Schiffer, P; Gopalan, V; Johnston-Halperin, E; Schlom, DG				Lee, June Hyuk; Fang, Lei; Vlahos, Eftihia; Ke, Xianglin; Jung, Young Woo; Kourkoutis, Lena Fitting; Kim, Jong-Woo; Ryan, Philip J.; Heeg, Tassilo; Roeckerath, Martin; Goian, Veronica; Bernhagen, Margitta; Uecker, Reinhard; Hammel, P. Chris; Rabe, Karin M.; Kamba, Stanislav; Schubert, Juergen; Freeland, John W.; Muller, David A.; Fennie, Craig J.; Schiffer, Peter; Gopalan, Venkatraman; Johnston-Halperin, Ezekiel; Schlom, Darrell G.			A strong ferroelectric ferromagnet created by means of spin-lattice coupling	NATURE			English	Article							MAGNETIC-PROPERTIES; OXIDE; SYSTEM	Ferroelectric ferromagnets are exceedingly rare, fundamentally interesting multiferroic materials that could give rise to new technologies in which the low power and high speed of field-effect electronics are combined with the permanence and routability of voltage-controlled ferromagnetism(1,2). Furthermore, the properties of the few compounds that simultaneously exhibit these phenomena(1-5) are insignificant in comparison with those of useful ferroelectrics or ferromagnets: their spontaneous polarizations or magnetizations are smaller by a factor of 1,000 or more. The same holds for magnetic-or electric-field-induced multiferroics(6-8). Owing to the weak properties of single-phase multiferroics, composite and multilayer approaches involving strain-coupled piezoelectric and magnetostrictive components are the closest to application today(1,2). Recently, however, a new route to ferroelectric ferromagnets was proposed(9) by which magnetically ordered insulators that are neither ferroelectric nor ferromagnetic are transformed into ferroelectric ferromagnets using a single control parameter, strain. The system targeted, EuTiO3, was predicted to exhibit strong ferromagnetism (spontaneous magnetization, similar to 7 Bohr magnetons per Eu) and strong ferroelectricity (spontaneous polarization, similar to 10 mu C cm(-2)) simultaneously under large biaxial compressive strain(9). These values are orders of magnitude higher than those of any known ferroelectric ferromagnet and rival the best materials that are solely ferroelectric or ferromagnetic. Hindered by the absence of an appropriate substrate to provide the desired compression we turned to tensile strain. Here we show both experimentally and theoretically the emergence of a multiferroic state under biaxial tension with the unexpected benefit that even lower strains are required, thereby allowing thicker high-quality crystalline films. This realization of a strong ferromagnetic ferroelectric points the way to high-temperature manifestations of this spin-lattice coupling mechanism(10). Our work demonstrates that a single experimental parameter, strain, simultaneously controls multiple order parameters and is a viable alternative tuning parameter to composition(11) for creating multiferroics.	[Lee, June Hyuk; Heeg, Tassilo; Schlom, Darrell G.] Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA; [Lee, June Hyuk; Vlahos, Eftihia; Gopalan, Venkatraman] Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA; [Fang, Lei; Jung, Young Woo; Hammel, P. Chris; Johnston-Halperin, Ezekiel] Ohio State Univ, Dept Phys, Columbus, OH 43210 USA; [Ke, Xianglin; Schiffer, Peter] Penn State Univ, Dept Phys, University Pk, PA 16802 USA; [Ke, Xianglin; Schiffer, Peter] Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA; [Kourkoutis, Lena Fitting; Muller, David A.; Fennie, Craig J.] Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; [Kim, Jong-Woo; Ryan, Philip J.; Freeland, John W.] Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA; [Roeckerath, Martin] Forschungszentrum Julich, JARA Fundamentals Future Informat Technol, Inst Bio & Nanosyst, D-52425 Julich, Germany; [Goian, Veronica; Kamba, Stanislav] Acad Sci Czech Republ, Inst Phys, Prague 18221 8, Czech Republic; [Bernhagen, Margitta; Uecker, Reinhard] Leibniz Inst Crystal Growth, D-12489 Berlin, Germany; [Rabe, Karin M.] Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; [Muller, David A.] Kavli Inst Cornell Nanoscale Sci, Ithaca, NY 14853 USA	Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Cornell University; United States Department of Energy (DOE); Argonne National Laboratory; Helmholtz Association; Research Center Julich; Czech Academy of Sciences; Institute of Physics of the Czech Academy of Sciences; Leibniz Institut fur Kristallzuchtung (IKZ); Rutgers State University New Brunswick	Schlom, DG (corresponding author), Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA.	schlom@cornell.edu	Schiffer, Peter/F-3227-2011; Goian, Veronica/G-6154-2014; Johnston-Halperin, Ezekiel/AAM-2564-2021; Kamba, Stanislav/G-5332-2014; Johnston-Halperin, Ezekiel/B-5902-2012; Hammel, P Chris/O-4845-2014; Schlom, Darrell G/J-2412-2013; Muller, David/A-7745-2010; Schubert, Jürgen/K-9543-2013; Kourkoutis, Lena/B-4229-2010	Goian, Veronica/0000-0002-7971-2224; Johnston-Halperin, Ezekiel/0000-0002-6240-3505; Kamba, Stanislav/0000-0003-4699-869X; Hammel, P Chris/0000-0002-4138-4798; Schlom, Darrell G/0000-0003-2493-6113; Muller, David/0000-0003-4129-0473; Schubert, Jürgen/0000-0003-0185-6794; Kim, Jong-Woo/0000-0001-9641-2947; Barnes, Eftihia/0000-0002-6075-6278; Kourkoutis, Lena/0000-0002-1303-1362; Schiffer, Peter/0000-0002-6430-6549; Hammel, Pascal/0000-0002-4630-4996; Ke, Xianglin/0000-0003-1882-9039	National Science Foundation [DMR-0507146]; National Science Foundation through MRSEC [DMR-0520404, DMR-0820404, DMR-0820414]; Czech Science Foundation [202/09/0682]; US Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]	National Science Foundation(National Science Foundation (NSF)); National Science Foundation through MRSEC; Czech Science Foundation(Grant Agency of the Czech Republic); US Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE))	The authors acknowledge discussions and interactions with M. D. Biegalski, D. H. A. Blank, C. B. Eom, M. B. Holcomb, M. Lezaic, J. Mannhart, L. W. Martin, D. V. Pelekhov, R. Ramesh, K. Z. Rushchanskii, N. Samarth, A. Schmehl, D. A. Tenne, J.-M. Triscone, D. Viehland and L. Yan. In addition, the financial support of the National Science Foundation through grant DMR-0507146 and the MRSEC program (DMR-0520404, DMR-0820404 and DMR-0820414), and of the Czech Science Foundation (project no. 202/09/0682), is gratefully acknowledged. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract no. DE-AC02-06CH11357.	Anisimov VI, 1997, J PHYS-CONDENS MAT, V9, P767, DOI 10.1088/0953-8984/9/4/002; Bayrashev A, 2004, SENSOR ACTUAT A-PHYS, V114, P244, DOI 10.1016/j.sna.2004.01.007; BEACH RS, 1993, PHYS REV LETT, V70, P3502, DOI 10.1103/PhysRevLett.70.3502; BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953; Bozovic I, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.107001; BROUS J, 1953, ACTA CRYSTALLOGR, V6, P67, DOI 10.1107/S0365110X53000156; Chae SC, 2009, J ELECTROCERAM, V22, P216, DOI 10.1007/s10832-008-9460-z; Choi KJ, 2004, SCIENCE, V306, P1005, DOI 10.1126/science.1103218; Chu MW, 2004, NAT MATER, V3, P87, DOI 10.1038/nmat1057; Das J, 2009, ADV MATER, V21, P2045, DOI 10.1002/adma.200803376; Eerenstein W, 2006, NATURE, V442, P759, DOI 10.1038/nature05023; Fennie CJ, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.267602; Fetisov YK, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2191950; Fuchs D, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.014434; Fujita K, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3072598; Gajek M, 2007, NAT MATER, V6, P296, DOI 10.1038/nmat1860; Goto T, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.257201; Haeni JH, 2004, NATURE, V430, P758, DOI 10.1038/nature02773; Hatabayashi K, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.100208; Hellwege KH, 1981, LANDOLTBORNSTEIN N A, V16, P59; Ikeda N, 2005, NATURE, V436, P1136, DOI 10.1038/nature04039; Junquera J, 2003, NATURE, V422, P506, DOI 10.1038/nature01501; Katsufuji T, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.054415; Ke X, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3117190; Kimura T, 2008, NAT MATER, V7, P291, DOI 10.1038/nmat2125; Kimura T, 2003, NATURE, V426, P55, DOI 10.1038/nature02018; Koster G, 1998, APPL PHYS LETT, V73, P2920, DOI 10.1063/1.122630; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; Kugimiya K, 2007, J MAGN MAGN MATER, V310, P2268, DOI 10.1016/j.jmmm.2006.10.839; Lee JH, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3133351; Lee JH, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.207204; Lottermoser T, 2004, NATURE, V430, P541, DOI 10.1038/nature02728; NGUYEN LD, 1992, IEEE T ELECTRON DEV, V39, P2007, DOI 10.1109/16.155871; Park JY, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2798597; Pertsev NA, 2000, PHYS REV B, V61, pR825, DOI 10.1103/PhysRevB.61.R825; Ramesh R, 2007, NAT MATER, V6, P21, DOI 10.1038/nmat1805; RIVERA JP, 1981, FERROELECTRICS, V36, P447, DOI 10.1080/00150198108218150; Schlom DG, 2007, ANNU REV MATER RES, V37, P589, DOI 10.1146/annurev.matsci.37.061206.113016; Shvartsman VV, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.064426; Steins M, 1997, Z KRIST-NEW CRYST ST, V212, P77, DOI 10.1524/ncrs.1997.212.1.77; Theis CD, 1996, J VAC SCI TECHNOL A, V14, P2677, DOI 10.1116/1.580185; Velickov B, 2007, Z KRISTALLOGR, V222, P466, DOI 10.1524/zkri.2007.222.9.466; Wang HH, 2004, J APPL PHYS, V96, P5324, DOI 10.1063/1.1794362; Zhai JY, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2172706	47	578	585	16	707	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2010	466	7309					954	U72		10.1038/nature09331	http://dx.doi.org/10.1038/nature09331			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	640ED	20725036				2022-12-28	WOS:000281030300030
J	Gostin, LO; Mok, EA				Gostin, Lawrence O.; Mok, Emily A.			The President's Global Health Initiative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gostin, Lawrence O.; Mok, Emily A.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA; [Gostin, Lawrence O.] Johns Hopkins Univ, Dept Publ Hlth, Baltimore, MD USA	Georgetown University; Johns Hopkins University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				[Anonymous], IMPL GLOB HLTH IN CO; *COMM US FED LED H, CTR STUD PRES C 21 C; GARRETT L, FUTURE FOREIGN ASSIS; GARRETT L, COMMUNICATION; *HJ KAIS FAM FDN, 2009, US GOV GLOB HLTH POL; *HJ KAIS FAM FDN, DISTR BIL MULT FUND; Institute of Medicine, 2008, US COMM GLOB HLTH RE; KATES J, US GLOBAL HLTH INITA; OECD, PAR DECL ACCR AG ACT; Roehr B, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2284	10	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2010	304	7					789	790		10.1001/jama.2010.1164	http://dx.doi.org/10.1001/jama.2010.1164			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639SB	20716742	Green Published			2022-12-28	WOS:000280993700027
J	Livingston, G; Leavey, G; Manela, M; Livingston, D; Rait, G; Sampson, E; Bavishi, S; Shahriyarmolki, K; Cooper, C				Livingston, Gill; Leavey, Gerard; Manela, Monica; Livingston, Deborah; Rait, Greta; Sampson, Elizabeth; Bavishi, Shilpa; Shahriyarmolki, Khodayar; Cooper, Claudia			Making decisions for people with dementia who lack capacity: qualitative study of family carers in UK	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CAREGIVERS; MEMBER	Objective To identify common difficult decisions made by family carers on behalf of people with dementia, and facilitators of and barriers to such decisions, in order to produce information for family carers about overcoming barriers. Design Qualitative study to delineate decision areas through focus groups and complexity of decision making in individual interviews. Setting Community settings in London. Participants 43 family carers of people with dementia in focus groups and 46 carers who had already made such decisions in individual interviews. Results Family carers identified five core problematic areas of decision making: accessing dementia related health and social services; care homes; legal-financial matters; non-dementia related health care; and making plans for the person with dementia if the carer became too ill to care for them. They highlighted the difficulties in making proxy decisions, especially against active resistance, and their altered role of patient manager while still a family member. Families devised strategies to gain agreement in order to ensure that the person with dementia retained dignity. Conclusions The following strategies helped with implementation of decisions: introducing change slowly; organising legal changes for the carer as well as the patient; involving a professional to persuade the patient to accept services; and emphasising that services optimised, not impeded, independence. To access services, carers made patients' general practice appointments, accompanied them to the surgery, pointed out symptoms, gained permission to receive confidential information, asked for referral to specialist services, and used professionals' authority to gain patients' agreement. End of life decisions were particularly difficult. They were helped by knowledge of the person with dementia's previous views, clear prognostic information, and family support. Information sheets to help carers to overcome barriers to proxy decision making have been developed; their impact in practice has yet to be evaluated.	[Livingston, Gill; Manela, Monica; Livingston, Deborah; Sampson, Elizabeth; Bavishi, Shilpa; Shahriyarmolki, Khodayar; Cooper, Claudia] UCL, Dept Mental Hlth Sci, London W1W 7FJ, England; [Leavey, Gerard] NIAMH, Belfast BT7 1HE, Antrim, North Ireland; [Leavey, Gerard] Univ Ulster, Belfast BT7 1HE, Antrim, North Ireland; [Rait, Greta] MRC Gen Practice Res Framework, London NW1 2ND, England	University of London; University College London; Ulster University	Livingston, G (corresponding author), UCL, Dept Mental Hlth Sci, London W1W 7FJ, England.	g.livingston@ucl.ac.uk	Cooper, Claudia A/C-1556-2008; Sampson, Elizabeth L/B-8647-2009; Livingston, G/C-7081-2008; Leavey, Gerard/AAU-2912-2020	Cooper, Claudia A/0000-0002-2777-7616; Sampson, Elizabeth L/0000-0001-8929-7362; Leavey, Gerard/0000-0001-8411-8919; Livingston, Gill/0000-0001-6741-5516; Rait, Greta/0000-0002-7216-7294	BUPA Foundation; MRC [MC_U122797163] Funding Source: UKRI; Medical Research Council [MC_U122797163] Funding Source: researchfish	BUPA Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The study was funded by BUPA Foundation, which had no role in the study design; the collection, analysis, and interpretation of data; or the writing of the article and the decision to submit it for publication. All the researchers are independent of the funders.	*ALZH RES FOR, 2008, AD RES PART INF CONS; [Anonymous], 2009, DEM ETH ISS; Butcher HK, 2001, RES NURS HEALTH, V24, P470, DOI 10.1002/nur.10005; Coffey A, 1996, MAKING SENSE QUALITA; Davies S, 2003, AGEING SOC, V23, P429, DOI 10.1017/S0144686X03001259; Department of Health, 2005, MENT CAP ACT 2005; Department of Health, 2009, LIVING WELL DEMENTIA; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Hansen L, 2004, J NURS SCHOLARSHIP, V36, P233, DOI 10.1111/j.1547-5069.2004.04043.x; Hirschman KB, 2006, AM J GERIAT PSYCHIAT, V14, P659, DOI 10.1097/01.JGP.0000203179.94036.69; Mezey M, 1996, J AM GERIATR SOC, V44, P144, DOI 10.1111/j.1532-5415.1996.tb02430.x; Miles M., 2013, QUALITATIVE DATA ANA; Potkins D, 2000, INT J GERIATR PSYCH, V15, P1005, DOI 10.1002/1099-1166(200011)15:11<1005::AID-GPS223>3.0.CO;2-0; Selwood A, 2007, J AFFECT DISORDERS, V101, P75, DOI 10.1016/j.jad.2006.10.025; Shah A, 2009, INT PSYCHOGERIATR, V21, P922, DOI 10.1017/S1041610209990391; Smith JA, 1996, PSYCHOL HEALTH, V11, P261, DOI 10.1080/08870449608400256; Wackerbarth S, 2002, GERONTOLOGIST, V42, P340; Wald C, 2003, INT J GERIATR PSYCH, V18, P313, DOI 10.1002/gps.828	18	146	147	0	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2010	341								c4184	10.1136/bmj.c4184	http://dx.doi.org/10.1136/bmj.c4184			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642KT	20719843	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000281213100007
J	WARDEN, J				WARDEN, J			DEMISE OF THE DHSS	BRITISH MEDICAL JOURNAL			English	Editorial Material																		WHITNEY R, 1988, BR MED J, V296, P726; 1988, BR MED J, V296, P303	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 7	1988	296	6632					1341	1341		10.1136/bmj.296.6632.1341	http://dx.doi.org/10.1136/bmj.296.6632.1341			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N3627	20742992	Green Published			2022-12-28	WOS:A1988N362700051
J	WARDEN, J				WARDEN, J			NO BLANK CHEQUES FROM MOORE	BRITISH MEDICAL JOURNAL			English	Editorial Material																		MOORE J, 1988, BR MED J, V296, P803	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1988	296	6624					800	800		10.1136/bmj.296.6624.800	http://dx.doi.org/10.1136/bmj.296.6624.800			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M5634	20742969	Green Published			2022-12-28	WOS:A1988M563400056
J	WARDEN, J				WARDEN, J			THE PRICE OF SUCCESS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1988	296	6619					440	440		10.1136/bmj.296.6619.440	http://dx.doi.org/10.1136/bmj.296.6619.440			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M0221	20742956	Green Published			2022-12-28	WOS:A1988M022100056
J	WARDEN, J				WARDEN, J			A LESSON IN REALPOLITIK	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1988	296	6618					368	368		10.1136/bmj.296.6618.368	http://dx.doi.org/10.1136/bmj.296.6618.368			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L9230	20742952	Green Published			2022-12-28	WOS:A1988L923000049
J	WARDEN, J				WARDEN, J			MAKE OR BREAK YEAR FOR NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1988	296	6617					302	302		10.1136/bmj.296.6617.302	http://dx.doi.org/10.1136/bmj.296.6617.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L8774	20742950	Green Published			2022-12-28	WOS:A1988L877400052
J	Nurden, AT				Nurden, Alan T.			Sustaining platelet counts in chronic ITP	LANCET			English	Editorial Material							THROMBOCYTOPENIC PURPURA; IMMUNE THROMBOCYTOPENIA; CONTROLLED-TRIAL; DOUBLE-BLIND; ROMIPLOSTIM; EFFICACY; SAFETY		Hop Xavier Arnozan, French Natl Reference Ctr Platelet Disorders, F-33600 Pessac, France	CHU Bordeaux	Nurden, AT (corresponding author), Hop Xavier Arnozan, French Natl Reference Ctr Platelet Disorders, F-33600 Pessac, France.	alan.nurden@cnrshl.u-bordeaux2.fr						BUSSEL J, 2010, 15 C EUR HAEM ASS BA; Bussel JB, 2009, LANCET, V373, P641, DOI 10.1016/S0140-6736(09)60402-5; Bussel JB, 2009, BLOOD, V113, P2161, DOI 10.1182/blood-2008-04-150078; CHENG G, 2010, LANCET          0824, DOI DOI 10.1016/50140-6736(10)60959; Gernsheimer TB, 2010, J THROMB HAEMOST, V8, P1372, DOI 10.1111/j.1538-7836.2010.03830.x; Kantarjian H, 2010, J CLIN ONCOL, V28, P437, DOI 10.1200/JCO.2009.24.7999; Kuter DJ, 2008, LANCET, V371, P395, DOI 10.1016/S0140-6736(08)60203-2; Metjian A, 2009, BIOL-TARGETS THER, V3, P499; Nurden AT, 2009, LANCET, V373, P1562, DOI 10.1016/S0140-6736(09)60255-5; Provan D, 2010, BLOOD, V115, P168, DOI 10.1182/blood-2009-06-225565	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN-FEB	2011	377	9763					358	360		10.1016/S0140-6736(10)61090-2	http://dx.doi.org/10.1016/S0140-6736(10)61090-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721ES	20739056				2022-12-28	WOS:000287337000006
J	Slater, R; Cornelissen, L; Fabrizi, L; Patten, D; Yoxen, J; Worley, A; Boyd, S; Meek, J; Fitzgerald, M				Slater, Rebeccah; Cornelissen, Laura; Fabrizi, Lorenzo; Patten, Debbie; Yoxen, Jan; Worley, Alan; Boyd, Stewart; Meek, Judith; Fitzgerald, Maria			Oral sucrose as an analgesic drug for procedural pain in newborn infants: a randomised controlled trial	LANCET			English	Article							LASER-EVOKED-POTENTIALS; SCHOOL-AGED CHILDREN; FLEXION REFLEX; MORPHINE; MANAGEMENT; RESPONSES	Background Many infants admitted to hospital undergo repeated invasive procedures. Oral sucrose is frequently given to relieve procedural pain in neonates on the basis of its effect on behavioural and physiological pain scores. We assessed whether sucrose administration reduces pain-specific brain and spinal cord activity after an acute noxious procedure in newborn infants. Methods In this double-blind, randomised controlled trial, 59 newborn infants at University College Hospital (London, UK) were randomly assigned to receive 0.5 mL 24% sucrose solution or 0.5 mL sterile water 2 mm before undergoing a clinically required heel lance. Randomisation was by a computer-generated randomisation code, and researchers, clinicians, participants, and parents were masked to the identity of the solutions. The primary outcome was pain-specific brain activity evoked by one time-locked heel lance, recorded with electroencephalography and identified by principal component analysis. Secondary measures were baseline behavioural and physiological measures, observational pain scores (PIPP), and spinal nociceptive reflex withdrawal activity. Data were analysed per protocol. This study is registered, number ISRCTN78390996. Findings 29 infants were assigned to receive sucrose and 30 to sterilised water; 20 and 24 infants, respectively, were included in the analysis of the primary outcome measure. Nociceptive brain activity after the noxious heel lance did not differ significantly between infants who received sucrose and those who received sterile water (sucrose: mean 0.10, 95% CI 0.04-0.16; sterile water: mean 0.08, 0.04-0.12; p=0.46). No significant difference was recorded between the sucrose and sterile water groups in the magnitude or latency of the spinal nociceptive reflex withdrawal recorded from the biceps femoris of the stimulated leg. The PIPP score was significantly lower in infants given sucrose than in those given sterile water (mean 5.8, 95% CI 3.7-7.8 vs 8.5, 7.3-9.8; p=0.02) and significantly more infants had no change in facial expression after sucrose administration (seven of 20 [35%] vs none of 24; p<0.0001). Interpretation Our data suggest that oral sucrose does not significantly affect activity in neonatal brain or spinal cord nociceptive circuits, and therefore might not be an effective analgesic drug. The ability of sucrose to reduce clinical observational scores after noxious events in newborn infants should not be interpreted as pain relief.	[Slater, Rebeccah; Cornelissen, Laura; Fabrizi, Lorenzo; Patten, Debbie; Yoxen, Jan; Fitzgerald, Maria] UCL, London WC1E 6BT, England; [Slater, Rebeccah] Univ Oxford, Nuffield Dept Anaesthet, Oxford, England; [Worley, Alan; Boyd, Stewart] Great Ormond St Hosp Sick Children, Dept Clin Neurophysiol, London WC1N 3JH, England; [Meek, Judith] Univ Coll London Hosp, London, England	University of London; University College London; University of Oxford; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University College London Hospitals NHS Foundation Trust; University of London; University College London	Slater, R (corresponding author), UCL, Gower St, London WC1E 6BT, England.	r.slater@ucl.ac.uk	Fitzgerald, Maria/C-5760-2008; Fabrizi, Lorenzo/H-8135-2019; Boyd, Stewart/O-3770-2019	Fabrizi, Lorenzo/0000-0002-9582-0727; Boyd, Stewart/0000-0001-7363-2453; Slater, Rebeccah/0000-0003-1595-4846; Cornelissen, Laura/0000-0001-8579-0870	Medical Research Council; MRC [G0502146] Funding Source: UKRI; Medical Research Council [G0502146] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council. We thank Sian Roberts (UCL, London, UK) for help with data acquisition, the UCL/UCH Comprehensive Biomedical Research Centre, the staff at UCH, and all the parents and infants who took part in this study.	ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; Anand KJS, 2005, CLIN THER, V27, P814, DOI 10.1016/j.clinthera.2005.06.021; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Andrews K, 1999, DEV MED CHILD NEUROL, V41, P696, DOI 10.1017/S0012162299001425; Anseloni V, 2004, PAIN, V109, P507, DOI 10.1016/j.pain.2004.02.031; Anseloni VCZ, 2005, NEUROSCIENCE, V133, P231, DOI 10.1016/j.neuroscience.2005.01.055; Carbajal R, 2008, JAMA-J AM MED ASSOC, V300, P60, DOI 10.1001/jama.300.1.60; Fitzgerald M, 2009, PAIN, V144, P9, DOI 10.1016/j.pain.2009.03.015; Fitzgerald M, 2009, NAT CLIN PRACT NEURO, V5, P35, DOI 10.1038/ncpneuro0984; Foo H, 2009, J NEUROSCI, V29, P13053, DOI 10.1523/JNEUROSCI.3514-09.2009; Hermann C, 2006, PAIN, V125, P278, DOI 10.1016/j.pain.2006.08.026; Hohmeister J, 2010, PAIN, V150, P257, DOI 10.1016/j.pain.2010.04.004; Hohmeister J, 2009, EUR J PAIN, V13, P94, DOI 10.1016/j.ejpain.2008.03.004; Holsti L, 2010, PEDIATRICS, V125, P1042, DOI 10.1542/peds.2009-2445; Lee MC, 2009, J NEUROSCI, V29, P7909, DOI 10.1523/JNEUROSCI.0014-09.2009; Lorenz J, 1997, EVOKED POTENTIAL, V104, P514, DOI 10.1016/S0168-5597(97)00064-6; Oberlander TF, 2002, PEDIATRICS, V110, P570, DOI 10.1542/peds.110.3.570; Oberlander TF, 2010, ALCOHOL CLIN EXP RES, V34, P681, DOI 10.1111/j.1530-0277.2009.01137.x; Prkachin KM, 2009, PAIN RES MANAG, V14, P53, DOI 10.1155/2009/542964; Puntillo KA, 2004, CRIT CARE MED, V32, P421, DOI 10.1097/01.CCM.0000108875.35298.D2; Ranger M, 2007, SEMIN PERINATOL, V31, P283, DOI 10.1053/j.semperi.2007.07.003; Roberts Katherine, 2008, BMC Anesthesiol, V8, P8, DOI 10.1186/1471-2253-8-8; Sandrini G, 2005, PROG NEUROBIOL, V77, P353, DOI 10.1016/j.pneurobio.2005.11.003; Simons SHP, 2003, ARCH PEDIAT ADOL MED, V157, P1058, DOI 10.1001/archpedi.157.11.1058; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Slater R, 2010, NEUROIMAGE, V52, P583, DOI 10.1016/j.neuroimage.2010.04.253; Slater R, 2010, EUR J PAIN, V14, P321, DOI 10.1016/j.ejpain.2009.05.005; Slater R, 2009, PAIN, V146, P177, DOI 10.1016/j.pain.2009.07.022; Slater R, 2008, PLOS MED, V5, P928, DOI 10.1371/journal.pmed.0050129; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; Stevens B, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001069.pub3; Taddio A, 2009, PEDIATRICS, V123, pe425, DOI 10.1542/peds.2008-3028; Truini A, 2010, EUR J PAIN, V14, P222, DOI 10.1016/j.ejpain.2009.05.001; van Boxtel GJM, 1998, BEHAV RES METH INS C, V30, P87, DOI 10.3758/BF03209419; Walker SM, 2008, BRIT J ANAESTH, V101, P101, DOI 10.1093/bja/aen097; WILLER JC, 1985, BRAIN RES, V331, P105, DOI 10.1016/0006-8993(85)90719-X	36	200	205	0	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2010	376	9748					1225	1232		10.1016/S0140-6736(10)61303-7	http://dx.doi.org/10.1016/S0140-6736(10)61303-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZT	20817247	Green Published			2022-12-28	WOS:000283003500032
J	Snelgrove, RJ; Jackson, PL; Hardison, MT; Noerager, BD; Kinloch, A; Gaggar, A; Shastry, S; Rowe, SM; Shim, YM; Hussell, T; Blalock, JE				Snelgrove, Robert J.; Jackson, Patricia L.; Hardison, Matthew T.; Noerager, Brett D.; Kinloch, Andrew; Gaggar, Amit; Shastry, Suresh; Rowe, Steven M.; Shim, Yun M.; Hussell, Tracy; Blalock, J. Edwin			A Critical Role for LTA(4)H in Limiting Chronic Pulmonary Neutrophilic Inflammation	SCIENCE			English	Article							LEUKOTRIENE-A4 HYDROLASE; ENZYME; CHEMOATTRACTANT	Leukotriene A(4) hydrolase (LTA(4)H) is a proinflammatory enzyme that generates the inflammatory mediator leukotriene B-4 (LTB4). LTA(4)H also possesses aminopeptidase activity with unknown substrate and physiological importance; we identified the neutrophil chemoattractant proline-glycine-proline (PGP) as this physiological substrate. PGP is a biomarker for chronic obstructive pulmonary disease (COPD) and is implicated in neutrophil persistence in the lung. In acute neutrophil-driven inflammation, PGP was degraded by LTA(4)H, which facilitated the resolution of inflammation. In contrast, cigarette smoke, a major risk factor for the development of COPD, selectively inhibited LTA(4)H aminopeptidase activity, which led to the accumulation of PGP and neutrophils. These studies imply that therapeutic strategies inhibiting LTA(4)H to prevent LTB4 generation may not reduce neutrophil recruitment because of elevated levels of PGP.	[Snelgrove, Robert J.; Jackson, Patricia L.; Hardison, Matthew T.; Gaggar, Amit; Shastry, Suresh; Rowe, Steven M.; Blalock, J. Edwin] Univ Alabama Birmingham, Dept Med, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA; [Snelgrove, Robert J.; Hussell, Tracy] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England; [Noerager, Brett D.] Univ Montevallo, Dept Biol Chem & Math, Montevallo, AL 35115 USA; [Kinloch, Andrew] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London W6 8LH, England; [Gaggar, Amit; Rowe, Steven M.; Blalock, J. Edwin] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Ctr, Birmingham, AL 35294 USA; [Gaggar, Amit] Birmingham VA Med Ctr, Birmingham, AL 35294 USA; [Rowe, Steven M.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; [Shim, Yun M.] Univ Virginia, Dept Med, Div Pulm & Crit Care Med, Charlottesville, VA 22908 USA	University of Alabama System; University of Alabama Birmingham; Imperial College London; Imperial College London; University of Oxford; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Alabama System; University of Alabama Birmingham; University of Virginia	Snelgrove, RJ (corresponding author), Univ Alabama Birmingham, Dept Med, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.	rjs198@imperial.ac.uk	Kinloch, Anthony J/F-6042-2011; Hussell, Tracy/O-4630-2014; Shim, Yun Michael/N-2049-2017	Kinloch, Anthony J/0000-0002-8752-7184; Hussell, Tracy/0000-0001-7186-6141; Shim, Yun Michael/0000-0002-3780-3371; Blalock, J. Edwin/0000-0001-5303-8123	Wellcome Trust [082727/Z/07/Z]; National Heart, Lung, and Blood Institute [HL07783, HL090999, HL087824, HL102371-A1, K08HL091127]; Cystic Fibrosis Foundation [GAGGAR07]; National Institute of Diabetes and Digestive and Kidney Diseases [1K23DK075788, 1R03DK084110-01]; Flight Attendant Medical Research Institute; Medical Research Council [P171/03/C1/048]; NIH [RR19231, P30CA13148, P50 AT00477, U54CA100949, P30AR050948, P30 DK079337]; MRC [G0802752, G0400795] Funding Source: UKRI; Medical Research Council [G0802752, G0400795] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA013148, U54CA100949] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P50AT000477] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019231] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL102371, F33HL007783, R01HL087824, K08HL091127, R01HL077783, R01HL090999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK075788, R03DK084110, P30DK079337] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome Trust); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Flight Attendant Medical Research Institute; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This project was supported by grants from the Wellcome Trust (082727/Z/07/Z to R.J.S.), the National Heart, Lung, and Blood Institute (HL07783, HL090999, and HL087824 to J.E.B. and HL102371-A1 to A. G.), the Cystic Fibrosis Foundation (GAGGAR07 to A. G.), the National Institute of Diabetes and Digestive and Kidney Diseases (1K23DK075788 and 1R03DK084110-01 to S. M. R.), the Flight Attendant Medical Research Institute (Young Clinical Scientist Award to Y.M.S.) and the National Heart, Lung, and Blood Institute (K08HL091127 to Y.M.S.), and the Medical Research Council (P171/03/C1/048 to T. H.). The Univ. of Alabama Birmingham (UAB) Lung Health Center Pulmonary Proteomics Laboratory is funded through the NIH (by grants RR19231, P30CA13148, P50 AT00477, U54CA100949, P30AR050948, and P30 DK079337). We thank R. Moore and L. Wilson of the UAB Targeted Metabolomics and Proteomics Laboratory for their technical assistance with mass spectrometry, D. Muccio of the UAB Chemistry Department for the use of his fast protein liquid chromatography system, G. Xia for technical assistance, and D. Saliba of the Kennedy Institute of Rheumatology, Imperial College London, for his technical assistance in the generation of murine LTA<INF>4</INF>H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the NIH.	Bailie MB, 1996, J IMMUNOL, V157, P5221; BLOMSTER M, 1995, EUR J BIOCHEM, V231, P528, DOI 10.1111/j.1432-1033.1995.tb20728.x; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; Eyles JL, 2006, NAT CLIN PRACT RHEUM, V2, P500, DOI 10.1038/ncprheum0291; FITZPATRICK F, 1983, P NATL ACAD SCI-BIOL, V80, P5425, DOI 10.1073/pnas.80.17.5425; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gaggar A, 2008, J IMMUNOL, V180, P5662, DOI 10.4049/jimmunol.180.8.5662; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Haddox JL, 1999, INVEST OPHTH VIS SCI, V40, P2427; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; Hardison MT, 2009, J IMMUNOL, V182, P4423, DOI 10.4049/jimmunol.0802457; MUNAFO DA, 1994, J CLIN INVEST, V93, P1042, DOI 10.1172/JCI117053; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; O'Donnell R, 2006, THORAX, V61, P448, DOI 10.1136/thx.2004.024463; O'Reilly P, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-38; ORNING L, 1994, J BIOL CHEM, V269, P11269; Orning L, 1999, ARCH BIOCHEM BIOPHYS, V368, P131, DOI 10.1006/abbi.1999.1289; ORNING L, 1992, BIOCHEMISTRY-US, V31, P4218, DOI 10.1021/bi00132a010; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184; Stuart LM, 2005, IMMUNITY, V22, P539, DOI 10.1016/j.immuni.2005.05.002; van Houwelingen AH, 2008, FASEB J, V22, P3403, DOI 10.1096/fj.07-096230; Weathington NM, 2006, NAT MED, V12, P317, DOI 10.1038/nm1361; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; Whittle BJR, 2008, BRIT J PHARMACOL, V153, P983, DOI 10.1038/sj.bjp.0707645	30	182	186	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	2010	330	6000					90	94		10.1126/science.1190594	http://dx.doi.org/10.1126/science.1190594			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656KW	20813919	Green Accepted			2022-12-28	WOS:000282334500042
J	Swedberg, K; Komajda, M; Bohm, M; Borer, JS; Ford, I; Dubost-Brama, A; Lerebours, G; Tavazzi, L				Swedberg, Karl; Komajda, Michel; Boehm, Michael; Borer, Jeffrey S.; Ford, Ian; Dubost-Brama, Ariane; Lerebours, Guy; Tavazzi, Luigi		SHIFT Investigators	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study	LANCET			English	Article							SYSTOLIC DYSFUNCTION BEAUTIFUL; CORONARY-ARTERY-DISEASE; CARDIAC-RHYTHM; RATE REDUCTION; DOUBLE-BLIND; GUIDELINES; MORBIDITY; SURVIVAL; CARVEDILOL; METOPROLOL	Background Chronic heart failure is associated with high mortality and morbidity. Raised resting heart rate is a risk factor for adverse outcomes. We aimed to assess the effect of heart-rate reduction by the selective sinus-node inhibitor ivabradine on outcomes in heart failure. Methods Patients were eligible for participation in this randomised, double-blind, placebo-controlled, parallel-group study if they had symptomatic heart failure and a left-ventricular ejection fraction of 35% or lower, were in sinus rhythm with heart rate 70 beats per min or higher, had been admitted to hospital for heart failure within the previous year, and were on stable background treatment including a beta blocker if tolerated. Patients were randomly assigned by computer-generated allocation schedule to ivabradine titrated to a maximum of 7.5 mg twice daily or matching placebo. Patients and investigators were masked to treatment allocation. The primary endpoint was the composite of cardiovascular death or hospital admission for worsening heart failure. Analysis was by intention to treat. This trial is registered, number ISRCTN70429960. Findings 6558 patients were randomly assigned to treatment groups (3268 ivabradine, 3290 placebo). Data were available for analysis for 3241 patients in the ivabradine group and 3264 patients allocated placebo. Median follow-up was 22.9 (IQR 18-28) months. 793 (24%) patients in the ivabradine group and 937 (29%) of those taking placebo had a primary endpoint event (HR 0.82, 95% CI 0.75-0.90, p<0.0001). The effects were driven mainly by hospital admissions for worsening heart failure (672 [21%] placebo vs 514 [16%] ivabradine; HR 0.74, 0.66-0.83; p<0.0001) and deaths due to heart failure (151 [5%] vs 113 [3%]; HR 0.74, 0.58-0.94, p=0.014). Fewer serious adverse events occurred in the ivabradine group (3388 events) than in the placebo group (3847; p=0.025). 150 (5%) of ivabradine patients had symptomatic bradycardia compared with 32 (1%) of the placebo group (p<0.0001). Visual side-effects (phosphenes) were reported by 89 (3%) of patients on ivabradine and 17 (1%) on placebo (p<0.0001). Interpretation Our results support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in heart failure and confirm the important role of heart rate in the pathophysiology of this disorder.	[Swedberg, Karl] Univ Gothenburg, Sahlgrenska Acad, Dept Emergency & Cardiovasc Med, Gothenburg, Sweden; [Komajda, Michel] Univ Paris 06, La Pitie Salpetriere Hosp, Dept Cardiol, Paris, France; [Boehm, Michael] Univ Saarlandes Kliniken, Innere Med Klin 3, Homburg, Germany; [Borer, Jeffrey S.] Suny Downstate Med Ctr, Div Cardiovasc Med, Brooklyn, NY 11203 USA; [Borer, Jeffrey S.] Suny Downstate Med Ctr, Howard Gilman Inst Heart Valve Dis, Brooklyn, NY 11203 USA; [Borer, Jeffrey S.] Suny Downstate Med Ctr, Div Cardiovasc Med, New York, NY USA; [Borer, Jeffrey S.] Suny Downstate Med Ctr, Howard Gilman Inst Heart Valve Dis, New York, NY USA; [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Dubost-Brama, Ariane; Lerebours, Guy] Inst Rech Int Servier, F-92415 Courbevoie, France; [Tavazzi, Luigi] Maria Cecilia Hosp, GVM Care & Res, Ettore Sansavini Hlth Sci Fdn, Cotignola, Italy	University of Gothenburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universitatsklinikum des Saarlandes; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Glasgow; Servier; Institut de Recherches Internationales Servier; Maria Cecilia Hospital	Swedberg, K (corresponding author), Sahlgrens Univ Hosp, Dept Med, SE-41685 Gothenburg, Sweden.	karl.swedberg@gu.se	Shpektor, Alexander V/B-1083-2016; Georgescu, Catalina Arsenescu/R-5709-2017; Arnold, Malcolm/G-2869-2011; Tavazzi, Luigi/ABD-5119-2020; Swedberg, Karl/B-2475-2008; Tomescu, Cleopatra M/F-5197-2011; Arkhipov, Mikhail V/Q-2316-2015; Pavlyukova, Elena/P-8477-2016; Ford, Ian/ABE-6145-2020; Nedogoda, Sergey V/O-4656-2014; Mareev, Vyacheslav Yurievich/Q-1375-2017; Korzh, Oleksii/E-4291-2016; Moiseeva, Olga/A-4580-2014; Ponikowski, Piotr/O-6454-2015; Bettencourt, Paulo/A-4434-2018	Georgescu, Catalina Arsenescu/0000-0001-5142-7598; Tavazzi, Luigi/0000-0003-0336-8356; Arkhipov, Mikhail V/0000-0002-7924-7668; Pavlyukova, Elena/0000-0002-3081-9477; Nedogoda, Sergey V/0000-0001-5981-1754; Braunschweig, Frieder/0000-0002-4966-1315; Naslund, Ulf/0000-0003-4100-8298; Mahon, Niall/0000-0002-2872-2297; Maurer, Gerald/0000-0002-9043-7657; Mareev, Vyacheslav Yurievich/0000-0002-7285-2048; Korzh, Oleksii/0000-0001-6838-4360; Melenovsky, Vojtech/0000-0001-8921-7078; Marchev, Sotir/0000-0001-9250-510X; Moiseeva, Olga/0000-0002-7817-3847; GALINIER, Michel/0000-0003-1735-3390; Kober, Lars/0000-0002-6635-1466; Howes, Laurence/0000-0002-1507-8260; Narusov, Oleg/0000-0003-2960-0950; Kraidashenko, Oleh/0000-0001-8727-8889; Ponikowski, Piotr/0000-0002-3391-7064; Bettencourt, Paulo/0000-0003-1638-3993	Amgen; AstraZeneca; Nile Therapeutics; Bristol-Myers Squibb; Sanofi-Aventis; Menarini; Merck; Medtronic; Biotronik; Solvay; Vifor Pharma; IKKF; GlaxoSmithKline; Boehringer Ingelheim; Pfizer; Celladon; Gilead; ARMGO; Novartis; Novacardia (Merck); BioMarin; Roche; Rigel; Salix; XOMA; Lux; Cardiopep; Cardioxyl; Abbot; Servier, France; Servier	Amgen(Amgen); AstraZeneca(AstraZeneca); Nile Therapeutics; Bristol-Myers Squibb(Bristol-Myers Squibb); Sanofi-Aventis(Sanofi-Aventis); Menarini(Menarini Group); Merck(Merck & Company); Medtronic(Medtronic); Biotronik; Solvay(Solvay SA); Vifor Pharma; IKKF; GlaxoSmithKline(GlaxoSmithKline); Boehringer Ingelheim(Boehringer Ingelheim); Pfizer(Pfizer); Celladon; Gilead(Gilead Sciences); ARMGO; Novartis(Novartis); Novacardia (Merck)(Merck & Company); BioMarin; Roche(Roche Holding); Rigel; Salix; XOMA; Lux; Cardiopep; Cardioxyl; Abbot; Servier, France(Servier); Servier(Servier)	KS, MK, MB, JSB, IF, and LT have received fees, research grants, or both from Servier. ADB and GL are employees of Servier. KS has received also research grants from Amgen and AstraZeneca, and honoraria from Amgen, Novartis, and AstraZeneca. MK has received consultancy fees from Nile Therapeutics and Bristol-Myers Squibb, and payment for service on speakers' bureau from Sanofi-Aventis, Menarini, Bristol-Myers Squibb, Merck, and AstraZeneca. IF has received fees from Medtronic, Biotronik, Solvay, Vifor Pharma, IKKF, and GlaxoSmithKline. MB has received fees AstraZeneca, Boehringer Ingelheim, Sanofi-Aventis, and Pfizer. JSB has received consulting fees from Celladon, Gilead, Sanofi-Aventis, ARMGO, Novartis, Novacardia (Merck), BioMarin, Roche, Pfizer, Rigel, BioTronik, Salix, XOMA, Lux, Cardiopep, Bristol-Myers Squibb, and Cardioxyl. LT has received consultancy fees from Medtronic and Menarini, and payment service for speakers' bureau from Abbot, AstraZeneca, and Pfizer.; Servier, France.	Alehagen U, 2009, EUR J HEART FAIL, V11, P354, DOI 10.1093/eurjhf/hfp024; Blair JEA, 2008, J AM COLL CARDIOL, V52, P1640, DOI 10.1016/j.jacc.2008.07.056; de Groote P, 2007, EUR J HEART FAIL, V9, P1205, DOI 10.1016/j.ejheart.2007.09.008; Diaz A, 2005, EUR HEART J, V26, P967, DOI 10.1093/eurheartj/ehi190; Dickstein K, 2008, EUR J HEART FAIL, V10, P933, DOI 10.1016/j.ejheart.2008.08.005; DiFrancesco D, 2006, PHARMACOL RES, V53, P399, DOI 10.1016/j.phrs.2006.03.006; Flannery G, 2008, AM J CARDIOL, V101, P865, DOI 10.1016/j.amjcard.2007.11.023; Fox K, 2008, LANCET, V372, P807, DOI 10.1016/S0140-6736(08)61170-8; Fox K, 2008, LANCET, V372, P817, DOI 10.1016/S0140-6736(08)61171-X; Gheorghiade M, 2003, CIRCULATION, V107, P1570, DOI 10.1161/01.CIR.0000065187.80707.18; Hjalmarson A, 1999, LANCET, V353, P2001; Jhund PS, 2009, CIRCULATION, V119, P515, DOI 10.1161/CIRCULATIONAHA.108.812172; KATZ AM, 1989, AM J CARDIOL, V63, pA12, DOI 10.1016/0002-9149(89)90386-X; Komajda M, 2003, EUR HEART J, V24, P464, DOI 10.1016/S0195-668X(02)00700-5; Lechat P, 2001, CIRCULATION, V103, P1428, DOI 10.1161/01.CIR.103.10.1428; McAlister FA, 2009, ANN INTERN MED, V150, P784, DOI 10.7326/0003-4819-150-11-200906020-00006; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; Pocock SJ, 2006, EUR HEART J, V27, P65, DOI 10.1093/eurheartj/ehi555; Savelieva I, 2008, DRUG SAFETY, V31, P95, DOI 10.2165/00002018-200831020-00001; Shafazand M, 2009, EUR HEART J, V30, P671, DOI 10.1093/eurheartj/ehn541; Swedberg K, 2005, EUR HEART J, V26, P1115, DOI 10.1093/eurheartj/ehi204; Swedberg K, 2010, EUR J HEART FAIL, V12, P75, DOI 10.1093/eurjhf/hfp154; Torp-Pedersen C, 2005, AM HEART J, V149, P370, DOI 10.1016/j.ahj.2004.10.002; Udelson JE, 2004, AM J CARDIOL, V93, p43B, DOI 10.1016/j.amjcard.2004.01.025; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065	26	1623	1730	2	138	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2010	376	9744					875	885		10.1016/S0140-6736(10)61198-1	http://dx.doi.org/10.1016/S0140-6736(10)61198-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653DW	20801500				2022-12-28	WOS:000282069100028
J	Solomon, GM; Janssen, S				Solomon, Gina M.; Janssen, Sarah			Health Effects of the Gulf Oil Spill	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Solomon, Gina M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94104 USA; [Solomon, Gina M.] Nat Resources Def Council, San Francisco, CA 94104 USA	University of California System; University of California San Francisco	Solomon, GM (corresponding author), Univ Calif San Francisco, Dept Med, 111 Sutter St,20th Floor, San Francisco, CA 94104 USA.	gsolomon@nrdc.org		Solomon, Gina/0000-0001-6004-0387				ATSDR (Agency for Toxic Substances and Disease Registry), 1999, TOX PROF TOT PETR HY; GORMA RW, 1991, HETA 89 200 89 273 2; Law R.J., 1999, ENV GEOSCI, V6, P90, DOI [10.1046/j.1526-0984.1999.08039.x, DOI 10.1046/J.1526-0984.1999.08039.X]; *NAT TOX PROGR, 2005, REP CARC; ONEILL AK, 2003, SELF REPORTED EXPOSU; PALINKAS LA, 1993, AM J PSYCHIAT, V150, P1517; Rodriguez-Trigo G, 2007, ARCH BRONCONEUMOL, V43, P628; Sabucedo JM, 2010, DISASTERS, V34, P809, DOI 10.1111/j.1467-7717.2010.01170.x; *US EPA, OD BP OIL SPILL; Zock JP, 2007, AM J RESP CRIT CARE, V176, P610, DOI 10.1164/rccm.200701-016OC	10	68	67	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1118	1119		10.1001/jama.2010.1254	http://dx.doi.org/10.1001/jama.2010.1254			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20713544				2022-12-28	WOS:000281559800024
J	Karumanchi, SA; Thadhani, R				Karumanchi, S. Ananth; Thadhani, Ravi			A complement to kidney disease: CFHR5 nephropathy	LANCET			English	Editorial Material							H-RELATED PROTEIN-5		[Karumanchi, S. Ananth] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA; [Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, Boston, MA 02215 USA; [Karumanchi, S. Ananth] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Thadhani, R (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.	thadhani.r@mgh.harvard.edu	Karumanchi, Subbian Ananth/AAI-1694-2021		Howard Hughes Medical Institute Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315; Cohen RA, 2003, NEW ENGL J MED, V348, P2330, DOI 10.1056/NEJMcp012694; Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8; McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250; McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200; Monteferrante G, 2007, MOL IMMUNOL, V44, P1704, DOI 10.1016/j.molimm.2006.08.004; Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873; Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342; Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620	9	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					748	750		10.1016/S0140-6736(10)60967-1	http://dx.doi.org/10.1016/S0140-6736(10)60967-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20800272				2022-12-28	WOS:000281831000006
J	von Ungern-Sternberg, BS; Boda, K; Chambers, NA; Rebmann, C; Johnson, C; Sly, PD; Habre, W				von Ungern-Sternberg, Britta S.; Boda, Krisztina; Chambers, Neil A.; Rebmann, Claudia; Johnson, Chris; Sly, Peter D.; Habre, Walid			Risk assessment for respiratory complications in paediatric anaesthesia: a prospective cohort study	LANCET			English	Article							LARYNGEAL MASK AIRWAY; TRACT INFECTIONS; REFLEX BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS; INTRAVENOUS LIDOCAINE; TRACHEAL INTUBATION; ADVERSE EVENTS; LUNG-FUNCTION; CHILDREN; ASTHMA	Background Perioperative respiratory adverse events in children are one of the major causes of morbidity and mortality during paediatric anaesthesia. We aimed to identify associations between family history, anaesthesia management, and occurrence of perioperative respiratory adverse events. Methods We prospectively included all children who had general anaesthesia for surgical or medical interventions, elective or urgent procedures at Princess Margaret Hospital for Children, Perth, Australia, from Feb 1,2007, to Jan 31, 2008. On the day of surgery, anaesthetists in charge of paediatric patients completed an adapted version of the International Study Group for Asthma and Allergies in Childhood questionnaire. We collected data on family medical history of asthma, atopy, allergy, upper respiratory tract infection, and passive smoking. Anaesthesia management and all perioperative respiratory adverse events were recorded. Findings 9297 questionnaires were available for analysis. A positive respiratory history (nocturnal dry cough, wheezing during exercise, wheezing more than three times in the past 12 months, or a history of present or past eczema) was associated with an increased risk for bronchospasm (relative risk [RR] 8.46, 95% Cl 6.18-11.59; p<0.0001), laryngospasm (4.13, 3.37-5.08; p<0.0001), and perioperative cough, desaturation, or airway obstruction (3.05, 2.76-3.37; p<0.0001). Upper respiratory tract infection was associated with an increased risk for perioperative respiratory adverse events only when symptoms were present (RR 2.05, 95% CI 1.82-2.31; p<0.0001) or less than 2 weeks before the procedure (2.34, 2.07-2.66; p<0.0001), whereas symptoms of upper respiratory tract infection 2-4 weeks before the procedure significantly lowered the incidence of perioperative respiratory adverse events (0.66, 0.53-0.81; p<0.0001). A history of at least two family members having asthma, atopy, or smoking increased the risk for perioperative respiratory adverse events (all p<0.0001). Risk was lower with intravenous induction compared with inhalational induction (all p<0.0001), inhalational compared with intravenous maintenance of anaesthesia (all p<0.0001), airway management by a specialist paediatric anaesthetist compared with a registrar (all p<0.0001), and use of face mask compared with tracheal intubation (all p<0.0001). Interpretation Children at high risk for perioperative respiratory adverse events could be systematically identified at the preanaesthetic assessment and thus can benefit from a specifically targeted anaesthesia management.	[von Ungern-Sternberg, Britta S.; Chambers, Neil A.; Rebmann, Claudia; Johnson, Chris] Princess Margaret Hosp Children, Dept Anaesthesia, Perth, WA, Australia; [von Ungern-Sternberg, Britta S.; Sly, Peter D.] Univ Western Australia, Telethon Inst Child Hlth Res, Div Clin Sci, Perth, WA 6009, Australia; [von Ungern-Sternberg, Britta S.; Sly, Peter D.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia; [von Ungern-Sternberg, Britta S.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Boda, Krisztina] Univ Szeged, Dept Med Informat, Szeged, Hungary; [Habre, Walid] Univ Geneva, Geneva Childrens Hosp, Paediat Anaesthesia Unit, Geneva, Switzerland	University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia; Szeged University; University of Geneva	von Ungern-Sternberg, BS (corresponding author), Princess Margaret Hosp Children, Dept Anaesthesia, Roberts Rd, Subiaco, WA 6008, Australia.	bvonungern@uhbs.ch	von Ungern-Sternberg, Britta/CAG-9904-2022; Sly, Peter D/F-1486-2010; von Ungern-Sternberg, Britta/S-5532-2019	von Ungern-Sternberg, Britta/0000-0002-8043-8541; Sly, Peter D/0000-0001-6305-2201; Boda, Krisztina/0000-0002-9937-0460	Department of Anaesthesia, Princess Margaret Hospital for Children; Swiss Foundation for Grants in Biology and Medicine; Swiss National Science Foundation; Voluntary Academic Society Basel, Switzerland	Department of Anaesthesia, Princess Margaret Hospital for Children; Swiss Foundation for Grants in Biology and Medicine; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Voluntary Academic Society Basel, Switzerland	This study was supported by the Department of Anaesthesia, Princess Margaret Hospital for Children, a grant of the Swiss Foundation for Grants in Biology and Medicine in cooperation with the Swiss National Science Foundation, and by the Voluntary Academic Society Basel, Switzerland. We thank all staff members of the Department of Anaesthesia and the nurses in postanaesthetic care unit, Princess Margaret Hospital for Children, Perth, Australia, for their tremendous support with this study.	Adamzik M, 2007, ANESTH ANALG, V104, P168, DOI 10.1213/01.ane.0000247884.94119.d5; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Backlund AB, 2006, ALLERGY, V61, P549, DOI 10.1111/j.1398-9995.2006.01027.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bhananker SM, 2007, ANESTH ANALG, V105, P344, DOI 10.1213/01.ane.0000268712.00756.dd; Bjerg A, 2007, PEDIATRICS, V120, P741, DOI 10.1542/peds.2006-3742; Bordet F, 2002, PAEDIATR ANAESTH, V12, P762, DOI 10.1046/j.1460-9592.2002.00987.x; BUCKNER CK, 1985, AM REV RESPIR DIS, V132, P305; Chang HYS, 2007, ANESTH ANALG, V104, P1109, DOI 10.1213/01.ane.0000260638.57139.87; COHEN MM, 1991, ANESTH ANALG, V72, P282; Forastiere F, 1996, AM J RESP CRIT CARE, V153, P1098, DOI 10.1164/ajrccm.153.3.8630551; Groeben H, 1996, ANESTHESIOLOGY, V84, P533, DOI 10.1097/00000542-199603000-00007; Groeben H, 1999, AM J RESP CRIT CARE, V159, P530, DOI 10.1164/ajrccm.159.2.9806102; Groeben H, 2000, CHEST, V118, P509, DOI 10.1378/chest.118.2.509; Habre W, 1996, BRIT J ANAESTH, V77, P739, DOI 10.1093/bja/77.6.739; Harnett M, 2000, CAN J ANAESTH, V47, P315, DOI 10.1007/BF03020944; Homer JR, 2007, PEDIATR ANESTH, V17, P154, DOI 10.1111/j.1460-9592.2006.02059.x; Jones DT, 2006, OTOLARYNG HEAD NECK, V135, P12, DOI 10.1016/j.otohns.2006.03.011; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; Joseph-Bowen J, 2004, AM J RESP CRIT CARE, V169, P850, DOI 10.1164/rccm.200304-556OC; Lakshmipathy N, 1996, ANESTH ANALG, V82, P724, DOI 10.1097/00000539-199604000-00008; Mamie C, 2004, PEDIATR ANESTH, V14, P218, DOI 10.1111/j.1460-9592.2004.01169.x; Murat I, 2004, PAEDIATR ANAESTH, V14, P158, DOI 10.1111/j.1460-9592.2004.01167.x; Parnis SJ, 2001, PAEDIATR ANAESTH, V11, P29, DOI 10.1046/j.1460-9592.2001.00607.x; Rooke GA, 1997, ANESTHESIOLOGY, V86, P1294, DOI 10.1097/00000542-199706000-00010; Schreiner MS, 1996, ANESTHESIOLOGY, V85, P475, DOI 10.1097/00000542-199609000-00005; Schutz N, 2004, BRIT J ANAESTH, V92, P254, DOI 10.1093/bja/aeh049; Skolnick ET, 1998, ANESTHESIOLOGY, V88, P1144, DOI 10.1097/00000542-199805000-00003; Tait AR, 1998, ANESTH ANALG, V86, P706, DOI 10.1097/00000539-199804000-00006; Tait AR, 2005, ANESTH ANALG, V100, P59, DOI 10.1213/01.ANE.0000139653.53618.91; Tait AR, 2001, ANESTHESIOLOGY, V95, P299, DOI 10.1097/00000542-200108000-00008; Tay CLM, 2001, PAEDIATR ANAESTH, V11, P711, DOI 10.1046/j.1460-9592.2001.00767.x; Varughese AM, 2006, PEDIATR ANESTH, V16, P723, DOI 10.1111/j.1460-9592.2006.01856.x; Von Ungern-Stemberg BS, 2007, ANESTHESIOLOGY, V107, P714, DOI 10.1097/01.anes.0000286925.25272.b5; von Ungern-Sternberg BS, 2008, ANESTHESIOLOGY, V108, P216, DOI 10.1097/01.anes.0000299430.90352.d5	35	286	292	1	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					773	783		10.1016/S0140-6736(10)61193-2	http://dx.doi.org/10.1016/S0140-6736(10)61193-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816545				2022-12-28	WOS:000281831000028
J	Garcia, RA; Mathur, S; Salabert, D; Ballot, J; Regulo, C; Metcalfe, TS; Baglin, A				Garcia, Rafael A.; Mathur, Savita; Salabert, David; Ballot, Jerome; Regulo, Clara; Metcalfe, Travis S.; Baglin, Annie			CoRoT Reveals a Magnetic Activity Cycle in a Sun-Like Star	SCIENCE			English	Article							ACOUSTIC MODES; SOLAR-CYCLE; OSCILLATIONS		[Garcia, Rafael A.] Univ Paris 07, Lab Astrophys Instrumentat & Modelisat, Inst Rech Lois Fondamentales Univ,Serv Astrophys, Direct Sci Mat,CNRS,CEA,Ctr Saclay, F-91191 Gif Sur Yvette, France; [Mathur, Savita; Metcalfe, Travis S.] NCAR, High Altitude Observ, Boulder, CO 80307 USA; [Salabert, David; Regulo, Clara] Inst Astrofis Canarias, Tenerife 38200, Spain; [Salabert, David; Regulo, Clara] Univ La Laguna, Dept Astrofis, E-38206 Tenerife, Spain; [Ballot, Jerome] Univ Toulouse, CNRS, Lab Astrophys Toulouse Tarbes, F-31400 Toulouse, France; [Baglin, Annie] Univ Paris 07, UMR8109, Lab Etud Spatiales & Instrumentat Astrophys, Univ Paris 06,Observ Paris, F-92195 Meudon, France	UDICE-French Research Universities; Universite Paris Cite; CEA; Centre National de la Recherche Scientifique (CNRS); Universite Paris Saclay; National Center Atmospheric Research (NCAR) - USA; Instituto de Astrofisica de Canarias; Universidad de la Laguna; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Universite Paris Cite	Garcia, RA (corresponding author), Univ Paris 07, Lab Astrophys Instrumentat & Modelisat, Inst Rech Lois Fondamentales Univ,Serv Astrophys, Direct Sci Mat,CNRS,CEA,Ctr Saclay, F-91191 Gif Sur Yvette, France.	Rafael.Garcia@cea.fr	Mathur, Savita/AAA-3102-2019; Ballot, Jérôme/G-1019-2010; Metcalfe, Travis/A-9388-2008	Metcalfe, Travis/0000-0003-4034-0416; Garcia, Rafael A./0000-0002-8854-3776; Ballot, Jerome/0000-0002-9649-1013; Mathur, Savita/0000-0002-0129-0316	Spanish National [PNAyA2007-62650]; CEA/Saclay; NSF	Spanish National; CEA/Saclay(French Atomic Energy Commission); NSF(National Science Foundation (NSF))	The CoRoT space mission has been developed and is operated by CNES, with contributions from Austria, Belgium, Brazil, European Space Agency (Research Science Support Department and Science Program), Germany, and Spain. This work has been partially supported by the Spanish National Research Plan (grant PNAyA2007-62650) and by the "Programme National de Physique Stellaire" at CEA/Saclay. NCAR is supported by NSF.	Appourchaux T, 2008, ASTRON ASTROPHYS, V488, P705, DOI 10.1051/0004-6361:200810297; BALIUNAS SL, 1995, ASTROPHYS J, V438, P269, DOI 10.1086/175072; Benomar O, 2009, ASTRON ASTROPHYS, V507, pL13, DOI 10.1051/0004-6361/200913111; Chaplin WJ, 2007, MON NOT R ASTRON SOC, V377, P17, DOI 10.1111/j.1365-2966.2007.11581.x; Charbonneau P, 2010, LIVING REV SOL PHYS, V7, DOI 10.12942/lrsp-2010-3; Gough DO, 1996, SCIENCE, V272, P1296, DOI 10.1126/science.272.5266.1296; Jimenez-Reyes SJ, 2004, ASTROPHYS J, V604, P969, DOI 10.1086/381936; Metcalfe T. S., 2007, MNRAS, V379, pL16, DOI DOI 10.1111/J.1745-3933.2007.00325.X; Michel E, 2008, SCIENCE, V322, P558, DOI 10.1126/science.1163004; Piau L, 2009, ASTRON ASTROPHYS, V506, P175, DOI 10.1051/0004-6361/200911947; Salabert D, 2009, ASTRON ASTROPHYS, V504, pL1, DOI 10.1051/0004-6361/200912736; Tripathy SC, 2010, ASTROPHYS J LETT, V711, pL84, DOI 10.1088/2041-8205/711/2/L84	12	181	181	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2010	329	5995					1032	1032		10.1126/science.1191064	http://dx.doi.org/10.1126/science.1191064			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642WZ	20798310	Green Submitted			2022-12-28	WOS:000281253500028
J	Abbott, A				Abbott, Alison			Levodopa: the story so far	NATURE			English	Editorial Material																			0	52	57	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2010	466	7310					S6	S7		10.1038/466S6a	http://dx.doi.org/10.1038/466S6a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20739934	Bronze			2022-12-28	WOS:000281203600059
J	Rose, KA; Sikes, EL; Guilderson, TP; Shane, P; Hill, TM; Zahn, R; Spero, HJ				Rose, Kathryn A.; Sikes, Elisabeth L.; Guilderson, Thomas P.; Shane, Phil; Hill, Tessa M.; Zahn, Rainer; Spero, Howard J.			Upper-ocean-to-atmosphere radiocarbon offsets imply fast deglacial carbon dioxide release	NATURE			English	Article							PACIFIC-OCEAN; NORTH-ATLANTIC; NEW-ZEALAND; CO2; VENTILATION; CALIBRATION; WESTERLIES; RECORD; AGES; BEDS	Radiocarbon in the atmosphere is regulated largely by ocean circulation, which controls the sequestration of carbon dioxide (CO2) in the deep sea through atmosphere-ocean carbon exchange. During the last glaciation, lower atmospheric CO2 levels were accompanied by increased atmospheric radiocarbon concentrations that have been attributed to greater storage of CO2 in a poorly ventilated abyssal ocean(1,2). The end of the ice age was marked by a rapid increase in atmospheric CO2 concentrations(2) that coincided with reduced C-14/C-12 ratios (Delta C-14) in the atmosphere(3), suggesting the release of very 'old' (C-14-depleted) CO2 from the deep ocean to the atmosphere(3). Here we present radiocarbon records of surface and intermediate-depth waters from two sediment cores in the southwest Pacific and Southern oceans. We find a steady 170 per mil decrease in Delta C-14 that precedes and roughly equals in magnitude the decrease in the atmospheric radiocarbon signal during the early stages of the glacial-interglacial climatic transition. The atmospheric decrease in the radiocarbon signal coincides with regionally intensified upwelling and marine biological productivity(4), suggesting that CO2 released by means of deep water upwelling in the Southern Ocean lost most of its original depleted-C-14 imprint as a result of exchange and isotopic equilibration with the atmosphere. Our data imply that the deglacial C-14 depletion previously identified in the eastern tropical North Pacific(5) must have involved contributions from sources other than the previously suggested carbon release by way of a deep Southern Ocean pathway(5), and may reflect the expanded influence of the C-14-depleted North Pacific carbon reservoir across this interval. Accordingly, shallow water masses advecting north across the South Pacific in the early deglaciation had little or no residual C-14-depleted signals owing to degassing of CO2 and biological uptake in the Southern Ocean.	[Sikes, Elisabeth L.] Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA; [Rose, Kathryn A.; Hill, Tessa M.; Spero, Howard J.] Univ Calif Davis, Dept Geol, Davis, CA 95616 USA; [Guilderson, Thomas P.] Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; [Guilderson, Thomas P.] Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA; [Shane, Phil] Univ Auckland, Sch Environm, Auckland 1142, New Zealand; [Zahn, Rainer] Univ Autonoma Barcelona, Inst Ciencia & Tecnol Ambientals, Dept Geol, Inst Catalana Recerca & Estudis Avancats,ICREA, Bellaterra 08193, Spain	Rutgers State University New Brunswick; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Santa Cruz; University of Auckland; Autonomous University of Barcelona; ICREA	Sikes, EL (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, 71 Dudley Rd, New Brunswick, NJ 08901 USA.	sikes@marine.rutgers.edu	Hill, Tessa Michelle/P-3401-2019	Hill, Tessa Michelle/0000-0003-4159-9104; Shane, Philip/0000-0002-7824-1184; Sikes, Elisabeth/0000-0003-2900-3283; Spero, Howard/0000-0001-5465-8607	National Science Foundation (NSF) [RR0503]; Evolving Earth Foundation; Geological Society of America; MICINN, Spain; US Department of Energy; Directorate For Geosciences [0823549, 0962077] Funding Source: National Science Foundation; ICREA Funding Source: Custom	National Science Foundation (NSF)(National Science Foundation (NSF)National Research Foundation of Korea); Evolving Earth Foundation; Geological Society of America; MICINN, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); US Department of Energy(United States Department of Energy (DOE)); Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); ICREA(ICREA)	We thank the captain and crew of the RV Revelle, and our shipboard colleagues during the Zheng leg 3 (RR0503) cruise funded by the National Science Foundation (NSF), which collected the RR core. Core MD97-2120 was collected through the International Marine Past Global Change Study (IMAGES) program and with the technical support of the Institut Polaire Francais Paul Emile Victor (IPEV) who made the research vessel Marion Dufresne available for core retrieval. H.J.S., E.L.S. and T.P.G., and the shore analyses, were supported by NSF awards and the Evolving Earth Foundation, and the Geological Society of America provided support for K.A.R. during her MSc. R.Z. acknowledges support from the MICINN, Spain. A portion of this work was performed under the auspices of the US Department of Energy by Lawrence Livermore National Laboratory. We especially thank M. Cook for discussions, continuing input and suggestions throughout this study.	Anderson RF, 2009, SCIENCE, V323, P1443, DOI 10.1126/science.1167441; Barbante C, 2006, NATURE, V444, P195, DOI 10.1038/nature05301; Bard E, 1988, PALEOCEANOGRAPHY, V3, P635, DOI 10.1029/PA003i006p00635; Bostock HC, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2004PA001047; Broecker W, 2007, EARTH PLANET SC LETT, V256, P90, DOI 10.1016/j.epsl.2007.01.015; Broecker W, 2008, EARTH PLANET SC LETT, V274, P322, DOI 10.1016/j.epsl.2008.07.035; Curry WB, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001021; Galbraith ED, 2007, NATURE, V449, P890, DOI 10.1038/nature06227; Gnanadesikan A, 2007, OCEAN SCI, V3, P43, DOI 10.5194/os-3-43-2007; Gnanadesikan A, 1999, SCIENCE, V283, P2077, DOI 10.1126/science.283.5410.2077; Hanawa K., 2001, OCEAN CIRCULATION CL, P373, DOI DOI 10.1016/S0074-6142(01)80129-7; Hughen K, 2006, QUATERNARY SCI REV, V25, P3216, DOI 10.1016/j.quascirev.2006.03.014; Keigwin LD, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2004PA001029; Key RM, 1996, RADIOCARBON, V38, P425, DOI 10.1017/S0033822200030071; Lowe DJ, 2008, QUATERNARY SCI REV, V27, P95, DOI 10.1016/j.quascirev.2007.01.013; Marchitto TM, 2007, SCIENCE, V316, P1456, DOI 10.1126/science.1138679; McManus JF, 2004, NATURE, V428, P834, DOI 10.1038/nature02494; Monnin E, 2001, SCIENCE, V291, P112, DOI 10.1126/science.291.5501.112; Muscheler R, 2004, EARTH PLANET SC LETT, V219, P325, DOI 10.1016/S0012-821X(03)00722-2; Pahnke K, 2005, SCIENCE, V307, P1741, DOI 10.1126/science.1102163; Pahnke K, 2003, SCIENCE, V301, P948, DOI 10.1126/science.1084451; POLHOLZ RD, 2010, NATURE GEOSCI, V3, P192; Reimer PJ, 2004, RADIOCARBON, V46, P1029, DOI 10.1017/S0033822200032999; Robinson LF, 2005, SCIENCE, V310, P1469, DOI 10.1126/science.1114832; Russell JL, 2006, J CLIMATE, V19, P6382, DOI 10.1175/JCLI3984.1; Sachs JP, 2005, NATURE, V434, P1118, DOI 10.1038/nature03544; SARNTHEIN M, 2007, GEOPHYS MONOGR SER, V173, P175, DOI DOI 10.1029/173GM13; Shane P, 2006, J VOLCANOL GEOTH RES, V154, P276, DOI 10.1016/j.jvolgeores.2006.03.021; Sikes EL, 2000, NATURE, V405, P555, DOI 10.1038/35014581; Spero HJ, 2002, SCIENCE, V296, P522, DOI 10.1126/science.1069401; Toggweiler JR, 2006, PALEOCEANOGRAPHY, V21, DOI 10.1029/2005PA001154; Toggweiler JR, 1999, PALEOCEANOGRAPHY, V14, P571, DOI 10.1029/1999PA900033	32	58	61	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2010	466	7310					1093	1097		10.1038/nature09288	http://dx.doi.org/10.1038/nature09288			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	642IK	20740012	Green Published			2022-12-28	WOS:000281203600037
J	Jong, P; McKelvie, R; Yusuf, S				Jong, Philip; McKelvie, Robert; Yusuf, Salim			Uncertainties Page Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction?	BRITISH MEDICAL JOURNAL			English	Editorial Material							SYSTOLIC FUNCTION; EUROPEAN-SOCIETY; MORTALITY; MORBIDITY; TRIAL; CANDESARTAN; CARDIOLOGY; REGISTRY; DIGOXIN		[Jong, Philip; McKelvie, Robert; Yusuf, Salim] McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada	McMaster University; Population Health Research Institute	Yusuf, S (corresponding author), McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca		Yusuf, Salim/0000-0003-4776-5601				Ahmed A, 2006, CIRCULATION, V114, P397, DOI 10.1161/CIRCULATIONAHA.106.628347; Bangalore S, 2008, J AM COLL CARDIOL, V52, P1062, DOI 10.1016/j.jacc.2008.05.057; Bhatia RS, 2006, NEW ENGL J MED, V355, P260, DOI 10.1056/NEJMoa051530; Cleland JGF, 2006, EUR HEART J, V27, P2338, DOI 10.1093/eurheartj/ehl250; Cleland JGF, 2009, EUR J HEART FAIL, V11, P1214, DOI 10.1093/eurjhf/hfp162; Dagenais GR, 2006, LANCET, V368, P581, DOI 10.1016/S0140-6736(06)69201-5; Flather MD, 2005, EUR HEART J, V26, P215, DOI 10.1093/eurheartj/ehi118; Fonarow GC, 2007, J AM COLL CARDIOL, V50, P768, DOI 10.1016/j.jacc.2007.04.064; Hogg K, 2004, J AM COLL CARDIOL, V43, P317, DOI 10.1016/j.jacc.2003.07.046; Massie BM, 2008, NEW ENGL J MED, V359, P2456, DOI 10.1056/NEJMoa0805450; National Institute Health and Clinical Excellence, 2010, CHRON HEART FAIL MAN; O'Meara E, 2004, EUR HEART J, V25, P1920, DOI 10.1016/j.ehj.2004.07.025; Owan TE, 2006, NEW ENGL J MED, V355, P251, DOI 10.1056/NEJMoa052256; Paulus WJ, 2007, EUR HEART J, V28, P2539, DOI 10.1093/eurheartj/ehm037; Perry G, 1997, NEW ENGL J MED, V336, P525; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7	16	7	7	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 25	2010	341								c4202	10.1136/bmj.c4202	http://dx.doi.org/10.1136/bmj.c4202			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645IH	20739364				2022-12-28	WOS:000281446000015
J	Farrell, AM; Brazier, M				Farrell, Anne-Maree; Brazier, Margaret			Consent for blood transfusion	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Farrell, Anne-Maree; Brazier, Margaret] Univ Manchester, Sch Law, Inst Sci Eth & Innovat, Ctr Social Eth & Policy, Manchester M13 9PL, Lancs, England	University of Manchester	Farrell, AM (corresponding author), Univ Manchester, Sch Law, Inst Sci Eth & Innovat, Ctr Social Eth & Policy, Manchester M13 9PL, Lancs, England.	a.m.farrell@manchester.ac.uk		Farrell, Anne-Maree/0000-0001-9522-6528	Wellcome Trust [087439] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ADV COMM SAF BLOO, 2010, PAT CONS BLOOD TRANS; *CMO NAT BLOOD TRA, 2008, BETT BLOOD TRANSF HS; CONNON W, 2007, COMMUNICATION   0316; General Medical Council, 2008, CONS PAT DOCT MAK DE; HEWITT B, 1997, BRIT MED J, V316, P397; Killion DF, 2007, TRANSFUSION, V47, P557, DOI 10.1111/j.1537-2995.2007.01185.x; MCCLELLAND D, 2007, HDB BLOOD TRANSFUSIO; Murphy MF, 1997, TRANSFUSION MED, V7, P287, DOI 10.1046/j.1365-3148.1997.d01-41.x; Re T, 1992, ALL ER, V4, P649; *SER HAZ TRANSF, ANN REP 2008 SUMM; Williams FG, 1997, BRIT MED J, V315, P380, DOI 10.1136/bmj.315.7105.380	11	8	8	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 24	2010	341								c4336	10.1136/bmj.c4336	http://dx.doi.org/10.1136/bmj.c4336			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IG	20736271	Green Submitted			2022-12-28	WOS:000281445900006
J	Gillett, M; Dallosso, HM; Dixon, S; Brennan, A; Carey, ME; Campbell, MJ; Heller, S; Khunti, K; Skinner, TC; Davies, MJ				Gillett, M.; Dallosso, H. M.; Dixon, S.; Brennan, A.; Carey, M. E.; Campbell, M. J.; Heller, S.; Khunti, K.; Skinner, T. C.; Davies, M. J.			Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLUSTER RANDOMIZED-TRIALS; QUALITY-OF-LIFE; UKPDS; MODEL; WEIGHT; IMPACT; STYLE; RISK	Objectives To assess the long term clinical and cost effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) intervention compared with usual care in people with newly diagnosed type 2 diabetes. Design We undertook a cost-utility analysis that used data from a 12 month, multicentre, cluster randomised controlled trial and, using the Sheffield type 2 diabetes model, modelled long term outcomes in terms of use of therapies, incidence of complications, mortality, and associated effect on costs and health related quality of life. A further cost-utility analysis was also conducted using current "real world" costs of delivering the intervention estimated for a hypothetical primary care trust. Setting Primary care trusts in the United Kingdom. Participants Patients with newly diagnosed type 2 diabetes. Intervention A six hour structured group education programme delivered in the community by two professional healthcare educators. Main outcome measures Incremental costs and quality adjusted life years (QALYs) gained. Results On the basis of the data in the trial, the estimated mean incremental lifetime cost per person receiving the DESMOND intervention is 209 pound (95% confidence interval -704 pound to 1137; pound (sic)251, -(sic)844 to (sic)1363; $326, -$1098 to $1773), the incremental gain in QALYs per person is 0.0392 (-0.0813 to 0.1786), and the mean incremental cost per QALY is 5387 pound. Using "real world" intervention costs, the lifetime incremental cost of the DESMOND intervention is 82 pound (-831 pound to 1010) pound and the mean incremental cost per QALY gained is 2092 pound. A probabilistic sensitivity analysis indicated that the likelihood that the DESMOND programme is cost effective at a threshold of 20 pound 000 per QALY is 66% using trial based intervention costs and 70% using "real world" costs. Results from a one way sensitivity analysis suggest that the DESMOND intervention is cost effective even under more modest assumptions that include the effects of the intervention being lost after one year. Conclusion Our results suggest that the DESMOND intervention is likely to be cost effective compared with usual care, especially with respect to the real world cost of the intervention to primary care trusts, with reductions in weight and smoking being the main benefits delivered.	[Gillett, M.; Dixon, S.; Brennan, A.; Campbell, M. J.] Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England; [Dallosso, H. M.; Carey, M. E.] Univ Hosp Leicester NHS Trust, DESMOND Project Off, Leicester, Leics, England; [Heller, S.] Univ Sheffield, Sch Med & Biomed Sci, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England; [Khunti, K.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Skinner, T. C.] Combined Univ Ctr Rural Hlth, Geraldton, Australia; [Davies, M. J.] Univ Leicester, Leicester Royal Infirm, Dept Cardiovasc Med, Leicester, Leics, England	University of Sheffield; University Hospitals of Leicester NHS Trust; University of Leicester; University of Sheffield; University of Leicester; University of Western Australia; University of Leicester	Gillett, M (corresponding author), Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England.	m.gillett@sheffield.ac.uk	/ABC-9527-2021; Skinner, Timothy/G-2865-2010; Skinner, Timothy C/N-2221-2013; Davies, Michael/GWV-2527-2022; Davies, Michael/AGX-9184-2022; Campbell, Michael J/I-4253-2014	Skinner, Timothy C/0000-0002-0018-6963; Davies, Michael/0000-0002-5196-6919; Campbell, Michael J/0000-0003-3529-2739; Heller, Simon/0000-0002-2425-9565; Davies, Melanie/0000-0002-9987-9371; Brennan, Alan/0000-0002-1025-312X; Khunti, Kamlesh/0000-0003-2343-7099	Diabetes UK	Diabetes UK(Diabetes UK)	The study was funded by a grant from Diabetes UK secured by the University Hospitals of Leicester NHS Trust. The analysis was independently designed and undertaken by the University of Sheffield School of Health and Related Research and collaborators. Researchers worked independently from the funders. Similarly the writing of the report and the decision to submit the article for publication was entirely independent of the funder. The study funder had no input into the study design or analysis, nor the interpretation of data.	[Anonymous], 2008, GUID METH TECHN APPR; Brennan A, 2006, HEALTH ECON, V15, P1295, DOI 10.1002/hec.1148; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Campbell MJ, 2007, STAT MED, V26, P2, DOI 10.1002/sim.2731; Campbell MJ, 2000, STAT METHODS MED RES, V9, P81, DOI 10.1191/096228000676246354; Clarke P, 2003, DIABETIC MED, V20, P442, DOI 10.1046/j.1464-5491.2003.00972.x; Clarke P, 2002, MED DECIS MAKING, V22, P340, DOI 10.1177/027298902400448902; Clarke PM, 2004, DIABETOLOGIA, V47, P1747, DOI 10.1007/s00125-004-1527-z; Coffey JT, 2002, DIABETES CARE, V25, P2238, DOI 10.2337/diacare.25.12.2238; CURTIS L, 2007, PERSONAL SOCIAL SERV; Davies MJ, 2008, BMJ-BRIT MED J, V336, P491, DOI 10.1136/bmj.39474.922025.BE; Deakin TA, 2006, DIABETIC MED, V23, P944, DOI 10.1111/j.1464-5491.2006.01906.x; Dennett SL, 2008, VALUE HEALTH, V11, P478, DOI 10.1111/j.1524-4733.2007.00260.x; Dinneen SF, 2008, BMJ-BRIT MED J, V336, P459, DOI 10.1136/bmj.39478.693715.80; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; HARRELL FE, 1998, STAT MED, V90, P144; HAWKINS J, 2007, THESIS U SHEFFIELD; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; *INT DIAB FED, 2007, IDF DIAB ATL PREV ES; Khunti K, 2008, DIABETIC MED, V25, P1454, DOI 10.1111/j.1464-5491.2008.02620.x; Kothari V, 2002, STROKE, V33, P1776, DOI 10.1161/01.STR.0000020091.07144.C7; Lindstrom J, 2005, P NUTR SOC, V64, P81, DOI 10.1079/PNS2004412; LOVEMAN E, 2008, HEALTH TECHNOL ASSES, V1, P116; Massi-Benedetti M, 2002, DIABETOLOGIA, V45, pS1, DOI 10.1007/s00125-002-0860-3; Morris AD, 2002, DIABETES-METAB RES, V18, pS32, DOI 10.1002/dmrr.295; *NAT I HLTH CLIN E, 2009, 87 NICE; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; National Institute for Clinical Excellence, 2003, 60 NICE, V60; *NHS INF CTR HLTH, 2008, PRESCR COSL AN ENGL; O'Hagan A, 2007, HEALTH ECON, V16, P1009, DOI 10.1002/hec.1199; O'Meara S, 2002, Health Technol Assess, V6, P1; Skinner TC, 2006, PATIENT EDUC COUNS, V64, P369, DOI 10.1016/j.pec.2006.04.007; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335; Trento M, 2004, DIABETES CARE, V27, P670, DOI 10.2337/diacare.27.3.670; URBANSKI P, 2008, J AM DIET ASS S1, V108, P6; Warren E, 2004, MED DECIS MAKING, V24, P9, DOI 10.1177/0272989X03261565	36	117	120	0	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 20	2010	341								c4093	10.1136/bmj.c4093	http://dx.doi.org/10.1136/bmj.c4093			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KY	20729270	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000281213600001
J	Viles, J; Monte, D; Gawkrodger, DJ				Viles, Jennifer; Monte, Darryl; Gawkrodger, David J.			A Patient's Journey Vitiligo	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Viles, Jennifer; Monte, Darryl] Vitiligo Soc, London SE11 6SF, England; [Gawkrodger, David J.] Univ Sheffield, Royal Hallamshire Hosp, Sheffield S10 2JF, England	University of Sheffield	Viles, J (corresponding author), Vitiligo Soc, London SE11 6SF, England.	jennifer_viles@vitiligosociety.org.uk; david.gawkrodger@sth.nhs.uk	GAWKRODGER, DAVID J./AFO-6373-2022	GAWKRODGER, DAVID J./0000-0002-6863-7011					0	3	4	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 20	2010	341								c3780	10.1136/bmj.c3780	http://dx.doi.org/10.1136/bmj.c3780			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KY	20729269				2022-12-28	WOS:000281213600014
J	Watts, G				Watts, Geoff			Research in Action Lost without translation?	BRITISH MEDICAL JOURNAL			English	Editorial Material												geoff@scileg.freeserve.co.uk						CONOVA S, 2005, IN VIVO, V4; *EUR COMM, FP7 PROGR; HM Treasury, 2021, UK PROSP REG REV CON, P11; *OFF STRAT COORD H, 2008, CHAIRM 1 PROGR REP; *UK CTR MED RES IN, 2010, SCI VIS RES STRAT	5	4	4	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 18	2010	341								c4363	10.1136/bmj.c4363	http://dx.doi.org/10.1136/bmj.c4363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KT	20719827				2022-12-28	WOS:000281213100001
J	Thomas, MJ				Thomas, Michael J.			Amylmetacresol and 2, 4-dichlorobenzyl alcohol lozenges were better than placebo lozenges for relief of acute sore throat	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																		Danchin MH, 2002, MED J AUSTRALIA, V177, P512, DOI 10.5694/j.1326-5377.2002.tb04925.x; Fuller H, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004883; Rausch S, 2009, B SOC SCI MED GRAND, V1, P79; Thomas M, 2000, BRIT J GEN PRACT, V50, P817	4	2	2	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4							JC2-6	10.7326/0003-4819-153-4-201008170-02006	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-02006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713785				2022-12-28	WOS:000280973000032
J	Cicardi, M; Banerji, A; Bracho, F; Malbran, A; Rosenkranz, B; Riedl, M; Bork, K; Lumry, W; Aberer, W; Bier, H; Bas, M; Greve, J; Hoffmann, TK; Farkas, H; Reshef, A; Ritchie, B; Yang, W; Grabbe, J; Kivity, S; Kreuz, W; Levy, RJ; Luger, T; Obtulowicz, K; Schmid-Grendelmeier, P; Bull, C; Sitkauskiene, B; Smith, WB; Toubi, E; Werner, S; Anne, S; Bjorkander, J; Bouillet, L; Cillari, E; Hurewitz, D; Jacobson, KW; Katelaris, CH; Maurer, M; Merk, H; Bernstein, JA; Feighery, C; Floccard, B; Gleich, G; Hebert, J; Kaatz, M; Keith, P; Kirkpatrick, CH; Langton, D; Martin, L; Pichler, C; Resnick, D; Wombolt, D; Romero, DSF; Zanichelli, A; Arcoleo, F; Knolle, J; Kravec, I; Dong, L; Zimmermann, J; Rosen, K; Fan, WT				Cicardi, M.; Banerji, A.; Bracho, F.; Malbran, A.; Rosenkranz, B.; Riedl, M.; Bork, K.; Lumry, W.; Aberer, W.; Bier, H.; Bas, M.; Greve, J.; Hoffmann, T. K.; Farkas, H.; Reshef, A.; Ritchie, B.; Yang, W.; Grabbe, J.; Kivity, S.; Kreuz, W.; Levy, R. J.; Luger, T.; Obtulowicz, K.; Schmid-Grendelmeier, P.; Bull, C.; Sitkauskiene, B.; Smith, W. B.; Toubi, E.; Werner, S.; Anne, S.; Bjorkander, J.; Bouillet, L.; Cillari, E.; Hurewitz, D.; Jacobson, K. W.; Katelaris, C. H.; Maurer, M.; Merk, H.; Bernstein, J. A.; Feighery, C.; Floccard, B.; Gleich, G.; Hebert, J.; Kaatz, M.; Keith, P.; Kirkpatrick, C. H.; Langton, D.; Martin, L.; Pichler, C.; Resnick, D.; Wombolt, D.; Fernandez Romero, D. S.; Zanichelli, A.; Arcoleo, F.; Knolle, J.; Kravec, I.; Dong, L.; Zimmermann, J.; Rosen, K.; Fan, W. -T.			Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C1 INHIBITOR CONCENTRATE; ANGIONEUROTIC EDEMA; LARYNGEAL EDEMA; TRANEXAMIC ACID	BACKGROUND Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. METHODS In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. The primary end point was the median time to clinically significant relief of symptoms. RESULTS A total of 56 and 74 patients underwent randomization in the FAST-1 and FAST-2 trials, respectively. The primary end point was reached in 2.5 hours with icatibant versus 4.6 hours with placebo in the FAST-1 trial (P=0.14) and in 2.0 hours with icatibant versus 12.0 hours with tranexamic acid in the FAST-2 trial (P<0.001). In the FAST-1 study, 3 recipients of icatibant and 13 recipients of placebo needed treatment with rescue medication. The median time to first improvement of symptoms, as assessed by patients and by investigators, was significantly shorter with icatibant in both trials. No icatibant-related serious adverse events were reported. CONCLUSIONS In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as compared with placebo in the other trial with regard to the primary end point. The early use of rescue medication may have obscured the benefit of icatibant in the placebo trial. (Funded by Jerini; ClinicalTrials.gov numbers, NCT00097695 and NCT00500656.)	[Banerji, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Banerji, A.] Harvard Univ, Sch Med, Boston, MA USA; [Cicardi, M.; Zanichelli, A.] Univ Milan, Milan, Italy; [Bracho, F.] Georgetown Univ Hosp, Lombardi Canc Ctr, Washington, DC 20007 USA; [Malbran, A.; Fernandez Romero, D. S.] Hosp Britan Buenos Aires, Buenos Aires, DF, Argentina; [Bork, K.] Johannes Gutenberg Univ Mainz, Mainz, Germany; [Bier, H.; Bas, M.] Tech Univ Munich, Munich, Germany; [Greve, J.; Hoffmann, T. K.] Univ Dusseldorf, Dusseldorf, Germany; [Grabbe, J.] Univ Hosp Lubeck, Lubeck, Germany; [Kreuz, W.] Goethe Univ Frankfurt, Frankfurt, Germany; [Luger, T.] Univ Hosp Munster, Munster, Germany; [Maurer, M.] Charite, D-13353 Berlin, Germany; [Merk, H.] Univ Hosp Rhein Westfal Tech Hsch Aachen, Aachen, Germany; [Kaatz, M.] Univ Jena, Jena, Germany; [Riedl, M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Lumry, W.] Asthma Allergy Res Associates Res Ctr, Dallas, TX USA; [Aberer, W.] Med Univ Graz, Graz, Austria; [Farkas, H.] Semmelweis Univ, H-1085 Budapest, Hungary; [Reshef, A.] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; [Kivity, S.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Toubi, E.] Bnai Zion Med Ctr, Haifa, Israel; [Ritchie, B.] Univ Alberta, Edmonton, AB, Canada; [Yang, W.] Allergy & Asthma Res Ctr, Ottawa, ON, Canada; [Hebert, J.] Ctr Rech Appl Allergie Quebec, Quebec City, PQ, Canada; [Keith, P.] McMaster Univ, Hamilton Hlth Sci Ctr, Hamilton, ON, Canada; [Levy, R. J.] Family Allergy & Asthma Ctr, Atlanta, GA USA; [Obtulowicz, K.] Szpital Uniwersytecki Krakowie, Krakow, Poland; [Schmid-Grendelmeier, P.; Bull, C.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Pichler, C.] Insel Spital BE Bern, Bern, Switzerland; [Sitkauskiene, B.] Kaunas Univ Med, Kaunas, Lithuania; [Smith, W. B.] Royal Adelaide Hosp, Adelaide, SA 5000, Australia; [Katelaris, C. H.] Westmead Hosp, Sydney, NSW, Australia; [Langton, D.] Frankston Hosp, Frankston, Vic, Australia; [Werner, S.] Univ Lund Hosp, S-22185 Lund, Sweden; [Bjorkander, J.] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Anne, S.] Asthma Allergy & Immunol Ctr, Flint, MI USA; [Bouillet, L.] CHU Grenoble, F-38043 Grenoble, France; [Floccard, B.] Hop Edouard Herriot, Lyon, France; [Martin, L.] Ctr Hosp Reg Orleans, Orleans, France; [Cillari, E.; Arcoleo, F.] Azienda Osped V Cervello, Palermo, Italy; [Hurewitz, D.] Allergy Clin Tulsa, Tulsa, OK USA; [Jacobson, K. W.] Allergy & Asthma Res Grp, Eugene, OR USA; [Bernstein, J. A.] Univ Cincinnati, Cincinnati, OH USA; [Feighery, C.] St James Hosp, Dublin, Ireland; [Gleich, G.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [Kirkpatrick, C. H.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Resnick, D.] Columbia Univ, Med Ctr, New York, NY USA; [Wombolt, D.] Clin Res Associates Tidewater, Norfolk, VA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Milan; Georgetown University; Hospital Britanico de Buenos Aires; Johannes Gutenberg University of Mainz; Technical University of Munich; Heinrich Heine University Dusseldorf; University of Lubeck; Goethe University Frankfurt; University of Munster; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; RWTH Aachen University; RWTH Aachen University Hospital; Friedrich Schiller University of Jena; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Medical University of Graz; Semmelweis University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Bnai Zion Medical Center; University of Alberta; McMaster University; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Zurich; University Zurich Hospital; University of Bern; University Hospital of Bern; Lithuanian University of Health Sciences; Royal Adelaide Hospital; University of Sydney; Frankston Hospital; Lund University; Skane University Hospital; Sahlgrenska University Hospital; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Lyon; Centre Hospitalier Regional d'Orleans; University System of Ohio; University of Cincinnati; Trinity College Dublin; Utah System of Higher Education; University of Utah; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Columbia University	Banerji, A (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,Cox 201, Boston, MA 02114 USA.	abanerji@partners.com	Bork, Konrad/AAE-4985-2022; Maurer, Marcus/ABG-2174-2020; Banerji, Aleena/ABG-1245-2021; Reshef, Avner/AAL-3638-2020; Martin, Ludovic/K-2674-2015; cicardi, marco/K-9219-2016; Greve, Jens/AAF-2688-2021; Malbran, Alejandro/C-3410-2017	Bork, Konrad/0000-0002-6084-4577; Maurer, Marcus/0000-0002-4121-481X; cicardi, marco/0000-0003-1251-225X; Smith, William/0000-0002-4610-998X; Bernstein, Jonathan/0000-0002-3476-1196; Smith, William/0000-0001-9640-1172; zanichelli, andrea/0000-0002-7512-4644; Ritchie, Bruce/0000-0003-4754-1050; Malbran, Alejandro/0000-0003-4228-4892; Reshef, Avner/0000-0002-3324-7072; Farkas, Henriette/0000-0003-2929-1721	Jerini [FAST-1]; National Institutes of Health [M01 RR-00051]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER	Jerini; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by Jerini and, for the FAST-1 trial only, in part by a grant from the National Institutes of Health (M01 RR-00051).	Bork K, 2000, MAYO CLIN PROC, V75, P349, DOI 10.4065/75.4.349; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510; COCKCROFT JR, 1994, BRIT J CLIN PHARMACO, V38, P317, DOI 10.1111/j.1365-2125.1994.tb04360.x; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001; Davis AE, 2006, IMMUNOL ALLERGY CLIN, V26, P633, DOI 10.1016/j.iac.2006.08.003; Fincham CI, 2009, EXPERT OPIN THER PAT, V19, P919, DOI 10.1517/13543770902994389; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nzeako UC, 2001, ARCH INTERN MED, V161, P2417, DOI 10.1001/archinte.161.20.2417; OHELA K, 1976, ACTA DERM-VENEREOL, V56, P61; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; ROSENKRANZ B, 2007, 26 EAACI C GOTH SWED; Sachse Michael M, 2006, J Drugs Dermatol, V5, P848; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; WIRTH KJ, 1995, CAN J PHYSIOL PHARM, V73, P797, DOI 10.1139/y95-108; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977	20	407	416	1	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					532	541		10.1056/NEJMoa0906393	http://dx.doi.org/10.1056/NEJMoa0906393			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818888	Green Accepted			2022-12-28	WOS:000280552700007
J	Jessel, P; Safdar, N; McCune, WJ; Saint, S; Kaul, DR				Jessel, Peter; Safdar, Nasia; McCune, W. Joseph; Saint, Sanjay; Kaul, Daniel R.			Thinking Inside the Box	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTITUMOR NECROSIS FACTOR; ENDOMYOCARDIAL BIOPSY; RHEUMATOID-ARTHRITIS; SERIOUS INFECTIONS; FACTOR ANTAGONISTS; MYOCARDITIS; THERAPY		[Kaul, Daniel R.] Univ Michigan, Med Ctr, Div Infect Dis, Dept Internal Med, Ann Arbor, MI 48109 USA; [Saint, Sanjay] Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA; [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA	University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison	Kaul, DR (corresponding author), Univ Michigan, Med Ctr, Div Infect Dis, Dept Internal Med, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	kauld@umich.edu	Postiglione, Gennaro/K-8933-2015; Saint, Sanjay/AAF-5126-2019	Postiglione, Gennaro/0000-0003-4886-4548; Jessel, Peter/0000-0003-0548-9047	National Institutes of Health [5K12 AG019247-05]; Human Genome Sciences; Genentech; Johnson Johnson; NATIONAL INSTITUTE ON AGING [K12AG019247] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Genome Sciences(GlaxoSmithKline); Genentech(Roche HoldingGenentech); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by an institutional training grant (5K12 AG019247-05) from the National Institutes of Health to the University of Wisconsin School of Medicine and Public Health (in support of Dr. Safdar).; Dr. McCune reports receiving support from Human Genome Sciences, Genentech, and Johnson & Johnson. No other potential conflict of interest relevant to this article was reported.	Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2482; CHOW LH, 1989, J AM COLL CARDIOL, V14, P915, DOI 10.1016/0735-1097(89)90465-8; Costa MF, 2008, SEMIN ARTHRITIS RHEU, V37, P381, DOI 10.1016/j.semarthrit.2007.08.003; Dixon WG, 2006, ARTHRITIS RHEUM-US, V54, P2368, DOI 10.1002/art.21978; Haddad F, 2007, J HEART LUNG TRANSPL, V26, P745, DOI 10.1016/j.healun.2007.04.010; HAUCK AJ, 1989, MAYO CLIN PROC, V64, P1235, DOI 10.1016/S0025-6196(12)61286-5; Lyon SA, 2008, FOODBORNE PATHOG DIS, V5, P253, DOI 10.1089/fpd.2007.0070; MANDELL GL, 2005, MANDELL DOUGLAS BENN; MCCUE MJ, 1979, HUM PATHOL, V10, P469, DOI 10.1016/S0046-8177(79)80052-0; STAMM AM, 1990, REV INFECT DIS, V12, P820; TICE AD, 1979, R I MED J, V62, P135; Wallis RS, 2004, CLIN INFECT DIS, V38, P1261, DOI 10.1086/383317; Walls RS, 2008, LANCET INFECT DIS, V8, P601, DOI 10.1016/S1473-3099(08)70227-5; Winthrop KL, 2008, CLIN INFECT DIS, V46, P1738, DOI 10.1086/587989	15	3	3	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					574	579		10.1056/NEJMcps0901467	http://dx.doi.org/10.1056/NEJMcps0901467			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818893				2022-12-28	WOS:000280552700013
